PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Castle, M; Nazarian, A; Yi, SS; Tempst, P				Castle, M; Nazarian, A; Yi, SS; Tempst, P			Lethal effects of apidaecin on Escherichia coli involve sequential molecular interactions with diverse targets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE ANTIBACTERIAL PEPTIDE; GRAM-NEGATIVE BACTERIA; SALMONELLA-TYPHIMURIUM; PIG INTESTINE; ANTIMICROBIAL PEPTIDES; BOVINE NEUTROPHILS; BINDING PROTEIN; OUTER-MEMBRANE; DIFFERENT MECHANISMS; ANTIBIOTIC PEPTIDES	Apidaecins, short proline-arginine-rich peptides from insects, are highly bactericidal through a mechanism that includes stereoselective elements but is completely devoid of any pore-forming activity. The spectrum of antibacterial activity, always limited to Gram-negatives, is further dependent on a small number of variable residues and can be manipulated. We show here that mutations in the evolutionary conserved regions result in a more general loss of function, and we have used such analogs to probe molecular interactions in Escherichia coli. First, an assay was developed to measure selectively chiral association with cellular targets. By using this method, we find that apidaecin uptake is energy driven and irreversible and yet can be partially competed by proline in a stereospecific fashion, results upholding a model of a permease/transporter-mediated mechanism. This putative transporter is not the end point of apidaecin action, for failure of certain peptide analogs to kill cells after entering indicates the existence of another downstream target. Tetracycline-induced loss of bactericidal activity and dose-dependent in vivo inhibition of translation by apidaecin point at components of the protein synthesis machinery as likely candidates. These findings provide new insights into the antibacterial mechanism of a unique group of peptides and perhaps, by extension, for distant mammalian relatives such as PR-39.	Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; Cornell Univ, Weill Grad Sch Med Sci, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Tempst, P (corresponding author), Mem Sloan Kettering Canc Ctr, Program Mol Biol, 1275 York Ave, New York, NY 10021 USA.	p-tempst@mskcc.org			NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA08748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGERBERTH B, 1991, EUR J BIOCHEM, V202, P849, DOI 10.1111/j.1432-1033.1991.tb16442.x; AMES GF, 1990, FEMS MICROBIOL REV, V6, P429; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; ANDREWS JC, 1985, J BACTERIOL, V161, P484, DOI 10.1128/JB.161.2.484-492.1985; BARAK Z, 1975, J BACTERIOL, V122, P1200, DOI 10.1128/JB.122.3.1200-1207.1975; Barry A.L., 1991, MANUAL CLIN MICROBIO; BERGER EA, 1973, P NATL ACAD SCI USA, V70, P1514, DOI 10.1073/pnas.70.5.1514; BERGER EA, 1974, J BIOL CHEM, V249, P7747; BESALLE R, 1990, FEBS LETT, V274, P151; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; BOMAN HG, 1981, TRENDS BIOCHEM SCI, V6, P306, DOI 10.1146/annurev.mi.41.100187.000535; BOMAN HG, 1993, INFECT IMMUN, V61, P2978, DOI 10.1128/IAI.61.7.2978-2984.1993; BULET P, 1991, J BIOL CHEM, V266, P24520; BULET P, 1993, J BIOL CHEM, V268, P14893; CASTEELS P, 1994, J BIOL CHEM, V269, P26107; CASTEELS P, 1994, BIOCHEM BIOPH RES CO, V199, P339, DOI 10.1006/bbrc.1994.1234; CASTEELS P, 1989, EMBO J, V8, P2387, DOI 10.1002/j.1460-2075.1989.tb08368.x; CASTEELS P, 1993, J BIOL CHEM, V268, P7044; CASTEELSJOSSON K, 1994, J BIOL CHEM, V269, P28569; CASTEELSJOSSON K, 1993, EMBO J, V12, P1569, DOI 10.1002/j.1460-2075.1993.tb05801.x; CHRISTENSEN B, 1988, P NATL ACAD SCI USA, V85, P5072, DOI 10.1073/pnas.85.14.5072; CRUCIANI RA, 1991, P NATL ACAD SCI USA, V88, P3792, DOI 10.1073/pnas.88.9.3792; CRUCIANI RA, 1992, EUR J PHARM-MOLEC PH, V226, P287, DOI 10.1016/0922-4106(92)90045-W; DIAMOND G, 1991, P NATL ACAD SCI USA, V88, P3952, DOI 10.1073/pnas.88.9.3952; Driessen AJM, 1997, MOL MICROBIOL, V24, P881, DOI 10.1046/j.1365-2958.1997.4071742.x; EISENHAUER PB, 1992, INFECT IMMUN, V60, P3556, DOI 10.1128/IAI.60.9.3556-3565.1992; Eliopoulos G.M., 1991, ANTIBIOTICS LAB MED, V3rd Edn, P432; FAYE I, 1975, INFECT IMMUN, V12, P1426, DOI 10.1128/IAI.12.6.1426-1438.1975; FRANK RW, 1990, J BIOL CHEM, V265, P18871; Frohm M, 1996, EUR J BIOCHEM, V237, P86, DOI 10.1111/j.1432-1033.1996.0086n.x; Fulton C, 1997, LANCET, V350, P1750, DOI 10.1016/S0140-6736(05)63574-X; FURLONG CE, 1986, METHOD ENZYMOL, V125, P279; GABAY JE, 1989, P NATL ACAD SCI USA, V86, P5610, DOI 10.1073/pnas.86.14.5610; Ganz T, 1997, Curr Opin Hematol, V4, P53; GARCIABUSTOS JF, 1985, ANTIMICROB AGENTS CH, V27, P791, DOI 10.1128/AAC.27.5.791; GUIJARRO JI, 1995, J BIOL CHEM, V270, P23520, DOI 10.1074/jbc.270.40.23520; GUYER CA, 1986, J BACTERIOL, V168, P775, DOI 10.1128/jb.168.2.775-779.1986; HIGGINS CF, 1986, METHOD ENZYMOL, V125, P365; HIGGINS CF, 1983, J BACTERIOL, V155, P1434, DOI 10.1128/JB.155.3.1434-1438.1983; HOFFMANN JA, 1990, RES IMMUNOL, V141, P910, DOI 10.1016/0923-2494(90)90192-2; HOFFMANN JA, 1995, CURR OPIN IMMUNOL, V7, P4, DOI 10.1016/0952-7915(95)80022-0; HOLTMARK D, 1993, TRENDS GENET, V9, P178; JACKSON MB, 1976, J BIOL CHEM, V251, P5300; JONES DE, 1992, J BIOL CHEM, V267, P23216; KLEINKAUF H, 1987, ANNU REV MICROBIOL, V41, P259, DOI 10.1146/annurev.mi.41.100187.001355; KONISKY J, 1982, ANNU REV MICROBIOL, V36, P125, DOI 10.1146/annurev.mi.36.100182.001013; LEE JY, 1989, P NATL ACAD SCI USA, V86, P9159, DOI 10.1073/pnas.86.23.9159; LEHRER RI, 1993, ANNU REV IMMUNOL, V11, P105, DOI 10.1146/annurev.iy.11.040193.000541; LEHRER RI, 1989, J CLIN INVEST, V84, P553, DOI 10.1172/JCI114198; LEHRER RI, 1991, CELL, V64, P229, DOI 10.1016/0092-8674(91)90632-9; Linton KJ, 1998, MOL MICROBIOL, V28, P5, DOI 10.1046/j.1365-2958.1998.00764.x; LUGTENBERG B, 1983, BIOCHIM BIOPHYS ACTA, V737, P51, DOI 10.1016/0304-4157(83)90014-X; MARTIN JF, 1989, ANNU REV MICROBIOL, V43, P173, DOI 10.1146/annurev.micro.43.1.173; MILLER SI, 1990, INFECT IMMUN, V58, P3706, DOI 10.1128/IAI.58.11.3706-3710.1990; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; OHTA M, 1992, ANTIMICROB AGENTS CH, V36, P1460, DOI 10.1128/AAC.36.7.1460; OKADA M, 1985, J BIOL CHEM, V260, P7174; OPPENHEIM FG, 1988, J BIOL CHEM, V263, P7472; ROMEO D, 1988, J BIOL CHEM, V263, P9573; Russell A.D., 1990, UNDERSTANDING ANTIBA; SCHONWETTER BS, 1995, SCIENCE, V267, P1645, DOI 10.1126/science.7886453; Schulz G.D., 1984, PRINCIPLES PROTEIN S; SELSTED ME, 1993, J BIOL CHEM, V268, P6641; SELSTED ME, 1992, J BIOL CHEM, V267, P4292; SELSTED ME, 1992, J CELL BIOL, V118, P929, DOI 10.1083/jcb.118.4.929; Shi JH, 1996, ANTIMICROB AGENTS CH, V40, P115, DOI 10.1128/AAC.40.1.115; Singh PK, 1998, P NATL ACAD SCI USA, V95, P14961, DOI 10.1073/pnas.95.25.14961; SKERLAVAJ B, 1990, INFECT IMMUN, V58, P3724, DOI 10.1128/IAI.58.11.3724-3730.1990; Taguchi S, 1996, APPL ENVIRON MICROB, V62, P4652, DOI 10.1128/AEM.62.12.4652-4655.1996; TAME JRH, 1994, SCIENCE, V264, P1578, DOI 10.1126/science.8202710; VAARA M, 1981, FEBS LETT, V129, P145, DOI 10.1016/0014-5793(81)80777-6; VILJANEN P, 1988, INFECT IMMUN, V56, P2324, DOI 10.1128/IAI.56.9.2324-2329.1988; Vunnam S, 1997, J PEPT RES, V49, P59; WADE D, 1990, P NATL ACAD SCI USA, V87, P4761, DOI 10.1073/pnas.87.12.4761; WOOD JM, 1988, J MEMBRANE BIOL, V106, P183, DOI 10.1007/BF01872157	75	117	128	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32555	32564		10.1074/jbc.274.46.32555	http://dx.doi.org/10.1074/jbc.274.46.32555			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551808	hybrid			2022-12-27	WOS:000083623000008
J	Ghosh, N; Piskurich, JF; Wright, G; Hassani, K; Ting, JPY; Wright, KL				Ghosh, N; Piskurich, JF; Wright, G; Hassani, K; Ting, JPY; Wright, KL			A novel element and a TEF-2-like element activate the major histocompatibility complex class II transactivator in B-lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOVIRUS DNA-REPLICATION; NUCLEAR FACTOR-I; HLA-DRA GENE; INTERFERON-GAMMA; TRANSCRIPTION FACTORS; INDUCIBLE EXPRESSION; INVIVO FOOTPRINT; CELL DEVELOPMENT; BINDING PROTEIN; SV40 ENHANCER	Major histocompatibility complex (MHC) class II molecules play a central role in immune responses, and transcription of this family of genes requires the MHC class II transactivator (CIITA). CIITA has four promoters, which are transcribed in a tissue-specific manner. CIITA promoter III is constitutively active in mature B-lymphocytes. This report now describes the minimal 319-base pair promoter region necessary for maximal transcriptional activity in B-lymphocytes. Ultratiolet light and dimethylsulfate in vivo genomic footprinting analyses reveal five occupied DNA sequence elements present in intact B-lymphocytes, Functional analysis of these elements using promoter deletions and site-specific mutations demonstrates that at least two of the sites occupied in vivo are critical for transcriptional activity. In vitro protein/DNA analysis suggests that one of the sites is a TEF-2-like element and the other is occupied by a novel transcription activator. In addition, nuclear factor-1 associates with the promoter both in vivo and in vitro. In myeloma cell lines, loss of CIITA transcription correlates with a completely unoccupied CIITA promoter III. These findings suggest that CIITA transcription in B-lymphocytes is activated through at least two strong promoter elements, while loss of expression in myeloma cells is mediated through changes in promoter assembly.	Univ S Florida, Coll Med, Dept Biochem & Mol Biol, H Lee Moffitt Canc Ctr, Tampa, FL 33612 USA; Univ N Carolina, Dept Microbiol Immunol, Chapel Hill, NC 27599 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; University of North Carolina; University of North Carolina Chapel Hill	Wright, KL (corresponding author), Univ S Florida, Coll Med, Dept Biochem & Mol Biol, H Lee Moffitt Canc Ctr, 12902 Bruce B Downs Blvd, Tampa, FL 33612 USA.	wrightkl@moffitt.usf.edu			NCI NIH HHS [CA80990] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080990] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENACERRAF B, 1981, SCIENCE, V212, P1229, DOI 10.1126/science.6165083; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHANG CH, 1994, J EXP MED, V180, P1367, DOI 10.1084/jem.180.4.1367; Chang CH, 1996, IMMUNITY, V4, P167, DOI 10.1016/S1074-7613(00)80681-0; CHIN KC, 1994, IMMUNITY, V1, P687, DOI 10.1016/1074-7613(94)90039-6; Creaser PC, 1996, NUCLEIC ACIDS RES, V24, P2597, DOI 10.1093/nar/24.13.2597; Crossley M, 1996, MOL CELL BIOL, V16, P1695; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; DELLABONA P, 1989, J IMMUNOL, V142, P2902; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EICHBAUM QG, 1994, J EXP MED, V179, P1985, DOI 10.1084/jem.179.6.1985; Frasca L, 1998, CRIT REV IMMUNOL, V18, P569, DOI 10.1615/CritRevImmunol.v18.i6.50; Gao J, 1999, J VIROL, V73, P1411, DOI 10.1128/JVI.73.2.1411-1418.1999; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; HALPER J, 1978, J IMMUNOL, V120, P1480; Heinemeyer T, 1999, NUCLEIC ACIDS RES, V27, P318, DOI 10.1093/nar/27.1.318; Henderson A, 1998, ANNU REV IMMUNOL, V16, P163, DOI 10.1146/annurev.immunol.16.1.163; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; LATRON F, 1988, P NATL ACAD SCI USA, V85, P2229, DOI 10.1073/pnas.85.7.2229; LEEGWATER PAJ, 1985, EMBO J, V4, P1515, DOI 10.1002/j.1460-2075.1985.tb03811.x; Lennon AM, 1997, IMMUNOGENETICS, V45, P266, DOI 10.1007/s002510050202; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; MERCURIO F, 1989, EMBO J, V8, P1455, DOI 10.1002/j.1460-2075.1989.tb03528.x; MIKI N, 1992, J IMMUNOL, V149, P801; MIYAGOE Y, 1994, J BIOL CHEM, V269, P8268; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; Muhlethaler-Mottet A, 1998, IMMUNITY, V8, P157, DOI 10.1016/S1074-7613(00)80468-9; MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851; NAGATA K, 1982, P NATL ACAD SCI-BIOL, V79, P6438, DOI 10.1073/pnas.79.21.6438; PFEIFER GP, 1992, MOL CELL BIOL, V12, P1798, DOI 10.1128/MCB.12.4.1798; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; Pfeifer GP, 1997, METHODS, V11, P189, DOI 10.1006/meth.1996.0405; Piskurich JF, 1998, J IMMUNOL, V160, P233; Piskurich JF, 1999, MOL CELL BIOL, V19, P431; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; SILACCI P, 1994, J EXP MED, V180, P1329, DOI 10.1084/jem.180.4.1329; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; TARLINTON D, 1993, INT IMMUNOL, V5, P1629, DOI 10.1093/intimm/5.12.1629; TING JPY, 1993, CURR OPIN IMMUNOL, V5, P8, DOI 10.1016/0952-7915(93)90074-3; TORNALETTI S, 1995, J MOL BIOL, V249, P714, DOI 10.1006/jmbi.1995.0331; VILEN BJ, 1992, J BIOL CHEM, V267, P23728; Williams GS, 1998, INT IMMUNOL, V10, P1957, DOI 10.1093/intimm/10.12.1957; WRIGHT KL, 1992, P NATL ACAD SCI USA, V89, P7601, DOI 10.1073/pnas.89.16.7601; WRIGHT KL, 1992, BIOCHEMISTRY-US, V31, P2812, DOI 10.1021/bi00125a023; Yi Q, 1997, BLOOD, V90, P1960, DOI 10.1182/blood.V90.5.1960	49	48	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32342	32350		10.1074/jbc.274.45.32342	http://dx.doi.org/10.1074/jbc.274.45.32342			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542275	hybrid, Green Published			2022-12-27	WOS:000083532100083
J	Ikeda, K; Emoto, N; Raharjo, SB; Nurhantari, Y; Saiki, K; Yokoyama, M; Matsuo, M				Ikeda, K; Emoto, N; Raharjo, SB; Nurhantari, Y; Saiki, K; Yokoyama, M; Matsuo, M			Molecular identification and characterization of novel membrane-bound metalloprotease, the soluble secreted form of which hydrolyzes a variety of vasoactive peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-CONVERTING ENZYME; NEUTRAL ENDOPEPTIDASE; EXPRESSION; PHARMACOLOGY; PROTEIN; CELLS; GENE; KELL; PEX	One class of zinc metalloproteases, represented by neutral endopeptidase 24.11 and endothelin-converting enzyme, has been shown to be involved in proteolytic activation or inactivation of many regulatory peptides. Here, we report molecular cloning and characterization of a novel member of this type II membrane-bound metalloprotease family, termed soluble secreted endopeptidase (SEP). Alternative splicing results in the generation of another transcript, SEPDelta, which lacks a 69-base pair nucleotide segment following the transmembrane helix, Both SEP and SEPDelta mRNA are detected in all mouse tissues examined. Transfection of an SEP cDNA expression construct resulted in the expression of the membrane-bound form of SEP in the early secretory pathway as well as the soluble secreted form of the enzyme in the culture medium. In contrast, transfection of the SEPDelta cDNA only results in the expression of the membrane-bound form. In vitro enzymological analysis of the recombinant soluble form of SEP demonstrated that it hydrolyzes a variety of vasoactive peptides, including endothelin-1, atrial natriuretic peptide, and angiotensin I. This activity of SEP was inhibited by phosphoramidon and the neutral endopeptidase 24.11 specific inhibitor thiorphan, but it was only partially inhibited by the endothelin-converting enzyme specific inhibitor FR901533. These findings suggest that SEP is a novel metalloprotease that possesses a broad substrate specificity and that it may be involved in the metabolism of biologically active peptides intracellulary as well as extracellularly.	Kobe Univ, Sch Med, Div Genet, Int Ctr Med Res, Kobe, Hyogo 6500017, Japan; Kobe Univ, Sch Med, Dept Internal Med 1, Kobe, Hyogo 6500017, Japan; Kobe Pharmaceut Univ, Kobe, Hyogo 6588558, Japan	Kobe University; Kobe University; Kobe Pharmaceutical University	Emoto, N (corresponding author), Kobe Univ, Sch Med, Div Genet, Int Ctr Med Res, 7-5-1 Kusunoki, Kobe, Hyogo 6500017, Japan.			Nurhantari, Yudha/0000-0003-1200-2014; ikeda, Koji/0000-0002-9972-7255; Emoto, Noriaki/0000-0001-6673-2616; raharjo, sunu budhi/0000-0001-5749-8231				Ahn K, 1998, ARCH BIOCHEM BIOPHYS, V359, P258, DOI 10.1006/abbi.1998.0913; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; EHLERS MRW, 1991, P NATL ACAD SCI USA, V88, P1009, DOI 10.1073/pnas.88.3.1009; Emoto N, 1999, J BIOL CHEM, V274, P1509, DOI 10.1074/jbc.274.3.1509; EMOTO N, 1995, J BIOL CHEM, V270, P1526; FRANCIS F, 1995, NAT GENET, V11, P130, DOI 10.1038/ng1095-130; HOOPER NM, 1994, FEBS LETT, V354, P1, DOI 10.1016/0014-5793(94)01079-X; HOOPER NM, 1991, INT J BIOCHEM, V23, P641, DOI 10.1016/0020-711X(91)90032-I; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Johnson GD, 1999, J BIOL CHEM, V274, P4053, DOI 10.1074/jbc.274.7.4053; Korth P, 1999, J HISTOCHEM CYTOCHEM, V47, P447, DOI 10.1177/002215549904700403; LEE S, 1991, P NATL ACAD SCI USA, V88, P6353, DOI 10.1073/pnas.88.14.6353; LU B, 1995, J EXP MED, V181, P2271, DOI 10.1084/jem.181.6.2271; Lu B, 1997, NAT MED, V3, P904, DOI 10.1038/nm0897-904; Ramaraj P, 1998, J CLIN INVEST, V102, P371, DOI 10.1172/JCI3545; RAMCHANDRAN R, 1994, J BIOL CHEM, V269, P2125; ROQUES BP, 1993, PHARMACOL REV, V45, P87; SEN I, 1991, J BIOL CHEM, V266, P21985; Shimada K, 1996, BIOCHEM J, V315, P863, DOI 10.1042/bj3150863; TSURUMI Y, 1994, J ANTIBIOT, V47, P619, DOI 10.7164/antibiotics.47.619; Turner AJ, 1997, FASEB J, V11, P355, DOI 10.1096/fasebj.11.5.9141502; Turner AJ, 1996, BIOCHEM PHARMACOL, V51, P91, DOI 10.1016/0006-2952(95)02036-5; Turner AJ, 1998, TRENDS PHARMACOL SCI, V19, P483, DOI 10.1016/S0165-6147(98)01251-6; Valdenaire O, 1999, MOL BRAIN RES, V64, P211, DOI 10.1016/S0169-328X(98)00321-0; VIJAYARAGHAVAN J, 1990, J BIOL CHEM, V265, P14150; WEI L, 1991, J BIOL CHEM, V266, P5540; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; Yanagisawa H, 1998, DEVELOPMENT, V125, P825; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YANAGISAWA M, 1994, CIRCULATION, V89, P1320, DOI 10.1161/01.CIR.89.3.1320	30	94	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32469	32477		10.1074/jbc.274.45.32469	http://dx.doi.org/10.1074/jbc.274.45.32469			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542292	hybrid			2022-12-27	WOS:000083532100100
J	Pilger, BD; Perozzo, R; Alber, F; Wurth, C; Folkers, G; Scapozza, L				Pilger, BD; Perozzo, R; Alber, F; Wurth, C; Folkers, G; Scapozza, L			Substrate diversity of herpes simplex virus thymidine kinase - Impact of the kinematics of the enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; THYMIDYLATE KINASE; ADENYLATE KINASE; GENE-THERAPY; AZT ACTIVATION; BINDING-SITE; TYPE-1; ACYCLOVIR; SEQUENCE; RESISTANT	Herpes simplex virus type 1 (HSV 1) thymidine kinase (TK) exhibits an extensive substrate diversity for nucleobases and sugar moieties, in contrast to other TKs, This substrate diversity is the crucial molecular basis of selective antiviral and suicide gene therapy. The mechanisms of substrate binding of HSV I TK were studied by means of site-directed mutagenesis combined with isothermal calorimetric measurements and guided by theoretical calculations and sequence comparison, The results show the link between the exceptionally broad substrate diversity of HSV I TH and the presence of structural features such as the residue triad His-58/ Met-128/Tyr-172. The mutation of Met-128 into a Phe and the double mutant M128F/Y172F result in mutants that have lost their activity. However, by exchanging His to form the triple mutant H58L/M128F/Y172F, the enzyme regains activity, Strikingly, this triple mutant becomes resistant toward acyclovir. Furthermore, we give evidence for the importance of Glu-225 of the flexible LID region for the catalytic reaction. The data presented give new insights to understand mechanisms ruling substrate diversity and thus are crucial for both the development of new antiviral drugs and engineering of mutant TKs apt to accept novel substrate analogs for gene therapeutic approaches.	Swiss Fed Inst Technol, Dept Pharm, CH-8057 Zurich, Switzerland; Int Sch Adv Studies, I-34014 Trieste, Italy; Ist Nazl Fis Mat, I-34014 Trieste, Italy	ETH Zurich; International School for Advanced Studies (SISSA); Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Padua	Scapozza, L (corresponding author), Swiss Fed Inst Technol, Dept Pharm, Winterthurerstr 190, CH-8057 Zurich, Switzerland.			Folkers, Gerd/0000-0002-3620-705X; Scapozza, Leonardo/0000-0003-1079-648X				ABELE G, 1991, Antiviral Chemistry and Chemotherapy, V2, P163; Alber F, 1998, PROTEINS, V31, P453, DOI 10.1002/(SICI)1097-0134(19980601)31:4<453::AID-PROT11>3.0.CO;2-E; BALASUBRAMANIAM NK, 1990, J GEN VIROL, V71, P2979, DOI 10.1099/0022-1317-71-12-2979; BARETTINO D, 1994, NUCLEIC ACIDS RES, V22, P541, DOI 10.1093/nar/22.3.541; Bonini C, 1997, SCIENCE, V276, P1719, DOI 10.1126/science.276.5319.1719; BRADSHAW HD, 1984, MOL CELL BIOL, V4, P2316, DOI 10.1128/MCB.4.11.2316; BROWN DG, 1995, NAT STRUCT BIOL, V2, P876, DOI 10.1038/nsb1095-876; Caruso M, 1997, VIRUS RES, V52, P133, DOI 10.1016/S0168-1702(97)00124-X; CHEN MS, 1979, J VIROL, V30, P942, DOI 10.1128/JVI.30.3.942-945.1979; CHEN MS, 1978, J BIOL CHEM, V253, P1325; Chen SH, 1998, J VIROL, V72, P6710, DOI 10.1128/JVI.72.8.6710-6715.1998; CHENG YC, 1983, P NATL ACAD SCI-BIOL, V80, P2767, DOI 10.1073/pnas.80.9.2767; Christians FC, 1999, NAT BIOTECHNOL, V17, P259, DOI 10.1038/7003; COEN DM, 1989, P NATL ACAD SCI USA, V86, P4736, DOI 10.1073/pnas.86.12.4736; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; CULVER KW, 1994, HUM GENE THER, V5, P343, DOI 10.1089/hum.1994.5.3-343; DARBY G, 1981, NATURE, V289, P81, DOI 10.1038/289081a0; EFSTATHIOU S, 1989, J GEN VIROL, V70, P869, DOI 10.1099/0022-1317-70-4-869; ELION GB, 1977, P NATL ACAD SCI USA, V74, P5716, DOI 10.1073/pnas.74.12.5716; ENGLUND JA, 1990, ANN INTERN MED, V112, P416, DOI 10.7326/0003-4819-76-3-112-6-416; FETZER J, 1994, PROTEIN EXPRES PURIF, V5, P432, DOI 10.1006/prep.1994.1062; FOLKERS G, 1987, MED SCI RES-BIOCHEM, V15, P1495; FURLONG N. BURR, 1963, ANALYT BIOCHEM, V5, P515; FYFE JA, 1983, MOL PHARMACOL, V24, P316; Gaudreau A, 1998, J INFECT DIS, V178, P297, DOI 10.1086/515626; Gerber S, 1996, BIOCHEM BIOPH RES CO, V225, P263, DOI 10.1006/bbrc.1996.1164; Gustafson EA, 1998, ANTIMICROB AGENTS CH, V42, P2923, DOI 10.1128/AAC.42.11.2923; HALPERN ME, 1984, J VIROL, V50, P733, DOI 10.1128/JVI.50.3.733-738.1984; HARRISON PT, 1991, J GEN VIROL, V72, P2583, DOI 10.1099/0022-1317-72-10-2583; INNIS MA, 1990, PCR PROTOCOLS GUIDE, P177; Jacobson JG, 1998, VIROLOGY, V242, P161, DOI 10.1006/viro.1997.9012; KELLER PM, 1981, BIOCHEM PHARMACOL, V30, P3071, DOI 10.1016/0006-2952(81)90495-0; KOONIN EV, 1992, VIRUS GENES, V6, P187, DOI 10.1007/BF01703067; Kussmann-Gerber S, 1998, EUR J BIOCHEM, V255, P472, DOI 10.1046/j.1432-1327.1998.2550472.x; Kussmann-Gerber S, 1999, NUCLEOS NUCLEOT, V18, P311, DOI 10.1080/15257779908043078; LARDER BA, 1983, J BIOL CHEM, V258, P2027; LARDER BA, 1983, J GEN VIROL, V64, P523, DOI 10.1099/0022-1317-64-3-523; Lavie A, 1997, NAT STRUCT BIOL, V4, P601, DOI 10.1038/nsb0897-601; Lavie A, 1998, P NATL ACAD SCI USA, V95, P14045, DOI 10.1073/pnas.95.24.14045; Lavie A, 1998, BIOCHEMISTRY-US, V37, P3677, DOI 10.1021/bi9720787; LIU QY, 1988, VIROLOGY, V163, P638, DOI 10.1016/0042-6822(88)90308-X; MASSON S, 1993, BIOCHEMISTRY-US, V32, P1025, DOI 10.1021/bi00055a005; Michael M, 1997, Pharm Acta Helv, V72, P139, DOI 10.1016/S0031-6865(97)00006-X; Muller CW, 1996, STRUCTURE, V4, P147, DOI 10.1016/S0969-2126(96)00018-4; MUNIR KM, 1992, J BIOL CHEM, V267, P6584; MUNIR KM, 1994, PROTEIN ENG, V7, P83, DOI 10.1093/protein/7.1.83; ROBERTS GB, 1993, BIOCHEM PHARMACOL, V46, P2209, DOI 10.1016/0006-2952(93)90611-Y; ROBERTSON GR, 1988, NUCLEIC ACIDS RES, V16, P11303, DOI 10.1093/nar/16.23.11303; STEINBERG RA, 1994, ANAL BIOCHEM, V219, P155, DOI 10.1006/abio.1994.1246; Tong XW, 1997, ANTICANCER RES, V17, P811; WILD K, 1995, FEBS LETT, V368, P289, DOI 10.1016/0014-5793(95)00680-8; Wild K, 1997, PROTEIN SCI, V6, P2097; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	53	70	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31967	31973		10.1074/jbc.274.45.31967	http://dx.doi.org/10.1074/jbc.274.45.31967			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542226	hybrid			2022-12-27	WOS:000083532100034
J	Ping, DS; Boekhoudt, G; Boss, JM				Ping, DS; Boekhoudt, G; Boss, JM			trans-retinoic acid blocks platelet-derived growth factor-BB-induced expression of the murine monocyte chemoattractant-1 gene by blocking the assembly of a promoter proximal Sp1 binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; OSTEOBLASTIC MC3T3-E1 CELLS; MESSENGER-RNA EXPRESSION; BARE-LYMPHOCYTE-SYNDROME; CLASS-II GENES; PROTEIN-1 GENE; ALLERGIC INFLAMMATION; CHEMOTACTIC PROTEIN-1; HISTONE ACETYLATION	Proper regulation of the CC chemokine MCP-1 (monocyte chemoattractant protein-1) is important for normal inflammatory responses. MCP-1 is regulated by a wide variety of agents, including platelet-derived growth factor-BB (PDGF-BB) and tumor necrosis factor-alpha (TNF). Using both in vivo and in vitro assays, the elements required for expression between these two cytokines were compared. In vivo genomic footprinting showed that PDGF-BB induction occurred through the occupancy of the proximal regulatory region, and unlike TNF induction, no changes in the NF-kappa B binding, distal regulatory region occurred. Treatment of cells with trans-retinoic acid, an inhibitor of PDGF-BB activity, resulted in a 50% reduction in PDGF-BB-mediated induction and a concomitant block in the assembly of the proximal regulatory region. trans-Retinoic acid had minimal effect on TNF induction or promoter occupancy. An inhibitor of histone deacetylation was found to stimulate expression of MCP-1 in a manner that correlated with increased accessibility to the proximal regulatory region, These results show that the mechanisms of PDGF-BB and TNF activation of MCP-1 are distinct, although they both require the proximal regulatory region Sp1 binding site. The results also suggest that part of the mechanism used by both of these cytokines involves a process that regulates transcription factor access to the regulatory regions.	Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA	Emory University	Boss, JM (corresponding author), Emory Univ, Sch Med, Dept Microbiol & Immunol, 1510 Clifton Rd,Rm 3131, Atlanta, GA 30322 USA.				NATIONAL CANCER INSTITUTE [R01CA074271] Funding Source: NIH RePORTER; NCI NIH HHS [CA74271] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Bogdanov VY, 1998, J BIOL CHEM, V273, P24932, DOI 10.1074/jbc.273.38.24932; BRACH MA, 1992, MOL PHARMACOL, V42, P63; Brown Z, 1996, J LEUKOCYTE BIOL, V59, P75, DOI 10.1002/jlb.59.1.75; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COLOTTA F, 1994, AM J PATHOL, V144, P975; Darnay BG, 1997, J LEUKOCYTE BIOL, V61, P559, DOI 10.1002/jlb.61.5.559; Faller DV, 1997, J CELL PHYSIOL, V172, P240, DOI 10.1002/(SICI)1097-4652(199708)172:2<240::AID-JCP11>3.3.CO;2-T; FRAZIERJESSEN MR, 1995, J IMMUNOL, V154, P1838; FRETER RR, 1992, MOL CELL BIOL, V12, P5288, DOI 10.1128/MCB.12.12.5288; Freter RR, 1996, J BIOL CHEM, V271, P17417, DOI 10.1074/jbc.271.29.17417; FRETER RR, 1995, MOL CELL BIOL, V15, P315, DOI 10.1128/MCB.15.1.315; Gibran NS, 1997, J SURG RES, V70, P1, DOI 10.1006/jsre.1997.5017; Glabinski AR, 1996, J IMMUNOL, V156, P4363; HANAZAWA S, 1994, J BIOL CHEM, V269, P21379; HANAZAWA S, 1993, J BIOL CHEM, V268, P9526; HASEGAWA SL, 1993, J IMMUNOL, V150, P1781; HASEGAWA SL, 1991, NUCLEIC ACIDS RES, V19, P1243, DOI 10.1093/nar/19.6.1243; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; Howard OMZ, 1996, TRENDS BIOTECHNOL, V14, P46, DOI 10.1016/0167-7799(96)80920-6; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; Izumi S, 1997, EUR J IMMUNOL, V27, P816, DOI 10.1002/eji.1830270404; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; KARA CJ, 1991, SCIENCE, V252, P709, DOI 10.1126/science.1902592; KAWAHARA RS, 1991, J BIOL CHEM, V266, P13261; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Lloyd CM, 1997, J LEUKOCYTE BIOL, V62, P676, DOI 10.1002/jlb.62.5.676; LouisPlence P, 1997, J IMMUNOL, V159, P3899; Luster AD, 1997, J LEUKOCYTE BIOL, V62, P620, DOI 10.1002/jlb.62.5.620; Martin T, 1997, EUR J IMMUNOL, V27, P1091, DOI 10.1002/eji.1830270508; MORENO CS, 1995, J IMMUNOL, V155, P4313; Moreno CS, 1999, IMMUNITY, V10, P143, DOI 10.1016/S1074-7613(00)80015-1; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MUELLER PR, 1994, CURRENT PROTOCOLS MO; Ping DS, 1999, J IMMUNOL, V162, P727; Ping DS, 1996, IMMUNITY, V4, P455, DOI 10.1016/S1074-7613(00)80412-4; Ransohoff Richard M., 1996, Cytokine and Growth Factor Reviews, V7, P35, DOI 10.1016/1359-6101(96)00003-2; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738; SCHWARTZ CJ, 1991, CLIN CARDIOL, V14, P11; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; Shyy JYJ, 1995, J BIOMECH, V28, P1451, DOI 10.1016/0021-9290(95)00093-3; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Sozzani S, 1997, J LEUKOCYTE BIOL, V62, P30, DOI 10.1002/jlb.62.1.30; SUN Y, 1993, GENE, V131, P301, DOI 10.1016/0378-1119(93)90311-P; TAKESHITA A, 1995, J IMMUNOL, V155, P419; TIMMERS HT, 1990, NUCLEIC ACIDS RES, V18, P23, DOI 10.1093/nar/18.1.23; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; UEDA A, 1994, J IMMUNOL, V153, P2052; Ueda A, 1997, J BIOL CHEM, V272, P31092, DOI 10.1074/jbc.272.49.31092; Valente AJ, 1998, J IMMUNOL, V161, P3719; VanLint C, 1996, EMBO J, V15, P1112, DOI 10.1002/j.1460-2075.1996.tb00449.x; Volejnikova S, 1997, AM J PATHOL, V150, P1711; Weiss L, 1997, J INFECT DIS, V176, P1621, DOI 10.1086/517341; Wong JM, 1998, EMBO J, V17, P520, DOI 10.1093/emboj/17.2.520; Zhou ZHL, 1998, J IMMUNOL, V160, P3908	61	26	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31909	31916		10.1074/jbc.274.45.31909	http://dx.doi.org/10.1074/jbc.274.45.31909			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542218	hybrid			2022-12-27	WOS:000083532100026
J	Aplin, AE; Short, SM; Juliano, RL				Aplin, AE; Short, SM; Juliano, RL			Anchorage-dependent regulation of the mitogen-activated protein kinase cascade by growth factors is supported by a variety of integrin alpha chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; FOCAL ADHESION KINASE; MAP KINASE; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; C-SRC; EXPRESSION; D1; RAS; PHOSPHORYLATION	Integrin cooperation with growth factor receptors to enable permissive signaling to the mitogen-activated protein (MAP) kinase pathway has important implications for cell proliferation, differentiation, and survival. Here we have sought to determine whether anchorage regulation of the MAP kinase pathway is specific to the alpha chain subunit of the integrins employed during adhesion. Human umbilical vein endothelial cells (HUVECs) anchored via endogenous alpha(2), alpha(3), or alpha(5) integrin subunits or NIH3T3 fibroblast cells lines anchored via ectopically expressed human integrin alpha(2) or alpha(5) subunits displayed comparable MAP kinase activation upon growth factor stimulation, regardless of the integrin alpha chain employed. In contrast, when either cell type was maintained in suspension, growth factor treatment inefficiently activated the MAP kinase pathway, The integrin-mediated enhancement of MAP kinase activation by growth factor correlated with the tyrosine phosphorylation of focal adhesion kinase but was independent of Shc. These data indicate that integrin modulation of the MAP kinase pathway is supported by a variety of integrin complexes and imply that other pathways may be required for the previously reported alpha chain-specific effects on cell cycle regulation and cell differentiation.	Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Juliano, RL (corresponding author), Univ N Carolina, Sch Med, Dept Pharmacol, CB 7365, Chapel Hill, NC 27599 USA.				NIGMS NIH HHS [GM 26165] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026165] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Aplin AE, 1999, J CELL SCI, V112, P695; Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Farrelly N, 1999, J CELL BIOL, V144, P1337, DOI 10.1083/jcb.144.6.1337; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Huang S, 1998, MOL BIOL CELL, V9, P3179, DOI 10.1091/mbc.9.11.3179; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Le Gall M, 1998, ONCOGENE, V17, P1271, DOI 10.1038/sj.onc.1202057; Lin TH, 1997, J BIOL CHEM, V272, P8849; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Resnitzky D, 1997, MOL CELL BIOL, V17, P5640, DOI 10.1128/MCB.17.9.5640; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; Sastry SK, 1996, J CELL BIOL, V133, P169, DOI 10.1083/jcb.133.1.169; Sastry SK, 1999, J CELL BIOL, V144, P1295, DOI 10.1083/jcb.144.6.1295; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Short SM, 1998, MOL BIOL CELL, V9, P1969, DOI 10.1091/mbc.9.8.1969; TARONE G, 1993, DEVELOPMENT, V117, P1369; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	34	63	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31223	31228		10.1074/jbc.274.44.31223	http://dx.doi.org/10.1074/jbc.274.44.31223			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531317	Green Published, hybrid			2022-12-27	WOS:000083379400021
J	Ausio, J				Ausio, J			Histone H1 and evolution of sperm nuclear basic proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							SPISULA-SOLIDISSIMA; H1-LIKE PROTEIN; CHROMOSOMAL-PROTEINS; COMPLETE SEQUENCE; BIVALVE MOLLUSKS; ENSIS-MINOR; PROTAMINES; MYTILUS; GENE; CHROMATIN		Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 3P6, Canada	University of Victoria	Ausio, J (corresponding author), Univ Victoria, Dept Biochem & Microbiol, POB 3055, Victoria, BC V8W 3P6, Canada.	jausio@uvic.ca						AUSIO J, 1987, BIOCHEMISTRY-US, V26, P975, DOI 10.1021/bi00378a001; AUSIO J, 1988, CELL DIFFER DEV, V23, P175, DOI 10.1016/0045-6039(88)90070-X; AUSIO J, 1982, J BIOL CHEM, V257, P2802; AUSIO J, 1986, COMP BIOCHEM PHYS B, V85, P439, DOI 10.1016/0305-0491(86)90025-8; Ausio J, 1997, J MOL EVOL, V45, P91, DOI 10.1007/PL00006207; AUSIO J, 1987, EUR J BIOCHEM, V165, P363, DOI 10.1111/j.1432-1033.1987.tb11449.x; AUSIO J, 1992, MOL CELL BIOCHEM, V115, P163; AUSIO J, 1992, BIOL BULL, V82, P31; AUSIO J, 1995, ADV SPERMATOZOAL TAX, V166, P447; Ausio J., 1995, ADV SPERMATOZOAL TAX, V166, P501; BANDIERA A, 1995, EUR J BIOCHEM, V233, P744, DOI 10.1111/j.1432-1033.1995.744_3.x; Bloch D.P., 1976, P139; BLOCH DP, 1969, GENETICS, V61, P93; BRIAND G, 1980, FEBS LETT, V112, P147, DOI 10.1016/0014-5793(80)80167-0; CARLOS S, 1993, J BIOL CHEM, V268, P185; CARLOS S, 1993, J BIOL CHEM, V268, P195; COLE RD, 1984, ANAL BIOCHEM, V136, P24, DOI 10.1016/0003-2697(84)90303-8; DOOLITTLE RF, 1994, TRENDS BIOCHEM SCI, V19, P15, DOI 10.1016/0968-0004(94)90167-8; FELIX K, 1960, ADV PROTEIN CHEM, V15, P1; Franzen A., 1987, REPRODUCTION MARINE, V9, P1; GIANCOTTI V, 1992, BIOCHIM BIOPHYS ACTA, V1119, P296, DOI 10.1016/0167-4838(92)90217-2; Hunt JG, 1996, J BIOL CHEM, V271, P23547, DOI 10.1074/jbc.271.38.23547; ISENBERG I, 1978, CELL NUCLEUS, V4, P135; JANKOWSKI JM, 1986, J MOL EVOL, V23, P1, DOI 10.1007/BF02100993; JUTGLAR L, 1991, J BIOL CHEM, V266, P8184; Kasinsky H. E., 1989, HISTONES OTHER BASIC, P73; Kleene KC, 1998, J MOL EVOL, V47, P275, DOI 10.1007/PL00006385; Kossel A, 1884, Z PHYSL CHEM, P511; KOSSEL A, 1896, Z PHYSL CHEM, V22, P176, DOI DOI 10.1515/BCHM2.1897.22.2.176; Kossel A., 1928, PROTAMINES HISTONES; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; MARTINPONTHIEU A, 1991, EUR J BIOCHEM, V195, P611, DOI 10.1111/j.1432-1033.1991.tb15744.x; MIESCHER F, 1870, HOPPESEYLERS MED CHE, V4, P441; Miescher F., 1874, Z F R ANALYTISCHE CH, V7, P376, DOI [10.1002/cber.187400701119, DOI 10.1002/CBER.187400701119, DOI 10.1007/BF01302341]; NEELIN JM, 1968, CAN J BIOCHEM CELL B, V46, P241, DOI 10.1139/o68-035; NIELSEN C, 1995, ANIMAL EVOLUTION, P25; OLIVA R, 1991, PROG NUCLEIC ACID RE, V40, P25; POCCIA D, 1995, ADV SPERMATOZOAL TAX, V166, P475; ROCCHINI C, 1995, FEBS LETT, V363, P37, DOI 10.1016/0014-5793(95)00275-E; ROCCHINI C, 1995, BIOCHEMISTRY-US, V34, P15704, DOI 10.1021/bi00048a015; Rocchini C, 1996, J MOL EVOL, V42, P240, DOI 10.1007/BF02198850; RUDDLE FH, 1994, DEVELOPMENT, P155; SAPERAS N, 1994, J MOL EVOL, V39, P282, DOI 10.1007/BF00160152; SAPERAS N, 1992, COMP BIOCHEM PHYS B, V103, P969, DOI 10.1016/0305-0491(92)90224-F; STRICKLAND WN, 1980, EUR J BIOCHEM, V104, P567, DOI 10.1111/j.1432-1033.1980.tb04460.x; SUBIRANA JA, 1973, BIOCHIM BIOPHYS ACTA, V317, P364, DOI 10.1016/0005-2795(73)90231-6; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TOBITA T, 1983, BIOCHIM BIOPHYS ACTA, V744, P141, DOI 10.1016/0167-4838(83)90083-3; Valcarcel J, 1996, TRENDS BIOCHEM SCI, V21, P296, DOI 10.1016/0968-0004(96)10039-6; van Holde K.E., 1988, CHROMATIN; Watson CE, 1998, J BIOL CHEM, V273, P6157, DOI 10.1074/jbc.273.11.6157; WELLS D, 1991, NUCLEIC ACIDS RES, V19, P2173, DOI 10.1093/nar/19.suppl.2173; WOUTERSTYROU D, 1995, BIOCHEM J, V309, P529, DOI 10.1042/bj3090529; ZALENSKAYA IA, 1980, COMP BIOCHEM PHYS B, V65, P369, DOI 10.1016/0305-0491(80)90028-0; ZALENSKAYA IA, 1980, COMP BIOCHEM PHYS B, V65, P375, DOI 10.1016/0305-0491(80)90029-2; ZUCKERKANDL E, 1994, J MOL EVOL, V39, P661, DOI 10.1007/BF00160412; [No title captured]	57	86	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31115	31118		10.1074/jbc.274.44.31115	http://dx.doi.org/10.1074/jbc.274.44.31115			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531297	hybrid			2022-12-27	WOS:000083379400001
J	Barbosa-Tessmann, IP; Chen, C; Zhong, C; Schuster, SM; Nick, HS; Kilberg, MS				Barbosa-Tessmann, IP; Chen, C; Zhong, C; Schuster, SM; Nick, HS; Kilberg, MS			Activation of the unfolded protein response pathway induces human asparagine synthetase gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; GLUCOSE; ELEMENT; CELLS; IDENTIFICATION; INDUCTION; CHOP	The gene for the amino acid biosynthetic activity asparagine synthetase (AS) is induced by both amino acid and glucose deprivation of cells. The data reported here document that the human AS gene is induced following activation of the Unfolded Response Pathway (UPR), also known as the Endoplasmic Reticulum Stress Response (ERSR) in mammals. Increased AS transcription occurs in response to glucose deprivation, tunicamycin, or azetidine-2-carboxylate, all known to activate the UPR/ERSR pathway. Previously identified ERSR target genes contain multiple copies of a single highly conserved cis-element. In contrast, the human AS gene does not contain the ERSR element, as it has been described for other responsive genes. Instead, AS induction requires an Spl-like sequence, a sequence previously shown to be associated with amino acid control of transcription, and possibly, a third region containing no consensus sequences for known transcription factors. Oligonucleotides covering each of these regions form DNA-protein complexes in vitro, and for some the amount of these complexes is greater when nuclear extracts from glucose-starved cells are tested. These results document that a wider range of metabolic activities are activated by the UPR/ERSR pathway than previously recognized and that genomic elements other than those already described can serve to enhance transcription of specific target genes.	Univ Florida, Coll Med, Dept Biochem & Mol Biol, JHMHC, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Neurosci, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Kilberg, MS (corresponding author), Univ Florida, Coll Med, Dept Biochem & Mol Biol, JHMHC, Box 100245, Gainesville, FL 32610 USA.		Barbosa-Tessmann, Ione Parra/H-3856-2012	Barbosa-Tessmann, Ione Parra/0000-0001-9860-378X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052064] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-52064] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARFIN SM, 1977, P NATL ACAD SCI USA, V74, P2367, DOI 10.1073/pnas.74.6.2367; Barbosa-Tessmann IP, 1999, BIOCHEM J, V339, P151, DOI 10.1042/0264-6021:3390151; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; BUSSOLATI O, 1995, EXP CELL RES, V220, P283, DOI 10.1006/excr.1995.1317; COUREY AJ, 1992, TRANSCRIPTIONAL REGU, P743; GRECO A, 1989, MOL CELL BIOL, V9, P2350, DOI 10.1128/MCB.9.6.2350; GUERRINI L, 1993, MOL CELL BIOL, V13, P3202, DOI 10.1128/MCB.13.6.3202; HAMER D H, 1982, Journal of Molecular and Applied Genetics, V1, P273; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hutson RG, 1997, AM J PHYSIOL-CELL PH, V272, pC1691, DOI 10.1152/ajpcell.1997.272.5.C1691; KERRIGAN LA, 1994, CURRENT PROTOCOLS MO; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; Li WW, 1997, MOL CELL BIOL, V17, P54, DOI 10.1128/MCB.17.1.54; Mori K, 1998, J BIOL CHEM, V273, P9912, DOI 10.1074/jbc.273.16.9912; PATTERSO.MK, 1970, CANCER RES, V30, P1064; Richards NGJ, 1998, ADV ENZYMOL RAMB, V72, P145; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; Schafer D, 1997, FEBS LETT, V417, P325, DOI 10.1016/S0014-5793(97)01314-8; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; Shamu CE, 1998, CURR BIOL, V8, pR121, DOI 10.1016/S0960-9822(98)70986-8; Sidrauski C, 1998, TRENDS CELL BIOL, V8, P245, DOI 10.1016/S0962-8924(98)01267-7; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; STORY MD, 1993, CANCER CHEMOTH PHARM, V32, P129, DOI 10.1007/BF00685615; Wang XZ, 1998, EMBO J, V17, P3619, DOI 10.1093/emboj/17.13.3619; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	27	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31139	31144		10.1074/jbc.274.44.31139	http://dx.doi.org/10.1074/jbc.274.44.31139			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531303	hybrid			2022-12-27	WOS:000083379400007
J	English, JM; Pearson, G; Hockenberry, T; Shivakumar, L; White, MA; Cobb, MH				English, JM; Pearson, G; Hockenberry, T; Shivakumar, L; White, MA; Cobb, MH			Contribution of the ERK5/MEK5 pathway to Ras/Raf signaling and growth control	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RAS TRANSFORMATION; EXPRESSION; EFFECTORS; SCAFFOLD; CASCADE	The activity of the catalytic domain of the orphan MAP kinase ERK5 is increased by Ras but not Raf-l in cells, which suggests that ERK5 might mediate Raf-independent signaling by Bas. We found that Raf-1 does contribute to Ras activation of ERK5 but in a manner that does not; correlate with Raf-l catalytic activity. A clue to the mechanism of action of Raf-1 on ERK5 comes from the observation that endogenous Raf-l binds to endogenous ERK5, suggesting the involvement of regulatory protein-protein interactions. This interaction is specific because Raf-l binds only to ERK5 and not ERK2 or SAPK. Finally, we demonstrate the ERK5/MEK5 pathway is required for Raf-dependent cellular transformation and that a constitutively active form of MEK5, MEK5DD, synergizes with Raf to transform NIH 3T3 cells. These observations suggest that ERK5 plays a large role in Raf-l-mediated signal transduction.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, Dallas, TX 75235 USA; Schering Plough Corp, Res Inst, Dept Biol Res Oncol, Kenilworth, NJ 07033 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Merck & Company; Schering Plough Corporation	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.			Cobb, Melanie/0000-0003-0833-5473	NCI NIH HHS [CA71443, T32-CA66187] Funding Source: Medline; NIDDK NIH HHS [DK34128] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071443, T32CA066187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034128, R37DK034128] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHOI KY, 1994, CELL, V78, P499; English JM, 1998, J BIOL CHEM, V273, P3854, DOI 10.1074/jbc.273.7.3854; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Mineo C, 1997, J BIOL CHEM, V272, P10345; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; Wang S, 1998, MOL CELL BIOL, V18, P7487, DOI 10.1128/MCB.18.12.7487; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	19	106	108	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31588	31592		10.1074/jbc.274.44.31588	http://dx.doi.org/10.1074/jbc.274.44.31588			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531364	hybrid			2022-12-27	WOS:000083379400068
J	Jacob, RF; Cenedella, RJ; Mason, RP				Jacob, RF; Cenedella, RJ; Mason, RP			Direct evidence for immiscible cholesterol domains in human ocular lens fiber cell plasma membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATIVE MEMBRANE; SPHINGOMYELIN; BILAYERS; PROTEIN; LIPIDS; PHOSPHATIDYLCHOLINE; CHROMATOGRAPHY; PHOSPHOLIPIDS	The molecular structure of human ocular lens fiber cell plasma membranes was examined directly using small angle x-ray diffraction approaches. A distinct biochemical feature of these membranes is their high relative levels of free cholesterol; the mole ratio of cholesterol to phospholipid (C/P) measured in these membranes ranges from 1 to 4. The organization of cholesterol in this membrane system is not well understood however. In this study, the structure of plasma membrane samples isolated from nuclear (3.3 C/P) and cortical (2.4 C/P) regions of human lenses was evaluated with x-ray diffraction approaches. Meridional diffraction patterns obtained from the oriented membrane samples demonstrated the presence of an immiscible cholesterol domain with a unit cell periodicity of 34.0 Angstrom consistent with a cholesterol monohydrate bilayer, The dimensions of the sterol-rich domains remained constant over a broad range of temperatures (5-20 degrees C) and relative humidity levels (31-97%). In contrast, dimensions of the surrounding sterol-poor phase were significantly affected by experimental conditions. Similar structural features were observed in membranes reconstituted from fiber cell plasma membrane lipid extracts. The results of this study indicate that the lens fiber cell plasma membrane is a complex structure consisting of separate sterol-rich and -poor domains. Maintenance of these separate domains may be required for the normal function of lens fiber cell plasma membrane and may interfere with the cataractogenic aggregation of soluble lens proteins at the membrane surface.	Med Coll Penn & Hahnemann Univ, Sch Med, Cardiovasc & Pulm Res Inst, Membrane Biophys Lab,Neurosci Grad Program, Pittsburgh, PA 15212 USA; Kirksville Coll Osteopath Med, Dept Biochem, Kirksville, MO 63501 USA	Drexel University	Mason, RP (corresponding author), Allegheny Gen Hosp, 320 East North Ave,2-ST, Pittsburgh, PA 15212 USA.				NEI NIH HHS [EY02568] Funding Source: Medline; NHLBI NIH HHS [HL22633] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY002568] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022633] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASSNETT S, 1995, INVEST OPHTH VIS SCI, V36, P1793; BITTMAN R, 1993, CHOLESTEROL MEMBRANE, P46; BLOEMENDAL H, 1972, Cell Differentiation, V1, P91, DOI 10.1016/0045-6039(72)90032-2; Borchman D, 1996, EXP EYE RES, V62, P191, DOI 10.1006/exer.1996.0023; BROEKHUYSE RM, 1974, EXP EYE RES, V19, P297, DOI 10.1016/0014-4835(74)90148-1; BROEKHUYSE RM, 1976, EXP EYE RES, V22, P653, DOI 10.1016/0014-4835(76)90010-5; BROEKHUYSE RM, 1977, LIPID METABOLISM MAM, V2, P145; Byrdwell WC, 1997, OPHTHALMIC RES, V29, P191; BYRDWELL WC, 1994, INVEST OPHTH VIS SCI, V35, P4333; CALHOUN WI, 1979, BIOCHEMISTRY-US, V18, P1717, DOI 10.1021/bi00576a013; CENEDELLA RJ, 1979, EXP EYE RES, V28, P673, DOI 10.1016/0014-4835(79)90068-X; CENEDELLA RJ, 1992, CURR EYE RES, V11, P801, DOI 10.3109/02713689209000753; CENEDELLA RJ, 1982, LIPIDS, V17, P443, DOI 10.1007/BF02535224; CHANDRASEKHER G, 1995, EXP EYE RES, V60, P707, DOI 10.1016/S0014-4835(05)80012-0; CRAVEN BM, 1976, NATURE, V260, P727, DOI 10.1038/260727a0; DEMEL RA, 1977, BIOCHIM BIOPHYS ACTA, V465, P1, DOI 10.1016/0005-2736(77)90350-9; EMMELOT P, 1977, MAMMALIAN CELL MEMBR, V2, P1; ENGELMAN DM, 1972, J BIOL CHEM, V247, P3694; FLESCHNER CR, 1991, J LIPID RES, V32, P45; GERSON RJ, 1990, EXP EYE RES, V50, P65, DOI 10.1016/0014-4835(90)90012-J; HARRIS JS, 1995, BIOCHEMISTRY-US, V34, P3851, DOI 10.1021/bi00011a043; Houslay MD, 1982, DYNAMICS BIOL MEMBRA, P71; KIRBY TJ, 1962, ARCH OPHTHALMOL-CHIC, V68, P486; LANGE Y, 1983, J BIOL CHEM, V258, P5130; LAUGHLIN RC, 1962, J AM MED ASS, V182; LEES MB, 1972, ANAL BIOCHEM, V47, P184, DOI 10.1016/0003-2697(72)90291-6; LI LK, 1985, J LIPID RES, V26, P600; LI LK, 1987, BIOCHIM BIOPHYS ACTA, V917, P112, DOI 10.1016/0005-2760(87)90291-8; LUNDKATZ S, 1988, BIOCHEMISTRY-US, V27, P3416, DOI 10.1021/bi00409a044; MASON RP, 1992, NEUROBIOL AGING, V13, P413, DOI 10.1016/0197-4580(92)90116-F; MCINTOSH TJ, 1992, BIOCHEMISTRY-US, V31, P2020, DOI 10.1021/bi00122a018; MULDERS SM, 1995, J BIOL CHEM, V270, P9010, DOI 10.1074/jbc.270.15.9010; POLLET S, 1978, J LIPID RES, V19, P916; Rafferty N. S., 1985, OCULAR LENS STRUCTUR, P1; RICE PA, 1989, P NATL ACAD SCI USA, V86, P6445, DOI 10.1073/pnas.86.17.6445; RUOCCO MJ, 1984, BIOPHYS J, V46, P695, DOI 10.1016/S0006-3495(84)84068-0; RUSSELL P, 1981, EXP EYE RES, V32, P511, DOI 10.1016/S0014-4835(81)80030-9; SLOTTE JP, 1995, BBA-BIOMEMBRANES, V1235, P419, DOI 10.1016/0005-2736(95)80031-A; SLOTTE JP, 1995, BBA-BIOMEMBRANES, V1237, P127, DOI 10.1016/0005-2736(95)00096-L; SPECTOR A, 1984, INVEST OPHTH VIS SCI, V25, P130; SUBRAMANIAM S, 1987, J PHYS CHEM-US, V91, P1715, DOI 10.1021/j100291a010; Tang DX, 1998, EXP EYE RES, V66, P559, DOI 10.1006/exer.1997.0467; Tulenko TN, 1998, J LIPID RES, V39, P947; WATTENBERG BW, 1983, J BIOL CHEM, V258, P2284; ZELENKA PS, 1984, CURR EYE RES, V3, P1337, DOI 10.3109/02713688409007421	45	80	80	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31613	31618		10.1074/jbc.274.44.31613	http://dx.doi.org/10.1074/jbc.274.44.31613			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531368	hybrid			2022-12-27	WOS:000083379400072
J	Pastorino, JG; Tafani, M; Rothman, RJ; Marcineviciute, A; Hoek, JB; Farber, JL				Pastorino, JG; Tafani, M; Rothman, RJ; Marcineviciute, A; Hoek, JB; Farber, JL			Functional consequences of the sustained or transient activation by Bax of the mitochondrial permeability transition pore	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; CYTOCHROME-C; CELL-DEATH; CYCLOSPORINE-A; CERAMIDE; APOPTOSIS; HEPATOCYTES; RELEASE; INDUCTION; STIMULATION	The overexpression of Bax kills cells by a mechanism that depends on induction of the mitochondrial permeability transition (MPT) (Pastorino, J. G., Chen, S.-T., Tafani, M., Snyder, J. W., and Farber, J. L. (1998) J. Biol Chem. 273, 7770-7775). In the present study, purified, recombinant Bax opened the mitochondrial permeability transition pore (PTP). Depending on its concentration, Bax had two distinct effects. Al a concentration of 125 nM, Bax caused the release of the intermembranous proteins cytochrome c and adenylate kinase and the release from the matrix of sequestered calcein, effects prevented by the inhibitor of the PTP cyclosporin A (CSA), AL this concentration of Bax, there was no detectable mitochondrial swelling or depolarization. These effects of low Bax concentrations are interpreted as the consequence of transient, non-synchronous activation of the PTP followed by a prompt recovery of mitochondrial integrity, By contrast, Bax concentrations between 250 nM and 1 mu M caused a sustained opening of the PTP with consequent persistent mitochondrial swelling and deenergization (the MPT). CSA prevented the RIFT induced by fax, Increasing concentrations of calcium caused a greater proportion of the mitochondrial to undergo the MPT in the presence of Bax. Importantly, two known mediators of apoptosis, ceramide and GD3 ganglioside, potentiated the induction by Bax of the MPT, The data imply that Bax mediates the opening of the mitochondrial PTP with the resultant release of cytochrome c from the intermembranous space.	Thomas Jefferson Univ, Dept Pathol, Philadelphia, PA 19107 USA	Jefferson University	Farber, JL (corresponding author), Thomas Jefferson Univ, Dept Pathol, Rm 208,Jefferson Alumni Hall, Philadelphia, PA 19107 USA.	John.Farber@mail.tju.edu	Tafani, Marco/U-7230-2019; Tafani, Marco/C-3275-2017	Tafani, Marco/0000-0001-7128-810X; Tafani, Marco/0000-0001-7128-810X; Hoek, Jan/0000-0001-7127-4218	NIDDK NIH HHS [DK38305] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038305] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arora AS, 1997, HEPATOLOGY, V25, P958, DOI 10.1002/hep.510250428; Bourteele S, 1998, J BIOL CHEM, V273, P31245, DOI 10.1074/jbc.273.47.31245; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; CRISS WE, 1970, J BIOL CHEM, V245, P6352; CRISS WE, 1970, CANCER RES, V30, P370; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; Hassouna I, 1996, NEUROSCI LETT, V204, P85, DOI 10.1016/0304-3940(96)12323-5; HOEK JB, 1980, J BIOL CHEM, V255, P1458; Hoek JB, 1997, MOL CELL BIOCHEM, V174, P173, DOI 10.1023/A:1006831703155; Huser J, 1998, BIOPHYS J, V74, P2129, DOI 10.1016/S0006-3495(98)77920-2; IGBAVBOA U, 1991, BIOCHIM BIOPHYS ACTA, V1059, P339, DOI 10.1016/S0005-2728(05)80219-1; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; NICOLLI A, 1993, BIOCHEMISTRY-US, V32, P4461, DOI 10.1021/bi00067a039; NIEMINEN AL, 1995, BIOCHEM J, V307, P99, DOI 10.1042/bj3070099; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; PASTORINO JG, 1993, J BIOL CHEM, V268, P13791; PASTORINO JG, 1995, AM J PHYSIOL-CELL PH, V268, pC676, DOI 10.1152/ajpcell.1995.268.3.C676; PETRONILLI V, 1993, J BIOL CHEM, V268, P21939; Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5; Schwandner R, 1998, J BIOL CHEM, V273, P5916, DOI 10.1074/jbc.273.10.5916; WOLDEGIORGIS G, 1982, J BIOL CHEM, V257, P4783; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Xu J, 1998, J BIOL CHEM, V273, P16521, DOI 10.1074/jbc.273.26.16521; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang JC, 1998, FREE RADICAL BIO MED, V24, P624, DOI 10.1016/S0891-5849(97)00367-5; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	34	252	260	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31734	31739		10.1074/jbc.274.44.31734	http://dx.doi.org/10.1074/jbc.274.44.31734			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531385	hybrid			2022-12-27	WOS:000083379400089
J	Yokouchi, M; Kondo, T; Houghton, A; Bartkiewicz, M; Horne, WC; Zhang, H; Yoshimura, A; Baron, R				Yokouchi, M; Kondo, T; Houghton, A; Bartkiewicz, M; Horne, WC; Zhang, H; Yoshimura, A; Baron, R			Ligand-induced ubiquitination of the epidermal growth factor receptor involves the interaction of the c-Cbl RING finger and UbcH7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-BINDING DOMAIN; TYROSINE KINASE; EGF RECEPTOR; P53-ASSOCIATED PROTEIN; SIGNAL-TRANSDUCTION; NEGATIVE REGULATOR; PROTOONCOGENE; PRODUCT; STIMULATION; ACTIVATION	c-Cbl plays a negative regulatory role in tyrosine kinase signaling by an as yet undefined mechanism. We demonstrate here, using the yeast two-hybrid system and an in vitro binding assay, that the c-Cbl RING finger domain interacts with UbcH7, a ubiquitin-conjugating enzyme (E2). UbcH7 interacted with the wild-type c-Cbl RING finger domain but not with a RING finger domain that lacks the amino acids that are deleted in 70Z-Cbl, an oncogenic mutant of c-Cbl. The in vitro interaction was enhanced by sequences on both the N- and C-terminal sides of the RING finger. In vivo and in vitro experiments revealed that c-Cbl and UbcH7 synergistically promote the ligand-induced ubiquitination of the epidermal growth factor receptor (EGFR), In contrast, 70Z-Cbl markedly reduced the ligand-induced, UbcH7-mediated ubiquitination of the EGFR. MG132, a proteasome inhibitor, significantly prolonged the ligand-induced phosphorylation of both the EGFR and c-Cbl, Thus, c-Cbl plays an essential role in the ligand-induced ubiquitination of the EGFR by a mechanism that involves an interaction of the RING finger domain with UbcH7. This mechanism participates in the down-regulation of tyrosine kinase receptors and loss of this function, as occurs in the naturally occurring 70Z-Cbl isoform, probably contributes to oncogenic transformation.	Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Orthopaed, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; Kurume Univ, Inst Life Sci, Kurume, Fukuoka 8390861, Japan	Yale University; Yale University; Yale University; Kurume University	Baron, R (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, 333 Cedar St, New Haven, CT 06510 USA.	roland.baron@yale.edu	Kondo, Takeshi/G-2103-2012; Yoshimura, Akihiko/K-5515-2013	Kondo, Takeshi/0000-0001-7455-5824; 	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042927] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-42927] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; Bailly V, 1997, J BIOL CHEM, V272, P23360, DOI 10.1074/jbc.272.37.23360; BODDY MN, 1994, TRENDS BIOCHEM SCI, V19, P198, DOI 10.1016/0968-0004(94)90020-5; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; Bustelo XR, 1997, ONCOGENE, V15, P2511, DOI 10.1038/sj.onc.1201430; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Ghiglione C, 1999, CELL, V96, P847, DOI 10.1016/S0092-8674(00)80594-2; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hime GR, 1997, ONCOGENE, V14, P2709, DOI 10.1038/sj.onc.1201223; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Hu G, 1999, MOL CELL BIOL, V19, P724; JONGEWARD GD, 1995, GENETICS, V139, P1553; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Leevers SJ, 1999, NAT CELL BIOL, V1, pE10, DOI 10.1038/8969; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nuber U, 1996, J BIOL CHEM, V271, P2795, DOI 10.1074/jbc.271.5.2795; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Rellahan BL, 1997, J BIOL CHEM, V272, P30806, DOI 10.1074/jbc.272.49.30806; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Smit L, 1997, CRIT REV ONCOGENESIS, V8, P359, DOI 10.1615/CritRevOncog.v8.i4.50; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; SWERDLOW PS, 1986, ANAL BIOCHEM, V156, P147, DOI 10.1016/0003-2697(86)90166-1; Thien CBF, 1997, ONCOGENE, V15, P2909, DOI 10.1038/sj.onc.1201468; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Tyers M, 1999, SCIENCE, V284, P601, DOI 10.1126/science.284.5414.601; Ueno H, 1997, J BIOL CHEM, V272, P8739, DOI 10.1074/jbc.272.13.8739; Wang Y, 1999, J CELL BIOCHEM, V72, P119; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; Weissman AM, 1997, IMMUNOL TODAY, V18, P189, DOI 10.1016/S0167-5699(97)84666-X; Yokouchi M, 1997, ONCOGENE, V15, P7, DOI 10.1038/sj.onc.1201163; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	46	282	287	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31707	31712		10.1074/jbc.274.44.31707	http://dx.doi.org/10.1074/jbc.274.44.31707			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531381	hybrid			2022-12-27	WOS:000083379400085
J	Kundra, R; Kornfeld, S				Kundra, R; Kornfeld, S			Asparagine-linked oligosaccharides protect Lamp-1 and Lamp-2 from intracellular proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL MEMBRANE-GLYCOPROTEINS; HAMSTER OVARY CELLS; MANNOSE 6-PHOSPHATE RECEPTOR; TRANS-GOLGI NETWORK; LATE ENDOSOMES; RAB9; GLYCOSYLATION; COMPARTMENTS; TRAFFICKING; BIOGENESIS	Lysosomes contain several integral membrane proteins (termed Lamps and Limps) that are extensively glycosylated with asparagine-linked oligosaccharides. It has been postulated that these glycans protect the underlying polypeptides from the proteolytic environment of the lysosome. Previous attempts to test this hypothesis have been inconclusive because they utilized approaches that prevent initial glycosylation and thereby impair protein folding. We have used endoglycosidase H to remove the Asn-linked glycans from fully folded lysosomal membrane proteins in living cells. Deglycosylation of Lamp-1 and Lamp-8 resulted in their rapid degradation, whereas Limp-a was relatively stable in the lysosome in the absence of high mannose Asn-linked oligosaccharides. Depletion of Lamp-1 and Lamp-2 had no measurable effect on endosomal/lysosomal pH, osmotic stability, or density, and cell viability was maintained. Transport of endocytosed material to dense lysosomes was delayed in endoglycosidase H treated cells, but the rate of degradation of internalized bovine serum albumin was unchanged. These data provide direct evidence that Asn-linked oligosaccharides protect a subset of lysosomal membrane proteins from proteolytic digestion in intact cells.	Washington Univ, Sch Med, Div Hematol, St Louis, MO 63110 USA	Washington University (WUSTL)	Kornfeld, S (corresponding author), Washington Univ, Sch Med, Div Hematol, 660 S Euclid Ave,Campus Box 8125, St Louis, MO 63110 USA.				NATIONAL CANCER INSTITUTE [R37CA008759, R01CA008759] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007088] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007200] Funding Source: NIH RePORTER; NCI NIH HHS [CA 08759] Funding Source: Medline; NHLBI NIH HHS [T32HL07088] Funding Source: Medline; NIGMS NIH HHS [T32 GM 07200] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKASAKI K, 1994, J BIOCHEM, V116, P670; Andrejewski N, 1999, J BIOL CHEM, V274, P12692, DOI 10.1074/jbc.274.18.12692; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BARRIOCANAL JG, 1986, J BIOL CHEM, V261, P6755; BISCHOFF J, 1984, BIOCHEM BIOPH RES CO, V125, P326; Brewer JW, 1997, EMBO J, V16, P7207, DOI 10.1093/emboj/16.23.7207; Bright NA, 1997, J CELL SCI, V110, P2027; BROTHERUS J, 1974, CHEM PHYS LIPIDS, V13, P178, DOI 10.1016/0009-3084(74)90034-6; CARLSSON SR, 1988, J BIOL CHEM, V263, P18911; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; FUKUDA M, 1988, J BIOL CHEM, V263, P18920; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; GOTTLIEB C, 1975, J BIOL CHEM, V250, P3303; GOTTLIEB C, 1974, P NATL ACAD SCI USA, V71, P1078, DOI 10.1073/pnas.71.4.1078; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; Hunziker W, 1996, BIOESSAYS, V18, P379, DOI 10.1002/bies.950180508; HUTERER S, 1974, CAN J BIOCHEM CELL B, V52, P507, DOI 10.1139/o74-075; JADOT M, 1992, J BIOL CHEM, V267, P11069; Jadot M, 1997, EUR J BIOCHEM, V249, P862, DOI 10.1111/j.1432-1033.1997.t01-1-00862.x; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS V, 1985, J CELL BIOL, V100, P1839, DOI 10.1083/jcb.100.6.1839; LIPPINCOTTSCHWARTZ J, 1987, CELL, V49, P669, DOI 10.1016/0092-8674(87)90543-5; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; MANE SM, 1989, ARCH BIOCHEM BIOPHYS, V268, P360, DOI 10.1016/0003-9861(89)90597-3; Mullock BM, 1998, J CELL BIOL, V140, P591, DOI 10.1083/jcb.140.3.591; Ohashi M, 1999, J CELL SCI, V112, P1125; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; RIEDERER MA, 1994, J CELL BIOL, V125, P573, DOI 10.1083/jcb.125.3.573; ROHRER J, 1995, J CELL BIOL, V130, P1297, DOI 10.1083/jcb.130.6.1297; RUDD PM, 1995, BBA-PROTEIN STRUCT M, V1248, P1, DOI 10.1016/0167-4838(94)00230-E; RUDD PM, 1994, BIOCHEMISTRY-US, V33, P17, DOI 10.1021/bi00167a003; SCHMID S, 1989, J CELL BIOL, V108, P1291, DOI 10.1083/jcb.108.4.1291; Sidrauski C, 1998, TRENDS CELL BIOL, V8, P245, DOI 10.1016/S0962-8924(98)01267-7; SOLDATI T, 1995, J BIOL CHEM, V270, P25541, DOI 10.1074/jbc.270.43.25541; STOCHAJ U, 1992, BIOCHIM BIOPHYS ACTA, V1122, P327, DOI 10.1016/0167-4838(92)90413-8; Tjelle TE, 1996, J CELL SCI, V109, P2905; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANBERKEL PHC, 1995, BIOCHEM J, V312, P107, DOI 10.1042/bj3120107; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WHERRETT JR, 1972, J BIOL CHEM, V247, P4114	41	138	153	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					31039	31046		10.1074/jbc.274.43.31039	http://dx.doi.org/10.1074/jbc.274.43.31039			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521503	hybrid			2022-12-27	WOS:000083276700099
J	Revington, M; McLachlin, DT; Shaw, GS; Dunn, SD				Revington, M; McLachlin, DT; Shaw, GS; Dunn, SD			The dimerization domain of the b subunit of the Escherichia coli F1F0-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-SYNTHASE; DELTA-SUBUNIT; 2ND STALK; BACKBONE DYNAMICS; F-0 PARTS; F1; RELAXATION; F1-ATPASE; MUTATION; INTERACT	In this study a series of N- and/or C-terminal truncations of the cytoplasmic domain of the b subunit of the Escherichia coli F1F0 ATP synthase were tested for their ability to form dimers using sedimentation equilibrium ultracentrifugation. The deletion of residues between positions 53 and. 122 resulted in a strongly decreased tendency to form dimers, whereas all the polypeptides that included that sequence exhibited high levels of dimer formation, b dimers existed in a reversible monomer-dimer equilibrium and when mixed with other b truncations formed heterodimers efficiently, provided both constructs included the 53-122 sequence. Sedimentation velocity and N-15 NMR relaxation measurements indicated that the dimerization region is highly extended in solution, consistent with an elongated second stalk structure, A cysteine introduced at position 105 was found to readily form intersubunit disulfides, whereas other single cysteines at positions 103-110 failed to form disulfides either with the identical mutant or when mixed with the other 103-110 cysteine mutants, These studies establish that the b subunit dimer depends on interactions that occur between residues in the 53-122 sequence and that the two subunits are oriented in a highly specific manner at the dimer interface.	Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Dunn, SD (corresponding author), Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada.	sdunn@julian.uwo.ca	Dunn, Stanley/D-3418-2013; Shaw, Gary S./C-7656-2009	Shaw, Gary S./0000-0002-4685-9625				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Caviston TL, 1998, FEBS LETT, V429, P201, DOI 10.1016/S0014-5793(98)00597-3; Cohn E., 1943, PROTEINS AMINO ACIDS, P157; Dmitriev O, 1999, J BIOL CHEM, V274, P15598, DOI 10.1074/jbc.274.22.15598; DUNN SD, 1992, J BIOL CHEM, V267, P7630; Dunn SD, 1998, J BIOL CHEM, V273, P8646, DOI 10.1074/jbc.273.15.8646; Engelbrecht S, 1997, FEBS LETT, V414, P485, DOI 10.1016/S0014-5793(97)00997-6; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Fillingame RH, 1998, ACTA PHYSIOL SCAND, V163, P163; GRASBERGER BL, 1993, J MOL BIOL, V230, P364, DOI 10.1006/jmbi.1993.1152; Howitt SM, 1996, J BIOL CHEM, V271, P7038, DOI 10.1074/jbc.271.12.7038; LUCKEN U, 1990, BIOCHEMISTRY-US, V29, P5339; McLachlin DT, 1998, J BIOL CHEM, V273, P15162, DOI 10.1074/jbc.273.24.15162; McLachlin DT, 1997, J BIOL CHEM, V272, P21233, DOI 10.1074/jbc.272.34.21233; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; PERLIN DS, 1983, J BIOL CHEM, V258, P9793; Philo JS, 1997, BIOPHYS J, V72, P435, DOI 10.1016/S0006-3495(97)78684-3; REYNAUD J, 1963, BIOCHIM BIOPHYS ACTA, V77, P521, DOI 10.1016/0006-3002(63)90535-3; Rodgers AJW, 1997, J BIOL CHEM, V272, P31058, DOI 10.1074/jbc.272.49.31058; Rodgers AJW, 1998, J BIOL CHEM, V273, P29406, DOI 10.1074/jbc.273.45.29406; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sorgen PL, 1998, J BIOL CHEM, V273, P27873, DOI 10.1074/jbc.273.43.27873; Steinmetz MO, 1998, EMBO J, V17, P1883, DOI 10.1093/emboj/17.7.1883; SVEDBERG T, 1940, ULTRACENTRIFUGE, P406; Tang CL, 1996, J BIOL CHEM, V271, P3018, DOI 10.1074/jbc.271.6.3018; Watts SD, 1997, J BIOL CHEM, V272, P15065, DOI 10.1074/jbc.272.24.15065; WEAST RC, 1970, CRC HDB CHEM PHYSICS, pD176; Wilkens S, 1998, NATURE, V393, P29, DOI 10.1038/29908	29	50	50	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					31094	31101		10.1074/jbc.274.43.31094	http://dx.doi.org/10.1074/jbc.274.43.31094			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521510	hybrid			2022-12-27	WOS:000083276700106
J	Schlodder, E; Witt, HT				Schlodder, E; Witt, HT			Stoichiometry of proton release from the catalytic center in photosynthetic water oxidation - Reexamination by a glass electrode study at pH 5.5-7.2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-EVOLVING COMPLEX; SPLITTING ENZYME-SYSTEM; CYANOBACTERIUM-SYNECHOCOCCUS SP; NANOSECOND REDUCTION KINETICS; PHOTOSYSTEM-II PARTICLES; OPTICAL CHARACTERIZATION; MANGANESE COMPLEX; POSSIBLE STATES; SINGLE FLASHES; S-0 STATE	The catalytic center (CC) of water oxidation in photosystem II passes through four stepwise increased oxidized states (S-0-S-4) before O-2 evolution takes place from 2H(2)O in the S-4 --> S-0 transition. The pattern of the release of the four protons from the CC cannot be followed directly in the medium, because proton release from unknown amino acid residues also takes place. However, pH-independent net charge oscillations of 0:0:1:1 in S-0:S-1:S-2:S-3 have been considered as an intrinsic indicator for the H+ release from the CC. The net charges have been proposed to be created as the charge difference between electron abstraction and H+ release from the CC. Then the H+ release from the CC is 1:0:1:2 for the S-0 --> S-1 --> S-2 --> S-3 --> S-0 transition. Strong support for this conclusion is given in this work with the analysis of the pH-dependent pattern of H+ release in the medium measured directly by a glass electrode between pH 5.5 and 7.2. Improved and crystallizable photosystem II core complexes from the cyanobacterium Synechococcus elongatus were used as material. The pattern can be explained by protons released from the CC with a stoichiometry of 1:0:1:2 and protons from an amino acid group (pK approximate to 5.7) that is deprotonated and reprotonated through electrostatic interaction with the oscillating net charges 0:0:1:1 in S-0:S-1:S-2:S-3. Possible water derivatives that circulate through the S states have been named.	Tech Univ Berlin, Max Volmer Inst Biophys & Phys Chem, D-10623 Berlin, Germany	Technical University of Berlin	Witt, HT (corresponding author), Tech Univ Berlin, Max Volmer Inst Biophys & Phys Chem, Str 17 Juni 135, D-10623 Berlin, Germany.	witt@phosis1.chem.tu-berlin.de	Schlodder, Eberhard/AAP-6766-2021					Ahlbrink R, 1998, BIOCHEMISTRY-US, V37, P1131, DOI 10.1021/bi9719152; Ahrling KA, 1997, BIOCHEMISTRY-US, V36, P13148, DOI 10.1021/bi971815w; BLANKENSHIP RE, 1975, FEBS LETT, V51, P287, DOI 10.1016/0014-5793(75)80909-4; BOGERSHAUSEN O, 1995, BBA-BIOENERGETICS, V1230, P177, DOI 10.1016/0005-2728(95)00057-P; BOUGES B, 1971, BIOCHIM BIOPHYS ACTA, V234, P103, DOI 10.1016/0005-2728(71)90135-6; BRETTEL K, 1984, BIOCHIM BIOPHYS ACTA, V766, P403, DOI 10.1016/0005-2728(84)90256-1; BRUDVIG G, 1987, PROGR PHOTOSYNTHETIC, V1, P491; DAU H, 1998, PHOTOSYNTHESIS MECH, V2, P1927; DEBUS RJ, 1988, P NATL ACAD SCI USA, V85, P427, DOI 10.1073/pnas.85.2.427; DEKKER JP, 1984, BIOCHIM BIOPHYS ACTA, V767, P1, DOI 10.1016/0005-2728(84)90073-2; DEKKER JP, 1988, BIOCHIM BIOPHYS ACTA, V936, P307, DOI 10.1016/0005-2728(88)90006-0; DISMUKES GC, 1986, PHOTOCHEM PHOTOBIOL, V43, P99, DOI 10.1111/j.1751-1097.1986.tb05598.x; DORING R, 1969, Z NATURFORSCH B, V24, P132; FORSTER V, 1985, PHOTOCHEM PHOTOBIOL, V41, P183, DOI 10.1111/j.1751-1097.1985.tb03469.x; FOWLER CF, 1977, BIOCHIM BIOPHYS ACTA, V462, P414, DOI 10.1016/0005-2728(77)90139-6; GERKEN S, 1988, FEBS LETT, V237, P69, DOI 10.1016/0014-5793(88)80174-1; Haumann M, 1997, FEBS LETT, V410, P243, DOI 10.1016/S0014-5793(97)00596-6; HAUMANN M, 1994, BIOCHEMISTRY-US, V33, P864, DOI 10.1021/bi00170a003; HAUMANN M, 1996, OXYGENIC PHOTOSYNTHE, P165; Hillier W, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P1307; Hoganson CW, 1997, SCIENCE, V277, P1953, DOI 10.1126/science.277.5334.1953; Iuzzolino L, 1998, BIOCHEMISTRY-US, V37, P17112, DOI 10.1021/bi9817360; JAHNS P, 1991, BIOCHIM BIOPHYS ACTA, V1057, P313, DOI 10.1016/S0005-2728(05)80142-2; JOLIOT P, 1969, PHOTOCHEM PHOTOBIOL, V10, P309, DOI 10.1111/j.1751-1097.1969.tb05696.x; KLEIN MP, 1993, PHOTOSYNTH RES, V38, P265, DOI 10.1007/BF00046751; KLIMOV VV, 1977, FEBS LETT, V82, P183, DOI 10.1016/0014-5793(77)80580-2; KOK B, 1970, PHOTOCHEM PHOTOBIOL, V11, P457, DOI 10.1111/j.1751-1097.1970.tb06017.x; KRETSCHMANN H, 1988, BIOCHIM BIOPHYS ACTA, V932, P358, DOI 10.1016/0005-2728(88)90171-5; KRETSCHMANN H, 1993, BIOCHIM BIOPHYS ACTA, V1144, P331, DOI 10.1016/0005-2728(93)90118-Y; Kretschmann H, 1996, BBA-BIOENERGETICS, V1274, P1, DOI 10.1016/0005-2728(95)00150-6; KRETSCHMANN H, 1991, BIOCHIM BIOPHYS ACTA, V1059, P208, DOI 10.1016/S0005-2728(05)80205-1; KUSUNOKI M, 1993, PHOTOSYNTH RES, V38, P331, DOI 10.1007/BF00046758; Messinger J, 1997, J AM CHEM SOC, V119, P11349, DOI 10.1021/ja972696a; MESSINGER J, 1995, P NATL ACAD SCI USA, V92, P3209, DOI 10.1073/pnas.92.8.3209; MEYER B, 1989, BIOCHIM BIOPHYS ACTA, V974, P36, DOI 10.1016/S0005-2728(89)80163-X; RAPPAPORT F, 1991, BIOCHEMISTRY-US, V30, P10004, DOI 10.1021/bi00105a027; SAPHON S, 1977, Z NATURFORSCH C, V32, P617; SAYGIN O, 1985, PHOTOBIOCH PHOTOBIOP, V10, P71; SAYGIN O, 1984, FEBS LETT, V176, P83, DOI 10.1016/0014-5793(84)80916-3; SAYGIN O, 1987, BIOCHIM BIOPHYS ACTA, V893, P452, DOI 10.1016/0005-2728(87)90097-1; SAYGIN O, 1985, FEBS LETT, V187, P224, DOI 10.1016/0014-5793(85)81246-1; STIEHL HH, 1969, Z NATURFORSCH PT B, VB 24, P1588; TIMASHEFF SN, 1990, PROTEIN STRUCTURE PR, P331; TOMMOS C, 1999, IN PRESS BIOCH BIOPH; VASS I, 1991, BIOCHEMISTRY-US, V30, P830, DOI 10.1021/bi00217a037; Zouni A, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P925	46	126	129	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30387	30392		10.1074/jbc.274.43.30387	http://dx.doi.org/10.1074/jbc.274.43.30387			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521415	hybrid			2022-12-27	WOS:000083276700011
J	Fry, CJ; Farnham, PJ				Fry, CJ; Farnham, PJ			Context-dependent transcriptional regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							SERUM RESPONSE FACTOR; C-MYC; BETA-CATENIN; ACTIVATES TRANSCRIPTION; FUNCTIONAL INTERACTION; FAMILY PROTEINS; BINDING SITES; FACTORS SP1; IN-VIVO; PROMOTER		Univ Wisconsin, Mcardle Lab Canc Res, Sch Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Farnham, PJ (corresponding author), Univ Wisconsin, Mcardle Lab Canc Res, Sch Med, 1400 Univ Ave, Madison, WI 53706 USA.			Farnham, Peggy/0000-0003-4469-7914				Bennett JD, 1996, ONCOGENE, V13, P1073; Bienz M, 1998, CURR OPIN CELL BIOL, V10, P366, DOI 10.1016/S0955-0674(98)80013-6; Bruhn L, 1997, GENE DEV, V11, P640, DOI 10.1101/gad.11.5.640; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EMAMI KH, 1995, MOL CELL BIOL, V15, P5906; Giese K, 1997, P NATL ACAD SCI USA, V94, P12845, DOI 10.1073/pnas.94.24.12845; GIESE K, 1993, EMBO J, V12, P4667, DOI 10.1002/j.1460-2075.1993.tb06155.x; Gregory RC, 1996, BLOOD, V87, P1793, DOI 10.1182/blood.V87.5.1793.bloodjournal8751793; GUALBERTO A, 1992, MOL CELL BIOL, V12, P4209, DOI 10.1128/MCB.12.9.4209; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; JANSON L, 1990, P NATL ACAD SCI USA, V87, P4732, DOI 10.1073/pnas.87.12.4732; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Kim JS, 1996, NUCLEIC ACIDS RES, V24, P4341, DOI 10.1093/nar/24.21.4341; KOLLMAR R, 1994, J BIOL CHEM, V269, P2252; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LEE TC, 1991, MOL CELL BIOL, V11, P5090, DOI 10.1128/MCB.11.10.5090; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Liu NS, 1998, ONCOGENE, V16, P2957, DOI 10.1038/sj.onc.1201838; Lucibello FC, 1997, NUCLEIC ACIDS RES, V25, P4921, DOI 10.1093/nar/25.24.4921; Luo X, 1996, MOL CELL BIOL, V16, P1367; MAJELLO B, 1995, ONCOGENE, V10, P1841; MCCOY C, 1995, MOL CELL BIOL, V15, P6100; MILTENBERGER RJ, 1995, CELL GROWTH DIFFER, V6, P549; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; Parr MJ, 1997, NAT MED, V3, P1145, DOI 10.1038/nm1097-1145; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; Saluja D, 1998, MOL CELL BIOL, V18, P5734, DOI 10.1128/MCB.18.10.5734; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHI Y, 1997, BIOCHIM BIOPHYS ACTA, V1332, P49; Shrivastava A, 1996, P NATL ACAD SCI USA, V93, P10638, DOI 10.1073/pnas.93.20.10638; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; Strom AC, 1996, NUCLEIC ACIDS RES, V24, P1981, DOI 10.1093/nar/24.11.1981; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; SUN D, 1994, BIOCHEMISTRY-US, V33, P9578, DOI 10.1021/bi00198a025; Usheva A, 1996, P NATL ACAD SCI USA, V93, P13571, DOI 10.1073/pnas.93.24.13571; vanGinkel PR, 1997, J BIOL CHEM, V272, P18367, DOI 10.1074/jbc.272.29.18367	43	133	135	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29583	29586		10.1074/jbc.274.42.29583	http://dx.doi.org/10.1074/jbc.274.42.29583			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514422	hybrid			2022-12-27	WOS:000083176400001
J	Jacobsen, BM; Skalnik, DG				Jacobsen, BM; Skalnik, DG			YY1 binds five cis-elements and trans-activates the myeloid cell-restricted gp91(phox) promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT DISPLACEMENT PROTEIN; CUT HOMEODOMAIN PROTEIN; CHRONIC GRANULOMATOUS-DISEASE; TRANSCRIPTION FACTOR YY1; IFN-GAMMA INDUCTION; RNA-POLYMERASE-II; C-MYC PROMOTER; DNA-BINDING; GENE-EXPRESSION; ADENOVIRUS E1A	Four transcriptional activating cis-elements within the gp91(phox) promoter bind a protein complex of similar mobility and binding specificity, denoted BID (binding increased during differentiation). The intensity of BID complexes increases upon myeloid cell differentiation, coincident with induction of gp91(phox) expression, and BID competes with the transcriptional repressor CDP for binding to each of these promoter elements. To determine the identity of BID, an expression Library was ligand screened with the BID-binding site that surrounds the -145-base pair (bp) region of the gp91(phox) promoter. One recovered factor that exhibits the expected binding specificity is YY1, a ubiquitous multifunctional transcription factor. BID complexes that form with the four binding sites within the gp91(phox) promoter are disrupted by YY1 antiserum, and a fifth YY1-binding site was detected in the -412-bp promoter region. Overexpression of YY1 in transient co-transfection assays trans-activates a minimal promoter containing two copies of the -145-bp binding site from the gp91(phox) promoter. Neither the level of YY1 protein nor DNA binding activity increases during myeloid cell differentiation, These studies identify a target gene of YY1 function in mature myeloid cells, and demonstrate that YY1 function can be controlled during myeloid development by the modulation of a competing DNA-binding factor.	Indiana Univ, Sch Med, Herman B Wells Ctr Pediat Res, Sect Pediat Hematol Oncol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Pediat, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Skalnik, DG (corresponding author), Indiana Univ, Sch Med, Herman B Wells Ctr Pediat Res, Sect Pediat Hematol Oncol, Canc Res Bldg,1044 W Walnut St,Rm 472, Indianapolis, IN 46202 USA.	dskalnik@iupui.edu		Jacobsen, Britta/0000-0001-8234-1690	NATIONAL CANCER INSTITUTE [R29CA058947, R01CA058947] Funding Source: NIH RePORTER; NCI NIH HHS [CA58947] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRES V, 1994, GENE DEV, V8, P245, DOI 10.1101/gad.8.2.245; ANDRES V, 1992, DEVELOPMENT, V116, P321; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BARKER KA, 1988, MOL CELL BIOL, V8, P2804, DOI 10.1128/MCB.8.7.2804; BECKER KG, 1994, GENE, V150, P259, DOI 10.1016/0378-1119(94)90435-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Coqueret O, 1998, EMBO J, V17, P4680, DOI 10.1093/emboj/17.16.4680; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUFORT D, 1994, MOL CELL BIOL, V14, P4251, DOI 10.1128/MCB.14.6.4251; Eklund EA, 1997, J BIOL CHEM, V272, P9344; Eklund EA, 1998, J BIOL CHEM, V273, P13957, DOI 10.1074/jbc.273.22.13957; Eklund EA, 1996, J IMMUNOL, V157, P2418; EKLUND EA, 1995, J BIOL CHEM, V270, P8267, DOI 10.1074/jbc.270.14.8267; ELHODIRI HM, 1995, MOL CELL BIOL, V15, P3587; GHOSH D, 1993, NUCLEIC ACIDS RES, V21, P3117, DOI 10.1093/nar/21.13.3117; Gilly M, 1996, GENE, V179, P237, DOI 10.1016/S0378-1119(96)00366-6; GUALBERTO A, 1992, MOL CELL BIOL, V12, P4209, DOI 10.1128/MCB.12.9.4209; GUO B, 1995, P NATL ACAD SCI USA, V92, P10526, DOI 10.1073/pnas.92.23.10526; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; Heuvel GBV, 1996, KIDNEY INT, V50, P453, DOI 10.1038/ki.1996.336; Higgy NA, 1997, BBA-GENE STRUCT EXPR, V1351, P313, DOI 10.1016/S0167-4781(96)00221-7; HUMMELL DS, 1993, J IMMUNOL, V151, P3131; HYDEDERUYSCHER RP, 1995, NUCLEIC ACIDS RES, V23, P5672; KhannaGupta A, 1997, BLOOD, V90, P2784, DOI 10.1182/blood.V90.7.2784.2784_2784_2795; Kim EC, 1997, CELL GROWTH DIFFER, V8, P1329; Kim JS, 1996, NUCLEIC ACIDS RES, V24, P4341, DOI 10.1093/nar/24.21.4341; Last TJ, 1998, GENE, V221, P267, DOI 10.1016/S0378-1119(98)00415-6; Lawson ND, 1998, BLOOD, V91, P2517, DOI 10.1182/blood.V91.7.2517.2517_2517_2524; LEE JS, 1995, NUCLEIC ACIDS RES, V23, P925, DOI 10.1093/nar/23.6.925; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; Li S, 1999, J BIOL CHEM, V274, P7803, DOI 10.1074/jbc.274.12.7803; Lien LL, 1997, MOL CELL BIOL, V17, P2279, DOI 10.1128/MCB.17.4.2279; LIEVENS PMJ, 1995, J BIOL CHEM, V270, P12745, DOI 10.1074/jbc.270.21.12745; Luo W, 1996, J BIOL CHEM, V271, P18203, DOI 10.1074/jbc.271.30.18203; Luo W, 1996, J BIOL CHEM, V271, P23445, DOI 10.1074/jbc.271.38.23445; Mailly F, 1996, MOL CELL BIOL, V16, P5346; NEWBURGER PE, 1988, P NATL ACAD SCI USA, V85, P5215, DOI 10.1073/pnas.85.14.5215; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Oei SL, 1998, J BIOL CHEM, V273, P31644, DOI 10.1074/jbc.273.48.31644; ORKIN SH, 1989, ANNU REV IMMUNOL, V7, P277; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Shi Y, 1997, BBA-REV CANCER, V1332, pF49, DOI 10.1016/S0304-419X(96)00044-3; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; SKALNIK DG, 1991, P NATL ACAD SCI USA, V88, P8505, DOI 10.1073/pnas.88.19.8505; SUPERTIFURGA G, 1988, EMBO J, V7, P3099, DOI 10.1002/j.1460-2075.1988.tb03176.x; Suzuki S, 1998, P NATL ACAD SCI USA, V95, P6085, DOI 10.1073/pnas.95.11.6085; TUCKER KA, 1987, BLOOD, V70, P372; VALARCHE I, 1993, DEVELOPMENT, V119, P881; vanWijnen AJ, 1996, P NATL ACAD SCI USA, V93, P11516, DOI 10.1073/pnas.93.21.11516; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; Voo KS, 1999, BLOOD, V93, P3512, DOI 10.1182/blood.V93.10.3512.410k19_3512_3520; Wang ZY, 1999, MOL CELL BIOL, V19, P284; Xie JP, 1998, J CELL BIOCHEM, V70, P489, DOI 10.1002/(SICI)1097-4644(19980915)70:4<489::AID-JCB6>3.0.CO;2-F; YamitHezi A, 1997, GENE, V185, P99, DOI 10.1016/S0378-1119(96)00636-1	61	28	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29984	29993		10.1074/jbc.274.42.29984	http://dx.doi.org/10.1074/jbc.274.42.29984			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514482	hybrid			2022-12-27	WOS:000083176400061
J	Kurashima, K; D'Souza, S; Szaszi, K; Ramjeesingh, R; Orlowski, J; Grinstein, S				Kurashima, K; D'Souza, S; Szaszi, K; Ramjeesingh, R; Orlowski, J; Grinstein, S			The apical Na+/H+ exchanger isoform NHE3 is regulated by the actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-A; CAMP-MEDIATED INHIBITION; CYTOPLASMIC DOMAIN; ATP DEPENDENCE; CELLS; MEMBRANE; IDENTIFICATION; PHOSPHORYLATION; SENSITIVITY; E3KARP	The epithelial isoform of the Na+/H+ exchanger, NHE3, associates with at least two related regulatory factors called NHERF1/EBP50 and NHERF2/TKA-1/ E3KARP. These factors in addition interact with the cytoskeletal protein ezrin, which in turn binds to actin. The possible linkage of NHE3 with the cytoskeleton prompted us to test the effect of actin-modifying agents on NHE3 activity. Cytochalasins B and D and latrunculin B, which interfere with actin polymerization, induced a profound inhibition of NHE3 activity. The effect was isoform-specific inasmuch as the "housekeeping" exchanger NHE1 was virtually unaffected. Cytoskeletal disorganization was associated with a subcellular redistribution of NHE3, which accumulated at sites where actin aggregated, suggesting a physical interaction of exchangers with the cytoskeleton. An interaction was further suggested by the co-sedimentation of a detergent-insoluble fraction of NHE3 with the actin cytoskeleton. Inhibition of transport was not due to diminution in the number of transporters at the plasmalemma. Functional analyses of NHE1/NHE3 chimeras revealed that the cytoplasmic domain of NHE3 conferred sensitivity to cytochalasin B. Progressive carboxyl-terminal and internal deletions of the cytoplasmic region of NHE3 indicated that the region between residues 650 and 684 is critical for this response. This region overlaps with the domain reported to interact with NHERF and also contains a putative ezrin-binding site; hence, it likely plays a role in interactions with the cytoskeleton.	Hosp Sick Children, Res Inst, Cell Biol Programme, Toronto, ON M5G 1X8, Canada; McGill Univ, Dept Physiol, Montreal, PQ H3G 1Y6, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); McGill University	Grinstein, S (corresponding author), Hosp Sick Children, Res Inst, Cell Biol Programme, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.		Szaszi, Katalin/J-7522-2012; Ramjeesingh, Ravi/AAB-3374-2022	Szaszi, Katalin/0000-0002-2490-8422; Orlowski, John/0000-0001-7371-175X; Ramjeesingh, Ravi/0000-0001-5584-3505				Berdiev BK, 1996, J BIOL CHEM, V271, P17704, DOI 10.1074/jbc.271.30.17704; Biemesderfer D, 1997, AM J PHYSIOL-RENAL, V273, pF289, DOI 10.1152/ajprenal.1997.273.2.F289; BORGESE F, 1992, P NATL ACAD SCI USA, V89, P6765, DOI 10.1073/pnas.89.15.6765; BUBB MR, 1994, J BIOL CHEM, V269, P14869; Cabado AG, 1996, J BIOL CHEM, V271, P3590; CANTIELLO HF, 1995, AM J PHYSIOL-RENAL, V269, pF637, DOI 10.1152/ajprenal.1995.269.5.F637; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; D'Souza S, 1998, J BIOL CHEM, V273, P2035, DOI 10.1074/jbc.273.4.2035; FERNANDEZ A, 1990, J CELL BIOL, V111, P103, DOI 10.1083/jcb.111.1.103; GOLDMAN JE, 1990, BRAIN RES, V528, P189, DOI 10.1016/0006-8993(90)91657-3; GOTTLIEB TA, 1993, J CELL BIOL, V120, P695, DOI 10.1083/jcb.120.3.695; Hallows KR, 1996, J CELL PHYSIOL, V167, P60, DOI 10.1002/(SICI)1097-4652(199604)167:1<60::AID-JCP7>3.0.CO;2-A; Janecki AJ, 1998, J BIOL CHEM, V273, P8790, DOI 10.1074/jbc.273.15.8790; KANDASAMY RK, 1995, J BIOL CHEM, V270, P29209, DOI 10.1074/jbc.270.49.29209; KAPUS A, 1994, J BIOL CHEM, V269, P23544; Kreisberg JI, 1997, AM J PHYSIOL-RENAL, V273, pF283, DOI 10.1152/ajprenal.1997.273.2.F283; Kurashima K, 1997, J BIOL CHEM, V272, P28672, DOI 10.1074/jbc.272.45.28672; Kurashima K, 1998, J BIOL CHEM, V273, P20828, DOI 10.1074/jbc.273.33.20828; Lamprecht G, 1998, J BIOL CHEM, V273, P29972, DOI 10.1074/jbc.273.45.29972; MACLEANFLETCHER S, 1980, CELL, V20, P329, DOI 10.1016/0092-8674(80)90619-4; Matthews JB, 1997, AM J PHYSIOL-CELL PH, V272, pC254, DOI 10.1152/ajpcell.1997.272.1.C254; Mauerer UR, 1998, J GEN PHYSIOL, V111, P161, DOI 10.1085/jgp.111.1.161; MOE OW, 1995, J CLIN INVEST, V96, P2187, DOI 10.1172/JCI118273; Noel J, 1996, J CELL SCI, V109, P929; Numata M, 1998, J BIOL CHEM, V273, P6951, DOI 10.1074/jbc.273.12.6951; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; PRAT AG, 1995, AM J PHYSIOL-CELL PH, V268, pC1552, DOI 10.1152/ajpcell.1995.268.6.C1552; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; ROTIN D, 1989, AM J PHYSIOL, V257, pC1158, DOI 10.1152/ajpcell.1989.257.6.C1158; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; WANG WH, 1994, AM J PHYSIOL-RENAL, V267, pF592, DOI 10.1152/ajprenal.1994.267.4.F592; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; Weinman EJ, 1998, J CLIN INVEST, V101, P2199, DOI 10.1172/JCI204; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; Yun CHC, 1998, J BIOL CHEM, V273, P25856, DOI 10.1074/jbc.273.40.25856; Zhang YB, 1996, AM J PHYSIOL-RENAL, V270, pF1004, DOI 10.1152/ajprenal.1996.270.6.F1004	39	110	111	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29843	29849		10.1074/jbc.274.42.29843	http://dx.doi.org/10.1074/jbc.274.42.29843			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514464	hybrid			2022-12-27	WOS:000083176400043
J	Sakai, T; Furuyama, T; Ohoka, Y; Miyazaki, N; Fujioka, S; Sugimoto, H; Amasaki, M; Hattori, S; Matsuya, T; Inagaki, S				Sakai, T; Furuyama, T; Ohoka, Y; Miyazaki, N; Fujioka, S; Sugimoto, H; Amasaki, M; Hattori, S; Matsuya, T; Inagaki, S			Mouse semaphorin H induces PC12 cell neurite outgrowth activating Ras-mitogen-activated protein kinase signaling pathway via Ca2+ influx	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; DEPENDENT ACTIVATION; PHORBOL ESTER; GROWTH; RECEPTOR; FAMILY; PHOSPHORYLATION; DIFFERENTIATION; IDENTIFICATION; TRANSMEMBRANE	We recently showed that mouse semaphorin H (MSH), a secreted semaphorin molecule, acts as a chemorepulsive factor on sensory neurites. In this study,we found for the first time that MSH induces neurite outgrowth in PC12 cells in a dose-dependent manner. Comparison of Ras-mitogen-activated protein kinase (MAPK) signaling pathways between MSH and nerve growth factor (NGF) revealed that these pathways are crucial for MSH action as well as NCF. K-252a, an inhibitor of tyrosine autophosphorylation of tyrosine kinase receptors (Trks), did not inhibit the action of MSH, suggesting that MSH action occurs via a different receptor than NGF. L- and N-types of voltage-dependent Ca2+ channel blockers, diltiazem and omega-conotoxin, inhibited MSH-induced neurite outgrowth and MAPK phosphorylation in a Ca2+-dependent manner. A transient elevation in intracellular Ca2+ level was observed upon MSH stimulation. These findings suggest that extracellular Ca2+ influx, followed by activation of the Ras-MAPK: signaling pathway, is required for MSH induced PC12 cell neurite outgrowth.	Osaka Univ, Fac Med, Sch Allied Hlth Sci, Neurobiol Grp, Suita, Osaka 5650871, Japan; Osaka Univ, Fac Dent, Dept Oral & Maxillofacial Surg 1, Suita, Osaka 5650871, Japan; Natl Inst Longev Sci, Dept Mol Genet Res, Ohbu 4745822, Japan; Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Div Biochem & Cellular Biol, Tokyo 1878502, Japan	Osaka University; Osaka University; National Center for Neurology & Psychiatry - Japan	Inagaki, S (corresponding author), Osaka Univ, Fac Med, Sch Allied Hlth Sci, Neurobiol Grp, Yamadaoka 1-7, Suita, Osaka 5650871, Japan.			Furuyama, Tatsuo/0000-0001-7349-103X				ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; Alonso M, 1998, EUR J CELL BIOL, V76, P93, DOI 10.1016/S0171-9335(98)80021-6; Bentley David, 1994, Current Opinion in Neurobiology, V4, P43, DOI 10.1016/0959-4388(94)90030-2; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; Burry RW, 1998, J NEUROSCI RES, V53, P214, DOI 10.1002/(SICI)1097-4547(19980715)53:2<214::AID-JNR10>3.0.CO;2-6; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; Douglas DN, 1999, BBA-MOL CELL RES, V1448, P439, DOI 10.1016/S0167-4889(98)00161-X; DYER D, 1992, MOL BRAIN RES, V14, P302, DOI 10.1016/0169-328X(92)90097-U; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; FUKUDA M, 1995, ONCOGENE, V11, P239; Furuyama T, 1996, J BIOL CHEM, V271, P33376, DOI 10.1074/jbc.271.52.33376; Graness A, 1997, BIOCHEM J, V327, P147, DOI 10.1042/bj3270147; HASHIMOTO S, 1988, J CELL BIOL, V107, P1531, DOI 10.1083/jcb.107.4.1531; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; INAGAKI S, 1995, FEBS LETT, V370, P269, DOI 10.1016/0014-5793(95)00850-9; IVINS JK, 1991, J NEUROSCI, V11, P1597; Jackson TR, 1996, J CELL SCI, V109, P289; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; KAHLE P, 1994, J NEUROCHEM, V62, P479; Kobayashi H, 1997, J NEUROSCI, V17, P8339; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Kruttgen A, 1998, P NATL ACAD SCI USA, V95, P9614, DOI 10.1073/pnas.95.16.9614; McLeod SJ, 1998, J BIOL CHEM, V273, P29218, DOI 10.1074/jbc.273.44.29218; Miyazaki N, 1999, NEUROSCI RES, V33, P269, DOI 10.1016/S0168-0102(99)00015-2; Miyazaki N, 1999, NEUROSCIENCE, V93, P401, DOI 10.1016/S0306-4522(99)00134-7; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Rosen LB, 1996, P NATL ACAD SCI USA, V93, P1113, DOI 10.1073/pnas.93.3.1113; ROVELLI G, 1993, P NATL ACAD SCI USA, V90, P8717, DOI 10.1073/pnas.90.18.8717; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; Song HJ, 1998, SCIENCE, V281, P1515, DOI 10.1126/science.281.5382.1515; Swanson KD, 1998, J BIOL CHEM, V273, P19965, DOI 10.1074/jbc.273.32.19965; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; VarelaEchavarria A, 1997, NEURON, V18, P193, DOI 10.1016/S0896-6273(00)80261-5	38	57	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29666	29671		10.1074/jbc.274.42.29666	http://dx.doi.org/10.1074/jbc.274.42.29666			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514436	hybrid			2022-12-27	WOS:000083176400015
J	Ohmura, K; Kohno, N; Kobayashi, Y; Yamagata, R; Sato, S; Kashiwabara, S; Baba, T				Ohmura, K; Kohno, N; Kobayashi, Y; Yamagata, R; Sato, S; Kashiwabara, S; Baba, T			A homologue of pancreatic trypsin is localized in the acrosome of mammalian sperm and is released during acrosome reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZONA-PELLUCIDA; SEQUENCE; FERTILIZATION; PENETRATION; EXPRESSION; PROTEINS; GENE	We have identified cDNA and genomic clones encoding a homologue of pancreatic trypsin, termed TESP4, as a candidate protein involved in the sperm penetration of the egg zona pellucida in mouse. The deduced amino acid sequence indicates that TESP4 is 90% identical to pancreatic trypsin. Analysis of Northern blotting and reverse transcriptase-polymerase chain reaction reveals that the mouse TESP4 gene is ubiquitously expressed in all tissues tested, including the pancreas and testis, and the transcript is present in the haploid stages of male germ cells. Moreover, immunochemical analysis of mouse cauda epididymal sperm using an affinity-purified antibody against bovine pancreatic trypsinogen shows that TESP4 is localized only in the sperm acrosome and is released during the acrosome reaction induced by calcium ionophore A23187. These findings may open a new point of view regarding the molecular mechanisms of the sperm/egg interactions, including the sperm penetration of the egg zona pellucida.	Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058572, Japan; Univ Tsukuba, Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058572, Japan; Natl Inst Adv Interdisciplinary Res, Tsukuba, Ibaraki 3058572, Japan	University of Tsukuba; University of Tsukuba; National Institute of Advanced Industrial Science & Technology (AIST)	Baba, T (corresponding author), Univ Tsukuba, Inst Appl Biochem, Tsukuba Sci City, Tsukuba, Ibaraki 3058572, Japan.							BABA T, 1989, J BIOL CHEM, V264, P11920; BABA T, 1994, J BIOL CHEM, V269, P31845; BABA T, 1994, J BIOL CHEM, V269, P10133; Bedford JM, 1998, BIOL REPROD, V59, P1275, DOI 10.1095/biolreprod59.6.1275; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; Eddy E. M., 1994, P29; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRASER LR, 1982, J REPROD FERTIL, V65, P185, DOI 10.1530/jrf.0.0650185; KASHIWABARA S, 1990, J BIOCHEM-TOKYO, V108, P785, DOI 10.1093/oxfordjournals.jbchem.a123281; KLEMM U, 1991, HUM GENET, V87, P635; Kohno N, 1998, BIOCHEM BIOPH RES CO, V245, P658, DOI 10.1006/bbrc.1998.8501; Koshikawa N, 1997, FEBS LETT, V409, P442, DOI 10.1016/S0014-5793(97)00565-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIYAMOTO H, 1973, BIOL REPROD, V9, P533, DOI 10.1093/biolreprod/9.5.533; Roach JC, 1997, J MOL EVOL, V45, P640, DOI 10.1007/PL00006268; Rowen L, 1996, SCIENCE, V272, P1755, DOI 10.1126/science.272.5269.1755; Stambaugh R., 1969, Biology of Reproduction, V1, P223, DOI 10.1095/biolreprod1.3.223; STEVENSON BJ, 1986, NUCLEIC ACIDS RES, V14, P8307, DOI 10.1093/nar/14.21.8307; Wassarman PM, 1999, CELL, V96, P175, DOI 10.1016/S0092-8674(00)80558-9; Yamagata K, 1998, ZYGOTE, V6, P311, DOI 10.1017/S0967199498000264; Yamagata K, 1998, J BIOL CHEM, V273, P10470, DOI 10.1074/jbc.273.17.10470; YAMAGATA K, 1999, IN PRESS DEV GENET; Yanagimachi R., 1994, P189; Yoda Y., 1971, JAPANESE J ANIM REPR, V16, P147, DOI [DOI 10.1262/JRD1955.16.147, 10.1262/jrd1955.16.147]; YOUNG CL, 1978, ATLAS PROTEIN SEQ S3, V5, P73; ZANEVELD LJD, 1971, P INT RES C PROTEINA, P236	26	47	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29426	29432		10.1074/jbc.274.41.29426	http://dx.doi.org/10.1074/jbc.274.41.29426			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506205	hybrid			2022-12-27	WOS:000083017800084
J	Amano, M; Chihara, K; Nakamura, N; Kaneko, T; Matsuura, Y; Kaibuchi, K				Amano, M; Chihara, K; Nakamura, N; Kaneko, T; Matsuura, Y; Kaibuchi, K			The COOH terminus of Rho-kinase negatively regulates Rho-kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; SERINE-THREONINE KINASE; ACTIN STRESS FIBERS; SMALL GTPASE RHO; LIGHT-CHAIN; FOCAL ADHESIONS; CATALYTIC SUBUNITS; MYOSIN PHOSPHATASE; PUTATIVE TARGET; COILED-COIL	Rho-kinase is implicated in the phosphorylation of myosin Light chain downstream of Rho, which is thought to induce smooth muscle contraction and stress fiber formation in non-muscle cells. Here, we examined the mode of action of inhibitors of Rho-kinase. The chemical compounds such as HA1077 and Y-32885 inhibited not only the Rho-kinase activity but also the activity of protein kinase N, one of the targets of Rho, but had less of an effect on the activity of myotonic dystrophy kinase-related Cdc42-binding kinase beta (MRCK beta). The COOH-terminal portion of Rho-kinase containing Rho-binding (RB) and pleckstrin homology (PH) domains (RB/PH (TT)), in which point mutations were introduced to abolish the Rho binding activity, interacted with Rho-kinase and thereby inhibited the Rho-kinase activity, whereas RB/PH (TT) had no effect on the activity of protein kinase N or MRCK beta, suggesting that the COOH-terminal region of Rho-kinase is a possible negative regulatory region of Rho-kinase. The expression of RB/PH (TT) specifically blocked the stress fiber and focal adhesion formation induced by the active form of Rho or Rho-kinase in NIH 3T3 cells, but not that induced by the active form of MRCK beta or myosin light chain. Thus, RB/PH (TT) appears to specifically inhibit Rho kinase in vivo.	Nara Inst Sci & Technol, Div Signal Transduct, Ikoma 6300101, Japan; Natl Inst Infect Dis, Dept Virol 2, Shinjuku Ku, Tokyo 1628640, Japan	Nara Institute of Science & Technology; National Institute of Infectious Diseases (NIID)	Kaibuchi, K (corresponding author), Nara Inst Sci & Technol, Div Signal Transduct, 8916-5 Takayama, Ikoma 6300101, Japan.		Amano, Mutsuki/M-4820-2014	Amano, Mutsuki/0000-0002-0662-1524				Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1998, GENES CELLS, V3, P177, DOI 10.1046/j.1365-2443.1998.00181.x; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; BRESNICK AR, 1995, BIOCHEMISTRY-US, V34, P12576, DOI 10.1021/bi00039a012; Cachero TG, 1998, CELL, V93, P1077, DOI 10.1016/S0092-8674(00)81212-X; Chihara K, 1997, J BIOL CHEM, V272, P25121, DOI 10.1074/jbc.272.40.25121; CHRZANOWSKAWODN.M, 1996, J CELL BIOL, V133, P139; Engh RA, 1996, J BIOL CHEM, V271, P26157, DOI 10.1074/jbc.271.42.26157; Fujisawa K, 1996, J BIOL CHEM, V271, P23022, DOI 10.1074/jbc.271.38.23022; Fukata Y, 1999, J CELL BIOL, V145, P347, DOI 10.1083/jcb.145.2.347; Gibson RM, 1997, J BIOL CHEM, V272, P16343, DOI 10.1074/jbc.272.26.16343; Gibson RM, 1997, PROTEIN SCI, V6, P1825, DOI 10.1002/pro.5560060903; Goto H, 1998, J BIOL CHEM, V273, P11728, DOI 10.1074/jbc.273.19.11728; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; KAMISOYAMA H, 1994, BIOCHEMISTRY-US, V33, P840, DOI 10.1021/bi00169a027; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kimura K, 1998, J BIOL CHEM, V273, P5542, DOI 10.1074/jbc.273.10.5542; Kosako H, 1997, J BIOL CHEM, V272, P10333; Kureishi Y, 1997, J BIOL CHEM, V272, P12257, DOI 10.1074/jbc.272.19.12257; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Madaule P, 1995, FEBS LETT, V377, P243, DOI 10.1016/0014-5793(95)01351-2; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V199, P897, DOI 10.1006/bbrc.1994.1313; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Oshiro N, 1998, J BIOL CHEM, V273, P34663, DOI 10.1074/jbc.273.52.34663; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; SWEENEY HL, 1994, P NATL ACAD SCI USA, V91, P1490, DOI 10.1073/pnas.91.4.1490; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Yasui Y, 1998, J CELL BIOL, V143, P1249, DOI 10.1083/jcb.143.5.1249	43	216	227	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32418	32424		10.1074/jbc.274.45.32418	http://dx.doi.org/10.1074/jbc.274.45.32418			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542285	hybrid			2022-12-27	WOS:000083532100093
J	Camerer, E; Rottingen, JA; Gjernes, E; Larsen, K; Skartlien, AH; Iversen, JG; Prydz, H				Camerer, E; Rottingen, JA; Gjernes, E; Larsen, K; Skartlien, AH; Iversen, JG; Prydz, H			Coagulation factors VIIa and Xa induce cell signaling leading to up-regulation of the egr-1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINASE-ACTIVATED RECEPTOR-2; VEIN ENDOTHELIAL-CELLS; CANINE KIDNEY-CELLS; SMOOTH-MUSCLE CELLS; TISSUE FACTOR; THROMBIN-RECEPTOR; MOLECULAR-CLONING; BLOOD-COAGULATION; EPITHELIAL-CELLS; HUMAN PLATELETS	Intracellular signaling induced by the coagulation factors (F) VIIa and Xa is poorly understood. We report here studies on these processes in a human keratinocyte line (HaCaT), which is a constitutive producer of tissue factor (TF) and responds to both FVIIa and FXa with elevation of cytosolic Ca2+, phosphorylation of extracellular signal-regulated kinase (Erk) 1/2, p38(MAPK), and c-Jun N-terminal kinase, and up-regulation of transcription of the early growth response gene-1 (egr-1). Using egr-1 as end point, we observed with both agonists that phosphatidylinositol-specific phospholipase C and the mitogen-activated protein kinase/Erk kinase/Erk pathway were mediators of the responses. The responses to FVIIa were TF-dependent and up-regulation of egr-1 mRNA did not require presence of the TF cytoplasmic domain. Antibodies to EPR-1 and factor V had no effect on the response to FXa. We have provided evidence that TF is not the sole component of the FVIIa receptor. The requirement for proteolytic activity of both FVIIa and FXa suggests that protease-activated receptors may be involved. We now report evidence suggesting that protease-activated receptor 2 or a close homologue may be a necessary but not sufficient component of this particular signal transduction pathway. The up-regulation of egr-1 describes one way by which the initiation of blood coagulation may influence gene transcription. The ability of these coagulation proteases to induce intracellular signals at concentrations at or below the plasma concentrations of their zymogen precursors suggests that these processes may occur also in vivo.	Ctr Biotechnol, N-0371 Oslo, Norway; Univ Oslo, Inst Basic Med Sci, Dept Physiol, Lab Intracellular Signaling, N-0371 Oslo, Norway	University of Oslo	Prydz, H (corresponding author), Ctr Biotechnol, Gaustadalleen 21, N-0371 Oslo, Norway.	hans.prydz@biotek.uio.no	Camerer, Eric/K-4161-2017	Camerer, Eric/0000-0002-6271-7125				Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; BLEASDALE JE, 1990, J PHARMACOL EXP THER, V255, P756; Bono F, 1997, J CELL PHYSIOL, V172, P36, DOI 10.1002/(SICI)1097-4652(199707)172:1<36::AID-JCP4>3.0.CO;2-E; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Brass LF, 1997, THROMB HAEMOSTASIS, V78, P234; Camerer E, 1996, BLOOD, V88, P1339, DOI 10.1182/blood.V88.4.1339.bloodjournal8841339; Camerer E, 1996, THROMB RES, V81, P1, DOI 10.1016/0049-3848(95)00209-X; Camerer E, 1996, J BIOL CHEM, V271, P29034, DOI 10.1074/jbc.271.46.29034; Coughlin SR, 1998, ARTERIOSCL THROM VAS, V18, P514, DOI 10.1161/01.ATV.18.4.514; Cui MZ, 1996, J BIOL CHEM, V271, P2731, DOI 10.1074/jbc.271.5.2731; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Fox MT, 1997, FEBS LETT, V417, P267, DOI 10.1016/S0014-5793(97)01298-2; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GAJDUSEK C, 1986, J CELL BIOL, V103, P419, DOI 10.1083/jcb.103.2.419; GASIC GP, 1992, P NATL ACAD SCI USA, V89, P2317, DOI 10.1073/pnas.89.6.2317; Grand RJA, 1996, BIOCHEM J, V313, P353, DOI 10.1042/bj3130353; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Herbert JM, 1998, J CLIN INVEST, V101, P993, DOI 10.1172/JCI1833; HUANG RP, 1994, BIOCHEM BIOPH RES CO, V200, P1271, DOI 10.1006/bbrc.1994.1588; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; Khachigian LM, 1997, CIRC RES, V81, P457, DOI 10.1161/01.RES.81.4.457; Ko FN, 1996, J CLIN INVEST, V98, P1493, DOI 10.1172/JCI118938; Nicholson AC, 1996, J BIOL CHEM, V271, P28407, DOI 10.1074/jbc.271.45.28407; NYSTEDT S, 1995, EUR J BIOCHEM, V232, P84, DOI 10.1111/j.1432-1033.1995.tb20784.x; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; Ollivier V, 1998, BLOOD, V91, P2698, DOI 10.1182/blood.V91.8.2698.2698_2698_2703; Ott I, 1998, J CELL BIOL, V140, P1241, DOI 10.1083/jcb.140.5.1241; PABORSKY LR, 1991, J BIOL CHEM, V266, P21911; Papapetropoulos A, 1998, P NATL ACAD SCI USA, V95, P4738, DOI 10.1073/pnas.95.8.4738; Pendurthi UR, 1997, P NATL ACAD SCI USA, V94, P12598, DOI 10.1073/pnas.94.23.12598; Poulsen LK, 1998, J BIOL CHEM, V273, P6228, DOI 10.1074/jbc.273.11.6228; Randolph GJ, 1998, BLOOD, V92, P4167, DOI 10.1182/blood.V92.11.4167.423k35_4167_4177; ROTNES JS, 1994, CELL CALCIUM, V15, P467, DOI 10.1016/0143-4160(94)90111-2; ROTNES JS, 1992, CELL CALCIUM, V13, P487, DOI 10.1016/0143-4160(92)90017-M; ROTTINGEN JA, 1995, J BIOL CHEM, V270, P4650, DOI 10.1074/jbc.270.9.4650; Schaeffer P, 1997, CIRC RES, V81, P824; Senden NHM, 1998, J IMMUNOL, V161, P4318; Taniguchi T, 1998, CANCER RES, V58, P4461; Taylor CW, 1998, TRENDS PHARMACOL SCI, V19, P370, DOI 10.1016/S0165-6147(98)01243-7; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V	42	154	165	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32225	32233		10.1074/jbc.274.45.32225	http://dx.doi.org/10.1074/jbc.274.45.32225			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542260	hybrid			2022-12-27	WOS:000083532100068
J	Garnerone, AM; Cabanes, D; Foussard, M; Boistard, P; Batut, J				Garnerone, AM; Cabanes, D; Foussard, M; Boistard, P; Batut, J			Inhibition of the FixL sensor kinase by the FixT protein in Sinorhizobium meliloti	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHIZOBIUM-MELILOTI; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; OXYGEN SENSOR; PHOSPHATASE-ACTIVITIES; NITROGEN-FIXATION; MODULAR STRUCTURE; GENE-EXPRESSION; HEME PROTEIN; PHOSPHORYLATION	Nitrogen fixation in symbiotic rhizobia is subject to multiple levels of gene regulation. In Sinorhizobium meliloti, the alfalfa symbiont, the FixLJ two component regulatory system plays a major role in inducing nitrogen fixation and respiration gene expression in response to the low ambient O-2 concentration of the nodule, Here we report on the mode of action of the FixT protein, a recently identified repressor of nitrogen fixation gene expression in S, meliloti, First, we provide evidence that FixT prevents transcription of the intermediate key regulatory genes nifA and fixK by counteracting the activity of the FixLJ two-component system under otherwise inducing microoxic conditions. Second, we demonstrate that FixT acts as an inhibitor of the sensor hemoprotein kinase FixL, preventing the production or the accumulation of its phosphorylated form. FixT is thus a new example of a regulatory protein that blocks signal transduction in two-component systems at the level of the sensor kinase.	INRA, CNRS, Lab Biol Mol Relat Plantes Microorganismes, F-31326 Castanet Tolosan, France	Centre National de la Recherche Scientifique (CNRS); INRAE	Batut, J (corresponding author), INRA, CNRS, Lab Biol Mol Relat Plantes Microorganismes, BP27, F-31326 Castanet Tolosan, France.		Cabanes, Didier/P-3052-2019; BATUT, Jacques/B-6506-2008; Cabanes, Didier/K-3917-2013	Cabanes, Didier/0000-0002-4001-1332; Cabanes, Didier/0000-0002-4001-1332				Akagawa E, 1995, MICROBIOL-UK, V141, P3241, DOI 10.1099/13500872-141-12-3241; BATUT J, 1989, EMBO J, V8, P1279, DOI 10.1002/j.1460-2075.1989.tb03502.x; DAHL MK, 1992, J BIOL CHEM, V267, P14509; DAVID M, 1988, CELL, V54, P671, DOI 10.1016/S0092-8674(88)80012-6; DEPHILIP P, 1992, MOL GEN GENET, V235, P49, DOI 10.1007/BF00286180; DEPHILIP P, 1990, J BACTERIOL, V172, P4255, DOI 10.1128/jb.172.8.4255-4262.1990; DITTA G, 1987, J BACTERIOL, V169, P3217, DOI 10.1128/jb.169.7.3217-3223.1987; FISCHER HM, 1994, MICROBIOL REV, V58, P352, DOI 10.1128/MMBR.58.3.352-386.1994; Foussard M, 1997, MOL MICROBIOL, V25, P27, DOI 10.1046/j.1365-2958.1997.4501814.x; GALINIER A, 1994, J BIOL CHEM, V269, P23784; GILLESGONZALEZ MA, 1994, BIOCHEMISTRY-US, V33, P8067, DOI 10.1021/bi00192a011; GILLESGONZALEZ MA, 1993, J BIOL CHEM, V268, P16293; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; Gong WM, 1998, P NATL ACAD SCI USA, V95, P15177, DOI 10.1073/pnas.95.26.15177; KAHN D, 1991, MOL MICROBIOL, V5, P987, DOI 10.1111/j.1365-2958.1991.tb00774.x; KEENER J, 1988, P NATL ACAD SCI USA, V85, P4976, DOI 10.1073/pnas.85.14.4976; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LOIS AF, 1993, J BIOL CHEM, V268, P4370; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; Mizuno T, 1997, DNA Res, V4, P161, DOI 10.1093/dnares/4.2.161; MONSON EK, 1992, P NATL ACAD SCI USA, V89, P4280, DOI 10.1073/pnas.89.10.4280; MONSON EK, 1995, J BIOL CHEM, V270, P5243, DOI 10.1074/jbc.270.10.5243; Ogino T, 1998, MOL MICROBIOL, V27, P573, DOI 10.1046/j.1365-2958.1998.00703.x; PEREGO M, 1994, CELL, V79, P1047, DOI 10.1016/0092-8674(94)90035-3; RENALIER MH, 1987, J BACTERIOL, V169, P2231, DOI 10.1128/jb.169.5.2231-2238.1987; REYRAT JM, 1994, J BACTERIOL, V176, P1969, DOI 10.1128/jb.176.7.1969-1976.1994; REYRAT JM, 1993, J BACTERIOL, V175, P6867, DOI 10.1128/jb.175.21.6867-6872.1993; SOUPENE E, 1995, P NATL ACAD SCI USA, V92, P3759, DOI 10.1073/pnas.92.9.3759; Wang L, 1997, GENE DEV, V11, P2569, DOI 10.1101/gad.11.19.2569	29	57	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32500	32506		10.1074/jbc.274.45.32500	http://dx.doi.org/10.1074/jbc.274.45.32500			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542296	hybrid			2022-12-27	WOS:000083532100104
J	Jimenez-Asensio, J; Colvis, CM; Kowalak, JA; Duglas-Tabor, Y; Datiles, MB; Moroni, M; Mura, U; Rao, CM; Balasubramanian, D; Janjani, A; Garland, D				Jimenez-Asensio, J; Colvis, CM; Kowalak, JA; Duglas-Tabor, Y; Datiles, MB; Moroni, M; Mura, U; Rao, CM; Balasubramanian, D; Janjani, A; Garland, D			An atypical form of alpha B-crystallin is present in high concentration in some human cataractous lenses - Identification and characterization of aberrant N- and C-terminal processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; CHAPERONE-LIKE ACTIVITY; BOVINE LENS; 2-DIMENSIONAL ELECTROPHORESIS; PHOSPHORYLATION SITES; MOLECULAR CHAPERONE; MASS-SPECTROMETRY; STRESS PROTEINS; A-CRYSTALLIN; AMINO-ACID	Two unique polypeptides, 22.4 and 16.4 kDa, were prominent in some human cataracts. Both proteins mere identified as modified forms of the small heat shock protein, alpha B-crystallin. The concentration of total alpha B-crystallin in most of these cataracts was significantly increased. The 22.4-kDa protein was subsequently designated as alpha B-g. Mass spectrometric analyses of tryptic and Asp-N digests showed alpha B-g is alpha B-crystallin minus the C-terminal lysine. alpha B-g constituted 10-90% of the total alpha B-crystallin in these cataracts and was preferentially phosphorylated over the typical form of alpha B-crystallin. Human alpha B-g and alpha B-crystallin were cloned and expressed in Escherichia coli. The differences in electrophoretic mobility and the large difference in native pI values suggest some structural differences exist. The chaperone-like activity of recombinant human alpha B-g was comparable to that of recombinant human alpha B-crystallin in preventing the aggregation of lactalbumin induced by dithiothreitol, The mechanism involved in generating alpha B-g is not known, but a premature termination of the alpha B-crystallin gene was ruled out by sequencing the polymerase chain reaction products of the last exon for the alpha B-crystallin gene from lenses containing alpha B-g. The 16.4-kDa protein was an N-terminally truncated fragment of alpha B-g. The high concentration of alpha B-crystallin in these cataracts is the first observation of this kind in human lenses.	NEI, Lab Mechanisms Ocular Dis, NIH, Bethesda, MD 20892 USA; NICHHD, NIH, Bethesda, MD 20892 USA; Univ Pisa, I-56100 Pisa, Italy; Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India; Ctr Cellular & Mol Biol, Hyderabad 500034, Andhra Pradesh, India; LV Prasad Eye Inst, Hyderabad 500034, Andhra Pradesh, India	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Pisa; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB); L. V. Prasad Eye Institute	Garland, D (corresponding author), NEI, Lab Mechanisms Ocular Dis, NIH, Bldg 6,Rm 235, Bethesda, MD 20892 USA.		Datiles, Manuel/S-1206-2019	Datiles, Manuel III B./0000-0003-4660-1664				ANDERSON EI, 1978, EXP EYE RES, V26, P407, DOI 10.1016/0014-4835(78)90128-8; Andley UP, 1996, J BIOL CHEM, V271, P31973, DOI 10.1074/jbc.271.50.31973; AOYAMA A, 1993, MOL CELL BIOL, V13, P1824, DOI 10.1128/MCB.13.3.1824; Augusteyn RC, 1998, EXP EYE RES, V66, P669, DOI 10.1006/exer.1998.0468; BARRETT AJ, 1998, HDB PROTEOLYTIC ENZY, P1341; Bhat SP, 1999, EUR J CELL BIOL, V78, P143, DOI 10.1016/S0171-9335(99)80016-8; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; BINDELS JG, 1983, COMP BIOCHEM PHYS B, V76, P47, DOI 10.1016/0305-0491(83)90169-4; BLOEMENDAL H, 1981, MOL CELLULAR BIOL EY, P279; CARTER JM, 1995, EXP EYE RES, V60, P181, DOI 10.1016/S0014-4835(95)80009-3; Carver JA, 1998, INT J BIOL MACROMOL, V22, P197, DOI 10.1016/S0141-8130(98)00017-8; CHIESA R, 1987, BIOCHEM BIOPH RES CO, V144, P1340, DOI 10.1016/0006-291X(87)91457-4; CHIESA R, 1987, J BIOL CHEM, V262, P1438; DASGUPTA S, 1992, EXP EYE RES, V54, P461, DOI 10.1016/0014-4835(92)90058-Z; de Jong W.W., 1988, Advances in Experimental Medicine and Biology, V231, P95; DEJONG WW, 1989, TRENDS BIOCHEM SCI, V14, P365, DOI 10.1016/0968-0004(89)90009-1; DELVECCHIO PJ, 1984, CURR EYE RES, V3, P1213; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; EMMONS T, 1992, EXP EYE RES, V55, P551, DOI 10.1016/S0014-4835(05)80167-8; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; Garland DL, 1996, EXP EYE RES, V62, P285, DOI 10.1006/exer.1996.0034; GOPALAKRISHNAN S, 1992, CURR EYE RES, V11, P929, DOI 10.3109/02713689209033490; GORTHY WC, 1992, CURR EYE RES, V11, P531, DOI 10.3109/02713689209001809; GROENEN PJTA, 1994, EUR J BIOCHEM, V220, P795, DOI 10.1111/j.1432-1033.1994.tb18681.x; GROENEN PJTA, 1994, EUR J BIOCHEM, V225, P1, DOI 10.1111/j.1432-1033.1994.00001.x; HARDING JJ, 1976, EXP EYE RES, V22, P1, DOI 10.1016/0014-4835(76)90033-6; HE SM, 1995, J MASS SPECTROM, V30, P424, DOI 10.1002/jms.1190300305; HOENDERS HJ, 1983, J GERONTOL, V38, P278, DOI 10.1093/geronj/38.3.278; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; Ito H, 1997, J BIOL CHEM, V272, P29934, DOI 10.1074/jbc.272.47.29934; IWAKI T, 1993, ACTA NEUROPATHOL, V85, P475; IWAKI T, 1993, AM J PATHOL, V143, P487; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; JAKOB U, 1993, J BIOL CHEM, V268, P1517; Kato K, 1997, CELL STRESS CHAPERON, V2, P199, DOI 10.1379/1466-1268(1997)002<0199:MOTAIE>2.3.CO;2; KATO K, 1993, J BIOCHEM-TOKYO, V114, P640, DOI 10.1093/oxfordjournals.jbchem.a124230; KLEMENZ R, 1994, VERH DEUT G, V78, P34; KLEMENZ R, 1993, J CELL BIOL, V120, P639, DOI 10.1083/jcb.120.3.639; Lin PP, 1997, EXP EYE RES, V65, P673, DOI 10.1006/exer.1997.0376; LORAND L, 1992, P NATL ACAD SCI USA, V89, P11161, DOI 10.1073/pnas.89.23.11161; MERCK KB, 1993, J BIOL CHEM, V268, P1046; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Plater ML, 1996, J BIOL CHEM, V271, P28558, DOI 10.1074/jbc.271.45.28558; ROQUEMORE EP, 1992, J BIOL CHEM, V267, P555; SHARMA KK, 1992, EXP EYE RES, V54, P1005, DOI 10.1016/0014-4835(92)90165-O; SMITH JB, 1995, J PROTEIN CHEM, V14, P179, DOI 10.1007/BF01980330; SMITH JB, 1992, PROTEIN SCI, V1, P601, DOI 10.1002/pro.5560010506; Smulders RHPH, 1996, J BIOL CHEM, V271, P29060, DOI 10.1074/jbc.271.46.29060; SPECTOR A, 1985, P NATL ACAD SCI USA, V82, P4712, DOI 10.1073/pnas.82.14.4712; SRINIVASAN AN, 1992, J BIOL CHEM, V267, P23337; STONE KL, 1993, PRACTICAL GUIDE PROT, P45; SWANSON AA, 1985, CURR EYE RES, V4, P43, DOI 10.3109/02713688508999965; TAKEMOTO L, 1994, EXP EYE RES, V59, P239, DOI 10.1006/exer.1994.1103; VOORTER CEM, 1989, FEBS LETT, V259, P50; Wang KY, 1996, EUR J BIOCHEM, V242, P56, DOI 10.1111/j.1432-1033.1996.0056r.x; WISTOW G, 1985, FEBS LETT, V181, P1, DOI 10.1016/0014-5793(85)81102-9	58	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32287	32294		10.1074/jbc.274.45.32287	http://dx.doi.org/10.1074/jbc.274.45.32287			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542268	hybrid			2022-12-27	WOS:000083532100076
J	Kreppel, LK; Hart, GW				Kreppel, LK; Hart, GW			Regulation of a cytosolic and nuclear O-GlcNAc transferase - Role of the tetratricopeptide repeats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-N-ACETYLGLUCOSAMINYLTRANSFERASE; EIF-2 ALPHA-SUBUNIT; LINKED GLYCOSYLATION; CYTOSKELETAL PROTEINS; CYTOPLASMIC PROTEINS; SNAP HELIX; PHOSPHORYLATION; TPR; PURIFICATION; DOMAIN	The O-GlcNAc transferase (OGT) is a unique nuclear and cytosolic glycosyltransferase that contains multiple tetratricopeptide repeats. We have begun to characterize the mechanisms regulating OGT using a combination of deletion analysis and kinetic studies. Here we show that the p110 subunit of the enzyme forms both homo- and heterotrimers that appear to have different binding affinities for UDP-GlcNAc. The multimerization domain of OGT lies within the tetratricopeptide repeat domain and is not necessary for activity. Kinetic analyses of the full-length trimer and the truncated monomer forms of OGT suggest that both forms function through a random bi-bi kinetic mechanism. Both the monomer and trimer have similar specific activities and similar K-m values for peptide substrates. However, they differ in their binding affinities for UDP-GlcNAc, indicating that subunit interactions affect enzyme activity. The findings that recombinant OGT has three distinct K-m values for UDP-GlcNAc and that UDP-GlcNAc concentrations modulates the affinity of OGT for peptides suggest that OGT is exquisitely regulated by the levels of UDP-GlcNAc within the nucleus and cytoplasm.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University	Hart, GW (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.			Hart, Gerald/0000-0001-7812-4351	NICHD NIH HHS [R01 HD13563] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD013563] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ausubel FM, 1988, MOL REPROD DEV; BOYLE JS, 1995, TRENDS GENET, V11, P8, DOI 10.1016/S0168-9525(00)88977-5; CHAKRABORTY A, 1994, BIOCHEMISTRY-US, V33, P6700, DOI 10.1021/bi00187a041; CHOU CF, 1993, J BIOL CHEM, V268, P4465; CHOU CF, 1992, J BIOL CHEM, V267, P3901; DATTA B, 1989, J BIOL CHEM, V264, P20620; Dong DLY, 1996, J BIOL CHEM, V271, P20845, DOI 10.1074/jbc.271.34.20845; DONG DLY, 1994, J BIOL CHEM, V269, P19321; FIELD MC, 1995, GLYCOBIOLOGY, V5, P463, DOI 10.1093/glycob/5.5.463; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; Haltiwanger R S, 1993, Methods Mol Biol, V14, P175; HALTIWANGER RS, 1990, J BIOL CHEM, V265, P2563; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315; Hart GW, 1996, GLYCOBIOLOGY, V6, P711, DOI 10.1093/glycob/6.7.711; Haucke V, 1996, EMBO J, V15, P1231, DOI 10.1002/j.1460-2075.1996.tb00464.x; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; KAPLAN HA, 1984, COMP BIOCHEM PHYS A, V77, P207, DOI 10.1016/0300-9629(84)90048-3; KEARSE KP, 1991, P NATL ACAD SCI USA, V88, P1701, DOI 10.1073/pnas.88.5.1701; KELLY WG, 1993, J BIOL CHEM, V268, P10416; Kreppel LK, 1997, J BIOL CHEM, V272, P9308; KREPPEL LK, 1999, MOL CELLULAR GLYCOBI; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; Lubas WA, 1997, J BIOL CHEM, V272, P9316; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; RAMEAU G, 1994, MOL CELL BIOL, V14, P822, DOI 10.1128/MCB.14.1.822; ROQUEMORE EP, 1994, METHOD ENZYMOL, V230, P443; Roquemore EP, 1996, BIOCHEMISTRY-US, V35, P3578, DOI 10.1021/bi951918j; SARNSTRAND B, 1987, ARCH BIOCHEM BIOPHYS, V252, P315, DOI 10.1016/0003-9861(87)90036-1; SCHULTZ J, 1990, MOL CELL BIOL, V10, P4744, DOI 10.1128/MCB.10.9.4744; Shaw P, 1996, ONCOGENE, V12, P921; Snow DM, 1998, INT REV CYTOL, V181, P43, DOI 10.1016/S0074-7696(08)60416-7; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; TZAMARIAS D, 1995, GENE DEV, V9, P821, DOI 10.1101/gad.9.7.821; WICE BM, 1985, J BIOL CHEM, V260, P139; ZHIVKOV V, 1975, COMP BIOCHEM PHYS B, V51, P421, DOI 10.1016/0305-0491(75)90032-2	39	308	332	0	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32015	32022		10.1074/jbc.274.45.32015	http://dx.doi.org/10.1074/jbc.274.45.32015			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542233	hybrid			2022-12-27	WOS:000083532100041
J	Reuven, NB; Arad, G; Maor-Shoshani, A; Livneh, Z				Reuven, NB; Arad, G; Maor-Shoshani, A; Livneh, Z			The mutagenesis protein UmuC is a DNA polymerase activated by UmuD ', RecA, and SSB and is specialized for translesion replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ULTRAVIOLET-LIGHT MUTAGENESIS; SINGLE-STRANDED VECTOR; ESCHERICHIA-COLI; UV MUTAGENESIS; BACTERIOPHAGE-LAMBDA; ABASIC SITE; MECHANISM; REPAIR; BYPASS; INVOLVEMENT	Replication of DNA lesions leads to the formation of mutations. In Escherichia coli this process is regulated by the SOS stress response, and requires the mutagenesis proteins UmuC and UmuD', Analysis of translesion replication using a recently reconstituted in vitro system (Reuven, N. B., Tomer, G., and Livneh, Z. (1998) Mol. Cell 2, 191-199) revealed that lesion bypass occurred with a UmuC fusion protein, UmuD', RecA, and SSB in the absence of added DNA polymerase, Further analysis revealed that UmuC was a DNA polymerase (E. coli DNA polymerase V), with a weak polymerizing activity. Upon addition of UmuD', RecA, and SSB, the UmuC DNA polymerase was greatly activated, and replicated a synthetic abasic site with great efficiency (45% bypass in 6 min), 10-100-fold higher than E. coli DNA polymerases I, II, or III holoenzyme, Analysis of bypass products revealed insertion of primarily dAMP (69%), and to a lesser degree dGMP (31%) opposite the abasic site. The UmuC104, mutant protein was defective both in lesion bypass and in DNA synthesis. These results indicate that UmuC is a UmuD'-, RecA-, and SSB-activated DNA polymerase, which is specialized for lesion bypass. UmuC is a member of a new family of DNA polymerases which are specialized for lesion bypass, and include the yeast RAD30 and the human XP-V genes, encoding DNA polymerase eta.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Livneh, Z (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	bclivneh@weizmann.weizmann.ac.il	Reuven, Nina/AAM-8711-2020	Reuven, Nina/0000-0003-1569-3818				BANERJEE SK, 1988, P NATL ACAD SCI USA, V85, P8141, DOI 10.1073/pnas.85.21.8141; BARZILAI R, 1973, J MOL BIOL, V74, P739, DOI 10.1016/0022-2836(73)90062-4; BRIDGES BA, 1976, MOL GEN GENET, V144, P53, DOI 10.1007/BF00277304; BRIDGES BA, 1990, MUTAGENESIS, V5, P35, DOI 10.1093/mutage/5.1.35; BROTCORNELANNOYE A, 1986, P NATL ACAD SCI USA, V83, P3904, DOI 10.1073/pnas.83.11.3904; BROTCORNELANNOYE A, 1985, MOL GEN GENET, V199, P64, DOI 10.1007/BF00327511; COHENFIX O, 1992, P NATL ACAD SCI USA, V89, P3300, DOI 10.1073/pnas.89.8.3300; COX MM, 1981, J BIOL CHEM, V256, P4676; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENSI; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; KOCH WH, 1992, MOL GEN GENET, V233, P443, DOI 10.1007/BF00265442; KUNKEL TA, 1984, P NATL ACAD SCI-BIOL, V81, P1494, DOI 10.1073/pnas.81.5.1494; LAWRENCE CW, 1990, NUCLEIC ACIDS RES, V18, P2153, DOI 10.1093/nar/18.8.2153; LIVNEH Z, 1993, CRIT REV BIOCHEM MOL, V28, P465, DOI 10.3109/10409239309085136; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; McDonald JP, 1997, GENETICS, V147, P1557; PazElizur T, 1997, BIOCHEMISTRY-US, V36, P1766, DOI 10.1021/bi9621324; PazElizur T, 1996, J BIOL CHEM, V271, P24662, DOI 10.1074/jbc.271.40.24662; RAJAGOPALAN M, 1992, P NATL ACAD SCI USA, V89, P10777, DOI 10.1073/pnas.89.22.10777; Reuven NB, 1998, MOL CELL, V2, P191, DOI 10.1016/S1097-2765(00)80129-X; STEINBORN G, 1978, MOL GEN GENET, V165, P87, DOI 10.1007/BF00270380; TAKESHITA M, 1994, NUCLEIC ACIDS RES, V22, P1897, DOI 10.1093/nar/22.10.1897; Tang MJ, 1999, P NATL ACAD SCI USA, V96, P8919, DOI 10.1073/pnas.96.16.8919; Tang MJ, 1998, P NATL ACAD SCI USA, V95, P9755, DOI 10.1073/pnas.95.17.9755; Tomer G, 1999, BIOCHEMISTRY-US, V38, P5948, DOI 10.1021/bi982599+; Tomer G, 1998, P NATL ACAD SCI USA, V95, P14106, DOI 10.1073/pnas.95.24.14106; Wagner J, 1999, MOL CELL, V4, P281, DOI 10.1016/S1097-2765(00)80376-7; WALKER GC, 1995, TRENDS BIOCHEM SCI, V20, P416, DOI 10.1016/S0968-0004(00)89091-X	29	289	293	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31763	31766		10.1074/jbc.274.45.31763	http://dx.doi.org/10.1074/jbc.274.45.31763			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542196	hybrid			2022-12-27	WOS:000083532100004
J	Alberdi, E; Aymerich, MS; Becerra, SP				Alberdi, E; Aymerich, MS; Becerra, SP			Binding of pigment epithelium-derived factor (PEDF) to retinoblastoma cells and cerebellar granule neurons - Evidence for a PEDF receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME COMPLEX RECEPTOR; AMYLOID-BETA PEPTIDE; NEUROTROPHIC ACTIVITY; NONINHIBITORY SERPIN; NEURITE OUTGROWTH; HEPATOMA-CELLS; NERVOUS-SYSTEM; BOVINE EYES; PROTEIN; GENE	Pigment epithelium-derived factor (PEDF);has neuronal differentiation and survival;activity on retinoblastoma and cerebellar granule (CG) cells. Here, we investigated the presence of PEDF receptors on retinoblastoma Y-79 and CG cells. PEDF radiolabeled with I-125 remained biologically active and was used for radioligand binding analysis. The binding was saturable and specific to a single class of receptors on both cells and with similar affinities (K-d = 1.7-3.6 nM, B-max = 10.5-2.7 x 10(5) sites/Y-79 cell; and K-d = 3.2 nM, B-max = 1.1 x 10(3) sites/CG cell). A polyclonal antiserum to PEDF, previously shown to block the PEDF neurotrophic activity, prevented the I-125-PEDF binding. We designed two peptides from a region previously shown to confer the neurotrophic property to human PEDF, synthetic peptides 34-mer (positions 44-77) and 44-mer (positions 78-121). Only peptide 44-mer competed for the binding to Y-79 cell receptors (EC50 = 5 nM) and exhibited neuronal differentiating activity. PEDF affinity column chromatography of membrane proteins from both cell types revealed a PEDF-binding protein of similar to 80 kDa. These results are the first demonstration of at PEDF-binding protein with characteristics of a PEDF receptor and suggest that the region comprising amino acid positions 78-121 of PEDF might be involved in ligand-receptor interactions.	NEI, Retinal Cell & Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Becerra, SP (corresponding author), NEI, Retinal Cell & Mol Biol Lab, NIH, Bldg 6,Rm 308,6 Ctr Dr,MSC 2740, Bethesda, MD 20892 USA.		Alberdi, Elena/D-6383-2017; Alberdi, Elena/AAH-1757-2019; Aymerich, M. S./H-2873-2017	Alberdi, Elena/0000-0002-8000-142X; Alberdi, Elena/0000-0002-8000-142X; Aymerich, M. S./0000-0001-9750-1538				Alberdi E, 1998, BIOCHEMISTRY-US, V37, P10643, DOI 10.1021/bi9802317; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Araki T, 1998, J NEUROSCI RES, V53, P7, DOI 10.1002/(SICI)1097-4547(19980701)53:1<7::AID-JNR2>3.3.CO;2-H; BALCIUNIENE J, 1995, GENOMICS, V30, P281, DOI 10.1006/geno.1995.9876; Becerra SP, 1997, ADV EXP MED BIOL, V425, P223; BECERRA SP, 1993, J BIOL CHEM, V268, P23148; BECERRA SP, 1995, J BIOL CHEM, V270, P25992, DOI 10.1074/jbc.270.43.25992; Becerra SP, 1999, RETINAL DEGENERATIVE DISEASES AND EXPERIMENTAL THERAPY, P519, DOI 10.1007/978-0-585-33172-0_49; Bilak MM, 1999, J NEUROPATH EXP NEUR, V58, P719, DOI 10.1097/00005072-199907000-00006; BOLAND K, 1995, J BIOL CHEM, V270, P28022; BU GJ, 1994, J BIOL CHEM, V269, P18521; DeCoster MA, 1999, J NEUROSCI RES, V56, P604; Festoff BW, 1996, J NEUROBIOL, V30, P255, DOI 10.1002/(SICI)1097-4695(199606)30:2<255::AID-NEU7>3.0.CO;2-4; GOLFATH R, 1996, MOL VIS, V2, P5; GURWITZ D, 1990, J CELL PHYSIOL, V142, P155, DOI 10.1002/jcp.1041420119; HOLTZMAN DM, 1995, P NATL ACAD SCI USA, V92, P9480, DOI 10.1073/pnas.92.21.9480; Houenou LJ, 1999, J COMP NEUROL, V412, P506; JOSLIN G, 1991, J BIOL CHEM, V266, P11282; JOSLIN G, 1993, J BIOL CHEM, V268, P1886; JOSLIN G, 1991, J BIOL CHEM, V266, P21897; Kohji T, 1998, NEUROSCI LETT, V243, P133, DOI 10.1016/S0304-3940(98)00109-8; Kounnas MZ, 1996, J BIOL CHEM, V271, P6523, DOI 10.1074/jbc.271.11.6523; Lotery AJ, 1996, HUM MOL GENET, V5, P705, DOI 10.1093/hmg/5.5.705; Narita M, 1997, J NEUROCHEM, V68, P587; Ortego J, 1996, INVEST OPHTH VIS SCI, V37, P2759; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; Perez-Mediavilla LA, 1998, BBA-GENE STRUCT EXPR, V1398, P203, DOI 10.1016/S0167-4781(98)00055-4; PERLMUTTER DH, 1990, P NATL ACAD SCI USA, V87, P3753, DOI 10.1073/pnas.87.10.3753; PIGNOLO RJ, 1993, J BIOL CHEM, V268, P8949; POLLER W, 1995, J BIOL CHEM, V270, P2841, DOI 10.1074/jbc.270.6.2841; Shirozu M, 1996, GENOMICS, V37, P273, DOI 10.1006/geno.1996.0560; SMIRNOVA IV, 1994, SEMIN THROMB HEMOST, V20, P426, DOI 10.1055/s-2007-1001931; STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526; STEIN PE, 1989, BIOCHEM J, V262, P103, DOI 10.1042/bj2620103; Stratikos E, 1996, PROTEIN SCI, V5, P2575, DOI 10.1002/pro.5560051220; Sugita Y, 1997, J NEUROSCI RES, V49, P710, DOI 10.1002/(SICI)1097-4547(19970915)49:6<710::AID-JNR5>3.0.CO;2-A; TANIWAKI T, 1995, J NEUROCHEM, V64, P2509; Taniwaki T, 1997, J NEUROCHEM, V68, P26; TOMBRANTINK J, 1994, GENOMICS, V19, P266, DOI 10.1006/geno.1994.1057; TOMBRANTINK J, 1995, J NEUROSCI, V15, P4992; TOMBRANTINK J, 1991, EXP EYE RES, V53, P411, DOI 10.1016/0014-4835(91)90248-D; WAGNER SL, 1991, J NEUROCHEM, V56, P234, DOI 10.1111/j.1471-4159.1991.tb02586.x; Wu YQ, 1996, INVEST OPHTH VIS SCI, V37, P1984; WU YQ, 1995, PROTEIN EXPRES PURIF, V6, P447, DOI 10.1006/prep.1995.1060	44	115	129	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31605	31612		10.1074/jbc.274.44.31605	http://dx.doi.org/10.1074/jbc.274.44.31605			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531367	hybrid			2022-12-27	WOS:000083379400071
J	Rubbi, L; Labarre-Mariotte, S; Chedin, S; Thuriaux, P				Rubbi, L; Labarre-Mariotte, S; Chedin, S; Thuriaux, P			Functional characterization of ABC10 alpha, an essential polypeptide shared by all three forms of eukaryotic DNA-dependent RNA polymerases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; SWINE FEVER VIRUS; SACCHAROMYCES-CEREVISIAE; COMMON SUBUNITS; ACTIVE-SITE; TRANSCRIPTION INITIATION; III MUTATIONS; YEAST; GENE; TRANSLATION	ABC10 alpha is a small polypeptide shared by the three yeast RNA polymerases, Homologous polypeptides in higher eukaryotes have a zinc-binding CX2C ... CX2C motif and a conserved basic C-terminal end. These features are also found in archaeal gene products that may encode an RNA polymerase subunit, The CX2C ... CX2C motif is partly dispensable, since only its first cysteine is essential for growth, whereas the basic C-terminal end is critical in vivo, A mutant in the latter domain has an RNA polymerase III-specific defect and, in vitro, impairs RNA polymerase III assembly. Polymerase activity was, however, not affected in various faithful transcription assays. The mutant is suppressed by a high gene dosage of the second largest subunit of RNA polymerase III, whereas the homologous subunits of RNA polymerase I and II have aggravating effects. In a two-hybrid assay, ABC10 alpha binds to the C-terminal half of the second largest subunit of RNA polymerase I, in a way that requires the integrity of the CX2C ... CX2C motif Thus, ABC10 alpha appears to interact directly with the second largest subunit during polymerase assembly. This interaction is presumably a major rate-limiting step in assembly, since diploid cells containing only one functional gene copy for ABC10 alpha have a partial growth defect.	CEA Saclay, Serv Biochim & Genet Mol, F-91191 Gif Sur Yvette, France	CEA; UDICE-French Research Universities; Universite Paris Saclay	Thuriaux, P (corresponding author), CEA Saclay, Serv Biochim & Genet Mol, Bat 142, F-91191 Gif Sur Yvette, France.							Brun I, 1997, EMBO J, V16, P5730, DOI 10.1093/emboj/16.18.5730; BUHLER JM, 1976, J BIOL CHEM, V251, P1712; CARLES C, 1991, J BIOL CHEM, V266, P24092; CARLES C, 1998, TRANSCRIPTION RIBOSO, V1, P9; CHAUSSIVERT N, 1995, J BIOL CHEM, V270, P15333; Chedin S, 1998, COLD SPRING HARB SYM, V63, P381, DOI 10.1101/sqb.1998.63.381; Chedin S, 1998, GENE DEV, V12, P3857, DOI 10.1101/gad.12.24.3857; Chuang RY, 1997, SCIENCE, V275, P1468, DOI 10.1126/science.275.5305.1468; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; DIECI G, 1995, EMBO J, V14, P3766, DOI 10.1002/j.1460-2075.1995.tb00046.x; Doolittle RF, 1996, SCIENCE, V271, P470, DOI 10.1126/science.271.5248.470; Flores A, 1999, P NATL ACAD SCI USA, V96, P7815, DOI 10.1073/pnas.96.14.7815; Gadal O, 1999, J BIOL CHEM, V274, P8421, DOI 10.1074/jbc.274.13.8421; Gari E, 1997, YEAST, V13, P837, DOI 10.1002/(SICI)1097-0061(199707)13:9<837::AID-YEA145>3.0.CO;2-T; HERMANNLEDENMAT S, 1994, MOL CELL BIOL, V14, P2905, DOI 10.1128/MCB.14.5.2905; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HUET J, 1985, J BIOL CHEM, V260, P5304; Huet J, 1996, METHOD ENZYMOL, V273, P249; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; KUZNAR J, 1980, VIROLOGY, V101, P169, DOI 10.1016/0042-6822(80)90493-6; LALO D, 1993, P NATL ACAD SCI USA, V90, P5524, DOI 10.1073/pnas.90.12.5524; LANGER D, 1995, P NATL ACAD SCI USA, V92, P5768, DOI 10.1073/pnas.92.13.5768; LANZENDORFER M, 1997, GENE DEV, V11, P1033; LEFEBVRE O, 1994, J BIOL CHEM, V269, P23374; Mangus DA, 1998, MOL CELL BIOL, V18, P7383, DOI 10.1128/MCB.18.12.7383; MANN C, 1987, CELL, V48, P627, DOI 10.1016/0092-8674(87)90241-8; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MCKUNE K, 1995, MOL CELL BIOL, V15, P6895; RIVA M, 1990, J BIOL CHEM, V265, P16498; SENTENAC A, 1985, CRC CR REV BIOCH MOL, V18, P31, DOI 10.3109/10409238509082539; Shaaban SA, 1996, MOL CELL BIOL, V16, P6468; Shpakovski GV, 1997, BIOORG KHIM+, V23, P110; SHPAKOVSKI GV, 1995, MOL CELL BIOL, V15, P4702; STETTLER S, 1993, MOL GEN GENET, V239, P169, DOI 10.1007/BF00281615; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; Thuillier V, 1996, EMBO J, V15, P618, DOI 10.1002/j.1460-2075.1996.tb00394.x; THUILLIER V, 1995, EMBO J, V14, P351, DOI 10.1002/j.1460-2075.1995.tb07009.x; TREICH I, 1992, NUCLEIC ACIDS RES, V20, P4721, DOI 10.1093/nar/20.18.4721; TREICH I, 1991, J BIOL CHEM, V266, P21971; Treich Isabelle, 1992, Gene Expression, V2, P31; VALENZUELA P, 1976, BIOCHEM BIOPH RES CO, V71, P1319, DOI 10.1016/0006-291X(76)90799-3; Voutsina A, 1999, NUCLEIC ACIDS RES, V27, P1047, DOI 10.1093/nar/27.4.1047; WOYCHIK NA, 1990, J BIOL CHEM, V265, P17816; WOYCHIK NA, 1990, GENE DEV, V4, P313, DOI 10.1101/gad.4.3.313; YANEZ RJ, 1995, VIROLOGY, V208, P249, DOI 10.1006/viro.1995.1149	47	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31485	31492		10.1074/jbc.274.44.31485	http://dx.doi.org/10.1074/jbc.274.44.31485			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531351	hybrid			2022-12-27	WOS:000083379400055
J	Schaeffer, ML; Khoo, KH; Besra, GS; Chatterjee, D; Brennan, PJ; Belisle, JT; Inamine, JM				Schaeffer, ML; Khoo, KH; Besra, GS; Chatterjee, D; Brennan, PJ; Belisle, JT; Inamine, JM			The pimB gene of Mycobacterium tuberculosis encodes a mannosyltransferase involved in lipoarabinomannan biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL PROLIFERATION; ANCHOR; GLYCOSYLTRANSFERASES; GLYCOPROTEIN; MACROPHAGES; ETHAMBUTOL; DEFINITION; LIPOMANNAN; SEQUENCE; STRAINS	The biosynthesis of lipoarabinomannan (LAM), a key mycobacterial lipoglycan that has been implicated in numerous immunoregulatory functions, was examined utilizing D-mannosamine (ManN) as a tool to identify mannosyltransferase genes involved in LAM synthesis, Cell-free reactions utilizing cellular membranes of mycobacteria as the enzyme source indicated that ManN inhibited the synthesis of phosphatidylinositol mannosides, early precursors to LAM, A selection strategy was devised to screen a Mycobacterium tuberculosis genomic library in Mycobacterium smegmatis for clones conferring conditional resistance to ManN, with the rationale that overexpression of the gene(s) encoding a target of ManN would impart a ManN-resistant phenotype under these conditions. This strategy led to the identification of pimB, whose deduced amino acid sequence shows similarity to mannosyltransferases and other glycosyltransferases. Partially purified recombinant PimB protein from Escherichia coli or membranes from M. smegmatis overexpressing the pimB gene were used in cell-free assays to show that PimB catalyzes the formation of triacylphosphatidylinositol dimannoside from GDP-mannose and triacylphosphatidylinositol monomannoside.	Colorado State Univ, Dept Microbiol, Mycobacteriol Res Labs, Ft Collins, CO 80523 USA; Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; Newcastle Univ, Sch Med, Sch Microbiol Immunol & Virol Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Colorado State University; Academia Sinica - Taiwan; Newcastle University - UK	Inamine, JM (corresponding author), Colorado State Univ, Dept Microbiol, Mycobacteriol Res Labs, Ft Collins, CO 80523 USA.	jinamine@cvmbs.colostate.edu	Belisle, John T/B-8944-2017; Khoo, Kay-Hooi/E-1989-2019	Belisle, John T/0000-0002-2539-2798; Khoo, Kay-Hooi/0000-0003-2906-406X; Besra, Gurdyal/0000-0002-5605-0395	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035220, R01AI037139, R21AI037139, U19AI038087] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-35220, AI-37139, AI-38087] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ausubel FM, 1991, CURRENT PROTOCOLS MO; BALLOU CE, 1972, METHOD ENZYMOL, V28, P493; BAULARD A, 1992, NUCLEIC ACIDS RES, V20, P4105, DOI 10.1093/nar/20.15.4105; Belanger AE, 1996, P NATL ACAD SCI USA, V93, P11919, DOI 10.1073/pnas.93.21.11919; BELISLE JT, 1991, J BACTERIOL, V173, P6991, DOI 10.1128/jb.173.21.6991-6997.1991; Besra GS, 1997, J BIOL CHEM, V272, P18460, DOI 10.1074/jbc.272.29.18460; Blanchard JS, 1996, ANNU REV BIOCHEM, V65, P215, DOI 10.1146/annurev.bi.65.070196.001243; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNAN P, 1967, J BIOL CHEM, V242, P3046; BRENNAN P, 1968, J BIOL CHEM, V243, P2975; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; CHAN J, 1991, INFECT IMMUN, V59, P1755, DOI 10.1128/IAI.59.5.1755-1761.1991; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6234; CHATTERJEE D, 1992, INFECT IMMUN, V60, P1249, DOI 10.1128/IAI.60.3.1249-1253.1992; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6228; Chopra I, 1998, TUBERCLE LUNG DIS, V78, P89, DOI 10.1016/S0962-8479(98)80001-4; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; DENG LY, 1995, ANTIMICROB AGENTS CH, V39, P694, DOI 10.1128/AAC.39.3.694; Dobos KM, 1996, J BACTERIOL, V178, P2498, DOI 10.1128/jb.178.9.2498-2506.1996; FIELD MC, 1995, GLYCOBIOLOGY, V5, P463, DOI 10.1093/glycob/5.5.463; FOLCH J, 1957, J BIOL CHEM, V226, P497; Geremia RA, 1996, BIOCHEM J, V318, P133, DOI 10.1042/bj3180133; HOROWITZ MI, 1991, ARCH BIOCHEM BIOPHYS, V288, P317, DOI 10.1016/0003-9861(91)90201-S; HUNTER SW, 1990, J BIOL CHEM, V265, P9272; JACOBS WR, 1991, METHOD ENZYMOL, V204, P537; KAPLAN G, 1987, J IMMUNOL, V138, P3028; KHOO KH, 1995, J BIOL CHEM, V270, P12380, DOI 10.1074/jbc.270.21.12380; KHOO KH, 1995, GLYCOBIOLOGY, V5, P117, DOI 10.1093/glycob/5.1.117; MIKUSOVA K, 1995, ANTIMICROB AGENTS CH, V39, P2484, DOI 10.1128/AAC.39.11.2484; MORENO C, 1988, CLIN EXP IMMUNOL, V74, P206; PANGBORN MC, 1966, J LIPID RES, V7, P627; RALTON JE, 1993, J BIOL CHEM, V268, P24183; SALMAN M, 1999, BIOCHIM BIOPHYS ACTA, V146, P437; SCHLESINGER LS, 1994, J IMMUNOL, V152, P4070; SIBLEY LD, 1988, INFECT IMMUN, V56, P1232, DOI 10.1128/IAI.56.5.1232-1236.1988; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; TAKAYAMA K, 1975, J LIPID RES, V16, P308; TAKAYAMA K, 1969, BIOCHIM BIOPHYS ACTA, V176, P196, DOI 10.1016/0005-2760(69)90089-7; YOUNG DB, 1995, ANNU REV MICROBIOL, V49, P641, DOI 10.1146/annurev.mi.49.100195.003233	40	100	107	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31625	31631		10.1074/jbc.274.44.31625	http://dx.doi.org/10.1074/jbc.274.44.31625			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531370	hybrid			2022-12-27	WOS:000083379400074
J	Stradal, TB; Gimona, M				Stradal, TB; Gimona, M			Ca2+-dependent association of S100A6 (Calcyclin) with the plasma membrane and the nuclear envelope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEINS; SMOOTH-MUSCLE CELLS; INTRACELLULAR CALCIUM; MOLECULAR-CLONING; ANNEXIN-XI; EXPRESSION; IDENTIFICATION; GENE; FIBROBLASTS; CALPONIN	Expression of S100A6 (Calcyclin), a member of the S100 family and of Zn2+-binding proteins is elevated in a number of malignant tumors. In vitro the protein associates with several actin-binding proteins and annexins in a Ca2+-dependent manner. We have now studied the subcellular localization of S100A6 using a new, specific monoclonal antibody. Immunofluorescence microscopy of unfixed, ultrathin, frozen sections demonstrated a dual localization of S100A6 at the nuclear envelope and the plasma membrane of porcine smooth muscle only in the presence of Ca2+. The same localization was found by immunofluorescence and immunogold electron microscopy as well as by confocal laser scanning microscopy with cultured, fixed, human CaKi-2 and porcine ST interphase cells. Upon cell division, however, S100A6 was found exclusively in the cytoplasm. Cell fractionation studies showed that S100A6 was present in the microsomal fraction in the presence of Ca2+ and was released from this fraction by the addition of EGTA/EDTA but not by Triton X-100. The data demonstrate that S100A6 is localized both at the plasma membrane and the nuclear envelope in vivo and suggest a Ca2+-dependent interaction with annexins or other components of the nuclear envelope.	Austrian Acad Sci, Inst Mol Biol, Dept Cell Biol, A-5020 Salzburg, Austria	Austrian Academy of Sciences	Gimona, M (corresponding author), Austrian Acad Sci, Inst Mol Biol, Dept Cell Biol, Billrothstr 11, A-5020 Salzburg, Austria.			Stradal, Theresia/0000-0002-0352-9474				Barwise JL, 1996, J CELL SCI, V109, P247; BAZAN HEP, 1992, EXP EYE RES, V55, P173, DOI 10.1016/0014-4835(92)90105-2; BRINCK U, 1995, J DERMATOL SCI, V10, P181, DOI 10.1016/0923-1811(95)00402-E; CALABRETTA B, 1986, J BIOL CHEM, V261, P2628; CALABRETTA B, 1985, P NATL ACAD SCI USA, V82, P4463, DOI 10.1073/pnas.82.13.4463; Carafoli E, 1997, CELL CALCIUM, V22, P313, DOI 10.1016/S0143-4160(97)90016-6; Filipek A, 1998, J NEUROCHEM, V70, P1793, DOI 10.1046/j.1471-4159.1998.70051793.x; Garbuglia M, 1998, CELL CALCIUM, V24, P177, DOI 10.1016/S0143-4160(98)90127-0; GHEZZO F, 1989, DNA-J MOLEC CELL BIO, V8, P171, DOI 10.1089/dna.1.1989.8.171; GILCHRIST JSC, 1994, MOL CELL BIOCHEM, V135, P79, DOI 10.1007/BF00925963; Gimona M, 1997, J CELL SCI, V110, P611; GIMONA M, 1990, FEBS LETT, V274, P159, DOI 10.1016/0014-5793(90)81353-P; Golitsina NL, 1996, BIOCHEM BIOPH RES CO, V220, P360, DOI 10.1006/bbrc.1996.0410; GUO XJ, 1990, CELL GROWTH DIFFER, V1, P333; Heizmann CW, 1998, BIOMETALS, V11, P383, DOI 10.1023/A:1009212521172; Kerkhoff C, 1998, BBA-MOL CELL RES, V1448, P200, DOI 10.1016/S0167-4889(98)00144-X; KIHLMARK M, 1988, CELL BIOL LAB MANUAL, P152; KINDY MS, 1991, J CELL BIOCHEM, V46, P345, DOI 10.1002/jcb.240460409; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; Kordowska J, 1998, EUR J BIOCHEM, V253, P57, DOI 10.1046/j.1432-1327.1998.2530057.x; KUZNICKI J, 1989, BIOCHEM J, V263, P951; KUZNICKI J, 1992, EXP CELL RES, V200, P425, DOI 10.1016/0014-4827(92)90191-A; Lesniak W, 1996, BIOCHEM BIOPH RES CO, V220, P269, DOI 10.1006/bbrc.1996.0394; Mandinova A, 1998, J CELL SCI, V111, P2043; MANI RS, 1995, J BIOL CHEM, V270, P6658, DOI 10.1074/jbc.270.12.6658; MARKS A, 1990, BIOESSAYS, V12, P381, DOI 10.1002/bies.950120806; MIZUTANI A, 1992, J BIOL CHEM, V267, P13498; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Sudo T, 1998, J BIOL CHEM, V273, P6351, DOI 10.1074/jbc.273.11.6351; Tan MJ, 1999, FEBS LETT, V445, P265, DOI 10.1016/S0014-5793(99)00135-0; TONINI GP, 1995, EUR J CANCER, V31A, P499, DOI 10.1016/0959-8049(95)00043-I; VOLTZ A, 1993, GENOMICS, V18, P92; WATANABE M, 1993, BIOCHEM BIOPH RES CO, V196, P1376, DOI 10.1006/bbrc.1993.2405; Watson PH, 1998, INT J BIOCHEM CELL B, V30, P567, DOI 10.1016/S1357-2725(97)00066-6; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WETERMAN MAJ, 1992, CANCER RES, V52, P1291; WILLS FL, 1994, PROTEIN SCI, V3, P2311, DOI 10.1002/pro.5560031216; Yamashita N, 1999, J COMP NEUROL, V404, P235; ZENG FY, 1993, INT J BIOCHEM, V25, P1019, DOI 10.1016/0020-711X(93)90116-V	39	36	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31593	31596		10.1074/jbc.274.44.31593	http://dx.doi.org/10.1074/jbc.274.44.31593			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531365	hybrid			2022-12-27	WOS:000083379400069
J	White, KA; Lin, SH; Cotter, RJ; Raetz, CRH				White, KA; Lin, SH; Cotter, RJ; Raetz, CRH			A Haemophilus influenzae gene that encodes a membrane bound 3-deoxy-D-manno-octulosonic acid (Kdo) kinase - Possible involvement of Kdo phosphorylation in bacterial virulence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; ESCHERICHIA-COLI; LIPID-A; LIPOPOLYSACCHARIDE BIOSYNTHESIS; BORDETELLA-PERTUSSIS; CHEMICAL-STRUCTURE; IDENTIFICATION; ENDOTOXIN; STRAIN; TRANSFERASE	The lipopolysaccharide of Haemophilus influenzae contains a single 3-deoxy-D-manno-octulosonic acid (Kdo) residue derivatized with either a phosphate or an ethanolamine pyrophosphate moiety at the 4-OH position. In previous studies, we identified a kinase unique to H. influenzae extracts that phosphorylates Kdo-lipid IVA, a key precursor of lipopolysaccharide in this organism. We have now identified the gene encoding the Kdo kinase by using an expression cloning approach. A cosmid library containing random DNA fragments from H. influenzae strain Rd was constructed in Escherichia coli. Extracts of 472 colonies containing individual hybrid cosmids were assayed for Kdo kinase activity. A single hybrid cosmid directing expression of the kinase was found. The kinase gene was identified by activity assays, sub-cloning, and DNA sequencing. When the putative kinase gene was expressed in E. coli behind a T7 promoter, massive overproduction of kinase activity was achieved (similar to 8000-fold higher than in H. influenzae membranes). The catalytic properties and the product generated by the overexpressed kinase, assayed with Kdo-lipid IV,as the substrate, were the same as observed with H. influenzae membranes. Unexpectedly, the kinase gene was identical to a previously characterized open reading frame (orfZ), which had been shown to be important for establishing bacteremia in an infant rat model (Hood, D. W., Deadman, M. E., Alien, T., Masoud, H., Martin, A., Brisson, J. R., Fleischmann, R., Venter, J, C., Richards, J. C., and Moxon, E. R. (1996) Mol. Microbiol. 22, 951-965). However, based solely on the genome sequence of H. influenzae Rd, no biochemical function had been assigned to the product of orfZ, which we now designate kdkA ("Kdo kinase A"). Although Kdo phosphorylation may be critical for bacterial virulence of H. influenzae, it does not appear to be required for growth.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Middle Atlantic Mass Spect Lab, Baltimore, MD 21205 USA	Duke University; Johns Hopkins University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Box 3711, Durham, NC 27710 USA.	raetz@biochem.duke.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051310, R01GM054882] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-51310, GM-54882] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andersson SGE, 1998, NATURE, V396, P133, DOI 10.1038/24094; Ausubel FM, 1988, MOL REPROD DEV; Basu SS, 1999, J BIOL CHEM, V274, P11139, DOI 10.1074/jbc.274.16.11139; BELUNIS CJ, 1995, J BIOL CHEM, V270, P27646, DOI 10.1074/jbc.270.46.27646; BELUNIS CJ, 1992, J BIOL CHEM, V267, P9988; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCK K, 1994, EUR J BIOCHEM, V225, P1029, DOI 10.1111/j.1432-1033.1994.1029b.x; BRADE H, 1985, J BACTERIOL, V161, P795, DOI 10.1128/JB.161.2.795-798.1985; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; BROZEK KA, 1987, J BIOL CHEM, V262, P5170; Carballo PMS, 1999, EUR J BIOCHEM, V261, P500, DOI 10.1046/j.1432-1327.1999.00299.x; CHABY R, 1975, EUR J BIOCHEM, V59, P277, DOI 10.1111/j.1432-1033.1975.tb02452.x; CLEMENTZ T, 1991, J BIOL CHEM, V266, P9687; Dotson GD, 1998, J BACTERIOL, V180, P330, DOI 10.1128/JB.180.2.330-337.1998; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Garrett TA, 1997, J BIOL CHEM, V272, P21855, DOI 10.1074/jbc.272.35.21855; GOLDMAN RC, 1986, J BIOL CHEM, V261, P5831; HAMPTON RY, 1988, J BIOL CHEM, V263, P14802; HELANDER IM, 1988, EUR J BIOCHEM, V177, P483, DOI 10.1111/j.1432-1033.1988.tb14398.x; HIGH NJ, 1993, MOL MICROBIOL, V9, P1275, DOI 10.1111/j.1365-2958.1993.tb01257.x; Hood DW, 1996, MOL MICROBIOL, V22, P951, DOI 10.1046/j.1365-2958.1996.01545.x; JAROSIK GP, 1994, INFECT IMMUN, V62, P4861, DOI 10.1128/IAI.62.11.4861-4867.1994; Kalman S, 1999, NAT GENET, V21, P385, DOI 10.1038/7716; KLEIN JO, 1997, PEDIATR INFECT DIS J, V16, P5; KUMADA H, 1993, FEMS MICROBIOL LETT, V108, P75; LEDUR A, 1978, EUR J BIOCHEM, V84, P579, DOI 10.1111/j.1432-1033.1978.tb12201.x; Masoud H, 1997, BIOCHEMISTRY-US, V36, P2091, DOI 10.1021/bi961989y; Miller J.H., 1972, EXPT MOL GENETICS; MORRISON DC, 1992, BACTERIAL ENDOTOXIC, V1; MOXON ER, 1992, J INFECT DIS S1, V165, P77; MOXON ER, 1991, REV INFECT DIS    S6, V13, P518; Murphy TF, 1997, ANN NY ACAD SCI, V830, P353, DOI 10.1111/j.1749-6632.1997.tb51907.x; Nikaido H., 1996, ESCHERICHIA COLI SAL, P29; NISHIJIMA M, 1979, J BIOL CHEM, V254, P7837; PHILLIPS NJ, 1992, BIOCHEMISTRY-US, V31, P4515, DOI 10.1021/bi00133a019; QURESHI N, 1988, J BIOL CHEM, V263, P11971; Raetz C. R. H., 1996, ESCHERICHIA COLI SAL, V1, P1035; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; Rietschel E. T., 1992, BACTERIAL ENDOTOXIC, V1, P3; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; ROSNER MR, 1979, J BIOL CHEM, V254, P5906; SCHNAITMAN CA, 1993, MICROBIOL REV, V57, P655, DOI 10.1128/MMBR.57.3.655-682.1993; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; WEISER JN, 1989, CELL, V59, P657, DOI 10.1016/0092-8674(89)90011-1; White KA, 1997, J BIOL CHEM, V272, P16555, DOI 10.1074/jbc.272.26.16555; WHITFIELD C, 1995, TRENDS MICROBIOL, V3, P178, DOI 10.1016/S0966-842X(00)88917-9; Wyckoff TJO, 1998, TRENDS MICROBIOL, V6, P154, DOI 10.1016/S0966-842X(98)01230-X; Wyckoff TJO, 1998, J BIOL CHEM, V273, P32369, DOI 10.1074/jbc.273.49.32369; ZAMZE SE, 1987, BIOCHEM J, V245, P583, DOI 10.1042/bj2450583; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466; [No title captured]	54	41	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31391	31400		10.1074/jbc.274.44.31391	http://dx.doi.org/10.1074/jbc.274.44.31391			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531340	hybrid			2022-12-27	WOS:000083379400044
J	Kapila, YL; Wang, SH; Johnson, PW				Kapila, YL; Wang, SH; Johnson, PW			Mutations in the heparin binding domain of fibronectin in cooperation with the V region induce decreases in pp125(FAK) levels plus proteoglycan-mediated apoptosis via caspases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; PERIODONTAL-LIGAMENT CELLS; MAMMARY EPITHELIAL-CELLS; HUMAN ENDOTHELIAL-CELLS; FN-C/H-V; INTEGRIN ALPHA-4-BETA-1; SYNTHETIC PEPTIDE; SYNOVIAL-FLUID; EXTRACELLULAR-MATRIX; SUPPRESSES APOPTOSIS	Intact fibronectin (FN) protects cells from apoptosis. When FN is fragmented, specific domains induce proteinase expression in fibroblasts. However, it is not known whether specific domains of FN can also regulate apoptosis. We exposed fibroblasts to four recombinant FN fragments and then assayed for apoptosis using criteria of cellular shape change, condensed nuclear morphology, and DNA fragmentation. The fragments extended from the RGD-containing repeat III10 to III15; they included (V+) or excluded (V-) the alternatively spliced V region and contained either a mutated (H-) or an unmutated (H+) heparin binding domain. Only the V+H- fragment triggered decreases in pp125(FAK) levels and apoptosis, which was rescued by intact FN and inhibitors of caspase-1 and caspase-3, This apoptotic mechanism was mediated by a chondroitin sulfate proteoglycan, since treating cells with chondroitin sulfate or chondroitinase reversed the apoptotic cell shape changes. The alpha 4 integrin receptor may also be involved, since using a blocking antibody to alpha 4 alone induced apoptotic cell shape changes, whereas co-treatment with this antibody plus V+H+ reversed these effects. These results demonstrate that the V and heparin binding domains of FN modulate pp125(FAK) levels and regulate apoptosis through a chondroitin sulfate proteoglycan- and possibly alpha 4 integrin-mediated pathway, which triggers a caspase cascade.	Univ Calif San Francisco, Dept Stomatol, Sch Dent, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Kapila, YL (corresponding author), Univ Calif San Francisco, Dept Stomatol, Sch Dent, HSW 604,Box 0512, San Francisco, CA 94143 USA.		Kapila, Yvonne/AAG-5418-2021		NIDCR NIH HHS [K15 DE00344] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [K15DE000344] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BOBERBARKALOW FJ, 1991, J BIOL CHEM, V266, P7812; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BUSBY TF, 1995, J BIOL CHEM, V270, P18558, DOI 10.1074/jbc.270.31.18558; CARSONS S, 1985, ARTHRITIS RHEUM, V28, P601, DOI 10.1002/art.1780280602; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; Crouch DH, 1996, ONCOGENE, V12, P2689; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Gervais FG, 1998, J BIOL CHEM, V273, P17102, DOI 10.1074/jbc.273.27.17102; Goh KL, 1997, DEVELOPMENT, V124, P4309; Goruppi S, 1996, ONCOGENE, V12, P471; GRIFFITHS AM, 1989, CLIN CHIM ACTA, V184, P133, DOI 10.1016/0009-8981(89)90283-0; HOMANDBERG GA, 1992, J BIOL CHEM, V267, P3597; HUHTALA P, 1995, J CELL BIOL, V129, P867, DOI 10.1083/jcb.129.3.867; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Iida J, 1998, J BIOL CHEM, V273, P5955, DOI 10.1074/jbc.273.10.5955; Ilic D, 1998, J CELL BIOL, V143, P547; JALKANEN S, 1992, J CELL BIOL, V116, P817, DOI 10.1083/jcb.116.3.817; Kapila YL, 1997, J BIOL CHEM, V272, P18932, DOI 10.1074/jbc.272.30.18932; Kapila YL, 1996, MATRIX BIOL, V15, P251, DOI 10.1016/S0945-053X(96)90116-X; Kapila YL, 1998, J PERIODONTOL, V69, P1008, DOI 10.1902/jop.1998.69.9.1008; Levkau B, 1998, J EXP MED, V187, P579, DOI 10.1084/jem.187.4.579; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; MOORADIAN DL, 1993, INVEST OPHTH VIS SCI, V34, P153; MOULD AP, 1991, J BIOL CHEM, V266, P3579; MOULD AP, 1991, EMBO J, V10, P4089, DOI 10.1002/j.1460-2075.1991.tb04985.x; OBrien V, 1996, EXP CELL RES, V224, P208, DOI 10.1006/excr.1996.0130; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; SANCHEZAPARICIO P, 1994, J CELL BIOL, V126, P271, DOI 10.1083/jcb.126.1.271; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; Scott G, 1997, J INVEST DERMATOL, V108, P147, DOI 10.1111/1523-1747.ep12332650; Short SM, 1998, MOL BIOL CELL, V9, P1969, DOI 10.1091/mbc.9.8.1969; SORSA T, 1992, INFECT IMMUN, V60, P4491, DOI 10.1128/IAI.60.11.4491-4495.1992; TALONPOIKA J, 1993, SCAND J DENT RES, V101, P375; TALONPOIKA J, 1993, MOL BIOL CELL, V5, P439; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VERFAILLIE CM, 1994, BLOOD, V84, P1802; VOGEL BE, 1990, J BIOL CHEM, V265, P5934; WILKE MS, 1993, J INVEST DERMATOL, V101, P43, DOI 10.1111/1523-1747.ep12358823; WOODS A, 1993, MOL BIOL CELL, V4, P605, DOI 10.1091/mbc.4.6.605; XIE DL, 1992, J RHEUMATOL, V19, P1448; XIE DL, 1994, ARCH BIOCHEM BIOPHYS, V311, P205, DOI 10.1006/abbi.1994.1228; Yoshikawa H, 1996, J IMMUNOL, V156, P1832; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161	45	54	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30906	30913		10.1074/jbc.274.43.30906	http://dx.doi.org/10.1074/jbc.274.43.30906			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521484	hybrid			2022-12-27	WOS:000083276700080
J	Solis-Herruzo, JA; Rippe, RA; Schrum, LW; de la Torre, P; Garcia, I; Jeffrey, JJ; Munoz-Yague, T; Brenner, DA				Solis-Herruzo, JA; Rippe, RA; Schrum, LW; de la Torre, P; Garcia, I; Jeffrey, JJ; Munoz-Yague, T; Brenner, DA			Interleukin-6 increases rat metalloproteinase-13 gene expression through stimulation of activator protein 1 transcription factor in cultured fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; HUMAN COLLAGENASE-3 GENE; ACUTE-PHASE RESPONSE; INTERSTITIAL COLLAGENASE; C-JUN; MATRIX METALLOPROTEINASES; TISSUE INHIBITOR; OKADAIC ACID; DIFFERENTIAL EXPRESSION; 5'-FLANKING REGION	The role of IL-6 in collagen production and tissue remodeling is controversial. In Rat-1 fibroblasts, we measured the effect of IL-6 on matrix metalloproteinase-13 (MMP-13), c-jun, junB, and c-fos gene expression, binding of activator protein 1 (AP1) to DNA, amount of AP1 proteins, immunoreactive MMP-13 and TIMP-1 proteins, and Jun N-terminal kinase activity. We show that IL-6 increased MMP-13-mRNA and MMP-13 protein. These effects were exerted by acting on the AP1-binding site of the MMP-13 promoter, as shown by transfecting cells with reporter plasmids containing mutations in this element. Mobility shift assays demonstrated that IL-6 induced the DNA binding activity of AP1. This effect was accompanied by a marked increase in c-Jun, JunB, and c-Fos mRNA, as well as in c-Jun protein and its phosphorylated form. The latter is not due to increased Jun N-terminal kinase activity but to a decreased serine/threonine phosphatase activity. We conclude that IL-6 increases interstitial MMP-13 gene expression at the promoter level. This effect seems to be mediated by the induction of c-jun, junB, and c-fos gene expression, by the binding of AP1 to DNA, by increasing phosphorylated c-Jun, and by the inhibition of serine/threonine phosphatase activity. These effects of IL-6 might contribute to remodeling connective tissue.	Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Hosp Univ 12 Octubre, Dept Med Gastroenterol, Madrid 28041, Spain; Albany Med Coll, Dept Med, Div Hematol, Albany, NY 12208 USA	University of North Carolina; University of North Carolina Chapel Hill; Hospital Universitario 12 de Octubre; Albany Medical College	Solis-Herruzo, JA (corresponding author), Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA.	jasolis@h12o.es	García-Ruiz, Inmaculada/G-8204-2015	García-Ruiz, Inmaculada/0000-0003-4185-8524; Brenner, David/0000-0003-2573-525X	NIDDK NIH HHS [DK 47361] Funding Source: Medline; NIGMS NIH HHS [GM41804] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047361] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041804] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALCAMI J, 1995, EMBO J, V14, P1552, DOI 10.1002/j.1460-2075.1995.tb07141.x; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; AUBLE DT, 1991, BIOCHEMISTRY-US, V30, P4629, DOI 10.1021/bi00232a039; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; Barber MD, 1999, CLIN SCI, V96, P83, DOI 10.1042/CS19980185; BELAAOUAJ A, 1995, J BIOL CHEM, V270, P14568, DOI 10.1074/jbc.270.24.14568; BELKA C, 1995, LEUKEMIA, V9, P288; Borden P, 1996, J BIOL CHEM, V271, P23577, DOI 10.1074/jbc.271.38.23577; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; Brown RT, 1995, J BIOL CHEM, V270, P31129, DOI 10.1074/jbc.270.52.31129; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COFFER P, 1995, ONCOGENE, V10, P985; COLLIER IE, 1988, J BIOL CHEM, V263, P10711; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; CURRAN T, 1987, ONCOGENE, V2, P79; DAFFADA AAI, 1994, BBA-MOL CELL RES, V1222, P234, DOI 10.1016/0167-4889(94)90174-0; DEVIERE J, 1992, GASTROENTEROLOGY, V103, P1296, DOI 10.1016/0016-5085(92)91519-A; DIBATTISTA JA, 1995, J RHEUMATOL, V22, P123; Diez Ruiz A., 1993, Alcohol and Alcoholism, V28, P319; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUNCAN MR, 1991, J INVEST DERMATOL, V97, P686, DOI 10.1111/1523-1747.ep12483971; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; EMONARD H, 1992, MATRIX, V12, P471, DOI 10.1016/S0934-8832(11)80091-0; EMONARD H, 1990, CELL MOL BIOL, V36, P131; FINI ME, 1987, BIOCHEMISTRY-US, V26, P6156, DOI 10.1021/bi00393a032; Franchimont N, 1997, J BIOL CHEM, V272, P12144, DOI 10.1074/jbc.272.18.12144; FUJITANI Y, 1994, BIOCHEM BIOPH RES CO, V202, P1181, DOI 10.1006/bbrc.1994.2053; GAIRE M, 1994, J BIOL CHEM, V269, P2032; Grumbles RM, 1997, J CELL BIOCHEM, V67, P92; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HENSCHLER R, 1991, FEBS LETT, V283, P47, DOI 10.1016/0014-5793(91)80550-M; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hirano T, 1998, Int Rev Immunol, V16, P249; HOUSSIAU FA, 1988, ARTHRITIS RHEUM, V31, P784, DOI 10.1002/art.1780310614; HUHTALA P, 1990, J BIOL CHEM, V265, P11077; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; Jenab S, 1997, ENDOCRINOLOGY, V138, P2740, DOI 10.1210/en.138.7.2740; KAKUMU S, 1991, AM J GASTROENTEROL, V86, P1804; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KHORUTS A, 1991, HEPATOLOGY, V13, P267, DOI 10.1016/0270-9139(91)92439-F; KIM SJ, 1990, CELL REGUL, V1, P269, DOI 10.1091/mbc.1.3.269; KOCH KS, 1992, BIOCHEM BIOPH RES CO, V183, P184, DOI 10.1016/0006-291X(92)91626-2; Kojima H, 1996, ONCOGENE, V12, P547; Kusano K, 1998, ENDOCRINOLOGY, V139, P1338, DOI 10.1210/en.139.3.1338; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; LOTZ M, 1991, J BIOL CHEM, V266, P2017; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MELAMED D, 1993, CELL GROWTH DIFFER, V4, P689; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; Pendas AM, 1997, GENOMICS, V40, P222, DOI 10.1006/geno.1996.4554; PETERSEN M, 1995, PHOTOCHEM PHOTOBIOL, V62, P444, DOI 10.1111/j.1751-1097.1995.tb02366.x; Rajakumar RA, 1996, MOL ENDOCRINOL, V10, P867, DOI 10.1210/me.10.7.867; REZZONICO R, 1995, J BIOL CHEM, V270, P1261, DOI 10.1074/jbc.270.3.1261; RICHARDS CD, 1993, J IMMUNOL, V150, P5596; RIPPE RA, 1990, MOL CELL BIOL, V10, P689, DOI 10.1128/MCB.10.2.689; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SATO T, 1990, BIOCHEM BIOPH RES CO, V170, P824, DOI 10.1016/0006-291X(90)92165-V; SATOH T, 1988, MOL CELL BIOL, V8, P3546, DOI 10.1128/MCB.8.8.3546; SCHORPP M, 1995, BIOCHEM J, V308, P211, DOI 10.1042/bj3080211; Sehgal I, 1999, MOL BIOL CELL, V10, P407, DOI 10.1091/mbc.10.2.407; SEKIYAMA KD, 1994, CLIN EXP IMMUNOL, V98, P71; SHINGU M, 1993, CLIN EXP IMMUNOL, V94, P145; Silacci P, 1998, J BIOL CHEM, V273, P13625, DOI 10.1074/jbc.273.22.13625; SIRUM KL, 1989, BIOCHEMISTRY-US, V28, P8691, DOI 10.1021/bi00448a004; Solis-Herruzo JA, 1998, CELL SIGNAL, V10, P173, DOI 10.1016/S0898-6568(97)00036-3; SUN YQ, 1992, J CLIN IMMUNOL, V12, P197, DOI 10.1007/BF00918089; Sweeting J, 1989, Gastroenterology, V97, P1056; TAGA T, 1992, HDB BASIC CLIN RES, P144; Tardif G, 1997, BIOCHEM J, V323, P13, DOI 10.1042/bj3230013; THEVENIN C, 1991, J BIOL CHEM, V266, P9363; THIELE DL, 1989, HEPATOLOGY, V9, P497, DOI 10.1002/hep.1840090325; VINCENTI MP, 1988, BIOCHEM J, V331, P341; WANG Y, 1995, GENE, V162, P285, DOI 10.1016/0378-1119(95)00295-H; WESTERMARCK J, 1994, CELL GROWTH DIFFER, V5, P1205; WESTWICK JK, 1995, METHOD ENZYMOL, V255, P342; WESTWICK JK, 1995, J CLIN INVEST, V95, P803, DOI 10.1172/JCI117730; WLASCHEK M, 1993, J INVEST DERMATOL, V101, P164, DOI 10.1111/1523-1747.ep12363644	82	57	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30919	30926		10.1074/jbc.274.43.30919	http://dx.doi.org/10.1074/jbc.274.43.30919			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521486	hybrid, Green Published			2022-12-27	WOS:000083276700082
J	Yusta, B; Somwar, R; Wang, F; Munroe, D; Grinstein, S; Klip, A; Drucker, DJ				Yusta, B; Somwar, R; Wang, F; Munroe, D; Grinstein, S; Klip, A; Drucker, DJ			Identification of glucagon-like peptide-2 (GLP-2)-activated signaling pathways in baby hamster kidney fibroblasts expressing the rat GLP-2 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ADENYLYL-CYCLASE; GENE-EXPRESSION; ACTIVATION; CELLS; GLUCOSE; TRANSDUCTION; HEPATOCYTES; INCREASE; CLONING	Glucagon-like peptide-2 (GLP-2) promotes the expansion of the intestinal epithelium through stimulation of the GLP-2 receptor, a recently identified member of the glucagon-secretin G protein-coupled receptor superfamily. Although activation of G protein-coupled receptors may lead to stimulation of cell growth, the mechanisms transducing the GLP-2 signal to mitogenic proliferation remain unknown. We now report studies of GLP-2R signaling in baby hamster kidney (BHK) cells expressing a transfected rat GLP-2 receptor (BHK-GLP-2R cells). GLP-2, but not glucagon or GLP-1, increased the levels of cAMP and activated both cAMP-response element- and AP-l-dependent transcriptional activity in a dose-dependent manner. The activation of AP-l-luciferase activity was protein kinase A (PKA) -dependent and markedly diminished in the presence of a dominant negative inhibitor of PKA. Although GLP-2 stimulated the expression of c-fos, c-jun, junB, and zif268, and transiently increased p70 S6 kinase in quiescent BHK-GLP-2R cells, GLP-2 also inhibited extracellular signal-regulated kinase 1/2 and reduced serum-stimulated Elk-1 activity. Furthermore, no rise in intracellular calcium was observed following GLP-2 exposure in BHK-GLP-2R cells. Although GLP-2 stimulated both cAMP accumulation and cell proliferation, 8-bromo-cyclic AMP alone did not promote, cell proliferation. These findings suggest that the GLP-2R may be coupled to activation of mitogenic signaling in heterologous cell types independent of PKA via as yet unidentified downstream mediators of GLP-2 action in vivo.	Univ Toronto, Toronto Gen Hosp, Dept Med, Toronto, ON M5G 2C4, Canada; Univ Toronto, Hosp Sick Children, Dept Cell Biol, Toronto, ON M5G 2C4, Canada; Univ Toronto, Hosp Sick Children, Dept Physiol, Toronto, ON M5G 2C4, Canada; Allelix Biopharmaceut Inc, Mississauga, ON L4V 1P1, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Drucker, DJ (corresponding author), Univ Toronto, Toronto Gen Hosp, Dept Med, 101 Coll St,CCRW3-838, Toronto, ON M5G 2C4, Canada.		Drucker, Daniel J/A-4092-2010					Barrie AP, 1997, J BIOL CHEM, V272, P19666, DOI 10.1074/jbc.272.32.19666; Brubaker PL, 1997, ENDOCRINOLOGY, V138, P4837, DOI 10.1210/en.138.11.4837; Cheeseman CI, 1996, AM J PHYSIOL-GASTR L, V271, pG477, DOI 10.1152/ajpgi.1996.271.3.G477; Cheeseman CI, 1997, AM J PHYSIOL-REG I, V273, pR1965, DOI 10.1152/ajpregu.1997.273.6.R1965; CHEN WB, 1995, ANAL BIOCHEM, V226, P349, DOI 10.1006/abio.1995.1235; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coppolino MG, 1997, NATURE, V386, P843, DOI 10.1038/386843a0; CORRELL LA, 1989, J BIOL CHEM, V264, P16672; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Dong JM, 1998, J BIOL CHEM, V273, P22554, DOI 10.1074/jbc.273.35.22554; DRUCKER DJ, 1989, P NATL ACAD SCI USA, V86, P3953, DOI 10.1073/pnas.86.11.3953; Drucker DJ, 1999, TRENDS ENDOCRIN MET, V10, P153, DOI 10.1016/S1043-2760(98)00136-2; Drucker DJ, 1999, AM J PHYSIOL-GASTR L, V276, pG79, DOI 10.1152/ajpgi.1999.276.1.G79; Drucker DJ, 1998, DIABETES, V47, P159, DOI 10.2337/diabetes.47.2.159; Drucker DJ, 1997, NAT BIOTECHNOL, V15, P673, DOI 10.1038/nbt0797-673; Drucker DJ, 1996, P NATL ACAD SCI USA, V93, P7911, DOI 10.1073/pnas.93.15.7911; Edvell A, 1999, ENDOCRINOLOGY, V140, P778, DOI 10.1210/en.140.2.778; GALANG CK, 1994, ONCOGENE, V9, P2913; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; Hansen LH, 1998, AM J PHYSIOL-CELL PH, V274, pC1552, DOI 10.1152/ajpcell.1998.274.6.C1552; Holz GG, 1999, J BIOL CHEM, V274, P14147, DOI 10.1074/jbc.274.20.14147; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; Jin TR, 1996, MOL CELL BIOL, V16, P19; Kaestner KH, 1999, GENE DEV, V13, P495, DOI 10.1101/gad.13.4.495; Landolfi B, 1998, J CELL BIOL, V142, P1235, DOI 10.1083/jcb.142.5.1235; Munroe DG, 1999, P NATL ACAD SCI USA, V96, P1569, DOI 10.1073/pnas.96.4.1569; ORSKOV C, 1987, SCAND J CLIN LAB INV, V47, P165; PITTNER RA, 1991, BIOCHEM J, V277, P371, DOI 10.1042/bj2770371; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Scott RB, 1998, AM J PHYSIOL-GASTR L, V275, pG911, DOI 10.1152/ajpgi.1998.275.5.G911; Serre V, 1998, ENDOCRINOLOGY, V139, P4448, DOI 10.1210/en.139.11.4448; Somwar R, 1998, AM J PHYSIOL-ENDOC M, V275, pE618, DOI 10.1152/ajpendo.1998.275.4.E618; Somwar R, 1998, CLIN THER, V20, P125, DOI 10.1016/S0149-2918(98)80040-4; Susini S, 1998, FASEB J, V12, P1173, DOI 10.1096/fasebj.12.12.1173; TANG EKY, 1992, BIOCHEM J, V283, P341, DOI 10.1042/bj2830341; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; Todisco A, 1997, AM J PHYSIOL-GASTR L, V273, pG891, DOI 10.1152/ajpgi.1997.273.4.G891; Tsai CH, 1997, AM J PHYSIOL-ENDOC M, V273, pE77, DOI 10.1152/ajpendo.1997.273.1.E77; WAKELAM MJO, 1986, NATURE, V323, P68, DOI 10.1038/323068a0; WHEELER MB, 1993, ENDOCRINOLOGY, V133, P57, DOI 10.1210/en.133.1.57; WIDMANN C, 1994, MOL PHARMACOL, V45, P1029; Wojdemann M, 1998, SCAND J GASTROENTERO, V33, P828; Xiao QA, 1999, GASTROENTEROLOGY, V117, P99, DOI 10.1016/S0016-5085(99)70555-X; YADA T, 1993, ENDOCRINOLOGY, V133, P1685, DOI 10.1210/en.133.4.1685	45	87	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30459	30467		10.1074/jbc.274.43.30459	http://dx.doi.org/10.1074/jbc.274.43.30459			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521425	hybrid			2022-12-27	WOS:000083276700021
J	Li, R				Li, R			Stimulation of DNA replication in Saccharomyces cerevisiae by a glutamine- and proline-rich transcriptional activation domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SP1; COMPLEX; PROTEIN; RECOGNITION; INTERACTS; PROMOTER; ELEMENTS; ORIGINS; CELLS	Glutamine-rich Sp1 and proline-rich CTF1, two extensively studied mammalian transcription factors, bind to origins of replication in DNA tumor viruses and stimulate viral DNA replication in mammalian cells. Here it is shown that, when tethered to a plasmid-borne cellular origin of replication, the activation domains of both proteins can enhance origin function in Saccharomyces cerevisiae, Hydrophobic patches in Spl and CTF1 that mediate transcriptional activation in higher eukaryotes are also important for activation of replication in yeast. However, only the activation domain of CTF1 can enhance initiation of replication from a chromosomally embedded origin. This correlates with the ability of CTF1 to alter the local chromatin structure around the chromosomal origin of replication. The CTF1-induced chromatin remodeling occurs at multiple stages of the cell cycle. These findings strongly suggest a high degree of conservation in the mechanisms used by various types of transcription factors to stimulate viral and cellular DNA replication in eukaryotes.	Univ Virginia, Hlth Sci Ctr, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia	Li, R (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057893] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM57893] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alevizopoulos A, 1995, GENE DEV, V9, P3051, DOI 10.1101/gad.9.24.3051; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Campbell JL, 1991, MOL CELLULAR BIOL YE, P41; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DEPAMPHILIS ML, 1993, TRENDS CELL BIOL, V3, P1161; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; EMAMI KH, 1995, MOL CELL BIOL, V15, P5906; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; HEINTZ N H, 1992, Current Opinion in Cell Biology, V4, P459, DOI 10.1016/0955-0674(92)90012-2; Hu YF, 1999, GENE DEV, V13, P637, DOI 10.1101/gad.13.6.637; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; KUNZLER M, 1994, EMBO J, V13, P641, DOI 10.1002/j.1460-2075.1994.tb06302.x; Li R, 1998, MOL CELL BIOL, V18, P1296, DOI 10.1128/MCB.18.3.1296; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MARAHRENS Y, 1994, EMBO J, V13, P3395, DOI 10.1002/j.1460-2075.1994.tb06642.x; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NEWLON CS, 1993, CURR OPIN GENET DEV, V3, P752, DOI 10.1016/S0959-437X(05)80094-2; PONTICELLI AS, 1995, MOL CELL BIOL, V15, P983; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAO H, 1995, P NATL ACAD SCI USA, V92, P2224, DOI 10.1073/pnas.92.6.2224; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; van der Vliet P.C., 1996, DNA REPLICATION EUKA, P87; Xiao H, 1998, J BIOL CHEM, V273, P22873, DOI 10.1074/jbc.273.36.22873	26	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30310	30314		10.1074/jbc.274.42.30310	http://dx.doi.org/10.1074/jbc.274.42.30310			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514526	hybrid			2022-12-27	WOS:000083176400105
J	Shimomura, I; Bashmakov, Y; Horton, JD				Shimomura, I; Bashmakov, Y; Horton, JD			Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL REGULATORY ELEMENT; BOUND TRANSCRIPTION FACTOR; STEAROYL-COA DESATURASE; LEUCINE ZIPPER PROTEIN; TRANSGENIC MICE; BINDING PROTEINS; ADIPOSE-TISSUE; CHOLESTEROL-SYNTHESIS; CULTURED-CELLS; ACID SYNTHESIS	Hepatic steatosis is common in non-insulin-dependent diabetes and can be associated with fibrosis and cirrhosis in a subset of individuals. Increased rates of fatty acid synthesis have been reported in livers from rodent models of diabetes and may contribute to the development of steatosis. Sterol regulatory element-binding proteins (SREBPs) are a family of regulated transcription factors that stimulate lipid synthesis in liver. In the current studies, we measured the content of SREBPs in livers from two mouse models of diabetes, obese ob/ob mice and transgenic aP2-SREBP-1c436 (aP2-SREBP-1c) mice that overexpress nuclear SREBP-1c only in adipose tissue. The aP2-SREBP-1c mice exhibit a syndrome that resembles congenital generalized lipodystrophy in humans. Both lines of mice develop hyperinsulinemia, hyperglycemia, and hepatic steatosis. Nuclear SREBP-1c protein levels were significantly elevated in livers from ob/ob and aP2-SREBP-1c mice compared with wild-type mice. Increased nuclear SREBP-1c protein was associated with elevated mRNA levels for known SREBP target genes involved in fatty acid biosynthesis, which led to significantly higher rates of hepatic fatty acid synthesis in vivo. These studies suggest that increased levels of nuclear SREBP-1c contribute to the elevated rates of hepatic fatty acid synthesis that leads to steatosis in diabetic mice.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Horton, JD (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd,Rm L5-238, Dallas, TX 75235 USA.		Adiels, Martin/C-9278-2011	Bashmakov, Yuriy/0000-0002-2265-3817	NHLBI NIH HHS [HL-20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRAY GA, 1979, PHYSIOL REV, V59, P719, DOI 10.1152/physrev.1979.59.3.719; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Burant CF, 1997, J CLIN INVEST, V100, P2900, DOI 10.1172/JCI119839; Foretz M, 1999, MOL CELL BIOL, V19, P3760; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 1999, CURR OPIN LIPIDOL, V10, P143, DOI 10.1097/00041433-199904000-00008; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; KAESTNER KH, 1989, J BIOL CHEM, V264, P14755; MARTIN RJ, 1974, LIFE SCI, V14, P1447, DOI 10.1016/0024-3205(74)90155-6; MEMON RA, 1994, HORM METAB RES, V26, P85, DOI 10.1055/s-2007-1000778; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; NTAMBI JM, 1995, PROG LIPID RES, V34, P139, DOI 10.1016/0163-7827(94)00010-J; Pai JT, 1998, J BIOL CHEM, V273, P26138, DOI 10.1074/jbc.273.40.26138; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimano H, 1997, J CLIN INVEST, V100, P2115, DOI 10.1172/JCI119746; Shimomura I, 1997, P NATL ACAD SCI USA, V94, P12354, DOI 10.1073/pnas.94.23.12354; Shimomura I, 1998, J BIOL CHEM, V273, P35299, DOI 10.1074/jbc.273.52.35299; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; TOWLE HC, 1995, J BIOL CHEM, V270, P23235, DOI 10.1074/jbc.270.40.23235; VANSTEENBERGEN W, 1995, INT J OBESITY, V19, pS27; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; YOKODE M, 1990, SCIENCE, V250, P1273, DOI 10.1126/science.2244210; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	31	552	571	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30028	30032		10.1074/jbc.274.42.30028	http://dx.doi.org/10.1074/jbc.274.42.30028			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514488	hybrid			2022-12-27	WOS:000083176400067
J	Ye, X; Mehlen, P; Rabizadeh, S; VanArsdale, T; Zhang, HY; Shin, H; Wang, JJL; Leo, E; Zapata, J; Hauser, CA; Reed, JC; Bredesen, DE				Ye, X; Mehlen, P; Rabizadeh, S; VanArsdale, T; Zhang, HY; Shin, H; Wang, JJL; Leo, E; Zapata, J; Hauser, CA; Reed, JC; Bredesen, DE			TRAF family proteins interact with the common neurotrophin receptor and modulate apoptosis induction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NECROSIS-FACTOR RECEPTOR; NERVE GROWTH-FACTOR; SIGNAL-TRANSDUCTION PATHWAYS; INDUCED CELL-DEATH; TERMINAL KINASE; BINDING-SITES; P75 RECEPTOR; TNF; ACTIVATION	The common neurotrophin receptor, p75(NTR), has been shown to signal in the absence of Trk tyrosine kinase receptors, including induction of neural apoptosis and activation of NF-kappa B. However, the mechanisms by which p75NTR initiates these intracellular signal transduction pathways are unknown. Here we report interactions between p75(NTR) and the six members of TRAF (tumor necrosis factor receptor-associated factors) family proteins. The binding of different TRAF proteins to p75(NTR) was mapped to distinct regions in p75NTR. Furthermore, TRAF4 interacted with dimeric p75(NTR), whereas TRAF2 interacted preferentially with monomeric p75(NTR). TRAF2-p75(NTR), TRAF4-p75(NTR), and TRAF6-p75(NTR) interactions modulated p75(NTR)-induced cell death and NF-kappa B activation with contrasting effects. Coexpression of TRAF2 with p75NTR enhanced cell death, whereas coexpression of TRAF6 was cytoprotective. Furthermore, overexpression of TRAF4 abrogated the ability of dimerization to prevent the induction of apoptosis normally mediated by monomeric p75NTR. TRAF4 also inhibited the NF-KB response, whereas TRAF2 and TRAF6 enhanced p75NTR-induced NF-kappa B activation. These results demonstrate that TRAF family proteins interact with p75(NTR) and differentially modulate its NF-kappa B activation and cell death induction.	Burnham Inst, Program Aging & Canc, La Jolla, CA 92037 USA; Burnham Inst, Program Apoptosis & Cell Death, La Jolla, CA 92037 USA; Burnham Inst, Program Gene Regulat, La Jolla, CA 92037 USA; Univ Lyon 1, CNRS, UMR 5534, Ctr Mol & Cellular Genet, F-69622 Villeurbanne, France; Univ Calif Los Angeles, Interdepartmental Program Neurosci, Los Angeles, CA 90024 USA; Univ Calif San Diego, Dept Neurosci, San Diego, CA 92093 USA	Sanford Burnham Prebys Medical Discovery Institute; Sanford Burnham Prebys Medical Discovery Institute; Sanford Burnham Prebys Medical Discovery Institute; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; University of California System; University of California Los Angeles; University of California System; University of California San Diego	Bredesen, DE (corresponding author), Buck Ctr Res Aging, POB 638, Novato, CA 94948 USA.		Zapata, Juan M/J-6304-2014	Zapata, Juan M/0000-0002-0110-0009	NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035155, R01NS033376] Funding Source: NIH RePORTER; NCI NIH HHS [CA69381] Funding Source: Medline; NINDS NIH HHS [NS33376, NS35155] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barker PA, 1998, CELL DEATH DIFFER, V5, P346, DOI 10.1038/sj.cdd.4400375; BARRETT GL, 1994, P NATL ACAD SCI USA, V91, P6501, DOI 10.1073/pnas.91.14.6501; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bredesen DE, 1998, CELL DEATH DIFFER, V5, P365, DOI 10.1038/sj.cdd.4400378; Bredesen DE, 1997, TRENDS NEUROSCI, V20, P287, DOI 10.1016/S0166-2236(96)01049-1; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Carter BD, 1997, NEURON, V18, P187, DOI 10.1016/S0896-6273(00)80259-7; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; Casaccia-Bonnefil P, 1998, CELL DEATH DIFFER, V5, P357, DOI 10.1038/sj.cdd.4400377; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Frade JM, 1996, NATURE, V383, P166; GALANG CK, 1994, ONCOGENE, V9, P2913; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Kawamata S, 1998, J BIOL CHEM, V273, P5808, DOI 10.1074/jbc.273.10.5808; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Khursigara G, 1999, J BIOL CHEM, V274, P2597, DOI 10.1074/jbc.274.5.2597; Krajewska M, 1998, AM J PATHOL, V152, P1549; Krajewski S, 1997, J IMMUNOL, V159, P5841; Liepinsh E, 1997, EMBO J, V16, P4999, DOI 10.1093/emboj/16.16.4999; Longo FM, 1997, J NEUROSCI RES, V48, P1, DOI 10.1002/(SICI)1097-4547(19970401)48:1<1::AID-JNR1>3.0.CO;2-K; MAH SP, 1993, J NEUROCHEM, V60, P1183, DOI 10.1111/j.1471-4159.1993.tb03275.x; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Masson R, 1998, MECH DEVELOP, V71, P187, DOI 10.1016/S0925-4773(97)00192-5; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Pullen SS, 1998, BIOCHEMISTRY-US, V37, P11836, DOI 10.1021/bi981067q; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; Srinivasan A, 1996, J NEUROSCI, V16, P5654; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Tsukamoto N, 1999, P NATL ACAD SCI USA, V96, P1234, DOI 10.1073/pnas.96.4.1234; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VanderZee CEEM, 1996, SCIENCE, V274, P1729, DOI 10.1126/science.274.5293.1729; Wallach D, 1997, TRENDS BIOCHEM SCI, V22, P107, DOI 10.1016/S0968-0004(97)01015-3; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Ye X., UNPUB; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yeo TT, 1997, J NEUROSCI, V17, P7594; Yoon SO, 1998, J NEUROSCI, V18, P3273	52	154	169	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30202	30208		10.1074/jbc.274.42.30202	http://dx.doi.org/10.1074/jbc.274.42.30202			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514511	hybrid			2022-12-27	WOS:000083176400090
J	Dong, WJ; Xing, J; Villain, M; Hellinger, M; Robinson, JM; Chandra, R; Solaro, RJ; Umeda, PK; Cheung, HC				Dong, WJ; Xing, J; Villain, M; Hellinger, M; Robinson, JM; Chandra, R; Solaro, RJ; Umeda, PK; Cheung, HC			Conformation of the regulatory domain of cardiac muscle troponin C in its complex with cardiac troponin I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; CALCIUM-BINDING; ORIENTATION FACTOR; ENERGY-TRANSFER; MODEL; FLUORESCENCE; CONTRACTION; TRANSITION; RESOLUTION	Calcium activation of fast striated muscle results from. an opening of the regulatory N-terminal domain of fast skeletal troponin C (fsTnC), and a substantial exposure of a hydrophobic patch, essential for Ca2+-dependent interaction with fast skeletal troponin I (fsTnI). This interaction is obligatory to relieve the inhibition of strong, force-generating actin-myosin interactions, We have determined intersite distances in the N-terminal domain of cardiac TnC (cTnC) by fluorescence resonance energy transfer measurements and found negligible increases in these distances when the single regulatory site is saturated with Ca2+. However, in the presence of bound cardiac TnI (cTnI), activator Ca2+ induces significant increases in the distances and a substantial opening of the N-domain, This open conformation within the cTnc.cTnI complex has properties favorable for the Ca2+-induced interaction with an additional segment of cTnI. Thus, the binding of cTnI to cTnC is a prerequisite to achieve a Ca2+-induced open N-domain similar to that previously observed in fsTnC with no bound fsTnI, This role of cardiac TnI has not been previously recognized. Our results also indicate that structural information derived from a single protein may not be sufficient for inference of a structure/function relationship.	Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Physiol & Biophys, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; Univ Illinois, Coll Med, Dept Physiol & Biophys, Chicago, IL 60612 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Cheung, HC (corresponding author), Univ Alabama Birmingham, Dept Biochem & Mol Genet, 520 CH-19, Birmingham, AL 35294 USA.	hccheung@uab.edu	Dong, Wenji/A-8579-2011		NHLBI NIH HHS [HL63377, HL52508] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063377, R01HL052508] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		DALE RE, 1979, BIOPHYS J, V26, P161, DOI 10.1016/S0006-3495(79)85243-1; Dong WJ, 1997, BIOCHEMISTRY-US, V36, P6754, DOI 10.1021/bi9622276; Dong WJ, 1997, J BIOL CHEM, V272, P19229, DOI 10.1074/jbc.272.31.19229; Dong WJ, 1997, BIOCHEMISTRY-US, V36, P6745, DOI 10.1021/bi962226d; Dong WJ, 1997, BIOPHYS J, V72, P850, DOI 10.1016/S0006-3495(97)78719-8; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; Gagne SM, 1997, BIOCHEMISTRY-US, V36, P4386, DOI 10.1021/bi963076+; Gong Z, 1998, BIOPHYS J, V74, pA51; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HERZBERG O, 1986, J BIOL CHEM, V261, P2638; Li MX, 1999, BIOCHEMISTRY-US, V38, P8289, DOI 10.1021/bi9901679; LIAO RL, 1994, BIOCHEMISTRY-US, V33, P12729, DOI 10.1021/bi00208a026; LIN ZY, 1989, GENE DEV, V3, P986, DOI 10.1101/gad.3.7.986; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; McKay RT, 1997, J BIOL CHEM, V272, P28494, DOI 10.1074/jbc.272.45.28494; MORIMOTO S, 1987, J BIOCHEM-TOKYO, V101, P291, DOI 10.1093/oxfordjournals.jbchem.a121913; Paakkonen K, 1998, J BIOL CHEM, V273, P15633, DOI 10.1074/jbc.273.25.15633; PUTKEY JA, 1991, J BIOL CHEM, V266, P14881; She MD, 1997, BIOPHYS J, V73, P1042, DOI 10.1016/S0006-3495(97)78137-2; She MD, 1998, J MOL BIOL, V281, P445, DOI 10.1006/jmbi.1998.1933; She MD, 1998, EUR J BIOCHEM, V252, P600, DOI 10.1046/j.1432-1327.1998.2520600.x; Sia SK, 1997, J BIOL CHEM, V272, P18216, DOI 10.1074/jbc.272.29.18216; Slupsky CM, 1995, BIOCHEMISTRY-US, V34, P15953, DOI 10.1021/bi00049a010; Spyracopoulos L, 1997, BIOCHEMISTRY-US, V36, P12138, DOI 10.1021/bi971223d; SUNDARALINGAM M, 1985, SCIENCE, V227, P945, DOI 10.1126/science.3969570; WANG CK, 1985, BIOPHYS J, V48, P727, DOI 10.1016/S0006-3495(85)83831-5; WU PG, 1992, BIOCHEMISTRY-US, V31, P7939, DOI 10.1021/bi00149a027	28	89	89	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31382	31390		10.1074/jbc.274.44.31382	http://dx.doi.org/10.1074/jbc.274.44.31382			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531339	hybrid			2022-12-27	WOS:000083379400043
J	Lee, CH; Wei, LN				Lee, CH; Wei, LN			Characterization of receptor-interacting protein 140 in retinoid receptor activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR HORMONE RECEPTORS; EMBRYONAL CARCINOMA-CELLS; TRANSCRIPTIONAL COACTIVATOR; HISTONE ACETYLTRANSFERASE; NEURONAL DIFFERENTIATION; ORPHAN RECEPTORS; CO-REPRESSOR; ACTIVATION; BINDING; LIGAND	Receptor-interacting protein 140 (RIP140) contains multiple receptor interaction domains and interacts with retinoic acid receptors in a ligand-dependent manner. Nine LXXLL receptor-interacting motifs are organized into two clusters within this molecule, each differentially interacting with retinoic acid receptor (RAR) and retinoid X receptor (RXR). RAR interacts with the 5' cluster, whereas RXR interacts with both clusters. Additionally, a third ligand-dependent receptor-interacting domain is assigned to the very C terminus of this molecule, which contains no LXXLL motif. In mammalian cells, receptor heterodimerization is required for efficient interaction of RAR/RXR with RIP140. Furthermore, the heterodimeric, holoreceptors cooperatively interact with RIP140, which requires the activation function 2 domains of both receptors, By using different retinoic acid reporter systems, it is demonstrates that RIP140 strongly suppresses retinoic acid induction of reporter activities, but coactivator SRC-1 enhances it. Furthermore, an intrinsic repressive activity of RIP140 is demonstrated in a GAL4 fusion system. Unlike receptor corepressor, which interacts with antagonist-bound RAR/RXRs, RIP140 does not interact with antagonist-occupied RAR/RXR dimers, These data suggest that RIP140 represents a third coregulator category that is able to suppress the activation of certain agonist-bound hormone receptors.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Wei, LN (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054733] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54733] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agarwal C, 1996, J BIOL CHEM, V271, P12209, DOI 10.1074/jbc.271.21.12209; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Botling J, 1997, J BIOL CHEM, V272, P9443; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Chinpaisal C, 1998, J BIOL CHEM, V273, P18077, DOI 10.1074/jbc.273.29.18077; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Hayashi Y, 1997, BIOCHEM BIOPH RES CO, V236, P83, DOI 10.1006/bbrc.1997.6911; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horn V, 1996, FASEB J, V10, P1071, DOI 10.1096/fasebj.10.9.8801169; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Lee CH, 1999, BIOCHEMISTRY-US, V38, P8820, DOI 10.1021/bi9903547; Lee CH, 1998, J BIOL CHEM, V273, P25209, DOI 10.1074/jbc.273.39.25209; Lee CH, 1998, MOL CELL BIOL, V18, P6745, DOI 10.1128/MCB.18.11.6745; Leers J, 1998, MOL CELL BIOL, V18, P6001, DOI 10.1128/MCB.18.10.6001; LHorset F, 1996, MOL CELL BIOL, V16, P6029; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Minucci S, 1997, MOL CELL BIOL, V17, P644, DOI 10.1128/MCB.17.2.644; Miyata KS, 1998, MOL CELL ENDOCRINOL, V146, P69; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; Takeshita A, 1996, ENDOCRINOLOGY, V137, P3594, DOI 10.1210/en.137.8.3594; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Treuter E, 1998, MOL ENDOCRINOL, V12, P864, DOI 10.1210/me.12.6.864; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; YAO M, 1995, J NEUROSCI RES, V41, P792, DOI 10.1002/jnr.490410610; Zhang X, 1998, MOL ENDOCRINOL, V12, P513, DOI 10.1210/me.12.4.513	41	61	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31320	31326		10.1074/jbc.274.44.31320	http://dx.doi.org/10.1074/jbc.274.44.31320			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531331	hybrid			2022-12-27	WOS:000083379400035
J	Bourne, Y; Grassi, J; Bougis, PE; Marchot, P				Bourne, Y; Grassi, J; Bougis, PE; Marchot, P			Conformational flexibility of the acetylcholinesterase tetramer suggested by X-ray crystallography	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRIC-EEL ACETYLCHOLINESTERASE; MONOCLONAL-ANTIBODIES; CRYSTAL-STRUCTURE; FASCICULIN; COMPLEX; TORPEDO; CHOLINESTERASES; ELECTROPHORUS; PROTEINS; FORMS	Acetylcholinesterase, a polymorphic enzyme, appears to form amphiphilic and nonamphiphilic tetramers from a single splice variant; this suggests discrete tetrameric arrangements where the amphipathic carboxyl-terminal sequences can be either buried or exposed. Two distinct, but related crystal structures of the soluble, trypsin-released tetramer of acetylcholinesterase from Electrophorus electricus were solved at 4.5 and 4.2 A resolution by molecular replacement. Resolution at these levels is sufficient to provide substantial information on the relative orientations of the subunits within the tetramer. The two structures, which show canonical homodimers of subunits assembled through four-helix bundles, reveal discrete geometries in the assembly of the dimers to form: (a) a loose, pseudo-square planar tetramer with antiparallel alignment of the two four-helix bundles and a large space in the center where the carboxyl-terminal sequences may be buried or (b) a compact, square nonplanar tetramer that may expose all four sequences on a single side. Comparison of these two structures points to significant conformational flexibility of the tetramer about the four-helix bundle axis and along the dimer-dimer interface. Hence, in solution, several conformational states of a flexible tetrameric arrangement of acetylcholinesterase catalytic subunits may exist to accommodate discrete carboxyl-terminal sequences of variable dimensions and amphipathicity.	Inst Biol & Microbiol Struct, CNRS, Unite Architecture & Fonct Macromol Biol 9039, F-13402 Marseille 20, France; CEA, Serv Pharmacol & Immunol, Dept Rech Med, F-91191 Gif Sur Yvette, France; Univ Mediterraneee, CNRS, Unite Mixte Rech 6560, Inst Federatif Jean Roche, F-13916 Marseille 20, France	Centre National de la Recherche Scientifique (CNRS); CEA; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Marchot, P (corresponding author), Inst Biol & Microbiol Struct, CNRS, Unite Architecture & Fonct Macromol Biol 9039, F-13402 Marseille 20, France.	marchot.p@jean-roche.univ-mrs.fr	MARCHOT, Pascale/AAC-4752-2022; Bourne, Yves/AAC-4635-2022; BOUGIS, Pierre E/I-2111-2013	MARCHOT, Pascale/0000-0003-0630-0541; Bourne, Yves/0000-0003-3850-0548; 				ANGLISTER L, 1978, J MOL BIOL, V125, P293, DOI 10.1016/0022-2836(78)90404-7; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BERMAN HA, 1985, BIOCHEMISTRY-US, V24, P7140, DOI 10.1021/bi00346a018; Blong RM, 1997, BIOCHEM J, V327, P747, DOI 10.1042/bj3270747; Bourne Y, 1999, J BIOL CHEM, V274, P2963, DOI 10.1074/jbc.274.5.2963; BOURNE Y, 1995, CELL, V83, P503, DOI 10.1016/0092-8674(95)90128-0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CARTAUD J, 1975, BRAIN RES, V88, P127, DOI 10.1016/0006-8993(75)90959-2; CARTAUD J, 1978, J CELL BIOL, V77, P315, DOI 10.1083/jcb.77.2.315; CHOTHIA C, 1975, J MOL BIOL, V97, P55, DOI 10.1016/S0022-2836(75)80021-0; CYGLER M, 1993, PROTEIN SCI, V2, P366; DUDAI Y, 1974, BIOCHEM BIOPH RES CO, V59, P117, DOI 10.1016/S0006-291X(74)80182-8; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Evans P. R., 1993, P CCP4 STUD WEEK DAT, P114; GENTRY MK, 1995, J NEUROCHEM, V64, P842; Giles K, 1997, PROTEIN ENG, V10, P677, DOI 10.1093/protein/10.6.677; GRASSI J, 1988, ANAL BIOCHEM, V168, P436, DOI 10.1016/0003-2697(88)90341-7; Harel M, 1995, STRUCTURE, V3, P1355, DOI 10.1016/S0969-2126(01)00273-8; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; Krejci E, 1997, J BIOL CHEM, V272, P22840, DOI 10.1074/jbc.272.36.22840; KREJCI E, 1991, EMBO J, V10, P1285, DOI 10.1002/j.1460-2075.1991.tb08070.x; LEE SL, 1982, J BIOL CHEM, V257, P2292; LEUZINGER W, 1968, P NATL ACAD SCI USA, V59, P620, DOI 10.1073/pnas.59.2.620; Marchot P, 1996, PROTEIN SCI, V5, P672; MARCHOT P, 1993, J BIOL CHEM, V268, P12458; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; RACHINSKY TL, 1990, NEURON, V5, P317, DOI 10.1016/0896-6273(90)90168-F; RALSTON JS, 1985, J BIOL CHEM, V260, P4312; Raves ML, 1998, STRUCTURE AND FUNCTION OF CHOLINESTERASES AND RELATED PROTEINS, P351; REMY MH, 1995, EUR J BIOCHEM, V231, P651, DOI 10.1111/j.1432-1033.1995.tb20744.x; RIEGER F, 1973, EUR J BIOCHEM, V34, P539, DOI 10.1111/j.1432-1033.1973.tb02792.x; ROSENBERRY TL, 1974, BIOCHEMISTRY-US, V13, P3068, DOI 10.1021/bi00712a012; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; SCHRAG JD, 1988, J BIOL CHEM, V263, P9795; Simon S, 1997, J BIOL CHEM, V272, P33045, DOI 10.1074/jbc.272.52.33045; Simon S, 1998, EMBO J, V17, P6178, DOI 10.1093/emboj/17.21.6178; SUSSMAN JL, 1988, J MOL BIOL, V203, P821, DOI 10.1016/0022-2836(88)90213-6; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAYLOR P, 1994, ANNU REV PHARMACOL, V34, P281, DOI 10.1146/annurev.pa.34.040194.001433; TAYLOR P, 1974, MOL PHARMACOL, V10, P78	45	139	142	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30370	30376		10.1074/jbc.274.43.30370	http://dx.doi.org/10.1074/jbc.274.43.30370			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521413	Green Published, hybrid			2022-12-27	WOS:000083276700009
J	Brinkman, BMN; Telliez, JB; Schievella, AR; Lin, LL; Goldfeld, AE				Brinkman, BMN; Telliez, JB; Schievella, AR; Lin, LL; Goldfeld, AE			Engagement of tumor necrosis factor (TNF) receptor 1 leads to ATF-2-and p38 mitogen-activated protein kinase-dependent TNF-alpha gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; SIGNAL-TRANSDUCTION; 55-KDA RECEPTOR; MICE DEFICIENT; CELL-DEATH; INFECTION; MONOCYTOGENES; ANTIBODIES; RESISTANT; PATHWAYS	Engagement of the tumor necrosis factor-alpha (TNF-alpha) receptors by the TNF-alpha ligand results in the rapid induction of TNF-alpha gene expression. The study presented here shows that autoregulation of TNF-alpha gene transcription by selective signaling through tumor necrosis factor receptor 1 (TNFR1) requires p38 mitogen-activated protein (MAP) kinase activity and the binding of the transcription factors ATF-2 and Jun to the TNF-alpha cAMP-response element (CRE) promoter element. Consistent with these findings, TNFR1 engagement results in increased p38 MAP kinase activity and p38-dependent phosphorylation of ATF-2. Furthermore, overexpression of MADD ((M) under bar AP kinase-(a) under bar ctivating (d) under bar eath (d) under bar omain protein), an adapter protein that binds to the death domain of TNFR1 and activates MAP kinase cascades, results in CRE-dependent induction of TNF-alpha gene expression. Thus, the TNF-alpha CRE site is the target of TNFR1 stimulation and mediates the autoregulation of TNF-alpha gene transcription.	Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Genet Inst, Small Molecule Drug Discovery Grp, Cambridge, MA 02139 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School	Goldfeld, AE (corresponding author), Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA.		Brinkman, Brigitta/C-1100-2009; Goldfeld, Anne/AAF-1818-2019		NATIONAL CANCER INSTITUTE [R29CA058735] Funding Source: NIH RePORTER; NCI NIH HHS [CA58735] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal B.B., 1995, HUMAN CYTOKINES THEI; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Boehm JC, 1996, J MED CHEM, V39, P3929, DOI 10.1021/jm960415o; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; FLYNN JL, 1995, IMMUNITY, V2, P561, DOI 10.1016/1074-7613(95)90001-2; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; HENSEL G, 1987, LYMPHOKINE RES, V6, P119; Hoffmeyer A, 1999, J BIOL CHEM, V274, P4319, DOI 10.1074/jbc.274.7.4319; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEITMAN DC, 1991, J BIOL CHEM, V266, P9343; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MARINO MW, 1997, P NATL ACAD SCI USA, V94, P8098; Nashleanas M, 1998, J IMMUNOL, V160, P5506; Pasparakis M, 1997, P NATL ACAD SCI USA, V94, P6319, DOI 10.1073/pnas.94.12.6319; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; Schievella AR, 1997, J BIOL CHEM, V272, P12069, DOI 10.1074/jbc.272.18.12069; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Tsai EY, 1996, MOL CELL BIOL, V16, P5232; TSAI EY, 1996, MOL CELL BIOL, V16, P458; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; WONG GHW, 1992, J IMMUNOL, V149, P3350; Wysk M, 1999, P NATL ACAD SCI USA, V96, P3763, DOI 10.1073/pnas.96.7.3763	33	82	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30882	30886		10.1074/jbc.274.43.30882	http://dx.doi.org/10.1074/jbc.274.43.30882			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521481	hybrid			2022-12-27	WOS:000083276700077
J	Fu, CA; Shen, M; Huang, BCB; Lasaga, J; Payan, DG; Luo, Y				Fu, CA; Shen, M; Huang, BCB; Lasaga, J; Payan, DG; Luo, Y			TNIK, a novel member of the germinal center kinase family that activates the c-Jun N-terminal kinase pathway and regulates the cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDRICH SYNDROME PROTEIN; SH2/SH3 ADAPTER PROTEIN; SIGNAL-TRANSDUCTION; TNF RECEPTOR-1; SAPK/JNK; STRESS; NCK; INFLAMMATION; DROSOPHILA; P38	Germinal center kinases (GCKs) compose a subgroup of the Ste20 family of kinases. Here we describe the cloning and characterization of a novel GCK family kinase, Traf2- and Nck-interacting kinase (TNIK) that interacts with both Traf2 and Nck. TNIK encodes a polypeptide of 1360 amino acids with eight spliced isoforms. It has 90% amino acid identity to the Nck-interacting kinase in both the N-terminal kinase domain and the C-terminal germinal center kinase homology region. The homology drops to 53% in the intermediate region. TNIK specifically activates the c-Jun N-terminal kinase pathway when transfected into Phoenix-A cells (derivatives of 293 cells), similar to many GCKs. However, in contrast to other GCKs, this activation is mediated solely by the GCK homology region of TNIK. In addition, in Phoenix-A, NIH-3T3, and Hela cells, overexpression of wild type TNIK, but not the kinase mutant form of TNIK, results in the disruption of F-actin structure and the inhibition of cell spreading. Furthermore, TNIK can phosphorylate Gelsolin in vitro. This is the first time that a GCK family kinase is shown to be potentially involved in the regulation of cytoskeleton.	Rigel Inc, S San Francisco, CA 94080 USA		Luo, Y (corresponding author), Rigel Inc, 240 E Grand Ave, S San Francisco, CA 94080 USA.							BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Basu S, 1998, ONCOGENE, V17, P3277, DOI 10.1038/sj.onc.1202570; COLIGAN JE, 1999, CURR PROTOCOLS IMM S, V31; Diener K, 1997, P NATL ACAD SCI USA, V94, P9687, DOI 10.1073/pnas.94.18.9687; Eichinger L, 1998, J BIOL CHEM, V273, P12952, DOI 10.1074/jbc.273.21.12952; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Kyriakis JM, 1999, J BIOL CHEM, V274, P5259, DOI 10.1074/jbc.274.9.5259; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Liu HZ, 1999, CURR BIOL, V9, P101, DOI 10.1016/S0960-9822(99)80023-2; McCarty JH, 1998, BIOESSAYS, V20, P913, DOI 10.1002/(SICI)1521-1878(199811)20:11<913::AID-BIES6>3.0.CO;2-T; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Shi CS, 1997, J BIOL CHEM, V272, P32102, DOI 10.1074/jbc.272.51.32102; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Treisman JE, 1997, GENE, V186, P119, DOI 10.1016/S0378-1119(96)00694-4; Yao ZB, 1999, J BIOL CHEM, V274, P2118, DOI 10.1074/jbc.274.4.2118; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681	25	136	146	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30729	30737		10.1074/jbc.274.43.30729	http://dx.doi.org/10.1074/jbc.274.43.30729			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521462	hybrid			2022-12-27	WOS:000083276700058
J	Igishi, T; Fukuhara, S; Patel, V; Katz, BZ; Yamada, KR; Gutkind, JS				Igishi, T; Fukuhara, S; Patel, V; Katz, BZ; Yamada, KR; Gutkind, JS			Divergent signaling pathways link focal adhesion kinase to mitogen-activated protein kinase cascades - Evidence for a role of paxillin in c-Jun NH2-terminal kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED TYROSINE PHOSPHORYLATION; BETA-GAMMA-SUBUNITS; COUPLED RECEPTORS; PHOSPHATIDYLINOSITOL 3-KINASE; MAP KINASE; V-CRK; TRANSDUCTION PATHWAY; SUBSTRATE P130(CAS); CELL-SURVIVAL; SRC	Stimulation of a number of cell surface receptors, including integrins and Cf protein-coupled receptors, results in the activation of a non-receptor tyrosine kinase known as focal adhesion kinase (FAK), In turn, this kinase is believed to play a critical role in signaling to intracellular kinase cascades controlling gene expression such as extracellular signal-regulated kinases (ERKs), by a yet poorly defined mechanism, Furthermore, whether this tyrosine kinase also mediates the activation of other mitogen-activated protein kinase family members, such as c-Jun NH2-terminal kinases (JNKs), is still unclear. We show here that the activation of FAK by anchoring to the cell membrane is itself sufficient to stimulate potently both ERK and JNK. These effects were found to be phosphatidylinositol 5-kinase-independent, as FAK effectively stimulated Akt, and wortmannin suppressed Akt but not ERK or JNK: activation. As previously reported by others, activation of ERK correlated with the ability of FAK to induce tyrosine phosphorylation of Shc. Surprisingly, however, stimulation of JNK was not dependent on the kinase activity of FAK or on the ability to induce tyrosine phosphorylation of FAK substrates. Instead, we provide evidence that FAK may stimulate JNK through a novel pathway involving the recruitment of paxillin to the plasma membrane and the subsequent activation of a biochemical route dependent on small GTP-binding proteins of the Rho family.	NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; NIDCR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Gutkind, JS (corresponding author), NIDCR, Oral & Pharyngeal Canc Branch, NIH, 30 Convent Dr,Bldg 30,Rm 212, Bethesda, MD 20892 USA.		Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	Gutkind, J. Silvio/0000-0002-5150-4482; Yamada, Kenneth/0000-0003-1512-6805	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000525, ZIADE000524] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000525, Z01DE000524] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES023025, ZIAES023025] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHAN PY, 1994, J BIOL CHEM, V269, P20567; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Choudhury GG, 1996, AM J PHYSIOL-RENAL, V270, pF295, DOI 10.1152/ajprenal.1996.270.2.F295; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; Coso OA, 1996, J BIOL CHEM, V271, P3963; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Guan JL, 1997, MATRIX BIOL, V16, P195, DOI 10.1016/S0945-053X(97)90008-1; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; GUTKIND JS, 1992, BIOCHEM BIOPH RES CO, V188, P155; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Igishi T, 1998, BIOCHEM BIOPH RES CO, V244, P5, DOI 10.1006/bbrc.1998.8208; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; Rozengurt E, 1997, ESSAYS BIOCHEM, V32, P73; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; Tanaka S, 1998, J BIOL CHEM, V273, P1281, DOI 10.1074/jbc.273.3.1281; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Tong X, 1997, J BIOL CHEM, V272, P33373, DOI 10.1074/jbc.272.52.33373; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; TURNER CE, 1994, J CELL SCI, V107, P1583; Vande Pol SB, 1998, ONCOGENE, V16, P43, DOI 10.1038/sj.onc.1201504; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6	61	77	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30738	30746		10.1074/jbc.274.43.30738	http://dx.doi.org/10.1074/jbc.274.43.30738			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521463	hybrid			2022-12-27	WOS:000083276700059
J	Jones, N; Master, Z; Jones, J; Bouchard, D; Gunji, Y; Sasaki, H; Daly, R; Alitalo, K; Dumont, DJ				Jones, N; Master, Z; Jones, J; Bouchard, D; Gunji, Y; Sasaki, H; Daly, R; Alitalo, K; Dumont, DJ			Identification of Tek/Tie2 binding partners - Binding to a multifunctional docking site mediates cell survival and migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNALING MOLECULES; ENDOTHELIAL-CELLS; TIE2 RECEPTOR; BETA-RECEPTOR; SH2 DOMAINS; PROTEIN; ANGIOGENESIS; ANGIOPOIETIN-1	The Tek/Tie2 receptor tyrosine kinase plays a pivotal role in vascular and hematopoietic development. To study the signal transduction pathways that are mediated by this receptor, we have used the yeast two-hybrid system to identify signaling molecules that associate with the phosphorylated Tek receptor. Using this approach, we demonstrate that five molecules, Grb2, Grb7, Grb14, Shp2, and the p85 subunit of phosphatidylinositol 3-kinase can interact with Tek in a phosphotyrosine-dependent manner through their SH2 domains. Mapping of the binding sites of these molecules on Tek. reveals the presence of a multisubstrate docking site in the carboxyl tail of Tek (Tyr(1100)). Mutation of this site abrogates binding of Grb2 and Grb7 to Tek in vivo, and this site is required for tyrosine phosphorylation of Grb7 and p85 in vivo. Furthermore, stimulation of Tek-expressing cells with Angiopoietin-1 results in phosphorylation of both Tek and p85 and in activation of endothelial cell migration and survival pathways that are dependent in part on phosphatidylinositol 3-kinase. Taken together, these results demonstrate that Angiopoietin-1-induced signaling from the Tek receptor is mediated by a multifunctional docking site that is responsible for activation of both cell migration and cell survival pathways.	Sunnybrook & Womens Coll Hlth Sci Ctr, Div Canc Biol Res, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M4N 3M5, Canada; Amgen Inst, Toronto, ON M5G 2G1, Canada; Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland; Natl Canc Ctr, Res Inst, Chuo Ku, Tokyo 104, Japan; St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Helsinki; National Cancer Center - Japan; Garvan Institute of Medical Research; St Vincents Hospital Sydney	Dumont, DJ (corresponding author), Sunnybrook & Womens Coll Hlth Sci Ctr, Div Canc Biol Res, 2075 Bayview Ave,Res Bldg,S-227, Toronto, ON M4N 3M5, Canada.	ddumont@srcl.sunnybrook.utoronto.ca	Alitalo, Kari K/J-5013-2014; Daly, Roger J/C-8179-2009	Alitalo, Kari K/0000-0002-7331-0902; Master, Zubin/0000-0002-3462-4546; Daly, Roger/0000-0002-5739-8027				Braunger J, 1997, ONCOGENE, V14, P2619, DOI 10.1038/sj.onc.1201123; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; COOPER JA, 1993, MOL CELL BIOL, V13, P1737, DOI 10.1128/MCB.13.3.1737; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; DUMONT DJ, 1992, ONCOGENE, V7, P1471; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Fiddes RJ, 1998, J BIOL CHEM, V273, P7717, DOI 10.1074/jbc.273.13.7717; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; He WM, 1998, J BIOL CHEM, V273, P6860, DOI 10.1074/jbc.273.12.6860; HUANG LW, 1995, ONCOGENE, V11, P2097; Janes PW, 1997, J BIOL CHEM, V272, P8490, DOI 10.1074/jbc.272.13.8490; Jones N, 1998, ONCOGENE, V17, P1097, DOI 10.1038/sj.onc.1202115; Kasus-Jacobi A, 1998, J BIOL CHEM, V273, P26026, DOI 10.1074/jbc.273.40.26026; Keegan K, 1996, ONCOGENE, V12, P1537; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; Kontos CD, 1998, MOL CELL BIOL, V18, P4131, DOI 10.1128/MCB.18.7.4131; Korpelainen EI, 1999, ONCOGENE, V18, P1, DOI 10.1038/sj.onc.1202288; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; Kwak HJ, 1999, FEBS LETT, V448, P249, DOI 10.1016/S0014-5793(99)00378-6; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Manser J, 1997, DEV BIOL, V184, P150, DOI 10.1006/dbio.1997.8516; Matzaris M, 1998, J BIOL CHEM, V273, P8256, DOI 10.1074/jbc.273.14.8256; Mitchell CA, 1996, BIOCHEM SOC T, V24, P994, DOI 10.1042/bst0240994; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Ottinger EA, 1998, J BIOL CHEM, V273, P729, DOI 10.1074/jbc.273.2.729; Papapetropoulos A, 1999, LAB INVEST, V79, P213; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shibuya M, 1999, CURR TOP MICROBIOL, V237, P59; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Valenzuela DM, 1999, P NATL ACAD SCI USA, V96, P1904, DOI 10.1073/pnas.96.5.1904; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514; Wong AL, 1997, CIRC RES, V81, P567, DOI 10.1161/01.RES.81.4.567; Yokote K, 1996, J BIOL CHEM, V271, P30942, DOI 10.1074/jbc.271.48.30942; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	47	171	184	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30896	30905		10.1074/jbc.274.43.30896	http://dx.doi.org/10.1074/jbc.274.43.30896			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521483	hybrid			2022-12-27	WOS:000083276700079
J	Trinel, PA; Plancke, Y; Gerold, P; Jouault, T; Delplace, F; Schwarz, RT; Strecker, G; Poulain, D				Trinel, PA; Plancke, Y; Gerold, P; Jouault, T; Delplace, F; Schwarz, RT; Strecker, G; Poulain, D			The Candida albicans phospholipomannan is a family of glycolipids presenting phosphoinositolmannosides with long linear chains of beta-1,2-linked mannose residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAS-LIQUID-CHROMATOGRAPHY; MYCOBACTERIUM-TUBERCULOSIS; OLIGOMANNOSIDIC EPITOPES; MONOCLONAL-ANTIBODY; SEROTYPE-A; CELL-WALL; NIH B-792; STRUCTURAL-ANALYSIS; MURINE MACROPHAGES; PARASITIC PROTOZOA	In a series of studies, we have shown that Candida albicans synthesizes a glycolipid, phospholipomannan (PLM), which reacted with antibodies specific for beta-1,2-oligomannosides and was biosynthetically labeled by [H-3]mannose, [H-3]palmitic acid, and [P-32]phosphorus. NMR studies evidenced linear chains of beta-1,2-oligomannose as the albicans cell wall and to bind to and stimulate macrophage cells. In this study, we show by thin layer chromatography scanning of metabolically radiolabeled extracts that the C. albicans PLM corresponds to a family of mannose and inositol co-labeled glycolipids. We describe the purification process of the molecule and the release of its glycan fraction through alkaline hydrolysis. Analysis of this glycan fraction by radiolabeling and methylation-methanolysis confirmed the presence of inositol and of 1,2-linked mannose units. NMR studies evidenced linear chains of beta-1,2-oligomannose as the major PLM components. Mass spectrometry analysis revealed that these chains were present in phosphoinositolmannosides with degrees of polymerization varying from 8 to 18 sugar residues. The PLM appears as a new type of eukaryotic inositol-tagged glycolipid in relationship to both the absence of glucosamine and the organization of its glycan chains. This first structural evidence for the presence of beta-1,2-oligomannosides in a glycoconjugate other than the C. albicans phosphopeptidomannan may have some pathophysiological relevance to the adhesive, protective epitope, and signaling properties thus far established for these residues.	Ctr Hosp Univ, Fac Med, Lab Mycol Fondamentale & Appl, INSERM,Equipe Mixte 9915, F-59045 Lille, France; Univ Lille 1, Chim Biol Lab, F-59655 Villeneuve Dascq, France; Univ Lille 1, CNRS, Unite Mixte 111, F-59655 Villeneuve Dascq, France; Univ Marburg, Zentrum Hyg & Med Mikrobiol, D-35037 Marburg, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Universite de Lille; Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille; Philipps University Marburg	Poulain, D (corresponding author), Ctr Hosp Univ, Fac Med, Lab Mycol Fondamentale & Appl, INSERM,Equipe Mixte 9915, Pl Verdun, F-59045 Lille, France.		Jouault, Thierry/I-1071-2018; Poulain, Daniel/C-8683-2014; Jouault, Thierry/J-7437-2012; Poulain, Daniel/I-6095-2018	Jouault, Thierry/0000-0003-1988-8647; Poulain, Daniel/0000-0002-0729-5468				BARNES PF, 1992, J IMMUNOL, V149, P541; CaesarTonThat TC, 1997, INFECT IMMUN, V65, P5354, DOI 10.1128/IAI.65.12.5354-5357.1997; CANTELLI C, 1995, MICROBIOL-SGM, V141, P2693, DOI 10.1099/13500872-141-10-2693; CASSONE A, 1988, J MED MICROBIOL, V27, P233, DOI 10.1099/00222615-27-4-233; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; Dahl KE, 1996, INFECT IMMUN, V64, P399, DOI 10.1128/IAI.64.2.399-405.1996; DeBernardis F, 1997, INFECT IMMUN, V65, P3399, DOI 10.1128/IAI.65.8.3399-3405.1997; FAILLE C, 1990, INFECT IMMUN, V58, P3537, DOI 10.1128/IAI.58.11.3537-3544.1990; Ferguson M. A. J., 1993, GLYCOBIOLOGY, P349; FOURNET B, 1981, ANAL BIOCHEM, V116, P489, DOI 10.1016/0003-2697(81)90393-6; Fradin C, 1996, J LEUKOCYTE BIOL, V60, P81, DOI 10.1002/jlb.60.1.81; Gale CA, 1998, SCIENCE, V279, P1355, DOI 10.1126/science.279.5355.1355; HERNANDO FL, 1993, J MED VET MYCOL, V31, P219; HOPWOOD V, 1986, INFECT IMMUN, V54, P222, DOI 10.1128/IAI.54.1.222-227.1986; IBRAHIM AS, 1995, INFECT IMMUN, V63, P1993, DOI 10.1128/IAI.63.5.1993-1998.1995; Jouault T, 1998, J INFECT DIS, V178, P792, DOI 10.1086/515361; JOUAULT T, 1994, IMMUNOLOGY, V83, P268; KAMERLING JP, 1975, BIOCHEM J, V151, P491, DOI 10.1042/bj1510491; KOBAYASHI H, 1991, BIOCHEM BIOPH RES CO, V175, P1003, DOI 10.1016/0006-291X(91)91664-X; KOBAYASHI H, 1994, INFECT IMMUN, V62, P615, DOI 10.1128/IAI.62.2.615-622.1994; Leberer E, 1997, CURR BIOL, V7, P539, DOI 10.1016/S0960-9822(06)00252-1; LI RK, 1993, J BIOL CHEM, V268, P18293; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; OKAWA Y, 1994, FEBS LETT, V45, P167; Pfaller MA, 1998, DIAGN MICR INFEC DIS, V31, P327, DOI 10.1016/S0732-8893(97)00240-X; POULAIN D, 1993, INFECT IMMUN, V61, P1164, DOI 10.1128/IAI.61.3.1164-1166.1993; Prigozy TI, 1997, IMMUNITY, V6, P187, DOI 10.1016/S1074-7613(00)80425-2; Schofield L, 1996, IMMUNOL CELL BIOL, V74, P555, DOI 10.1038/icb.1996.89; SHIBATA N, 1985, ARCH BIOCHEM BIOPHYS, V243, P338, DOI 10.1016/0003-9861(85)90511-9; SHIBATA N, 1992, INFECT IMMUN, V60, P4100, DOI 10.1128/IAI.60.10.4100-4110.1992; SHIBATA N, 1989, CARBOHYD RES, V187, P239, DOI 10.1016/0008-6215(89)80006-0; SHIBATA N, 1986, ARCH BIOCHEM BIOPHYS, V251, P697, DOI 10.1016/0003-9861(86)90379-6; Soll DR, 1997, MICROBIOL-UK, V143, P279, DOI 10.1099/00221287-143-2-279; TOJO M, 1988, CLIN CHEM, V34, P539; TRINEL PA, 1992, INFECT IMMUN, V60, P3845, DOI 10.1128/IAI.60.9.3845-3851.1992; Trinel PA, 1997, FEBS LETT, V416, P203, DOI 10.1016/S0014-5793(97)01205-2; TRINEL PA, 1993, INFECT IMMUN, V61, P4398, DOI 10.1128/IAI.61.10.4398-4405.1993; Trinel PA, 1996, MICROBIOL-UK, V142, P2263, DOI 10.1099/13500872-142-8-2263; Yoshida A, 1997, INFECT IMMUN, V65, P1953, DOI 10.1128/IAI.65.5.1953-1955.1997	39	41	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30520	30526		10.1074/jbc.274.43.30520	http://dx.doi.org/10.1074/jbc.274.43.30520			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521433	hybrid			2022-12-27	WOS:000083276700029
J	Waldhoer, M; Wise, A; Milligan, G; Freissmuth, M; Nanoff, C				Waldhoer, M; Wise, A; Milligan, G; Freissmuth, M; Nanoff, C			Kinetics of ternary complex formation with fusion proteins composed of the A(1)-adenosine receptor and G protein alpha-subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A(1) ADENOSINE RECEPTORS; COUPLED RECEPTORS; SIGNAL-TRANSDUCTION; BOVINE BRAIN; ADRENERGIC-RECEPTORS; ADENYLYL-CYCLASE; PERTUSSIS-TOXIN; AGONIST; BINDING; ACTIVATION	High affinity agonist binding to G protein-coupled receptors depends on the formation of a ternary complex between agonist, receptor, and G protein. This process is too slow to be accounted for by a simple diffusion-controlled mechanism. We have tested if the interaction between activated receptor and G; protein is rate-limiting by fusing the coding sequence of the human A1-adenosine receptor to that of G alpha(i.1) (A1/G alpha(i-1)) and of G alpha(o) (A(1)/G alpha(o)). Fusion proteins of the expected molecular mass were detected following transfection of HEK293 cells. Ternary complex formation was monitored by determining the kinetics for binding of the high affinity agonist (-)-N-6-3[I-125] (iodo-4-hydroxyphenylisopropyl)adenosine; these were similar in the wild-type receptor and the fusion proteins over the temperature range of 10 to 30 degrees C. Agonist dissociation may be limited by the stability of the ternary complex. This assumption was tested by creating fusion proteins in which the Cys(351) of G alpha(i-1) was replaced with glycine (A(1)/G alpha(i-1)C351G) or isoleucine (A(1)/G alpha(i-1)C351I) to lower the affinity of the receptor for the G protein. In these mutated fusion proteins, the dissociation rate of the ternary complex was accelerated; in contrast, the rate of the forward reaction was not affected. We therefore conclude that (i) receptor activation per se rather than its interaction with the G; protein is rate-limiting in ternary complex formation; (ii) the stability of the ternary complex is determined by the dissociation rate of the Gr protein. These features provide for a kinetic proofreading mechanism that sustains the fidelity of receptor-G protein coupling.	Univ Vienna, Inst Pharmacol, A-1090 Vienna, Austria; Glaxo Wellcome Res & Dev Ltd, Receptor Syst Unit, Stevenage SG1 2NY, Herts, England; Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland	University of Vienna; GlaxoSmithKline; University of Glasgow	Freissmuth, M (corresponding author), Univ Vienna, Inst Pharmacol, Wahringer Str 13A, A-1090 Vienna, Austria.	freissmuth@univie.ac.at	Milligan, Graeme/F-9426-2011; Waldhoer, Maria/HDO-0619-2022	Milligan, Graeme/0000-0002-6946-3519; Waldhoer, Maria/0000-0003-3534-1959; nanoff, christian/0000-0002-8857-2470; Freissmuth, Michael/0000-0001-9398-1765				Bahia DS, 1998, BIOCHEMISTRY-US, V37, P11555, DOI 10.1021/bi980284o; BERTIN B, 1994, P NATL ACAD SCI USA, V91, P8827, DOI 10.1073/pnas.91.19.8827; Burt AR, 1998, J BIOL CHEM, V273, P10367, DOI 10.1074/jbc.273.17.10367; CASADO V, 1993, J PHARMACOL EXP THER, V266, P1463; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; Conklin BR, 1996, MOL PHARMACOL, V50, P885; Felber S, 1996, BIOPHYS J, V71, P3051, DOI 10.1016/S0006-3495(96)79499-7; Figler RA, 1996, MOL PHARMACOL, V50, P1587; FREISSMUTH M, 1991, J BIOL CHEM, V266, P17778; Freissmuth M, 1996, MOL PHARMACOL, V49, P602; Freissmuth M, 1999, TRENDS PHARMACOL SCI, V20, P237, DOI 10.1016/S0165-6147(99)01337-1; FREUND S, 1994, N-S ARCH PHARMACOL, V350, P49; GANTZOS RD, 1988, BIOCHEM PHARMACOL, V37, P2815, DOI 10.1016/0006-2952(88)90045-7; Gao ZH, 1999, BIOCHEM J, V338, P729, DOI 10.1042/0264-6021:3380729; GEORGOUSSI Z, 1993, MOL PHARMACOL, V44, P62; GETHER U, 1995, J BIOL CHEM, V270, P28268; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Gilchrist A, 1998, J BIOL CHEM, V273, P14912, DOI 10.1074/jbc.273.24.14912; Gudermann T, 1997, ANNU REV NEUROSCI, V20, P399, DOI 10.1146/annurev.neuro.20.1.399; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; Holler C, 1999, CELL MOL LIFE SCI, V55, P257, DOI 10.1007/s000180050288; Huang CF, 1997, MOL BIOL CELL, V8, P2365, DOI 10.1091/mbc.8.12.2365; Jackson VN, 1999, MOL PHARMACOL, V55, P195, DOI 10.1124/mol.55.2.195; JOCKERS R, 1994, J BIOL CHEM, V269, P32077; JOHNSON RA, 1991, METHOD ENZYMOL, V195, P3; Kenakin T, 1996, PHARMACOL REV, V48, P413; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; LINDEN J, 1984, MOL PHARMACOL, V26, P414; MUMBY SM, 1994, METHOD ENZYMOL, V237, P254; MUNSHI R, 1991, J BIOL CHEM, V266, P22285; NAKATA H, 1990, J BIOL CHEM, V265, P671; Nanoff C, 1997, NEUROPHARMACOLOGY, V36, P1211, DOI 10.1016/S0028-3908(97)00135-4; NANOFF C, 1995, MOL PHARMACOL, V48, P806; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; NEUHIG RR, 1988, BIOCHEMISTRY-US, V27, P2374; RASENICK MM, 1994, J BIOL CHEM, V269, P21519; Saunders C, 1996, J BIOL CHEM, V271, P995, DOI 10.1074/jbc.271.2.995; SCHUTZ W, 1992, TRENDS PHARMACOL SCI, V13, P376, DOI 10.1016/0165-6147(92)90116-N; Seifert R, 1998, EUR J BIOCHEM, V255, P369, DOI 10.1046/j.1432-1327.1998.2550369.x; Seifert R, 1999, TRENDS PHARMACOL SCI, V20, P383, DOI 10.1016/S0165-6147(99)01368-1; SELZER E, 1993, P NATL ACAD SCI USA, V90, P1609, DOI 10.1073/pnas.90.4.1609; THOMSEN WJ, 1989, BIOCHEMISTRY-US, V28, P8778, DOI 10.1021/bi00448a015; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Waldhoer M, 1998, MOL PHARMACOL, V53, P808; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; Wise A, 1997, J BIOL CHEM, V272, P24673, DOI 10.1074/jbc.272.39.24673; Wise A, 1999, BIOCHEMISTRY-US, V38, P2272, DOI 10.1021/bi982054f	48	46	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30571	30579		10.1074/jbc.274.43.30571	http://dx.doi.org/10.1074/jbc.274.43.30571			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521440	hybrid			2022-12-27	WOS:000083276700036
J	Muchowski, PJ; Hays, LG; Yates, JR; Clark, JI				Muchowski, PJ; Hays, LG; Yates, JR; Clark, JI			ATP and the core "alpha-crystallin" domain of the small heat-shock protein alpha B-crystallin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAPERONE-LIKE ACTIVITY; INDUCED CONFORMATIONAL-CHANGES; LIMITED PROTEOLYTIC SITES; MOLECULAR CHAPERONE; A-CRYSTALLIN; ALZHEIMERS-DISEASE; MASS-SPECTROMETRY; MISSENSE MUTATION; LENS CRYSTALLINS; BINDING DOMAINS	Electrospray ionization mass spectrometry (ESI-LC/MS) of tryptic digests of human alpha B-crystallin in the presence and absence of ATP identified four residues located within the core "alpha-crystallin" domain, Lys(82), Lys(103), Arg(116), and Arg(123) that were shielded from the action of trypsin in the presence of ATP. In control experiments, chymotrypsin was used in place of trypsin. The chymotryptic fragments of human alpha B-crystallin produced in the presence and absence of ATP were analyzed using liquid chromatography-tandem mass spectrometry (LC-MS/MS), Seven chymotryptic cleavage sites, Trp(60), Phe(61), Phe(75), Phe(84), Phe(113), Phe(118), and Tyr(122), located near or within the core alpha-crystallin domain, were shielded from the action of chymotrypsin in the presence of ATP. Chemically similar analogs of ATP were less protective than ATP against proteolysis by trypsin or chymotrypsin. ATP had no effect on the enzymatic: activity of trypsin and the K-m for trypsin was 0.031 mM in the presence of ATP and 0.029 mM in the absence of ATP. The results demonstrated an ATP-de; pendent structural modification in the Gore alpha-crystallin domain conserved in nearly all identified small heat-shock proteins that act as molecular chaperones.	Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA; Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA; Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Clark, JI (corresponding author), Univ Washington, Dept Biol Struct, Box 357420, Seattle, WA 98195 USA.				NEI NIH HHS [T 32 EY07031, EY0452, R01 EY004542] Funding Source: Medline; NATIONAL EYE INSTITUTE [T32EY007031, R01EY004542] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Andley UP, 1996, J BIOL CHEM, V271, P31973, DOI 10.1074/jbc.271.50.31973; BANEYX F, 1992, J BIOL CHEM, V267, P11637; Barrett A. J., 1998, HDB PROTEOLYTIC ENZY; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; Branden C., 1999, INTRO PROTEIN STRUCT; Briand L, 1999, FEBS LETT, V442, P43, DOI 10.1016/S0014-5793(98)01611-1; BUCHBERGER A, 1995, J BIOL CHEM, V270, P16903, DOI 10.1074/jbc.270.28.16903; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; CASPERS GJ, 1995, J MOL EVOL, V40, P238, DOI 10.1007/BF00163229; CHAO KL, 1990, J BIOL CHEM, V265, P1067; Collada C, 1997, PLANT PHYSIOL, V115, P71, DOI 10.1104/pp.115.1.71; Creighton T. E., 1993, PROTEINS STRUCTURE M; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Fung KL, 1996, J BIOL CHEM, V271, P21559, DOI 10.1074/jbc.271.35.21559; Gatlin CL, 1998, ANAL BIOCHEM, V263, P93, DOI 10.1006/abio.1998.2809; GROENEN PJTA, 1994, EUR J BIOCHEM, V225, P1, DOI 10.1111/j.1432-1033.1994.00001.x; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Hubbard SJ, 1998, PROTEIN ENG, V11, P349, DOI 10.1093/protein/11.5.349; HUBBARD SJ, 1994, PROTEIN SCI, V3, P757; Hubbard SJ, 1998, BBA-PROTEIN STRUCT M, V1382, P191, DOI 10.1016/S0167-4838(97)00175-1; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KANTOROW M, 1995, J BIOL CHEM, V270, P17215, DOI 10.1074/jbc.270.29.17215; KANTOROW M, 1994, P NATL ACAD SCI USA, V91, P3112, DOI 10.1073/pnas.91.8.3112; Kantorow M, 1998, INT J BIOL MACROMOL, V22, P307, DOI 10.1016/S0141-8130(98)00028-2; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Kim R, 1998, P NATL ACAD SCI USA, V95, P9129, DOI 10.1073/pnas.95.16.9129; LEE GJ, 1995, J BIOL CHEM, V270, P10432, DOI 10.1074/jbc.270.18.10432; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Leroux MR, 1997, J BIOL CHEM, V272, P12847, DOI 10.1074/jbc.272.19.12847; Leroux MR, 1997, J BIOL CHEM, V272, P24646, DOI 10.1074/jbc.272.39.24646; Liao JH, 1998, BIOCHEM BIOPH RES CO, V244, P131, DOI 10.1006/bbrc.1998.8226; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; Link AJ, 1997, ELECTROPHORESIS, V18, P1314, DOI 10.1002/elps.1150180808; Litt M, 1998, HUM MOL GENET, V7, P471, DOI 10.1093/hmg/7.3.471; MANN M, 1989, ANAL CHEM, V61, P1702, DOI 10.1021/ac00190a023; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MENDOZA JA, 1994, J BIOL CHEM, V269, P2447; MENDOZA JA, 1991, J BIOL CHEM, V266, P16973; MERCK KB, 1993, J BIOL CHEM, V268, P1046; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; Muchowski PJ, 1998, P NATL ACAD SCI USA, V95, P1004, DOI 10.1073/pnas.95.3.1004; Muchowski PJ, 1997, J BIOL CHEM, V272, P2578; NADEAU K, 1993, J BIOL CHEM, V268, P1479; PALMISANO DV, 1995, BBA-PROTEIN STRUCT M, V1246, P91, DOI 10.1016/0167-4838(94)00176-H; Plater ML, 1996, J BIOL CHEM, V271, P28558, DOI 10.1074/jbc.271.45.28558; Ranson NA, 1998, BIOCHEM J, V333, P233, DOI 10.1042/bj3330233; RAO PV, 1993, BIOCHEM BIOPH RES CO, V190, P786, DOI 10.1006/bbrc.1993.1118; RAO PV, 1994, J BIOL CHEM, V269, P13266; Rawat U, 1998, J BIOL CHEM, V273, P9415, DOI 10.1074/jbc.273.16.9415; REDDY MC, 1992, BIOCHEM BIOPH RES CO, V189, P1578, DOI 10.1016/0006-291X(92)90256-K; RENKAWEK K, 1992, ACTA NEUROPATHOL, V83, P324, DOI 10.1007/BF00296796; RENKAWEK K, 1994, ACTA NEUROPATHOL, V87, P155, DOI 10.1007/BF00296185; RIEDEL A, 1959, Z PHYSIOL CHEM, V316, P61; SADIS S, 1992, BIOCHEMISTRY-US, V31, P9406, DOI 10.1021/bi00154a012; SHEVCHENKO A, 1996, ANAL CHEM, V68, P3202; SHINOHARA H, 1993, J NEUROL SCI, V119, P203, DOI 10.1016/0022-510X(93)90135-L; SMITH JB, 1992, PROTEIN SCI, V1, P601, DOI 10.1002/pro.5560010506; SRINIVASAN AN, 1992, J BIOL CHEM, V267, P23337; Sun TX, 1997, J BIOL CHEM, V272, P6220, DOI 10.1074/jbc.272.10.6220; VANNOORT JM, 1995, NATURE, V375, P798, DOI 10.1038/375798a0; Veinger L, 1998, J BIOL CHEM, V273, P11032, DOI 10.1074/jbc.273.18.11032; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; VOORTER CEM, 1989, FEBS LETT, V259, P50; WANG KY, 1995, INVEST OPHTH VIS SCI, V36, P311; WANG KY, 1994, J BIOL CHEM, V269, P13601; WISTOW G, 1985, FEBS LETT, V181, P1, DOI 10.1016/0014-5793(85)81102-9; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; YATES JR, 1995, ANAL CHEM, V67, P3202, DOI 10.1021/ac00114a016; ZIMMERMAN M, 1977, ANAL BIOCHEM, V78, P47, DOI 10.1016/0003-2697(77)90006-9; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431	73	57	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30190	30195		10.1074/jbc.274.42.30190	http://dx.doi.org/10.1074/jbc.274.42.30190			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514509	hybrid			2022-12-27	WOS:000083176400088
J	Kardassis, D; Papakosta, P; Pardali, K; Moustakas, A				Kardassis, D; Papakosta, P; Pardali, K; Moustakas, A			c-Jun transactivates the promoter of the human p21(WAF1/Cip1) gene by acting as a superactivator of the ubiquitous transcription factor Spl	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING-GROWTH-FACTOR; TGF-BETA; CELL-GROWTH; BINDING PROTEIN; P53-INDEPENDENT PATHWAY; FUNCTIONAL INTERACTIONS; SYNERGISTIC ACTIVATION; FAMILY PROTEINS; SMAD PROTEINS; PC12 CELLS	The cell cycle inhibitor protein p21(WAF1/Cip1) (p21) is a critical downstream effector in p53-dependent mechanisms of growth control and p53-independent pathways of terminal differentiation. We have recently reported that the transforming growth factor-p pathway-specific Smad3 and Smad4 proteins transactivate the human p21 promoter via a short proximal region, which contains multiple binding sites for the ubiquitous transcription factor Spl. In the present study we show that the Sp1-occupied promoter region mediates transactivation of the p21 promoter by c-Jun and the related proteins JunB, JunD, and ATF-2. By using gel electrophoretic mobility shift assays we show that this region does not contain a binding site for c-Jun. In accordance with the DNA binding data, c-Jun was unable to transactivate the p21 promoter when overexpressed in the Sp1-deficient Drosophila-derived SL2 cells. Coexpression of c-Jun and Sp1 in these cells resulted in a strong synergistic transactivation of this promoter. In addition, a chimeric promoter consisting of six tandem high affinity Sp1-binding sites fused with the CAT gene was transactivated by overexpressed c-Jun in HepG2 cells. The above data propose functional cooperation between c-Jun and Sp1. Physical interactions between the two factors were demonstrated in vitro by using GST-Sp1 hybrid proteins expressed in bacteria and in vitro transcribed-translated c-Sun. The region of c-Jun mediating interaction with Sp1 was mapped within the basic region leucine zipper domain. In vivo, functional interactions between c-Jun and Sp1 were demonstrated using a GAL4-based transactivation assay. Overexpressed c-Jun transactivated a chimeric promoter consisting of five tandem GAL1-binding sites only when coexpressed with GAL4-(Sp1-(83-778) fusion proteins in HepG2 cells. By utilizing the same assay, we found that the glutamine-rich segment of the B domain of Sp1 (Bc, amino acids 424-542) was sufficient: for c-Jun-induced transactivation of the p21 promoter. In conclusion, our data support a mechanism of superactivation of Sp1 by c-Jun, which is based on physical and functional interactions between these two transcription factors on the human p21 and possibly other Sp1-dependent promoters.	Univ Crete, Sch Med, Dept Basic Sci, GR-71110 Heraklion, Crete, Greece; Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, GR-71110 Heraklion, Crete, Greece	University of Crete; Foundation for Research & Technology - Hellas (FORTH)	Kardassis, D (corresponding author), Univ Crete, Sch Med, Dept Basic Sci, GR-71110 Heraklion, Crete, Greece.			Pardali, Katerina/0000-0002-4360-730X				AKASHI M, 1995, J BIOL CHEM, V270, P19181, DOI 10.1074/jbc.270.32.19181; Albrecht JH, 1997, HEPATOLOGY, V25, P557, DOI 10.1002/hep.510250311; Bannister AJ, 1995, ONCOGENE, V11, P2509; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Black AR, 1999, J BIOL CHEM, V274, P1207, DOI 10.1074/jbc.274.3.1207; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Cook T, 1998, J BIOL CHEM, V273, P25929, DOI 10.1074/jbc.273.40.25929; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Erhardt JA, 1998, J BIOL CHEM, V273, P23517, DOI 10.1074/jbc.273.36.23517; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; Hunt KK, 1998, CANCER RES, V58, P5656; Jacks T, 1998, SCIENCE, V280, P1035, DOI 10.1126/science.280.5366.1035; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; JIANG HP, 1994, ONCOGENE, V9, P3397; KARDASSIS D, 1992, J BIOL CHEM, V267, P2622; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Kim Y, 1998, J BIOL CHEM, V273, P33750, DOI 10.1074/jbc.273.50.33750; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; Li JM, 1998, NUCLEIC ACIDS RES, V26, P2449, DOI 10.1093/nar/26.10.2449; LI L, 1990, J BIOL CHEM, V265, P1556; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; McDonough PM, 1997, J BIOL CHEM, V272, P24046, DOI 10.1074/jbc.272.38.24046; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MICHIELI P, 1994, CANCER RES, V54, P3391; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; Noti JD, 1997, J BIOL CHEM, V272, P24038, DOI 10.1074/jbc.272.38.24038; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; Saluja D, 1998, MOL CELL BIOL, V18, P5734, DOI 10.1128/MCB.18.10.5734; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; Ui M, 1998, FEBS LETT, V429, P289, DOI 10.1016/S0014-5793(98)00618-8; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; Wong C, 1999, MOL CELL BIOL, V19, P1821; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; Xiao HY, 1999, J CELL BIOCHEM, V73, P291, DOI 10.1002/(SICI)1097-4644(19990601)73:3<291::AID-JCB1>3.0.CO;2-5; Yan GZ, 1997, J NEUROSCI, V17, P6122; YIEH L, 1995, P NATL ACAD SCI USA, V92, P6102, DOI 10.1073/pnas.92.13.6102; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zauberman A, 1997, ONCOGENE, V15, P1705, DOI 10.1038/sj.onc.1201348; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	68	177	181	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29572	29581		10.1074/jbc.274.41.29572	http://dx.doi.org/10.1074/jbc.274.41.29572			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506225				2022-12-27	WOS:000083017800104
J	O'Reilly, MS; Wiederschain, D; Stetler-Stevenson, WG; Folkman, J; Moses, MA				O'Reilly, MS; Wiederschain, D; Stetler-Stevenson, WG; Folkman, J; Moses, MA			Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELECTIN ADHESION MOLECULE; LEWIS-LUNG-CARCINOMA; GROWTH-FACTOR; ANGIOGENESIS INHIBITOR; ENDOTHELIAL-CELLS; IDENTIFICATION; COLLAGENASE; IV; PLASMINOGEN; ECTODOMAIN	We have previously reported the identification of the endogenous angiogenesis inhibitor angiostatin, a specific inhibitor of endothelial cell proliferation in vitro and angiogenesis in vivo. In our original studies, we demonstrated that a Lewis lung carcinoma (LLC-LM) primary tumor could suppress the growth of its metastases by generating angiostatin. Angiostatin, a 38-kDa internal fragment of plasminogen, was purified from the serum and urine of mice bearing LLC-LM, and its discovery provides the first proven mechanism for concomitant resistance (O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A, Moses, BZ A, Lane, W. S., Cao, Y., Sage, E. II., and Folkman, J. (1999 Cell 79, 315-328). Subsequently, we have shown that systemic administration of angiostatin can regress a wide variety of malignant tumors in vivo. However, at the time of our initial discovery of angiostatin, the source of the protein was unclear. We hypothesized that the tumor or stromal cells might produce an enzyme that could cleave plasminogen sequestered by the primary tumor into angiostatin. Alternatively, we speculated that the tumor cells might express angiostatin. By Northern analysis, however, we have found no evidence that the tumor cells express angiostatin or other fragments of plasminogen (data not shown). me now report that gelatinase A (matrix metalloproteinase-2), produced directly by the LLC-LM cells, is responsible for the production of angiostatin, which suppresses the growth of metastases in our original model.	Childrens Hosp, Dept Surg, Surg Res Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Joint Ctr Radiat Therapy, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Moses, MA (corresponding author), Childrens Hosp, Dept Surg, Surg Res Lab, Boston, MA 02115 USA.		Stetler-Stevenson, William G/H-6956-2012; Stetler-Stevenson, William/AAE-3501-2020	Stetler-Stevenson, William G/0000-0002-5500-5808; Stetler-Stevenson, William/0000-0002-5500-5808	DIVISION OF CLINICAL SCIENCES - NCI [Z01SC009164] Funding Source: NIH RePORTER	DIVISION OF CLINICAL SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Bennett TA, 1996, J IMMUNOL, V156, P3093; BRAUNHUT SJ, 1994, J BIOL CHEM, V269, P13472; CLAPP C, 1993, ENDOCRINOLOGY, V133, P1292, DOI 10.1210/en.133.3.1292; Couet J, 1996, J BIOL CHEM, V271, P4545; Dong ZY, 1997, CELL, V88, P801, DOI 10.1016/S0092-8674(00)81926-1; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Falcone DJ, 1998, J BIOL CHEM, V273, P31480, DOI 10.1074/jbc.273.47.31480; Feehan C, 1996, J BIOL CHEM, V271, P7019, DOI 10.1074/jbc.271.12.7019; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; Gately S, 1996, CANCER RES, V56, P4887; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HERRON GS, 1986, J BIOL CHEM, V261, P2814; Levi E, 1996, P NATL ACAD SCI USA, V93, P7069, DOI 10.1073/pnas.93.14.7069; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MOSES MA, 1990, SCIENCE, V248, P1408, DOI 10.1126/science.1694043; MULLBERG J, 1995, J IMMUNOL, V155, P5198; NELSON J, 1995, CANCER RES, V55, P3772; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Patterson BC, 1997, J BIOL CHEM, V272, P28823, DOI 10.1074/jbc.272.46.28823; Stathakis P, 1997, J BIOL CHEM, V272, P20641, DOI 10.1074/jbc.272.33.20641; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; Walcheck B, 1996, NATURE, V380, P720, DOI 10.1038/380720a0	29	208	214	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29568	29571		10.1074/jbc.274.41.29568	http://dx.doi.org/10.1074/jbc.274.41.29568			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506224	hybrid			2022-12-27	WOS:000083017800103
J	Dutta, B; Huang, W; Molero, M; Kekuda, R; Leibach, FH; Devoe, LD; Ganapathy, V; Prasad, PD				Dutta, B; Huang, W; Molero, M; Kekuda, R; Leibach, FH; Devoe, LD; Ganapathy, V; Prasad, PD			Cloning of the human thiamine transporter, a member of the folate transporter family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORGANIC CATION TRANSPORTER; BORDER MEMBRANE-VESICLES; RENAL BRUSH-BORDER; FUNCTIONAL EXPRESSION; HUMAN PLACENTA; INTESTINE; PROTEIN; SYSTEM	We have isolated a cDNA from human placenta, which, when expressed heterologously in mammalian cells, mediates the transport of the water-soluble vitamin thiamine. The cDNA codes for a protein of 497 amino acids containing 12 putative transmembrane domains, Northern blot analysis indicates that this transporter is widely expressed in human tissues. When expressed in HeLa cells, the cDNA induces the transport of thiamine (K-i = 2.5 +/- 0.6 mu M) in a Na+-independent manner, The cDNA-mediated transport of thiamine is stimulated by an outwardly directed H+ gradient. Substrate specificity assays indicate that the transporter is specific to thiamine, Even though thiamine is an organic cation, the cDNA-induced thiamine transport is not inhibited by other organic cations. Similarly, thiamine is not a substrate for the known members of mammalian organic cation transporter family. The thiamine transporter gene, located on human chromosome 1q24, consists of 6 exons and is most likely the gene defective in the metabolic disorder, thiamine-responsive megaloblastic anemia. At the level of amino acid sequence, the thiamine transporter is most closely related to the reduced-folate transporter and thus represents member of the folate transporter family.	Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Obstet & Gynecol, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University	Prasad, PD (corresponding author), Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA.	pprasad@mail.mcg.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD033347] Funding Source: NIH RePORTER; NICHD NIH HHS [HD33347] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ATTWOOD TK, 1991, GENE, V98, P153, DOI 10.1016/0378-1119(91)90168-B; BETTENDORFF L, 1994, J BIOL CHEM, V269, P14379; CASIROLA D, 1990, J MEMBRANE BIOL, V118, P11, DOI 10.1007/BF01872201; CHEN CP, 1978, J NUTR SCI VITAMINOL, V24, P351, DOI 10.3177/jnsv.24.351; DANCIS J, 1988, AM J OBSTET GYNECOL, V159, P1435, DOI 10.1016/0002-9378(88)90570-4; GANAPATHY V, 1988, J BIOL CHEM, V263, P4561; Grassl SM, 1998, BBA-BIOMEMBRANES, V1371, P213, DOI 10.1016/S0005-2736(98)00019-4; GRUNDEMANN D, 1994, NATURE, V372, P549, DOI 10.1038/372549a0; HOYUMPA AM, 1975, GASTROENTEROLOGY, V68, P1218; Kekuda R, 1998, J BIOL CHEM, V273, P15971, DOI 10.1074/jbc.273.26.15971; Kekuda R, 1999, J BIOL CHEM, V274, P3422, DOI 10.1074/jbc.274.6.3422; Koepsell H, 1999, J MEMBRANE BIOL, V167, P103, DOI 10.1007/s002329900475; KOMAI T, 1974, J NUTR SCI VITAMINOL, V20, P179, DOI 10.3177/jnsv.20.179; Kumar CK, 1998, AM J PHYSIOL-CELL PH, V274, pC289, DOI 10.1152/ajpcell.1998.274.1.C289; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Laforenza U, 1997, AM J CLIN NUTR, V66, P320, DOI 10.1093/ajcn/66.2.320; Laforenza U, 1998, J MEMBRANE BIOL, V161, P151, DOI 10.1007/s002329900322; MIYAMOTO Y, 1988, AM J PHYSIOL, V255, pG85, DOI 10.1152/ajpgi.1988.255.1.G85; Neufeld EJ, 1997, AM J HUM GENET, V61, P1335, DOI 10.1086/301642; *NUTR FDN INC, 1989, NUTR REV PRES KNOWL; Okuda M, 1996, BIOCHEM BIOPH RES CO, V224, P500, DOI 10.1006/bbrc.1996.1056; OTT RJ, 1991, AM J PHYSIOL, V261, pF443, DOI 10.1152/ajprenal.1991.261.3.F443; Pan BF, 1999, TOXICOL SCI, V47, P181, DOI 10.1093/toxsci/47.2.181; Prasad PD, 1999, ARCH BIOCHEM BIOPHYS, V366, P95, DOI 10.1006/abbi.1999.1213; PRASAD PD, 1995, BIOCHEM BIOPH RES CO, V206, P681, DOI 10.1006/bbrc.1995.1096; PRASAD PD, 1992, J BIOL CHEM, V267, P23632; Prasad PD, 1998, J BIOL CHEM, V273, P7501, DOI 10.1074/jbc.273.13.7501; ROGERS LE, 1969, J PEDIATR-US, V74, P494, DOI 10.1016/S0022-3476(69)80031-4; SCHENKER S, 1990, J LAB CLIN MED, V116, P106; SETH P, 1999, FASEB J, V13; Smith RF, 1996, GENOME RES, V6, P454, DOI 10.1101/gr.6.5.454; Stagg AR, 1999, J CLIN INVEST, V103, P723, DOI 10.1172/JCI3895; Tamai I, 1997, FEBS LETT, V419, P107, DOI 10.1016/S0014-5793(97)01441-5; Tsukaguchi H, 1999, NATURE, V399, P70, DOI 10.1038/19986; Wang HP, 1999, J BIOL CHEM, V274, P14875, DOI 10.1074/jbc.274.21.14875; WRIGHT SH, 1987, AM J PHYSIOL, V253, pF1040, DOI 10.1152/ajprenal.1987.253.5.F1040; ZEMPLENI J, 1992, INT J VITAM NUTR RES, V62, P165	37	150	154	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31925	31929		10.1074/jbc.274.45.31925	http://dx.doi.org/10.1074/jbc.274.45.31925			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542220	hybrid			2022-12-27	WOS:000083532100028
J	McGraw, DW; Forbes, SL; Kramer, LA; Witte, DP; Fortner, CN; Paul, RJ; Liggett, SB				McGraw, DW; Forbes, SL; Kramer, LA; Witte, DP; Fortner, CN; Paul, RJ; Liggett, SB			Transgenic overexpression of beta(2)-adrenergic receptors in airway smooth muscle alters myocyte function and ablates bronchial hyperreactivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED TRACHEA; GUINEA-PIG; MICE; EXPRESSION; BETA-1-ADRENOCEPTORS; DESENSITIZATION; TRANSDUCTION; RELAXATION; PATTERNS; FAILURE	beta(2)-Adrenergic receptors (beta(2)AR) act to relax airway smooth muscle and can serve to counteract hyperresponsiveness, although the effect may not be ablative even in the presence of exogenous agonist, Within this signaling cascade that ultimately transduces smooth muscle relaxation, a significant "spare receptor" pool has been hypothesized to be present in the airway. In order to modify the relationship between beta(2)AR and downstream effecters, transgenic mice (TG) were created overexpressing beta(2)AR similar to 75-fold in airway smooth muscle using a mouse smooth muscle a-actin promoter. While >90% of these receptors were expressed on the smooth muscle cell surface, the percentage of receptors able to form the agonist-promoted high affinity complex was less than that found with nontransgenic (NTG) cells (R-H = 18 versus 36%). Nevertheless, beta(2)AR signaling was found to be enhanced. Intact airway smooth muscle cells from TG had basal cAMP levels that were greater than NTG cells. A marked increase in agonist-stimulated cAMP levels was found in the TG (similar to 200% stimulation over basal) compared with NTG (similar to 50% over basal) cells. Adenylyl cyclase studies gave similar results and also showed a 10-fold lower EC50 for TC: cells. Tracheal rings from TG mice that were precontracted with acetylcholine had an enhanced responsiveness (relaxation) to beta-agonist, with a 60-fold decrease in the ED50, indicating that the enhanced signaling imposed by overexpression results in an increase in the coordinated function of the intact airway cells. In vivo studies showed a significantly blunted airway resistance response to the inhaled bronchoconstrictor methacholine in the TG mice. Indeed, with beta-agonist pretreatment, the TG mice displayed no response whatsoever to methacholine. These results are consistent with beta(2)AR being the limiting factor in the transduction system. Increases in the initial component of this transduction system (the beta(2)AR) are sufficient to markedly alter signaling and airway smooth muscle function to the extent that bronchial hyperresponsiveness is ablated, consistent with an antiasthma phenotype.	Univ Cincinnati, Coll Med, Dept Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Mol Genet, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Physiol, Cincinnati, OH 45267 USA; Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center	Liggett, SB (corresponding author), Univ Cincinnati, Coll Med, Dept Med, 231 Bethesda Ave, Cincinnati, OH 45267 USA.	Stephen.Liggett@UC.edu	liggett, stephen b/E-7453-2012	Liggett, Stephen B./0000-0002-0128-3669	NHLBI NIH HHS [HL41496, HL45967, HL54829] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054829, R37HL045967, R01HL045967, P01HL041496, R56HL045967] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVNER BP, 1979, P W PHARMACOL SOC, V22, P177; BAI TR, 1992, LUNG, V170, P125; BARNES PJ, 1985, BRIT J PHARMACOL, V86, P685, DOI 10.1111/j.1476-5381.1985.tb08946.x; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; Dorn GW, 1999, P NATL ACAD SCI USA, V96, P6400, DOI 10.1073/pnas.96.11.6400; FOSTER DN, 1992, J BIOL CHEM, V267, P11995; GREEN SA, 1994, J BIOL CHEM, V269, P26215; GREEN SA, 1995, AM J RESP CELL MOL, V13, P25, DOI 10.1165/ajrcmb.13.1.7598936; GREEN SA, 1996, GENETICS ASTHMA, P67; Hakonarson H, 1998, AM J RESP CRIT CARE, V158, pS115, DOI 10.1164/ajrccm.158.supplement_2.13tac700; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; HENRY PJ, 1990, BRIT J PHARMACOL, V99, P136, DOI 10.1111/j.1476-5381.1990.tb14667.x; HENRY PJ, 1990, BRIT J PHARMACOL, V99, P131, DOI 10.1111/j.1476-5381.1990.tb14666.x; Kao J, 1999, AM J PHYSIOL-LUNG C, V277, pL264, DOI 10.1152/ajplung.1999.277.2.L264; KENAKIN T, 1988, LIFE SCI, V43, P1095, DOI 10.1016/0024-3205(88)90467-5; Laporte JD, 1998, AM J PHYSIOL-LUNG C, V275, pL491, DOI 10.1152/ajplung.1998.275.3.L491; LEMOINE H, 1992, J PHARMACOL EXP THER, V261, P258; LEMOINE H, 1982, N-S ARCH PHARMACOL, V320, P130, DOI 10.1007/BF00506313; LIGGETT SB, 1989, MOL PHARMACOL, V36, P641; LIGGETT SB, 1997, LUNG SCI FDN, P19; McGraw DW, 1998, CELL SIGNAL, V10, P197, DOI 10.1016/S0898-6568(97)00112-5; McGraw DW, 1997, J BIOL CHEM, V272, P7338, DOI 10.1074/jbc.272.11.7338; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; MILLIGAN G, 1995, MOL CELL BIOCHEM, V149, P213, DOI 10.1007/BF01076579; ODONNELL SR, 1972, EUR J PHARMACOL, V19, P371, DOI 10.1016/0014-2999(72)90104-5; PAUL RJ, 1996, GENETICS ASTHMA, P91; Postma DS, 1998, AM J RESP CRIT CARE, V158, pS187, DOI 10.1164/ajrccm.158.supplement_2.13tac170; Rockman HA, 1998, P NATL ACAD SCI USA, V95, P7000, DOI 10.1073/pnas.95.12.7000; SUTLIFF RL, 1998, DEV CARDIOVASC MED, V210, P247; TODA N, 1978, J PHARMACOL EXP THER, V207, P311; Turki J, 1996, P NATL ACAD SCI USA, V93, P10483, DOI 10.1073/pnas.93.19.10483; Wang JW, 1997, J CLIN INVEST, V100, P1425, DOI 10.1172/JCI119663; WEIBEL ER, 1988, PULMONARY DIS DISORD, P20	34	45	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32241	32247		10.1074/jbc.274.45.32241	http://dx.doi.org/10.1074/jbc.274.45.32241			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542262	hybrid			2022-12-27	WOS:000083532100070
J	Schottelius, AJG; Mayo, MW; Sartor, RB; Badwin, AS				Schottelius, AJG; Mayo, MW; Sartor, RB; Badwin, AS			Interleukin-10 signaling blocks inhibitor of kappa B kinase activity and nuclear factor kappa B DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLAMMATORY BOWEL-DISEASE; TUMOR-NECROSIS-FACTOR; GROWTH-FACTOR-BETA; CYTOKINE PRODUCTION; REGULATORY REGION; HUMAN MONOCYTES; IN-VIVO; ACTIVATION; ALPHA; IL-10	The transcription factor nuclear factor kappa B (NF-kappa B) coordinates the activation of numerous genes in response to pathogens and proinflammatory cytokines and is, therefore, pivotal in the development of acute and chronic inflammatory diseases. In its inactive state, NF-kappa B is constitutively present in the cytoplasm as a p50-p65 heterodimer bound to its inhibitory protein I kappa B, Proinflammatory cytokines, such as tumor necrosis factor (TNF), activate NF-kappa B by stimulating the activity of the I kappa B kinases (IKKs) which phosphorylate I kappa B alpha on serine residues 32 and 36, targeting it for rapid degradation by the 26 S proteasome, This enables the release and nuclear translocation of the NF-kappa B complex and activation of gene transcription. Interleukin-10 (IL-10) is a pleiotropic cytokine that controls inflammatory processes by suppressing the production of proinflammatory cytokines which are known to be transcriptionally controlled by NF-kappa B. Conflicting data exists on the effects of IL-10 on TNF- and LPS-induced NF-kappa B activity in human monocytes and the molecular mechanisms involved have not been elucidated. In this study, we show that IL-10 functions to block NF-kappa B activity at two levels: 1) through the suppression of IKK activity and 2) through the inhibition of NF-kappa B DNA binding activity. This is the first evidence of an anti-inflammatory protein inhibiting IKK activity and demonstrates that IKK is a logical target for blocking inflammatory diseases.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Gastronintestinal Biol & Dis, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Badwin, AS (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.				NATIONAL CANCER INSTITUTE [R01CA075080] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI035098, R01AI035098] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047700] Funding Source: NIH RePORTER; NCI NIH HHS [CA75080] Funding Source: Medline; NIAID NIH HHS [AI35098] Funding Source: Medline; NIDDK NIH HHS [R01 DK 47700] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, INT J BIOCHEM CELL B, V29, P867, DOI 10.1016/S1357-2725(96)00159-8; BECKER H, 1995, CLIN EXP IMMUNOL, V99, P325; BOGDAN C, 1992, J BIOL CHEM, V267, P23301; BOGDAN C, 1991, J EXP MED, V174, P1549, DOI 10.1084/jem.174.6.1549; BOGDAN C, 1993, ANN NY ACAD SCI, V685, P713, DOI 10.1111/j.1749-6632.1993.tb35934.x; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Burkhardt H, 1997, RHEUMATOL INT, V17, P85, DOI 10.1007/s002960050014; Cheshire JL, 1997, MOL CELL BIOL, V17, P6746, DOI 10.1128/MCB.17.11.6746; Clarke CJP, 1998, EUR J IMMUNOL, V28, P1719, DOI 10.1002/(SICI)1521-4141(199805)28:05<1719::AID-IMMU1719>3.0.CO;2-Q; DE WMR, 1991, J EXP MED, V174, P1209; DELPRETE G, 1993, J IMMUNOL, V150, P353; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dokter WHA, 1996, LEUKEMIA, V10, P1308; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; GENG Y, 1994, P NATL ACAD SCI USA, V91, P8602, DOI 10.1073/pnas.91.18.8602; GERARD C, 1993, J EXP MED, V177, P547, DOI 10.1084/jem.177.2.547; Handel ML, 1995, ARTHRITIS RHEUM, V38, P1762, DOI 10.1002/art.1780381209; Herfarth HH, 1998, GASTROENTEROLOGY, V115, P856, DOI 10.1016/S0016-5085(98)70257-4; Herfarth HH, 1996, GUT, V39, P836, DOI 10.1136/gut.39.6.836; Jobin C, 1998, GUT, V42, P779, DOI 10.1136/gut.42.6.779; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Lentsch AB, 1997, J CLIN INVEST, V100, P2443, DOI 10.1172/JCI119786; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.iy.11.040193.001121; Mori N, 1997, EUR J HAEMATOL, V59, P162; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; PENNLINE KJ, 1994, CLIN IMMUNOL IMMUNOP, V71, P169, DOI 10.1006/clin.1994.1068; Poe JC, 1997, J IMMUNOL, V159, P846; POWRIE F, 1993, INT IMMUNOL, V5, P1461, DOI 10.1093/intimm/5.11.1461; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rogler G, 1998, GASTROENTEROLOGY, V115, P357, DOI 10.1016/S0016-5085(98)70202-1; Romano MF, 1996, J IMMUNOL, V156, P2119; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; ROTT O, 1994, EUR J IMMUNOL, V24, P1434, DOI 10.1002/eji.1830240629; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; Schottelius AJG, 1999, INT J COLORECTAL DIS, V14, P18, DOI 10.1007/s003840050178; Schreiber S, 1998, GUT, V42, P477, DOI 10.1136/gut.42.4.477; SCHREIBER S, 1995, GASTROENTEROLOGY, V108, P1434, DOI 10.1016/0016-5085(95)90692-4; SHIRAKAWA F, 1993, MOL CELL BIOL, V13, P1332, DOI 10.1128/MCB.13.3.1332; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; vanDeventer SJH, 1997, GASTROENTEROLOGY, V113, P383, DOI 10.1053/gast.1997.v113.pm9247454; VANLAETHEM JL, 1995, GASTROENTEROLOGY, V108, P1917, DOI 10.1016/0016-5085(95)90158-2; Walmsley M, 1996, ARTHRITIS RHEUM-US, V39, P495, DOI 10.1002/art.1780390318; WANG P, 1994, J IMMUNOL, V153, P811; WANG P, 1995, J BIOL CHEM, V270, P9558, DOI 10.1074/jbc.270.16.9558; WANG P, 1994, BLOOD, V83, P2678, DOI 10.1182/blood.V83.9.2678.bloodjournal8392678; WILLEMS F, 1994, EUR J IMMUNOL, V24, P1007, DOI 10.1002/eji.1830240435; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	55	423	446	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31868	31874		10.1074/jbc.274.45.31868	http://dx.doi.org/10.1074/jbc.274.45.31868			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542212	hybrid, Green Published			2022-12-27	WOS:000083532100020
J	Widlund, HR; Kuduvalli, PN; Bengtsson, M; Cao, H; Tullius, TD; Kubista, M				Widlund, HR; Kuduvalli, PN; Bengtsson, M; Cao, H; Tullius, TD; Kubista, M			Nucleosome structural features and intrinsic properties of the TATAAACGCC repeat sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOTONIC-DYSTROPHY GENE; POSITIONING SEQUENCES; CRYSTAL-STRUCTURE; TRIPLET REPEATS; DNA FLEXIBILITY; HELICAL REPEAT; BASE-PAIRS; CHROMATIN; MOBILITY; COMPLEX	Nucleosomes, the fundamental building blocks of chromatin, play an architectural role in ensuring the integrity of the genome and act as a regulator of transcription. Intrinsic properties of the underlying DNA sequence, such as flexibility and intrinsic bending, direct the formation of nucleosomes, We have earlier identified genomic nucleosome-positioning sequences with increased in vitro ability for nucleosome formation. One group of sequences bearing a 10-base pair consensus repeat sequence of TATAAACGCC had the highest reported nucleosome affinity from genomic material. Here, we report the intrinsic physical properties of this sequence and the structural details of the nucleosome it forms, as analyzed by footprinting techniques, The minor groove is buried toward the histone octamer at the AA steps and facing outwards at the CC steps. By cyclization kinetics, the overall helical repeat of the free DNA sequence was found to be 10.5 base pairs/turn. Our experiments also showed that this sequence is highly flexible, having a J-factor 25-fold higher than that of random sequence DNA, In addition, the data suggest that twist flexibility is an important determinant for translational nucleosome positioning, particularly over the dyad region.	Chalmers Univ Technol, Lundberg Inst, Dept Biochem & Biophys, SE-41390 Gothenburg, Sweden; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Boston Univ, Dept Chem, Boston, MA 02215 USA	Chalmers University of Technology; Howard Hughes Medical Institute; Johns Hopkins University; Boston University	Kubista, M (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Dana 630,44 Binney St, Boston, MA 02115 USA.	Mikael.Kubista@molbiotech.chalmers.se	Kubista, Mikael/A-5689-2008; Tullius, Thomas D./A-9685-2008	Kubista, Mikael/0000-0002-2940-352X; Tullius, Thomas D./0000-0003-4425-796X; Widlund, Hans/0000-0002-7506-2447	NIGMS NIH HHS [GM41930, R01 GM041930-10, R01 GM041930] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041930] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bacolla A, 1997, J BIOL CHEM, V272, P16783, DOI 10.1074/jbc.272.27.16783; BOLSHOY A, 1995, NAT STRUCT BIOL, V2, P446, DOI 10.1038/nsb0695-446; CROTHERS DM, 1992, METHOD ENZYMOL, V212, P3; de Souza ON, 1998, BIOPOLYMERS, V46, P403; DIXON WJ, 1991, METHOD ENZYMOL, V208, P380; DLAKIC M, 1995, J BIOL CHEM, V270, P29945; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; El Hassan MA, 1998, J MOL BIOL, V282, P331, DOI 10.1006/jmbi.1998.1994; ElHassan MA, 1996, J MOL BIOL, V259, P95, DOI 10.1006/jmbi.1996.0304; Godde JS, 1996, J BIOL CHEM, V271, P15222, DOI 10.1074/jbc.271.25.15222; HAYES JJ, 1990, P NATL ACAD SCI USA, V87, P7405, DOI 10.1073/pnas.87.19.7405; Hunter CA, 1997, J MOL BIOL, V265, P603, DOI 10.1006/jmbi.1996.0755; Imbalzano AN, 1998, CRIT REV EUKAR GENE, V8, P225, DOI 10.1615/CritRevEukarGeneExpr.v8.i3-4.10; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KUDUVALLI PN, 1995, BIOCHEMISTRY-US, V34, P3899, DOI 10.1021/bi00012a005; Lowary PT, 1997, P NATL ACAD SCI USA, V94, P1183, DOI 10.1073/pnas.94.4.1183; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; POLACH KJ, 1995, J MOL BIOL, V254, P130, DOI 10.1006/jmbi.1995.0606; RHODES D, 1979, NUCLEIC ACIDS RES, V6, P1805, DOI 10.1093/nar/6.5.1805; SATCHWELL SC, 1986, J MOL BIOL, V191, P659, DOI 10.1016/0022-2836(86)90452-3; SHORE D, 1981, P NATL ACAD SCI-BIOL, V78, P4833, DOI 10.1073/pnas.78.8.4833; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; SIMPSON RT, 1991, PROG NUCLEIC ACID RE, V40, P143; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; TANAKA S, 1992, EMBO J, V11, P1187, DOI 10.1002/j.1460-2075.1992.tb05159.x; TAYLOR WH, 1990, J MOL BIOL, V212, P363, DOI 10.1016/0022-2836(90)90131-5; Thastrom A, 1999, J MOL BIOL, V288, P213, DOI 10.1006/jmbi.1999.2686; WANG YH, 1995, GENOMICS, V25, P570, DOI 10.1016/0888-7543(95)80061-P; WANG YH, 1994, SCIENCE, V265, P669, DOI 10.1126/science.8036515; WEINTRAUB H, 1983, CELL, V32, P1191, DOI 10.1016/0092-8674(83)90302-1; Widlund HR, 1997, J MOL BIOL, V267, P807, DOI 10.1006/jmbi.1997.0916; WOLFFE AP, 1994, CELL, V77, P13, DOI 10.1016/0092-8674(94)90229-1	33	70	78	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31847	31852		10.1074/jbc.274.45.31847	http://dx.doi.org/10.1074/jbc.274.45.31847			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542209	hybrid			2022-12-27	WOS:000083532100017
J	Ghafourifar, P; Schenk, U; Klein, SD; Richter, C				Ghafourifar, P; Schenk, U; Klein, SD; Richter, C			Mitochondrial nitric-oxide synthase stimulation causes cytochrome c release from isolated mitochondria - Evidence for intramitochondrial peroxynitrite formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; LIPID-PEROXIDATION; MEDIATED APOPTOSIS; HL-60 CELLS; SUPEROXIDE; CALCIUM; DYSFUNCTION; NEUROTOXICITY; CALMODULIN; ACTIVATION	Nitric oxide (NO) is synthesized by members of the NO synthase (NOS) family. Recently the existence of a mitochondrial NOS (mtNOS), its Ca2+ dependence, and its relevance for mitochondrial bioenergetics was reported (Ghafourifar, P., and Richter, C. (1997) FEBS Lett. 418, 291-296; Giulivi, C., Poderoso, J. J., and Boveris, A. (1998) J. Biol. Chem. 273, 11038-11043). Here we report on the possible involvement of mtNOS in apoptosis. We show that uptake of Ca2+ by mitochondria triggers mtNOS activity and causes the release of cytochrome c from isolated mitochondria in a Bcl-2-sensitive manner. mtNOS-induced cytochrome c release was paralleled by increased lipid peroxidation. The release of cytochrome c as well as increase in lipid peroxidation were prevented by NOS inhibitors, a superoxide dismutase mimic, and a peroxynitrite scavenger. We show that mtNOS-induced cytochrome c release is not mediated via the mitochondrial permeability transition pore because the release was aggravated by cyclosporin A and abolished by blockade of mitochondrial calcium uptake by ruthenium red. We conclude that, upon Ca2+-induced mtNOS activation, peroxynitrite is formed within mitochondria, which causes the release of cytochrome c from isolated mitochondria, and we propose a mechanism by which elevated Ca2+ levels induce apoptosis.	Swiss Fed Inst Technol, Inst Biochem, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Ghafourifar, P (corresponding author), Swiss Fed Inst Technol, Inst Biochem, CH-8092 Zurich, Switzerland.		Klein, Sabine D./T-2854-2019	Klein, Sabine D./0000-0001-6843-1454				Almeida A, 1998, BRAIN RES, V790, P209, DOI 10.1016/S0006-8993(98)00064-X; Baek JH, 1997, INT J CANCER, V73, P725, DOI 10.1002/(SICI)1097-0215(19971127)73:5<725::AID-IJC19>3.3.CO;2-T; Brune B, 1997, J BIOL CHEM, V272, P7253, DOI 10.1074/jbc.272.11.7253; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; DARLEYUSMAR V, 1994, MITOCHONDRIA DNA PRO, P1; Dolinska M, 1998, NEUROCHEM INT, V33, P233, DOI 10.1016/S0197-0186(98)00020-5; Estevez AG, 1998, J NEUROSCI, V18, P923; Ferrante RJ, 1999, BRAIN RES, V823, P177, DOI 10.1016/S0006-8993(99)01166-X; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; Ghafourifar P, 1997, FEBS LETT, V418, P291, DOI 10.1016/S0014-5793(97)01397-5; GHAFOURIFAR P, 1999, SYMBIOSIS EUKARYOTIS, V7, P503; Giulivi C, 1998, J BIOL CHEM, V273, P11038, DOI 10.1074/jbc.273.18.11038; Gonzalez-Zulueta M, 1998, J NEUROSCI, V18, P2040; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HATASE O, 1985, BIOCHEM BIOPH RES CO, V132, P63, DOI 10.1016/0006-291X(85)90988-X; Hirsch T, 1997, BIOSCIENCE REP, V17, P67, DOI 10.1023/A:1027339418683; ITANO T, 1986, BIOCHEM INT, V13, P787; Keller JN, 1998, J NEUROSCI, V18, P687; Kissner R, 1997, CHEM RES TOXICOL, V10, P1285, DOI 10.1021/tx970160x; Klein SD, 1997, ARCH BIOCHEM BIOPHYS, V348, P313, DOI 10.1006/abbi.1997.0437; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; Kruman I, 1998, J NEUROSCI RES, V51, P293, DOI 10.1002/(SICI)1097-4547(19980201)51:3<293::AID-JNR3>3.0.CO;2-B; Kruman II, 1998, EXP NEUROL, V154, P276, DOI 10.1006/exnr.1998.6958; Kruman II, 1999, J NEUROCHEM, V72, P529, DOI 10.1046/j.1471-4159.1999.0720529.x; LE WD, 1995, BRAIN RES, V686, P49, DOI 10.1016/0006-8993(95)00450-5; Leist M, 1997, MOL MED, V3, P750, DOI 10.1007/BF03401713; LIN KT, 1995, J BIOL CHEM, V270, P16487, DOI 10.1074/jbc.270.28.16487; Lin KT, 1998, AM J PHYSIOL-CELL PH, V274, pC855, DOI 10.1152/ajpcell.1998.274.4.C855; LOTSCHER HR, 1980, J BIOL CHEM, V255, P9325; Martinou I, 1999, J CELL BIOL, V144, P883, DOI 10.1083/jcb.144.5.883; McConkey DJ, 1997, BIOCHEM BIOPH RES CO, V239, P357, DOI 10.1006/bbrc.1997.7409; Messmer UK, 1996, FEBS LETT, V384, P162; MONCADA S, 1991, PHARMACOL REV, V43, P109; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; REMBOLD H, 1972, EUR J BIOCHEM, V28, P586, DOI 10.1111/j.1432-1033.1972.tb01947.x; Richter C, 1999, METHOD ENZYMOL, V301, P381; RICHTER C, 1990, BIOCHEM PHARMACOL, V40, P779, DOI 10.1016/0006-2952(90)90315-C; RUBBO H, 1994, J BIOL CHEM, V269, P26066; Stout AK, 1998, NAT NEUROSCI, V1, P366, DOI 10.1038/1577; Szabo C, 1997, J CLIN INVEST, V100, P723, DOI 10.1172/JCI119585; Williamson J R, 1979, Methods Enzymol, V55, P200	41	283	294	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31185	31188		10.1074/jbc.274.44.31185	http://dx.doi.org/10.1074/jbc.274.44.31185			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531311	hybrid			2022-12-27	WOS:000083379400015
J	Shistik, E; Keren-Raifman, T; Idelson, GH; Blumenstein, Y; Dascal, N; Ivanina, T				Shistik, E; Keren-Raifman, T; Idelson, GH; Blumenstein, Y; Dascal, N; Ivanina, T			The N terminus of the cardiac L-type Ca2+ channel alpha(1C) subunit - The initial segment is ubiquitous and crucial for protein kinase C modulation, but is not directly phosphorylated	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; ACTIVATED CALCIUM CHANNELS; FUNCTIONAL EXPRESSION; XENOPUS OOCYTES; CURRENTS; NEURONS; ENHANCEMENT; REQUIREMENT; DIVERSITY; MYOCYTES	The first 46 amino acids (aa) of the N terminus of the rabbit heart (RH) L-type cardiac Ca2+ channel alpha(1C) subunit are crucial for the stimulating action of protein kinase C (PKC) and also hinder channel gating (Shistik, E,, Ivanina, T,, Blumenstein, Y., and Dascal, N, (1998) J, Biol Chem, 273, 17901-17909); The mechanism of PKC action and the location of the PKC target site are not known. Moreover, uncertainties in the genomic sequence of the N-terminal region of alpha(1C) leave open the question of the presence of RH-type N terminus in L-type channels in mammalian tissues. Here, we demonstrate the presence of alpha(1C) protein containing an RH-type initial N-terminal segment in rat heart and brain by using a newly prepared polyclonal antibody. Using deletion mutants of alpha(1C) expressed in Xenopus oocytes, we further narrowed down the part of the N terminus crucial for both inhibitory gating and for PKC effect to the first 20 amino acid residues, and we identify the first 5 aa as an important determinant of PKC action and of N-terminal effect on gating, The absence of serines and threonines in the first 5 aa and the absence of phosphorylation by PKC of a glutathione S-transferase-fusion protein containing the initial segment suggest that the effect of PKC does not arise through a direct phosphorylation of this segment. We propose that PKC acts by attenuating the inhibitory action of the N terminus via phosphorylation of a remote site, in the channel or in an auxiliary protein, that interacts with the initial segment of the N terminus.	Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL-69978 Ramat Aviv, Israel; Alomone Labs Ltd, IL-91042 Jerusalem, Israel	Tel Aviv University; Sackler Faculty of Medicine	Ivanina, T (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL-69978 Ramat Aviv, Israel.	dascaln@post.tau.ac.il	Dascal, Nathan/O-3915-2015	Dascal, Nathan/0000-0002-5397-4146				Asai T, 1996, AM J PHYSIOL-HEART C, V270, pH620, DOI 10.1152/ajpheart.1996.270.2.H620; BIEL M, 1990, FEBS LETT, V269, P409, DOI 10.1016/0014-5793(90)81205-3; BOURINET E, 1992, PFLUG ARCH EUR J PHY, V421, P247, DOI 10.1007/BF00374834; Bouron A, 1995, FEBS LETT, V377, P159, DOI 10.1016/0014-5793(95)01327-X; Brereton HM, 1997, CELL CALCIUM, V22, P39, DOI 10.1016/S0143-4160(97)90088-9; CATTERALL WA, 1993, TRENDS NEUROSCI, V16, P500, DOI 10.1016/0166-2236(93)90193-P; CHIEN AJ, 1995, J BIOL CHEM, V270, P30036; Chik CL, 1996, FASEB J, V10, P1310, DOI 10.1096/fasebj.10.11.8836045; De Waard M, 1996, Ion Channels, V4, P41; DOERNER D, 1988, J NEUROSCI, V8, P4069; DOSEMECI A, 1988, CIRC RES, V62, P347, DOI 10.1161/01.RES.62.2.347; FFRENCHMULLEN JMH, 1995, J NEUROSCI, V15, P903; Finkbeiner S, 1998, J NEUROBIOL, V37, P171, DOI 10.1002/(SICI)1097-4695(199810)37:1<171::AID-NEU13>3.0.CO;2-H; Gao TY, 1997, J BIOL CHEM, V272, P19401, DOI 10.1074/jbc.272.31.19401; HALL KE, 1995, J NEUROSCI, V15, P6069; HERMAN MD, 1993, J PHYSIOL-LONDON, V462, P645, DOI 10.1113/jphysiol.1993.sp019574; Hsu KS, 1996, AM J PHYSIOL-CELL PH, V271, pC1269, DOI 10.1152/ajpcell.1996.271.4.C1269; KATO H, 1992, BIOCHEM BIOPH RES CO, V188, P934, DOI 10.1016/0006-291X(92)91145-G; Khan I, 1998, BIOCHEM MOL BIOL INT, V45, P895; KLEPPISCH T, 1992, BRAIN RES, V591, P283, DOI 10.1016/0006-8993(92)91709-N; KOCH WJ, 1990, J BIOL CHEM, V265, P17786; Kozasa T, 1996, J BIOL CHEM, V271, P12562, DOI 10.1074/jbc.271.21.12562; LACERDA AE, 1988, NATURE, V335, P249, DOI 10.1038/335249a0; McHugh D, 1997, J PHYSIOL-LONDON, V500, P311, DOI 10.1113/jphysiol.1997.sp022022; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; Puri TS, 1997, BIOCHEMISTRY-US, V36, P9605, DOI 10.1021/bi970500d; REUTER H, 1983, NATURE, V301, P569, DOI 10.1038/301569a0; SCHULTZ D, 1993, P NATL ACAD SCI USA, V90, P6228, DOI 10.1073/pnas.90.13.6228; Shistik E, 1998, J BIOL CHEM, V273, P17901, DOI 10.1074/jbc.273.28.17901; SHISTIK E, 1995, J PHYSIOL-LONDON, V489, P55, DOI 10.1113/jphysiol.1995.sp021029; SINGERLAHAT D, 1992, FEBS LETT, V306, P113, DOI 10.1016/0014-5793(92)80980-U; Snutch T P, 1992, Curr Opin Neurobiol, V2, P247, DOI 10.1016/0959-4388(92)90111-W; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; SOLDATOV NM, 1994, GENOMICS, V22, P77, DOI 10.1006/geno.1994.1347; TAKAGI T, 1991, ADV ELECTROPHORESIS, V4, P391; TRAUTWEIN W, 1990, ANNU REV PHYSIOL, V52, P257, DOI 10.1146/annurev.ph.52.030190.001353; TSENG GN, 1991, AM J PHYSIOL, V261, pH364, DOI 10.1152/ajpheart.1991.261.2.H364; TSIEN RW, 1983, ANNU REV PHYSIOL, V45, P341, DOI 10.1146/annurev.ph.45.030183.002013; Wei X, 1996, RECEPTOR CHANNEL, V4, P205; WEI XY, 1995, J BIOL CHEM, V270, P27106, DOI 10.1074/jbc.270.45.27106; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865; YANG J, 1993, NEURON, V10, P127, DOI 10.1016/0896-6273(93)90305-B; Yang Y, 1999, BIOPHYS J, V76, pA341; YOSHIDA A, 1992, FEBS LETT, V309, P343, DOI 10.1016/0014-5793(92)80804-P; ZHANG ST, 1995, CIRC RES, V76, P592, DOI 10.1161/01.RES.76.4.592	45	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31145	31149		10.1074/jbc.274.44.31145	http://dx.doi.org/10.1074/jbc.274.44.31145			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531304	hybrid			2022-12-27	WOS:000083379400008
J	Suen, TC; Goss, PE				Suen, TC; Goss, PE			Transcription of BRCA1 is dependent on the formation of a specific protein-DNA complex on the minimal BRCA1 bi-directional promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPORADIC BREAST-CANCER; EARLY EMBRYONIC LETHALITY; SUPPRESSOR GENE BRCA1; RNA-POLYMERASE-II; CELL-CYCLE; OVARIAN-CANCER; NUCLEAR PHOSPHOPROTEIN; MAMMALIAN-CELLS; FAMILIAL BREAST; MEIOTIC CELLS	BRCA1 is the first tumor suppressor gene linked to hereditary breast and ovarian cancers. Its involvement in sporadic breast cancer, however, remains nuclear. Recent studies showed that a loss or lowered expression of BRCA1 is not uncommon in nonfamilial breast cancers, In addition, there have been eases of inherited BRCA1-linked breast cancer with as yet unidentified mutation. Misregulation of BRCA1 at the transcription level is a possible mechanism for loss of BRCA1 expression. To understand transcriptional regulation of the BRCA1 gene, we cloned and examined the BRCA1 promoter, by both functional reporter gene analyses and protein-DNA complex formation electrophorectic mobility shift assays, A bi-directional promoter could be located within a 229-base pair (bp) intergenic region between BRCA1 and its neighboring gene, NBR2. Deletion analyses further delineated a minimal 56-bp EcoRI-HaeIII fragment, which could drive transcription in the NBR2 gene direction 2-4-fold higher than in the BRCA1 direction in all cell lines tested. Furthermore, transcriptional activity in the BRCA1 direction was undetectable in the muscle cell line C2C12, whereas activity in the NBR2 direction was maintained. These results were consistent with the expression pattern of the respective genes. A specific protein-DNA complex was detected when nuclear extracts from HeLa cells and Caco2, a colon cell line, were incubated with the 56-bp minimal promoter. This protein binding activity was further localized to an 18-bp fragment and might involve a tissue-specific factor, because binding was not detected in the C2C12 cell line. The correlation of the detection of this protein-DNA complex only in those cell lines that expressed the chloramphenicol acetyltransferase reporter gene in the BRCA1 direction suggests a significant positive role of this complex in the transcription of the BRCA1 gene.	Princess Margaret Hosp, Dept Med Oncol, Breast Grp, Toronto, ON M5G 2M9, Canada; Toronto Hosp, Oncol Res Labs, Breast Canc Prevent Program, Canadian Blood Serv, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Canadian Blood Services; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Goss, PE (corresponding author), Princess Margaret Hosp, Dept Med Oncol, Breast Grp, Rm 5-303,610 Univ Ave, Toronto, ON M5G 2M9, Canada.	pegoss@interlog.com						Barker DF, 1996, GENOMICS, V38, P215, DOI 10.1006/geno.1996.0618; Bertwistle D, 1998, CURR OPIN GENET DEV, V8, P14, DOI 10.1016/S0959-437X(98)80056-7; Bienstock RJ, 1996, CANCER RES, V56, P2539; Blackshear PE, 1998, ONCOGENE, V16, P61, DOI 10.1038/sj.onc.1201506; BROWN JA, 1996, NEUROSURG FOCUS, V1, P2; BROWN MA, 1994, NATURE, V372, P733, DOI 10.1038/372733a0; Casey Graham, 1997, Current Opinion in Oncology, V9, P88; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen YM, 1996, CANCER RES, V56, P3168; Crook T, 1997, LANCET, V350, P638, DOI 10.1016/S0140-6736(05)63327-2; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dobrovic A, 1997, CANCER RES, V57, P3347; Feunteun J, 1996, BBA-REV CANCER, V1242, P177, DOI 10.1016/0304-419X(95)00016-9; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GAYTHER SA, 1995, NAT GENET, V11, P428, DOI 10.1038/ng1295-428; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Haile DT, 1999, J BIOL CHEM, V274, P2113, DOI 10.1074/jbc.274.4.2113; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; HOSKING L, 1995, NAT GENET, V9, P343, DOI 10.1038/ng0495-343; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Rao VN, 1996, ONCOGENE, V12, P523; Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; SassoneCorsi P, 1995, ANNU REV CELL DEV BI, V11, P355, DOI 10.1146/annurev.cellbio.11.1.355; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Sourvinos G, 1998, BIOCHEM BIOPH RES CO, V245, P75, DOI 10.1006/bbrc.1998.8379; SUEN TC, 1990, MOL CELL BIOL, V10, P6306, DOI 10.1128/MCB.10.12.6306; Swensen J, 1997, HUM MOL GENET, V6, P1513, DOI 10.1093/hmg/6.9.1513; Thomas JE, 1997, CELL GROWTH DIFFER, V8, P801; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; VOGELSTEIN B, 1994, CELL, V79, P1, DOI 10.1016/0092-8674(94)90393-X; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; Xu CF, 1996, SEMIN CANCER BIOL, V7, P33, DOI 10.1006/scbi.1996.0005; Xu CF, 1997, HUM MOL GENET, V6, P1057, DOI 10.1093/hmg/6.7.1057; XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	58	30	32	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31297	31304		10.1074/jbc.274.44.31297	http://dx.doi.org/10.1074/jbc.274.44.31297			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531328	hybrid			2022-12-27	WOS:000083379400032
J	Valentin, E; Ghomashchi, F; Gelb, MH; Lazdunski, M; Lambeau, G				Valentin, E; Ghomashchi, F; Gelb, MH; Lazdunski, M; Lambeau, G			On the diversity of secreted phospholipases A(2) - Cloning, tissue distribution, and functional expression of two novel mouse group II enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-MOLECULAR-WEIGHT; PANCREATIC PHOSPHOLIPASE-A2; RECOMBINANT EXPRESSION; INTERFACIAL CATALYSIS; P388D(1) MACROPHAGES; MESSENGER-RNA; BETA-CELLS; GENE; VESICLES; RECEPTOR	Over the last decade, an expanding diversity of secreted phospholipases A(2) (sPLA(2)s) has been identified in mammals. Here, we report the cloning in mice of three additional sPLA(2)s called mouse group IIE (mGIIE), IIF (mGIIF), and X (mGX) sPLA(2)s, thus giving rise to eight distinct sPLA(2)s in this species. Both mGIIE and mGIIF sPLA(2)s contain the typical cysteines of group II sPLA(2)s, but have relatively low levels of identity (less than 51%) with other mouse sPLA(2)s, indicating that these enzymes are novel group II sPLA(2)s. However, a unique feature of mGIIF sPLA(2) is the presence of a C-terminal extension of 23 amino acids containing a single cysteine. mGX sPLA(2) has 72% identity with the previously cloned human group X (hGX) sPLA(2) and displays similar structural features, making it likely that mGX sPLA(2) is the ortholog of hGX sPLA(2). Genes for mGIIE and mGrIIF sPLA(2)s are located on chromosome 4, and that of mGX sPLA(2) on chromosome 16. Northern and dot blot experiments with 22 tissues indicate that all eight mouse sPLA(2)s have different tissue distributions, suggesting specific functions for each, mGIIE sPLA(2) is highly expressed in uterus, and at lower levels in various other tissues. mGIIF sPLA(2) is strongly expressed during embryogenesis and in adult testis. mGX sPLA(2) is mostly expressed in adult testis and stomach. When the cDNAs for the eight mouse sPLA(2)s were transiently transfected in COS cells, sPLA(2) activity was found to accumulate in cell medium, indicating that each enzyme is secreted and catalytically active. Using COS cell medium as a source of enzymes, pH rate profile and phospholipid headgroup specificity of the novel sPLA(2)s were analyzed and compared with the other mouse sPLA(2)s.	CNRS UPR 411, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Lazdunski, M (corresponding author), CNRS UPR 411, Inst Pharmacol Mol & Cellulaire, 660 Route Lucioles, F-06560 Valbonne, France.	ipmc@ipmc.cnrs.fr	Lambeau, Gerard/GRJ-5624-2022	Lambeau, Gerard/0000-0002-9239-518X; gelb, michael/0000-0001-7000-5219	NHLBI NIH HHS [HL36235] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL036235, R23HL036235, R01HL036235] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balboa MA, 1997, J BIOL CHEM, V272, P8576, DOI 10.1074/jbc.272.13.8576; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; Chen J, 1997, J CELL BIOCHEM, V64, P369, DOI 10.1002/(SICI)1097-4644(19970301)64:3<369::AID-JCB3>3.0.CO;2-T; CHEN J, 1994, J BIOL CHEM, V269, P2365; CHEN J, 1994, J BIOL CHEM, V269, P23018; CHEN J, 1994, BBA-LIPID LIPID MET, V1215, P115, DOI 10.1016/0005-2760(94)90099-X; CHO WW, 1988, J BIOL CHEM, V263, P11237; CORDELLAMIELE E, 1990, J BIOL CHEM, V265, P17180; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; Cupillard L, 1999, J BIOL CHEM, V274, P7043, DOI 10.1074/jbc.274.11.7043; Cupillard L, 1997, J BIOL CHEM, V272, P15745, DOI 10.1074/jbc.272.25.15745; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; FEUCHTERMURTHY AE, 1993, NUCLEIC ACIDS RES, V21, P135, DOI 10.1093/nar/21.1.135; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; Ganz T, 1997, SEMIN HEMATOL, V34, P343; GELB MH, 1995, ANNU REV BIOCHEM, V64, P653; GHOMASHCHI F, 1992, BIOCHEMISTRY-US, V31, P3814, DOI 10.1021/bi00130a012; GHOMASHCHI F, 1991, BIOCHEMISTRY-US, V30, P7318, DOI 10.1021/bi00243a037; GUTIERREZ JM, 1995, TOXICON, V33, P1405, DOI 10.1016/0041-0101(95)00085-Z; Han SK, 1999, J BIOL CHEM, V274, P11881, DOI 10.1074/jbc.274.17.11881; Hanasaki K, 1997, J BIOL CHEM, V272, P32792, DOI 10.1074/jbc.272.52.32792; HARWIG SSL, 1995, J CLIN INVEST, V95, P603, DOI 10.1172/JCI117704; Hawgood B., 1991, HDB NATURAL TOXINS R, V5, P3; HIGASHINO K, 1994, EUR J BIOCHEM, V225, P375, DOI 10.1111/j.1432-1033.1994.00375.x; JAIN MK, 1982, BIOCHIM BIOPHYS ACTA, V688, P341, DOI 10.1016/0005-2736(82)90345-5; JAIN MK, 1991, METHOD ENZYMOL, V197, P112; Kim TS, 1997, J BIOL CHEM, V272, P2542; Kini RM, 1999, J MOL EVOL, V48, P125, DOI 10.1007/PL00006450; KINI RM, 1989, TOXICON, V27, P613, DOI 10.1016/0041-0101(89)90013-5; Kordis D, 1998, BIOCHEM BIOPH RES CO, V251, P613, DOI 10.1006/bbrc.1998.9528; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; Kundu GC, 1997, J BIOL CHEM, V272, P2346; Lambeau G, 1999, TRENDS PHARMACOL SCI, V20, P162, DOI 10.1016/S0165-6147(99)01300-0; Lambeau G, 1997, VENOM PHOSPHOLIPASE, P389; Larsson PKA, 1998, J BIOL CHEM, V273, P207, DOI 10.1074/jbc.273.1.207; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Ma ZM, 1997, J BIOL CHEM, V272, P11118; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; McCarthy LC, 1997, GENOME RES, V7, P1153, DOI 10.1101/gr.7.12.1153; METZ S, 1991, FEBS LETT, V295, P110, DOI 10.1016/0014-5793(91)81397-Q; MULHERKAR R, 1993, BIOCHEM BIOPH RES CO, V195, P1254, DOI 10.1006/bbrc.1993.2179; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; NEVALAINEN TJ, 1994, INVEST OPHTH VIS SCI, V35, P417; OGAWA M, 1991, RES COMMUN CHEM PATH, V74, P241; OHARA O, 1995, PROG LIPID RES, V34, P117, DOI 10.1016/0163-7827(94)00009-B; Ohmachi H, 1996, INT J ONCOL, V9, P511; Ohno M, 1998, PROG NUCLEIC ACID RE, V59, P307; Pickard RT, 1999, J BIOL CHEM, V274, P8823, DOI 10.1074/jbc.274.13.8823; Portilla D, 1998, J AM SOC NEPHROL, V9, P1178; Qu XD, 1998, INFECT IMMUN, V66, P2791, DOI 10.1128/IAI.66.6.2791-2797.1998; Rae D, 1996, SCAND J GASTROENTERO, V31, P24, DOI 10.3109/00365529609104995; Ramanadham S, 1998, BBA-LIPID LIPID MET, V1390, P301, DOI 10.1016/S0005-2760(97)00189-6; RAMIREZ F, 1991, PROTEINS, V9, P229, DOI 10.1002/prot.340090402; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; SEILHAMER JJ, 1989, J CELL BIOCHEM, V39, P327, DOI 10.1002/jcb.240390312; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; SEILHAMER JJ, 1986, DNA-J MOLEC CELL BIO, V5, P519, DOI 10.1089/dna.1.1986.5.519; Shinohara H, 1999, J BIOL CHEM, V274, P12263, DOI 10.1074/jbc.274.18.12263; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; Tischfield JA, 1996, GENOMICS, V32, P328, DOI 10.1006/geno.1996.0126; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; VADAS P, 1993, J LIPID MEDIATOR, V8, P1; Valentin E, 1999, J BIOL CHEM, V274, P19152, DOI 10.1074/jbc.274.27.19152; VERHEIJ HM, 1981, REV PHYSIOL BIOCH P, V91, P91; Verpy E, 1999, P NATL ACAD SCI USA, V96, P529, DOI 10.1073/pnas.96.2.529; WAITE M, 1987, HDB LIPID RES, V5, P111; Wang YX, 1998, P NATL ACAD SCI USA, V95, P15345, DOI 10.1073/pnas.95.26.15345; Zambrowicz BP, 1998, NATURE, V392, P608, DOI 10.1038/33423	74	160	167	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31195	31202		10.1074/jbc.274.44.31195	http://dx.doi.org/10.1074/jbc.274.44.31195			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531313	hybrid, Green Submitted			2022-12-27	WOS:000083379400017
J	Craxton, A; Jiang, AM; Kurosaki, T; Clark, EA				Craxton, A; Jiang, AM; Kurosaki, T; Clark, EA			Syk and Bruton's tyrosine kinase are required for B cell antigen receptor-mediated activation of the kinase Aht	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN-HOMOLOGY DOMAIN; GLYCOGEN-SYNTHASE KINASE-3; LYN-DEFICIENT MICE; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOLIPASE C-GAMMA-2; SIGNALING PATHWAYS; CA2+ MOBILIZATION; P85 SUBUNIT; PHOSPHORYLATION	Activation of Akt by multiple stimuli including B cell antigen receptor (BCR) engagement requires phosphatidylinositol 3-kinase and regulates processes including cell survival, proliferation, and metabolism. BCR crosslinking activates three families of non-receptor protein tyrosine kinases (PTKs) and these are transducers of signaling events including phospholipase C and mitogen-activated protein kinase activation; however, the relative roles of PTKs in ECR-mediated Akt activation are unknown. We examined Akt activation in Lyn-, Syk- and Btk-deficient DT40 cells and B cells from Lyn(-/-) mice. BCR-mediated Akt activation required Syk and was partially dependent upon Btk. Increased BCR-induced Akt phosphorylation was observed in Lyn-deficient DT40 cells and Lyn(-/-) mice compared with wildtype cells suggesting that Lyn may negatively regulate Akt function. BCR-induced tyrosine phosphorylation of the phosphatidylinositol 3-kinase catalytic subunit was abolished in Syk-deficient cells consistent with a receptor-proximal role for Syk in BCR-mediated phosphatidylinositol 3-kinase activation; in contrast, it was maintained in Btk-deficient cells, suggesting Btk functions downstream of phosphatidylinositol 3-kinase. Calcium depletion did not influence BCR-induced Akt phosphorylation/activation, showing that neither Syk. nor Btk mediates its effects via changes in calcium levels. Thus, BCR-mediated Akt stimulation is regulated by multiple non-receptor PTK families which regulate Akt both proximal and distal to phosphatidylinositol 3-kinase activation.	Univ Washington, Dept Microbiol, Seattle, WA 98195 USA; Univ Washington, Dept Immunol, Seattle, WA 98195 USA; Kansai Med Univ, Inst Liver Res, Dept Mol Genet, Moriguchi, Osaka 570, Japan	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Kansai Medical University	Craxton, A (corresponding author), Univ Washington, Dept Microbiol, Box 357242, Seattle, WA 98195 USA.		Clark, Edward/K-3462-2012; Jones, Jeffrey A/E-9827-2013; Kurosaki, Tomohiro/D-1306-2009	Kurosaki, Tomohiro/0000-0002-6352-304X; Clark, Edward A/0000-0001-8061-5475	NCRR NIH HHS [RR00166] Funding Source: Medline; NIAID NIH HHS [AI44250] Funding Source: Medline; NIGMS NIH HHS [GM37905] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044250] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037905] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Aman MJ, 1998, J BIOL CHEM, V273, P33922, DOI 10.1074/jbc.273.51.33922; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; August A, 1997, P NATL ACAD SCI USA, V94, P11227, DOI 10.1073/pnas.94.21.11227; BOLEN JB, 1995, CURR OPIN IMMUNOL, V7, P306, DOI 10.1016/0952-7915(95)80103-0; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Buhl AM, 1997, J EXP MED, V186, P1897, DOI 10.1084/jem.186.11.1897; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHAN WV, 1997, IMMUNITY, V7, P69; CHEN CLH, 1982, J IMMUNOL, V129, P2580; Conus NM, 1998, J BIOL CHEM, V273, P4776, DOI 10.1074/jbc.273.8.4776; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DeFranco AL, 1998, SEMIN IMMUNOL, V10, P299, DOI 10.1006/smim.1998.0122; DeFranco AL, 1997, CURR OPIN IMMUNOL, V9, P296, DOI 10.1016/S0952-7915(97)80074-X; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; delPeso L, 1997, SCIENCE, V278, P687; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fluckiger AC, 1998, EMBO J, V17, P1973, DOI 10.1093/emboj/17.7.1973; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Jiang A, 1998, J EXP MED, V188, P1297, DOI 10.1084/jem.188.7.1297; Kurosaki T, 1997, J BIOL CHEM, V272, P15595, DOI 10.1074/jbc.272.25.15595; Kurosaki T, 1997, CURR OPIN IMMUNOL, V9, P309, DOI 10.1016/S0952-7915(97)80075-1; Kuwahara K, 1996, INT IMMUNOL, V8, P1273, DOI 10.1093/intimm/8.8.1273; Li HL, 1997, J BIOL CHEM, V272, P18200, DOI 10.1074/jbc.272.29.18200; Lu YL, 1998, J IMMUNOL, V161, P5404; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Satterthwaite AB, 1998, J EXP MED, V188, P833, DOI 10.1084/jem.188.5.833; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Sidorenko SP, 1996, IMMUNITY, V5, P353, DOI 10.1016/S1074-7613(00)80261-7; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wang JY, 1996, J EXP MED, V184, P831, DOI 10.1084/jem.184.3.831; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118	45	127	131	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30644	30650		10.1074/jbc.274.43.30644	http://dx.doi.org/10.1074/jbc.274.43.30644			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521450	hybrid			2022-12-27	WOS:000083276700046
J	Dupressoir, A; Barbot, W; Loireau, RP; Heidmann, T				Dupressoir, A; Barbot, W; Loireau, RP; Heidmann, T			Characterization of a mammalian gene related to the yeast CCR4 general transcription factor and revealed by transposon insertion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; REGULATORY COMPLEX; MOUSE-LIVER; EXPRESSION; PROMOTER; PROTEIN; FAMILY; IDENTIFICATION; RETROTRANSPOSONS; SUPPRESSION	Murine intracisternal A-particles (IAPs) are reiterated retrovirus-like transposable elements that can act as insertional mutagens, Accordingly, we previously identified a chimeric transcript initiated at an IAP promoter and extending through a 3'-located open reading frame with significant similarity to the C-terminal domain of the yeast CCR4 general transcription factor. In this report, we characterize the corresponding murine gene, mCCR4, and its human homologue, thus providing the first description of CCR4-like factors in mammals, cDNA cloning revealed two mCCR4 mRNAs of 2.7 and 3.1 kilobases, differing by their transcription start sites within the native mCCR4 gene promoter, and encoding a putative 430-amino acid protein. The mCCR4 gene contains three exons and two introns spanning almost 27 kilobases. The IAP insertion, detected only in some laboratory mouse strains, is recent and lies within the first intron, The 5'-region of the gene has features of housekeeping gene promoters. It lacks a TATA box but contains a CpG island and Spl sites. This region discloses strong promoter activity in transient transfection assays and also stimulates transcription in the reverse orientation, a feature common to other CpG island-containing promoters, Transcripts were detected in all the organs tested, although at a variable level, and displayed no strain-dependent differences relative to the IAP insertion, suggesting the existence of mechanisms preserving mCCR4 transcription from the usually deleterious effects of intronic transposition, The strong amino acid conservation between the human, murine, and the previously identified Xenopus CCR4-like proteins, is consistent with an important and conserved role for this protein in vertebrates.	Inst Gustave Roussy, CNRS, UMR 1573, Unite Retrovirus Endogenes & Elements Retroides E, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Heidmann, T (corresponding author), Inst Gustave Roussy, CNRS, UMR 1573, Unite Retrovirus Endogenes & Elements Retroides E, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.		Dupressoir, Anne/M-5280-2018	Dupressoir, Anne/0000-0002-3464-8513				Bae K, 1998, MOL CELL BIOL, V18, P6142, DOI 10.1128/MCB.18.10.6142; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; DENIS CL, 1984, GENETICS, V108, P833; DENIS CL, 1990, GENETICS, V124, P283; DRAPER MP, 1994, MOL CELL BIOL, V14, P4522, DOI 10.1128/MCB.14.7.4522; DRAPER MP, 1995, MOL CELL BIOL, V15, P3487; Dupressoir A, 1996, MOL CELL BIOL, V16, P4495; Dupressoir A, 1995, BBA-GENE STRUCT EXPR, V1264, P397, DOI 10.1016/0167-4781(95)00181-6; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Green CB, 1996, P NATL ACAD SCI USA, V93, P14884, DOI 10.1073/pnas.93.25.14884; Gwynn B, 1998, MOL CELL BIOL, V18, P6474, DOI 10.1128/MCB.18.11.6474; Hamilton BA, 1997, NEURON, V18, P711, DOI 10.1016/S0896-6273(00)80312-8; HEIDMANN O, 1991, CELL, V64, P159, DOI 10.1016/0092-8674(91)90217-M; HENIKOFF S, 1994, GENOMICS, V19, P97, DOI 10.1006/geno.1994.1018; ISRAEL DI, 1993, NUCLEIC ACIDS RES, V21, P2627, DOI 10.1093/nar/21.11.2627; KUFF EL, 1988, ADV CANCER RES, V51, P183, DOI 10.1016/S0065-230X(08)60223-7; KUFF EL, 1990, CANCER CELL-MON REV, V2, P398; LIAO WC, 1994, NUCLEIC ACIDS RES, V22, P4044, DOI 10.1093/nar/22.20.4044; Liu HY, 1997, EMBO J, V16, P5289, DOI 10.1093/emboj/16.17.5289; Liu HY, 1998, EMBO J, V17, P1096, DOI 10.1093/emboj/17.4.1096; MALVAR T, 1992, GENETICS, V132, P951; MCKENZIE EA, 1993, MOL GEN GENET, V240, P374, DOI 10.1007/BF00280389; Puech A, 1997, J BIOL CHEM, V272, P5995, DOI 10.1074/jbc.272.9.5995; Qvist H, 1998, BIOL CHEM, V379, P75; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; Sangoram AM, 1998, NEURON, V21, P1101, DOI 10.1016/S0896-6273(00)80627-3; SCHILD D, 1995, GENETICS, V140, P115; SCHILLING LJ, 1995, CELL GROWTH DIFFER, V6, P541; SEKI S, 1991, BIOCHIM BIOPHYS ACTA, V1079, P57, DOI 10.1016/0167-4838(91)90024-T; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Tosini G, 1996, SCIENCE, V272, P419, DOI 10.1126/science.272.5260.419; Vasicek TJ, 1997, GENETICS, V147, P777; Verdone L, 1997, J BIOL CHEM, V272, P30828, DOI 10.1074/jbc.272.49.30828; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7; XIAO GH, 1995, ONCOGENE, V11, P81; ZACHAR Z, 1985, GENETICS, V111, P495; Zylka MJ, 1998, NEURON, V21, P1115, DOI 10.1016/S0896-6273(00)80628-5	38	23	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					31068	31075		10.1074/jbc.274.43.31068	http://dx.doi.org/10.1074/jbc.274.43.31068			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521507	hybrid			2022-12-27	WOS:000083276700103
J	Jaspers, I; Samet, JM; Reed, W				Jaspers, I; Samet, JM; Reed, W			Arsenite exposure of cultured airway epithelial cells activates kappa B-dependent interleukin-8 gene expression in the absence of nuclear factor-kappa B nuclear translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; PROTEIN-KINASE-A; INFLAMMATORY CYTOKINES; DNA-BINDING; TRANSCRIPTIONAL ACTIVITY; TYROSINE KINASE; FACTOR-ALPHA; NF-KB; STRESS; INDUCTION	Airway epithelial cells respond to certain environmental stresses by mounting a proinflammatory response, which is characterized by enhanced synthesis and release of the neutrophil chemotactic and activating factor interleukin-8 (IL-8). IL-8 expression is regulated at the transcriptional level in part by the transcription factor nuclear factor (NF)-kappa B, We compared intracellular signaling mediating IL-8 gene expression in bronchial epithelial cells cultured in vitro and exposed to two inducers of cellular stress, sodium arsenite (As-III), and vanadyl sulfate (V-IV). Unstimulated bronchial epithelial cells expressed IL-8, and exposure to both metal compounds significantly enhanced IL-8 expression. Overexpression of a dominant negative inhibitor of NF-kappa B depressed both basal and metal-induced IL-8 expression. Low levels of nuclear NF-kappa B were constitutively present in unstimulated cultures. These levels were augmented by exposure to V-IV, but not As-III. Accordingly, V-IV induced I kappa B alpha breakdown and NF-kappa B nuclear translocation, whereas AsIII did not. However, both As-III and VN enhanced kappa B-dependent transcription. In addition, As-III activation of an IL-8 promoter-reporter construct was partially kappa B-dependent. These data suggested that AsIII enhanced IL-8 gene transcription independently of I kappa B alpha breakdown and nuclear translocation of NF-kappa B in part by enhancing transcription mediated by low levels of constitutive nuclear NF-kappa B.	Univ N Carolina, Sch Med, Ctr Environm Med & Lung Biol, Chapel Hill, NC 27599 USA; US EPA, Natl Hlth & Environm Effects Res Lab, Human Studies Div, Res Triangle Pk, NC 27711 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; United States Environmental Protection Agency	Reed, W (corresponding author), Univ N Carolina, Sch Med, Ctr Environm Med & Lung Biol, CB 7310,104 Mason Farm Rd, Chapel Hill, NC 27599 USA.		Jaspers, Ilona/AAZ-5035-2020					ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; ARIS RM, 1993, AM REV RESPIR DIS, V148, P1363, DOI 10.1164/ajrccm/148.5.1363; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Balmes JR, 1996, AM J RESP CRIT CARE, V153, P904, DOI 10.1164/ajrccm.153.3.8630571; BECKER SE, 1999, IN PRESS AM J RESP C; Bergmann M, 1998, J BIOL CHEM, V273, P6607, DOI 10.1074/jbc.273.12.6607; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Carter JD, 1997, TOXICOL APPL PHARM, V146, P180, DOI 10.1006/taap.1997.8254; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Chinery R, 1997, J BIOL CHEM, V272, P30356, DOI 10.1074/jbc.272.48.30356; DEVLIN RB, 1994, AM J PHYSIOL, V266, P612; DOBRZANSKI P, 1994, EMBO J, V13, P4608, DOI 10.1002/j.1460-2075.1994.tb06782.x; Elbirt KK, 1998, J BIOL CHEM, V273, P8922, DOI 10.1074/jbc.273.15.8922; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; Holz O, 1999, AM J RESP CRIT CARE, V159, P776, DOI 10.1164/ajrccm.159.3.9806098; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; JANSSEN YMW, 1995, P NATL ACAD SCI USA, V92, P8458, DOI 10.1073/pnas.92.18.8458; Janssen-Heininger YMW, 1999, AM J RESP CELL MOL, V20, P942, DOI 10.1165/ajrcmb.20.5.3452; Jaspers I, 1998, J CELL PHYSIOL, V177, P313, DOI 10.1002/(SICI)1097-4652(199811)177:2<313::AID-JCP13>3.0.CO;2-A; KUNSCH C, 1994, J IMMUNOL, V153, P153; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Liu YS, 1996, FREE RADICAL BIO MED, V21, P771, DOI 10.1016/0891-5849(96)00176-1; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; Meier R, 1996, EUR J BIOCHEM, V236, P796, DOI 10.1111/j.1432-1033.1996.00796.x; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PAN JL, 1995, J BIOL CHEM, V270, P23077, DOI 10.1074/jbc.270.39.23077; Paul A, 1997, CELL SIGNAL, V9, P403, DOI 10.1016/S0898-6568(97)00042-9; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Quay JL, 1998, AM J RESP CELL MOL, V19, P98, DOI 10.1165/ajrcmb.19.1.3132; Rashtchian A, 1992, PCR Methods Appl, V2, P124; Rashtchian Ayoub, 1995, Current Opinion in Biotechnology, V6, P30, DOI 10.1016/0958-1669(95)80006-9; REDDEL RR, 1988, CANCER RES, V48, P1904; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; Richman-Eisenstat JB, 1993, AM J PHYSIOL, V264, P413; Rodriguez MS, 1999, J BIOL CHEM, V274, P9108, DOI 10.1074/jbc.274.13.9108; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Samet JM, 1998, AM J PHYSIOL-LUNG C, V275, pL551, DOI 10.1152/ajplung.1998.275.3.L551; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Shapiro L, 1997, EXP CELL RES, V231, P354, DOI 10.1006/excr.1997.3476; ShattuckBrandt RL, 1997, CANCER RES, V57, P3032; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; Thomas LH, 1998, J IMMUNOL, V161, P1007; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; Turpin P, 1999, J BIOL CHEM, V274, P6804, DOI 10.1074/jbc.274.10.6804; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; Wood KM, 1998, ONCOGENE, V16, P2131, DOI 10.1038/sj.onc.1201735; Wu GD, 1997, J BIOL CHEM, V272, P2396; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Yoza BK, 1996, J BIOL CHEM, V271, P18306, DOI 10.1074/jbc.271.31.18306; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	62	50	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					31025	31033		10.1074/jbc.274.43.31025	http://dx.doi.org/10.1074/jbc.274.43.31025			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521501	hybrid			2022-12-27	WOS:000083276700097
J	Ning, YM; Robins, DM				Ning, YM; Robins, DM			AML3/CBF alpha 1 is required for androgen-specific activation of the enhancer of the mouse sex-limited protein (Slp) gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; TRANSCRIPTIONAL REGULATION; OSTEOBLAST DIFFERENTIATION; GLUCOCORTICOID RECEPTORS; NONRECEPTOR FACTORS; DEPENDENT ENHANCER; RESPONSE ELEMENT; DOMAIN PROTEINS; FUSION PROTEIN; NERVOUS-SYSTEM	A complex 120-base pair enhancer, derived from the mouse sex-limited protein (Slp) gene, is activated solely by the androgen receptor (AR) in specific tissues, although it contains a hormone response element recognized by several steroid receptors. The generation of this transcriptional specificity has been ascribed to the interactions of the receptor with tissue-specific nonreceptor factors bound to accessory sites within the enhancer. Protein-DNA interaction assays revealed two factors binding the 5' part of the enhancer that differ widely in abundance between cells showing AR-specific activation of the Sip element compared with those that also permit activation by glucocorticoid receptor (GR). The factor designated B formed a complex centered on the sequence TGTGGT, a core motif recognized by members of the AML/CBF alpha transcription factor family. This complex was competed by a high affinity binding site specific for AML/CBF alpha and was specifically supershifted by an antibody to AML3/CBF alpha 1, placing factor B within the AML3/CBF alpha 1 subclass. Interestingly, this factor was shown to bind to a second site in the 3' part of the enhancer, positioned between the two critical AR binding sites. Transfection studies revealed that AML1-ETO, a dominant-negative AML/CBF alpha construct, abrogated AR induction of the enhancer, but not of simple hormone response elements. Furthermore, overexpression of AML3/CBF alpha 1 could rescue the AML1-ETO repression. Finally, glutathione S-transferase-AML/CBF alpha fusion proteins demonstrated direct interaction between AML/ CBF alpha and steroid receptors. Although this interaction was equivalent between AML1/CBF alpha 2 and AR or GR, AML3/CBF alpha 1 showed stronger interaction with AR than with GR. These data demonstrate that AML3/CBF alpha 1 is functionally required for hormonal induction of the Sip enhancer and that direct, preferential protein-protein interactions may contribute to AR-specific activation. These results demonstrate an intriguing role of AML3/ CBF alpha 1 in steroid- as well as tissue-specific activation of target genes.	Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Robins, DM (corresponding author), Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA.	drobins@umich.edu		Robins, Diane M./0000-0001-6727-6309	NIDDK NIH HHS [F32DK09764] Funding Source: Medline; NIGMS NIH HHS [GM31546] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009764] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031546] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER AJ, 1993, MOL CELL BIOL, V13, P6326, DOI 10.1128/MCB.13.10.6326; ADLER AJ, 1991, MOL ENDOCRINOL, V5, P1587, DOI 10.1210/mend-5-11-1587; ADLER AJ, 1992, P NATL ACAD SCI USA, V89, P11660, DOI 10.1073/pnas.89.24.11660; Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097-4644(19970701)66:1<1::AID-JCB1>3.0.CO;2-V; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; Claessens F, 1996, J BIOL CHEM, V271, P19013, DOI 10.1074/jbc.271.32.19013; CLEUTJENS CB, 1999, ENDOCRINOLOGY, V138, P5293; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Frank R, 1995, ONCOGENE, V11, P2667; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Geoffroy V, 1998, MAMM GENOME, V9, P54, DOI 10.1007/s003359900679; GORDON DA, 1995, EXP CELL RES, V217, P368, DOI 10.1006/excr.1995.1099; Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972; HEMENWAY C, 1987, P NATL ACAD SCI USA, V84, P4816, DOI 10.1073/pnas.84.14.4816; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; Komori T, 1998, CURR OPIN GENET DEV, V8, P494, DOI 10.1016/S0959-437X(98)80123-8; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; LENNY N, 1995, ONCOGENE, V11, P1761; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; Lu JM, 1998, J BIOL CHEM, V273, P31528, DOI 10.1074/jbc.273.47.31528; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Meyers S, 1996, ONCOGENE, V13, P303; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Meyers S, 1995, CRIT REV EUKAR GENE, V5, P365, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.70; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Nelson SA, 1997, MOL CELL ENDOCRINOL, V133, P89, DOI 10.1016/S0303-7207(97)00150-0; NING YM, 1995, J STEROID BIOCHEM, V52, P187, DOI 10.1016/0960-0760(94)00162-F; NING YM, 1993, J BIOL CHEM, V268, P6073; NITSCH D, 1993, P NATL ACAD SCI USA, V90, P5479, DOI 10.1073/pnas.90.12.5479; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; ROBINS DM, 1994, J STEROID BIOCHEM, V49, P251, DOI 10.1016/0960-0760(94)90265-8; ROY AK, 1995, CRIT REV EUKAR GENE, V5, P157, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.30; RUNDLETT SE, 1995, MOL CELL ENDOCRINOL, V109, P1, DOI 10.1016/0303-7207(95)03477-O; SCARLETT CO, 1995, MOL ENDOCRINOL, V9, P413, DOI 10.1210/me.9.4.413; Scarlett CO, 1997, DNA CELL BIOL, V16, P45, DOI 10.1089/dna.1997.16.45; Scheller A, 1998, J BIOL CHEM, V273, P24216, DOI 10.1074/jbc.273.37.24216; Scheller A, 1996, MOL CELL ENDOCRINOL, V121, P75, DOI 10.1016/0303-7207(96)03854-3; Speck NA, 1995, CRIT REV EUKAR GENE, V5, P337, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.60; STAVENHAGEN JB, 1988, CELL, V55, P247, DOI 10.1016/0092-8674(88)90047-5; Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; SUN WW, 1995, J VIROL, V69, P4941, DOI 10.1128/JVI.69.8.4941-4949.1995; Thackray VG, 1998, J STEROID BIOCHEM, V66, P171, DOI 10.1016/S0960-0760(98)00044-2; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; THORNELL A, 1991, J VIROL, V65, P42, DOI 10.1128/JVI.65.1.42-50.1991; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; Tsuji K, 1998, BONE, V22, P87, DOI 10.1016/S8756-3282(97)00267-6; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Xiao ZS, 1998, GENE, V214, P187, DOI 10.1016/S0378-1119(98)00227-3; Zhang DE, 1996, MOL CELL BIOL, V16, P1231	58	40	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30624	30630		10.1074/jbc.274.43.30624	http://dx.doi.org/10.1074/jbc.274.43.30624			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521447	hybrid			2022-12-27	WOS:000083276700043
J	Ferrari, SL; Behar, V; Chorev, M; Rosenblatt, M; Bisello, A				Ferrari, SL; Behar, V; Chorev, M; Rosenblatt, M; Bisello, A			Endocytosis of ligand-human parathyroid hormone receptor 1 complexes is protein kinase C-dependent and involves beta-arrestin2 - Real-time monitoring by fluorescence microscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PTH/PTHRP RECEPTOR; OSTEOBLAST-LIKE CELLS; COUPLED RECEPTOR; MEDIATED INTERNALIZATION; BIMOLECULAR INTERACTIONS; CROSS-LINKING; DESENSITIZATION; PEPTIDE; MECHANISMS; TRAFFICKING	Endocytosis and intracellular trafficking of the human parathyroid hormone receptor subtype 1 (hPTH1-Rc) and its ligands was monitored independently by real-time fluorescence microscopy in stably transfected HEK-293 cells. Complexes of fluorescence-labeled parathyroid hormone (PTH)-(1-34) agonist bound to the hPTH1-Rc internalized rapidly at 37 degrees C via clathrin-coated vesicles, whereas fluorescent PTH-(7-34) antagonist-hPTH1Rc complexes did not. A functional C terminus epitope-tagged receptor (C-Tag-hPTH1-Rc) was immunolocalized to the cell membrane and, to a lesser extent, the cytoplasm, PTH and PTH-related protein agonists stimulated C-Tag-hPTH1-Rc internalization. Relocalization to the cell membrane occurred 1 h after removal of the ligand. Endocytosis of fluorescent PTH agonist-hPTH1-Rc complexes was blocked by the protein kinase C (PKC) inhibitor staurosporine but not by the specific protein kinase A inhibitor N-(2-(methylamino)ethyl)-5-isoquinoline-sulfonamide. Fluorescent PTH antagonist-hPTH1-Rc complexes were rapidly internalized after PKC activation by phorbol 12-myristate 13-acetate or thrombin, but not after stimulation of the cAMP/protein kinase A pathway by forskolin. In cells co-expressing the hPTH1-Rc and a green fluorescent protein-beta-arrestin2 fusion protein (beta-Arr2-GFP), PTH agonists stimulated beta-Arr2-GFP mobilization to the cell membrane. Subsequently, fluorescent PTH-(1-34)hPTH1Rc complexes and beta-Arr2-GFP co-localized intracellularly. In conclusion, agonist-activated hPTHI-Rc internalization involves beta-arrestin mobilization and targeting to clathrin-coated vesicles. Our results also indicate that receptor occupancy, rather than receptor-mediated signaling, is necessary, although not sufficient, for endocytosis of the hPTH1-Rc, Activation of PKC, however, is absolutely required.	Beth Israel Deaconess Med Ctr, Div Bone & Mineral Metab HIM 944, Harvard Thorndike & Charles A Dana Res Labs, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Bisello, A (corresponding author), Beth Israel Deaconess Med Ctr, Div Bone & Mineral Metab HIM 944, Harvard Thorndike & Charles A Dana Res Labs, Dept Med, 330 Brookline Ave, Boston, MA 02215 USA.	abisello@caregroup.harvard.edu	Ferrari, Serge/ABD-2730-2020	Ferrari, Serge/0000-0002-1372-4417	NIDDK NIH HHS [R01-DK47940] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047940] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ADAMS AE, 1995, BIOCHEMISTRY-US, V34, P10553, DOI 10.1021/bi00033a030; ASHWORTH R, 1995, P NATL ACAD SCI USA, V92, P512, DOI 10.1073/pnas.92.2.512; Awaji T, 1998, MOL ENDOCRINOL, V12, P1099, DOI 10.1210/me.12.8.1099; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Behar V, 1996, ENDOCRINOLOGY, V137, P2748, DOI 10.1210/en.137.7.2748; Bhowmick N, 1998, ENDOCRINOLOGY, V139, P3185, DOI 10.1210/en.139.7.3185; Bisello A, 1998, J BIOL CHEM, V273, P22498, DOI 10.1074/jbc.273.35.22498; BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; Chuang TT, 1996, TRENDS PHARMACOL SCI, V17, P416, DOI 10.1016/S0165-6147(96)10048-1; CIVITELLI R, 1989, ENDOCRINOLOGY, V125, P1204, DOI 10.1210/endo-125-3-1204; Dong MQ, 1999, J BIOL CHEM, V274, P903, DOI 10.1074/jbc.274.2.903; Ferguson SSG, 1998, SEMIN CELL DEV BIOL, V9, P119, DOI 10.1006/scdb.1997.0216; Ferguson SSG, 1998, LIFE SCI, V62, P1561, DOI 10.1016/S0024-3205(98)00107-6; Fitzpatrick Lorraine A., 1996, P339; FUKAYAMA S, 1992, ENDOCRINOLOGY, V131, P1757, DOI 10.1210/en.131.4.1757; Fukayama S, 1997, CELL SIGNAL, V9, P469, DOI 10.1016/S0898-6568(97)00044-2; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; Hein L, 1997, MOL ENDOCRINOL, V11, P1266, DOI 10.1210/me.11.9.1266; Huang ZM, 1999, ENDOCRINOLOGY, V140, P1294, DOI 10.1210/en.140.3.1294; HUANG ZM, 1995, J BIOL CHEM, V270, P151, DOI 10.1074/jbc.270.1.151; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P232, DOI 10.1016/S0165-6147(00)89032-X; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Leff P, 1997, TRENDS PHARMACOL SCI, V18, P355, DOI 10.1016/S0165-6147(97)90664-7; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Malecz N, 1998, MOL ENDOCRINOL, V12, P1846, DOI 10.1210/me.12.12.1846; Mannstadt M, 1998, J BIOL CHEM, V273, P16890, DOI 10.1074/jbc.273.27.16890; NAKAMOTO C, 1995, BIOCHEMISTRY-US, V34, P10546, DOI 10.1021/bi00033a029; PERNALETE N, 1990, ENDOCRINOLOGY, V126, P407, DOI 10.1210/endo-126-1-407; Pines M, 1996, BONE, V18, P381, DOI 10.1016/8756-3282(96)00008-7; PINES M, 1994, ENDOCRINOLOGY, V135, P1713, DOI 10.1210/en.135.4.1713; Qian F, 1998, BIOCHEMISTRY-US, V37, P6240, DOI 10.1021/bi9726281; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; Roettger BF, 1997, MOL PHARMACOL, V51, P357; ROETTGER BF, 1995, J CELL BIOL, V130, P579, DOI 10.1083/jcb.130.3.579; ROUBINI E, 1992, BIOCHEMISTRY-US, V31, P4026, DOI 10.1021/bi00131a018; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Schlador ML, 1997, J BIOL CHEM, V272, P18882, DOI 10.1074/jbc.272.30.18882; SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L; SILVE CM, 1982, J CELL BIOL, V94, P379, DOI 10.1083/jcb.94.2.379; Stroop SD, 1996, ENDOCRINOLOGY, V137, P4752, DOI 10.1210/en.137.11.4752; TEITELBAUM AP, 1986, ENDOCRINOLOGY, V118, P595, DOI 10.1210/endo-118-2-595; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhang J, 1999, J BIOL CHEM, V274, P10999, DOI 10.1074/jbc.274.16.10999; Zhou AT, 1997, P NATL ACAD SCI USA, V94, P3644, DOI 10.1073/pnas.94.8.3644	46	132	133	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29968	29975		10.1074/jbc.274.42.29968	http://dx.doi.org/10.1074/jbc.274.42.29968			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514480	hybrid			2022-12-27	WOS:000083176400059
J	Maegawa, H; Hasegawa, M; Sugai, S; Obata, T; Ugi, S; Morino, K; Egawa, K; Fujita, T; Sakamoto, T; Nishio, Y; Kojima, H; Haneda, M; Yasuda, H; Kikkawa, R; Kashiwagi, A				Maegawa, H; Hasegawa, M; Sugai, S; Obata, T; Ugi, S; Morino, K; Egawa, K; Fujita, T; Sakamoto, T; Nishio, Y; Kojima, H; Haneda, M; Yasuda, H; Kikkawa, R; Kashiwagi, A			Expression of a dominant negative SHP-2 in transgenic mice induces insulin resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; SRC HOMOLOGY-2 DOMAINS; SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; RAT ADIPOSE-CELLS; RECEPTOR SUBSTRATE-1; MAP KINASE; SYP; ACTIVATION; SHPTP2; PHOSPHORYLATION	To elucidate the roles of SHP-2 genic (Tg) mice expressing a dominant negative mutant lacking protein tyrosine phosphatase domain (Delta PTP). On examining two lines of Tg mice identified by Southern blot, the transgene product Tvas expressed in skeletal muscle, liver, and adipose tissues, and insulin-induced association of insulin receptor substrate 1 with endogenous SHP-2 was inhibited, confirming that Delta PTP has a dominant negative property. The intraperitoneal glucose loading test demonstrated an increase in blood glucose levels in Tg mice. Plasma insulin levels in Tg mice after 4 h fasting were 3 times greater with comparable blood glucose levels. To estimate insulin sensitivity by a constant glucose, insulin, and somatostatin infusion, steady state blood glucose levels were higher, suggesting the presence of insulin resistance. Furthermore, we observed the impairment of insulin-stimulated glucose uptake in muscle and adipocytes in the presence of physiological concentrations of insulin. Moreover, tyrosine phosphorylation of insulin receptor substrate-1 and stimulation of phosphatidylinositol 3-kinase and Akt kinase activities by insulin were attenuated in muscle and liver. These results indicate that the inhibition of endogenous SHP-2 function by the overexpression of a dominant negative mutant may lead to impaired insulin sensitivity of glucose metabolism, and thus SHP-2 may function to modulate insulin signaling in target tissues.	Shiga Univ Med Sci, Dept Med 3, Otsu, Shiga 5202192, Japan; Ono Pharmaceut, Fukui Inst Safety Res, Fukui 913, Japan	Shiga University of Medical Science; Ono Pharmaceutical Co Ltd	Maegawa, H (corresponding author), Shiga Univ Med Sci, Dept Med 3, Otsu, Shiga 5202192, Japan.		MORINO, KATSUTARO/I-3207-2019	MORINO, KATSUTARO/0000-0003-2420-3817; Maegawa, Hiroshi/0000-0002-4611-8149				ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Arrandale JM, 1996, J BIOL CHEM, V271, P21353, DOI 10.1074/jbc.271.35.21353; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; Chen H, 1997, J BIOL CHEM, V272, P8026, DOI 10.1074/jbc.272.12.8026; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; HAUSDORFF SF, 1995, J BIOL CHEM, V270, P12965, DOI 10.1074/jbc.270.22.12965; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; KAHN CR, 1994, DIABETES, V43, P1066, DOI 10.2337/diab.43.8.1066; KASHIWAGI A, 1983, J CLIN INVEST, V72, P1246, DOI 10.1172/JCI111080; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; KHARITONENKOV A, 1995, J BIOL CHEM, V270, P29189, DOI 10.1074/jbc.270.49.29189; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; Lawrence JC, 1997, DIABETES, V46, P541, DOI 10.2337/diabetes.46.4.541; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; MAEGAWA H, 1986, AM J PHYSIOL, V251, pE616, DOI 10.1152/ajpendo.1986.251.5.E616; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; Myers MG, 1998, J BIOL CHEM, V273, P26908, DOI 10.1074/jbc.273.41.26908; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; O'Reilly AM, 1998, MOL CELL BIOL, V18, P161, DOI 10.1128/MCB.18.1.161; Obata T, 1998, J BIOCHEM-TOKYO, V123, P813; Ottinger EA, 1998, J BIOL CHEM, V273, P729, DOI 10.1074/jbc.273.2.729; PERALDI P, 1994, P NATL ACAD SCI USA, V91, P5002, DOI 10.1073/pnas.91.11.5002; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; Rocchi S, 1998, MOL ENDOCRINOL, V12, P914, DOI 10.1210/me.12.7.914; SAITOU M, 1995, NATURE, V374, P159, DOI 10.1038/374159a0; SAWADA T, 1995, BIOCHEM BIOPH RES CO, V214, P737, DOI 10.1006/bbrc.1995.2347; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; Ugi S, 1996, J BIOL CHEM, V271, P12595, DOI 10.1074/jbc.271.21.12595; UGI S, 1994, FEBS LETT, V340, P216, DOI 10.1016/0014-5793(94)80141-X; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Walter AO, 1999, ONCOGENE, V18, P1911, DOI 10.1038/sj.onc.1202513; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664	49	57	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30236	30243		10.1074/jbc.274.42.30236	http://dx.doi.org/10.1074/jbc.274.42.30236			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514516	hybrid			2022-12-27	WOS:000083176400095
J	Choi, KS; Eom, YW; Kang, Y; Ha, MJ; Rhee, H; Yoon, JW; Kim, SJ				Choi, KS; Eom, YW; Kang, Y; Ha, MJ; Rhee, H; Yoon, JW; Kim, SJ			Cdc2 and Cdk2 kinase activated by transforming growth factor-beta 1 trigger apoptosis through the phosphorylation of retinoblastoma protein in FaO hepatoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; BETA-INDUCED APOPTOSIS; TGF-BETA; EPITHELIAL-CELLS; GENE-PRODUCT; C-MYC; DIFFERENTIAL REGULATION; TRANSGENIC MICE; INHIBITS GROWTH; MAMMALIAN-CELLS	The signaling pathway leading to TGF-beta 1-induced apoptosis was investigated using a TGF-beta 1-sensitive hepatoma cell line, FaO. Cell cycle analysis demonstrated that the accumulation of apoptotic cells was pre ceded by a progressive decrease of the cell, population in the G(1) phase concomitant with a slight increase of the cell population in the G(2)/M phase in response to TGB-beta 1. TGF-beta 1 induced a transient increase in the expression of Cdc2, cyclin A, cyclin B, and cyclin D1 at an early phase of apoptosis. During TGF-beta 1-induced apoptosis, the transient increase in cyclin-dependent kinase (Cdk) activities coincides with a dramatic increase in the hyperphosphorylated forms of RE. Treatment with roscovitine or olomoucine, inhibitors of Cdc2 and Cdk2, blocked TGF-beta 1-induced apoptosis by inhibiting RE phosphorylation. Overexpression of Bcl-2 or adenovirus E1B 19K suppressed TGF-beta 1-induced apoptosis by blocking the induction of Cdc2 mRNA and the subsequent activation of Cdc2 kinase, whereas activation of Cdk2 was not affected, suggesting that Cdc2 plays a more critical role in TGF-beta 1-induced apoptosis. in conclusion, we present the evidence that Cdc2 and Cdk2 kinase activity transiently induced by TGF-beta 1 phosphorylates RE as a physiological target in FaO cells and that RE hyperphosphorylation may trigger abrupt cell cycle progression, leading to irreversible cell death.	Ajou Univ, Sch Med, Inst Med Sci, Lab Endocrinol,Paldal Gu, Suwon 442749, South Korea; Ajou Univ, Sch Med, Inst Med Sci, Lab Med Genet,Paldal Gu, Suwon 442749, South Korea; NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA; Univ Calgary, Fac Med,Julia McFarlane Diabet Res Ctr, Dept Microbiol & Infect Dis, Lab Viral & Immunopathogeneis Diabet, Calgary, AB T2N 4N1, Canada	Ajou University; Ajou University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Calgary	Choi, KS (corresponding author), Ajou Univ, Sch Med, Inst Med Sci, Lab Endocrinol,Paldal Gu, 5 Wonchon Dong, Suwon 442749, South Korea.	kschoi@madang.ajou.ac.kr	Eom, Young/AAW-4659-2021	Choi, Kyeong Sook/0000-0003-2331-0856				ALEXANDROW MG, 1995, CANCER RES, V55, P1452; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; BenBassat H, 1997, CANCER RES, V57, P3741; Borner C, 1996, J BIOL CHEM, V271, P12695, DOI 10.1074/jbc.271.22.12695; BORTNER DM, 1995, CELL GROWTH DIFFER, V6, P1579; Buske C, 1997, LEUKEMIA, V11, P386, DOI 10.1038/sj.leu.2400586; Chen RH, 1997, CELL GROWTH DIFFER, V8, P821; CHIOU SK, 1994, J VIROL, V68, P6553, DOI 10.1128/JVI.68.10.6553-6566.1994; Choi KS, 1998, HEPATOLOGY, V27, P415, DOI 10.1002/hep.510270215; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518, DOI 10.1111/j.1432-1033.1997.0518a.x; DeLuca A, 1997, J CELL BIOCHEM, V64, P579; Dobashi Y, 1998, BIOCHEM BIOPH RES CO, V253, P609, DOI 10.1006/bbrc.1998.9825; DONALDSON KL, 1994, CELL GROWTH DIFFER, V5, P1041; EBLEN ST, 1994, CELL GROWTH DIFFER, V5, P109; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; Fan GS, 1996, ONCOGENE, V12, P1909; FAUTSCH MP, 1995, J CELL BIOCHEM, V58, P517, DOI 10.1002/jcb.240580415; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GRANA X, 1995, ONCOGENE, V11, P211; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; Han EKH, 1996, CELL GROWTH DIFFER, V7, P699; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harvey KJ, 1998, MOL CELL BIOL, V18, P2912, DOI 10.1128/MCB.18.5.2912; Hsing AY, 1996, CANCER RES, V56, P5146; Huang DCS, 1997, ONCOGENE, V14, P405, DOI 10.1038/sj.onc.1200848; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; KO TC, 1995, ONCOGENE, V10, P177; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; Lafon C, 1996, CELL GROWTH DIFFER, V7, P1095; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAWRENCE DA, 1995, KIDNEY INT, V47, pS19; LEES E, 1995, CURR OPIN CELL BIOL, V7, P773, DOI 10.1016/0955-0674(95)80060-3; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; Lim IK, 1997, INT J CANCER, V72, P351, DOI 10.1002/(SICI)1097-0215(19970717)72:2<351::AID-IJC25>3.0.CO;2-H; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LIN JK, 1992, CANCER RES, V52, P385; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; MARTIN SJ, 1995, SCIENCE, V269, P106, DOI 10.1126/science.7604270; Mazel S, 1996, J EXP MED, V183, P2219, DOI 10.1084/jem.183.5.2219; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MEMON SA, 1995, J IMMUNOL, V155, P4644; Newton K, 1998, CURR OPIN GENET DEV, V8, P68, DOI 10.1016/S0959-437X(98)80064-6; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; Palumbo GA, 1997, CANCER RES, V57, P2434; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PANDEY S, 1995, J CELL BIOCHEM, V58, P135, DOI 10.1002/jcb.240580203; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Rao L, 1997, ONCOGENE, V15, P1587, DOI 10.1038/sj.onc.1201323; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P421; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SATTERWHITE DJ, 1994, CELL GROWTH DIFFER, V5, P789; SELVAM S, 1994, TRENDS LIFE SCI, V9, P1; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; Shi LF, 1996, J IMMUNOL, V157, P2381; SHIMIZU T, 1995, CANCER RES, V55, P228; SIMON KE, 1995, CELL GROWTH DIFFER, V6, P1261; Stewart SA, 1997, J VIROL, V71, P5579, DOI 10.1128/JVI.71.7.5579-5592.1997; Sweeney KJ, 1997, ONCOGENE, V14, P1329, DOI 10.1038/sj.onc.1200951; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; Yao SL, 1996, CANCER RES, V56, P4551; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738	76	72	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31775	31783		10.1074/jbc.274.45.31775	http://dx.doi.org/10.1074/jbc.274.45.31775			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542199	hybrid			2022-12-27	WOS:000083532100007
J	Yan, Y; Mumby, MC				Yan, Y; Mumby, MC			Distinct roles for PP1 and PP2A in phosphorylation of the retinoblastoma protein - PP2A regulates the activities of G(1) cyclin-dependent kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE PHOSPHATASES; INHIBITOR OKADAIC ACID; SV40 LARGE-T; CELL-CYCLE; GENE-PRODUCT; TUMOR-SUPPRESSOR; GROWTH-FACTOR; CALYCULIN-A; G1 ARREST; H1 KINASE	The function of the retinoblastoma protein (pRB) in controlling the G(1) to S transition is regulated by phosphorylation and dephosphorylation on serine and threonine residues. While the roles of cyclin-dependent kinases in phosphorylating and inactivating pRB have been characterized in detail, the roles of protein phosphatases in regulating the G(1)/S transition are not as well understood. We used cell-permeable inhibitors of protein phosphatases 1 and 2A to assess the contributions of these phosphatases in regulating cyclin-dependent kinase activity and pRB phosphorylation, Treating asynchronously growing Balb/c 3T3 cells with PP2A-selective concentrations of either okadaic acid or calyculin A caused a time- and dose-dependent decrease in PRE phosphorylation, Okadaic acid and calyculin A had no effect on pRB phosphatase activity even though PP2A was completely inhibited. The decrease in pRB phosphorylation correlated with inhibitor-induced suppression of G(1) cyclin dependent kinases including CDK2, CDK4, and CDK6. The inhibitors also caused decreases in the levels of cyclin D2 and cyclin E, and induction of the cyclin-dependent kinase inhibitors p21(Cip1) and p27(Kip1). The decrease in cyclin dependent kinase activities were not dependent on induction of cyclin-dependent kinase inhibitors since CDK inhibition still occurred in the presence of actinomycin D or cycloheximide. In contrast, selective inhibition of protein phosphatase 1 with tautomycin inhibited pRB phosphatase activity and maintained pRB in a highly phosphorylated state. The results show that protein phosphatase 1 and protein phosphatase 2A, or SA-like phosphatases, play distinct roles in regulating PRE function. Protein phosphatase 1 is associated with the direct dephosphorylation of pRB while protein phosphatase ZA is involved in pathways regulating G(1) cyclin-dependent kinase activity.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Mumby, MC (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	marc.mumby@email.swmed.edu			NHLBI NIH HHS [HL31107] Funding Source: Medline; NIGMS NIH HHS [GM49505] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031107] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049505] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal D, 1996, MOL CELL BIOL, V16, P4327; ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; Allen PB, 1998, J BIOL CHEM, V273, P4089, DOI 10.1074/jbc.273.7.4089; Berndt N, 1997, CURR BIOL, V7, P375, DOI 10.1016/S0960-9822(06)00185-0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; COHEN P, 1991, METHOD ENZYMOL, V201, P389; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; Cohen PTW, 1997, TRENDS BIOCHEM SCI, V22, P245, DOI 10.1016/S0968-0004(97)01060-8; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; FELIX MA, 1990, EMBO J, V9, P675, DOI 10.1002/j.1460-2075.1990.tb08159.x; Harlow E., 1988, ANTIBODIES LAB MANUA; Iavarone A, 1997, NATURE, V387, P417; ISHIDA Y, 1992, J CELL PHYSIOL, V150, P484, DOI 10.1002/jcp.1041500308; JAGIELLO I, 1995, J BIOL CHEM, V270, P17257, DOI 10.1074/jbc.270.29.17257; JaramilloBabb VL, 1996, J BIOL CHEM, V271, P5988, DOI 10.1074/jbc.271.11.5988; KIM TA, 1993, P NATL ACAD SCI USA, V90, P5460, DOI 10.1073/pnas.90.12.5460; KINOSHITA N, 1993, GENE DEV, V7, P1059, DOI 10.1101/gad.7.6.1059; KINOSHITA N, 1990, CELL, V63, P405, DOI 10.1016/0092-8674(90)90173-C; Kreivi JP, 1997, FEBS LETT, V420, P57, DOI 10.1016/S0014-5793(97)01485-3; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P2168, DOI 10.1073/pnas.94.6.2168; LEE TH, 1995, SEMIN CANCER BIOL, V6, P203, DOI 10.1006/scbi.1995.0027; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; LEE TH, 1994, MOL BIOL CELL, V5, P323, DOI 10.1091/mbc.5.3.323; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LUDLOW JW, 1995, SEMIN CANCER BIOL, V6, P195, DOI 10.1006/scbi.1995.0026; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MACKINTOSH C, 1994, TRENDS BIOCHEM SCI, V19, P444, DOI 10.1016/0968-0004(94)90127-9; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; Mayer-Jaekel Regina E., 1994, Trends in Cell Biology, V4, P287, DOI 10.1016/0962-8924(94)90219-4; MELLGREN G, 1993, EXP CELL RES, V205, P293, DOI 10.1006/excr.1993.1089; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUMBY MC, 1987, J BIOL CHEM, V262, P6257; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Nelson DA, 1997, J BIOL CHEM, V272, P4528, DOI 10.1074/jbc.272.7.4528; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; Rost B, 1996, METHOD ENZYMOL, V266, P525; SCHONTHAL A, 1993, ONCOGENE, V8, P433; Sheikh MS, 1996, CELL GROWTH DIFFER, V7, P1599; Sheppeck JE, 1997, BIOORGAN MED CHEM, V5, P1739, DOI 10.1016/S0968-0896(97)00146-6; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; TAKAI A, 1995, BIOCHEM J, V306, P657, DOI 10.1042/bj3060657; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; VANDRE DD, 1992, J CELL SCI, V101, P79; WALTER G, 1993, BIOCHIM BIOPHYS ACTA, V1155, P207, DOI 10.1016/0304-419X(93)90005-W; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; Xiong Y, 1996, Biochim Biophys Acta, V1288, P01; Yan Y, 1997, J BIOL CHEM, V272, P15220, DOI 10.1074/jbc.272.24.15220; YOU JS, 1995, J CELL PHYSIOL, V164, P424, DOI 10.1002/jcp.1041640223; Zeng YX, 1996, ONCOGENE, V12, P1557	59	104	106	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31917	31924		10.1074/jbc.274.45.31917	http://dx.doi.org/10.1074/jbc.274.45.31917			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542219	hybrid			2022-12-27	WOS:000083532100027
J	Feng, ZW; Porter, AG				Feng, ZW; Porter, AG			NF-kappa B/Rel proteins are required for neuronal differentiation of SH-SY5Y neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURAL DIFFERENTIATION; B-ALPHA; BCL-2; APOPTOSIS; TRANSCRIPTION; GROWTH; ACTIVATION; EXPRESSION; MICE	The expression, cellular localization, and activation of the NF-kappa B/Rel transcription factors are altered during neuronal differentiation, but the significance is unclear. Here we investigate the requirement for NF-kappa B/Rel proteins in neuronal differentiation. SH-SY5Y neuroblastoma cells were induced to differentiate with retinoic acid (RA) or 12-O-tetradecanoylphorbol 13-acetate (TPA), and differentiation was demonstrated by morphological criteria and the enhanced expression of Bcl-2. NF-kappa B was transiently activated after the addition of the differentiation inducers before the morphological signs of differentiation and the enhanced Bcl-2 synthesis. The onset of NF-kappa B activation coincided with a significant reduction in the amount of only one of four NF-kappa B-inhibitory proteins examined (I-kappa B beta). In contrast, NF-kappa B activation and the reduction in I-kappa B beta failed to occur in SH-SY5Y cells transformed with I-kappa B alpha M, a dominant-negative inhibitor of NF-kappa B/Rel proteins. These I-kappa B alpha M-expressing cells failed to differentiate into neuronal cell types when treated with RA or TPA, and the increased Bcl-2 synthesis was blocked. Therefore, NF-kappa B/Rel proteins are require(d) for neuronal differentiation of SH-SY5Y neuroblastoma cells.	Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Porter, AG (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.							Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baichwal V. R., 1997, CURR BIOL, V7, P94; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; Bernier PJ, 1998, J NEUROSCI, V18, P2486; Boothby MR, 1997, J EXP MED, V185, P1897, DOI 10.1084/jem.185.11.1897; DeLuca C, 1998, VIROLOGY, V244, P27, DOI 10.1006/viro.1998.9085; Esslinger CW, 1997, J IMMUNOL, V158, P5075; FENG ZW, 1995, J CELL BIOL, V131, P1095, DOI 10.1083/jcb.131.4.1095; HANADA M, 1993, CANCER RES, V53, P4978; Hilton M, 1997, CURR BIOL, V7, P798, DOI 10.1016/S0960-9822(06)00339-3; Katoh S, 1996, BIOCHEM BIOPH RES CO, V229, P653, DOI 10.1006/bbrc.1996.1859; KORNER M, 1994, J NEUROCHEM, V62, P1716; KURATA S, 1993, FEBS LETT, V321, P201, DOI 10.1016/0014-5793(93)80108-7; LASORELLA A, 1995, CANCER RES, V55, P4711; Lipton SA, 1997, NAT MED, V3, P20, DOI 10.1038/nm0197-20; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Ochoa-Garay J, 1998, J IMMUNOL, V160, P3835; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; PAHLMAN S, 1995, EUR J CANCER, V31A, P453, DOI 10.1016/0959-8049(95)00033-F; ROWE M, 1994, J VIROL, V68, P5602, DOI 10.1128/JVI.68.9.5602-5612.1994; SHEPPARD AM, 1995, J BIOL CHEM, V270, P3710, DOI 10.1074/jbc.270.8.3710; Siebenlist U, 1997, BBA-REV CANCER, V1332, pR7, DOI 10.1016/S0304-419X(96)00038-8; Snapper CM, 1996, J IMMUNOL, V156, P183; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Zhang KZ, 1996, P NATL ACAD SCI USA, V93, P4504, DOI 10.1073/pnas.93.9.4504	27	64	69	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30341	30344		10.1074/jbc.274.43.30341	http://dx.doi.org/10.1074/jbc.274.43.30341			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521406	hybrid			2022-12-27	WOS:000083276700002
J	Ji, CH; Chen, Y; McCarthy, TL; Centrella, M				Ji, CH; Chen, Y; McCarthy, TL; Centrella, M			Cloning the promoter for transforming growth factor-beta type III receptor - Basal and conditional expression in fetal rat osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-2; ENRICHED CELL-CULTURES; TRANSCRIPTION FACTOR; CYCLIC ADENOSINE-3',5'-MONOPHOSPHATE; NUCLEOTIDE-SEQUENCE; COLLAGEN-SYNTHESIS; ENDOTHELIAL-CELLS; I EXPRESSION; CPG ISLANDS; BINDING	Transforming growth factor-p binds to three high affinity cell surface molecules that directly or indirectly regulate its biological effects. The type III receptor (TRIII) is a proteoglycan that lacks significant intracellular signaling or enzymatic motifs but may facilitate transforming growth factor-p binding to other receptors, stabilize multimeric receptor complexes, or segregate growth factor from activating receptors, Because various agents or events that regulate osteoblast function rapidly modulate TRIII expression, we cloned the 5' region of the rat TRIII gene to assess possible control elements. DNA fragments from this region directed high reporter gene expression in osteoblasts. Sequencing showed no consensus TATA or CCAAT boxes, whereas several nuclear factors binding sequences within the 3' region of the promoter co-mapped with multiple transcription initiation sites, DNase I footprints, gel mobility shift analysis, or loss of activity by deletion or mutation. An upstream enhancer was evident 5' proximal to nucleotide -979, and a silencer region occurred between nucleotides -2014 and -2194. Glucocorticoid sensitivity mapped between nucleotides -687 and -253, whereas bone morphogenetic protein 2 sensitivity co-mapped within the silencer region. Thus, the TRIII promoter contains cooperative basal elements and dispersed growth factor- and hormone-sensitive regulatory regions that can control TRIII expression by osteoblasts.	Yale Univ, Sch Med, Dept Surg, Plast Surg Sect, New Haven, CT 06520 USA	Yale University	Centrella, M (corresponding author), Yale Univ, Sch Med, Dept Surg, Plast Surg Sect, 333 Cedar St,POB 208041, New Haven, CT 06520 USA.	michael.centrella@yale.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR039201, R01AR039201] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047421] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39201] Funding Source: Medline; NIDDK NIH HHS [DK47421] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Austen M, 1997, CURR TOP MICROBIOL, V224, P123; BAE HW, 1995, J BIOL CHEM, V270, P29460, DOI 10.1074/jbc.270.49.29460; Breed DR, 1997, ENDOCRINOLOGY, V138, P5527, DOI 10.1210/en.138.12.5527; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; Carpenter TO, 1998, ENDOCRINOLOGY, V139, P35, DOI 10.1210/en.139.1.35; Centrella M, 1997, J CELL BIOCHEM, V67, P528, DOI 10.1002/(SICI)1097-4644(19971215)67:4<528::AID-JCB10>3.3.CO;2-5; CENTRELLA M, 1994, ENDOCRINOLOGY, V135, P1611, DOI 10.1210/en.135.4.1611; CENTRELLA M, 1989, ENDOCRINOLOGY, V125, P199, DOI 10.1210/endo-125-1-199; Centrella M, 1996, ANN NY ACAD SCI, V785, P224, DOI 10.1111/j.1749-6632.1996.tb56267.x; CENTRELLA M, 1988, P NATL ACAD SCI USA, V85, P5889, DOI 10.1073/pnas.85.16.5889; CENTRELLA M, 1987, J BIOL CHEM, V262, P2869; CENTRELLA M, 1995, MOL CELL BIOL, V15, P3273; CENTRELLA M, 1991, MOL CELL BIOL, V11, P4490, DOI 10.1128/MCB.11.9.4490; Centrella M, 1996, J BIOL CHEM, V271, P18616, DOI 10.1074/jbc.271.31.18616; Chang DJ, 1998, J BIOL CHEM, V273, P4892, DOI 10.1074/jbc.273.9.4892; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; COCHET C, 1988, J BIOL CHEM, V263, P5707; EWTON DZ, 1988, J BIOL CHEM, V263, P4029; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Ji CH, 1996, J CELL BIOCHEM, V63, P478; Ji CH, 1997, J BIOL CHEM, V272, P21260, DOI 10.1074/jbc.272.34.21260; Ji CH, 1998, J CELL BIOCHEM, V69, P353, DOI 10.1002/(SICI)1097-4644(19980601)69:3<353::AID-JCB12>3.3.CO;2-W; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; KYPRIANOU N, 1988, ENDOCRINOLOGY, V123, P2124, DOI 10.1210/endo-123-4-2124; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MCCARTHY TL, 1995, ENDOCRINOLOGY, V136, P3901, DOI 10.1210/en.136.9.3901; Miao K, 1999, ARCH BIOCHEM BIOPHYS, V361, P7, DOI 10.1006/abbi.1998.0977; NAKAYAMA H, 1994, EXP CELL RES, V211, P301, DOI 10.1006/excr.1994.1091; OHTSUKI M, 1992, MOL CELL BIOL, V12, P261, DOI 10.1128/MCB.12.1.261; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sankar S, 1996, J CLIN INVEST, V97, P1436, DOI 10.1172/JCI118565; SANKAR S, 1995, J BIOL CHEM, V270, P13567, DOI 10.1074/jbc.270.22.13567; Shin JH, 1997, J BIOL CHEM, V272, P23498, DOI 10.1074/jbc.272.38.23498; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; TRUETT MA, 1985, DNA-J MOLEC CELL BIO, V4, P333, DOI 10.1089/dna.1985.4.333; Turner BC, 1998, CANCER RES, V58, P5466; Umayahara Y, 1997, J BIOL CHEM, V272, P31793, DOI 10.1074/jbc.272.50.31793; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	48	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30487	30494		10.1074/jbc.274.43.30487	http://dx.doi.org/10.1074/jbc.274.43.30487			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521429	hybrid			2022-12-27	WOS:000083276700025
J	Lindahl, B; Westling, C; Gimenez-Gallego, G; Lindahl, U; Salmivirta, M				Lindahl, B; Westling, C; Gimenez-Gallego, G; Lindahl, U; Salmivirta, M			Common binding sites for beta-amyloid fibrils and fibroblast growth factor-2 in heparan sulfate from human cerebral cortex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; A-BETA; BASIC FGF; PEPTIDES; PROTEOGLYCANS; AGGREGATION; INHIBITION; PERLECAN; PLAQUES; AMYLIN	Heparan sulfate found in the cerebral plaques of Alzheimer's disease binds to beta-amyloid (A beta) fibrils. This interaction has been proposed to enhance fibril deposition and mediate A beta-induced glia activation and neurotoxicity. On the other hand, heparan sulfate augments signaling of fibroblast growth factor-2 (FGF-2), a neuroprotective factor that antagonizes the neurotoxic effects of A beta. We defined structures in heparan sulfate from human cerebral cortex that bind A beta fibrils. The minimal binding site is found in N-sulfated hexasaccharide domains and contains critical 2-O-sulfated iduronic acid residues. By contrast, binding of A beta monomers requires, in addition, 6-O-sulfate groups on glucosamine residues. The binding specificity of fibrillar A beta is shared by FGF-2, and we here show that cerebral heparan sulfate domains selected for binding to A beta-(1-40) fibrils bind also to FGF-2. These data suggest that neurotoxic and neuroprotective signals may converge by competing for the same binding sites on the heparan sulfate chain.	Univ Uppsala, Ctr Biomed, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden; Ctr Invest Biol, E-28006 Madrid, Spain	Uppsala University; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Salmivirta, M (corresponding author), Univ Uppsala, Ctr Biomed, Dept Med Biochem & Microbiol, Box 575, S-75123 Uppsala, Sweden.							BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BRUNDEN KR, 1993, J NEUROCHEM, V61, P2147, DOI 10.1111/j.1471-4159.1993.tb07453.x; Castillo GM, 1998, DIABETES, V47, P612, DOI 10.2337/diabetes.47.4.612; Castillo GM, 1999, J NEUROCHEM, V72, P1681, DOI 10.1046/j.1471-4159.1999.721681.x; Castillo GM, 1997, J NEUROCHEM, V69, P2452; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Feyzi E, 1997, J BIOL CHEM, V272, P5518, DOI 10.1074/jbc.272.9.5518; Giulian D, 1998, J BIOL CHEM, V273, P29719, DOI 10.1074/jbc.273.45.29719; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Guo Q, 1999, P NATL ACAD SCI USA, V96, P4125, DOI 10.1073/pnas.96.7.4125; GUPTABANSAL R, 1995, J BIOL CHEM, V270, P18666, DOI 10.1074/jbc.270.31.18666; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; KATO T, 1991, NEUROSCI LETT, V122, P33, DOI 10.1016/0304-3940(91)90186-W; KUSCHE M, 1988, BIOCHEM J, V253, P885, DOI 10.1042/bj2530885; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; LINDAHL B, 1995, BIOCHEM J, V306, P177, DOI 10.1042/bj3060177; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MACCARANA M, 1993, GLYCOBIOLOGY, V3, P271, DOI 10.1093/glycob/3.3.271; Mark RJ, 1997, BRAIN RES, V756, P205, DOI 10.1016/S0006-8993(97)00196-0; Morita H, 1995, VIRCHOWS ARCH, V427, P395; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SNOW AD, 1989, NEUROBIOL AGING, V10, P481, DOI 10.1016/0197-4580(89)90108-5; SNOW AD, 1988, AM J PATHOL, V133, P456; Tjernberg LO, 1996, J BIOL CHEM, V271, P8545, DOI 10.1074/jbc.271.15.8545; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Watson DJ, 1997, J BIOL CHEM, V272, P31617, DOI 10.1074/jbc.272.50.31617; ZAZO M, 1992, GENE, V113, P231, DOI 10.1016/0378-1119(92)90400-J	30	58	70	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30631	30635		10.1074/jbc.274.43.30631	http://dx.doi.org/10.1074/jbc.274.43.30631			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521448	hybrid, Green Published			2022-12-27	WOS:000083276700044
J	Loisel, TP; Ansanay, H; Adam, L; Marullo, S; Seifert, R; Lagace, M; Bouvier, M				Loisel, TP; Ansanay, H; Adam, L; Marullo, S; Seifert, R; Lagace, M; Bouvier, M			Activation of the beta(2)-adrenergic receptor-G alpha(s) complex leads to rapid depalmitoylation and inhibition of repalmitoylation of both the receptor and G alpha(s)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE PALMITOYLATION SITE; PROTEIN ALPHA-SUBUNITS; BETA-2-ADRENERGIC RECEPTOR; FUSION PROTEIN; CYTOPLASMIC TAIL; PLASMA-MEMBRANE; DOWN-REGULATION; SF9 CELLS; ACETYLCHOLINE-RECEPTORS; INDUCED INTERNALIZATION	Palmitoylation is unique among lipid modifications in that it is reversible. In recent years, dynamic palmitoylation of G protein alpha subunits and of their cognate receptors has attracted considerable attention. However, very little is known concerning the acylation/deacylation cycle of the proteins in relation to their activity status. In particular, the relative contribution of the activation and desensitization of the signaling unit to the regulation of the receptors and G proteins palmitoylation state is unknown. To address this issue, we took advantage of the fact that a fusion protein composed of the stimulatory alpha subunit of trimeric G protein (G alpha(s)) covalently attached to the beta(2)-adrenergic receptor (beta(2)AR) as a carboxyl-terminal extension (beta(2)AR-G alpha(s)) can be stimulated by agonists but does not undergo rapid inactivation, desensitization, or internalization. When expressed in Sf9 cells, both the receptor and the G alpha(s) moieties of the fusion protein were found to be palmitoylated via thioester linkage. Stimulation with the beta-adrenergic agonist isoproterenol led to a rapid depalmitoylation of both the beta(2)AR and G alpha(s) and inhibited repalmitoylation. The extent of depalmitoylation induced by a series of agonists was correlated (0.99) with activity. However, forskolin-stimulated cAMP production did not affect the palmitoylation state of beta(2)AR-G alpha(s), indicating that the agonist-promoted depalmitoylation is linked to conformational changes and not to second messenger generation. Given that, upon activation, the fusion protein mimics the activated receptor-G protein complex but cannot undergo desensitization, the data demonstrate that early steps in the activation process lead to the depalmitoylation of both receptor and G protein and that repalmitoylation requires later events that cannot be accommodated by the activated fusion protein.	Univ Montreal, Fac Med, Dept Biochim, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Grp Rech Syst Nerveux Autonome, Montreal, PQ H3C 3J7, Canada; Inst Cochin Genet Mol, CNRS, URA 1534, Dept Pharmacol Cellulaire & Mol, Paris, France; Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA	Universite de Montreal; Universite de Montreal; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Howard Hughes Medical Institute; Stanford University	Bouvier, M (corresponding author), Univ Montreal, Fac Med, Dept Biochim, POB 6128,Succ Ctr Ville, Montreal, PQ H3C 3J7, Canada.	bouvier@bcm.umontreal.ca	Bouvier, Michel/H-2758-2014; Seifert, Roland/G-3189-2013; Marullo, Stefano/C-6142-2008	Bouvier, Michel/0000-0003-1128-0100; Marullo, Stefano/0000-0001-9604-9973				BENOVIC JL, 1984, BIOCHEMISTRY-US, V23, P4510, DOI 10.1021/bi00315a002; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BERTHIAUME L, 1995, J BIOL CHEM, V270, P22399, DOI 10.1074/jbc.270.38.22399; Bertin B, 1997, RECEPTOR CHANNEL, V5, P41; BERTIN B, 1994, P NATL ACAD SCI USA, V91, P8827, DOI 10.1073/pnas.91.19.8827; Bertin B, 1997, INT J CANCER, V71, P1029; Bohm SK, 1997, BIOCHEM J, V322, P1; BONATTI S, 1989, J BIOL CHEM, V264, P12590; BOUVIER M, 1988, MOL PHARMACOL, V33, P133; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; Drmota T, 1998, J BIOL CHEM, V273, P21699, DOI 10.1074/jbc.273.34.21699; Duncan JA, 1996, J BIOL CHEM, V271, P23594, DOI 10.1074/jbc.271.38.23594; Duncan JA, 1998, J BIOL CHEM, V273, P15830, DOI 10.1074/jbc.273.25.15830; EASON MG, 1994, P NATL ACAD SCI USA, V91, P11178, DOI 10.1073/pnas.91.23.11178; GRASSIE MA, 1994, BIOCHEM J, V302, P913, DOI 10.1042/bj3020913; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; Hayashi MK, 1997, ARCH BIOCHEM BIOPHYS, V340, P376, DOI 10.1006/abbi.1997.9906; Horstmeyer A, 1996, J BIOL CHEM, V271, P20811, DOI 10.1074/jbc.271.34.20811; Iiri T, 1996, P NATL ACAD SCI USA, V93, P14592, DOI 10.1073/pnas.93.25.14592; JENSEN AA, 1995, J NEUROCHEM, V65, P1325, DOI 10.1046/j.1471-4159.1995.65031325.x; Jones TLZ, 1997, BIOCHEMISTRY-US, V36, P7185, DOI 10.1021/bi9628376; KARNIK SS, 1993, P NATL ACAD SCI USA, V90, P40, DOI 10.1073/pnas.90.1.40; KAWATE N, 1994, J BIOL CHEM, V269, P30651; KENNEDY ME, 1994, J BIOL CHEM, V269, P31915; LEGOCKI RP, 1981, ANAL BIOCHEM, V111, P385, DOI 10.1016/0003-2697(81)90577-7; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; Loisel TP, 1996, BIOCHEMISTRY-US, V35, P15923, DOI 10.1021/bi9611321; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MCCALLUM JF, 1995, BIOCHEM J, V310, P1021, DOI 10.1042/bj3101021; MILLIGAN G, 1993, TRENDS PHARMACOL SCI, V14, P413, DOI 10.1016/0165-6147(93)90064-Q; Milligan G, 1998, TRENDS ENDOCRIN MET, V9, P13, DOI 10.1016/S1043-2760(98)00004-6; Moffett S, 1996, J BIOL CHEM, V271, P21490, DOI 10.1074/jbc.271.35.21490; Morales J, 1998, MOL BIOL CELL, V9, P1, DOI 10.1091/mbc.9.1.1; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; Mumby SM, 1997, CURR OPIN CELL BIOL, V9, P148, DOI 10.1016/S0955-0674(97)80056-7; NG GYK, 1994, J NEUROCHEM, V63, P1589; NG GYK, 1994, EUR J PHARM-MOLEC PH, V267, P7, DOI 10.1016/0922-4106(94)90219-4; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; Okamoto Y, 1997, J BIOL CHEM, V272, P21589, DOI 10.1074/jbc.272.34.21589; OMARY MB, 1981, J BIOL CHEM, V256, P2888; OMARY MB, 1981, J BIOL CHEM, V256, P4715; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Schulein R, 1996, BIOCHEM J, V313, P611, DOI 10.1042/bj3130611; Seifert R, 1998, EUR J BIOCHEM, V255, P369, DOI 10.1046/j.1432-1327.1998.2550369.x; Seifert R, 1999, EUR J BIOCHEM, V260, P661, DOI 10.1046/j.1432-1327.1999.00161.x; Seifert R, 1998, J BIOL CHEM, V273, P5109, DOI 10.1074/jbc.273.9.5109; SEIFERT R, 1999, IN PRESS TRENDS PHAR; SVOBODA P, 1994, EUR J BIOCHEM, V224, P455, DOI 10.1111/j.1432-1033.1994.00455.x; Svoboda P, 1996, MOL PHARMACOL, V49, P646; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; VANDEWESTERLO E, 1995, BIOCHEM J, V310, P559, DOI 10.1042/bj3100559; Veit M, 1998, BBA-LIPID LIPID MET, V1394, P90, DOI 10.1016/S0005-2760(98)00097-6; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6	57	52	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					31014	31019		10.1074/jbc.274.43.31014	http://dx.doi.org/10.1074/jbc.274.43.31014			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521499	hybrid			2022-12-27	WOS:000083276700095
J	Pethe, V; Shekhar, PVM				Pethe, V; Shekhar, PVM			Estrogen inducibility of c-Ha-ras transcription in breast cancer cells - Identification of functional estrogen-responsive transcriptional regulatory elements in exon 1/intron 1 of the c-Ha-ras gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLADDER-CARCINOMA ONCOGENE; MOUSE MAMMARY-TUMOR; 5' FLANKING REGION; NUCLEOTIDE-SEQUENCE; ELEVATED EXPRESSION; SYNERGISTIC ACTION; MAMMALIAN-CELLS; POINT MUTATION; MCF-7 CELLS; CARCINOGENESIS	Although mutation of ras gene is rare in human breast cancer, overexpression of normal c-Ha-ras gene is frequently observed. Using a mouse mammary metastasis model consisting of genetically related mammary tumor sublines with variant metastatic potential, we have previously (i) demonstrated a direct correlation between c-Ha-ras mRNA and protein levels and metastatic potential and (ii) identified a novel hormone-responsive transcriptional regulatory element in intron 1 of the mouse c-Ha-ras gene that contains the consensus half-site of a glucocorticoid response element and flanking consensus half-sites for estrogen response element. Here, we have examined the functionality of intron 1 sequence in context of upstream sequences by using transient transfection assays with plasmids expressing chloramphenicol acetyltransferase. Intron 1 sequence and sequences similar to intron 1 element located in exon 1 function as transcriptional regulatory elements that confer hormonal inducibility to chloramphenicol acetyltransferase gene expression both independently and in context of 5'-flanking sequences, Measurement of c-Ha-ras transcription rates and protein expression by nuclear run-on and metabolic labeling assays showed a 5-12-fold enhancement, respectively, following treatment with 17 beta-estradiol that was blunted by ICI 182,780 in the nonmetastatic variant, In contrast, constitutive overexpression of c-Ha-ras transcripts and protein in the metastatic subline was unaffected by estrogen and ICI 182,780. Gel shift assays demonstrated specific interaction of c-Ha-ras exon 1 sequence with nuclear proteins of human breast cancer MCF-7 cells with formation of two complexes, one of which contains estrogen receptor, Our data demonstrate a direct (i) interaction of c-Ha-ras sequence with estrogen receptor and (ii) stimulatory effect of estrogen on c-Ha-ras gene transcription and suggest that alteration in transcriptional regulation of c-Ha-ras gene by estrogen may play an important role in progression of breast cancer.	Karmanos Canc Inst, Breast Canc Program, Detroit, MI 48201 USA; Karmanos Canc Inst, Dept Pathol, Detroit, MI 48201 USA; Wayne State Univ, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; Wayne State University	Shekhar, PVM (corresponding author), Karmanos Canc Inst, Breast Canc Program, 110 E Warren Ave, Detroit, MI 48201 USA.	shekharm@kci.wayne.edu		Shekhar, Malathy/0000-0003-2721-7202	NCI NIH HHS [CA60881, R29 CA060881-06, CA22453] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA060881, P30CA022453] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMI HO, 1990, INT J CANCER, P22; ANKENBAUER W, 1988, P NATL ACAD SCI USA, V85, P7526, DOI 10.1073/pnas.85.20.7526; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; BALMAIN A, 1983, NATURE, V303, P72, DOI 10.1038/303072a0; BORTNER DM, 1993, CRIT REV ONCOGENESIS, V4, P137; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BROWN K, 1988, MOL CARCINOGEN, V1, P161, DOI 10.1002/mc.2940010304; CHANG EH, 1982, NATURE, V297, P479, DOI 10.1038/297479a0; CLARK GJ, 1995, BREAST CANCER RES TR, V35, P133, DOI 10.1007/BF00694753; DAMANTE G, 1987, P NATL ACAD SCI USA, V84, P774, DOI 10.1073/pnas.84.3.774; DEBIASI F, 1989, INT J CANCER, V43, P431, DOI 10.1002/ijc.2910430315; DICKSON RB, 1987, P NATL ACAD SCI USA, V84, P837, DOI 10.1073/pnas.84.3.837; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FASANO O, 1984, P NATL ACAD SCI-BIOL, V81, P4008, DOI 10.1073/pnas.81.13.4008; GALAND P, 1971, J ENDOCRINOL, V49, P243, DOI 10.1677/joe.0.0490243; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; GELMANN EP, 1992, INT J CANCER, V50, P665, DOI 10.1002/ijc.2910500431; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBERG ME, CURRENT PROTOCOLS MO, pCH4; ISONISHI S, 1991, CANCER RES, V51, P5903; KASID A, 1987, J STEROID BIOCHEM, V27, P465, DOI 10.1016/0022-4731(87)90341-4; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; KUMAR R, 1990, SCIENCE, V248, P1101, DOI 10.1126/science.2188364; KYPRIANOU N, 1991, CANCER RES, V51, P162; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; MUELLER GC, 1958, RECENT PROG HORM RES, V14, P95; NEADES R, 1991, MOL CARCINOGEN, V4, P369, DOI 10.1002/mc.2940040508; PALEJWALA S, 1992, P NATL ACAD SCI USA, V89, P4202, DOI 10.1073/pnas.89.9.4202; PELLING JC, 1987, CARCINOGENESIS, V8, P1481, DOI 10.1093/carcin/8.10.1481; PELLING JC, 1986, CARCINOGENESIS, V7, P1599, DOI 10.1093/carcin/7.9.1599; PETERS GJ, 1993, INT J CANCER, V54, P450, DOI 10.1002/ijc.2910540316; REDDY EP, 1983, SCIENCE, V220, P1061, DOI 10.1126/science.6844927; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; RUTA M, 1986, MOL CELL BIOL, V6, P1706, DOI 10.1128/MCB.6.5.1706; SCANLON KJ, 1991, PHARMACOL THERAPEUT, V52, P385, DOI 10.1016/0163-7258(91)90033-I; SCREPANTI I, 1991, INT J CANCER, V47, P445, DOI 10.1002/ijc.2910470323; SHEKHAR PVM, 1994, INVAS METAST, V14, P27; SHEKHAR PVM, 1995, CANC MOL BIOL, V2, P529; SKLAR MD, 1988, CANCER RES, V48, P793; SOMMERS CL, 1990, CANCER RES, V50, P67; SPANDIDOS DA, 1984, ANTICANCER RES, V4, P269; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; SUKUMAR S, 1989, CURR TOP MICROBIOL, V148, P93; SUKUMAR S, 1988, SCIENCE, V240, P524, DOI 10.1126/science.3282307; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TANAKA T, 1986, CANCER RES, V46, P437; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; TELLIEZ JB, 1995, MOL CARCINOGEN, V12, P137, DOI 10.1002/mc.2940120305; THOR A, 1986, LAB INVEST, V55, P603; VANROY F, 1990, INT J CANCER, V46, P522, DOI 10.1002/ijc.2910460332; WALKER P, 1984, NUCLEIC ACIDS RES, V12, P8611, DOI 10.1093/nar/12.22.8611; WESTAWAY D, 1986, EMBO J, V5, P301, DOI 10.1002/j.1460-2075.1986.tb04213.x; WOLF DM, 1993, BREAST CANCER RES TR, V27, P27, DOI 10.1007/BF00683191; WORLAND PJ, 1989, CANCER RES, V49, P51; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	56	39	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30969	30978		10.1074/jbc.274.43.30969	http://dx.doi.org/10.1074/jbc.274.43.30969			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521493	hybrid			2022-12-27	WOS:000083276700089
J	Thompson, PR; Schwartzenhauer, J; Hughes, DW; Berghuis, AM; Wright, GD				Thompson, PR; Schwartzenhauer, J; Hughes, DW; Berghuis, AM; Wright, GD			The COOH terminus of aminoglycoside phosphotransferase (3 ')-IIIa is critical for antibiotic recognition and resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3'-PHOSPHOTRANSFERASE TYPE IIIA; PROTEIN-KINASE; NUCLEIC-ACIDS; FORCE-FIELD; SPECTROSCOPY; ENZYMES	The aminoglycoside phosphotransferases (APHs) are widely distributed among pathogenic bacteria and are employed to covalently modify, and thereby detoxify, the clinically relevant aminoglycoside antibiotics. The crystal structure for one of these aminoglycoside kinases, APH(3')-IIIa, has been determined in complex with ADP and analysis of the electrostatic surface potential indicates that there is a large anionic depression present adjacent to the terminal phosphate group of the nucleotide, This region also includes a conserved COOH-terminal alpha-helix that contains the COOH-terminal residue phe(264). We report here mutagenesis and computer modeling studies aimed at examining the mode of aminoglycoside binding to APH(3')-IIIa. Specifically, seven site mutants were studied, five from the COOH-terminal helix (Asp(261), Glu(262), and Phe(264)), and two additional residues that line the wall of the anionic depression (Tyr(55) and Arg(211)). Using a molecular modeling approach, six ternary complexes of APH(3')-IIIa;ATP with the antibiotics, kanamycin, amikacin, butirosin, and ribostamycin were independently constructed and these agree well with the mutagenesis data. The results obtained show that the COOH-terminal carboxylate of Phe(264) is critical for proper function of the enzyme. Furthermore, these studies demonstrate that there exists multiple binding modes for the aminoglycosides, which provides a molecular basis for the broad substrate- and regiospecificity observed for this enzyme.	McMaster Univ, Antimicrobial Res Ctr, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Chem, Hamilton, ON L8N 3Z5, Canada	McMaster University; McMaster University; McMaster University	Wright, GD (corresponding author), McMaster Univ, Antimicrobial Res Ctr, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.		Berghuis, Albert M/A-6495-2008; Wright, G/ABB-7666-2021	Berghuis, Albert/0000-0002-2663-025X; Wright, Gerard/0000-0002-9129-7131				BOTTO RE, 1983, J AM CHEM SOC, V105, P1021, DOI 10.1021/ja00342a062; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; Cox JR, 1997, BIOCHEMISTRY-US, V36, P2353, DOI 10.1021/bi9626822; Cox JR, 1996, J AM CHEM SOC, V118, P1295, DOI 10.1021/ja952994c; CUNNINGHAM RP, 1986, J BACTERIOL, V168, P1120, DOI 10.1128/jb.168.3.1120-1127.1986; Daigle DM, 1997, J BIOL CHEM, V272, P24755, DOI 10.1074/jbc.272.40.24755; Daigle DM, 1999, CHEM BIOL, V6, P11, DOI 10.1016/S1074-5521(99)80016-7; DiGiammarino EL, 1998, BIOCHEMISTRY-US, V37, P3638, DOI 10.1021/bi972778b; Halgren TA, 1996, J COMPUT CHEM, V17, P490, DOI 10.1002/(SICI)1096-987X(199604)17:5/6<616::AID-JCC5>3.0.CO;2-X; HART TN, 1992, PROTEINS, V13, P206, DOI 10.1002/prot.340130304; Hon WC, 1997, CELL, V89, P887, DOI 10.1016/S0092-8674(00)80274-3; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; McKay GA, 1996, ANTIMICROB AGENTS CH, V40, P2648, DOI 10.1128/AAC.40.11.2648; MCKAY GA, 1994, BIOCHEMISTRY-US, V33, P6936, DOI 10.1021/bi00188a024; MERRIT EA, 1994, ACTA CRYSTALLOGR D, V40, P869; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; OWEN DJ, 1995, STRUCTURE, V3, P467, DOI 10.1016/S0969-2126(01)00180-0; SHAW KJ, 1993, MICROBIOL REV, V57, P138, DOI 10.1128/MMBR.57.1.138-163.1993; Thompson PR, 1996, CHEM BIOL, V3, P747, DOI 10.1016/S1074-5521(96)90251-3; Thompson PR, 1996, BIOCHEMISTRY-US, V35, P8686, DOI 10.1021/bi960389w; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; WRIGHT GD, 1999, RESOLVING ANTIBIOTIC, P27; Wright Gerard D., 1999, Frontiers in Bioscience, V4, pD9, DOI 10.2741/Wright	26	32	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30697	30706		10.1074/jbc.274.43.30697	http://dx.doi.org/10.1074/jbc.274.43.30697			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521458	hybrid			2022-12-27	WOS:000083276700054
J	Agadir, A; Chen, GQ; Bost, F; Li, Y; Mercola, D; Zhang, XK				Agadir, A; Chen, GQ; Bost, F; Li, Y; Mercola, D; Zhang, XK			Differential effect of retinoic acid on growth regulation by phorbol ester in human cancer cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NUCLEAR RECEPTORS; TRANSCRIPTIONAL ACTIVATION; P21(WAF1/CIP1) EXPRESSION; SIGNAL-TRANSDUCTION; TUMOR PROMOTION; THYROID-HORMONE; LEUKEMIA-CELLS; AP-1; INHIBITION	Phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) and all-trans-retinoic acid (trans-RA) are potent regulators of growth of cancer cells. In this study, we investigated the effect of TPA and trans-RA alone or their combination on proliferation of human breast cancer ZR75-1 and T47D and lung cancer H460 and H292 cell lines. trans-RA caused various degrees of growth inhibition of these cell lines. However, TPA showed inhibition of proliferation of H460 and H292 cells and induction of ZR75-1 cell growth. Although trans-RA did not significantly regulate the growth inhibitory effect of TPA, it completely prevented its growth stimulating function. The divergent effects of TPA were associated with specific disruption of cell cycle events, an induction of G(0)/G(1) arrest in H460 and H292 cells and inhibition of G(0)/G(1) arrest with increase of S phase in ZR75-1 cells. Induction of G(0)/G(1) arrest was accompanied by induction of p21(WAF1) and ERK activity, whereas inhibition of G(0)/G(1) arrest was associated with enhanced activity of JNK and AP-1 but not ERK. trans-RA did not affect TPA-induced p21(WAF1) expression. However, it inhibited TPA-induced AP-1 activity in ZR75-1 cells and the constitutive AP-1 activity in H460 and H292 cells, Thus, trans-RA modulates TPA activity through its interaction through TPA-induced JNK/AP-1 pathway but not TPA-induced ERK/p21(WAF1) pathway.	Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA; Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA	Sanford Burnham Prebys Medical Discovery Institute	Zhang, XK (corresponding author), Burnham Inst, Canc Res Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		mercola, dan/L-4182-2013; BOST, Frederic/AAN-4691-2020	mercola, dan/0000-0002-0281-9840; BOST, Frederic/0000-0003-4509-4701	NATIONAL CANCER INSTITUTE [R01CA060988] Funding Source: NIH RePORTER; NCI NIH HHS [CA60988, CA51933] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agadir A, 1997, CANCER RES, V57, P3444; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARITA Y, 1992, CANCER RES, V52, P4514; BLOBE GC, 1994, CANCER METAST REV, V13, P411, DOI 10.1007/BF00666107; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; COLLINS SJ, 1987, BLOOD, V70, P1233; COPPOCK DL, 1995, EXP CELL RES, V221, P92, DOI 10.1006/excr.1995.1356; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Esposito F, 1997, EUR J BIOCHEM, V245, P730, DOI 10.1111/j.1432-1033.1997.00730.x; Gudas Lorraine J., 1994, P443; HARPER JW, 1993, CELL, V75, P805; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hong Waun Ki, 1994, P597; HORIGUCHIYAMADA J, 1994, MOL CELL BIOCHEM, V132, P31, DOI 10.1007/BF00925672; HUNER T, 1992, CELL, V70, P375; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG HP, 1994, ONCOGENE, V9, P3397; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KIKAWA U, 1989, ANNU REV BIOCHEM, V58, P31; Kiley S C, 1994, Trends Cell Biol, V4, P223, DOI 10.1016/0962-8924(94)90146-5; KUMAR R, 1994, CARCINOGENESIS, V15, P701, DOI 10.1093/carcin/15.4.701; LAFYATIS R, 1990, MOL ENDOCRINOL, V4, P973, DOI 10.1210/mend-4-7-973; LALLEMAIN G, 1991, MOL CELL BIOL, V11, P1002, DOI 10.1128/MCB.11.2.1002; Li JJ, 1996, CANCER RES, V56, P483; LIN M, 1996, J BIOL CHEM, V271, P31723; Liu Y, 1996, MOL CELL BIOL, V16, P1138; Liu Y, 1996, CANCER RES, V56, P31; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1989, JAMA-J AM MED ASSOC, V262, P1826, DOI 10.1001/jama.262.13.1826; NORI M, 1992, MOL CELL BIOL, V12, P936, DOI 10.1128/MCB.12.3.936; OBRIAN CA, 1989, CANCER RES, V49, P3215; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; SCITA G, 1994, CARCINOGENESIS, V15, P1043, DOI 10.1093/carcin/15.5.1043; STEINMAN RA, 1994, ONCOGENE, V9, P3389; VILLEVAL JL, 1983, EXP CELL RES, V146, P428, DOI 10.1016/0014-4827(83)90145-3; YAMADA K, 1984, BIOCH BIOL INT, V34, P827; YANGYEN HF, 1991, NEW BIOL, V3, P1206; ZHANG W, 1995, CANCER RES, V55, P668; ZHANG XK, 1993, TRENDS ENDOCRIN MET, V4, P156, DOI 10.1016/1043-2760(93)90105-N; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	48	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29779	29785		10.1074/jbc.274.42.29779	http://dx.doi.org/10.1074/jbc.274.42.29779			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514454	hybrid			2022-12-27	WOS:000083176400033
J	Grober, J; Zaghini, I; Fujii, H; Jones, SA; Kliewer, SA; Willson, TM; Ono, T; Besnard, P				Grober, J; Zaghini, I; Fujii, H; Jones, SA; Kliewer, SA; Willson, TM; Ono, T; Besnard, P			Identification of a bile acid-responsive element in the human ileal bile acid-binding protein gene - Involvement of the farnesoid X receptor/9-cis-retinoic acid receptor heterodimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORT ACTIVITY; RAT; EXPRESSION; ABSORPTION; CLONING; RABBIT; LIVER; CHOLESTEROL; INTESTINE; ILEUM	Intestinal bile acid-binding protein (I-BABP) iis a cytosolic protein that binds bile acids (BAs) with a high affinity. In the small intestine, its expression is restricted to the ileum where it is involved in the enterohepatic circulation of BAs, Using the human enterocyte-like Caco-2 cell line, we have recently shown that BAs increased I-BABP gene expression. To determine whether this regulation occurs in vivo, the effect of BA depletion or supplementation was studied in mice, A dramatic drop in I-BABP mRNA levels was observed in mice treated with the BA-binding resin cholestyramine, whereas an increase was found in animals fed with taurocholic acid. BAs are physiological ligands for the nuclear farnesoid X receptor (FXR), Both FXR and I-BABP are co-expressed along the small intestine and in Caco-2 cells. To determine the role of FXR in the regulation of I-BABP expression, the promoter of the human I-BABP gene was cloned. In Caco-2 cells, cotransfection of FXR and RXR alpha is required to obtain the full transactivation of the I-BABP promoter by BAs, Deletion and mutation analyses demonstrate that the FXR/RXR alpha heterodimer activates transcription through an inverted repeat bile acid responsive element located in position -160/-148 of the human I-BABP promoter. In conclusion, we show that FXR is a physiological BA sensor that is likely to play an essential role in BA homeostasis through the regulation of genes involved in their enterohepatic circulation.	ENSBANA, EP 1777 CNRS, CESG, F-21000 Dijon, France; Niigata Univ, Sch Med, Dept Biochem, Niigata 951, Japan; Glaxo Wellcome Res & Dev Ltd, Dept Mol Endocrinol, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Res & Dev Ltd, Dept Med Chem, Res Triangle Pk, NC 27709 USA	Institut Agro; AgroSup Dijon; Universite de Bourgogne; Niigata University; GlaxoSmithKline; GlaxoSmithKline	Besnard, P (corresponding author), ENSBANA, EP 1777 CNRS, CESG, 1 Esplanade Erasme, F-21000 Dijon, France.		feinstein, doug/M-9414-2019					Aldini R, 1996, GASTROENTEROLOGY, V110, P459, DOI 10.1053/gast.1996.v110.pm8566593; Amelsberg A, 1996, GASTROENTEROLOGY, V110, P1098, DOI 10.1053/gast.1996.v110.pm8612999; Arrese M, 1998, HEPATOLOGY, V28, P1081, DOI 10.1002/hep.510280424; Bernlohr DA, 1997, ANNU REV NUTR, V17, P277, DOI 10.1146/annurev.nutr.17.1.277; BESNARD P, 1993, FEBS LETT, V327, P219, DOI 10.1016/0014-5793(93)80173-R; CHIANG JYL, 1994, J BIOL CHEM, V269, P17502; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coppola CP, 1998, GASTROENTEROLOGY, V115, P1172, DOI 10.1016/S0016-5085(98)70088-5; Craddock AL, 1998, AM J PHYSIOL-GASTR L, V274, pG157, DOI 10.1152/ajpgi.1998.274.1.G157; CROSSMAN MW, 1994, J CELL BIOL, V126, P1547, DOI 10.1083/jcb.126.6.1547; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; FUJII H, 1993, BIOCHEM BIOPH RES CO, V190, P175, DOI 10.1006/bbrc.1993.1027; FUJITA M, 1995, EUR J BIOCHEM, V233, P406, DOI 10.1111/j.1432-1033.1995.406_2.x; GORDON JI, 1983, J BIOL CHEM, V258, P3356; Kanda T, 1998, BIOCHEM J, V330, P261, DOI 10.1042/bj3300261; KRAMER W, 1993, J BIOL CHEM, V268, P18035; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Oelkers P, 1997, J CLIN INVEST, V99, P1880, DOI 10.1172/JCI119355; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4749; SHIAU YF, 1985, AM J PHYSIOL, V248, pG608, DOI 10.1152/ajpgi.1985.248.6.G608; Stengelin S, 1996, EUR J BIOCHEM, V239, P887, DOI 10.1111/j.1432-1033.1996.0887u.x; Thumser AEA, 1996, BIOCHEM J, V320, P729, DOI 10.1042/bj3200729; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; WONG MH, 1995, J BIOL CHEM, V270, P27228, DOI 10.1074/jbc.270.45.27228; Zavacki AM, 1997, P NATL ACAD SCI USA, V94, P7909, DOI 10.1073/pnas.94.15.7909	26	290	305	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29749	29754		10.1074/jbc.274.42.29749	http://dx.doi.org/10.1074/jbc.274.42.29749			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514450	hybrid			2022-12-27	WOS:000083176400029
J	Healy, AM; Peters-Golden, M; Yao, JP; Brock, TG				Healy, AM; Peters-Golden, M; Yao, JP; Brock, TG			Identification of a bipartite nuclear localization sequence necessary for nuclear import of 5-lipoxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; HUMAN ALVEOLAR MACROPHAGES; BASOPHILIC LEUKEMIA-CELLS; GREEN FLUORESCENT PROTEIN; HUMAN NEUTROPHILS; ACTIVATING PROTEIN; HUMAN-LEUKOCYTES; EXPRESSION; TRANSLOCATION; CLONING	5-Lipoxygenase catalyzes the synthesis of leukotrienes from arachidonic acid. This enzyme can reside either in the cytoplasm or the nucleus; its subcellular distribution is influenced by extracellular factors, and its nuclear import correlates with changes in leukotriene synthetic capacity. To identify sequences responsible for the nuclear import of B-lipoxygenase, we transfected NIH 3T3 cells and RAW 264.7 macrophages with expression vectors encoding various 5-lipoxygenase constructs fused to green fluorescent protein. Overexpression of wild type 5-lipoxygenase with or without fusion to green fluorescent protein resulted in a predominantly intranuclear pattern of fluorescence, similar to the distribution of native 5-lipoxygenase in primary alveolar macrophages. Within the 5-lipoxygenase protein is a sequence (Arg(638)-Lys(655)) that closely resembles a bipartite nuclear localization signal. Studies using deletion mutants indicated that this region was necessary for nuclear import of 5-lipoxygenase. Analysis of mutants containing specific amino acid substitutions within this sequence confirmed that it was this sequence that was necessary for nuclear import of 5-Lipoxygenase and that a specific arginine residue was critical for this function. As nuclear import of 5-lipoxygenase may regulate leukotriene production, natural or induced mutations in this bipartite nuclear localization sequence may also be important in affecting leukotriene synthesis.	Univ Michigan, Dept Internal Med, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Brock, TG (corresponding author), Univ Michigan, Dept Internal Med, Div Pulm & Crit Care Med, 6301 MSRB 3, Ann Arbor, MI 48109 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047391] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI043574] Funding Source: NIH RePORTER; NCI NIH HHS [CA695568] Funding Source: Medline; NHLBI NIH HHS [R01 HL47391] Funding Source: Medline; NIAID NIH HHS [R29 AI43574] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAMOVITZ M, 1993, EUR J BIOCHEM, V215, P105, DOI 10.1111/j.1432-1033.1993.tb18012.x; BALCAREK JM, 1988, J BIOL CHEM, V263, P13937; Bozza PT, 1997, J EXP MED, V186, P909, DOI 10.1084/jem.186.6.909; Brock TG, 1997, J BIOL CHEM, V272, P8276, DOI 10.1074/jbc.272.13.8276; BROCK TG, 1994, J BIOL CHEM, V269, P22059; Brock TG, 1996, J IMMUNOL, V156, P2522; Brock TG, 1999, J IMMUNOL, V162, P1669; BROCK TG, 1995, J BIOL CHEM, V270, P21652, DOI 10.1074/jbc.270.37.21652; CHEN XS, 1995, J BIOL CHEM, V270, P17993, DOI 10.1074/jbc.270.30.17993; Chen XS, 1998, J BIOL CHEM, V273, P31237, DOI 10.1074/jbc.273.47.31237; COFFEY MJ, 1994, AM J RESP CELL MOL, V11, P153, DOI 10.1165/ajrcmb.11.2.8049076; Covin RB, 1998, AM J PHYSIOL-LUNG C, V275, pL303, DOI 10.1152/ajplung.1998.275.2.L303; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DIXON RAF, 1988, P NATL ACAD SCI USA, V85, P416, DOI 10.1073/pnas.85.2.416; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; Drazen JM, 1998, AM J RESP CRIT CARE, V158, pS193, DOI 10.1164/ajrccm.158.supplement_2.13tac180; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; KAIN SR, 1995, BIOTECHNIQUES, V19, P650; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kitzler JW, 1996, PROSTAG LEUKOTR ESS, V55, P269, DOI 10.1016/S0952-3278(96)90008-3; LEPLEY RA, 1994, J BIOL CHEM, V269, P24163; Lepley RA, 1996, J BIOL CHEM, V271, P6179, DOI 10.1074/jbc.271.11.6179; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; NAKAMURA T, 1992, EMBO J, V11, P4917, DOI 10.1002/j.1460-2075.1992.tb05598.x; OCHI K, 1983, J BIOL CHEM, V258, P5754; PETERSEN MM, 1992, IMMUNOLOGY, V75, P275; PETERSGOLDEN M, 1993, BIOCHEM BIOPH RES CO, V196, P147, DOI 10.1006/bbrc.1993.2227; POULIOT M, 1994, J EXP MED, V179, P1225, DOI 10.1084/jem.179.4.1225; Provost P, 1999, P NATL ACAD SCI USA, V96, P1881, DOI 10.1073/pnas.96.5.1881; PUERINGER RJ, 1992, J APPL PHYSIOL, V73, P781, DOI 10.1152/jappl.1992.73.2.781; ROUZER CA, 1988, J BIOL CHEM, V263, P10980; Schlenstedt G, 1996, FEBS LETT, V389, P75, DOI 10.1016/0014-5793(96)00583-2; STANKOVA J, 1995, BLOOD, V85, P3719, DOI 10.1182/blood.V85.12.3719.bloodjournal85123719; STEINHILBER D, 1993, BIOCHIM BIOPHYS ACTA, V1178, P1, DOI 10.1016/0167-4889(93)90104-W; SUZUKI K, 1993, AM J RESP CELL MOL, V8, P500, DOI 10.1165/ajrcmb/8.5.500; WOODS JW, 1995, J CLIN INVEST, V95, P2035, DOI 10.1172/JCI117889; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935	38	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29812	29818		10.1074/jbc.274.42.29812	http://dx.doi.org/10.1074/jbc.274.42.29812			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514459	hybrid			2022-12-27	WOS:000083176400038
J	Amiri, F; Venema, VJ; Wang, XD; Ju, H; Venema, RC; Marrero, MB				Amiri, F; Venema, VJ; Wang, XD; Ju, H; Venema, RC; Marrero, MB			Hyperglycemia enhances angiotensin II-induced janus-activated kinase/STAT signaling in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATES TYROSINE PHOSPHORYLATION; AT(1) RECEPTOR; PROLIFERATION; PATHWAY; TRANSCRIPTION; GROWTH	We have shown previously that angiotensin II (Ang II) activates the janus-activated kinase (JAK)/signal transducers and activators of transcription (STAT) pathway in vascular smooth muscle cells (VSMCs) and that activation of the JAK/STAT pathway is required for Ang II induction of VSMC proliferation. In the present study, we examined the effects of hyperglycemia (HG) on Ang IT-induced JAK/STAT signaling events in cultured VSMCs. HG increases Ang II-induced JAK2 tyrosine phosphorylation and promotes a partial tyrosine phosphorylation of the enzyme under basal conditions. In addition, HG increases both basal. and Ang II-induced complex formation of JAK2 with the Ang II AT, receptor. The extent of STAT1 and STAT3 tyrosine and serine phosphorylation are also increased under HG conditions. Furthermore, the tyrosine phosphorylation and activities of the SHP-1 and SHP-2 tyrosine phosphatases, enzymes that regulate Ang II-induced JAK2 tyrosine phosphorylation, are altered by HG. SHP-1, which is responsible for JAK2 tyrosine dephosphorylation in VSMC, is completely deactivated in HG, resulting in a prolonged duration of JAK2 phosphorylation under HG conditions. HG also enhances Ang II induction of VSMC proliferation. Taken together, these data suggest that HG augments Ang II induction of VSMC proliferation by increasing signal transduction through the JAK/STAT pathway.	Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA; Med Coll Georgia, Dept Pediat, Augusta, GA 30912 USA; Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University	Marrero, MB (corresponding author), Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA.		Tehrani, Fahimeh Ramezani/H-6133-2017	Tehrani, Fahimeh Ramezani/0000-0002-4609-065X	NHLBI NIH HHS [HL62152, HL57201, HL58139] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057201, R29HL057201, R01HL062152, R01HL058139, R29HL058139] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ali MS, 1997, J BIOL CHEM, V272, P12373, DOI 10.1074/jbc.272.19.12373; Ali MS, 1997, J BIOL CHEM, V272, P23382, DOI 10.1074/jbc.272.37.23382; DAEMEN MJAP, 1991, CIRC RES, V68, P450, DOI 10.1161/01.RES.68.2.450; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; King GL, 1996, ENDOCRIN METAB CLIN, V25, P255, DOI 10.1016/S0889-8529(05)70324-8; Liang HY, 1999, J BIOL CHEM, V274, P19846, DOI 10.1074/jbc.274.28.19846; Marrero MB, 1998, AM J PHYSIOL-CELL PH, V275, pC1216, DOI 10.1152/ajpcell.1998.275.5.C1216; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; Marrero MB, 1997, J BIOL CHEM, V272, P24684, DOI 10.1074/jbc.272.39.24684; Natarajan R, 1999, HYPERTENSION, V33, P378, DOI 10.1161/01.HYP.33.1.378; NATARAJAN R, 1992, BIOCHEM BIOPH RES CO, V187, P552, DOI 10.1016/S0006-291X(05)81529-3; POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370; Schieffer B, 1997, AM J PHYSIOL-CELL PH, V272, pC2019, DOI 10.1152/ajpcell.1997.272.6.C2019; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SOWERS JR, 1995, HYPERTENSION, V26, P869, DOI 10.1161/01.HYP.26.6.869; Venema RC, 1998, J BIOL CHEM, V273, P30795, DOI 10.1074/jbc.273.46.30795; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; XIA P, 1994, DIABETES, V43, P1122, DOI 10.2337/diabetes.43.9.1122	19	73	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32382	32386		10.1074/jbc.274.45.32382	http://dx.doi.org/10.1074/jbc.274.45.32382			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542280	hybrid			2022-12-27	WOS:000083532100088
J	Dickeson, SK; Mathis, NL; Rahman, M; Bergelson, JM; Santoro, SA				Dickeson, SK; Mathis, NL; Rahman, M; Bergelson, JM; Santoro, SA			Determinants of ligand binding specificity of the alpha(1)beta(1) and alpha(2)beta(1) integrins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-DOMAIN; A-DOMAIN; COLLAGEN RECEPTOR; CRYSTAL-STRUCTURE; ECHOVIRUS-1 INTERACTION; DEPENDENT ADHESION; NEURITE OUTGROWTH; LAMININ RECEPTOR; ALPHA-2 SUBUNIT; CR3 CD11B/CD18	The alpha(1)beta(1) and alpha(2)beta(1) integrins are cell surface collagen receptors, Cells expressing the alpha(1)beta(1) integrin preferentially adhere to collagen TV, whereas cells expressing the alpha(2)beta(1) integrin preferentially adhere to collagen I. Recombinant a, and a, integrin I domains exhibit the same collagen type preferences as the intact integrins, Ttl addition, the alpha(2) integrin I domain binds echovirus 1; the a, I domain does not. To identify the structural components of the I domains responsible for the varying ligand specificities, we have engineered several alpha(1)/alpha(2) integrin I domain chimeras and evaluated their virus and collagen binding activities. Initially, large secondary structural components of the alpha(2) I domain were replaced with corresponding regions of the a, I domain. Following analysis in echovirus 1 and collagen binding assays, chimeras with successively smaller regions of alpha(1) I were constructed and analyzed. The chimeras were analyzed by ELISA with several different alpha(2) integrin monoclonal antibodies to assess their proper folding. Three different regions of the alpha(1) I domain, when present in the alpha(2) I domain, conferred enhanced collagen IV binding activity upon the alpha(2) I domain. These include the alpha 3 and alpha 5 helices and a portion of the as helix. Echovirus 1 binding was lost in a chimera containing the alpha C-alpha 6 loop; higher resolution mapping identified Asn(289) as playing a critical role in echovirus 1 binding. Asn289 had not been implicated in previous echovirus 1 binding studies. Taken together, these data reveal the existence of multiple determinants of ligand binding specificities within the alpha(1) and alpha(2) integrin I domains.	Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA	Washington University (WUSTL); University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Santoro, SA (corresponding author), Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA.		Rahman, Moazur/C-5515-2019	Rahman, Moazur/0000-0003-2892-1250	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040506, R01HL063446] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035667] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL40506, HL63446] Funding Source: Medline; NIAID NIH HHS [AI35667] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERGELSON JM, 1993, J VIROL, V67, P6847, DOI 10.1128/JVI.67.11.6847-6852.1993; BERGELSON JM, 1994, CELL ADHES COMMUN, V2, P455, DOI 10.3109/15419069409004455; BERGELSON JM, 1992, SCIENCE, V255, P1718, DOI 10.1126/science.1553561; BRIESEWITZ R, 1993, J BIOL CHEM, V268, P2989; Calderwood DA, 1997, J BIOL CHEM, V272, P12311, DOI 10.1074/jbc.272.19.12311; Dickeson SK, 1998, CELL MOL LIFE SCI, V54, P556, DOI 10.1007/s000180050184; Dickeson SK, 1998, BIOCHEMISTRY-US, V37, P11280, DOI 10.1021/bi9727848; Dickeson SK, 1997, J BIOL CHEM, V272, P7661, DOI 10.1074/jbc.272.12.7661; Dickeson SK, 1998, CELL ADHES COMMUN, V5, P273, DOI 10.3109/15419069809040297; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Filman DJ, 1998, ACTA CRYSTALLOGR D, V54, P1261, DOI 10.1107/S0907444998002790; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KERN A, 1993, EUR J BIOCHEM, V215, P151, DOI 10.1111/j.1432-1033.1993.tb18017.x; KERN A, 1994, J BIOL CHEM, V269, P22811; King SL, 1997, J BIOL CHEM, V272, P28518, DOI 10.1074/jbc.272.45.28518; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; RIEU P, 1994, J CELL BIOL, V127, P2081, DOI 10.1083/jcb.127.6.2081; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; SANTORO SA, 1995, THROMB HAEMOSTASIS, V74, P813; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TURNER DC, 1987, DEV BIOL, V121, P510, DOI 10.1016/0012-1606(87)90187-4; TURNER DC, 1989, J NEUROSCI, V9, P3287	30	71	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32182	32191		10.1074/jbc.274.45.32182	http://dx.doi.org/10.1074/jbc.274.45.32182			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542255	hybrid			2022-12-27	WOS:000083532100063
J	Soriano, S; Chyung, ASC; Chen, XH; Stokin, GB; Lee, VMY; Koo, EH				Soriano, S; Chyung, ASC; Chen, XH; Stokin, GB; Lee, VMY; Koo, EH			Expression of beta-amyloid precursor protein-CD3 gamma chimeras to demonstrate the selective generation of amyloid beta(1-40) and amyloid beta(1-42) peptides within secretory and endocytic compartments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; PROTEIN-PRECURSOR; NT2N CELLS; PATHWAY; TRAFFICKING; PROTEASOME; CLEAVAGE; DEGRADATION; DERIVATIVES; MECHANISMS	Amyloid beta-protein (A beta) is the main constituent of amyloid fibrils found in senile plaques and cerebral vessels in Alzheimer's disease (AD) and is derived by proteolysis from the beta-amyloid precursor protein (APP), We have analyzed the amyloidogenic processing of APP using chimeric proteins stably transfected in Chinese hamster ovary cells. The extracellular and transmembrane domains of APP were fused to the cytoplasmic region derived from the CD3 gamma chain of the T cell antigen receptor (CD3 gamma), CD3 gamma contains an endoplasmic reticulum (ER) retention motif (RKK), in the absence of which the protein is targeted to lysosomes without going through the cell surface (Letourneur, F., and Klausner, R.D. (1992) Cell 69, 1143-1157). We used the wild-type sequence of CD3 gamma to create an APP chimera predicted to remain in the ER (gamma APP(ER)). Deletion of the RKK motif at the C terminus directed the protein directly to the lysosomes (gamma APP(LYS)). A third chimera was created by removing both lysosomal targeting signals in addition to RKK (gamma APP(Delta Delta)), This last construct does not contain known targeting signals and consequently accumulates at the cell surface. We show by immunofluorescence and by biochemical methods that all three APP chimeras localize to the predicted compartments within the cell, thus providing a useful model to study the processing of APP. We found that A beta(1-40) is generated in the early secretory and endocytic pathways, whereas A beta(1-42) is made mainly in the secretory pathway, More importantly, we provide evidence that, unlike in neuronal models, both ER/intermediate compartment- and endocytic-derived A beta forms can enter the secretable pool. Finally, we directly demonstrate that lysosomal processing is not involved in the generation or secretion of either A beta(1-40) or A beta(1-42).	Univ Calif San Diego, Dept Neurosci 0691, La Jolla, CA 92093 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of California System; University of California San Diego; University of Pennsylvania	Koo, EH (corresponding author), Univ Calif San Diego, Dept Neurosci 0691, 9500 Gilman Dr, La Jolla, CA 92093 USA.	edkoo@ucsd.edu	Stokin, Gorazd Bernard/D-9480-2015	Stokin, Gorazd Bernard/0000-0001-8430-8755	NIA NIH HHS [AG12376] Funding Source: Medline; NINDS NIH HHS [NS01812] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K04NS001812] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012376] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Borg JP, 1998, J BIOL CHEM, V273, P14761, DOI 10.1074/jbc.273.24.14761; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; CAPORASO GL, 1994, J NEUROSCI, V14, P3122; Cataldo AM, 1997, J NEUROSCI, V17, P6142; Chyung ASC, 1997, J CELL BIOL, V138, P671, DOI 10.1083/jcb.138.3.671; COLE GM, 1992, ANN NY ACAD SCI, V674, P103; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Klafki HW, 1996, J BIOL CHEM, V271, P28655, DOI 10.1074/jbc.271.45.28655; Koo EH, 1996, J CELL SCI, V109, P991; KOO EH, 1994, J BIOL CHEM, V269, P17386; KUENTZEL SL, 1993, BIOCHEM J, V15, P367; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; MarquezSterling NR, 1997, J NEUROSCI, V17, P140, DOI 10.1523/JNEUROSCI.17-01-00140.1997; Ono Y, 1997, J BIOCHEM-TOKYO, V121, P585; Peraus GC, 1997, J NEUROSCI, V17, P7714; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; REFOLO LM, 1995, J NEUROSCI RES, V40, P694, DOI 10.1002/jnr.490400515; Sabo SL, 1999, J BIOL CHEM, V274, P7952, DOI 10.1074/jbc.274.12.7952; SchraderFischer G, 1997, J NEUROCHEM, V68, P1571; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; Skovronsky DM, 1998, J CELL BIOL, V141, P1031, DOI 10.1083/jcb.141.4.1031; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Tienari PJ, 1997, P NATL ACAD SCI USA, V94, P4125, DOI 10.1073/pnas.94.8.4125; Turner RS, 1996, J BIOL CHEM, V271, P8966, DOI 10.1074/jbc.271.15.8966; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Yang AJ, 1998, J NEUROSCI RES, V52, P691, DOI 10.1002/(SICI)1097-4547(19980615)52:6<691::AID-JNR8>3.0.CO;2-3	38	77	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32295	32300		10.1074/jbc.274.45.32295	http://dx.doi.org/10.1074/jbc.274.45.32295			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542269	hybrid			2022-12-27	WOS:000083532100077
J	Weng, BY; Thompson, WC; Kim, HJ; Levine, RL; Moss, J				Weng, BY; Thompson, WC; Kim, HJ; Levine, RL; Moss, J			Modification of the ADP-ribosyltransferase and NAD glycohydrolase activities of a mammalian transferase (ADP-ribosyltransferase 5) by auto-ADP-ribosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINAMIDE ADENINE-DINUCLEOTIDE; LYMPHOCYTE ALLOANTIGEN RT6.1; SKELETAL-MUSCLE CELLS; CYTOTOXIC T-CELLS; MOLECULAR CHARACTERIZATION; BACTERIAL TOXINS; NITRIC-OXIDE; EXPRESSION; SURFACE; PROTEIN	Mono-ADP-ribosylation, a post-translational modification in which the ADP-ribose moiety of NAD is transferred to an acceptor protein, is catalyzed by a family of amino acid-specific ADP-ribosyltransferases. ADP-ribosyltransferase 5 (ARTS), a murine transferase originally isolated from Yac-1 lymphoma cells, differed in properties from previously identified eukaryotic transferases in that it exhibited significant NAD glycohydrolase (NADase) activity. To investigate the mechanism of regulation of transferase and NADase activities, ARTS was synthesized as a FLAG fusion protein in Escherichia coli, Agmatine was used as the ADP-ribose acceptor to quantify transferase activity. ARTS was found to be primarily an NADase at 10 mu M NAD, whereas at higher NAD concentrations (1 mM), after some delay, transferase activity increased, whereas NADase activity fell. This change in catalytic activity was correlated with auto-ADP-ribosylation and occurred in a time- and NAD concentration-dependent manner. Based on the change in mobility of auto-ADP-ribosylated ARTS by SDS-poly acrylamide gel electrophoresis, the modification appeared to be stoichiometric and resulted in the addition of at least two ADP-ribose moieties, Auto-ADP-ribosylated ARTE isolated after incubation with NAD was primarily a transferase. These findings suggest that auto-ADP-ribosylation of ARTS was stoichiometric, resulted in at least two modifications and converted ARTS from an NADase to a transferase, and could be one mechanism for regulating enzyme activity.	NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA; NHLBI, Biochem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Weng, BY (corresponding author), NHLBI, Pulm Crit Care Med Branch, NIH, Bldg 10,10 Ctr Dr,MSC 1434,Rm 5N307, Bethesda, MD 20892 USA.		Levine, Rodney L/D-9885-2011		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000622] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		APFFEL A, 1995, J CHROMATOGR A, V712, P177, DOI 10.1016/0021-9673(95)00175-M; COLLIER RJ, 1990, ADP RIBOSYLATING TOX, P3, DOI DOI 10.1126/SCIENCE.250.4982.841-A; DAVIS T, 1995, GENE, V164, P371, DOI 10.1016/0378-1119(95)00504-Y; Donnelly LE, 1996, BIOCHEM J, V315, P635, DOI 10.1042/bj3150635; Han MK, 1996, BIOCHEM J, V318, P903, DOI 10.1042/bj3180903; Hara N, 1996, J BIOL CHEM, V271, P29552, DOI 10.1074/jbc.271.47.29552; KHARADIA SV, 1992, EXP CELL RES, V201, P33, DOI 10.1016/0014-4827(92)90345-9; KIM UH, 1993, ARCH BIOCHEM BIOPHYS, V305, P147, DOI 10.1006/abbi.1993.1404; KochNolte F, 1996, J BIOL CHEM, V271, P7686, DOI 10.1074/jbc.271.13.7686; LIEBERMAN I, 1957, J BIOL CHEM, V225, P883; Maehama T, 1996, FEBS LETT, V388, P189, DOI 10.1016/0014-5793(96)00568-6; MAEHAMA T, 1995, J BIOL CHEM, V270, P22747, DOI 10.1074/jbc.270.39.22747; MCDONALD LJ, 1993, P NATL ACAD SCI USA, V90, P6238, DOI 10.1073/pnas.90.13.6238; MOSS J, 1980, J BIOL CHEM, V255, P5838; MOSS J, 1988, ADV ENZYMOL RAMB, V61, P303; Moss J, 1997, J BIOL CHEM, V272, P4342, DOI 10.1074/jbc.272.7.4342; Nemoto E, 1996, J IMMUNOL, V156, P85; OHNO T, 1995, ANAL BIOCHEM, V231, P115, DOI 10.1006/abio.1995.1510; Okamoto S, 1998, J IMMUNOL, V160, P4190; Okazaki IJ, 1996, J BIOL CHEM, V271, P22052, DOI 10.1074/jbc.271.36.22052; Okazaki IJ, 1996, BLOOD, V88, P915; Okazaki IJ, 1998, J BIOL CHEM, V273, P23617, DOI 10.1074/jbc.273.37.23617; OKAZAKI IJ, 1994, BIOCHEMISTRY-US, V33, P12828, DOI 10.1021/bi00209a014; PEKALA PH, 1980, MOL CELL BIOCHEM, V31, P49, DOI 10.1007/BF00817890; PROCHAZKA M, 1991, IMMUNOGENETICS, V33, P152, DOI 10.1007/BF00210829; Rigby MR, 1996, J IMMUNOL, V156, P4259; SCHUMAN EM, 1994, P NATL ACAD SCI USA, V91, P11958, DOI 10.1073/pnas.91.25.11958; SOMAN G, 1991, BIOCHEM BIOPH RES CO, V176, P301, DOI 10.1016/0006-291X(91)90924-V; TAKADA T, 1994, J BIOL CHEM, V269, P9420; TSUCHIYA M, 1994, J BIOL CHEM, V269, P27451; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73; UI M, 1990, ADP RIBOSYLATING TOX, P45; Wang J, 1996, J IMMUNOL, V156, P2819; WANG J, 1994, J IMMUNOL, V153, P4048; Williamson K., 1990, ADP RIBOSYLATING TOX, P493; Yu YJ, 1997, DNA CELL BIOL, V16, P235, DOI 10.1089/dna.1997.16.235; ZOLKIEWSKA A, 1993, J BIOL CHEM, V268, P25273; ZOLKIEWSKA A, 1994, MOL CELL BIOCHEM, V138, P107, DOI 10.1007/BF00928450; ZOLKIEWSKA A, 1992, P NATL ACAD SCI USA, V89, P11352, DOI 10.1073/pnas.89.23.11352	39	27	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31797	31803		10.1074/jbc.274.45.31797	http://dx.doi.org/10.1074/jbc.274.45.31797			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542202	hybrid			2022-12-27	WOS:000083532100010
J	Roig, J; Traugh, JA				Roig, J; Traugh, JA			p21-activated protein kinase gamma-PAK is activated by ionizing radiation and other DNA-damaging agents - Similarities and differences to alpha-PAK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS OOCYTES; TYROSINE KINASE; CELL-CYCLE; STRESS; CDC42; CLEAVAGE; FAMILY; ACTIN; 1-BETA-D-ARABINOFURANOSYLCYTOSINE; AUTOPHOSPHORYLATION	The p21-activated protein kinase gamma-PAK is activated 2-5-fold in response to ionizing radiation (IR) in 3T3-L1 fibroblasts and U937 leukemia cells. gamma-PAK is activated in a dose- and time-dependent manner. Doses from 1 to 100 Gy result in significant stimulation of activity at 30 min, whereas maximal stimulation is observed at 120 min after irradiation. UV (80 J/m(2)) and the DNA-damaging drugs cytosine beta-D-arabinofuranoside (AraC) and cis-platinum(II)diammine dichloride (cisplatin) also induce gamma-PAK activation. The activation of gamma-PAK in response to IR or AraC is dependent on tyrosine kinase and phosphoinositide 3-kinase activity, as demonstrated by use of the inhibitors genistein and wortmannin; in contrast activation of gamma-PAK by cisplatin and UV is not affected significantly by these inhibitors, suggesting that gamma-PAK can be activated by more than one pathway in response to different types of DNA damage. In contrast to gamma-PAK, alpha-PAK and JNK are activated only by cisplatin and UV in 3T3-L1 cells, suggesting differential regulation of the protein kinases. This is the first time that members of the Ste20/PAK family of protein kinases have been shown to be involved in the cellular response to IR and other DNA-damaging agents.	Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA	University of California System; University of California Riverside	Traugh, JA (corresponding author), Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA.	jolinda.traugh@ucr.edu	Roig, Joan/E-2836-2017	Roig, Joan/0000-0002-3872-4712	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026738] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26738] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BERNHARD EJ, 1995, RADIAT ENVIRON BIOPH, V34, P79, DOI 10.1007/BF01275210; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dharmawardhane S, 1997, J CELL BIOL, V138, P1265, DOI 10.1083/jcb.138.6.1265; Faure S, 1999, J BIOL CHEM, V274, P3573, DOI 10.1074/jbc.274.6.3573; Faure S, 1997, EMBO J, V16, P5550, DOI 10.1093/emboj/16.18.5550; Gatti A, 1999, J BIOL CHEM, V274, P8022, DOI 10.1074/jbc.274.12.8022; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Huang ZD, 1999, FASEB J, V13, pA1578; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; KHARBANDA S, 1994, J BIOL CHEM, V269, P20739; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; KUFE DW, 1984, MOL PHARMACOL, V26, P128; Lee N, 1997, P NATL ACAD SCI USA, V94, P13642, DOI 10.1073/pnas.94.25.13642; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; Rhind N, 1998, CURR OPIN CELL BIOL, V10, P749, DOI 10.1016/S0955-0674(98)80118-X; Roig J, 1999, FASEB J, V13, pA1579; Rooney RD, 1996, J BIOL CHEM, V271, P21498, DOI 10.1074/jbc.271.35.21498; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; SHERMAN SE, 1987, CHEM REV, V87, P1153, DOI 10.1021/cr00081a013; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tsakiridis T, 1996, J BIOL CHEM, V271, P19664, DOI 10.1074/jbc.271.33.19664; Tuazon PT, 1999, FASEB J, V13, pA1490; Tuazon PT, 1998, BIOCHEMISTRY-US, V37, P17024, DOI 10.1021/bi982103o; Turchi JJ, 1997, BIOCHEMISTRY-US, V36, P7586, DOI 10.1021/bi963124q; Walter BN, 1998, J BIOL CHEM, V273, P28733, DOI 10.1074/jbc.273.44.28733; Wang JYJ, 1998, CURR OPIN CELL BIOL, V10, P240, DOI 10.1016/S0955-0674(98)80146-4; Woloschak GE, 1997, STRESS-INDUCIBLE PROCESSES IN HIGHER EUKARYOTIC CELLS, P185; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153; Zhou KM, 1998, J BIOL CHEM, V273, P16782, DOI 10.1074/jbc.273.27.16782	38	51	52	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31119	31122		10.1074/jbc.274.44.31119	http://dx.doi.org/10.1074/jbc.274.44.31119			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531298	hybrid			2022-12-27	WOS:000083379400002
J	Milla, ME; Leesnitzer, MA; Moss, ML; Clay, WC; Carter, HL; Miller, AB; Su, JL; Lambert, MH; Willard, DH; Sheeley, DM; Kost, TA; Burkhart, W; Moyer, M; Blackburn, RK; Pahel, GL; Mitchell, JL; Hoffmann, R; Becherer, JD				Milla, ME; Leesnitzer, MA; Moss, ML; Clay, WC; Carter, HL; Miller, AB; Su, JL; Lambert, MH; Willard, DH; Sheeley, DM; Kost, TA; Burkhart, W; Moyer, M; Blackburn, RK; Pahel, GL; Mitchell, JL; Hoffmann, R; Becherer, JD			Specific sequence elements are required for the expression of functional tumor necrosis factor-alpha-converting enzyme (TACE)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; CATALYTIC DOMAIN; CYTOPLASMIC DOMAIN; CYSTEINE SWITCH; METALLOPROTEINASE; PRECURSOR; CLEAVAGE; FURIN; STROMELYSIN-1; LOCALIZATION	The tumor necrosis factor-alpha-converting enzyme (TACE) is a membrane-anchored zinc metalloprotease involved in precursor tumor necrosis factor-alpha secretion. We designed a series of constructs containing full-length human TACE and several truncate forms for overexpression in insect cells. Here, we demonstrate that full-length TACE is expressed in insect cells inefficiently: only minor amounts of this enzyme are converted from an inactive precursor to the mature, functional form. Removal of the cytoplasmic and transmembrane domains resulted in the efficient secretion of mature, active TACE. Further removal of the cysteine-rich domain located between the catalytic and transmembrane domains resulted in the secretion of mature catalytic domain in association with the precursor (pro) domain. This complex was inactive and function was only restored after dissociation of the complex by dilution or treatment with 4-aminophenylmercuric acetate. Therefore, the pro domain of TACE is an inhibitor of the catalytic domain, and the cysteine-rich domain appears to play a role in the release of the pro domain. Insect cells failed to secrete a deletion mutant encoding the catalytic domain but lacking the inhibitory pro domain. This truncate was inactive and extensively degraded intracellularly, suggesting that the pro domain is required for the secretion of functional TACE.	Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Johnson Res Fdn, Philadelphia, PA 19104 USA; Glaxo Wellcome Res & Dev Ltd, Div Biochem, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Res & Dev Ltd, Div Chem, Res Triangle Pk, NC 27709 USA	University of Pennsylvania; University of Pennsylvania; GlaxoSmithKline; GlaxoSmithKline	Milla, ME (corresponding author), Univ Penn, Sch Med, Dept Biochem & Biophys, 3620 Hamilton Walk, Philadelphia, PA 19104 USA.	mmilla@mail.med.upenn.edu						BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; BECKER JW, 1995, PROTEIN SCI, V4, P1966, DOI 10.1002/pro.5560041002; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; BRAVO DA, 1994, J BIOL CHEM, V269, P25830; Clarke HRG, 1998, PROTEIN EXPRES PURIF, V13, P104, DOI 10.1006/prep.1998.0861; Cohn E., 1943, PROTEINS AMINO ACIDS, P157; DURCHSCHLAG H, 1986, THERMODYNAMIC DATA B, P45; FENOUILLET E, 1995, J GEN VIROL, V76, P1509, DOI 10.1099/0022-1317-76-6-1509; Galazka G, 1996, BIOCHEMISTRY-US, V35, P11221, DOI 10.1021/bi960618e; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; GRAMS F, 1993, FEBS LETT, V335, P76, DOI 10.1016/0014-5793(93)80443-X; LAUE TM, 1992, ANAL ULTRACENTRIFUGA, P102; Maskos K, 1998, P NATL ACAD SCI USA, V95, P3408, DOI 10.1073/pnas.95.7.3408; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Moss ML, 1999, PROG INFLAM RES, P187; OLD LJ, 1985, SCIENCE, V230, P630, DOI 10.1126/science.2413547; PRADINESFIGUERES A, 1992, J BIOL CHEM, V267, P23261; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; TAKAHASHI S, 1995, J BIOL CHEM, V270, P28397; Tang P, 1996, BIOCHEMISTRY-US, V35, P8226, DOI 10.1021/bi952183l; Tang P, 1996, BIOCHEMISTRY-US, V35, P8216, DOI 10.1021/bi952182t; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; Wang L, 1998, BIOCHEMISTRY-US, V37, P3165, DOI 10.1021/bi972741r; Wetmore DR, 1996, BIOCHEMISTRY-US, V35, P6549, DOI 10.1021/bi9530752; YAMSHCHIKOV GV, 1995, VIROLOGY, V214, P50, DOI 10.1006/viro.1995.9955	32	139	147	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30563	30570		10.1074/jbc.274.43.30563	http://dx.doi.org/10.1074/jbc.274.43.30563			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521439	hybrid			2022-12-27	WOS:000083276700035
J	Thomas, RL; Matsko, CM; Lotze, MT; Amoscato, AA				Thomas, RL; Matsko, CM; Lotze, MT; Amoscato, AA			Mass spectrometric identification of increased C16 ceramide levels during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; CELL-FREE SYSTEM; SPHINGOMYELIN CYCLE; FACTOR-ALPHA; GENE-EXPRESSION; DIFFERENTIATION; ACTIVATION; GENERATION; PATHWAY; CD95	A variety of molecular changes occur during the process of apoptosis. Much of the recent work has focused on changes in critical cellular proteins, proteins necessary for the initiation and continuation of the apoptotic process. Given the fact that numerous membrane changes occur throughout the apoptotic process, we initiated an investigation aimed at determining the major lipid changes that occurred during programmed cell death. When ionizing radiation was used to initiate the apoptotic process in Jurkat cells, one of the major changes that occurred within 24 h was an increase in a species with a m/z of 572 as determined by negative ion electrospray mass spectrometry, This particular mass ion displayed high performance liquid chromatography characteristics of a neutral lipid species. Further analysis by collision-induced-dissociation tandem mass spectrometry indicated only one daughter species indicative of a Cl adduct and therefore a parental mass of 537. Comparison to a commercial C16 ceramide yielded identical spectra by mass spectrometry (MS) and MS/MS analysis in the negative ion mode. Increases in C16 ceramide levels occurred 2 h after initiation of apoptosis by ionizing radiation, and its accumulation paralleled apoptosis as determined by cellular morphology. Interestingly, radiation-sensitive Jurkat cells displayed increased levels of long term C16 ceramide accumulation, whereas radiation-resistant R562 cells did not. These findings were supported by increases in caspase-3 activity in Jurkat cells, whereas caspase-3 activity in K562 cells remained unchanged. C16 ceramide accumulation and sensitivity to ionizing radiation was investigated further in a melanoma cell line. Only those cells that were radiation sensitive (approximately 70-75%) displayed increases in long term ceramide accumulation, Taken together, these results indicated a correlation between increases in C16 ceramide accumulation and radiation sensitivity. Increases in long term C16 ceramide accumulation were also seen in Fas-induced apoptosis, which occurred at time points greater than 2 h. Analysis of mitochondrial modifications using the mitochondrial probe nonyl acridine orange (NAO) indicated that initial increases in C16 ceramide levels closely paralleled the decrease in mitochondrial mass during Fas or radiation-induced apoptosis, Taken together, these results support a role for C16 ceramide in the effector (mitochondrial) phase of apoptosis.	Univ Pittsburgh, Ctr Biotechnol & Bioengn, Mass Spectrometry Facil, Pittsburgh, PA 15219 USA; Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Amoscato, AA (corresponding author), Univ Pittsburgh, Ctr Biotechnol & Bioengn, Mass Spectrometry Facil, Pittsburgh, PA 15219 USA.			Amoscato, Andrew/0000-0002-1340-9150	NCI NIH HHS [1PO1CA73743] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA073743] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRIEU N, 1994, BIOCHEM J, V303, P341, DOI 10.1042/bj3030341; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; CHEN JQ, 1995, J BIOL CHEM, V270, P25233, DOI 10.1074/jbc.270.42.25233; Chmura SJ, 1997, CANCER RES, V57, P1270; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DOBROWSKY RT, 1995, J BIOL CHEM, V270, P22135, DOI 10.1074/jbc.270.38.22135; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Gu M, 1997, ANAL BIOCHEM, V244, P347, DOI 10.1006/abio.1996.9915; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; LEPRAT P, 1990, EXP CELL RES, V186, P130, DOI 10.1016/0014-4827(90)90219-Z; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; Ritov VB, 1996, BBA-BIOMEMBRANES, V1283, P127, DOI 10.1016/0005-2736(96)00083-1; Saba JD, 1996, PHILOS T ROY SOC B, V351, P233, DOI 10.1098/rstb.1996.0021; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; SPENCE MW, 1993, ADV LIPID RES; Tepper AD, 1997, J BIOL CHEM, V272, P24308, DOI 10.1074/jbc.272.39.24308; Watts JD, 1997, P NATL ACAD SCI USA, V94, P7292, DOI 10.1073/pnas.94.14.7292; YANAGA F, 1994, BIOCHEM J, V298, P733, DOI 10.1042/bj2980733; Zhang P, 1997, J BIOL CHEM, V272, P9609	35	126	129	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30580	30588		10.1074/jbc.274.43.30580	http://dx.doi.org/10.1074/jbc.274.43.30580			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521441	hybrid			2022-12-27	WOS:000083276700037
J	Vyas, DR; McCarthy, JJ; Tsika, RW				Vyas, DR; McCarthy, JJ; Tsika, RW			Nuclear protein binding at the beta-myosin heavy chain A/T-rich element is enriched following increased skeletal muscle activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE ELEMENT; ZINC-FINGER PROTEIN; TRANSCRIPTION FACTOR; GENE-EXPRESSION; CARDIAC-MUSCLE; IN-VIVO; MEF2 BINDING; E-BOX; ENHANCER; PROMOTER	In adult mouse skeletal muscle, beta-myosin heavy chain (beta MyHC) gene expression is primarily restricted to slow-type I fibers but can be induced in fast-type II fibers by mechanical overload (MOV). Our previous transgenic analyses have delimited an 89-base pair (bp) MOV-responsive region (-293 to -205), and shown that mutation of the MCAT and C-rich elements within this region did not abolish beta MyHC transgene induction by MOV. In this study we describe an AIT-rich element (beta A/T-rich; -269 5'-GGAGATATTTTT-3'-258) located within this 89-bp region that, only under MOV conditions, revealed enriched binding as characterized by electrophoretic mobility shift assays and dimethyl sulfate and diethyl pyrocarbonate interference footprinting, Direct, competition, and supershift electrophoretic mobility shift assays revealed highly enriched specific binding activity at the beta A/T-rich element that was antigenically distinct from GATA-4, MEF2A-D, SRF, and Oct-1, nuclear proteins that were previously shown to bind A/T-rich elements. In vitro translated GATA-4, MEF2C, SRF, and Oct-1 bound to consensus GATA, MEF2, SRE, and Oct-1 elements, respectively, but not to the beta A/T-rich element. Two-dimensional UV cross-linking of the bromodeoxyuridine-substituted beta A/T-rich element with mechanically overloaded plantaris (MOV-P) nuclear extract detected two proteins (44 and 48 kDa). Our results indicate that the beta A/T-rich element may function in vivo as a beta MyHC MOV-inducible element during hypertrophy of adult skeletal muscle by binding two distinct proteins identified only in MOV-P nuclear extract.	Univ Missouri, Dept Vet Biomed Sci, Sch Vet Med, Columbia, MO 65211 USA; Univ Missouri, Sch Med, Dept Biochem, Columbia, MO 65211 USA; Univ Missouri, Dalton Cardiovasc Res Ctr, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Tsika, RW (corresponding author), Univ Missouri, Dept Vet Biomed Sci, Sch Vet Med, 1600 E Rollins Ave,W112 Vet Med Bldg, Columbia, MO 65211 USA.	tsikar@missouri.edu			NIAMS NIH HHS [R01 AR41464] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041464] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AcakpoSatchivi LJR, 1997, J CELL BIOL, V139, P1219, DOI 10.1083/jcb.139.5.1219; ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; ATTAR RM, 1992, MOL CELL BIOL, V12, P2432, DOI 10.1128/MCB.12.5.2432; BARANY M, 1967, J GEN PHYSIOL, V50, P197, DOI 10.1085/jgp.50.6.197; BASSELDUBY R, 1992, MOL CELL BIOL, V12, P5024, DOI 10.1128/MCB.12.11.5024; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Bonnefoy E, 1999, MOL CELL BIOL, V19, P2803; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG KC, 1993, J CELL SCI, V106, P331; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Di Lisi R, 1998, J BIOL CHEM, V273, P25371, DOI 10.1074/jbc.273.39.25371; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; Evans T, 1997, TRENDS CARDIOVAS MED, V7, P75, DOI 10.1016/S1050-1738(97)00010-8; Ferrari S, 1997, CELL GROWTH DIFFER, V8, P23; Fickett JW, 1996, MOL CELL BIOL, V16, P437; GASTAIGER M, 1995, NATURE, V373, P360; GRAYSON J, 1995, MOL CELL BIOL, V15, P1870; Hasegawa K, 1997, CIRCULATION, V96, P3943; HAUSCHKA SD, 1994, MYOLOGY, P3; Herzig TC, 1997, P NATL ACAD SCI USA, V94, P7543, DOI 10.1073/pnas.94.14.7543; Inamoto S, 1997, J BIOL CHEM, V272, P29852, DOI 10.1074/jbc.272.47.29852; IP HS, 1994, MOL CELL BIOL, V14, P7517, DOI 10.1128/MCB.14.11.7517; Lakich MM, 1998, J BIOL CHEM, V273, P15217, DOI 10.1074/jbc.273.24.15217; Larkin SB, 1996, MOL CELL BIOL, V16, P3742; LI H, 1994, EMBO J, V13, P3580, DOI 10.1002/j.1460-2075.1994.tb06665.x; LIEW CC, 1990, NUCLEIC ACIDS RES, V18, P3647, DOI 10.1093/nar/18.12.3647; LIU ML, 1994, J BIOL CHEM, V269, P28514; Lu JR, 1999, MOL CELL BIOL, V19, P4495; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; McCarthy JJ, 1999, J BIOL CHEM, V274, P14270, DOI 10.1074/jbc.274.20.14270; McCarthy JJ, 1997, AM J PHYSIOL-REG I, V272, pR1552, DOI 10.1152/ajpregu.1997.272.5.R1552; McGrew MJ, 1996, MOL CELL BIOL, V16, P4524; Molkentin JD, 1996, MOL CELL BIOL, V16, P3814; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947, DOI 10.1128/MCB.14.7.4947; Montgomery MO, 1997, GENE, V187, P159, DOI 10.1016/S0378-1119(96)00738-X; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; Morrisey EE, 1997, DEV BIOL, V183, P21, DOI 10.1006/dbio.1996.8485; NAVANKASATTUSAS S, 1992, MOL CELL BIOL, V12, P1469, DOI 10.1128/MCB.12.4.1469; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PARMACEK MS, 1994, MOL CELL BIOL, V14, P1870, DOI 10.1128/MCB.14.3.1870; PARMACEK MS, 1999, HEART DEV, P291; REISER PJ, 1985, J BIOL CHEM, V260, P9077; RINDT H, 1993, J BIOL CHEM, V268, P5332; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; Salminen M, 1996, MOL CELL BIOL, V16, P76; Sartorius CA, 1998, J CELL BIOL, V141, P943, DOI 10.1083/jcb.141.4.943; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; STURM R, 1987, GENE DEV, V1, P1147, DOI 10.1101/gad.1.10.1147; Svensson EC, 1999, P NATL ACAD SCI USA, V96, P956, DOI 10.1073/pnas.96.3.956; Tevosian SG, 1999, P NATL ACAD SCI USA, V96, P950, DOI 10.1073/pnas.96.3.950; THUERAUF DJ, 1994, J BIOL CHEM, V269, P17772; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Tsika GL, 1996, AM J PHYSIOL-CELL PH, V271, pC690, DOI 10.1152/ajpcell.1996.271.2.C690; VANDELOISE C, 1995, FRANCAIS MODERN, V63, P85; VANDENBURGH HH, 1993, J CELL PHYSIOL, V155, P63, DOI 10.1002/jcp.1041550109; WANG RX, 1994, J MOL CELL CARDIOL, V26, P1155, DOI 10.1006/jmcc.1994.1134; Weiss A, 1996, ANNU REV CELL DEV BI, V12, P417, DOI 10.1146/annurev.cellbio.12.1.417; Weiss A, 1999, P NATL ACAD SCI USA, V96, P2958, DOI 10.1073/pnas.96.6.2958; Yu YT, 1996, J BIOL CHEM, V271, P24675	60	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30832	30842		10.1074/jbc.274.43.30832	http://dx.doi.org/10.1074/jbc.274.43.30832			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521475	hybrid			2022-12-27	WOS:000083276700071
J	Croce, R; Weiss, S; Bassi, R				Croce, R; Weiss, S; Bassi, R			Carotenoid-binding sites of the major light-harvesting complex II of higher plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYSTEM-II; ENERGY-TRANSFER; CHLOROPHYLL-A; ANTENNA COMPLEX; SPECTRAL FORMS; IN-VITRO; PROTEIN; RECONSTITUTION; ABSORPTION; SUBUNIT	Recombinant light-harvesting complex II (LHCII) proteins with modified carotenoid composition have been obtained by in vitro reconstitution of the Lhcb1, protein overexpressed in bacteria. The monomeric protein possesses three xanthophyll-binding sites. The L1 and L2 sites, localized by electron crystallography in the helix A/helix B cross, have the highest affinity for lutein, but also bind violaxanthin and zeaxanthin with lower affinity. The latter xanthophyll causes disruption of excitation energy transfer. The occupancy of at Yeast one of these sites, probably L1, is essential for protein folding. Neoxanthin is bound to a distinct site (N1) that iis highly selective for this species and whose occupancy is not essential for protein folding. Whereas xanthophylls in the L1 and L2 sites interact mainly with chlorophyll a, neoxanthin shows strong interaction with chlorophyll b, inducing the hyperchromic effect of the 652 nm absorption band. This observation explains the recent results of energy transfer from carotenoids to chlorophyll b obtained by femtosecond absorption spectroscopy. Whereas xanthophylls in the L1 and L2 sites are active in photoprotection through chlorophyll-triplet quenching, neoxanthin seems to act mainly in O-1*(2) scavenging.	Univ Verona, Fac Sci Matemat Fisiche Nat Biotecnol Vegetali, Dipartimento Sci & Technol, I-37134 Verona, Italy	University of Verona	Croce, R (corresponding author), Univ Verona, Fac Sci Matemat Fisiche Nat Biotecnol Vegetali, Dipartimento Sci & Technol, Strada Grazie, I-37134 Verona, Italy.	croce@mpi-muelheim.mpg.de	Croce, Roberta/F-1174-2014; Croce, Roberta/N-4067-2014; Croce, Roberta/HGU-9554-2022; Croce, Roberta/ABG-3595-2021	Croce, Roberta/0000-0003-3469-834X; Croce, Roberta/0000-0003-3469-834X; Croce, Roberta/0000-0003-3469-834X; bassi, roberto/0000-0002-4140-8446				ANDERSSON PO, 1991, PHOTOCHEM PHOTOBIOL, V54, P353, DOI 10.1111/j.1751-1097.1991.tb02027.x; BASSI R, 1993, EUR J BIOCHEM, V212, P297, DOI 10.1111/j.1432-1033.1993.tb17662.x; BASSI R, 1991, J PHOTOCHEM PHOTOBIO, V6, P381; BASSI R, 1999, IN PRESS P NATL ACAD; BUJARD H, 1987, METHOD ENZYMOL, V155, P416; Carbonera D., 1992, REND LINCEI-SCI FIS, V3, P361; Connelly JP, 1997, BIOCHEMISTRY-US, V36, P281, DOI 10.1021/bi962467l; CRIMI M, 1999, IN PRESS BIOCHEMISTR; Croce R, 1996, BIOCHEMISTRY-US, V35, P11142, DOI 10.1021/bi960652t; Croce R, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P421; DAINESE P, 1990, PHOTOCHEM PHOTOBIOL, V51, P693, DOI 10.1111/php.1990.51.6.693; DAINESE P, 1991, J BIOL CHEM, V266, P8136; Desamero RZB, 1998, J PHYS CHEM B, V102, P8151, DOI 10.1021/jp980911j; DUNSMUIR P, 1985, NUCLEIC ACIDS RES, V13, P2503, DOI 10.1093/nar/13.7.2503; EADS DD, 1989, J PHYS CHEM-US, V93, P8271, DOI 10.1021/j100363a001; FRANK HA, 1994, PHOTOSYNTH RES, V41, P389, DOI 10.1007/BF02183041; GILMORE AM, 1991, J CHROMATOGR, V543, P137, DOI 10.1016/S0021-9673(01)95762-0; Giuffra E, 1997, BIOCHEMISTRY-US, V36, P12984, DOI 10.1021/bi9711339; Giuffra E, 1996, EUR J BIOCHEM, V238, P112, DOI 10.1111/j.1432-1033.1996.0112q.x; GREEN BR, 1991, TRENDS BIOCHEM SCI, V16, P181, DOI 10.1016/0968-0004(91)90072-4; Hirs C. H. W., 1967, METHOD ENZYMOL, V11, P325; HOBE S, 1994, EMBO J, V13, P3423, DOI 10.1002/j.1460-2075.1994.tb06647.x; HUDSON BS, 1972, CHEM PHYS LETT, V14, P299, DOI 10.1016/0009-2614(72)80119-2; IDE JP, 1987, BIOCHIM BIOPHYS ACTA, V893, P349, DOI 10.1016/0005-2728(87)90056-9; JENNINGS RC, 1993, BIOCHEMISTRY-US, V32, P3203, DOI 10.1021/bi00064a002; Koyama Y, 1996, PHOTOCHEM PHOTOBIOL, V63, P243, DOI 10.1111/j.1751-1097.1996.tb03021.x; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; MATSUOKA M, 1987, NUCLEIC ACIDS RES, V15, P6302, DOI 10.1093/nar/15.15.6302; NUSSBERGER S, 1993, J MOL BIOL, V234, P347, DOI 10.1006/jmbi.1993.1591; Pagano A, 1998, J BIOL CHEM, V273, P17154, DOI 10.1074/jbc.273.27.17154; PAULSEN H, 1990, PLANTA, V181, P204, DOI 10.1007/BF02411539; Peterman EJG, 1997, BIOCHEMISTRY-US, V36, P12208, DOI 10.1021/bi9711689; Peterman EJG, 1995, BIOPHYS J, V69, P2670, DOI 10.1016/S0006-3495(95)80138-4; Pichersky E., 1996, OXYGENIC PHOTOSYNTHE, P507; PLUMLEY FG, 1987, P NATL ACAD SCI USA, V84, P146, DOI 10.1073/pnas.84.1.146; Pogson BJ, 1998, P NATL ACAD SCI USA, V95, P13324, DOI 10.1073/pnas.95.22.13324; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; REMELLI R, 1999, IN PRESS J BIOL CHEM, V274; Ros F, 1998, EUR J BIOCHEM, V253, P653, DOI 10.1046/j.1432-1327.1998.2530653.x; Ruban AV, 1997, BIOCHEMISTRY-US, V36, P7855, DOI 10.1021/bi9630725; Sandona D, 1998, BBA-BIOENERGETICS, V1365, P207, DOI 10.1016/S0005-2728(98)00068-1; van der Vos R, 1991, APPL MAGN RESON, V2, P179, DOI 10.1007/BF03166035; VANDERVOS R, 1994, BBA-BIOENERGETICS, V1188, P243, DOI 10.1016/0005-2728(94)90042-6; Verhoeven AS, 1999, PLANT PHYSIOL, V120, P727, DOI 10.1104/pp.120.3.727	44	209	217	0	46	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29613	29623		10.1074/jbc.274.42.29613	http://dx.doi.org/10.1074/jbc.274.42.29613			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514429	hybrid			2022-12-27	WOS:000083176400008
J	Ikebe, R; Reardon, S; Mitsui, T; Ikebe, M				Ikebe, R; Reardon, S; Mitsui, T; Ikebe, M			Role of the N-terminal region of the regulatory light chain in the dephosphorylation of myosin by myosin light chain phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; PHOSPHORYLATION-DEPENDENT REGULATION; PROTEIN KINASE-C; PURIFICATION; SITES; IDENTIFICATION; CONFORMATION; PROTEOLYSIS; MEROMYOSIN; SEQUENCE	Myosin regulatory light chain (RLC) is phosphorylated at various sites at its N-terminal region, and heterotrimeric myosin light chain phosphatase (MLCP) has phosphorylates myosin in vivo. Specificity of MLCP toward the various phosphorylation sites of RLC was studied, as well as the role of the N-terminal region of RLC in the dephosphorylation of myosin by MLCP. MLCP dephosphorylated phosphoserine 19, phosphothreonine 18, and phosphothreonine 9 efficiently with almost identical rates, whereas it failed to dephosphorylate phosphorylated serine 1/serine 2. Deletion of the N-terminal seven amino acid residues of RLC markedly decreased the dephosphorylation rate of phosphoserine 19 of RLC incorporated in the myosin molecule, whereas this deletion did not significantly affect the dephosphorylation rate of isolated RLC. On the other hand, deletion of only four N-terminal amino acid residues showed no effect on dephosphorylation of phosphoserine 19 of incorporated RLC, The inhibition of dephosphorylation by deletion of the seven N-terminal residues was also found with the catalytic subunit of MLCP. Phosphorylation at serine 1/serine 2 and threonine 9 did not influence the dephosphorylation rate of serine 19 and threonine 18 by MLCP. These results suggest that the N-terminal region of RLC plays an important role in substrate recognition of MLCP.	Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Ikebe, M (corresponding author), Univ Massachusetts, Sch Med, Dept Physiol, 55 Lake Ave N, Worcester, MA 01655 USA.		Mitsui, Toshiaki/N-9773-2017	Mitsui, Toshiaki/0000-0002-9165-8830	NHLBI NIH HHS [HL41776, HL61426, HL60381] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041776, R01HL061426] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLESSI D, 1992, EUR J BIOCHEM, V210, P1023; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; BENGUR AR, 1987, J BIOL CHEM, V262, P7613; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; GONG MC, 1992, J BIOL CHEM, V267, P21492; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, V1, P423; IKEBE M, 1987, J BIOL CHEM, V262, P9569; IKEBE M, 1994, J BIOL CHEM, V269, P28165; IKEBE M, 1982, J BIOCHEM-TOKYO, V91, P1809, DOI 10.1093/oxfordjournals.jbchem.a133874; IKEBE M, 1988, J BIOL CHEM, V263, P10698; IKEBE M, 1985, J BIOL CHEM, V260, P3146; IKEBE M, 1991, J BIOL CHEM, V266, P21339; Ikebe M, 1998, J BIOL CHEM, V273, P17702, DOI 10.1074/jbc.273.28.17702; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; IKEBE M, 1987, J BIOL CHEM, V262, P13828; IKEBE M, 1986, J BIOL CHEM, V261, P36; IKEBE M, 1985, J BIOL CHEM, V260, P27; KAMISOYAMA H, 1993, BIOCHEMISTRY-US, V30, P9539; KAMM KE, 1989, ANNU REV PHYSIOL, V51, P299; KAWAMOTO S, 1989, J BIOL CHEM, V264, P2258; Mayer-Jaekel Regina E., 1994, Trends in Cell Biology, V4, P287, DOI 10.1016/0962-8924(94)90219-4; MITSUI T, 1992, J BIOL CHEM, V267, P16727; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; PATO MD, 1985, J BIOL CHEM, V260, P2359; PATO MD, 1983, J BIOL CHEM, V258, P7047; PERSECHINI A, 1981, SCIENCE, V213, P1383, DOI 10.1126/science.6455737; PERSECHINI A, 1984, BIOCHEMISTRY-US, V23, P4144, DOI 10.1021/bi00313a021; SATTERWHITE LL, 1992, J CELL BIOL, V118, P595, DOI 10.1083/jcb.118.3.595; Sellers JR, 1991, CURR OPIN CELL BIOL, V3, P98, DOI 10.1016/0955-0674(91)90171-T; SELLERS JR, 1983, J BIOL CHEM, V258, P4181; Sellers JR, 1987, ENZYMES, V18, ppp381, DOI 10.1016/S1874-6047(08)60264-4; SHIMIZU H, 1994, J BIOL CHEM, V269, P30407; SHIRAZI A, 1994, J BIOL CHEM, V269, P31598; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; TRYBUS KM, 1994, J CELL BIOL, V124, P963, DOI 10.1083/jcb.124.6.963; TULLOCH AG, 1991, J BIOL CHEM, V266, P20168; WALSH MP, 1983, METHOD ENZYMOL, V99, P279	38	16	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30122	30126		10.1074/jbc.274.42.30122	http://dx.doi.org/10.1074/jbc.274.42.30122			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514500	hybrid			2022-12-27	WOS:000083176400079
J	Kroll, SL; Paulding, WR; Schnell, PO; Barton, MC; Conaway, JW; Conaway, RC; Czyzyk-Krzeska, MF				Kroll, SL; Paulding, WR; Schnell, PO; Barton, MC; Conaway, JW; Conaway, RC; Czyzyk-Krzeska, MF			von Hippel-Lindau protein induces hypoxia-regulated arrest of tyrosine hydroxylase transcript elongation in pheochromocytoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TUMOR-SUPPRESSOR PROTEIN; FACTOR MESSENGER-RNA; GENE-PRODUCT; TERMINATION SITES; DNA-SEQUENCE; FACTOR-SIII; ELONGIN-C; DISEASE; IDENTIFICATION	Rat pheochromocytoma (PC12) cells were stably transfected with either wild type or mutated human von Hippel-Lindau tumor suppressor protein (hpVHL). These proteins have opposing effects on regulating expression of the gene encoding tyrosine hydroxylase (TH), the rate-limiting enzyme in catecholamine synthesis. Whereas wild type hpVHL represses levels of TH mRNA and protein 5-fold, a truncated pVHL mutant, pVHL(1-115), induces accumulation of TH mRNA and protein 3-fold. hpVHL-induced inhibition of TH gene expression does not involve either a decrease in TH mRNA stability or repression of TH promoter activity. However, repression results from inhibition of RNA elongation at a downstream region of the TH gene. This elongation pause is accompanied by hpVHL sequestration in the nuclear extracts of elongins B and C, regulatory components of the transcription elongation heterotrimer SIII (elongin A/B/C). Hypoxia, a physiological stimulus for TH gene expression, alleviates the elongation block. A truncated pVHL mutant, pVHL(1-115), stimulates TH gene expression by increasing the efficiency of TH transcript elongation. This is the first report showing pVHL-dependent regulation of specific transcript elongation in vivo, as well as dominant negative activity of pVHL mutants in pheochromocytoma cells.	Univ Cincinnati, Coll Med, Dept Mol & Cellular Physiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Mol Genet, Cincinnati, OH 45267 USA; Oklahoma Med Res Fdn, Program Mol & Cell Biol, Oklahoma City, OK 73104 USA; Howard Hughes Med Inst, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Oklahoma Medical Research Foundation; Howard Hughes Medical Institute; University of Oklahoma System; University of Oklahoma Health Sciences Center	Czyzyk-Krzeska, MF (corresponding author), Univ Cincinnati, Coll Med, Dept Mol & Cellular Physiol, POB 670576, Cincinnati, OH 45267 USA.	Maria.Czyzykkrzeska@uc.edu		Barton, Michelle/0000-0002-4042-1374; Conaway, Joan/0000-0002-2786-0663	NHLBI NIH HHS [HL51078, HL58687, T32 HL07571] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007571, R29HL051078, R01HL058687] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; Atuk NO, 1998, J CLIN ENDOCR METAB, V83, P117, DOI 10.1210/jc.83.1.117; BAEK KH, 1986, P NATL ACAD SCI USA, V83, P7623, DOI 10.1073/pnas.83.20.7623; Blakenship C, 1999, ONCOGENE, V18, P1529; Bouloux PMG, 1995, CLIN ENDOCRINOL, V43, P657, DOI 10.1111/j.1365-2265.1995.tb00531.x; BRADSHER JN, 1993, J BIOL CHEM, V268, P25594; BRADSHER JN, 1993, J BIOL CHEM, V268, P25587; CROSSEY PA, 1995, J MED GENET, V32, P885, DOI 10.1136/jmg.32.11.885; CZYZYKKRZESKA MF, 1994, J BIOL CHEM, V269, P760; CZYZYKKRZESKA MF, 1992, J NEUROCHEM, V58, P1538, DOI 10.1111/j.1471-4159.1992.tb11376.x; DEDRICK RL, 1987, J BIOL CHEM, V262, P9098; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; DUAN DR, 1995, P NATL ACAD SCI USA, V92, P6459, DOI 10.1073/pnas.92.14.6459; Eng C, 1996, NEW ENGL J MED, V335, P943, DOI 10.1056/NEJM199609263351307; FELDMAN JM, 1979, J CLIN ENDOCR METAB, V49, P445, DOI 10.1210/jcem-49-3-445; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Iliopoulos O, 1998, P NATL ACAD SCI USA, V95, P11661, DOI 10.1073/pnas.95.20.11661; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Isobe K, 1998, EUR J ENDOCRINOL, V138, P383, DOI 10.1530/eje.0.1380383; Ivanov SV, 1998, P NATL ACAD SCI USA, V95, P12596, DOI 10.1073/pnas.95.21.12596; Kenady Daniel E., 1997, Current Opinion in Oncology, V9, P61; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Maher ER, 1997, MEDICINE, V76, P381, DOI 10.1097/00005792-199711000-00001; Maher ER, 1996, J MED GENET, V33, P328, DOI 10.1136/jmg.33.4.328; Moreland RJ, 1998, J BIOL CHEM, V273, P26610, DOI 10.1074/jbc.273.41.26610; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; Paulding WR, 1999, J BIOL CHEM, V274, P2532, DOI 10.1074/jbc.274.4.2532; REINES D, 1987, J MOL BIOL, V196, P299, DOI 10.1016/0022-2836(87)90691-7; Richards FM, 1998, J INTERN MED, V243, P527; SATO K, 1986, MOL CELL BIOL, V6, P1032, DOI 10.1128/MCB.6.4.1032; Schoenfeld A, 1998, P NATL ACAD SCI USA, V95, P8817, DOI 10.1073/pnas.95.15.8817; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Takagi Y, 1997, J BIOL CHEM, V272, P27444, DOI 10.1074/jbc.272.43.27444	38	41	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30109	30114		10.1074/jbc.274.42.30109	http://dx.doi.org/10.1074/jbc.274.42.30109			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514498	hybrid			2022-12-27	WOS:000083176400077
J	Nalca, A; Qiu, SGF; El-Guendy, N; Krishnan, S; Rangnekar, VM				Nalca, A; Qiu, SGF; El-Guendy, N; Krishnan, S; Rangnekar, VM			Oncogenic Ras sensitizes cells to apoptosis by Par-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ZIPPER PROTEIN PAR-4; MAMMALIAN-CELL; KINASE-C; ACTIVATION; EXPRESSION; RESISTANCE; SIGNAL; PHOSPHORYLATION; TRANSFORMATION	Certain mutations in the mammalian ras gene are oncogenic and are often detected in human cancers. Oncogenic Bas induces the transcription activity of NF-KB that confers cell survival. Oncogenic Ras also down-modulates the expression of Par-4, a transcriptional repressor protein, that is essential but not sufficient on its own to induce apoptosis, Were we show that reintroduction of Par-4 by transient transfection leads to apoptosis in cells expressing oncogenic Ras but not in those that lack oncogenic Ras expression. Par-4 abrogates oncogenic Ras-inducible NF-KB transcription activity but does not interfere with cytoplasmic activation, or the DNA binding activity, of NF-KB. Because abrogation of NF-KB transcription activity is sufficient to cause apoptosis in cells expressing oncogenic Was, our findings identify Par-4 as a novel example of a pro-apoptotic protein that selectively inhibits oncogenic Ras-dependent NF-kappa B function at the transcription level and suggest a mechanism by which Par-4 expression may selectively induce apoptosis in oncogenic Ras-expressing cells.	Univ Kentucky, Dept Surg, Div Urol, Lexington, KY 40536 USA; Univ Kentucky, Dept Microbiol & Immunol, Lexington, KY 40536 USA; Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA; Univ Kentucky, Markey Canc Ctr, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky	Rangnekar, VM (corresponding author), Univ Kentucky, Dept Surg, Div Urol, Combs Res Bldg,Rm 303,800 Rose St, Lexington, KY 40536 USA.		Nalca, Aysegul/L-8149-2019	Nalca, Aysegul/0000-0001-8581-7535; El-Guendy, Nadia/0000-0002-0770-3740	NATIONAL CANCER INSTITUTE [R01CA060872] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA60872] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; Boghaert ER, 1997, CELL GROWTH DIFFER, V8, P881; BOS JL, 1989, CANCER RES, V49, P4682; Cook J, 1999, ONCOGENE, V18, P1205, DOI 10.1038/sj.onc.1202416; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; FILMUS J, 1992, ONCOGENE, V7, P521; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; GALANG CK, 1994, ONCOGENE, V9, P2913; Guo Q, 1998, NAT MED, V4, P957, DOI 10.1038/nm0898-957; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; ISONISHI S, 1991, CANCER RES, V51, P5903; Johnstone RW, 1996, MOL CELL BIOL, V16, P6945; JOSHIBARVE SS, 1993, J BIOL CHEM, V268, P18018; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Meier P, 1998, CELL, V95, P295, DOI 10.1016/S0092-8674(00)81760-2; NOOTER K, 1995, BRIT J CANCER, V71, P556, DOI 10.1038/bjc.1995.109; PARK M, 1998, ONCOGENES, P205; Qiu GF, 1999, ONCOGENE, V18, P623, DOI 10.1038/sj.onc.1202344; Rangnekar VM, 1998, APOPTOSIS, V3, P61, DOI 10.1023/A:1009666705875; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; Sells SF, 1997, MOL CELL BIOL, V17, P3823, DOI 10.1128/MCB.17.7.3823; SELLS SF, 1994, CELL GROWTH DIFFER, V5, P457; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; TAMANOI F, 1988, BIOCHIM BIOPHYS ACTA, V948, P1, DOI 10.1016/0304-419X(88)90002-9; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3	40	83	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29976	29983		10.1074/jbc.274.42.29976	http://dx.doi.org/10.1074/jbc.274.42.29976			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514481	hybrid			2022-12-27	WOS:000083176400060
J	Petrotchenko, EV; Doerflein, ME; Kakuta, Y; Pedersen, LC; Negishi, M				Petrotchenko, EV; Doerflein, ME; Kakuta, Y; Pedersen, LC; Negishi, M			Substrate gating confers steroid specificity to estrogen sulfotransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATASE ACTIVITY; MOLECULAR-BIOLOGY; CRYSTAL-STRUCTURE; SULFURYL TRANSFER; MECHANISM	Estrogen sulfotransferase (EST) exhibits a high substrate specificity and catalytic efficiency toward estro; gens such as estradiol (E2) but insignificant ability to sulfate hydroxysteroids such as dehydroepiandrosterone (DHEA). To provide the structural basis for this estrogen specificity, we mutated amino acid residues that constitute the substrate-binding site of EST. Among these mutants, only Tyr-81 decreased E2 and increased DHEA sulfotransferase activities. Substitution for Tyr-81 by smaller hydrophobic residues increased K-m(E2) for E2 activity, whereas the K-cat(E2) remained relatively constant. The Y81L mutant exhibited the same DHEA activity as wild-type hydroxysteroid sulfotransferase, for which K-m(DHEA) remained relatively constant, and k(cat(DHEA)) was markedly increased. The side chain of Tyr-81 is directed at the A-ring of the E2 molecule in the substrate-binding pocket of EST, constituting a steric gate with Phe-142 sandwiching E2 from the opposite side. The present mutagenesis study indicates that the 3b-hydroxyl group of the DHEA molecule is excluded from the catalytic site of EST through steric hindrance of Tyr-81 with the C-19 methyl group of DHEA. Thus, this stricture-like gating caused by steric hindrance appears to be a structural principle for conferring estrogen specificity to EST.	NIEHS, Pharmacogenet Sect, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Negishi, M (corresponding author), NIEHS, Pharmacogenet Sect, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA.		Pedersen, Lars/C-6173-2019; Negishi, Masahiko/F-7805-2019	Pedersen, Lars/0000-0002-4488-4077; Negishi, Masahiko/0000-0002-2076-8928				Ahmed S, 1999, BIOCHEM BIOPH RES CO, V254, P811, DOI 10.1006/bbrc.1998.9934; Brix LA, 1999, BIOCHEM J, V337, P337, DOI 10.1042/0264-6021:3370337; Dajani R, 1998, MOL PHARMACOL, V54, P942, DOI 10.1124/mol.54.6.942; DUFFEL MW, 1981, J BIOL CHEM, V256, P1123; EVANS TRJ, 1994, BRIT J CANCER, V69, P555, DOI 10.1038/bjc.1994.101; GrahamLorence S, 1997, J BIOL CHEM, V272, P1127, DOI 10.1074/jbc.272.2.1127; HOBKIRK R, 1993, TRENDS ENDOCRIN MET, V4, P69, DOI 10.1016/S1043-2760(05)80018-9; Kakuta Y, 1999, J BIOL CHEM, V274, P10673, DOI 10.1074/jbc.274.16.10673; Kakuta Y, 1998, TRENDS BIOCHEM SCI, V23, P129, DOI 10.1016/S0968-0004(98)01182-7; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; Kakuta Y, 1998, J BIOL CHEM, V273, P27325, DOI 10.1074/jbc.273.42.27325; Kakuta Y, 1998, BIOCHEM PHARMACOL, V55, P313, DOI 10.1016/S0006-2952(97)00465-6; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LINDBERG R, 1989, NATURE, V338, P632; Negishi M, 1996, FASEB J, V10, P683, DOI 10.1096/fasebj.10.7.8635685; Selcer KW, 1996, J STEROID BIOCHEM, V59, P83, DOI 10.1016/S0960-0760(96)00089-1; SLOANE DL, 1991, NATURE, V354, P149, DOI 10.1038/354149a0; SONG WC, 1995, ENDOCRINOLOGY, V136, P2477, DOI 10.1210/en.136.6.2477; Sueyoshi T, 1998, FEBS LETT, V433, P211, DOI 10.1016/S0014-5793(98)00913-2; Utsumi T, 1999, CANCER RES, V59, P377; Varin L, 1997, FASEB J, V11, P517, DOI 10.1096/fasebj.11.7.9212075; Weinshilboum RM, 1997, FASEB J, V11, P3, DOI 10.1096/fasebj.11.1.9034160; Wyckoff TJO, 1998, J BIOL CHEM, V273, P32369, DOI 10.1074/jbc.273.49.32369; Zhang HP, 1998, J BIOL CHEM, V273, P10888, DOI 10.1074/jbc.273.18.10888	24	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30019	30022		10.1074/jbc.274.42.30019	http://dx.doi.org/10.1074/jbc.274.42.30019			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514486	hybrid			2022-12-27	WOS:000083176400065
J	Uddin, S; Majchrzak, B; Woodson, J; Arunkumar, P; Alsayed, Y; Pine, R; Young, PR; Fish, EN; Platanias, LC				Uddin, S; Majchrzak, B; Woodson, J; Arunkumar, P; Alsayed, Y; Pine, R; Young, PR; Fish, EN; Platanias, LC			Activation of the p38 mitogen-activated protein kinase by type I interferons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATES TYROSINE PHOSPHORYLATION; VAV PROTOONCOGENE PRODUCT; MAP KINASE; GENE-EXPRESSION; HEMATOPOIETIC-CELLS; ALPHA; PATHWAYS; INTERLEUKIN-1; APOPTOSIS; DISTINCT	The p38 mitogen-activated protein (Map) kinase plays a critical role in the generation of signals in response to stress stimuli, but its role in interferon (IFN) signaling and its potential regulatory role in the activation of Jak-signal transducer and activator of transcription (Stat) pathway are not known. In the present study, we provide evidence that the p38 Map kinase is rapidly phosphorylated and activated during treatment of cells with Type I interferons (IFN alpha and IFN beta). Furthermore, the Type I IFN-dependent activation of p38 regulates induction of the catalytic domains of MapKap kinase-2 and MapKap kinase-3, strongly suggesting the existence of an IFN alpha signaling cascade activated downstream of the p38 kinase. The engagement of this pathway in interferon signaling plays a critical role in interferon-dependent transcriptional regulation, as evidenced by the fact that inhibition of p38 activation results in abrogation of interferon-dependent gene transcription via interferon-stimulated response elements. Interestingly, inhibition of the kinase activity of the p38 blocks IFN alpha-induced gene transcription without inhibiting DNA binding or tyrosine phosphorylation of Stat proteins, suggesting that the p38 pathway acts in cooperation with the Stat pathway. Thus, the p38 kinase signaling cascade is activated by the Type I interferon receptor and plays a critical role in interferon signaling and interferon-dependent transcriptional regulation.	Univ Illinois, Dept Mol Biol, Div Cardiovasc Dis, Hematol Oncol Sect, Chicago, IL 60607 USA; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 3E2, Canada; Publ Hlth Res Inst, New York, NY 10016 USA; SmithKline Beecham Pharmaceut, Dept Mol Biol, King Of Prussia, PA 19406 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Toronto; GlaxoSmithKline	Platanias, LC (corresponding author), Univ Illinois, Dept Mol Biol, Div Cardiovasc Dis, Hematol Oncol Sect, MBRB,MC-734,Rm 3150,900 S Ashland Ave, Chicago, IL 60607 USA.			Uddin, Shahab/0000-0003-1886-6710	NATIONAL CANCER INSTITUTE [R29CA073381, R01CA077816] Funding Source: NIH RePORTER; NCI NIH HHS [CA77816, CA73381] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad S, 1997, J BIOL CHEM, V272, P29991, DOI 10.1074/jbc.272.48.29991; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Fish EN, 1999, J BIOL CHEM, V274, P571, DOI 10.1074/jbc.274.2.571; Foltz IN, 1997, J BIOL CHEM, V272, P3296, DOI 10.1074/jbc.272.6.3296; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Ghislain JJ, 1996, J BIOL CHEM, V271, P12408, DOI 10.1074/jbc.271.21.12408; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; KRUMER JL, 1997, J BIOL CHEM, V272, P20490; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; Miyazawa K, 1998, J BIOL CHEM, V273, P24832, DOI 10.1074/jbc.273.38.24832; Platanias LC, 1996, J BIOL CHEM, V271, P278, DOI 10.1074/jbc.271.1.278; PLATANIAS LC, 1994, J BIOL CHEM, V269, P3143; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Schafer C, 1998, J BIOL CHEM, V273, P24173, DOI 10.1074/jbc.273.37.24173; Shapiro L, 1995, P NATL ACAD SCI USA, V92, P12230, DOI 10.1073/pnas.92.26.12230; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Uddin S, 1997, J IMMUNOL, V158, P2390; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; Uddin S, 1997, BLOOD, V90, P2574; Uddin S, 1997, FEBS LETT, V403, P31, DOI 10.1016/S0014-5793(97)00023-9; WEN Z, 1995, CELL, V28, P241; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963; Zhu XJ, 1997, MOL CELL BIOL, V17, P6618, DOI 10.1128/MCB.17.11.6618	34	197	205	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30127	30131		10.1074/jbc.274.42.30127	http://dx.doi.org/10.1074/jbc.274.42.30127			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514501	hybrid			2022-12-27	WOS:000083176400080
J	van Geest, M; Lolkema, JS				van Geest, M; Lolkema, JS			Transmembrane segment (TMS) VIII of the Na+/citrate transporter CitS requires downstream TMS IX for insertion in the Escherichia coli membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; IN-VITRO TRANSLATION; DEPENDENT CITRATE CARRIER; ENDOPLASMIC-RETICULUM; PROTEIN TRANSLOCATION; KLEBSIELLA-PNEUMONIAE; TOPOLOGY; PURIFICATION; BIOGENESIS; SEQUENCES	The amino acid sequence of the sodium ion-dependent citrate transporter CitS of IL pneumoniae contains 12 hydrophobic stretches that could form membrane-spanning segments. A previous analysis of the membrane topology in Escherichia coli using the PhoA gene fusion technique indicated that only nine of these hydrophobic segments span the membrane, while three segments, Vb, VIII and IX were predicted to have a periplasmic location (Van Geest, IM., and Lolkema, J. S. (1996) J. Biol. Chem. 271, 25582-25589), A topology study of C-terminally truncated CitS molecules in dog pancreas microsomes revealed that the protein traverses the endoplasmic reticulum membrane 11 times. In agreement with the PhoA fusion data, segment Vb was predicted to have a periplasmic location, but, in contrast, segments VIII and IX were found to be membrane-spanning (Van Geest, M., Nilsson, I., von Heijne, G., and Lolkema, J, S, (1999) J. Biol, Chem. 274, 2816-2823), In the present study, using site-directed Cys labeling, the topology of segments VIII and IX in the fall-length CitS protein was determined in the E. coli membrane, Engineered cysteine residues in the loop between the two segments were accessible to a membrane-impermeable thiol reagent exclusively from the cytoplasmic side of the membrane, demonstrating that transmembrane segments (TMSs) VIII and M are both membrane-spanning. It follows that the folding of CitS in the E. cold and endoplasmic reticulum membrane is the same. Cysteine accessibility studies of CitS-PhoA fusion molecules dem; onstrated that in the E. coli membrane segment VIII is exported to the periplasm in the absence of the C-terminal CitS sequences, thus explaining why the PhoA fusions do not correctly predict the topology. An engineered cysteine residue downstream of TMS VIII moved from a periplasmic to a cytoplasmic location when the fusion protein containing TMSs I-VIII was extended with segment IX, Thus, downstream segment M is both essential and sufficient for the insertion of segment VIII of CitS in the E. coli membrane.	Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands	University of Groningen	Lolkema, JS (corresponding author), Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, Kerklaan 30, NL-9751 NN Haren, Netherlands.							ANDERSSON H, 1993, J BIOL CHEM, V268, P21389; BAMBERG K, 1994, J BIOL CHEM, V269, P16909; BAYLE D, 1995, J BIOL CHEM, V270, P25678, DOI 10.1074/jbc.270.43.25678; Bayle D, 1997, J BIOL CHEM, V272, P19697, DOI 10.1074/jbc.272.32.19697; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; BOYD D, 1993, J BACTERIOL, V175, P553, DOI 10.1128/JB.175.2.553-556.1993; de Gier JWL, 1998, P NATL ACAD SCI USA, V95, P14646, DOI 10.1073/pnas.95.25.14646; DRIESSEN AJM, 1996, HDB BIOL PHYS, V2, P759; Duong F, 1997, CELL, V91, P567, DOI 10.1016/S0092-8674(00)80444-4; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; Gaillard I, 1996, BIOCHEMISTRY-US, V35, P6150, DOI 10.1021/bi953005v; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; Liao SR, 1997, CELL, V90, P31, DOI 10.1016/S0092-8674(00)80311-6; Lu Y, 1998, J BIOL CHEM, V273, P568, DOI 10.1074/jbc.273.1.568; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; Matos M, 1996, J BIOL CHEM, V271, P18571, DOI 10.1074/jbc.271.31.18571; Mothes W, 1997, CELL, V89, P523, DOI 10.1016/S0092-8674(00)80234-2; Ota K, 1998, J BIOL CHEM, V273, P28286, DOI 10.1074/jbc.273.43.28286; POS KM, 1994, FEBS LETT, V347, P37, DOI 10.1016/0014-5793(94)00502-8; Sambrook J., 2002, MOL CLONING LAB MANU; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Seluanov A, 1997, J BIOL CHEM, V272, P2053; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; Valent QA, 1998, EMBO J, V17, P2504, DOI 10.1093/emboj/17.9.2504; van Geest M, 1999, J BIOL CHEM, V274, P2816, DOI 10.1074/jbc.274.5.2816; VANDERREST ME, 1992, J BIOL CHEM, V267, P8971; vanGeest M, 1996, J BIOL CHEM, V271, P25582, DOI 10.1074/jbc.271.41.25582	27	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29705	29711		10.1074/jbc.274.42.29705	http://dx.doi.org/10.1074/jbc.274.42.29705			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514443	Green Published, hybrid			2022-12-27	WOS:000083176400022
J	Wu, C; Ghosh, S				Wu, C; Ghosh, S			beta-TrCP mediates the signal-induced ubiquitination of I kappa B beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE COMPLEX; ACTIVATION; ALPHA; DEGRADATION; IDENTIFICATION; COMPONENT; PROTEIN; PATHWAY	We have examined the role of beta-TrCP (beta-transducin repeat-containing protein) in the ubiquitination and degradation of I kappa B beta, one of the two major I kappa B isoforms in mammalian cells. We demonstrate that beta-TrCP interacts specifically with I kappa B beta, and such interaction is dependent on prior phosphorylation of I kappa B beta on serines 19 and 23. Interaction with beta-TrCP is also necessary for ubiquitination of I kappa B beta upon stimulation of cells, and deletion of the F-box in beta-TrCP abolishes its ability to ubiquitinate I kappa B beta. Therefore, these results indicate that beta-TrCP plays a critical role in the activation of NF-kappa B by assembling the ubiquitin ligase complex for both phosphorylated I kappa B alpha and I kappa B beta.	Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; Yale University	Ghosh, S (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06520 USA.			Ghosh, Sankar/0000-0002-3227-0588	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033443] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI33443] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Kroll M, 1999, J BIOL CHEM, V274, P7941, DOI 10.1074/jbc.274.12.7941; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Marikawa Y, 1998, MECH DEVELOP, V77, P75, DOI 10.1016/S0925-4773(98)00134-8; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Suzuki H, 1999, BIOCHEM BIOPH RES CO, V256, P127, DOI 10.1006/bbrc.1999.0289; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; Weil R, 1997, J BIOL CHEM, V272, P9942; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159	24	52	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29591	29594		10.1074/jbc.274.42.29591	http://dx.doi.org/10.1074/jbc.274.42.29591			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514424	hybrid			2022-12-27	WOS:000083176400003
J	Grietzen, KF; Virshup, DM				Grietzen, KF; Virshup, DM			Identification of inhibitory autophosphorylation sites in casein kinase I epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							40 DNA-REPLICATION; SCHIZOSACCHAROMYCES-POMBE; SUBSTRATE DETERMINANTS; PROTEIN-KINASES; PHOSPHORYLATION; EXPRESSION; CYCLE; DELTA; GENE; ISOFORM	Casein kinase I epsilon (CKI epsilon) is a widely expressed protein kinase implicated in the regulation of diverse cellular processes including DNA replication and repair, nuclear trafficking, and circadian rhythm. CKI epsilon and the closely related CKI delta are regulated in part through autophosphorylation of their carboxyl-terminal extensions, resulting in down-regulation of enzyme activity. Treatment of CKI epsilon with any of several serine/threonine phosphatases causes a marked increase in kinase activity that is self-limited. To identify the sites of inhibitory autophosphorylation, a series of carboxyl-terminal dele deletion mutants was constructed by site-directed mutagenesis, Truncations that eliminated specific phosphopeptides present in the wild-type kinase were used to guide construction of specific serine/threonine to alanine mutants, Amino acids Ser-323, Thr-325, Thr-334, Thr-337, Ser-368, Ser-405, Thr-407, and Ser-408 in the carboxyl-terminal tail of CKI epsilon were identified as probable in vivo autophosphorylation sites. A recombinant CKI epsilon protein with serine and threonine to alanine mutations eliminating these autophosphorylation sites was 8-fold more active than wild-type CKI epsilon using I kappa B alpha as a substrate. The identified autophosphorylation sites do not conform to CKI substrate motifs identified in peptide substrates.	Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, Div Mol Biol & Genet, Salt Lake City, UT 84132 USA; Univ Utah, Dept Pediat, Div Hematol Oncol, Salt Lake City, UT 84132 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Virshup, DM (corresponding author), Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, Div Mol Biol & Genet, 5C334 Hlth Sci Ctr,50 N Med Dr, Salt Lake City, UT 84132 USA.		Virshup, David M/C-1449-2009	Virshup, David M/0000-0001-6976-850X	NCI NIH HHS [CA71074, CA42014] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071074, P30CA042014] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGOSTINIS P, 1989, FEBS LETT, V259, P75, DOI 10.1016/0014-5793(89)81498-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCKMAN JL, 1992, P NATL ACAD SCI USA, V89, P9454, DOI 10.1073/pnas.89.20.9454; CARMEL G, 1994, J BIOL CHEM, V269, P7304; CEGIELSKA A, 1994, J VIROL, V68, P269, DOI 10.1128/JVI.68.1.269-275.1994; Cegielska A, 1998, J BIOL CHEM, V273, P1357, DOI 10.1074/jbc.273.3.1357; CEGIELSKA A, 1993, MOL CELL BIOL, V13, P1202, DOI 10.1128/MCB.13.2.1202; DHILLON N, 1994, EMBO J, V13, P2777, DOI 10.1002/j.1460-2075.1994.tb06571.x; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; FLOTOW H, 1989, J BIOL CHEM, V264, P9126; FLOTOW H, 1991, J BIOL CHEM, V266, P3724; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; GRAVES PR, 1995, J BIOL CHEM, V270, P21689, DOI 10.1074/jbc.270.37.21689; Gross SD, 1997, J CELL SCI, V110, P3083; Gross SD, 1998, CELL SIGNAL, V10, P699, DOI 10.1016/S0898-6568(98)00042-4; HARDIE DG, 1995, PROTEIN PHOSPHORYLAT, P61; HOEKSTRA MF, 1991, SCIENCE, V253, P1031, DOI 10.1126/science.1887218; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; MILNE DM, 1992, ONCOGENE, V7, P1361; Panek HR, 1997, EMBO J, V16, P4194, DOI 10.1093/emboj/16.14.4194; Rivers A, 1998, J BIOL CHEM, V273, P15980, DOI 10.1074/jbc.273.26.15980; Santos JA, 1996, J CELL SCI, V109, P1847; SONGYANG Z, 1996, MOL CELL BIOL, V16, P4846; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; VANCURA A, 1994, J BIOL CHEM, V269, P1921; VANDERGEER P, 1995, PROTEIN PHOSHORYLATI, P31; WANG PC, 1992, MOL BIOL CELL, V3, P275, DOI 10.1091/mbc.3.3.275; Wang XM, 1996, MOL CELL BIOL, V16, P5375; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	32	102	108	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32063	32070		10.1074/jbc.274.45.32063	http://dx.doi.org/10.1074/jbc.274.45.32063			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542239	hybrid			2022-12-27	WOS:000083532100047
J	Nozaki, T; Asai, T; Sanchez, LB; Kobayashi, S; Nakazawa, M; Takeuchi, T				Nozaki, T; Asai, T; Sanchez, LB; Kobayashi, S; Nakazawa, M; Takeuchi, T			Characterization of the gene encoding serine acetyltransferase, a regulated enzyme of cysteine biosynthesis from the protist parasites Entamoeba histolytica and Entamoeba dispar - Regulation and possible function of the cysteine biosynthetic pathway in entamoeba	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; ACETYLSERINE THIOL LYASE; ARABIDOPSIS-THALIANA; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; O-ACETYLSERINE; SPINACH-CHLOROPLASTS; KINETIC-PROPERTIES; HYDROGEN-PEROXIDE; IDENTIFICATION	The enteric protist parasites Entamoeba histolytica and Entamoeba dispar possess a cysteine biosynthetic pathway, unlike their mammalian host, and are capable of de novo production of L-cysteine. We cloned and characterized cDNAs that encode the regulated enzyme serine acetyltransferase (SAT) in this pathway from these amoebae by genetic complementation of a cysteine-auxotrophic Escherichia coli strain with the amoebic cDNA libraries. The deduced amino acid sequences of the amoebic SATs exhibited, within the most conserved region, 36-52% identities with the bacterial and plant SATs. The amoebic SATs contain a unique insertion of eight amino acids, also found in the corresponding region of a plasmid-encoded SAT from Synechococcus sp., which showed the highest overall. identities to the amoebic SATs, Phylogenetic reconstruction also revealed a close kinship of the amoebic SATs with cyanobacterial SATs, Biochemical characterization of the recombinant E. histolytica SAT revealed several enzymatic features that distinguished the amoebic enzyme from the bacterial and plant enzymes: 1) inhibition by L-cysteine in a competitive manner with L-serine; 2) inhibition by L-cystine; and 3) no association with cysteine synthase. Genetically engineered amoeba strains that overproduced cysteine synthase and SAT were created. The cysteine synthase-overproducing amoebae had a higher level of cysteine synthase activity and total thiol content and revealed increased resistance to hydrogen peroxide, These results indicate that the cysteine biosynthetic pathway plays an important role in antioxidative defense of these enteric parasites.	Natl Inst Infect Dis, Dept Parasitol, Shinjuku Ku, Tokyo 1628640, Japan; Keio Univ, Sch Med, Dept Trop Med & Parasitol, Shinjuku Ku, Tokyo 1608582, Japan; Rockefeller Univ, New York, NY 10021 USA	National Institute of Infectious Diseases (NIID); Keio University; Rockefeller University	Nozaki, T (corresponding author), Natl Inst Infect Dis, Dept Parasitol, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628640, Japan.	nozaki@nih.go.jp	Kobayashi, seiki/L-4026-2013		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI011942] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 11942] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adachi J., 1996, COMPUT SCI MONOGR, V28, P1; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAECKER PA, 1980, ANAL BIOCHEM, V102, P16, DOI 10.1016/0003-2697(80)90310-3; BAKKERGRUNWALD T, 1995, J EUKARYOT MICROBIOL, V42, P346, DOI 10.1111/j.1550-7408.1995.tb01592.x; BEILAN HS, 1983, ANAL BIOCHEM, V128, P169, DOI 10.1016/0003-2697(83)90358-5; Bogdanova N, 1997, PLANT J, V11, P251, DOI 10.1046/j.1365-313X.1997.11020251.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruchhaus I, 1997, BIOCHEM J, V326, P785, DOI 10.1042/bj3260785; BRUCHHAUS I, 1995, MOL BIOCHEM PARASIT, V70, P187, DOI 10.1016/0166-6851(94)00214-8; DENK D, 1987, J GEN MICROBIOL, V133, P515; DIAMOND LS, 1978, T ROY SOC TROP MED H, V72, P431, DOI 10.1016/0035-9203(78)90144-X; DIAMOND LS, 1972, J VIROL, V9, P326, DOI 10.1128/JVI.9.2.326-341.1972; DROUX M, 1992, ARCH BIOCHEM BIOPHYS, V295, P379, DOI 10.1016/0003-9861(92)90531-Z; Droux M, 1998, EUR J BIOCHEM, V255, P235, DOI 10.1046/j.1432-1327.1998.2550235.x; EVANS DJ, 1991, J BACTERIOL, V173, P5457, DOI 10.1128/jb.173.17.5457-5469.1991; FAHEY RC, 1984, SCIENCE, V224, P70, DOI 10.1126/science.6322306; GAGNON Y, 1994, J BIOL CHEM, V269, P7473; GAITONDE MK, 1967, BIOCHEM J, V104, P627, DOI 10.1042/bj1040627; GILLIN FD, 1980, J PROTOZOOL, V27, P220; GILLIN FD, 1984, MOL BIOCHEM PARASIT, V13, P1, DOI 10.1016/0166-6851(84)90096-3; GILLIN FD, 1981, EXP PARASITOL, V52, P9, DOI 10.1016/0014-4894(81)90055-2; GILLIN FD, 1980, J PROTOZOOL, V27, P474, DOI 10.1111/j.1550-7408.1980.tb05402.x; GUARENTE L, 1993, P NATL ACAD SCI USA, V90, P1639, DOI 10.1073/pnas.90.5.1639; HAMANN L, 1995, P NATL ACAD SCI USA, V92, P8975, DOI 10.1073/pnas.92.19.8975; HEDIGER MA, 1985, P NATL ACAD SCI USA, V82, P6414, DOI 10.1073/pnas.82.19.6414; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOCELYN PC, 1987, METHOD ENZYMOL, V143, P44; KADIN H, 1987, METHOD ENZYMOL, V143, P257; Kaneko T, 1997, PLANT CELL PHYSIOL, V38, P1171, DOI 10.1093/oxfordjournals.pcp.a029103; KISHINO H, 1990, J MOL EVOL, V31, P151, DOI 10.1007/BF02109483; KOBAYASHI S, 1998, J EUKARYOT MICROBI S, V45, P3; KREDICH NM, 1969, J BIOL CHEM, V244, P2428; KREDICH NM, 1992, MOL MICROBIOL, V6, P2747, DOI 10.1111/j.1365-2958.1992.tb01453.x; LAI CY, 1992, GENE, V119, P113, DOI 10.1016/0378-1119(92)90074-Y; McNabb DS, 1996, CURR OPIN BIOTECH, V7, P554, DOI 10.1016/S0958-1669(96)80061-9; Mehlotra RK, 1996, CRIT REV MICROBIOL, V22, P295, DOI 10.3109/10408419609105484; MIRELMAN D, 1986, INFECT IMMUN, V54, P827, DOI 10.1128/IAI.54.3.827-832.1986; MURAKOSHI I, 1985, PHYTOCHEMISTRY, V24, P1907, DOI 10.1016/S0031-9422(00)83090-3; Murillo M, 1995, CELL MOL BIOL RES, V41, P425; MURRAY HW, 1981, MOL BIOCHEM PARASIT, V3, P381, DOI 10.1016/0166-6851(81)90038-4; NAKAMURA K, 1988, PLANT CELL PHYSIOL, V29, P689; Netto LES, 1996, J BIOL CHEM, V271, P15315, DOI 10.1074/jbc.271.26.15315; NEUENSCHWANDER U, 1991, PLANT PHYSIOL, V97, P253, DOI 10.1104/pp.97.1.253; NICHOLSON ML, 1995, MOL GEN GENET, V247, P623, DOI 10.1007/BF00290354; NICKEL R, 1994, P NATL ACAD SCI USA, V91, P7095, DOI 10.1073/pnas.91.15.7095; NOAZAKI T, 1998, BIOCHIM BIOPHYS ACTA, V1429, P284; Noji M, 1998, J BIOL CHEM, V273, P32739, DOI 10.1074/jbc.273.49.32739; Nozaki T, 1998, MOL BIOCHEM PARASIT, V97, P33, DOI 10.1016/S0166-6851(98)00129-7; Nozaki T, 1995, MOL BIOCHEM PARASIT, V75, P55, DOI 10.1016/0166-6851(95)02512-X; Olvera A, 1997, Arch Med Res, V28 Spec No, P49; PHILIPPE H, 1993, NUCLEIC ACIDS RES, V21, P5264, DOI 10.1093/nar/21.22.5264; RAETZ CRH, 1995, SCIENCE, V270, P997, DOI 10.1126/science.270.5238.997; REED SL, 1992, INFECT IMMUN, V60, P542, DOI 10.1128/IAI.60.2.542-549.1992; REEVES RE, 1980, EXP PARASITOL, V49, P83, DOI 10.1016/0014-4894(80)90059-4; RENNENBERG H, 1983, PLANT PHYSIOL, V73, P560, DOI 10.1104/pp.73.3.560; Roberts MA, 1996, PLANT MOL BIOL, V30, P1041, DOI 10.1007/BF00020814; Rosenthal B, 1997, J BACTERIOL, V179, P3736, DOI 10.1128/jb.179.11.3736-3745.1997; RUFFET ML, 1994, PLANT PHYSIOL, V104, P597, DOI 10.1104/pp.104.2.597; RUFFET ML, 1995, EUR J BIOCHEM, V227, P500, DOI 10.1111/j.1432-1033.1995.tb20416.x; SAETRE R, 1978, ANAL CHEM, V50, P276, DOI 10.1021/ac50024a027; SAITO K, 1995, J BIOL CHEM, V270, P16321, DOI 10.1074/jbc.270.27.16321; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Singh U, 1997, P NATL ACAD SCI USA, V94, P8812, DOI 10.1073/pnas.94.16.8812; SMABROOK J, 1989, MOL CLONING LAB MANU; SURIN BP, 1988, MOL MICROBIOL, V2, P173, DOI 10.1111/j.1365-2958.1988.tb00019.x; TENNIGKEIT J, 1991, GENE, V98, P113, DOI 10.1016/0378-1119(91)90112-O; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WEINBACH EC, 1976, J PARASITOL, V62, P127, DOI 10.2307/3279066; *WHO, 1995, WORLD HEALTH FORUM, V16, P377	69	100	100	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32445	32452		10.1074/jbc.274.45.32445	http://dx.doi.org/10.1074/jbc.274.45.32445			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542289	hybrid			2022-12-27	WOS:000083532100097
J	Proudfoot, AEI; Buser, R; Borlat, F; Alouani, S; Soler, D; Offord, RE; Schroder, JM; Power, CA; Wells, TNC				Proudfoot, AEI; Buser, R; Borlat, F; Alouani, S; Soler, D; Offord, RE; Schroder, JM; Power, CA; Wells, TNC			Amino-terminally modified RANTES analogues demonstrate differential effects on RANTES receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOKINE RECEPTOR; CCR5 EXPRESSION; ANTAGONIST; HIV; MONOCYTES; INFECTION; INTERNALIZATION; INTERLEUKIN-8; INFLAMMATION; ENDOCYTOSIS	Modification of the amino terminus of regulated on activated normal T-cell expressed (RANTES) has been shown to have a significant effect on biological activity and produces proteins with antagonist properties. Two amino-terminally modified RANTES proteins, Met-RANTES and aminooxypentane-RANTES (AOP-RANTES), exhibit differential inhibitory properties on both monocyte and eosinophil chemotaxis, We have investigated their binding properties as well as their ability to activate the RANTES receptors CCR1, CCR3, and CCR5 in cell lines overexpressing these receptors, We show that Met-RANTES has weak activity in eliciting a calcium response in Chinese hamster ovary cells expressing CCR1, CCR3, and CCR5, whereas AOP-RANTES has full agonist activity on CCR5 but is less effective on CCR3 and CCR1, Their ability to induce chemotaxis of the murine pre-B lymphoma cell line, L1.2, transfected with the same receptors, consolidates these results, Monocytes have detectable mRNA for CCR1, CCR2, CCR3, CCR4, and CCR5, and they respond to the ligands for these receptors in chemotaxis but not always in calcium mobilization, AOP-RANTES does not induce calcium mobilization in circulating monocytes but is able to do so as these cells acquire the macrophage phenotype, which coincides with a concomitant up-regulation of CCR5, We have also tested the ability of both modified proteins to induce chemotaxis of freshly isolated monocytes and eosinophils, Cells from most donors do not respond, but occasionally cells from a particular donor do respond, particularly to AOP-RANTES, We therefore hypothesize that the occasional activity of AOP-RANTES to induce leukocyte chemotaxis is due to donor to donor variation of receptor expression.	Serono Pharmaceut Res Inst, Geneva, Switzerland; LeukoSite Inc, Cambridge, MA 02142 USA; Univ Kiel, Dept Dermatol & Allergol, Kiel, Germany; Ctr Med Univ Geneva, Dept Biochim Med, CH-1228 Geneva, Switzerland	University of Kiel; University of Geneva	Proudfoot, AEI (corresponding author), Serono Pharmaceut Res Inst, 14 Chem Aulx,1228 Plan Ouates, Geneva, Switzerland.	amanda.proudfoot@serono.com	Schroeder, Jens M/B-3994-2009	Wells, Timothy/0000-0001-9796-847X				Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; Bonecchi R, 1999, J IMMUNOL, V162, P474; Campbell EM, 1998, J IMMUNOL, V161, P7047; Clemons MJ, 1998, BLOOD, V92, P1532, DOI 10.1182/blood.V92.5.1532.417k18_1532_1540; Coulin F, 1997, EUR J BIOCHEM, V248, P507, DOI 10.1111/j.1432-1033.1997.00507.x; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; Gong JH, 1996, J BIOL CHEM, V271, P10521, DOI 10.1074/jbc.271.18.10521; GONG JH, 1995, J EXP MED, V181, P631, DOI 10.1084/jem.181.2.631; Gong JH, 1997, J EXP MED, V186, P131, DOI 10.1084/jem.186.1.131; Gonzalo JA, 1998, J EXP MED, V188, P157, DOI 10.1084/jem.188.1.157; Grewal IS, 1997, J IMMUNOL, V159, P401; Grone HJ, 1999, FASEB J, V13, P1371, DOI 10.1096/fasebj.13.11.1371; Kledal TN, 1997, SCIENCE, V277, P1656, DOI 10.1126/science.277.5332.1656; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; Lee B, 1999, J BIOL CHEM, V274, P9617, DOI 10.1074/jbc.274.14.9617; Lloyd GM, 1997, J EXP MED, V185, P1371, DOI 10.1084/jem.185.7.1371; Loetscher P, 1996, J EXP MED, V184, P569, DOI 10.1084/jem.184.2.569; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; LUSTINARASIMHAN M, 1995, J BIOL CHEM, V270, P2716, DOI 10.1074/jbc.270.6.2716; Mack M, 1998, J EXP MED, V187, P1215, DOI 10.1084/jem.187.8.1215; MASSARI FE, 1990, J IMMUNOL, V144, P4628; MOSER B, 1993, J BIOL CHEM, V268, P7125; Naif HM, 1998, J VIROL, V72, P830, DOI 10.1128/JVI.72.1.830-836.1998; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; Nieto M, 1997, J EXP MED, V186, P153, DOI 10.1084/jem.186.1.153; PlaterZyberk C, 1997, IMMUNOL LETT, V57, P117, DOI 10.1016/S0165-2478(97)00075-8; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599; Proudfoot AEI, 1999, BIOCHEM PHARMACOL, V57, P451; PROUDFOOT AEI, 1995, FEBS LETT, V376, P19, DOI 10.1016/0014-5793(95)01235-X; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Schroder JM, 1997, METHOD ENZYMOL, V288, P266; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; Solari R, 1997, J BIOL CHEM, V272, P9617; Sozzani S, 1998, J EXP MED, V187, P439, DOI 10.1084/jem.187.3.439; Wells TNC, 1998, TRENDS PHARMACOL SCI, V19, P376, DOI 10.1016/S0165-6147(98)01247-4; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; ZHANG YJ, 1995, MOL CELL BIOL, V15, P4851	38	126	134	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32478	32485		10.1074/jbc.274.45.32478	http://dx.doi.org/10.1074/jbc.274.45.32478			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542293	hybrid			2022-12-27	WOS:000083532100101
J	Crottet, P; Peitsch, MC; Servis, C; Corthesy, B				Crottet, P; Peitsch, MC; Servis, C; Corthesy, B			Covalent homodimers of murine secretory component induced by epitope substitution unravel the capacity of the polymeric Ig receptor to dimerize noncovalently in the absence of IgA ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL IMMUNOGLOBULIN-A; MANNOSE 6-PHOSPHATE RECEPTOR; WHEAT-GERM-AGGLUTININ; CYTOPLASMIC DOMAIN; MOLECULAR-CLONING; VIBRIO-CHOLERAE; BINDING-SITE; SIALIC-ACID; ANTIBODIES; PROTECTS	Recombinant secretory immunoglobulin A containing a bacterial epitope in domain I of the secretory component (SC) moiety can serve as a mucosal delivery vehicle triggering both mucosal and systemic responses (Corthesy, B., Kaufmann, M., Phalipon, A., Peitsch, M., Neutra, M. R., and Kraehenbuhl, J.-P. (1996) J. Biol. Chem. 271, 33670-33677), To load recombinant secretory IgA with multiple B and T epitopes and extend its biological functions, we selected, based on molecular modeling, five surface-exposed sites in domains II and III of murine SC, Loops predicted to be exposed at the surface of SC domains were replaced with the DYKDDDDK octapeptide (FLAG), Another two mutants were obtained with the FLAG inserted in between domains II and III or at the carboxyl terminus of SC. As shown by mass spectrometry, internal substitution of the FLAG into four of the mutants induced the formation of disulfide-linked homodimers, Three of the dimers and two of the monomers from SC mutants could be affinity-purified using an antibody to the FLAG, mapping them as candidates for insertion. FLAG-induced dimerization also occurred with the polymeric immunoglobulin receptor (pIgR) and might reflect the so-far nondemonstrated capacity of the receptor to oligomerize, By co-expressing in COS-7 cells and epithelial Caco-2 cells two pIgR constructs tagged at the carboxyl terminus with hexahistidine or FLAG, we provide the strongest evidence reported to date that the pIgR dimerizes noncovalently in the plasma membrane in the absence of polymeric IgA ligand, The implication of this finding is discussed in terms of IgA transport and specific antibody response at mucosal surfaces.	CHU Vaudois, Div Immunol & Allergie, CH-1011 Lausanne, Switzerland; Inst Suisse Rech Expt Canc, CH-1066 Epalinges, Switzerland; Glaxo Welcome Expt Res, CH-1228 Plan Les Ouates, Switzerland; Univ Lausanne, Inst Biochim, CH-1066 Epalinges, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne	Corthesy, B (corresponding author), CHU Vaudois, Div Immunol & Allergie, BH18-701,Rue Bugnon, CH-1011 Lausanne, Switzerland.		Peitsch, Manuel/J-7416-2017	Peitsch, Manuel/0000-0001-5324-359X				ALBERINI CM, 1990, NATURE, V347, P485, DOI 10.1038/347485a0; APTER FM, 1993, INFECT IMMUN, V61, P5279, DOI 10.1128/IAI.61.12.5279-5285.1993; BAKOS MA, 1991, J IMMUNOL, V147, P3419; BAKOS MA, 1993, J IMMUNOL, V151, P1346; BAKOS MA, 1994, MOL IMMUNOL, V31, P165, DOI 10.1016/0161-5890(94)90088-4; BAKOS MA, 1991, J IMMUNOL, V146, P162; BEALE D, 1988, INT J BIOCHEM, V20, P873, DOI 10.1016/0020-711X(88)90077-8; BHAVANANDAN VP, 1979, J BIOL CHEM, V254, P4000; BLANCHARD TG, 1995, INFECT IMMUN, V63, P1394, DOI 10.1128/IAI.63.4.1394-1399.1995; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; Cardone MH, 1996, J CELL BIOL, V133, P997, DOI 10.1083/jcb.133.5.997; Chapin SJ, 1996, J BIOL CHEM, V271, P1336, DOI 10.1074/jbc.271.3.1336; CLEVELAND MG, 1991, J IMMUNOL, V147, P181; Corthesy B, 1996, J BIOL CHEM, V271, P33670, DOI 10.1074/jbc.271.52.33670; Cottet S, 1997, EUR J BIOCHEM, V246, P23, DOI 10.1111/j.1432-1033.1997.00023.x; COYNE RS, 1994, J BIOL CHEM, V269, P31620; Crottet P, 1999, BIOCHEM J, V341, P299, DOI 10.1042/0264-6021:3410299; Crottet P, 1998, J IMMUNOL, V161, P5445; Crottet P, 1999, J BIOL CHEM, V274, P31456, DOI 10.1074/jbc.274.44.31456; DAHMS NM, 1989, J BIOL CHEM, V264, P11458; EIFFERT H, 1991, BIOL CHEM H-S, V372, P119, DOI 10.1515/bchm3.1991.372.1.119; FRUTIGER S, 1986, J BIOL CHEM, V261, P6673; GALLAGHER JT, 1985, BIOCHEM J, V231, P115, DOI 10.1042/bj2310115; GUENZI S, 1994, EUR J IMMUNOL, V24, P2477, DOI 10.1002/eji.1830241033; Guimaraes MJ, 1996, J BIOL CHEM, V271, P13697, DOI 10.1074/jbc.271.23.13697; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; Hendrickson BA, 1996, J IMMUNOL, V157, P750; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HIRT RP, 1993, CELL, V74, P245, DOI 10.1016/0092-8674(93)90416-N; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; Lullau E, 1996, J BIOL CHEM, V271, P16300, DOI 10.1074/jbc.271.27.16300; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; Luton F, 1999, MOL BIOL CELL, V10, P1409, DOI 10.1091/mbc.10.5.1409; Luton F, 1998, MOL BIOL CELL, V9, P1787, DOI 10.1091/mbc.9.7.1787; MA JKC, 1990, INFECT IMMUN, V58, P3407, DOI 10.1128/IAI.58.10.3407-3414.1990; MICHETTI P, 1992, INFECT IMMUN, V60, P1786, DOI 10.1128/IAI.60.5.1786-1792.1992; Morissey J. H., 1981, ANAL BIOCHEM, V117, P307; Mortz E, 1996, J MASS SPECTROM, V31, P1109, DOI 10.1002/(SICI)1096-9888(199610)31:10<1109::AID-JMS400>3.0.CO;2-9; PARR EL, 1995, J IMMUNOL METHODS, V180, P147, DOI 10.1016/0022-1759(94)00310-S; PHALIPON A, 1995, J EXP MED, V182, P769, DOI 10.1084/jem.182.3.769; PISKURICH JF, 1995, J IMMUNOL, V154, P1735; Punnonen EL, 1996, EUR J BIOCHEM, V237, P809, DOI 10.1111/j.1432-1033.1996.0809p.x; Reddy P, 1996, EMBO J, V15, P2077, DOI 10.1002/j.1460-2075.1996.tb00561.x; RINDISBACHER L, 1995, J BIOL CHEM, V270, P14220, DOI 10.1074/jbc.270.23.14220; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Singer KL, 1998, MOL BIOL CELL, V9, P901, DOI 10.1091/mbc.9.4.901; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOLARI R, 1984, CELL, V36, P61, DOI 10.1016/0092-8674(84)90074-6; SOLARI R, 1985, J BIOL CHEM, V260, P1141; SONG WX, 1995, J IMMUNOL, V155, P715; VANDRIEL IR, 1987, J BIOL CHEM, V262, P16127; WELTZIN R, 1994, ANTIMICROB AGENTS CH, V38, P2785, DOI 10.1128/AAC.38.12.2785; WINNER L, 1991, INFECT IMMUN, V59, P977, DOI 10.1128/IAI.59.3.977-982.1991; Wu H, 1997, NATURE, V387, P527, DOI 10.1038/387527a0	54	13	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31445	31455		10.1074/jbc.274.44.31445	http://dx.doi.org/10.1074/jbc.274.44.31445			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531346	hybrid			2022-12-27	WOS:000083379400050
J	Hawkins, M; Hu, MZ; Yu, JH; Eder, H; Vuguin, P; She, L; Barzilai, N; Leiser, M; Backer, JM; Rossetti, L				Hawkins, M; Hu, MZ; Yu, JH; Eder, H; Vuguin, P; She, L; Barzilai, N; Leiser, M; Backer, JM; Rossetti, L			Discordant effects of glucosamine on insulin-stimulated glucose metabolism and phosphatidylinositol 3-kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE ACTIVITY; SKELETAL-MUSCLE; 3T3-L1 ADIPOCYTES; IN-VIVO; GLUTAMINE-FRUCTOSE-6-PHOSPHATE AMIDOTRANSFERASE; PHOSPHOINOSITIDE 3-KINASE; HEXOSAMINE BIOSYNTHESIS; GLUT-4 TRANSLOCATION; INHIBITOR WORTMANNIN; DIABETIC RATS	The impact of increased GlcN availability on insulin-stimulated p85/p110 phosphatidylinositol 3-kinase (PI3K) activity in skeletal muscle was examined in relation to GlcN-induced defects in peripheral insulin action. Primed continuous GlcN infusion (750 mu mol/kg bolus; 30 mu mol/kg min) in conscious rats limited both maximal stimulation of muscle PI3K by acute insulin (1) (1 unit/kg) bolus (I + GlcN = 1.9-fold versus saline = 3.3-fold above fasting levels; p < 0.01) and chronic activation of PI3K following 3-h euglycemic, hyperinsulinemic (18 milliunits/kg min) clamp studies (I + GlcN = 1,2-fold versus saline = 2,6-fold stimulation;p < 0.01). To determine the time course of GlcN-induced defects in insulin-stimulated PI3K activity and peripheral insulin action, GlcN was administered for 30, 60, 90, or 120 min during 2-h euglycemic, hyperinsulinemic clamp studies. Activation of muscle PI3K by insulin was attenuated following only 30 min of GlcN infusion (GlcN 30 min = 1.5-fold versus saline = 2.5-fold stimulation; p < 0.05). In contrast, the first impairment in insulin-mediated glucose uptake (Rd) developed following 110 min of GlcN infusion (110 min = 39.9 +/- 1.8 versus 30 min = 42.8 +/- 1.4 mg/kg.min, p < 0.05), However, the ability of insulin to stimulate phosphatidylinositol 3,4,5-trisphosphate production and to activate glycogen synthase in skeletal muscle was preserved following up to 180 min of GlcN infusion. Thus, increased GlcN availability induced (a) profound and early inhibition of proximal insulin signaling at the level of PI3K and (b) delayed effects on insulin-mediated glucose uptake, yet, (c) complete sparing of insulin-mediated glycogen synthase activation, The pattern and time sequence of GlcN-induced defects suggest that the etiology of peripheral insulin resistance may be distinct from the rapid and marked impairment in insulin signaling.	Yeshiva Univ Albert Einstein Coll Med, Dept Med, Div Endocrinol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Ctr Diabet Res & Training, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Rossetti, L (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Med, Div Endocrinol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	rossetti@aecom.yu.edu		vuguin, patricia/0000-0002-4982-0400	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048321, R29DK045024, P60DK020541, P30DK020541, R01DK045024, R37DK048321] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48321, DK20541, DK 45024] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANUMULA KR, 1991, ANAL BIOCHEM, V197, P113, DOI 10.1016/0003-2697(91)90365-Z; BACKER JM, 1993, J BIOL CHEM, V268, P8204; Baron AD, 1995, J CLIN INVEST, V96, P2792, DOI 10.1172/JCI118349; Brown RA, 1999, J BIOL CHEM, V274, P14529, DOI 10.1074/jbc.274.21.14529; CHANG PY, 1994, J BIOL CHEM, V269, P16034; CROOK ED, 1995, DIABETES, V44, P314, DOI 10.2337/diabetes.44.3.314; Crook ED, 1996, DIABETES, V45, P322, DOI 10.2337/diabetes.45.3.322; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DeFea K, 1997, BIOCHEMISTRY-US, V36, P12939, DOI 10.1021/bi971157f; Domin J, 1997, BIOCHEM J, V326, P139, DOI 10.1042/bj3260139; DONG DLY, 1994, J BIOL CHEM, V269, P19321; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; FOLLI F, 1993, J CLIN INVEST, V92, P1787, DOI 10.1172/JCI116768; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; Frevert EU, 1998, DIABETES, V47, pA36; GIACCARI A, 1992, J CLIN INVEST, V89, P36, DOI 10.1172/JCI115583; GOODYEAR LJ, 1995, J CLIN INVEST, V95, P2195, DOI 10.1172/JCI117909; Hart GW, 1996, GLYCOBIOLOGY, V6, P711, DOI 10.1093/glycob/6.7.711; Hawkins M, 1997, J BIOL CHEM, V272, P4889, DOI 10.1074/jbc.272.8.4889; Hawkins M, 1997, J CLIN INVEST, V99, P2173, DOI 10.1172/JCI119390; HEYDRICK SJ, 1995, AM J PHYSIOL-ENDOC M, V268, pE604, DOI 10.1152/ajpendo.1995.268.4.E604; Hresko RC, 1998, J BIOL CHEM, V273, P20658, DOI 10.1074/jbc.273.32.20658; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; Katagiri H, 1996, J BIOL CHEM, V271, P16987, DOI 10.1074/jbc.271.29.16987; Kim YB, 1999, DIABETES, V48, P310, DOI 10.2337/diabetes.48.2.310; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kolm-Litty V, 1998, J CLIN INVEST, V101, P160, DOI 10.1172/JCI119875; Kreppel LK, 1997, J BIOL CHEM, V272, P9308; Krook A, 1996, J BIOL CHEM, V271, P7134, DOI 10.1074/jbc.271.12.7134; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; OKADA T, 1994, J BIOL CHEM, V269, P3568; PASSONNEAU JV, 1993, ENZYMATIC ANAL PRACT, P122; Patti ME, 1999, DIABETES, V48, P1562, DOI 10.2337/diabetes.48.8.1562; ROBINSON KA, 1995, DIABETES, V44, P1438, DOI 10.2337/diabetes.44.12.1438; ROBINSON KA, 1993, DIABETES, V42, P1333, DOI 10.2337/diabetes.42.9.1333; ROSSETTI L, 1993, J CLIN INVEST, V92, P2963, DOI 10.1172/JCI116919; ROSSETTI L, 1990, J CLIN INVEST, V85, P1785, DOI 10.1172/JCI114636; ROSSETTI L, 1995, J CLIN INVEST, V96, P132, DOI 10.1172/JCI118013; ROSSETTI L, 1993, AM J PHYSIOL, V265, pE761, DOI 10.1152/ajpendo.1993.265.5.E761; ROSSETTI L, 1989, J CLIN INVEST, V84, P892, DOI 10.1172/JCI114250; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; Snow DM, 1998, INT REV CYTOL, V181, P43, DOI 10.1016/S0074-7696(08)60416-7; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TRAXINGER RR, 1991, J BIOL CHEM, V266, P10148; vanderKaay J, 1997, J BIOL CHEM, V272, P5477, DOI 10.1074/jbc.272.9.5477; Wang JL, 1998, NATURE, V393, P684, DOI 10.1038/31474; Wojtaszewski JFP, 1997, DIABETES, V46, P1775, DOI 10.2337/diabetes.46.11.1775	51	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31312	31319		10.1074/jbc.274.44.31312	http://dx.doi.org/10.1074/jbc.274.44.31312			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531330	hybrid			2022-12-27	WOS:000083379400034
J	Krych-Goldberg, M; Hauhart, RE; Subramanian, VB; Yurcisin, BM; Crimmins, DL; Hourcade, DE; Atkinson, JP				Krych-Goldberg, M; Hauhart, RE; Subramanian, VB; Yurcisin, BM; Crimmins, DL; Hourcade, DE; Atkinson, JP			Decay accelerating activity of complement receptor type 1 (CD35) - Two active sites are required for dissociating C5 convertases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHORT CONSENSUS REPEATS; C3B C4B RECEPTOR; C3B/C4B RECEPTOR; HUMAN-ERYTHROCYTE; CR3 CD11B/CD18; CR-1 CD35; FACTOR-H; IDENTIFICATION; MUTAGENESIS; EXPRESSION	The goal of this study was to identify the site(s) in CRI that mediate the dissociation of the C3 and C5 convertases. To that end, truncated derivatives of CR1 whose extracellular part is composed of 30 tandem repealing modules, termed complement control protein repeats (CCPs), were generated. Site 1 (CCPs 1-3) alone mediated the decay acceleration of the classical and alternative pathway C3 convertases, Site 2 (CCPs 8-10 or the nearly identical CCPs 15-17) had one-fifth the activity of site 1. In contrast, for the C5 convertase, site 1 had only 0.5% of the decay accelerating activity, while site 2 had no detectable activity. Efficient C5 decay accelerating activity was detected in recombinants that carried both site 1 and site 2, The activity was reduced if the intervening repeats between site 1 and site 2 were deleted. The results indicate that, for the C5 convertases, decay accelerating activity is mediated primarily by site 1. A properly spaced site 2 has an important auxiliary role, which may involve its C3b binding capacity. Moreover, using homologous substitution mutagenesis, residues important in site 1 for dissociating activity were identified. Based on these results, we generated proteins one-fourth the size of CR1 but with enhanced decay accelerating activity for the C3 convertases.	Washington Univ, Sch Med, Dept Med, Div Rheumatol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, Div Lab Med, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Atkinson, JP (corresponding author), Washington Univ, Sch Med, Dept Med, Div Rheumatol, 660 S Euclid Ave,Box 8045, St Louis, MO 63110 USA.			Atkinson, John/0000-0002-2514-3441	NIAID NIH HHS [R01 AI41592] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041592] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahearn JM, 1996, IMMUNITY, V4, P251, DOI 10.1016/S1074-7613(00)80433-1; BRODBECK WG, 1998, MOL IMMUNOL, V35, P426; CERVONI F, 1993, J IMMUNOL, V151, P939; COOPER NR, 1991, IMMUNOL TODAY, V12, P327, DOI 10.1016/0167-5699(91)90010-Q; CORNACOFF JB, 1983, J CLIN INVEST, V71, P236, DOI 10.1172/JCI110764; DYKMAN TR, 1983, P NATL ACAD SCI-BIOL, V80, P1698, DOI 10.1073/pnas.80.6.1698; EHLENBERGER AG, 1977, J EXP MED, V145, P357, DOI 10.1084/jem.145.2.357; FALLMAN M, 1993, J IMMUNOL, V151, P330; FEARON DT, 1980, J EXP MED, V152, P20, DOI 10.1084/jem.152.1.20; FISCHER E, 1986, CELL IMMUNOL, V97, P297, DOI 10.1016/0008-8749(86)90400-4; HEBERT LA, 1987, KIDNEY INT, V31, P870; HOGG N, 1984, EUR J IMMUNOL, V14, P236, DOI 10.1002/eji.1830140307; HONG KS, 1991, J IMMUNOL, V146, P1868; HOURCADE D, 1988, J EXP MED, V168, P1255, DOI 10.1084/jem.168.4.1255; HOURCADE DE, 1995, J BIOL CHEM, V270, P19716, DOI 10.1074/jbc.270.34.19716; Hourcade DE, 1999, IMMUNOPHARMACOLOGY, V42, P167, DOI 10.1016/S0162-3109(99)00005-3; KALLI KR, 1991, J EXP MED, V174, P1451, DOI 10.1084/jem.174.6.1451; KINOSHITA T, 1987, J IMMUNOL, V138, P2994; KLICKSTEIN LB, 1988, J EXP MED, V168, P1699, DOI 10.1084/jem.168.5.1699; KLICKSTEIN LB, 1987, J EXP MED, V165, P1095, DOI 10.1084/jem.165.4.1095; KRYCH M, 1991, P NATL ACAD SCI USA, V88, P4353, DOI 10.1073/pnas.88.10.4353; Krych M, 1998, J BIOL CHEM, V273, P8623, DOI 10.1074/jbc.273.15.8623; Krych M., 1997, Journal of Allergy and Clinical Immunology, V99, pS373; Krych M, 1998, MOL IMMUNOL, V35, P403, DOI 10.1016/S0161-5890(98)90822-7; KRYCH M, 1994, J BIOL CHEM, V269, P13273; KRYCH M, 1996, MOL IMMUNOL, V33, P33; Kuhn S, 1996, EUR J IMMUNOL, V26, P2383, DOI 10.1002/eji.1830261017; KuttnerKondo L, 1996, PROTEIN ENG, V9, P1143, DOI 10.1093/protein/9.12.1143; Liszewski MK, 1996, ADV IMMUNOL, V61, P201; MAKRIDES SC, 1992, J BIOL CHEM, V267, P24754; MEDOF ME, 1984, J EXP MED, V159, P1669, DOI 10.1084/jem.159.6.1669; MEDOF ME, 1987, P NATL ACAD SCI USA, V84, P2007, DOI 10.1073/pnas.84.7.2007; Molina H, 1996, P NATL ACAD SCI USA, V93, P3357, DOI 10.1073/pnas.93.8.3357; MORGAN BP, 1999, COMPLEMENT REGULATOR, P250; NELSON RA, 1953, SCIENCE, V118, P733, DOI 10.1126/science.118.3077.733; NICKELLS MW, 1994, J IMMUNOL, V152, P676; NICKELLS MW, 1990, J IMMUNOL, V144, P4262; OSHEA JJ, 1985, J IMMUNOL, V135, P1325; PANGBURN MK, 1986, J IMMUNOL, V136, P2216; Pruitt SK, 1997, TRANSPLANTATION, V63, P900, DOI 10.1097/00007890-199703270-00017; Rowe JA, 1997, NATURE, V388, P292, DOI 10.1038/40888; TEDDER TF, 1983, J IMMUNOL, V130, P1668; THIEBLEMONT N, 1993, CLIN EXP IMMUNOL, V92, P106; THYPHRONITIS G, 1991, J IMMUNOL, V147, P224; WEISMAN HF, 1990, SCIENCE, V249, P146, DOI 10.1126/science.2371562; WILSON JG, 1983, J IMMUNOL, V131, P684; WONG WW, 1991, J IMMUNOL, V146, P656	47	78	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31160	31168		10.1074/jbc.274.44.31160	http://dx.doi.org/10.1074/jbc.274.44.31160			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531307	hybrid			2022-12-27	WOS:000083379400011
J	Maroun, CR; Moscatello, DK; Naujokas, MA; Holgado-Madruga, M; Wong, AJ; Park, M				Maroun, CR; Moscatello, DK; Naujokas, MA; Holgado-Madruga, M; Wong, AJ; Park, M			A conserved inositol phospholipid binding site within the pleckstrin homology domain of the Gab1 docking protein is required for epithelial morphogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; FACTOR SCATTER FACTOR; LINKED AGAMMAGLOBULINEMIA XLA; C-MET RECEPTOR; PLASMA-MEMBRANE; HIGH-AFFINITY; PHOSPHOINOSITIDE BINDING; SIGNALING MOLECULES; BILAYER-MEMBRANES	Stimulation of the hepatocyte growth factor receptor tyrosine kinase, Met, induces the inherent morphogenic program of epithelial cells. The multisubstrate binding protein Gab1 (Grb2-associated binder-1) is the major phosphorylated protein in epithelial cells following activation of Met. Gab1 contains a pleckstrin homology domain and multiple tyrosine residues that act to couple Met with multiple signaling proteins. Met receptor mutants that are impaired in their association with Gab1 fail to induce a morphogenic program in epithelial cells, which is rescued by overexpression of Gab1. The Gab1 pleckstrin homology domain binds to, phosphatidylinositol 3,4,5-trisphosphate and contains conserved residues, shown from studies of other pleckstrin homology domains to be crucial for phospholipid binding. Mutation of conserved phospholipid binding residues tryptophan 26 and arginine 29, generates Gab1 proteins with decreased phosphatidylinositol 3,4,5-trisphosphate binding, decreased localization at sites of cell-cell contact, and reduced ability to rescue Met-dependent morphogenesis. We conclude that the ability of the Gab1 pleckstrin homology domain to bind phosphatidylinositol 3,4,5-trisphosphate is critical for subcellular localization of Gab1 and for efficient morphogenesis downstream from the Met receptor.	McGill Univ, Ctr Hosp, Mol Oncol Grp, Dept Med, Montreal, PQ H31 1A1, Canada; McGill Univ, Ctr Hosp, Mol Oncol Grp, Dept Oncol, Montreal, PQ H31 1A1, Canada; McGill Univ, Ctr Hosp, Mol Oncol Grp, Dept Biochem, Montreal, PQ H31 1A1, Canada; Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Kimmel Canc Inst, Dept Pharmacol, Philadelphia, PA 19107 USA	McGill University; McGill University; McGill University; Jefferson University; Jefferson University	Park, M (corresponding author), Royal Victoria Hosp, Mol Oncol Grp, 687 Pine Ave W,Rm H5-10, Montreal, PQ H3A 1A1, Canada.	morag@lan1.molonc.mcgill.ca			NCI NIH HHS [CA69495] Funding Source: Medline; NINDS NIH HHS [NS 34514] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069495] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS034514] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; BELLACOSA A, 1993, ONCOGENE, V8, P745; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; Burks DJ, 1997, J BIOL CHEM, V272, P27716, DOI 10.1074/jbc.272.44.27716; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CIFUENTES ME, 1994, J BIOL CHEM, V269, P1945; Ebens A, 1996, NEURON, V17, P1157, DOI 10.1016/S0896-6273(00)80247-0; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Faletto D L, 1993, EXS, V65, P107; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Fourier TM, 1996, J BIOL CHEM, V271, P22211, DOI 10.1074/jbc.271.36.22211; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; Hyvonen M, 1997, EMBO J, V16, P3396, DOI 10.1093/emboj/16.12.3396; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; KOMADA M, 1993, ONCOGENE, V8, P2381; KOMADA M, 1992, EUR J BIOCHEM, V204, P857, DOI 10.1111/j.1432-1033.1992.tb16705.x; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; KONISHI H, 1994, BIOCHEM BIOPH RES CO, V205, P1770, DOI 10.1006/bbrc.1994.2874; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Maina F, 1997, GENE DEV, V11, P3341, DOI 10.1101/gad.11.24.3341; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; Mattsson PT, 1996, BIOESSAYS, V18, P825, DOI 10.1002/bies.950181009; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; Nagel W, 1998, J BIOL CHEM, V273, P14853, DOI 10.1074/jbc.273.24.14853; NAKAMURA T, 1991, Progress in Growth Factor Research, V3, P67, DOI 10.1016/0955-2235(91)90014-U; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Paterson HF, 1995, BIOCHEM J, V312, P661, DOI 10.1042/bj3120661; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Rawlings D J, 1995, Semin Immunol, V7, P237, DOI 10.1006/smim.1995.0028; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; RONSIN C, 1993, ONCOGENE, V8, P1195; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; SIDERAS P, 1994, J IMMUNOL, V153, P5607; SORIANO JV, 1995, J CELL SCI, V108, P413; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Varnai P, 1999, J BIOL CHEM, V274, P10983, DOI 10.1074/jbc.274.16.10983; Vihinen M, 1996, NUCLEIC ACIDS RES, V24, P160, DOI 10.1093/nar/24.1.160; Wang DS, 1996, BIOCHEM BIOPH RES CO, V225, P420, DOI 10.1006/bbrc.1996.1189; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; Yagisawa H, 1998, J BIOL CHEM, V273, P417, DOI 10.1074/jbc.273.1.417; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; YANG XM, 1995, LAB INVEST, V73, P483; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608; ZARNEGAR R, 1989, CANCER RES, V49, P3314; Zheng J, 1997, J BIOL CHEM, V272, P30340, DOI 10.1074/jbc.272.48.30340; ZHU H, 1994, CELL GROWTH DIFFER, V5, P359; ZHU H, 1994, J BIOL CHEM, V269, P29943	77	72	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31719	31726		10.1074/jbc.274.44.31719	http://dx.doi.org/10.1074/jbc.274.44.31719			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531383	hybrid			2022-12-27	WOS:000083379400087
J	Wettreich, A; Sebollela, A; Carvalho, MA; Azevedo, SP; Borojevic, R; Ferreira, ST; Coelho-Sampaio, T				Wettreich, A; Sebollela, A; Carvalho, MA; Azevedo, SP; Borojevic, R; Ferreira, ST; Coelho-Sampaio, T			Acidic pH modulates the interaction between human granulocyte-macrophage colony-stimulating factor and glycosaminoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; HEPARIN-LIKE MOLECULES; HIGH-AFFINITY RECEPTOR; BASIC FIBROBLAST; EXTRACELLULAR-MATRIX; INTERFERON-GAMMA; BINDING DOMAIN; GM-CSF; SULFATE; CELLS	Granulocyte-macrophage colony-stimulating factor (GM-CSF) controls growth and differentiation of hematopoietic cells. Previous reports have indicated that the mitogenic activity of GM-CSF may be modulated by the glycosidic moiety of proteoglycans associated with the membrane of stromal cells. In this work, we have performed in vitro studies of the interaction between GM-CSF and glycosaminoglycans. The addition of heparin promoted a marked blue shift in the fluorescence emission spectrum of GM-CSF as well as a 30-fold increase in the intensity of light scattering, which indicates formation of large molecular weight complexes between the two molecules. Interestingly, heparin-induced changes in the spectral properties of GM-CSF were only observed at acidic pH. The dependence on acidic pH, together with a strict dependence on glycosaminoglycan sulfation and the fact that high ionic strength destabilized the interaction, indicates that the association between GM-CSF and glycosaminoglycans is mediated by electrostatic interactions. These interactions probably involve sulfate groups in the glycosaminoglycans and positively charged histidine residues in GM-CSF. We propose that negatively charged glycolipids present on the plasma membrane of the hematopoietic and/or the stromal cell could promote an acidic microenvironment capable of triggering interaction between GM-CSF and membrane-bound proteoglycans in vivo.	Univ Fed Rio de Janeiro, Dept Bioquim Med, Hosp Univ Clementino Fraga Filho, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Dept Histol & Embriol, Hosp Univ Clementino Fraga Filho, Inst Ciencias Biomed, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, PABCAM, Hosp Univ Clementino Fraga Filho, BR-21941590 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro	Coelho-Sampaio, T (corresponding author), Univ Fed Rio de Janeiro, Dept Bioquim Med, Cidade Univ, BR-21941590 Rio De Janeiro, Brazil.		Sebollela, Adriano/O-4385-2014; Ferreira, Sergio/AAZ-1576-2020; Borojevic, Radovan/V-8500-2019; Carvalho, Marcelo A/J-7144-2012; Carvalho, Marcelo/T-2014-2019	Sebollela, Adriano/0000-0002-7444-9156; Ferreira, Sergio/0000-0001-7160-9866; Borojevic, Radovan/0000-0002-2393-7280; Carvalho, Marcelo A/0000-0002-7053-0053; 				ALLEN TD, 1990, COLONY STIMULATING F; AlvarezSilva M, 1996, J LEUKOCYTE BIOL, V59, P435, DOI 10.1002/jlb.59.3.435; ALVAREZSILVA M, 1993, J CELL SCI, V104, P477; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BOHLEN P, 1985, FEBS LETT, V185, P177, DOI 10.1016/0014-5793(85)80765-1; BREMER EG, 1982, BIOCHEM BIOPH RES CO, V106, P711, DOI 10.1016/0006-291X(82)91769-7; BRUNDEN KR, 1993, J NEUROCHEM, V61, P2147, DOI 10.1111/j.1471-4159.1993.tb07453.x; Cantor C.R., 1980, BIOPHYSICAL CHEM 2, P838; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; DECRISTAN G, 1990, J CELL PHYSIOL, V144, P505; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; GALLAGHER JT, 1988, EXPT HAEMATOLOGY TOD, P36; GORDON MY, 1987, NATURE, V326, P403, DOI 10.1038/326403a0; GOSPODAROWICZ D, 1984, P NATL ACAD SCI-BIOL, V81, P6963, DOI 10.1073/pnas.81.22.6963; Gupta P, 1996, BLOOD, V87, P3229, DOI 10.1182/blood.V87.8.3229.bloodjournal8783229; GUPTABANSAL R, 1995, J BIOL CHEM, V270, P18666, DOI 10.1074/jbc.270.31.18666; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; ISHIHARA M, 1993, J BIOL CHEM, V268, P4675; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KOIKE M, 1994, INT ARCH ALLERGY IMM, V104, P1, DOI 10.1159/000236702; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LEHNINGER AL, 1968, P NATL ACAD SCI USA, V60, P1069, DOI 10.1073/pnas.60.4.1069; LI LY, 1994, GROWTH FACTORS, V11, P1, DOI 10.3109/08977199409015046; Lipscombe RJ, 1998, J LEUKOCYTE BIOL, V63, P342, DOI 10.1002/jlb.63.3.342; LOBB RR, 1984, BIOCHEMISTRY-US, V23, P6295, DOI 10.1021/bi00321a001; Lortat-Jacob H, 1996, J BIOL CHEM, V271, P16139, DOI 10.1074/jbc.271.27.16139; LORTAT-JACOB H, 1995, BIOCHEM J, V310, P497, DOI 10.1042/bj3100497; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; MCCAFFREY TA, 1992, J CELL PHYSIOL, V152, P430, DOI 10.1002/jcp.1041520226; METCALF D, 1986, BLOOD, V67, P257; Meuillet E, 1996, GLIA, V17, P206, DOI 10.1002/(SICI)1098-1136(199607)17:3<206::AID-GLIA3>3.0.CO;2-Z; Modrowski D, 1998, J CELL PHYSIOL, V177, P187, DOI 10.1002/(SICI)1097-4652(199810)177:1<187::AID-JCP19>3.0.CO;2-A; MUTHER H, 1994, GROWTH FACTORS, V10, P17, DOI 10.3109/08977199409019600; NAGASAWA K, 1980, METHODS CARBOHYDR CH, V8, P287; Naito M, 1997, BLOOD, V89, P2060, DOI 10.1182/blood.V89.6.2060; NARHI LO, 1991, J PROTEIN CHEM, V10, P359, DOI 10.1007/BF01025250; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; PINEDALUCENA A, 1994, EUR J BIOCHEM, V222, P425, DOI 10.1111/j.1432-1033.1994.tb18881.x; Rietveld AWM, 1998, BIOCHEMISTRY-US, V37, P933, DOI 10.1021/bi9721593; ROBERTS R, 1988, NATURE, V332, P376, DOI 10.1038/332376a0; Rourke AM, 1996, BIOCHEMISTRY-US, V35, P11913, DOI 10.1021/bi960491t; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; Stringer SE, 1997, J BIOL CHEM, V272, P20508, DOI 10.1074/jbc.272.33.20508; STRYER L, 1968, SCIENCE, V162, P526, DOI 10.1126/science.162.3853.526; TILLACK TW, 1983, BIOCHIM BIOPHYS ACTA, V733, P15, DOI 10.1016/0005-2736(83)90086-X; Valente-Mesquita VL, 1998, BIOPHYS J, V75, P471, DOI 10.1016/S0006-3495(98)77535-6; VANBROCKLYN J, 1993, J NEUROCHEM, V61, P371; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; WANG HM, 1991, BIOCHEM J, V278, P689, DOI 10.1042/bj2780689; WINGFIELD P, 1988, EUR J BIOCHEM, V173, P65, DOI 10.1111/j.1432-1033.1988.tb13967.x; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	51	31	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31468	31475		10.1074/jbc.274.44.31468	http://dx.doi.org/10.1074/jbc.274.44.31468			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531349	hybrid			2022-12-27	WOS:000083379400053
J	Ding, M; Shi, XL; Dong, ZG; Chen, F; Lu, YJ; Castranova, V; Vallyathan, V				Ding, M; Shi, XL; Dong, ZG; Chen, F; Lu, YJ; Castranova, V; Vallyathan, V			Freshly fractured crystalline silica induces activator protein-1 activation through ERKs and p38 MAPK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; FREE-RADICALS; INDUCED TRANSFORMATION; AP-1 TRANSACTIVATION; POTENTIAL ROLE; KINASE KINASE; GROWTH-FACTOR; LUNG INJURY; JB6 CELLS; C-JUN	The transcription factor activator protein-1 (AP-1) reportedly plays an important role in the induction of neoplastic transformation and multiple genes involved in cell proliferation, differentiation, and inflammation. To investigate the mechanisms of silica-induced carcinogenesis, AP-1-luciferase reporter transgenic mice were used as an in vivo model, whereas the JB6 mouse epidermal cell line and a rat lung epithelial cell line were employed as in vitro models to study the effects of silica at the molecular level. Freshly fractured silica caused an 8-fold increase in AP-1 activity in JB6 cells and a 2.5-fold increase in rat lung epithelial cells. The induction of AP-1 activity in cultured cell lines was time- and dose-dependent. Intratracheal administration of silica was also able to induce AP-1 transactivation in transgenic mice. AP-1 activation was first observed at 2 days after silica administration and reached its maximum at 3 days post-exposure of the mice to silica. The signal transduction pathways for AP-1 activation were also investigated using these cell lines. The results demonstrate that freshly fractured silica stimulates mitogen-activated protein kinase (MAPK) family members, as determined by the phosphorylation of p38 MAPK and extracellular signal-regulated protein kinases (ERKs). Inhibition of ERKs with PD98059 or of p38 with SB203580 significantly inhibited silica-induced AP-1 activation. These findings demonstrate for the first time that freshly fractured silica induces AP-1 activation, which may be mediated through p38 MAPK and ERK pathways. Unraveling the complex mechanisms associated with these events may provide insights into the initiation and progression of silica-induced carcinogenesis.	NIOSH, Hlth Effects Lab Div, Pathol & Physiol Res Branch, Morgantown, WV 26505 USA; Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); University of Minnesota System	Vallyathan, V (corresponding author), NIOSH, Hlth Effects Lab Div, Pathol & Physiol Res Branch, 1095 Willowdale Rd, Morgantown, WV 26505 USA.		Shi, Xianglin/B-8588-2012					ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; [Anonymous], 1997, IARC Monogr Eval Carcinog Risks Hum, V68, P1; Barthelman M, 1998, CANCER RES, V58, P711; BERNSTEIN LR, 1994, J BIOL CHEM, V269, P9401; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; BERNSTEIN LR, 1992, MOL CARCINOGEN, V6, P221, DOI 10.1002/mc.2940060308; Chen F, 1998, ANN CLIN LAB SCI, V28, P1; COLBURN NH, 1979, NATURE, V281, P589, DOI 10.1038/281589a0; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRAIGHEAD JE, 1980, JAMA-J AM MED ASSOC, V244, P1939, DOI 10.1001/jama.244.17.1939; Crawford HC, 1996, ENZYME PROTEIN, V49, P20, DOI 10.1159/000468614; DALAL NS, 1990, J TOXICOL ENV HEALTH, V29, P307, DOI 10.1080/15287399009531393; DALAL NS, 1990, FREE RADICAL RES COM, V9, P259, DOI 10.3109/10715769009145684; DANIEL LN, 1993, FREE RADICAL BIO MED, V14, P463, DOI 10.1016/0891-5849(93)90103-2; Daniel LN, 1995, SCAND J WORK ENV HEA, V21, P22; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Ding M, 1999, CANCER RES, V59, P1884; DONG ZG, 1995, CARCINOGENESIS, V16, P749, DOI 10.1093/carcin/16.4.749; Dong ZG, 1997, J BIOL CHEM, V272, P9962; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; Foletta VC, 1998, J LEUKOCYTE BIOL, V63, P139, DOI 10.1002/jlb.63.2.139; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Huang CS, 1997, J BIOL CHEM, V272, P26325, DOI 10.1074/jbc.272.42.26325; *INT AG RES CANC, 1987, IARC MON EV CARC RIS, V42, P1; JOHNSON NF, 1987, AM J IND MED, V11, P93, DOI 10.1002/ajim.4700110110; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li JJ, 1996, CANCER RES, V56, P483; Li JJ, 1997, CANCER RES, V57, P3569; MCDONNELL S, 1990, CANCER METAST REV, V9, P305; MUHLE H, 1989, AM J IND MED, V15, P343, DOI 10.1002/ajim.4700150309; Muhle H, 1995, SCAND J WORK ENV HEA, V21, P27; Muller JM, 1997, METHODS, V11, P301, DOI 10.1006/meth.1996.0424; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; REISER KM, 1979, TOXICOLOGY, V13, P51, DOI 10.1016/S0300-483X(79)80010-4; RINCON M, 1994, EMBO J, V13, P4370, DOI 10.1002/j.1460-2075.1994.tb06757.x; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SHI XG, 1988, J TOXICOL ENV HEALTH, V25, P237, DOI 10.1080/15287398809531205; SHI XL, 1994, ENVIRON HEALTH PERSP, V102, P149, DOI 10.2307/3432231; Shi XL, 1998, J TOXICOL ENV HEAL B, V1, P181, DOI 10.1080/10937409809524551; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; VALLYATHAN V, 1995, AM J RESP CRIT CARE, V152, P1003, DOI 10.1164/ajrccm.152.3.7663775; VALLYATHAN V, 1988, AM REV RESPIR DIS, V138, P1213, DOI 10.1164/ajrccm/138.5.1213; WEHNER AP, 1986, ENVIRON RES, V40, P499, DOI 10.1016/S0013-9351(86)80125-6; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; ZISKIND M, 1976, AM REV RESPIR DIS, V113, P643	49	86	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30611	30616		10.1074/jbc.274.43.30611	http://dx.doi.org/10.1074/jbc.274.43.30611			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521445	hybrid			2022-12-27	WOS:000083276700041
J	Carr-Schmid, A; Durko, N; Cavallius, J; Merrick, WC; Kinzy, TG				Carr-Schmid, A; Durko, N; Cavallius, J; Merrick, WC; Kinzy, TG			Mutations in a GTP-binding motif of eukaryotic elongation factor 1A reduce both translational fidelity and the requirement for nucleotide exchange	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-TU; SACCHAROMYCES-CEREVISIAE; FACTOR 1-ALPHA; GUANINE-NUCLEOTIDE; AMINO-ACID; AMINOGLYCOSIDE ANTIBIOTICS; PHENOTYPIC SUPPRESSION; GUANOSINE DIPHOSPHATE; ESCHERICHIA-COLI; MUTANTS	A series of mutations in the highly conserved N(153)KMD(156)GTP-binding motif of the Saccharomyces cerevisiae translation elongation factor 1A (eEF1A) affect the GTP-dependent functions of the protein and increase misincorporation of amino acids in vitro. Two critical regulatory processes of translation elongation, guanine nucleotide exchange and translational fidelity, were analyzed in strains with the N153T, D156N, and N153T/D156E mutations. These strains are omnipotent suppressors of nonsense mutations, indicating reduced A site fidelity, which correlates with changes either in total translation rates in vivo or in GTPase activity in vitro, All three mutant proteins also show an increase in the K-m for GTP. An in vivo system lacking the guanine nucleotide exchange factor eukaryotic elongation factor 1B alpha (eEF1B alpha) and supported for growth by excess eEF1A was used to show the two mutations with the highest K-m for GTP restore most but not all growth defects found in these eEF1Ba deficient-strains to near wild type. An increase in K-m alone, however, is not sufficient for suppression and may indicate eEF1B alpha performs additional functions. Additionally, eEF1A mutations that suppress the requirement for guanine nucleotide exchange may not effectively perform all the functions of eEF1A in vivo.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA; Canc Inst New Jersey, Piscataway, NJ 08854 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Case Western Reserve University	Kinzy, TG (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, 675 Hoes Ln, Piscataway, NJ 08854 USA.			Kinzy, Terri/0000-0003-1394-9226	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057483] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM57483, R01 GM057483] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Carr-Schmid A, 1999, MOL CELL BIOL, V19, P5257; CARVALHO MDD, 1984, ARCH BIOCHEM BIOPHYS, V234, P603, DOI 10.1016/0003-9861(84)90310-2; Cavallius J, 1998, J BIOL CHEM, V273, P28752, DOI 10.1074/jbc.273.44.28752; CHERNOFF YO, 1994, EMBO J, V13, P906, DOI 10.1002/j.1460-2075.1994.tb06334.x; CONDEELIS J, 1995, TRENDS BIOCHEM SCI, V20, P169, DOI 10.1016/S0968-0004(00)88998-7; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; Dinman JD, 1997, RNA, V3, P870; DONG HJ, 1995, J MOL BIOL, V248, P551, DOI 10.1006/jmbi.1995.0242; Edmonds BT, 1998, J BIOL CHEM, V273, P10288, DOI 10.1074/jbc.273.17.10288; Farabaugh PJ, 1998, RNA, V4, P38; HANEY SA, 1994, J BIOL CHEM, V269, P16541; HIRAGA K, 1993, FEBS LETT, V316, P165, DOI 10.1016/0014-5793(93)81208-H; HWANG YW, 1987, J BIOL CHEM, V262, P13081; HWANG YW, 1989, J BIOL CHEM, V264, P8304; HWANG YW, 1992, J BIOL CHEM, V267, P22198; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KINZY TG, 1995, GENETICS, V141, P481; KURLAND CG, 1990, RIBOSOME, P513; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; MORIKAWA K, 1978, J MOL BIOL, V125, P325, DOI 10.1016/0022-2836(78)90406-0; PALMER E, 1979, NATURE, V277, P148, DOI 10.1038/277148a0; SANDBAKEN MG, 1988, GENETICS, V120, P923; SELIGER LS, 1987, J BIOL CHEM, V262, P16289; Sherman F., 1986, METHODS YEAST GENETI; SINGH A, 1979, NATURE, V277, P146, DOI 10.1038/277146a0; STOFFEL M, 1993, HUM MOL GENET, V2, P1, DOI 10.1093/hmg/2.1.1; WEIJLAND A, 1994, BIOCHEMISTRY-US, V33, P10711, DOI 10.1021/bi00201a019; WEIJLAND A, 1993, FEBS LETT, V330, P334, DOI 10.1016/0014-5793(93)80899-6; YAMADA M, 1989, J BIOL CHEM, V264, P19192	31	71	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30297	30302		10.1074/jbc.274.42.30297	http://dx.doi.org/10.1074/jbc.274.42.30297			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514524	hybrid			2022-12-27	WOS:000083176400103
J	Davare, MA; Dong, F; Rubin, CS; Hell, JW				Davare, MA; Dong, F; Rubin, CS; Hell, JW			The A-kinase anchor protein MAP2B and cAMP-dependent protein kinase are associated with class C L-type calcium channels in neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY BINDING; 2 SIZE FORMS; DIFFERENTIAL SUBCELLULAR-LOCALIZATION; DIFFERENT COOH-TERMINI; HIPPOCAMPAL-NEURONS; REGULATORY SUBUNIT; CA2+ CHANNELS; CATALYTIC SUBUNIT; ALPHA-1 SUBUNIT; RAT-BRAIN	Phosphorylation by cAMP-dependent protein kinase (PKA) increases the activity of class C L-type Ca2+ channels which are clustered at postsynaptic sites and are important regulators of neuronal functions. We investigated a possible mechanism that could ensure rapid and efficient phosphorylation of these channels by PKA upon stimulation of cAMP-mediated signaling pathways. A kinase anchor proteins (AKAPs) bind to the regulatory R subunits of PRA and target the holoenzyme to defined subcellular compartments and substrates. Class C channels isolated from rat brain extracts by immunoprecipitation contain an endogenous kinase that phosphorylates kemptide, a classic PRA substrate peptide, and also the main phosphorylation site for PRA in the pore-forming ru, subunit of the class C channel complex, serine 1928. The kinase activity is inhibited by the PHA inhibitory peptide PKI(5-24) and stimulated by cAMP. Physical association of the catalytic C subunit of PHA with the immunoisolated class C channel complex was confirmed by immunoblotting, A direct protein overlay binding assay performed with P-32-labeled RII beta revealed a prominent AKAP with an M-r of 280,000 in class C channel complexes. The protein was identified by immunoblotting as the microtubule-associated protein MAP2B, a well established AKAP. Class C channels did not contain tubulin and MAP2B association was not disrupted by dilution or addition of nocodazole, two treatments that cause dissociation of microtubules, In vitro experiments show that MAP2B can directly bind to the cu, subunit of the class C channel. Our findings indicate that PKA is an integral part of neuronal class C L-type Ca2+ channels and suggest that the AKAP MAP2B may mediate this interaction. Neither PKA nor MAP2B were detected in immunoprecipitates of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid-type glutamate receptors or class B N-type Ca2+ channels. Accordingly, MAP2B docked at class C Ca2+ channels may be important for recruiting PHA to postsynaptic sites.	Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	University of Wisconsin System; University of Wisconsin Madison; Yeshiva University; Albert Einstein College of Medicine	Hell, JW (corresponding author), Univ Wisconsin, Dept Pharmacol, 3770 MSC,1300 Univ Ave, Madison, WI 53706 USA.		Hell, Johannes W./P-5085-2019	Davare, Monika/0000-0003-1802-7597	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022792] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035563] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22792] Funding Source: Medline; NINDS NIH HHS [R01-NS35563] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BEAN BP, 1984, NATURE, V307, P371, DOI 10.1038/307371a0; BLOSE SH, 1984, J CELL BIOL, V98, P847, DOI 10.1083/jcb.98.3.847; BOLSHAKOV VY, 1994, SCIENCE, V264, P148; BREGMAN DB, 1991, J BIOL CHEM, V266, P7207; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; CACERES A, 1984, J NEUROSCI, V4, P394; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; Christie BR, 1997, J NEUROPHYSIOL, V77, P1651, DOI 10.1152/jn.1997.77.3.1651; CORBIN JD, 1973, J BIOL CHEM, V248, P1813; DeJongh KS, 1996, BIOCHEMISTRY-US, V35, P10392, DOI 10.1021/bi953023c; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; Fraser IDC, 1998, EMBO J, V17, P2261, DOI 10.1093/emboj/17.8.2261; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GLANTZ SB, 1992, MOL BIOL CELL, V3, P1215, DOI 10.1091/mbc.3.11.1215; Graves LM, 1996, J BIOL CHEM, V271, P505, DOI 10.1074/jbc.271.1.505; Gray PC, 1998, NEURON, V20, P1017, DOI 10.1016/S0896-6273(00)80482-1; Gray PC, 1998, CURR OPIN NEUROBIOL, V8, P330, DOI 10.1016/S0959-4388(98)80057-3; Gray PC, 1997, J BIOL CHEM, V272, P6297, DOI 10.1074/jbc.272.10.6297; GRAY R, 1987, NATURE, V327, P620, DOI 10.1038/327620a0; GROSS RA, 1990, J PHYSIOL-LONDON, V429, P483, DOI 10.1113/jphysiol.1990.sp018268; GROSS RE, 1990, J BIOL CHEM, V265, P6896; GROVER LM, 1990, NATURE, V347, P477, DOI 10.1038/347477a0; HARRIS KM, 1994, ANNU REV NEUROSCI, V17, P341, DOI 10.1146/annurev.ne.17.030194.002013; HELL JW, 1995, EMBO J, V14, P3036, DOI 10.1002/j.1460-2075.1995.tb07306.x; HELL JW, 1994, J BIOL CHEM, V269, P7390; HELL JW, 1993, J CELL BIOL, V123, P949, DOI 10.1083/jcb.123.4.949; Hell JW, 1996, P NATL ACAD SCI USA, V93, P3362, DOI 10.1073/pnas.93.8.3362; HELL JW, 1993, J BIOL CHEM, V268, P19451; HELL JW, 1994, ANN NY ACAD SCI, V747, P282; JOHNSON BD, 1994, P NATL ACAD SCI USA, V91, P11492, DOI 10.1073/pnas.91.24.11492; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; Leonard AS, 1998, J BIOL CHEM, V273, P19518, DOI 10.1074/jbc.273.31.19518; Leonard AS, 1997, J BIOL CHEM, V272, P12107, DOI 10.1074/jbc.272.18.12107; Lester LB, 1996, J BIOL CHEM, V271, P9460, DOI 10.1074/jbc.271.16.9460; LEVENTHAL PS, 1993, J BIOL CHEM, V268, P13906; LOHMANN SM, 1984, P NATL ACAD SCI-BIOL, V81, P6723, DOI 10.1073/pnas.81.21.6723; Marrion NV, 1998, NATURE, V395, P900, DOI 10.1038/27674; NDUBUKA C, 1993, J BIOL CHEM, V268, P7621; PETRALIA RS, 1992, J COMP NEUROL, V318, P329, DOI 10.1002/cne.903180309; REUTER H, 1983, NATURE, V301, P569, DOI 10.1038/301569a0; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; RUBINO HM, 1989, NEURON, V3, P631, DOI 10.1016/0896-6273(89)90273-0; SCULPTOREANU A, 1993, P NATL ACAD SCI USA, V90, P10135, DOI 10.1073/pnas.90.21.10135; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; Tibbs VC, 1998, J BIOL CHEM, V273, P25783, DOI 10.1074/jbc.273.40.25783; VALLEE RB, 1981, J CELL BIOL, V90, P568, DOI 10.1083/jcb.90.3.568; WALTON GM, 1987, ANAL BIOCHEM, V161, P425, DOI 10.1016/0003-2697(87)90471-4; WEI XY, 1994, J BIOL CHEM, V269, P1635; WENTHOLD RJ, 1992, J BIOL CHEM, V267, P501; WESTENBROEK RE, 1992, NEURON, V9, P1099, DOI 10.1016/0896-6273(92)90069-P; YANG S, 1995, BIOCHEMISTRY-US, P6267	53	114	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30280	30287		10.1074/jbc.274.42.30280	http://dx.doi.org/10.1074/jbc.274.42.30280			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514522	hybrid			2022-12-27	WOS:000083176400101
J	Lindley, TE; Scheiderer, CL; Walsh, PJ; Wood, CM; Bergman, HL; Bergman, AL; Laurent, P; Wilson, P; Anderson, PM				Lindley, TE; Scheiderer, CL; Walsh, PJ; Wood, CM; Bergman, HL; Bergman, AL; Laurent, P; Wilson, P; Anderson, PM			Muscle as the primary site of urea cycle enzyme activity in an alkaline lake-adapted tilapia, Oreochromis alcalicus grahami	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBAMOYL-PHOSPHATE SYNTHETASE; AIR-BREATHING TELEOST; ACETYL-L-GLUTAMATE; HETEROPNEUSTES-FOSSILIS; SQUALUS-ACANTHIAS; MESSENGER-RNA; SUBCELLULAR-LOCALIZATION; MICROPTERUS-SALMOIDES; BATRACHOIDID FISHES; MAGADI TILAPIA	The tilapia fish Oreochromis alcalicus grahami from Kenya has adapted to living in waters at pH 10.5 by excreting the end product of nitrogen metabolism as urea rather than as ammonia directly across the gills as occurs in most fish, The level of activity in liver of the first enzyme in the urea cycle pathway, carbamoyl-phosphate synthetase III (CPSase III), is too low to account for the observed high rates of urea excretion. We report here the surprising finding that CPSase III and all other urea cycle enzyme activities are present in muscle of this species at levels more than sufficient to account for the rate of urea excretion; in addition, the basic kinetic properties of the CPSase III appear to be different hom those of other known type III CPSases. The sequence of the CPSase III cDNA is reported as well as the finding that glutamine synthetase activity is present in liver but not in muscle. This unusual form of adaptation may have occurred because of the apparent impossibility of packaging the needed amount of urea cycle enzymes in liver.	Univ Minnesota, Sch Med, Dept Biochem & Mol Biol, Duluth, MN 55812 USA; Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, Miami, FL 33149 USA; McMaster Univ, Dept Biol, Hamilton, ON L8S 4K1, Canada; Univ Wyoming, Dept Zool & Physiol, Laramie, WY 82071 USA	University of Minnesota System; University of Minnesota Duluth; University of Miami; McMaster University; University of Wyoming	Anderson, PM (corresponding author), Univ Minnesota, Sch Med, Dept Biochem & Mol Biol, Duluth, MN 55812 USA.	panderso@d.umn.edu	Wood, Chris M/C-3021-2009	Wood, Chris M/0000-0002-9542-2219				Anderson PA, 1995, AAOS INSTR COURS LEC, V44, P57; ANDERSON PM, 1981, J BIOL CHEM, V256, P2228; ANDERSON PM, 1995, J EXP BIOL, V198, P755; ANDERSON PM, 1995, NITROGEN METABOLISM, P33; Campbell J.W., 1991, Biochemistry and Molecular Biology of Fishes, V1, P43; CASEY CA, 1983, J BIOL CHEM, V258, P8723; CHAKRAVORTY J, 1989, BIOCHEM INT, V19, P519; CURTHOYS NP, 1973, J BIOL CHEM, V248, P162; DKHAR J, 1991, BIOCHEM INT, V25, P1061; Felskie AK, 1998, COMP BIOCHEM PHYS B, V119, P355, DOI 10.1016/S0305-0491(97)00361-1; HONG J, 1995, J BIOL CHEM, V270, P14130, DOI 10.1074/jbc.270.23.14130; Julsrud EA, 1998, ARCH BIOCHEM BIOPHYS, V350, P55, DOI 10.1006/abbi.1997.0511; Kong HY, 1998, ARCH BIOCHEM BIOPHYS, V350, P157, DOI 10.1006/abbi.1997.0522; Korte JJ, 1997, J BIOL CHEM, V272, P6270, DOI 10.1074/jbc.272.10.6270; NYUNOYA H, 1985, J BIOL CHEM, V260, P9346; RAIJMAN L, 1976, ARCH BIOCHEM BIOPHYS, V175, P270, DOI 10.1016/0003-9861(76)90508-7; RANDALL DJ, 1989, NATURE, V337, P165, DOI 10.1038/337165a0; RUBIO V, 1983, EUR J BIOCHEM, V134, P337, DOI 10.1111/j.1432-1033.1983.tb07572.x; Saha N, 1997, COMP BIOCHEM PHYS B, V116, P57, DOI 10.1016/S0305-0491(96)00193-9; SAHA N, 1987, J EXP ZOOL, V241, P137, DOI 10.1002/jez.1402410117; SHANKAR RA, 1985, ARCH BIOCHEM BIOPHYS, V239, P248, DOI 10.1016/0003-9861(85)90833-1; Walsh PJ, 1997, ANNU REV PHYSIOL, V59, P299, DOI 10.1146/annurev.physiol.59.1.299; Wood Chris M., 1993, P379; WOOD CM, 1994, J EXP BIOL, V189, P13; WOOD CM, 1989, RESP PHYSIOL, V77, P1, DOI 10.1016/0034-5687(89)90025-X; XIONG XF, 1989, ARCH BIOCHEM BIOPHYS, V270, P198, DOI 10.1016/0003-9861(89)90021-0	26	59	61	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29858	29861		10.1074/jbc.274.42.29858	http://dx.doi.org/10.1074/jbc.274.42.29858			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514466	hybrid			2022-12-27	WOS:000083176400045
J	Schinke, T; Karsenty, G				Schinke, T; Karsenty, G			Characterization of Osf1, an osteoblast-specific transcription factor binding to a critical cis-acting element in the mouse Osteocalcin promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; TRANSGENIC MICE; CYCLIC-AMP; CLEIDOCRANIAL DYSPLASIA; GENE-EXPRESSION; SOMATOSTATIN GENE; IN-VIVO; PROTEINS; BONE; DIFFERENTIATION	To elucidate the mechanisms of osteoblast-specific gene expression we are studying the regulation of osteocalcin, the most osteoblast-specific gene. Previous studies of OG2, one of the two mouse osteocalcin genes, identified two osteoblast-specific cia-acting elements, OSE1 and OSE2, the latter being the binding site of Cbfa1, the only osteoblast-specific transcription factor known to date. Here we show that OSE1. is a cis-acting element as important as OSE2 for the osteoblast-specific expression of OG2 in cell culture and transgenic mice. We also show that OSE1 is present in the promoter of several osteoblast-specific genes including Cbfa1 itself. These biological features demonstrate the importance of OSE1 and led us to further characterize this site and the factor binding to it, provisionally termed Osf1, We first defined the core OSE1 sequence, 5'-TTACATCA-3', which is necessary and sufficient for Osf1 binding do DNA. This sequence has no strong homology to any known transcription factor-binding sites. As a first step in identifying Osf1, we performed an analytical purification of this protein using nuclear extracts from two different osteoblastic cell lines, We purified Osf1 to homogeneity through a five-step procedure including a renaturation experiment and found that its apparent molecular mass is 40 kDa, In conclusion, this study indicates the existence of multiple osteoblast-specific cia-acting elements of equal importance in controlling OG2 promoter activity and provides the first biochemical characterization of Osf1, a novel osteoblast-specific transcription factor.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	Baylor College of Medicine	Karsenty, G (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011290] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR43655] Funding Source: Medline; NIDCR NIH HHS [R01 DE11290] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ARNOTT D, 1993, CLIN CHEM, V39, P2005; Aubin Jane E., 1996, P51; Ausubel FM, 1995, CURRENT PROTOCOL MOL; BEDALOV A, 1995, J BONE MINER RES, V10, P1443; BYERS PH, 1992, ANNU REV MED, V43, P269, DOI 10.1146/annurev.med.43.1.269; Chen JK, 1996, J BONE MINER RES, V11, P654; Clemens TL, 1997, J BONE MINER RES, V12, P1570, DOI 10.1359/jbmr.1997.12.10.1570; DERYCKERE F, 1994, BIOTECHNIQUES, V16, P405; DESBOIS C, 1994, J BIOL CHEM, V269, P1183; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; Frendo JL, 1998, J BIOL CHEM, V273, P30509, DOI 10.1074/jbc.273.46.30509; Gorski JP, 1998, CURR OPIN CELL BIOL, V10, P586, DOI 10.1016/S0955-0674(98)80033-1; HAI T, 1988, GENE DEV, V2, P1216, DOI 10.1101/gad.2.10.1216; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HAUSCHKA PV, 1989, PHYSIOL REV, V69, P990, DOI 10.1152/physrev.1989.69.3.990; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; Ishida Y, 1998, J BONE MINER RES, V13, P1822, DOI 10.1359/jbmr.1998.13.12.1822; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KLEEREKOPER M, 1998, METABOLIC BONE DIS, P387; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797-307; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; MONTECINO M, 1994, BIOCHEMISTRY-US, V33, P348, DOI 10.1021/bi00167a045; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MORRISON NA, 1989, SCIENCE, V246, P1158, DOI 10.1126/science.2588000; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; ORKIN SH, 1995, CURR OPIN CELL BIOL, V7, P870, DOI 10.1016/0955-0674(95)80072-7; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; POLIARD A, 1993, J CELL SCI, V106, P503; PROCKOP DJ, 1984, NEW ENGL J MED, V311, P376, DOI 10.1056/NEJM198408093110606; Rossert JA, 1996, P NATL ACAD SCI USA, V93, P1027, DOI 10.1073/pnas.93.3.1027; Rowe D.W., 1998, METABOLIC BONE DIS C, V3, P651, DOI [10.1016/B978-012068700-8/50024-4, DOI 10.1016/B978-012068700-8/50024-4]; Ryoo HM, 1997, MOL ENDOCRINOL, V11, P1681, DOI 10.1210/me.11.11.1681; Treier M, 1996, CURR OPIN CELL BIOL, V8, P833, DOI 10.1016/S0955-0674(96)80085-8; Umayahara Y, 1999, J BIOL CHEM, V274, P10609, DOI 10.1074/jbc.274.15.10609; Umayahara Y, 1997, J BIOL CHEM, V272, P31793, DOI 10.1074/jbc.272.50.31793; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8; Zhang R, 1997, J BIOL CHEM, V272, P110, DOI 10.1074/jbc.272.1.110	46	52	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30182	30189		10.1074/jbc.274.42.30182	http://dx.doi.org/10.1074/jbc.274.42.30182			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514508	hybrid			2022-12-27	WOS:000083176400087
J	Blander, G; Kipnis, J; Leal, JFM; Yu, CE; Schellenberg, GD; Oren, M				Blander, G; Kipnis, J; Leal, JFM; Yu, CE; Schellenberg, GD; Oren, M			Physical and functional interaction between p53 and the Werner's syndrome protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME GENE-PRODUCT; DNA HELICASE ACTIVITY; WILD-TYPE P53; MONOCLONAL-ANTIBODIES; SPONTANEOUS IMMORTALIZATION; TUMOR SUPPRESSION; CELL SENESCENCE; MUTANT P53; FIBROBLASTS; EXPRESSION	Werner's syndrome is a human autosomal recessive disorder leading to premature aging. The mutations responsible for this disorder have recently been localized to a gene (WRN) encoding a protein that possesses DNA helicase and exonuclease activities. Patients carrying WRN gene mutations exhibit an elevated rate of cancer, accompanied by increased genomic instability. The latter features are also characteristic of the loss of function of p53, a tumor suppressor that is very frequently inactivated in human cancer. Moreover, changes in the activity of p53 have been implicated in the onset of cellular replicative senescence. We report here that the WRN protein can form a specific physical interaction with p53. This interaction involves the carboxyl-terminal part of WRN and the extreme carboxyl terminus of p53, a region that plays an important role in regulating the functional state of p53. A small fraction of WRN can be found in complex with endogenous p53 in nontransfected cells. Overexpression of WRN leads to augmented p53-dependent transcriptional activity and induction of p21(Waf1) protein expression. These findings support the existence of a cross-talk between WRN and p53, which may be important for maintaining genomic integrity and for preventing the accumulation of aberrations that can give rise to premature senescence and cancer.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Vet Affairs Med Ctr, Seattle, WA 98108 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Neurol, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	Weizmann Institute of Science; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Oren, M (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	lioren@wiccmail.weizmann.ac.il	Kipnis, Jonathan/AGG-9735-2022; Leal, Juan F Martinez/N-6328-2013	Kipnis, Jonathan/0000-0002-3714-517X; Leal, Juan F Martinez/0000-0002-7538-0875; Oren, Moshe/0000-0003-4311-7172	NCI NIH HHS [R01 CA40099] Funding Source: Medline; NIA NIH HHS [AG120192] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040099] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; Bennett WP, 1999, J PATHOL, V187, P8, DOI 10.1002/(SICI)1096-9896(199901)187:1<8::AID-PATH232>3.0.CO;2-Y; BLOM T, 1992, EUR J IMMUNOL, V22, P2025, DOI 10.1002/eji.1830220811; Bond J, 1996, ONCOGENE, V13, P2097; BOND JA, 1995, CANCER RES, V55, P2404; CHENG RZ, 1990, MUTAT RES, V237, P259, DOI 10.1016/0921-8734(90)90008-F; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; Collister M, 1998, CARCINOGENESIS, V19, P2115, DOI 10.1093/carcin/19.12.2115; El-Deiry WS, 1998, CURR TOP MICROBIOL, V227, P121; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; FARAGHER RGA, 1993, P NATL ACAD SCI USA, V90, P12030, DOI 10.1073/pnas.90.24.12030; Goto M, 1996, CANCER EPIDEM BIOMAR, V5, P239; Gottlieb E, 1998, EMBO J, V17, P3587, DOI 10.1093/emboj/17.13.3587; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Hollstein M, 1997, Recent Results Cancer Res, V143, P369; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Kipling D, 1997, J CLIN PATHOL-MOL PA, V50, P234; Lebel M, 1998, P NATL ACAD SCI USA, V95, P13097, DOI 10.1073/pnas.95.22.13097; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MARSTON NJ, 1995, ONCOGENE, V10, P1709; Martin GM, 1997, MOL MED, V3, P356, DOI 10.1007/BF03401682; Matuoka K, 1998, BBA-MOL CELL RES, V1401, P211, DOI 10.1016/S0167-4889(97)00133-X; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MITSUDOMI T, 1992, ONCOGENE, V7, P171; POOT M, 1992, EXP CELL RES, V202, P267, DOI 10.1016/0014-4827(92)90074-I; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Prives C, 1999, J PATHOL, V187, P112; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Shen JC, 1998, NUCLEIC ACIDS RES, V26, P2879, DOI 10.1093/nar/26.12.2879; Sinclair DA, 1997, SCIENCE, V277, P1313, DOI 10.1126/science.277.5330.1313; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; Smith JR, 1997, AGING-CLIN EXP RES, V9, P437; Spillare EA, 1999, GENE DEV, V13, P1355, DOI 10.1101/gad.13.11.1355; STEFANINI M, 1989, MUTAT RES, V219, P179, DOI 10.1016/0921-8734(89)90013-1; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; Tirode F, 1999, MOL CELL, V3, P87, DOI 10.1016/S1097-2765(00)80177-X; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Wang YC, 1998, ONCOGENE, V17, P1923, DOI 10.1038/sj.onc.1202113; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; Yamabe Y, 1998, MOL CELL BIOL, V18, P6191, DOI 10.1128/MCB.18.11.6191; Yan H, 1998, NAT GENET, V19, P375, DOI 10.1038/1263; Yu CE, 1997, AM J HUM GENET, V60, P330; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	67	140	141	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29463	29469		10.1074/jbc.274.41.29463	http://dx.doi.org/10.1074/jbc.274.41.29463			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506209	hybrid			2022-12-27	WOS:000083017800088
J	Snapp, EL; Landfear, SM				Snapp, EL; Landfear, SM			Characterization of a targeting motif for a flagellar membrane protein in Leishmania enriettii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPANOSOMA-BRUCEI; GLUCOSE TRANSPORTERS; GENE; EXPRESSION; MOTILITY; POCKET; DOMAIN; LOCALIZATION; EVOLUTION; ISOFORMS	The surface membranes of eukaryotic flagella and cilia are contiguous with the plasma membrane. Despite the absence of obvious physical structures that could form a barrier between the two membrane domains, the lipid and protein compositions of flagella and cilia are distinct from the rest of the cell surface membrane. We have exploited a flagellar glucose transporter from the parasitic protozoan Leishmania enriettii as a model system to characterize the first targeting motif for a flagellar membrane protein in any eukaryotic organism. In this study, we demonstrate that the flagellar membrane-targeting motif is recognized by several species of Leishmania. Previously, we demonstrated that the 130 amino acid NH2-terminal cytoplasmic domain of isoform 1 glucose transporter was sufficient to target a nonflagellar integral membrane protein into the flagellar membrane. We have now determined that an essential flagellar targeting signal is located between amino acids 20 and 35 of the NH2-terminal domain. We have further analyzed the role of specific amino acids in this region by alanine replacement mutagenesis and determined that single amino acid substitutions did not abrogate targeting to the flagellar membrane. However, individual mutations located within a cluster of five contiguous amino acids, RTGTT, conferred differences in the degree of targeting to the flagellar membrane and the flagellar pocket, implying a role for these residues in the mechanism of flagellar trafficking.	Oregon Hlth Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA	Oregon Health & Science University	Landfear, SM (corresponding author), Oregon Hlth Sci Univ, Dept Mol Microbiol & Immunol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.		Snapp, Erik Lee/H-7152-2019	Snapp, Erik Lee/0000-0001-9482-2272; Landfear, Scott/0000-0002-1643-6664	NIAID NIH HHS [AI01162, AI25920] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025920] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALEXANDRE S, 1990, MOL BIOCHEM PARASIT, V43, P279, DOI 10.1016/0166-6851(90)90152-C; BALBER AE, 1990, CRIT REV IMMUNOL, V10, P177; BLOODGOOD RA, 1992, BIOL CELL, V76, P291, DOI 10.1016/0248-4900(92)90431-Y; CAIRNS BR, 1989, P NATL ACAD SCI USA, V85, P2130; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; Colbert HA, 1997, J NEUROSCI, V17, P8259; Cosson J, 1996, CELL BIOL INT, V20, P83, DOI 10.1006/cbir.1996.0012; Croan DG, 1997, MOL BIOCHEM PARASIT, V89, P149, DOI 10.1016/S0166-6851(97)00111-4; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; Dwyer ND, 1998, CELL, V93, P455, DOI 10.1016/S0092-8674(00)81173-3; ENGMAN DM, 1989, J BIOL CHEM, V264, P18627; FERNANDES AP, 1993, P NATL ACAD SCI USA, V90, P11608, DOI 10.1073/pnas.90.24.11608; Godsel LM, 1999, EMBO J, V18, P2057, DOI 10.1093/emboj/18.8.2057; IOVANNISCI DM, 1983, J PARASITOL, V69, P633, DOI 10.2307/3281131; KANESHIRO ES, 1989, CILIARY FLAGELLAR ME, P241; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KOZMINSKI KG, 1995, J CELL BIOL, V131, P1517, DOI 10.1083/jcb.131.6.1517; KOZMINSKI KG, 1993, P NATL ACAD SCI USA, V90, P5519, DOI 10.1073/pnas.90.12.5519; Lindemann CB, 1997, INT REV CYTOL, V173, P1; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Overath P, 1997, TRENDS CELL BIOL, V7, P27, DOI 10.1016/S0962-8924(97)10046-0; Owen DJ, 1998, SCIENCE, V282, P1327, DOI 10.1126/science.282.5392.1327; PAINDAVOINE P, 1992, MOL CELL BIOL, V12, P1218, DOI 10.1128/MCB.12.3.1218; PIPER RC, 1995, J CELL BIOL, V128, P499, DOI 10.1083/jcb.128.4.499; Roayaie K, 1998, NEURON, V20, P55, DOI 10.1016/S0896-6273(00)80434-1; Rosenbaum JL, 1999, J CELL BIOL, V144, P385, DOI 10.1083/jcb.144.3.385; SCHAFFHAUSEN B, 1995, BBA-REV CANCER, V1242, P61, DOI 10.1016/0304-419X(95)00004-Y; Sengupta P, 1996, CELL, V84, P899, DOI 10.1016/S0092-8674(00)81068-5; Seyfang A, 1997, J BIOL CHEM, V272, P24210, DOI 10.1074/jbc.272.39.24210; Shinohara H, 1998, EUR J NEUROSCI, V10, P699, DOI 10.1046/j.1460-9568.1998.00088.x; Snapp EL, 1997, J CELL BIOL, V139, P1775, DOI 10.1083/jcb.139.7.1775; STACK SP, 1990, MOL CELL BIOL, V10, P6785, DOI 10.1128/MCB.10.12.6785; THORENS B, 1990, DIABETES CARE, V13, P209, DOI 10.2337/diacare.13.3.209; WEBSTER P, 1993, PARASITOL TODAY, V9, P201, DOI 10.1016/0169-4758(93)90008-4; WU YM, 1994, BIOCHEM J, V304, P833, DOI 10.1042/bj3040833	36	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29543	29548		10.1074/jbc.274.41.29543	http://dx.doi.org/10.1074/jbc.274.41.29543			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506220	hybrid			2022-12-27	WOS:000083017800099
J	Buton, X; Mamdouh, Z; Ghosh, R; Du, H; Kuriakose, G; Beatini, N; Grabowski, GA; Maxfield, FR; Tabas, I				Buton, X; Mamdouh, Z; Ghosh, R; Du, H; Kuriakose, G; Beatini, N; Grabowski, GA; Maxfield, FR; Tabas, I			Unique cellular events occurring during the initial interaction of macrophages with matrix-retained or methylated aggregated low density lipoprotein (LDL) - Prolonged cell-surface contact during which LDL-cholesteryl ester hydrolysis exceeds LDL protein degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; MOUSE PERITONEAL-MACROPHAGES; HUMAN MONOCYTE-MACROPHAGES; TO-RETENTION HYPOTHESIS; COATED PIT FORMATION; SCAVENGER RECEPTOR; FRUSTRATED PHAGOCYTOSIS; ATHEROGENIC LIPOPROTEINS; ATHEROSCLEROTIC LESIONS; HUMAN-FIBROBLASTS	A critical event in atherogenesis is the interaction of arterial wall macrophages with subendothelial lipoproteins, Although most studies have investigated this interaction by incubating cultured macrophages with monomeric lipoproteins dissolved in media, arterial wall macrophages encounter lipoproteins that are mostly bound to subendothelial extracellular matrix, and these lipoproteins are often aggregated or fused. Herein, we utilize a specialized cell-culture system to study the initial interaction of macrophages with aggregated low density lipoprotein (LDL) bound to extracellular matrix. The aggregated LDL remains extracellular for a relatively prolonged period of time and becomes lodged in invaginations in the surface of the macrophages. As expected, the degradation of the protein moiety of the LDL was very slow. Remarkably, however, hydrolysis of the cholesteryl ester (CE) moiety of the LDL was 3-7-fold higher than that of the protein moiety, in stark contrast to the situation with receptor-mediated endocytosis of acetyl-LDL, Similar results were obtained using another experimental system in which the degradation of aggregated LDL protein was delayed by LDL methylation rather than by retention on matrix. Additional experiments indicated the following properties of this interaction: Co) LDL-CE hydrolysis is catalyzed by lysosomal acid lipase; (b) neither scavenger receptors nor the LDL receptor appear necessary for the excess LDL-CE hydrolysis; and Cc) LDL-CE hydrolysis in this system is resistant to cellular potassium depletion, which further distinguishes this process from receptor-mediated endocytosis. In summary, experimental systems specifically designed to mimic the in vivo interaction of arterial wall macrophages with subendothelial Lipoproteins have demonstrated an initial period of prolonged cell-surface contact in which CE hydrolysis exceeds protein degradation.	Columbia Univ, Dept Med, New York, NY 10032 USA; Columbia Univ, Dept Anat & Cell Biol, New York, NY USA; Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA; Childrens Hosp Res Fdn, Div Human Genet, Cincinnati, OH 45229 USA	Columbia University; Columbia University; Cornell University; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Tabas, I (corresponding author), Columbia Univ, Dept Med, 630 W 168th St, New York, NY 10032 USA.		Maxfield, Fred/M-6747-2019; Maxfield, Fred/A-1718-2011	Maxfield, Fred/0000-0003-4396-8866; 	NHLBI NIH HHS [HL-57560, HL-56984] Funding Source: Medline; NIDDK NIH HHS [DK-36729] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056984, R01HL057560] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036729] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMAD TY, 1985, J LIPID RES, V26, P1160; AVIRAM M, 1995, BIOCHEM BIOPH RES CO, V216, P501, DOI 10.1006/bbrc.1995.2651; BAINTON DF, 1989, AM J PATHOL, V134, P15; BALL RY, 1995, ATHEROSCLEROSIS, V114, P45, DOI 10.1016/0021-9150(94)05463-S; Bergstrand H, 1990, Agents Actions Suppl, V30, P199; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; BOTTALICO LA, 1993, J BIOL CHEM, V268, P8569; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BRUCE C, 1995, J BIOL CHEM, V270, P11532, DOI 10.1074/jbc.270.19.11532; CARPENTIER JL, 1989, J CELL PHYSIOL, V138, P519, DOI 10.1002/jcp.1041380311; CORDIER G, 1981, ANN INST PASTEUR IMM, VD132, P3; CORNICELLI JA, 1983, ARTERIOSCLEROSIS, V3, P560, DOI 10.1161/01.ATV.3.6.560; CUPERS P, 1994, J CELL BIOL, V127, P725, DOI 10.1083/jcb.127.3.725; Du H, 1998, HUM MOL GENET, V7, P1347, DOI 10.1093/hmg/7.9.1347; Fluiter K, 1997, BIOCHEM J, V326, P515, DOI 10.1042/bj3260515; FOGELMAN AM, 1981, J LIPID RES, V22, P1131; GARDINER EE, 1994, EUR J BIOCHEM, V221, P871, DOI 10.1111/j.1432-1033.1994.tb18802.x; GERRITY RG, 1981, AM J PATHOL, V103, P181; Goldberg IJ, 1996, J LIPID RES, V37, P693; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GOLDSTEIN JL, 1981, ARTERIOSCLEROSIS, V1, P210, DOI 10.1161/01.ATV.1.3.210; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2; Guyton JR, 1996, ARTERIOSCL THROM VAS, V16, P4, DOI 10.1161/01.ATV.16.1.4; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HENRIKSEN T, 1981, P NATL ACAD SCI-BIOL, V78, P6499, DOI 10.1073/pnas.78.10.6499; HOFF HF, 1995, CURR OPIN LIPIDOL, V6, P317, DOI 10.1097/00041433-199510000-00012; HOFF HF, 1992, J BIOL CHEM, V267, P602; HOFF HF, 1985, ANN NY ACAD SCI, V454, P183, DOI 10.1111/j.1749-6632.1985.tb11857.x; HOFF HF, 1990, EUR HEART J, V11, P105, DOI 10.1093/eurheartj/11.suppl_E.105; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; KHOO JC, 1988, ARTERIOSCLEROSIS, V8, P348, DOI 10.1161/01.ATV.8.4.348; KHOO JC, 1989, BIOCHIM BIOPHYS ACTA, V1012, P215, DOI 10.1016/0167-4889(89)90099-2; Koval M, 1998, EXP CELL RES, V242, P265, DOI 10.1006/excr.1998.4110; KRUSKAL BA, 1987, J CELL BIOL, V105, P2685, DOI 10.1083/jcb.105.6.2685; Kruth HS, 1997, CURR OPIN LIPIDOL, V8, P246, DOI 10.1097/00041433-199710000-00002; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; Libby Peter, 1993, Current Opinion in Lipidology, V4, P355, DOI 10.1097/00041433-199310000-00003; LISZT F, 1991, EUR J CLIN CHEM CLIN, V29, P123; MAHLEY RW, 1980, J LIPID RES, V21, P970; MYERS JN, 1993, J CELL BIOL, V123, P1389, DOI 10.1083/jcb.123.6.1389; NIEVELSTEIN PFEM, 1991, ARTERIOSCLER THROMB, V11, P1795, DOI 10.1161/01.ATV.11.6.1795; NIEVELSTEINPOST P, 1994, ARTERIOSCLER THROMB, V14, P1151, DOI 10.1161/01.ATV.14.7.1151; Pentikainen MO, 1996, J LIPID RES, V37, P2638; PITAS RE, 1981, ARTERIOSCLEROSIS, V1, P177, DOI 10.1161/01.ATV.1.3.177; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; Reaven E, 1998, ENDOCRINOLOGY, V139, P2847, DOI 10.1210/en.139.6.2847; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Rigotti A, 1997, CURR OPIN LIPIDOL, V8, P181, DOI 10.1097/00041433-199706000-00009; RINNINGER F, 1995, BBA-LIPID LIPID MET, V1255, P141, DOI 10.1016/0005-2760(94)00228-Q; ROSS AC, 1984, J BIOL CHEM, V259, P815; SCHAFFNER T, 1980, AM J PATHOL, V100, P57; Schissel SL, 1996, J CLIN INVEST, V98, P1455, DOI 10.1172/JCI118934; Schissel SL, 1998, J BIOL CHEM, V273, P2738, DOI 10.1074/jbc.273.5.2738; SMITH EB, 1976, ATHEROSCLEROSIS, V25, P71, DOI 10.1016/0021-9150(76)90049-6; SMITH JD, 1995, P NATL ACAD SCI USA, V92, P8264, DOI 10.1073/pnas.92.18.8264; SRIPADA PK, 1987, J LIPID RES, V28, P710; Stangl H, 1998, J BIOL CHEM, V273, P31002, DOI 10.1074/jbc.273.47.31002; STEINBRECHER UP, 1992, ARTERIOSCLER THROMB, V12, P608, DOI 10.1161/01.ATV.12.5.608; SUITS AG, 1989, P NATL ACAD SCI USA, V86, P2713, DOI 10.1073/pnas.86.8.2713; TABAS I, 1993, J BIOL CHEM, V268, P20419; TABAS I, 1990, J CELL BIOL, V111, P929, DOI 10.1083/jcb.111.3.929; TABAS I, 1995, CURR OPIN LIPIDOL, V6, P260, DOI 10.1097/00041433-199510000-00004; TABAS I, 1999, CHOLESTEROL TRAFFICK; TAKEMURA R, 1986, J CELL BIOL, V102, P55, DOI 10.1083/jcb.102.1.55; Tamminen M, 1999, ARTERIOSCL THROM VAS, V19, P847, DOI 10.1161/01.ATV.19.4.847; TERTOV VV, 1989, BIOCHEM BIOPH RES CO, V163, P489, DOI 10.1016/0006-291X(89)92163-3; VANBERKEL TJC, 1991, J BIOL CHEM, V266, P2282; WEISGRABER KH, 1978, J BIOL CHEM, V253, P9053; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551; Williams KJ, 1998, CURR OPIN LIPIDOL, V9, P471, DOI 10.1097/00041433-199810000-00012; WOLF DE, 1985, BIOCHEMISTRY-US, V24, P582, DOI 10.1021/bi00324a006; XU XX, 1991, J BIOL CHEM, V266, P24849; ZHA X, 1996, ARTERIOSCLER THROMB, V90, P1421; Zhang WY, 1997, J BIOL CHEM, V272, P31700, DOI 10.1074/jbc.272.50.31700	77	58	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32112	32121		10.1074/jbc.274.45.32112	http://dx.doi.org/10.1074/jbc.274.45.32112			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542246	hybrid			2022-12-27	WOS:000083532100054
J	Hede, SE; Amstrup, J; Christoffersen, BC; Novak, I				Hede, SE; Amstrup, J; Christoffersen, BC; Novak, I			Purinoceptors evoke different electrophysiological responses in pancreatic ducts - P2Y inhibits K+ conductance, and P2X stimulates cation conductance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SUBMANDIBULAR-GLAND; PAROTID ACINAR-CELLS; EXTRACELLULAR-ATP; INTRACELLULAR CALCIUM; NUCLEOTIDE RECEPTOR; MEMBRANE VOLTAGE; EPITHELIAL-CELLS; FUNCTIONAL EXPRESSION; PURINERGIC RECEPTORS; TRANSPORT-SYSTEMS	In epithelia, extracellular nucleotides are often associated with regulation of ion transporters, especially Cl- channels. In this study, we investigated which purinoceptors are present in native pancreatic ducts and how they regulate ion transport. We applied whole-cell patch-clamp recordings, intracellular Ca2+ and pH measurements, and reverse transcription-polymerase chain reaction (RT-PCR) analysis. The data show two types of purinoceptors and cellular responses. UTP and ATP produced large Ca2+ transients, a decrease in intracellular pH, 8-10-mV depolarization of the membrane voltage, and a decrease in the whole-cell conductance. The membrane effects were due to closure of K+ channels, as confirmed by dependence on extracellular K+. UTP/ATP effects could be associated with P2Y(2) purinoceptors, and RT-PCR revealed mRNAs for P2Y(2) and P2Y(4) receptors. On the other hand, 2',3'-O-4-benzoylbenzoyl-ATP induced Ca2+ influx and similar to 20-mV depolarization of the membrane voltage with a concomitant increase in the whole-cell conductance. These effects were depend ent on extracellular Na+, not Cl-, indicating opening of cation channels associated with P2X(7) purinoceptors. RT-PCR showed mRNAs for P2X(7) and P2X(4) receptors. In microperfused ducts, luminal (but not basolateral) ATP caused large depolarizations of membrane voltages recorded with microelectrodes, consistent with luminal localization of P2X(7) receptors. Thus, P2Y(2) (and possibly P2Y(4)) purinoceptors inhibit K+ channels and may not support secretion in native duets. P2X(7) (and possibly P2X(4)) receptors are associated with cation channels and may contribute to regulation of secretion.	Univ Copenhagen, August Krogh Inst, DK-2100 Copenhagen O, Denmark	University of Copenhagen	Novak, I (corresponding author), Univ Copenhagen, August Krogh Inst, Univ Pk 13, DK-2100 Copenhagen O, Denmark.	inovak@aki.ku.dk	Novak, Ivana/M-2791-2014	Novak, Ivana/0000-0002-8917-8010				Alzola E, 1998, J BIOL CHEM, V273, P30208, DOI 10.1074/jbc.273.46.30208; Amsallem H, 1996, AM J PHYSIOL-CELL PH, V271, pC1546, DOI 10.1152/ajpcell.1996.271.5.C1546; BLEICH M, 1990, PFLUG ARCH EUR J PHY, V415, P449, DOI 10.1007/BF00373623; Bogdanov YD, 1998, BRIT J PHARMACOL, V124, P428, DOI 10.1038/sj.bjp.0701880; Buell G, 1996, EMBO J, V15, P55, DOI 10.1002/j.1460-2075.1996.tb00333.x; Chan HC, 1996, AM J PHYSIOL-CELL PH, V271, pC469, DOI 10.1152/ajpcell.1996.271.2.C469; Cheung CY, 1998, BIOL SIGNAL RECEPT, V7, P321; Christoffersen BC, 1998, PFLUG ARCH EUR J PHY, V436, P33, DOI 10.1007/s004240050601; Communi D, 1996, BIOCHEM BIOPH RES CO, V222, P303, DOI 10.1006/bbrc.1996.0739; Filippov AK, 1998, J NEUROSCI, V18, P5170, DOI 10.1523/JNEUROSCI.18-14-05170.1998; GarciaGuzman M, 1997, MOL PHARMACOL, V51, P109, DOI 10.1124/mol.51.1.109; GRAY MA, 1990, J MEMBRANE BIOL, V115, P203, DOI 10.1007/BF01868636; GRAY MA, 1988, J MEMBRANE BIOL, V105, P131, DOI 10.1007/BF02009166; GROMADA J, 1995, PFLUG ARCH EUR J PHY, V429, P578, DOI 10.1007/BF00704164; HUG H, 1994, PFLUG ARCH EUR J PHY, V426, P412, DOI 10.1007/BF00388304; Hug MJ, 1996, PFLUG ARCH EUR J PHY, V432, P278, DOI 10.1007/s004240050134; HURLEY TW, 1993, AM J PHYSIOL, V265, pC1472, DOI 10.1152/ajpcell.1993.265.6.C1472; Inoue CN, 1997, AM J PHYSIOL-CELL PH, V272, pC1862, DOI 10.1152/ajpcell.1997.272.6.C1862; JORGENSEN TD, 1995, BIOCHEM J, V312, P457, DOI 10.1042/bj3120457; KUBOKAWA M, 1995, AM J PHYSIOL-RENAL, V269, pF355, DOI 10.1152/ajprenal.1995.269.3.F355; KUBOKAWA M, 1995, AM J PHYSIOL-RENAL, V268, pF211, DOI 10.1152/ajprenal.1995.268.2.F211; Lazarowski ER, 1997, P NATL ACAD SCI USA, V94, P2599, DOI 10.1073/pnas.94.6.2599; Lee MG, 1997, J BIOL CHEM, V272, P32951, DOI 10.1074/jbc.272.52.32951; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; Marcus DC, 1997, AM J PHYSIOL-CELL PH, V273, pC2022, DOI 10.1152/ajpcell.1997.273.6.C2022; MASON SJ, 1991, BRIT J PHARMACOL, V103, P1649, DOI 10.1111/j.1476-5381.1991.tb09842.x; MCMILLIAN MK, 1988, BIOCHEM J, V255, P291; McNicholas CM, 1996, AM J PHYSIOL-RENAL, V271, pF275, DOI 10.1152/ajprenal.1996.271.2.F275; Metioui M, 1996, J CELL PHYSIOL, V168, P462, DOI 10.1002/(SICI)1097-4652(199608)168:2<462::AID-JCP25>3.0.CO;2-3; Montserrat C, 1996, FEBS LETT, V393, P264, DOI 10.1016/0014-5793(96)00900-3; Nguyen T, 1995, J BIOL CHEM, V270, P30845, DOI 10.1074/jbc.270.52.30845; Nguyen TD, 1998, AM J PHYSIOL-GASTR L, V275, pG104, DOI 10.1152/ajpgi.1998.275.1.G104; NOVAK I, 1993, PFLUG ARCH EUR J PHY, V425, P272, DOI 10.1007/BF00374178; NOVAK I, 1988, PFLUG ARCH EUR J PHY, V411, P58, DOI 10.1007/BF00581647; NOVAK I, 1991, PFLUG ARCH EUR J PHY, V419, P76, DOI 10.1007/BF00373750; NOVAK I, 1988, PFLUG ARCH EUR J PHY, V411, P546, DOI 10.1007/BF00582376; Novak I, 1998, GASTROENTEROLOGY, V115, P714, DOI 10.1016/S0016-5085(98)70151-9; Novak I, 1997, COMP BIOCHEM PHYS A, V118, P409, DOI 10.1016/S0300-9629(96)00331-3; NOVAK I, 1995, CELL PHYSIOL BIOCHEM, V5, P344, DOI 10.1159/000154770; NOVAK I, 1993, PFLUEGERS ARCH EUR J, V422, pR71; NOVAK I, 1988, PH HOMEOSTATIS MECHA, P447; OGDEN DC, 1994, MICROELECTRODE TECHN, P63; PAHL C, 1993, PFLUG ARCH EUR J PHY, V424, P315, DOI 10.1007/BF00384358; Park MK, 1997, AM J PHYSIOL-CELL PH, V272, pC1388, DOI 10.1152/ajpcell.1997.272.4.C1388; PARR CE, 1994, P NATL ACAD SCI USA, V91, P3275, DOI 10.1073/pnas.91.8.3275; Petrou S, 1997, FEBS LETT, V411, P339, DOI 10.1016/S0014-5793(97)00700-X; Ralevic V, 1998, PHARMACOL REV, V50, P413; SASAKI T, 1990, FEBS LETT, V264, P130, DOI 10.1016/0014-5793(90)80782-E; SOLTOFF SP, 1990, J GEN PHYSIOL, V95, P319, DOI 10.1085/jgp.95.2.319; SOLTOFF SP, 1992, AM J PHYSIOL, V262, pC934, DOI 10.1152/ajpcell.1992.262.4.C934; Soto F, 1996, P NATL ACAD SCI USA, V93, P3684, DOI 10.1073/pnas.93.8.3684; Stansfeld CE, 1996, P NATL ACAD SCI USA, V93, P9910, DOI 10.1073/pnas.93.18.9910; STUTTS MJ, 1992, P NATL ACAD SCI USA, V89, P1621, DOI 10.1073/pnas.89.5.1621; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Turner JT, 1997, AM J PHYSIOL-CELL PH, V273, pC1100, DOI 10.1152/ajpcell.1997.273.3.C1100; VINCENT P, 1992, J PHYSIOL-LONDON, V449, P313, DOI 10.1113/jphysiol.1992.sp019088; Wang CZ, 1996, BIOCHEM BIOPH RES CO, V220, P196, DOI 10.1006/bbrc.1996.0380; WARTH R, 1993, CELL PHYSIOL BIOCHEM, V3, P2, DOI 10.1159/000154663; Wu WL, 1998, BIOCHEM BIOPH RES CO, V248, P728, DOI 10.1006/bbrc.1998.9051; Zeng WZ, 1997, J BIOL CHEM, V272, P32956, DOI 10.1074/jbc.272.52.32956	61	70	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31784	31791		10.1074/jbc.274.45.31784	http://dx.doi.org/10.1074/jbc.274.45.31784			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542200	hybrid			2022-12-27	WOS:000083532100008
J	Horn, C; Namane, A; Pescher, P; Riviere, M; Romain, F; Puzo, G; Barzu, O; Marchal, G				Horn, C; Namane, A; Pescher, P; Riviere, M; Romain, F; Puzo, G; Barzu, O; Marchal, G			Decreased capacity of recombinant 45/47-kDa molecules (Apa) of Mycobacterium tuberculosis to stimulate T lymphocyte responses related to changes in their mannosylation pattern	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN COMPLEX; 45-KILODALTON GLYCOPROTEIN; MANNOSE RECEPTOR; KDA ANTIGEN; GLYCOSYLATION; RECOGNITION; PROTEINS; CELLS; IDENTIFICATION; CARBOHYDRATE	The Apa molecules secreted by Mycobacterium tuberculosis, Mycobacterium bovis, or BCG have been identified as major immunodominant antigens, Mass spectrometry analysis indicated similar mannosylation, a complete pattern from 1 up to 9 hexose residues/mole of protein, of the native species from the 3 reference strains. The recombinant antigen expressed in M. smegmatis revealed a different mannosylation pattern: species containing 7 to 9 sugar residues/mole of protein were in the highest proportion, whereas species bearing a low number of sugar residues were almost absent. The 45/47-kDa recombinant antigen expressed in E. coli was devoid of sugar residues. The proteins purified from II M.. tuberculosis, M. bovis, or BCG have a high capacity to elicit in vivo potent delayed-type hypersensitivity (DTH) reactions and to stimulate in vitro sensitized T lymphocytes of guinea pigs immunized with living BCG, The recombinant Apa expressed in Mycobacterium smegmatis was 4-fold less potent in vivo in the DTH assay and 10-fold less active in vitro to stimulate sensitized T lymphocytes than the native proteins. The recombinant protein expressed in Escherichia coli was nearly unable to elicit DTH reactions in vivo or to stimulate T lymphocytes in vitro, Thus the observed biological effects were related to the extent of glycosylation of the antigen.	Inst Pasteur, Unite Physiopathol Infect, F-75724 Paris 15, France; Inst Pasteur, Lab Chim Struct Macromol, F-75724 Paris 15, France; CNRS, Inst Pharmacol & Biol Struct, F-31077 Toulouse 15, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Marchal, G (corresponding author), Inst Pasteur, Unite Physiopathol Infect, 25 Rue Dr Roux, F-75724 Paris 15, France.	gmarchal@pasteur.fr	Namane, Abdelkader/O-1857-2013	Namane, Abdelkader/0000-0001-7180-7619; Pescher, Pascale/0000-0003-2796-7855				ANDERSEN P, 1994, INFECT IMMUN, V62, P2536, DOI 10.1128/IAI.62.6.2536-2544.1994; BOCK K, 1994, J BIOL CHEM, V269, P7137; Carbone FR, 1997, GLYCOBIOLOGY, V7, P725, DOI 10.1093/glycob/7.6.725-d; DECK B, 1995, J IMMUNOL, V155, P1074; DOBOS KM, 1995, INFECT IMMUN, V63, P2846, DOI 10.1128/IAI.63.8.2846-2853.1995; Dobos KM, 1996, J BACTERIOL, V178, P2498, DOI 10.1128/jb.178.9.2498-2506.1996; DUBOS RJ, 1953, J EXP MED, V97, P207, DOI 10.1084/jem.97.2.207; ESPITIA C, 1989, CLIN EXP IMMUNOL, V77, P378; FURTHMAYR H, 1971, ANAL BIOCHEM, V41, P510, DOI 10.1016/0003-2697(71)90173-4; GARBE T, 1993, INFECT IMMUN, V61, P260, DOI 10.1128/IAI.61.1.260-267.1993; HARLOW E, 1988, ANTIBODIES LAB MAHUA; HAURUM JS, 1994, J EXP MED, V180, P739, DOI 10.1084/jem.180.2.739; Herrmann JL, 1996, EMBO J, V15, P3547, DOI 10.1002/j.1460-2075.1996.tb00724.x; Horn C, 1996, J IMMUNOL METHODS, V197, P151, DOI 10.1016/0022-1759(96)00141-X; HORWITZ MA, 1995, P NATL ACAD SCI USA, V92, P1530, DOI 10.1073/pnas.92.5.1530; KANAI K, 1966, JPN J MED SCI BIOL, V19, P181, DOI 10.7883/yoken1952.19.181; LAQUEYRERIE A, 1995, INFECT IMMUN, V63, P4003, DOI 10.1128/IAI.63.10.4003-4010.1995; MESCHER MF, 1976, J BIOL CHEM, V251, P2005; Mortz E, 1996, J MASS SPECTROM, V31, P1109, DOI 10.1002/(SICI)1096-9888(199610)31:10<1109::AID-JMS400>3.0.CO;2-9; ORME IM, 1988, INFECT IMMUN, V56, P3310, DOI 10.1128/IAI.56.12.3310-3312.1988; PLUMMER TH, 1995, J BIOL CHEM, V270, P13192, DOI 10.1074/jbc.270.22.13192; ROMAIN F, 1993, INFECT IMMUN, V61, P742, DOI 10.1128/IAI.61.2.742-750.1993; ROMAIN F, 1999, IN PRESS INFECT IMMU, V67; Sambrook J., 2002, MOL CLONING LAB MANU; SCHARER LL, 1995, TUBERCULOSIS AIDS RE; Schluger NW, 1998, AM J RESP CRIT CARE, V157, P679, DOI 10.1164/ajrccm.157.3.9708002; Stahl PD, 1998, CURR OPIN IMMUNOL, V10, P50, DOI 10.1016/S0952-7915(98)80031-9; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; STIMSON E, 1995, MOL MICROBIOL, V17, P1201, DOI 10.1111/j.1365-2958.1995.mmi_17061201.x; Tan MCAA, 1997, EUR J IMMUNOL, V27, P2426, DOI 10.1002/eji.1830270942	30	76	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32023	32030		10.1074/jbc.274.45.32023	http://dx.doi.org/10.1074/jbc.274.45.32023			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542234	hybrid			2022-12-27	WOS:000083532100042
J	Li, SL; Schlegel, W; Valente, AJ; Clark, RA				Li, SL; Schlegel, W; Valente, AJ; Clark, RA			Critical flanking sequences of PU.1 binding sites in myeloid-specific promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; TRANSCRIPTION FACTOR PU.1; HEMATOLOGICALLY IMPORTANT MUTATIONS; STIMULATING FACTOR-RECEPTOR; GENE-EXPRESSION; B-LYMPHOCYTES; ETS FAMILY; REQUIRES; MACROPHAGE; C/EBP	The myeloid-specific transcription factor PU.1 is essential for expression of p47(phox), a component of the superoxide-forming phagocyte NADPH oxidase. The consensus PU.1 binding sequence (GAGGAA) is located on the non-coding strand from position -40 to -45 relative to the transcriptional start site of the p47phox promoter. A promoter construct extending to -46 was sufficient to drive tissue-specific expression of the luciferase reporter gene, but extension of the promoter from -46 to -48 resulted in a significant increase in reporter expression. Mutations of the nucleotides G at -46 and/or T at -47 reduced both reporter expression and PU.1 binding, whereas mutations at -48 had no effect, The PU.1 binding avidity of these sequences correlated closely with their capacity to dictate reporter gene transcription. In parallel studies on the functional PU.1 site in the promoter of CD18, mutations of nucleotides G and T at positions -76 and -77 (corresponding to -46 and -47, respectively, of the p47phox promoter) reduced PU.1 binding and nearly abolished the contribution of this element to promoter activity. We conclude that the immediate flanking nucleotides of the PU.1 consensus motif have significant effects on PU.1 binding avidity and activity and that this region is the dominant cis element regulating p47phox expression.	Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA; S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78229 USA; Univ Geneva, Fdn Rech Med, CH-1211 Geneva, Switzerland	University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; University of Geneva	Clark, RA (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.		Clark, Robert/Q-6764-2019	Clark, Robert/0000-0002-4892-3619	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020866, R01AI020866] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20866, R37 AI020866, R01 AI020866] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; BACK AL, 1992, J BIOL CHEM, V267, P5482; Bodger MP, 1998, BRIT J HAEMATOL, V102, P986, DOI 10.1046/j.1365-2141.1998.00863.x; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; Clark RA, 1999, J INFECT DIS, V179, pS309, DOI 10.1086/513849; Cross AR, 1996, BLOOD CELL MOL DIS, V22, P268, DOI 10.1006/bcmd.1996.0109; Cross AR, 1996, BLOOD CELL MOL DIS, V22, P90, DOI 10.1006/bcmd.1996.0013; Egan BS, 1999, J BIOL CHEM, V274, P9098, DOI 10.1074/jbc.274.13.9098; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; EKLUND EA, 1995, J BIOL CHEM, V270, P8267, DOI 10.1074/jbc.270.14.8267; Friedman AD, 1996, CURR TOP MICROBIOL, V211, P149; Gorlach A, 1997, J CLIN INVEST, V100, P1907, DOI 10.1172/JCI119721; Heydemann A, 1997, J BIOL CHEM, V272, P29527, DOI 10.1074/jbc.272.47.29527; Himmelmann A, 1996, BLOOD, V87, P1036, DOI 10.1182/blood.V87.3.1036.bloodjournal8731036; Himmelmann A, 1997, BLOOD, V90, P3984, DOI 10.1182/blood.V90.10.3984; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; KOMINATO Y, 1995, MOL CELL BIOL, V15, P58; Li SL, 1997, J BIOL CHEM, V272, P17802, DOI 10.1074/jbc.272.28.17802; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; NEWBURGER PE, 1994, J CLIN INVEST, V94, P1205, DOI 10.1172/JCI117437; PAHL HL, 1993, J BIOL CHEM, V268, P5014; Paxton LLL, 1997, J BIOL CHEM, V272, P15928, DOI 10.1074/jbc.272.25.15928; PEREZ C, 1994, MOL CELL BIOL, V14, P5023, DOI 10.1128/MCB.14.8.5023; Pio F, 1996, J BIOL CHEM, V271, P23329, DOI 10.1074/jbc.271.38.23329; RAYGALLET D, 1995, ONCOGENE, V11, P303; ROSMARIN AG, 1995, P NATL ACAD SCI USA, V92, P801, DOI 10.1073/pnas.92.3.801; Simon MC, 1996, CURR TOP MICROBIOL, V211, P113; Smith LT, 1996, BLOOD, V88, P1234, DOI 10.1182/blood.V88.4.1234.bloodjournal8841234; Smith MF, 1998, J BIOL CHEM, V273, P24272, DOI 10.1074/jbc.273.37.24272; Suzuki S, 1998, P NATL ACAD SCI USA, V95, P6085, DOI 10.1073/pnas.95.11.6085; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Zhang DE, 1996, CURR TOP MICROBIOL, V211, P137; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	36	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32453	32460		10.1074/jbc.274.45.32453	http://dx.doi.org/10.1074/jbc.274.45.32453			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542290	hybrid			2022-12-27	WOS:000083532100098
J	Segrest, JP; Jones, MK; Klon, AE; Sheldahl, CJ; Hellinger, M; De Loof, H; Harvey, SC				Segrest, JP; Jones, MK; Klon, AE; Sheldahl, CJ; Hellinger, M; De Loof, H; Harvey, SC			A detailed molecular belt model for apolipoprotein A-I in discoidal high density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA LIPOPROTEINS; AMPHIPATHIC HELIX; CONFORMATION; PEPTIDES; DOMAINS	Apolipoprotein A-I (apoA-I) is the principal protein of high density lipoprotein particles (HDL). ApoA-I contains a globular N-terminal domain (residues 1-43) and a lipid-binding C-terminal domain (residues 44-243), Here we propose a detailed model for the smallest discoidal HDL, consisting of two apoA-I molecules wrapped beltwise around a small patch of bilayer containing 160 lipid molecules. The C-terminal domain of each monomer is ringlike, a curved, planar amphipathic alpha helix with an average of 3.67 residues per turn, and with the hydrophobic surface curved toward the lipids. We have explored all possible geometries for forming the dimer of stacked rings, subject to the hypothesis that the optimal geometry will maximize intermolecular salt bridge interactions. The resulting model is an antiparallel arrangement with an alignment matching that of the (nonplanar) crystal structure of lipid-free apoA-I.	Univ Alabama, Med Ctr, Dept Med, Birmingham, AL 35294 USA; Univ Alabama, Med Ctr, Atherosclerosis Res Unit, Birmingham, AL 35294 USA; Univ Alabama, Med Ctr, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Segrest, JP (corresponding author), Univ Alabama, Med Ctr, Dept Med, Birmingham, AL 35294 USA.		De Loof, Hans WY/B-8504-2008; De Loof, Hans/K-5774-2019	De Loof, Hans WY/0000-0003-4488-551X; De Loof, Hans/0000-0003-4488-551X	NHLBI NIH HHS [P01 HL-34343] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034343] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Atkinson D, 1980, Ann N Y Acad Sci, V348, P284, DOI 10.1111/j.1749-6632.1980.tb21308.x; BLUNDELL T, 1983, NATURE, V306, P281, DOI 10.1038/306281a0; Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; BROUILLETTE CG, 1995, BBA-LIPID LIPID MET, V1256, P103, DOI 10.1016/0005-2760(95)00018-8; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; FITCH WM, 1977, GENETICS, V86, P623; HELLER H, 1993, J PHYS CHEM-US, V97, P8343, DOI 10.1021/j100133a034; JONAS A, 1990, J BIOL CHEM, V265, P22123; JONES MK, 1992, J LIPID RES, V33, P287; Koppaka V, 1999, J BIOL CHEM, V274, P14541, DOI 10.1074/jbc.274.21.14541; Mishra VK, 1996, BIOCHEMISTRY-US, V35, P11210, DOI 10.1021/bi960760f; NOLTE RT, 1992, BIOPHYS J, V63, P1221, DOI 10.1016/S0006-3495(92)81698-3; Palgunachari MN, 1996, ARTERIOSCL THROM VAS, V16, P328, DOI 10.1161/01.ATV.16.2.328; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; Rogers DP, 1998, BIOCHEMISTRY-US, V37, P11714, DOI 10.1021/bi973112k; Rogers DP, 1997, BIOCHEMISTRY-US, V36, P288, DOI 10.1021/bi961876e; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SEGREST JP, 1977, CHEM PHYS LIPIDS, V18, P7, DOI 10.1016/0009-3084(77)90023-8; SEGREST JP, 1974, FEBS LETT, V38, P247, DOI 10.1016/0014-5793(74)80064-5; SEGREST JP, 1992, J LIPID RES, V33, P141; TALL AR, 1977, J BIOL CHEM, V252, P4701; WALD JH, 1990, J BIOL CHEM, V265, P20044; WLODAWER A, 1979, FEBS LETT, V104, P231, DOI 10.1016/0014-5793(79)80821-2; ZHOU NE, 1992, J AM CHEM SOC, V114, P4320, DOI 10.1021/ja00037a042	24	298	321	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31755	31758		10.1074/jbc.274.45.31755	http://dx.doi.org/10.1074/jbc.274.45.31755			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542194	hybrid			2022-12-27	WOS:000083532100002
J	Teixeira, MT; Fabre, E; Dujon, B				Teixeira, MT; Fabre, E; Dujon, B			Self-catalyzed cleavage of the yeast nucleoporin Nup145p precursor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PORE COMPLEX; NUCLEOCYTOPLASMIC TRANSPORT; SACCHAROMYCES-CEREVISIAE; GLFG NUCLEOPORIN; MESSENGER-RNA; PROTEIN; EXPORT; TRANSFORMATION; RECOMBINATION; MODULATION	Nup145p is a component of the nuclear pore complex of Saccharomyces cerevisiae and is essential for mRNA export. Nup145p and its apparent vertebrate homologue are the only known nucleoporins to be composed of two functionally independent peptide moieties resulting from the post-translational cleavage of a large precursor molecule. In this study, the proteolytic cleavage site of Nup145p has been mapped upstream of an evolutionary conserved serine residue. Cleavage occurs at the same site when a precursor is artificially expressed in Escherichia coli. A hydroxyl-containing residue is critical for the reaction, although a thiol-containing residue offers an acceptable replacement. In vitro kinetics experiments using a purified precursor molecule demonstrate that the cleavage is self-catalyzed and that the catalytic domain lies within the N-terminal moiety. Taken altogether, our data are consistent with a proteolytic mechanism involving an N > 0 acyl rearrangement and a subsequent ester intermediate uncovered in other self-processing proteins.	Inst Pasteur, Dept Biotechnol, CNRS, URA 1300,Unite Genet Mol Levures, F-75724 Paris 15, France; Univ Paris 06, Dept Biotechnol, Inst Pasteur, UPR 927, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Sorbonne Universite	Teixeira, MT (corresponding author), Inst Pasteur, Dept Biotechnol, CNRS, URA 1300,Unite Genet Mol Levures, 25 Rue Dr Roux, F-75724 Paris 15, France.	teresatf@pasteur.fr	Dujon, Bernard A/F-4971-2010; Teixeira, Maria Teresa/A-2100-2011	Teixeira, Maria Teresa/0000-0002-9466-7951; FABRE, Emmanuelle/0000-0002-0009-4604				Allen TD, 1997, SCANNING, V19, P403, DOI 10.1002/sca.4950190603; Ando, 1967, METHOD ENZYMOL, V11, P263; ARIS JP, 1988, J CELL BIOL, V107, P17, DOI 10.1083/jcb.107.1.17; Arthur TM, 1998, J BIOL CHEM, V273, P31381, DOI 10.1074/jbc.273.47.31381; BURNS JA, 1991, J ORG CHEM, V56, P2648, DOI 10.1021/jo00008a014; CHEN DC, 1992, CURR GENET, V21, P83, DOI 10.1007/BF00318659; Chong SR, 1998, J BIOL CHEM, V273, P10567, DOI 10.1074/jbc.273.17.10567; Colland F, 1998, MOL MICROBIOL, V27, P819, DOI 10.1046/j.1365-2958.1998.00729.x; Corbett AH, 1997, MICROBIOL MOL BIOL R, V61, P193, DOI 10.1128/.61.2.193-211.1997; Dockendorff TC, 1997, MOL CELL BIOL, V17, P906, DOI 10.1128/MCB.17.2.906; Emtage JLT, 1997, J CELL SCI, V110, P911; FABRE E, 1994, CELL, V78, P275, DOI 10.1016/0092-8674(94)90297-6; Fabre E, 1997, ANNU REV GENET, V31, P277, DOI 10.1146/annurev.genet.31.1.277; Fairhead C, 1996, YEAST, V12, P1439; Fontoura BMA, 1999, J CELL BIOL, V144, P1097, DOI 10.1083/jcb.144.6.1097; Gari E, 1997, YEAST, V13, P837, DOI 10.1002/(SICI)1097-0061(199707)13:9<837::AID-YEA145>3.0.CO;2-T; Guan C, 1998, J BIOL CHEM, V273, P9695, DOI 10.1074/jbc.273.16.9695; Guan CD, 1996, J BIOL CHEM, V271, P1732, DOI 10.1074/jbc.271.3.1732; JENCKS WP, 1960, J BIOL CHEM, V235, P3608; LITTLE JW, 1993, J BACTERIOL, V175, P4943, DOI 10.1128/JB.175.16.4943-4950.1993; MA H, 1987, GENE, V58, P201, DOI 10.1016/0378-1119(87)90376-3; Marshak DR, 1996, STRATEGIES PROTEIN P; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MEILHOC E, 1990, BIO-TECHNOL, V8, P223, DOI 10.1038/nbt0390-223; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; Perler FB, 1998, NAT STRUCT BIOL, V5, P249, DOI 10.1038/nsb0498-249; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4; PORTER JA, 1996, SCIENCE, V274, P256; POWERS MA, 1995, J CELL BIOL, V128, P721, DOI 10.1083/jcb.128.5.721; Powers MA, 1997, J CELL BIOL, V136, P241, DOI 10.1083/jcb.136.2.241; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; Schmidtke G, 1996, EMBO J, V15, P6887, DOI 10.1002/j.1460-2075.1996.tb01081.x; Shao Y, 1996, BIOCHEMISTRY-US, V35, P3810, DOI 10.1021/bi952592h; Sherman F., 1986, METHODS YEAST GENETI; Siniossoglou S, 1996, CELL, V84, P265, DOI 10.1016/S0092-8674(00)80981-2; Teixeira MT, 1997, EMBO J, V16, P5086, DOI 10.1093/emboj/16.16.5086; VANPOELJE PD, 1990, ANNU REV BIOCHEM, V59, P29, DOI 10.1146/annurev.bi.59.070190.000333; WENTE SR, 1994, J CELL BIOL, V125, P955, DOI 10.1083/jcb.125.5.955; Xu MQ, 1996, EMBO J, V15, P5146, DOI 10.1002/j.1460-2075.1996.tb00898.x; Yang Q, 1998, MOL CELL, V1, P223, DOI 10.1016/S1097-2765(00)80023-4	42	29	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32439	32444		10.1074/jbc.274.45.32439	http://dx.doi.org/10.1074/jbc.274.45.32439			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542288	hybrid			2022-12-27	WOS:000083532100096
J	Yamada, K; Ogawa, H; Honda, S; Harada, N; Okazaki, T				Yamada, K; Ogawa, H; Honda, S; Harada, N; Okazaki, T			A GCM motif protein is involved in placenta-specific expression of human aromatase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT GENE; MESSENGER-RIBONUCLEIC-ACID; TISSUE-SPECIFIC EXPRESSION; TRANSCRIPTION FACTOR; CYTOCHROME-P-450 GENE; CHORIOCARCINOMA CELLS; ENHANCER FUNCTION; DROSOPHILA; PROMOTERS; BINDING	A new cis-element, trophoblast-specific element 2 (TSE2) is located in the placenta-specific enhancer of the human aromatase gene that dictates its tissue-specific expression, In the minimum enhancer region, an element similar to the trophoblast-specific element (TSE), originally described for the human chorionic gonadotropin alpha-subunit gene, also exists (Yamada, K., Harada, N., Honda, S., and Takagi, Y. (1995) J. Biol. Chem, 270, 25064-25069). The co-presence of TSE and TSE2 is required to direct trophoblast-specific expression driven by a heterologous thymidine kinase promoter. A 2562-base pair cDNA clone encoding a 436-amino acid protein that binds to TSE2 was isolated from a human placental cDNA library using a yeast one-hybrid system with the TSE2 as a reporter sequence, The protein was revealed to be identical to hGCMa, a mammalian homologue of the Drosophila GCM (glia cells missing) protein. Expression of hGCMa is restricted to the placenta, The protein also binds to PLE1 in the leptin promoter among other cis-elements reported to confer placenta-specific expression, suggesting that hGCMa is a placenta-specific transcription regulator, possibly involved in the expression of multiple placenta-specific genes.	Fujita Hlth Univ, Inst Comprehens Med Sci, Sch Med, Aichi 4701192, Japan; Fujita Hlth Univ, Japan Sci & Technol Corp, CREST, Sch Med, Aichi 4701192, Japan; Fujita Hlth Univ, Sch Med, Dept Biol, Aichi 4701192, Japan; Fujita Hlth Univ, Sch Med, Dept Biochem, Aichi 4701192, Japan	Fujita Health University; Fujita Health University; Japan Science & Technology Agency (JST); Fujita Health University; Fujita Health University	Yamada, K (corresponding author), Fujita Hlth Univ, Inst Comprehens Med Sci, Sch Med, Aichi 4701192, Japan.	kyamada@fujita-hu.ac.jp						Akiyama Y, 1996, P NATL ACAD SCI USA, V93, P14912, DOI 10.1073/pnas.93.25.14912; Altshuller Y, 1996, FEBS LETT, V393, P201, DOI 10.1016/0014-5793(96)00890-3; Bi S, 1997, J BIOL CHEM, V272, P30583, DOI 10.1074/jbc.272.48.30583; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Firulli AB, 1998, NAT GENET, V18, P266, DOI 10.1038/ng0398-266; GUILLEMOT F, 1994, NATURE, V371, P333, DOI 10.1038/371333a0; HARADA N, 1992, ENDOCRINOLOGY, V131, P2306, DOI 10.1210/en.131.5.2306; HARADA N, 1993, P NATL ACAD SCI USA, V90, P11312, DOI 10.1073/pnas.90.23.11312; HARADA N, 1990, BIOCHEM BIOPH RES CO, V166, P365, DOI 10.1016/0006-291X(90)91954-Q; HECKERT LL, 1995, J BIOL CHEM, V270, P26497, DOI 10.1074/jbc.270.44.26497; HOSOYA T, 1995, CELL, V82, P1025, DOI 10.1016/0092-8674(95)90281-3; Jacquemin P, 1997, J BIOL CHEM, V272, P12928, DOI 10.1074/jbc.272.20.12928; JACQUEMIN P, 1994, MOL CELL BIOL, V14, P93, DOI 10.1128/MCB.14.1.93; JAMESON JL, 1989, MOL ENDOCRINOL, V3, P763, DOI 10.1210/mend-3-5-763; JIANG SW, 1995, J BIOL CHEM, V270, P13906, DOI 10.1074/jbc.270.23.13906; Jiang SW, 1997, MOL ENDOCRINOL, V11, P1223, DOI 10.1210/me.11.9.1223; Johnson W, 1997, J BIOL CHEM, V272, P15405, DOI 10.1074/jbc.272.24.15405; JONES BW, 1995, CELL, V82, P1013, DOI 10.1016/0092-8674(95)90280-5; Kamat A, 1999, P NATL ACAD SCI USA, V96, P4575, DOI 10.1073/pnas.96.8.4575; Kanemura Y, 1999, FEBS LETT, V442, P151, DOI 10.1016/S0014-5793(98)01650-0; Kim JS, 1998, P NATL ACAD SCI USA, V95, P12364, DOI 10.1073/pnas.95.21.12364; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; MAHENDROO MS, 1991, J BIOL CHEM, V266, P11276; MEANS GD, 1991, MOL ENDOCRINOL, V5, P2005, DOI 10.1210/mend-5-12-2005; MEANS GD, 1989, J BIOL CHEM, V264, P19385; MOROHASHI K, 1992, J BIOL CHEM, V267, P17913; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; Ogawa H, 1996, NEUROCHEM INT, V29, P553, DOI 10.1016/0197-0186(95)00012-7; PITTMAN RH, 1994, J BIOL CHEM, V269, P19360; Reifegerste R, 1999, MECH DEVELOP, V82, P141, DOI 10.1016/S0925-4773(99)00027-1; RITVOS O, 1992, ENDOCRINOLOGY, V130, P61, DOI 10.1210/en.130.1.61; ROSELLI CE, 1985, ENDOCRINOLOGY, V117, P2471, DOI 10.1210/endo-117-6-2471; Schreiber J, 1997, P NATL ACAD SCI USA, V94, P4739, DOI 10.1073/pnas.94.9.4739; Shi DQ, 1997, J BIOL CHEM, V272, P2334, DOI 10.1074/jbc.272.4.2334; Shi DQ, 1998, J BIOL CHEM, V273, P27331, DOI 10.1074/jbc.273.42.27331; STEGER DJ, 1991, MOL ENDOCRINOL, V5, P243, DOI 10.1210/mend-5-2-243; Sun TJ, 1998, ENDOCRINOLOGY, V139, P1684, DOI 10.1210/en.139.4.1684; THOMPSON EA, 1974, J BIOL CHEM, V249, P5364; TODA K, 1992, EUR J BIOCHEM, V205, P303, DOI 10.1111/j.1432-1033.1992.tb16781.x; Wang ZY, 1998, J BIOL CHEM, V273, P26069, DOI 10.1074/jbc.273.40.26069; YAMADA K, 1995, J BIOL CHEM, V270, P25064, DOI 10.1074/jbc.270.42.25064	44	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32279	32286		10.1074/jbc.274.45.32279	http://dx.doi.org/10.1074/jbc.274.45.32279			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542267	hybrid			2022-12-27	WOS:000083532100075
J	Mathisen, PM; Johnson, JM; Kawczak, JA; Tuohy, VK				Mathisen, PM; Johnson, JM; Kawczak, JA; Tuohy, VK			Visinin-like protein (VILIP) is a neuron-specific calcium-dependent double-stranded RNA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNAS; KINASE; LOCALIZATION; DOMAIN; IDENTIFICATION; RECOGNITION; INTERFERON; RECOVERIN; MEMBRANE; SEQUENCE	Double-stranded RNA-binding proteins function in regulating the stability, translation, and localization of specific mRNAs. In this study, we have demonstrated that the neuron-specific, calcium-binding protein, visinin-like protein (VILIP) contains one double-stranded RNA-binding domain, a protein motif conserved among many double-stranded RNA-binding proteins. We showed that VILIP can specifically bind double-stranded RNA, and this interaction specifically requires the presence of calcium. Mobility shift studies indicated that VILIP binds double-stranded RNA as a single protein-RNA complex with an apparent equilibrium dissociation constant of 9.0 x 10(-6) M. To our knowledge, VILIP is the first double-stranded RNA-binding protein shown to be calcium-dependent. Furthermore, VILIP specifically binds the 3'-untranslated region of the neurotrophin receptor, trkB, an mRNA localized to hippocampal dendrites in an activity-dependent manner. Given that VILIP is also expressed in the hippocampus, these data suggest that VILIP may employ a novel, calcium-dependent mechanism to regulate its binding to important localized mRNAs in the central nervous system.	Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Mathisen, PM (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, NB-30,9500 Euclid Ave, Cleveland, OH 44195 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036054] Funding Source: NIH RePORTER; NINDS NIH HHS [NS36054] Funding Source: Medline; CSR NIH HHS [RG2768] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); CSR NIH HHS		AHN BY, 1990, MOL CELL BIOL, V10, P5433, DOI 10.1128/MCB.10.10.5433; AINGER K, 1993, J CELL BIOL, V123, P431, DOI 10.1083/jcb.123.2.431; Bashirullah A, 1998, ANNU REV BIOCHEM, V67, P335, DOI 10.1146/annurev.biochem.67.1.335; BASS BL, 1994, CURR BIOL, V4, P301, DOI 10.1016/S0960-9822(00)00069-5; Bevilacqua PC, 1996, BIOCHEMISTRY-US, V35, P9983, DOI 10.1021/bi9607259; Boekhoff I, 1997, EUR J CELL BIOL, V72, P151; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CAREY J, 1991, METHOD ENZYMOL, V208, P103; COX JA, 1994, J BIOL CHEM, V269, P32807; DRAPER DE, 1995, ANNU REV BIOCHEM, V64, P593, DOI 10.1146/annurev.bi.64.070195.003113; Friesen WJ, 1998, NAT STRUCT BIOL, V5, P543, DOI 10.1038/794; Gao FB, 1998, BIOESSAYS, V20, P70, DOI 10.1002/(SICI)1521-1878(199801)20:1<70::AID-BIES10>3.0.CO;2-5; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; Harada K, 1996, NATURE, V380, P175, DOI 10.1038/380175a0; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; Johnson WC, 1997, BBA-PROTEIN STRUCT M, V1342, P164, DOI 10.1016/S0167-4838(97)00091-5; KUNO T, 1992, BIOCHEM BIOPH RES CO, V184, P1219, DOI 10.1016/S0006-291X(05)80012-9; Laird-Offringa IA, 1998, NAT STRUCT BIOL, V5, P665, DOI 10.1038/1356; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; LENZ SE, 1992, MOL BRAIN RES, V15, P133, DOI 10.1016/0169-328X(92)90160-D; Lenz SE, 1996, BIOCHEM BIOPH RES CO, V225, P1078, DOI 10.1006/bbrc.1996.1298; MANCHE L, 1992, MOL CELL BIOL, V12, P5238, DOI 10.1128/MCB.12.11.5238; MARCH PE, 1985, NUCLEIC ACIDS RES, V13, P4677, DOI 10.1093/nar/13.13.4677; MARQUET R, 1991, NUCLEIC ACIDS RES, V19, P2349, DOI 10.1093/nar/19.9.2349; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; NADURI S, 1998, EMBO J, V17, P5458; PATEL RC, 1992, J BIOL CHEM, V267, P7671; SAITOH S, 1995, NEUROSCI RES, V23, P383, DOI 10.1016/0168-0102(95)00968-Y; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; STEITZ TA, 1997, RNA WORLD, P219; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; Tan RY, 1996, J BIOL CHEM, V271, P7479, DOI 10.1074/jbc.271.13.7479; Tongiorgi E, 1997, J NEUROSCI, V17, P9492; YISRAELI JK, 1990, DEVELOPMENT, V108, P289	34	25	27	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31571	31576		10.1074/jbc.274.44.31571	http://dx.doi.org/10.1074/jbc.274.44.31571			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531361	hybrid			2022-12-27	WOS:000083379400065
J	Kim, T; Kim, TY; Song, YH; Min, IM; Yim, J; Kim, TK				Kim, T; Kim, TY; Song, YH; Min, IM; Yim, J; Kim, TK			Activation of interferon regulatory factor 3 in response to DNA-damaging agents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR IRF-1; BOX-BINDING-PROTEIN; GENE-EXPRESSION; NUCLEAR TRANSLOCATION; BETA ENHANCEOSOME; VIRUS-INFECTION; MDR1 GENE; IN-VITRO; P53; INDUCTION	Genotoxic stress triggers signal transduction pathways that mediate either the protection or apoptosis of affected cells. The interferon regulatory factors (IRFs) are involved in a wide range of host defense mechanisms against environmental stresses. Treatment with DNA-damaging agents, including doxorubicin and UV radiation, caused phosphorylation of the IRF3 transcription factor. Phosphorylation of IRF3 induced its interaction with the transcriptional co-activator cAMP-response element binding protein-binding protein. Furthermore, genotoxic stress-induced phosphorylation of IRF3 resulted in its movement from the cytoplasm to the nucleus, where it activated transcription from its binding site. These observations suggest that IRF3 plays a role in the defensive responses induced by genotoxic stress.	Seoul Natl Univ, Inst Mol Biol & Genet, Natl Creat Res Initiat Ctr Genet Reprogramming, Seoul 151742, South Korea; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Inst Chem & Cell Biol, Boston, MA 02115 USA	Seoul National University (SNU); Harvard University; Harvard Medical School	Kim, TK (corresponding author), Seoul Natl Univ, Inst Mol Biol & Genet, Natl Creat Res Initiat Ctr Genet Reprogramming, Seoul 151742, South Korea.		Min, Irene/AAQ-4186-2021	Min, Irene/0000-0002-1057-4804				Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; Bauerle PA, 1996, CELL, V87, P13; CHERNOVA OB, 1995, TRENDS BIOCHEM SCI, V20, P431, DOI 10.1016/S0968-0004(00)89094-5; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUJITA T, 1989, P NATL ACAD SCI USA, V86, P9936, DOI 10.1073/pnas.86.24.9936; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GOLDSMITH ME, 1993, J BIOL CHEM, V268, P5856; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARLOW H, 1988, ANTIBODIES LAB MANNU; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Juang YT, 1998, P NATL ACAD SCI USA, V95, P9837, DOI 10.1073/pnas.95.17.9837; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kim TK, 1998, P NATL ACAD SCI USA, V95, P12191, DOI 10.1073/pnas.95.21.12191; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Koike K, 1997, FEBS LETT, V417, P390, DOI 10.1016/S0014-5793(97)01296-9; LADOMERY M, 1995, BIOESSAYS, V17, P9, DOI 10.1002/bies.950170104; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Maniatis T, 1998, COLD SPRING HARB SYM, V63, P609, DOI 10.1101/sqb.1998.63.609; Navarro L, 1998, MOL CELL BIOL, V18, P3796, DOI 10.1128/MCB.18.7.3796; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Ohga T, 1996, CANCER RES, V56, P4224; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sambrook J., 2002, MOL CLONING LAB MANU; Sato M, 1998, FEBS LETT, V425, P112, DOI 10.1016/S0014-5793(98)00210-5; Schafer SL, 1998, J BIOL CHEM, V273, P2714, DOI 10.1074/jbc.273.5.2714; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Taniguchi T, 1997, J CELL PHYSIOL, V173, P128, DOI 10.1002/(SICI)1097-4652(199711)173:2<128::AID-JCP8>3.0.CO;2-P; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; WOLFFE AP, 1992, NEW BIOL, V4, P290; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087	45	81	84	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30686	30689		10.1074/jbc.274.43.30686	http://dx.doi.org/10.1074/jbc.274.43.30686			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521456	hybrid			2022-12-27	WOS:000083276700052
J	Rubinfeld, H; Hanoch, T; Seger, R				Rubinfeld, H; Hanoch, T; Seger, R			Identification of a cytoplasmic-retention sequence in ERK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NERVE GROWTH-FACTOR; NUCLEAR EXPORT SIGNAL; MAP KINASE; PC12 CELLS; CASCADE; TRANSLOCATION; LOCALIZATION	A key step in the signaling mechanism of the mitogen-activated protein kinase/extracellular signal-responsive kinase (ERK) cascade is its translocation into the nucleus where it regulates transcription and other nuclear processes. In an attempt to characterize the subcellular localization of ERK2, we fused it to the S'-end of the gene expressing green fluorescent protein (GFP), resulting in a GFP-ERK2 protein. The expression of this construct in ;CHO cells resulted in a nuclear localization of the GFP-ERK2 protein. However, coexpression of the GFP-ERK2 with its upstream activator, MEK1, resulted in a cytosolic retention of the GFP-ERK2, which was the result of its association with MEK1, and was reversed upon stimulation. We then examined the role of the C-terminal region of ERK2 in its subcellular localization. Substitution of residues 312-319 of GFP-ERK2 to alanine residues prevented the cytosolic retention of ERK2 as well as its association with MEK1, without affecting its activity. Most important for the cytosolic retention are three acidic amino acids at positions 316, 319, and 320 of ERK2. Substitution of residues 321-327 to alanines impaired the nuclear translocation of ERK2 upon mitogenic stimulation. Thus, we conclude that residues 312-320 of ERK2 are responsible for its cytosolic retention, and residues 321-327 play a role in the mechanism of ERK2 nuclear translocation.	Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Seger, R (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.							Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Camps M, 1998, FEBS LETT, V425, P271, DOI 10.1016/S0014-5793(98)00250-6; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Jaaro H, 1997, P NATL ACAD SCI USA, V94, P3742, DOI 10.1073/pnas.94.8.3742; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Silverman MA, 1999, J BIOL CHEM, V274, P2631, DOI 10.1074/jbc.274.5.2631; Tolwinski NS, 1999, J BIOL CHEM, V274, P6168, DOI 10.1074/jbc.274.10.6168; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143	22	114	121	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30349	30352		10.1074/jbc.274.43.30349	http://dx.doi.org/10.1074/jbc.274.43.30349			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521408	hybrid			2022-12-27	WOS:000083276700004
J	Galbiati, F; Volonte, D; Engelman, JA; Scherer, PE; Lisanti, MP				Galbiati, F; Volonte, D; Engelman, JA; Scherer, PE; Lisanti, MP			Targeted down-regulation of caveolin-3 is sufficient to inhibit myotube formation in differentiating C2C12 myoblasts - Transient activation of p38 mitogen-activated protein kinase is required for induction of caveolin-3 expression and subsequent myotube formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONCOGENICALLY TRANSFORMED-CELLS; HUMAN BREAST-CANCER; ROUS-SARCOMA VIRUS; MUSCULAR-DYSTROPHY; INTEGRAL COMPONENT; TRANSPORT VESICLES; MEMBRANE DOMAINS; PLASMA-MEMBRANE; SMOOTH-MUSCLE; GENE FAMILY	Caveolin-8 is the principal structural protein of caveolae membrane domains in striated muscle cells. Caveolin-3 mRNA and protein expression are dramatically induced during the differentiation of C2C12 skeletal myoblasts, coincident with myoblast fusion. In these myotubes, caveolin-3 localizes to the sarcolemma (muscle cell plasma membrane), where it associates with the dystrophin-glycoprotein complex. However, it remains unknown what role caveolin-3 plays in myoblast differentiation and myotube formation. Here, we employ an antisense approach to derive stable C2C12 myoblasts that fail to express the caveolin-3 protein. We show that C2C12 cells harboring caveolin-3 antisense undergo differentiation and express normal amounts of four muscle-specific marker proteins. However, C2C12 cells harboring caveolin-3 antisense fail to undergo myoblast fusion and, therefore, do not form myotubes, Interestingly, treatment with specific p38 mitogen-activated protein kinase inhibitors blocks both myotube formation and caveolin-3 expression, but does not affect the expression of other muscle-specific proteins. In addition, we find that three human rhabdomyosarcoma cell lines do not express caveolin-3 and fail to undergo myoblast fusion, Taken together, these results support the idea that caveolin-3 expression is required fear myoblast fusion and myotube formation, and suggest that p38 is an upstream regulator of caveolin-3 expression.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Lisanti, MP (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Scherer, Philipp E/K-7819-2012; Lisanti, Michael P/C-6866-2013; Galbiati, Ferruccio/AAF-3527-2020; Lisanti, Michael/B-6131-2018	Scherer, Philipp E/0000-0003-0680-3392; Lisanti, Michael/0000-0003-2034-1382				BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BONILLA E, 1981, AM J PATHOL, V104, P167; COLE F, 1993, J BIOL CHEM, V268, P1580; Couet J, 1997, TRENDS CARDIOVAS MED, V7, P103, DOI 10.1016/S1050-1738(97)00001-7; Crosbie RH, 1998, FEBS LETT, V427, P279, DOI 10.1016/S0014-5793(98)00442-6; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; Engelman JA, 1998, AM J HUM GENET, V63, P1578, DOI 10.1086/302172; Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GLENNEY JR, 1992, FEBS LETT, V314, P45, DOI 10.1016/0014-5793(92)81458-X; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; Minetti C, 1998, NAT GENET, V18, P365, DOI 10.1038/ng0498-365; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Nagata Y, 1998, BLOOD, V92, P1859, DOI 10.1182/blood.V92.6.1859.418k37_1859_1869; NORTH AJ, 1993, J CELL BIOL, V120, P1159, DOI 10.1083/jcb.120.5.1159; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SAGER R, 1994, COLD SPRING HARB SYM, V59, P537, DOI 10.1101/SQB.1994.059.01.060; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; Scherer PE, 1997, J BIOL CHEM, V272, P20698, DOI 10.1074/jbc.272.33.20698; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193	34	117	121	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30315	30321		10.1074/jbc.274.42.30315	http://dx.doi.org/10.1074/jbc.274.42.30315			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514527	hybrid			2022-12-27	WOS:000083176400106
J	Murakami, M; Kambe, T; Shimbara, S; Yamamoto, S; Kuwata, H; Kudo, I				Murakami, M; Kambe, T; Shimbara, S; Yamamoto, S; Kuwata, H; Kudo, I			Functional association of type IIA secretory phospholipase A, with the glycosylphosphatidylinositol-anchored heparan sulfate proteoglycan in the cyclooxygenase-2-mediated delayed prostanoid-biosynthetic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; FIBROBLAST GROWTH-FACTOR; SMOOTH-MUSCLE CELLS; A(2) TYPE-II; MAST-CELLS; SUBCELLULAR-LOCALIZATION; PROSTAGLANDIN SYNTHESIS; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; ENDOTHELIAL-CELLS	An emerging body of evidence suggests that type IIA secretory phospholipase A(2) (sPLA(2)-IIA) participates in the amplification of the stimulus-induced cyclooxygenase (COX)-2-dependent delayed prostaglandin (PG)-biosynthetic response in several cell types. However, the biological importance of the ability of sPLA(2)-IIA to bind to heparan sulfate proteoglycan (HSPG) on cell surfaces has remained controversial. Here we show that glypican, a glycosylphosphatidylinositol (GPI)-anchored HSPG, acts as a physical and functional adaptor for sPLA(2)-IIA. sPLA(2)-IIA-dependent PGE(2) generation by interleukin-1-stimulated cells was markedly attenuated by treatment of the cells with heparin, heparinase or GPI-specific phospholipase C, which solubilized the cell surface-associated sPLA(2)-IIA. Overexpression of glypican-1 increased the association of sPLA(2)-IIA with the cell membrane, and glypican-1 was coimmunoprecipitated by the antibody against sPLA(2)-IIA Glypican-1 overexpression led to marked augmentation of sPLA(2)-IIA-mediated arachidonic acid release, PGE(2) generation, and COX-2 induction in interleukin-1-stimulated cells, particularly when the sPLA(2)-IIA expression level was suboptimal. Immunofluorescent microscopic analyses of cytokine-stimulated cells revealed that sPLA(2)-IIA was present in the caveolae, a microdomain in which GPI-anchored proteins reside, and also appeared in the perinuclear area in proximity to COX-2. We therefore propose that a GPI-anchored HSPG glypican facilitates the trafficking of sPLA(2)-IIA into particular subcellular compartments, and arachidonic acid thus released from the compartments may link efficiently to the downstream COX-2-mediated PG biosynthesis.	Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, Tokyo 142, Japan	Showa University	Kudo, I (corresponding author), Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 142, Japan.	kudo@pharm.showa-u.ac.jp	Kuwata, Hiro/N-2023-2019	Kuwata, Hiro/0000-0002-5023-1777				AARSMAN AJ, 1989, J BIOL CHEM, V264, P10008; AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Arbibe L, 1998, J CLIN INVEST, V102, P1152, DOI 10.1172/JCI3236; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balsinde J, 1998, P NATL ACAD SCI USA, V95, P7951, DOI 10.1073/pnas.95.14.7951; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; BUSCH SJ, 1992, J CELL BIOL, V116, P31, DOI 10.1083/jcb.116.1.31; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; Fayard JM, 1998, J CELL SCI, V111, P985; FEDARKO NS, 1986, J CELL BIOL, V102, P587, DOI 10.1083/jcb.102.2.587; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; Han SK, 1999, J BIOL CHEM, V274, P11881, DOI 10.1074/jbc.274.17.11881; HARA S, 1995, BBA-LIPID LIPID MET, V1257, P11, DOI 10.1016/0005-2760(95)00011-Z; Hernandez M, 1998, J BIOL CHEM, V273, P606, DOI 10.1074/jbc.273.1.606; HORIGOME K, 1987, J BIOCHEM-TOKYO, V101, P625, DOI 10.1093/jb/101.3.625; Ilangumaran S, 1996, TRENDS CELL BIOL, V6, P163, DOI 10.1016/0962-8924(96)20012-1; ISHIHARA M, 1986, J BIOL CHEM, V261, P3575; ISHIZAKI J, 1994, J BIOL CHEM, V269, P5897; Ishizaki J, 1999, J BIOL CHEM, V274, P24973, DOI 10.1074/jbc.274.35.24973; KIMURA H, 1993, P NATL ACAD SCI USA, V90, P2165, DOI 10.1073/pnas.90.6.2165; Koduri RS, 1998, J BIOL CHEM, V273, P32142, DOI 10.1074/jbc.273.48.32142; Koumanov K, 1997, BIOCHEM J, V326, P227, DOI 10.1042/bj3260227; Koumanov KS, 1998, BIOCHEM J, V336, P625, DOI 10.1042/bj3360625; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KURIHARA H, 1991, BIOCHIM BIOPHYS ACTA, V1082, P285, DOI 10.1016/0005-2760(91)90204-U; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; Liang Y, 1997, J CELL BIOL, V139, P851, DOI 10.1083/jcb.139.4.851; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MARSHALL LA, 1992, BIOCHEM PHARMACOL, V44, P1849, DOI 10.1016/0006-2952(92)90081-S; MATSUMOTO R, 1995, J BIOL CHEM, V270, P19524, DOI 10.1074/jbc.270.33.19524; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; Menschikowski M, 1995, ATHEROSCLEROSIS, V118, P173, DOI 10.1016/0021-9150(95)05604-1; Mertens G, 1996, J CELL BIOL, V132, P487, DOI 10.1083/jcb.132.3.487; MOROIANU J, 1994, P NATL ACAD SCI USA, V91, P1677, DOI 10.1073/pnas.91.5.1677; MURAKAMI M, 1991, FEBS LETT, V294, P247, DOI 10.1016/0014-5793(91)81440-J; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami M, 1996, J BIOL CHEM, V271, P30041, DOI 10.1074/jbc.271.47.30041; MURAKAMI M, 1992, EUR J BIOCHEM, V209, P257, DOI 10.1111/j.1432-1033.1992.tb17284.x; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; MURAKAMI M, 1990, BIOCHIM BIOPHYS ACTA, V1043, P34, DOI 10.1016/0005-2760(90)90107-9; MURAKAMI M, 1999, IN PRESS J BIOL CHEM, V274; NAKANO T, 1990, J BIOL CHEM, V265, P12745; NAKAZATO Y, 1991, J BIOL CHEM, V266, P14119; Oishi T, 1996, FEBS LETT, V394, P55, DOI 10.1016/0014-5793(96)00929-5; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; PFEILSCHIFTER J, 1993, J CLIN INVEST, V92, P2516, DOI 10.1172/JCI116860; Polgar J, 1997, BIOCHEM J, V327, P259, DOI 10.1042/bj3270259; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; Sartipy P, 1996, J BIOL CHEM, V271, P26307, DOI 10.1074/jbc.271.42.26307; Sartipy P, 1998, ARTERIOSCL THROM VAS, V18, P1934, DOI 10.1161/01.ATV.18.12.1934; SAWADA H, 1999, IN PRESS EUR J BIOCH; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; Shinohara H, 1999, J BIOL CHEM, V274, P12263, DOI 10.1074/jbc.274.18.12263; Smart EJ, 1996, J CELL BIOL, V134, P1169, DOI 10.1083/jcb.134.5.1169; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; Sperinde GV, 1998, BIOCHEMISTRY-US, V37, P13153, DOI 10.1021/bi980600z; Steinfeld R, 1996, J CELL BIOL, V133, P405, DOI 10.1083/jcb.133.2.405; SUGA H, 1993, EUR J BIOCHEM, V218, P807, DOI 10.1111/j.1432-1033.1993.tb18435.x; Surette ME, 1998, BIOCHEM J, V330, P915; Tada K, 1998, J IMMUNOL, V161, P5008; Takasaki J, 1998, FEBS LETT, V440, P377, DOI 10.1016/S0014-5793(98)01490-2; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; Valentin E, 1999, J BIOL CHEM, V274, P19152, DOI 10.1074/jbc.274.27.19152; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; WRIGHT GW, 1990, J BIOL CHEM, V265, P6675; Zvaritch E, 1996, J BIOL CHEM, V271, P250, DOI 10.1074/jbc.271.1.250	76	153	156	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29927	29936		10.1074/jbc.274.42.29927	http://dx.doi.org/10.1074/jbc.274.42.29927			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514475	hybrid			2022-12-27	WOS:000083176400054
J	Lim, S; Naisbitt, S; Yoon, J; Hwang, JI; Suh, PG; Sheng, M; Kim, E				Lim, S; Naisbitt, S; Yoon, J; Hwang, JI; Suh, PG; Sheng, M; Kim, E			Characterization of the Shank family of synaptic proteins - Multiple genes, alternative splicing, and differential expression in brain and development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; TUMOR-SUPPRESSOR PROTEIN; NITRIC-OXIDE SYNTHASE; POSTSYNAPTIC DENSITY; NMDA RECEPTOR; INTERACTING PROTEIN; ALPHA-DYSTROGLYCAN; BINDING PROTEIN; PSD-95 FAMILY; PDZ DOMAIN	Shank1, Shank2, and Shank3 constitute a family of proteins that may function as molecular scaffolds in the postsynaptic density (PSD). Shank directly interacts with GKAP and Homer, thus potentially bridging the N-methyl-D-aspartate receptor-PSD-95-GKAP complex and the mGluR-Homer complex in synapses (Naisbitt, S., Kim, E., Tu, J. C., Xiao, B., Sala, S., Valtschanoff, J., Weinberg, R J., morley, P. F., and Sheng, M. (1999) Neuron 23, 569-582; Tu, J. C., Xiao, B., Naisbitt, S., Yuan, J. P., Petralia, R. S., Brakeman, P., Dean, A., Aakalu, V. K., Lanahan, A. A., Sheng, M., and Worley, P. F. (1999) Neuron 23, 583-592). Shank contains multiple domains for protein-protein interaction including ankyrin repeats, an SH3 domain, a PSD-95/DIg/ZO-1 domain, a sterile a motif domain, and a proline-rich region. By characterizing Shank cDNA clones and RT-PCR products, we found that there are four sites far alternative splicing in Shank1 and another four sites in Shank2, some of which result in deletion of specific domains of the Shank protein. In addition, the expression of the splice variants is differentially regulated in different regions of rat brain during development. Immunoblot analysis of Shank proteins in rat brain using five different Shank antibodies reveals marked heterogeneity in size (120-240 kDa) and differential. spatiotemporal expression. Shank1 immunoreactivity is concentrated at excitatory synaptic sites in adult brain, and the punctate staining of Shank1 is seen in developing rat brains as early as postnatal day 7. These results suggest that alternative splicing in the Shank family may be a mechanism that regulates the molecular structure of Shank and the spectrum of Shank-interacting proteins in the PSDs of adult and developing brain.	Pusan Natl Univ, Dept Pharmacol, Pusan 609735, South Korea; Massachusetts Gen Hosp, Howard Hughes Med Inst, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, South Korea	Pusan National University; Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Pohang University of Science & Technology (POSTECH)	Kim, E (corresponding author), Pusan Natl Univ, Dept Pharmacol, Pusan 609735, South Korea.		Suh, Pann-Ghill/F-3610-2010; Kim, Eunjoon/C-1566-2011	Hwang, Jong-Ik/0000-0002-0729-1782	NINDS NIH HHS [NS35050] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035050] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alagarsamy S, 1999, NAT NEUROSCI, V2, P234, DOI 10.1038/6338; Barr MM, 1996, MOL CELL BIOL, V16, P5597; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brenman JE, 1996, J NEUROSCI, V16, P7407; Campanelli JT, 1996, DEVELOPMENT, V122, P1663; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Du YR, 1998, MOL CELL BIOL, V18, P5838, DOI 10.1128/MCB.18.10.5838; Gesemann M, 1996, NEURON, V16, P755, DOI 10.1016/S0896-6273(00)80096-3; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Kato A, 1998, J BIOL CHEM, V273, P23969, DOI 10.1074/jbc.273.37.23969; Kennedy MB, 1997, TRENDS NEUROSCI, V20, P264, DOI 10.1016/S0166-2236(96)01033-8; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Lau LF, 1996, J BIOL CHEM, V271, P21622, DOI 10.1074/jbc.271.35.21622; Masuko N, 1999, J BIOL CHEM, V274, P5782, DOI 10.1074/jbc.274.9.5782; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Naisbitt S, 1999, NEURON, V23, P569, DOI 10.1016/S0896-6273(00)80809-0; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Niethammer M, 1996, J NEUROSCI, V16, P2157; O'Brien RJ, 1998, CURR OPIN NEUROBIOL, V8, P364, DOI 10.1016/S0959-4388(98)80062-7; OToole JJ, 1996, P NATL ACAD SCI USA, V93, P7369, DOI 10.1073/pnas.93.14.7369; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PONTING CP, 1995, PROTEIN SCI, V4, P1928, DOI 10.1002/pro.5560040927; Rao A, 1997, NEURON, V19, P801, DOI 10.1016/S0896-6273(00)80962-9; Satoh K, 1997, GENES CELLS, V2, P415, DOI 10.1046/j.1365-2443.1997.1310329.x; Schultz J, 1997, PROTEIN SCI, V6, P249; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; Srivastava S, 1998, NEURON, V21, P581, DOI 10.1016/S0896-6273(00)80568-1; Stapleton D, 1999, NAT STRUCT BIOL, V6, P44; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Tezuka T, 1999, P NATL ACAD SCI USA, V96, P435, DOI 10.1073/pnas.96.2.435; Thanos CD, 1999, SCIENCE, V283, P833, DOI 10.1126/science.283.5403.833; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Tu JC, 1999, NEURON, V23, P583, DOI 10.1016/S0896-6273(00)80810-7; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; Watanabe M, 1998, EUR J NEUROSCI, V10, P478, DOI 10.1046/j.1460-9568.1998.00063.x; Xiao B, 1998, NEURON, V21, P707, DOI 10.1016/S0896-6273(00)80588-7; Ziff EB, 1997, NEURON, V19, P1163, DOI 10.1016/S0896-6273(00)80409-2	51	211	219	2	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29510	29518		10.1074/jbc.274.41.29510	http://dx.doi.org/10.1074/jbc.274.41.29510			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506216	hybrid			2022-12-27	WOS:000083017800095
J	Rangaraj, P; Ryle, MJ; Lanzilotta, WN; Goodwin, PJ; Dean, DR; Shah, VK; Ludden, PW				Rangaraj, P; Ryle, MJ; Lanzilotta, WN; Goodwin, PJ; Dean, DR; Shah, VK; Ludden, PW			Inhibition of iron-molybdenum cofactor biosynthesis by L127 Delta NifH and evidence for a complex formation between L127 Delta NifH and NifNE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE REDUCTION PROPERTIES; IN-VITRO SYNTHESIS; APO-MOFE PROTEIN; AZOTOBACTER-VINELANDII; KLEBSIELLA-PNEUMONIAE; SIGNAL-TRANSDUCTION; INVITRO SYNTHESIS; ELECTRON-TRANSFER; GENE-PRODUCT; NITROGENASE	Besides serving as the obligate electron donor to dinitrogenase during nitrogenase turnover, dinitrogenase reductase (NifH) is required for the biosynthesis of the iron-molybdenum cofactor (FeMo-co) and for the maturation of alpha(2)beta(2) apo-dinitrogenase (apo-dinitrogenase maturation). In an attempt to understand the role of NifH in FeMo-co biosynthesis, a site-specific altered form of NifH in which leucine at position 127 has been deleted, L127 Delta, was employed in in vitro FeMo-co synthesis assays, This altered form of NifH has been shown to inhibit substrate reduction by the wild-type nitrogenase complex, forming a tight protein complex with dinitrogenase. The L127 Delta NifH was found to inhibit in vitro FeMo-co synthesis by wild-type NifH as detected by the gamma gel shift assay, Increasing the concentration of NifNE and NifB-cofactor (NifB-co) relieved the inhibition of FeMo-co synthesis by L127 Delta NifH. The formation of a complex of L127 Delta NifH with NifNE was investigated by gel filtration chromatography, We herein report the formation of a complex between L127 Delta NifH and NifNE in the presence of NifB-co, This work presents evidence for one of the possible roles for NifH in FeMo-co biosynthesis, Le. the interaction of NifH with a NifNE.NifB-co complex.	Univ Wisconsin, Coll Agr & Life Sci, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Coll Agr & Life Sci, Ctr Study Nitrogen Fixat, Madison, WI 53706 USA; Utah State Univ, Dept Chem & Biochem, Logan, UT 84322 USA; Virginia Tech, Fralin Biotechnol Ctr, Dept Biochem, Blacksburg, VA 24061 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Utah System of Higher Education; Utah State University; Virginia Polytechnic Institute & State University	Ludden, PW (corresponding author), Univ Wisconsin, Coll Agr & Life Sci, Dept Biochem, Madison, WI 53706 USA.	ludden@biochem.wisc.edu			NIGMS NIH HHS [GM 35332] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM035332, R01GM035332] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN RM, 1994, CRIT REV BIOTECHNOL, V14, P225, DOI 10.3109/07388554409079834; ALLEN RM, 1993, J BIOL CHEM, V268, P23670; ALLEN RM, 1995, J BIOL CHEM, V270, P26890, DOI 10.1074/jbc.270.45.26890; BRANDNER JP, 1989, J BACTERIOL, V171, P360, DOI 10.1128/jb.171.1.360-368.1989; BRIGLE KE, 1987, J BACTERIOL, V169, P1547, DOI 10.1128/jb.169.4.1547-1553.1987; BURRIS RH, 1991, J BIOL CHEM, V266, P9339; Chatterjee R, 1997, J BIOL CHEM, V272, P21604, DOI 10.1074/jbc.272.34.21604; Christiansen J, 1998, BIOCHEMISTRY-US, V37, P12611, DOI 10.1021/bi981165b; FILLER WA, 1986, EUR J BIOCHEM, V160, P371, DOI 10.1111/j.1432-1033.1986.tb09981.x; Fortune WB, 1938, IND ENG CHEM, V10, P0060, DOI 10.1021/ac50118a004; GAVINI N, 1992, J BIOL CHEM, V267, P21179; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; Goodwin PJ, 1998, BIOCHEMISTRY-US, V37, P10420, DOI 10.1021/bi980435n; HAUSINGER RP, 1983, J BIOL CHEM, V258, P3486; HOMER MJ, 1995, J BIOL CHEM, V270, P24745, DOI 10.1074/jbc.270.42.24745; HOOVER TR, 1986, J BACTERIOL, V167, P999, DOI 10.1128/jb.167.3.999-1003.1986; HOWARD JB, 1994, ANNU REV BIOCHEM, V63, P235, DOI 10.1146/annurev.bi.63.070194.001315; IMPERIAL J, 1989, BIOCHEMISTRY-US, V28, P7796, DOI 10.1021/bi00445a040; IMPERIAL J, 1984, J BACTERIOL, V158, P187, DOI 10.1128/JB.158.1.187-194.1984; Lanzilotta WN, 1996, BIOCHEMISTRY-US, V35, P7188, DOI 10.1021/bi9603985; LJONES T, 1972, BIOCHIM BIOPHYS ACTA, V275, P93, DOI 10.1016/0005-2728(72)90027-8; MACNEIL T, 1978, J BACTERIOL, V136, P253, DOI 10.1128/JB.136.1.253-266.1978; MADDEN MS, 1990, P NATL ACAD SCI USA, V87, P6517, DOI 10.1073/pnas.87.17.6517; PAUSTIAN TD, 1989, P NATL ACAD SCI USA, V86, P6082, DOI 10.1073/pnas.86.16.6082; Rangaraj P, 1997, P NATL ACAD SCI USA, V94, P11250, DOI 10.1073/pnas.94.21.11250; ROBINSON AC, 1989, J BIOL CHEM, V264, P10088; ROLL JT, 1995, J BIOL CHEM, V270, P4432, DOI 10.1074/jbc.270.9.4432; Ryle MJ, 1996, BIOCHEMISTRY-US, V35, P4766, DOI 10.1021/bi960026w; Schindelin N, 1997, NATURE, V387, P370, DOI 10.1038/387370a0; Seefeldt LC, 1997, ACCOUNTS CHEM RES, V30, P260, DOI 10.1021/ar960260e; Shah V. K., 1988, Nitrogen fixation: Hundred years after. Proceedings of the 7th International Congress on Nitrogen Fixation, Koln (Cologne), FRG, March 13-20, 1988., P115; SHAH VK, 1972, BIOCHIM BIOPHYS ACTA, V256, P498, DOI 10.1016/0005-2728(72)90078-3; SHAH VK, 1994, J BIOL CHEM, V269, P1154; SHAH VK, 1986, P NATL ACAD SCI USA, V83, P1636, DOI 10.1073/pnas.83.6.1636; SHAH VK, 1977, P NATL ACAD SCI USA, V74, P3249, DOI 10.1073/pnas.74.8.3249; SHAH VK, 1985, J BIOL CHEM, V260, P3891; SMITH PK, 1985, ANAL BIOCHEM, V150, P175; Thorneley R. N. F., 1985, MOLYBDENUM ENZYMES, P221; WAUGH SI, 1995, J BACTERIOL, V177, P1505, DOI 10.1128/jb.177.6.1505-1510.1995; WOLLE D, 1992, SCIENCE, V258, P992, DOI 10.1126/science.1359643; Zheng LM, 1997, J BACTERIOL, V179, P5963, DOI 10.1128/jb.179.18.5963-5966.1997	41	14	15	6	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29413	29419		10.1074/jbc.274.41.29413	http://dx.doi.org/10.1074/jbc.274.41.29413			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506203	hybrid			2022-12-27	WOS:000083017800082
J	Noguchi, K; Kitanaka, C; Yamana, H; Kokubu, A; Mochizuki, T; Kuchino, Y				Noguchi, K; Kitanaka, C; Yamana, H; Kokubu, A; Mochizuki, T; Kuchino, Y			Regulation of c-Myc through phosphorylation at Ser-62 and Ser-71 by c-Jun N-terminal kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; FAS LIGAND EXPRESSION; APOPTOTIC CELL-DEATH; PROTEIN-KINASE; ACTIVATION DOMAIN; RESPONSE ELEMENT; GENE-EXPRESSION; INDUCTION; JNK; GROWTH	The expression of c-myc promotes cell proliferation and also sensitizes cells to various extracellular apoptotic stimuli. However, signal pathways regulating the function of myc proteins during apoptosis are unknown. c-Jun N-terminal kinase (JNK) is activated by various apoptotic stimuli, but neither the target molecule(s) or the action of JNK has been identified in Myc-mediated apoptosis. Here, we found that JNK selectively interacted with, and phosphorylated, c-Myc at Ser-62 and Ser-71 as confirmed with phospho-c-Myc-specific antibodies. Interestingly, dominant negative mutant JNK(APF) impaired the c-Myc-dependent apoptosis, but not mutated c-Myc (S62A/S71A)-dependent apoptosis triggered by UV irradiation. Furthermore, c-Myc (S62A/S71A)-expressing NIH3T3 cells were not sensitized like wild type c-Myc-expressing NIH3T3 cells to JNK-activating apoptotic stimuli, such as UV and Taxol These results indicate that the JNK pathway is selectively involved in the c-Myc-mediated apoptosis and that the apoptotic function of c-myc is directly regulated by JNK pathway through phosphorylation at Ser-62 and Ser-71.	Natl Canc Ctr, Res Inst, Div Biophys, Chuo Ku, Tokyo 1040045, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Kawaguchi, Saitama 3320012, Japan	National Cancer Center - Japan; Japan Science & Technology Agency (JST)	Kuchino, Y (corresponding author), Natl Canc Ctr, Res Inst, Div Biophys, Chuo Ku, Tokyo 1040045, Japan.							Adler V, 1997, P NATL ACAD SCI USA, V94, P1686, DOI 10.1073/pnas.94.5.1686; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; Butterfield L, 1997, J BIOL CHEM, V272, P10110; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dong JA, 1997, ONCOGENE, V15, P639, DOI 10.1038/sj.onc.1201237; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; Faris M, 1998, J IMMUNOL, V160, P134; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; Flinn EM, 1998, MOL CELL BIOL, V18, P5961, DOI 10.1128/MCB.18.10.5961; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; Khwaja A, 1997, J CELL BIOL, V139, P1017, DOI 10.1083/jcb.139.4.1017; KITANAKA C, 1995, CELL DEATH DIFFER, V2, P123; Lee LF, 1998, J BIOL CHEM, V273, P28253, DOI 10.1074/jbc.273.43.28253; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Nesbit CE, 1998, CELL GROWTH DIFFER, V9, P731; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; PULVERER BJ, 1994, ONCOGENE, V9, P59; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; SETH A, 1993, MOL CELL BIOL, V13, P4125, DOI 10.1128/MCB.13.7.4125; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; Smith A, 1997, CURR BIOL, V7, P893, DOI 10.1016/S0960-9822(06)00380-0; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Sugiyama A, 1999, GENE, V226, P273, DOI 10.1016/S0378-1119(98)00547-2; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899	51	143	162	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32580	32587		10.1074/jbc.274.46.32580	http://dx.doi.org/10.1074/jbc.274.46.32580			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551811	hybrid			2022-12-27	WOS:000083623000011
J	Schiffer, G; Holtje, JV				Schiffer, G; Holtje, JV			Cloning and characterization of PBP1C, a third member of the multimodular class A penicillin-binding proteins of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; CELL-WALL PEPTIDOGLYCAN; BETA-LACTAM ANTIBIOTICS; MONOFUNCTIONAL GLYCOSYLTRANSFERASE; MUREIN SYNTHESIS; TRANSGLYCOSYLASE; DIVISION; GROWTH; POLYMERIZATION; TRANSPEPTIDASE	All proteins of Escherichia coli that covalently bind penicillin have been cloned except for the penicillin-binding protein (PBP) 1C, For a detailed understanding of the mode of action of beta-lactam antibiotics, cloning of the gene encoding PBP1C was of major importance. Therefore, the structural gene was identified in the E. coli genomic lambda library of Kohara and subcloned, and PBP1C was characterized biochemically. PBP1C is a close homologue to the bifunctional transpeptidases/transglycosylases PBP1A and PBP1B and likewise shows murein polymerizing activity, which can be blocked by the transglycosylase inhibitor moenomycin. Covalently linked to activated Sepharose, PBP1C specifically retained PBP1B and the transpeptidases PBP2 and -3 in addition to the murein hydrolase MltA. The specific interaction with these proteins suggests that PBP1C is assembled into a multienzyme complex consisting of both murein polymerases and hydrolases, Overexpression of PBP1C does not support growth of a PBP1A(tS)/PBP1B double mutant at the restrictive temperature, and PBP1C does not bind to the same variety of penicillin derivatives as PBPs 1A and 1B. Deletion of PBP1C resulted in an altered mode of murein synthesis. It is suggested that PBP1C functions in vivo as a transglycosylase only.	Max Planck Inst Entwicklungsbiol, Biochem Abt, D-72076 Tubingen, Germany	Max Planck Society	Holtje, JV (corresponding author), Max Planck Inst Entwicklungsbiol, Biochem Abt, Spemannstr 35, D-72076 Tubingen, Germany.	joachim-volker.hoeltje@tuebingen.mpg.de						Adam M, 1997, J BACTERIOL, V179, P6005, DOI 10.1128/jb.179.19.6005-6009.1997; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BISHOP RE, 1993, FEMS MICROBIOL LETT, V114, P349, DOI 10.1111/j.1574-6968.1993.tb06597.x; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CASADABAN M, 1980, J MOL BIOL, V13, P179; DEJONGE BLM, 1989, J BACTERIOL, V171, P5783, DOI 10.1128/jb.171.11.5783-5794.1989; DiBerardino M, 1996, FEBS LETT, V392, P184, DOI 10.1016/0014-5793(96)00809-5; EDWARDS DH, 1993, FEMS SYMP, P369; Ghuysen JM, 1996, MICROB DRUG RESIST, V2, P163, DOI 10.1089/mdr.1996.2.163; GLAUNER B, 1988, ANAL BIOCHEM, V172, P451, DOI 10.1016/0003-2697(88)90468-X; GLAUNER B, 1988, J BIOL CHEM, V263, P10088; Goffin C, 1998, MICROBIOL MOL BIOL R, V62, P1079, DOI 10.1128/MMBR.62.4.1079-1093.1998; Goffin C, 1996, J BACTERIOL, V178, P5402, DOI 10.1128/jb.178.18.5402-5409.1996; HARZ H, 1990, ANAL BIOCHEM, V190, P120, DOI 10.1016/0003-2697(90)90144-X; HENDERSON TA, 1995, J BACTERIOL, V177, P2074, DOI 10.1128/jb.177.8.2074-2079.1995; Holtje JV, 1996, MICROBIOL-SGM, V142, P1911, DOI 10.1099/13500872-142-8-1911; Holtje JV, 1998, MICROBIOL MOL BIOL R, V62, P181; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; ISHINO F, 1980, BIOCHEM BIOPH RES CO, V97, P287, DOI 10.1016/S0006-291X(80)80166-5; KATO J, 1985, MOL GEN GENET, V200, P272, DOI 10.1007/BF00425435; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KRAUS W, 1987, J BACTERIOL, V169, P3099, DOI 10.1128/jb.169.7.3099-3103.1987; KULAKAUSKAS S, 1991, J BACTERIOL, V173, P2633, DOI 10.1128/jb.173.8.2633-2638.1991; LABIA R, 1985, J ANTIMICROB CHEMOTH, V15, P9, DOI 10.1093/jac/15.1.9; LUGTENBERG B, 1975, FEBS LETT, V58, P254, DOI 10.1016/0014-5793(75)80272-9; MATSUHASHI M, 1990, RES MICROBIOL, V141, P89, DOI 10.1016/0923-2508(90)90101-U; Matsuhashi M., 1994, BACTERIAL CELL WALL, P55; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MURRAY MG, 1980, NUCLEIC ACIDS RES, V8, P111; NAKAGAWA J, 1984, J BIOL CHEM, V259, P3937; Paik J, 1997, J BACTERIOL, V179, P4061, DOI 10.1128/jb.179.12.4061-4065.1997; PARK JT, 1973, BIOCHEM BIOPH RES CO, V51, P863, DOI 10.1016/0006-291X(73)90006-5; Park JT, 1996, ESCHERICHIA COLI SAL, P48; ROMEIS T, 1994, J BIOL CHEM, V269, P21603; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHALLER K, 1982, J BACTERIOL, V152, P994; SCHMIDT LS, 1981, J BACTERIOL, V145, P632, DOI 10.1128/JB.145.1.632-637.1981; SCHWARZ U, 1981, FEMS MICROBIOL LETT, V10, P107, DOI 10.1111/j.1574-6968.1981.tb06217.x; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH RF, 1992, PROTEIN ENG, V5, P35, DOI 10.1093/protein/5.1.35; SPRATT BG, 1975, P NATL ACAD SCI USA, V72, P2999, DOI 10.1073/pnas.72.8.2999; SUZUKI H, 1978, P NATL ACAD SCI USA, V75, P664, DOI 10.1073/pnas.75.2.664; SUZUKI H, 1980, FEBS LETT, V110, P245, DOI 10.1016/0014-5793(80)80083-4; TOMASZ A, 1986, REV INFECT DIS, V8, pS260; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANHEIJENOORT J, 1988, ANTIBIOTIC INHIBITIO, P549; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; Vollmer W, 1999, J BIOL CHEM, V274, P6726, DOI 10.1074/jbc.274.10.6726; vonRechenberg M, 1996, MICROB DRUG RESIST, V2, P155, DOI 10.1089/mdr.1996.2.155; WAXMAN DJ, 1983, ANNU REV BIOCHEM, V52, P825, DOI 10.1146/annurev.bi.52.070183.004141; WIENTJES FB, 1991, RES MICROBIOL, V142, P333, DOI 10.1016/0923-2508(91)90049-G; YOUSIF SY, 1985, J GEN MICROBIOL, V131, P2839	54	78	80	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32031	32039		10.1074/jbc.274.45.32031	http://dx.doi.org/10.1074/jbc.274.45.32031			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542235	hybrid			2022-12-27	WOS:000083532100043
J	Kabil, O; Banerjee, R				Kabil, O; Banerjee, R			Deletion of the regulatory domain in the pyridoxal phosphate-dependent heme protein cystathionine beta-synthase alleviates the defect observed in a catalytic site mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOCYSTEINE; METABOLISM; DISEASE	The most common cause of severely elevated homocysteine or homocystinuria is inherited disorders in cystathionine beta-synthase. The latter enzyme is a unique hemeprotein that catalyzes pyridoxal phosphate (PLP)dependent condensation of serine and homocysteine to give cystathionine, thus committing homocysteine to catabolism. A point mutation, V168M,has been described in a homocystinuric cell line and is associated with a B-6-responsive phenotype. In this study, we have examined the kinetic properties of this mutant and demonstrate that the mutation affects the PLP but not the heme content. The similar to 13-fold diminution in activity because of the mutation corresponds to an similar to 7-fold decrease in the level of bound PLP. This may be explained by half of the sites activity associated with cystathionine beta-synthase. The addition of PLP results in partial but not full restoration of activity to wild type levels. Elimination of the C-terminal quarter of the mutant protein results in alleviation of the catalytic penalty imposed by the V168M mutation. The resulting truncated protein is very similar to the corresponding truncated enzyme with wild type sequence and is now able to bind the full complement of both heme and PLP cofactors. These results indicate that the V168M mutation per se does not affect binding of PLP directly and that interactions between the regulatory C terminus and the catalytic N terminus are important in modulating the co-factor content and therefore the activity of the full-length enzyme. These studies provide the first biochemical explanation for the B-6-responsive phenotype associated with a cystathionine beta-synthase-impaired homocystinuric genotype.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Banerjee, R (corresponding author), Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA.	rbanerjee1@unl.edu	Kabil, Omer/AAJ-1435-2020		NHLBI NIH HHS [HL58984] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058984] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BORCSOK E, 1982, ARCH BIOCHEM BIOPHYS, V213, P695, DOI 10.1016/0003-9861(82)90600-2; Cornish-Bowden A., 1995, FUNDAMENTALS ENZYME; DRUMMOND JT, 1995, ANAL BIOCHEM, V228, P323, DOI 10.1006/abio.1995.1358; FINKELSTEIN JD, 1984, J BIOL CHEM, V259, P9508; FINKELSTEIN JD, 1975, BIOCHEM BIOPH RES CO, V66, P81, DOI 10.1016/S0006-291X(75)80297-X; Gallagher DT, 1998, STRUCTURE, V6, P465, DOI 10.1016/S0969-2126(98)00048-3; HYDE CC, 1988, J BIOL CHEM, V263, P17857; JONES JB, 1977, COMMUN SOIL SCI PLAN, V8, P349, DOI 10.1080/00103627709366727; Kery V, 1999, BIOCHEMISTRY-US, V38, P2716, DOI 10.1021/bi981808n; KERY V, 1994, J BIOL CHEM, V269, P25283; KRAUS JP, 1994, J INHERIT METAB DIS, V17, P383, DOI 10.1007/BF00711354; KRAUS JP, 1996, 3 WORKSH METH MET, P12; MILLS JL, 1995, LANCET, V345, P149, DOI 10.1016/S0140-6736(95)90165-5; MUDD SH, 1995, METABOLIC MOL BASIS; Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31; Shan XY, 1998, NAT GENET, V19, P91, DOI 10.1038/ng0598-91; Taoka S, 1999, BIOCHEMISTRY-US, V38, P2738, DOI 10.1021/bi9826052; Taoka S, 1998, J BIOL CHEM, V273, P25179, DOI 10.1074/jbc.273.39.25179; TAOKA S, 1999, IN PRESS BIOCHEMISTR, V38	19	19	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31256	31260		10.1074/jbc.274.44.31256	http://dx.doi.org/10.1074/jbc.274.44.31256			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531322	hybrid			2022-12-27	WOS:000083379400026
J	Qu, BH; Karas, M; Koval, A; LeRoith, D				Qu, BH; Karas, M; Koval, A; LeRoith, D			Insulin receptor substrate-4 enhances insulin-like growth factor-I-induced cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADIPOSE-CELLS; SIGNAL-TRANSDUCTION; PHOSPHOTYROSINE PROTEIN; TYROSINE KINASE; IRS-1; DOMAIN; TRANSFORMATION; TRANSLOCATION; ACTIVATION; ADIPOCYTES	The insulin receptor substrates (IRSs)-1-4 play important roles in signal transduction emanating from the insulin and insulin-like growth factor (IGF)-I receptors. IRS-4 is the most recently characterized member, which has been found primarily in human cells and tissues. It interacts with SH2-containing proteins such ars phosphatidylinositol 3'-kinase (PI3K), Grb2, Crk-II, and CrkL. In this study, we transfected IRS-4 in mouse NIH-3T3 cells that overexpress IGF-I receptors. Clones expressing IRS-4 showed enhanced cellular proliferation when cells were cultured in 1% fetal bovine serum without added IGF-I. Addition of IGF-I enhanced cellular proliferation in cells overexpressing the IGF-I receptor alone but had an even greater proliferative effect in cells overexpressing both the IGF-I receptors and IRS-4. When etoposide and methylmethane sulfonate (MMS), both DNA damaging agents, were added to the cells, they uniformly induced cell cycle arrest. Fluorescence-activated cell sorter analysis demonstrated that the arrest of the cell cycle occurred at the G(1) checkpoint, and furthermore no significant degree of apoptosis was demonstrated with the use of either agent. In cells, overexpressing IGF-I receptors alone, IG;F-I addition enhanced cellular proliferation, even in the presence of etoposide and MMS. In cells overexpressing IGF-I receptors and IRS-4, the effect of IGF-I in overcoming the cell cycle arrest was even more pronounced. These results suggest that IRS-4 is implicated in the IGF-I receptor mitogenic signaling pathway.	NIDDK, Clin Endocrinol Branch, NIH, Sect Mol & Cellular Physiol, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	LeRoith, D (corresponding author), NIDDK, Clin Endocrinol Branch, NIH, Sect Mol & Cellular Physiol, Rm 8D12,Bldg 10, Bethesda, MD 20892 USA.							BLAKESLEY VA, 1995, J BIOL CHEM, V270, P2764, DOI 10.1074/jbc.270.6.2764; Bruning JC, 1997, CELL, V88, P561, DOI 10.1016/S0092-8674(00)81896-6; Chen G, 1997, ONCOGENE, V15, P1643, DOI 10.1038/sj.onc.1201347; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; Fantin VR, 1998, J BIOL CHEM, V273, P10726, DOI 10.1074/jbc.273.17.10726; Fantin VR, 1999, ENDOCRINOLOGY, V140, P1329, DOI 10.1210/en.140.3.1329; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Ito T, 1996, MOL CELL BIOL, V16, P943; Koval AP, 1998, J BIOL CHEM, V273, P14780, DOI 10.1074/jbc.273.24.14780; Kuo ML, 1997, MOL CARCINOGEN, V18, P221, DOI 10.1002/(SICI)1098-2744(199704)18:4<221::AID-MC6>3.0.CO;2-G; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; Liang L, 1999, ENDOCRINOLOGY, V140, P1972, DOI 10.1210/en.140.5.1972; Liu SCH, 1999, J BIOL CHEM, V274, P18093, DOI 10.1074/jbc.274.25.18093; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PERROTTI N, 1987, P NATL ACAD SCI USA, V84, P3137, DOI 10.1073/pnas.84.10.3137; QUON MJ, 1994, J BIOL CHEM, V269, P27920; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TOBE K, 1995, J BIOL CHEM, V270, P5698, DOI 10.1074/jbc.270.11.5698; UCHIDA T, 1999, AM DIAB ASS 59 SCI S, pA331; Valverde AM, 1998, MOL ENDOCRINOL, V12, P688, DOI 10.1210/me.12.5.688; WANG LM, 1995, STEM CELLS, V13, P360, DOI 10.1002/stem.5530130407; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Xu P, 1999, J BIOL CHEM, V274, P15262, DOI 10.1074/jbc.274.21.15262; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; Zhou LX, 1997, J BIOL CHEM, V272, P29829, DOI 10.1074/jbc.272.47.29829; Zhou LX, 1999, MOL ENDOCRINOL, V13, P505, DOI 10.1210/me.13.3.505	29	50	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31179	31184		10.1074/jbc.274.44.31179	http://dx.doi.org/10.1074/jbc.274.44.31179			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531310	hybrid			2022-12-27	WOS:000083379400014
J	Carter, AB; Knudtson, KL; Monick, MM; Hunninghake, GW				Carter, AB; Knudtson, KL; Monick, MM; Hunninghake, GW			The p38 mitogen-activated protein kinase is required for NF-kappa B-dependent gene expression - The role of TATA-binding protein (TBP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; TRANSCRIPTION FACTOR-IIB; RNA-POLYMERASE-II; FACTOR-ALPHA GENE; INFLAMMATORY CYTOKINES; BASAL TRANSCRIPTION; IN-VITRO; PHOSPHORYLATION; LIPOPOLYSACCHARIDE; INTERLEUKIN-6	Endotoxin-induced cytokine gene transcription in monocytes and macrophages is regulated in part by NF-kappa B. We have previously shown that the p38 mitogen-activated protein (MAP) kinase is necessary for endotoxin-induced cytokine gene transcription. Due to the fact that most cytokine promoter sequences have active NF-kappa B sites, we hypothesized that the p38 MAP kinase was necessary for NF-kappa B-dependent gene expression. We found that NF-kappa B-dependent gene expression was reduced to near control levels with either SB 203580 or a dominant-negative p38 MAP kinase expression vector. Inhibition of the p38 MAP kinase did not alter NF-kappa B activation at any level, but it significantly reduced the DNA binding of TATA-binding protein (TBP) to the TATA box, The dominant-negative p38 MAP kinase expression vector interfered with the direct interaction of native TFIID (TBP) with a co-transfected p65 fusion protein. Likewise, this dominant-negative plasmid also interfered with the direct interaction of a co-transfected TBP fusion protein with the native p65 subunit. The p38 kinase also phosphorylated TFIID (TBP) in vitro, and SB 203580 inhibited phosphorylation of TFIID (TBP) in vivo. Thus, the p38 MAP kinase regulates NF-kappa B-dependent gene transcription, in part, by modulating activation of TFIID (TBP).	Univ Iowa, Coll Med, Iowa City, IA 52242 USA; Vet Adm Med Ctr, Iowa City, IA 52242 USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Carter, AB (corresponding author), Univ Iowa Hosp & Clin, Div Pulm & Crit Care Med, C33 GH,200 Hawkins Dr, Iowa City, IA 52242 USA.				NHLBI NIH HHS [HL03860, HL60316] Funding Source: Medline; NIAID NIH HHS [AI35018] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL060316] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035018] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; BLAIR WS, 1994, MOL CELL BIOL, V14, P7226, DOI 10.1128/MCB.14.11.7226; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P28766, DOI 10.1074/jbc.273.44.28766; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Carter AB, 1998, AM J RESP CELL MOL, V18, P384, DOI 10.1165/ajrcmb.18.3.2972; Carter AB, 1999, AM J RESP CELL MOL, V20, P751, DOI 10.1165/ajrcmb.20.4.3420; Chibazakura T, 1997, EUR J BIOCHEM, V247, P1166, DOI 10.1111/j.1432-1033.1997.01166.x; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; GOLDFELD AE, 1991, J EXP MED, V174, P73, DOI 10.1084/jem.174.1.73; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; KUNSCH C, 1994, J IMMUNOL, V153, P153; Lee JC, 1996, J LEUKOCYTE BIOL, V59, P152, DOI 10.1002/jlb.59.2.152; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LESCURE A, 1994, EMBO J, V13, P1166, DOI 10.1002/j.1460-2075.1994.tb06366.x; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; MATTHEWS JR, 1995, INT J BIOCHEM CELL B, V27, P865, DOI 10.1016/1357-2725(95)00071-V; Monick MM, 1999, J IMMUNOL, V162, P3005; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; Nick JA, 1996, J IMMUNOL, V156, P4867; O'Connell MA, 1998, J BIOL CHEM, V273, P30410, DOI 10.1074/jbc.273.46.30410; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; Shapiro L, 1995, P NATL ACAD SCI USA, V92, P12230, DOI 10.1073/pnas.92.26.12230; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; TIMMERS HTM, 1992, P NATL ACAD SCI USA, V89, P8140, DOI 10.1073/pnas.89.17.8140; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; XU X, 1993, MOL CELL BIOL, V13, P6733, DOI 10.1128/MCB.13.11.6733; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; ZHANG Y, 1990, MOL CELL BIOL, V10, P3818, DOI 10.1128/MCB.10.7.3818	45	404	416	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30858	30863		10.1074/jbc.274.43.30858	http://dx.doi.org/10.1074/jbc.274.43.30858			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521478	hybrid			2022-12-27	WOS:000083276700074
J	Gaudry, CA; Verderio, E; Aeschlimann, D; Cox, A; Smith, C; Griffin, M				Gaudry, CA; Verderio, E; Aeschlimann, D; Cox, A; Smith, C; Griffin, M			Cell surface localization of tissue transglutaminase is dependent on a fibronectin-binding site in its N-terminal beta-sandwich domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG LIVER TRANSGLUTAMINASE; CROSS-LINKING ENZYMES; EXTRACELLULAR-MATRIX; 3T3 FIBROBLASTS; PROTEIN; EXPRESSION; ADHESION; COMPLEXES; DIFFERENTIATION; OSTEONECTIN	Increasing evidence indicates that tissue transglutaminase (tTG) plays a role in the assembly and remodeling of extracellular matrices and promotes cell adhesion. Using an inducible system we have previously shown that tTG associates with the extracellular matrix deposited by stably transfected 3T3 fibroblasts overexpressing the enzyme. We now show by confocal microscopy that tTG colocalizes with pericellular fibronectin in these cells, and by immunogold electron microscopy that the two proteins are found in clusters at the cell surface, Expression vectors encoding the full-length tTG or a N-terminal truncated tTG lacking the proposed fibronectin-binding site (fused to the bacterial reporter enzyme beta-galactosidase) were generated to characterize the role of fibronectin in sequestration of tTG; in the pericellular matrix. Enzyme-linked immunosorbent assay style procedures using extracts of transiently transfected COS-7 cells and immobilized fibronectin showed that the truncation abolished fibronectin binding. Similarly, the association of tTG with the pericellular matrix of cells in suspension or with the extracellular matrix deposited by cell monolayers was prevented by the truncation. These results demonstrate that tTG binds to the pericellular fibronectin coat of cells via its N-terminal beta-sandwich domain and that this interaction is crucial for cell surface association of tTG.	Nottingham Trent Univ, Dept Life Sci, Nottingham NG11 8NS, England; Univ Wisconsin, Div Orthoped Surg, Madison, WI 53792 USA; Unilever Res, Bedford, England	Nottingham Trent University; University of Wisconsin System; University of Wisconsin Madison; Unilever	Griffin, M (corresponding author), Nottingham Trent Univ, Dept Life Sci, Clifton Lane, Nottingham NG11 8NS, England.		Verderio, Elisabetta/H-2789-2016	Verderio, Elisabetta/0000-0001-9153-8997; Aeschlimann, Daniel/0000-0003-0930-7706; Griffin, Martin/0000-0003-3824-306X				ACHYUTHAN KE, 1995, J IMMUNOL METHODS, V180, P69, DOI 10.1016/0022-1759(94)00300-L; AESCHLIMANN D, 1995, J CELL BIOL, V129, P881, DOI 10.1083/jcb.129.3.881; AESCHLIMANN D, 1991, J BIOL CHEM, V266, P15308; AESCHLIMANN D, 1993, J CELL BIOL, V120, P1461, DOI 10.1083/jcb.120.6.1461; AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BARSIGIAN C, 1991, J BIOL CHEM, V266, P22501; BIRCKBICHLER PJ, 1985, HYBRIDOMA, V4, P179, DOI 10.1089/hyb.1985.4.179; BOISSEL JP, 1985, P NATL ACAD SCI USA, V82, P8448, DOI 10.1073/pnas.82.24.8448; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Chen P, 1997, J CELL BIOL, V136, P251, DOI 10.1083/jcb.136.2.251; Corbett SA, 1997, J BIOL CHEM, V272, P24999, DOI 10.1074/jbc.272.40.24999; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; FESUS L, 1986, EUR J BIOCHEM, V154, P371, DOI 10.1111/j.1432-1033.1986.tb09407.x; GENTILE V, 1992, J CELL BIOL, V119, P463, DOI 10.1083/jcb.119.2.463; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HAND D, 1988, BIOCHIM BIOPHYS ACTA, V970, P137, DOI 10.1016/0167-4889(88)90172-3; HARSFALVI J, 1987, BIOCHIM BIOPHYS ACTA, V923, P42, DOI 10.1016/0304-4165(87)90123-1; HOHENADL C, 1995, J BIOL CHEM, V270, P23415, DOI 10.1074/jbc.270.40.23415; ICHINOSE A, 1990, J BIOL CHEM, V265, P13411; Iismaa SE, 1997, BIOCHEMISTRY-US, V36, P11655, DOI 10.1021/bi970545e; IKURA K, 1988, BIOCHEMISTRY-US, V27, P2898, DOI 10.1021/bi00408a035; IKURA K, 1990, EUR J BIOCHEM, V187, P705, DOI 10.1111/j.1432-1033.1990.tb15357.x; IKURA K, 1989, BIOCHEMISTRY-US, V28, P2344, DOI 10.1021/bi00431a054; JEONG JM, 1995, J BIOL CHEM, V270, P5654, DOI 10.1074/jbc.270.10.5654; Johnson TS, 1997, J CLIN INVEST, V99, P2950, DOI 10.1172/JCI119490; JOHNSON TS, 1999, IN PRESS J AM SOC NE; Jones RA, 1997, J CELL SCI, V110, P2461; KLEMAN JP, 1995, BIOCHEMISTRY-US, V34, P13768, DOI 10.1021/bi00042a007; Kuchler K, 1990, CURR OPIN CELL BIOL, V2, P617, DOI 10.1016/0955-0674(90)90102-K; LEMOSY EK, 1992, J BIOL CHEM, V267, P7880; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; MARTINEZ J, 1994, BIOCHEMISTRY-US, V33, P2538, DOI 10.1021/bi00175a024; MIAN S, 1995, FEBS LETT, V370, P27, DOI 10.1016/0014-5793(95)00782-5; Nunes I, 1997, J CELL BIOL, V136, P1151, DOI 10.1083/jcb.136.5.1151; Raghunath M, 1996, J CLIN INVEST, V98, P1174, DOI 10.1172/JCI118901; RISINGER MA, 1992, J BIOL CHEM, V267, P5680; Schittny JC, 1997, AM J RESP CELL MOL, V17, P334, DOI 10.1165/ajrcmb.17.3.2737; SHREIBER V, 1994, GENE AMST, V150, P411; SLIFE CW, 1987, ARCH BIOCHEM BIOPHYS, V257, P39, DOI 10.1016/0003-9861(87)90540-6; Smethurst PA, 1996, BIOCHEM J, V313, P803, DOI 10.1042/bj3130803; Steinert PM, 1996, J BIOL CHEM, V271, P26242, DOI 10.1074/jbc.271.42.26242; STEINHARDT RA, 1994, SCIENCE, V263, P390, DOI 10.1126/science.7904084; TAKAHASHI N, 1986, P NATL ACAD SCI USA, V83, P8019, DOI 10.1073/pnas.83.21.8019; TYRRELL DJ, 1988, J BIOL CHEM, V263, P8464; UPCHURCH HF, 1991, J CELL PHYSIOL, V149, P375, DOI 10.1002/jcp.1041490304; Verderio E, 1999, J HISTOCHEM CYTOCHEM, V47, P1417, DOI 10.1177/002215549904701108; Verderio E, 1998, EXP CELL RES, V239, P119, DOI 10.1006/excr.1997.3874; YEE VC, 1994, P NATL ACAD SCI USA, V91, P7296, DOI 10.1073/pnas.91.15.7296; Zhang QH, 1996, J BIOL CHEM, V271, P33284, DOI 10.1074/jbc.271.52.33284	50	121	124	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30707	30714		10.1074/jbc.274.43.30707	http://dx.doi.org/10.1074/jbc.274.43.30707			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521459	Green Published, Green Accepted, hybrid			2022-12-27	WOS:000083276700055
J	Shumway, SD; Maki, M; Miyamoto, S				Shumway, SD; Maki, M; Miyamoto, S			The PEST domain of I kappa B alpha is necessary and sufficient for in vitro degradation by mu-calpain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-INDUCED DEGRADATION; CASEIN KINASE-II; CONSTITUTIVE PHOSPHORYLATION; UBIQUITIN-LIGASE; ANKYRIN REPEATS; DNA-BINDING; C-REL; PROTEOLYSIS; ACTIVATION; SEQUENCES	Polypeptide sequences enriched in proline (P), glutamate (E), serine (S), and threonine (T), dubbed PEST domains, are proposed to expedite the degradation of proteins. The proteolysis of one PEST-containing protein, I kappa B alpha, is prerequisite to the activation of the transcription factor NF-kappa B, Two mechanisms of I kappa B alpha degradation in vivo have been described, one well characterized through the ubiquitin-proteasome pathway, and another less characterized through calpain. In this report, a mutational analysis was done to identify any regions of I kappa B alpha that facilitate its recognition and proteolysis by calpain in, vitro. These studies revealed that the PEST sequence of I kappa B alpha is critical for its calpain-dependent degradation. Furthermore, the I kappa B alpha-PEST domain binds to the calmodulin-like domain of the large subunit of mu-calpain (mu CaMLD). Transfer of the I kappa B alpha-PEST domain to a protein incapable of either binding to or being degraded by mu-calpain allowed for the interaction of the chimeric protein with mu CaMLD and resulted in its susceptibility to calpain proteolysis. Moreover, the mu CaMLD of calpain acts as a competitive inhibitor of calpain-dependent I kappa B alpha degradation. Our data demonstrate that the I kappa B alpha-PEST sequence acts as a modular domain to promote the physical association with and subsequent degradation by mu-calpain and suggest a functional role for PEST sequences in other proteins as potential calpain-targeting units.	Univ Wisconsin, Sch Med, Dept Pharmacol, Clin Sci Ctr K4 554, Madison, WI 53792 USA; Univ Wisconsin, Sch Med, Program Cellular & Mol Biol, Madison, WI 53792 USA; Nagoya Univ, Sch Bioagr Sci, Lab Mol & Cellular Regulat, Chikusa Ku, Nagoya, Aichi 4648601, Japan	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Nagoya University	Miyamoto, S (corresponding author), Univ Wisconsin, Sch Med, Dept Pharmacol, Clin Sci Ctr K4 554, 600 Highland Ave, Madison, WI 53792 USA.		Maki, Masatoshi/AAM-6839-2021	Maki, Masatoshi/0000-0001-9144-5491	NCI NIH HHS [R01CA81065] Funding Source: Medline; NIGMS NIH HHS [T32GM07215] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081065] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007215] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aoki T, 1996, ONCOGENE, V12, P1159; Baghdiguian S, 1999, NAT MED, V5, P503, DOI 10.1038/8385; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; BAUERLE PA, 1988, SCIENCE, V242, P540; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Brown K, 1997, MOL CELL BIOL, V17, P3021, DOI 10.1128/MCB.17.6.3021; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; Carillo S, 1996, BIOCHEM J, V313, P245, DOI 10.1042/bj3130245; Chen F, 1997, ARCH BIOCHEM BIOPHYS, V342, P383, DOI 10.1006/abbi.1997.0132; Chen Z, 1995, GENE DEV, P1586; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; ERNST MK, 1995, MOL CELL BIOL, V15, P872; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Han YQ, 1999, J BIOL CHEM, V274, P787, DOI 10.1074/jbc.274.2.787; HUNTER T, 1980, COLD SPRING HARB SYM, V44, P931, DOI 10.1101/SQB.1980.044.01.100; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Johnson GVW, 1997, BIOESSAYS, V19, P1011, DOI 10.1002/bies.950191111; Kawasaki H, 1996, MOL MEMBR BIOL, V13, P217, DOI 10.3109/09687689609160599; Krappmann D, 1996, EMBO J, V15, P6716, DOI 10.1002/j.1460-2075.1996.tb01061.x; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; Lin RT, 1996, MOL CELL BIOL, V16, P1401; Luque I, 1998, MOL CELL BIOL, V18, P1213, DOI 10.1128/MCB.18.3.1213; MA H, 1993, J BIOCHEM, V113, P591, DOI 10.1093/oxfordjournals.jbchem.a124088; Marchal C, 1998, MOL CELL BIOL, V18, P314, DOI 10.1128/MCB.18.1.314; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Miyamoto S, 1998, MOL CELL BIOL, V18, P19, DOI 10.1128/MCB.18.1.19; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; MIYAMOTO S, 1994, MOL CELL BIOL, V14, P3276, DOI 10.1128/MCB.14.5.3276; MOLINARI M, 1995, J BIOL CHEM, V270, P2032, DOI 10.1074/jbc.270.5.2032; Mykles DL, 1998, INT REV CYTOL, V184, P157, DOI 10.1016/S0074-7696(08)62181-6; NISHIMURA T, 1991, J BIOL CHEM, V266, P11842; NIXON PJ, 1995, J BIOL CHEM, V270, P14919, DOI 10.1074/jbc.270.25.14919; Noguchi M, 1997, P NATL ACAD SCI USA, V94, P11534, DOI 10.1073/pnas.94.21.11534; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; RODRIGUEZ MS, 1995, MOL CELL BIOL, V15, P2413; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TSIEN RY, 1981, NATURE, V290, P527, DOI 10.1038/290527a0; VanAntwerp DJ, 1996, MOL CELL BIOL, V16, P6037; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang JL, 1998, AM J PHYSIOL-LUNG C, V275, pL461, DOI 10.1152/ajplung.1998.275.3.L461	56	161	166	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30874	30881		10.1074/jbc.274.43.30874	http://dx.doi.org/10.1074/jbc.274.43.30874			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521480	hybrid			2022-12-27	WOS:000083276700076
J	Ozono, K; Saito, M; Miura, D; Michigami, T; Nakajima, S; Ishizuka, S				Ozono, K; Saito, M; Miura, D; Michigami, T; Nakajima, S; Ishizuka, S			Analysis of the molecular mechanism for the antagonistic action of a novel 1 alpha,25-dihydroxyvitamin D-3 analogue toward vitamin D receptor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-RESPONSIVE ELEMENTS; ESTROGEN-RECEPTOR; 24-HYDROXYLASE GENE; THYROID-HORMONE; RETINOIC ACID; DNA-BINDING; COACTIVATOR; DOMAIN; TRANSCRIPTION; ANTIESTROGEN	We have recently reported that 23(S)-25-dehydro-1 alpha-hydroxyvitamin D-3-26,23-lactone (TEI-9647) efficiently blocks the differentiation of HL-60 cells induced by 1 alpha,25-dihydroxyvitamin D-3 (1 alpha,25(OH)(2)D-3) (Miura, D., Manabe, H., Ozone, K., Saito, M., Gao, Q., Norman, A. W., and Ishizuka, S. (1999) J. Biol. Chem. 274, 16392-16399). To clarify the molecular mechanisms of this antagonism, we examined whether TEI-9647 antagonizes the genomic effects of 1 alpha,25(OH)(2)D-3. 10(-7) to 10(-9) M TEI-9647 inhibited the transactivation effect of 10(-8) m 1 alpha,25(OH)(2)D-3 in a dose-dependent manner, while TEI-9647 alone did not activate the reporter activity driven by SV40 promoter containing two vitamin D response elements in Saos-2 cells. The antagonistic effect of TEI-9647 was also observed using the rat 24-hydroxylase gene promoter, but the effect was weaker in HeLa and COS-7 cells than in Saos-2 cells. TEI-9647 also exhibited antagonism in an assay system where the VDR fused to the GAL4 DNA-binding domain and the reporter plasmid containing the GAL4 binding site were used in Saos-2 cells, but did not in HeLa cells, TEI-9647 reduced the interaction between VDR and RXR alpha according to the results obtained from the mammalian two-hybrid system in Saos-2 cells, but did not in HeLa cells. The two-hybrid system also revealed that the interaction between VDR and SRC-1 was reduced by TEI-9647 in Saos-2 cells. These results demonstrate that the novel 1 alpha,25(OH)(2)D-3 analogue, TEI-9647, is the first synthetic ligand for the VDR that efficiently antagonizes the action of 1 alpha,25(OH)(2)D-3, although the extent of its antagonism depends on cell type.	Med Ctr, Dept Environm Med, Osaka 5941101, Japan; Res Inst Maternal & Child Hlth, Osaka 5941101, Japan; Teijin Inst Biomed Res, Tokyo 1918512, Japan		Ozono, K (corresponding author), Med Ctr, Dept Environm Med, 840 Murodo Cho, Osaka 5941101, Japan.		Michigami, Toshimi/AAU-2326-2021					BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; Barsony J, 1997, J BIOL CHEM, V272, P5774, DOI 10.1074/jbc.272.9.5774; BOUILLON R, 1995, ENDOCR REV, V16, P200, DOI 10.1210/er.16.2.200; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CHEN KS, 1995, BBA-GENE STRUCT EXPR, V1263, P1, DOI 10.1016/0167-4781(95)00060-T; CLEMENS TL, 1988, ENDOCRINOLOGY, V122, P1224, DOI 10.1210/endo-122-4-1224; Devin-Leclerc J, 1998, MOL ENDOCRINOL, V12, P842, DOI 10.1210/me.12.6.842; DUSSO AS, 1991, ENDOCRINOLOGY, V128, P1687, DOI 10.1210/endo-128-4-1687; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Gill RK, 1998, MOL ENDOCRINOL, V12, P57, DOI 10.1210/mend.12.1.0048; Grese TA, 1997, P NATL ACAD SCI USA, V94, P14105, DOI 10.1073/pnas.94.25.14105; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; Hsieh JC, 1998, J CELL BIOCHEM, V70, P94, DOI 10.1002/(SICI)1097-4644(19980701)70:1<94::AID-JCB10>3.3.CO;2-Q; HUGHES MR, 1988, SCIENCE, V242, P1702, DOI 10.1126/science.2849209; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KRAUS WL, 1995, MOL CELL BIOL, V15, P1847; Lala DS, 1996, NATURE, V383, P450, DOI 10.1038/383450a0; Lee MO, 1996, J BIOL CHEM, V271, P11897, DOI 10.1074/jbc.271.20.11897; Lemon BD, 1997, MOL CELL BIOL, V17, P1923, DOI 10.1128/MCB.17.4.1923; Li YC, 1997, P NATL ACAD SCI USA, V94, P9831, DOI 10.1073/pnas.94.18.9831; MACDONALD PN, 1993, MOL CELL BIOL, V13, P5907, DOI 10.1128/MCB.13.9.5907; MacGregor JI, 1998, PHARMACOL REV, V50, P151; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Masuyama H, 1997, MOL ENDOCRINOL, V11, P1507, DOI 10.1210/me.11.10.1507; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; MICHIGAMI T, 1998, BONE, V23, pS257; Miura D, 1999, J BIOL CHEM, V274, P16392, DOI 10.1074/jbc.274.23.16392; Nakajima S, 1998, MOL CELL ENDOCRINOL, V139, P15, DOI 10.1016/S0303-7207(98)00077-X; Nakajima S, 1997, BIOCHEM BIOPH RES CO, V232, P806, DOI 10.1006/bbrc.1997.6376; NAKAJIMA S, 1994, MOL ENDOCRINOL, V8, P159, DOI 10.1210/me.8.2.159; NORMAN AW, 1993, J BIOL CHEM, V268, P20022; Norman AW, 1998, J BONE MINER RES, V13, P1360, DOI 10.1359/jbmr.1998.13.9.1360; Ohyama Y, 1996, J BIOL CHEM, V271, P30381, DOI 10.1074/jbc.271.48.30381; OHYAMA Y, 1994, J BIOL CHEM, V269, P10545; ONATE SA, 1995, SCIENCE, V270, P1354; Peleg S, 1998, MOL ENDOCRINOL, V12, P525, DOI 10.1210/me.12.4.525; Pike J. W., 1997, Vitamin D., P105; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; SONE T, 1991, MOL ENDOCRINOL, V5, P1578, DOI 10.1210/mend-5-11-1578; Takeyama KI, 1999, MOL CELL BIOL, V19, P1049; VandenBemd GJCM, 1996, P NATL ACAD SCI USA, V93, P10685, DOI 10.1073/pnas.93.20.10685; VEGETO E, 1992, CELL, V69, P703, DOI 10.1016/0092-8674(92)90234-4; Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391; Zhao XY, 1997, MOL ENDOCRINOL, V11, P366, DOI 10.1210/me.11.3.366	45	65	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32376	32381		10.1074/jbc.274.45.32376	http://dx.doi.org/10.1074/jbc.274.45.32376			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542279	hybrid			2022-12-27	WOS:000083532100087
J	Seoane, J; Barbera, A; Telemaque-Potts, S; Newgard, CB; Guinovart, JJ				Seoane, J; Barbera, A; Telemaque-Potts, S; Newgard, CB; Guinovart, JJ			Glucokinase overexpression restores glucose utilization and storage in cultured hepatocytes from male Zucker diabetic fatty rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE; HEXOKINASE-I; GENE-EXPRESSION; ISOLATED ISLETS; GLUCOSE-6-PHOSPHATASE; LIVER; PHOSPHORYLASE; INSULIN; INACTIVATION; ADENOVIRUS	Zucker diabetic fatty rats develop type 2 diabetes concomitantly with peripheral insulin resistance. Hepatocytes from these rats and their control lean counter parts have been cultured, and a number of hey parameters of glucose metabolism have been determined. Glucokinase activity was 4.5-fold lower in hepatocytes from diabetic rats than in hepatocytes from healthy ones. In contrast, hexokinase activity was about a-fold higher in hepatocytes from diabetic animals than in healthy ones. Glucose-6-phosphatase activity was not significantly different. Despite the altered ratios of glucokinase to hexokinase activity, intracellular glucose 6-phosphate concentrations were similar in the two types of cells when they where incubated with 1-25 mM glucose, However, glycogen levels and glycogen synthase activity ratio were lower in hepatocytes from diabetic animals. Total pyruvate kinase activity and its activity ratio as well as fructose 2,6-bisphosphate concentration and lactate production were also lower in cells from diabetic animals. All of these data indicate that glucose metabolism is clearly impaired in hepatocytes from Zucker diabetic fatty rats. Glucokinase overexpression using adenovirus restored glucose metabolism in diabetic hepatocytes, In glucokinase-overexpressing cells, glucose 6-phosphate levels increased. Moreover, glycogen deposition was greatly enhanced due to the activation of glycogen synthase, Pyruvate kinase was also activated, and fructose-2,6-bisphosphate concentration and lactate production were increased in glucokinase-overexpressing diabetic hepatocytes, Overexpression of hexokinase I did not increase glycogen deposition. In conclusion, hepatocytes from Zucker diabetic fatty rats showed depressed glycogen and glycolytic metabolism, but glucokinase overexpression improved their glucose utilization and storage.	Univ Barcelona, Fac Quim, Dept Bioquim & Biol Mol, E-08028 Barcelona, Spain; Univ Texas, SW Med Ctr, Dept Biochem, Gifford Labs Diabet Res, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA	University of Barcelona; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Guinovart, JJ (corresponding author), Univ Barcelona, Fac Quim, Dept Bioquim & Biol Mol, Marti & Franques 1, E-08028 Barcelona, Spain.	guino@sun.bq.ub.es	Seoane, Joan/AAG-9173-2019	Seoane, Joan/0000-0002-6541-5974; Barbera, Albert/0000-0003-4080-3572	PHS HHS [P50H2598801] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALEGRE M, 1988, ANAL BIOCHEM, V173, P185, DOI 10.1016/0003-2697(88)90176-5; BARZILAI N, 1993, J BIOL CHEM, V268, P25019; Becker TC, 1996, J BIOL CHEM, V271, P390, DOI 10.1074/jbc.271.1.390; BECKER TC, 1994, J BIOL CHEM, V269, P21234; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURCHELL A, 1985, DIABETOLOGIA, V28, P852, DOI 10.1007/BF00291077; CARABAZA A, 1992, FEBS LETT, V296, P211, DOI 10.1016/0014-5793(92)80381-P; CHAN TM, 1976, ANAL BIOCHEM, V71, P96, DOI 10.1016/0003-2697(76)90014-2; CIUDAD CJ, 1986, BIOCHEM BIOPH RES CO, V141, P1195, DOI 10.1016/S0006-291X(86)80171-1; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; FELIU JE, 1977, EUR J BIOCHEM, V81, P609, DOI 10.1111/j.1432-1033.1977.tb11988.x; Ferre T, 1996, P NATL ACAD SCI USA, V93, P7225, DOI 10.1073/pnas.93.14.7225; GIRARD J, 1994, FASEB J, V8, P36, DOI 10.1096/fasebj.8.1.7905448; Gutmann I., 1974, METHODS ENZYMATIC AN, P1464; Hariharan N, 1997, DIABETES, V46, P11, DOI 10.2337/diabetes.46.1.11; KUWAJIMA M, 1986, J BIOL CHEM, V261, P8849; LANG G, 1974, METHOD ENZYMAT AN, V3, P1238; MASSAGUE J, 1977, FEBS LETT, V82, P317, DOI 10.1016/0014-5793(77)80610-8; Massillon D, 1996, J BIOL CHEM, V271, P9871, DOI 10.1074/jbc.271.17.9871; MASSILLON D, 1995, J BIOL CHEM, V270, P19351, DOI 10.1074/jbc.270.33.19351; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; O'Doherty RM, 1999, DIABETES, V48, P2022, DOI 10.2337/diabetes.48.10.2022; O'meara NM, 1994, JOSLINS DIABETES MEL, P81; ODoherty RM, 1996, J BIOL CHEM, V271, P20524, DOI 10.1074/jbc.271.34.20524; Peterson R.G., 1990, ILAR NEWS, V32, P16, DOI [10.1093/ilar.32.3.16, DOI 10.1093/ILAR.32.3.16, DOI 10.1093/ILAR.32.3.16)]; PORTE D, 1991, DIABETES, V40, P166, DOI 10.2337/diabetes.40.2.166; Seoane J, 1996, J BIOL CHEM, V271, P23756, DOI 10.1074/jbc.271.39.23756; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888	30	31	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31833	31838		10.1074/jbc.274.45.31833	http://dx.doi.org/10.1074/jbc.274.45.31833			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542207	hybrid			2022-12-27	WOS:000083532100015
J	Mukherjee, S; Bhattacharyya, SN; Adhya, S				Mukherjee, S; Bhattacharyya, SN; Adhya, S			Stepwise transfer of tRNA through the double membrane of Leishmania mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENCODED TRANSFER-RNAS; TRYPANOSOMA-BRUCEI; IN-VITRO; IMPORT; DONOVANI; PROTEIN; IDENTIFICATION; PROMASTIGOTES; ORGANIZATION; LOCALIZATION	Import of tRNA into Leishmania mitochondria involves transfer through a double membrane barrier. To examine whether specific sorting mechanisms for individual tRNAs direct them to different mitochondrial compartments, the distribution of tRNA transcripts, internalized in vitro, was examined by suborganellar fractionation. Significant amounts of tRNA(Tyr) were localized in the matrix and on the outer face of the inner mitochondrial membrane. With time, the matrix:membrane ratio increased. Translocation through the inner membrane apparently required the presence of a specific signal in the D arm of tRNA(Tyr), and tRNA(Gln)(CUG), lacking this sequence, was excluded. Hydrolysis of ATP was necessary at both the outer and inner membranes. However, the protonophores carbonylcyanide m-chlorophenylhydrazone and nigericin, the K+ ionophore valinomycin, and the F1F0 ATPase inhibitor oligomycin had only marginal effects on uptake through the outer membrane but severely inhibited inner membrane translocation, indicating the unusual requirement of both the electrical and chemical components of the electromotive force generated across the inner membrane, The results are consistent with a mechanism involving stepwise transfer of tRNA through distinct outer and inner membrane channels.	Indian Inst Chem Biol, Genet Engn Lab, Calcutta 700032, W Bengal, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)	Adhya, S (corresponding author), Indian Inst Chem Biol, Genet Engn Lab, 4 Raja Sc Mullick Rd, Calcutta 700032, W Bengal, India.							Adhya S, 1997, J BIOL CHEM, V272, P21396, DOI 10.1074/jbc.272.34.21396; BAKALARA N, 1989, J BIOL CHEM, V264, P18679; CHEN LB, 1988, ANNU REV CELL BIOL, V4, P155, DOI 10.1146/annurev.cb.04.110188.001103; CHIU N, 1975, J MOL BIOL, V99, P37, DOI 10.1016/S0022-2836(75)80157-4; DAS A, 1993, MOL BIOCHEM PARASIT, V60, P293, DOI 10.1016/0166-6851(93)90140-S; DAS S, 1990, J BIOSCIENCES, V15, P239, DOI 10.1007/BF02702665; DIETRICH A, 1992, ANNU REV CELL BIOL, V8, P115, DOI 10.1146/annurev.cb.08.110192.000555; EMAUS RK, 1986, BIOCHIM BIOPHYS ACTA, V850, P436, DOI 10.1016/0005-2728(86)90112-X; GASSER SM, 1982, J BIOL CHEM, V257, P3034; GHOSH A, 1994, NUCLEIC ACIDS RES, V22, P1663, DOI 10.1093/nar/22.9.1663; HANCOCK K, 1990, J BIOL CHEM, V265, P19208; Hannavy K, 1993, CURR OPIN CELL BIOL, V5, P694, DOI 10.1016/0955-0674(93)90142-D; HAUSER R, 1995, EMBO J, V14, P4212, DOI 10.1002/j.1460-2075.1995.tb00095.x; KLEINSMITH LJ, 1988, PRINCIPLES CELL BIOL, P208; Kumar R, 1996, MOL GEN GENET, V252, P404, DOI 10.1007/BF02173005; LANOUE KF, 1979, ANNU REV BIOCHEM, V48, P871, DOI 10.1146/annurev.bi.48.070179.004255; Lima BD, 1996, RNA, V2, P429; LYE LF, 1993, MOL BIOCHEM PARASIT, V58, P233, DOI 10.1016/0166-6851(93)90045-Y; MAHAPATRA S, 1994, NUCLEIC ACIDS RES, V22, P3381, DOI 10.1093/nar/22.16.3381; Mahapatra S, 1998, NUCLEIC ACIDS RES, V26, P2037, DOI 10.1093/nar/26.9.2037; Mahapatra S, 1996, J BIOL CHEM, V271, P20432, DOI 10.1074/jbc.271.34.20432; MARTIN RP, 1979, BIOCHEMISTRY-US, V18, P4600, DOI 10.1021/bi00588a021; McIntosh MT, 1998, MOL BIOCHEM PARASIT, V95, P69, DOI 10.1016/S0166-6851(98)00093-0; MOTTRAM JC, 1991, J BIOL CHEM, V266, P18313; MYLER PJ, 1993, NUCLEIC ACIDS RES, V21, P687, DOI 10.1093/nar/21.3.687; NAGLEY P, 1989, TRENDS GENET, V5, P67, DOI 10.1016/0168-9525(89)90028-0; Ragan MT, 1987, MITOCHONDRIA PRACTIC, P79; SCHLEYER M, 1982, EUR J BIOCHEM, V125, P109, DOI 10.1111/j.1432-1033.1982.tb06657.x; SCHNEIDER A, 1994, MOL CELL BIOL, V14, P2317, DOI 10.1128/MCB.14.4.2317; SCHNELL DJ, 1993, J CELL BIOL, V120, P103, DOI 10.1083/jcb.120.1.103; SHI XM, 1994, MOL BIOCHEM PARASIT, V65, P23, DOI 10.1016/0166-6851(94)90112-0; SIMPSON AM, 1989, NUCLEIC ACIDS RES, V17, P5427, DOI 10.1093/nar/17.14.5427; SLOOF P, 1992, MOL BIOCHEM PARASIT, V56, P289, DOI 10.1016/0166-6851(92)90178-M; ZILBERSTEIN D, 1988, BIOCHEM J, V256, P13, DOI 10.1042/bj2560013	34	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31249	31255		10.1074/jbc.274.44.31249	http://dx.doi.org/10.1074/jbc.274.44.31249			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531321	hybrid			2022-12-27	WOS:000083379400025
J	Ratnatilleke, A; Vrijbloed, JW; Robinson, JA				Ratnatilleke, A; Vrijbloed, JW; Robinson, JA			Cloning and sequencing of the coenzyme B-12-binding domain of isobutyryl-CoA mutase from Streptomyces cinnamonensis, reconstitution of mutase activity, and characterization of the recombinant enzyme produced in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT GLUTAMATE MUTASE; CLOSTRIDIUM-TETANOMORPHUM; A MUTASE; BINDING; EXPRESSION; SUBUNIT; B-12; SUBSTRATE; GENES	Isobutyryl-CoA mutase (ICM) catalyzes the reversible, coenzyme B-12-dependent rearrangement of isobutyryl-CoA to n-butyryl-CoA, which is similar to, but distinct from, that catalyzed by methylmalong-CoA mutase, ICM has been detected so far in a variety of aerobic and anaerobic bacteria, where it appears to play a key role in valine and fatty acid catabolism, ICM from Streptomyces cinnamonensis is composed of a large subunit (IcmA) of 62.5 kDa and a small subunit (IcmB) of 14.3 kDa, icmB encodes a protein of 136 residues with high sequence similarity to the cobalamin-binding domains of methylmalonyl-CoA mutase, glutamate mutase, methyleneglutarate mutase, and cobalamin-dependent methionine synthase, including a conserved DXHXXG cobalamin-binding motif, Using IcmA and IcmB produced separately in Escherichia coli, we show that IcmB is necessary and sufficient with IcmA and coenzyme B-12 to afford the active ICM holoenzyme. The large subunit (IcmA) forms a tightly associated homodimer, whereas IcmB alone exists as a monomer, In the absence of coenzyme B-12, the association between IcmA and IcmB is weak. The ICM holoenzyme appears to comprise an alpha(2)beta(2)-heterotetramer with up to two molecules of bound coenzyme B-12. The equilibrium constant for the ICM reaction at 30 degrees C is 1.7 in favor of isobutyryl-CoA, and the pH optimum is near 7.4, The K-m values for isobutyryl-CoA, n-butyryl-CoA, and coenzyme B-12 determined with an equimolar ratio of IcmA and IcmB are 57 +/- 13, 54 +/- 12, and 12 +/- 2 mu M, respectively. A V-max of 38 +/- 3 units/mg IcmA and a k(cat) of 39 +/- 3 s(-1) were determined under saturating molar ratios of IcmB to IcmA.	Univ Zurich, Inst Organ Chem, CH-8057 Zurich, Switzerland	University of Zurich	Robinson, JA (corresponding author), Univ Zurich, Inst Organ Chem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.							Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BIRCH A, 1993, J BACTERIOL, V175, P3511, DOI 10.1128/jb.175.11.3511-3519.1993; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENDELBERGER G, 1988, ANGEW CHEM INT EDIT, V27, P1089, DOI 10.1002/anie.198810891; Chen HP, 1997, BIOCHEMISTRY-US, V36, P14939, DOI 10.1021/bi971374g; Cornish-Bowden A., 1995, ANAL ENZYME KINETIC; CORNISHBOWDEN A, 1994, LEONORA COMPUTER PRO; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRENNAN CL, 1994, SCIENCE, V266, P1669, DOI 10.1126/science.7992050; HOLLOWAY DE, 1994, J BIOL CHEM, V269, P20425; HOPWOOD DA, 1985, CENETIC MANIPULATION; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; KELLERMEYER RW, 1964, J BIOL CHEM, V239, P2562; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Mancia F, 1998, STRUCTURE, V6, P711, DOI 10.1016/S0969-2126(98)00073-2; Mancia F, 1996, STRUCTURE, V4, P339, DOI 10.1016/S0969-2126(96)00037-8; Mancia F, 1999, BIOCHEMISTRY-US, V38, P7999, DOI 10.1021/bi9903852; MARSH EN, 1989, BIOCHEM J, V260, P345, DOI 10.1042/bj2600345; MARSH ENG, 1992, FEBS LETT, V310, P167, DOI 10.1016/0014-5793(92)81321-C; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; Retey J., 1982, B12, VII, P357; REYNOLDS KA, 1988, J CHEM SOC P1, P3185; Segel IH., 1993, ENZYME KINETICS BEHA; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Thoma NH, 1998, BIOCHEMISTRY-US, V37, P14386, DOI 10.1021/bi981375o; Tollinger M, 1998, STRUCTURE, V6, P1021, DOI 10.1016/S0969-2126(98)00103-8; Watanabe F, 1996, MICROBIOL-SGM, V142, P2631, DOI 10.1099/00221287-142-9-2631; Zerbe-Burkhardt K, 1998, J BIOL CHEM, V273, P6508, DOI 10.1074/jbc.273.11.6508	28	41	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31679	31685		10.1074/jbc.274.44.31679	http://dx.doi.org/10.1074/jbc.274.44.31679			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531377	hybrid			2022-12-27	WOS:000083379400081
J	Tapia, JA; Ferris, HA; Jensen, RT; Garcia, LJ				Tapia, JA; Ferris, HA; Jensen, RT; Garcia, LJ			Cholecystokinin activates PYK2/CAK beta by a phospholipase C-dependent mechanism and its association with the mitogen-activated protein kinase signaling pathway in pancreatic acinar cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; EPIDERMAL GROWTH-FACTOR; STIMULATES TYROSINE PHOSPHORYLATION; VASCULAR SMOOTH-MUSCLE; LIVER EPITHELIAL-CELLS; N-TERMINAL KINASE; SWISS 3T3 CELLS; ANGIOTENSIN-II; COUPLED RECEPTORS; MAP-KINASE	PYK2/CAK beta is a recently described cytoplasmic tyrosine kinase related to p125 focal adhesion kinase (p125(FAK)) that can be activated by a number of stimuli including growth factors, lipids, and some G protein-coupled receptors. Studies suggest PYK2/CAK beta may be important for coupling various G protein-coupled receptors to the mitogen-activated protein kinase (MAPK) cascade. The hormone neurotransmitter cholecystokinin (CCK) is known to activate both phospholipase C-dependent cascades and MAPK signaling pathways; however, the relationship between these remain unclear. In rat pancreatic acini, CCK-8 (10 nM) rapidly stimulated tyrosine phosphorylation and! activation of PYK2/CAK beta by both activation of high affinity and low affinity CCKA receptor states. Blockage of CCK-stimulated increases in protein kinase C activity or CCK-stimulated increases in [Ca2+](i), inhibited by 40-50% PYK2/CAK beta but not p125FAK tyrosine phosphorylation. Simultaneous blockage of both phospholipase C cascades inhibited PYK2/CAK beta tyrosine phosphorylation completely and p125(FAK) tyrosine phosphorylation by 50%. CCK-8 stimulated a rapid increase in PYK2/CAK beta kinase activity assessed by both an in vitro kinase assay and autophosphorylation. Total PYK2/CAK beta under basal conditions was largely localized (77 +/- 7%) in the membrane fraction, whereas total p125(FAK) was largely localized (86 +/- 3%) in the cytosolic fraction. With CCK stimulation, both p125(FAK) and PYK2/CAK beta translocated to the plasma membrane. Moreover CCK stimulation causes a rapid formation of both PYK2/CAK beta-Grb2 and PYK2/CAK beta-Crk complexes. These results demonstrate that PYK2/CAK beta and p125(FAK) are regulated differently by CCKA receptor stimulation and that PYK2/CAK beta is probably an important mediator of downstream signals by CCK-8, especially in its ability to activate the MAPK signaling pathway, which possibly mediates CCK growth effects in normal and neoplastic tissues.	NIDDKD, Digest Dis Branch, NIH, Bethesda, MD 20892 USA; Univ Extremadura, Dept Fisiol, Caceres 10071, Spain	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Universidad de Extremadura	Jensen, RT (corresponding author), NIDDKD, Digest Dis Branch, NIH, 10 Ctr Dr,MSC 1804, Bethesda, MD 20892 USA.		Garcia-Marin, Luis J/L-4680-2014; Tapia, Jose A./C-5181-2008	Garcia-Marin, Luis J/0000-0002-1795-7381; Tapia, Jose A./0000-0002-3614-6867; Ferris, Heather/0000-0002-6321-3447	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK053101, Z01DK053101] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; AKTORIES K, 1987, FEBS LETT, V212, P109, DOI 10.1016/0014-5793(87)81566-1; Astier A, 1997, J BIOL CHEM, V272, P228; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; BABER NS, 1989, PAIN, V39, P307, DOI 10.1016/0304-3959(89)90045-6; Blakesley VA, 1997, J BIOL CHEM, V272, P16211, DOI 10.1074/jbc.272.26.16211; Bragado MJ, 1996, CLIN SCI, V91, P365, DOI 10.1042/cs0910365; Brinson AE, 1998, J BIOL CHEM, V273, P1711, DOI 10.1074/jbc.273.3.1711; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Charlesworth A, 1996, ONCOGENE, V12, P1337; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; Dabrowski A, 1996, J BIOL CHEM, V271, P27125, DOI 10.1074/jbc.271.43.27125; Dabrowski A, 1996, J BIOL CHEM, V271, P5686, DOI 10.1074/jbc.271.10.5686; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; DUAN RD, 1995, AM J PHYSIOL-GASTR L, V268, pG1060, DOI 10.1152/ajpgi.1995.268.6.G1060; DUAN RD, 1994, AM J PHYSIOL, V267, pG401, DOI 10.1152/ajpgi.1994.267.3.G401; Felsch JS, 1998, P NATL ACAD SCI USA, V95, P5051, DOI 10.1073/pnas.95.9.5051; Ferris HA, 1999, BIOCHEMISTRY-US, V38, P1497, DOI 10.1021/bi981903w; FEURLE GE, 1995, PANCREAS, V10, P281, DOI 10.1097/00006676-199504000-00010; FORCE T, 1991, J BIOL CHEM, V266, P6650; GALAS MC, 1988, AM J PHYSIOL, V254, pG176, DOI 10.1152/ajpgi.1988.254.2.G176; Ganju RK, 1997, J EXP MED, V185, P1055, DOI 10.1084/jem.185.6.1055; Garcia LJ, 1999, ADV MOL CELL ENDOCR, V3, P119; Garcia LJ, 1997, BBA-MOL CELL RES, V1358, P189, DOI 10.1016/S0167-4889(97)00056-6; Garcia LJ, 1997, BIOCHEM J, V327, P461; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HARRO J, 1993, TRENDS PHARMACOL SCI, V14, P244, DOI 10.1016/0165-6147(93)90020-K; Hatch WC, 1998, BLOOD, V91, P3967, DOI 10.1182/blood.V91.10.3967.3967_3967_3973; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Hiregowdara D, 1997, J BIOL CHEM, V272, P10804; HONDA T, 1993, AM J PHYSIOL, V264, pG1142; HOSHI H, 1993, AM J PHYSIOL, V265, pG1177, DOI 10.1152/ajpgi.1993.265.6.G1177; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; Hunter T, 1998, PHILOS T R SOC B, V353, P583, DOI 10.1098/rstb.1998.0228; Jensen Robert T., 1994, P1377; JENSEN RT, 1982, J BIOL CHEM, V257, P5554; JENSEN RT, 1989, TRENDS PHARMACOL SCI, V10, P418, DOI 10.1016/0165-6147(89)90192-2; JORPES JE, 1973, HDB EXPT PHARM; KITSUKAWA Y, 1994, AM J PHYSIOL, V266, pG613, DOI 10.1152/ajpgi.1994.266.4.G613; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; KRIMS PE, 1988, PANCREAS, V3, P383, DOI 10.1097/00006676-198808000-00003; KUMAGAI N, 1993, FEBS LETT, V329, P273, DOI 10.1016/0014-5793(93)80236-N; LEEBLUNDBERG LMF, 1994, J BIOL CHEM, V269, P24328; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; Li X, 1998, EMBO J, V17, P2574, DOI 10.1093/emboj/17.9.2574; Li XO, 1997, J BIOL CHEM, V272, P14996, DOI 10.1074/jbc.272.23.14996; Liddle RA., 1994, GUT PEPTIDES BIOCH P; LOGSDON CD, 1986, AM J PHYSIOL, V251, pG487, DOI 10.1152/ajpgi.1986.251.4.G487; LU L, 1992, AM J PHYSIOL, V263, pG327, DOI 10.1152/ajpgi.1992.263.3.G327; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1997, ADV SEC MESS PHOSPH, V31, P263; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; METZ DC, 1992, J BIOL CHEM, V267, P20620; MEYER BM, 1989, LANCET, V2, P12, DOI 10.1016/S0140-6736(89)90255-9; Mitaka T, 1997, AM J PATHOL, V150, P267; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; MORAN TP, 1994, HUM-COMPUT INTERACT, V9, P1, DOI 10.1207/s15327051hci0901_1; Murasawa S, 1998, HYPERTENSION, V32, P668, DOI 10.1161/01.HYP.32.4.668; Nakamoto T, 1997, MOL CELL BIOL, V17, P3884, DOI 10.1128/MCB.17.7.3884; Ojaniemi M, 1997, J BIOL CHEM, V272, P25993, DOI 10.1074/jbc.272.41.25993; Okazaki H, 1997, J BIOL CHEM, V272, P32443, DOI 10.1074/jbc.272.51.32443; Owyang C, 1996, AM J PHYSIOL-GASTR L, V271, pG1, DOI 10.1152/ajpgi.1996.271.1.G1; PEIKIN SR, 1978, AM J PHYSIOL-ENDOC M, V235, P743; Raja S, 1997, J BIOL CHEM, V272, P10941; Sabri A, 1998, CIRC RES, V83, P841, DOI 10.1161/01.RES.83.8.841; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SALMON ED, 1984, J CELL BIOL, V99, P1066, DOI 10.1083/jcb.99.3.1066; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SATO S, 1989, AM J PHYSIOL, V257, pG202, DOI 10.1152/ajpgi.1989.257.2.G202; Schaller MD, 1997, J BIOL CHEM, V272, P25319, DOI 10.1074/jbc.272.40.25319; SCHRAW W, 1995, BIOCHEMISTRY-US, V34, P13760, DOI 10.1021/bi00042a006; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; Siciliano JC, 1996, J BIOL CHEM, V271, P28942, DOI 10.1074/jbc.271.46.28942; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; Solomon Travis E., 1994, P1499; Soltoff SP, 1998, J BIOL CHEM, V273, P2653, DOI 10.1074/jbc.273.5.2653; Soltoff SP, 1998, J BIOL CHEM, V273, P23110, DOI 10.1074/jbc.273.36.23110; STARK HA, 1989, BIOCHIM BIOPHYS ACTA, V1010, P145, DOI 10.1016/0167-4889(89)90154-7; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; Yule David I., 1994, P1447; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384	95	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31261	31271		10.1074/jbc.274.44.31261	http://dx.doi.org/10.1074/jbc.274.44.31261			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531323	hybrid			2022-12-27	WOS:000083379400027
J	Borowski, P; zur Wiesch, JS; Resch, K; Feucht, H; Laufs, R; Schmitz, H				Borowski, P; zur Wiesch, JS; Resch, K; Feucht, H; Laufs, R; Schmitz, H			Protein kinase C recognizes the protein kinase A-binding motif of nonstructural protein 3 of hepatitis C virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; GROWTH-FACTOR RECEPTOR; CELLULAR-TRANSFORMATION; NS3 PROTEIN; PHOSPHORYLATION; DOMAIN; IDENTIFICATION; PEPTIDE; REQUIREMENTS; ACTIVATION	The nonstructural protein 3 (NS3) of hepatitis C virus (HCV) inhibits the nuclear transport and the enzymatic activity of the catalytic subunit of protein kinase A. This inhibition is mediated by an arginine-rich domain localized between amino acids 1487-1500 of the HCV polyprotein, The data presented here indicate that the arginine-rich domain, when embedded in recombinant fragments of NS3, interacts with the catalytic site of protein kinase C (PKC) and inhibits the phosphorylation mediated by this enzyme in vitro and in vivo. Furthermore, a direct binding of PKC to the NS3 fragments leads to an inhibition of the free shuttling of the kinase between the cytoplasm and the particulate fraction. in contrast, a peptide corresponding to the arginine-rich domain (HCV (1487-1500)), despite also being a PFC inhibitor, did not influence the PRC shuttling process and was transported to the particulate fraction by the translocating kinase upon activation with tetradecanoylphorbol-13-acetate. Using the tetradecanoylphorbol-13-acetate -stimulated respiratory burst of NS3-introduced neutrophils as a model system, we could demonstrate that NS3 is able to block. PKC-mediated functions within intact cells, Our data support the possibility that NS3 disrupts the PKC-mediated signal transduction.	Bernhard Nocht Inst Trop Med, Abt Virol, D-20359 Hamburg, Germany; Univ Hamburg, Krankenhaus Eppendorf, Inst Med Mikrobiol & Immunol, D-20246 Hamburg, Germany	Bernhard Nocht Institut fur Tropenmedizin; University of Hamburg	Borowski, P (corresponding author), Bernhard Nocht Inst Trop Med, Abt Virol, Bernhard Nocht Str 74, D-20359 Hamburg, Germany.	borowski@bni.uni-hamburg.de	Wiesch, Julian Schulze zur/AAT-8452-2021					BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P1974, DOI 10.1021/bi00381a029; Borowski P, 1996, EUR J BIOCHEM, V237, P611, DOI 10.1111/j.1432-1033.1996.0611p.x; Borowski P, 1997, J VIROL, V71, P2838, DOI 10.1128/JVI.71.4.2838-2843.1997; Borowski P, 1999, BIOL CHEM, V380, P403, DOI 10.1515/BC.1999.054; Borowski P, 1996, BIOCHEM MOL BIOL INT, V39, P635; BOROWSKI P, 1999, IN PRESS BIOL CHEM H; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CHOO QL, 1990, BRIT MED BULL, V46, P423, DOI 10.1093/oxfordjournals.bmb.a072408; CORNISHB.A, 1974, BIOCHEM J, V137, P143, DOI 10.1042/bj1370143; FEITELSON MA, 1993, ONCOGENE, V8, P1109; FEUCHT HH, 1995, J CLIN MICROBIOL, V33, P620, DOI 10.1128/JCM.33.3.620-624.1995; HANNUN YA, 1986, J BIOL CHEM, V261, P9341; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; JUDD RC, 1982, INFECT IMMUN, V37, P632, DOI 10.1128/IAI.37.2.632-641.1982; KAPOOR M, 1995, J BIOL CHEM, V270, P19100, DOI 10.1074/jbc.270.32.19100; KEMP BE, 1991, METHOD ENZYMOL, V200, P121; KRAWCZYNSKI K, 1992, GASTROENTEROLOGY, V103, P622, DOI 10.1016/0016-5085(92)90856-T; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMONS R, 1988, ANAL BIOCHEM, V172, P219, DOI 10.1016/0003-2697(88)90435-6; LOOMIS CR, 1988, J BIOL CHEM, V263, P1682; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHADEVAN LC, 1987, EMBO J, V6, P921, DOI 10.1002/j.1460-2075.1987.tb04839.x; MARKERT M, 1984, METHOD ENZYMOL, V105, P358; Matsumoto M, 1997, J VIROL, V71, P1301, DOI 10.1128/JVI.71.2.1301-1309.1997; MEYER AN, 1994, P NATL ACAD SCI USA, V91, P4634, DOI 10.1073/pnas.91.11.4634; MILLER RH, 1990, P NATL ACAD SCI USA, V87, P2057, DOI 10.1073/pnas.87.6.2057; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MULLER GH, 1980, J CELL SCI, V43, P319; Muramatsu S, 1997, J VIROL, V71, P4954, DOI 10.1128/JVI.71.7.4954-4961.1997; OPPERMANN H, 1981, P NATL ACAD SCI-BIOL, V78, P1067, DOI 10.1073/pnas.78.2.1067; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; REVISGUPTA S, 1991, P NATL ACAD SCI USA, V88, P5954, DOI 10.1073/pnas.88.14.5954; RODRIGUEZPENA A, 1985, EMBO J, V4, P71, DOI 10.1002/j.1460-2075.1985.tb02319.x; ROGUE P, 1990, J BIOL CHEM, V265, P4161; RON D, 1995, P NATL ACAD SCI USA, V92, P492, DOI 10.1073/pnas.92.2.492; SCOTT JD, 1985, P NATL ACAD SCI USA, V82, P4379, DOI 10.1073/pnas.82.13.4379; SMITH MK, 1990, J BIOL CHEM, V265, P1837; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; TAKAMIZAWA A, 1991, J VIROL, V65, P1105, DOI 10.1128/JVI.65.3.1105-1113.1991; THOMPSON NT, 1988, BIOCHEM J, V255, P417, DOI 10.1042/bj2550417; TIEMANN F, 1995, J VIROL, V69, P6115, DOI 10.1128/JVI.69.10.6115-6121.1995; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDOORN LJ, 1994, J MED VIROL, V43, P345, DOI 10.1002/jmv.1890430406; WARRENER P, 1993, J VIROL, V67, P989, DOI 10.1128/JVI.67.2.989-996.1993; WHITE E, 1995, CURR TOP MICROBIOL, V199, P33; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Yao NH, 1997, NAT STRUCT BIOL, V4, P463, DOI 10.1038/nsb0697-463	49	26	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30722	30728		10.1074/jbc.274.43.30722	http://dx.doi.org/10.1074/jbc.274.43.30722			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521461	hybrid			2022-12-27	WOS:000083276700057
J	Knoops, B; Clippe, A; Bogard, C; Arsalane, K; Wattiez, R; Hermans, C; Duconseille, E; Falmagne, P; Bernard, A				Knoops, B; Clippe, A; Bogard, C; Arsalane, K; Wattiez, R; Hermans, C; Duconseille, E; Falmagne, P; Bernard, A			Cloning and characterization of AOEB166, a novel mammalian antioxidant enzyme of the peroxiredoxin family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOL-SPECIFIC ANTIOXIDANT; PEROXISOMAL-TARGETING SIGNAL-1; ALKYL HYDROPEROXIDE REDUCTASE; THIOREDOXIN PEROXIDASE; ASPERGILLUS-FUMIGATUS; CONSERVED CYSTEINE; HYDROGEN-PEROXIDE; PROTEIN IMPORT; APOPTOSIS; BRAIN	Using two-dimensional electrophoresis, we have recently identified in human bronchoalveolar lavage fluid a novel protein, termed B166, with a molecular mass of 17 kDa. Here, we report the cloning of human and rat cDNAs encoding B166, which has been renamed AOEB166 for (a) under bar nti (o) under bar xidant enzyme <(B166)under bar>. Indeed, the deduced amino acid sequence reveals that AOEB166 represents a new mammalian subfamily of AhpC/TSA peroxiredoxin antioxidant enzymes. Human AOEB166 shares 63% similarity with Escherichia coli AhpC22 alkyl hydroperoxide reductase and 66% similarity with a recently identified Saccharomyces cerevisiae alkyl hydroperoxide reductase/thioredoxin peroxidase. Moreover, recombinant AOEB166 expressed in E. coli exhibits a peroxidase activity, and an antioxidant activity comparable with that of catalase was demonstrated with the glutamine synthetase protection assay against dithiothreitol/Fe3+/O-2 oxidation. The analysis of AOEB166 mRNA distribution in 30 different human tissues and in 10 cell lines shows that the gene is widely expressed in the body. Of interest, the analysis of N- and C-terminal domains of both human and rat AOEB166 reveals amino acid sequences presenting features of mitochondrial and peroxisomal targeting sequences. Furthermore, human AOEB166 expressed as a fusion protein with GFP in HepG2 cell line is sorted to these organelles. Finally, acute inflammation induced in rat lung by lipopolysaccharide is associated with an increase of AOEB166 mRNA levels in lung, suggesting a protective role for AOEB166 in oxidative and inflammatory processes.	Catholic Univ Louvain, Cell Biol Lab, Dept Biol, B-1348 Louvain, Belgium; Catholic Univ Louvain, Sch Med, Unit Ind Toxicol & Occupat Med, B-1200 Brussels, Belgium; Univ Mons, Dept Biol Chem, B-7000 Mons, Belgium	Universite Catholique Louvain; Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Mons	Knoops, B (corresponding author), Catholic Univ Louvain, Cell Biol Lab, Dept Biol, Pl Croix Sud 5, B-1348 Louvain, Belgium.	knoops@bani.ucl.ac.be	BERNARD, Alfred M/A-6511-2010	BERNARD, Alfred M/0000-0003-3171-3743; wattiez, ruddy/0000-0003-2071-4310				BEAL MF, 1995, ANN NEUROL, V38, P357, DOI 10.1002/ana.410380304; CHAE HZ, 1993, J BIOL CHEM, V268, P16815; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7022, DOI 10.1073/pnas.91.15.7022; Choi HJ, 1998, NAT STRUCT BIOL, V5, P400, DOI 10.1038/nsb0598-400; Crameri R, 1996, J EXP MED, V184, P265, DOI 10.1084/jem.184.1.265; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; DEDUVE C, 1966, PHYSIOL REV, V46, P323, DOI 10.1152/physrev.1966.46.2.323; FELSENSTEIN J, 1993, PHYLIP VERSION 3572; Fisher AB, 1999, J BIOL CHEM, V274, P21326, DOI 10.1074/jbc.274.30.21326; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; Hemmann S, 1997, AM J RESP CRIT CARE, V156, P1956, DOI 10.1164/ajrccm.156.6.9702087; Ichimiya S, 1997, DNA CELL BIOL, V16, P311, DOI 10.1089/dna.1997.16.311; Jeong JS, 1999, BIOCHEMISTRY-US, V38, P776, DOI 10.1021/bi9817818; Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; KAWAI S, 1994, J BIOCHEM-TOKYO, V115, P641, DOI 10.1093/oxfordjournals.jbchem.a124388; KIM KW, 1988, J BIOL CHEM, V263, P4704; Knoops B, 1997, NEUROREPORT, V8, P795, DOI 10.1097/00001756-199702100-00043; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Lametschwandtner G, 1998, J BIOL CHEM, V273, P33635, DOI 10.1074/jbc.273.50.33635; Lee J, 1999, J BIOL CHEM, V274, P4537, DOI 10.1074/jbc.274.8.4537; LIM YS, 1994, GENE, V140, P279, DOI 10.1016/0378-1119(94)90558-4; MANNAERTS GP, 1993, BIOCHIMIE, V75, P147, DOI 10.1016/0300-9084(93)90072-Z; Mano T, 1997, HORM METAB RES, V29, P351; Mignotte B, 1998, EUR J BIOCHEM, V252, P1, DOI 10.1046/j.1432-1327.1998.2520001.x; MOSLEN MT, 1994, ADV EXP MED BIOL, V366, P17; MOTLEY A, 1995, J CELL BIOL, V131, P95, DOI 10.1083/jcb.131.1.95; Netto LES, 1996, J BIOL CHEM, V271, P15315, DOI 10.1074/jbc.271.26.15315; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Poole LB, 1996, BIOCHEMISTRY-US, V35, P65, DOI 10.1021/bi951888k; PROSPERI MT, 1993, J BIOL CHEM, V268, P11050; Rabilloud T, 1995, BIOCHEM J, V312, P699, DOI 10.1042/bj3120699; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SHAU HG, 1994, IMMUNOGENETICS, V40, P129; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vanhooren JCT, 1996, EUR J BIOCHEM, V239, P302, DOI 10.1111/j.1432-1033.1996.0302u.x; Verdoucq L, 1999, J BIOL CHEM, V274, P19714, DOI 10.1074/jbc.274.28.19714; WATABE S, 1994, J BIOCHEM, V115, P648, DOI 10.1093/oxfordjournals.jbchem.a124390; Wattiez R, 1999, ELECTROPHORESIS, V20, P1634, DOI 10.1002/(SICI)1522-2683(19990601)20:7<1634::AID-ELPS1634>3.0.CO;2-J; YIM MB, 1994, J BIOL CHEM, V269, P1621; YU BP, 1994, PHYSIOL REV, V74, P139, DOI 10.1152/physrev.1994.74.1.139; Zhang P, 1997, J BIOL CHEM, V272, P30615, DOI 10.1074/jbc.272.49.30615	47	206	218	4	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30451	30458		10.1074/jbc.274.43.30451	http://dx.doi.org/10.1074/jbc.274.43.30451			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521424	hybrid			2022-12-27	WOS:000083276700020
J	Kumar, S; Avraham, S; Bharti, A; Goyal, J; Pandey, P; Kharbanda, S				Kumar, S; Avraham, S; Bharti, A; Goyal, J; Pandey, P; Kharbanda, S			Negative regulation of PYK2/related adhesion focal tyrosine kinase signal transduction by hematopoietic tyrosine phosphatase SHPTP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; MYELOID-LEUKEMIA CELLS; GRB2-MEDIATED ASSOCIATION; DIFFERENTIAL REGULATION; C-ABL; PYK2; DNA; PP125(FAK); SRC; EXPRESSION	Related adhesion focal tyrosine kinase (RAFTK) (also known as PYK2) is a cytoplasmic tyrosine kinase related to the focal adhesion kinase (FAK) p125(FAK). RAFTK is rapidly phosphorylated on tyrosine residues in response to various stimuli, such as tumor necrosis factor-alpha, changes in osmolarity, elevation in intracellular calcium concentration, lysophosphatidic acid, and bradykinin. Overexpression of RAFTK induces activation of c-Jun amino-terminal kinase (also known as stress-activated protein kinase), mitogen-activated protein kinase (MAPK), and p38 MAPK. The present studies demonstrate that RAFTK binds constitutively to the protein tyrosine phosphatase SHPTP1. In contrast to PTP1B, overexpression of wild-type SHPTP1 blocks tyrosine phosphorylation of RAFTK. The results further demonstrate that RAFTK is a direct substrate of SHPTP1 in vitro. Moreover, treatment of PC12 cells with bradykinin is associated with inhibition in tyrosine phosphorylation of RAFTK in the presence of SHPTP1. Furthermore, in contrast to the phosphatase-dead SHPTP1 C4535 mutant, overexpression of wild-type SHPTP1 blocks interaction of RAFTK with the SH2-domain of c-Src and inhibits RAFTK-mediated MAPK activation. Significantly, cotransfection of RAFTK with SHPTP1 did not inhibit RAFTK-mediated c-Jun amino-terminal kinase activation. Taken together, these findings suggest that SHPTP1 plays a negative role in PYK2/RAFTK signaling by dephosphorylating RAFTK.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med, Boston, MA 02115 USA; Harvard Inst Med, Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA 02115 USA; New England Med Ctr, Dept Radiat Oncol, Boston, MA 02111 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Tufts Medical Center	Kharbanda, S (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.				NCI NIH HHS [CA75216] Funding Source: Medline; NHLBI NIH HHS [HL55445] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075216] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055445] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Astier A, 1997, J BIOL CHEM, V272, P228; Astier A, 1997, J BIOL CHEM, V272, P19719, DOI 10.1074/jbc.272.32.19719; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Dikic I, 1998, J BIOL CHEM, V273, P14301, DOI 10.1074/jbc.273.23.14301; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Jeschke M, 1998, J BIOL CHEM, V273, P11354, DOI 10.1074/jbc.273.18.11354; KHARBANDA S, 1995, P NATL ACAD SCI USA, V92, P6132, DOI 10.1073/pnas.92.13.6132; KHARBANDA S, 1995, J BIOL CHEM, V270, P18871, DOI 10.1074/jbc.270.32.18871; KHARBANDA S, 1994, J BIOL CHEM, V269, P872; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kumar S, 1998, J BIOL CHEM, V273, P25654, DOI 10.1074/jbc.273.40.25654; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Pandey P, 1999, J BIOL CHEM, V274, P10140, DOI 10.1074/jbc.274.15.10140; Pandey P, 1999, J BIOL CHEM, V274, P8618, DOI 10.1074/jbc.274.13.8618; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; Raja S, 1997, J BIOL CHEM, V272, P10941; SALEEM A, 1995, J IMMUNOL, V154, P4150; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHLAEPFER DD, 1994, NATURE, V372, P786; Siciliano JC, 1996, J BIOL CHEM, V271, P28942, DOI 10.1074/jbc.271.46.28942; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; TOPPMAIR J, 1994, J BIOL CHEM, V269, P7030; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384	36	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30657	30663		10.1074/jbc.274.43.30657	http://dx.doi.org/10.1074/jbc.274.43.30657			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521452	hybrid			2022-12-27	WOS:000083276700048
J	Lei, SB; Lu, WY; Xiong, ZG; Orser, BA; Valenzuela, CF; MacDonald, JF				Lei, SB; Lu, WY; Xiong, ZG; Orser, BA; Valenzuela, CF; MacDonald, JF			Platelet-derived growth factor receptor-induced feed-forward inhibition of excitatory transmission between hippocampal pyramidal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SIGNAL-REGULATED KINASE-2; D-ASPARTATE RECEPTORS; SMOOTH-MUSCLE CELLS; SRC TYROSINE KINASE; COUPLED RECEPTORS; CYCLIC-AMP; ADENYLYL CYCLASES; NMDA RECEPTORS; NR1 SUBUNIT	Growth factor receptors provide a major mechanism for the activation of the nonreceptor tyrosine kinase c-Src, and this kinase in turn up-regulates the activity of N-methyl-D-aspartate (NMDA) receptors in CA1 hippocampal neurons (1). Unexpectedly, applications of platelet-derived growth factor (PDGF)-BB to cultured and isolated CA1 hippocampal neurons depressed NMDA-evoked currents. The PDGF-induced depression was blocked by a PDGF-selective tyrosine kinase inhibitor, by a selective inhibitor of phospholipase C-gamma, and by blocking the intracellular release of Ca2+. Inhibitors of cAMP-dependent protein kinase (PKA) also eliminated the PDGF-induced depression, whereas a phosphodiesterase inhibitor enhanced it. The NMDA receptor-mediated component of excitatory synaptic currents was also inhibited by PDGF, and this inhibition was prevented by co-application of a PKA inhibitor. Src inhibitors also prevented this depression. In recordings from inside-out patches, the catalytic fragment of PKA did not itself alter NMDA single channel activity, but it blocked the up-regulation of these channels by a Src activator peptide. Thus, PDGF receptors depress NMDA channels through a Ca2+- and PHA-dependent inhibition of their modulation by c-Src.	Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Anaesthesia, Toronto, ON M5S 1A8, Canada; Univ New Mexico, Hlth Sci Ctr, Dept Neurosci, Albuquerque, NM 87131 USA	University of Toronto; University of Toronto; University of Toronto; University of New Mexico; University of New Mexico's Health Sciences Center	MacDonald, JF (corresponding author), Univ Toronto, Dept Physiol, Med Sci Bldg, Toronto, ON M5S 1A8, Canada.	j.macdonald@utoronto.ca	Lu, Wei-Yang/K-4404-2013					Antoni F A, 1998, Adv Second Messenger Phosphoprotein Res, V32, P153; BENJAMIN CW, 1988, P NATL ACAD SCI USA, V85, P4345, DOI 10.1073/pnas.85.12.4345; Bornfeldt KE, 1995, ANN NY ACAD SCI, V766, P416, DOI 10.1111/j.1749-6632.1995.tb26691.x; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHETKOVICH DM, 1991, P NATL ACAD SCI USA, V88, P6467, DOI 10.1073/pnas.88.15.6467; CHETKOVICH DM, 1993, J NEUROCHEM, V61, P1933, DOI 10.1111/j.1471-4159.1993.tb09836.x; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; DEBLAQUIERE J, 1994, J BIOL CHEM, V269, P4812; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; EHLERS MD, 1995, SCIENCE, V269, P1734, DOI 10.1126/science.7569904; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; Graves LM, 1996, J BIOL CHEM, V271, P505, DOI 10.1074/jbc.271.1.505; GREENGARD P, 1991, SCIENCE, V253, P1135, DOI 10.1126/science.1716001; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hansen K, 1997, BIOCHEM BIOPH RES CO, V241, P355, DOI 10.1006/bbrc.1997.7743; Heldin CH, 1997, FEBS LETT, V410, P17, DOI 10.1016/S0014-5793(97)00318-9; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; Kennedy MB, 1997, TRENDS NEUROSCI, V20, P264, DOI 10.1016/S0166-2236(96)01033-8; Leonard AS, 1997, J BIOL CHEM, V272, P12107, DOI 10.1074/jbc.272.18.12107; LIU XQ, 1993, ONCOGENE, V8, P1119; Lu WY, 1999, NAT NEUROSCI, V2, P331, DOI 10.1038/7243; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MACDONALD JF, 1989, J PHYSIOL-LONDON, V414, P17, DOI 10.1113/jphysiol.1989.sp017674; Mathias RS, 1998, AM J PHYSIOL-CELL PH, V274, pC1456, DOI 10.1152/ajpcell.1998.274.6.C1456; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; Murray D, 1998, BIOCHEMISTRY-US, V37, P2145, DOI 10.1021/bi972012b; NAKANISHI S, 1994, ANNU REV BIOPH BIOM, V23, P319, DOI 10.1146/annurev.bb.23.060194.001535; PATSCHINSKY T, 1986, J VIROL, V59, P73, DOI 10.1128/JVI.59.1.73-81.1986; PYNE NJ, 1994, BIOCHEM J, V304, P611, DOI 10.1042/bj3040611; Raman IM, 1996, NEURON, V16, P415, DOI 10.1016/S0896-6273(00)80059-8; RHEE SG, 1992, J BIOL CHEM, V267, P12393; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; Sawutz DG, 1996, BIOCHEM PHARMACOL, V51, P1631, DOI 10.1016/0006-2952(96)00112-8; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; Tingley WG, 1997, J BIOL CHEM, V272, P5157, DOI 10.1074/jbc.272.8.5157; Valenzuela CF, 1995, MOL PHARMACOL, V48, P1099; Valenzuela CF, 1997, BRAIN RES REV, V24, P77; Valenzuela CF, 1996, J BIOL CHEM, V271, P16151, DOI 10.1074/jbc.271.27.16151; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WALKER F, 1993, J BIOL CHEM, V268, P19552; Wan Q, 1997, NATURE, V388, P686, DOI 10.1038/41792; WANG LY, 1995, J PHYSIOL-LONDON, V486, P83, DOI 10.1113/jphysiol.1995.sp020792; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455; Xia ZG, 1997, CURR OPIN NEUROBIOL, V7, P391, DOI 10.1016/S0959-4388(97)80068-2; YACIUK P, 1989, MOL CELL BIOL, V9, P2453, DOI 10.1128/MCB.9.6.2453; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674	48	41	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30617	30623		10.1074/jbc.274.43.30617	http://dx.doi.org/10.1074/jbc.274.43.30617			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521446	hybrid			2022-12-27	WOS:000083276700042
J	Munshi, C; Thiel, DJ; Mathews, II; Aarhus, R; Walseth, TF; Lee, HC				Munshi, C; Thiel, DJ; Mathews, II; Aarhus, R; Walseth, TF; Lee, HC			Characterization of the active site of ADP-ribosyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGG-SPECIFIC NADASE; INOSITOL TRISPHOSPHATE; CRYSTAL-STRUCTURE; 2ND-MESSENGER ENZYME; CYCLIC METABOLITE; CD38; CYCLIZATION; HYDROLYSIS; BST-1; FERMENTATION	ADP-ribosyl cyclase synthesizes two Ca2+ messengers by cyclizing NAD to produce cyclic ADP-ribose and exchanging nicotinic acid with the nicotinamide group of NADP to produce nicotinic acid adenine dinucleotide phosphate, Recombinant Aplysia cyclase was expressed in yeast and co-crystallized with a substrate, nicotinamide. x-ray crystallography showed that the nicotinamide was bound in a pocket formed in part by a conserved segment and was near the central cleft of the cyclase. Glu(98), Asn(107) and Trp(140) were within 3.5 Angstrom of the bound nicotinamide and appeared to coordinate it. Substituting Glu(98) With either Gln, Gly, Leu, or Asn reduced the cyclase activity by 16-222-fold, depending on the substitution. The mutant N107G exhibited only a 2-fold decrease in activity, while the activity of W140G was essentially eliminated. The base exchange activity of all mutants followed a similar pattern of reduction, suggesting that both reactions occur at the same active site. In addition to NAD, the wild-type cyclase also cyclizes nicotinamide guanine dinucleotide to cyclic GDP-ribose, AU mutant enzymes had at least half of the GDP-ribosyl cyclase activity of the wild type, some even 2-3-fold higher, indicating that the three coordinating amino acids are responsible for positioning of the substrate but not absolutely critical for catalysis. To search for the catalytic residues, other amino acids in the binding pocket were mutagenized, E179G: was totally devoid of GDP-ribosyl cyclase activity, and both its ADP-ribosyl cyclase and the base exchange activities were reduced by 10,000- and 18,000-fold, respectively. Substituting Glu(179) With either Asn, Leu, Asp, or Gln produced similar inactive enzymes; and so was the conversion of Trp(77) to Gly, However, both E179G and the double mutant E179G/W77G retained NAD-binding ability as shown by photoaffinity labeling with [P-32]8-azido-NAD, These results indicate that both Glu(179) and Trp(77) are crucial for catalysis and that Glu(179) may indeed be the catalytic residue.	Univ Minnesota, Dept Physiol, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA; Cornell Univ, Biochem Mol & Cell Biol Sect, Ithaca, NY 14853 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Cornell University	Lee, HC (corresponding author), Univ Minnesota, Dept Physiol, 435 Delaware St SE,6-255 Millard Hall, Minneapolis, MN 55455 USA.		Lee, Hon Cheung/C-4329-2009; Walseth, Timothy F/F-9518-2010	Walseth, Timothy F/0000-0003-2558-7859	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017484] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA011806] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-01646] Funding Source: Medline; NICHD NIH HHS [HD17484] Funding Source: Medline; NIDA NIH HHS [DA11806] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Aarhus R, 1995, J BIOL CHEM, V270, P30327, DOI 10.1074/jbc.270.51.30327; Albrieux M, 1998, J BIOL CHEM, V273, P14566, DOI 10.1074/jbc.273.23.14566; Barth H, 1998, J BIOL CHEM, V273, P29506, DOI 10.1074/jbc.273.45.29506; Bell CE, 1996, BIOCHEMISTRY-US, V35, P1137, DOI 10.1021/bi9520848; BRUNGER AT, 1992, XPLOR VERSION 3 1; Cancela JM, 1999, NATURE, V398, P74, DOI 10.1038/18032; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; De Flora A, 1997, INT J BIOCHEM CELL B, V29, P1149, DOI 10.1016/S1357-2725(97)00062-9; Franco L, 1998, FASEB J, V12, P1507; GLICK DL, 1991, CELL REGUL, V2, P211, DOI 10.1091/mbc.2.3.211; Graeff RM, 1996, BIOCHEMISTRY-US, V35, P379, DOI 10.1021/bi952083f; GRAEFF RM, 1994, J BIOL CHEM, V269, P30260; HELLMICH MR, 1991, CELL REGUL, V2, P193, DOI 10.1091/mbc.2.3.193; HIRATA Y, 1994, FEBS LETT, V356, P244, DOI 10.1016/0014-5793(94)01279-2; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; Hussain AMM, 1998, PROTEIN EXPRES PURIF, V12, P133, DOI 10.1006/prep.1997.0811; ITOH M, 1994, BIOCHEM BIOPH RES CO, V203, P1309, DOI 10.1006/bbrc.1994.2325; JONES TA, 1992, MOL REPLACEMENT, P91; KIM H, 1993, SCIENCE, V261, P1330, DOI 10.1126/science.8395705; KIM H, 1993, BIOCHEM BIOPH RES CO, V194, P1143, DOI 10.1006/bbrc.1993.1941; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LEE B, 1991, HOUS POLICY DEBATE, V2, P3; LEE HC, 1995, BIOCHIMIE, V77, P345, DOI 10.1016/0300-9084(96)88145-4; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; LEE HC, 1994, NAT STRUCT BIOL, V1, P143, DOI 10.1038/nsb0394-143; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; LEE HC, 1989, J BIOL CHEM, V264, P1608; Lee HC, 1996, RECENT PROG HORM RES, V51, P355; Lee HC, 1997, ADV EXP MED BIOL, V419, P411; LEE HC, 1993, BIOCHIM BIOPHYS ACTA, V1164, P68, DOI 10.1016/0167-4838(93)90113-6; MullerSteffner HM, 1996, J BIOL CHEM, V271, P23967, DOI 10.1074/jbc.271.39.23967; Munshi C, 1997, PROTEIN EXPRES PURIF, V11, P104, DOI 10.1006/prep.1997.0773; Munshi C, 1998, BBA-PROTEIN STRUCT M, V1388, P428, DOI 10.1016/S0167-4838(98)00204-0; Munshi CB, 1997, METHOD ENZYMOL, V280, P318; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Prasad GS, 1996, NAT STRUCT BIOL, V3, P957, DOI 10.1038/nsb1196-957; RUSINKO N, 1989, J BIOL CHEM, V264, P11725; Sauve AA, 1998, BIOCHEMISTRY-US, V37, P13239, DOI 10.1021/bi981248s; STATES DJ, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90337-9; Tao W, 1996, BIOCHEMISTRY-US, V35, P14, DOI 10.1021/bi951898l; THIEL DJ, 1996, REV SCI INSTRUM, V67, P1; Tong L, 1997, METHOD ENZYMOL, V276, P594, DOI 10.1016/S0076-6879(97)76080-4; Walseth TF, 1997, METHOD ENZYMOL, V280, P294; WALSETH TF, 1993, J BIOL CHEM, V268, P26686	44	54	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30770	30777		10.1074/jbc.274.43.30770	http://dx.doi.org/10.1074/jbc.274.43.30770			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521467	hybrid			2022-12-27	WOS:000083276700063
J	Danilkovitch, A; Miller, M; Leonard, EJ				Danilkovitch, A; Miller, M; Leonard, EJ			Interaction of macrophage-stimulating protein with its receptor - Residues critical for beta chain binding and evidence for independent alpha chain binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; TYROSINE KINASE; MET PROTOONCOGENE; GENE-PRODUCT; EXPRESSION; DOMAIN; FAMILY; MSP; IDENTIFICATION; SPECIFICITY	Macrophage-stimulating protein (MSP) and hepatocyte growth factor/scatter factor (HGF/SF) are plasminogen-related growth and motility factors that interact with cell-surface protein tyrosine kinase receptors. Each one is a heterodimeric protein comprising a disulfide-linked alpha chain and a serine protease-like beta chain. Despite structural similarities between MSP and HGF, the primary receptor binding site is located on the alpha chain of HGF/SF but on the beta chain of MSP. To obtain insight into the structural basis for MSP beta chain binding, beta chain structure was modeled from coordinates of an existing model of the HGF beta chain. The model revealed that the region corresponding to the S1 specificity pocket in trypsin is filled by the Asn(682)/Glu(648) interacting pair, leaving a shallow cavity far possible beta chain interaction with the receptor. Mutants in this region were created, and their binding characteristics were determined. A double mutation of Asn(682)/Glu(648) caused diminished binding of the P chain to the MSP receptor, and a single mutation of neighboring Arg(683) completely abolished binding. Thus, this region of the molecule is critical for binding. We also found that at equimolar concentrations of free alpha and beta chains, LY chain binding to receptor was detectable, at levels considerably lower than beta chain binding. The EC(50) values determined by quantitative enzyme-linked immunosorbent assay are 0.25 and 16.9 nM for beta and alpha chain, respectively. The data suggest that MSP has two independent binding sites with high and low affinities located in beta and alpha chain, respectively, and that the two sites together mediate receptor dimerization and subsequent activation.	NCI, Frederick Canc Res & Dev Ctr, Immunobiol Lab, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Macromol Struct Lab, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Danilkovitch, A (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Immunobiol Lab, Bldg 560,Rm 12-46, Frederick, MD 21702 USA.	danilkovitch@mail.ncifcrf.gov	Miller, Maria/I-1636-2013	Miller, Maria/0000-0003-0252-5348				BEZERRA JA, 1993, HEPATOLOGY, V18, P394, DOI 10.1016/0270-9139(93)90024-H; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Danilkovitch A, 1999, J LEUKOCYTE BIOL, V65, P345, DOI 10.1002/jlb.65.3.345; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DONATE LE, 1994, PROTEIN SCI, V3, P2378, DOI 10.1002/pro.5560031222; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; IWAMA A, 1995, BLOOD, V86, P3394, DOI 10.1182/blood.V86.9.3394.bloodjournal8693394; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; JIN L, 1992, J MOL BIOL, V226, P851, DOI 10.1016/0022-2836(92)90636-X; JONES TA, 1985, METHOD ENZYMOL, V115, P157; Khan AR, 1998, PROTEIN SCI, V7, P815; LEONARD EJ, 1976, EXP CELL RES, V102, P434, DOI 10.1016/0014-4827(76)90065-3; Leonard EJ, 1997, CIBA F SYMP, V212, P183; LOKKER NA, 1994, PROTEIN ENG, V7, P895, DOI 10.1093/protein/7.7.895; Matsumoto K, 1997, BIOCHEM BIOPH RES CO, V239, P639, DOI 10.1006/bbrc.1997.7517; MATSUMOTO K, 1992, Critical Reviews in Oncogenesis, V3, P27; Miller M, 1998, FEBS LETT, V429, P1, DOI 10.1016/S0014-5793(98)00533-X; Nanney LB, 1998, J INVEST DERMATOL, V111, P573, DOI 10.1046/j.1523-1747.1998.00332.x; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; Perona JJ, 1997, J BIOL CHEM, V272, P29987, DOI 10.1074/jbc.272.48.29987; RONSIN C, 1993, ONCOGENE, V8, P1195; Sakata H, 1997, J BIOL CHEM, V272, P9457; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; Wahl RC, 1997, J BIOL CHEM, V272, P15053, DOI 10.1074/jbc.272.24.15053; Waltz SE, 1997, J BIOL CHEM, V272, P30526, DOI 10.1074/jbc.272.48.30526; Wang MH, 1996, EXP CELL RES, V226, P39, DOI 10.1006/excr.1996.0200; WANG MH, 1994, J BIOL CHEM, V269, P14027; WANG MH, 1995, P NATL ACAD SCI USA, V92, P3933, DOI 10.1073/pnas.92.9.3933; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; WANG MH, 1993, J LEUKOCYTE BIOL, V54, P289, DOI 10.1002/jlb.54.4.289; Wang MH, 1997, J BIOL CHEM, V272, P16999, DOI 10.1074/jbc.272.27.16999; WANG MH, 1994, J BIOL CHEM, V269, P3436; Yoshikawa W, 1999, ARCH BIOCHEM BIOPHYS, V363, P356, DOI 10.1006/abbi.1998.1090; YOSHIMURA T, 1993, J BIOL CHEM, V268, P15461	36	34	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29937	29943		10.1074/jbc.274.42.29937	http://dx.doi.org/10.1074/jbc.274.42.29937			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514476	hybrid			2022-12-27	WOS:000083176400055
J	Dorin, D; Alano, P; Boccaccio, I; Ciceron, L; Doerig, C; Sulpice, R; Parzy, D; Doerig, C				Dorin, D; Alano, P; Boccaccio, I; Ciceron, L; Doerig, C; Sulpice, R; Parzy, D; Doerig, C			An atypical mitogen-activated protein kinase (MAPK) homologue expressed in gametocytes of the human malaria parasite Plasmodium falciparum - Identification of a MAPK signature	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE; CLONING; SPECIFICITY; CEREVISIAE; SEQUENCE; MOSQUITO; FAMILY; FUS3; ERK2	The cDNA encoding Pfmap-2, an enzyme of the human malaria parasite Plasmodium falciparum, was cloned, sequenced, and expressed in Escherichia coli, The open reading frame carried by the Pfmap-2 cDNA encodes a 508-amino acid polypeptide of 59.2 kDa with maximal homology to mitogen-activated protein kinases (MAPKs) from various organisms. The purified recombinant enzyme displayed functional characteristics of MAPKs such as (i) ability to undergo autophosphorylation, (ii) ability to phosphorylate myelin basic protein, a classical MAPK substrate, (iii) regulation of kinase activity by a MAPK-specific phosphatase, and (iv) ability to be activated by component(s) present in cell extracts. Mutational analysis of the recombinant protein allowed the identification of residues that are important for enzymatic activity. Northern blot analysis and immunofluorescence assays indicated that Pfmap-2 is expressed specifically in gametocytes, the form that is responsible for transmission of the parasite to the mosquito vector. Gametocyte extracts activated recombinant Pfmap-2 more efficiently than extracts from asexual parasites, which is consistent with this stage specificity, Despite its overall high level of homology to MAPKs, Pfmap-2 presents the peculiarity of not possessing the conserved threonine-X-tyrosine activation motif usually found in enzymes of this family; instead, it has a threonine-serine-histidine at the same location. This atypical feature formed the basis for a detailed analysis of the primary structure of MAPKs, allowing us to define an operational MAPK signature, which is shared by Pfmap-2. The fact that no MAPK from vertebrates diverge in the activation motif suggests that the fine mechanisms of Pfmap-2 regulation may offer an opportunity for antimalarial drug targeting.	INSERM, U511, F-75013 Paris, France; Ist Super Sanita, I-00161 Rome, Italy; INSERM U399, F-13005 Marseille, France; Inst Trop Med, Serv Sante Armees, F-13007 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Istituto Superiore di Sanita (ISS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Doerig, C (corresponding author), INSERM, U511, 91 Bd Hop, F-75013 Paris, France.	doerig@ext.jussieu.fr	ALANO, PIETRO/C-2946-2016; Sulpice, Ronan/I-2738-2013; Doerig, Christian/Q-9900-2019	ALANO, PIETRO/0000-0003-0092-9840; Sulpice, Ronan/0000-0002-6113-9570; Doerig, Christian/0000-0002-3188-094X; Huynh, Chien/0000-0001-9801-845X				ALANO P, 1990, ANNU REV MICROBIOL, V44, P429, DOI 10.1146/annurev.mi.44.100190.002241; Alano P, 1995, MOL BIOCHEM PARASIT, V74, P143, DOI 10.1016/0166-6851(95)02491-3; ALANO P, 1991, MOL BIOCHEM PARASIT, V46, P81, DOI 10.1016/0166-6851(91)90201-G; BAIROCH A, 1988, NATURE, V331, P22, DOI 10.1038/331022a0; BARDWELL L, 1994, DEV BIOL, V166, P363, DOI 10.1006/dbio.1994.1323; Billker O, 1998, NATURE, V392, P289, DOI 10.1038/32667; BRIGGS WH, 1992, P NATL ACAD SCI USA, V89, P6295; Carter R, 1993, Methods Mol Biol, V21, P67; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; DOERIG C, 1995, MOL BIOCHEM PARASIT, V70, P167, DOI 10.1016/0166-6851(95)00033-W; Doerig CM, 1996, GENE, V177, P1, DOI 10.1016/0378-1119(96)00281-8; DONTFRAID FF, 1994, BIOCHEM BIOPH RES CO, V201, P423, DOI 10.1006/bbrc.1994.1718; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; Graeser R, 1997, MOL MICROBIOL, V23, P151, DOI 10.1046/j.1365-2958.1997.2071571.x; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HER JH, 1991, NUCLEIC ACIDS RES, V19, P3743, DOI 10.1093/nar/19.13.3743; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KAPPES B, 1995, MOL BIOCHEM PARASIT, V72, P163, DOI 10.1016/0166-6851(95)00075-C; Lin DT, 1996, MOL BIOCHEM PARASIT, V78, P67, DOI 10.1016/S0166-6851(96)02608-4; Madhani HD, 1998, TRENDS GENET, V14, P151, DOI 10.1016/S0168-9525(98)01425-5; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MIZOGUCHI T, 1993, FEBS LETT, V336, P440, DOI 10.1016/0014-5793(93)80852-L; Nakashima S, 1999, J BIOL CHEM, V274, P9976, DOI 10.1074/jbc.274.15.9976; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; SAMBROOK J, 1989, MOL CLONING, V1, P7; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; Sinden RE, 1996, ADV PARASIT, V38, P53, DOI 10.1016/S0065-308X(08)60033-0; SULTAN AA, 1994, MOL BIOCHEM PARASIT, V65, P331, DOI 10.1016/0166-6851(94)90083-3; THOMPSON J, 1994, MOL BIOCHEM PARASIT, V68, P189, DOI 10.1016/0166-6851(94)90164-3; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; Waters AP, 1997, METHODS, V13, P134, DOI 10.1006/meth.1997.0506; White NJ, 1998, ANN TROP MED PARASIT, V92, P449, DOI 10.1080/00034989859429; World Health Organization, 1997, Weekly Epidemiological Record, V72, P269; WurglerMurphy SM, 1997, TRENDS BIOCHEM SCI, V22, P172, DOI 10.1016/S0968-0004(97)01036-0; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0	37	91	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29912	29920		10.1074/jbc.274.42.29912	http://dx.doi.org/10.1074/jbc.274.42.29912			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514473	hybrid			2022-12-27	WOS:000083176400052
J	Fagan, AM; Holtzman, DM; Munson, G; Mathur, T; Schneider, D; Chang, LK; Getz, GS; Reardon, CA; Lukens, J; Shah, JA; LaDu, MJ				Fagan, AM; Holtzman, DM; Munson, G; Mathur, T; Schneider, D; Chang, LK; Getz, GS; Reardon, CA; Lukens, J; Shah, JA; LaDu, MJ			Unique lipoproteins secreted by primary astrocytes from wild type, apoE (-/-), and human apoE transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; RECEPTOR-RELATED PROTEIN; HUMAN APOLIPOPROTEIN-E; AMYLOID-BETA-PEPTIDE; E MESSENGER-RNA; HUMAN CEREBROSPINAL-FLUID; HIGH-DENSITY-LIPOPROTEIN; ISOFORM-SPECIFIC BINDING; ALZHEIMERS-DISEASE; HUMAN PLASMA	Composition of central nervous system lipoproteins affects the metabolism of lipoprotein constituents within the brain. The epsilon 4 allele of apolipoprotein E (apoE) is a risk factor for Alzheimer's disease via an unknown mechanism(s). As glia are the primary central nervous system cell type that synthesize apoE, we characterized lipoproteins secreted by astrocytes from wild type (WT), apoE (-/-), and apoE transgenic mice expressing human apoE3 or apoE4 in a mouse apoE (-/-) background. Nondenaturing size exclusion chromatography demonstrates that WT, apoE3, and apoE4 astrocytes secrete particles the size of plasma high density lipoprotein (HDL) composed of phospholipid, free cholesterol, and protein, primarily apoE and apoJ. However, the lipid:apoE ratio of particles containing human apoE is significantly lower than WT. ApoE localizes across HDL-like particle sizes. ApoJ localizes to the smallest HDL-like particles. ApoE (-/-) astrocytes secrete little phospholipid or free cholesterol despite comparable apoJ expression, suggesting that apoE is required for normal secretion of astrocyte lipoproteins. Further, particles were not detected in apoE (-/-) samples by electron microscopy. Nondenaturing immunoprecipitation experiments indicate that apoE and apoJ reside predominantly on distinct particles. These studies suggest that apoE expression influences the unique structure of astrocyte lipoproteins, a process further modified by apoE species.	Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Ctr Study Nervous Syst Injury, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pharmacol, St Louis, MO 63110 USA; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of Chicago	Fagan, AM (corresponding author), Washington Univ, Sch Med, Dept Neurol, Box 8111,660 S Euclid Ave, St Louis, MO 63110 USA.		Shah, Javeed/J-4906-2017; Shah, Javeed/J-2716-2019	Shah, Javeed/0000-0002-2997-7988; Shah, Javeed/0000-0002-2997-7988; LaDu, Mary Jo/0000-0003-2141-1450	NATIONAL INSTITUTE ON AGING [R01AG013956, R37AG013956, P50AG005681] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG013956, AG00861-01, AG13956, AG05681-16] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARONOW BJ, 1993, P NATL ACAD SCI USA, V90, P725, DOI 10.1073/pnas.90.2.725; Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; Boggs LN, 1996, J NEUROCHEM, V67, P1324; BOYLES JK, 1985, J CLIN INVEST, V76, P1501, DOI 10.1172/JCI112130; CASTANO EM, 1995, BIOCHEM J, V306, P599, DOI 10.1042/bj3060599; CASTRO GR, 1984, J LIPID RES, V25, P58; CHOIMIURA NH, 1992, ACTA NEUROPATHOL, V83, P260, DOI 10.1007/BF00296787; Christie RH, 1996, J NEUROPATH EXP NEUR, V55, P491, DOI 10.1097/00005072-199604000-00012; DESILVA HV, 1990, J BIOL CHEM, V265, P13240; DESILVA HV, 1990, BIOCHEMISTRY-US, V29, P5380, DOI 10.1021/bi00474a025; DONG LM, 1994, J BIOL CHEM, V269, P22358; Dong LM, 1996, J BIOL CHEM, V271, P19053, DOI 10.1074/jbc.271.32.19053; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P203, DOI 10.1073/pnas.82.1.203; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; Fagan AM, 1996, J BIOL CHEM, V271, P30121, DOI 10.1074/jbc.271.47.30121; FORTE TM, 1986, METHOD ENZYMOL, V128, P442; Gelissen IC, 1998, BIOCHEM J, V331, P231, DOI 10.1042/bj3310231; GHISO J, 1993, BIOCHEM J, V293, P27, DOI 10.1042/bj2930027; Guyton JR, 1998, J NEUROCHEM, V70, P1235; Hammad SM, 1997, J BIOL CHEM, V272, P18644, DOI 10.1074/jbc.272.30.18644; Hochstrasser A C, 1988, Appl Theor Electrophor, V1, P73; HOLTZMAN DM, 1995, P NATL ACAD SCI USA, V92, P9480, DOI 10.1073/pnas.92.21.9480; Holtzman DM, 1999, J CLIN INVEST, V103, pR15, DOI 10.1172/JCI6179; Innerarity T L, 1986, Methods Enzymol, V129, P542; INNERARITY TL, 1978, BIOCHEMISTRY-US, V17, P1440, DOI 10.1021/bi00601a013; JENNE DE, 1991, J BIOL CHEM, V266, P11030; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; KOUDINOV A, 1994, BIOCHEM BIOPH RES CO, V205, P1164, DOI 10.1006/bbrc.1994.2788; Koudinov AR, 1996, BIOCHEM BIOPH RES CO, V223, P592, DOI 10.1006/bbrc.1996.0940; Kounnas M Z, 1994, In Vivo, V8, P343; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P13070, DOI 10.1074/jbc.270.22.13070; Kouzmin A., 1993, J CONTING CRISIS MAN, V1, P1, DOI DOI 10.1111/JCCM.1993.1.ISSUE-1; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KRUL ES, 1988, J LIPID RES, V29, P1309; LADU MJ, 1994, J BIOL CHEM, V269, P23403; LADU MJ, 1995, J BIOL CHEM, V270, P9039, DOI 10.1074/jbc.270.16.9039; LaDu MJ, 1998, J NEUROCHEM, V70, P2070; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Ma JY, 1996, NEUROBIOL AGING, V17, P773; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; MATSUBARA E, 1995, J BIOL CHEM, V270, P7563, DOI 10.1074/jbc.270.13.7563; MAY PC, 1992, TRENDS NEUROSCI, V15, P391, DOI 10.1016/0166-2236(92)90190-J; MOBLEY WC, 1989, NEURON, V3, P655, DOI 10.1016/0896-6273(89)90276-6; Mouchel Y, 1995, NEUROREPORT, V7, P205; Nakai M, 1996, NEUROSCI LETT, V211, P41, DOI 10.1016/0304-3940(96)12716-6; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; NEWMAN TC, 1985, J BIOL CHEM, V260, P2452; Nishida HI, 1997, BBA-LIPID LIPID MET, V1349, P222, DOI 10.1016/S0005-2760(97)00133-1; Novak S, 1996, J BIOL CHEM, V271, P11732, DOI 10.1074/jbc.271.20.11732; ODA T, 1995, EXP NEUROL, V136, P22, DOI 10.1006/exnr.1995.1080; ODA T, 1994, BIOCHEM BIOPH RES CO, V204, P1131, DOI 10.1006/bbrc.1994.2580; PASINETTI GM, 1993, NEUROSCIENCE, V53, P199; PASINETTI GM, 1994, J COMP NEUROL, V339, P387, DOI 10.1002/cne.903390307; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; PITAS RE, 1987, J BIOL CHEM, V262, P14352; POIRIER J, 1991, MOL BRAIN RES, V11, P97, DOI 10.1016/0169-328X(91)90111-A; Reardon CA, 1998, J LIPID RES, V39, P1372; REBECK GW, 1993, NEURON, V11, P575; ROHEIM PS, 1979, P NATL ACAD SCI USA, V76, P4646, DOI 10.1073/pnas.76.9.4646; SANAN DA, 1994, J CLIN INVEST, V94, P860, DOI 10.1172/JCI117407; SCHREIBER SS, 1993, NEUROSCI LETT, V153, P17, DOI 10.1016/0304-3940(93)90066-T; SLOOP CH, 1987, J LIPID RES, V28, P225; Stone DJ, 1997, EXP NEUROL, V143, P313, DOI 10.1006/exnr.1996.6360; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; Sun YL, 1998, J NEUROSCI, V18, P3261; WEISGRABER KH, 1990, J LIPID RES, V31, P1503; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; Wisniewski T, 1997, NEUROBIOL DIS, V4, P313, DOI 10.1006/nbdi.1997.0147; ZLOKOVIC BV, 1994, BIOCHEM BIOPH RES CO, V205, P1431, DOI 10.1006/bbrc.1994.2825; Zlokovic BV, 1996, P NATL ACAD SCI USA, V93, P4229, DOI 10.1073/pnas.93.9.4229; [No title captured]	72	165	169	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30001	30007		10.1074/jbc.274.42.30001	http://dx.doi.org/10.1074/jbc.274.42.30001			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514484	hybrid			2022-12-27	WOS:000083176400063
J	Gorgani, NN; Parish, CR; Altin, JG				Gorgani, NN; Parish, CR; Altin, JG			Differential binding of histidine-rich glycoprotein (HRG) to human IgG subclasses and IgG molecules containing kappa and lambda light chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSOLUBLE IMMUNE-COMPLEXES; RESONANT MIRROR; BIOMOLECULAR INTERACTIONS; IONIC-STRENGTH; PROLINE; COMPLEMENT; PLASMA; ZINC; ANTIBODIES; NEUTRALIZATION	In previous studies we showed that the plasma protein histidine-rich glycoprotein (HRG) binds strongly to pooled human IgG. In the present work myeloma proteins consisting of different human IgG subclasses were examined for their ability to interact with human HRG. Using an IAsys optical biosensor we found initially that IgG subclasses differ substantially in their affinity of interaction with HRG. However, the most striking finding was the observation that the kinetics of the HRG interaction was dramatically affected by whether the IgG subclasses contained the kappa or lambda light (L)-chains. Thus, the on-rate for the binding of HRG to the kappa L-chain containing IgG1 and IgG2 (IgG1 kappa and IgG2 kappa) was similar to 4- and similar to 10-fold faster than that for the binding of HRG to lambda L-chain containing IgG1 and IgG2 (IgG1 lambda and IgG2 lambda), respectively, with the dissociation constants (K-d) in the range 3-5 nM and 112-189 nM for the kappa and lambda isoforms, respectively. In contrast, the on-rate for the binding of HRG to IgG3 kappa and IgG4 kappa was found to be 9- and 20-fold slower than that for the binding of HRG to IgG3 lambda and IgG4 lambda, respectively, with the K-d in the range 147-268 nM and 96-109 nM for the kappa and lambda isoforms, respectively. The binding of HRG to immunoglobulins containing the kappa L-chain (particularly IgG1 kappa) was generally potentiated in the presence of a physiological concentration (20 mu M) of Zn2+ (K-d decreased to 0.60 +/- 0.01 for IgG1 kappa), but Zn2+ had no effect or slightly inhibited the binding of HRG to immobilized IgG subclasses possessing the lambda L-chain. Interestingly, HRG also bound differentially to, pence Jones (BJ) proteins containing kappa and lambda L-chains, with HRG having a 14-fold lower K-d for BJ kappa than for BJ lambda when 20 mu M Zn2+ was present. HRG also bound to IgM (IgM kappa), but the affinity of this interaction (K-d similar to 1.99 +/- 0.05 mu M) was markedly lower than the interaction with IgG, and the affinity was actually decreased 4-fold in the presence of Zn2+. The results demonstrate that both the heavy (H)- and L-chain type have a profound effect on the binding of HRG to different IgG subclasses and provide the first evidence of a functional difference between the kappa and lambda L-chains of immunoglobulins.	Australian Natl Univ, Fac Sci, Sch Life Sci, Div Biochem & Mol Biol, Canberra, ACT 0200, Australia; Australian Natl Univ, Fac Sci, Sch Life Sci, John Curtin Sch Med Res,Div Immunol & Cell Biol, Canberra, ACT 0200, Australia	Australian National University; Australian National University; John Curtin School of Medical Research	Altin, JG (corresponding author), Australian Natl Univ, Fac Sci, Sch Life Sci, Div Biochem & Mol Biol, Canberra, ACT 0200, Australia.		Altin, Joseph G/C-9935-2009; Gorgani, Nick/GXF-5438-2022	Parish, Christopher/0000-0001-7740-0430				ABBAS AK, 1991, CELLULAR MOL IMMUNOL, P45; Abrass Christine K., 1997, P291; AIKEN SP, 1992, J PHYSIOL-LONDON, V445, P69, DOI 10.1113/jphysiol.1992.sp018912; Bellotti V, 1996, BBA-MOL BASIS DIS, V1317, P161, DOI 10.1016/S0925-4439(96)00049-X; Borza DB, 1996, BIOCHEMISTRY-US, V35, P1925, DOI 10.1021/bi952061t; Borza DB, 1998, J BIOL CHEM, V273, P5493, DOI 10.1074/jbc.273.10.5493; BROWN KJ, 1994, BIOCHEMISTRY-US, V33, P13918, DOI 10.1021/bi00250a047; BROWN PB, 1982, ARTHRITIS RHEUM-US, V25, P1101, DOI 10.1002/art.1780250911; BUCKLE PE, 1993, BIOSENS BIOELECTRON, V8, P355, DOI 10.1016/0956-5663(93)80074-Y; BUXANIRICE S, 1994, J NEUROCHEM, V62, P665; Carayannopoulos Leon, 1993, P283; CHANG NS, 1992, BLOOD, V79, P2973; CUSH R, 1993, BIOSENS BIOELECTRON, V8, P347, DOI 10.1016/0956-5663(93)80073-X; Drasin T, 1996, THROMB RES, V84, P179, DOI 10.1016/0049-3848(96)00174-0; GEORGE AJT, 1995, J IMMUNOL METHODS, V183, P51, DOI 10.1016/0022-1759(95)00031-5; Gorgani NN, 1997, BIOCHEMISTRY-US, V36, P6653, DOI 10.1021/bi962573n; Gorgani NN, 1999, INT IMMUNOL, V11, P1275, DOI 10.1093/intimm/11.8.1275; Gorgani NN, 1996, BBA-MOL BASIS DIS, V1317, P45, DOI 10.1016/0925-4439(96)00036-1; GORODETSKY R, 1993, AM J HEMATOL, V42, P278, DOI 10.1002/ajh.2830420307; HEBERT LA, 1991, AM J KIDNEY DIS, V17, P877; HEIMER R, 1982, ARTHRITIS RHEUM, V25, P1298, DOI 10.1002/art.1780251105; Kluszynski BA, 1997, J BIOL CHEM, V272, P13541, DOI 10.1074/jbc.272.21.13541; LAMBWHARTON RJ, 1993, CELL IMMUNOL, V152, P544, DOI 10.1006/cimm.1993.1311; LEUNG LLK, 1986, J CLIN INVEST, V77, P1305, DOI 10.1172/JCI112435; LEUNG LLK, 1984, J CLIN INVEST, V73, P5, DOI 10.1172/JCI111206; LIJNEN HR, 1983, J BIOL CHEM, V258, P3803; MORGAN WT, 1985, BIOCHEMISTRY-US, V24, P1496, DOI 10.1021/bi00327a031; NASU H, 1980, CLIN EXP IMMUNOL, V42, P378; Olsen HM, 1996, IMMUNOLOGY, V88, P198, DOI 10.1111/j.1365-2567.1996.tb00005.x; PARISH CR, 1984, J CELL SCI, V67, P145; PREUDHOMME JL, 1994, KIDNEY INT, V46, P965, DOI 10.1038/ki.1994.355; RANDEN J, 1993, SCAND J IMMUNOL, V37, P638; RYLATT DB, 1981, EUR J BIOCHEM, V119, P641, DOI 10.1111/j.1432-1033.1981.tb05655.x; SAEZ CT, 1995, BIOCHEMISTRY-US, V34, P2496, DOI 10.1021/bi00008a013; SCHIFFERLI JA, 1987, IMMUNOL LETT, V14, P225, DOI 10.1016/0165-2478(87)90105-2; SHATSKY M, 1989, J BIOL CHEM, V264, P8254; SOLOMON A, 1991, NEW ENGL J MED, V324, P1845, DOI 10.1056/NEJM199106273242603; SOLOMONS NW, 1979, AM J CLIN NUTR, V32, P856, DOI 10.1093/ajcn/32.4.856; Walport MJ, 1996, RES IMMUNOL, V147, P103, DOI 10.1016/0923-2494(96)87182-3	39	39	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29633	29640		10.1074/jbc.274.42.29633	http://dx.doi.org/10.1074/jbc.274.42.29633			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514432	hybrid			2022-12-27	WOS:000083176400011
J	Sugars, JM; Cellek, S; Manifava, M; Coadwell, J; Ktistakis, NT				Sugars, JM; Cellek, S; Manifava, M; Coadwell, J; Ktistakis, NT			Fatty acylation of phospholipase D1 on cysteine residues 240 and 241 determines localization on intracellular membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING MOLECULES; D DEFINES; TRANSPORT; ISOFORM	We have reported previously that phospholipase D1 (PLD1) is labeled specifically with [H-3]palmitate following transient expression and immunoprecipitation and that this modification appeared important both for membrane localization and catalytic activity, In this work we identify by mutagenesis that the acylation sites on PLD1 are cysteine residues 240 and 241, with the cysteine at position 241 accounting for most but not all of the modification, Replacement of both cysteine residues with either serines or alanines resulted in a mutant protein that contained undetectable [H-3]palmitate. In comparison with the wild type protein, the double mutant showed reduced catalytic activity in vivo, whereas its activity in vitro was unchanged. In addition, the localization of the double mutant was altered in comparison with the wild type protein, whereas wild type PLD1 is primarily on intracellular membranes and on punctate structures, the double mutant was on plasma membrane. Because cysteines 240 and 241 lie within a putative pleckstrin homology domain of PLD1, it is likely that fatty acylation on these residues modulates the function of the PLD1 pleckstrin homology domain.	Babraham Inst, Dept Signalling, Cambridge CB2 4AT, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Ktistakis, NT (corresponding author), Babraham Inst, Dept Signalling, Cambridge CB2 4AT, England.			Cellek, Selim/0000-0002-4856-285X				Bi K, 1997, CURR BIOL, V7, P301, DOI 10.1016/S0960-9822(06)00153-9; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; Gottlin EB, 1998, P NATL ACAD SCI USA, V95, P9202, DOI 10.1073/pnas.95.16.9202; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Ktistakis NT, 1998, BIOESSAYS, V20, P495; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; Manifava M, 1999, J BIOL CHEM, V274, P1072, DOI 10.1074/jbc.274.2.1072; SCHLESINGER MJ, 1993, LIPID MODIFICATIONS, P2; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; SINGER WD, 1997, ANNU REV BIOCHEM, V66, P457; Steed PM, 1998, FASEB J, V12, P1309, DOI 10.1096/fasebj.12.13.1309; Sung TC, 1999, J BIOL CHEM, V274, P494, DOI 10.1074/jbc.274.1.494; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441	16	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30023	30027		10.1074/jbc.274.42.30023	http://dx.doi.org/10.1074/jbc.274.42.30023			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514487	hybrid			2022-12-27	WOS:000083176400066
J	Altiok, S; Batt, D; Altiok, N; Papautsky, A; Downward, J; Roberts, TM; Avraham, H				Altiok, S; Batt, D; Altiok, N; Papautsky, A; Downward, J; Roberts, TM; Avraham, H			Heregulin induces phosphorylation of BRCA1 through phosphatidylinositol 3-kinase/AKT in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; DNA-DAMAGE; CYCLE; GENE; AKT; EXPRESSION; DIFFERENTIATION; REQUIREMENT; INVOLVEMENT; INHIBITION	The breast cancer susceptibility gene BRCA1 encodes a nuclear phosphoprotein that acts as a tumor suppressor, Phosphorylation of BRCA1 has been implicated in altering its function, however, the pathway(s) that leads to the phosphorylation of BRCA1 has not been described, Here, a signaling pathway by which heregulin induces cell cycle-independent phosphorylation of BRCA1 was delineated. We showed that heregulin stimulation induced the phosphorylation of BRCA1 and concomitant activation of the serine/threonine kinase AKT in T47D human breast cancer cells. Heregulin-induced phosphorylation of BRCA1 was abrogated by phosphatidylinositol 3-kinase (PI3K) inhibitors and by a dominant-negative AKT, In the absence of heregulin, the ectopic expression of the constitutively active p110 subunit of PI3K: was sufficient to induce BRCA1 phosphorylation. Furthermore, the purified glutathione S-transferase/AKT kinase phosphorylated BRCA1 in vitro. We have also shown that the phosphorylation of BRCA1 by ABT occurs on the residue Thr-509, which is located in the nuclear localization signal. These results reveal a novel signaling pathway that links extracellular signals to the phosphorylation of BRCA1 in breast cancer cells.	Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med, Boston, MA 02115 USA; Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Childrens Hosp, Div Neurosci, Boston, MA 02115 USA; Imperial Canc Res Fund, Signal Transduct Lab, London WC2A 3PX, England	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Cancer Research UK	Avraham, H (corresponding author), Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med, 3rd Fl,4 Blackfan Circle, Boston, MA 02115 USA.			ALTIOK, NEDRET/0000-0001-5989-8482; Downward, Julian/0000-0002-2331-4729	NATIONAL CANCER INSTITUTE [R01CA076226] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051456, R01HL055445] Funding Source: NIH RePORTER; NCI NIH HHS [CA76226] Funding Source: Medline; NHLBI NIH HHS [HL55445, HL51456] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Altiok N, 1997, EMBO J, V16, P717, DOI 10.1093/emboj/16.4.717; Altiok S, 1997, GENE DEV, V11, P1987, DOI 10.1101/gad.11.15.1987; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Coffer PJ, 1998, BIOCHEM J, V335, P1; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; EASTON DF, 1995, AM J HUM GENET, V56, P265; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; HYNES NE, 1993, SEMIN CANCER BIOL, V4, P19; Krane IM, 1996, ONCOGENE, V12, P1781; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Lewis GD, 1996, CANCER RES, V56, P1457; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Shao NS, 1996, ONCOGENE, V13, P1; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Tang CK, 1996, CANCER RES, V56, P3350; Thomas JE, 1997, CELL GROWTH DIFFER, V8, P801	29	103	108	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32274	32278		10.1074/jbc.274.45.32274	http://dx.doi.org/10.1074/jbc.274.45.32274			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542266	hybrid			2022-12-27	WOS:000083532100074
J	Kubicka, S; Kuhnel, F; Zender, L; Rudolph, KL; Plumpe, J; Manns, M; Trautwein, C				Kubicka, S; Kuhnel, F; Zender, L; Rudolph, KL; Plumpe, J; Manns, M; Trautwein, C			p53 represses CAAT enhancer-binding protein (C/EBP)-dependent transcription of the albumin gene - A molecular mechanism involved in viral liver infection with implications for hepatocarcinogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR GENE; HEPATOCELLULAR-CARCINOMA; DNA-BINDING; WILD-TYPE; FUNCTION MUTATIONS; ACTIVATION DOMAIN; PRODUCT P53; PROMOTER; MODULATION; NF-IL6	p53 is a transcription factor that is activated by genotoxic stress and mediates cell cycle arrest and apoptosis. Here we demonstrate that infection of mouse liver with recombinant E1/E3-deleted adenovirus leads to p53 activation and simultaneously to the down-regulation of albumin gene expression. In vitro transcription assays indicate that transcriptional mechanisms mediated through the albumin promoter are responsible for reduced albumin mRNA levels during viral infection. Albumin expression is maintained in the liver by a combination of liver-enriched transcription factors such as CAAT enhancer binding protein (C/EBP)alpha and C/EBP beta, We show that p53 wild type and tumor-derived p53 mutations repress C/EBP-mediated transactivation of the albumin promoter. The binding of C/EBP alpha or -beta to its cognate sequence in the albumin promoter is not inhibited by p53 expression, Deletion analysis and domain swapping experiments show that repression of C/EBP beta-mediated transactivation is dependent on the N-terminal domain of p53 and the transactivation domain, leucine zipper domain, and the inhibitory domain II (amino acids 163-191) of C/EBP beta, Our results provide a molecular explanation for the p53-mediated down-regulation of liver-specific gene expression after viral infection. Additionally, as overexpression of p53 mutants is frequently found in undifferentiated hepatocellular carcinomas, the same mechanisms may contribute to the lack of liver-specific gene transcription in these tumors.	Med Hsch Hannover, Dept Gastroenterol & Hepatol, D-30625 Hannover, Germany	Hannover Medical School	Kubicka, S (corresponding author), Med Hsch Hannover, Dept Gastroenterol & Hepatol, Carl Neubergstr 1, D-30625 Hannover, Germany.			Rudolph, Karl Lenhard/0000-0002-4839-2862				Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; AGUILAR F, 1993, P NATL ACAD SCI USA, V90, P8586, DOI 10.1073/pnas.90.18.8586; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; BUCK M, 1994, EMBO J, V13, P851, DOI 10.1002/j.1460-2075.1994.tb06328.x; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Dugimont T, 1998, ONCOGENE, V16, P2395, DOI 10.1038/sj.onc.1201742; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Hayashi H, 1995, HEPATOLOGY, V22, P1702; HSIAO M, 1994, AM J PATHOL, V145, P702; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; Hussain SP, 1998, CANCER RES, V58, P4023; Iotsova V, 1996, ONCOGENE, V13, P2331; KUBICKA S, 1995, J HEPATOL, V23, P412, DOI 10.1016/0168-8278(95)80199-5; Kubicka S, 1997, HEPATOLOGY, V25, P867, DOI 10.1002/hep.510250414; Lee LA, 1996, J CLIN INVEST, V97, P1687, DOI 10.1172/JCI118595; LEVRAT F, 1993, EXP CELL RES, V209, P307, DOI 10.1006/excr.1993.1315; Li J, 1997, P NATL ACAD SCI USA, V94, P10885, DOI 10.1073/pnas.94.20.10885; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MARGULIES L, 1993, J BIOL CHEM, V268, P15096; Mink S, 1996, P NATL ACAD SCI USA, V93, P6635, DOI 10.1073/pnas.93.13.6635; Morris GF, 1996, P NATL ACAD SCI USA, V93, P895, DOI 10.1073/pnas.93.2.895; ODA T, 1992, CANCER RES, V52, P6358; OZTURK M, 1991, LANCET, V338, P1356, DOI 10.1016/0140-6736(91)92236-U; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PIETRANGELO A, 1992, J CLIN INVEST, V89, P1755, DOI 10.1172/JCI115778; POLL V, 1990, CELL, V63, P643; PONCHEL F, 1994, CANCER RES, V54, P2064; RAGIMOV N, 1993, ONCOGENE, V8, P1183; SANG BC, 1994, ONCOGENE, V9, P853; SELIVANOVA G, 1995, ADV CANCER RES, V66, P143, DOI 10.1016/S0065-230X(08)60253-5; SHAULIAN E, 1995, ONCOGENE, V10, P671; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; Soriano HE, 1998, HEPATOLOGY, V27, P392, DOI 10.1002/hep.510270212; SUBLER MA, 1994, ONCOGENE, V9, P1351; SUN Y, 1993, P NATL ACAD SCI USA, V90, P2827, DOI 10.1073/pnas.90.7.2827; TANAKA S, 1993, CANCER RES, V53, P2884; TERAMOTO T, 1994, CANCER RES, V54, P231; Trautwein C, 1996, J BIOL CHEM, V271, P22262, DOI 10.1074/jbc.271.36.22262; TRAUTWEIN C, 1994, J CLIN INVEST, V93, P2554, DOI 10.1172/JCI117266; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; UEBA T, 1994, P NATL ACAD SCI USA, V91, P9009, DOI 10.1073/pnas.91.19.9009; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; UNSAL H, 1994, P NATL ACAD SCI USA, V91, P822, DOI 10.1073/pnas.91.2.822; WANG L, 1995, J BIOL CHEM, V270, P23159, DOI 10.1074/jbc.270.39.23159; Watkins PJ, 1996, CANCER RES, V56, P1063; Webster NJG, 1996, CANCER RES, V56, P2781; WEDEL A, 1995, IMMUNOBIOLOGY, V193, P171, DOI 10.1016/S0171-2985(11)80541-3; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; Yin L, 1998, HEPATOLOGY, V27, P73, DOI 10.1002/hep.510270113	57	49	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32137	32144		10.1074/jbc.274.45.32137	http://dx.doi.org/10.1074/jbc.274.45.32137			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542249	hybrid			2022-12-27	WOS:000083532100057
J	Hasegawa, M; Hidaka, Y; Matsumoto, Y; Sanni, T; Shimonishi, Y				Hasegawa, M; Hidaka, Y; Matsumoto, Y; Sanni, T; Shimonishi, Y			Determination of the binding site on the extracellular domain of guanylyl cyclase C to heat-stable enterotoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXIGENIC ESCHERICHIA-COLI; AMINO-ACID-SEQUENCE; FUNCTIONAL EXPRESSION; RECEPTOR; IDENTIFICATION; INTESTINE; PROTEINS; HORMONE; PEPTIDE; ANALOG	Guanylyl cyclase C, one of the family of membrane-bound guanylyl cyclases, consists of an extracellular domain and an intracellular domain, which are connected by a single transmembrane polypeptide. The extracellular domain binds unique small polypeptides with high specificity, which include the endogenous peptide hormones, guanylin and uroguanylin, as well as an exogenous enterotoxigenic peptide, heat-stable enterotoxin, secreted by pathogenic Escherichia coli. Information on this specific binding is propagated into the intracellular domain, followed by the synthesis of cGMP, a second messenger that regulates a variety of intracellular physiological processes. This study reports the design of a photoaffinity labeled analog of heat-stable enterotoxin (biotinyl-(AC(5))(2)-[Gly(4),Pap(11)]STp(4-17)), which incorporates a Pap residue (p-azidophenylalanine) at position 11 and a biotin moiety at the N terminus, and the use of this analog to determine the ligand-binding region of the extracellular domain of guanylyl cyclase C, The endoproteinase Lys-C digestion of the extracellular domain, which was covalently labeled by this ligand, and mass spectrometric analyses of the digest revealed that the ligand specifically binds to the region (residue 387 to residue 393) of guanylyl cyclase C. This region is localized close to the transmembrane portion of guanylyl cyclase C on the external cellular surface. This result was further confirmed by characterization of site-directed mutants of guanylyl cyclase C in which each amino acid residue was substituted by an Ala residue instead of residues normally located in the region. This experiment provides the first direct demonstration of the ligand-binding site of guanylyl cyclase C and will contribute toward an understanding of the receptor recognition of a ligand and the modeling of the interaction of the receptor and its ligand at the molecular level.	Osaka Univ, Inst Prot Res, Div Prot Organ Chem, Suita, Osaka 5650871, Japan	Osaka University	Shimonishi, Y (corresponding author), Osaka Univ, Inst Prot Res, Div Prot Organ Chem, Yamadaoka 3-2, Suita, Osaka 5650871, Japan.	simonisi@protein.osaka-u.ac.jp		HIDAKA, YUJI/0000-0002-3131-2619				AIMOTO S, 1983, BIOCHEM BIOPH RES CO, V112, P320, DOI 10.1016/0006-291X(83)91833-8; AIMOTO S, 1982, EUR J BIOCHEM, V129, P257, DOI 10.1111/j.1432-1033.1982.tb07047.x; Bayley H, 1977, Methods Enzymol, V46, P69; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CURRIE MG, 1992, P NATL ACAD SCI USA, V89, P947, DOI 10.1073/pnas.89.3.947; DESAUVAGE FJ, 1991, J BIOL CHEM, V266, P17912; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DUPONT HL, 1993, NEW ENGL J MED, V328, P1821, DOI 10.1056/NEJM199306243282507; EBERLE AN, 1985, METHOD ENZYMOL, V109, P129; GARBERS DL, 1992, CELL, V71, P1; HAMRA FK, 1993, P NATL ACAD SCI USA, V90, P10464, DOI 10.1073/pnas.90.22.10464; Hasegawa M, 1997, LETT PEPT SCI, V4, P1; Hasegawa M, 1999, PROTEIN EXPRES PURIF, V15, P271, DOI 10.1006/prep.1998.1019; KUBOTA H, 1989, BIOCHEM BIOPH RES CO, V161, P229, DOI 10.1016/0006-291X(89)91585-4; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; OZAKI H, 1991, J BIOL CHEM, V266, P5934; PANDEY KN, 1986, BIOCHEMISTRY-US, V25, P8467, DOI 10.1021/bi00374a022; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; RUDNER XL, 1995, P NATL ACAD SCI USA, V92, P5169, DOI 10.1073/pnas.92.11.5169; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; SINGH S, 1991, BIOCHEM BIOPH RES CO, V179, P1455, DOI 10.1016/0006-291X(91)91736-V; TAKAO T, 1983, FEBS LETT, V152, P1, DOI 10.1016/0014-5793(83)80469-4; VAANDRAGER AB, 1993, J BIOL CHEM, V268, P2174; VAANDRAGER AB, 1994, J BIOL CHEM, V269, P16409; Wada A, 1996, INFECT IMMUN, V64, P5144, DOI 10.1128/IAI.64.12.5144-5150.1996; WADA A, 1994, MICROBIOL IMMUNOL, V38, P535, DOI 10.1111/j.1348-0421.1994.tb01819.x; Wedel BJ, 1997, FEBS LETT, V410, P29, DOI 10.1016/S0014-5793(97)00358-X; YAMASAKI S, 1990, B CHEM SOC JPN, V63, P2063, DOI 10.1246/bcsj.63.2063	28	24	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31713	31718		10.1074/jbc.274.44.31713	http://dx.doi.org/10.1074/jbc.274.44.31713			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531382	hybrid			2022-12-27	WOS:000083379400086
J	Snyder, CH; Trumpower, BL				Snyder, CH; Trumpower, BL			Ubiquinone at center N is responsible for triphasic reduction of cytochrome b in the cytochrome bc(1) complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEADY-STATE KINETICS; PROTONMOTIVE-Q-CYCLE; IRON-SULFUR PROTEIN; ELECTRON-TRANSFER; C OXIDOREDUCTASE; Q-POOL; MITOCHONDRIAL; YEAST; EQUILIBRIUM; SUCCINATE	We have examined the pre-steady state reduction kinetics of the Saccharomyces cerevisiae cytochrome bc(1) complex by menaquinol in the presence and absence of endogenous ubiquinone to elucidate the mechanism of triphasic cytochrome b reduction. With cytochrome bc(1) complex from wild type yeast, cytochrome b reduction was triphasic, consisting of a rapid partial reduction phase, an apparent partial reoxidation phase, and a slow rereduction phase. Absorbance spectra taken by rapid scanning spectroscopy at 1-ms intervals before, during, and after the apparent reoxidation phase showed that this was caused by a bona fide reoxidation of cytochrome b and not by any negative spectral contribution from cytochrome c(1). With cytochrome bc(1) complex from a yeast mutant that cannot synthesize ubiquinone, cytochrome b reduction by either menaquinol or ubiquinol was rapid and monophasic, Addition of ubiquinone restored triphasic cytochrome b reduction, and the duration of the reoxidation phase increased as the ubiquinone concentration increased. When reduction of the cytochrome bc(1) complex through center P was blocked, cytochrome b reduction through center N was biphasic and was slowed by the addition of exogenous ubiquinone. These results show that ubiquinone residing at center N in the oxidized cytochrome bc(1) complex is responsible for the triphasic reduction of cytochrome b.	Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Trumpower, BL (corresponding author), Dartmouth Med Sch, Dept Biochem, 7200 Vail, Hanover, NH 03755 USA.				NIGMS NIH HHS [GM 20379, GM 18811] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020379, R37GM020379] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHBY MN, 1992, J BIOL CHEM, V267, P4128; BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; CHEN M, 1986, BIOCHIM BIOPHYS ACTA, V851, P457, DOI 10.1016/0005-2728(86)90082-4; DELAROSA FF, 1983, FEBS LETT, V163, P140, DOI 10.1016/0014-5793(83)81181-8; Denke E, 1998, J BIOL CHEM, V273, P9085, DOI 10.1074/jbc.273.15.9085; DEVRIES S, 1983, BIOCHIM BIOPHYS ACTA, V723, P91, DOI 10.1016/0005-2728(83)90013-0; DEVRIES S, 1982, BIOCHIM BIOPHYS ACTA, V681, P41, DOI 10.1016/0005-2728(82)90276-6; KAUTEN R, 1987, J BIOL CHEM, V262, P8658; Kroger A., 1985, COENZYME Q, P285; LINKE P, 1986, EUR J BIOCHEM, V158, P615, DOI 10.1111/j.1432-1033.1986.tb09799.x; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; OHNISHI T, 1980, J BIOL CHEM, V255, P3278; RICH PR, 1983, BIOCHIM BIOPHYS ACTA, V722, P271, DOI 10.1016/0005-2728(83)90073-7; RICH PR, 1984, BIOCHIM BIOPHYS ACTA, V768, P53, DOI 10.1016/0304-4173(84)90007-7; SIEDOW JN, 1978, J BIOL CHEM, V253, P2392; Snyder C, 1998, BBA-BIOENERGETICS, V1365, P125, DOI 10.1016/S0005-2728(98)00052-8; TANG HL, 1986, J BIOL CHEM, V261, P6209; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; TSAI AL, 1983, BIOCHIM BIOPHYS ACTA, V722, P349, DOI 10.1016/0005-2728(83)90083-X; TSOU CL, 1982, BIOCHIM BIOPHYS ACTA, V682, P315, DOI 10.1016/0005-2728(82)90044-5; VANHOEK AN, 1987, BIOCHIM BIOPHYS ACTA, V892, P152, DOI 10.1016/0005-2728(87)90257-X; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; YU CA, 1981, BIOCHIM BIOPHYS ACTA, V639, P99, DOI 10.1016/0304-4173(81)90007-0; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	26	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31209	31216		10.1074/jbc.274.44.31209	http://dx.doi.org/10.1074/jbc.274.44.31209			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531315	hybrid			2022-12-27	WOS:000083379400019
J	Hoying, JB; Yin, MY; Diebold, R; Ormsby, I; Becker, A; Doetschman, T				Hoying, JB; Yin, MY; Diebold, R; Ormsby, I; Becker, A; Doetschman, T			Transforming growth factor beta 1 enhances platelet aggregation through a non-transcriptional effect on the fibrinogen receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; TGF-BETA; LIGAND-BINDING; SHAPE-CHANGE; ACTIVATION; MICE; GENE; FACTOR-BETA-1; BLOOD; PROTEIN	Upon activation, platelets store and release large amounts of the peptide transforming growth factor beta 1 (TGF beta 1). The released TGF beta 1 can then act on nearby vascular cells to mediate subsequent vessel repair. In addition, TGF beta 1 may circulate to bone marrow and regulate megakaryocyte activity. It is not known what effect, if any, TGF beta 1 has on platelets. Adult TGF beta 1-deficient mice exhibit thrombocythemia and a mild bleeding disorder that is shown to result, from faulty platelet aggregation. TGF beta 1-deficient platelets are shown to contain functional receptors, and preincubation with recombinant TGF beta 1 improves aggregation, demonstrating that TGF beta 1 plays an active role in platelet aggregation, TGF beta 1-deficient platelets fail to retain bound fibrinogen in response to aggregation agonists, but they possess normal levels of the alpha(IIb)/beta(3) fibrinogen receptor. Signaling from agonist receptors is normal because the platelets change shape, produce thromboxane A(2), and present P-selectin in response to stimulation, Consequently, activation and maintenance of alpha(IIb)/beta(3) into a fibrinogen-binding conformation is impaired in the absence of TGF beta 1. 4-Phorbol 12-myristate 13-acetate treatment and protein kinase C activity measurements suggest a defect downstream of protein kinase C in its activation cascade. Because platelets lack nuclei, these data demonstrate for the first time a non-transcriptionally mediated TGF beta 1 signaling pathway that enhances the activation and maintenance of integrin function.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Program Excellence Mol Biol, Cincinnati, OH 45267 USA; Cincinnati Childrens Hosp, Div Hematol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center	Doetschman, T (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Program Excellence Mol Biol, 231 Bethesda Ave,ML 524, Cincinnati, OH 45267 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026471] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041496] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41496] Funding Source: Medline; NICHD NIH HHS [HD26471] Funding Source: Medline; NIEHS NIH HHS [ES05652] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; BJORKERUD S, 1991, ARTERIOSCLER THROMB, V11, P892, DOI 10.1161/01.ATV.11.4.892; BOIVIN GP, 1995, AM J PATHOL, V146, P276; CARLINO JA, 1992, EXP HEMATOL, V20, P943; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Diebold RJ, 1995, P NATL ACAD SCI USA, V92, P12215, DOI 10.1073/pnas.92.26.12215; DORN GW, 1991, AM J PHYSIOL, V260, pH327, DOI 10.1152/ajpheart.1991.260.2.H327; FINDER J, 1995, AM J PHYSIOL-LUNG C, V268, pL862, DOI 10.1152/ajplung.1995.268.5.L862; GAMBLE JR, 1988, SCIENCE, V242, P97; GRAINGER DJ, 1995, NAT MED, V1, P932, DOI 10.1038/nm0995-932; HEIMARK RL, 1986, SCIENCE, V233, P1078, DOI 10.1126/science.3461562; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; ISHIBASHI T, 1987, BLOOD, V69, P1737; Johnson EN, 1998, P NATL ACAD SCI USA, V95, P3100, DOI 10.1073/pnas.95.6.3100; KAWABATA M, 1995, J BIOL CHEM, V270, P29628; KOVACSOVICS TJ, 1995, J BIOL CHEM, V270, P11358, DOI 10.1074/jbc.270.19.11358; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Kropf J, 1997, CLIN CHEM, V43, P1965; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; KUTER DJ, 1992, BLOOD, V79, P619; LAWRENCE R, 1994, J BIOL CHEM, V269, P9603; MASSAGUE J, 1985, J BIOL CHEM, V260, P2636; NABEL EG, 1993, P NATL ACAD SCI USA, V90, P10759, DOI 10.1073/pnas.90.22.10759; OYEKAN AO, 1991, HAEMOSTASIS, V21, P360; RINK TJ, 1982, FEBS LETT, V148, P21, DOI 10.1016/0014-5793(82)81234-9; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; Shi Y, 1996, ARTERIOSCL THROM VAS, V16, P1298, DOI 10.1161/01.ATV.16.10.1298; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Tobelem G, 1989, Baillieres Clin Haematol, V2, P719, DOI 10.1016/S0950-3536(89)80040-X; TURITTO VT, 1985, BLOOD, V65, P823; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; VLODAVSKY I, 1982, THROMB RES, V28, P179, DOI 10.1016/0049-3848(82)90260-2; Wang TW, 1996, SCIENCE, V271, P1120, DOI 10.1126/science.271.5252.1120; WARKENTIN TE, 1990, BRIT J HAEMATOL, V76, P387, DOI 10.1111/j.1365-2141.1990.tb06373.x; Webb DJ, 1996, J BIOL CHEM, V271, P24982, DOI 10.1074/jbc.271.40.24982; Wehmeier A, 1997, SEMIN THROMB HEMOST, V23, P391, DOI 10.1055/s-2007-996114; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang J, 1996, J BIOL CHEM, V271, P6265, DOI 10.1074/jbc.271.11.6265	41	35	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					31008	31013		10.1074/jbc.274.43.31008	http://dx.doi.org/10.1074/jbc.274.43.31008			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521498	hybrid			2022-12-27	WOS:000083276700094
J	Suzuki, H; Nishiyama, K; Tokuda, H				Suzuki, H; Nishiyama, K; Tokuda, H			Increases in acidic phospholipid contents specifically restore protein translocation in a cold-sensitive secA or secG null mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON MOTIVE FORCE; ESCHERICHIA-COLI; MEMBRANE-VESICLES; PHOSPHATIDYLGLYCEROPHOSPHATE SYNTHASE; LOW-TEMPERATURE; PREPROTEIN TRANSLOCATION; PRESECRETORY PROTEINS; PLASMA-MEMBRANE; ATP; MACHINERY	Both the secAcsR11 and Delta secG::kan mutations cause cold-sensitive growth, although the growth defect due to the latter mutation occurs in a strain-specific manner. Overexpression of pgsA encoding phosphatidylglycerophosphate synthase suppresses the growth defects of the two mutants. We investigated the mechanism underlying the pgsA-dependent suppression of the two mutations using purified mutant SecA and inverted membrane vesicles (IMVs) prepared from pgsA-overexpressing cells. The acidic phospholipid content increased by about 10% upon pgsA overexpression. This increase resulted in the stimulation of proOmpA translocation only when mutant SecA or SecG-depleted IMVs were used. The translocation-coupled ATPase activity of SecA was significantly defective with the mutant SecA or SecG-depleted IMVs, but it recovered to a near normal level when the acidic phospholipid level was increased. The stimulation of ATPase activity was observed only at low temperature. The steady-state level of membrane-inserted SecA was low with the mutant SEcA or SecG-depleted IMVs, and ii decreased further upon the increase in the acidic phospholipid content. However, the level of SecA insertion markedly increased upon the inhibition of SecA deinsertion by the addition of beta,gamma-imido adenosine 5'-triphosphate (AMP-PNP), especially with IMVs containing increased levels of acidic phospholipids. These results indicate that the increase in the level of acidic phospholipids stimulates the SecA cycle in the two mutants by facilitating both the insertion and deinsertion of SecA.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	University of Tokyo	Tokuda, H (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.							AKITA M, 1990, J BIOL CHEM, V265, P8164; BOST S, 1995, EMBO J, V14, P4412, DOI 10.1002/j.1460-2075.1995.tb00120.x; BREUKINK E, 1992, BIOCHEMISTRY-US, V31, P1119, DOI 10.1021/bi00119a021; CRONAN JE, 1978, ANNU REV BIOCHEM, V47, P163, DOI 10.1146/annurev.bi.47.070178.001115; Danese PN, 1998, ANNU REV GENET, V32, P59, DOI 10.1146/annurev.genet.32.1.59; DENBLAAUWEN T, 1996, BIOCHEMISTRY-US, V35, P11194; DEVRIJE T, 1988, NATURE, V334, P173, DOI 10.1038/334173a0; Driessen AJM, 1998, CURR OPIN MICROBIOL, V1, P216, DOI 10.1016/S1369-5274(98)80014-3; Duong F, 1997, EMBO J, V16, P2756, DOI 10.1093/emboj/16.10.2756; Duong F, 1997, CELL, V91, P567, DOI 10.1016/S0092-8674(00)80444-4; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; GOPALAKRISHNAN AS, 1986, J BIOL CHEM, V261, P1329; HANADA M, 1994, J BIOL CHEM, V269, P23625; Hanada M, 1996, FEBS LETT, V381, P25, DOI 10.1016/0014-5793(96)00066-X; Ito K, 1996, GENES CELLS, V1, P337, DOI 10.1046/j.1365-2443.1996.34034.x; KAWASAKI S, 1993, J BIOL CHEM, V268, P8193; KIMURA E, 1991, J BIOL CHEM, V266, P6600; KONTINEN VP, 1995, FEBS LETT, V364, P157, DOI 10.1016/0014-5793(95)00378-M; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; LILL R, 1990, CELL, V60, P259; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Matsumoto G, 1997, EMBO J, V16, P6384, DOI 10.1093/emboj/16.21.6384; MATSUYAMA S, 1992, BIOCHIM BIOPHYS ACTA, V1122, P77, DOI 10.1016/0167-4838(92)90130-6; MATSUYAMA S, 1990, FEBS LETT, V279, P233; NISHIYAMA K, 1991, BIOCHIM BIOPHYS ACTA, V1065, P89, DOI 10.1016/0005-2736(91)90015-Z; Nishiyama K, 1999, EMBO J, V18, P1049, DOI 10.1093/emboj/18.4.1049; NISHIYAMA K, 1994, EMBO J, V13, P3272, DOI 10.1002/j.1460-2075.1994.tb06628.x; Nishiyama KI, 1996, CELL, V85, P71, DOI 10.1016/S0092-8674(00)81083-1; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; RAETZ CRH, 1978, MICROBIOL REV, V42, P614, DOI 10.1128/MMBR.42.3.614-659.1978; RIETVELD AG, 1995, EMBO J, V14, P5506, DOI 10.1002/j.1460-2075.1995.tb00237.x; RIGGS PD, 1988, GENETICS, V118, P571; SCHATZ PJ, 1991, EMBO J, V10, P1749, DOI 10.1002/j.1460-2075.1991.tb07699.x; Shimizu H, 1997, MOL MICROBIOL, V26, P1013, DOI 10.1046/j.1365-2958.1997.6392003.x; SHINKAI A, 1991, J BIOL CHEM, V266, P5827; Suzuki H, 1998, MOL MICROBIOL, V29, P331, DOI 10.1046/j.1365-2958.1998.00937.x; TANI K, 1989, J BIOL CHEM, V264, P18582; TANI K, 1990, J BIOL CHEM, V265, P17341; ULBRANDT ND, 1992, J BIOL CHEM, V267, P15184; USUI M, 1994, J BACTERIOL, V176, P3389, DOI 10.1128/jb.176.11.3389-3392.1994; van der Does C, 1998, BIOCHEMISTRY-US, V37, P201, DOI 10.1021/bi972105t; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; YAMADA H, 1989, J BIOL CHEM, V264, P1723; YAMANE K, 1987, J BIOL CHEM, V262, P2358	46	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					31020	31024		10.1074/jbc.274.43.31020	http://dx.doi.org/10.1074/jbc.274.43.31020			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521500	hybrid			2022-12-27	WOS:000083276700096
J	Walker, CS; Steel, D; Jacobsen, RB; Lirazan, MB; Cruz, LJ; Hooper, D; Shetty, R; DelaCruz, RC; Nielsen, JS; Zhou, LM; Bandyopadhyay, P; Craig, AG; Olivera, BM				Walker, CS; Steel, D; Jacobsen, RB; Lirazan, MB; Cruz, LJ; Hooper, D; Shetty, R; DelaCruz, RC; Nielsen, JS; Zhou, LM; Bandyopadhyay, P; Craig, AG; Olivera, BM			The T-superfamily of conotoxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTORS; K-DEPENDENT CARBOXYLASE; CONUS SNAIL; CHANNEL; PRECURSOR; PEPTIDES; TARGETS	We report the discovery and initial characterization of the T-superfamily of conotoxins. Eight different T-superfamily peptides from five Conus species were identified; they share a consensus signal sequence, and a conserved arrangement of cysteine residues (- -CC--CC-), T-superfamily peptides were found expressed in venom ducts of all major feeding types of Conus; the results suggest that the T-superfamily will be a large and diverse group of peptides, widely distributed in the 500 different Conus species. These peptides are likely to be functionally diverse; although the peptides are small (11-17 amino acids), their sequences are strikingly divergent, with different peptides of the superfamily exhibiting varying extents of post-translational modification. Of the three peptides tested for in vivo biological activity, only one was active on mice but all three had effects on fish. The peptides that have been extensively characterized are as follows: p5a, GCCP-KQMRCCTL*; tx5a, gamma CC gamma DGW(+)CCT AAO; and au5a, FC-CPFIRYCCW (where gamma = gamma-carboxyglutamate, W+ = bromotryptophan, O = hydroxyproline, T = glycosylated threonine, and * = COOH-terminal amidation). We also demonstrate that the precursor of tx5a contains a functional gamma-carboxylation recognition signal in the -1 to -20 propeptide region, consistent with the presence of gamma-carboxyglutamate residues in this peptide.	Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Univ Philippines, Dept Phys Sci & Math, Manila 1000, Philippines; Univ Philippines, Inst Marine Sci, Quezon 1101, Philippines; Cognetix Inc, Salt Lake City, UT 84108 USA; Salk Inst, Clayton Fdn Labs Peptide Biol, San Diego, CA 92186 USA	Utah System of Higher Education; University of Utah; University of the Philippines System; University of the Philippines Manila; University of the Philippines System; University of the Philippines Diliman; Salk Institute	Olivera, BM (corresponding author), Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA.			Hooper, David/0000-0001-8732-4291	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM048677] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 48677] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; [Anonymous], 1995, MANUAL LIVING CONIDA; Bandyopadhyay PK, 1998, J BIOL CHEM, V273, P5447, DOI 10.1074/jbc.273.10.5447; Cartier G. E., 1996, Society for Neuroscience Abstracts, V22, P268; Cartier GE, 1996, J BIOL CHEM, V271, P7522, DOI 10.1074/jbc.271.13.7522; COLLEDGE CJ, 1992, TOXICON, V30, P1111, DOI 10.1016/0041-0101(92)90056-B; COTTER RJ, 1989, BIOMED ENVIRON MASS, V18, P513, DOI 10.1002/bms.1200180803; Craig AG, 1999, J BIOL CHEM, V274, P13752, DOI 10.1074/jbc.274.20.13752; DORFMAN DM, 1989, BIOTECHNIQUES, V7, P568; *GEN COMP GROUP, 1997, AN WISC PACK VERS 9; HILLENKAMP F, 1991, ANAL CHEM, V63, pA1193; HOPKINS C, 1995, J BIOL CHEM, V270, P22361, DOI 10.1074/jbc.270.38.22361; Jacobsen R, 1997, J BIOL CHEM, V272, P22531, DOI 10.1074/jbc.272.36.22531; Jimenez EC, 1997, BIOCHEMISTRY-US, V36, P989, DOI 10.1021/bi962840p; KOHN AJ, 1960, ANN NY ACAD SCI, V90, P706, DOI 10.1111/j.1749-6632.1960.tb26416.x; McIntosh JM, 1999, ANNU REV BIOCHEM, V68, P59, DOI 10.1146/annurev.biochem.68.1.59; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MONJE VD, 1993, NEUROPHARMACOLOGY, V32, P1141, DOI 10.1016/0028-3908(93)90008-Q; Olivera BM, 1999, ANN NY ACAD SCI, V870, P223, DOI 10.1111/j.1749-6632.1999.tb08883.x; OLIVERA BM, 1985, SCIENCE, V230, P1338, DOI 10.1126/science.4071055; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; Olivera BM, 1997, MOL BIOL CELL, V8, P2101, DOI 10.1091/mbc.8.11.2101; Sambrook J., 2002, MOL CLONING LAB MANU; Shon KJ, 1998, J BIOL CHEM, V273, P33, DOI 10.1074/jbc.273.1.33; Stanley TB, 1997, FEBS LETT, V407, P85, DOI 10.1016/S0014-5793(97)00299-8	25	118	136	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30664	30671		10.1074/jbc.274.43.30664	http://dx.doi.org/10.1074/jbc.274.43.30664			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521453	hybrid			2022-12-27	WOS:000083276700049
J	Wong, UW; Tang, YZ; Feyfant, E; Sali, A; Li, LX; Li, Y; Huang, CF; Friend, DS; Krilis, SA; Stevens, RL				Wong, UW; Tang, YZ; Feyfant, E; Sali, A; Li, LX; Li, Y; Huang, CF; Friend, DS; Krilis, SA; Stevens, RL			Identification of a new member of the tryptase family of mouse and human mast cell proteases which possesses a novel COOH-terminal hydrophobic extension	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY GRANULE PROTEASES; SERINE PROTEASES; GEL-ELECTROPHORESIS; HEMATOPOIETIC-CELLS; COMPLEMENTARY-DNA; MESSENGER-RNA; EXPRESSION; CLONING; SEQUENCE; PURIFICATION	Mapping of the tryptase locus on chromosome 17 revealed a novel gene 2.3 kilobase 3' of the mouse mast cell protease (mMCP) 6 gene. This 3.7-kilobase gene encodes the first example of a protease in the tryptase family that contains a membrane-spanning segment located at its COOH terminus. Comparative structural studies indicated that the putative transmembrane tryptase (TMT) possesses a unique substrate-binding cleft. As assessed by RNA blot analyses, mTMT is expressed in mice in both strain- and tissue-dependent manners. Thus, different transcriptional and/or post-transcriptional mechanisms are used to control the expression of mTMT in vivo. Analysis of the corresponding tryptase locus in the human genome resulted in the isolation and characterization of the hTMT gene. The hTMT transcript is expressed in numerous tissues and is also translated. Analysis of the tryptase family of genes in mice and humans now indicates that a primordial serine protease gene duplicated early and often during the evolution of mammals to generate a panel of homologous tryptases in each species that differ in their tissue expression, substrate specificities, and physical properties.	Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Rockefeller Univ, New York, NY 10021 USA; St George Hosp, Dept Immunol Allergy & Infect Dis, Kogarah, NSW 2217, Australia; Univ New S Wales, Kogarah, NSW 2217, Australia	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Rockefeller University; St George Hospital; University of New South Wales Sydney	Stevens, RL (corresponding author), Brigham & Womens Hosp, Dept Med, Smith Bldg,Rm 616B,1 Jimmy Fund Way, Boston, MA 02115 USA.			Wong, G. William/0000-0002-5286-6506; Li, Yong/0000-0002-8910-9787	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023483] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054762, R01GM054762] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-36110] Funding Source: Medline; NIAID NIH HHS [AI-23483] Funding Source: Medline; NIGMS NIH HHS [GM-54762] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; BENYON RC, 1993, J IMMUNOL, V151, P2699; BRAGANZA VJ, 1991, BIOCHEMISTRY-US, V30, P4997, DOI 10.1021/bi00234a023; BROWN BD, 1993, GENE DEV, V7, P1620, DOI 10.1101/gad.7.8.1620; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROMLISH JA, 1987, J BIOL CHEM, V262, P1363; CROSBY JL, 1990, GENOMICS, V6, P252, DOI 10.1016/0888-7543(90)90564-B; EKLUND KK, 1993, J IMMUNOL, V151, P4266; Friend DS, 1998, J IMMUNOL, V160, P5537; GHILDYAL N, 1994, J IMMUNOL, V153, P2624; Ghildyal N, 1996, J EXP MED, V184, P1061, DOI 10.1084/jem.184.3.1061; GURISH MF, 1994, MAMM GENOME, V5, P656, DOI 10.1007/BF00411467; GURISH MF, 1993, J BIOL CHEM, V268, P11372; GURISH MF, 1995, IMMUNITY, V3, P175, DOI 10.1016/1074-7613(95)90087-X; HUANG C, 1998, J IMMUNOL, V160, P5537; Huang CF, 1997, J BIOL CHEM, V272, P31885, DOI 10.1074/jbc.272.50.31885; Huang CF, 1998, J CLIN IMMUNOL, V18, P169, DOI 10.1023/A:1020574820797; Hunt JE, 1996, J BIOL CHEM, V271, P2851, DOI 10.1074/jbc.271.5.2851; Hunt JE, 1997, J BIOL CHEM, V272, P29158, DOI 10.1074/jbc.272.46.29158; IDE H, 1995, J BIOCHEM-TOKYO, V118, P210, DOI 10.1093/oxfordjournals.jbchem.a124880; JOHNSON DA, 1992, PROTEIN SCI, V1, P370; Lutzelschwab C, 1997, J EXP MED, V185, P13, DOI 10.1084/jem.185.1.13; MATSUMOTO R, 1995, J BIOL CHEM, V270, P19524, DOI 10.1074/jbc.270.33.19524; MCNEIL HP, 1992, P NATL ACAD SCI USA, V89, P11174, DOI 10.1073/pnas.89.23.11174; MILLER JS, 1990, J CLIN INVEST, V86, P864, DOI 10.1172/JCI114786; MILLER JS, 1989, J CLIN INVEST, V84, P1188, DOI 10.1172/JCI114284; MORRI E, 1996, BLOOD, V88, P2488; MURAKUMO Y, 1995, BIOCHEM J, V309, P921, DOI 10.1042/bj3090921; Pallaoro M, 1999, J BIOL CHEM, V274, P3355, DOI 10.1074/jbc.274.6.3355; Pereira PJB, 1998, NATURE, V392, P306, DOI 10.1038/32703; PERSONA JJ, 1995, PROTEIN SCI, V4, P337; RAYMOND WW, 1995, J BIOL CHEM, V270, P13164, DOI 10.1074/jbc.270.22.13164; RAZIN E, 1984, J IMMUNOL, V132, P1479; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; REYNOLDS DS, 1990, P NATL ACAD SCI USA, V87, P3230, DOI 10.1073/pnas.87.8.3230; Rowen L, 1996, SCIENCE, V272, P1755, DOI 10.1126/science.272.5269.1755; SALI A, 1993, J BIOL CHEM, V268, P9023; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ LB, 1981, J BIOL CHEM, V256, P1939; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SMITH TJ, 1984, J BIOL CHEM, V259, P1046; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEVENS RL, 1994, P NATL ACAD SCI USA, V91, P128, DOI 10.1073/pnas.91.1.128; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VANDERSLICE P, 1989, BIOCHEMISTRY-US, V28, P4148, DOI 10.1021/bi00436a004; VANDERSLICE P, 1990, P NATL ACAD SCI USA, V87, P3811, DOI 10.1073/pnas.87.10.3811; Xia ZN, 1996, J BIOL CHEM, V271, P8747, DOI 10.1074/jbc.271.15.8747	47	80	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30784	30793		10.1074/jbc.274.43.30784	http://dx.doi.org/10.1074/jbc.274.43.30784			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521469	hybrid			2022-12-27	WOS:000083276700065
J	Ansari, K; Martin, S; Farkasovsky, M; Ehbrecht, IM; Kuntzel, H				Ansari, K; Martin, S; Farkasovsky, M; Ehbrecht, IM; Kuntzel, H			Phospholipase C binds to the receptor-like GPR1 protein and controls pseudohyphal differentiation in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHEROMONE RESPONSE PATHWAY; FILAMENTOUS GROWTH; COUPLED RECEPTOR; SHUTTLE VECTORS; YEAST; GENE; KINASE; RAS; ISOZYMES; ELEMENTS	The hormone receptor-like protein Gpr1p physically interacts with phosphatidylinositol-specific phospholipase C (Plc1p) and with the G alpha protein Gpa2p, as shown by two-hybrid assays and co-immune precipitation of epitope-tagged proteins. Plc1p binds to Gpr1p in either the presence or absence of Gpa2, whereas the Gpr1p/Gpa2p association depends on the presence of Plc1p. Genetic interactions between the null mutations plc1D, gpr1D, gpa2 Delta, and ras2 Delta suggest that Plc1p acts together with Gpr1p and Gpa2p in a growth control pathway operating in parallel to the Ras2p function, Diploid cells lacking Gpr1p, Plc1p, or Gpa2p fail to form pseudohyphae upon nitrogen depletion, and the filamentation defect of gpr1D and plc1D strains is rescued by activating a mitogen-activated protein kinase pathway via STE11-4 or by activating a cAMP pathway via overexpressed Tpk2p, Plc1p is also required for efficient expression of the FG(TyA)::lacZ reporter gene under nitrogen depletion. In conclusion, we have identified two physically interacting proteins, Gpr1p and Plc1p, as novel components of a nitrogen signaling pathway controlling the developmental switch from yeast-like to pseudohyphal growth. Our data suggest that phospholipase C modulates the interaction of the putative nutrient sensor Gpr1p with the G alpha protein Gpa2p as a downstream effector of filamentation control.	Max Planck Inst Expt Med, D-37075 Gottingen, Germany; Slovak Acad Sci, Inst Mol Biol, Bratislava 84251, Slovakia	Max Planck Society; Slovak Academy of Sciences	Kuntzel, H (corresponding author), Max Planck Inst Expt Med, Hermann Rein Str 3, D-37075 Gottingen, Germany.							Ashcroft FM, 1998, SCIENCE, V282, P1059, DOI 10.1126/science.282.5391.1059; DeMarini DJ, 1997, J CELL BIOL, V139, P75, DOI 10.1083/jcb.139.1.75; FARKASOVSKY M, 1995, J CELL BIOL, V131, P1003, DOI 10.1083/jcb.131.4.1003; Feng JF, 1996, J BIOL CHEM, V271, P16451, DOI 10.1074/jbc.271.28.16451; FLICK JS, 1993, MOL CELL BIOL, V13, P5861, DOI 10.1128/MCB.13.9.5861; Flick JS, 1998, GENETICS, V148, P33; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; KORMANEC J, 1991, MOL GEN GENET, V230, P277, DOI 10.1007/BF00290678; Kubler E, 1997, J BIOL CHEM, V272, P20321, DOI 10.1074/jbc.272.33.20321; LALOUX I, 1994, NUCLEIC ACIDS RES, V22, P999, DOI 10.1093/nar/22.6.999; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; Lorenz MC, 1997, EMBO J, V16, P7008, DOI 10.1093/emboj/16.23.7008; Lorenz MC, 1998, EMBO J, V17, P1236, DOI 10.1093/emboj/17.5.1236; MARTIN S, 1998, THESIS U GOTTINGEN; Mosch HU, 1999, MOL BIOL CELL, V10, P1325, DOI 10.1091/mbc.10.5.1325; Mosch HU, 1996, P NATL ACAD SCI USA, V93, P5352, DOI 10.1073/pnas.93.11.5352; NAKAFUKU M, 1988, P NATL ACAD SCI USA, V85, P1374, DOI 10.1073/pnas.85.5.1374; NOH DY, 1995, BBA-REV CANCER, V1242, P99, DOI 10.1016/0304-419X(95)00006-0; PAYNE WE, 1993, MOL CELL BIOL, V13, P4351, DOI 10.1128/MCB.13.7.4351; POWERS S, 1984, CELL, V36, P607, DOI 10.1016/0092-8674(84)90340-4; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; Robertson LS, 1998, P NATL ACAD SCI USA, V95, P13783, DOI 10.1073/pnas.95.23.13783; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; Rupp S, 1999, EMBO J, V18, P1257, DOI 10.1093/emboj/18.5.1257; SCHOMERUS C, 1992, FEBS LETT, V307, P249, DOI 10.1016/0014-5793(92)80688-D; Sherman F., 1986, METHODS YEAST GENETI, P163; SIKORSKI RS, 1989, GENETICS, V122, P19; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Xue Y, 1998, EMBO J, V17, P1996, DOI 10.1093/emboj/17.7.1996; YOKOO T, 1993, P NATL ACAD SCI USA, V90, P1804, DOI 10.1073/pnas.90.5.1804; Yun CW, 1998, BIOCHEM BIOPH RES CO, V252, P29, DOI 10.1006/bbrc.1998.9600	39	67	67	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30052	30058		10.1074/jbc.274.42.30052	http://dx.doi.org/10.1074/jbc.274.42.30052			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514491	hybrid			2022-12-27	WOS:000083176400070
J	Halim, AB; LeGros, L; Geller, A; Kotb, M				Halim, AB; LeGros, L; Geller, A; Kotb, M			Expression and functional interaction of the catalytic and regulatory subunits of human methionine adenosyltransferase in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLMETHIONINE SYNTHETASE; RAT-LIVER; MOLECULAR MECHANISMS; NUCLEOTIDE-SEQUENCE; HUMAN-ERYTHROCYTES; HUMAN-LYMPHOCYTES; ISOZYMES; CLONING; METHYLTRANSFERASES; FRACTIONATION	Methionine adenosyltransferase (MAT) catalyzes the synthesis of S-adenosylmethionine (AdoMet). The mammalian MAT II isozyme consists of catalytic alpha(2) and regulatory beta subunits, The aim of this study was to investigate the interaction and kinetic behavior of the human MAT II subunit proteins in mammalian cells. COS-1 cells were transiently transfected with pTargeT vector harboring fall-length cDNA that encodes for the MAT II alpha(2) or beta subunits. Expression of the His-tagged recombinant alpha(2) (r alpha(2)) subunit in COS-1 cells markedly increased MAT II activity and resulted in a shift in the K-m, for L-methionine (L-Met) from 15 mu M (endogenous MAT II) to 75 mu M (r alpha(2)), and with the apparent existence of two kinetic forms of MAT in the transfected COS-I cell extracts, By contrast, expression of the recombinant beta (r beta) subunit had no effect on the K-m for L-Met of the endogenous MAT II, while it did cause an increase in both the V-max and the specific activity of endogenous MAT. Go-expression of both r alpha(2) and r beta subunits resulted in a significant increase of MAT specific activity with the appearance of a single kinetic form of MAT (K-m = 20 mu M). The recombinant MAT II alpha(2) and r beta suibunit associated spontaneously either in cell-free system or in COS-1 cells coexpressing both subunits, Analysis of nickel-agarose-purified His-tagged r alpha(2) subunit from COS-1 cell extracts showed that the beta subunit co-purified with the alpha(2) subunit. Furthermore, the alpha(2) and beta subunits co-migrated in native polyacrylamide gels. Together, the data provide evidence for alpha(2) and beta MAT subunit association. In addition, the beta subunit regulated MAT II activity by reducing its K-m for L-Met and by rendering the enzyme more susceptible to feedback inhibition by AdoMet. We believe that the previously described differential expression of MAT II beta subunit may be an important mechanism by which MAT activity can be modulated to provide different levels of AdoMet that may be required at different stages of cell growth and differentiation.	Univ Tennessee, Dept Surg, Memphis, TN 38104 USA; Univ Tennessee, Dept Immunol & Microbiol, Memphis, TN 38104 USA; Univ Tennessee, Dept Biochem, Memphis, TN 38104 USA; Vet Affairs Med Ctr, Memphis, TN 38104 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center	Kotb, M (corresponding author), Univ Tennessee, 956 Court Ave,Suite A-202, Memphis, TN 38163 USA.				NIGMS NIH HHS [GM-54892-08] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054892] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVAREZ L, 1993, BIOCHEM J, V293, P481, DOI 10.1042/bj2930481; CANTONI GL, 1953, J BIOL CHEM, V204, P403; Chiang PK, 1996, FASEB J, V10, P471, DOI 10.1096/fasebj.10.4.8647346; CORRALES F, 1991, HEPATOLOGY, V14, P528, DOI 10.1002/hep.1840140320; CORRALES F, 1990, HEPATOLOGY, V11, P216, DOI 10.1002/hep.1840110210; DELAROSA J, 1991, BIOCHIM BIOPHYS ACTA, V1077, P225, DOI 10.1016/0167-4838(91)90062-5; DELAROSA J, 1992, J BIOL CHEM, V267, P10699; DELAROSA J, 1995, J BIOL CHEM, V270, P21860; FINKELSTEIN JD, 1975, BIOCHEM BIOPH RES CO, V66, P81, DOI 10.1016/S0006-291X(75)80297-X; FUJIOKA M, 1992, INT J BIOCHEM, V24, P1917, DOI 10.1016/0020-711X(92)90287-B; HOFFMAN JL, 1983, METHOD ENZYMOL, V94, P223; HORIKAWA S, 1990, J BIOL CHEM, V265, P13683; HORIKAWA S, 1991, BIOCHEM INT, V25, P81; KOTB M, 1990, BIOCHIM BIOPHYS ACTA, V1040, P137, DOI 10.1016/0167-4838(90)90068-Q; KOTB M, 1993, PHARMACOL THERAPEUT, V59, P125, DOI 10.1016/0163-7258(93)90042-C; Kotb M, 1997, TRENDS GENET, V13, P51; Koth M, 1985, J BIOL CHEM, V260, P3923; LANGKAMPHENKEN B, 1994, BBA-GEN SUBJECTS, V1201, P397, DOI 10.1016/0304-4165(94)90068-X; LeGros HL, 1997, J BIOL CHEM, V272, P16040, DOI 10.1074/jbc.272.25.16040; LIAU MC, 1979, CANCER RES, V39, P162; Mato JM, 1997, PHARMACOL THERAPEUT, V73, P265, DOI 10.1016/S0163-7258(96)00197-0; MATO JM, 1994, ADV EXP MED BIOL, V368, P113; Mingorance J, 1997, INT J BIOCHEM CELL B, V29, P485, DOI 10.1016/S1357-2725(96)00151-3; MITSUI KI, 1988, J BIOL CHEM, V263, P11211; MUDD SH, 1995, MOL METABOLIC BASIS; ODEN KL, 1983, BIOCHEMISTRY-US, V22, P2978, DOI 10.1021/bi00281a030; OKADA G, 1981, BIOCHEMISTRY-US, V20, P934, DOI 10.1021/bi00507a045; PAJARES MA, 1992, FEBS LETT, V309, P1, DOI 10.1016/0014-5793(92)80726-W; Roth M, 1998, J BIOL CHEM, V273, P17333, DOI 10.1074/jbc.273.28.17333; SAKATA SF, 1993, J BIOL CHEM, V268, P13978; SULLIVAN DM, 1983, BIOCHEMISTRY-US, V22, P1636, DOI 10.1021/bi00276a017; SUMA Y, 1986, J BIOCHEM, V100, P67, DOI 10.1093/oxfordjournals.jbchem.a121707; UBAGAI T, 1995, J CLIN INVEST, V96, P1943, DOI 10.1172/JCI118240	33	78	81	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29720	29725		10.1074/jbc.274.42.29720	http://dx.doi.org/10.1074/jbc.274.42.29720			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514445	hybrid			2022-12-27	WOS:000083176400024
J	Mulvaney, JM; Zhang, T; Fewtrell, C; Roberson, MS				Mulvaney, JM; Zhang, T; Fewtrell, C; Roberson, MS			Calcium influx through L-type channels is required for selective activation of extracellular signal-regulated kinase by gonadotropin-releasing hormone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-T3-1 CELL-LINE; SMOOTH-MUSCLE CELLS; PROTEIN-KINASE; PITUITARY GONADOTROPHS; GENE-EXPRESSION; TRANSDUCTION PATHWAYS; CA2+ CHANNELS; MAP KINASE; PHOSPHORYLATION; DEPOLARIZATION	The hypothalamic decapeptide gonadotropin-releasing hormone stimulates mobilization of two discrete pools of calcium in clonal (alpha T3-1) and primary pituitary gonadotropes, A multidisciplinary approach was implemented to investigate the effects of discrete calcium fluctuations on the signaling pathways linking the gonadotropin-releasing hormone receptor to activation of mitogen-activated protein kinases and immediate early genes. Blockade of calcium influx through nifedipine-sensitive voltage-gated calcium channels reduced buserelin-induced activation of extracellular signal-regulated kinase (ERK) and c-Fos while activation of c-Jun N-terminal kinase and c-Jun was unaffected, Inhibition of buserelin-stimulated ERK activity by nifedipine was also observed in rat pituitary cells in primary culture. Direct activation of alpha T3-1 cell L-type calcium channels with the agonist Bay-K 8644 resulted in phosphorylation of ERK. and induction of c-Fos. However, simple voltage-induced channel activation did not produce a sufficient calcium signal, since depolarization with 35 mM KCl failed to induce activation of ERR, Depletion of intracellular calcium stores with thapsigargin did not affect buserelin-induced ERR activation. An inhibitor of protein kinase C decreased calcium influx through nifedipine-sensitive calcium channels and phosphorylation of ERK induced by buserelin. pharmacological inhibition of protein kinase C did not block Bay-K 8644-induced ERK activation. These observations suggest that calcium influx through L-type channels is required for GnRH-induced activation of ERK and c-Fos and that the influence of calcium lies downstream of protein kinase C.	Cornell Univ, Dept Biomed Sci, Coll Vet Med, Ithaca, NY 14853 USA; Cornell Univ, Dept Mol Med, Coll Vet Med, Ithaca, NY 14853 USA	Cornell University; Cornell University	Roberson, MS (corresponding author), Cornell Univ, Dept Biomed Sci, Coll Vet Med, T6-008A Vet Res Tower, Ithaca, NY 14853 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD034722] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD034722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [F32MH011105] Funding Source: NIH RePORTER; NICHD NIH HHS [HD34722] Funding Source: Medline; NIMH NIH HHS [MH11105] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Aquilla E, 1996, J BIOL CHEM, V271, P31572, DOI 10.1074/jbc.271.49.31572; Berridge M, 1999, CURR BIOL, V9, pR157, DOI 10.1016/S0960-9822(99)80101-8; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; CESNJAJ M, 1994, ENDOCRINOLOGY, V135, P692, DOI 10.1210/en.135.2.692; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; Egea J, 1999, J BIOL CHEM, V274, P75, DOI 10.1074/jbc.274.1.75; Eguchi S, 1996, J BIOL CHEM, V271, P14169, DOI 10.1074/jbc.271.24.14169; Evans JJ, 1997, ENDOCRINOLOGY, V138, P2049, DOI 10.1210/en.138.5.2049; Finkbeiner S, 1997, BIOESSAYS, V19, P657, DOI 10.1002/bies.950190803; Groschner K, 1996, BIOCHEM J, V318, P513, DOI 10.1042/bj3180513; HADLEY RW, 1992, AM J PHYSIOL, V262, pH472, DOI 10.1152/ajpheart.1992.262.2.H472; HAMERNIK DL, 1988, ENDOCRINOLOGY, V122, P959, DOI 10.1210/endo-122-3-959; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; HILLE B, 1995, RECENT PROG HORM RES, V50, P75; HOLSTOCK JG, 1996, MOL ENDOCRINOL, V10, P1308; HOSHI T, 1987, J NEUROSCI, V7, P571; IIDA T, 1991, MOL ENDOCRINOL, V5, P949, DOI 10.1210/mend-5-7-949; IZUMI S, 1990, BIOCHEM BIOPH RES CO, V170, P359, DOI 10.1016/0006-291X(90)91282-W; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KRUSE HJ, 1994, J CARDIOVASC PHARM, V24, P328, DOI 10.1097/00005344-199424020-00020; LAIRD AD, 1995, J BIOL CHEM, V270, P26742, DOI 10.1074/jbc.270.45.26742; Levi NL, 1998, MOL ENDOCRINOL, V12, P815, DOI 10.1210/me.12.6.815; MCARDLE CA, 1992, MOL CELL NEUROSCI, V3, P124, DOI 10.1016/1044-7431(92)90016-U; MITCHELL R, 1994, J ENDOCRINOL, V140, pR15, DOI 10.1677/joe.0.140R015; Neher E, 1998, NEURON, V20, P389, DOI 10.1016/S0896-6273(00)80983-6; PREVARSKAYA N, 1994, MOL CELL NEUROSCI, V5, P699, DOI 10.1006/mcne.1994.1084; Reiss N, 1997, ENDOCRINOLOGY, V138, P1673, DOI 10.1210/en.138.4.1673; Roberson MS, 1999, ENDOCRINOLOGY, V140, P1310, DOI 10.1210/en.140.3.1310; ROBERSON MS, 1995, MOL CELL BIOL, V15, P3531; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Saunders BD, 1998, ENDOCRINOLOGY, V139, P1835, DOI 10.1210/en.139.4.1835; Smith RD, 1999, ENDOCRINOLOGY, V140, P1385, DOI 10.1210/en.140.3.1385; Sundaresan S, 1996, ENDOCRINOLOGY, V137, P304, DOI 10.1210/en.137.1.304; TSE A, 1992, SCIENCE, V255, P462, DOI 10.1126/science.1734523; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; Vichi P, 1999, AM J RESP CELL MOL, V20, P99, DOI 10.1165/ajrcmb.20.1.3210; White BR, 1999, MOL ENDOCRINOL, V13, P566, DOI 10.1210/me.13.4.566; Yamaoka K, 1998, PFLUG ARCH EUR J PHY, V435, P329, DOI 10.1007/s004240050519	39	108	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29796	29804		10.1074/jbc.274.42.29796	http://dx.doi.org/10.1074/jbc.274.42.29796			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514457	hybrid			2022-12-27	WOS:000083176400036
J	Skuta, G; Ho, CH; Grinnell, F				Skuta, G; Ho, CH; Grinnell, F			Increased myosin light chain phosphorylation is not required for growth factor stimulation of collagen matrix contraction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CONTRACTION; LYSOPHOSPHATIDIC ACID; WOUND CONTRACTION; CELL-MIGRATION; CYCLIC-AMP; MORPHOLOGICAL-CHANGES; LATTICE CONTRACTION; ACTIN CYTOSKELETON; STRESS-RELAXATION; PROTEIN-KINASE	Previous research suggested the possibility that contraction of floating collagen matrices by human fibroblasts required increased myosin light chain (MLC) phosphorylation. In the current studies, we show that increased MLC phosphorylation was neither necessary for platelet-derived growth factor (PDGF)-dependent matrix contraction nor sufficient for lysophosphatidic acid (LPA)-dependent contraction. In contrast, increased MLC phosphorylation did appear to be coupled to the formation of stress fibers by cells spreading in monolayer culture. Signal transduction pathways required for PDGF- and LPA-dependent matrix contraction involved phosphatidylinositol 3-kinase and the G(i) class of heterotrimeric G proteins, respectively. Our re,suits indicate that PDGF- and LPA-dependent contraction of floating collagen matrices can be uncoupled from an increase in MLC phosphorylation.	Univ Texas, SW Med Sch, Dept Neurosci & Cell Biol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Grinnell, F (corresponding author), Univ Texas, SW Med Sch, Dept Neurosci & Cell Biol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	frederick.grinnell@email.swmed.edu			NIGMS NIH HHS [GM31321] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031321, R37GM031321] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Ahlen K, 1998, CELL ADHES COMMUN, V5, P461, DOI 10.3109/15419069809005604; BELL E, 1979, P NATL ACAD SCI USA, V76, P1274, DOI 10.1073/pnas.76.3.1274; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Desmouliere A, 1996, MOL CELLULAR BIOL WO, P391; Dong JM, 1998, J BIOL CHEM, V273, P22554, DOI 10.1074/jbc.273.35.22554; EHRLICH HP, 1991, J CELL PHYSIOL, V146, P1, DOI 10.1002/jcp.1041460102; EHRLICH HP, 1990, TISSUE CELL, V22, P407, DOI 10.1016/0040-8166(90)90070-P; EHRLICH HP, 1984, J INVEST DERMATOL, V83, P230, DOI 10.1111/1523-1747.ep12263616; Gallagher PJ, 1997, J MUSCLE RES CELL M, V18, P1, DOI 10.1023/A:1018616814417; GOECKELER ZM, 1995, J CELL BIOL, V130, P613, DOI 10.1083/jcb.130.3.613; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Grinnell F, 1999, J BIOL CHEM, V274, P918, DOI 10.1074/jbc.274.2.918; GRINNELL F, 1994, J CELL BIOL, V124, P401, DOI 10.1083/jcb.124.4.401; GROSS J, 1995, P NATL ACAD SCI USA, V92, P5982, DOI 10.1073/pnas.92.13.5982; HALLIDAY NL, 1995, EXP CELL RES, V217, P109, DOI 10.1006/excr.1995.1069; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HE YJ, 1994, J CELL BIOL, V126, P457, DOI 10.1083/jcb.126.2.457; Horowitz A, 1996, PHYSIOL REV, V76, P967, DOI 10.1152/physrev.1996.76.4.967; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KOLODNEY MS, 1995, P NATL ACAD SCI USA, V92, P10252, DOI 10.1073/pnas.92.22.10252; KOLODNEY MS, 1993, J BIOL CHEM, V268, P23850; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; KREISBERG JI, 1986, AM J PHYSIOL, V251, pC505, DOI 10.1152/ajpcell.1986.251.4.C505; Kureishi Y, 1997, J BIOL CHEM, V272, P12257, DOI 10.1074/jbc.272.19.12257; LAMB NJC, 1988, J CELL BIOL, V106, P1955, DOI 10.1083/jcb.106.6.1955; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; Lau KS, 1998, FEBS LETT, V431, P71, DOI 10.1016/S0014-5793(98)00728-5; Laudanna C, 1997, J BIOL CHEM, V272, P24141, DOI 10.1074/jbc.272.39.24141; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lin YC, 1997, MOL BIOL CELL, V8, P59, DOI 10.1091/mbc.8.1.59; Lummen G, 1997, N-S ARCH PHARMACOL, V356, P769, DOI 10.1007/PL00005117; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MOCHITATE K, 1991, EXP CELL RES, V193, P198, DOI 10.1016/0014-4827(91)90556-A; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; NAKANISHI S, 1990, MOL PHARMACOL, V37, P482; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Obermeier A, 1998, EMBO J, V17, P4328, DOI 10.1093/emboj/17.15.4328; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; PERSECHINI A, 1986, J BIOL CHEM, V261, P6293; Pietruck F, 1997, N-S ARCH PHARMACOL, V355, P1; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; TANG DC, 1992, J BIOL CHEM, V267, P11839; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; TOMASEK JJ, 1992, ANAT REC, V232, P359, DOI 10.1002/ar.1092320305; Van Eyk JE, 1998, J BIOL CHEM, V273, P23433, DOI 10.1074/jbc.273.36.23433; VANBOCKXMEER FM, 1984, EXP CELL RES, V155, P413, DOI 10.1016/0014-4827(84)90202-7; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WORD RA, 1991, AM J PHYSIOL, V260, pC861, DOI 10.1152/ajpcell.1991.260.4.C861; Zent R, 1998, EXP CELL RES, V240, P134, DOI 10.1006/excr.1998.4008	51	27	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30163	30168		10.1074/jbc.274.42.30163	http://dx.doi.org/10.1074/jbc.274.42.30163			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514506	hybrid			2022-12-27	WOS:000083176400085
J	Ilouz, N; Branski, L; Parnis, J; Parnas, H; Linial, M				Ilouz, N; Branski, L; Parnis, J; Parnas, H; Linial, M			Depolarization affects the binding properties of muscarinic acetylcholine receptors and their interaction with proteins of the exocytic apparatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRESYNAPTIC CALCIUM CHANNELS; CA2+ CHANNELS; NEUROTRANSMITTER RELEASE; N-TYPE; SNARE PROTEINS; FUNCTIONAL IMPLICATIONS; SYMPATHETIC NEURONS; INTERACTION SITE; HIGH-AFFINITY; RAT-BRAIN	Membrane depolarization is the signal that triggers release of neurotransmitter from nerve terminals. As a result of depolarization, voltage-dependent Ca2+ channels open, level of intracellular Ca2+ increases. and release of neurotransmitter commences. Previous study had shown that in rat brain synaptosomes, muscarinic acetylcholine (ACh) receptors (mAChRs) interact with soluble NSF attachment protein receptor proteins of the exocytic machinery in a voltage-dependent manner. It was suggested that this interaction might control the rapid, synchronous release of acetylcholine, The present study investigates the mechanism for such a voltage-dependent interaction. Here we show that depolarization shifts mAChRs, specifically the m2 receptor subtype, to a low affinity state toward its agonists, At resting potential, mAChRs are in a high affinity state (K-d of similar to 20 nM) and they shift to a low affinity state (K-d of tens of mu M) upon membrane depolarization. In addition, interaction between m2 receptor subtype and the exocytic machinery increases with receptor occupancy. Both phenomena are independent of Ca2+ influx. We propose that these results may explain control of ACh release from nerve terminals. At resting potential the exocytic machinery is clamped due to its interaction with the occupied mAChR and depolarization relieves this interaction. This, together with Ca2+ influx, enables release of ACh to commence.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel; Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Otto Loewi Ctr Mol & Cellular Neurobiol, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem	Linial, M (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel.	michall@leonardo.ls.huji.ac.il	Linial, Michal/B-9143-2011; Parnis, Julia/D-1751-2013	Linial, Michal/0000-0002-9357-4526				ANWYL R, 1991, BRAIN RES REV, V16, P265, DOI 10.1016/0165-0173(91)90010-6; BENNETT MK, 1995, CURR OPIN CELL BIOL, V7, P581, DOI 10.1016/0955-0674(95)80016-6; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; BIRDSALL NJM, 1978, MOL PHARMACOL, V14, P723; BOEHM S, 1995, NEUROSCIENCE, V69, P221, DOI 10.1016/0306-4522(95)00235-B; BRANN MR, 1993, PROG BRAIN RES, V98, P121; BURGERMEISTER W, 1978, MOL PHARMACOL, V14, P751; CANDURA SM, 1992, NEUROCHEM RES, V17, P1133, DOI 10.1007/BF00967291; CAULFIELD MP, 1993, PHARMACOL THERAPEUT, V58, P319, DOI 10.1016/0163-7258(93)90027-B; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; COHEN-ARMON M, 1988, BIOCHEMISTRY-US, V27, P368, DOI 10.1021/bi00401a055; COHEN-ARMON M, 1991, J BIOL CHEM, V266, P2595; ELMSLIE KS, 1990, NEURON, V5, P75, DOI 10.1016/0896-6273(90)90035-E; Fujita Y, 1996, J BIOL CHEM, V271, P7265, DOI 10.1074/jbc.271.13.7265; Green MA, 1997, BIOCHEMISTRY-US, V36, P7380, DOI 10.1021/bi961940s; GURWITZ D, 1985, MOL PHARMACOL, V28, P297; Hanson PI, 1997, CURR OPIN NEUROBIOL, V7, P310, DOI 10.1016/S0959-4388(97)80057-8; Hay JC, 1997, CURR OPIN CELL BIOL, V9, P505, DOI 10.1016/S0955-0674(97)80026-9; Hirling H, 1996, P NATL ACAD SCI USA, V93, P11945, DOI 10.1073/pnas.93.21.11945; HIRNING LD, 1990, BRAIN RES, V532, P120, DOI 10.1016/0006-8993(90)91751-2; Kim K, 1997, P NATL ACAD SCI USA, V94, P14782, DOI 10.1073/pnas.94.26.14782; LEVEY AI, 1991, J NEUROSCI, V11, P3218; LEVEY AI, 1993, LIFE SCI, V52, P441, DOI 10.1016/0024-3205(93)90300-R; LI C, 1995, J BIOL CHEM, V270, P24898, DOI 10.1074/jbc.270.42.24898; Linial M, 1997, J NEUROCHEM, V69, P1781; Linial M, 1997, J PHYSIOL-LONDON, V504, P251, DOI 10.1111/j.1469-7793.1997.251be.x; Linial M, 1996, BBA-REV BIOMEMBRANES, V1286, P117, DOI 10.1016/0304-4157(96)00007-X; LIPSCOMBE D, 1989, NATURE, V340, P639, DOI 10.1038/340639a0; LUETJE CW, 1988, J NEUROCHEM, V50, P1775, DOI 10.1111/j.1471-4159.1988.tb02478.x; MARTY A, 1989, J PHYSIOL-LONDON, V419, P665, DOI 10.1113/jphysiol.1989.sp017892; MAUBECIN VA, 1995, J NEUROCHEM, V64, P2544; Meffert MK, 1996, NEURON, V16, P1229, DOI 10.1016/S0896-6273(00)80149-X; Mochida S, 1997, NEUROSCIENCE, V77, P937; Mochida S, 1998, P NATL ACAD SCI USA, V95, P14523, DOI 10.1073/pnas.95.24.14523; Nathanson NM, 1996, PROG BRAIN RES, V109, P165; PEARCE LB, 1991, J NEUROCHEM, V57, P636, DOI 10.1111/j.1471-4159.1991.tb03795.x; RAMACHANDRAN J, 1989, BIOESSAYS, V10, P54, DOI 10.1002/bies.950100205; Rhim H, 1996, BRIT J PHARMACOL, V118, P1341, DOI 10.1111/j.1476-5381.1996.tb15543.x; Rouse ST, 1997, LIFE SCI, V60, P1031, DOI 10.1016/S0024-3205(97)00044-1; SCHELLER RH, 1995, NEURON, V14, P893; Schiavo G, 1996, P NATL ACAD SCI USA, V93, P13327, DOI 10.1073/pnas.93.23.13327; SCHWEITZ H, 1994, P NATL ACAD SCI USA, V91, P878, DOI 10.1073/pnas.91.3.878; Seagar M, 1998, J BIOENERG BIOMEMBR, V30, P347, DOI 10.1023/A:1021937605818; Sheng ZH, 1998, J BIOENERG BIOMEMBR, V30, P335, DOI 10.1023/A:1021985521748; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Stanley EF, 1997, NATURE, V385, P340, DOI 10.1038/385340a0; Stefani A, 1996, MOL NEUROBIOL, V13, P81, DOI 10.1007/BF02740753; YAWO H, 1993, NATURE, V365, P256, DOI 10.1038/365256a0; Yokoyama CT, 1997, J NEUROSCI, V17, P6929; Zamponi GW, 1998, CURR OPIN NEUROBIOL, V8, P351, DOI 10.1016/S0959-4388(98)80060-3	50	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29519	29528		10.1074/jbc.274.41.29519	http://dx.doi.org/10.1074/jbc.274.41.29519			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506217	hybrid			2022-12-27	WOS:000083017800096
J	Szczesna, D; Zhang, R; Zhao, JJ; Jones, M; Potter, JD				Szczesna, D; Zhang, R; Zhao, JJ; Jones, M; Potter, JD			The role of the NH2- and COOH-terminal domains of the inhibitory region of troponin I in the regulation of skeletal muscle contraction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; BIOLOGICAL-ACTIVITY; THIN FILAMENT; ATPASE ACTIVITY; RABBIT; ACTIN; BINDING; CA2+; SEQUENCE; PEPTIDE	The role of the inhibitory region of troponin (Tn) I in the regulation of skeletal muscle contraction was studied with three deletion mutants of its inhibitory region: I) complete (TnI-(Delta 96-116)), 2) the COOH-terminal domain (TnI-(Delta 105-115)), and 3) the NH2-terminal domain (TnI-(Delta 95-106)). Measurements of Ca2+-regulated force and relaxation were performed in skinned skeletal muscle fibers whose endogenous TnI (along with TnT and TnC) was displaced with high concentrations of added troponin T. Reconstitution of the Tn-displaced fibers with a TnI TnC complex restored the Ca2+ sensitivity of force; however, the levels of relaxation and force development varied. Relaxation of the fibers (pCa 8) was drastically impaired with two of the inhibitory region deletion mutants, TnT-(Delta 96-116).TnC and TnI-(Delta 105-115).TnC. The TnI-(Delta 95-106).TnC mutant retained similar to 55% relaxation when reconstituted in the Tn-displaced fibers. Activation in skinned skeletal muscle fibers was enhanced with all TnI mutants compared with wild-type TnI. Interestingly, all three mutants of TnI increased the Ca2+ sensitivity of contraction. None of the TnI deletion mutants, when reconstituted into Tn, could inhibit actin-tropomyosin-activated myosin ATPase in the absence of Ca2+, and two of them (TnT-(Delta 96-116) and TnI(Delta 105-115)) gave significant activation in the absence of Ca2+. These results suggest that the COOH terminus of the inhibitory region of TnI (residues 105-115) is much more critical for the biological activity of TnI than the NH2-terminal region, consisting of residues 95-106. Presumably, the COOH-terminal domain of the inhibitory region of TnI is a part of the Ca2+-sensitive molecular switch during muscle contraction.	Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA	University of Miami	Jones, M (corresponding author), Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, 1600 NW 10th Ave, Miami, FL 33136 USA.	jdpotter@miami.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045391] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 45391-01] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CACHIA PJ, 1983, BIOCHEMISTRY-US, V22, P4145, DOI 10.1021/bi00286a024; CAMPBELL AP, 1991, J MOL BIOL, V222, P405, DOI 10.1016/0022-2836(91)90219-V; CHANDRA M, 1994, BIOCHEMISTRY-US, V33, P2961, DOI 10.1021/bi00176a028; FARAH CS, 1994, J BIOL CHEM, V269, P5230; Fiske CH, 1925, J BIOL CHEM, V66, P375; Gergely J, 1998, ADV EXP MED BIOL, V453, P169; HATAKENAKA M, 1992, EUR J BIOCHEM, V205, P985, DOI 10.1111/j.1432-1033.1992.tb16865.x; Hernandez G, 1999, BIOCHEMISTRY-US, V38, P6911, DOI 10.1021/bi990150q; HERZBERG O, 1986, J BIOL CHEM, V261, P2638; Hill AV, 1910, J PHYSIOL-LONDON, V40, P190; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lehrer SS, 1998, J MOL BIOL, V277, P1081, DOI 10.1006/jmbi.1998.1654; LESZYK J, 1987, BIOCHEMISTRY-US, V26, P7042, DOI 10.1021/bi00396a028; LESZYK J, 1990, BIOCHEMISTRY-US, V29, P299, DOI 10.1021/bi00453a041; LEVINE BA, 1988, EUR J BIOCHEM, V172, P389, DOI 10.1111/j.1432-1033.1988.tb13899.x; Malnic B, 1998, J BIOL CHEM, V273, P10594, DOI 10.1074/jbc.273.17.10594; McKay RT, 1997, J BIOL CHEM, V272, P28494, DOI 10.1074/jbc.272.45.28494; McKay RT, 1998, BIOCHEMISTRY-US, V37, P12419, DOI 10.1021/bi9809019; Pearlstone JR, 1997, BIOCHEMISTRY-US, V36, P7601, DOI 10.1021/bi970200w; POTTER JD, 1995, J BIOL CHEM, V270, P2557, DOI 10.1074/jbc.270.6.2557; POTTER JD, 1982, METHOD ENZYMOL, V85, P241; Reinach FC, 1997, CELL STRUCT FUNCT, V22, P219, DOI 10.1247/csf.22.219; SHIRAISHI F, 1994, J BIOCHEM-TOKYO, V115, P171, DOI 10.1093/oxfordjournals.jbchem.a124296; STEPKOWSKI D, 1985, BIOCHIM BIOPHYS ACTA, V831, P321, DOI 10.1016/0167-4838(85)90114-1; Stone DB, 1998, J MOL BIOL, V281, P689, DOI 10.1006/jmbi.1998.1965; STRZELECKAGOLASZEWSKA H, 1975, EUR J BIOCHEM, V55, P221, DOI 10.1111/j.1432-1033.1975.tb02154.x; SYSKA H, 1976, BIOCHEM J, V153, P375, DOI 10.1042/bj1530375; SZCZESNA D, 1999, MOL INTERACTIONS ACT, V2; TALBOT JA, 1979, J BIOL CHEM, V254, P3720; TALBOT JA, 1981, J BIOL CHEM, V256, P2798; Tripet B, 1997, J MOL BIOL, V271, P728, DOI 10.1006/jmbi.1997.1200; VANEYK JE, 1991, BIOCHEMISTRY-US, V30, P9974, DOI 10.1021/bi00105a023; VanEyk JE, 1997, J BIOL CHEM, V272, P10529; VANEYK JE, 1988, J BIOL CHEM, V263, P1726; Vassylyev DG, 1998, P NATL ACAD SCI USA, V95, P4847, DOI 10.1073/pnas.95.9.4847	35	15	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29536	29542		10.1074/jbc.274.41.29536	http://dx.doi.org/10.1074/jbc.274.41.29536			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506219	hybrid			2022-12-27	WOS:000083017800098
J	Leissring, MA; Parker, I; LaFerla, FM				Leissring, MA; Parker, I; LaFerla, FM			Presenilin-2 mutations modulate amplitude and kinetics of inositol 1,4,5-trisphosphate-mediated calcium signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; AMYLOID-BETA-PEPTIDE; ENDOPLASMIC-RETICULUM; NEURONAL EXPRESSION; PC12 CELLS; FIBROBLASTS; APOPTOSIS; GENE; BRAIN; LOCALIZATION	Mutations in the two presenilin genes (PS1, PS2) account for the majority of early-onset familial Alzheimer's disease (FAD) cases. Converging evidence from a variety of experimental systems, including fibroblasts from FAD patients and transgenic animals, indicates that PSI mutations modulate intracellular calcium signaling pathways. Despite the potential relevance of these changes to the pathogenesis of FAD, a comparable effect for PS2 has not yet been demonstrated experimentally. We examined the effects of wild-type PS2, and both of the identified FAD mutations in PS2, on intracellular calcium signaling in Xenopus oocytes. Inositol 1,4,5-trisphosphate (IP3)-evoked calcium signals were significantly potentiated in cells expressing either of the PS2 mutations relative to wild-type PS2-expressing cells and controls. Decay rates of calcium signals were also significantly accelerated in mutant PS2-expressing cells in a manner dependent upon IF, concentration, The finding that mutations in both PS1 and PS2 modulate intracellular calcium signaling suggests that these disturbances may represent a common pathogenic mechanism of presenilin-associated FAD.	Univ Calif Irvine, Dept Neurobiol & Behav, Gillespie Neurosci Facil 1109, Lab Mol Neuropathogenesis, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Neurobiol & Behav, Cellular & Mol Neurobiol Lab, Irvine, CA 92697 USA; Univ Calif Irvine, Ctr Neurobiol Learning & Memory, Irvine, CA 92697 USA; Univ Calif Irvine, Inst Brain Aging & Dementia, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	LaFerla, FM (corresponding author), Univ Calif Irvine, Dept Neurobiol & Behav, Gillespie Neurosci Facil 1109, Lab Mol Neuropathogenesis, Irvine, CA 92697 USA.		LEISSRING, MALCOLM/AAW-5361-2021	LEISSRING, MALCOLM/0000-0001-7185-4255	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048071, R37GM048071] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-48071] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Begley JG, 1999, J NEUROCHEM, V72, P1030, DOI 10.1046/j.1471-4159.1999.0721030.x; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; Buxbaum JD, 1998, NAT MED, V4, P1177, DOI 10.1038/2673; Callamaras N, 1998, Methods Enzymol, V291, P380; Cribbs DH, 1996, AM J PATHOL, V148, P1797; Cruts M, 1998, HUM MOL GENET, V7, P43, DOI 10.1093/hmg/7.1.43; Deng GM, 1996, FEBS LETT, V397, P50, DOI 10.1016/S0014-5793(96)01142-8; DISTERHOFT JF, 1994, ANN NY ACAD SCI, V747, P382; Etcheberrigaray R, 1998, NEUROBIOL DIS, V5, P37, DOI 10.1006/nbdi.1998.0176; Gibson GE, 1997, NEUROBIOL AGING, V18, P573, DOI 10.1016/S0197-4580(97)00149-8; Gibson GE, 1996, BBA-MOL BASIS DIS, V1316, P71, DOI 10.1016/0925-4439(96)00002-6; Guo Q, 1999, NAT MED, V5, P101, DOI 10.1038/4789; Guo Q, 1996, NEUROREPORT, V8, P379, DOI 10.1097/00001756-199612200-00074; Guo Q, 1997, J NEUROSCI, V17, P4212; Hong CS, 1999, J NEUROSCI, V19, P637; ITO E, 1994, P NATL ACAD SCI USA, V91, P534, DOI 10.1073/pnas.91.2.534; KHACHATURIAN ZS, 1987, NEUROBIOL AGING, V8, P345, DOI 10.1016/0197-4580(87)90073-X; Kim T.-W., 1998, Society for Neuroscience Abstracts, V24, P757; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; Leissring MA, 1999, J NEUROCHEM, V72, P1061, DOI 10.1046/j.1471-4159.1999.0721061.x; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; MATTSON MP, 1991, MOL CHEM NEUROPATHOL, V15, P117, DOI 10.1007/BF03159951; Mattson MP, 1998, J NEUROCHEM, V70, P1; Meyers MB, 1998, J BIOL CHEM, V273, P18930, DOI 10.1074/jbc.273.30.18930; MEYERS MB, 1995, J BIOL CHEM, V270, P26411, DOI 10.1074/jbc.270.44.26411; QUERFURTH HW, 1994, BIOCHEMISTRY-US, V33, P4550, DOI 10.1021/bi00181a016; Querfurth HW, 1997, J NEUROCHEM, V69, P1580; Renbaum P, 1998, CELL MOL LIFE SCI, V54, P910, DOI 10.1007/s000180050220; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Saura CA, 1999, J BIOL CHEM, V274, P13818, DOI 10.1074/jbc.274.20.13818; Sun XP, 1998, J PHYSIOL-LONDON, V509, P67, DOI 10.1111/j.1469-7793.1998.067bo.x; Tsujimura A, 1997, BIOCHEM BIOPH RES CO, V231, P392, DOI 10.1006/bbrc.1996.6043; Vito P, 1996, J BIOL CHEM, V271, P31025, DOI 10.1074/jbc.271.49.31025; Walter J, 1998, BIOCHEMISTRY-US, V37, P5961, DOI 10.1021/bi971763a; YAO Y, 1993, J PHYSIOL-LONDON, V468, P275, DOI 10.1113/jphysiol.1993.sp019771; Zhang JM, 1998, J BIOL CHEM, V273, P12436, DOI 10.1074/jbc.273.20.12436	37	117	130	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32535	32538		10.1074/jbc.274.46.32535	http://dx.doi.org/10.1074/jbc.274.46.32535			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551803	hybrid			2022-12-27	WOS:000083623000003
J	Yin, HL; Stull, JT				Yin, HL; Stull, JT			Proteins that regulate dynamic actin remodeling in response to membrane signaling minireview series	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review									Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Yin, HL (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA.							Anderson RA, 1999, J BIOL CHEM, V274, P9907, DOI 10.1074/jbc.274.15.9907; Bailly M, 1999, J CELL BIOL, V145, P331, DOI 10.1083/jcb.145.2.331; Eddy RJ, 1997, J CELL BIOL, V139, P1243, DOI 10.1083/jcb.139.5.1243; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Svitkina TM, 1999, J CELL BIOL, V145, P1009, DOI 10.1083/jcb.145.5.1009; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; Toker A, 1998, CURR OPIN CELL BIOL, V10, P254, DOI 10.1016/S0955-0674(98)80148-8	7	30	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32529	32530		10.1074/jbc.274.46.32529	http://dx.doi.org/10.1074/jbc.274.46.32529			2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551801	hybrid			2022-12-27	WOS:000083623000001
J	Chung, HY; Brazil, MI; Soe, TT; Maxfield, FR				Chung, HY; Brazil, MI; Soe, TT; Maxfield, FR			Uptake, degradation, and release of fibrillar and soluble forms of Alzheimer's amyloid beta-peptide by microglial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRECURSOR MESSENGER-RNA; TRANSGENIC MICE; SCAVENGER RECEPTOR; CULTURED-CELLS; SENILE PLAQUES; DOWN-SYNDROME; PROTEIN; DISEASE; SURFACE; DEPOSITION	Microglia are phagocytic cells that are the main inflammatory response cells of the central nervous system, In Alzheimer's disease brain, activated microglia are concentrated in regions of compact amyloid deposits that contain the 39-43-amino acid A beta peptide. We examined the uptake, degradation, and release of small aggregates of fibrillar A beta (fA beta) or soluble A beta (sA beta) by microglia, We found that although some degradation of fA beta was observed over 3 days, no further degradation was observed over the next 9 days, Instead, there was a slow release of intact A beta. The poor degradation was not due to inhibition of lysosomal function, since the rate of alpha 2-macroglobulin degradation was not affected by the presence of fA beta in the late endosomes/lysosomes. In contrast to fA beta, internalization of sA beta was not saturable. After internalization, sA beta was released rapidly from microglia, and very little was degraded. These data show that fA beta and sA beta interact differently with microglia but that after internalization a large fraction of both are released without degradation.	Cornell Univ, Dept Biochem, Weill Med Coll, New York, NY 10021 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA	Cornell University; Columbia University	Maxfield, FR (corresponding author), Cornell Univ, Dept Biochem, Weill Med Coll, 1300 York Ave,Rm E215, New York, NY 10021 USA.		Maxfield, Fred/A-1718-2011; Maxfield, Fred/M-6747-2019	Maxfield, Fred/0000-0003-4396-8866	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034761] Funding Source: NIH RePORTER; NINDS NIH HHS [NS34761] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BANATI RB, 1993, GLIA, V9, P199, DOI 10.1002/glia.440090305; BAUER J, 1991, FEBS LETT, V282, P335, DOI 10.1016/0014-5793(91)80508-Z; BESTERMAN JM, 1981, J CELL BIOL, V91, P716, DOI 10.1083/jcb.91.3.716; BORDEN LA, 1990, J BIOL CHEM, V265, P8497; BURDICK D, 1992, J BIOL CHEM, V267, P546; del Rio Hortega P, 1932, CYTOLOGY CELLULAR PA, P481; DOVEY HF, 1993, NEUROREPORT, V4, P1039, DOI 10.1097/00001756-199308000-00011; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; ElKhoury J, 1996, NATURE, V382, P716; FRACKOWIAK J, 1992, ACTA NEUROPATHOL, V84, P225; Frautschy SA, 1998, AM J PATHOL, V152, P307; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Geuze HJ, 1998, IMMUNOL TODAY, V19, P282, DOI 10.1016/S0167-5699(98)01269-9; GHOSH RN, 1995, J CELL BIOL, V128, P549, DOI 10.1083/jcb.128.4.549; GIULIAN D, 1995, J NEUROSCI, V15, P7712; Giulian D, 1996, J NEUROSCI, V16, P6021; GIULIAN D, 1995, NEUROCHEM INT, V27, P119, DOI 10.1016/0197-0186(95)00067-I; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOEDERT M, 1987, EMBO J, V6, P3627, DOI 10.1002/j.1460-2075.1987.tb02694.x; Goldgaber D, 1990, Adv Neurol, V51, P163; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1991, J NEUROSCI, V11, P3783; HALVERSON K, 1990, BIOCHEMISTRY-US, V29, P2639, DOI 10.1021/bi00463a003; Harper JD, 1997, CHEM BIOL, V4, P951, DOI 10.1016/S1074-5521(97)90303-3; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; ITAGAKI S, 1989, J NEUROIMMUNOL, V24, P173, DOI 10.1016/0165-5728(89)90115-X; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; Iwatsubo T, 1996, AM J PATHOL, V149, P1823; IWATSUBO T, 1995, ANN NEUROL, V37, P294, DOI 10.1002/ana.410370305; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; KNAUER MF, 1992, P NATL ACAD SCI USA, V89, P7437, DOI 10.1073/pnas.89.16.7437; Kusumoto Y, 1998, P NATL ACAD SCI USA, V95, P12277, DOI 10.1073/pnas.95.21.12277; LEBLANC AC, 1991, FEBS LETT, V292, P171, DOI 10.1016/0014-5793(91)80861-V; Lemere CA, 1996, NEUROBIOL DIS, V3, P16, DOI 10.1006/nbdi.1996.0003; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; Lomakin A, 1997, P NATL ACAD SCI USA, V94, P7942, DOI 10.1073/pnas.94.15.7942; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MAYOR S, 1995, MOL BIOL CELL, V6, P929, DOI 10.1091/mbc.6.7.929; Mukherjee S, 1998, BIOPHYS J, V75, P1915, DOI 10.1016/S0006-3495(98)77632-5; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Mukherjee S, 1999, J CELL BIOL, V144, P1271, DOI 10.1083/jcb.144.6.1271; Paresce DM, 1997, J BIOL CHEM, V272, P29390, DOI 10.1074/jbc.272.46.29390; Paresce DM, 1996, NEURON, V17, P553, DOI 10.1016/S0896-6273(00)80187-7; Rodriguez A, 1997, J CELL BIOL, V137, P93, DOI 10.1083/jcb.137.1.93; ROZEMULLER JM, 1992, NEUROSCI LETT, V140, P137, DOI 10.1016/0304-3940(92)90087-N; SALZMAN NH, 1988, J CELL BIOL, V106, P1083, DOI 10.1083/jcb.106.4.1083; SALZMAN NH, 1989, J CELL BIOL, V109, P2067; SAVAGE MJ, 1995, J EXP CLIN INVEST, V2, P234; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; SCOTT SA, 1993, EXP NEUROL, V121, P113, DOI 10.1006/exnr.1993.1076; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TABAS I, 1994, J BIOL CHEM, V269, P22547; TERRY RD, 1994, ALZHEIMER DIS, P9; TYCKO B, 1983, ANN NY ACAD SCI, V421, P424, DOI 10.1111/j.1749-6632.1983.tb18136.x; VIGOPELFREY C, 1993, J NEUROCHEM, V61, P1965, DOI 10.1111/j.1471-4159.1993.tb09841.x; WAITE J, 1992, NEUROBIOL AGING, V13, P595, DOI 10.1016/0197-4580(92)90062-3; WISNIEWSKI HM, 1992, ACTA NEUROPATHOL, V84, P117, DOI 10.1007/BF00311383; YAMASHIRO DJ, 1989, J CELL PHYSIOL, V139, P377, DOI 10.1002/jcp.1041390221; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; Yang AJ, 1998, J NEUROSCI RES, V52, P691, DOI 10.1002/(SICI)1097-4547(19980615)52:6<691::AID-JNR8>3.0.CO;2-3	67	177	194	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32301	32308		10.1074/jbc.274.45.32301	http://dx.doi.org/10.1074/jbc.274.45.32301			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542270	hybrid			2022-12-27	WOS:000083532100078
J	Francki, A; Bradshaw, AD; Bassuk, JA; Howe, CC; Couser, WG; Sage, EH				Francki, A; Bradshaw, AD; Bassuk, JA; Howe, CC; Couser, WG; Sage, EH			SPARC regulates the expression of collagen type I and transforming growth factor-beta 1 in mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; FACTOR-BETA; EXTRACELLULAR-MATRIX; GENE-EXPRESSION; ENDOTHELIAL-CELLS; ANGIOGENESIS INVITRO; DEPENDENT PATHWAY; PROTEIN-SYNTHESIS; RAT; PROLIFERATION	The matricellular protein SPARC is expressed at high levels in cells that participate in tissue remodeling and is thought to regulate mesangial cell proliferation and extracellular matrix production in the kidney glomerulus in a rat model of glomerulonephritis (Pichler, R. H., Bassuk, J. A., Hugo, C., Reed, RI. J., Eng, E., Gordon, K. L., Pippin, J., Alpers, C. E., Couser, W. G., Sage, E. H., and Johnson, R. J. (1997) Am. J. Pathol. 148, 1153-1167). A potential mechanism by which SPARC controls both cell cycle and matrix production has been attributed to its regulation of a pleiotropic growth factor. In this study we used primary mesangial cell cultures from wild-type mice and from mice with a targeted disruption of the SPARC gene. SPARC-null cells displayed diminished expression of collagen type I mRNA and protein, relative to wild-type cells, by the criteria of immunocytochemistry, immunoblotting, and the reverse transcription-polymerase chain reaction. The SPARC-null cells also showed significantly decreased steady-state levels of transforming growth factor-beta 1 (TGF-beta 1) mRNA and secreted TGF-beta 1 protein. Addition of recombinant SPARC to SPARC-null cells restored the expression of collagen type I mRNA to 70% and TGF-beta 1 mRNA to 100% of wildtype levels. We conclude that SPARC regulates the expression of collagen type I and TGF-beta 1 in kidney mesangial cells. Since increased mitosis and matrix deposition by mesangial cells are characteristics of glomerulopathies, we propose that SPARC is one of the factors that maintains the balance between cell proliferation and matrix production in the glomerulus.	Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA; Univ Washington, Dept Urol, Seattle, WA 98195 USA; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Univ Washington, Div Nephrol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; The Wistar Institute; University of Washington; University of Washington Seattle	Sage, EH (corresponding author), Hope Heart Inst, Dept Vasc Biol, 528 18th Ave, Seattle, WA 98122 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040711] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 18645] Funding Source: Medline; NIDDK NIH HHS [DK 47459] Funding Source: Medline; NIGMS NIH HHS [GM 40711] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRASS CK, 1995, KIDNEY INT, V47, P25, DOI 10.1038/ki.1995.3; Bassuk JA, 1996, ARCH BIOCHEM BIOPHYS, V325, P8, DOI 10.1006/abbi.1996.0002; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bradshaw AD, 1999, MOL BIOL CELL, V10, P1569, DOI 10.1091/mbc.10.5.1569; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; ENGELMANN GL, 1993, CARDIOVASC RES, V27, P1598, DOI 10.1093/cvr/27.9.1598; FLOEGE J, 1991, AM J KIDNEY DIS, V17, P673, DOI 10.1016/S0272-6386(12)80349-0; FLOEGE J, 1993, AM J PATHOL, V142, P637; Frank R, 1996, J INVEST DERMATOL, V106, P36, DOI 10.1111/1523-1747.ep12327182; FUNK SE, 1991, P NATL ACAD SCI USA, V88, P2648, DOI 10.1073/pnas.88.7.2648; Gilbert RE, 1998, KIDNEY INT, V54, P1052, DOI 10.1046/j.1523-1755.1998.00081.x; Gooden MD, 1999, J CELL BIOCHEM, V74, P152, DOI 10.1002/(SICI)1097-4644(19990801)74:2<152::AID-JCB2>3.0.CO;2-4; Goswami PC, 1997, CELL PROLIFERAT, V30, P271, DOI 10.1111/j.1365-2184.1997.tb00940.x; Grande JP, 1997, J LAB CLIN MED, V130, P476, DOI 10.1016/S0022-2143(97)90124-4; IruelaArispe ML, 1996, DEV DYNAM, V207, P171, DOI 10.1002/(SICI)1097-0177(199610)207:2<171::AID-AJA5>3.0.CO;2-E; IWANO M, 1994, CLIN EXP IMMUNOL, V97, P309; JOHNSON RJ, 1992, J EXP MED, V175, P1413, DOI 10.1084/jem.175.5.1413; Kagami S, 1996, EXP CELL RES, V229, P1, DOI 10.1006/excr.1996.0336; Kupprion C, 1998, J BIOL CHEM, V273, P29635, DOI 10.1074/jbc.273.45.29635; LANE TF, 1992, J BIOL CHEM, V267, P16736; LANE TF, 1994, FASEB J, V8, P163, DOI 10.1096/fasebj.8.2.8119487; Lenz O, 1998, J AM SOC NEPHROL, V9, P2040; Lloyd GM, 1997, J EXP MED, V185, P1371, DOI 10.1084/jem.185.7.1371; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Motamed K, 1998, J CELL BIOCHEM, V70, P543, DOI 10.1002/(SICI)1097-4644(19980915)70:4<543::AID-JCB10>3.0.CO;2-I; Norose K, 1998, INVEST OPHTH VIS SCI, V39, P2674; Pepper Michael S., 1997, Cytokine and Growth Factor Reviews, V8, P21, DOI 10.1016/S1359-6101(96)00048-2; Pichler RH, 1996, AM J PATHOL, V148, P1153; Poncelet AC, 1998, AM J PHYSIOL-RENAL, V275, pF458; Porte H, 1998, CLIN CANCER RES, V4, P1375; RADEKE HH, 1992, CLIN INVESTIGATOR, V70, P825; RAINES EW, 1992, P NATL ACAD SCI USA, V89, P1281, DOI 10.1073/pnas.89.4.1281; REED MJ, 1994, J CELL PHYSIOL, V158, P169, DOI 10.1002/jcp.1041580121; REED MJ, 1993, J HISTOCHEM CYTOCHEM, V41, P1467, DOI 10.1177/41.10.8245406; Rosenblatt S, 1997, BIOCHEM J, V324, P311, DOI 10.1042/bj3240311; Sasaki T, 1998, EMBO J, V17, P1625, DOI 10.1093/emboj/17.6.1625; SATO N, 1993, AM J PATHOL, V142, P1119; Satoh M, 1996, J CELL BIOL, V133, P469, DOI 10.1083/jcb.133.2.469; Shankavaram UT, 1997, J CELL PHYSIOL, V173, P327, DOI 10.1002/(SICI)1097-4652(199712)173:3<327::AID-JCP4>3.3.CO;2-R; TREMBLE PM, 1993, J CELL BIOL, V121, P1433, DOI 10.1083/jcb.121.6.1433; UNEMORI E N, 1991, Current Opinion in Rheumatology, V3, P953, DOI 10.1097/00002281-199112000-00010; Varedi M, 1997, J CELL PHYSIOL, V172, P192, DOI 10.1002/(SICI)1097-4652(199708)172:2<192::AID-JCP6>3.0.CO;2-J; WOLTHUIS A, 1993, AM J PATHOL, V143, P1209; WRANA JL, 1991, EUR J BIOCHEM, V197, P519, DOI 10.1111/j.1432-1033.1991.tb15940.x; Yamamoto T, 1996, KIDNEY INT, V49, P461, DOI 10.1038/ki.1996.65; ZIYADEH FN, 1994, J CLIN INVEST, V93, P536, DOI 10.1172/JCI117004	47	155	160	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32145	32152		10.1074/jbc.274.45.32145	http://dx.doi.org/10.1074/jbc.274.45.32145			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542250	hybrid			2022-12-27	WOS:000083532100058
J	Brendza, KM; Rose, DJ; Gilbert, SP; Saxton, WM				Brendza, KM; Rose, DJ; Gilbert, SP; Saxton, WM			Lethal kinesin mutations reveal amino acids important for ATPase activation and structural coupling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOTOR-PROTEIN COMPLEX; DIMERIC KINESIN; HEAVY-CHAIN; MICROTUBULE PROTOFILAMENTS; CRYOELECTRON MICROSCOPY; 3-DIMENSIONAL STRUCTURE; DROSOPHILA KINESIN; KINETIC MECHANISM; CRYSTAL-STRUCTURE; ADP RELEASE	To study the relationship between conventional kinesin's structure and function, we identified 13 lethal mutations in the Drosophila kinesin heavy chain motor domain and tested a subset for effects on mechanochemistry, S246F is a moderate mutation that occurs in loop 11 between the ATP- and microtubule-binding sites. While ATP and microtubule binding appear normal, there is a 3-fold decrease in the rate of ATP turnover, This is consistent with the hypothesis that loop 11 provides a structural link that is important for the activation of ATP turnover by microtubule binding. T291M is a severe mutation that occurs in alpha-helix 5 near the center of the microtubule-binding surface. It impairs the microtubule-kinesin interaction and directly effects the ATP-binding pocket, allowing an increase in ATP turnover in the absence of microtubules. The T291M mutation may mimic the structure of a microtubule-bound, partially activated state. E164K is a moderate mutation that occurs at the beta-sheet 5a/loop 8b junction, remote from the ATP pocket. Surprisingly, it causes both tighter ATP-binding and a 2-fold decrease in ATP turnover We propose that E164 forms an ionic bridge with alpha-helix 5 and speculate that it helps coordinate the alternating site catalysis of dimerized kinesin heavy chain motor domains.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA; Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA	Indiana University System; Indiana University Bloomington; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Saxton, WM (corresponding author), Indiana Univ, Dept Biol, Jordan Hall 336, Bloomington, IN 47405 USA.				NIGMS NIH HHS [R37 GM054141, R01 GM054141, R01 GM046295-09, GM-54141, R01 GM046295, GM-46295] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM054141, R01GM046295, R01GM054141] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alonso MC, 1998, EMBO J, V17, P945, DOI 10.1093/emboj/17.4.945; Arnal I, 1998, STRUCTURE, V6, P33, DOI 10.1016/S0969-2126(98)00005-7; BERLINER E, 1995, NATURE, V373, P718, DOI 10.1038/373718a0; BERLINER E, 1994, J BIOL CHEM, V269, P8610; BLOOM GS, 1994, PROTEIN PROFILE, V1, P1059; CORREIA JJ, 1995, BIOCHEMISTRY-US, V34, P4898, DOI 10.1021/bi00014a047; Coy DL, 1999, J BIOL CHEM, V274, P3667, DOI 10.1074/jbc.274.6.3667; DECUEVAS M, 1993, ANAL STALK DROSOPHIL; ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; GHO M, 1992, SCIENCE, V258, P313, DOI 10.1126/science.1384131; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; GILBERT SP, 1994, BIOCHEMISTRY-US, V33, P1951, DOI 10.1021/bi00173a044; GILBERT SP, 1993, BIOCHEMISTRY-US, V32, P4677, DOI 10.1021/bi00068a028; Gilbert SP, 1998, BIOCHEMISTRY-US, V37, P792, DOI 10.1021/bi971117b; GOODSON HV, 1994, J CELL SCI, V107, P1875; Grummt M, 1998, EMBO J, V17, P5536, DOI 10.1093/emboj/17.19.5536; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; HACKNEY DD, 1995, NATURE, V377, P488; Hancock WO, 1998, J CELL BIOL, V140, P1395, DOI 10.1083/jcb.140.6.1395; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Hirose K, 1996, P NATL ACAD SCI USA, V93, P9539, DOI 10.1073/pnas.93.18.9539; HIROSE K, 1995, NATURE, V376, P277, DOI 10.1038/376277a0; Hoenger A, 1996, J MOL BIOL, V263, P114, DOI 10.1006/jmbi.1996.0561; Hoenger A, 1997, J MOL BIOL, V265, P553, DOI 10.1006/jmbi.1996.0757; HOENGER A, 1995, NATURE, V376, P271, DOI 10.1038/376271a0; Hoenger A, 1998, J CELL BIOL, V141, P419, DOI 10.1083/jcb.141.2.419; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; Hua W, 1997, NATURE, V388, P390, DOI 10.1038/41118; Inoue Y, 1997, P NATL ACAD SCI USA, V94, P7275, DOI 10.1073/pnas.94.14.7275; Jiang W, 1997, J BIOL CHEM, V272, P5616, DOI 10.1074/jbc.272.9.5616; KIKKAWA M, 1995, NATURE, V376, P274, DOI 10.1038/376274a0; Kozielski F, 1998, CURR BIOL, V8, P191, DOI 10.1016/S0960-9822(98)70083-1; Kozielski F, 1997, CELL, V91, P985, DOI 10.1016/S0092-8674(00)80489-4; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; KUZNETSOV SA, 1986, P NATL ACAD SCI USA, V83, P8530, DOI 10.1073/pnas.83.22.8530; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LOCKHART A, 1995, FEBS LETT, V368, P531, DOI 10.1016/0014-5793(95)00723-M; Ma YZ, 1997, J BIOL CHEM, V272, P724, DOI 10.1074/jbc.272.2.724; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13233, DOI 10.1021/bi00040a039; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13242, DOI 10.1021/bi00040a040; Ma YZ, 1997, J BIOL CHEM, V272, P717, DOI 10.1074/jbc.272.2.717; Moyer ML, 1996, BIOCHEMISTRY-US, V35, P6321, DOI 10.1021/bi960017n; Moyer ML, 1998, BIOCHEMISTRY-US, V37, P800, DOI 10.1021/bi9711184; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; Romberg L, 1998, J CELL BIOL, V140, P1407, DOI 10.1083/jcb.140.6.1407; Sack S, 1997, BIOCHEMISTRY-US, V36, P16155, DOI 10.1021/bi9722498; SAXTON WM, 1991, CELL, V64, P1093, DOI 10.1016/0092-8674(91)90264-Y; SAXTON WM, 1988, P NATL ACAD SCI USA, V85, P1109, DOI 10.1073/pnas.85.4.1109; Schnitzer MJ, 1997, NATURE, V388, P386, DOI 10.1038/41111; Song HB, 1998, NATURE, V396, P587, DOI 10.1038/25153; Sosa H, 1997, CELL, V90, P217, DOI 10.1016/S0092-8674(00)80330-X; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; Thormahlen' M, 1998, J MOL BIOL, V275, P795, DOI 10.1006/jmbi.1997.1503; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; Woehlke G, 1997, CELL, V90, P207, DOI 10.1016/S0092-8674(00)80329-3; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332	59	61	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31506	31514		10.1074/jbc.274.44.31506	http://dx.doi.org/10.1074/jbc.274.44.31506			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531353	Green Accepted, hybrid			2022-12-27	WOS:000083379400057
J	Crottet, P; Corthesy, B				Crottet, P; Corthesy, B			Mapping the interaction between murine IgA and murine secretory component carrying epitope substitutions reveals a role of domains II and III in covalent binding to IgA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERIC IMMUNOGLOBULIN RECEPTOR; LIGAND; LIVER; ANTIBODIES; PROTEINS; PURIFICATION; EXPRESSION; SUBUNIT; DIMERS; CELLS	We have identified sites for epitope insertion in the murine secretory component (SC) by replacing individual surface-exposed loops in domains I, II, and III with the FLAG sequence (Crottet, P., Peitsch, M. C., Servis, C., and Corthesy, B. (1999) J. Biol Chem. 274, 31445-31455). We had previously shown that epitope-carrying SC reassociated with dimeric IgA (IgA(d)) can serve as a mucosal delivery vehicle. When analyzing the capacity of SC mutants to associate with IgA(d), we found that all domain II and III mutants bound specifically with immobilized IgA(d), and their affinity for IgA(d) was comparable to that of the wild type protein (IC50 similar to 1 nM), We conclude that domains II and III in SC are permissive to local mutation and represent convenient sites to antigenize the SC molecule. No mutant bound to monomeric IgA SC mutants exposing the FLAG at their surface maintained this property once bound to IgA(d), thereby defining regions not required for high affinity binding to IgA(d), Association of IgA(d) with SC mutants carrying a buried FLAG did not expose de novo the epitope, consistent with limited, local changes in the SC structure upon binding. Only wild type and two mutant SCs bound covalently to IgA(d), thus implicating domains II and III in the correct positioning of the reactive cysteine in SC. This establishes that the integrity of murine SC domains II and III is not essential to preserve specific IgA(d) binding but is necessary for covalency to take place. Finally, SC mutants existing in the monomeric and dimeric forms exhibit-ed the same IgA(d) binding capacity as monomeric wild type SC known to bind with a 1:1 stoichiometry.	CHU Vaudois, Div Immunol & Allergie, CH-1011 Lausanne, Switzerland; Inst Suisse Rech Expt Canc, CH-1066 Epalinges, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Corthesy, B (corresponding author), CHU Vaudois, Div Immunol & Allergie, BH18-701,Rue Bugnon, CH-1011 Lausanne, Switzerland.							BAKOS MA, 1991, J IMMUNOL, V147, P3419; BAKOS MA, 1993, J IMMUNOL, V151, P1346; BAKOS MA, 1994, MOL IMMUNOL, V31, P165, DOI 10.1016/0161-5890(94)90088-4; BAKOS MA, 1991, J IMMUNOL, V146, P162; BEALE D, 1988, INT J BIOCHEM, V20, P873, DOI 10.1016/0020-711X(88)90077-8; Brandtzaeg P, 1994, HDB MUCOSAL IMMUNOLO, P113; Chapin SJ, 1996, J BIOL CHEM, V271, P1336, DOI 10.1074/jbc.271.3.1336; Corthesy B, 1996, J BIOL CHEM, V271, P33670, DOI 10.1074/jbc.271.52.33670; COYNE RS, 1994, J BIOL CHEM, V269, P31620; Crottet P, 1999, BIOCHEM J, V341, P299, DOI 10.1042/0264-6021:3410299; Crottet P, 1998, J IMMUNOL, V161, P5445; Crottet P, 1999, J BIOL CHEM, V274, P31445, DOI 10.1074/jbc.274.44.31445; CUNNINGHAMRUNDLES C, 1975, J BIOL CHEM, V250, P1987; DANIEL TO, 1983, J BIOL CHEM, V258, P4606; Enrich C, 1996, HEPATOLOGY, V24, P226, DOI 10.1002/hep.510240136; FALLGREENGEBAUER E, 1993, BIOL CHEM H-S, V374, P1023, DOI 10.1515/bchm3.1993.374.7-12.1023; FRUTIGER S, 1986, J BIOL CHEM, V261, P6673; FRUTIGER S, 1987, J BIOL CHEM, V262, P1712; KNIGHT KL, 1975, J IMMUNOL, V115, P595; KUHN LC, 1979, J BIOL CHEM, V254, P1066; KUHN LC, 1981, J BIOL CHEM, V256, P2490; LINDH E, 1976, EUR J BIOCHEM, V62, P263, DOI 10.1111/j.1432-1033.1976.tb10156.x; Lullau E, 1996, J BIOL CHEM, V271, P16300, DOI 10.1074/jbc.271.27.16300; MESTECKY J, 1987, ADV IMMUNOL, V40, P515; MOSTOV KE, 1994, ANNU REV IMMUNOL, V12, P63, DOI 10.1146/annurev.immunol.12.1.63; Nion S, 1997, BIOCHEM J, V328, P415, DOI 10.1042/bj3280415; NORGARD KE, 1993, P NATL ACAD SCI USA, V90, P1068, DOI 10.1073/pnas.90.3.1068; PARR EL, 1995, J IMMUNOL METHODS, V180, P147, DOI 10.1016/0022-1759(94)00310-S; RINDISBACHER L, 1995, J BIOL CHEM, V270, P14220, DOI 10.1074/jbc.270.23.14220; SOLARI R, 1985, J BIOL CHEM, V260, P1141; SONG WX, 1995, J IMMUNOL, V155, P715; TAMER CM, 1995, J IMMUNOL, V155, P707; WEICKER J, 1975, J IMMUNOL, V114, P1337; YannarielloBrown J, 1997, GLYCOBIOLOGY, V7, P15, DOI 10.1093/glycob/7.1.15; YannarielloBrown J, 1996, BIOCHEM BIOPH RES CO, V218, P314, DOI 10.1006/bbrc.1996.0055; Zeng FY, 1996, GLYCOBIOLOGY, V6, P247, DOI 10.1093/glycob/6.3.247	36	20	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31456	31462		10.1074/jbc.274.44.31456	http://dx.doi.org/10.1074/jbc.274.44.31456			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531347	hybrid			2022-12-27	WOS:000083379400051
J	Ho, HH; Du, DY; Gershengorn, MC				Ho, HH; Du, DY; Gershengorn, MC			The N terminus of Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor is necessary for high affinity chemokine binding but not for constitutive activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROTROPIN-RELEASING-HORMONE; CHEMOTACTIC CYTOKINES; CALCITONIN RECEPTOR; ACTIVATION; LIGAND; DOMAIN; DETERMINANTS; EXPRESSION; ANTIGEN; GENES	Kaposi's sarcoma-associated herpesvirus (KSHV) contains a gene encoding a G protein-coupled receptor (KSHV-GPCR) that is homologous to mammalian chemokine receptors, KSHV-GPCR signals constitutively (in an agonist-independent manner) via the phosphoinositide-inositol 1,4,5-trisphosphate pathway. Because it has been proposed that the N terminus (N-TERM) of other GPCRs may act as tethered agonists, we determined whether the N-TERM of KSHV-GPCR is necessary for constitutive signaling activity or ligand binding or both. We show that replacement of the entire N-TERM of KSHV-GPCR with those of two other GPCRs, deletion of residues within the N-TERM, and disruption of a putative disulfide bond that may hold the N-TERM in close proximity to extracellular loop 3 do not affect constitutive signaling activity but decrease chemokine binding. There were differences in the effects of mutation of the N-TERM on binding of the chemokines growth-related oncogene a, which is an agonist, and interferon-gamma-inducible protein-10, which is an inverse agonist. The effects on chemokine binding were accompanied by changes in chemokine regulation of KSHV-GPCR signaling. We conclude that the N-TERM is not necessary for constitutive KSHV-GPCR signaling, i.e. the N-TERM is not a tethered agonist, but plays a crucial role in binding of chemokine ligands and of chemokine regulation of KSHV-GPCR signaling.	Cornell Univ, Weill Med Coll, Program Mol Med, Dept Med,Div Mol Med, New York, NY 10021 USA; Cornell Univ, Weill Grad Sch Med Sci, Program Mol Med, New York, NY 10021 USA	Cornell University; Cornell University	Gershengorn, MC (corresponding author), Cornell Univ, Weill Med Coll, Program Mol Med, Dept Med,Div Mol Med, 1300 York Ave,Rm A328, New York, NY 10021 USA.				NCI NIH HHS [CA 75918] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075918] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Arvanitakis L, 1998, TRENDS ENDOCRIN MET, V9, P27, DOI 10.1016/S1043-2760(98)00007-1; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Blanpain C, 1999, J BIOL CHEM, V274, P18902, DOI 10.1074/jbc.274.27.18902; Boshoff C, 1998, ADV CANCER RES, V75, P57, DOI 10.1016/S0065-230X(08)60739-3; CHEN J, 1994, J BIOL CHEM, V269, P16041; Geras-Raaka E, 1998, J EXP MED, V188, P405, DOI 10.1084/jem.188.2.405; Geras-Raaka E, 1998, BIOCHEM BIOPH RES CO, V253, P725, DOI 10.1006/bbrc.1998.9557; Gershengorn MC, 1998, J CLIN INVEST, V102, P1469, DOI 10.1172/JCI4461; Hadley TJ, 1997, BLOOD, V89, P3077, DOI 10.1182/blood.V89.9.3077; Herzig MCS, 1996, J BIOL CHEM, V271, P29746, DOI 10.1074/jbc.271.47.29746; Ho HH, 1999, BIOCHEMISTRY-US, V38, P1866, DOI 10.1021/bi981195e; IMAI A, 1987, METHOD ENZYMOL, V141, P100; Laakkonen L, 1996, MOL PHARMACOL, V49, P1092; Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963; Lu DS, 1998, MOL ENDOCRINOL, V12, P592, DOI 10.1210/me.12.4.592; LU ZH, 1995, J BIOL CHEM, V270, P26239; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Monteclaro FS, 1997, J BIOL CHEM, V272, P23186, DOI 10.1074/jbc.272.37.23186; Murphy PM, 1997, NATURE, V385, P296, DOI 10.1038/385296a0; NUSSENZVEIG DR, 1994, J BIOL CHEM, V269, P28123; OSMAN R, 1999, STRUCTURE FUNCTION G; Pease JE, 1998, J BIOL CHEM, V273, P19972, DOI 10.1074/jbc.273.32.19972; Rosenkilde MM, 1999, J BIOL CHEM, V274, P956, DOI 10.1074/jbc.274.2.956; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Stroop SD, 1996, ENDOCRINOLOGY, V137, P4752, DOI 10.1210/en.137.11.4752; STROOP SD, 1995, BIOCHEMISTRY-US, V34, P1050, DOI 10.1021/bi00003a040; Tournamille C, 1997, J BIOL CHEM, V272, P16274, DOI 10.1074/jbc.272.26.16274; Weng YM, 1998, J BIOL CHEM, V273, P18288, DOI 10.1074/jbc.273.29.18288	31	45	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31327	31332		10.1074/jbc.274.44.31327	http://dx.doi.org/10.1074/jbc.274.44.31327			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531332	hybrid			2022-12-27	WOS:000083379400036
J	Bertrand, L; Alessi, DR; Deprez, J; Deak, M; Viaene, E; Rider, MH; Hue, L				Bertrand, L; Alessi, DR; Deprez, J; Deak, M; Viaene, E; Rider, MH; Hue, L			Heart 6-phosphofructo-2-kinase activation by insulin results from Ser-466 and Ser-483 phosphorylation and requires 3-phosphoinositide-dependent kinase-1, but not protein kinase B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE 3-KINASE; MECHANISM; MUTAGENESIS; GLYCOLYSIS; INHIBITION; PATHWAY; DOMAIN; IGF-1; B/AKT; SITE	Previous studies have shown that (i) the insulin-induced activation of heart 6-phosphofructo-2-kinase (PFK-2) is wortmannin-sensitive, but is insensitive to rapamycin, suggesting the involvement of phosphatidylinositol 3-kinase; and (ii) protein kinase B (PKB) activates PFK-S in vitro by phosphorylating Ser-466 and Ser-483, In this work, we have studied the effects of phosphorylation of these residues on PFK-2 activity by replacing each or both residues with glutamate. Mutation of Ser-466 increased the V-max of PFK-2, whereas mutation of Ser-483 decreased citrate inhibition. Mutation of both residues was required to decrease the K-m for fructose 6-phosphate. We also studied the insulin-induced activation of heart PFK-2 in transfection experiments performed in human embryonic kidney 293 cells. Insulin activated transfected PFK-S by phosphorylating Ser-466 and Ser-483. Kinase-dead (KD) PKB and KD 3-phosphoinositide-dependent kinase-1 (PDK-1) cotransfectants acted as dominant negatives because both prevented the insulin-induced activation of PKB as well as the inactivation of glycogen-synthase kinase-3, an established substrate of PKB. However, the insulin-induced activation of PFK-2 was prevented only by KD PDK-1, but not by KD PKB. These results indicate that the insulin-induced activation of heart PFK-S its mediated by a PDK-1-activated protein kinase other than PKB.	Univ Catholique Louvain, Hormone & Metab Res Unit, B-1200 Brussels, Belgium; Inst Cellular Pathol, B-1200 Brussels, Belgium; Univ Dundee, Dept Biochem, MRC, Prot Phosphorylat Unit, Dundee DD1 4HN, Scotland	Universite Catholique Louvain; University of Dundee	Hue, L (corresponding author), ICP UCL 75 29, HORM Unit, Ave Hippocrate 75, B-1200 Brussels, Belgium.			Bertrand, Luc/0000-0003-0655-7099; Alessi, Dario/0000-0002-2140-9185				Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ALLEN G, 1989, SEQUENCING PROTEINS, P140; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Barbieri MA, 1998, J BIOL CHEM, V273, P19367, DOI 10.1074/jbc.273.31.19367; Bertrand L, 1998, EUR J BIOCHEM, V254, P490, DOI 10.1046/j.1432-1327.1998.2540490.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Coffer PJ, 1998, BIOCHEM J, V335, P1; CREPIN KM, 1993, J BIOL CHEM, V268, P15277; CROSS DAE, 1995, NATURE, V378, P229; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Depre C, 1998, EUR J BIOCHEM, V258, P277, DOI 10.1046/j.1432-1327.1998.2580277.x; Depre C, 1998, J CLIN INVEST, V101, P390, DOI 10.1172/JCI1168; Deprez J, 1997, J BIOL CHEM, V272, P17269, DOI 10.1074/jbc.272.28.17269; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lefebvre V, 1996, J BIOL CHEM, V271, P22289, DOI 10.1074/jbc.271.37.22289; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; Shaw M, 1997, FEBS LETT, V416, P307, DOI 10.1016/S0014-5793(97)01235-0; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299; Wang D, 1998, J BIOL CHEM, V273, P25420, DOI 10.1074/jbc.273.39.25420; Wang QH, 1999, MOL CELL BIOL, V19, P4008	26	58	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30927	30933		10.1074/jbc.274.43.30927	http://dx.doi.org/10.1074/jbc.274.43.30927			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521487	hybrid			2022-12-27	WOS:000083276700083
J	Morris, SK; Lindsley, JE				Morris, SK; Lindsley, JE			Yeast topoisomerase II is inhibited by etoposide after hydrolyzing the first ATP and before releasing the second ADP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL FRAGMENT; GYRASE-B-PROTEIN; DRUG-INTERACTION DOMAINS; STEADY-STATE ANALYSIS; DNA TOPOISOMERASE; SACCHAROMYCES-CEREVISIAE; TARGETED DRUGS; ANTINEOPLASTIC DRUGS; CRYSTAL-STRUCTURE; ANTITUMOR DRUGS	Topoisomerase II-catalyzed DNA transport requires coordination between two distinct reactions: ATP hydrolysis and DNA cleavage/religation. To further understand how these reactions are coupled, inhibition by the clinically used anticancer drug etoposide was studied. The IC50 for perturbing the DNA cleavage/religation equilibrium is nucleotide-dependent; its value is 6 mu M in the presence of ATP, 25 mu M in the presence of a nonhydrolyzable ATP analog, and 45 mu M, in the presence of ADP or no nucleotide. This inhibition was further characterized using steady-state and pre-steady-state ATPase and decatenation assays. Etoposide is a hyperbolic noncompetitive inhibitor of the ATPase activity with a K-i(app) of 5.6 mu M; no inhibition of ATP hydrolysis is seen in the absence of DNA cleavage. In order to determine which steps of the ATPase mechanism etoposide inhibits, pre; steady-state analysis was performed. These results showed that etoposide does not reduce the rate of binding two ATP, hydrolyzing the first ATP, or releasing the second ADP. Inhibition is therefore associated with the first product release step or hydrolysis of the second ATP, suggesting that DNA religation normally occurs at one of these two steps. Multiple turnover decatenation is inhibited when etoposide is present; however, single turnover decatenation occurs normally. The implications of these results are discussed in terms of their contribution to our current model for the topoisomerase II mechanism.	Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah	Lindsley, JE (corresponding author), Univ Utah, Sch Med, Dept Biochem, 50 N Med Dr, Salt Lake City, UT 84132 USA.				NIGMS NIH HHS [5T32GM08753, GM51194] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008753, R01GM051194] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI JA, 1993, BIOCHEMISTRY-US, V32, P2717, DOI 10.1021/bi00061a033; ALI JA, 1995, BIOCHEMISTRY-US, V34, P9801, DOI 10.1021/bi00030a018; BAIRD CL, 1999, IN PRESS P NATL ACAD; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; Cabral JHM, 1997, NATURE, V388, P903, DOI 10.1038/42294; CHEN GL, 1984, J BIOL CHEM, V259, P3560; Cline SD, 1997, BIOCHEMISTRY-US, V36, P13095, DOI 10.1021/bi971770z; CORBETT AH, 1993, J BIOL CHEM, V268, P14394; Elsea SH, 1997, BIOCHEMISTRY-US, V36, P2919, DOI 10.1021/bi962488f; ENGLUND PT, 1978, CELL, V14, P157, DOI 10.1016/0092-8674(78)90310-0; Fass D, 1999, NAT STRUCT BIOL, V6, P322; Felix CA, 1998, BBA-GENE STRUCT EXPR, V1400, P233, DOI 10.1016/S0167-4781(98)00139-0; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; Hammonds TR, 1997, J BIOL CHEM, V272, P32696, DOI 10.1074/jbc.272.51.32696; Hande KR, 1998, BBA-GENE STRUCT EXPR, V1400, P173, DOI 10.1016/S0167-4781(98)00134-1; Harkins TT, 1998, BIOCHEMISTRY-US, V37, P7299, DOI 10.1021/bi9729108; Harkins TT, 1998, BIOCHEMISTRY-US, V37, P7292, DOI 10.1021/bi9729099; HOLM C, 1994, CELL, V77, P955, DOI 10.1016/0092-8674(94)90433-2; HUFF AC, 1990, J BIOL CHEM, V265, P20496; Kingma PS, 1999, BIOCHEMISTRY-US, V38, P3457, DOI 10.1021/bi982855i; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; LIU LF, 1983, J BIOL CHEM, V258, P5365; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LIU LF, 1994, DNA TOPOISOMERASES T, P1; Maxwell A, 1999, BIOCHEM SOC T, V27, P48, DOI 10.1042/bst0270048; Morris SNK, 1999, J BIOL CHEM, V274, P3446, DOI 10.1074/jbc.274.6.3446; NITISS JL, 1994, DNA TOPOISOMERASES T, P201; Olland S, 1999, J BIOL CHEM, V274, P21688, DOI 10.1074/jbc.274.31.21688; OSHEROFF N, 1989, BIOCHEMISTRY-US, V28, P6157, DOI 10.1021/bi00441a005; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; Reid RJD, 1998, BBA-GENE STRUCT EXPR, V1400, P289, DOI 10.1016/S0167-4781(98)00142-0; ROBINSON MJ, 1993, BIOCHEMISTRY-US, V32, P3638, DOI 10.1021/bi00065a016; ROBINSON MJ, 1991, BIOCHEMISTRY-US, V30, P1807, DOI 10.1021/bi00221a012; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; Rubnitz JE, 1998, J PEDIAT HEMATOL ONC, V20, P1, DOI 10.1097/00043426-199801000-00001; SANDER M, 1983, J BIOL CHEM, V258, P8421; Segel IH., 1993, ENZYME KINETICS BEHA; Wang JC, 1998, Q REV BIOPHYS, V31, P107, DOI 10.1017/S0033583598003424; Warburton PE, 1997, BIOESSAYS, V19, P97, DOI 10.1002/bies.950190203; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; WORLAND ST, 1989, J BIOL CHEM, V264, P4412	42	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30690	30696		10.1074/jbc.274.43.30690	http://dx.doi.org/10.1074/jbc.274.43.30690			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521457	hybrid			2022-12-27	WOS:000083276700053
J	Barton, RM; Worman, HJ				Barton, RM; Worman, HJ			Prenylated prelamin A interacts with Narf, a novel nuclear protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP-DISSOCIATION INHIBITOR; LAMIN-A PRECURSOR; INTERMEDIATE FILAMENT PROTEINS; RETINOBLASTOMA GENE-PRODUCT; CHROMATIN BINDING-SITE; GAMMA-SUBUNIT; MEMBRANE ATTACHMENT; GTP-BINDING; CELL-LINE; RAS	Prelamin A is farnesylated and methylated on the cysteine residue of a carboxyl-terminal CaaX motif, In the nucleus, prelamin A is processed to lamin A by endoproteolytic removal of the final 18 amino acids, including the farnesylated cysteine residue, Using the yeast two-hybrid assay, we isolated a novel human protein, Narf, that binds the carboxyl-terminal tail of prelamin A. Narf has limited homology to iron-only bacterial hydrogenases and eukaryotic proteins of unknown function. Narf is encoded by a 2-kilobase mRNA expressed in all human cell lines and tissues examined. The protein is detected in the nuclear fraction of HeLa cell lysates on Western blots and can be extracted from nuclear envelopes with 0.5 M NaCl. When a FLAG epitope-tagged Narf is expressed in HeLa cells, it is exclusively nuclear and partially co-localizes with the nuclear lamina, The farnesylation status of prelamin A determines its ability to bind to Narf. Inhibition of farnesyltransferase and mutation or deletion of the CaaX motif from the prelamin A tail domain inhibits Narf binding in yeast two-hybrid and in vitro binding assays. The prenyl-dependent binding of Narf to prelamin A is an important first step in understanding the functional significance of the lamin A precursor.	Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Anat & Cell Biol, New York, NY 10032 USA	Columbia University; Columbia University	Worman, HJ (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Med, 630 W 168th St,P&S 10-508, New York, NY 10032 USA.				NCI NIH HHS [5-P30-CA13696, CA66974] Funding Source: Medline; NCRR NIH HHS [1S10-RR10506] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066974, P30CA013696] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR010506] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Adams MWW, 1998, SCIENCE, V282, P1842, DOI 10.1126/science.282.5395.1842; BECK LA, 1990, J CELL BIOL, V110, P1489, DOI 10.1083/jcb.110.5.1489; BERANGER F, 1994, J BIOL CHEM, V269, P13637; BHATTACHARYA S, 1995, P NATL ACAD SCI USA, V92, P2984, DOI 10.1073/pnas.92.7.2984; BRIDGER JM, 1993, J CELL SCI, V104, P297; BUTRYNSKI JE, 1992, BIOCHEMISTRY-US, V31, P8030, DOI 10.1021/bi00149a037; CANCE WG, 1992, J EXP CLIN CANC RES, V11, P233; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; FENTON RG, 1992, J CELL BIOL, V117, P347, DOI 10.1083/jcb.117.2.347; FISHER DZ, 1986, P NATL ACAD SCI USA, V83, P6450, DOI 10.1073/pnas.83.17.6450; Fricker M, 1997, J CELL BIOL, V136, P531, DOI 10.1083/jcb.136.3.531; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GLASS CA, 1993, EMBO J, V12, P4413, DOI 10.1002/j.1460-2075.1993.tb06126.x; GLASS JR, 1990, J CELL BIOL, V111, P1047, DOI 10.1083/jcb.111.3.1047; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; GOLDMAN AE, 1992, J CELL BIOL, V119, P725, DOI 10.1083/jcb.119.4.725; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GUILLY MN, 1990, EXP CELL RES, V189, P145, DOI 10.1016/0014-4827(90)90267-E; GUILLY MN, 1987, EMBO J, V6, P3795, DOI 10.1002/j.1460-2075.1987.tb02715.x; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; HENNEKES H, 1994, J CELL SCI, V107, P1019; HOZAK P, 1995, J CELL SCI, V108, P635; Kilic F, 1997, J BIOL CHEM, V272, P5298, DOI 10.1074/jbc.272.8.5298; KISSELEV O, 1995, J BIOL CHEM, V270, P25356, DOI 10.1074/jbc.270.43.25356; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; LEBEL S, 1987, J CELL BIOL, V105, P1099, DOI 10.1083/jcb.105.3.1099; LIN F, 1993, J BIOL CHEM, V268, P16321; LUTZ RJ, 1992, P NATL ACAD SCI USA, V89, P3000, DOI 10.1073/pnas.89.7.3000; MANCINI MA, 1994, P NATL ACAD SCI USA, V91, P418, DOI 10.1073/pnas.91.1.418; MANNE V, 1995, DRUG DEVELOP RES, V34, P121, DOI 10.1002/ddr.430340205; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; Martincic I, 1997, J BIOL CHEM, V272, P26991, DOI 10.1074/jbc.272.43.26991; MUSHA T, 1992, J BIOL CHEM, V267, P9821; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; OZAKI T, 1994, ONCOGENE, V9, P2649; PAULINLEVASSEUR M, 1988, EUR J CELL BIOL, V47, P121; PAULINLEVASSEUR M, 1989, J CELL SCI, V92, P361; Peters JW, 1998, SCIENCE, V282, P1853, DOI 10.1126/science.282.5395.1853; POLLARD KM, 1990, MOL CELL BIOL, V10, P2164, DOI 10.1128/MCB.10.5.2164; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; ROBER RA, 1989, DEVELOPMENT, V105, P365; Sambrook J., 2002, MOL CLONING LAB MANU; SANFORD JC, 1995, J BIOL CHEM, V270, P26904, DOI 10.1074/jbc.270.45.26904; SASSEVILLE AMJ, 1995, J CELL SCI, V108, P273; SINENSKY M, 1994, J CELL SCI, V107, P61; SINENSKY M, 1994, J CELL SCI, V107, P2215; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; STEWART C, 1987, CELL, V51, P383, DOI 10.1016/0092-8674(87)90634-9; TANIURA H, 1995, J CELL BIOL, V131, P33, DOI 10.1083/jcb.131.1.33; Thissen JA, 1997, J BIOL CHEM, V272, P30362, DOI 10.1074/jbc.272.48.30362; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; VORBURGER K, 1989, EMBO J, V8, P4007, DOI 10.1002/j.1460-2075.1989.tb08583.x; WEBER K, 1989, FEBS LETT, V257, P411, DOI 10.1016/0014-5793(89)81584-4; Wilson AL, 1996, J BIOL CHEM, V271, P10932, DOI 10.1074/jbc.271.18.10932; WORMAN HJ, 1988, J BIOL CHEM, V263, P12135; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; Yasuda H, 1996, J BIOL CHEM, V271, P18588, DOI 10.1074/jbc.271.31.18588; YUAN J, 1991, J BIOL CHEM, V266, P9211; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	64	86	93	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30008	30018		10.1074/jbc.274.42.30008	http://dx.doi.org/10.1074/jbc.274.42.30008			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514485	hybrid			2022-12-27	WOS:000083176400064
J	Esposti, MD; Hatzinisiriou, I; McLennan, H; Ralph, S				Esposti, MD; Hatzinisiriou, I; McLennan, H; Ralph, S			Bcl-2 and mitochondrial oxygen radicals - New approaches with reactive oxygen species-sensitive probes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NICOTINAMIDE NUCLEOTIDE TRANSHYDROGENASE; CERAMIDE-INDUCED APOPTOSIS; PROGRAMMED CELL-DEATH; HYDROGEN-PEROXIDE; HEART MITOCHONDRIA; RESPIRATORY-CHAIN; GENERATION; SUPEROXIDE; INVOLVEMENT	Investigations into the capacity of the Bcl-2 protein to prevent apoptosis have targeted mitochondria as key sites of the preventative action accorded by Bcl-2 to cells. Using novel approaches with fluorescence probes and autofluorescence detection of endogenous NAD(P)H, we have examined the effects of expressing Bcl-2 in the Bcl-2 negative Burkitt's lymphoma cell line Daudi. We evaluated for the first time the effect of Bcl-2 expression on the intracellular distribution and production of hydrogen peroxide, under basal conditions and after treatment with apoptosis inducing agents, ceramide analogs and tumor necrosis factor (TNF)-alpha. Increased availability of mitochondrial NAD(P)H was detected in Bcl-2-expressing cells and was correlated with an increased constitutive mitochondrial production of hydrogen peroxide. Although production of hydrogen peroxide was increased by either C-6-ceramide or TNF-alpha in Bcl-2 negative Daudi cells commensurate with the early phases of apoptosis, this increase did not occur in Bcl-2-expressing cells. Thus, Bcl-2 appears to allow cells to adapt to an increased state of oxidative stress, fortifying the cellular anti-oxidant defenses and counteracting the radical overproduction imposed by different cell death stimuli. Furthermore, we report altered cytological features of mitochondria during the early phases of apoptosis induced by C-6-ceramide and TNF-alpha. In particular, mitochondria changed in appearance, clustering in the perinuclear region and Bcl-2 expression prevented these changes from occurring.	Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3168, Australia	Monash University	Esposti, MD (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Wellington Rd, Clayton, Vic 3168, Australia.	maurolit@hotmail.com		Degli Esposti, Mauro/0000-0002-0977-119X; Ralph, Stephen/0000-0002-4335-092X				BLACK MJ, 1974, ANAL BIOCHEM, V58, P246, DOI 10.1016/0003-2697(74)90464-3; Budd SL, 1997, FEBS LETT, V415, P21, DOI 10.1016/S0014-5793(97)01088-0; CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; De Vos K, 1998, J BIOL CHEM, V273, P9673, DOI 10.1074/jbc.273.16.9673; Degli Esposti M, 1998, FEBS LETT, V430, P338, DOI 10.1016/S0014-5793(98)00688-7; DiPietro R, 1997, CYTOKINE, V9, P463, DOI 10.1006/cyto.1996.0189; Ellerby LM, 1996, J NEUROCHEM, V67, P1259; ENG J, 1989, BIOPHYS J, V55, P621, DOI 10.1016/S0006-3495(89)82859-0; Esposti MD, 1996, ARCH BIOCHEM BIOPHYS, V330, P395, DOI 10.1006/abbi.1996.0267; Esposti MD, 1996, BIOCHEM J, V313, P327, DOI 10.1042/bj3130327; FARKAS DL, 1989, BIOPHYS J, V56, P1053, DOI 10.1016/S0006-3495(89)82754-7; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Garland JM, 1997, J BIOL CHEM, V272, P4680, DOI 10.1074/jbc.272.8.4680; Genestier L, 1998, J BIOL CHEM, V273, P5060, DOI 10.1074/jbc.273.9.5060; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Hansford RG, 1997, J BIOENERG BIOMEMBR, V29, P89, DOI 10.1023/A:1022420007908; Hatefi Y, 1996, FASEB J, V10, P444, DOI 10.1096/fasebj.10.4.8647343; Haugland R.P., 1996, HDB FLUORESCENT PROB, P491; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOEK JB, 1988, BIOCHEM J, V254, P1; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Kroemer G, 1997, CELL DEATH DIFFER, V4, P443, DOI 10.1038/sj.cdd.4400266; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; Macho A, 1996, CYTOMETRY, V25, P333, DOI 10.1002/(SICI)1097-0320(19961201)25:4<333::AID-CYTO4>3.0.CO;2-E; Metivier D, 1998, IMMUNOL LETT, V61, P157, DOI 10.1016/S0165-2478(98)00013-3; Nicholls DG, 1998, BBA-BIOENERGETICS, V1366, P97, DOI 10.1016/S0005-2728(98)00123-6; Nieminen AL, 1997, AM J PHYSIOL-CELL PH, V272, pC1286; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; PEZZELLA F, 1990, AM J PATHOL, V137, P225; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; STEINMAN HM, 1995, J BIOL CHEM, V270, P3487; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Turrens JF, 1997, BIOSCIENCE REP, V17, P3, DOI 10.1023/A:1027374931887; Uhlmann EJ, 1998, J BIOL CHEM, V273, P17926, DOI 10.1074/jbc.273.28.17926; Virgili F, 1998, FREE RADICAL BIO MED, V24, P93, DOI 10.1016/S0891-5849(97)00215-3; VLESSIS AA, 1990, J BIOL CHEM, V265, P1448; Voehringer DW, 1998, P NATL ACAD SCI USA, V95, P2956, DOI 10.1073/pnas.95.6.2956; WHITAKER JE, 1991, BIOCHEM BIOPH RES CO, V175, P387, DOI 10.1016/0006-291X(91)91576-X; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; WOLVETANG EJ, 1994, FEBS LETT, V339, P40, DOI 10.1016/0014-5793(94)80380-3; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zamzami N, 1998, ONCOGENE, V16, P1055, DOI 10.1038/sj.onc.1201864	54	138	143	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29831	29837		10.1074/jbc.274.42.29831	http://dx.doi.org/10.1074/jbc.274.42.29831			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514462	hybrid			2022-12-27	WOS:000083176400041
J	Guo, SY; Tabor, S; Richardson, CC				Guo, SY; Tabor, S; Richardson, CC			The linker region between the helicase and primase domains of the bacteriophage T7 gene 4 protein is critical for hexamer formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE 5'-TRIPHOSPHATASE ACTIVITY; NUCLEOTIDE-BINDING SITE; DNA-POLYMERASE ACTIVITY; SINGLE-STRANDED-DNA; ESCHERICHIA-COLI; DEOXYRIBONUCLEIC-ACID; CONFERS PROCESSIVITY; TEMPLATE RECOGNITION; CRYSTAL-STRUCTURE; REPLICATION FORK	The gene 4 protein of bacteriophage T7, a functional hexamer, comprises DNA helicase and primase activities. Both activities depend on the unidirectional movement of the protein along single-stranded DNA in a reaction coupled to the hydrolysis of dTTP, We have characterized dTTPase activity and hexamer formation for the full-length gene 4 protein (gp4) as well as for three carboxyl-terminal fragments starting at residues 219 (gp4-C219), 241 (gp4-C241), and 272 (gp4-C272), The region between residues 242 and 271, residing between the primase and helicase domains, is critical for oligomerization of the gene 4 protein. A functional TPase active site is dependent on oligomerization, During native gel electrophoresis, gp4, gp4-C219, and gp4-C241 migrate as oligomers, whereas gp4-C272 is monomeric, The steady-state k(cat) for dTTPase activity of gp4-C272 increases sharply with protein concentration, indicating that it forms oligomers only at high concentrations. gp4-C219 and gp4-C241 both form a stable complex with gp4, whereas gp4-C272 interacts only weakly with gp4, Measurements of surface plasmon resonance indicate that a monomer of T7 DNA polymerase binds to a dimer of gp4, gp4-C219, or gp4-C241 but to a monomer of gp4-C272, Like the homologous RecA and F-1-ATPase proteins, the oligomerization domain of the gene 4 protein is adjacent to the amino terminus of the NTP-binding domain.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Richardson, CC (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI006045, R01AI006045] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-06045] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Allison TJ, 1998, NAT STRUCT BIOL, V5, P352, DOI 10.1038/nsb0598-352; Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4205, DOI 10.1093/nar/26.18.4205; Bedford E, 1997, P NATL ACAD SCI USA, V94, P479, DOI 10.1073/pnas.94.2.479; BERNSTEIN JA, 1988, J BIOL CHEM, V263, P14891; BERNSTEIN JA, 1989, J BIOL CHEM, V264, P13066; BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P396, DOI 10.1073/pnas.85.2.396; Bird LE, 1997, NUCLEIC ACIDS RES, V25, P2620, DOI 10.1093/nar/25.13.2620; DEBYSER Z, 1994, CELL, V77, P157, DOI 10.1016/0092-8674(94)90243-7; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; FERGUSON KA, 1964, METABOLISM, V13, P985, DOI 10.1016/S0026-0495(64)80018-4; Frick DN, 1998, P NATL ACAD SCI USA, V95, P7957, DOI 10.1073/pnas.95.14.7957; GRIEP MA, 1995, INDIAN J BIOCHEM BIO, V32, P171; HEDRICK JL, 1968, ARCH BIOCHEM BIOPHYS, V126, P155, DOI 10.1016/0003-9861(68)90569-9; HINGORANI MM, 1993, BIOCHEMISTRY-US, V32, P12478, DOI 10.1021/bi00097a028; Hingorani MM, 1996, BIOCHEMISTRY-US, V35, P2218, DOI 10.1021/bi9521497; HUBER HE, 1986, J BIOL CHEM, V261, P5006; ILYINA TV, 1992, J MOL EVOL, V34, P351, DOI 10.1007/BF00160243; KIM YT, 1992, J BIOL CHEM, V267, P15032; KOLODNER R, 1978, J BIOL CHEM, V253, P566; Kong DC, 1997, J BIOL CHEM, V272, P8380; Kong DC, 1996, EMBO J, V15, P2010, DOI 10.1002/j.1460-2075.1996.tb00552.x; Lee J, 1998, MOL CELL, V1, P1001, DOI 10.1016/S1097-2765(00)80100-8; MALMQVIST M, 1993, NATURE, V361, P186, DOI 10.1038/361186a0; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MENDELMAN LV, 1994, EMBO J, V13, P3909, DOI 10.1002/j.1460-2075.1994.tb06702.x; MENDELMAN LV, 1992, P NATL ACAD SCI USA, V89, P10638, DOI 10.1073/pnas.89.22.10638; MENDELMAN LV, 1993, J BIOL CHEM, V268, P27208; MENDELMAN LV, 1991, J BIOL CHEM, V266, P23240; NAKAI H, 1986, J BIOL CHEM, V261, P5208; Notarnicola SM, 1997, J BIOL CHEM, V272, P18425, DOI 10.1074/jbc.272.29.18425; NOTARNICOLA SM, 1993, J BIOL CHEM, V268, P27198; NOTARNICOLA SM, 1995, J BIOL CHEM, V270, P20215, DOI 10.1074/jbc.270.34.20215; Park K, 1998, J BIOL CHEM, V273, P5260, DOI 10.1074/jbc.273.9.5260; PATEL SS, 1993, J BIOL CHEM, V268, P10668; PATEL SS, 1994, BIOCHEMISTRY-US, V33, P7857, DOI 10.1021/bi00191a013; Picha KM, 1998, J BIOL CHEM, V273, P27315, DOI 10.1074/jbc.273.42.27315; RICHARDSON CC, 1983, CELL, V33, P315, DOI 10.1016/0092-8674(83)90411-7; Rosenberg AH, 1996, J BIOL CHEM, V271, P26819, DOI 10.1074/jbc.271.43.26819; ROSENBERG AH, 1992, J BIOL CHEM, V267, P15005; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; TABOR S, 1981, P NATL ACAD SCI-BIOL, V78, P205, DOI 10.1073/pnas.78.1.205; TABOR S, 1987, J BIOL CHEM, V262, P16212; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Washington MT, 1996, J BIOL CHEM, V271, P26825, DOI 10.1074/jbc.271.43.26825; Yu X, 1996, NAT STRUCT BIOL, V3, P740, DOI 10.1038/nsb0996-740; Yu X, 1997, NAT STRUCT BIOL, V4, P101, DOI 10.1038/nsb0297-101	50	77	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30303	30309		10.1074/jbc.274.42.30303	http://dx.doi.org/10.1074/jbc.274.42.30303			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514525	hybrid, Green Published			2022-12-27	WOS:000083176400104
J	Stark, JM; Cooper, TA; Roth, MB				Stark, JM; Cooper, TA; Roth, MB			The relative strengths of SR protein-mediated associations of alternative and constitutive exons can influence alternative splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; TROPONIN-T-GENE; ENHANCER; MUSCLE; RECOGNITION; COMPLEX; BINDING; INTRON; SITES	We have characterized the functional role of SR protein-mediated exon/exon associations in the alternative splicing of exon 5 of chicken cardiac troponin T (cTnT). We have previously shown that SR proteins can promote the association of the alternative exon 5 with the flanking constitutive exon 6 of this pre-mRNA. In this study, we have shown that when exons 2, 3, and 4 of the cTnT pre-mRNA are spliced together, the composite exon 2/3/4 contains an additional SR protein binding site. Furthermore, we have found that SR proteins can also promote interactions between the pairs of exons 2/3/4-5 and 2/3/ 4-6. We then asked whether the SR protein binding sites in these exons play a role in cTnT alternative splicing in vivo. We found that the SR protein binding sites in exons 2/3/4 and 6 promote exon 5 skipping, and it has previously been shown that the SR protein binding site in exon 5 promotes exon 5 inclusion. Consistent with these results, we find that the SR protein-mediated association of exon 2/3/4 with 6 is preferred over associations involving exon 5, in that exons 2/3/4 and 6 are more efficient than exon 5 in competing an SR protein-mediated exon/exon association. We suggest that the relative strengths of SR protein-mediated associations of alternative and constitutive exons play a role in determining alternative splicing patterns.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98104 USA; Fred Hutchinson Canc Res Ctr, Mol & Cellular Biol Program, Seattle, WA 98104 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; Baylor College of Medicine; Baylor College of Medicine	Roth, MB (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1124 Columbia St, Seattle, WA 98104 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL045565, R01HL045565] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270, R01GM048435] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45565] Funding Source: Medline; NIGMS NIH HHS [GM48435, T32 GM07270] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abovich N, 1997, CELL, V89, P403, DOI 10.1016/S0092-8674(00)80221-4; BAUREN G, 1994, CELL, V76, P183, DOI 10.1016/0092-8674(94)90182-1; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; BEYER AL, 1988, GENE DEV, V2, P754, DOI 10.1101/gad.2.6.754; BLACK DL, 1995, RNA, V1, P763; COOPER TA, 1988, NUCLEIC ACIDS RES, V16, P8443, DOI 10.1093/nar/16.17.8443; Cooper TA, 1998, MOL CELL BIOL, V18, P4519, DOI 10.1128/MCB.18.8.4519; COOPER TA, 1985, J BIOL CHEM, V260, P1140; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; HELFMAN DM, 1988, GENE DEV, V2, P1627, DOI 10.1101/gad.2.12a.1627; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; MOORE JM, 1993, RNA WORLD, P303; Nagel RJ, 1998, RNA, V4, P11; NASIM F, 1990, GENE DEV, V7, P1172; NEEL H, 1993, GENE DEV, V7, P2194, DOI 10.1101/gad.7.11.2194; RAMCHATESINGH J, 1995, MOL CELL BIOL, V15, P4898; Ryan KJ, 1996, MOL CELL BIOL, V16, P4014; STAKNIS D, 1994, MOL CELL BIOL, V14, P7670, DOI 10.1128/MCB.14.11.7670; Stark JM, 1998, P NATL ACAD SCI USA, V95, P2163, DOI 10.1073/pnas.95.5.2163; TSUKAHARA T, 1994, NUCLEIC ACIDS RES, V22, P2318, DOI 10.1093/nar/22.12.2318; WANG Z, 1995, RNA, V1, P21; XU RS, 1993, MOL CELL BIOL, V13, P3660, DOI 10.1128/MCB.13.6.3660; ZAHLER AM, 1993, MOL CELL BIOL, V13, P4023, DOI 10.1128/MCB.13.7.4023; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356	25	7	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29838	29842		10.1074/jbc.274.42.29838	http://dx.doi.org/10.1074/jbc.274.42.29838			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514463	hybrid			2022-12-27	WOS:000083176400042
J	Stephens, DJ; Banting, G				Stephens, DJ; Banting, G			Direct interaction of the trans-Golgi network membrane protein, TGN38, with the F-actin binding protein, neurabin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAIN; CYTOSOLIC DOMAIN; ADAPTER-COMPLEX; CELL-SURFACE; MONOCLONAL-ANTIBODY; MYOSIN-II; LOCALIZATION; RECEPTOR; IDENTIFICATION; CYTOSKELETON	TGN38 is a type I integral membrane protein that constitutively cycles between the trans-Golgi network (TGN) and plasma membrane. The cytosolic domain of TGN38 interacts with AP2 clathrin adaptor complexes via the tyrosine-containing motif (-SDYQRL-) to direct internalization from the plasma membrane, This motif has previously been shown to direct both internalization and subsequent TGN targeting of TGN38. We have used the cytosolic domain of TGN38 in a two-hybrid screen, and we have identified the brain-specific F-actin binding protein neurabin-I as a TGN38-binding protein. We demonstrate a direct interaction between TGN38 and the ubiquitous homologue of neurabin-I, neurabin-II (also called spinophilin), We have used a combination of yeast two-hybrid and in vitro protein interaction assays to show that this interaction is dependent on the serine (but not tyrosine) residue of the known TGN38 trafficking motif, We shaw that TGN38 interacts with the coiled coil region of neurabin in vitro and binds preferentially with the dimeric form of neurabin. TGN38 and neurabin also interact in vivo as demonstrated by coimmunoprecipitation from stably transfected PC12 cells, These data suggest that neurabin provides a direct physical link between TGN38-containing membranes and the actin cytoskeleton.	Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Bristol	Banting, G (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Univ Walk, Bristol BS8 1TD, Avon, England.			Stephens, David/0000-0001-5297-3240; Banting, George/0000-0001-8249-1621				Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; Banting G, 1997, BBA-MOL CELL RES, V1355, P209, DOI 10.1016/S0167-4889(96)00146-2; BARON MD, 1990, J BIOL CHEM, V265, P19928; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; BURKE B, 1982, EMBO J, V1, P1621, DOI 10.1002/j.1460-2075.1982.tb01364.x; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P8351, DOI 10.1073/pnas.95.14.8351; Chen LH, 1998, J BIOL CHEM, V273, P33524, DOI 10.1074/jbc.273.50.33524; Crump CM, 1998, J BIOL CHEM, V273, P28073, DOI 10.1074/jbc.273.43.28073; Diaz E, 1998, CELL, V93, P433, DOI 10.1016/S0092-8674(00)81171-X; Durrbach A, 1996, J CELL SCI, V109, P457; FATH KR, 1993, J CELL BIOL, V120, P117, DOI 10.1083/jcb.120.1.117; FATH KR, 1994, J CELL BIOL, V126, P661, DOI 10.1083/jcb.126.3.661; Fernandez-Larrea J, 1999, MOL CELL, V3, P423, DOI 10.1016/S1097-2765(00)80470-0; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Heimann K, 1999, J BIOL CHEM, V274, P10743, DOI 10.1074/jbc.274.16.10743; HORN M, 1994, BIOCHEM J, V301, P69, DOI 10.1042/bj3010069; Hsu SC, 1999, TRENDS CELL BIOL, V9, P150, DOI 10.1016/S0962-8924(99)01516-0; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; JONES SM, 1993, J CELL BIOL, V122, P775, DOI 10.1083/jcb.122.4.775; Jones SM, 1997, J CELL BIOL, V139, P339, DOI 10.1083/jcb.139.2.339; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KUZNETSOV SA, 1992, NATURE, V356, P722, DOI 10.1038/356722a0; Lamaze C, 1997, J BIOL CHEM, V272, P20332, DOI 10.1074/jbc.272.33.20332; Liu GP, 1997, J CELL BIOL, V139, P1719, DOI 10.1083/jcb.139.7.1719; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; Meyer SC, 1997, J BIOL CHEM, V272, P2914, DOI 10.1074/jbc.272.5.2914; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; Musch A, 1997, J CELL BIOL, V138, P291, DOI 10.1083/jcb.138.2.291; Nakanishi H, 1997, J CELL BIOL, V139, P951, DOI 10.1083/jcb.139.4.951; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; OHTA Y, 1991, CELL, V67, P275, DOI 10.1016/0092-8674(91)90179-3; PONNAMBALAM S, 1994, J CELL BIOL, V125, P253, DOI 10.1083/jcb.125.2.253; REAVES B, 1993, MOL BIOL CELL, V4, P93, DOI 10.1091/mbc.4.1.93; REAVES B, 1992, BIOCHEM J, V283, P313, DOI 10.1042/bj2830313; Roquemore EP, 1998, MOL BIOL CELL, V9, P2125, DOI 10.1091/mbc.9.8.2125; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SALMON ED, 1989, CURR OPIN CELL BIOL, V1, P89; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; Satoh A, 1998, J BIOL CHEM, V273, P3470, DOI 10.1074/jbc.273.6.3470; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Seaman MNJ, 1997, J CELL BIOL, V137, P79, DOI 10.1083/jcb.137.1.79; Seaman MNJ, 1998, J CELL BIOL, V142, P665, DOI 10.1083/jcb.142.3.665; SHARMA CP, 1995, J IMMUNOL, V154, P3461; Smith FD, 1999, J BIOL CHEM, V274, P19894, DOI 10.1074/jbc.274.28.19894; Stephens DJ, 1997, FEBS LETT, V416, P27, DOI 10.1016/S0014-5793(97)01165-4; Stephens DJ, 1997, J BIOL CHEM, V272, P14104, DOI 10.1074/jbc.272.22.14104; Stephens DJ, 1998, BIOCHEM J, V335, P567, DOI 10.1042/bj3350567; Stow JL, 1998, TRENDS CELL BIOL, V8, P138, DOI 10.1016/S0962-8924(98)01238-0; Stow JL, 1998, BBA-MOL CELL RES, V1404, P161, DOI 10.1016/S0167-4889(98)00055-X; VAJTEK AB, 1993, CELL, V74, P205; Valderrama F, 1998, EUR J CELL BIOL, V76, P9, DOI 10.1016/S0171-9335(98)80012-5; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; WHITBY FG, 1992, J MOL BIOL, V227, P441, DOI 10.1016/0022-2836(92)90899-U; WILDE A, 1992, FEBS LETT, V313, P235, DOI 10.1016/0014-5793(92)81199-V; WONG SH, 1993, J BIOL CHEM, V268, P22853; ZEHAVIFEFERMAN R, 1995, FEBS LETT, V368, P122, DOI 10.1016/0014-5793(95)00613-E	58	41	45	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30080	30086		10.1074/jbc.274.42.30080	http://dx.doi.org/10.1074/jbc.274.42.30080			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514494	hybrid			2022-12-27	WOS:000083176400073
J	Cassano, S; Di Lieto, A; Cerillo, R; Avvedimento, EV				Cassano, S; Di Lieto, A; Cerillo, R; Avvedimento, EV			Membrane-bound cAMP-dependent protein kinase controls cAMP-induced differentiation in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; CYCLIC-AMP; II-BETA; GENE-EXPRESSION; REGULATORY SUBUNIT; HYDROXYLASE GENE; A-KINASE; TRANSCRIPTION; LOCALIZATION; STIMULATION	The A126 cell line, a derivative of PC12, is defective in cAMP-induced transcription and does not differentiate in the presence of cAMP. In these cells overexpression of a cAMP-dependent protein kinase (PKA) anchor protein, AKAP75, and of the PKA catalytic subunit substantially increased the fraction of PKAIII bound to the membrane, stimulated the transcription of cAMP-induced genes, and induced terminal differentiation. Conversely, wild type PC12 cells expressing a derivative of the AKAP75 protein, AKAP45, which binds the PKA regulatory subunits RII, but fails to locate them to the membranes, induced translocation of PKAII to the cytosol, These cells did not efficiently accumulate PRA catalytic subunit in the nuclei when stimulated with CAMP, did not transcribe cAMP-induced genes, and failed to differentiate when exposed to cAMP. These data indicate that membrane-bound PKA positively controls the transcription of cAMP-induced genes and differentiation in PC12 cells.	Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Mol & Cellulare, CNR,Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Univ Catanzaro Magna Graecia, Fac Med & Chirurg, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Magna Graecia University of Catanzaro	Cassano, S (corresponding author), Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Mol & Cellulare, CNR,Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy.			CASSANO, SILVANA/0000-0001-9868-7936				Cassano S, 1996, J BIOL CHEM, V271, P29870, DOI 10.1074/jbc.271.47.29870; Corbitt J, 1998, J NEUROCHEM, V71, P478; DAMON DH, 1990, J CELL BIOL, V110, P1333, DOI 10.1083/jcb.110.4.1333; Feliciello A, 1997, CURR BIOL, V7, P1011, DOI 10.1016/S0960-9822(06)00424-6; Feliciello A, 1998, J BIOL CHEM, V273, P23361, DOI 10.1074/jbc.273.36.23361; Feliciello A, 1996, J BIOL CHEM, V271, P25350, DOI 10.1074/jbc.271.41.25350; GALLO A, 1992, GENE DEV, V6, P1621, DOI 10.1101/gad.6.9.1621; GLANTZ SB, 1993, J BIOL CHEM, V268, P12796; GLANTZ SB, 1992, MOL BIOL CELL, V3, P1215, DOI 10.1091/mbc.3.11.1215; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HENDERSON LP, 1994, J NEUROSCI, V14, P1153, DOI 10.1523/JNEUROSCI.14-03-01153.1994; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; HOFMANN F, 1975, J BIOL CHEM, V250, P7795; KAANG BK, 1992, P NATL ACAD SCI USA, V89, P1133, DOI 10.1073/pnas.89.3.1133; KIM KS, 1994, J NEUROSCI, V14, P7200; LEISER M, 1986, J BIOL CHEM, V261, P1904; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; NDUBUKA C, 1993, J BIOL CHEM, V268, P7621; POSSENTI R, 1992, P NATL ACAD SCI USA, V89, P3815, DOI 10.1073/pnas.89.9.3815; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; Sambrook J., 2002, MOL CLONING LAB MANU; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; URSINI MV, 1988, BIOCHEM BIOPH RES CO, V150, P287, DOI 10.1016/0006-291X(88)90518-9; VANBUSKIRK R, 1985, MOL CELL BIOL, V5, P1984, DOI 10.1128/MCB.5.8.1984	29	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32574	32579		10.1074/jbc.274.46.32574	http://dx.doi.org/10.1074/jbc.274.46.32574			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551810	hybrid			2022-12-27	WOS:000083623000010
J	Blanchard, CZ; Chapman-Smith, A; Wallace, JC; Waldrop, GL				Blanchard, CZ; Chapman-Smith, A; Wallace, JC; Waldrop, GL			The biotin domain peptide from the biotin carboxyl carrier protein of Escherichia coli acetyl-CoA carboxylase causes a marked increase in the catalytic efficiency of biotin carboxylase and carboxyltransferase relative to free biotin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A CARBOXYLASE; PURIFICATION; SUBUNIT; EXPRESSION; BINDING	Acetyl-CoA carboxylase catalyzes the first committed step in the biosynthesis of long-chain fatty acids. The Escherichia coli form of the enzyme consists of a biotin carboxylase activity, a biotin carboxyl carrier protein, and a carboxyltransferase activity. The C-terminal 87 amino acids of the biotin carboxyl carrier protein (BCCP87) form a domain that can be independently expressed, biotinylated, and purified (Chapman-Smith, A., Turner, D. L., Cronan, J. E., Morris, T. W., and Wallace, J, C, (1994) Biochem, J, 302, 881-887), The ability of the biotinylated form of this 87-residue protein (holo BCCP87) to act as a substrate for biotin carboxylase and carboxyltransferase was assessed and compared with the results with free biotin, In the case of biotin carboxylase holoBCCP87 was an excellent substrate with a K-m, of 0.16 +/- 0.05 mM and V-max of 1000.8 +/- 182.0 min(-1). The V/K or catalytic efficiency of biotin carboxylase with holoBCCP87 as substrate was 8000-fold greater than with biotin as substrate. Stimulation of the ATP synthesis reaction of biotin carboxylase where carbamyl phosphate reacted with ADP by holoBCCP87 was 5-fold greater than with an equivalent amount of biotin, The interaction of holoBCCP87 with carboxyltransferase was characterized in the reverse direction where malonyl-CoA reacted with holoBCCP87 to form acetyl-CoA and carboxyholoBCCP87, The K-m for holoBCCP87 was 0.45 +/- 0.07 mM while the V-max was 2031.8 +/- 231.0 min(-1). The V/K or catalytic efficiency of carboxyltransferase.	Louisiana State Univ, Dept Biol Sci, Div Biochem & Mol Biol, Baton Rouge, LA 70803 USA; Univ Adelaide, Dept Biochem, Adelaide, SA 5005, Australia	Louisiana State University System; Louisiana State University; University of Adelaide	Waldrop, GL (corresponding author), Louisiana State Univ, Dept Biol Sci, Div Biochem & Mol Biol, Rm 508 Life Sci Bldg, Baton Rouge, LA 70803 USA.		, John/AAP-5150-2020		NIGMS NIH HHS [GM51261] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051261] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Athappilly FK, 1995, STRUCTURE, V3, P1407, DOI 10.1016/S0969-2126(01)00277-5; Blanchard CZ, 1998, J BIOL CHEM, V273, P19140, DOI 10.1074/jbc.273.30.19140; Blanchard CZ, 1999, BIOCHEMISTRY-US, V38, P3393, DOI 10.1021/bi982660a; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; ChapmanSmith A, 1997, J BIOL CHEM, V272, P26017, DOI 10.1074/jbc.272.41.26017; CHAPMANSMITH A, 1994, BIOCHEM J, V302, P881, DOI 10.1042/bj3020881; CLIMENT I, 1986, ARCH BIOCHEM BIOPHYS, V251, P465, DOI 10.1016/0003-9861(86)90353-X; CRONAN JE, 1988, J BIOL CHEM, V263, P10332; FALL RR, 1973, J BIOL CHEM, V248, P2078; GUCHHAIT RB, 1974, J BIOL CHEM, V249, P6633; JENCKS WP, 1987, COLD SPRING HARB SYM, V52, P65, DOI 10.1101/SQB.1987.052.01.010; KONDO H, 1983, B CHEM SOC JPN, V56, P1176, DOI 10.1246/bcsj.56.1176; Lane M D, 1974, Curr Top Cell Regul, V8, P139; Nenortas E, 1996, J BIOL CHEM, V271, P7559, DOI 10.1074/jbc.271.13.7559; NERVI AM, 1971, ARCH BIOCHEM BIOPHYS, V143, P401, DOI 10.1016/0003-9861(71)90227-X; POLAKIS SE, 1974, J BIOL CHEM, V249, P6657; Roberts EL, 1999, BIOCHEMISTRY-US, V38, P5045, DOI 10.1021/bi982466o; TANABE T, 1975, EUR J BIOCHEM, V57, P15, DOI 10.1111/j.1432-1033.1975.tb02272.x; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WHITTY A, 1995, BIOCHEMISTRY-US, V34, P11678, DOI 10.1021/bi00037a005; Yao X, 1997, BIOCHEMISTRY-US, V36, P15089, DOI 10.1021/bi971485f; Yao X, 1999, PROTEIN SCI, V8, P307	22	27	27	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31767	31769		10.1074/jbc.274.45.31767	http://dx.doi.org/10.1074/jbc.274.45.31767			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542197	hybrid			2022-12-27	WOS:000083532100005
J	Vanden Berghe, W; De Bosscher, K; Boone, E; Plaisance, S; Haegeman, G				Vanden Berghe, W; De Bosscher, K; Boone, E; Plaisance, S; Haegeman, G			The nuclear factor-kappa B engages CBP/p300 and histone acetyltransferase activity for transcriptional activation of the interleukin-6 gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; STEROID-RECEPTOR COACTIVATOR-1; DEPENDENT TRANSCRIPTION; SIGNAL-TRANSDUCTION; PROTEIN-SYNTHESIS; FACTOR-ALPHA; NF-Y; ACETYLATION; DEACETYLASE; CHROMATIN	Expression of the pleiotropic cytokine interleukin (IL)-6 can be stimulated by the proinflammatory cytokine tumor necrosis factor (TNF) and the microbial alkaloid staurosporine (STS). In this report, the transcriptional mechanisms were thoroughly investigated. Whereas transcription factors binding to the activator protein-1-, cAMP-responsive element-, and CAAT enhancer-binding protein-responsive sequences are necessary for gene activation by STS, nuclear factor (NF)-kappa B alone is responsible and sufficient for inducibility by TNF, which reveals distinct signaling pathways for both compounds. At the cofactor level, cAMP-responsive element-binding protein-binding protein (CBP) or p300 potentiate basal and induced IL-6 promoter activation via multiple protein-protein interactions with all transcription factors bound to the promoter DNA. However, the strongest promoter activation relies on the p65 NF-kappa B subunit, which specifically engages CBP/p300 for maximal transcriptional stimulation by its histone acetyltransferase activity. Moreover, treatment of chromatin-integrated promoter constructions with the histone deacetylase inhibitor trichostatin A exclusively potentiates TNF-dependent (ie. NF-kappa B-mediated) gene activation, while basal or STS-stimulated IL-6 promoter activity remains completely unchanged. Similar observations were recorded with other natural NF-kappa B-driven promoters, namely IL-8 and endothelial leukocyte adhesion molecule (ELAM). We conclude that, within an "enhanceosome-like" structure, NF-kappa B is the central mediator of TNF-induced IL-6 gene expression, involving CBP/p300 and requiring histone acetyltransferase activity.	Univ Ghent, Dept Mol Biol, B-9000 Ghent, Belgium; Flanders Interuniv Inst Biotechnol, B-9000 Ghent, Belgium	Ghent University	Haegeman, G (corresponding author), Univ Ghent, Dept Mol Biol, KL Ledeganckstr 35, B-9000 Ghent, Belgium.	guy.haegeman@dmb.rug.ac.be	Vanden Berghe, Wim/HGE-4696-2022; Plaisance, Stephane/B-3488-2009; Berghe, Wim Vanden/S-6425-2018; Plaisance, Stephane/ABI-6307-2020	Plaisance, Stephane/0000-0002-1651-241X; Berghe, Wim Vanden/0000-0003-0161-7355; Plaisance, Stephane/0000-0002-1651-241X; De Bosscher, Karolien/0000-0001-5059-9718				Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; Berger SL, 1999, CURR OPIN CELL BIOL, V11, P336, DOI 10.1016/S0955-0674(99)80046-5; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; Bestor TH, 1998, NATURE, V393, P311, DOI 10.1038/30613; BEYAERT R, 1993, CANCER RES, V53, P2623; Bjorklund S, 1999, CELL, V96, P759, DOI 10.1016/S0092-8674(00)80586-3; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Bruening W, 1998, NUCLEIC ACIDS RES, V26, P486, DOI 10.1093/nar/26.2.486; Calkhoven CF, 1996, BIOCHEM J, V317, P329, DOI 10.1042/bj3170329; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; DENDORFER U, 1994, MOL CELL BIOL, V14, P4443, DOI 10.1128/MCB.14.7.4443; Eckner R, 1996, BIOL CHEM, V377, P685; Espinos E, 1999, MOL CELL BIOL, V19, P3474; Gadient RA, 1997, PROG NEUROBIOL, V52, P379, DOI 10.1016/S0301-0082(97)00021-X; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Hampsey M, 1999, CURR OPIN GENET DEV, V9, P132, DOI 10.1016/S0959-437X(99)80020-3; Han J, 1999, NAT CELL BIOL, V1, pE39, DOI 10.1038/10032; Hsieh JJD, 1999, P NATL ACAD SCI USA, V96, P23, DOI 10.1073/pnas.96.1.23; Ikeda K, 1999, MOL CELL BIOL, V19, P855; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269; Keller ET, 1996, FRONT BIOSCI, V1, P340, DOI DOI 10.2741/A136; Koj A, 1996, BBA-MOL BASIS DIS, V1317, P84, DOI 10.1016/S0925-4439(96)00048-8; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; Li Q, 1998, EMBO J, V17, P6300, DOI 10.1093/emboj/17.21.6300; Liu YZ, 1998, J BIOL CHEM, V273, P32400, DOI 10.1074/jbc.273.49.32400; Magnaghi-Jaulin L, 1999, SEMIN CELL DEV BIOL, V10, P197, DOI 10.1006/scdb.1999.0301; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Medina V, 1997, CANCER RES, V57, P3697; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Minucci S, 1997, P NATL ACAD SCI USA, V94, P11295, DOI 10.1073/pnas.94.21.11295; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; Myers CA, 1998, MOL CELL BIOL, V18, P2184, DOI 10.1128/MCB.18.4.2184; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Parekh BS, 1999, MOL CELL, V3, P125, DOI 10.1016/S1097-2765(00)80181-1; Parker D, 1998, MOL CELL, V2, P353, DOI 10.1016/S1097-2765(00)80279-8; Perissi V, 1999, P NATL ACAD SCI USA, V96, P3652, DOI 10.1073/pnas.96.7.3652; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Plaisance S, 1997, MOL CELL BIOL, V17, P3733, DOI 10.1128/MCB.17.7.3733; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; Sheridan PL, 1997, GENE DEV, V11, P3327, DOI 10.1101/gad.11.24.3327; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Thomson S, 1999, SEMIN CELL DEV BIOL, V10, P205, DOI 10.1006/scdb.1999.0302; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; VanLint C, 1996, EMBO J, V15, P1112, DOI 10.1002/j.1460-2075.1996.tb00449.x; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	64	290	297	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32091	32098		10.1074/jbc.274.45.32091	http://dx.doi.org/10.1074/jbc.274.45.32091			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542243	hybrid			2022-12-27	WOS:000083532100051
J	Wilkens, S; Vasilyeva, E; Forgac, M				Wilkens, S; Vasilyeva, E; Forgac, M			Structure of the vacuolar ATPase by electron microscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICLE PROTON PUMP; V-TYPE ATPASE; H+-ATPASE; ESCHERICHIA-COLI; NEUROSPORA-CRASSA; 2ND STALK; SUBUNIT; SYNTHASE; COMPLEX; F-0	The structure of the vacuolar ATPase from bovine brain clathrin-coated vesicles has been determined by electron microscopy of negatively stained, detergent-solubilized enzyme molecules. Preparations of both lipid-containing and delipidated enzyme have been analyzed, The complex is organized in two major domains, a V-1 and V-0, with overall dimensions of 28 x 14 x 14 nm, The V-1 is a more or less spherical molecule with a central cavity. The V-0 has the shape of a flattened sphere or doughnut with a radius of about 100 Angstrom. The V-1 and V-0 are joined by a 60-Angstrom long and 40-Angstrom wide central stalk, consisting of several individual protein densities. Two kinds of smaller densities are visible at the top periphery of the V-1, and one of these seems to extend all the way down to the stalk domain in some averages. Images of both the lipid-containing and the delipidated complex show a 30-50-kDa protein density on the lumenal side of the complex, opposite the central stalk, centered in the ring of c subunits. A large trans-membrane mass, probably the C-terminal domain of the 100-kDa subunit a, is seen at the periphery of the c subunit ring in some projections. This large mass has both a lumenal and a cytosolic domain, and it is the cytosolic domain that interacts with the central stalk. Two to three additional protein densities can be seen in the V-1-V-0 interface, all connected to the central stalk. Overall, the structure of the V-ATPase is similar to the structure of the related F1F0-ATP synthase, confirming their common origin.	Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA; Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA	University of California System; University of California Riverside; Tufts University	Wilkens, S (corresponding author), Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034478, R37GM034478] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM034478, GM34478] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ARAI H, 1987, BIOCHEMISTRY-US, V26, P6632, DOI 10.1021/bi00395a011; ARAI H, 1988, J BIOL CHEM, V263, P8796; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; BIRKENHAGER R, 1995, EUR J BIOCHEM, V230, P58, DOI 10.1111/j.1432-1033.1995.tb20534.x; Boekema EJ, 1998, PHOTOSYNTH RES, V57, P267, DOI 10.1023/A:1006044931980; Boekema EJ, 1997, P NATL ACAD SCI USA, V94, P14291, DOI 10.1073/pnas.94.26.14291; Bottcher B, 1998, J MOL BIOL, V281, P757, DOI 10.1006/jmbi.1998.1957; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; Capaldi RA, 1996, J BIOENERG BIOMEMBR, V28, P397, DOI 10.1007/BF02113980; DSCHIDA WJ, 1992, J BIOL CHEM, V267, P18783; DUBE P, 1993, EMBO J, V12, P1303, DOI 10.1002/j.1460-2075.1993.tb05775.x; Fillingame RH, 1997, J EXP BIOL, V200, P217; Finbow ME, 1997, BIOCHEM J, V324, P697, DOI 10.1042/bj3240697; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; HO MN, 1993, J BIOL CHEM, V268, P18286; Jones PC, 1995, BIOCHEM J, V312, P739, DOI 10.1042/bj3120739; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; KANE PM, 1995, J BIOL CHEM, V270, P17025; Leng XH, 1996, J BIOL CHEM, V271, P22487, DOI 10.1074/jbc.271.37.22487; Leng XH, 1999, J BIOL CHEM, V274, P14655, DOI 10.1074/jbc.274.21.14655; LUCKEN U, 1990, BIOCHEMISTRY-US, V29, P5339; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; PALI T, 1995, BIOCHEMISTRY-US, V34, P9211, DOI 10.1021/bi00028a034; PUOPOLO K, 1992, J BIOL CHEM, V267, P5171; Rodgers AJW, 1998, J BIOL CHEM, V273, P29406, DOI 10.1074/jbc.273.45.29406; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SUPEK F, 1994, J BIOL CHEM, V269, P24102; Supekova L, 1996, J EXP BIOL, V199, P1147; TAIZ SL, 1991, BOT ACTA, V104, P117, DOI 10.1111/j.1438-8677.1991.tb00206.x; Tomashek JJ, 1997, J BIOL CHEM, V272, P26787, DOI 10.1074/jbc.272.42.26787; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; Wilkens S, 1998, NATURE, V393, P29, DOI 10.1038/29908; XIE XS, 1994, J BIOL CHEM, V269, P25809; Yasuda R, 1997, J BIOENERG BIOMEMBR, V29, P207, DOI 10.1023/A:1022449708449; ZHANG JM, 1992, J BIOL CHEM, V267, P9773; Zhou YT, 1997, P NATL ACAD SCI USA, V94, P10583, DOI 10.1073/pnas.94.20.10583; Zhou ZM, 1998, J BIOL CHEM, V273, P5878, DOI 10.1074/jbc.273.10.5878; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	40	122	123	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31804	31810		10.1074/jbc.274.45.31804	http://dx.doi.org/10.1074/jbc.274.45.31804			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542203	hybrid			2022-12-27	WOS:000083532100011
J	Pollack, BP; Kotenko, SV; He, W; Izotova, LS; Barnoski, BL; Pestka, S				Pollack, BP; Kotenko, SV; He, W; Izotova, LS; Barnoski, BL; Pestka, S			The human homologue of the yeast proteins Skb1 and Hsl7p interacts with Jak kinases and contains protein methyltransferase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOKINE-RECEPTOR SUPERFAMILY; ADENOSYLMETHIONINE-DEPENDENT METHYLTRANSFERASES; ADENOSYL-L-METHIONINE; MYELIN BASIC-PROTEIN; MICE LACKING JAK3; SIGNAL-TRANSDUCTION; S-ADENOSYLMETHIONINE; SACCHAROMYCES-CEREVISIAE; JAK/STAT PATHWAY; TYROSINE KINASE	To expand our understanding of the role of Jak2 in cellular signaling, we used the yeast two-hybrid system to identify Jak2-interacting proteins. One of the clones identified represents a human homologue of the Schizosaccaromyces pombe Shk1 kinase-binding protein 1, Skb1, and the protein encoded by the Saccharomyces cerevisiae HSL7 (histone synthetic lethal 7) gene. Since no functional motifs or biochemical activities for this protein or its homologues had been reported, we sought to determine a biochemical function for this human protein. We demonstrate that this protein is a protein methyltransferase. This protein, designated JBP1 (Jak-binding protein 1), and its homologues contain motifs conserved among protein methyltransferases. JBP1 can be cross-linked to radiolabeled S-adenosylmethionine (AdoMet) and methylates histones (H2A and H4) and myelin basic protein. Mutants containing substitutions within a conserved region likely to be involved in AdoMet binding exhibit little or no activity. We mapped the JBP1 gene to chromosome 14q11.2-21. In addition, JBP1 co-immunoprecipitates with several other proteins, which serve as methyl group accepters and which may represent physiological targets of this methlyltransferase. Messenger RNA for JBP1 is widely expressed in human tissues. We have also identified and sequenced a homologue of JBP1 in Drosophila melanogaster. This report provides a clue to the biochemical function for this conserved protein and suggests that protein methyltransferases may have a role in cellular signaling.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA; Cooper Univ Hosp, Childrens Reg Hosp, Div Pediat Hematol Oncol, Camden, NJ 08103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Cooper University Hospital	Pestka, S (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, 675 Hoes Ln, Piscataway, NJ 08854 USA.				NCI NIH HHS [R01-CA46465] Funding Source: Medline; NIAID NIH HHS [2T32AI07403, R01 AI36450] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046465] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007403, R01AI036450] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abramovich C, 1997, EMBO J, V16, P260, DOI 10.1093/emboj/16.2.260; Aleta JM, 1998, TRENDS BIOCHEM SCI, V23, P89, DOI 10.1016/S0968-0004(98)01185-2; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BALDWIN GS, 1971, SCIENCE, V171, P579, DOI 10.1126/science.171.3971.579; BRISCOE J, 1994, CURR BIOL, V4, P1033, DOI 10.1016/S0960-9822(00)00236-0; Briscoe J, 1996, EMBO J, V15, P799, DOI 10.1002/j.1460-2075.1996.tb00415.x; BROSTOFF S, 1971, P NATL ACAD SCI USA, V68, P765, DOI 10.1073/pnas.68.4.765; CANNIZZARO LA, 1984, CYTOGENET CELL GENET, V38, P308, DOI 10.1159/000132079; CHAUHAN D, 1995, J EXP MED, V182, P1801, DOI 10.1084/jem.182.6.1801; CHENG XD, 1993, CELL, V74, P299, DOI 10.1016/0092-8674(93)90421-L; Clarke S, 1993, CURR OPIN CELL BIOL, V5, P977, DOI 10.1016/0955-0674(93)90080-A; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Das R, 1996, ONCOGENE, V13, P1139; Djordjevic S, 1997, STRUCTURE, V5, P545, DOI 10.1016/S0969-2126(97)00210-4; FAROOQUI JZ, 1985, J BIOL CHEM, V260, P537; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIELDS S, 1993, CELLULAR INTERACTION, P153; FINBLOOM DS, 1995, CELL SIGNAL, V7, P739, DOI 10.1016/0898-6568(95)02004-7; FUHRER DK, 1995, J BIOL CHEM, V270, P24826, DOI 10.1074/jbc.270.42.24826; Fuhrer DK, 1996, BIOCHEM BIOPH RES CO, V224, P289, DOI 10.1006/bbrc.1996.1023; GAROTTA G, 1990, J BIOL CHEM, V265, P6908; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; Gary JD, 1996, J BIOL CHEM, V271, P12585, DOI 10.1074/jbc.271.21.12585; Gauzzi MC, 1997, P NATL ACAD SCI USA, V94, P11839, DOI 10.1073/pnas.94.22.11839; *GEN COMP GROUP, WISC PACK VERS 9 1; GHOSH SK, 1988, J BIOL CHEM, V263, P19024; Gilbreth M, 1998, P NATL ACAD SCI USA, V95, P14781, DOI 10.1073/pnas.95.25.14781; Gilbreth M, 1996, P NATL ACAD SCI USA, V93, P13802, DOI 10.1073/pnas.93.24.13802; GILMOUR KC, 1995, GENE EXPRESSION, V5, P1; GIORGETTI-PERALDI S, 1995, EUR J BIOCHEM, V234, P656, DOI 10.1111/j.1432-1033.1995.656_b.x; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; GuilletDeniau I, 1997, J BIOL CHEM, V272, P14825, DOI 10.1074/jbc.272.23.14825; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARPER JW, 1993, CELL, V75, P805; HE TC, 1995, J BIOL CHEM, V270, P11055, DOI 10.1074/jbc.270.19.11055; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; Ihle J N, 1995, Semin Immunol, V7, P247, DOI 10.1006/smim.1995.0029; IHLE JN, 1994, BAILLIERE CLIN HAEM, V7, P17, DOI 10.1016/S0950-3536(05)80005-8; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; Ihle JN, 1995, ADV IMMUNOL, V60, P1, DOI 10.1016/S0065-2776(08)60582-9; IHLE JN, 1994, BLOOD CELLS, V20, P65; INGROSSO D, 1989, J BIOL CHEM, V264, P20131; Jiao HY, 1996, MOL CELL BIOL, V16, P6985; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; Katsanis N, 1997, MAMM GENOME, V8, P526, DOI 10.1007/s003359900491; Kim S, 1997, BIOCHEMISTRY-US, V36, P5185, DOI 10.1021/bi9625509; Kim S, 1997, INT J BIOCHEM CELL B, V29, P743, DOI 10.1016/S1357-2725(97)00009-5; Kirken Robert A., 1994, Progress in Growth Factor Research, V5, P195, DOI 10.1016/0955-2235(94)90005-1; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Kotenko SV, 1997, EMBO J, V16, P5894, DOI 10.1093/emboj/16.19.5894; Krapivinsky G, 1998, J BIOL CHEM, V273, P10811, DOI 10.1074/jbc.273.18.10811; KUWANO A, 1991, AM J HUM GENET, V49, P707; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; LEE HW, 1977, BIOCHEMISTRY-US, V16, P78, DOI 10.1021/bi00620a013; Liao HJ, 1997, VIROLOGY, V235, P235, DOI 10.1006/viro.1997.8694; LIM JK, 1993, BIOCHIM BIOPHYS ACTA, V1173, P314, DOI 10.1016/0167-4781(93)90129-2; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; LUO H, 1995, EMBO J, V14, P1412, DOI 10.1002/j.1460-2075.1995.tb07127.x; Luo H, 1997, MOL CELL BIOL, V17, P1562, DOI 10.1128/MCB.17.3.1562; Ma XJ, 1996, GENE DEV, V10, P1327, DOI 10.1101/gad.10.11.1327; Maegawa H, 1996, BIOCHEM BIOPH RES CO, V228, P122, DOI 10.1006/bbrc.1996.1626; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; Nikawa J, 1996, GENE, V171, P107, DOI 10.1016/0378-1119(96)00073-X; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; Pan J, 1997, CIRC RES, V81, P611, DOI 10.1161/01.RES.81.4.611; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; POLLACK BP, 1996, EUR CYTOKINE NETW, V7, P478; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; Rui LY, 1997, MOL CELL BIOL, V17, P6633, DOI 10.1128/MCB.17.11.6633; Shen EC, 1998, GENE DEV, V12, P679, DOI 10.1101/gad.12.5.679; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SPRINGER MS, 1977, P NATL ACAD SCI USA, V74, P3312, DOI 10.1073/pnas.74.8.3312; SPRINGER MS, 1979, NATURE, V280, P279, DOI 10.1038/280279a0; SUBBARAMAIAH K, 1992, J BIOL CHEM, V267, P8636; SUSSMAN DJ, 1984, MOL CELL BIOL, V4, P1641, DOI 10.1128/MCB.4.8.1641; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WANG XY, 1995, J BIOL CHEM, V270, P27999; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WILKS AF, 1994, BIOESSAYS, V16, P313, DOI 10.1002/bies.950160505; Wilks AF, 1996, CANCER SURV, V27, P139; Winston LA, 1996, CURR BIOL, V6, P668, DOI 10.1016/S0960-9822(09)00445-X; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369	92	232	248	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31531	31542		10.1074/jbc.274.44.31531	http://dx.doi.org/10.1074/jbc.274.44.31531			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531356	hybrid			2022-12-27	WOS:000083379400060
J	Walker, JKL; Premont, RT; Barak, LS; Caron, MG; Shetzline, MA				Walker, JKL; Premont, RT; Barak, LS; Caron, MG; Shetzline, MA			Properties of secretin receptor internalization differ from those of the beta(2)-adrenergic receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; COATED VESICLE FORMATION; BETA-ARRESTIN; MEDIATED ENDOCYTOSIS; DESENSITIZATION; KINASES; PHOSPHORYLATION; RESENSITIZATION; INHIBITORS; DYNAMIN	The endocytic pathway of the secretin receptor, a class II GPCR, is unknown, Some class I G protein-coupled receptors (GPCRs), such as the beta(2)-adrenergic receptor (beta(2)-AR), internalize in clathrin-coated vesicles and this process is mediated by G protein-coupled receptor kinases (GRKs), beta-arrestin, and dynamin, However, other class I GPCRs, for example, the angiotensin II type 1A receptor (AT(1A)R), exhibit different internalization properties than the beta(2)-AR, The secretin receptor, a class II GPCR, is a GRK substrate, suggesting that like the beta(2)-AR, it may internalize via a beta-arrestin and dynamin directed process, In this paper we characterize the internalization of a wild-type and carboxyl-terminal (COOH-terminal) truncated secretin receptor using flow cytometry and fluorescence imaging, and compare the properties of secretin receptor internalization to that of the beta(2)-AR, In HEK 293 cells, sequestration of both the wild-type and COOH-terminal truncated secretin receptors was unaffected by GRK phosphorylation, whereas inhibition of cAMP-dependent protein kinase mediated phosphorylation markedly decreased sequestration, Addition of secretin to cells resulted in a rapid translocation of beta-arrestin to plasma membrane localized receptors; however, secretin receptor internalization was not reduced by expression of dominant negative beta-arrestin, Thus, like the AT(1A)R, secretin receptor internalization is not inhibited by reagents that interfere with clathrin-coated vesicle-mediated internalization and in accordance with these results, we show that secretin and AT(1A) receptors colocalize in endocytic vesicles. This study demonstrates that the ability of secretin receptor to undergo GRK phosphorylation and beta-arrestin binding is not sufficient to facilitate or mediate its internalization. These results suggest that other receptors may undergo endocytosis by mechanisms used by the secretin and AT(1A) receptors and that kinases other than GRKs may play a greater role in GPCR endocytosis than previously appreciated.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Cell Biol,Div Gastroenterol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Cell Biol,Div Cardiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med,Div Cardiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med,Div Gastroenterol, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute	Caron, MG (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Cell Biol,Div Gastroenterol, Box 3287, Durham, NC 27710 USA.		Walker, Julia/R-7585-2017	Premont, Richard/0000-0002-8053-5026	NIDDK NIH HHS [DK02544-01, 5T32DK07568] Funding Source: Medline; NINDS NIH HHS [NS19576] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002544, T32DK007568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019576] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; CLARK RB, 1988, P NATL ACAD SCI USA, V85, P1442, DOI 10.1073/pnas.85.5.1442; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DAUKAS G, 1985, J CELL BIOL, V101, P1673, DOI 10.1083/jcb.101.5.1673; FAROUK M, 1992, GASTROENTEROLOGY, V102, P963, DOI 10.1016/0016-5085(92)90183-Y; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Goretzki L, 1997, J CELL SCI, V110, P1395; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HIDAKA H, 1992, ANNU REV PHARMACOL, V32, P377, DOI 10.1146/annurev.pharmtox.32.1.377; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Holtmann MH, 1996, J BIOL CHEM, V271, P23566, DOI 10.1074/jbc.271.38.23566; Krueger KM, 1997, J BIOL CHEM, V272, P5; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; Mundell SJ, 1998, BRIT J PHARMACOL, V125, P1594, DOI 10.1038/sj.bjp.0702234; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; SALOMON Y, 1991, METHOD ENZYMOL, V195, P22; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Shetzline MA, 1998, J BIOL CHEM, V273, P6756, DOI 10.1074/jbc.273.12.6756; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; Tiberi M, 1996, J BIOL CHEM, V271, P3771; VON ZM, 1992, J BIOL CHEM, V267, P3530; Zhang J, 1999, J BIOL CHEM, V274, P10999, DOI 10.1074/jbc.274.16.10999; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	31	96	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31515	31523		10.1074/jbc.274.44.31515	http://dx.doi.org/10.1074/jbc.274.44.31515			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531354	hybrid			2022-12-27	WOS:000083379400058
J	Bertrand, F; Desbois-Mouthon, C; Cadoret, A; Prunier, C; Robin, H; Capeau, J; Atfi, A; Cherqui, G				Bertrand, F; Desbois-Mouthon, C; Cadoret, A; Prunier, C; Robin, H; Capeau, J; Atfi, A; Cherqui, G			Insulin antiapoptotic signaling involves insulin activation of the nuclear factor kappa B-dependent survival genes encoding tumor necrosis factor receptor-associated factor 2 and manganese-superoxide dismutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CELL-DEATH; INDUCED APOPTOSIS; FACTOR-KB; TNF; EXPRESSION; PHOSPHORYLATION; OVEREXPRESSION; RESISTANCE; INDUCTION; PROTEIN	We recently showed that the antiapoptotic function of insulin requires nuclear factor kappa B (NF-kappa B) activation (Bertrand, F., Atfi, A, Cadoret, A., L'Allemain, G., Robin, H., Lascols, O., Capeau, J., and Cherqui, G. (1998) J. Biol. Chem. 273, 2931-2938). Here we sought to identify the NF-kappa B-dependent survival genes that are activated by insulin to mediate this function. Insulin increased the expression of tumor necrosis factor receptor-associated factor 2 (TRAF2) mRNA and protein in Chinese hamster ovary cells overexpressing insulin receptors (IRs). This effect required (i) IR activation since it was abrogated by IR mutation at tyrosines 1162 and 1163 and (ii) NF-kappa B activation since it was abolished by overexpression of dominant-negative I kappa B-alpha(A32/36) and mimicked by overexpression of the NF-kappa B c-Rel subunit. TRAF2 contributed to insulin protection against serum withdrawal-induced apoptosis since TRAF2 overexpression mimicked insulin protection, whereas overexpression of dominant-negative TRAF2-(87-501) reduced this process. Along with its protective effect, overexpressed TRAF2 increased basal and insulin-stimulated NF-kappa B activities. All effects were inhibited by I kappa B-alpha(A32/36), suggesting that an amplification loop involving TRAF2 activation of NF-kappa B is implicated in insulin antiapoptotic signaling. We also show that insulin increased manganese-superoxide dismutase (Mn-SOD) mRNA expression through NF-kappa B activation and that Mn-SOD contributed to insulin antiapoptotic signaling since expression of antisense Mn-SOD RNA decreased this process. This study provides the first evidence that insulin activates the NF-kappa B-dependent survival genes encoding TRAF2 and Mn-SOD and thereby clarifies the role of NF-kappa B in the antiapoptotic function of insulin.	Fac Med St Antoine, INSERM, U402, Paris, France; Hop St Antoine, INSERM, U482, F-75571 Paris 12, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Cherqui, G (corresponding author), Fac Med St Antoine, INSERM, U402, 27 Rue Chaligny, Paris, France.		Frottier, Celine Prunier/G-8259-2017; Desbois-Mouthon, Christele/M-7076-2017; Cadoret, Axelle/L-2529-2017	Frottier, Celine Prunier/0000-0002-7784-0273; Desbois-Mouthon, Christele/0000-0002-0772-1711; Cadoret, Axelle/0000-0002-4283-6864				Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Bertrand F, 1998, J BIOL CHEM, V273, P2931, DOI 10.1074/jbc.273.5.2931; BERTRAND F, 1995, J BIOL CHEM, V270, P24435, DOI 10.1074/jbc.270.41.24435; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cadoret A, 1997, ONCOGENE, V14, P1589, DOI 10.1038/sj.onc.1200992; Cai ZZ, 1997, J BIOL CHEM, V272, P96; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Desbois-Mouthon C, 1998, BIOCHEM BIOPH RES CO, V243, P765, DOI 10.1006/bbrc.1998.8181; Dragovich T, 1998, ONCOGENE, V17, P3207, DOI 10.1038/sj.onc.1202587; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; Guo YS, 1998, J CELL PHYSIOL, V175, P141, DOI 10.1002/(SICI)1097-4652(199805)175:2<141::AID-JCP3>3.0.CO;2-O; HIROSE K, 1993, FASEB J, V7, P361, DOI 10.1096/fasebj.7.2.8440412; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Lee-Kwon W, 1998, BIOCHEMISTRY-US, V37, P15747, DOI 10.1021/bi9805947; Lieberthal W, 1998, AM J PHYSIOL-RENAL, V275, pF691, DOI 10.1152/ajprenal.1998.275.5.F691; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Min W, 1998, J IMMUNOL, V161, P319; Natoli G, 1998, J BIOL CHEM, V273, P31262, DOI 10.1074/jbc.273.47.31262; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Peraldi P, 1998, MOL CELL BIOCHEM, V182, P169, DOI 10.1023/A:1006865715292; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; SARMA V, 1995, J BIOL CHEM, V270, P12343, DOI 10.1074/jbc.270.21.12343; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yenush L, 1998, MOL CELL BIOL, V18, P6784, DOI 10.1128/MCB.18.11.6784; Zhou G, 1997, J BIOL CHEM, V272, P15174, DOI 10.1074/jbc.272.24.15174	36	44	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30596	30602		10.1074/jbc.274.43.30596	http://dx.doi.org/10.1074/jbc.274.43.30596			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521443	hybrid			2022-12-27	WOS:000083276700039
J	Essler, M; Retzer, M; Bauer, M; Heemskerk, JW; Aepfelbacher, M; Siess, W				Essler, M; Retzer, M; Bauer, M; Heemskerk, JW; Aepfelbacher, M; Siess, W			Mildly oxidized low density lipoprotein induces contraction of human endothelial cells through activation of Rho/Rho kinase and inhibition of myosin light chain phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE; RHO-KINASE; PROTEIN-KINASE; REORGANIZATION; SENSITIZATION; PERMEABILITY; CYTOSKELETON; RECEPTOR; FAMILY; ALPHA	Mildly oxidized low density lipoprotein (mox-LDL) is critically involved in the early atherogenic responses of the endothelium and increases endothelial permeability through an unknown signal pathway. Here we show that (i) exposure of confluent human endothelial cells (HUVEC) to mox-LDL but not to native LDL induces the formation of actin stress fibers and intercellular gaps within minutes, leading to an increase in endothelial permeability; (ii) mox-LDL induces a transient decrease in myosin light chain (MLC) phosphatase that is paralleled by an increase in MLC phosphorylation; (iii) phosphorylated MLC stimulated by mox-LDL is incorporated into stress fibers; (iv) cytoskeletal rearrangements and MLC phosphorylation are inhibited by C3 transferase from Clostridium botulinum, a specific Rho inhibitor, and Y-27632, an inhibitor of Rho kinase; and (v) mox-LDL does not increase intracellular Ca2+ concentration. Our data indicate that mox-LDL induces endothelial cell contraction through activation of Rho and its effector Rho kinase which inhibits MLC phosphatase and phosphorylates MLC. We suggest that inhibition of this novel cell signaling pathway of mox-LDL could be relevant for the prevention of atherosclerosis.	Univ Munich, Inst Prophylaxe & Epidemiol Kreislaufkrankheiten, D-80336 Munich, Germany; Max Von Pettenkofer Inst Med Mikrobiol, D-80336 Munich, Germany; Univ Maastriccht, Cardiovasc Res Inst, Dept Biochem, NL-6200 MD Maastricht, Netherlands	University of Munich; University of Munich; Maastricht University	Essler, M (corresponding author), Univ Munich, Inst Prophylaxe & Epidemiol Kreislaufkrankheiten, Pettenkoferstr 9, D-80336 Munich, Germany.		Heemskerk, Johan/AAM-8323-2021; Siess, Wolfgang/A-6430-2009	Heemskerk, Johan/0000-0002-2848-5121; Siess, Wolfgang/0000-0003-0698-6416				Auge N, 1996, CIRC RES, V79, P871, DOI 10.1161/01.RES.79.4.871; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Colangelo S, 1998, ARTERIOSCL THROM VAS, V18, P52, DOI 10.1161/01.ATV.18.1.52; Essler M, 1998, J BIOL CHEM, V273, P21867, DOI 10.1074/jbc.273.34.21867; Essler M, 1998, J IMMUNOL, V161, P5640; Fu XH, 1998, FEBS LETT, V440, P183, DOI 10.1016/S0014-5793(98)01455-0; GOECKELER ZM, 1995, J CELL BIOL, V130, P613, DOI 10.1083/jcb.130.3.613; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Gong MC, 1996, P NATL ACAD SCI USA, V93, P1340, DOI 10.1073/pnas.93.3.1340; Grand RJA, 1996, BIOCHEM J, V313, P353, DOI 10.1042/bj3130353; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Leung T, 1996, MOL CELL BIOL, V16, P5313; LIAO LX, 1995, ARTERIOSCL THROM VAS, V15, P2305, DOI 10.1161/01.ATV.15.12.2305; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; RANGASWAMY S, 1997, CIRC RES, V80, P73; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SHIRAZI A, 1994, J BIOL CHEM, V269, P31598; Siess W, 1999, P NATL ACAD SCI USA, V96, P6931, DOI 10.1073/pnas.96.12.6931; Somlyo AP, 1997, NATURE, V389, P908, DOI 10.1038/40002; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; vanHinsbergh VWM, 1997, ARTERIOSCL THROM VAS, V17, P1018, DOI 10.1161/01.ATV.17.6.1018; vanIJzendoorn SCD, 1996, BBA-MOL CELL RES, V1311, P64, DOI 10.1016/0167-4889(95)00191-3; WEIDTMANN A, 1995, ARTERIOSCL THROM VAS, V15, P1131, DOI 10.1161/01.ATV.15.8.1131; Wojciak-Stothard B, 1998, J CELL PHYSIOL, V176, P150, DOI 10.1002/(SICI)1097-4652(199807)176:1<150::AID-JCP17>3.0.CO;2-B	25	104	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30361	30364		10.1074/jbc.274.43.30361	http://dx.doi.org/10.1074/jbc.274.43.30361			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521411	hybrid			2022-12-27	WOS:000083276700007
J	Yokota, N; Kuroda, T; Matsuyama, S; Tokuda, H				Yokota, N; Kuroda, T; Matsuyama, S; Tokuda, H			Characterization of the LolA-LolB system as the general lipoprotein localization mechanism of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE LIPOPROTEIN; CYTOPLASMIC MEMBRANE; CHROMOSOME; SEQUENCE; BACTERIA; CLONING; PROTEIN	The major outer membrane lipoprotein (Lpp) of Escherichia coli requires LolA for its release from the cytoplasmic membrane, and LolB for its localization to the outer membrane. We examined the significance of the LolA-LolB system as to the outer membrane localization of other lipoproteins, All lipoproteins possessing an outer membrane-directed signal at the N-terminal second position were efficiently released from the inner membrane in the presence of LolA, Some lipoproteins were released in the absence of externally added LolA, albeit at a slower rate and to a lesser extent. This LolA-independent release was also strictly dependent on the outer membrane sorting signal. A lipoprotein-LolA complex was formed when the release took place in the presence of LolA, whereas lipoproteins released in the absence of LolA existed as heterogeneous complexes, suggesting that the release and the formation of a complex with LolA are distinct events. The release of LolB, an outer membrane lipoprotein functioning as the receptor for a lipoprotein-LolA complex, occurred with a trace amount of LolA, and therefore was extremely efficient. The LolA-dependent release of lipoproteins was found to be crucial for the specific incorporation of lipoproteins into the outer membrane, whereas lipoproteins released in the absence of LolA were nonspecifically and inefficiently incorporated into the membrane. The outer membrane incorporation of lipoproteins including LolB per se was dependent on LolB in the outer membrane. From these results, we conclude that lipoproteins in E. coli generally utilize the LolA-LolB system for efficient release from the inner membrane and specific localization to the outer membrane.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	University of Tokyo	Tokuda, H (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.							ALEXANDER DM, 1994, MOL MICROBIOL, V11, P1059, DOI 10.1111/j.1365-2958.1994.tb00383.x; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BOUVIER J, 1991, J BACTERIOL, V173, P5523, DOI 10.1128/jb.173.17.5523-5531.1991; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; HAYASHI S, 1990, J BIOENERG BIOMEMBR, V22, P451, DOI 10.1007/BF00763177; HIROTA Y, 1977, P NATL ACAD SCI USA, V74, P1417, DOI 10.1073/pnas.74.4.1417; HUSSAIN M, 1980, J BIOL CHEM, V255, P3707; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MA D, 1993, J BACTERIOL, V175, P6299, DOI 10.1128/JB.175.19.6299-6313.1993; MATSUYAMA S, 1995, EMBO J, V14, P3365, DOI 10.1002/j.1460-2075.1995.tb07342.x; Matsuyama S, 1997, EMBO J, V16, P6947, DOI 10.1093/emboj/16.23.6947; Miller J.H., 1972, EXPT MOL GENETICS; MIZUNO T, 1979, J BIOCHEM-TOKYO, V86, P991, DOI 10.1093/oxfordjournals.jbchem.a132631; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Tajima T, 1998, FEBS LETT, V439, P51, DOI 10.1016/S0014-5793(98)01334-9; TAKASE I, 1987, J BACTERIOL, V169, P5692, DOI 10.1128/jb.169.12.5692-5699.1987; Yakushi T, 1998, J BIOL CHEM, V273, P32576, DOI 10.1074/jbc.273.49.32576; Yakushi T, 1997, J BACTERIOL, V179, P2857, DOI 10.1128/jb.179.9.2857-2862.1997; YAMAGUCHI K, 1988, CELL, V53, P423, DOI 10.1016/0092-8674(88)90162-6; YU F, 1986, J BIOL CHEM, V261, P2284	22	79	80	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30995	30999		10.1074/jbc.274.43.30995	http://dx.doi.org/10.1074/jbc.274.43.30995			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521496	hybrid			2022-12-27	WOS:000083276700092
J	Shaulian, E; Karin, M				Shaulian, E; Karin, M			Stress-induced JNK: Activation is independent of Gadd45 induction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE PATHWAY; P53-REGULATED PROTEIN; TYROSINE KINASES; UV-IRRADIATION; GROWTH-FACTOR; CELL-DEATH; DNA-DAMAGE; APOPTOSIS; GENE; P53	DNA damage and environmental stress activate signaling and induce genes involved in cell cycle and cell death. Expression of the Gadd45 protein is induced following DNA damage and other stress. Gadd45 is believed to play a role in growth arrest and possibly in cell death. The JNK signaling pathway is also activated by some DNA-damaging agents. This activation leads to phosphorylation and activation of transcription factors, such as c-Jun/AP-1 and ATF2, which mediate immediate early gene induction. Recently Gadd45 was suggested to be involved in JNK activation. However, as this suggestion relied on in vitro experiments and ectopic overexpression of Gadd45 protein, we examined whether physiological levels of Gadd45 that are induced following exposure to DNA damaging agents and stress can lead to JNK induction. We found that JNK activation by UV irradiation and anisomycin treatment precedes the induction of gadd45 mRNA by these agents. Gadd45 protein induction by methyl methanesulfonate also lagged behind JNK activation. The use of protein synthesis inhibitors suggested that newly synthesized proteins, including the stress-induced Gadd45, make only a marginal contribution to JNK activation. We also found that stresses such as gamma irradiation induce Gadd45 and do not activate JNK in mouse fibroblasts. Therefore, stress-induced JNK does not depend on Gadd45 induction.	Univ Calif San Diego, Sch Med, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Karin, M (corresponding author), Univ Calif San Diego, Sch Med, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA.				NCI NIH HHS [CA76188] Funding Source: Medline; NIEHS NIH HHS [ES04151] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076188] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES004151, R01ES004151] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABDOLLAHI A, 1991, ONCOGENE, V6, P165; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; Carrier F, 1999, MOL CELL BIOL, V19, P1673; CARRIER F, 1994, J BIOL CHEM, V269, P32672; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Goldwasser F, 1996, ONCOL RES, V8, P317; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Kultz D, 1998, J BIOL CHEM, V273, P13645, DOI 10.1074/jbc.273.22.13645; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; Ohtani-Fujita N, 1998, BIOCHEM BIOPH RES CO, V251, P648, DOI 10.1006/bbrc.1998.9511; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Sabapathy K, 1999, CURR BIOL, V9, P116, DOI 10.1016/S0960-9822(99)80065-7; Smith A, 1997, CURR BIOL, V7, P893, DOI 10.1016/S0960-9822(06)00380-0; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Smith ML, 1996, ONCOGENE, V13, P2255; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Torp R, 1998, NEUROBIOL DIS, V5, P245, DOI 10.1006/nbdi.1998.0201; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; ZHAN Q, 1999, ONCOGENE, V18, P7485; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	35	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29595	29598		10.1074/jbc.274.42.29595	http://dx.doi.org/10.1074/jbc.274.42.29595			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514425	hybrid			2022-12-27	WOS:000083176400004
J	Svensson, S; Stromberg, P; Hoog, JO				Svensson, S; Stromberg, P; Hoog, JO			A novel subtype of class II alcohol dehydrogenase in rodents - Unique Pro(47) and Ser(182) modulates hydride transfer in the mouse enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINAMIDE ADENINE-DINUCLEOTIDE; HORSE LIVER; ALDEHYDE DEHYDROGENASE; MOLECULAR-PROPERTIES; HUMAN BETA-1-BETA-1; TERNARY COMPLEX; PI-ADH; CLONING; MECHANISM; BINDING	Mice and rats were found to possess class II alcohol dehydrogenases with novel enzymatic and structural properties. A cDNA was isolated from mouse liver and the encoded alcohol dehydrogenase showed high identity (93.1%) with the rat class II alcohol dehydrogenase which stands in contrast to the pronounced overall variability of the class II: line. The two heterologously expressed rodent class II enzymes exhibited over 100-fold lower catalytic efficiency (k(cat)/K-m) for oxidation of alcohols as compared with other alcohol dehydrogenases and were not saturated with ethanol. Hydride transfer limited the rate of octanol oxidation as indicated by a deuterium isotope effect of 4.8. The mutation P47H improved hydride transfer and turnover rates were increased to the same level as for the human class II enzyme. Michaelis constants for alcohols and aldehydes were decreased while they were increased for the coenzyme. The rodent class Ii enzymes catalyzed reduction of p-benzoquinone with about the same maximal turnover as for the human form. This activity was not affected by the P47H mutation while a S182T mutation increased the K-m value for benzoquinone 10-fold. omega-Hydroxy fatty acids were catalyzed extremely slow but functioned as patent inhibitors by binding to the enzyme-NAD(+) complex, AU these data indicate that the mammalian class II alcohol dehydrogenase line is divided into two structurally and functionally distinct subgroups.	Karolinska Inst, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden	Karolinska Institutet	Hoog, JO (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden.							ALGAR EM, 1983, EUR J BIOCHEM, V137, P139, DOI 10.1111/j.1432-1033.1983.tb07807.x; Bahnson BJ, 1997, P NATL ACAD SCI USA, V94, P12797, DOI 10.1073/pnas.94.24.12797; BOSRON WF, 1979, BIOCHEMISTRY-US, V18, P1101, DOI 10.1021/bi00573a026; CHEN S, 1993, ARCH BIOCHEM BIOPHYS, V302, P72, DOI 10.1006/abbi.1993.1182; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cleland W W, 1979, Methods Enzymol, V63, P103; DAVIS GJ, 1994, ARCH BIOCHEM BIOPHYS, V311, P307, DOI 10.1006/abbi.1994.1242; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DITLOW CC, 1984, BIOCHEMISTRY-US, V23, P6363, DOI 10.1021/bi00321a012; Duester G, 1996, BIOCHEMISTRY-US, V35, P12221, DOI 10.1021/bi961176+; EDENBERG HJ, 1985, P NATL ACAD SCI USA, V82, P2262, DOI 10.1073/pnas.82.8.2262; EHRIG T, 1991, BIOCHEMISTRY-US, V30, P1062, DOI 10.1021/bi00218a026; EKLUND H, 1976, J MOL BIOL, V102, P27, DOI 10.1016/0022-2836(76)90072-3; EKLUND H, 1982, J BIOL CHEM, V257, P4349; EKLUND H, 1984, BIOCHEMISTRY-US, V23, P5982, DOI 10.1021/bi00320a014; EKLUND H, 1981, J MOL BIOL, V146, P561, DOI 10.1016/0022-2836(81)90047-4; Estonius M, 1996, FEBS LETT, V397, P338, DOI 10.1016/S0014-5793(96)01204-5; ESTONIUS M, 1993, EUR J BIOCHEM, V215, P497, DOI 10.1111/j.1432-1033.1993.tb18059.x; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Fersht A., 1984, ENZYME STRUCTURE MEC; Fromm H J, 1979, Methods Enzymol, V63, P467; GOULD RM, 1990, BIOCHEMISTRY-US, V29, P5463, DOI 10.1021/bi00475a009; HARTLEY DP, 1995, ARCH BIOCHEM BIOPHYS, V316, P197, DOI 10.1006/abbi.1995.1028; HENNECKE M, 1983, BIOCHEMISTRY-US, V22, P3721, DOI 10.1021/bi00285a001; HJELMQVIST L, 1995, P NATL ACAD SCI USA, V92, P10904, DOI 10.1073/pnas.92.24.10904; HOLMES RS, 1977, GENETICS, V87, P709; HOOG JO, 1995, ADV EXP MED BIOL, V372, P355; HOOG JO, 1995, FEBS LETT, V368, P445, DOI 10.1016/0014-5793(95)00707-G; Hur M W, 1992, DNA Seq, V3, P167, DOI 10.3109/10425179209034012; HURLEY TD, 1991, P NATL ACAD SCI USA, V88, P8149, DOI 10.1073/pnas.88.18.8149; Inoue J, 1998, BIOCHEMISTRY-US, V37, P3305, DOI 10.1021/bi970726g; JORNVALL H, 1995, ALCOHOL ALCOHOLISM, V30, P153; JORNVALL H, 1984, P NATL ACAD SCI-BIOL, V81, P3024, DOI 10.1073/pnas.81.10.3024; Kedishvili NY, 1997, J BIOL CHEM, V272, P7494, DOI 10.1074/jbc.272.11.7494; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P3873, DOI 10.1093/nar/12.9.3873; LI TK, 1977, P NATL ACAD SCI USA, V74, P4378, DOI 10.1073/pnas.74.10.4378; LIGHT DR, 1992, J BIOL CHEM, V267, P12592; MARDH G, 1986, P NATL ACAD SCI USA, V83, P8908, DOI 10.1073/pnas.83.23.8908; MARDH G, 1986, BIOCHEMISTRY-US, V25, P7279, DOI 10.1021/bi00371a005; MASKOS Z, 1994, J BIOL CHEM, V269, P31579; MEAD DA, 1991, BIO-TECHNOL, V9, P657, DOI 10.1038/nbt0791-657; OKUDA A, 1983, J BIOL CHEM, V258, P2899; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; PARES X, 1990, FEBS LETT, V277, P115, DOI 10.1016/0014-5793(90)80822-Z; Ramaswamy S, 1996, PROTEIN SCI, V5, P663; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEKHAR VC, 1988, BIOCHEMISTRY-US, V27, P5082, DOI 10.1021/bi00414a020; SELLIN S, 1991, BIOCHEMISTRY-US, V30, P2514, DOI 10.1021/bi00223a031; STONE CL, 1993, J BIOL CHEM, V268, P892; Svensson S, 1998, EUR J BIOCHEM, V251, P236, DOI 10.1046/j.1432-1327.1998.2510236.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WU CI, 1985, P NATL ACAD SCI USA, V82, P1741, DOI 10.1073/pnas.82.6.1741; Yang ZN, 1997, J MOL BIOL, V265, P330, DOI 10.1006/jmbi.1996.0731; YANG ZN, 1994, ALCOHOL CLIN EXP RES, V18, P587, DOI 10.1111/j.1530-0277.1994.tb00914.x; ZGOMBICKNIGHT M, 1995, J BIOL CHEM, V270, P10868, DOI 10.1074/jbc.270.18.10868	56	35	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29712	29719		10.1074/jbc.274.42.29712	http://dx.doi.org/10.1074/jbc.274.42.29712			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514444	hybrid			2022-12-27	WOS:000083176400023
J	Oettgen, P; Kas, K; Dube, A; Gu, XS; Grall, F; Thamrongsak, U; Akbarali, Y; Finger, E; Boltax, J; Endress, G; Munger, K; Kunsch, C; Libermann, TA				Oettgen, P; Kas, K; Dube, A; Gu, XS; Grall, F; Thamrongsak, U; Akbarali, Y; Finger, E; Boltax, J; Endress, G; Munger, K; Kunsch, C; Libermann, TA			Characterization of ESE-2, a novel ESE-1-related Ets transcription factor that is restricted to glandular epithelium and differentiated keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; SALIVARY-GLAND; TERMINAL DIFFERENTIATION; REGULATES EXPRESSION; MYELOID-LEUKEMIA; GENE-EXPRESSION; FAMILY PROTEINS; ENDOA ENHANCER; GROWTH-FACTOR; FUSION	Epithelial cell differentiation is tightly controlled by distinct sets of transcription factors that regulate the expression of stage-specific genes. We recently isolated the first epithelium-specific Ets transcription factor (ESE-1), Here we describe the characterization of ESE-2, a second epithelium-restricted ESE-1-related Ets factor. Like ESE-1, ESE-2 is induced during keratinocyte differentiation. However, whereas ESE-1 is expressed in the majority of epithelial cell types, ESE-2 expression is restricted to differentiated keratinocytes and glandular epithelium such as salivary gland, prostate, mammary gland, and kidney. In contrast to ESE-1, full-length ESE-2 binds poorly to DNA due to the presence of a negative regulatory domain at the amino terminus. Furthermore, although ESE-1 and the amino-terminally deleted ESE-2 bind with similar affinity to the canonical E74 Ets site, ESE-2 and ESE-1 differ strikingly in their relative affinity toward binding sites in the c-MET and PSMA promoters. Similarly, ESE-1 and ESE-2 drastically differ in their ability to transactivate epithelium-specific promoters, Thus, ESE-2, but not ESE-1, transactivates the parotid gland specific PSP promoter and the prostate-specific PSA promoter. In contrast, ESE-1 transactivates the keratinocyte-specific SPRR2A promoter Ets site and the prostate-specific PSMA promoter significantly better than ESE-2, Our results demonstrate the existence of a unique class of related epithelium-specific Ets factors with distinct functions in epithelial cell gene regulation.	Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Dept Med,New England Baptist Bone & Joint Inst, Boston, MA 02115 USA; Univ Louvain, Ctr Human Genet, Oncol Mol Lab, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol, B-3000 Louvain, Belgium; Human Genome Sci Inc, Rockville, MD 20850 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; New England Baptist Hospital; GlaxoSmithKline; Human Genome Sciences Inc; Harvard University; Harvard Medical School	Libermann, TA (corresponding author), Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Dept Med,New England Baptist Bone & Joint Inst, 4 Blackfan Circle, Boston, MA 02115 USA.	tliberma@bidmc.harvard.edu	Oettgen, Peter/AAF-5026-2021; Libermann, Towia/F-9866-2010	Libermann, Towia/0000-0002-4006-8179; Munger, Karl/0000-0003-3288-9935	NATIONAL CANCER INSTITUTE [P01CA072009, K08CA071429] Funding Source: NIH RePORTER; NCI NIH HHS [P01/CA 72009, K08/CA 71429] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andreoli JM, 1997, NUCLEIC ACIDS RES, V25, P4287, DOI 10.1093/nar/25.21.4287; Ann DK, 1997, CRIT REV ORAL BIOL M, V8, P244, DOI 10.1177/10454411970080030101; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; FARR A, 1992, NUCLEIC ACIDS RES, V20, P920, DOI 10.1093/nar/20.4.920; Fischer DF, 1999, GENOMICS, V55, P88, DOI 10.1006/geno.1998.5622; Fischer DF, 1996, MOL CELL BIOL, V16, P5365, DOI 10.1128/mcb.16.10.5365; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; FUJIMURA Y, 1994, NUCLEIC ACIDS RES, V22, P613, DOI 10.1093/nar/22.4.613; Gambarotta G, 1996, ONCOGENE, V13, P1911; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; HOHL D, 1995, J INVEST DERMATOL, V104, P902, DOI 10.1111/1523-1747.ep12606176; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JEON IS, 1995, ONCOGENE, V10, P1229; JOHN S, 1995, MOL CELL BIOL, V15, P1786; KLAMBT C, 1993, DEVELOPMENT, V117, P163; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; Kyba M, 1998, MOL CELL BIOL, V18, P2712, DOI 10.1128/MCB.18.5.2712; Laursen J, 1997, GENE, V198, P367, DOI 10.1016/S0378-1119(97)00339-9; Laursen J, 1998, TRANSGENIC RES, V7, P413, DOI 10.1023/A:1008806325102; Lee JH, 1996, J BIOL CHEM, V271, P4561; LIBERMANN TA, 1987, EMBO J, V6, P1627, DOI 10.1002/j.1460-2075.1987.tb02410.x; LIBERMANN TA, 1993, MOL CELL BIOL, V13, P5957, DOI 10.1128/MCB.13.10.5957; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; McLean TW, 1996, BLOOD, V88, P4252; Neve R, 1998, FASEB J, V12, P1541, DOI 10.1096/fasebj.12.14.1541; NOLET S, 1991, BIOCHIM BIOPHYS ACTA, V1089, P247, DOI 10.1016/0167-4781(91)90016-F; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; Oettgen P, 1999, GENOMICS, V55, P358, DOI 10.1006/geno.1998.5681; Oettgen P, 1997, GENOMICS, V45, P456, DOI 10.1006/geno.1997.4974; Oettgen P, 1996, MOL CELL BIOL, V16, P5091; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; PANKOV R, 1994, MOL CELL BIOL, V14, P7744, DOI 10.1128/MCB.14.12.7744; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; REBAY I, 1995, CELL, V81, P857, DOI 10.1016/0092-8674(95)90006-3; Rheinwald J G, 1982, Natl Cancer Inst Monogr, V60, P133; RHEINWALD JG, 1981, CANCER RES, V41, P1657; Sark MWJ, 1998, J BIOL CHEM, V273, P24683, DOI 10.1074/jbc.273.38.24683; SCHLEGEL R, 1988, EMBO J, V7, P3181, DOI 10.1002/j.1460-2075.1988.tb03185.x; Schultz J, 1997, PROTEIN SCI, V6, P249; SETH A, 1994, ONCOGENE, V9, P469; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; SHIRASUNA K, 1981, CANCER, V48, P745, DOI 10.1002/1097-0142(19810801)48:3<745::AID-CNCR2820480314>3.0.CO;2-7; SHORE P, 1995, J BIOL CHEM, V270, P5805, DOI 10.1074/jbc.270.11.5805; Stapleton D, 1999, NAT STRUCT BIOL, V6, P44; Svendsen P, 1998, NUCLEIC ACIDS RES, V26, P2761, DOI 10.1093/nar/26.11.2761; Tymms MJ, 1997, ONCOGENE, V15, P2449, DOI 10.1038/sj.onc.1201427; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Zhou J, 1998, ONCOGENE, V17, P2719, DOI 10.1038/sj.onc.1202198	61	90	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29439	29452		10.1074/jbc.274.41.29439	http://dx.doi.org/10.1074/jbc.274.41.29439			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506207	hybrid			2022-12-27	WOS:000083017800086
J	Fernandez-Chacon, R; de Toledo, GA; Hammer, RE; Sudhof, TC				Fernandez-Chacon, R; de Toledo, GA; Hammer, RE; Sudhof, TC			Analysis of SCAMP1 function in secretory vesicle exocytosis by means of gene targeting in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARRIER MEMBRANE-PROTEINS; MAST-CELLS; CAPACITANCE MEASUREMENTS; GRANULE MEMBRANES; FUSION PORE; RELEASE; PRODUCTS; SYNAPTOPHYSIN	Secretory carrier membrane proteins (SCAMPs) comprise a family of ubiquitous membrane proteins of transport vesicles with no known function. Their universal presence in all cells suggests a fundamental role in membrane traffic, SCAMPs are particularly highly expressed in organelles that undergo regulated exocytosis, such as synaptic vesicles and mast cell granules. Of the three currently known SCAMPs, SCAMPI is the most abundant. To investigate the possible functions of SCAMPI, we generated mice that lack SCAMP1, SCAMP1-deficient mice are viable and fertile. They exhibit no changes in the overall architecture or the protein composition of the brain or alterations in peripheral organs. Capacitance measurements in mast cells demonstrated that exocytosis could be triggered reliably by GTP gamma S in SCAMP1-deficient cells. The initial overall capacitance of mast cells was similar between wild type and mutant mice, but the final cell capacitance after completion of exocytosis, was significantly smaller in SCAMP1-deficient cells than in wild type cells, Furthermore, there was an increased proportion of reversible fusion events, which may have caused the decrease in the overall capacitance change observed after exocytosis, Our data show that SCAMP1 is not essential for exocytosis, as such, and does not determine the stability or size of secretory vesicles, but is required for the full execution of stable exocytosis in mast cells, This phenotype could be the result of a function of SCAMP1 in the formation of stable fusion pores during exocytosis or of a role of SCAMPI in the regulation of endocytosis after formation of fusion pores.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Ctr Basic Neurosci, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Sevilla, Fac Med, Dept Fisiol Med & Biofis, E-41009 Seville, Spain	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Sevilla	Sudhof, TC (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Rm NA4-118,6000 Harry Hines Blvd, Dallas, TX 75235 USA.		Alvarez de Toledo, Guillermo/I-2888-2015; Fernandez-Chacon, Rafael/E-6303-2010; IBIS, FISIOLOGIA/O-9485-2015	Alvarez de Toledo, Guillermo/0000-0001-7193-2663; Fernandez-Chacon, Rafael/0000-0002-9845-9885				ALMERS W, 1987, J PHYSIOL-LONDON, V386, P205, DOI 10.1113/jphysiol.1987.sp016530; BRAND SH, 1991, J BIOL CHEM, V266, P18949; BRAND SH, 1993, EMBO J, V12, P3753, DOI 10.1002/j.1460-2075.1993.tb06053.x; BRUMELL JH, 1995, J IMMUNOL, V155, P5750; CAMERON RS, 1986, J CELL BIOL, V103, P1299, DOI 10.1083/jcb.103.4.1299; DETOLEDO GA, 1993, NATURE, V363, P554, DOI 10.1038/363554a0; DETOLEDO GA, 1990, J CELL BIOL, V110, P1033, DOI 10.1083/jcb.110.4.1033; FERNANDEZ JM, 1984, NATURE, V312, P453, DOI 10.1038/312453a0; FERNANDEZCHACON R, 1995, FEBS LETT, V363, P221, DOI 10.1016/0014-5793(95)00319-5; Fischer Y, 1997, J BIOL CHEM, V272, P7085, DOI 10.1074/jbc.272.11.7085; FYKSE EM, 1993, J NEUROSCI, V13, P4997; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Guo ZH, 1998, CELL, V94, P537, DOI 10.1016/S0092-8674(00)81594-9; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; JOHNSTON PA, 1989, J BIOL CHEM, V264, P1268; LAURIE SM, 1993, J BIOL CHEM, V268, P19110; LINDAU M, 1991, Q REV BIOPHYS, V24, P75, DOI 10.1017/S0033583500003279; LINDAU M, 1991, BIOCHIM BIOPHYS ACTA, V1071, P429, DOI 10.1016/0304-4157(91)90006-I; McMahon HT, 1996, P NATL ACAD SCI USA, V93, P4760, DOI 10.1073/pnas.93.10.4760; Milgram SL, 1997, J CELL SCI, V110, P695; MONCK JR, 1990, P NATL ACAD SCI USA, V87, P7804, DOI 10.1073/pnas.87.20.7804; Oberhauser AF, 1996, P NATL ACAD SCI USA, V93, P14349, DOI 10.1073/pnas.93.25.14349; ROSAHL TW, 1995, NATURE, V375, P488, DOI 10.1038/375488a0; Sambrook J., 2002, MOL CLONING LAB MANU; Singleton DR, 1997, J CELL SCI, V110, P2099; Wen GP, 1998, MAMM GENOME, V9, P536, DOI 10.1007/s003359900814; Wu TT, 1998, MOL BIOL CELL, V9, P1661, DOI 10.1091/mbc.9.7.1661	27	49	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32551	32554		10.1074/jbc.274.46.32551	http://dx.doi.org/10.1074/jbc.274.46.32551			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551807	hybrid			2022-12-27	WOS:000083623000007
J	Cadefau, JA; Parra, J; Tauler, A; Cusso, R				Cadefau, JA; Parra, J; Tauler, A; Cusso, R			Contractile activity modifies Fru-2,6-P-2 metabolism in rabbit fast twitch skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-FREQUENCY STIMULATION; FRUCTOSE 2,6-BISPHOSPHATE; HEXOKINASE-II; 6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE; RAT-LIVER; EXPRESSION; ISOZYMES; 6-PHOSPHOFRUCTO-2-KINASE/FRUCTOSE-2,6-BISPHOSPHATASE; PURIFICATION; RESPONSES	Modification of muscular contractile patterns by denervation and chronic low frequency stimulation induces structural, physiological, and biochemical alterations in fast twitch skeletal muscles. Fructose 2,6-bisphosphate is a potent activator of 6-phosphofructo-1-kinase, a key regulatory enzyme of glycolysis in animal tissues. The concentration of Fru-2,6-P-2, depends on the activity of the bifunctional enzyme, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFK-2/FBPase-2), which catalyzes the synthesis and degradation of this metabolite. This enzyme has several isoforms, the relative abundance of which depends on the tissue metabolic properties. Skeletal muscle expresses two of these isoforms; it mainly contains the muscle isozyme (RI-type) and a small amount of the liver isozyme (L-type), whose expression is under hormonal control. Moreover, contractile activity regulates expression of muscular proteins related with glucose metabolism. Fast twitch rabbit skeletal muscle denervation or chronic low frequency stimulation can provide information about the regulation of this enzyme. Our results show an increase in Fru-2,6-P-2, concentration after 2 days of denervation or stimulation. In denervated muscle, this increase is mediated by a rise in liver PFK-2/FBPase-2 isozyme, while in stimulated muscle it is mediated by a rise in muscle PFK-2/FBPase-2 isozyme, In conclusion, our results show that contractile activity could alter the expression of PFK-2/FBPase-2.	Univ Barcelona, Fac Med, Dept Ciencias Fisiol 1, E-08036 Barcelona, Spain; Univ Barcelona, Inst Invest Biomed August Pi & Sunyer, Dept Biochem & Mol Biol, Div 4, E-08036 Barcelona, Spain	University of Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Cadefau, JA (corresponding author), Univ Barcelona, Fac Med, Dept Ciencias Fisiol 1, C Casanova 143, E-08036 Barcelona, Spain.		Cadefau, Joan Aureli/G-2906-2016; Cadefau, Joan AurelI/M-7934-2018; Tauler, Albert/D-5183-2014	Cadefau, Joan Aureli/0000-0001-6020-189X; Cadefau, Joan AurelI/0000-0001-6020-189X; Tauler, Albert/0000-0003-0193-0667				ANDRES V, 1990, DIFFERENTIATION, V43, P98, DOI 10.1111/j.1432-0436.1990.tb00435.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CADEFAU JA, 1993, PFLUG ARCH EUR J PHY, V424, P529, DOI 10.1007/BF00374918; CARROLL NV, 1956, J BIOL CHEM, V220, P583; CASTELLO A, 1993, J BIOL CHEM, V268, P14998; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CREPIN KM, 1989, BIOCHEM J, V264, P151, DOI 10.1042/bj2640151; CREPIN KM, 1992, J BIOL CHEM, V267, P21698; CREPIN KM, 1988, FEBS LETT, V227, P136, DOI 10.1016/0014-5793(88)80884-6; CREPIN KM, 1989, EUR J BIOCHEM, V183, P433, DOI 10.1111/j.1432-1033.1989.tb14946.x; DALBIS A, 1994, EUR J BIOCHEM, V223, P249, DOI 10.1111/j.1432-1033.1994.tb18989.x; ELMAGHRABI MR, 1982, P NATL ACAD SCI-BIOL, V79, P315, DOI 10.1073/pnas.79.2.315; GREEN HJ, 1991, FEBS LETT, V282, P107, DOI 10.1016/0014-5793(91)80455-C; Gundersen K, 1998, ACTA PHYSIOL SCAND, V162, P333, DOI 10.1046/j.1365-201X.1998.0336e.x; GUTMANN E, 1976, ANNU REV PHYSIOL, V38, P177, DOI 10.1146/annurev.ph.38.030176.001141; Handberg A, 1996, AM J PHYSIOL-ENDOC M, V271, pE50, DOI 10.1152/ajpendo.1996.271.1.E50; HOFMANN S, 1994, EUR J BIOCHEM, V219, P307, DOI 10.1111/j.1432-1033.1994.tb19942.x; HUE L, 1987, BIOCHEM J, V245, P313, DOI 10.1042/bj2450313; Jones JP, 1997, BIOCHEM BIOPH RES CO, V238, P53, DOI 10.1006/bbrc.1997.7241; KITAMURA K, 1989, J BIOL CHEM, V264, P9799; Kraus W E, 1994, Exerc Sport Sci Rev, V22, P313; MINATOGAWA Y, 1984, BIOCHEM J, V223, P73, DOI 10.1042/bj2230073; Passonneau J.V., 1972, FLEXIBLE SYSTEM ENZY; PETTE D, 1992, REV PHYSIOL BIOCH P, V120, P115, DOI 10.1007/BFb0036123; Pette D, 1997, Int Rev Cytol, V170, P143, DOI 10.1016/S0074-7696(08)61622-8; PILKIS SJ, 1995, ANNU REV BIOCHEM, V64, P799, DOI 10.1146/annurev.bi.64.070195.004055; ROSA JL, 1990, BIOCHEM J, V270, P645, DOI 10.1042/bj2700645; ROSEN KM, 1990, BIOTECHNIQUES, V8, P398; SCHWARZ G, 1983, PFLUG ARCH EUR J PHY, V398, P130, DOI 10.1007/BF00581060; SIMARD C, 1985, COMP BIOCH PHYSL, V2, P539; SIMONEAU JA, 1989, PFLUG ARCH EUR J PHY, V413, P679, DOI 10.1007/BF00581821; Spitz F, 1998, J BIOL CHEM, V273, P14975, DOI 10.1074/jbc.273.24.14975; TANIYAMA M, 1988, BIOCHEM BIOPH RES CO, V157, P949, DOI 10.1016/S0006-291X(88)80966-5; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191; VANSCHAFTINGEN E, 1986, EUR J BIOCHEM, V159, P359; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V124, P143; VENTURA F, 1991, NATO ASI SER H, V56, P131; WEBER FE, 1988, FEBS LETT, V238, P71, DOI 10.1016/0014-5793(88)80227-8; WINDER WW, 1992, AM J PHYSIOL, V262, pE919, DOI 10.1152/ajpendo.1992.262.6.E919	39	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31961	31966		10.1074/jbc.274.45.31961	http://dx.doi.org/10.1074/jbc.274.45.31961			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542225	hybrid			2022-12-27	WOS:000083532100033
J	Chen, DH; Xu, XP; Zhu, LJ; Angervo, M; Li, QX; Bagchi, MK; Bagchi, IC				Chen, DH; Xu, XP; Zhu, LJ; Angervo, M; Li, QX; Bagchi, MK; Bagchi, IC			Cloning and uterus/oviduct-specific expression of a novel estrogen-regulated gene (ERG1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER RIBONUCLEIC-ACID; IMMATURE RAT UTERUS; DIFFERENTIAL DISPLAY; RECEPTOR SUPERFAMILY; MOUSE UTERUS; C-FOS; GROWTH; IDENTIFICATION; PROTEIN; RNA	The steroid hormone estrogen profoundly influences growth and differentiation programs in the reproductive tract of cycling and pregnant mamals, It is thought that estrogen exerts its cellular effects by regulating the expression of specific target genes. We utilized a messenger RNA differential display method to identify the genes whose expression is modulated by estrogen in the preimplantation rat uterus, Here we report the cloning of a novel gene (ERG1) that is tightly regulated by estrogen in two key reproductive tissues, the uterus and oviduct. Spatio-temporal analyses reveal that ERG1 mRNA is expressed in a highly stage-specific manner in the uterus and oviduct, and its expression is restricted to the surface epithelium of both of these tissues, Nucleotide sequence analysis of the full-length ERG1 cDNA indicates that it has an open reading frame of 1821 nuceotides encoding a putative protein of 607 amino acids with a single transmembrane domain and a short cytoplasmic tail. The extracellular part of the protein contains several distinct structural motifs. These include a zona pellucida binding domain, which is present in a number of proteins such as the zona pellucida sperm binding proteins, and uromodulin, In addition, there is a repeat of a motif called CUB domain, which exists in a number of genes involved in development and differentiation such as bone morphogenetic protein 1 (BMP1), Although the precise function of ERG1 eludes us presently, its unique pattern of expression in the uterus and oviduct and its regulation by estrogen, a principal reproductive hormone, lead us to speculate that this novel gene plays an important role in events during the reproductive cycle and early pregnancy.	Populat Council, New York, NY 10021 USA; Rockefeller Univ, New York, NY 10021 USA	Population Council; Rockefeller University	Bagchi, IC (corresponding author), Populat Council, 1230 York Ave, New York, NY 10021 USA.		Chen, Dahu/AAX-6349-2021		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD034760, R01HD034527] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050257] Funding Source: NIH RePORTER; NICHD NIH HHS [UO1 HD-34760, R01 HD-34527] Funding Source: Medline; NIDDK NIH HHS [R01-DK-50257] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIELLO LP, 1994, P NATL ACAD SCI USA, V91, P6231, DOI 10.1073/pnas.91.13.6231; Allen E, 1928, J MORPHOL PHYSIOL, V46, P479, DOI 10.1002/jmor.1050460205; Allen E, 1928, AM J ANAT, V42, P467, DOI 10.1002/aja.1000420207; ANDERSON JN, 1975, ENDOCRINOLOGY, V96, P160, DOI 10.1210/endo-96-1-160; BAULIEU EE, 1989, SCIENCE, V245, P1351, DOI 10.1126/science.2781282; BAULIEU EE, 1991, TRENDS ENDOCRIN MET, V2, P233, DOI 10.1016/1043-2760(91)90030-Q; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BORK P, 1992, FEBS LETT, V300, P237, DOI 10.1016/0014-5793(92)80853-9; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; BORK P, 1991, FEBS LETT, V282, P9, DOI 10.1016/0014-5793(91)80433-4; CHIAPPETTA C, 1992, J STEROID BIOCHEM, V41, P113, DOI 10.1016/0960-0760(92)90037-J; CROXATTO HB, 1996, REPROD ENDOCRINOLOGY, V1, P385; CULLINANBOVE K, 1993, ENDOCRINOLOGY, V133, P829, DOI 10.1210/en.133.2.829; DIAUGUSTINE RP, 1988, ENDOCRINOLOGY, V122, P2355, DOI 10.1210/endo-122-6-2355; DONNELLY KM, 1991, MOL ENDOCRINOL, V5, P356, DOI 10.1210/mend-5-3-356; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FINN CA, 1971, BIOL UTERUS, P246; GHAHARY A, 1989, ENDOCRINOLOGY, V125, P597, DOI 10.1210/endo-125-2-597; Harper Michael J. K., 1994, P123; JENSEN EV, 1972, ANNU REV BIOCHEM, V41, P203, DOI 10.1146/annurev.bi.41.070172.001223; Kasik JW, 1998, BIOCHEM J, V330, P947; KATZENELLENBOGE.BS, 1975, BIOCHEMICAL ACTION H, V3, P187; Katzenellenbogen BS, 1997, ENDOCRINOLOGY, V138, P861, DOI 10.1210/en.138.3.861; KAYE AM, 1972, BIOCHIM BIOPHYS ACTA, V261, P475, DOI 10.1016/0304-4165(72)90072-4; KIRKLAND JL, 1979, BIOL REPROD, V21, P269, DOI 10.1095/biolreprod21.2.269; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LINGHAM RB, 1988, MOL ENDOCRINOL, V2, P230, DOI 10.1210/mend-2-3-230; LOOSEMITCHELL DS, 1988, MOL ENDOCRINOL, V2, P946, DOI 10.1210/mend-2-10-946; MURPHY LJ, 1987, MOL ENDOCRINOL, V1, P445, DOI 10.1210/mend-1-7-445; MURPHY LJ, 1987, ENDOCRINOLOGY, V120, P1882, DOI 10.1210/endo-120-5-1882; NELSON KG, 1992, ENDOCRINOLOGY, V131, P1657, DOI 10.1210/en.131.4.1657; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; PENNICA D, 1987, SCIENCE, V236, P83, DOI 10.1126/science.3453112; PSYCHOYOS A, 1973, VITAM HORM, V31, P205; PSYCHOYOS A, 1973, HDB PHYSL, P187; QUARMBY VE, 1984, ENDOCRINOLOGY, V114, P694, DOI 10.1210/endo-114-3-694; TRAVERS MT, 1987, FEBS LETT, V211, P27, DOI 10.1016/0014-5793(87)81267-X; UTANS U, 1994, P NATL ACAD SCI USA, V91, P6463, DOI 10.1073/pnas.91.14.6463; WAKELING AE, 1988, J STEROID BIOCHEM, V30, P141, DOI 10.1016/0022-4731(88)90086-6; WEISZ A, 1988, MOL ENDOCRINOL, V2, P816, DOI 10.1210/mend-2-9-816; WIEST WG, 1970, ENDOCRINOLOGY, V87, P43, DOI 10.1210/endo-87-1-43; YOSHINAGA K, 1969, ENDOCRINOLOGY, V85, P103, DOI 10.1210/endo-85-1-103	42	18	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32215	32224		10.1074/jbc.274.45.32215	http://dx.doi.org/10.1074/jbc.274.45.32215			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542259	hybrid			2022-12-27	WOS:000083532100067
J	Dong, LA; Wang, WL; Wang, F; Stoner, M; Reed, JC; Harigai, M; Samudio, I; Kladde, MP; Vyhlidal, C; Safe, S				Dong, LA; Wang, WL; Wang, F; Stoner, M; Reed, JC; Harigai, M; Samudio, I; Kladde, MP; Vyhlidal, C; Safe, S			Mechanisms of transcriptional activation of bcl-2 gene expression by 17 beta-estradiol in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR SP1; HUMAN FOLLICULAR LYMPHOMA; ELEMENT-BINDING PROTEIN; CATHEPSIN-D GENE; CHROMOSOMAL BREAKPOINT; INDEPENDENT ACTIVATION; RESPONSIVE ELEMENT; INDUCED APOPTOSIS; DOWN-REGULATION; LINE MCF-7	bcl-2 gene expression is induced by 17 beta-estradiol (E2) in T47D and MCF-7 human breast cancer cells, and the mechanism of E2 responsiveness was further investigated by analysis of the bcl-2 gene promoter. The -1602 to -1534 distal region (bcl-2j) of the promoter was E2-responsive; however, in gel mobility shift assays, the estrogen receptor alpha (ERalpha) did not bind [P-32]bcl-2j, whereas Spl protein formed a retarded band complex. Further analysis demonstrated that the upstream region (-1603 to -1579) of the bcl-2 gene promoter contained two GC/GA-rich sites at -1601 (5'-GGGCTGG-3') and -1588 (3'-GGAGGG-5') that bound Spl protein. Subsequent studies confirmed that transactivation by E2 was dependent on ERalpha/Sp1 interactions with both GC-rich sites, and this was confirmed by in uitro footprinting. In contrast, a 21-base pair E2-responsive downstream region (-1578 to -1534) did not bind Spl or ER, protein; however, analysis of a complex binding pattern with nuclear extracts showed that ATF-1 and CREB-1 bound to this motif, These data coupled,with results of transient transfection studies demonstrated that transcriptional activation by E2 of the -1578 to -1534 region of the bcl-2 gene promoter was dependent on induction of cAMP and subsequent activation through a cAMP response element, Thus, hormone regulation of bcl-2 gene expression in breast cancer cells involves multiple enhancer elements and E2-mediated transactivation does not require direct binding of the estrogen receptor with promoter DNA.	Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Burnham Inst, La Jolla, CA 92037 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Sanford Burnham Prebys Medical Discovery Institute	Safe, S (corresponding author), Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA.		Samudio, Ismael/D-3581-2013	Samudio, Ismael/0000-0001-8676-1035	NATIONAL CANCER INSTITUTE [R01CA076636] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009106] Funding Source: NIH RePORTER; NCI NIH HHS [CA76636] Funding Source: Medline; NIEHS NIH HHS [ES09106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adam L, 1997, CANCER RES, V57, P1023; ALDERSON LM, 1995, CANCER RES, V55, P999; ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517; AUGEREAU P, 1994, MOL ENDOCRINOL, V8, P693, DOI 10.1210/me.8.6.693; Baba M, 1996, INT J ONCOL, V8, P355; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BRONNER MP, 1995, AM J PATHOL, V146, P20; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; CRAIG RW, 1995, SEMIN CANCER BIOL, V6, P35, DOI 10.1006/scbi.1995.0005; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; DOGLIONI C, 1994, VIRCHOWS ARCH, V424, P47; Duan R, 1998, ENDOCRINOLOGY, V139, P1981, DOI 10.1210/en.139.4.1981; ELIOPOULOS AG, 1995, ONCOGENE, V11, P1217; ElTanani MKK, 1996, MOL CELL ENDOCRINOL, V124, P71, DOI 10.1016/S0303-7207(96)03930-5; ElTanani MKK, 1997, MOL ENDOCRINOL, V11, P928, DOI 10.1210/me.11.7.928; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALDAR S, 1994, CANCER RES, V54, P2095; HENRIKSEN R, 1995, BRIT J CANCER, V72, P1324, DOI 10.1038/bjc.1995.509; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Kaiser UB, 1998, J BIOL CHEM, V273, P12943, DOI 10.1074/jbc.273.21.12943; Kandouz M, 1996, INT J CANCER, V68, P120, DOI 10.1002/(SICI)1097-0215(19960927)68:1<120::AID-IJC21>3.0.CO;2-E; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kladde MP, 1996, METHOD ENZYMOL, V274, P214; Kladde MP, 1996, EMBO J, V15, P6290, DOI 10.1002/j.1460-2075.1996.tb01019.x; Kobayashi S, 1997, BREAST CANCER RES TR, V42, P173, DOI 10.1023/A:1005760013810; Krajewski S, 1997, CLIN CANCER RES, V3, P199; KRISHNAN V, 1994, J BIOL CHEM, V269, P15912; Kumar R, 1996, CLIN CANCER RES, V2, P1215; Lapointe J, 1999, ENDOCRINOLOGY, V140, P416, DOI 10.1210/en.140.1.416; LEEK RD, 1994, BRIT J CANCER, V69, P135, DOI 10.1038/bjc.1994.22; Lundblad JR, 1998, J BIOL CHEM, V273, P19251, DOI 10.1074/jbc.273.30.19251; Margana RK, 1997, J BIOL CHEM, V272, P3083, DOI 10.1074/jbc.272.5.3083; McDonnell TJ, 1996, EXPERIENTIA, V52, P1008, DOI 10.1007/BF01920110; MIYASHITA T, 1994, CANCER RES, V54, P3131; NAKASU S, 1994, ACTA NEUROPATHOL, V88, P520; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; Piche A, 1998, CANCER RES, V58, P2134; Porter W, 1997, MOL ENDOCRINOL, V11, P1569, DOI 10.1210/me.11.11.1569; Qin CH, 1999, ENDOCRINOLOGY, V140, P2501, DOI 10.1210/en.140.6.2501; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Roder K, 1997, J BIOL CHEM, V272, P21616, DOI 10.1074/jbc.272.34.21616; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; Schanke JT, 1998, MOL ENDOCRINOL, V12, P405, DOI 10.1210/me.12.3.405; Scholz A, 1998, J BIOL CHEM, V273, P4360, DOI 10.1074/jbc.273.8.4360; SUMANTRAN VN, 1995, CANCER RES, V55, P2507; Sun GL, 1998, MOL ENDOCRINOL, V12, P882, DOI 10.1210/me.12.6.882; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; WAGNER SA, 1993, SCIENCE, V266, P395; Wang F, 1998, NUCLEIC ACIDS RES, V26, P3044, DOI 10.1093/nar/26.12.3044; WANG TTY, 1995, CANCER RES, V55, P2487; WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978; Xie W, 1999, ENDOCRINOLOGY, V140, P219, DOI 10.1210/en.140.1.219; Yamagata T, 1997, MOL CELL BIOL, V17, P4272, DOI 10.1128/MCB.17.8.4272; Yamaguchi A, 1997, INT J ONCOL, V10, P581; ZHANG DE, 1994, J BIOL CHEM, V269, P11425; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	61	231	241	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32099	32107		10.1074/jbc.274.45.32099	http://dx.doi.org/10.1074/jbc.274.45.32099			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542244	hybrid			2022-12-27	WOS:000083532100052
J	Ober, D; Hartmann, T				Ober, D; Hartmann, T			Deoxyhypusine synthase from tobacco - cDNA isolation, characterization, and bacterial expression of an enzyme with extended substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR 5A; HYPUSINE-CONTAINING PROTEIN; MOLECULAR-CLONING; SACCHAROMYCES-CEREVISIAE; HOMOSPERMIDINE SYNTHASE; PYRROLIZIDINE ALKALOIDS; LIQUID-CHROMATOGRAPHY; FUNCTIONAL EXPRESSION; SYM-HOMOSPERMIDINE; HAMSTER EPIDIDYMIS	Deoxyhypusine synthase catalyzes the formation of a deoxyhypusine residue in the translation eukaryotic initiation factor 5A (eIF5A) precursor protein by transferring an aminobutyl moiety from spermidine onto a conserved lysine residue within the eIF5A polypeptide chain. This reaction commences the activation of the initiation factor in fungi and vertebrates, A mechanistically identical reaction is known in the biosynthetic pathway leading to pyrrolizidine alkaloids in plants. Deoxyhypusine synthase from tobacco was cloned and expressed in active form in Escherichia coli. It catalyzes the formation of a deoxyhypusine residue in the tobacco eIF5A substrate as shown by gas chromatography coupled with a mass spectrometer. The enzyme also accepts free putrescine as the aminobutyl acceptor, instead of lysine bound in the eIF5A polypeptide chain, yielding homospermidine. Conversely, it accepts homospermidine instead of spermidine as the aminobutyl donor, whereby the reactions with putrescine and homospermidine proceed at the same rate as those involving the authentic substrates. The conversion of deoxyhypusine synthase-catalyzed eIF5A deoxyhypusinylation pinpoints a function for spermidine in plant metabolism. Furthermore, and quite unexpectedly, the substrate spectrum of deoxyhypusine synthase hints at a biochemical basis behind the sparse and skew occurrence of both homospermidine and its pyrrolizidine derivatives across distantly related plant taxa.	Tech Univ Braunschweig, Inst Pharmazeut Biol, D-38106 Braunschweig, Germany	Braunschweig University of Technology	Hartmann, T (corresponding author), Tech Univ Braunschweig, Inst Pharmazeut Biol, Mendelssohnstr 1, D-38106 Braunschweig, Germany.							Abid MR, 1997, J BIOCHEM-TOKYO, V121, P769; BARTIG D, 1992, J CHROMATOGR, V606, P43, DOI 10.1016/0021-9673(92)85255-R; BARTIG D, 1990, SYST APPL MICROBIOL, V13, P112, DOI 10.1016/S0723-2020(11)80156-6; BOTTCHER F, 1994, CAN J CHEM, V72, P80, DOI 10.1139/v94-013; BOTTCHER F, 1993, PHYTOCHEMISTRY, V32, P679, DOI 10.1016/S0031-9422(00)95154-9; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Chen KY, 1997, BIOL SIGNAL, V6, P105; COOPER HL, 1983, P NATL ACAD SCI-BIOL, V80, P1854, DOI 10.1073/pnas.80.7.1854; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; EVANS PT, 1989, ANNU REV PLANT PHYS, V40, P235, DOI 10.1146/annurev.pp.40.060189.001315; Galston AW, 1997, BOT ACTA, V110, P197, DOI 10.1111/j.1438-8677.1997.tb00629.x; GALSTON AW, 1985, PLANT HORMONES, P158; GORDON ED, 1987, J BIOL CHEM, V262, P16585; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Graser G, 1998, PHYTOCHEMISTRY, V47, P1017, DOI 10.1016/S0031-9422(97)00600-6; HAMANA K, 1988, FEMS MICROBIOL LETT, V50, P11; Hamana K, 1998, CAN J BOT, V76, P130, DOI 10.1139/cjb-76-1-130; HAMANA K, 1979, FEBS LETT, V99, P325, DOI 10.1016/0014-5793(79)80983-7; HAMANA K, 1992, CRIT REV MICROBIOL, V18, P261, DOI 10.3109/10408419209113518; Hartmann T, 1999, PLANTA, V207, P483, DOI 10.1007/s004250050508; Hartmann T., 1995, CHEM BIOL PERSPECT, V9, P155; Henikoff JG, 1996, METHOD ENZYMOL, V266, P88; HUSEK P, 1992, ANAL CHIM ACTA, V259, P185, DOI 10.1016/0003-2670(92)85367-F; IN JG, 1997, PLANT PHYSIOL, V115, P864; JOE YA, 1995, J BIOL CHEM, V270, P22386, DOI 10.1074/jbc.270.38.22386; KAISER FE, 1974, J CHROMATOGR, V94, P113, DOI 10.1016/S0021-9673(01)92361-1; KANG HA, 1994, J BIOL CHEM, V269, P3934; KEMPER WM, 1976, J BIOL CHEM, V251, P5551; KLIER H, 1995, FEBS LETT, V364, P207, DOI 10.1016/0014-5793(95)00394-O; KRISTIAK J, 1993, J PHYS IV, V3, P265, DOI 10.1051/jp4:1993441; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liao DI, 1998, STRUCTURE, V6, P23, DOI 10.1016/S0969-2126(98)00004-5; MAGDOLEN V, 1994, MOL GEN GENET, V244, P646, DOI 10.1007/BF00282755; MATSUZAKI S, 1982, BIOCHEM BIOPH RES CO, V107, P307, DOI 10.1016/0006-291X(82)91705-3; MATSUZAKI S, 1987, BIOCHEM INT, V15, P817; MEHTA AM, 1994, PLANT PHYSIOL, V106, P1413, DOI 10.1104/pp.106.4.1413; PARK MH, 1993, BIOFACTORS, V4, P95; Park MH, 1997, BIOL SIGNAL, V6, P115; PARK MH, 1988, J BIOL CHEM, V263, P15264; PARK MH, 1991, J BIOL CHEM, V266, P7988; PAY A, 1991, PLANT MOL BIOL, V17, P927, DOI 10.1007/BF00037075; Peat TS, 1998, STRUCT FOLD DES, V6, P1207, DOI 10.1016/S0969-2126(98)00120-8; SANO A, 1984, BIOCHIM BIOPHYS ACTA, V800, P135; SANO A, 1985, POLYAMINES BASIC CLI, P81; Sasaki K, 1996, FEBS LETT, V384, P151, DOI 10.1016/0014-5793(96)00310-9; SCHERER P, 1983, J BACTERIOL, V154, P1315, DOI 10.1128/JB.154.3.1315-1322.1983; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TAO Y, 1995, J BIOL CHEM, V270, P383, DOI 10.1074/jbc.270.1.383; TAO Y, 1995, J BIOL CHEM, V270, P23984, DOI 10.1074/jbc.270.41.23984; Tholl D, 1996, EUR J BIOCHEM, V240, P373, DOI 10.1111/j.1432-1033.1996.0373h.x; Walden R, 1997, PLANT PHYSIOL, V113, P1009, DOI 10.1104/pp.113.4.1009; Wolff EC, 1999, YEAST, V15, P43; WOLFF EC, 1990, J BIOL CHEM, V265, P4793; WOLFF EC, 1995, J BIOL CHEM, V270, P8660, DOI 10.1074/jbc.270.15.8660; Wolff EC, 1997, J BIOL CHEM, V272, P15865, DOI 10.1074/jbc.272.25.15865; YAN SCB, 1989, TRENDS BIOCHEM SCI, V14, P264, DOI 10.1016/0968-0004(89)90060-1; Yan YP, 1996, BIOCHEM J, V315, P429, DOI 10.1042/bj3150429; Yoneyama T, 1998, J EXP BOT, V49, P521, DOI 10.1093/jexbot/49.320.521	59	76	83	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32040	32047		10.1074/jbc.274.45.32040	http://dx.doi.org/10.1074/jbc.274.45.32040			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542236	hybrid			2022-12-27	WOS:000083532100044
J	Pavlova, NV; Yuziuk, JA; Nakagawa, H; Kiso, M; Li, SC; Li, YT				Pavlova, NV; Yuziuk, JA; Nakagawa, H; Kiso, M; Li, SC; Li, YT			2-Keto-3-deoxy-D-glycero-D-galacto-nononic acid (KDN)- and N-acetylneuraminic acid-cleaving sialidase (KDN-sialidase) and KDN-cleaving hydrolase (KDNase) from the hepatopancreas of oyster, Crassostrea virginica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEAMINATED NEURAMINIC ACID; RAINBOW-TROUT EGGS; 3-DEOXY-D-GLYCERO-D-GALACTO-2-NONULOSONIC ACID; POLY(ALPHA-2,8-DEAMINONEURAMINIC ACID); FLUOROMETRIC ASSAY; MAMMALIAN-TISSUES; EXPRESSION; IDENTIFICATION; PURIFICATION; GLYCOPROTEIN	KDN (2-keto-3-deoxy-D-glycero-D-galacto-nononic acid), a sialic acid analog, has been found to be widely distributed in nature. Despite the structural similarity between KDN and Neu5Ac, alpha-ketosides of KDN me refractory to conventional sialidases. Ne found that the hepatopancreas of the oyster, Crassostrea virginica, contains two KDN-cleaving sialidases but is devoid of conventional sialidase. The major sialidase, KDN-sialidase, effectively cleaves alpha-ketosidically linked KDN and also slowly cleaves the alpha-ketosides of Neu5Ac. The minor sialidase, KDNase, is specific for alpha-ketosides of KDN. Ne were able to separate these two KDN-cleaving enzymes using hydrophobic interaction and cation-exchange chromatographies. The rate of hydrolysis of 4-methylumbelliferyl-alpha-KDN (MU-KDN) by KDN-sialidase is 30 times faster than that of MU-Neu5Ac in the presence of 0.2 M NaCl, whereas in the absence of NaCl this ratio is only 8. KDNase hydrolyzes MU-KDN over 500 times faster than MU-Neu5Ac and is not affected by NaCl. KDN-sialidase purified to electrophoretically homogeneous form was found to have a molecular mass of 25 kDa and an isoelectric point of 8.4. One of the three tryptic peptides derived from KDN-sialidase contains the consensus motif, SXDXGXTW, that has been found in all conventional sialidases. Kinetic analysis of the inhibition of the hydrolysis of MU-KDN and MU-Neu5Ac by 2,3-dehydro-2-deoxy-KDN (KDN2-en) and 2,3-dehydro-2-deoxy-(Neu5Ac2-en) suggests that KDN-sialidase contains two separate active sites for the hydrolysis of KDN and Neu5Ac. Both KDN-sialidase and KDNase effectively hydrolyze KDN-G(M3), KDN alpha 2-->3Gal beta 1-->4Glc, KDN alpha 2-->6Gal beta 1-->4Glc, KDN alpha 2-->6-N-acetylgalactosaminitol, KDN alpha 2-->6(KDN alpha 2-->3)N-acetylgalactosaminitol and KDN alpha 2-->6(GlcNAc beta 1-->3)N-acetylgalactosaminitol. However, only KDN-sialidase also slowly hydrolyzes G(M3), Neu5Ac alpha 2-->3Gal beta 1-->4Glc, and Neu5Ac alpha 2-->6Gal beta 1-->4Glc. These two KDN-cleaving sialidases should be useful for studying the structure and function of KDN-containing glycoconjugates.	Tulane Univ, Sch Med, Dept Biochem, New Orleans, LA 70112 USA; Saga Univ, Fac Agr, Div Biometry & Appl Sci, Saga 840, Japan; Gifu Univ, Dept Bioorgan Chem, Gifu 50111, Japan	Tulane University; Saga University; Gifu University	Li, YT (corresponding author), Tulane Univ, Sch Med, Dept Biochem, 1430 Tulane Ave, New Orleans, LA 70112 USA.	yli@tmcpop.tmc.tulane.edu			NINDS NIH HHS [NS 09626] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS009626] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANGATA T, 1994, GLYCOBIOLOGY, V4, P517, DOI 10.1093/glycob/4.4.517; BOEKER EA, 1982, BIOCHEM J, V203, P117, DOI 10.1042/bj2030117; Corfield A.P., 1981, PERSPECTIVES INHERIT, V4, P3; DOUCET JP, 1988, ANAL BIOCHEM, V168, P265, DOI 10.1016/0003-2697(88)90317-X; FERRARI J, 1994, GLYCOBIOLOGY, V4, P367, DOI 10.1093/glycob/4.3.367; HARRIS G, 1954, CHEM IND-LONDON, P249; HEUERMANN D, 1991, GLYCOCONJUGATE J, V8, P95, DOI 10.1007/BF00731018; Inoue S, 1996, J BIOL CHEM, V271, P24341, DOI 10.1074/jbc.271.40.24341; Inoue S, 1998, J BIOL CHEM, V273, P27199, DOI 10.1074/jbc.273.42.27199; INOUE S, 1988, BIOCHEM BIOPH RES CO, V153, P172, DOI 10.1016/S0006-291X(88)81204-X; IWASAKI M, 1987, BIOCHEMISTRY-US, V26, P1452, DOI 10.1021/bi00379a036; JASPARD E, 1993, J BIOL CHEM, V268, P9496; KIMURA M, 1994, J BIOL CHEM, V269, P32138; KITAJIMA K, 1994, J BIOL CHEM, V269, P21415; KNIREL YA, 1989, CARBOHYD RES, V188, P145, DOI 10.1016/0008-6215(89)84067-4; Li Y.-T., 1972, METHOD ENZYMOL, V28, P702; LI YT, 1994, ARCH BIOCHEM BIOPHYS, V310, P243, DOI 10.1006/abbi.1994.1163; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIYAGI T, 1993, J BIOL CHEM, V268, P26435; MOORE GL, 1969, ANAL BIOCHEM, V32, P122, DOI 10.1016/0003-2697(69)90111-0; MYERS RW, 1980, ANAL BIOCHEM, V101, P166, DOI 10.1016/0003-2697(80)90056-1; NADANO D, 1986, J BIOL CHEM, V261, P1550; NAKAGAWA H, 1987, J BIOCHEM-TOKYO, V101, P855, DOI 10.1093/oxfordjournals.jbchem.a121952; NAKAMURA M, 1991, CHEM PHARM BULL, V39, P3140; Nishino S, 1996, J BIOL CHEM, V271, P2909, DOI 10.1074/jbc.271.6.2909; POTIER M, 1979, ANAL BIOCHEM, V94, P287, DOI 10.1016/0003-2697(79)90362-2; Qu BX, 1996, P NATL ACAD SCI USA, V93, P8995, DOI 10.1073/pnas.93.17.8995; RIVERASAGREDO A, 1992, EUR J BIOCHEM, V209, P415, DOI 10.1111/j.1432-1033.1992.tb17304.x; ROGGENTIN P, 1989, GLYCOCONJUGATE J, V6, P349, DOI 10.1007/BF01047853; Rosenberg A, 1976, BIOL ROLES SIALIC AC, P295; SONG Y, 1991, J BIOL CHEM, V266, P21929; STRECKER G, 1992, FEBS LETT, V298, P39, DOI 10.1016/0014-5793(92)80018-C; Terada T, 1997, J BIOL CHEM, V272, P5452, DOI 10.1074/jbc.272.9.5452; TERADA T, 1993, J CARBOHYD CHEM, V12, P425, DOI 10.1080/07328309308019398; TRONSMO A, 1993, ANAL BIOCHEM, V208, P74, DOI 10.1006/abio.1993.1010; Yuziuk JA, 1996, BIOCHEM J, V315, P1041, DOI 10.1042/bj3151041; Ziak M, 1996, P NATL ACAD SCI USA, V93, P2759, DOI 10.1073/pnas.93.7.2759; Ziak M, 1999, J AM SOC NEPHROL, V10, P203	38	8	8	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31974	31980		10.1074/jbc.274.45.31974	http://dx.doi.org/10.1074/jbc.274.45.31974			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542227	hybrid			2022-12-27	WOS:000083532100035
J	Zeremski, M; Hill, JE; Kwek, SSS; Grigorian, IA; Gurova, KV; Garkavtsev, IV; Diatchenko, L; Koonin, EV; Gudkov, AV				Zeremski, M; Hill, JE; Kwek, SSS; Grigorian, IA; Gurova, KV; Garkavtsev, IV; Diatchenko, L; Koonin, EV; Gudkov, AV			Structure and regulation of the mouse ing1 gene - Three alternative transcripts encode two PHD finger proteins that have opposite effects on p53 function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANDIDATE TUMOR-SUPPRESSOR; REGION; MDM2; DEGRADATION; FIBROBLASTS; PROMOTES; RNA	The human ING1 gene encodes nuclear protein p33(,)(ING1) CII previously shown to cooperate with p53 in cell growth control (Garkavtsev, I., Grigorian, I. A., Ossovskaya, V. S., Chernov, M. V., Chumakov, P, M., and Gudkov, A. V, (1998) Nature 391, 295-298), p33(ING1) belongs to a small family of proteins from human, mouse, and yeast of approximately the same size that show significant similarity to one another within the C-terminaI PHD finger domain and also contain an additional N-terminal region with subtle but reliably detectable sequence conservation Mouse ing1 is transcribed from three differently regulated promoters localized within a 4-kilobase pair region of genomic DNA The resulting transcripts share a long common region encoded by a common exon and differ in their 5'-exon sequences. Two transcripts are translated into the same protein of 185 amino acids, the mouse equivalent of the human p33(ING1), while the third transcript encodes a longer protein that has 94 additional N-terminal amino acids. Overexpression of the longer protein interferes with the accumulation of p53 protein and activation of p53-responsive promoters after DNA damage. Between the two products of ing1, only the longer one forms a complex with p53 detectable by immunoprecipitation, These results indicate that a single gene, ing1, encodes both p53-suppressing and p53-activating proteins that are regulated by alternative promoters.	Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA; CLONTECH Labs Inc, Palo Alto, CA 94303 USA; Genome Therapeut Corp, Dept Funct Gen, Waltham, MA 02154 USA; Natl Lib Med, Natl Ctr Biotechnol Informat, NIH, Bethesda, MD 20894 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)	Gudkov, AV (corresponding author), Univ Illinois, Coll Med, Dept Mol Genet, M-C 669,900 S Ashland Ave, Chicago, IL 60607 USA.			Gudkov, Andrei/0000-0003-2548-0154; Hill, Jason/0000-0003-2512-1661	NATIONAL CANCER INSTITUTE [R01CA060730, R01CA075179] Funding Source: NIH RePORTER; NCI NIH HHS [CA60730, CA75179] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; CHENCHIK A, 1998, GENE CLONING ANAL RT, P305; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Cui JQ, 1998, ONCOL REP, V5, P585; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Garkavtsev I, 1997, HYBRIDOMA, V16, P537, DOI 10.1089/hyb.1997.16.537; Garkavtsev I, 1997, MOL CELL BIOL, V17, P2014, DOI 10.1128/MCB.17.4.2014; Garkavtsev I, 1997, CYTOGENET CELL GENET, V76, P176, DOI 10.1159/000134539; Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; GUDKOV AV, 1989, INT J CANCER, V44, P1052, DOI 10.1002/ijc.2910440619; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Helbing CC, 1997, CANCER RES, V57, P1255; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; NEUWALD AF, 1995, PROTEIN SCI, V4, P1618, DOI 10.1002/pro.5560040820; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; QUELLE DE, 1995, CELL, V83, P993; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sambrook J., 2002, MOL CLONING LAB MANU; SCHINDLER U, 1993, PLANT J, V4, P1357; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SMALE S.T., 1994, TRANSCRIPTION MECHAN, P63; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; STASSEN MJ, 1995, MECH DEVELOP, V52, P209, DOI 10.1016/0925-4773(95)00402-M; THLIVERIS A, 1994, CANCER RES, V54, P2991; XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259	31	65	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32172	32181		10.1074/jbc.274.45.32172	http://dx.doi.org/10.1074/jbc.274.45.32172			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542254	hybrid			2022-12-27	WOS:000083532100062
J	Bingham, CO; Fijneman, RJA; Friend, DS; Goddeau, RP; Rogers, RA; Austen, KF; Arm, JP				Bingham, CO; Fijneman, RJA; Friend, DS; Goddeau, RP; Rogers, RA; Austen, KF; Arm, JP			Low molecular weight group IIA and group V phospholipase A(2) enzymes have different intracellular locations in mouse bone marrow-derived mast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; ARACHIDONIC-ACID RELEASE; SECRETORY PHOSPHOLIPASE-A2; PROSTAGLANDIN PRODUCTION; 5-LIPOXYGENASE PATHWAY; P388D(1) MACROPHAGES; SIGNAL-TRANSDUCTION; NUCLEAR-ENVELOPE; EXPRESSION; CLONING	The subcellular location of the enzymes of eicosanoid biosynthesis is critical for their co-ordinate action in the generation of leukotrienes and prostaglandins. This activity is thought to occur predominantly at a perinuclear location. Whereas the subcellular locations of cytosolic phospholipase (PL) A(2) and each of the pathway enzymes of eicosanoid generation have been defined, the distribution of the low molecular weight species of PLA(2) has remained elusive because of the lack of antibodies that distinguish among homologous family members. We have prepared affinity-purified rabbit antipeptide IgG antibodies that distinguish mouse group IIA PLA(2) and group V PLA(2). Immunofluorescence staining and immunogold electron microscopy reveal different subcellular locations for the enzymes. Group IIA(2) PLA(2) is present in the secretory granules of mouse bone marrow-derived mast cells, consistent with its putative role in facilitating secretory granule exocytosis and its consequent extracellular action. In contrast, group V PLA(2) is associated with various membranous organelles including the Golgi apparatus, nuclear envelope, and plasma membrane. The perinuclear location of group V PLA(2) is consistent with a putative interaction with translocated cytosolic PLA(2) in supplying arachidonic acid for generation of eicosanoid products, while the location in Golgi cisternae may also reflect its action as a secreted enzyme. The spatial segregation of group IIA PLA(2) and group V PLA(2) implies that these enzymes are not functionally redundant.	Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA; Brigham & Womens Hosp, Partners Asthma Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Biomed Imaging Lab, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health	Arm, JP (corresponding author), Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Smith Res Bldg,Rm 638B,1 Jimmy Fund Way, Boston, MA 02115 USA.		Fijneman, Remond/X-4199-2019	Fijneman, Remond/0000-0003-2076-5521	NHLBI NIH HHS [HL36110] Funding Source: Medline; NIAID NIH HHS [AI31599, AI22531] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI031599, R01AI022531, R37AI022531, U19AI031599] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AARSMAN AJ, 1989, J LIPID MEDIATOR, V1, P49; ANCIAN P, 1995, J BIOL CHEM, V270, P8963, DOI 10.1074/jbc.270.15.8963; Arm JP, 1997, J IMMUNOL, V159, P2342; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balsinde J, 1998, P NATL ACAD SCI USA, V95, P7951, DOI 10.1073/pnas.95.14.7951; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; Bingham CO, 1996, J BIOL CHEM, V271, P25936, DOI 10.1074/jbc.271.42.25936; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; BROCK TG, 1995, ADV PROSTAG THROMB L, V23, P151; Brock TG, 1997, J BIOL CHEM, V272, P8276, DOI 10.1074/jbc.272.13.8276; BROCK TG, 1995, J BIOL CHEM, V270, P21652, DOI 10.1074/jbc.270.37.21652; CHEN J, 1994, J BIOL CHEM, V269, P2365; CHEN J, 1994, BBA-LIPID LIPID MET, V1215, P115, DOI 10.1016/0005-2760(94)90099-X; CHOCK SP, 1994, BIOCHEM J, V300, P619, DOI 10.1042/bj3000619; CORDELLAMIELE E, 1993, P NATL ACAD SCI USA, V90, P10290, DOI 10.1073/pnas.90.21.10290; Cupillard L, 1999, J BIOL CHEM, V274, P7043, DOI 10.1074/jbc.274.11.7043; Cupillard L, 1997, J BIOL CHEM, V272, P15745, DOI 10.1074/jbc.272.25.15745; DEHAAS GH, 1968, BIOCHIM BIOPHYS ACTA, V159, P103, DOI 10.1016/0005-2744(68)90248-9; DEJONG JGN, 1987, EUR J BIOCHEM, V164, P129; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; DURSTIN M, 1994, P NATL ACAD SCI USA, V91, P3142, DOI 10.1073/pnas.91.8.3142; Emadi S, 1998, BRIT J HAEMATOL, V100, P365, DOI 10.1046/j.1365-2141.1998.00580.x; FONTEH AN, 1994, J IMMUNOL, V152, P5438; Fonteh AN, 1998, BBA-LIPID LIPID MET, V1393, P253, DOI 10.1016/S0005-2760(98)00079-4; Fujishima H, 1999, P NATL ACAD SCI USA, V96, P4803, DOI 10.1073/pnas.96.9.4803; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; Han SK, 1997, BBA-LIPID LIPID MET, V1346, P185, DOI 10.1016/S0005-2760(97)00034-9; ISHIZAKI J, 1994, J BIOL CHEM, V269, P5897; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; Lam BK, 1997, J BIOL CHEM, V272, P13923, DOI 10.1074/jbc.272.21.13923; Lambeau G, 1999, TRENDS PHARMACOL SCI, V20, P162, DOI 10.1016/S0165-6147(99)01300-0; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MELAN MA, 1992, J CELL SCI, V101, P731; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; MULHERKAR R, 1993, FEBS LETT, V317, P263, DOI 10.1016/0014-5793(93)81289-C; MURAKAMI M, 1991, FEBS LETT, V294, P247, DOI 10.1016/0014-5793(91)81440-J; Murakami M, 1996, J BIOL CHEM, V271, P30041, DOI 10.1074/jbc.271.47.30041; MURAKAMI M, 1993, J IMMUNOL, V151, P5675; MURAKAMI M, 1992, EUR J BIOCHEM, V209, P257, DOI 10.1111/j.1432-1033.1992.tb17284.x; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; Murakami M, 1997, FEBS LETT, V413, P249, DOI 10.1016/S0014-5793(97)00916-2; Naraba H, 1998, J IMMUNOL, V160, P2974; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OTTO JC, 1994, J BIOL CHEM, V269, P19868; Peters-Golden M, 1998, AM J RESP CRIT CARE, V157, pS227, DOI 10.1164/ajrccm.157.6.mar4; PETERSGOLDEN M, 1993, BIOCHEM BIOPH RES CO, V196, P147, DOI 10.1006/bbrc.1993.2227; Reddy ST, 1996, J BIOL CHEM, V271, P186, DOI 10.1074/jbc.271.1.186; Reddy ST, 1997, J BIOL CHEM, V272, P3231, DOI 10.1074/jbc.272.6.3231; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; ROSENTHAL MD, 1995, BIOCHEM BIOPH RES CO, V208, P650, DOI 10.1006/bbrc.1995.1388; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; SUGA H, 1993, EUR J BIOCHEM, V218, P807, DOI 10.1111/j.1432-1033.1993.tb18435.x; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; Tischfield JA, 1996, GENOMICS, V32, P328, DOI 10.1006/geno.1996.0126; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935	63	56	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31476	31484		10.1074/jbc.274.44.31476	http://dx.doi.org/10.1074/jbc.274.44.31476			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531350	hybrid			2022-12-27	WOS:000083379400054
J	Liao, J; Piwien-Pilipuk, G; Ross, SE; Hodge, CL; Sealy, L; MacDougald, OA; Schwartz, J				Liao, J; Piwien-Pilipuk, G; Ross, SE; Hodge, CL; Sealy, L; MacDougald, OA; Schwartz, J			CCAAT/enhancer-binding protein beta (C/EEP beta) and C/EBP delta contribute to growth hormone-regulated transcription of c-fos	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE ELEMENT; TYROSINE PHOSPHORYLATION; GENE-EXPRESSION; 3T3-L1 ADIPOCYTES; ACTIVATOR PROTEIN; LEUCINE ZIPPER; ALPHA-GENE; KINASE-A; IN-VIVO; FAMILY	Using the c-fos enhancer as a model to analyze growth hormone (GH)-promoted gene expression, the roles of CCAAT/enhancer-binding proteins (C/EBPs) in GH-regulated transcription were investigated. In 3T3-F442A fibroblasts stably expressing the c-fos promoter mutated at the C/EBP binding site upstream of luciferase, c-fos promoter activity is stimulated by GH 6-7-fold; wild type c-fos promoter shows only a 2-fold induction by GH, This suggests that C/EBP restrains GH-stimulated expression of c-fos. Electrophoretic mobility shift assays with nuclear extracts from 3T3-F442A cells indicate that GH rapidly (2-5 min) increases binding of C/EBP beta and C/EBP delta, to the c-fos C/EBP binding site. Both liver activating protein (LAP) and liver inhibitory protein (LIP), forms of C/EBP delta, are detected in 3T3-F442A cells by immunoblotting, GH increases the binding of LAP/LAP and LAP/LIP dimers, Overexpression elf LIP interferes with GH-promoted reporter expression in CHO cells expressing GH receptors, consistent with the possibility that LIP restrains GH-stimulated c-fos expression. Overexpression of LAP elevates basal luciferase activity but does not influence promoter activation by GH, while overexpressed C/EBP delta elevates basal promoter activity and enhances the stimulation by GH. GH stimulates the expression of mRNA for C/EBP beta and -delta and increases levels of C/EBP delta. Although C/EBP beta is not detectably altered, GH induces a shift to more rapidly migrating forms of LIP and LAP upon immunoblotting. Treatment of extracts from GH-treated cells with alkaline phosphatase causes a shift of the slower migrating form to the rapidly migrating form, consistent with GH promoting dephosphorylation of LIP and LAP. These studies implicate C/EBP beta and -delta in GH-regulated gene expression. They also indicate that GH stimulates the blinding of C/EBP beta and -delta to the c-fos promoter and promotes the dephosphorylation of LIP and LAP. These events may contribute to the ability of C/EBP beta and -delta to regulate GH-stimulated expression of c-fos.	Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Program Mol & Cellular Biol, Ann Arbor, MI 48109 USA; Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Vanderbilt University	Schwartz, J (corresponding author), Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA.			MacDougald, Ormond/0000-0001-6907-7960	NCI NIH HHS [CA43720] Funding Source: Medline; NIDDK NIH HHS [DK 51563, DK 46072] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA043720] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051563, R01DK046072] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN CM, 1995, ENDOCRINOLOGY, V136, P4505, DOI 10.1210/en.136.10.4505; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; Chinery R, 1997, J BIOL CHEM, V272, P30356, DOI 10.1074/jbc.272.48.30356; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CLARKSON RWE, 1995, MOL ENDOCRINOL, V9, P108, DOI 10.1210/me.9.1.108; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; Gong TWL, 1998, ENDOCRINOLOGY, V139, P1863, DOI 10.1210/en.139.4.1863; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; GRONOWSKI AM, 1995, MOL ENDOCRINOL, V9, P171, DOI 10.1210/me.9.2.171; HARVAT BL, 1995, CELL GROWTH DIFFER, V6, P955; Hemati N, 1997, J BIOL CHEM, V272, P25913, DOI 10.1074/jbc.272.41.25913; Hemati N, 1998, BIOCHEM BIOPH RES CO, V244, P20, DOI 10.1006/bbrc.1998.8204; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; LEE YH, 1994, MOL CELL BIOL, V14, P1383, DOI 10.1128/MCB.14.2.1383; Liao JF, 1997, J BIOL CHEM, V272, P25951, DOI 10.1074/jbc.272.41.25951; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; MACDOUGALD OA, 1995, J BIOL CHEM, V270, P647, DOI 10.1074/jbc.270.2.647; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; METZ R, 1991, ONCOGENE, V6, P2165; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MEYER DJ, 1993, P NATL ACAD SCI USA, V90, P6721, DOI 10.1073/pnas.90.14.6721; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; MOLLER C, 1992, J BIOL CHEM, V267, P23403; Montaner S, 1999, J BIOL CHEM, V274, P8506, DOI 10.1074/jbc.274.13.8506; Muller R, 1986, Biochim Biophys Acta, V823, P207, DOI 10.1016/0304-419X(86)90003-X; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; Ram PA, 1996, J BIOL CHEM, V271, P5929, DOI 10.1074/jbc.271.10.5929; RICHTER H, 1998, 80 M END SOC, P85; Sealy L, 1997, MOL CELL BIOL, V17, P1744, DOI 10.1128/MCB.17.3.1744; Sotiropoulos A, 1996, MOL ENDOCRINOL, V10, P998, DOI 10.1210/me.10.8.998; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; TAE HJ, 1995, J BIOL CHEM, V270, P21487, DOI 10.1074/jbc.270.37.21487; TRAUTWEIN C, 1994, J CLIN INVEST, V93, P2554, DOI 10.1172/JCI117266; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448	46	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31597	31604		10.1074/jbc.274.44.31597	http://dx.doi.org/10.1074/jbc.274.44.31597			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531366	hybrid			2022-12-27	WOS:000083379400070
J	Ren, H; Dou, C; Stelzer, MS; Allison, WS				Ren, H; Dou, C; Stelzer, MS; Allison, WS			Oxidation of the alpha(3)(beta D311C/R333C)(3)gamma subcomplex of the thermophilic Bacillus PS3F(1)-ATPase indicates that only two beta subunits can exist in the closed conformation simultaneously	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEART MITOCHONDRIAL F1-ATPASE; CATALYTIC SITES; NONCATALYTIC SITES; NUCLEOTIDE-BINDING; ESCHERICHIA-COLI; ALPHA(3)BETA(3)GAMMA COMPLEX; WILD-TYPE; ATP; PS3; ADP	In the crystal structure of the bovine heart mitochondrial F-1-ATPase (Abrahams, J.P., Leslie, A. G. W., Lutter, R., and Walker, J. E. (1994) Nature 370, 621-628), the two liganded beta subunits, one with MgAMP-PNP bound to the catalytic site (beta(T)) and the other with MgADP bound (beta(D)) have closed conformations. The empty beta subunit (beta(E)) has an open conformation. In beta(T) and beta(D), the distance between the carboxylate of beta-Asp(315) and the guanidinium of beta-Arg(337) is 3.0-4.0 Angstrom. These side chains are at least 10 Angstrom apart in beta(E). The alpha(3)(beta D311C/R333C)(3)gamma subcomplex of TF1 with the corresponding residues substituted with cysteine has very low ATPase activity unless it is reduced prior to assay or assayed in the presence of dithiothreitol. The reduced subcomplex hydrolyzes ATP at 50% the rate of wild-type and is rapidly inactivated by oxidation by CuCl2 with or without magnesium nucleotides bound to catalytic sites. Titration of the subcomplex with iodo[C-14]acetamide after prolonged treatment with CuCl2 in the presence or absence of 1 mM MgADP revealed nearly two free sulfhydryl groups/mol of enzyme. Therefore, one pair of introduced cysteines is located on a beta subunit that exists in the open or partially open conformation even when catalytic sites are saturated with MgADP. Since V-max of ATP hydrolysis is attained when three catalytic sites of F-1 are saturated, the catalytic site that binds ATP must be closing as the catalytic site that releases products is opening.	Univ Calif San Diego, Dept Biochem & Chem, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Allison, WS (corresponding author), Univ Calif San Diego, Dept Biochem & Chem, La Jolla, CA 92093 USA.	wsa@checfs2.ucsd.edu			NIGMS NIH HHS [GM16974] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Allison WS, 1998, ACCOUNTS CHEM RES, V31, P819, DOI 10.1021/ar960257v; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLOUGH DA, 1988, J BIOL CHEM, V263, P14053; Dou C, 1998, BIOCHEMISTRY-US, V37, P16757, DOI 10.1021/bi981717q; Dou C, 1997, BIOCHEMISTRY-US, V36, P3719, DOI 10.1021/bi962353+; Grodsky NB, 1998, BIOCHEMISTRY-US, V37, P1007, DOI 10.1021/bi972349d; Gruber G, 1996, J BIOL CHEM, V271, P32623, DOI 10.1074/jbc.271.51.32623; Jault JM, 1995, BIOCHEMISTRY-US, V34, P16412, DOI 10.1021/bi00050a023; JAULT JM, 1994, J BIOL CHEM, V269, P319; Kinosita K, 1998, CELL, V93, P21, DOI 10.1016/S0092-8674(00)81142-3; MATSUI T, 1995, BBA-BIOENERGETICS, V1231, P139, DOI 10.1016/0005-2728(95)00070-Y; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; Shirakihara Y, 1997, STRUCTURE, V5, P825, DOI 10.1016/S0969-2126(97)00236-0; Tsunoda SP, 1999, J BIOL CHEM, V274, P5701, DOI 10.1074/jbc.274.9.5701; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; WEBER J, 1993, J BIOL CHEM, V268, P20126	20	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31366	31372		10.1074/jbc.274.44.31366	http://dx.doi.org/10.1074/jbc.274.44.31366			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531337	hybrid			2022-12-27	WOS:000083379400041
J	Tran, POT; Gleason, CE; Poitout, V; Robertson, RP				Tran, POT; Gleason, CE; Poitout, V; Robertson, RP			Prostaglandin E-2 mediates inhibition of insulin secretion by interleukin-1 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT ISLETS; HIT CELLS; PANCREATIC-ISLETS; PGE2 INHIBITION; PERTUSSIS TOXIN; CAMP METABOLISM; IN-VITRO; CYCLOOXYGENASE-2; LANGERHANS; EXPOSURE	Interleukin-1 beta (IL-1 beta) and prostaglandin E-2 (PGE(2)), frequently co-participants in inflammatory states, are two well recognized inhibitors of glucose-induced insulin secretion. Previous reports have concluded that the inhibitory effects of these two autacoids on pancreatic beta cell function are not related because indomethacin, a potent prostaglandin synthesis inhibitor, does not prevent IL-1 beta effects. However, indomethacin is not a specific cyclooxygenase inhibitor, and its other pharmacologic effects are likely to inhibit insulin secretion independently. Since we recently observed that IL-1 beta induces cyclooxygenase-2 (COX-2) gene expression and PGE(2) synthesis in islet beta cells, we have reassessed the possibility that PGE(2) mediates IL-1 beta effects on beta function. By using two cell lines (HIT-T15 and beta HC13) as well as Wistar rat isolated pancreatic islets, we examined the ability of two COX-2-specific antagonists, NS-398 and SC-236, to prevent IL-1 beta inhibition of insulin secretion. Both drugs prevented IL-1 beta from inducing PGE(2) synthesis and inhibiting insulin secretion; adding back exogenous PGE(2) re-established inhibition of insulin secretion in the presence of IL-1 beta. We also found that EP3, the PGE(2) receptor subtype whose post-receptor effect is to decrease adenylyl cyclase activity and, thereby, insulin secretion, is the dominant mRNA subtype expressed. We conclude that endogenous PGE(2) mediates the inhibitory effects of exogenous IL-1 beta on beta cell function.	Pacific NW Res Inst, Seattle, WA 98122 USA; Univ Washington, Dept Med & Pharmacol, Seattle, WA 98122 USA	University of Washington; University of Washington Seattle	Robertson, RP (corresponding author), Pacific NW Res Inst, 720 Broadway, Seattle, WA 98122 USA.		Roberston, R Paul/AAX-5613-2021	Poitout, Vincent/0000-0002-6555-5053				Boie Y, 1997, EUR J PHARMACOL, V340, P227, DOI 10.1016/S0014-2999(97)01383-6; BURR IM, 1974, ENDOCRINOLOGY, V94, P835, DOI 10.1210/endo-94-3-835; CHEN M, 1979, PROSTAGLANDINS, V18, P557, DOI 10.1016/0090-6980(79)90023-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COMENS PG, 1987, DIABETES, V36, P963, DOI 10.2337/diabetes.36.8.963; EIZIRIK DL, 1991, ENDOCRINOLOGY, V128, P1611, DOI 10.1210/endo-128-3-1611; FUJIMOTO WY, 1984, DIABETES, V33, P872, DOI 10.2337/diabetes.33.9.872; Gierse JK, 1996, J BIOL CHEM, V271, P15810, DOI 10.1074/jbc.271.26.15810; GIUGLIANO D, 1983, AM J PHYSIOL, V245, pE591, DOI 10.1152/ajpendo.1983.245.6.E591; HELQVIST S, 1994, DAN MED BULL, V41, P151; HUGHES JH, 1989, DIABETES, V38, P1251, DOI 10.2337/diabetes.38.10.1251; Kawai S, 1998, EUR J PHARMACOL, V347, P87, DOI 10.1016/S0014-2999(98)00078-8; MandrupPoulsen T, 1996, DIABETOLOGIA, V39, P1005, DOI 10.1007/BF00400649; McDaniel ML, 1996, P SOC EXP BIOL MED, V211, P24; METZ SA, 1981, DIABETES, V30, P551, DOI 10.2337/diabetes.30.7.551; PALMER JP, 1989, DIABETES, V38, P1211, DOI 10.2337/diabetes.38.10.1211; Robertson R P, 1977, Trans Assoc Am Physicians, V90, P353; ROBERTSON RP, 1974, J CLIN INVEST, V54, P310, DOI 10.1172/JCI107766; ROBERTSON RP, 1983, DIABETES, V32, P231, DOI 10.2337/diabetes.32.3.231; ROBERTSON RP, 1987, DIABETES, V36, P1047, DOI 10.2337/diabetes.36.9.1047; SACCA L, 1975, ACTA ENDOCRINOL-COP, V79, P266, DOI 10.1530/acta.0.0790266; SEAQUIST ER, 1989, DIABETES, V38, P1439, DOI 10.2337/diabetes.38.11.1439; Sjoholm A, 1996, BBA-MOL CELL RES, V1313, P106; Sorli CH, 1998, P NATL ACAD SCI USA, V95, P1788, DOI 10.1073/pnas.95.4.1788; ZAWALICH WS, 1989, ENDOCRINOLOGY, V124, P2350, DOI 10.1210/endo-124-5-2350; ZHANG HJ, 1989, DIABETES, V38, P44, DOI 10.2337/diabetes.38.1.44	26	85	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31245	31248		10.1074/jbc.274.44.31245	http://dx.doi.org/10.1074/jbc.274.44.31245			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531320	hybrid			2022-12-27	WOS:000083379400024
J	Coulon, V; Veyrune, JL; Tourkine, N; Vie, A; Hipskind, RA; Blanchard, JM				Coulon, V; Veyrune, JL; Tourkine, N; Vie, A; Hipskind, RA; Blanchard, JM			A novel calcium signaling pathway targets the c-fos intragenic transcriptional pausing site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; IMMEDIATE-EARLY GENES; MULTIPLE SEQUENCE ELEMENTS; MESSENGER-RNA DEGRADATION; EPIDERMAL GROWTH-FACTOR; EXPRESSION; PROMOTER; CELLS; ACTIVATION; INDUCTION	In many cell types, increased intracellular calcium gives rise to a robust induction of c-fos gene expression. Here we show that in mouse Ltk(-) fibroblasts, calcium ionophore acts in synergy with either cAMP or PMA to strongly induce the endogenous c-fos gene. Run-on analysis shows that this corresponds to a substantial increase in active polymerases on downstream gene sequences, i.e. relief of an elongation block by calcium. Correspondingly a chimeric gene, in which the human metallothionein promoter is fused to the fos gene, is strongly induced by ionophore alone, unlike a c-fos promoter/beta-globin coding unit chimeric construct. Internal deletions in the hMT-fos reporter localize the intragenic calcium regulatory element to the 5' portion of intron 1, thereby confirming and extending previous in vitro mapping data. Ionophore induced cAMP response element-binding protein phosphorylation on Ser(133) without affecting the extracellular signal-regulated kinase cascade. Surprisingly, induction involved neither CaM-Ks nor calcineurin, while the calmodulin antagonist W7 activated c-fos transcription on its own. These data suggest that a novel calcium signaling pathway mediates intragenic regulation of c-fos expression via suppression of a transcriptional pause site.	Inst Genet Mol, CNRS, UMR 5535, IFR24, Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Blanchard, JM (corresponding author), Inst Genet Mol, CNRS, UMR 5535, IFR24, 1919 Route Mende, Montpellier 5, France.		Coulon, Vincent/B-2437-2009; Coulon, Vincent/AFF-7934-2022	Coulon, Vincent/0000-0002-3168-8755; Coulon, Vincent/0000-0002-3168-8755				ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; Antoine M, 1996, MOL CELL ENDOCRINOL, V120, P1, DOI 10.1016/0303-7207(96)03806-3; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BONNIEU A, 1989, ONCOGENE, V4, P881; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; Bravo R, 1990, Semin Cancer Biol, V1, P37; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; Carrion AM, 1999, NATURE, V398, P80, DOI 10.1038/18044; CHEN CYA, 1994, MOL CELL BIOL, V14, P416, DOI 10.1128/MCB.14.1.416; CLIPSTONE NA, 1993, ANN NY ACAD SCI, V696, P20; COLLART MA, 1989, ONCOGENE, V4, P237; COLLART MA, 1991, MOL CELL BIOL, V11, P2826, DOI 10.1128/MCB.11.5.2826; CORNELIUSSEN B, 1994, NATURE, V368, P760, DOI 10.1038/368760a0; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; CRUZALEGUI FH, 1992, P NATL ACAD SCI USA, V89, P12127, DOI 10.1073/pnas.89.24.12127; ENSLEN H, 1994, J BIOL CHEM, V269, P20872; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; FORT P, 1987, NUCLEIC ACIDS RES, V15, P5657, DOI 10.1093/nar/15.14.5657; Gamby C, 1996, J BIOL CHEM, V271, P26698, DOI 10.1074/jbc.271.43.26698; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; Ginty DD, 1997, NEURON, V18, P183, DOI 10.1016/S0896-6273(00)80258-5; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; GREENBERG ME, 1992, J PHYSIOLOGY-PARIS, V86, P99, DOI 10.1016/S0928-4257(05)80013-0; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; JANKNECHT R, 1995, IMMUNOBIOLOGY, V193, P137, DOI 10.1016/S0171-2985(11)80536-X; Krebs J, 1996, BBA-MOL CELL RES, V1313, P217, DOI 10.1016/0167-4889(96)00092-4; LAMB NJC, 1990, CELL, V61, P485, DOI 10.1016/0092-8674(90)90530-R; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEE G, 1994, MOL CELL BIOL, V14, P4579, DOI 10.1128/MCB.14.7.4579; LI SL, 1994, J MOL ENDOCRINOL, V13, P303, DOI 10.1677/jme.0.0130303; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; LUCIBELLO FC, 1991, NUCLEIC ACIDS RES, V19, P3583, DOI 10.1093/nar/19.13.3583; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MECHTI N, 1991, MOL CELL BIOL, V11, P2832, DOI 10.1128/MCB.11.5.2832; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; PIECHACZYK M, 1994, CRIT REV ONCOL HEMAT, V17, P93, DOI 10.1016/1040-8428(94)90021-3; PLET A, 1995, ONCOGENE, V10, P319; RAHMSDORF HJ, 1987, NUCLEIC ACIDS RES, V15, P1643, DOI 10.1093/nar/15.4.1643; RAN W, 1986, P NATL ACAD SCI USA, V83, P8216, DOI 10.1073/pnas.83.21.8216; RECH J, 1989, NUCLEIC ACIDS RES, V17, P2874, DOI 10.1093/nar/17.7.2874; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SOBCZAK J, 1989, ONCOGENE, V4, P1503; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; THOMPSON MA, 1995, J BIOL CHEM, V270, P4224, DOI 10.1074/jbc.270.9.4224; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; VELCICH A, 1990, MOL CELL BIOL, V10, P6273, DOI 10.1128/MCB.10.12.6273; VISVADER J, 1988, P NATL ACAD SCI USA, V85, P9474, DOI 10.1073/pnas.85.24.9474; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Wang Y, 1996, MOL CELL BIOL, V16, P5915; WERLEN G, 1993, J BIOL CHEM, V268, P16596; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959	67	31	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30439	30446		10.1074/jbc.274.43.30439	http://dx.doi.org/10.1074/jbc.274.43.30439			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521422	hybrid			2022-12-27	WOS:000083276700018
J	Falcon, CM; Matthews, KS				Falcon, CM; Matthews, KS			Glycine insertion in the hinge region of lactose repressor protein alters DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; RESTRAINED MOLECULAR-DYNAMICS; AMINO-TERMINAL FRAGMENT; TRYPSIN-RESISTANT CORE; LAC-REPRESSOR; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; PURINE REPRESSOR; GLUCOCORTICOID RECEPTOR; OPERATOR BINDING	Amino acid alterations were designed at the C terminus of the hinge segment (amino acids similar to 51-59) that links two functional domains within lactose repressor protein (LacI), Gly was introduced between Gly(58) and Lys(59) to generate Gly(58+1); Gln(60) was changed to Gly or Pro, and up to three additional glycines were inserted following Gln(60) --> Gly, All mutant proteins exhibited purification behavior, CD spectra, assembly state, and inducer binding properties similar to wild-type LacI and only small differences in trypsin proteolysis patterns. In contrast, significant differences were observed in DNA binding properties. Gly(58+1) exhibited a decrease of similar to 100-fold in affinity for O-1 operator, and sequential Gly insertion C-terminal to Gln(60) --> Gly resulted in progressively decreased affinity for O-1 operator, approaching nonspecific levels for insertion of greater than or equal to 2 glycines. Where sufficient affinity for O-1 operator existed, decreased binding to O-1 in the presence of inducer indicated no disruption in the allosteric response for these proteins. Collectively, these results indicate that flexibility and/or spacing between the core and N-terminal domains did not significantly affect folding or assembly, but these alterations in the hinge domain profoundly altered affinity of the lactose repressor protein for its wild-type target sequence.	Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77251 USA	Rice University	Matthews, KS (corresponding author), Rice Univ, Dept Biochem & Cell Biol, POB 1892, Houston, TX 77251 USA.				NIGMS NIH HHS [GM 22441] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022441] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTI S, 1993, EMBO J, V12, P3227, DOI 10.1002/j.1460-2075.1993.tb05992.x; ALBERTI S, 1991, NEW BIOL, V3, P57; AURORA R, 1994, SCIENCE, V264, P1126, DOI 10.1126/science.8178170; Aurora R, 1998, PROTEIN SCI, V7, P21, DOI 10.1002/pro.5560070103; Barry JK, 1997, BIOCHEMISTRY-US, V36, P15632, DOI 10.1021/bi971685r; Barry JK, 1999, BIOCHEMISTRY-US, V38, P3579, DOI 10.1021/bi982577n; BOELENS R, 1987, J MOL BIOL, V193, P213, DOI 10.1016/0022-2836(87)90638-3; Bourgeois S, 1976, Adv Protein Chem, V30, P1, DOI 10.1016/S0065-3233(08)60478-7; BOURGEOIS S, 1971, METHODS ENZYMOLOGY D, V21, P491; BUCK F, 1978, FEBS LETT, V96, P335, DOI 10.1016/0014-5793(78)80430-X; Capp MW, 1996, J MOL BIOL, V258, P25, DOI 10.1006/jmbi.1996.0231; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P22206; CHANG WI, 1993, J BIOL CHEM, V268, P17613; CHEN J, 1992, J BIOL CHEM, V267, P13843; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; CHUPRINA VP, 1993, J MOL BIOL, V234, P446, DOI 10.1006/jmbi.1993.1598; DALY TJ, 1986, BIOCHEMISTRY-US, V25, P5479, DOI 10.1021/bi00367a020; DALY TJ, 1986, BIOCHEMISTRY-US, V25, P5474, DOI 10.1021/bi00367a019; DEUSCHLE U, 1986, P NATL ACAD SCI USA, V83, P4134, DOI 10.1073/pnas.83.12.4134; Dickerson RE, 1997, BIOPOLYMERS, V44, P361, DOI 10.1002/(SICI)1097-0282(1997)44:4<361::AID-BIP4>3.0.CO;2-X; FILES JG, 1976, J BIOL CHEM, V251, P3386; Frank DE, 1997, J MOL BIOL, V267, P1186, DOI 10.1006/jmbi.1997.0920; FRIEDMAN AM, 1995, SCIENCE, V268, P1721, DOI 10.1126/science.7792597; GEISLER N, 1977, BIOCHEMISTRY-US, V16, P938, DOI 10.1021/bi00624a020; GEISLER N, 1978, FEBS LETT, V87, P215, DOI 10.1016/0014-5793(78)80335-4; GILBERT W, 1966, P NATL ACAD SCI USA, V56, P1891, DOI 10.1073/pnas.56.6.1891; Gunasekaran K, 1998, J MOL BIOL, V275, P917, DOI 10.1006/jmbi.1997.1505; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HILL ROBERT L., 1965, ADVANCE PROTEIN CHEM, V20, P37, DOI 10.1016/S0065-3233(08)60388-5; JOVIN TM, 1977, NATURE, V269, P668, DOI 10.1038/269668a0; Kaptein R, 1995, TOXICOL LETT, V82-3, P591, DOI 10.1016/0378-4274(95)03586-9; KAPTEIN R, 1985, J MOL BIOL, V182, P179, DOI 10.1016/0022-2836(85)90036-1; KHOURY AM, 1991, J MOL BIOL, V219, P623, DOI 10.1016/0022-2836(91)90659-T; KLEINA LG, 1990, J MOL BIOL, V212, P295, DOI 10.1016/0022-2836(90)90126-7; LAIKEN SL, 1972, J MOL BIOL, V66, P143, DOI 10.1016/S0022-2836(72)80012-3; LEE JY, 1991, CELL, V66, P793, DOI 10.1016/0092-8674(91)90122-F; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; LIN SY, 1975, BIOCHEM BIOPH RES CO, V62, P704, DOI 10.1016/0006-291X(75)90456-8; Lu F, 1998, BIOCHEMISTRY-US, V37, P15680, DOI 10.1021/bi981617k; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MARKIEWICZ P, 1994, J MOL BIOL, V240, P421, DOI 10.1006/jmbi.1994.1458; Matthews KS, 1998, PROG NUCLEIC ACID RE, V58, P127; Miller J. H., 1980, OPERON; Muller-Hill B, 1975, Prog Biophys Mol Biol, V30, P227; NAGADOI A, 1995, STRUCTURE, V3, P1217, DOI 10.1016/S0969-2126(01)00257-X; OGATA RT, 1978, P NATL ACAD SCI USA, V75, P5851, DOI 10.1073/pnas.75.12.5851; OGORMAN RB, 1980, J BIOL CHEM, V255, P107; OGORMAN RB, 1980, J BIOL CHEM, V255, P100; Pace HC, 1997, TRENDS BIOCHEM SCI, V22, P334, DOI 10.1016/S0968-0004(97)01104-3; PLATT T, 1973, J BIOL CHEM, V248, P110; PRESTA LG, 1988, SCIENCE, V240, P1632, DOI 10.1126/science.2837824; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; RIGGS AD, 1968, J MOL BIOL, V34, P361, DOI 10.1016/0022-2836(68)90260-X; RIGGS AD, 1968, J MOL BIOL, V34, P365, DOI 10.1016/0022-2836(68)90261-1; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P1310, DOI 10.1021/bi00219a022; SCHLAX PJ, 1995, J MOL BIOL, V245, P331, DOI 10.1006/jmbi.1994.0028; SCHMITZ A, 1976, J BIOL CHEM, V251, P3359; SCHUMACHER MA, 1995, CELL, V83, P147, DOI 10.1016/0092-8674(95)90243-0; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; SERRANO L, 1989, NATURE, V342, P296, DOI 10.1038/342296a0; SIBANDA BL, 1985, NATURE, V316, P170, DOI 10.1038/316170a0; Slijper M, 1996, J MOL BIOL, V259, P761, DOI 10.1006/jmbi.1996.0356; Smyth DG., 1967, METHOD ENZYMOL, V11, P214; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Spronk CAEM, 1996, NAT STRUCT BIOL, V3, P916, DOI 10.1038/nsb1196-916; STRANEY SB, 1987, CELL, V51, P699, DOI 10.1016/0092-8674(87)90093-6; Suckow J, 1996, J MOL BIOL, V261, P509, DOI 10.1006/jmbi.1996.0479; von Hippel P H, 1974, Proc Natl Acad Sci U S A, V71, P4808; WADEJARDETZKY N, 1979, J MOL BIOL, V128, P259, DOI 10.1016/0022-2836(79)90129-3; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; ZUIDERWEG ERP, 1985, BIOCHIMIE, V67, P707, DOI 10.1016/S0300-9084(85)80158-9	72	40	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30849	30857		10.1074/jbc.274.43.30849	http://dx.doi.org/10.1074/jbc.274.43.30849			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521477	hybrid			2022-12-27	WOS:000083276700073
J	Gogos, A; Clarke, ND				Gogos, A; Clarke, ND			Characterization of an 8-oxoguanine DNA glycosylase from Methanococcus jannaschii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; SUBSTRATE-SPECIFICITY; CATALYTIC MECHANISM; OGG1 GENE; 7,8-DIHYDRO-8-OXOGUANINE; CLONING; REPAIR; CLEAVAGE; PROTEIN; ENZYME	A thermostable 8-oxoguanine (oxoG) DNA glycosylase from Methanococcus jannaschii has been expressed in Escherichia coli, purified, and characterized. The enzyme, which has been named mjOgg, belongs to the same diverse DNA glycosylase superfamily as the 8-oxoguanine DNA glycosylases from yeast (yOgg1) and human (hOgg1) but is substantially different in sequence. In addition, unlike its eukaryotic counterparts, which have a strong preference for oxoG.C base pairs, mjOgg has little specificity for the base opposite oxoG. mjOgg has both DNA glycosylase and DNA lyase (beta-elimination) activity, and the combined glycosylase/lyase activity occurs at a rate comparable with the glycosylase activity alone. Mutation of Lys-129, analogous to Lys-241 of yOgg1, abolishes glycosylase activity.	Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21205 USA	Johns Hopkins University	Clarke, ND (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.		Clarke, Neil/D-9613-2014	Gogos, Arhonda/0000-0003-3634-0114				Alamo MJP, 1998, NUCLEIC ACIDS RES, V26, P5199, DOI 10.1093/nar/26.22.5199; Arai K, 1997, ONCOGENE, V14, P2857, DOI 10.1038/sj.onc.1201139; Bjoras M, 1997, EMBO J, V16, P6314, DOI 10.1093/emboj/16.20.6314; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Burrows CJ, 1998, CHEM REV, V98, P1109, DOI 10.1021/cr960421s; CASTAING B, 1993, NUCLEIC ACIDS RES, V21, P2899, DOI 10.1093/nar/21.12.2899; DODSON ML, 1994, J BIOL CHEM, V269, P32709; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Girard PM, 1997, NUCLEIC ACIDS RES, V25, P3204, DOI 10.1093/nar/25.16.3204; Lu RZ, 1997, CURR BIOL, V7, P397, DOI 10.1016/S0960-9822(06)00187-4; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Noll DM, 1999, BIOCHEMISTRY-US, V38, P6374, DOI 10.1021/bi990335x; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197	16	23	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30447	30450		10.1074/jbc.274.43.30447	http://dx.doi.org/10.1074/jbc.274.43.30447			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521423	hybrid			2022-12-27	WOS:000083276700019
J	Cline, SD; Osheroff, N				Cline, SD; Osheroff, N			Cytosine arabinoside lesions are position-specific topoisomerase II poisons and stimulate DNA cleavage mediated by the human type II enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARA-C; POLYMERASE-ALPHA; ABASIC SITES; CELL-CYCLE; 1-BETA-D-ARABINOFURANOSYLCYTOSINE INCORPORATION; DEOXYADENOSINE STACKS; HELIX OPPOSITE; PROTON-NMR; ARABINOSYLCYTOSINE; BETA	Cytosine arabinoside (araC) is an important drug used for the treatment of human leukemias. In order to exert its cytotoxic effects, araC must be incorporated into chromosomal DNA,Although specific DNA lesions that involve base loss or modification stimulate nucleic acid cleavage mediated by type II topoisomerases, the effects of deoxyribose sugar ring modification on enzyme activity have not been examined. Therefore, the effects of incorporated araC residues on the DNA cleavage/religation equilibrium of human topoisomerase II alpha and beta were characterized. AraC lesions were position-specific topoisomerase II poisons and stimulated DNA scission mediated by both human type II enzymes. However, the positional specificity of araC residues differed from that previously reported for other cleavage-enhancing DNA lesions. Finally, additive or synergistic increases in DNA cleavage were observed in the presence of araC lesions and etoposide. These findings broaden the range of DNA lesions known to alter topoisomerase II function and raise the possibility that this enzyme may mediate some of the cellular effects of araC.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med Hematol Oncol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Osheroff, N (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 654 Med Res Bldg 1, Nashville, TN 37232 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008320] Funding Source: NIH RePORTER; NIGMS NIH HHS [5 T32 GM08320, GM53960] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Austin CA, 1998, BIOESSAYS, V20, P215, DOI 10.1002/(SICI)1521-1878(199803)20:3<215::AID-BIES5>3.0.CO;2-Q; BAKIC M, 1987, BIOCHEM PHARMACOL, V36, P4067, DOI 10.1016/0006-2952(87)90563-6; BERGER RD, 1998, J BIOL CHEM, V273, P15565; Bigioni M, 1996, BIOCHEMISTRY-US, V35, P153, DOI 10.1021/bi951736p; BURDEN DA, 1993, BIOCHEM J, V293, P297, DOI 10.1042/bj2930297; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; Chabner BA, 1996, CANC CHEMOTHERAPY BI, P213; CLINE SD, 1998, AM ASS CANC RES SPEC, P8; CORBETT AH, 1993, CHEM RES TOXICOL, V6, P585, DOI 10.1021/tx00035a001; CUNIASSE P, 1987, NUCLEIC ACIDS RES, V15, P8003, DOI 10.1093/nar/15.19.8003; CUNIASSE P, 1990, J MOL BIOL, V213, P303, DOI 10.1016/S0022-2836(05)80192-5; FELIX CA, 1995, CANCER RES, V55, P4287; FRAM RJ, 1983, LEUKEMIA RES, V7, P243, DOI 10.1016/0145-2126(83)90014-0; GAO YG, 1991, BIOCHEMISTRY-US, V30, P9922, DOI 10.1021/bi00105a016; Gmeiner WH, 1999, BIOCHEMISTRY-US, V38, P1166, DOI 10.1021/bi981702s; GOLJER I, 1995, J BIOL CHEM, V270, P22980, DOI 10.1074/jbc.270.39.22980; Goz B, 1997, MUTAT RES-DNA REPAIR, V384, P89, DOI 10.1016/S0921-8777(97)00016-5; Grant S, 1998, ADV CANCER RES, V72, P197; HARRINGTON C, 1995, J BIOL CHEM, V270, P26664, DOI 10.1074/jbc.270.44.26664; HECK MMS, 1988, P NATL ACAD SCI USA, V85, P1086, DOI 10.1073/pnas.85.4.1086; HOLDEN JA, 1992, ONCOL RES, V4, P157; Isaacs RJ, 1998, BBA-GENE STRUCT EXPR, V1400, P121, DOI 10.1016/S0167-4781(98)00131-6; JONES PA, 1976, CANCER RES, V36, P3789; KALNIK MW, 1989, BIOCHEMISTRY-US, V28, P3373, DOI 10.1021/bi00434a037; KALNIK MW, 1988, BIOCHEMISTRY-US, V27, P924, DOI 10.1021/bi00403a013; Kingma PS, 1997, BIOCHEMISTRY-US, V36, P5934, DOI 10.1021/bi970507v; Kingma PS, 1997, J BIOL CHEM, V272, P1148, DOI 10.1074/jbc.272.2.1148; KINGMA PS, 1995, J BIOL CHEM, V270, P21441, DOI 10.1074/jbc.270.37.21441; Kingma PS, 1998, BBA-GENE STRUCT EXPR, V1400, P223, DOI 10.1016/S0167-4781(98)00138-9; Kingma PS, 1997, J BIOL CHEM, V272, P7488, DOI 10.1074/jbc.272.11.7488; Kingma PS, 1998, J BIOL CHEM, V273, P17999, DOI 10.1074/jbc.273.29.17999; KUFE DW, 1984, MOL PHARMACOL, V26, P128; KUFE DW, 1980, J BIOL CHEM, V255, P8997; KUFE DW, 1985, SEMIN ONCOL, V12, P34; LIU LF, 1983, J BIOL CHEM, V258, P5365; MAJOR PP, 1981, P NATL ACAD SCI-BIOL, V78, P3235, DOI 10.1073/pnas.78.5.3235; MAJOR PP, 1982, BIOCHEM PHARMACOL, V31, P2937, DOI 10.1016/0006-2952(82)90266-0; MIKITA T, 1988, BIOCHEMISTRY-US, V27, P4698, DOI 10.1021/bi00413a018; OHNO Y, 1988, CANCER RES, V48, P1494; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P4303, DOI 10.1021/bi00388a018; PERRINO FW, 1992, J BIOL CHEM, V267, P23043; PLAGEMANN PGW, 1978, CANCER RES, V38, P978; RAAP J, 1987, J BIOMOL STRUCT DYN, V5, P219, DOI 10.1080/07391102.1987.10506391; RASHBAUM SA, 1976, NATURE, V264, P679, DOI 10.1038/264679a0; RIVERA G, 1975, EUR J CANCER, V11, P639, DOI 10.1016/0014-2964(75)90099-7; SCHWEITZER BI, 1994, BIOCHEMISTRY-US, V33, P11460, DOI 10.1021/bi00204a008; TOWNSEND AJ, 1987, MOL PHARMACOL, V32, P330; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WANG KY, 1997, BIOCHEMISTRY-US, V36, P11626; Whitlock JA, 1997, LEUKEMIA, V11, P185, DOI 10.1038/sj.leu.2400572; WOESSNER RD, 1991, CELL GROWTH DIFFER, V2, P209; WOODCOCK DM, 1979, EXP CELL RES, V123, P157, DOI 10.1016/0014-4827(79)90432-4; WOODCOCK DM, 1979, CANCER RES, V39, P1418; WOODCOCK DM, 1982, CANCER RES, V42, P4744; YOSHIDA S, 1977, BIOCHIM BIOPHYS ACTA, V477, P144, DOI 10.1016/0005-2787(77)90230-1	55	26	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29740	29743		10.1074/jbc.274.42.29740	http://dx.doi.org/10.1074/jbc.274.42.29740			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514448	hybrid			2022-12-27	WOS:000083176400027
J	Jiang, SN; Cai, JY; Wallace, DC; Jones, DP				Jiang, SN; Cai, JY; Wallace, DC; Jones, DP			Cytochrome c-mediated apoptosis in cells lacking mitochondrial DNA - Signaling pathway involving release and caspase 3 activation is conserved	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; BCL-2; MEMBRANE; PROTEIN; DEATH; GLUTATHIONE; REQUIREMENT; SUPEROXIDE; GENERATION; INHIBITION	Mitochondria serve as a pivotal component of the apoptotic cell death machinery. However, cells that lack mitochondrial DNA (rho(0) cells) retain apparently normal apoptotic signaling. In the present study, we examined mitochondrial mechanisms of apoptosis in rho(0) osteosarcoma cells treated with staurosporine. Immunohistochemistry revealed that rho(0) cells maintained a normal cytochrome c distribution in mitochondria even though these cells were deficient in respiration. Upon staurosporine treatment, cytochrome c was released concomitantly with activation of caspase 3 and loss of mitochondrial membrane potential (Delta psi(m)). After mitochondrial loss of cytochrome c, rho(0) cells underwent little change in glutathione (GSH) redox potential whereas a dramatic oxidation in GSH/glutathione disulfide (GSSG) pool occurred in parental rho(+) cells. These results show that mitochondrial signaling of apoptosis via cytochrome c release was preserved in cells lacking mtDNA. However, intracellular oxidation that normally accompanies apoptosis was lost, indicating that the mitochondrial respiratory chain provides the major source of redox signaling in apoptosis.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Ctr Mol Med, Atlanta, GA 30322 USA	Emory University; Emory University	Jones, DP (corresponding author), Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA.				NIEHS NIH HHS [ES09047] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009047] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adachi S, 1997, J BIOL CHEM, V272, P21878, DOI 10.1074/jbc.272.35.21878; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BAI CL, 1989, ANAL BIOCHEM, V179, P114, DOI 10.1016/0003-2697(89)90209-1; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; Cai JY, 1998, BBA-BIOENERGETICS, V1366, P139, DOI 10.1016/S0005-2728(98)00109-1; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; Higuchi M, 1997, J CLIN INVEST, V99, P1751, DOI 10.1172/JCI119339; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; Jiang SN, 1997, CELL DEATH DIFFER, V4, P39, DOI 10.1038/sj.cdd.4400204; JONES DP, 1995, IMMUNOL LETT, V45, P205, DOI 10.1016/0165-2478(95)00004-O; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; Krippner A, 1996, J BIOL CHEM, V271, P21629, DOI 10.1074/jbc.271.35.21629; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; LI K, 1995, AM J PHYSIOL-CELL PH, V269, pC1265, DOI 10.1152/ajpcell.1995.269.5.C1265; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mancini M, 1998, J CELL BIOL, V140, P1485, DOI 10.1083/jcb.140.6.1485; Marchetti P, 1996, J IMMUNOL, V157, P4830; Marchetti P, 1996, CANCER RES, V56, P2033; Mignotte B, 1998, EUR J BIOCHEM, V252, P1, DOI 10.1046/j.1432-1327.1998.2520001.x; Murphy RC, 1998, FEBS LETT, V425, P259, DOI 10.1016/S0014-5793(98)00245-2; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NIJTMANS LGJ, 1995, BBA-MOL CELL RES, V1265, P117, DOI 10.1016/0167-4889(94)00203-Q; QUILLETMARY A, 1997, J BIOL CHEM, V272, P21338; RATAN RR, 1994, J NEUROCHEM, V62, P376; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Samali A, 1998, FEBS LETT, V431, P167, DOI 10.1016/S0014-5793(98)00740-6; STUART RA, 1990, BIOCHIMIE, V72, P115, DOI 10.1016/0300-9084(90)90136-5; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; TROUNCE I, 1994, P NATL ACAD SCI USA, V91, P8334, DOI 10.1073/pnas.91.18.8334; UCKUN FM, 1992, P NATL ACAD SCI USA, V89, P9005, DOI 10.1073/pnas.89.19.9005; vandenDobbelsteen DJ, 1996, J BIOL CHEM, V271, P15420, DOI 10.1074/jbc.271.26.15420; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zamzami N, 1996, FEBS LETT, V384, P53, DOI 10.1016/0014-5793(96)00280-3; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	46	152	159	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29905	29911		10.1074/jbc.274.42.29905	http://dx.doi.org/10.1074/jbc.274.42.29905			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514472	hybrid			2022-12-27	WOS:000083176400051
J	Maestes, DC; Potter, RM; Prossnitz, ER				Maestes, DC; Potter, RM; Prossnitz, ER			Differential phosphorylation paradigms dictate desensitization and internalization of the N-formyl peptide receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; PROTEIN-COUPLED RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; CHEMOATTRACTANT RECEPTORS; BETA-ARRESTIN; KINASES; CELLS; MECHANISMS; ACTIVATION; CLONING	Following activation by ligand, most G protein-coupled receptors undergo rapid phosphorylation, This is accompanied by a drastic decrease in the efficacy of continued or repeated stimulation, due to receptor uncoupling from G protein and receptor internalization. Such processing steps have been shown to be absolutely dependent on receptor phosphorylation in the case of the N-formyl peptide receptor (FPR), In this study, we report results that indicate that the mechanisms responsible for desensitization and internalization are distinct. Using site-directed mutagenesis of the serine and threonine residues of the FPR carboxyl terminus, we have characterized regions that differentially regulate these two processes. Whereas substitution of all 11 Ser/Thr residues in the carboxyl terminus prevents both desensitization and internalization, substitution of four Ser/Thr residues between 328-332 blocks desensitization but has no effect on internalization, Similarly, substitution of four Ser/Thr residues between positions 334 and 339 results in a deficit in desensitization but again no decrease in internalization, suggesting that phosphorylation at either site evokes receptor internalization, whereas maximal desensitization requires phosphorylation at both sites. These results also indicate that receptor internalization is not involved in the process of desensitization. Further analysis of the residues between 328-332 revealed that restoration either of Ser(328) and Thr(329) or of Thr(331) and Ser(332) was sufficient to restore desensitization, suggesting that phosphorylation within either of these two sites, in addition to sites between residues 334 and 339, is sufficient to produce desensitization. Taken together, these results indicate that the mechanisms involved in FPR processing ( uncoupling from G; proteins and internalization) are regulated differentially by phosphorylation at distinct sites within the carboxyl terminus of the FPR, The relevance of this paradigm to other G protein-coupled receptors is discussed.	Univ New Mexico, Ctr Hlth Sci, Dept Physiol & Cell Biol, Albuquerque, NM 87131 USA	University of New Mexico	Prossnitz, ER (corresponding author), Univ New Mexico, Ctr Hlth Sci, Dept Physiol & Cell Biol, Albuquerque, NM 87131 USA.		Prossnitz, Eric R./B-4543-2008	Prossnitz, Eric/0000-0001-9190-8302	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036357, R29AI036357] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40115, AI36357] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BOULAY F, 1991, BIOCHEMISTRY-US, V30, P2993, DOI 10.1021/bi00226a002; Choe H, 1998, ARCH PHARM RES, V21, P634, DOI 10.1007/BF02976749; COBBOLD PH, 1987, BIOCHEM J, V248, P313, DOI 10.1042/bj2480313; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Hartig P R, 1993, Psychopharmacol Ser, V10, P15; Hsu MH, 1997, J BIOL CHEM, V272, P29426, DOI 10.1074/jbc.272.47.29426; Kew RR, 1997, J LEUKOCYTE BIOL, V61, P329, DOI 10.1002/jlb.61.3.329; Lazari RDM, 1998, J BIOL CHEM, V273, P18316, DOI 10.1074/jbc.273.29.18316; Lefkowitz RJ, 1996, NAT BIOTECHNOL, V14, P283, DOI 10.1038/nbt0396-283; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Nakamura K, 1998, J BIOL CHEM, V273, P24346, DOI 10.1074/jbc.273.38.24346; NAWATA H, 1995, STEROIDS, V60, P28, DOI 10.1016/0039-128X(94)00022-5; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P14152, DOI 10.1074/jbc.272.22.14152; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; Prossnitz ER, 1997, J BIOL CHEM, V272, P15213, DOI 10.1074/jbc.272.24.15213; PROSSNITZ ER, 1991, BIOCHEM BIOPH RES CO, V179, P471, DOI 10.1016/0006-291X(91)91394-R; PROSSNITZ ER, 1993, BIOCHEM J, V294, P581, DOI 10.1042/bj2940581; PROSSNITZ ER, 1995, J BIOL CHEM, V270, P1130, DOI 10.1074/jbc.270.3.1130; Prossnitz ER, 1999, BIOCHEMISTRY-US, V38, P2240, DOI 10.1021/bi982274t; Prossnitz ER, 1997, PHARMACOL THERAPEUT, V74, P73, DOI 10.1016/S0163-7258(96)00203-3; THOMAS KM, 1991, J BIOL CHEM, V266, P14839; Vilven JC, 1998, J RECEPT SIGNAL TR R, V18, P187, DOI 10.3109/10799899809047744; Ye R D, 1997, Adv Pharmacol, V39, P221, DOI 10.1016/S1054-3589(08)60073-3; Zhang J, 1997, RECEPTOR CHANNEL, V5, P193	28	49	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29791	29795		10.1074/jbc.274.42.29791	http://dx.doi.org/10.1074/jbc.274.42.29791			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514456	hybrid			2022-12-27	WOS:000083176400035
J	Nosaka, Y; Arai, A; Miyasaka, N; Miura, O				Nosaka, Y; Arai, A; Miyasaka, N; Miura, O			CrkL mediates Ras-dependent activation of the Raf/ERK pathway through the guanine nucleotide exchange factor C3G in hematopoietic cells stimulated with erythropoietin or interleukin-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE PATHWAY; CHRONIC MYELOGENOUS LEUKEMIA; NERVE GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; SIGNALING PATHWAYS; ADAPTER PROTEIN; MAP KINASE; V-CRK; MEGAKARYOCYTIC DIFFERENTIATION; PHOSPHATIDYLINOSITOL 3-KINASE	CrkL is an SH2 and SH3 domain-containing adaptor protein implicated in pathogenesis of chronic myelogenous leukemia. Here, we demonstrate that overexpression of CrkL enhances the erythropoietin (Epo)- or interleukin (IL)-3-induced activation of Elk-1 and the c-fos gene promoter activity in 32D/EpoR-Wt cells. Moreover, the Epo-induced activation of ERK1 and ERK2 was augmented and prolonged in cells inducibly overexpressing CrkL. A moderate increase in Epo-induced activation of JNK was also observed in cells overexpressing CrkL. Overexpression of C3G enhanced the Elk-l activation synergistically with CrkL, while a C3G mutant lacking the guanine nucleotide exchange domain showed an inhibitory effect. Studies using a dominant negative Ha-Ras mutant demonstrated that the Elk-1 and ERK2 activation enhanced by CrkL and C3G was dependent on Ras. Consistent with this, the Epo-induced activation of Ras was augmented in cells inducibly overexpressing CrkL. Most importantly, a CrkL mutant defective in the SH2 or N-terminal SH3 domain showed an inhibitory effect on the Epo-induced activation of ERK2. These data indicate that the CrkL-C3G; complex plays a role in Epo- or IL-L-induced, Ras-dependent activation of the Raf/ERK pathway leading to the activation of Elk-l and the c-fos gene transcription.	Tokyo Med & Dent Univ, Dept Internal Med 1, Bunkyo Ku, Tokyo 113, Japan	Tokyo Medical & Dental University (TMDU)	Miura, O (corresponding author), Tokyo Med & Dent Univ, Dept Internal Med 1, Bunkyo Ku, 1-5-45 Yushima, Tokyo 113, Japan.	miura.med1@med.tmd.ac.jp		Miura, Osamu/0000-0002-0981-3054				Arai A, 1999, BLOOD, V93, P3713, DOI 10.1182/blood.V93.11.3713.411a36_3713_3722; Chin H, 1997, BIOCHEM BIOPH RES CO, V239, P412, DOI 10.1006/bbrc.1997.7480; Chin H, 1996, BLOOD, V88, P4415, DOI 10.1182/blood.V88.12.4415.bloodjournal88124415; Chin H, 1998, BLOOD, V91, P3734; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; DEJONG R, 1995, ONCOGENE, V11, P1469; deJong R, 1997, ONCOGENE, V14, P507, DOI 10.1038/sj.onc.1200885; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; FELLER SM, 1995, ONCOGENE, V10, P1465; Foltz IN, 1997, BLOOD, V89, P3092, DOI 10.1182/blood.V89.9.3092; Gesbert F, 1998, J BIOL CHEM, V273, P3986, DOI 10.1074/jbc.273.7.3986; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Greulich H, 1996, CELL GROWTH DIFFER, V7, P1443; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ingham RJ, 1996, J BIOL CHEM, V271, P32306, DOI 10.1074/jbc.271.50.32306; Ishimaru S, 1999, EMBO J, V18, P145, DOI 10.1093/emboj/18.1.145; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Koval AP, 1998, J BIOL CHEM, V273, P14780, DOI 10.1074/jbc.273.24.14780; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; Matsumura I, 1998, MOL CELL BIOL, V18, P4282, DOI 10.1128/MCB.18.7.4282; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MIURA O, 1994, J BIOL CHEM, V269, P614; MIURA Y, 1994, J BIOL CHEM, V269, P29962; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; Nagata Y, 1997, BLOOD, V89, P2664, DOI 10.1182/blood.V89.8.2664; Nakamura N, 1996, J BIOL CHEM, V271, P19483, DOI 10.1074/jbc.271.32.19483; NICHOLS GL, 1994, BLOOD, V84, P2912; Oda A, 1996, BLOOD, V88, P4304; ODA T, 1994, J BIOL CHEM, V269, P22925; Racke FK, 1997, J BIOL CHEM, V272, P23366, DOI 10.1074/jbc.272.37.23366; Rausch O, 1997, MOL CELL BIOL, V17, P1170, DOI 10.1128/MCB.17.3.1170; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; Sattler M, 1997, J BIOL CHEM, V272, P10248; Senechal K, 1998, MOL CELL BIOL, V18, P5082, DOI 10.1128/MCB.18.9.5082; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; Sorokin A, 1998, ONCOGENE, V16, P2425, DOI 10.1038/sj.onc.1201781; Tanaka S, 1998, J BIOL CHEM, V273, P1281, DOI 10.1074/jbc.273.3.1281; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; TENG KK, 1995, J BIOL CHEM, V270, P20677, DOI 10.1074/jbc.270.35.20677; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; Terada K, 1997, J BIOL CHEM, V272, P4544, DOI 10.1074/jbc.272.7.4544; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WATANABE S, 1993, MOL CELL BIOL, V13, P1440, DOI 10.1128/MCB.13.3.1440; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	62	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30154	30162		10.1074/jbc.274.42.30154	http://dx.doi.org/10.1074/jbc.274.42.30154			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514505	hybrid			2022-12-27	WOS:000083176400084
J	Sidoux-Walter, F; Lucien, N; Olives, B; Gobin, R; Rousselet, G; Kamsteeg, EJ; Ripoche, P; Deen, PMT; Cartron, JP; Bailly, P				Sidoux-Walter, F; Lucien, N; Olives, B; Gobin, R; Rousselet, G; Kamsteeg, EJ; Ripoche, P; Deen, PMT; Cartron, JP; Bailly, P			At physiological expression levels the Kidd blood group/urea transporter protein is not a water channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UREA TRANSPORTER; MESSENGER-RNA; FUNCTIONAL EXPRESSION; RAT-KIDNEY; RED-CELLS; CLONING; GENE; UT3; MICROSCOPY; MUTATIONS	The Kidd (JK) blood group locus encodes a urea transporter that is expressed on human red cells and on endothelial cells of the vasa recta in the kidney, Here, we report the identification in human erythroblasts of a novel cDNA, designated HUT11A, which encodes a protein identical to the previously reported erythroid HUT11 urea transporter, except for a Lys(44) --> Glu substitution and a Val-Gly dipeptide deletion after proline 227, which leads to a polypeptide of 389 residues versus 391 in HUT11. Genomic typing by polymerase chain reaction and transcript analysis by ribonuclease protection assay demonstrated that HUT11A encodes the true Kidd blood group/urea transporter protein, which carries only 2 Val-Gly motifs. Upon expression at high levels in Xenopus oocytes, the physiological Kidd/urea transporter HUT11A conferred a rapid transfer of urea (which was insensitive to p-chloromercuribenzene sulfonate or phloretin), a high water permeability, and a selective uptake of small solutes including amides and diols, but not glycerol and meso-erythritol. However, at plasma membrane expression levels close to the level observed in the red cell membrane, HUT11A-mediated water transport and small solutes uptake were absent and the urea transport was poorly inhibited by p-chloromercuribenzene sulfonate, but strongly inhibited by phloretin. These findings show that, at physiological expression levels, the HUT11A transporter confers urea permeability but not water permeability, and that the observed water permeability is a feature of the red cell urea transporter when expressed at unphysiological high levels.	Inst Natl Transfus Sanguine, INSERM, U76, F-75015 Paris, France; CEA Saclay, Dept Biol Cellulaire & Mol, F-91191 Gif Sur Yvette, France; Univ Nijmegen, Dept Cell Physiol, NL-6500 HB Nijmegen, Netherlands	Institut National de la Sante et de la Recherche Medicale (Inserm); CEA; UDICE-French Research Universities; Universite Paris Saclay; Radboud University Nijmegen	Cartron, JP (corresponding author), Inst Natl Transfus Sanguine, INSERM, U76, 6 Rue Alexandre Cabanel, F-75015 Paris, France.		Deen, Peter MT/B-9854-2013; Kamsteeg, Erik-Jan/L-4421-2015; Rousselet, Germain/E-3525-2018; Deen, P.M.T./H-8023-2014	Deen, Peter MT/0000-0002-7868-4655; Rousselet, Germain/0000-0002-1710-1639; Deen, P.M.T./0000-0002-7868-4655				ABRAMI L, 1995, PFLUG ARCH EUR J PHY, V430, P447, DOI 10.1007/BF00373921; BANKIR L, 1995, KIDNEY, P571; Berger UV, 1998, ANAT EMBRYOL, V197, P405, DOI 10.1007/s004290050152; BRAHM J, 1983, J GEN PHYSIOL, V82, P1, DOI 10.1085/jgp.82.1.1; Couriaud C, 1996, BBA-GENE STRUCT EXPR, V1309, P197, DOI 10.1016/S0167-4781(96)00172-8; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; DIX JA, 1985, BIOCHIM BIOPHYS ACTA, V821, P243, DOI 10.1016/0005-2736(85)90093-8; Eskandari S, 1998, P NATL ACAD SCI USA, V95, P11235, DOI 10.1073/pnas.95.19.11235; GILLIN AG, 1993, SEMIN NEPHROL, V13, P146; Hediger MA, 1996, KIDNEY INT, V49, P1615, DOI 10.1038/ki.1996.235; IZRAELI S, 1991, NUCLEIC ACIDS RES, V19, P6051; Lucien N, 1998, J BIOL CHEM, V273, P12973, DOI 10.1074/jbc.273.21.12973; MACEY RI, 1988, AM J PHYSIOL, V254, pC669, DOI 10.1152/ajpcell.1988.254.5.C669; Maillet P, 1996, HUM MUTAT, V7, P61, DOI 10.1002/(SICI)1098-1004(1996)7:1<61::AID-HUMU9>3.3.CO;2-T; MANNUZZU LM, 1993, J MEMBRANE BIOL, V133, P85; Martial S, 1996, AM J PHYSIOL-RENAL, V271, pF1264, DOI 10.1152/ajprenal.1996.271.6.F1264; MARTIAL S, 1991, BIOCHIM BIOPHYS ACTA, V1090, P86, DOI 10.1016/0167-4781(91)90040-S; MASOUREDIS SP, 1980, BLOOD, V56, P969; Mathai JC, 1996, J BIOL CHEM, V271, P1309, DOI 10.1074/jbc.271.3.1309; MAYRAND RR, 1983, J GEN PHYSIOL, V81, P221, DOI 10.1085/jgp.81.2.221; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; Mulders SM, 1997, J AM SOC NEPHROL, V8, P242; Olives B, 1997, HUM MOL GENET, V6, P1017, DOI 10.1093/hmg/6.7.1017; OLIVES B, 1994, J BIOL CHEM, V269, P31649; Olives B, 1996, FEBS LETT, V386, P156, DOI 10.1016/0014-5793(96)00425-5; OLIVES B, 1995, J BIOL CHEM, V270, P15607, DOI 10.1074/jbc.270.26.15607; PALLONE TL, 1994, AM J PHYSIOL, V267, pR260, DOI 10.1152/ajpregu.1994.267.1.R260; Promeneur D, 1996, J AM SOC NEPHROL, V7, P852; Roudier N, 1998, J BIOL CHEM, V273, P8407, DOI 10.1074/jbc.273.14.8407; SANDS JM, 1992, J AM SOC NEPHROL, V2, P1689; Sands JM, 1997, AM J PHYSIOL-RENAL, V273, pF321, DOI 10.1152/ajprenal.1997.273.3.F321; Smith CP, 1999, AM J PHYSIOL-REG I, V276, pR622, DOI 10.1152/ajpregu.1999.276.2.R622; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsukaguchi H, 1997, J CLIN INVEST, V99, P1506, DOI 10.1172/JCI119313; VERBAVATZ JM, 1996, AM SOC NEPHROL, V7, P1274; Xu YC, 1997, KIDNEY INT, V51, P138, DOI 10.1038/ki.1997.17; Yang BX, 1998, J BIOL CHEM, V273, P9369, DOI 10.1074/jbc.273.16.9369; ZAMPIGHI GA, 1995, J MEMBRANE BIOL, V148, P65	38	47	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30228	30235		10.1074/jbc.274.42.30228	http://dx.doi.org/10.1074/jbc.274.42.30228			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514515	Green Published, hybrid			2022-12-27	WOS:000083176400094
J	Yamashita, H; Avraham, S; Jiang, SX; London, R; Van Veldhoven, PP; Subramani, S; Rogers, RA; Avraham, H				Yamashita, H; Avraham, S; Jiang, SX; London, R; Van Veldhoven, PP; Subramani, S; Rogers, RA; Avraham, H			Characterization of human and murine PMP20 peroxisomal proteins that exhibit antioxidant activity in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOL PEROXIDASE-ACTIVITY; CANDIDA-BOIDINII; TARGETING SIGNAL-1; PTS1 RECEPTOR; MEMBRANE; IMPORT; BIOGENESIS; PROLIFERATION; DISORDERS; PATHWAYS	We have isolated the cDNAs encoding human and mouse homologues of a yeast protein, termed peroxisomal membrane protein 20 (PMP20). Comparison of the amino acid sequences of human (HsPMP20) and mouse (MmPMP20) PMP20 proteins revealed a high degree of identity (93%), whereas resemblance to the yeast Candida boidinii PMP20A and PMP20B (CbPMP20A and CbPMP20B) was less (30% identity). Both HsPMP20 and MmPMP20 lack transmembrane regions, as do CbPMP20A and CbPMP20B. HsPMP20 mRNA expression was low in human fetal tissues, especially in the brain, in adult tissues, HsPMP20 mRNA was expressed in the majority of tissues tested. HsPMP20 and MmPMP20 contained the C-terminal tripeptide sequence Ser-Gln-Leu (SQL), which is similar to the peroxisomal targeting signal 1 utilized for protein im. port into peroxisomes. HsPMP20 bound directly to the human peroxisomal targeting signal 1 receptor, HsPEX5. Mutagenesis analysis showed that the C-terminal tripeptide sequence, SQL, of HsPMP20 is necessary for its binding to HsPEX5. Subcellular fractionation of HeLa cells, expressing epitope-tagged PMP20, revealed that HsPMP20 is localized in the cytoplasm and in a particulate fraction containing peroxisomes. Double-staining immunofluorescence studies showed colocalization of HsPMP20 and thiolase, a bona fide peroxisomal protein. The amino acid sequence alignment of HsPMP20, MmPMP20, CbPMP20A, and CbPMP20B displayed high similarity to thiol-specific antioxidant proteins. HsPMP20 exerted an inhibitory effect on the inactivation of glutamine synthetase in the thiol metal-catalyzed oxidation system but not in the nonthiol metal-catalyzed oxidation system, suggesting that HsPMP20 possesses thiol-specific antioxidant activity. in addition, HsPMP20 removed hydrogen peroxide by its thiol-peroxidase activity. These results indicate that HsPMP20 is imported into the peroxisomal matrix via PEX5p and may work to protect peroxisomal proteins against oxidative stress. Because some portion of PMP20 might also be present in the cytosol, HsPMP20 may also have a protective effect in the cytoplasm.	Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med,Sch Med, Boston, MA 02115 USA; Katholieke Univ Leuven, Afdeling Farmakol, B-3000 Louvain, Belgium; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Harvard Univ, Med Sch Publ Hlth, BioMed Imaging Lab, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; KU Leuven; University of California System; University of California San Diego; Harvard University; Harvard T.H. Chan School of Public Health	Avraham, H (corresponding author), Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med,Sch Med, 4 Blackfan Circle, Boston, MA 02115 USA.		, Van Veldhoven Paul/U-6359-2019	, Van Veldhoven Paul/0000-0002-4478-2564; Avraham, Hava/0000-0002-7545-3640	NCI NIH HHS [CA76226] Funding Source: Medline; NHLBI NIH HHS [HL55445, HL51456] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076226] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055445, R01HL051456] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKAO Y, 1994, CANCER RES, V54, P2468; Albertini M, 1997, CELL, V89, P83, DOI 10.1016/S0092-8674(00)80185-3; Antonenkov VD, 1997, J BIOL CHEM, V272, P26023, DOI 10.1074/jbc.272.41.26023; Cha MK, 1996, BIOCHEM BIOPH RES CO, V222, P619, DOI 10.1006/bbrc.1996.0793; Distel B, 1996, J CELL BIOL, V135, P1, DOI 10.1083/jcb.135.1.1; Dodt G, 1996, J CELL BIOL, V135, P1763, DOI 10.1083/jcb.135.6.1763; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; Dyer JM, 1996, J CELL BIOL, V133, P269, DOI 10.1083/jcb.133.2.269; Elgersma Y, 1996, J BIOL CHEM, V271, P26375, DOI 10.1074/jbc.271.42.26375; FRANSEN M, 1995, J BIOL CHEM, V270, P7731, DOI 10.1074/jbc.270.13.7731; GARRARD LJ, 1989, J BIOL CHEM, V264, P13929; GOODMAN JM, 1990, J CELL SCI, V97, P193; GOULD SJ, 1990, EMBO J, V9, P85, DOI 10.1002/j.1460-2075.1990.tb08083.x; KIM KW, 1988, J BIOL CHEM, V263, P4704; Kim TA, 1998, J CELL BIOL, V141, P553, DOI 10.1083/jcb.141.3.553; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; MANNAERTS GP, 1999, IN PRESS CELL BIOCH; Marshall PA, 1996, J CELL BIOL, V135, P123, DOI 10.1083/jcb.135.1.123; MARSHALL PA, 1995, J CELL BIOL, V129, P345, DOI 10.1083/jcb.129.2.345; MCCAMMON MT, 1994, J CELL BIOL, V124, P915, DOI 10.1083/jcb.124.6.915; MCNEW JA, 1994, J CELL BIOL, V127, P1245, DOI 10.1083/jcb.127.5.1245; McNew JA, 1996, TRENDS BIOCHEM SCI, V21, P54, DOI 10.1016/S0968-0004(96)80181-2; Netto LES, 1996, J BIOL CHEM, V271, P15315, DOI 10.1074/jbc.271.26.15315; Sheikh FG, 1998, P NATL ACAD SCI USA, V95, P2961, DOI 10.1073/pnas.95.6.2961; Subramani S, 1996, CURR OPIN CELL BIOL, V8, P513, DOI 10.1016/S0955-0674(96)80029-9; Subramani S, 1998, PHYSIOL REV, V78, P171, DOI 10.1152/physrev.1998.78.1.171; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; TOLBERT NE, 1981, ANNU REV BIOCHEM, V50, P133, DOI 10.1146/annurev.bi.50.070181.001025; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; VEENHUIS M, 1990, J CELL SCI, V96, P583; WIEMER EAC, 1995, J CELL BIOL, V130, P51, DOI 10.1083/jcb.130.1.51	32	96	100	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29897	29904		10.1074/jbc.274.42.29897	http://dx.doi.org/10.1074/jbc.274.42.29897			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514471	hybrid			2022-12-27	WOS:000083176400050
J	Jung, YS; Gao-Sheridan, HS; Christiansen, J; Dean, DR; Burgess, BK				Jung, YS; Gao-Sheridan, HS; Christiansen, J; Dean, DR; Burgess, BK			Purification and biophysical characterization of a new [2Fe-2S] ferredoxin from Azotobacter vinelandii, a putative [Fe-S] cluster assembly/repair protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; IRON-SULFUR CLUSTERS; MAGNETIC CIRCULAR-DICHROISM; ELEMENT BINDING-PROTEIN; ESCHERICHIA-COLI; CLOSTRIDIUM-PASTEURIANUM; NITROGEN-FIXATION; 4FE-4S CLUSTER; 2<4FE-4S> FERREDOXIN; NUCLEOTIDE-SEQUENCE	During the purification of site-directed mutant variants of Azotobacter vinelandii ferredoxin I (FdI), a pink protein, which was not observed in native FdI preparations, appeared to associate specifically with variants that had mutations in ligands to FdI [Fe-S] clusters. That protein, which me designate FdIV has now been purified. NH2-terminal sequence analysis revealed that the protein is the product of a previously described gene, herein designated fdxD, that is in the A. vinelandii iscSUA operon that encodes proteins involved in iron-sulfur cluster assembly or repair. An apoprotein molecular mass of 12,434.03 +/- 0.21 Da was determined by mass spectrometry consistent with the known gene sequence, The monomeric protein was shown to contain a single [2Fe-2S](2+/+) cluster by UV/visible, CD, and EPR spectroscopies with a reduction potential of -344 mV versus the standard hydrogen electrode. When overexpressed in Escherichia coli, recombinant FdIV holoprotein was successfully assembled. However, the polypeptide of the recombinant protein was modified in some way such that the apoprotein molecular mass increased by 52 Da. Antibodies raised against FdIV and EPR spectroscopy were used to examine the relative levels of FdIV and FdI in various A. vinelandii strains leading to the conclusion that FdIV levels appear to be specifically increased under conditions where another protein, NADPH:ferredoxin reductase is also up-regulated. In that case, the fpr gene is known to be activated in response to oxidative stress. This suggests that the fdxD gene and other genes in the iron-sulfur cluster assembly or repair operon might be similarly up-regulated in response to oxidative stress.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Virginia Polytech Inst & State Univ, Dept Biochem, Blacksburg, VA 24061 USA	University of California System; University of California Irvine; Virginia Polytechnic Institute & State University	Burgess, BK (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045209] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-45209] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; Atta M, 1998, BIOCHEMISTRY-US, V37, P15974, DOI 10.1021/bi9812928; BAUR J R, 1990, Biofactors, V2, P197; Beinert H, 1996, FEBS LETT, V382, P218, DOI 10.1016/0014-5793(96)00140-8; BEINERT H, 1990, FASEB J, V4, P2483, DOI 10.1096/fasebj.4.8.2185975; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; Beinert H, 1996, CHEM REV, V96, P2335, DOI 10.1021/cr950040z; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BOHME H, 1989, PLANT MOL BIOL, V12, P667, DOI 10.1007/BF00044157; BRODERICK JB, 1997, J AM CHEM SOC, V119, P7936; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; CAMMACK R, 1992, ADV INORG CHEM, V38, P281, DOI 10.1016/S0898-8838(08)60066-5; Chatelet C, 1999, J BIOL INORG CHEM, V4, P311, DOI 10.1007/s007750050317; CHEN JC, 1992, BIOCHIM BIOPHYS ACTA, V1131, P122, DOI 10.1016/0167-4781(92)90111-C; CHENG H, 1994, BIOCHEMISTRY-US, V33, P3155, DOI 10.1021/bi00177a003; Clark MA, 1998, CURR MICROBIOL, V36, P158, DOI 10.1007/PL00006760; COGHLAN VM, 1989, P NATL ACAD SCI USA, V86, P835, DOI 10.1073/pnas.86.3.835; CROUSE BR, 1994, J BIOL CHEM, V269, P21030; CUPP JR, 1988, J BIOL CHEM, V263, P17418; DAVASSE V, 1992, BIOCHEM BIOPH RES CO, V185, P341, DOI 10.1016/S0006-291X(05)80991-X; Farinas E, 1998, PROTEIN SCI, V7, P1939, DOI 10.1002/pro.5560070909; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Flint DH, 1996, CHEM REV, V96, P2315, DOI 10.1021/cr950041r; Frey P A, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P1; Gao-Sheridan HS, 1998, J BIOL CHEM, V273, P5514, DOI 10.1074/jbc.273.10.5514; GAOSHERIDANS HS, 1998, THESIS U CALIFORNIA; Gaudu P, 1996, P NATL ACAD SCI USA, V93, P10094, DOI 10.1073/pnas.93.19.10094; Golinelli MP, 1998, BIOCHEMISTRY-US, V37, P10429, DOI 10.1021/bi9806394; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; HIDALGO E, 1995, J BIOL CHEM, V270, P20908, DOI 10.1074/jbc.270.36.20908; Holm RH, 1996, CHEM REV, V96, P2239, DOI 10.1021/cr9500390; HOWARD JB, 1991, ADV PROTEIN CHEM, V42, P199; Hugo N, 1998, J BIOL CHEM, V273, P9622, DOI 10.1074/jbc.273.16.9622; IISMAA SE, 1991, J BIOL CHEM, V266, P21563; ISAS JM, 1994, J BIOL CHEM, V269, P19404; JACOBSON BL, 1993, BIOCHEMISTRY-US, V32, P6788, DOI 10.1021/bi00077a033; JACOBSON MR, 1989, J BACTERIOL, V171, P1017, DOI 10.1128/jb.171.2.1017-1027.1989; JOERGER RD, 1988, J BACTERIOL, V170, P1475, DOI 10.1128/jb.170.4.1475-1487.1988; JOHNSON MK, 1994, ENCY INORGANIC CHEM, V4, P1896; JOUANNEAU Y, 1992, BIOCHEM J, V286, P267; Jung YS, 1999, J BIOL CHEM, V274, P2978, DOI 10.1074/jbc.274.5.2978; Kemper MA, 1998, BIOCHEMISTRY-US, V37, P12829, DOI 10.1021/bi9810499; KHOROSHILOVA N, 1995, P NATL ACAD SCI USA, V92, P2499, DOI 10.1073/pnas.92.7.2499; KNOELL HE, 1974, EUR J BIOCHEM, V50, P245, DOI 10.1111/j.1432-1033.1974.tb03893.x; Lazazzera BA, 1996, J BIOL CHEM, V271, P2762, DOI 10.1074/jbc.271.5.2762; LE O, 1993, J BACTERIOL, V175, P7707, DOI 10.1128/JB.175.23.7707-7710.1993; LINDAHL PA, 1990, J CLUST SCI, V1, P29; LOVENBERG W, 1963, IRON SULFUR PROTEINS, V1; MARTIN AE, 1990, P NATL ACAD SCI USA, V87, P598, DOI 10.1073/pnas.87.2.598; MATSUBARA H, 1992, ADV INORG CHEM, V38, P223, DOI 10.1016/S0898-8838(08)60065-3; Meyer J, 1997, BIOCHEMISTRY-US, V36, P13374, DOI 10.1021/bi971775w; MITTAL S, 1988, ARCH BIOCHEM BIOPHYS, V264, P383, DOI 10.1016/0003-9861(88)90303-7; MORGAN TV, 1988, J BIOL CHEM, V263, P1370; MORTENSON LE, 1962, BIOCHEM BIOPH RES CO, V7, P448, DOI 10.1016/0006-291X(62)90333-9; MOSHIRI F, 1994, MOL MICROBIOL, V14, P101, DOI 10.1111/j.1365-2958.1994.tb01270.x; Nicolet Y, 1999, STRUCTURE, V7, P13, DOI 10.1016/S0969-2126(99)80005-7; PEISACH J, 1971, J BIOL CHEM, V246, P5877; Peters JW, 1998, SCIENCE, V282, P1853, DOI 10.1126/science.282.5395.1853; PETERSON JA, 1990, J BIOL CHEM, V265, P6066; PETILLOT Y, 1995, ANAL BIOCHEM, V228, P56, DOI 10.1006/abio.1995.1314; RAINA R, 1993, MOL GEN GENET, V236, P459, DOI 10.1007/BF00277149; RAINA R, 1988, MOL GEN GENET, V214, P121, DOI 10.1007/BF00340189; REICHARD P, 1993, J BIOL CHEM, V268, P8383; Reyntjens B, 1997, J BIOL INORG CHEM, V2, P595, DOI 10.1007/s007750050174; RODRIGUEZQUINONES F, 1993, J BACTERIOL, V175, P2926; ROUAULT TA, 1992, BIOMETALS, V5, P131, DOI 10.1007/BF01061319; SCHERINGS G, 1977, EUR J BIOCHEM, V77, P621, DOI 10.1111/j.1432-1033.1977.tb11706.x; SHEN B, 1995, P NATL ACAD SCI USA, V92, P10064, DOI 10.1073/pnas.92.22.10064; SHEN BH, 1993, J BIOL CHEM, V268, P25928; SHETHNA YI, 1968, BIOCHEM BIOPH RES CO, V31, P862, DOI 10.1016/0006-291X(68)90531-7; Siuzdak G., 1996, MASS SPECTROMETRY BI, P56; Staples CR, 1996, BIOCHEMISTRY-US, V35, P11425, DOI 10.1021/bi961007p; STEPHENS PJ, 1991, BIOCHEMISTRY-US, V30, P3200, DOI 10.1021/bi00227a007; STEPHENS PJ, 1978, BIOCHEMISTRY-US, V17, P4770, DOI 10.1021/bi00615a026; Sundin GW, 1996, MOL MICROBIOL, V20, P965, DOI 10.1111/j.1365-2958.1996.tb02538.x; TA DT, 1992, J BIOL CHEM, V267, P11120; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TSUKIHARA T, 1990, J MOL BIOL, V216, P399, DOI 10.1016/S0022-2836(05)80330-4; UHLMANN H, 1992, BIOCHEM BIOPH RES CO, V188, P1131, DOI 10.1016/0006-291X(92)91349-U; VAZQUEZ A, 1994, PROTEIN EXPRES PURIF, V5, P96, DOI 10.1006/prep.1994.1014; Vidakovic MS, 1996, J BIOL CHEM, V271, P14734, DOI 10.1074/jbc.271.25.14734; WIENTJENS R, 1993, THESIS AGR U WAGENIN; Yannone SM, 1998, J BIOL INORG CHEM, V3, P253, DOI 10.1007/s007750050229; YOCH DC, 1972, J BIOL CHEM, V247, P4514; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	86	57	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32402	32410		10.1074/jbc.274.45.32402	http://dx.doi.org/10.1074/jbc.274.45.32402			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542283	hybrid			2022-12-27	WOS:000083532100091
J	Manya, H; Aoki, J; Kato, H; Ishii, J; Hino, S; Arai, H; Inoue, K				Manya, H; Aoki, J; Kato, H; Ishii, J; Hino, S; Arai, H; Inoue, K			Biochemical characterization of various catalytic complexes of the brain platelet-activating factor acetylhydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; SUBUNIT; PURIFICATION; EXPRESSION	Brain intracellular platelet-activating factor acetylhydrolase (PAF-AH) isoform I is a member of a family of complex enzymes composed of mutually homologous alpha(1) and alpha(2) subunits, both of which account for catalytic activity, and the beta subunit. We previously demonstrated that the expression of one catalytic subunit, alpha(1), is developmentally regulated, resulting in a switching of the catalytic complex from alpha(1)/alpha(2) to alpha(2)/alpha(2) during brain development (Manya, H., Aoki, J., Watanabe, M., Adachi, T., Asou, H., Inoue, Y., Arai, H., and Inoue, K. (1998) J. Biol. Chem. 273, 18567-18572). In this study, we explored the biochemical differences in three possible catalytic dimers, alpha(1)/alpha(1), alpha(1)/alpha(2), and alpha(2)/alpha(2). The alpha(2)/alpha(2) homodimer exhibited different substrate specificity from the alpha(1)/alpha(1) homodimer and the alpha(1)/alpha(2) heterodimer, both of which showed similar substrate specificity. The alpha(2)/alpha(2) homodimer hydrolyzed PAF and 1-O-alkyl-2-acetyl-sn-glycero-3-phosphorylethanolamine (AAGPE) most efficiently among 1-O-alkyl-2-acetyl-phospholipids. In contrast, both alpha(1)/alpha(1) and alpha(1)/alpha(2) hydrolyzed 1-O-alkyl-2-acetyl-sn-glycero-3-phosphoric acid more efficiently than PAF. AAGPE was the poorest substrate for these enzymes. The beta subunit bound to all three catalytic dimers but modulated the enzyme activity in a catalytic dimer composition-dependent manner. The beta subunit strongly accelerated the enzyme activity of the alpha(2)/alpha(2) homodimer but rather suppressed the activity of the alpha(1)/alpha(1) homodimer and had little effect on that of the alpha(1)/alpha(2) heterodimer. The (His(149) to Arg) mutant beta, which has been recently identified in isolated lissencephaly sequence patients, lost the ability to either associate with the catalytic complexes or modulate their enzyme activity. The enzyme activity of PAF-AH isoform I may be regulated in multiple ways by switching the composition of the catalytic subunit and by manipulating the beta subunit.	Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Hlth Chem, Bunkyo Ku, Tokyo 113, Japan	University of Tokyo	Arai, H (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Hlth Chem, Bunkyo Ku, 7-3-1 Hongo, Tokyo 113, Japan.			Aoki, Junken/0000-0001-9435-1896; Manya, Hiroshi/0000-0003-1573-9177				Albrecht U, 1996, DEV BIOL, V180, P579, DOI 10.1006/dbio.1996.0330; Baker RR, 1995, NEUROCHEM RES, V20, P1345, DOI 10.1007/BF00992510; HATTORI K, 1995, J BIOL CHEM, V270, P22308, DOI 10.1074/jbc.270.38.22308; Hattori M, 1995, J BIOL CHEM, V270, P31345, DOI 10.1074/jbc.270.52.31345; HATTORI M, 1993, J BIOL CHEM, V268, P18748; HATTORI M, 1994, J BIOL CHEM, V269, P23150; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; Ho YS, 1997, NATURE, V385, P89, DOI 10.1038/385089a0; LEE TC, 1992, J BIOL CHEM, V267, P19992; LO NC, 1997, HUM MOL GENET, V6, P157; Manya H, 1998, J BIOL CHEM, V273, P18567, DOI 10.1074/jbc.273.29.18567; Pilz DT, 1998, HUM MOL GENET, V7, P2029, DOI 10.1093/hmg/7.13.2029; SATOUCHI K, 1981, J BIOL CHEM, V256, P4425; Snyder F, 1996, ADV EXP MED BIOL, V416, P5; TOKUMURA A, 1992, LIFE SCI, V51, P303, DOI 10.1016/0024-3205(92)90089-8	15	48	55	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31827	31832		10.1074/jbc.274.45.31827	http://dx.doi.org/10.1074/jbc.274.45.31827			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542206	hybrid			2022-12-27	WOS:000083532100014
J	Fukuda, M; Kanno, E; Mikoshiba, K				Fukuda, M; Kanno, E; Mikoshiba, K			Conserved N-terminal cysteine motif is essential for homo- and heterodimer formation of synaptotagmins III, V, VI, and X	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-POLYPHOSPHATE BINDING; SQUID GIANT SYNAPSE; PHOSPHOLIPID-BINDING; C2B DOMAIN; INOSITOL-1,3,4,5-TETRAKISPHOSPHATE BINDING; TRANSMITTER RELEASE; ANTIBODY INJECTION; VESICLE FUSION; CELLS; PROTEINS	The synaptotagmins now constitute a large family of membrane proteins characterized by one transmembrane region and two C2 domains. Dimerization of synaptotagmin (Syt) I, a putative low affinity Ca2+ sensor for neurotransmitter release, is thought to be important for expression of function during exocytosis of synaptic vesicles. However, little is known about the self-dimerization properties of other isoforms. In this study, we demonstrate that a subclass of synaptotagmins (III, V, VI, and X) (Ibata, K., Fukuda, Ri., and Mikoshiba, K. (1998) J. Biol. Chem. 273, 12267-12273) forms beta-mercaptoethanol-sensitive homodimers and identify three evolutionarily conserved cysteine residues at the N terminus (N-terminal cysteine motif, at amino acids 10, 21, and 33 of mouse Syt III) that are not conserved in other isoforms. Site-directed mutagenesis of these cysteine residues and co-immunoprecipitation experiments clearly indicate that the first cysteine residue is essential for the stable homodimer formation of Syt III, V, or VI, and heterodimer formation between Syts II, V, VI, and X. We also show that native Syt III from mouse brain forms a beta-mercaptoethanol-sensitive homodimer. Our results suggest that the cysteine-based heterodimerization between Syt III and Syt V, VI, or X, which have different biochemical properties, may modulate the proposed function of Syt III as a putative high affinity Ca2+ sensor for neurotransmitter release.	RIKEN, Inst Phys & Chem Res, Brain Sci Inst, Dev Neurobiol Lab, Wako, Saitama 3510198, Japan; Univ Tokyo, Inst Med Sci, Dept Mol Neurobiol, Minato Ku, Tokyo 1088639, Japan; Japan Sci & Technol Corp, Calciosignal Net Project, Bunkyo Ku, Tokyo 1130021, Japan	RIKEN; University of Tokyo; Japan Science & Technology Agency (JST)	Fukuda, M (corresponding author), RIKEN, Inst Phys & Chem Res, Brain Sci Inst, Dev Neurobiol Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	mnfukuda@brain.riken.go.jp	Mikoshiba, Katsuhiko/N-7943-2015; Fukuda, MItsunori/I-1511-2015	Fukuda, MItsunori/0000-0002-8620-5853				Babity JM, 1997, P NATL ACAD SCI USA, V94, P2638, DOI 10.1073/pnas.94.6.2638; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; Chapman ER, 1996, J BIOL CHEM, V271, P5844, DOI 10.1074/jbc.271.10.5844; Chapman ER, 1998, J BIOL CHEM, V273, P32966, DOI 10.1074/jbc.273.49.32966; Chapman ER, 1996, BIOCHEM BIOPH RES CO, V225, P326, DOI 10.1006/bbrc.1996.1174; CRAXTON M, 1995, FEBS LETT, V361, P196, DOI 10.1016/0014-5793(95)00176-A; Damer CK, 1996, J NEUROCHEM, V67, P1661; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; Fukuda M, 1997, BIOESSAYS, V19, P593, DOI 10.1002/bies.950190710; Fukuda M, 1999, J BIOL CHEM, V274, P31428, DOI 10.1074/jbc.274.44.31428; Fukuda M, 1996, J BIOL CHEM, V271, P8430, DOI 10.1074/jbc.271.14.8430; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; Fukuda M, 1997, BIOCHEM J, V323, P421, DOI 10.1042/bj3230421; FUKUDA M, 1995, P NATL ACAD SCI USA, V92, P10708, DOI 10.1073/pnas.92.23.10708; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; HILBUSH BS, 1994, P NATL ACAD SCI USA, V91, P8195, DOI 10.1073/pnas.91.17.8195; HUDSON AW, 1995, P NATL ACAD SCI USA, V92, P5895, DOI 10.1073/pnas.92.13.5895; Ibata K, 1998, J BIOL CHEM, V273, P12267, DOI 10.1074/jbc.273.20.12267; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Lang JC, 1997, EMBO J, V16, P5837, DOI 10.1093/emboj/16.19.5837; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LI C, 1995, J BIOL CHEM, V270, P24898, DOI 10.1074/jbc.270.42.24898; Linial M, 1997, J NEUROCHEM, V69, P1781; LITTLETON JT, 1995, TRENDS NEUROSCI, V18, P177; MIKOSHIBA K, 1995, P NATL ACAD SCI USA, V92, P10703, DOI 10.1073/pnas.92.23.10703; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MIZUTA M, 1994, J BIOL CHEM, V269, P11675; Mochida S, 1997, NEUROSCIENCE, V77, P937; NIINOBE M, 1994, BIOCHEM BIOPH RES CO, V205, P1036, DOI 10.1006/bbrc.1994.2770; OharaImaizumi M, 1997, P NATL ACAD SCI USA, V94, P287, DOI 10.1073/pnas.94.1.287; Osborne SL, 1999, J BIOL CHEM, V274, P59, DOI 10.1074/jbc.274.1.59; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; Schiavo G, 1998, BIOCHEM BIOPH RES CO, V248, P1, DOI 10.1006/bbrc.1998.8527; SOLLNER T, 1994, TRENDS NEUROSCI, V17, P344, DOI 10.1016/0166-2236(94)90178-3; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; Sugimori M, 1998, NEUROSCIENCE, V86, P39, DOI 10.1016/S0306-4522(97)00689-1; Sugita S, 1996, J BIOL CHEM, V271, P1262, DOI 10.1074/jbc.271.3.1262; Thompson CC, 1996, J NEUROSCI, V16, P7832; Veit M, 1996, FEBS LETT, V385, P119, DOI 10.1016/0014-5793(96)00362-6; vonPoser C, 1997, J BIOL CHEM, V272, P14314, DOI 10.1074/jbc.272.22.14314; WENDLAND B, 1991, NEURON, V6, P993, DOI 10.1016/0896-6273(91)90239-V	44	148	157	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31421	31427		10.1074/jbc.274.44.31421	http://dx.doi.org/10.1074/jbc.274.44.31421			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531343	hybrid			2022-12-27	WOS:000083379400047
J	Graber, R; Kasper, P; Malashkevich, VN; Strop, P; Gehring, H; Jansonius, JN; Christen, P				Graber, R; Kasper, P; Malashkevich, VN; Strop, P; Gehring, H; Jansonius, JN; Christen, P			Conversion of aspartate aminotransferase into an L-aspartate beta-decarboxylase by a triple active-site mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE SULFINIC ACID; ESCHERICHIA-COLI; SUBSTRATE-SPECIFICITY; DIRECTED MUTAGENESIS; ENZYME; TYROSINE-225; HISTIDINE; MECHANISM; REDESIGN; MUTANT	The conjoint substitution of three active-site residues in aspartate aminotransferase (AspAT) of Escherichia coli (Y225R/R292K/R386A) increases the ratio of L-aspartate P-decarboxylase activity to transaminase activity >25 million-fold. This result was achieved by combining an arginine shift mutation (Y225R/R386A) with a conservative substitution of a substrate-binding residue (R292K), In the wild-type enzyme, Arg(386) interacts with the cw-carboxylate group of the substrate and is one of the four residues that are invariant in all aminotransferases; Tyr(225) is in its vicinity, forming a hydrogen bond with O-3' of the cofactor; and Arg(292) interacts with the distal carboxylate group of the substrate. In the triple-mutant enzyme, k(cat)' for beta-decarboxylation of L-aspartate was 0.08 s(-1), whereas k(cat)' for transamination was decreased to 0.01 s(-1). AspAT was thus converted into an L-aspartate beta-decarboxylase that catalyzes transamination as a side reaction. The major pathway of beta-decarboxylation directly produces L-alanine without intermediary formation of pyruvate, The various single- or double-mutant AspATs corresponding to the triple-mutant enzyme showed, with the exception of AspAT Y225R/R386A, no measurable or only very law beta-decarboxylase activity. The arginine shift mutation Y225R/R386A elicits beta-decarboxylase activity, whereas the R292K substitution suppresses transaminase activity, The reaction specificity of the triple-mutant enzyme is thus achieved in the same way as that of wild-tape pyridoxal 5'-phosphate-dependent enzymes in general and possibly of many other enzymes, i.e. by accelerating the specific reaction and suppressing potential side reactions.	Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland; Univ Basel, Bioctr, Abt Strukturbiol, CH-4056 Basel, Switzerland	University of Zurich; University of Basel	Christen, P (corresponding author), Univ Zurich, Inst Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	christen@biocfebs.unizh.ch						ALEXANDER FW, 1994, EUR J BIOCHEM, V219, P953, DOI 10.1111/j.1432-1033.1994.tb18577.x; ALMO SC, 1994, PROTEIN ENG, V7, P405, DOI 10.1093/protein/7.3.405; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRADLEY M, 1991, BIOCHEMISTRY-US, V30, P6124, DOI 10.1021/bi00239a006; CRONIN CN, 1988, BIOCHEMISTRY-US, V27, P4572, DOI 10.1021/bi00412a052; Dufour E, 1995, BIOCHEMISTRY-US, V34, P16382, DOI 10.1021/bi00050a019; DUNATHAN HC, 1966, P NATL ACAD SCI USA, V55, P712, DOI 10.1073/pnas.55.4.712; FURUMO NC, 1995, ARCH BIOCHEM BIOPHYS, V319, P49, DOI 10.1006/abbi.1995.1265; GALLAGHER T, 1989, J BIOL CHEM, V264, P12737; Goldberg JM, 1996, BIOCHEMISTRY-US, V35, P5280, DOI 10.1021/bi952138d; GOLDBERG JM, 1991, BIOCHEMISTRY-US, V30, P305, DOI 10.1021/bi00215a041; GRABER R, 1995, EUR J BIOCHEM, V232, P686, DOI 10.1111/j.1432-1033.1995.tb20861.x; GREENGARD L, 1987, J COMPUT PHYS, V73, P325, DOI 10.1016/0021-9991(87)90140-9; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; HURLEY JH, 1992, J AM CHEM SOC, V114, P4769, DOI 10.1021/ja00038a047; HWANG JK, 1988, NATURE, V334, P270, DOI 10.1038/334270a0; INOUE K, 1991, J BIOCHEM, V109, P570, DOI 10.1093/oxfordjournals.jbchem.a123421; JAGER J, 1994, J MOL BIOL, V239, P285, DOI 10.1006/jmbi.1994.1368; KAMITORI S, 1987, J BIOCHEM, V101, P813, DOI 10.1093/jb/101.3.813; KIRSCH JF, 1984, J MOL BIOL, V174, P497, DOI 10.1016/0022-2836(84)90333-4; KOCHHAR S, 1988, EUR J BIOCHEM, V175, P433, DOI 10.1111/j.1432-1033.1988.tb14213.x; KURAMITSU S, 1990, BIOCHEMISTRY-US, V29, P5469, DOI 10.1021/bi00475a010; Leslie AGW, 1994, MOSFLM USERS GUIDE; LEUSSING DL, 1980, J AM CHEM SOC, V102, P5635, DOI 10.1021/ja00537a039; MALCOLM BA, 1985, BIOCHEM BIOPH RES CO, V132, P915, DOI 10.1016/0006-291X(85)91894-7; METZLER DE, 1977, BIOCH CHEM REACTIONS, P444; Mouratou B, 1999, J BIOL CHEM, V274, P1320, DOI 10.1074/jbc.274.3.1320; ONUFFER JJ, 1995, PROTEIN SCI, V4, P1750, DOI 10.1002/pro.5560040910; Oue S, 1999, J BIOL CHEM, V274, P2344, DOI 10.1074/jbc.274.4.2344; PARSONS B, 1984, BRAIN RES, V294, P193, DOI 10.1016/0006-8993(84)91331-3; PICOT D, 1991, EUR J BIOCHEM, V196, P329, DOI 10.1111/j.1432-1033.1991.tb15821.x; SCUTTON NS, 1990, NATURE, V343, P38; Shao ZX, 1996, CURR OPIN STRUC BIOL, V6, P513, DOI 10.1016/S0959-440X(96)80117-5; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VACCA RA, 1995, EUR J BIOCHEM, V227, P481, DOI 10.1111/j.1432-1033.1995.tb20413.x; Vacca RA, 1997, J BIOL CHEM, V272, P21932, DOI 10.1074/jbc.272.35.21932; WEINSTEIN CL, 1988, J BIOL CHEM, V263, P16568; WILKS HM, 1988, SCIENCE, V242, P1541, DOI 10.1126/science.3201242; YANO T, 1993, BIOCHEMISTRY-US, V32, P1810, DOI 10.1021/bi00058a015; Yano T, 1998, P NATL ACAD SCI USA, V95, P5511, DOI 10.1073/pnas.95.10.5511; YANO T, 1991, J BIOL CHEM, V266, P6079	41	36	39	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31203	31208		10.1074/jbc.274.44.31203	http://dx.doi.org/10.1074/jbc.274.44.31203			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531314	Green Accepted, hybrid			2022-12-27	WOS:000083379400018
J	Wang, J; Frost, JA; Cobb, MH; Ross, EM				Wang, J; Frost, JA; Cobb, MH; Ross, EM			Reciprocal signaling between heterotrimeric G proteins and the pal-stimulated Protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; BETA-GAMMA-SUBUNITS; ALPHA-SUBUNIT; CRYSTAL-STRUCTURE; C PHOSPHORYLATES; BINDING PROTEIN; PERTUSSIS TOXIN; HUMAN-PLATELETS; REGULATOR; COMPLEX	p21-activated protein kinase (PAK)-1 phosphorylated G alpha(z), a member of the G alpha(i) family that is found in time brain, platelets, and adrenal medulla. Phosphorylation approached 1 mol of phosphate/mol of G alpha(z) in vitro. In transfected cells, G alpha(z) was phosphorylated both by wildtype PAK1 when stimulated by the GTP-binding protein Rad and by constitutively active PAK1 mutants. In vitro, phosphorylation occurred only at Ser(16), one of two Ser residues that are the major substrate sites for protein kinase C (PKC). PAK1 did not phosphorylate other G alpha subunits (il, i2, i3, o, s, or q), PAK1-phosphorylated G alpha(z) was resistant both to RGSZ1, a G(z)-selective GTPase-activating protein (GAP), and to RGS4, a relatively nonselective GAP for the G(i) and G(q) families of G proteins. Phosphorylation of Ser(27) by PKC did not alter sensitivity to either GAP. The previously described inhibition of G, GAPs by PKC is therefore mediated lay phosphorylation of Ser(16). Phosphorylation of either Ser(16) by PAK1 or Ser(27) by PKC decreased the affinity of G alpha(z) for G beta gamma; phosphorylation of both residues by PKC caused no further effect. PAK1 thus regulates G alpha(z) function by attenuating the inhibitory effects of both GAPs and G beta gamma. In this context, the kinase activity of PAK1 toward several protein substrates was directly inhibited by G beta gamma, suggesting that PAK1 acts as a G beta gamma-regulated effector protein. This inhibition of mammalian PAK1 by G beta gamma contrasts with the stimulation of the PAK homolog Ste20p in Saccharomyces cerevisiae by the G beta gamma homolog Ste4p/Ste18p.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Ross, EM (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	ross@utsw.swmed.edu		Cobb, Melanie/0000-0003-0833-5473; Frost, Jeffrey/0000-0001-9722-1536	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030355, R37GM030355] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM16926, GM53032, GM30355] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aragay AM, 1999, J BIOL CHEM, V274, P4807, DOI 10.1074/jbc.274.8.4807; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; FIELDS TA, 1995, J BIOL CHEM, V270, P23119, DOI 10.1074/jbc.270.39.23119; Filtz TM, 1999, BIOCHEM J, V338, P257, DOI 10.1042/0264-6021:3380257; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; Frost JA, 1998, J BIOL CHEM, V273, P28191, DOI 10.1074/jbc.273.43.28191; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; GARIBAY JLR, 1991, BIOCHIM BIOPHYS ACTA, V1094, P193, DOI 10.1016/0167-4889(91)90008-L; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; Glick JL, 1998, J BIOL CHEM, V273, P26008, DOI 10.1074/jbc.273.40.26008; HINTON DR, 1990, J NEUROSCI, V10, P2763; Hutchison M, 1998, J BIOL CHEM, V273, P28625, DOI 10.1074/jbc.273.44.28625; Ishikawa Y, 1998, Adv Second Messenger Phosphoprotein Res, V32, P99; Izadi KD, 1998, EXP CELL RES, V245, P330, DOI 10.1006/excr.1998.4259; KATADA T, 1985, EUR J BIOCHEM, V151, P431, DOI 10.1111/j.1432-1033.1985.tb09120.x; Kozasa T, 1996, J BIOL CHEM, V271, P12562, DOI 10.1074/jbc.271.21.12562; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEBERER E, 1992, EMBO J, V11, P4805, DOI 10.1002/j.1460-2075.1992.tb05586.x; Leberer E, 1997, EMBO J, V16, P83, DOI 10.1093/emboj/16.1.83; Leeuw T, 1998, NATURE, V391, P191, DOI 10.1038/34448; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; LOUNSBURY KM, 1991, J BIOL CHEM, V266, P22051; LOUNSBURY KM, 1993, J BIOL CHEM, V268, P3494; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; MUMBY SM, 1994, METHOD ENZYMOL, V237, P254; Obermeier A, 1998, EMBO J, V17, P4328, DOI 10.1093/emboj/17.15.4328; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wang J, 1997, J BIOL CHEM, V272, P5732, DOI 10.1074/jbc.272.9.5732; Wang J, 1998, J BIOL CHEM, V273, P26014, DOI 10.1074/jbc.273.40.26014; XU HP, 1994, MOL CELL BIOL, V14, P50, DOI 10.1128/MCB.14.1.50; Yue CP, 1998, J BIOL CHEM, V273, P18023, DOI 10.1074/jbc.273.29.18023	45	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31641	31647		10.1074/jbc.274.44.31641	http://dx.doi.org/10.1074/jbc.274.44.31641			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531372	hybrid			2022-12-27	WOS:000083379400076
J	Geisbrecht, BV; Gould, SJ				Geisbrecht, BV; Gould, SJ			The human PICD gene encodes a cytoplasmic and peroxisomal NADP(+)-dependent isocitrate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER PEROXISOMES; SACCHAROMYCES-CEREVISIAE; BETA-OXIDATION; CANDIDA-TROPICALIS; TARGETING SIGNAL; MEMBRANE-PROTEIN; REFSUM-DISEASE; PTS1 RECEPTOR; FATTY-ACIDS; COA	Human PICD was identified by homology probing the data base of expressed sequence tags with the protein sequence of Saccharomyces cerevisiae Idp3p, a peroxisomal NADP(+)-dependent isocitrate dehydrogenase. The human PICD cDNA contains a 1242-base pair open reading frame, and its deduced protein sequence is 59% identical to yeast Idp3p. Expression of PICD partially rescued the fatty acid growth defect of the yeast idp3 deletion mutant suggesting that PICD is functionally homologous to Idp3p. Kinetic studies on bacterially expressed PICD demonstrated that this enzyme catalyzed the oxidative decarboxylation of isocitrate to 2-oxoglutarate with a specific activity of 22.5 units/mg and that PICD displayed K-M values of 76 mu M for isocitrate and 112 mu M for NADP(+). In subcellular fractionation experiments, we found PICD in both peroxisomes and cytoplasm of human and rat liver cells, with approximately 27% of total PICD protein associated with peroxisomes. The presence of PICD in mammalian peroxisomes suggests roles in the regeneration of NADPH for intraperoxisomal reductions, such as the conversion of 2,4-dienoyl-CoAs to 3-enoyl-CoAs, as well as in peroxisomal reactions that consume 2-oxoglutarate, namely the alpha-hydroxylation of phytanic acid. As for cytoplasmic PICD, the phenotypes of patients with glucose-6-phosphate dehydrogenase deficiency (Luzzatto, L., and Mehta, A (1995) in The Metabolic and Molecular Bases of Inherited Disease (Scriver, C. R., Beaudet, A. L., Sly, W. S., and Valle, D., eds) Vol. 3, 7th Ed., pp. 3367-3398, McGraw-Hill Inc., New York) suggest that PICD serves a significant role in cytoplasmic NADPH production, particularly under conditions that do not favor the use of the hexose monophosphate shunt (Luzzatto et al.).	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University	Gould, SJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045787] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45787] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKERBRACHMANN C, 1998, YEAST, V14, P115; BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; CRANE DI, 1994, J BIOL CHEM, V269, P21835; DELAGARZA MM, 1985, EUR J BIOCHEM, V148, P285, DOI 10.1111/j.1432-1033.1985.tb08837.x; Dodt G, 1996, J CELL BIOL, V135, P1763, DOI 10.1083/jcb.135.6.1763; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P5419, DOI 10.1073/pnas.86.14.5419; FLINT APF, 1970, BIOCHEM J, V117, P73, DOI 10.1042/bj1170073; Fransen M, 1999, BIOCHEM J, V340, P561, DOI 10.1042/0264-6021:3400561; Geisbrecht BV, 1998, J BIOL CHEM, V273, P33184, DOI 10.1074/jbc.273.50.33184; Geisbrecht BV, 1999, J BIOL CHEM, V274, P21797, DOI 10.1074/jbc.274.31.21797; Geisbrecht BV, 1999, J BIOL CHEM, V274, P25814, DOI 10.1074/jbc.274.36.25814; Geraghty MT, 1999, P NATL ACAD SCI USA, V96, P2937, DOI 10.1073/pnas.96.6.2937; GOULD SJ, 1990, J CELL BIOL, V110, P27, DOI 10.1083/jcb.110.1.27; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; Henke B, 1998, J BIOL CHEM, V273, P3702, DOI 10.1074/jbc.273.6.3702; Jansen GA, 1997, NAT GENET, V17, P190, DOI 10.1038/ng1097-190; JENNINGS GT, 1994, J BIOL CHEM, V269, P23128; KAMIJO K, 1990, J BIOL CHEM, V265, P4534; KELLER GA, 1986, J CELL BIOL, V103, P875, DOI 10.1083/jcb.103.3.875; KELLER GA, 1985, P NATL ACAD SCI USA, V82, P770, DOI 10.1073/pnas.82.3.770; KLINKEN SP, 1977, EUR J BIOCHEM, V81, P327, DOI 10.1111/j.1432-1033.1977.tb11955.x; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Krisans SK, 1996, ANN NY ACAD SCI, V804, P142, DOI 10.1111/j.1749-6632.1996.tb18614.x; KRISANS SK, 1994, J BIOL CHEM, V269, P14165; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; LOFTUS TM, 1994, BIOCHEMISTRY-US, V33, P9661, DOI 10.1021/bi00198a035; LombardPlatet G, 1996, P NATL ACAD SCI USA, V93, P1265, DOI 10.1073/pnas.93.3.1265; LUZZATTO L, 1995, METABOLIC MOL BASES, V3, P3367; Matsuzono Y, 1999, P NATL ACAD SCI USA, V96, P2116, DOI 10.1073/pnas.96.5.2116; MCCOLLUM D, 1993, J CELL BIOL, V121, P761, DOI 10.1083/jcb.121.4.761; Mihalik SJ, 1997, NAT GENET, V17, P185, DOI 10.1038/ng1097-185; MIHALIK SJ, 1995, EUR J BIOCHEM, V232, P545, DOI 10.1111/j.1432-1033.1995.tb20842.x; MIHALIK SJ, 1992, PROG CLIN BIOL RES, V357, P239; MOSSER J, 1994, HUM MOL GENET, V3, P265, DOI 10.1093/hmg/3.2.265; PENNINGTON R, 1961, BIOCHEM J, V80, P649, DOI 10.1042/bj0800649; PETERS TJ, 1972, J EXP MED, V136, P1117, DOI 10.1084/jem.136.5.1117; PLAUT GWE, 1983, BIOCHIM BIOPHYS ACTA, V760, P300, DOI 10.1016/0304-4165(83)90177-0; PLAUT GWE, 1970, CURR TOP CELL REGUL, V2, P1; RAMACHANDRAN N, 1980, J BIOL CHEM, V255, P8859; RUSNAK N, 1987, BIOCHEM BIOPH RES CO, V148, P890, DOI 10.1016/0006-291X(87)90959-4; Shani N, 1997, HUM MOL GENET, V6, P1925, DOI 10.1093/hmg/6.11.1925; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; van Roermund CWT, 1998, EMBO J, V17, P677, DOI 10.1093/emboj/17.3.677; VANDERLEIJ I, 1993, P NATL ACAD SCI USA, V90, P11782, DOI 10.1073/pnas.90.24.11782; VANROERMUND CWT, 1995, EMBO J, V14, P3480, DOI 10.1002/j.1460-2075.1995.tb07354.x; VANVELDHOVEN PP, 1987, J BIOL CHEM, V262, P4310; Wanders RJA, 1998, MOL ASPECTS MED, V19, P71, DOI 10.1016/S0098-2997(98)00003-X; Wanders RJA, 1996, ANN NY ACAD SCI, V804, P450, DOI 10.1111/j.1749-6632.1996.tb18636.x; Wylin T, 1998, EUR J BIOCHEM, V258, P332, DOI 10.1046/j.1432-1327.1998.2580332.x; YAMAMOTO S, 1995, ARCH MICROBIOL, V163, P104, DOI 10.1007/BF00381783	53	139	166	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30527	30533		10.1074/jbc.274.43.30527	http://dx.doi.org/10.1074/jbc.274.43.30527			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521434	hybrid			2022-12-27	WOS:000083276700030
J	Sinha, R; Perumal, K; Chen, YH; Reddy, R				Sinha, R; Perumal, K; Chen, YH; Reddy, R			Post-transcriptional adenylation of signal recognition particle RNA is carried out by an enzyme different from mRNA poly(A) polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; CCA-ADDING ENZYME; NUCLEOTIDYLTRANSFERASE SUPERFAMILY; SACCHAROMYCES-CEREVISIAE; 3'-END FORMATION; MULTIPLE FORMS; HUMAN-CELLS; POLYADENYLATION; YEAST; GENE	A fraction of the signal recognition particle (SRP) RNA from human, rat, Xenopus, and Saccharomyces cerevisiae cells contains a single post-transcriptionally added adenylic acid residue on its 3'-end; in the ease of human SRP RNA, over 60% of the SRP RNA molecules contain a nontemplated adenylic acid residue on their 3'-ends (Sinha, K. M., Gu, J., Chen, Y., and Reddy, R. (1998) J. Biol. Chem. 273, 6853-6859), In this study, we investigated the enzyme that is involved in this 3'-end adenylation of SRP RNA. A U1A protein peptide conjugated to albumin completely inhibited the polyadenylation of a SV40 mRNA by HeLa cell nuclear extract in vitro; however, the 3'-end adenylation of human SRP RNA or Alu RNA which corresponds to 5' and 3'-ends of SRP RNA, was not affected by this U1A peptide conjugate. SRP RNA from mutant strains of S. cerevisiae with a temperature-sensitive mRNA poly(A) polymerase grown at a restrictive temperature of 37 degrees C also contained a post-transcriptionally added adenylic acid residue just like SRP RNA from wild-type cells and mutant cells grown at permissive temperature of 23 degrees C. In addition, binding of SRP 9/14-kDa protein heterodimer was required for adenylation of Alu RNA in vitro, These lines of evidence, along with other data, show that post-transcriptional adenylation of SRP and Alu RNAs is carried out by a novel enzyme that is distinct from the mRNA poly(A) polymerase, CCA-adding enzyme, and nonspecific terminal transferase.	Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA	Baylor College of Medicine	Reddy, R (corresponding author), Baylor Coll Med, Dept Pharmacol, 1 Baylor Plaza, Houston, TX 77030 USA.	rreddy@bcm.tmc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052901] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-52901, GM-38320] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTARDI G, 1985, INT REV CYTOL, V93, P93, DOI 10.1016/S0074-7696(08)61373-X; BASERGA SJ, 1985, GENE, V35, P305, DOI 10.1016/0378-1119(85)90009-5; Chapon C, 1997, RNA, V3, P1337; CHEN J, 1992, MOL CELL BIOL, V12, P3470, DOI 10.1128/MCB.12.8.3470; Chen YH, 1998, J BIOL CHEM, V273, P35023, DOI 10.1074/jbc.273.52.35023; CLAYTON DA, 1992, INT REV CYTOL, V141, P217, DOI 10.1016/S0074-7696(08)62067-7; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EIRSE DEA, 1997, EMBO J, V16, P3757; Elela SA, 1998, EMBO J, V17, P3738, DOI 10.1093/emboj/17.13.3738; ENGLARD S, 1990, METHOD ENZYMOL, V182, P285; Gunderson SI, 1997, GENE DEV, V11, P761, DOI 10.1101/gad.11.6.761; HE XP, 1994, J CELL SCI, V107, P903; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P345, DOI 10.1016/S0968-0004(00)89071-4; KELLER W, 1995, CELL, V81, P829, DOI 10.1016/0092-8674(95)90001-2; LARSEN N, 1991, NUCLEIC ACIDS RES, V19, P209, DOI 10.1093/nar/19.2.209; Li ZW, 1998, P NATL ACAD SCI USA, V95, P12158, DOI 10.1073/pnas.95.21.12158; LINGNER J, 1991, NATURE, V354, P496, DOI 10.1038/354496a0; MANLEY JL, 1995, CURR OPIN GENET DEV, V5, P222, DOI 10.1016/0959-437X(95)80012-3; MINVIELLESEBASTIA L, 1994, SCIENCE, V266, P1702, DOI 10.1126/science.7992054; PATEL D, 1992, MOL CELL BIOL, V12, P3297, DOI 10.1128/MCB.12.7.3297; PIPER PW, 1983, EMBO J, V2, P353, DOI 10.1002/j.1460-2075.1983.tb01430.x; PREKER PJ, 1995, CELL, V81, P379, DOI 10.1016/0092-8674(95)90391-7; Reuven NB, 1997, J BIOL CHEM, V272, P33255, DOI 10.1074/jbc.272.52.33255; RYNER LC, 1989, MOL CELL BIOL, V9, P4229, DOI 10.1128/MCB.9.10.4229; SHEETS MD, 1987, MOL CELL BIOL, V7, P1518, DOI 10.1128/MCB.7.4.1518; Shi PY, 1998, EMBO J, V17, P3197, DOI 10.1093/emboj/17.11.3197; Sinha KM, 1998, J BIOL CHEM, V273, P6853, DOI 10.1074/jbc.273.12.6853; STRUB K, 1991, MOL CELL BIOL, V11, P3949, DOI 10.1128/MCB.11.8.3949; Szalewska-Palasz A, 1998, FEBS LETT, V432, P70, DOI 10.1016/S0014-5793(98)00834-5; TAKAGAKI Y, 1988, CELL, V52, P731, DOI 10.1016/0092-8674(88)90411-4; THURESSON AC, 1994, P NATL ACAD SCI USA, V91, P979, DOI 10.1073/pnas.91.3.979; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Weichenrieder O, 1997, RNA, V3, P1262; XU FF, 1995, NATURE, V374, P180, DOI 10.1038/374180a0; Yokobori S, 1997, J MOL BIOL, V265, P95, DOI 10.1006/jmbi.1996.0728; Yue DX, 1996, RNA, V2, P895; ZIEVE GW, 1990, CRIT REV BIOCHEM MOL, V25, P1, DOI 10.3109/10409239009090604; ZWIERZYNSKI TA, 1989, NUCLEIC ACIDS RES, V17, P4647, DOI 10.1093/nar/17.12.4647	40	12	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30826	30831		10.1074/jbc.274.43.30826	http://dx.doi.org/10.1074/jbc.274.43.30826			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521474				2022-12-27	WOS:000083276700070
J	Tirupati, HK; Shaw, LC; Lewin, AS				Tirupati, HK; Shaw, LC; Lewin, AS			An RNA binding motif in the Cbp2 protein required for protein-stimulated RNA catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-I INTRON; DOUBLE-STRANDED-RNA; PHOTOCHEMICAL CROSS-LINKING; PRE-MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; HIGH-YIELD; DOMAIN; KINASE; ACID; SYNTHETASE	The fifth and terminal intron of yeast cytochrome b pre-mRNA (a group I intron) requires a protein encoded by the nuclear gene CBP2 for splicing. Because catalysis is intrinsic to the RNA, the protein is believed to promote formation of secondary and tertiary structure of the RNA, resulting in a catalytically competent intron, In vitro, this mitochondrial intron can be made to self-splice or undergo protein-facilitated splicing by varying the Mg2+ and monovalent salt concentrations. This two-component system, therefore, provides a good model for understanding the role of proteins in RNA folding. A UV cross-linking experiment was initiated to identify RNA binding sites on Cbp2 and gain insights into Cb22-intron interactions. A 12-amino acid region containing a presumptive contact site near the amino terminus was targeted for mutagenesis, and mutant proteins were characterized for RNA binding and stimulation of splicing. Mutations in this region resulted in partial or complete loss of function, demonstrating the importance of this determinant for stimulation of RNA splicing. Several of the mutations that severely reduced splicing did not significantly shift the overall binding isotherm of Cbp2 for the precursor RNA, suggesting that contacts critical for activity are not necessarily reflected in the dissociation constant. This analysis has identified a unique RNA binding motif of alternating basic and aromatic residues that is essential for protein facilitated splicing.	Univ Florida, Dept Mol Genet & Microbiol, Coll Med, Gainesville, FL 32605 USA	State University System of Florida; University of Florida	Lewin, AS (corresponding author), Univ Florida, Dept Mol Genet & Microbiol, Coll Med, Box 100266, Gainesville, FL 32605 USA.			Lewin, Alfred/0000-0002-4192-9727				AKINS RA, 1987, CELL, V50, P331, DOI 10.1016/0092-8674(87)90488-0; ANDERSON JT, 1993, MOL CELL BIOL, V13, P6102, DOI 10.1128/MCB.13.10.6102; Bevilacqua PC, 1996, BIOCHEMISTRY-US, V35, P9983, DOI 10.1021/bi9607259; Bornstein P, 1977, Methods Enzymol, V47, P132; Caprara MG, 1996, J MOL BIOL, V257, P512, DOI 10.1006/jmbi.1996.0182; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; CHANG BY, 1993, BIOCHEM J, V294, P43, DOI 10.1042/bj2940043; CHERNIACK AD, 1990, CELL, V62, P745, DOI 10.1016/0092-8674(90)90119-Y; Chu DM, 1997, J BIOL CHEM, V272, P31922, DOI 10.1074/jbc.272.50.31922; CLEGHON V, 1992, J BIOL CHEM, V267, P17872; DEGANI Y, 1974, BIOCHEMISTRY-US, V13, P1, DOI 10.1021/bi00698a001; GAMPEL A, 1987, MOL CELL BIOL, V7, P2545, DOI 10.1128/MCB.7.7.2545; GAMPEL A, 1989, MOL CELL BIOL, V9, P5424, DOI 10.1128/MCB.9.12.5424; GATIGNOL A, 1993, MOL CELL BIOL, V13, P2193, DOI 10.1128/MCB.13.4.2193; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; HAY RT, 1993, NUCLEIC ACIDS RES, V21, P4592, DOI 10.1093/nar/21.19.4592; HERSCHLAG D, 1994, EMBO J, V13, P2913, DOI 10.1002/j.1460-2075.1994.tb06586.x; HILL J, 1985, J BIOL CHEM, V260, P3235; HUNTER T, 1975, J BIOL CHEM, V250, P409; Ikeda M, 1996, J BIOL CHEM, V271, P23096, DOI 10.1074/jbc.271.38.23096; JACOBSON GR, 1973, J BIOL CHEM, V248, P6583; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; Liu X, 1996, P NATL ACAD SCI USA, V93, P4554, DOI 10.1073/pnas.93.10.4554; MCCORMACK SJ, 1992, VIROLOGY, V188, P47, DOI 10.1016/0042-6822(92)90733-6; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; Modarress KJ, 1997, J BIOL CHEM, V272, P23986, DOI 10.1074/jbc.272.38.23986; MOHR G, 1994, NATURE, V370, P147, DOI 10.1038/370147a0; Parker EJ, 1998, NUCLEIC ACIDS RES, V26, P1240, DOI 10.1093/nar/26.5.1240; PARTONO S, 1988, MOL CELL BIOL, V8, P2562, DOI 10.1128/MCB.8.6.2562; SAFER B, 1988, MOL CELL BIOL, V8, P105, DOI 10.1128/MCB.8.1.105; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHAW LC, 1995, J BIOL CHEM, V270, P21552, DOI 10.1074/jbc.270.37.21552; Shaw LC, 1996, NUCLEIC ACIDS RES, V24, P3415, DOI 10.1093/nar/24.17.3415; SHAW LC, 1997, NUCLEIC ACIDS RES, V25, P1587; SHETLAR M, 1980, PHOTOCH PHOTOBIO SCI, P105; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Towbin H, 1979, 10 1073 PNAS 76 9 43, V76, P4350, DOI [10.1073/pnas.76.9.4350, DOI 10.1073/PNAS.76.9.4350]; Vaisanen S, 1997, EUR J BIOCHEM, V248, P156, DOI 10.1111/j.1432-1033.1997.t01-1-00156.x; Weeks KM, 1996, SCIENCE, V271, P345, DOI 10.1126/science.271.5247.345; WEEKS KM, 1995, CELL, V82, P221, DOI 10.1016/0092-8674(95)90309-7; WEEKS KM, 1995, BIOCHEMISTRY-US, V34, P7728, DOI 10.1021/bi00023a020; WILLIAMS KR, 1991, METHOD ENZYMOL, V208, P516; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	47	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30393	30401		10.1074/jbc.274.43.30393	http://dx.doi.org/10.1074/jbc.274.43.30393			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521416	hybrid			2022-12-27	WOS:000083276700012
J	Tavares, D; Tully, K; Dobner, PR				Tavares, D; Tully, K; Dobner, PR			Sequences required for induction of neurotensin receptor gene expression during neuronal differentiation of N1E-115 neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KRUPPEL-LIKE FACTOR; SPONTANEOUS MOTOR-ACTIVITY; VENTRAL TEGMENTAL AREA; RAT SUBSTANTIA-NIGRA; TRANSCRIPTION FACTOR; HIGH-AFFINITY; MESSENGER-RNA; NEUROMEDIN-N; FUNCTIONAL EXPRESSION; HYPOTHALAMIC PEPTIDE	The promoter region of the mouse high affinity neurotensin receptor (Ntr-1) gene was characterized, and sequences required for expression in neuroblastoma cell lines that express high affinity NT-binding sites were characterized. Me2SO-induced neuronal differentiation of N1E-115 neuroblastoma cells increased both the expression of the endogenous Ntr-1 gene and reporter genes driven by NTR-1 promoter sequences by 3-4-fold. Deletion analysis revealed that an 83-base pair promoter region containing the transcriptional start site is required for Me2SO activation. Detailed mutational analysis of this region revealed that a CACCC box and the central region of a large GC-rich palindrome are the crucial cis-regulatory elements required for Me2SO induction. The CACCC box is bound by at least one factor that is induced upon Me2SO treatment of N1E-115 cells. The Me2SO effect was found to be both selective and cell type-restricted. Basal expression in the neuroblastoma cell lines required a distinct set of sequences, including an Sp1-like sequence, and a sequence resembling an NGFI-A-binding site; however, a more distal 5' sequence was found to repress basal activity in N1E-115 cells. These results provide evidence that Ntr-1 gene regulation involves both positive and negative regulatory elements located in the 5'-flanking region and that Ntr-2 gene activation involves the coordinate activation or induction of several factors, including a CACCC box binding complex.	Univ Massachusetts, Sch Med, Program Neurosci, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Dept Mol Genet & Microbiol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Dobner, PR (corresponding author), Univ Massachusetts, Sch Med, Program Neurosci, Worcester, MA 01655 USA.	paul.dobner@umassmed.edu			NHLBI NIH HHS [R01 HL333072] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMANO T, 1972, P NATL ACAD SCI USA, V69, P258, DOI 10.1073/pnas.69.1.258; ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; AZZI M, 1994, NEUROSCI LETT, V172, P97, DOI 10.1016/0304-3940(94)90671-8; Azzi M, 1996, MOL BRAIN RES, V42, P213, DOI 10.1016/S0169-328X(96)00124-6; Betancur C, 1997, MOL BRAIN RES, V44, P334, DOI 10.1016/S0169-328X(96)00289-6; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BOLDENWATSON C, 1993, J NEUROCHEM, V61, P1141, DOI 10.1111/j.1471-4159.1993.tb03631.x; Botto JM, 1997, NEUROSCI LETT, V223, P193, DOI 10.1016/S0304-3940(97)13437-1; Boudin H, 1996, J COMP NEUROL, V373, P76; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BRAY SJ, 1991, GENE DEV, V5, P1672, DOI 10.1101/gad.5.9.1672; BULLOCK BP, 1994, MOL BRAIN RES, V27, P232, DOI 10.1016/0169-328X(94)90005-1; CARRAWAY R, 1975, J BIOL CHEM, V250, P1907; Chalon P, 1996, FEBS LETT, V386, P91, DOI 10.1016/0014-5793(96)00397-3; CHOWDHURY K, 1988, EMBO J, V7, P1345, DOI 10.1002/j.1460-2075.1988.tb02950.x; Crossley M, 1996, MOL CELL BIOL, V16, P1695; CUSACK B, 1991, EUR J PHARM-MOLEC PH, V206, P339, DOI 10.1016/0922-4106(91)90119-3; DOBNER PR, 1987, P NATL ACAD SCI USA, V84, P3516, DOI 10.1073/pnas.84.10.3516; ERVIN GN, 1981, NATURE, V291, P73, DOI 10.1038/291073a0; EVERS BM, 1995, MOL CELL BIOL, V15, P3870; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; HARRISON RJ, 1995, MOL ENDOCRINOL, V9, P981, DOI 10.1210/me.9.8.981; Hasan SJ, 1995, J NEUROCYTOL, V24, P984, DOI 10.1007/BF01215647; Henke W, 1997, NUCLEIC ACIDS RES, V25, P3957, DOI 10.1093/nar/25.19.3957; HERVE D, 1986, P NATL ACAD SCI USA, V83, P6203, DOI 10.1073/pnas.83.16.6203; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; JIANG ZG, 1994, J PHYSIOL-LONDON, V474, P119, DOI 10.1113/jphysiol.1994.sp020007; KALIVAS PW, 1982, EUR J PHARMACOL, V78, P471, DOI 10.1016/0014-2999(82)90491-5; KALIVAS PW, 1981, BRAIN RES, V229, P525, DOI 10.1016/0006-8993(81)91016-7; KALIVAS PW, 1984, NEUROSCIENCE, V11, P919, DOI 10.1016/0306-4522(84)90203-3; KIMHI Y, 1976, P NATL ACAD SCI USA, V73, P462, DOI 10.1073/pnas.73.2.462; KISLAUSKIS E, 1988, J BIOL CHEM, V263, P4963; Kuo CT, 1997, SCIENCE, V277, P1986, DOI 10.1126/science.277.5334.1986; Le F, 1997, J BIOL CHEM, V272, P1315, DOI 10.1074/jbc.272.2.1315; Maeno H, 1996, MOL BRAIN RES, V40, P97; Mazella J, 1996, J NEUROSCI, V16, P5613; MEADORWOODRUFF JH, 1989, P NATL ACAD SCI USA, V86, P7625, DOI 10.1073/pnas.86.19.7625; MERCHANT KM, 1994, J PHARMACOL EXP THER, V269, P806; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MINOWA T, 1992, BIOCHEMISTRY-US, V31, P8389, DOI 10.1021/bi00151a001; MINOWA T, 1994, J BIOL CHEM, V269, P11656; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; NAKAGAWA Y, 1984, J NEUROSCI, V4, P1653; NEMEROFF CB, 1977, BRAIN RES, V128, P485, DOI 10.1016/0006-8993(77)90173-1; NICOT A, 1994, J COMP NEUROL, V341, P407, DOI 10.1002/cne.903410310; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; Ouyang L, 1998, J BIOL CHEM, V273, P23019, DOI 10.1074/jbc.273.36.23019; Payen E, 1998, J BIOL CHEM, V273, P9099, DOI 10.1074/jbc.273.15.9099; PERKINS AC, 1995, NATURE, V375, P318; PINNOCK RD, 1985, BRAIN RES, V338, P151, DOI 10.1016/0006-8993(85)90258-6; POUSTIS C, 1984, J NEUROCHEM, V42, P1094, DOI 10.1111/j.1471-4159.1984.tb12715.x; REINECKE M, 1985, PROG HISTOCHEM CYTOC, V16, P1; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHI WX, 1991, BRAIN RES, V543, P315, DOI 10.1016/0006-8993(91)90043-U; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; STRAUSS EC, 1992, P NATL ACAD SCI USA, V89, P5809, DOI 10.1073/pnas.89.13.5809; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; SZIGETHY E, 1989, J COMP NEUROL, V279, P128, DOI 10.1002/cne.902790111; TANAKA K, 1990, NEURON, V4, P847, DOI 10.1016/0896-6273(90)90137-5; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Wang JL, 1997, J NEUROSCI RES, V50, P23, DOI 10.1002/(SICI)1097-4547(19971001)50:1<23::AID-JNR3>3.3.CO;2-Y; WEIH F, 1990, GENE DEV, V4, P1437, DOI 10.1101/gad.4.8.1437; WOULFE J, 1989, BRAIN RES, V479, P402, DOI 10.1016/0006-8993(89)91649-1	69	8	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30066	30079		10.1074/jbc.274.42.30066	http://dx.doi.org/10.1074/jbc.274.42.30066			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514493	hybrid			2022-12-27	WOS:000083176400072
J	Bellin, RM; Sernett, SW; Becker, B; Ip, W; Huiatt, TW; Robson, RM				Bellin, RM; Sernett, SW; Becker, B; Ip, W; Huiatt, TW; Robson, RM			Molecular characteristics and interactions of the intermediate filament protein synemin - Interactions with alpha-actinin may anchor synemin-containing heterofilaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE; VIMENTIN FILAMENTS; SKELETAL-MUSCLE; ELECTROPHORETIC TRANSFER; POLYACRYLAMIDE GELS; RNA LOCALIZATION; DESMIN; CELLS; NITROCELLULOSE; IMMUNOELECTRON	Synemin is a cytoskeletal protein originally identified as an intermediate filament (IF)-associated protein because of its colocalization and copurification with the IF proteins desmin and vimentin in muscle cells. Our sequencing studies have shown that synemin is an unusually large member (1,604 residues, 182,187 Da) of the IF protein superfamily, with the majority of the molecule consisting of a long C-terminal tail domain. Molecular interaction studies demonstrate that purified synemin interacts with desmin, the major IF protein in mature muscle cells, and with cy-actinin, an integral myofibrillar Z-line protein. Furthermore, expressed synemin rod and tail domains interact, respectively, with desmin and a-actinin. Analysis of endogenous protein expression in SW13 clonal lines reveals that synemin is coexpressed and colocalized with vimentin Ifs in SW13.C1 vim+ cells but is absent in SW13.C2 vim - cells. Transfection studies indicate that synemin requires the presence of another IF protein, such as vimentin, in order to assemble into Ifs. Taken in tote, our results suggest synemin functions as a component of heteropolymeric Ifs and plays an important cytoskeletal cross-linking role by linking these Ifs to other components of the cytoskeleton. Synemin in striated muscle cells may enable these heterofilaments to help link Z-lines of adjacent myofibrils and, thereby, play an important role in cytoskeletal integrity.	Iowa State Univ, Muscle Biol Grp, Dept Biochem, Ames, IA 50011 USA; Iowa State Univ, Muscle Biol Grp, Dept Biophys, Ames, IA 50011 USA; Iowa State Univ, Muscle Biol Grp, Dept Mol Biol, Ames, IA 50011 USA; Iowa State Univ, Muscle Biol Grp, Dept Anim Sci, Ames, IA 50011 USA; Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA	Iowa State University; Iowa State University; Iowa State University; Iowa State University; University System of Ohio; University of Cincinnati	Robson, RM (corresponding author), Iowa State Univ, Muscle Biol Grp, Dept Biochem, 3110 Mol Biol Bldg, Ames, IA 50011 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD023144] Funding Source: NIH RePORTER; NICHD NIH HHS [N01-HD-2-3144] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abumuhor IA, 1998, J STRUCT BIOL, V123, P187, DOI 10.1006/jsbi.1998.4040; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Athlan ES, 1997, J NEUROSCI RES, V47, P300; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BECKER B, 1995, BIOCHEM BIOPH RES CO, V213, P796, DOI 10.1006/bbrc.1995.2200; BELLIN RM, 1999, GUIDEBOOK CYTOSKELET; BENNETT GS, 1979, J CELL BIOL, V82, P577, DOI 10.1083/jcb.82.2.577; Bilak SR, 1998, ARCH BIOCHEM BIOPHYS, V355, P63, DOI 10.1006/abbi.1998.0702; BRECKLER J, 1982, J CELL BIOL, V92, P795, DOI 10.1083/jcb.92.3.795; BRYAN J, 1989, J MUSCLE RES CELL M, V10, P95, DOI 10.1007/BF01739964; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHEN WJ, 1994, J CELL SCI, V107, P2299; CHING GY, 1993, J CELL BIOL, V122, P1323, DOI 10.1083/jcb.122.6.1323; CRAIG SW, 1982, METHOD ENZYMOL, V85, P316; Foisner R, 1991, CURR OPIN CELL BIOL, V3, P75, DOI 10.1016/0955-0674(91)90168-X; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; GEISLER N, 1980, EUR J BIOCHEM, V111, P425, DOI 10.1111/j.1432-1033.1980.tb04957.x; Goldman RD, 1996, J CELL BIOL, V134, P971, DOI 10.1083/jcb.134.4.971; GRANGER BL, 1979, CELL, V18, P1053, DOI 10.1016/0092-8674(79)90218-6; GRANGER BL, 1980, CELL, V22, P727, DOI 10.1016/0092-8674(80)90549-8; GRANGER BL, 1982, CELL, V30, P263, DOI 10.1016/0092-8674(82)90032-0; Hemken PM, 1997, J BIOL CHEM, V272, P32489, DOI 10.1074/jbc.272.51.32489; HEMMATIBRIVANLOU A, 1992, NEURON, V9, P417, DOI 10.1016/0896-6273(92)90180-L; HEMMINGS L, 1995, BIOCHEM SOC T, V23, P619, DOI 10.1042/bst0230619; Herrmann H, 1999, J MOL BIOL, V286, P1403, DOI 10.1006/jmbi.1999.2528; Herrmann H, 1998, CURR OPIN STRUC BIOL, V8, P177, DOI 10.1016/S0959-440X(98)80035-3; Hijikata T, 1999, J CELL SCI, V112, P867; HUIATT TW, 1980, J BIOL CHEM, V255, P6981; ImanakaYoshida K, 1996, CELL MOTIL CYTOSKEL, V33, P263, DOI 10.1002/(SICI)1097-0169(1996)33:4<263::AID-CM3>3.0.CO;2-A; Inagaki M, 1996, BIOESSAYS, V18, P481, DOI 10.1002/bies.950180610; IP W, 1985, ANN NY ACAD SCI, V455, P185, DOI 10.1111/j.1749-6632.1985.tb50412.x; IP W, 1985, J MOL BIOL, V183, P365, DOI 10.1016/0022-2836(85)90007-5; KLYMKOWSKY MW, 1995, CURR OPIN CELL BIOL, V7, P46, DOI 10.1016/0955-0674(95)80044-1; KNUDSEN KA, 1985, ANAL BIOCHEM, V147, P285, DOI 10.1016/0003-2697(85)90273-8; KOUKLIS PD, 1993, J CELL SCI, V106, P919; LAZARIDES E, 1980, NATURE, V283, P249, DOI 10.1038/283249a0; LEE MK, 1993, J CELL BIOL, V122, P1337, DOI 10.1083/jcb.122.6.1337; Lee MK, 1996, ANNU REV NEUROSCI, V19, P187, DOI 10.1146/annurev.ne.19.030196.001155; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; MAKAROVA I, 1994, CELL MOTIL CYTOSKEL, V28, P265, DOI 10.1002/cm.970280309; Marvin NJ, 1998, J CELL SCI, V111, P1951; Meng JJ, 1996, J BIOL CHEM, V271, P1599, DOI 10.1074/jbc.271.3.1599; MOON RT, 1983, P NATL ACAD SCI-BIOL, V80, P5495, DOI 10.1073/pnas.80.18.5495; Oleynikov Y, 1998, TRENDS CELL BIOL, V8, P381, DOI 10.1016/S0962-8924(98)01348-8; PRICE MG, 1983, J CELL BIOL, V97, P1860, DOI 10.1083/jcb.97.6.1860; RAATS JMH, 1990, J CELL BIOL, V111, P1971, DOI 10.1083/jcb.111.5.1971; RICHARDSON FL, 1981, EUR J CELL BIOL, V26, P91; Robson RM, 1989, CURR OPIN CELL BIOL, V1, P36, DOI 10.1016/S0955-0674(89)80034-1; SANDOVAL IV, 1983, J BIOL CHEM, V258, P2568; SARRIA AJ, 1994, J CELL SCI, V107, P1593; Schroder R, 1999, EUR J CELL BIOL, V78, P288, DOI 10.1016/S0171-9335(99)80062-4; Seki N, 1997, DNA Res, V4, P345, DOI 10.1093/dnares/4.5.345; Steinbock FA, 1999, BIOL CHEM, V380, P151, DOI 10.1515/BC.1999.023; Steinert PM, 1999, J BIOL CHEM, V274, P9881, DOI 10.1074/jbc.274.14.9881; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; SUZUKI A, 1976, J BIOL CHEM, V251, P6860; TOKUYASU KT, 1983, J CELL BIOL, V96, P1727, DOI 10.1083/jcb.96.6.1727; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WICHE G, 1983, J CELL BIOL, V97, P887, DOI 10.1083/jcb.97.3.887; WILHELM JE, 1993, J CELL BIOL, V123, P269, DOI 10.1083/jcb.123.2.269; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; YAMAGUCHI M, 1985, J MOL BIOL, V184, P621, DOI 10.1016/0022-2836(85)90308-0; Yuan J, 1999, ARCH BIOCHEM BIOPHYS, V363, P314, DOI 10.1006/abbi.1998.1096	65	89	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29493	29499		10.1074/jbc.274.41.29493	http://dx.doi.org/10.1074/jbc.274.41.29493			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506213	hybrid			2022-12-27	WOS:000083017800092
J	Higgs, HN; Pollard, TD				Higgs, HN; Pollard, TD			Regulation of actin polymerization by Arp2/3 complex and WASp/Scar proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							WISKOTT-ALDRICH-SYNDROME; N-WASP; SCHIZOSACCHAROMYCES-POMBE; TYROSINE PHOSPHORYLATION; LISTERIA-MONOCYTOGENES; DEPOLYMERIZING PROTEIN; CELL MOTILITY; IN-VITRO; YEAST; BINDING		Salk Inst Biol Studies, Struct Biol Lab, La Jolla, CA 92037 USA	Salk Institute	Pollard, TD (corresponding author), Salk Inst Biol Studies, Struct Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Higgs, Henry/0000-0002-2917-9644				Baba Y, 1999, BLOOD, V93, P2003, DOI 10.1182/blood.V93.6.2003.406k13_2003_2012; Bailly M, 1999, J CELL BIOL, V145, P331, DOI 10.1083/jcb.145.2.331; Balasubramanian MK, 1996, EMBO J, V15, P6426, DOI 10.1002/j.1460-2075.1996.tb01034.x; Banin S, 1996, CURR BIOL, V6, P981, DOI 10.1016/S0960-9822(02)00642-5; Bear JE, 1998, J CELL BIOL, V142, P1325, DOI 10.1083/jcb.142.5.1325; Beckerle MC, 1998, CELL, V95, P741, DOI 10.1016/S0092-8674(00)81697-9; Blanchoin L, 1998, J BIOL CHEM, V273, P25106, DOI 10.1074/jbc.273.39.25106; CARSON M, 1986, J CELL BIOL, V103, P2707, DOI 10.1083/jcb.103.6.2707; Chan AY, 1998, J CELL SCI, V111, P199; Cory GOC, 1996, J IMMUNOL, V157, P3791; Cossart P, 1998, EMBO J, V17, P3797, DOI 10.1093/emboj/17.14.3797; Guinamard R, 1998, FEBS LETT, V434, P431, DOI 10.1016/S0014-5793(98)01016-3; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; KELLEHER JF, 1995, J CELL BIOL, V131, P385, DOI 10.1083/jcb.131.2.385; Lechler T, 1997, J CELL BIOL, V138, P95, DOI 10.1083/jcb.138.1.95; LEESMILLER JP, 1992, P NATL ACAD SCI USA, V89, P80, DOI 10.1073/pnas.89.1.80; Leonard SA, 1997, NAT STRUCT BIOL, V4, P369, DOI 10.1038/nsb0597-369; Li R, 1997, J CELL BIOL, V136, P649, DOI 10.1083/jcb.136.3.649; Ma L, 1998, J CELL BIOL, V140, P1125; Ma L, 1998, P NATL ACAD SCI USA, V95, P15362, DOI 10.1073/pnas.95.26.15362; Machesky LM, 1997, BIOCHEM J, V328, P105; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; McCollum D, 1996, EMBO J, V15, P6438, DOI 10.1002/j.1460-2075.1996.tb01035.x; Miki H, 1998, BIOCHEM BIOPH RES CO, V243, P73, DOI 10.1006/bbrc.1997.8064; Miki H, 1998, EMBO J, V17, P6932, DOI 10.1093/emboj/17.23.6932; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Mogilner A, 1996, BIOPHYS J, V71, P3030, DOI 10.1016/S0006-3495(96)79496-1; Moreau V, 1996, J CELL BIOL, V134, P117, DOI 10.1083/jcb.134.1.117; Moreau V, 1997, MOL BIOL CELL, V8, P1361, DOI 10.1091/mbc.8.7.1361; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; Mullins RD, 1999, CURR BIOL, V9, P405, DOI 10.1016/S0960-9822(99)80187-0; Mullins RD, 1998, MOL BIOL CELL, V9, P841, DOI 10.1091/mbc.9.4.841; Mullins RD, 1997, J CELL BIOL, V136, P331, DOI 10.1083/jcb.136.2.331; Mullins RD, 1999, CURR OPIN STRUC BIOL, V9, P244; Naqvi SN, 1998, CURR BIOL, V8, P959, DOI 10.1016/S0960-9822(98)70396-3; Ochs HD, 1998, SEMIN HEMATOL, V35, P332; Oda A, 1998, BLOOD, V92, P1852, DOI 10.1182/blood.V92.6.1852.418k36_1852_1858; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; PREHODA KE, 1999, IN PRESS CELL; Ramesh N, 1997, P NATL ACAD SCI USA, V94, P14671, DOI 10.1073/pnas.94.26.14671; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rudolph MG, 1998, J BIOL CHEM, V273, P18067, DOI 10.1074/jbc.273.29.18067; Schafer DA, 1996, J CELL BIOL, V135, P169, DOI 10.1083/jcb.135.1.169; Schafer DA, 1998, J CELL BIOL, V143, P1919, DOI 10.1083/jcb.143.7.1919; SCHWOB E, 1992, NATURE, V355, P179, DOI 10.1038/355179a0; She HY, 1997, MOL BIOL CELL, V8, P1709, DOI 10.1091/mbc.8.9.1709; Stewart DM, 1999, J IMMUNOL, V162, P5019; Suetsugu S, 1998, EMBO J, V17, P6516, DOI 10.1093/emboj/17.22.6516; Svitkina TM, 1999, J CELL BIOL, V145, P1009, DOI 10.1083/jcb.145.5.1009; Svitkina TM, 1997, J CELL BIOL, V139, P397, DOI 10.1083/jcb.139.2.397; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Vaduva G, 1997, J CELL BIOL, V139, P1821, DOI 10.1083/jcb.139.7.1821; Welch MD, 1997, J CELL BIOL, V138, P375, DOI 10.1083/jcb.138.2.375; Welch MD, 1998, SCIENCE, V281, P105, DOI 10.1126/science.281.5373.105; Winter D, 1999, CURR BIOL, V9, P501, DOI 10.1016/S0960-9822(99)80218-8; Winter D, 1997, CURR BIOL, V7, P519, DOI 10.1016/S0960-9822(06)00223-5; Winter DC, 1999, P NATL ACAD SCI USA, V96, P7288, DOI 10.1073/pnas.96.13.7288; Yarar D, 1999, CURR BIOL, V9, P555, DOI 10.1016/S0960-9822(99)80243-7; Zigmond SH, 1998, J CELL BIOL, V142, P1001, DOI 10.1083/jcb.142.4.1001; Zigmond SH, 1997, J CELL BIOL, V138, P363, DOI 10.1083/jcb.138.2.363	66	206	211	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32531	32534		10.1074/jbc.274.46.32531	http://dx.doi.org/10.1074/jbc.274.46.32531			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551802	hybrid			2022-12-27	WOS:000083623000002
J	Cestra, G; Castagnoli, L; Dente, L; Minenkova, O; Petrelli, A; Migone, N; Hoffmuller, U; Schneider-Mergener, J; Cesareni, G				Cestra, G; Castagnoli, L; Dente, L; Minenkova, O; Petrelli, A; Migone, N; Hoffmuller, U; Schneider-Mergener, J; Cesareni, G			The SH3 domains of endophilin and amphiphysin bind to the proline-rich region of synaptojanin 1 at distinct sites that display an unconventional binding specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULOSE MEMBRANE SUPPORTS; SRC HOMOLOGY-3 DOMAIN; PEPTIDE LIBRARIES; SYNAPSIN-I; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; SPOT-SYNTHESIS; DYNAMIN BINDS; IDENTIFICATION; ENDOCYTOSIS	The proline-rich domain of synaptojanin 1, a synaptic protein with phosphatidylinositol phosphatase activity, binds to amphiphysin and to a family of recently discovered proteins known as the SH3p4/8/13, the SH3-GL, or the endophilin family. These interactions are mediated by SH3 domains and are believed to play a regulatory role in synaptic vesicle recycling, We have precisely mapped the target peptides on human synaptojanin that are recognized by the SH3 domains of endophilins and amphiphysin and proven that they are distinct. By a combination of different approaches, selection of phage displayed peptide libraries, substitution analyses of peptides synthesized on cellulose membranes, and a peptide scan spanning a 252-residue long synaptojanin fragment, we have concluded that amphiphysin binds to two sites, PIRPSR and PTIPPR, whereas endophilin has a distinct preferred binding site, PKRPPPPR, The comparison of the results obtained by phage display and substitution analysis permitted the identification of proline and arginine at positions 4 and 6 in the PIRPSR and PTIPPR target sequence as the major determinants of the recognition specificity mediated by the SH3 domain of amphiphysin I. More complex is the structural rationalization of the preferred endophilin ligands where SH3 binding cannot be easily interpreted in the framework of the "classical" type I or type II SH3 binding models. Our results suggest that the binding repertoire of SH3 domains may be more complex than originally predicted.	Univ Rome, Dept Biol, I-00133 Rome, Italy; Humboldt Univ, Univ Frankfurt Charite, D-10117 Berlin, Germany; Univ Turin, Dipartimento Genet Biol & Biochim, I-10126 Turin, Italy	Sapienza University Rome; Humboldt University of Berlin; University of Turin	Cesareni, G (corresponding author), Univ Rome, Dept Biol, Via Della Ric Sci, I-00133 Rome, Italy.	Cesareni@uniroma2.it	Cesareni, Gianni/AAW-1382-2020; cestra, gianluca/AAL-4736-2021	Castagnoli, Luisa/0000-0001-5283-8671; DENTE, LUCIANA/0000-0002-9617-0922				Anderson BL, 1998, J CELL BIOL, V141, P1357, DOI 10.1083/jcb.141.6.1357; CHEADLE C, 1994, J BIOL CHEM, V269, P24034; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; FELICI F, 1991, J MOL BIOL, V222, P301, DOI 10.1016/0022-2836(91)90213-P; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Frank R, 1996, Methods Mol Biol, V66, P149; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; Giachino C, 1997, GENOMICS, V41, P427, DOI 10.1006/geno.1997.4645; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Kramer A, 1997, CELL, V91, P799, DOI 10.1016/S0092-8674(00)80468-7; Kramer A, 1998, METH MOL B, V87, P25; KRAMER A, 1993, PEPTIDE RES, V6, P314; Kramer A, 1998, PROTEIN ENG, V11, P941, DOI 10.1093/protein/11.10.941; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; Lee CH, 1996, CELL, V85, P931, DOI 10.1016/S0092-8674(00)81276-3; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Micheva KD, 1997, J BIOL CHEM, V272, P27239, DOI 10.1074/jbc.272.43.27239; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; Nemoto Y, 1997, J BIOL CHEM, V272, P30817, DOI 10.1074/jbc.272.49.30817; Okamoto PM, 1997, J BIOL CHEM, V272, P11629; Onofri F, 1997, P NATL ACAD SCI USA, V94, P12168, DOI 10.1073/pnas.94.22.12168; Owen DJ, 1998, EMBO J, V17, P5273, DOI 10.1093/emboj/17.18.5273; Pelicci G, 1996, ONCOGENE, V13, P633; Qualmann B, 1999, MOL BIOL CELL, V10, P501, DOI 10.1091/mbc.10.2.501; RICKLES FR, 1995, THROMB HAEMOSTASIS, V74, P391; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; Singer-Kruger B, 1998, J CELL SCI, V111, P3347; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; Srinivasan S, 1997, EUR J CELL BIOL, V74, P350; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	43	94	104	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32001	32007		10.1074/jbc.274.45.32001	http://dx.doi.org/10.1074/jbc.274.45.32001			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542231	hybrid			2022-12-27	WOS:000083532100039
J	Kamata, T; Liddington, RC; Takada, Y				Kamata, T; Liddington, RC; Takada, Y			Interaction between collagen and the alpha(2) I-domain of integrin alpha(2)beta(1) - Critical role of conserved residues in the metal ion-dependent adhesion site (MIDAS) region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; COMPLEMENT RECEPTOR TYPE-3; AMINO-ACID SEQUENCE; FACTOR A1 DOMAIN; CRYSTAL-STRUCTURE; LIGAND-BINDING; DIRECTED MUTAGENESIS; ALPHA-2-BETA-1 VLA-2; VONWILLEBRAND-FACTOR; MOLECULAR-CLONING	A docking model of the cu, I-domain and collagen has been proposed based on their crystal structures (Emsley, J., Ring, S., Bergelson, J., and Liddington, R. C. (1997) J. Biol. Chem. 272, 28512-28517). In this model, several amino acid residues in the I domain make direct contact with collagen (Asn-154, Asp-219, Leu-220, Glu-256, His-258, Tyr-285, Asn-289, Leu-291, Asn-295, and Lys-298), and the protruding C-helix of alpha(2) (residues 284-288) determines ligand specificity. Because most of the pro posed critical residues are not conserved, different I-domains are predicted to bind to collagen differently. We found that deleting the entire C-helix or mutating the predicted critical residues had no effect on collagen binding to whole alpha(2)beta(1), with the exception that mutating Asn-154, Asp-219, and His-258 had a moderate effect. We performed further studies and found that mutating the conserved surface-exposed residues in the metal ion-dependent adhesion site (MIDAS) (Tyr-157 and Gln-215) significantly blocks collagen binding. me have revised the docking model based on the mutagenesis data. In the revised model, conserved Tyr-157 makes contact with collagen in addition to the previously proposed Asn-154, Asp-219, His-258, and Tyr-285 residues. These results suggest that the collagen-binding I-domains (e.g. alpha(1), alpha(2), and alpha(10)) bind to collagen in a similar fashion.	Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA; Burnham Inst, La Jolla, CA 92037 USA	Scripps Research Institute; Sanford Burnham Prebys Medical Discovery Institute	Takada, Y (corresponding author), Scripps Res Inst, Dept Vasc Biol, 10550 N Torrey Pines Rd,VB-1,Pines Rd, La Jolla, CA 92037 USA.			takada, yoshikazu/0000-0001-5481-9589	NIGMS NIH HHS [GM49899, GM47157] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047157, R01GM049899] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNAOUT MA, 1988, J CELL BIOL, V106, P2153, DOI 10.1083/jcb.106.6.2153; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; Bienkowska J, 1997, J BIOL CHEM, V272, P25162, DOI 10.1074/jbc.272.40.25162; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; BRIESEWITZ R, 1993, J BIOL CHEM, V268, P2989; Calderwood DA, 1997, J BIOL CHEM, V272, P12311, DOI 10.1074/jbc.272.19.12311; CAMBILLAU C, 1984, J MOL GRAPHICS, V2, P53, DOI 10.1016/0263-7855(84)80036-3; Camper L, 1998, J BIOL CHEM, V273, P20383, DOI 10.1074/jbc.273.32.20383; Celikel R, 1998, NAT STRUCT BIOL, V5, P189, DOI 10.1038/nsb0398-189; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; CORBI AL, 1988, J BIOL CHEM, V263, P12403; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Emsley J, 1998, J BIOL CHEM, V273, P10396, DOI 10.1074/jbc.273.17.10396; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; Huizinga EG, 1997, STRUCTURE, V5, P1147, DOI 10.1016/S0969-2126(97)00266-9; IGNATIUS MJ, 1990, J CELL BIOL, V111, P709, DOI 10.1083/jcb.111.2.709; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KERN A, 1994, J BIOL CHEM, V269, P22811; Knight CG, 1998, J BIOL CHEM, V273, P33287, DOI 10.1074/jbc.273.50.33287; LARSON RS, 1989, J CELL BIOL, V108, P703, DOI 10.1083/jcb.108.2.703; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; PYTELA R, 1988, EMBO J, V7, P1371, DOI 10.1002/j.1460-2075.1988.tb02953.x; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; SANTORO SA, 1995, THROMB HAEMOSTASIS, V74, P813; Sasaki T, 1998, EMBO J, V17, P1625, DOI 10.1093/emboj/17.6.1625; SHAW SK, 1994, J BIOL CHEM, V269, P6016; Symersky J, 1997, NAT STRUCT BIOL, V4, P833, DOI 10.1038/nsb1097-833; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TENCHINI ML, 1993, CELL ADHES COMMUN, V1, P55, DOI 10.3109/15419069309095681; TUCKWELL D, 1995, J CELL SCI, V108, P1629; VanderVieren M, 1995, IMMUNITY, V3, P683, DOI 10.1016/1074-7613(95)90058-6	35	43	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32108	32111		10.1074/jbc.274.45.32108	http://dx.doi.org/10.1074/jbc.274.45.32108			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542245	hybrid			2022-12-27	WOS:000083532100053
J	Lienard, H; Bruhns, P; Malbec, O; Fridman, WH; Daeron, M				Lienard, H; Bruhns, P; Malbec, O; Fridman, WH; Daeron, M			Signal regulatory proteins negatively regulate immunoreceptor-dependent cell activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE SHP-1; AFFINITY IGE RECEPTOR; FC-GAMMA RECEPTOR; INHIBITORY RECEPTOR; STEEL FACTOR; MAST-CELLS; ASSOCIATION; LEUKEMIA; PHOSPHORYLATION; EXPRESSION	Signal regulatory proteins of the alpha subtype (SIRP alpha) are ubiquitous molecules of the immunoglobulin superfamily that negatively regulate protein tyrosine kinase receptor-dependent cell proliferation. Their intracytoplasmic domain contains four motifs that resemble immunoreceptor tyrosine-based inhibition motifs (ITIMs) and that, when tyrosyl-phosphorylated, recruit cytoplasmic SH2 domain-bearing protein tyrosine phosphatases (SHPs). ITIMs are borne by molecules that negatively regulate cell activation induced by receptors bearing immunoreceptor tyrosine-based activation motifs (ITAMs), Because SIRP alpha are coexpressed with ITAM-bearing receptors in hematopoietic cells, we investigated whether SIRP alpha could negatively regulate ITAM-dependent cell activation. We found SIRPa transcripts in human mast cells, and we show that a chimeric molecule having the transmembrane and intracytoplasmic domains of SIRP alpha could inhibit IgE-induced mediator secretion and cytokine synthesis by mast cells. Inhibition required that the SIRP alpha chimera was coaggregated with ITAM-bearing high affinity IgE receptors (Fc epsilon RI). It was correlated with the tyrosyl phosphorylation of the SIRP alpha chimera and the recruitment of SHP-1 and SHP-2. The phosphorylation of Fc epsilon RI ITAMs was decreased; the mobilization of intracellular Ca2+ and the influx of extracellular Ca2+ were reduced, and the activation of the mitogen-activated protein kinases Erk1 and Erk2 was abolished. SIRP alpha can therefore negatively regulate not only receptor tyrosine kinase-dependent cell proliferation but also ITAM-dependent cell activation.	Inst Curie, INSERM, U255, Lab Immunol Cellulaire & Clin, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Daeron, M (corresponding author), Inst Curie, INSERM, U255, Lab Immunol Cellulaire & Clin, 26 Rue Ulm, F-75005 Paris, France.		Bruhns, Pierre/F-5567-2013	Bruhns, Pierre/0000-0002-4709-8936; fridman, wolf herman/0000-0002-1332-0973				Adams S, 1998, J IMMUNOL, V161, P1853; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; Binstadt BA, 1996, IMMUNITY, V5, P629, DOI 10.1016/S1074-7613(00)80276-9; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; Bruhns P, 1999, J IMMUNOL, V162, P3168; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; Cherif-Zahar B, 1998, BLOOD, V92, P2535, DOI 10.1182/blood.V92.7.2535.2535_2535_2540; DAERON M, 1992, J IMMUNOL, V149, P1365; DAERON M, 1995, IMMUNITY, V3, P635, DOI 10.1016/1074-7613(95)90134-5; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; DAERON M, 1997, IMMUNOLOGIST, V5, P79; Fong DC, 1996, IMMUNOL LETT, V54, P83, DOI 10.1016/S0165-2478(96)02654-5; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Furusawa T, 1998, J BIOCHEM-TOKYO, V123, P101; Gadina M, 1998, J IMMUNOL, V160, P4657; Ghannadan M, 1998, J INVEST DERMATOL, V111, P689, DOI 10.1046/j.1523-1747.1998.00359.x; Heldin Carl-Henrik, 1996, Cytokine and Growth Factor Reviews, V7, P3, DOI 10.1016/1359-6101(96)00002-0; Jiang PH, 1999, J BIOL CHEM, V274, P559, DOI 10.1074/jbc.274.2.559; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; KISHI K, 1985, LEUKEMIA RES, V9, P381, DOI 10.1016/0145-2126(85)90060-8; LATOUR S, 1992, J IMMUNOL, V149, P2155; LIU FT, 1980, J IMMUNOL, V124, P2728; Malbec O, 1998, J IMMUNOL, V160, P1647; Malbec O, 1999, J IMMUNOL, V162, P4424; MATOZAKI T, 1994, BIOCHEM BIOPH RES CO, V204, P874, DOI 10.1006/bbrc.1994.2541; Moretta A, 1997, IMMUNOL REV, V155, P105, DOI 10.1111/j.1600-065X.1997.tb00943.x; Ohnishi H, 1996, J BIOL CHEM, V271, P25569, DOI 10.1074/jbc.271.41.25569; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; Parkos CA, 1996, J CELL BIOL, V132, P437, DOI 10.1083/jcb.132.3.437; PFEFFERKORN LC, 1994, J IMMUNOL, V153, P3228; RA C, 1989, NATURE, V341, P752, DOI 10.1038/341752a0; Reinhold MI, 1997, J EXP MED, V185, P1, DOI 10.1084/jem.185.1.1; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; Saito H, 1996, J IMMUNOL, V157, P343; Scharenberg AM, 1996, CELL, V87, P961, DOI 10.1016/S0092-8674(00)81790-0; SCHOLL PR, 1993, P NATL ACAD SCI USA, V90, P8847, DOI 10.1073/pnas.90.19.8847; Stofega MR, 1998, J BIOL CHEM, V273, P7112, DOI 10.1074/jbc.273.12.7112; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Timms JF, 1998, MOL CELL BIOL, V18, P3838, DOI 10.1128/MCB.18.7.3838; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; Veillette A, 1998, J BIOL CHEM, V273, P22719, DOI 10.1074/jbc.273.35.22719; Vivier E, 1997, IMMUNOL TODAY, V18, P286, DOI 10.1016/S0167-5699(97)80025-4; WAGTMANN N, 1995, IMMUNITY, V2, P439, DOI 10.1016/1074-7613(95)90025-X; Waterhouse P, 1996, IMMUNOL REV, V153, P183, DOI 10.1111/j.1600-065X.1996.tb00925.x	47	57	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32493	32499		10.1074/jbc.274.45.32493	http://dx.doi.org/10.1074/jbc.274.45.32493			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542295	hybrid			2022-12-27	WOS:000083532100103
J	Park, JS; Park, SJ; Peng, XD; Wang, M; Yu, MA; Lee, SH				Park, JS; Park, SJ; Peng, XD; Wang, M; Yu, MA; Lee, SH			Involvement of DNA-dependent protein kinase in UV-induced replication arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; SIMIAN VIRUS-40 DNA; CELL NUCLEAR ANTIGEN; RNA-POLYMERASE-II; SV40 T-ANTIGEN; RADIATION-INDUCED PHOSPHORYLATION; BINDING-PROTEIN; ATAXIA-TELANGIECTASIA; PHOSPHATIDYLINOSITOL 3-KINASE; IONIZING-RADIATION	Cells exposed to UV irradiation are predominantly arrested at S-phase as web as at the G(1)/S boundary while repair occurs. It is not known how UV irradiation induces S-phase arrest and yet permits DNA repair; however, UV-induced inhibition of replication is efficiently reversed by the addition of replication protein A (RPA), suggesting a role for RPA in this regulatory event. Here, we show evidence that DNA-dependent protein kinase (DNA-PK), plays a role in W-induced replication arrest, DNA synthesis of M059K (DNA-PK catalytic subunit-positive (DNA-PKcs(+))), as measured by [H-3]thymidine incorporation, was significantly arrested by 4 h following UV irradiation, whereas M059J (DNA-PKcs(-)) cells were much less affected. Similar results were obtained with the in vitro replication reactions where immediate replication arrest occurred in DNA-PKcs(+) cells following UV irradiation, and only a gradual decrease in replication activity was observed in DNA-PKcs(-) cells. Reversal of replication arrest was observed at 8 h following UV irradiation in DNA-PKcs(+) cells but not in DNA-PKcs(-) cells. Reversal of W-induced replication arrest was also observed in vitro by the addition of a DNA-PK inhibitor, wortmannin, or by immunodepletion of DNA-PKcs, supporting a positive role for DNA-PK in damage-induced replication arrest. The RPA-containing fraction from UV-irradiated DNA-PKcs(+) cells poorly supported DNA replication, whereas the replication activity of the RPA-containing fraction from DNA-PKcs(-) cells was not affected by UV, suggesting that DNA-PKcs may be involved in UV-induced replication arrest through modulation of RPA activity. Together, our results strongly suggest a role for DNA-PK in S-phase (replication) arrest in response to UV irradiation.	Indiana Univ, Ctr Canc, Dept Biochem & Mol Biol, Sch Med,Walther Oncol Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Lee, SH (corresponding author), Indiana Univ, Ctr Canc, Dept Biochem & Mol Biol, Sch Med,Walther Oncol Ctr, Indianapolis, IN 46202 USA.	slee@iupui.edu	Yu, Michelle/CAH-1357-2022		NIGMS NIH HHS [GM52358] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052358] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramova NA, 1997, P NATL ACAD SCI USA, V94, P7186, DOI 10.1073/pnas.94.14.7186; BOUBNOV NV, 1995, MOL CELL BIOL, V15, P5700; BRUSH GS, 1994, P NATL ACAD SCI USA, V91, P12520, DOI 10.1073/pnas.91.26.12520; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; Cheng XB, 1996, RADIOTHER ONCOL, V39, P43, DOI 10.1016/0167-8140(96)01712-4; Chibazakura T, 1997, EUR J BIOCHEM, V247, P1166, DOI 10.1111/j.1432-1033.1997.01166.x; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; COLLINS KL, 1993, EMBO J, V12, P4555, DOI 10.1002/j.1460-2075.1993.tb06144.x; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; DORNREITER I, 1990, EMBO J, V9, P3329, DOI 10.1002/j.1460-2075.1990.tb07533.x; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; Drissi R, 1998, BIOCHEM J, V330, P181, DOI 10.1042/bj3300181; DVIR A, 1993, J BIOL CHEM, V268, P10440; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Fried LM, 1996, P NATL ACAD SCI USA, V93, P13825, DOI 10.1073/pnas.93.24.13825; Galloway AM, 1999, ONCOGENE, V18, P1361, DOI 10.1038/sj.onc.1202433; GANNON J V, 1990, New Biologist, V2, P84; Gasior SL, 1998, GENE DEV, V12, P2208, DOI 10.1101/gad.12.14.2208; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; GUZDER SN, 1995, J BIOL CHEM, V270, P12973, DOI 10.1074/jbc.270.22.12973; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Henricksen LA, 1996, NUCLEIC ACIDS RES, V24, P3107, DOI 10.1093/nar/24.15.3107; HEYER WD, 1990, EMBO J, V9, P2321, DOI 10.1002/j.1460-2075.1990.tb07404.x; Jackson SP, 1997, INT J BIOCHEM CELL B, V29, P935, DOI 10.1016/S1357-2725(97)00006-X; Jin SF, 1997, CANCER SURV, V29, P221; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; KUHN A, 1995, GENE DEV, V9, P193, DOI 10.1101/gad.9.2.193; LABHART P, 1995, P NATL ACAD SCI USA, V92, P2934, DOI 10.1073/pnas.92.7.2934; LEE SH, 1995, J BIOL CHEM, V270, P12801, DOI 10.1074/jbc.270.21.12801; LEE SH, 1991, J BIOL CHEM, V266, P22707; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Lin RZ, 1997, J BIOL CHEM, V272, P31196, DOI 10.1074/jbc.272.49.31196; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; Longhese MP, 1996, NUCLEIC ACIDS RES, V24, P3533, DOI 10.1093/nar/24.18.3533; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; McConnell K, 1996, CURR OPIN CELL BIOL, V8, P325, DOI 10.1016/S0955-0674(96)80005-6; MELENDY T, 1993, J BIOL CHEM, V268, P3389; Morgan SE, 1997, CANCER RES, V57, P3386; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; Muller C, 1998, NUCLEIC ACIDS RES, V26, P1382, DOI 10.1093/nar/26.6.1382; Muller C, 1997, ONCOGENE, V15, P2343, DOI 10.1038/sj.onc.1201402; MURAKAMI Y, 1993, J BIOL CHEM, V268, P11008; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; Orren DK, 1997, MOL BIOL CELL, V8, P1129, DOI 10.1091/mbc.8.6.1129; PAN ZQ, 1995, P NATL ACAD SCI USA, V92, P4636, DOI 10.1073/pnas.92.10.4636; PETERSON SR, 1995, J BIOL CHEM, V270, P1449, DOI 10.1074/jbc.270.3.1449; POLTORATSKY VP, 1995, J IMMUNOL, V155, P4529; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; Rotman G, 1997, BIOESSAYS, V19, P911, DOI 10.1002/bies.950191011; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; Shao RG, 1999, EMBO J, V18, P1397, DOI 10.1093/emboj/18.5.1397; Shen HX, 1997, ONCOL RES, V9, P295; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SMALE ST, 1986, MOL CELL BIOL, V6, P4077, DOI 10.1128/MCB.6.11.4077; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STIGGER E, 1994, P NATL ACAD SCI USA, V91, P579, DOI 10.1073/pnas.91.2.579; Stigger E, 1998, J BIOL CHEM, V273, P9337, DOI 10.1074/jbc.273.15.9337; Treuner K, 1999, J BIOL CHEM, V274, P15556, DOI 10.1074/jbc.274.22.15556; Vairapandi M, 1996, ONCOGENE, V12, P2579; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wang Y, 1998, RADIAT RES, V149, P284, DOI 10.2307/3579962; Wang Y, 1999, J BIOL CHEM, V274, P22060, DOI 10.1074/jbc.274.31.22060; Weaver DT, 1997, NATURE, V388, P428, DOI 10.1038/41225; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; Yuan ZM, 1997, J BIOL CHEM, V272, P23485, DOI 10.1074/jbc.272.38.23485	70	52	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32520	32527		10.1074/jbc.274.45.32520	http://dx.doi.org/10.1074/jbc.274.45.32520			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542299	hybrid			2022-12-27	WOS:000083532100107
J	Kim, GD; Choi, YH; Dimtchev, A; Jeong, SJ; Dritschilo, A; Jung, M				Kim, GD; Choi, YH; Dimtchev, A; Jeong, SJ; Dritschilo, A; Jung, M			Sensing of ionizing radiation-induced DNA damage by ATM through interaction with histone deacetylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; REPRESS TRANSCRIPTION; KAPPA-B; CHROMATIN; GENE; ACETYLTRANSFERASE; ACETYLATION; EXPRESSION; COMPLEX	The ATM gene is mutated in individuals with ataxia telangiectasia, a human genetic disease! characterized by extreme sensitivity to radiation. The ATM protein acts as a sensor of radiation-induced cellular damage and contributes to cell cycle regulation, signal transduction, and DNA repair; however, the mechanisms underlying these functions of ATM remain largely unknown. Binding and immunoprecipitation assays have now shown that ATM interacts with the histone deacetylase HDAC1 both in vitro and in vivo, and that the extent of this association is increased after exposure of MRC5CV1 human fibroblasts to ionizing radiation. Histone deacetylase activity was also detected in immunoprecipitates prepared from these cells with antibodies to ATM, and this activity was blocked by the histone deacetylase inhibitor trichostatin A. These results suggest a previously unanticipated role for ATM in the modification of chromatin components in response to ionizing radiation.	Georgetown Univ, Med Ctr, Dept Radiat Med, Div Radiat Res,Vincent T Lombardi Canc Ctr, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Microbiol, Div Radiat Res,Vincent T Lombardi Canc Ctr, Washington, DC 20007 USA	Georgetown University; Georgetown University	Jung, M (corresponding author), Georgetown Univ, Med Ctr, Dept Radiat Med, Div Radiat Res,Vincent T Lombardi Canc Ctr, Res Bldg,Rm E211A,3970 Reservoir Rd NW, Washington, DC 20007 USA.				NCI NIH HHS [P01 CA 74175] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA074175] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Brehm A, 1999, TRENDS BIOCHEM SCI, V24, P142, DOI 10.1016/S0968-0004(99)01368-7; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Carmen AA, 1996, J BIOL CHEM, V271, P15837, DOI 10.1074/jbc.271.26.15837; DePinho RA, 1998, NATURE, V391, P533, DOI 10.1038/35257; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Grant PA, 1998, MOL CELL, V2, P863, DOI 10.1016/S1097-2765(00)80300-7; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Guo CY, 1999, J BIOL CHEM, V274, P18715, DOI 10.1074/jbc.274.26.18715; Jung M, 1997, CANCER RES, V57, P24; Lee SJ, 1998, ONCOGENE, V17, P1821, DOI 10.1038/sj.onc.1202088; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; OLEINICK NL, 1994, INT J RADIAT BIOL, V66, P523, DOI 10.1080/09553009414551561; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Siddique H, 1998, ONCOGENE, V16, P2283, DOI 10.1038/sj.onc.1202003; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Vassilev A, 1998, MOL CELL, V2, P869, DOI 10.1016/S1097-2765(00)80301-9; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983	31	97	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31127	31130		10.1074/jbc.274.44.31127	http://dx.doi.org/10.1074/jbc.274.44.31127			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531300	hybrid			2022-12-27	WOS:000083379400004
J	Krasko, A; Schroder, HC; Perovic, S; Steffen, R; Kruse, M; Reichert, W; Muller, IM; Muller, WEG				Krasko, A; Schroder, HC; Perovic, S; Steffen, R; Kruse, M; Reichert, W; Muller, IM; Muller, WEG			Ethylene modulates gene expression in cells of the marine sponge Suberites domuncula and reduces the degree of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; DISSOLVED ORGANIC-CARBON; GEODIA-CYDONIUM; RESPONSE PATHWAY; BACTERIA; SEQUENCE; ARABIDOPSIS; SEAWATER; MONOXIDE; ORIGIN	Sponges (phylum Porifera) live in an aqueous milieu that contains dissolved organic carbon. This is degraded photochemically by ultraviolet radiation to alkenes, particularly to ethylene. This study demonstrates that sponge cells (here the demosponge Suberites domuncula has been used), which have assembled to primmorphs, react to 5 mu M ethylene with a significant up-regulation of intracellular Ca2+ concentration and with a reduction of starvation-induced apoptosis, In primmorphs from S. domuncula the expression of two genes is up-regulated after exposure to ethylene. The cDNA of the first gene (SDERR) isolated from S. domuncula encodes a potential ethylene-responsive protein, termed ERR_SUBDO; its putative M-r is 32,704. Data bank, search revealed that the sponge polypeptide shares high similarity (82% on amino acid level) with the corresponding plant molecule, the ethylene-inducible protein from Hevea brasiliensis. Until now no other metazoan ethylene-responsive proteins have been identified. The second gene, whose expression is up-regulated in response to ethylene is a Ca2+/calmodulin-dependent protein kinase II. Its cDNA, SDCCdPK; encodes a M-r 54,863 putative kinase that shares 69% similarity with the corresponding enzyme from Drosophila melanogaster. The expression of both genes in primmorphs from S. domuncula is increased by approximate to 5-fold after a 3-day incubation period with ethylene, It is concluded that also metazoan cells, with sponge cells as at model, may react to ethylene with an activation of cell metabolism including gene induction.	Johannes Gutenberg Univ Mainz, Inst Physiol Chem, Angew Mol Biol Abt, D-55099 Mainz, Germany	Johannes Gutenberg University of Mainz	Muller, WEG (corresponding author), Johannes Gutenberg Univ Mainz, Inst Physiol Chem, Angew Mol Biol Abt, Duesbergweg 6, D-55099 Mainz, Germany.	WMUELLER@mail.UNI-Mainz.DE	Müller, W. E. G./AAR-8651-2020	Müller, W. E. G./0000-0002-8223-3689; Schroder, Heinz C./0000-0003-0992-6427				Abeles F, 1992, ETHYLENE PLANT BIOL; Althoff K, 1998, MAR BIOL, V130, P529, DOI 10.1007/s002270050273; Atkinson RG, 1998, PLANT MOL BIOL, V38, P449, DOI 10.1023/A:1006065926397; BERKNER LV, 1964, FARADAY SOC DISC P, V37, P122; Blumbach B, 1999, IMMUNOGENETICS, V49, P751, DOI 10.1007/s002510050549; CALMAN BG, 1999, IN PRESS J PHOTOCHEM; Canfield DE, 1996, NATURE, V382, P127, DOI 10.1038/382127a0; CHO KO, 1991, NEURON, V7, P439, DOI 10.1016/0896-6273(91)90296-C; Crossman LC, 1997, MICROBIOL-SGM, V143, P3775, DOI 10.1099/00221287-143-12-3775; Custodio MR, 1998, MECH AGEING DEV, V105, P45, DOI 10.1016/S0047-6374(98)00078-5; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; Dayhoff M, 1978, ATLAS PROTEIN SEQ ST, P345; FELSENSTEIN J, 1993, PHYLIP VERSION 35; FEREK RJ, 1984, NATURE, V307, P148, DOI 10.1038/307148a0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HARDIE G, 1995, PROTEIN KINASE FACT; Hata Y, 1996, J NEUROSCI, V16, P2488; HIDAKA H, 1996, INTRACELLULAR SIGNAL, P193; Hoch B, 1999, CIRC RES, V84, P713, DOI 10.1161/01.RES.84.6.713; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; Kieber JJ, 1997, ANNU REV PLANT PHYS, V48, P277, DOI 10.1146/annurev.arplant.48.1.277; KREBS J, 1991, ENCY HUMAN BIOL, V2, P89; Kruse M, 1997, MOL BIOL EVOL, V14, P1326, DOI 10.1093/oxfordjournals.molbev.a025742; Kurelec B., 1977, Rapports et Proces-Verbaux des Reunions Commission Internationale pour l'Exploration Scientifique de la Mer Mediterranee Monaco, V24, P67; Li CW, 1998, SCIENCE, V279, P879, DOI 10.1126/science.279.5352.879; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; Moore DD, 1995, GLOB MOB SURV; Muller WEG, 1999, MAR ECOL PROG SER, V178, P205, DOI 10.3354/meps178205; Muller WEG, 1997, CELL TISSUE RES, V289, P383, DOI 10.1007/s004410050885; Muller WEG, 1998, NATURWISSENSCHAFTEN, V85, P11, DOI 10.1007/s001140050444; MULLER WEG, 1995, NATURWISSENSCHAFTEN, V82, P321; MULLER WEG, 1986, PROG MOL SUBCELL BIO, V17, P183; MULLER WEG, 1999, IN PRESS TRANSPLANTA; Nicholas KB., 1997, GENEDOC TOOL EDITING; Pahler S, 1998, J EXP ZOOL, V282, P332, DOI 10.1002/(SICI)1097-010X(19981015)282:3<332::AID-JEZ6>3.3.CO;2-6; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; *PC GENE, 1995, DAT BANKS CD ROM; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Perovic S, 1999, CELL TISSUE RES, V296, P395, DOI 10.1007/s004410051299; Ratte M, 1998, J GEOPHYS RES-ATMOS, V103, P5707, DOI 10.1029/97JD03473; RICHMAN S, 1975, LIMNOL OCEANOGR, V20, P918, DOI 10.4319/lo.1975.20.6.0918; ROTTMANN M, 1987, EMBO J, V6, P3939, DOI 10.1002/j.1460-2075.1987.tb02735.x; RYDEN TA, 1989, MOL CELL BIOL, V9, P1155, DOI 10.1128/MCB.9.3.1155; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; Simpson T., 1984, CELL BIOL SPONGES; SIVASUBRAMANIAM S, 1995, PLANT MOL BIOL, V29, P173, DOI 10.1007/BF00019129; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; STANLEY PE, 1990, BIOLUMINESCENCE CHEM; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOWE KM, 1994, EARLY LIFE EARTH, P36; VOGEL S, 1977, P NATL ACAD SCI USA, V74, P2069, DOI 10.1073/pnas.74.5.2069; Wagner C, 1998, MAR BIOL, V131, P411, DOI 10.1007/s002270050334; Wiens M, 1998, MAR ECOL PROG SER, V165, P247, DOI 10.3354/meps165247; WILSON DF, 1970, SCIENCE, V168, P1577, DOI 10.1126/science.168.3939.1577; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Wimmer W, 1999, EUR J BIOCHEM, V260, P156, DOI 10.1046/j.1432-1327.1999.00146.x; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; ZUO YG, 1995, NATURWISSENSCHAFTEN, V82, P472, DOI 10.1007/s001140050217	59	32	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31524	31530		10.1074/jbc.274.44.31524	http://dx.doi.org/10.1074/jbc.274.44.31524			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531355	hybrid			2022-12-27	WOS:000083379400059
J	Reddy, VS; Safadi, F; Zielinski, RE; Reddy, ASN				Reddy, VS; Safadi, F; Zielinski, RE; Reddy, ASN			Interaction of a kinesin-like protein with calmodulin isoforms from Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; DEPENDENT ENZYMES; YEAST CALMODULIN; TARGET ENZYMES; GENE FAMILY; NAD KINASE; SEQUENCE; EXPRESSION; CDNA; ACTIVATION	In Arabidopsis and other plants there are multiple calmodulin isoforms. However, the role of these isoforms in regulating the activity of target proteins is obscure. Here, we analyzed the interaction between a kinesin-like calmodulin-binding motor protein (Reddy, A. S. N., Safadi, F., Narasimhulu, S. B., Golovkin, M., and Hu, X. (1996) J. Biol. Chem. 271, 7052-7060) and three calmodulin isoforms (calmodulin-2, -4, and -6) from Arabidopsis using different approaches. Gel mobility and fluorescence shift assays revealed that the motor binds to all calmodulin isoforms in a calcium-dependent manner. Furthermore, all calmodulin isoforms were able to activate bovine calcium/calmodulin-dependent phosphodiesterase. However, the concentration of calmodulin-2 required for half-maximal activation of phosphodiesterase is 2- and 6-fold lower compared with calmodulin-4 and -6, respectively. The dissociation constants of the motor to calmodulin-2, -4, and -6 are 12.8, 27.0, and 27.8 nM, respectively, indicating that calmodulin-2 has 8-fold higher affinity for the motor than calmodulin-l and -6. Similar results were obtained using another assay that involves the binding of S-35-labeled calmodulin isoforms to the motor. The binding saturation curves of the motor with calmodulin isoforms have confirmed that calmodulin-a has S-fold higher affinity to the motor. However, the affinity of calmodulin-4 and -6 isoforms for the motor was about the same. Based on these studies, we conclude that all calmodulin isoforms bind to the motor protein but with different affinities.	Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA; Colorado State Univ, Program Mol & Cell Biol, Ft Collins, CO 80523 USA; Univ Illinois, Dept Plant Biol, Urbana, IL 61801 USA; Univ Illinois, Physiol & Mol Plant Biol Program, Urbana, IL 61801 USA	Colorado State University; Colorado State University; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Reddy, ASN (corresponding author), Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA.		Safadi, Fayez/AAU-8699-2021	Reddy, Anireddy/0000-0002-4038-4091; Zielinski, Ray/0000-0003-0324-7407				Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; BARNETT MJ, 1990, NUCLEIC ACIDS RES, V18, P3395, DOI 10.1093/nar/18.11.3395; BARTLING D, 1993, PLANT PHYSIOL, V102, P1059, DOI 10.1104/pp.102.3.1059; BOUDREAU RJ, 1975, ANAL BIOCHEM, V63, P388, DOI 10.1016/0003-2697(75)90361-9; BRAAM J, 1997, PLANTA, V203, P35; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cho MJ, 1998, BIOCHEMISTRY-US, V37, P15593, DOI 10.1021/bi981497g; COX JA, 1985, J BIOL CHEM, V260, P2527; DAVIS TN, 1989, P NATL ACAD SCI USA, V86, P7909, DOI 10.1073/pnas.86.20.7909; Deavours BE, 1998, CELL MOTIL CYTOSKEL, V40, P408, DOI 10.1002/(SICI)1097-0169(1998)40:4<408::AID-CM8>3.0.CO;2-6; EDMAN CF, 1994, EUR J BIOCHEM, V226, P725, DOI 10.1111/j.1432-1033.1994.tb20101.x; ERICKSONVIITANEN S, 1987, METHOD ENZYMOL, V139, P455; FISCHER R, 1988, J BIOL CHEM, V263, P17055; Fromm H, 1992, PLANT MOL BIOL REP, V10, P199, DOI 10.1007/BF02668347; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Harding SA, 1997, EMBO J, V16, P1137, DOI 10.1093/emboj/16.6.1137; Heiman RG, 1996, P NATL ACAD SCI USA, V93, P2420, DOI 10.1073/pnas.93.6.2420; Heo WD, 1999, P NATL ACAD SCI USA, V96, P766, DOI 10.1073/pnas.96.2.766; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee SH, 1997, J BIOL CHEM, V272, P9252, DOI 10.1074/jbc.272.14.9252; LEE SH, 1995, J BIOL CHEM, V270, P21806, DOI 10.1074/jbc.270.37.21806; Liao BR, 1996, ARCH BIOCHEM BIOPHYS, V327, P53, DOI 10.1006/abbi.1996.0092; LING V, 1993, PLANT MOL BIOL, V22, P207, DOI 10.1007/BF00014929; LING V, 1989, PLANT PHYSIOL, V90, P714, DOI 10.1104/pp.90.2.714; Liu ZH, 1998, PLANT MOL BIOL, V38, P889, DOI 10.1023/A:1006019001200; Nakashima K, 1996, BIOCHEMISTRY-US, V35, P5602, DOI 10.1021/bi952586l; Narasimhulu SB, 1998, PLANT CELL, V10, P957, DOI 10.1105/tpc.10.6.957; OHYA Y, 1994, SCIENCE, V263, P963, DOI 10.1126/science.8310294; PATIL S, 1995, P NATL ACAD SCI USA, V92, P4897, DOI 10.1073/pnas.92.11.4897; POOVAIAH BW, 1993, CRIT REV PLANT SCI, V12, P185, DOI 10.1080/713608046; PUTKEY JA, 1986, J BIOL CHEM, V261, P9896; Reddy ASN, 1996, J BIOL CHEM, V271, P7052, DOI 10.1074/jbc.271.12.7052; ROBERTS DM, 1992, ANNU REV PLANT PHYS, V43, P375, DOI 10.1146/annurev.pp.43.060192.002111; SISTRUNK ML, 1994, PLANT CELL, V6, P1553, DOI 10.1105/tpc.6.11.1553; Snedden WA, 1998, TRENDS PLANT SCI, V3, P299, DOI 10.1016/S1360-1385(98)01284-9; Song H, 1997, P NATL ACAD SCI USA, V94, P322, DOI 10.1073/pnas.94.1.322; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAKEZAWA D, 1995, PLANT MOL BIOL, V27, P693, DOI 10.1007/BF00020223; Trewavas AJ, 1997, PLANT CELL, V9, P1181, DOI 10.1105/tpc.9.7.1181; Tsien RY, 1998, SCIENCE, V280, P1954, DOI 10.1126/science.280.5371.1954; WATILLON B, 1992, PLANT SCI, V82, P201, DOI 10.1016/0168-9452(92)90221-7; Yang TB, 1996, MOL GEN GENET, V252, P684, DOI 10.1007/BF02173974; Zielinski RE, 1998, ANNU REV PLANT PHYS, V49, P697, DOI 10.1146/annurev.arplant.49.1.697; ZIMMER WE, 1988, J BIOL CHEM, V263, P19370	44	45	54	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31727	31733		10.1074/jbc.274.44.31727	http://dx.doi.org/10.1074/jbc.274.44.31727			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531384	hybrid			2022-12-27	WOS:000083379400088
J	Xu, N; Dahlback, B				Xu, N; Dahlback, B			A novel human apolipoprotein (apoM)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-LIPOPROTEINS; PROTEIN; SEQUENCE; BINDING; IDENTIFICATION; PREDICTION; MEMBRANES; DATABASE; PEPTIDES	A novel human apolipoprotein designated apolipoprotein IM (apoM) is described. The unique N-terminal amino acid sequence of apoM was found in an approximately 26-kDa protein present in a protein extract of triglyceride-rich lipoproteins (TGRLP). The isolated apoM cDNA (734 base pairs) encoded a 188-amino acid residue-long protein, distantly related to the lipocalin family. The mRNA of apoM was detected in the liver and kidney. Western blotting demonstrated apoM to be present in high density lipoprotein (HDL) and to a lesser extent in TGRLP and low density lipoproteins (LDL). The first 20 amino acid residues of apoM constituted a hydrophobic segment with characteristic features of a signal peptide. This was retained in the mature protein because of the lack of a signal peptidase cleavage site, In vitro translation in the presence of microsomes demonstrated translocation of apoM over the membrane and glycosylation but no signal peptide cleavage. The in vitro translated product remained associated with the microsomes after treatment with carbonate at pH 11, demonstrating that apoM is an integral protein. This finding suggests that apoM is linked to the single phospholipid layer of lipoproteins with a hydrophobic signal anchor. In conclusion, a novel human apolipoprotein, the function of which remains to be determined, is described.	Univ Lund Hosp, Dept Clin Chem, S-20502 Malmo, Sweden	Lund University; Skane University Hospital	Dahlback, B (corresponding author), Univ Lund Hosp, Dept Clin Chem, S-20502 Malmo, Sweden.			Dahlback, Bjorn/0000-0003-1546-0328				Alaupovic P, 1996, METHOD ENZYMOL, V263, P32; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BLATTER MC, 1990, BIOCHIM BIOPHYS ACTA, V1042, P19, DOI 10.1016/0005-2760(90)90051-X; BOCSKEI Z, 1992, NATURE, V360, P186, DOI 10.1038/360186a0; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; Duchateau PN, 1997, J BIOL CHEM, V272, P25576, DOI 10.1074/jbc.272.41.25576; Fischer D, 1996, PROTEIN SCI, V5, P947; Flower DR, 1996, BIOCHEM J, V318, P1; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; HILLARP A, 1987, J BIOL CHEM, V262, P11300; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACKIN WM, 1983, ANAL BIOCHEM, V131, P430, DOI 10.1016/0003-2697(83)90195-1; Martoglio B, 1998, TRENDS CELL BIOL, V8, P410, DOI 10.1016/S0962-8924(98)01360-9; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Nielsen H, 1999, PROTEIN ENG, V12, P3, DOI 10.1093/protein/12.1.3; OSBORNE JC, 1986, METHOD ENZYMOL, V128, P213; Patsch W, 1996, METHOD ENZYMOL, V263, P3; SCHUMAKER VN, 1986, METHOD ENZYMOL, V128, P155; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wang XX, 1999, J BIOL CHEM, V274, P1814, DOI 10.1074/jbc.274.3.1814; WEECH PK, 1991, PROG LIPID RES, V30, P259, DOI 10.1016/0163-7827(91)90023-X; WYCKOFF M, 1977, ANAL BIOCHEM, V78, P459, DOI 10.1016/0003-2697(77)90107-5; Xu N, 1998, ARTERIOSCL THROM VAS, V18, P33, DOI 10.1161/01.ATV.18.1.33	26	260	314	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31286	31290		10.1074/jbc.274.44.31286	http://dx.doi.org/10.1074/jbc.274.44.31286			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531326	hybrid			2022-12-27	WOS:000083379400030
J	Dorstyn, L; Read, SH; Quinn, LM; Richardson, H; Kumar, S				Dorstyn, L; Read, SH; Quinn, LM; Richardson, H; Kumar, S			DECAY, a novel Drosophila caspase related to mammalian caspase-3 and caspase-7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; APOPTOSIS; PROTEASES; IDENTIFICATION; ACTIVATION; EXPRESSION; PRECURSOR; PRODOMAIN; EFFECTOR; ELEGANS	Caspases are key effecters of programmed cell death in metazoans. In Drosophila, four caspases have been described so far. Here we describe the identification and characterization of the fifth Drosophila caspase, DECAY. DECAY shares a high degree of homology with the members of the mammalian caspase-3 subfamily, particularly caspase-3 and caspase-7, DECAY lacks a long prodomain and thus appears to be a class II effector caspase;Ectopic expression of DECAY in cultured cells induces apoptosis. Recombinant DECAY exhibited substrate specificity similar to the mammalian caspase-3 subfamily. Low levels of decay mRNA are ubiquitously expressed in Drosophila embryos during early stages of development but its expression becomes somewhat spatially restricted in some tissues. During oogenesis decay mRNA was detected in egg chambers of all stages consistent with a rob for DECAY in apoptosis of nurse cells, Relatively high levels of decay mRNA are expressed in larval salivary glands and midgut, two tissues which undergo histolysis during larval/pupal metamorphosis, suggesting that DECAY may play a role in developmentally programmed cell death in Drosophila.	Inst Med & Vet Sci, Hanson Ctr Canc Res, Adelaide, SA 5000, Australia; Univ Adelaide, Dept Genet, Adelaide, SA 5001, Australia; Univ Adelaide, Dept Med, Adelaide, SA 5001, Australia	Institute Medical & Veterinary Science Australia; University of Adelaide; University of Adelaide	Kumar, S (corresponding author), Inst Med & Vet Sci, Hanson Ctr Canc Res, POB 14,Rundle Mall,Frome Rd, Adelaide, SA 5000, Australia.	sharad.kumar@imvs.sa.gov.au	Dorstyn, Loretta/F-3673-2013; Kumar, Sharad/AAX-7787-2020; Richardson, Helena E/A-8080-2013	Dorstyn, Loretta/0000-0001-9886-0989; Kumar, Sharad/0000-0001-7126-9814; Richardson, Helena E/0000-0003-3852-4953; Quinn, Leonie/0000-0002-3911-6508				ABRAMS JM, 1993, DEVELOPMENT, V117, P29; Butt AJ, 1998, J BIOL CHEM, V273, P6763, DOI 10.1074/jbc.273.12.6763; Chen P, 1998, DEV BIOL, V201, P202, DOI 10.1006/dbio.1998.9000; Colussi PA, 1998, J BIOL CHEM, V273, P26566, DOI 10.1074/jbc.273.41.26566; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Dorstyn L, 1999, P NATL ACAD SCI USA, V96, P4307, DOI 10.1073/pnas.96.8.4307; Dorstyn L, 1997, CELL DEATH DIFFER, V4, P570, DOI 10.1038/sj.cdd.4400281; EDGAR BA, 1986, CELL, V44, P871, DOI 10.1016/0092-8674(86)90009-7; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; Foley K, 1998, DEVELOPMENT, V125, P1075; Fraser AG, 1997, EMBO J, V16, P6192, DOI 10.1093/emboj/16.20.6192; Fraser AG, 1997, EMBO J, V16, P2805, DOI 10.1093/emboj/16.10.2805; Harvey NL, 1997, J BIOL CHEM, V272, P13134, DOI 10.1074/jbc.272.20.13134; Harvey NL, 1996, GENES CELLS, V1, P673, DOI 10.1046/j.1365-2443.1996.00255.x; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Jiang CG, 1997, DEVELOPMENT, V124, P4673; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Kumar S, 1996, CELL DEATH DIFFER, V3, P255; Kumar S, 1999, CLIN EXP PHARMACOL P, V26, P295, DOI 10.1046/j.1440-1681.1999.03031.x; Kumar S, 1997, CELL DEATH DIFFER, V4, P378, DOI 10.1038/sj.cdd.4400251; Kumar S, 1999, TRENDS BIOCHEM SCI, V24, P1, DOI 10.1016/S0968-0004(98)01332-2; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; McCall K, 1998, SCIENCE, V279, P230, DOI 10.1126/science.279.5348.230; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Rathmell JC, 1999, ANNU REV IMMUNOL, V17, P781, DOI 10.1146/annurev.immunol.17.1.781; Shaham S, 1998, J BIOL CHEM, V273, P35109, DOI 10.1074/jbc.273.52.35109; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Song ZW, 1997, SCIENCE, V275, P536, DOI 10.1126/science.275.5299.536; Talanian RV, 1997, J BIOL CHEM, V272, P9677; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; WOLFF T, 1991, DEVELOPMENT, V113, P825	34	101	105	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30778	30783		10.1074/jbc.274.43.30778	http://dx.doi.org/10.1074/jbc.274.43.30778			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521468	hybrid			2022-12-27	WOS:000083276700064
J	Kawabe, H; Hata, Y; Takeuchi, M; Ide, N; Mizoguchi, A; Takai, Y				Kawabe, H; Hata, Y; Takeuchi, M; Ide, N; Mizoguchi, A; Takai, Y			nArgBP2, a novel neural member of ponsin/ArgBP2/vinexin family that interacts with synapse-associated protein 90/postsynaptic density-95-associated protein (SAPAP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTSYNAPTIC DENSITY; TRANSFORMED CELLS; DOMAIN; DISKS; SRC; ABL	Postsynaptic density (PSD)-95/synapse-associated protein (SAP) 90 and synaptic scaffolding molecule (S-SCAM) are synaptic membrane-associated guanylate kinases. Both the proteins interact with SAP90/PSD-95-associated protein (SAPAP) (also called guanylate kinase-associated protein/Dlg-associated protein). SAPAP is a protein highly enriched in the PSD fraction and may link PSD-95/SAP90 and S-SCAM to Triton X-100-insoluble structures. We found here a novel SAPAP-interacting protein, which was specifically expressed in neural tissue and was present in the postsynaptic density fraction in brain. This protein had a sorbin homology domain in the N terminus, a zinc finger motif in the middle region, and three src homology (SB) 3 domains in the C terminus and was homologous to the ponsin/ArgBP2/vinexin family proteins, We named this protein nArgBP2 because it was the most homologous to ArgBP2. nArgBP2 is a neural member of a growing family of SH3-containing proteins. nArgBP2 bound to the proline-rich region of SAPAP via its third SH3 domain and tvas coimmunoprecipitated with SAPAP from the extract of rat brain. Furthermore, nArgBP2 was colocalized with SAPAP at synapses in cerebellum. nArgBP2 bound to not only SAPAP but also vinculin and l-afadin, known to bind to ponsin and vinexin. nArgBP2 may be implicated in the protein network around SAPAP in the PSD.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan; JCR Pharmaceut Co Ltd, Japan Sci & Technol Corp, ERATO, Takai Biotimer Project, Kobe, Hyogo 6512241, Japan; Tokyo Med & Dent Univ, Dept Med Biochem, Bunkyo Ku, Tokyo 1138519, Japan; Kyoto Univ, Grad Sch, Dept Anat & Neurobiol, Kyoto 6068315, Japan	Osaka University; Japan Science & Technology Agency (JST); Tokyo Medical & Dental University (TMDU); Kyoto University	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan.		Kawabe, Hiroshi/U-7325-2018	Kawabe, Hiroshi/0000-0001-5650-8696				CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Deguchi M, 1998, J BIOL CHEM, V273, P26269, DOI 10.1074/jbc.273.41.26269; GEIGER B, 1990, CELL DIFFER DEV, V32, P343, DOI 10.1016/0922-3371(90)90049-3; Hirao K, 1998, J BIOL CHEM, V273, P21105, DOI 10.1074/jbc.273.33.21105; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kioka N, 1999, J CELL BIOL, V144, P59, DOI 10.1083/jcb.144.1.59; KISTNER U, 1993, J BIOL CHEM, V268, P4580; Mandai K, 1999, J CELL BIOL, V144, P1001, DOI 10.1083/jcb.144.5.1001; Ribon V, 1998, MOL CELL BIOL, V18, P872, DOI 10.1128/MCB.18.2.872; Satoh K, 1997, GENES CELLS, V2, P415, DOI 10.1046/j.1365-2443.1997.1310329.x; Sattler M, 1998, LEUKEMIA, V12, P637, DOI 10.1038/sj.leu.2401010; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; Wang BL, 1997, J BIOL CHEM, V272, P17542, DOI 10.1074/jbc.272.28.17542; Yao I, 1999, J BIOL CHEM, V274, P27463, DOI 10.1074/jbc.274.39.27463; Yao I, 1999, J BIOL CHEM, V274, P11889, DOI 10.1074/jbc.274.17.11889	19	69	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30914	30918		10.1074/jbc.274.43.30914	http://dx.doi.org/10.1074/jbc.274.43.30914			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521485	hybrid			2022-12-27	WOS:000083276700081
J	Scheid, MP; Schubert, KM; Duronio, V				Scheid, MP; Schubert, KM; Duronio, V			Regulation of bad phosphorylation and association with Bcl-x(L) by the MAPK/Erk kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NERVE GROWTH-FACTOR; GLYCOGEN-SYNTHASE KINASE-3; MAP KINASE; CELL-DEATH; GENE-EXPRESSION; CYCLIC-AMP; SURVIVAL; AKT; INHIBITOR	Phosphorylation of the Bcl-2 family protein Bad may represent an important bridge between survival signaling by growth factor receptors and the prevention of apoptosis. Bead phosphorylation was examined following cytokine stimulation, which revealed phosphorylation on a critical residue, serine 112, in a MEK-dependent manner. Furthermore, Bad phosphorylation also increased on several sites distinct from serine 112 but could not be detected on serine 136, previously thought to be a protein kinase B/Akt-targeted residue. Serine 112 phosphorylation was shown to be absolutely required for dissociation of Bad from Bcl-x(L). These results demonstrate for the first time in mammalian cells the involvement of the Ras-MAPK pathway in the phosphorylation of Bad and the regulation of its function.	Univ British Columbia, Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada	University of British Columbia	Duronio, V (corresponding author), Univ British Columbia, Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada.	vduronio@vanhosp.bc.ca						Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Andjelkovic M, 1999, MOL CELL BIOL, V19, P5061; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; Coffer PJ, 1998, BIOCHEM J, V335, P1; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; delPeso L, 1997, SCIENCE, V278, P687; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; Hinton HJ, 1999, J IMMUNOL, V162, P7002; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kelekar A, 1997, MOL CELL BIOL, V17, P7040, DOI 10.1128/MCB.17.12.7040; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Parrizas M, 1997, J BIOL CHEM, V272, P154; Peli J, 1999, EMBO J, V18, P1824, DOI 10.1093/emboj/18.7.1824; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Scheid MP, 1999, BLOOD, V93, P217, DOI 10.1182/blood.V93.1.217.401k16_217_225; Scheid MP, 1996, J BIOL CHEM, V271, P18134, DOI 10.1074/jbc.271.30.18134; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; SCHEID MP, 1995, BIOCHEM J, V312, P159, DOI 10.1042/bj3120159; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Sutor SL, 1999, J BIOL CHEM, V274, P7002, DOI 10.1074/jbc.274.11.7002; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Weissinger EM, 1997, MOL CELL BIOL, V17, P3229, DOI 10.1128/MCB.17.6.3229; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yao H, 1998, J BIOL CHEM, V273, P8240, DOI 10.1074/jbc.273.14.8240; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	51	345	351	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					31108	31113		10.1074/jbc.274.43.31108	http://dx.doi.org/10.1074/jbc.274.43.31108			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521512	hybrid			2022-12-27	WOS:000083276700108
J	Brattsand, M; Egelrud, T				Brattsand, M; Egelrud, T			Purification, molecular cloning, and expression of a human stratum corneum trypsin-like serine protease with possible function in desquamation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHYMOTRYPTIC ENZYME; ENDOGENOUS PROTEOLYSIS; DESMOGLEIN-I; PROTEINASE; SKIN; INVOLVEMENT; KERATINIZATION; DEPENDENCE; EPIDERMIS; FOLLICLES	A new human 33-kDa serine protease was purified from human epidermis, and its cDNA was domed from a keratinocyte library, from mRNA from a human keratinocyte line (HaCat) and from mRNA from human skin. Polyclonal antibodies specific for the new protein detected three groups of proteins in partially purified extracts of cornified eptihelium of human plantar skin. The three components are proposed to correspond to proenzyme, active enzyme, and proteolytically modified active enzyme. After N-deglycosylation, there was a decrease in apparent molecular mass of all detected components. Expression of the cloned cDNA in a eukaryotic virus-derived system yielded a recombinant protein that could be converted to an active protease by treatment with trypsin. Polymerase chain reaction analyses of cDNA from a number of human tissues showed high expression of the new enzyme in the skin and low expression in brain, placenta, and kidney. Homology searches yielded the highest score for porcine enamel matrix protease (55% amino acid sequence homology). High scores were also obtained for human and mouse neuropsin and for human stratum corneum chymotryptic enzyme. The function of this new protease, tentatively named stratum corneum tryptic enzyme, may be related to stratum corneum turnover and desquamation in the epidermis.	Univ Umea Hosp, Dept Publ Hlth & Clin Med, SE-90185 Umea, Sweden	Umea University	Egelrud, T (corresponding author), Univ Umea Hosp, Dept Publ Hlth & Clin Med, SE-90185 Umea, Sweden.		Brattsand, Maria/AAG-7777-2019	Brattsand, Maria/0000-0001-7175-1336				AUSUBEL FA, 1995, CURRENT PROTOCOLS MO, V2; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CHAPMAN SJ, 1990, ARCH DERMATOL RES, V282, P304, DOI 10.1007/BF00375724; EGELRUD T, 1993, J INVEST DERMATOL, V101, P200, DOI 10.1111/1523-1747.ep12363804; EGELRUD T, 1991, ARCH DERMATOL RES, V283, P108, DOI 10.1007/BF00371618; EGELRUD T, 1990, J INVEST DERMATOL, V95, P456, DOI 10.1111/1523-1747.ep12555620; EGELRUD T, 1989, ACTA DERM-VENEREOL, V69, P470; Ekholm E, 1998, ACTA DERM-VENEREOL, V78, P343; Ekholm E, 1998, BRIT J DERMATOL, V139, P585; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HANSSON L, 1994, J BIOL CHEM, V269, P19420; HORIE N, 1984, COMP BIOCHEM PHYS B, V77, P349, DOI 10.1016/0305-0491(84)90342-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUNDSTROM A, 1991, ACTA DERM-VENEREOL, V71, P471; LUNDSTROM A, 1988, J INVEST DERMATOL, V91, P340, DOI 10.1111/1523-1747.ep12475679; LUNDSTROM A, 1990, J INVEST DERMATOL, V94, P216, DOI 10.1111/1523-1747.ep12874531; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Polg?r L., 1987, NEW COMPREHENSIVE BI, V16, P159; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P19; Sambrook J., 2002, MOL CLONING LAB MANU; SKYTT A, 1995, BIOCHEM BIOPH RES CO, V211, P586, DOI 10.1006/bbrc.1995.1853; SONDELL B, 1995, J INVEST DERMATOL, V104, P819, DOI 10.1111/1523-1747.ep12607007; SONDELL B, 1994, J HISTOCHEM CYTOCHEM, V42, P459, DOI 10.1177/42.4.7510318; Sondell B, 1996, ACTA DERM-VENEREOL, V76, P177; SUZUKI Y, 1993, ARCH DERMATOL RES, V285, P372, DOI 10.1007/BF00371839; SUZUKI Y, 1994, ARCH DERMATOL RES, V286, P249, DOI 10.1007/BF00387596; Suzuki Y, 1996, BRIT J DERMATOL, V134, P460, DOI 10.1046/j.1365-2133.1996.31794.x	27	175	183	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30033	30040		10.1074/jbc.274.42.30033	http://dx.doi.org/10.1074/jbc.274.42.30033			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514489	hybrid			2022-12-27	WOS:000083176400068
J	Gallis, B; Corthals, GL; Goodlett, DR; Ueba, H; Kim, F; Presnell, SR; Figeys, D; Harrison, DG; Berk, BC; Aebersold, R; Corson, MA				Gallis, B; Corthals, GL; Goodlett, DR; Ueba, H; Kim, F; Presnell, SR; Figeys, D; Harrison, DG; Berk, BC; Aebersold, R; Corson, MA			Identification of flow-dependent endothelial nitric-oxide synthase phosphorylation sites by mass spectrometry and regulation of phosphorylation and nitric oxide production by the phosphatidylinositol 3-kinase inhibitor LY294002	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE PHOSPHORYLATION; MOLECULAR-CLONING; ELECTROSPRAY-IONIZATION; POLYACRYLAMIDE GELS; ESCHERICHIA-COLI; BINDING DOMAIN; KINASE-II; T-CELLS; CAVEOLIN; EXPRESSION	Endothelial cells release nitric oxide (NO) acutely in response to increased laminar fluid shear stress, and the increase is correlated with enhanced phosphorylation of endothelial nitric-oxide synthase (eNOS). Phosphoamino acid analysis of eNOS from bovine aortic endothelial cells labeled with [P-32]orthophosphate demonstrated that only phosphoserine was present in eNOS under both static and flow conditions. Fluid shear stress induced phosphate incorporation into two specific eNOS tryptic peptides as early as 30 s after initiation of flow. The flow-induced tryptic phosphopeptides were enriched, separated by capillary electrophoresis with intermittent voltage drops, also known as 'peak parking," and analyzed by collision-induced dissociation in a tandem mass spectrometer. Two phosphopeptide sequences determined by tandem mass spectrometry, TQpSFSLQER and KLQTRPpSPGPPPAEQLLSQAR, were confirmed as the two flow-dependent phosphopeptides by co-migration with synthetic phosphopeptides. Because the sequence (RIR)TQpSFSLQER contains a consensus substrate site for protein kinase B (PKB or Akt), we demonstrated that LY294002, an inhibitor of the upstream activator of PKB, phosphatidylinositol 3-kinase, inhibited flow-induced eNOS phosphorylation by 97% and NO production by 68%. Finally, PKB phosphorylated eNOS in vitro at the same site phosphorylated in the cell and increased eNOS enzymatic activity by 15-20-fold.	Univ Washington, Div Cardiol, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA; Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA; Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Emory University; University System of Georgia; Georgia Institute of Technology	Gallis, B (corresponding author), Univ Washington, Div Cardiol, Dept Med, Box 359748, Seattle, WA 98195 USA.	bgallis@u.washington.edu	Corthals, Garry/G-9417-2016	Corthals, Garry/0000-0001-9423-5596; Berk, Bradford/0000-0002-2767-4115; Figeys, Daniel/0000-0002-5373-7546	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039006, R01HL030946] Funding Source: NIH RePORTER; NHLBI NIH HHS [1RO1HL58000, 1RO1HL39006, 1RO1HL30946] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACRES RB, 1986, J BIOL CHEM, V261, P6210; AFFOLTER M, 1994, ANAL BIOCHEM, V223, P74, DOI 10.1006/abio.1994.1549; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Corson MA, 1996, CIRC RES, V79, P984, DOI 10.1161/01.RES.79.5.984; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Davis MT, 1998, J AM SOC MASS SPECTR, V9, P194, DOI 10.1016/S1044-0305(97)00282-1; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; Figeys D, 1996, ANAL CHEM, V68, P1822, DOI 10.1021/ac960191h; Figeys D, 1996, NAT BIOTECHNOL, V14, P1579, DOI 10.1038/nbt1196-1579; Figeys D, 1999, ANAL CHEM, V71, P2279, DOI 10.1021/ac9813991; FLETCHER MC, 1993, J BIOL CHEM, V268, P23697; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GEIGER RV, 1992, AM J PHYSIOL, V262, pC1411, DOI 10.1152/ajpcell.1992.262.6.C1411; Go YM, 1998, AM J PHYSIOL-HEART C, V275, pH1898, DOI 10.1152/ajpheart.1998.275.5.H1898; Gygi SP, 1999, ELECTROPHORESIS, V20, P310, DOI 10.1002/(SICI)1522-2683(19990201)20:2<310::AID-ELPS310>3.0.CO;2-M; Hidaka H, 1996, Adv Pharmacol, V36, P193, DOI 10.1016/S1054-3589(08)60583-9; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; IGNARRO LJ, 1989, CIRC RES, V65, P1, DOI 10.1161/01.RES.65.1.1; JAMES NL, 1995, FASEB J, V9, P968, DOI 10.1096/fasebj.9.10.7615166; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; Kumar VB, 1999, ANAL BIOCHEM, V269, P17, DOI 10.1006/abio.1999.4013; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; Liu JW, 1996, BIOCHEMISTRY-US, V35, P13277, DOI 10.1021/bi961720e; LOO JA, 1993, ANAL CHEM, V65, P425, DOI 10.1021/ac00052a020; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; Michel JB, 1997, J BIOL CHEM, V272, P25907, DOI 10.1074/jbc.272.41.25907; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; Moritz RL, 1996, ELECTROPHORESIS, V17, P907, DOI 10.1002/elps.1150170512; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PELTZ GA, 1987, ANAL BIOCHEM, V167, P239, DOI 10.1016/0003-2697(87)90159-X; RADOMSKI MW, 1993, CARDIOVASC RES, V27, P1380, DOI 10.1093/cvr/27.7.1380; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; RodriguezCrespo I, 1996, J BIOL CHEM, V271, P11462, DOI 10.1074/jbc.271.19.11462; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; TRAUB O, 1999, MECH FORCES ENDOTHEL; VANDERGEER P, 1994, ELECTROPHORESIS, V15, P544, DOI 10.1002/elps.1150150173; VENEMA RC, 1995, J BIOL CHEM, V270, P14705, DOI 10.1074/jbc.270.24.14705; Venema VJ, 1996, BIOCHEM BIOPH RES CO, V226, P703, DOI 10.1006/bbrc.1996.1417; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; YATES JR, 1995, ANAL CHEM, V67, P1426, DOI 10.1021/ac00104a020; ZICK Y, 1990, BIOCHEMISTRY-US, V29, P10240, DOI 10.1021/bi00496a013	59	277	289	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30101	30108		10.1074/jbc.274.42.30101	http://dx.doi.org/10.1074/jbc.274.42.30101			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514497	hybrid			2022-12-27	WOS:000083176400076
J	Grossel, MJ; Baker, GL; Hinds, PW				Grossel, MJ; Baker, GL; Hinds, PW			cdk6 can shorten G(1) phase dependent upon the N-terminal INK4 interaction domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE ARREST; KINASE-ACTIVITY; RETINOBLASTOMA PROTEIN; TUMOR-SUPPRESSOR; MAMMALIAN-CELLS; INHIBITOR; GROWTH; P21; P16(INK4A); FAMILY	Deregulated activity of cdk4 or cdk6 can lead to inappropriate cellular proliferation and tumorigenesis accompanied by unchecked inactivation of the retinoblastoma tumor suppressor protein. Certain tumor types preferentially activate either cdk4 or cdk6, suggesting that these kinases may not be equivalently oncogenic in all cell types. Although it is clear that cdk4 can act as an oncogene at least in part by evading inhibition by p16(INK4a), the role of cdk6 in tumorigenesis is less well understood. To investigate the consequences of aberrant expression of cdk6, the requirements for proliferation caused by cdk6 overexpression were studied, cdk6-transfected U20S cells displayed an accelerated progression through G(1) phase that was dependent on kinase activity and that did not correlate with p27 binding. Furthermore, a mutation that prevents cdk6 interaction with INK4 proteins (cdk6R31C) was found to inactivate the proliferative effect of cdk6 and increase cytoplasmic localization, despite the fact that this mutant could phosphorylate the retinoblastoma protein in vitro. Together, these data suggest a role for the cdk6 INK4 interaction domain in the generation of functional, nuclear cdk6 complexes and demonstrate the importance of elevated cdk6 kinase activity in G(1) acceleration.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Hinds, PW (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055684] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM55684] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BROTHERTON D, 1998, NATURE, V395; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Costello JF, 1997, CANCER RES, V57, P1250; Easton J, 1998, CANCER RES, V58, P2624; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARPER JW, 1993, CELL, V75, P805; Jiang H, 1998, MOL CELL BIOL, V18, P5284, DOI 10.1128/MCB.18.9.5284; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KHATIB ZA, 1993, CANCER RES, V53, P5535; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LADANYI M, 1995, J PATHOL, V175, P211, DOI 10.1002/path.1711750209; Lapointe J, 1996, CANCER RES, V56, P4586; Latham KM, 1996, MOL CELL BIOL, V16, P4445; Mahony D, 1998, ONCOGENE, V16, P603, DOI 10.1038/sj.onc.1201570; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORGAN D, 1995, NATURE, V474, P131; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Nagasawa M, 1997, J IMMUNOL, V158, P5146; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Parry D, 1999, MOL CELL BIOL, V19, P1775; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Timmermann S, 1997, CELL GROWTH DIFFER, V8, P361; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	41	48	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29960	29967		10.1074/jbc.274.42.29960	http://dx.doi.org/10.1074/jbc.274.42.29960			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514479	hybrid			2022-12-27	WOS:000083176400058
J	Jensen, NA; West, MJ; Celis, JE				Jensen, NA; West, MJ; Celis, JE			Oligodendrocyte programmed cell death and central myelination deficiency induced in transgenic mice by synergism between c-Myc and Oct-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; TRANSCRIPTION FACTOR SCIP; MULTIPLE-SCLEROSIS BRAIN; CENTRAL-NERVOUS-SYSTEM; POU FACTOR OCT-6; PRE-B-CELLS; V-H-RAS; INDUCED APOPTOSIS; GENE-EXPRESSION; JC VIRUS	The basic helix-loop-helix transcription factor c-Myc is a potent trigger of programmed cell death when overexpressed during late oligodendrocyte development in transgenic mice. Here we provide evidence that c-Myc can act synergistically with the Pit, Oct, Unc homeodomain transcription factor Oct-6 to produce myelin disease pathogenesis in transgenic mice. More than 70% of c-myc/Oct-6 bitransgenic mice, obtained from crosses between phenotypically normal heterozygous mice of various My (c-Myc) and Oc (Oct-6) transgenic strains that express c-myc and oct-6 transgenes under transcriptional control of the myelin basic protein gene) developed severe neurological disturbances characterized by action tremors, recurrent seizures, and premature death. Affected bitransgenic mice exhibited multiple hypomyelinated lesions in the white matter that did not stain with myelin-specific antibodies against myelin ba sic protein, proteolipid protein, CNPase, and myelin-associated glycoprotein. The mice also exhibited a larger number of terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end-labeling positive cells in the white matter as well as ultrastructural evidence of glial cell death and astrogliosis. These observations indicate that the myelin lesions observed in the c-myc/oct-6 bitransgenic mice result from the untimely programmed cell death of oligodendroglia and that the c-myc and oct-6 transgenes act synergistically in producing the lesions.	Aarhus Univ, Dept Med Biochem, DK-8000 Aarhus C, Denmark; Aarhus Univ, Dept Neurobiol, DK-8000 Aarhus, Denmark	Aarhus University; Aarhus University	Jensen, NA (corresponding author), Panum Inst, Lab Expt Mol Genet, Inst Med Biochem & Genet, 6-5 Blegdamsvej 3B, DK-2200 Copenhagen N, Denmark.							ABDELRAHMAN B, 1995, HUM REPROD, V10, P2787, DOI 10.1093/oxfordjournals.humrep.a135792; ADAMS JM, 1991, BIOCHIM BIOPHYS ACTA, V1072, P9, DOI 10.1016/0304-419X(91)90004-5; ALEXANDER WS, 1989, MOL CELL BIOL, V9, P67, DOI 10.1128/MCB.9.1.67; ALVAREZBOLADO G, 1995, J COMP NEUROL, V355, P237, DOI 10.1002/cne.903550207; Banerjee M, 1996, INT J CANCER, V65, P730, DOI 10.1002/(SICI)1097-0215(19960315)65:6<730::AID-IJC3>3.0.CO;2-#; BERGER JR, 1995, J NEUROVIROL, V1, P5, DOI 10.3109/13550289509111006; Bermingham JR, 1996, GENE DEV, V10, P1751, DOI 10.1101/gad.10.14.1751; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; Bonetti B, 1997, ANN NEUROL, V42, P74, DOI 10.1002/ana.410420113; Campagnoni Anthony T., 1995, P555; CELIS JE, 1997, CELL BIOL LAB HDB, V2, P429; CELIS JE, 1997, CELL BIOL LAB HDB, P375; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; COLLARINI EJ, 1992, DEVELOPMENT, V116, P193; Dowling P, 1996, J EXP MED, V184, P1513, DOI 10.1084/jem.184.4.1513; Dowling P, 1997, J NEUROL SCI, V149, P1, DOI 10.1016/S0022-510X(97)05213-1; DSouza SD, 1996, J EXP MED, V184, P2361, DOI 10.1084/jem.184.6.2361; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FAUS I, 1994, MOL CELL BIOL, V14, P3263, DOI 10.1128/MCB.14.5.3263; FRANTZ GD, 1994, J NEUROSCI, V14, P472; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Green DR, 1997, SCIENCE, V278, P1246, DOI 10.1126/science.278.5341.1246; HE X, 1991, MOL CELL BIOL, V11, P1739, DOI 10.1128/MCB.11.3.1739; Hisahara S, 1997, J NEUROCHEM, V69, P10; Hueber AO, 1998, TRENDS GENET, V14, P364, DOI 10.1016/S0168-9525(98)01520-0; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Jaegle M, 1996, SCIENCE, V273, P507, DOI 10.1126/science.273.5274.507; Jensen NA, 1998, ELECTROPHORESIS, V19, P2014, DOI 10.1002/elps.1150191121; Jensen NA, 1998, J CLIN INVEST, V101, P1292, DOI 10.1172/JCI1807; Jensen NA, 1998, ONCOGENE, V16, P2123, DOI 10.1038/sj.onc.1201739; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; Kangas AL, 1998, ONCOGENE, V16, P387, DOI 10.1038/sj.onc.1201779; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kidd VJ, 1998, ANNU REV PHYSIOL, V60, P533, DOI 10.1146/annurev.physiol.60.1.533; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; LANGDON WY, 1989, ONCOGENE RES, V4, P253; LEGER H, 1995, MOL CELL BIOL, V15, P3738; LITTLEWOOD T, 1998, PROTEIN PROFILE, P1; LITTLEWOOD TD, 1995, PROTEIN PROFILE, V2, P621; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; MAJOR EO, 1992, CLIN MICROBIOL REV, V5, P49, DOI 10.1128/CMR.5.1.49-73.1992; MONUKI ES, 1989, NEURON, V3, P783, DOI 10.1016/0896-6273(89)90247-X; Morell Pierre, 1994, P117; Pedersen KM, 1999, ELECTROPHORESIS, V20, P249, DOI 10.1002/(SICI)1522-2683(19990201)20:2<249::AID-ELPS249>3.0.CO;2-F; Pfeiffer Steve E., 1993, Trends in Cell Biology, V3, P191, DOI 10.1016/0962-8924(93)90213-K; RENNER K, 1994, P NATL ACAD SCI USA, V91, P6433, DOI 10.1073/pnas.91.14.6433; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; Ryan KM, 1996, BIOCHEM J, V314, P713, DOI 10.1042/bj3140713; SCHERER SS, 1994, J NEUROSCI, V14, P1930; SCHOLER HR, 1991, TRENDS GENET, V7, P323, DOI 10.1016/0168-9525(91)90422-M; Schreiber J, 1997, J BIOL CHEM, V272, P32286, DOI 10.1074/jbc.272.51.32286; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; STEINMAN L, 1993, SCI AM, V269, P106, DOI 10.1038/scientificamerican0993-106; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; STREIT WJ, 1995, SCI AM, V273, P54, DOI 10.1038/scientificamerican1195-54; SUZUKI N, 1990, EMBO J, V9, P3723, DOI 10.1002/j.1460-2075.1990.tb07585.x; Szuchet Sara, 1995, P23; Tenenbaum L, 1996, NEUROPATH APPL NEURO, V22, P302, DOI 10.1111/j.1365-2990.1996.tb01108.x; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; ZORNIG M, 1995, ONCOGENE, V10, P2397; Zwart R, 1996, MECH DEVELOP, V54, P185, DOI 10.1016/0925-4773(95)00472-6	67	6	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29921	29926		10.1074/jbc.274.42.29921	http://dx.doi.org/10.1074/jbc.274.42.29921			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514474	hybrid			2022-12-27	WOS:000083176400053
J	Lopez, R; Carron, C; Oury, C; Gardellin, P; Bernard, O; Ghysdael, J				Lopez, R; Carron, C; Oury, C; Gardellin, P; Bernard, O; Ghysdael, J			TEL is a sequence-specific transcriptional repressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; ETS-DOMAIN PROTEIN; CHRONIC MYELOMONOCYTIC LEUKEMIA; FUSION PROTEIN; DROSOPHILA EYE; DNA-BINDING; GENE FUSION; KINASE; ACTIVATION; TRANSLOCATION	TEL is a gene frequently involved in specific chromosomal translocations in human leukemia and sarcoma that encodes a member of the ETS family of transcriptional regulators. TEL is unusual among other ETS proteins by its ability to self-associate in vivo, a property that is essential to the oncogenic activation of TEL-derived fusion proteins. We show here that TEL is a sequence-specific transcriptional repressor of ETS-binding site-driven transcription of model and natural promoters, Deletion of the oligomerization domain of TEL or its substitution by the homologous region of monomeric ETS1 impaired the ability of TEL to repress. In contrast, substitution of the oligomerization domain of TEL by unrelated oligomerization domains resulted in an active repressor, showing that the ability of TEL to repress depends on its ability to self-associate. The study of the properties of TEL fusions to the heterologous DNA binding domain of Gal4 identified two autonomous repression domains in TEL, distinct from its oligomerization domain, that are essential do the ability of TEL to repress ETS-binding site-containing promoters. These results have implications for the normal function of TEL, its relation to other ETS proteins, and its role in leukemogenesis.	Ctr Univ Orsay, Sect Rech, Inst Curie, CNRS UMR 146, F-91405 Orsay, France; Ctr Etud Polymorphisme Humain, INSERM U434, F-75010 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm)	Ghysdael, J (corresponding author), Ctr Univ Orsay, Sect Rech, Inst Curie, CNRS UMR 146, Batiment 110, F-91405 Orsay, France.	Jacques.Ghysdael@curie.u-psud.fr	GHYSDAEL, Jacques/F-3377-2013; Carron, Clémence/AAG-6304-2021; Bernard, Olivier A./E-5721-2016	Oury, Cecile/0000-0002-7561-0132; Carron, Clemence/0000-0002-8776-7380; Bernard, Olivier/0000-0002-0463-9747				AUSUBEL FM, 1992, SHORT PROTOCOLS MOL, P8; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; Bornemann D, 1996, DEVELOPMENT, V122, P1621; BUIJS A, 1995, ONCOGENE, V10, P1511; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; Chase A, 1999, BLOOD, V93, P1025, DOI 10.1182/blood.V93.3.1025.403a20_1025_1031; FLEMINGTON E, 1990, P NATL ACAD SCI USA, V87, P9459, DOI 10.1073/pnas.87.23.9459; GALANG CK, 1994, ONCOGENE, V9, P2913; GHYSDAEL J, 1997, ONCOGENES TRANSCRIPT, V1, P29; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; ITO Y, 1997, ONCOGENES TRANSCRIPT, V2, P107; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Kim DH, 1996, BLOOD, V88, P785, DOI 10.1182/blood.V88.3.785.bloodjournal883785; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; Maira SM, 1996, EMBO J, V15, P5849, DOI 10.1002/j.1460-2075.1996.tb00972.x; McLean TW, 1996, BLOOD, V88, P4252; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; Pereira R, 1999, ONCOGENE, V18, P1597, DOI 10.1038/sj.onc.1202534; Peterson AJ, 1997, MOL CELL BIOL, V17, P6683, DOI 10.1128/MCB.17.11.6683; Poirel H, 1997, ONCOGENE, V14, P349, DOI 10.1038/sj.onc.1200829; REBAY I, 1995, CELL, V81, P857, DOI 10.1016/0092-8674(95)90006-3; RiesgoEscovar JR, 1997, GENE DEV, V11, P1717, DOI 10.1101/gad.11.13.1717; Rogge R, 1995, DEVELOPMENT, V121, P3947; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; Starck J, 1999, MOL CELL BIOL, V19, P121; TREIER M, 1995, CELL, V83, P753, DOI 10.1016/0092-8674(95)90188-4; Uchida H, 1999, ONCOGENE, V18, P1015, DOI 10.1038/sj.onc.1202383; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392	44	135	135	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30132	30138		10.1074/jbc.274.42.30132	http://dx.doi.org/10.1074/jbc.274.42.30132			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514502	hybrid, Green Published			2022-12-27	WOS:000083176400081
J	Moilanen, LH; Fukushige, T; Freedman, JH				Moilanen, LH; Fukushige, T; Freedman, JH			Regulation of metallothionein gene transcription - Identification of upstream regulatory elements and transcription factors responsible for cell-specific expression of the metallothionein genes from Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-INHIBITORY FACTOR; SEA-URCHIN EMBRYOS; HEAVY-METALS; DROSOPHILA-MELANOGASTER; BINDING PROTEIN; MESSENGER-RNA; FACTOR GATA-1; FACTOR MTF-1; I GENES; PROMOTER	Metallothioneins are small, cysteine-rich proteins that function in metal detoxification and homeostasis. Metallothionein transcription is controlled by cell-specific factors, as well as developmentally modulated and metal-responsive pathways. By using the nematode Caenorhabditis elegans as a model system, the mechanism that controls cell-specific metallothionein transcription in vivo was investigated. The inducible expression of the C. elegans metallothionein genes, mtl-1 and mtl-2, occurs exclusively in intestinal cells. Sequence comparisons of these genes with other C. elegans intestinal cell-specific genes identified multiple repeats of GATA transcription factor-binding sites (i.e. GATA elements). In vivo deletion and site-directed mutation analyses confirm that one GATA element in mtl-1 and two in mtl-2 are required for transcription. Electrophoretic mobility shift assays show that the C, elegans GATA transcription factor ELT-2 specifically binds to these elements. Ectopic expression of ELT-S in non-intestinal cells of C. elegans activates mtl-2 transcription in these cells. Likewise, mtl-2 is not expressed in nematodes in which elt-2 has been disrupted. These results indicate that cell-specific transcription of the C. elegans metallothionein Genes is regulated by the binding of ELT-S to GATA elements in these promoters. Furthermore, a model is proposed where ELT-S constitutively activates metallothionein expression; however, a second metal-responsive factor prevents transcription in the absence of metals.	Duke Univ, Nicholas Sch Environm, Durham, NC 27708 USA; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Duke Univ, Med Ctr, Dept Microbiol, Durham, NC 27710 USA	Duke University; University of Calgary; Duke University	Freedman, JH (corresponding author), Duke Univ, Nicholas Sch Environm, Box 90328, Durham, NC 27708 USA.	jonf@duke.edu			NATIONAL CANCER INSTITUTE [R01CA061337] Funding Source: NIH RePORTER; NCI NIH HHS [CA 61337] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AAMODT EJ, 1991, SCIENCE, V252, P579, DOI 10.1126/science.2020855; ABEL T, 1993, DEVELOPMENT, V119, P623; Aniskovitch LP, 1997, ARCH BIOCHEM BIOPHYS, V341, P337, DOI 10.1006/abbi.1997.9976; ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; Ausubel FM, 1998, CURRENT PROTOCOLS MO; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; BEMONDELLI P, 1997, FEBS LETT, V416, P254; BONNETON F, 1995, DEV GENET, V16, P253, DOI 10.1002/dvg.1020160305; Bonneton F, 1996, FEBS LETT, V380, P33, DOI 10.1016/0014-5793(95)01544-2; Britton C, 1998, J MOL BIOL, V283, P15, DOI 10.1006/jmbi.1998.2093; CZUPRYN M, 1992, P NATL ACAD SCI USA, V89, P10395, DOI 10.1073/pnas.89.21.10395; DURLIAT M, 1995, BIOMETALS, V8, P339; DURNAM DM, 1981, J BIOL CHEM, V256, P5712; EGAN CR, 1995, DEV BIOL, V170, P397, DOI 10.1006/dbio.1995.1225; Evans T, 1997, TRENDS CARDIOVAS MED, V7, P75, DOI 10.1016/S1050-1738(97)00010-8; FAICH N, 1995, EMBO J, V14, P801; FIRE A, 1992, GENET ANAL-BIOMOL E, V9, P151, DOI 10.1016/1050-3862(92)90042-4; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; FITZGERALD K, 1998, AM J PHYSIOL, pG314; FOSTER R, 1988, J BIOL CHEM, V263, P11528; FREEDMAN JH, 1993, J BIOL CHEM, V268, P2554; Fukushige T, 1998, DEV BIOL, V198, P286, DOI 10.1016/S0012-1606(98)80006-7; Gao XP, 1998, MOL CELL BIOL, V18, P2901, DOI 10.1128/MCB.18.5.2901; Garrett SH, 1998, ENVIRON HEALTH PERSP, V106, P587, DOI 10.2307/3434234; Ghatak S, 1996, PROSTATE, V29, P91, DOI 10.1002/(SICI)1097-0045(199608)29:2<91::AID-PROS4>3.0.CO;2-K; Ghoshal K, 1998, P NATL ACAD SCI USA, V95, P10390, DOI 10.1073/pnas.95.18.10390; Gilleard JS, 1999, DEV BIOL, V208, P265, DOI 10.1006/dbio.1999.9202; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; Haun C, 1998, P NATL ACAD SCI USA, V95, P5072, DOI 10.1073/pnas.95.9.5072; HAWKINS MG, 1995, J BIOL CHEM, V270, P14666, DOI 10.1074/jbc.270.24.14666; HEGUY A, 1986, MOL CELL BIOL, V6, P2149, DOI 10.1128/MCB.6.6.2149; Herzig TC, 1997, P NATL ACAD SCI USA, V94, P7543, DOI 10.1073/pnas.94.14.7543; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; IMAGAWA M, 1995, J BIOL CHEM, V270, P20898, DOI 10.1074/jbc.270.36.20898; Imbert J, 1990, Adv Inorg Biochem, V8, P139; JAHROUDI N, 1990, J BIOL CHEM, V265, P6506; KAWANA M, 1995, MOL CELL BIOL, V15, P4225; KENNEDY BP, 1993, J MOL BIOL, V229, P890, DOI 10.1006/jmbi.1993.1094; KENYON C, 1988, SCIENCE, V240, P1448, DOI 10.1126/science.3287621; KOIZUMI S, 1991, CHEM-BIOL INTERACT, V80, P145, DOI 10.1016/0009-2797(91)90021-X; KOROPATNICK J, 1989, RADIAT RES, V119, P356, DOI 10.2307/3577626; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAND M, 1994, J BIOL CHEM, V269, P9234; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; Lewis JA, 1995, METHOD CELL BIOL, V48, P3; Liang LC, 1996, MOL REPROD DEV, V43, P25, DOI 10.1002/(SICI)1098-2795(199601)43:1&lt;25::AID-MRD4&gt;3.0.CO;2-W; LIN WH, 1995, J BIOL CHEM, V270, P25150, DOI 10.1074/jbc.270.42.25150; LINCKE CR, 1992, J MOL BIOL, V228, P701, DOI 10.1016/0022-2836(92)90855-E; Liu HD, 1996, GENE DEV, V10, P592; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; MACMORRIS M, 1992, MOL CELL BIOL, V12, P1652, DOI 10.1128/MCB.12.4.1652; MADURO M, 1995, GENETICS, V141, P977; Mello C, 1995, METHOD CELL BIOL, V48, P451; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; Moffatt P, 1998, DNA CELL BIOL, V17, P501, DOI 10.1089/dna.1998.17.501; NEMER M, 1991, J BIOL CHEM, V266, P6586; NEMER M, 1995, MECH DEVELOP, V50, P131, DOI 10.1016/0925-4773(94)00330-P; Nonchev S, 1996, DEVELOPMENT, V122, P543; Page BD, 1997, GENE DEV, V11, P1651, DOI 10.1101/gad.11.13.1651; PALMITER RD, 1994, P NATL ACAD SCI USA, V91, P1219, DOI 10.1073/pnas.91.4.1219; Palmiter RD, 1998, P NATL ACAD SCI USA, V95, P8428, DOI 10.1073/pnas.95.15.8428; PALMITER RD, 1992, P NATL ACAD SCI USA, V89, P6333, DOI 10.1073/pnas.89.14.6333; PRICEHAUGHEY J, 1987, BIOCHIM BIOPHYS ACTA, V908, P158, DOI 10.1016/0167-4781(87)90055-8; QUAIFE CJ, 1994, BIOCHEMISTRY-US, V33, P7250, DOI 10.1021/bi00189a029; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; Rehorn KP, 1996, DEVELOPMENT, V122, P4023; Satyal SH, 1998, GENE DEV, V12, P1962, DOI 10.1101/gad.12.13.1962; SCHMIDT CJ, 1986, P NATL ACAD SCI USA, V83, P3346, DOI 10.1073/pnas.83.10.3346; Searle P F, 1987, Experientia Suppl, V52, P407; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Sharkey M, 1997, TRENDS GENET, V13, P145, DOI 10.1016/S0168-9525(97)01096-2; SHWORAK NW, 1993, J BIOL CHEM, V268, P24460; SILAR P, 1990, J MOL BIOL, V215, P217, DOI 10.1016/S0022-2836(05)80340-7; SIMON MC, 1995, NAT GENET, V11, P9, DOI 10.1038/ng0995-9; SOUDAIS C, 1995, DEVELOPMENT, V121, P3877; SPIETH J, 1985, MOL CELL BIOL, V5, P2495, DOI 10.1128/MCB.5.10.2495; STERN MJ, 1993, MOL BIOL CELL, V4, P1175, DOI 10.1091/mbc.4.11.1175; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; Su YC, 1998, GENE DEV, V12, P2371, DOI 10.1101/gad.12.15.2371; SULSTON J, 1988, NEMATODE CAENORHABDI, P123; Sulston J., 1988, NEMATODE CAENORHABDI, P587; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; Suzuki Keiji, 1994, Biological Signals, V3, P188; TAMURA S, 1993, P NATL ACAD SCI USA, V90, P10876, DOI 10.1073/pnas.90.22.10876; UCHIDA Y, 1991, NEURON, V7, P337, DOI 10.1016/0896-6273(91)90272-2; VARSHNEY U, 1986, MOL CELL BIOL, V6, P26, DOI 10.1128/MCB.6.1.26; WALTERS M, 1992, P NATL ACAD SCI USA, V89, P10444, DOI 10.1073/pnas.89.21.10444; WILKINSON DG, 1987, MOL CELL BIOL, V7, P48, DOI 10.1128/MCB.7.1.48; Yamagata T, 1997, MOL CELL BIOL, V17, P4272, DOI 10.1128/MCB.17.8.4272; Yoshida T, 1997, FEBS LETT, V414, P333, DOI 10.1016/S0014-5793(97)01017-X; ZHANG R, 1995, J BIOL CHEM, V270, P15320, DOI 10.1074/jbc.270.25.15320; Zhu JW, 1997, GENE DEV, V11, P2883, DOI 10.1101/gad.11.21.2883; [No title captured]	95	73	82	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29655	29665		10.1074/jbc.274.42.29655	http://dx.doi.org/10.1074/jbc.274.42.29655			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514435	hybrid			2022-12-27	WOS:000083176400014
J	Nasonkin, I; Alikasifoglu, A; Ambrose, C; Cahill, P; Cheng, M; Sarniak, A; Egan, M; Thomas, PM				Nasonkin, I; Alikasifoglu, A; Ambrose, C; Cahill, P; Cheng, M; Sarniak, A; Egan, M; Thomas, PM			A novel sulfonylurea receptor family member expressed in the embryonic Drosophila dorsal vessel and tracheal system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA; K+ CHANNEL; GENE; SEQUENCE; INFANCY; SHAKER; REGULATOR; SUBUNITS; PROTEINS; INSIGHTS	Sulfonylurea receptors (SURx) are required subunits of the ATP-sensitive potassium channel. SURx: alone is electrophysiologically inert. However, when SURx is combined with an inward rectifier Kir6.2 subunit, ATP-sensitive potassium channel activity is generated. We report the identification, characterization, and localization of Dsur, a novel Drosophila gene that is highly related to the vertebrate SUR family. The Dsur coding sequence contains structural features characteristic of the ABC transporter family and, in addition, harbors 1.7 kilobases of a distinctive sequence that does not share homology with any known gene. When Dsur alone is expressed in Xenopus oocytes glibenclamide-sensitive potassium channel activity occurs. During Drosophila embryogenesis, the Dsur gene is specifically expressed in the developing tracheal system and dorsal vessel. Studies of the Drosophila genome support that only a single Dsur gene is present. Our data reveal conservation of glibenclamide-sensitive potassium channels in Drosophila and suggest that Dsur may play an important role during Drosophila embryogenesis. The lack of gene duplication in the Drosophila system provides a unique opportunity for functional studies of SUR using a genetic approach.	Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Communicable Dis, Ann Arbor, MI 48109 USA; Yale Univ, Dept Pediat, New Haven, CT 06520 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Yale University	Thomas, PM (corresponding author), Univ Michigan, Dept Pediat, MSRB III,Rm 8220A,Box 0646,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.				NICHD NIH HHS [HD28820] Funding Source: Medline; NIDDK NIH HHS [R01DK53428] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053428] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Arias A.M., 1993, DEV DROSOPHILA, P609; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; AYNSLEYGREEN A, 1981, ARCH DIS CHILD, V56, P496, DOI 10.1136/adc.56.7.496; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CLEGG NJ, 1993, GENETICS, V134, P221; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Decottignies A, 1997, NAT GENET, V15, P137, DOI 10.1038/ng0297-137; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Isomoto S, 1996, J BIOL CHEM, V271, P24321, DOI 10.1074/jbc.271.40.24321; Kane C, 1996, NAT MED, V2, P1344, DOI 10.1038/nm1296-1344; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; LEHMAN R, 1994, DROSOPHILA MELANOGAS, V44; McNicholas CM, 1996, P NATL ACAD SCI USA, V93, P8083, DOI 10.1073/pnas.93.15.8083; Miklos GLG, 1996, CELL, V86, P521, DOI 10.1016/S0092-8674(00)80126-9; Nestorowicz A, 1998, HUM MOL GENET, V7, P1119, DOI 10.1093/hmg/7.7.1119; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; PONGS O, 1988, EMBO J, V7, P1087, DOI 10.1002/j.1460-2075.1988.tb02917.x; ROST B, 1995, PROTEIN SCI, V4, P521; SEINO S, 1996, DIABETES REV, V4, P177; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; Thomas P, 1996, HUM MOL GENET, V5, P1809, DOI 10.1093/hmg/5.11.1809; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; Tusnady GE, 1997, FEBS LETT, V402, P1, DOI 10.1016/S0014-5793(96)01478-0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WORLEY KC, 1995, GENOME RES, V5, P173, DOI 10.1101/gr.5.2.173; WU CT, 1991, MOL CELL BIOL, V11, P3940, DOI 10.1128/MCB.11.8.3940	30	60	61	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29420	29425		10.1074/jbc.274.41.29420	http://dx.doi.org/10.1074/jbc.274.41.29420			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506204	hybrid			2022-12-27	WOS:000083017800083
J	Smith, L; Su, XJ; Lin, PJ; Zhi, G; Stull, JT				Smith, L; Su, XJ; Lin, PJ; Zhi, G; Stull, JT			Identification of a novel actin binding motif in smooth muscle myosin light chain kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTAGENESIS; SEQUENCE; SITE; PHOSPHORYLATION; CONTRACTION; FIBROBLASTS; DOMAIN; CDNA	Phosphorylation of the 20-kDa regulatory light chain of myosin catalyzed by a Ca2+/calmodulin-dependent myosin light chain kinase is important in the initiation of smooth muscle contraction and other contractile processes in non-muscle cells. It has been previously shown that residues 1-142 of smooth muscle myosin light chain kinase are necessary for high-affinity binding to actin-containing filaments in cells (1), To further localize the region of the kinase required for binding, a series of N-terminal deletion mutants as well as several N-terminal glutathione S-transferase fusion proteins were constructed. Cosedimentation assays showed that a peptide containing residues 1-75 binds to purified smooth muscle myofilaments, Furthermore, the N-terminal peptide was sufficient for high-affinity binding to actin stress fibers in smooth muscle cells in vivo. Alanine scanning mutagenesis in the fusion protein identified residues Asp-30, Phe-31, Arg-32, and Leu-35 as important for binding in vitro. There are two additional DFRXXL motifs located at residues 2-7 and 58-63. The DFR residues in these three motifs were individually replaced by alanine residues in the full-length kinase, Each of these mutations significantly decreased myosin light chain kinase binding to myofilaments in vitro, and each abolished high-affinity binding to actin-containing filaments in smooth muscle cells in vivo. These results identify a unique structural motif comprised of three repeat consensus sequences in the N terminus of myosin light chain kinase necessary for high-affinity binding to actin-containing filaments.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Smith, L (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	jstull@mednet.swmed.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL026043] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37 HL26043-19] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELSTEIN RS, 1982, METHOD ENZYMOL, V85, P298; BENIAN GM, 1989, NATURE, V342, P45, DOI 10.1038/342045a0; FAUX MC, 1993, MOL CELL BIOCHEM, V128, P81, DOI 10.1007/BF01076759; Gallagher PJ, 1997, MOL CELL BIOCHEM, V173, P51, DOI 10.1023/A:1006876318155; Gallagher PJ, 1997, J MUSCLE RES CELL M, V18, P1, DOI 10.1023/A:1018616814417; HASHIMOTO Y, 1994, BBA-MOL CELL RES, V1223, P163, DOI 10.1016/0167-4889(94)90222-4; HERRING BP, 1990, J BIOL CHEM, V265, P16588; HOLZAPFEL G, 1983, EXP CELL RES, V148, P117, DOI 10.1016/0014-4827(83)90192-1; KANOH S, 1993, BIOCHEMISTRY-US, V32, P8902, DOI 10.1021/bi00085a023; KOBAYASHI H, 1992, J BIOCHEM-TOKYO, V112, P786, DOI 10.1093/oxfordjournals.jbchem.a123976; KOLODNEY MS, 1993, J BIOL CHEM, V268, P23850; KUHLMAN PA, 1992, FEBS LETT, V304, P201, DOI 10.1016/0014-5793(92)80619-R; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lin PJ, 1999, J BIOL CHEM, V274, P5987, DOI 10.1074/jbc.274.9.5987; Lin PJ, 1997, J BIOL CHEM, V272, P7412, DOI 10.1074/jbc.272.11.7412; LUBYPHELPS K, 1995, J BIOL CHEM, V270, P21532, DOI 10.1074/jbc.270.37.21532; MAMIYA S, 1989, J BIOL CHEM, V264, P8575; NUNNALLY MH, 1984, J BIOL CHEM, V259, P1776; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; ROUSH CL, 1988, J BIOL CHEM, V263, P10510; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SELLERS JR, 1984, J BIOL CHEM, V259, P7740; SHIRINSKY VP, 1993, J BIOL CHEM, V268, P16578; STULL JT, 1988, ACTA PHYSL SCAND, V164, P471; STULL JT, 1996, BIOCH SMOOTH MUSCLE, P119; TAKIO K, 1986, BIOCHEMISTRY-US, V25, P8049, DOI 10.1021/bi00372a038; TANSEY MG, 1990, FEBS LETT, V270, P219, DOI 10.1016/0014-5793(90)81272-P; Ye LH, 1997, J BIOL CHEM, V272, P32182, DOI 10.1074/jbc.272.51.32182; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	29	51	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29433	29438		10.1074/jbc.274.41.29433	http://dx.doi.org/10.1074/jbc.274.41.29433			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506206	hybrid			2022-12-27	WOS:000083017800085
J	Gordon, J; Sengupta, TK; Phillips, CA; O'Malley, SM; Williams, KR; Spicer, EK				Gordon, J; Sengupta, TK; Phillips, CA; O'Malley, SM; Williams, KR; Spicer, EK			Identification of the RNA binding domain of T4 RegA protein by structure-based mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; GENE-44 MESSENGER-RNA; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; ALPHA-HELIX; BACTERIOPHAGE-T4; SPECIFICITY; RECOGNITION; COMPLEX; REGION	The T4 translational repressor RegA protein folds into two structural domains, as revealed by the crystal structure (Kang, C.-H., Chan, R., Berger, I., Lockshin, C., Green, L,, Gold, L,, and Rich, A. (1995) Science 268, 1170-1173). Domain I of the RegA protein contains a four-stranded beta-sheet and two alpha-helices. Domain II contains a four-stranded beta-sheet and an unusual 3/10 helix, Since beta-sheet residues play a role in a number of protein-RNA interactions, one or both of the beta-sheet regions in Reg-A protein may be involved in RNA binding, To test this possibility, mutagenesis of residues on both beta-sheets was performed, and the effects on the RNA binding affinities of RegA protein were measured. Additional sites for mutagenesis were selected from molecular modeling of RegA protein. The RNA binding affinities of three purified mutant RegA proteins were evaluated by fluorescence quenching equilibrium binding assays. The activities of the remainder of the mutant proteins were evaluated by quantitative RNA gel mobility shift assays using lysed cell supernatants, The results of this mutagenesis study ruled out the participation of beta-sheet residues. Instead, the RNA binding site was found to be a surface pocket formed by residues on two loops and an alpha-helix. Thus, RegA protein appears to use a unique structural motif in binding RNA, which may be related to its unusual RNA recognition properties.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06510 USA	Medical University of South Carolina; Howard Hughes Medical Institute; Yale University; Yale University	Spicer, EK (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave, Charleston, SC 29425 USA.		Sengupta, Tapas K/P-7126-2014; Williams, Kenneth/B-5986-2016	Williams, Kenneth/0000-0001-7792-9588				ADARI HY, 1985, P NATL ACAD SCI USA, V82, P1901, DOI 10.1073/pnas.82.7.1901; Allain FHT, 1996, NATURE, V380, P646, DOI 10.1038/380646a0; Allen SV, 1999, ANAL BIOCHEM, V269, P32, DOI 10.1006/abio.1999.4025; Battiste JL, 1996, SCIENCE, V273, P1547, DOI 10.1126/science.273.5281.1547; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BRANDON C, 1998, INTRO PROTEIN STRUCT, P129; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; DRAPER DE, 1995, ANNU REV BIOCHEM, V64, P593, DOI 10.1146/annurev.bi.64.070195.003113; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; FRIED MG, 1983, NUCLEIC ACIDS RES, V11, P141, DOI 10.1093/nar/11.1.141; HALL KB, 1994, BIOCHEMISTRY-US, V33, P10076, DOI 10.1021/bi00199a035; Jain C, 1996, CELL, V87, P115, DOI 10.1016/S0092-8674(00)81328-8; JESSEN TH, 1991, EMBO J, V10, P3447, DOI 10.1002/j.1460-2075.1991.tb04909.x; JOHNSON BH, 1994, BIOTECHNOLOGY, V12, P114; JOZWIK CE, 1992, P NATL ACAD SCI USA, V89, P5053, DOI 10.1073/pnas.89.11.5053; KANG CH, 1995, SCIENCE, V268, P1170, DOI 10.1126/science.7761833; KARAM J, 1981, P NATL ACAD SCI-BIOL, V78, P4669, DOI 10.1073/pnas.78.8.4669; MCSWIGGEN JA, 1988, J MOL BIOL, V199, P609, DOI 10.1016/0022-2836(88)90305-1; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; OMALLEY SM, 1995, J BIOL CHEM, V270, P5107, DOI 10.1074/jbc.270.10.5107; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; Phillips CA, 1996, NUCLEIC ACIDS RES, V24, P4319, DOI 10.1093/nar/24.21.4319; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; Sambrook J., 2002, MOL CLONING LAB MANU; Shamoo Y, 1997, NAT STRUCT BIOL, V4, P215, DOI 10.1038/nsb0397-215; SZEWCZAK AA, 1991, J BIOL CHEM, V266, P17832; TAN RY, 1993, CELL, V73, P1031, DOI 10.1016/0092-8674(93)90280-4; UNNITHAN S, 1990, NUCLEIC ACIDS RES, V18, P7083, DOI 10.1093/nar/18.23.7083; VALEGARD K, 1994, NATURE, V371, P623, DOI 10.1038/371623a0; WEBSTER KR, 1992, J BIOL CHEM, V267, P26097; WEBSTER KR, 1989, NUCLEIC ACIDS RES, V17, P10047, DOI 10.1093/nar/17.23.10047; WEBSTER KR, 1991, BIOTECHNIQUES, V11, P658; WEBSTER KR, 1990, J BIOL CHEM, V265, P19007; WINTER RB, 1987, P NATL ACAD SCI USA, V84, P7822, DOI 10.1073/pnas.84.22.7822	35	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32265	32273		10.1074/jbc.274.45.32265	http://dx.doi.org/10.1074/jbc.274.45.32265			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542265	hybrid			2022-12-27	WOS:000083532100073
J	Rani, MRS; Leaman, DW; Han, YL; Leung, S; Croze, E; Fish, EN; Wolfman, A; Ransohoff, RM				Rani, MRS; Leaman, DW; Han, YL; Leung, S; Croze, E; Fish, EN; Wolfman, A; Ransohoff, RM			Catalytic ally active TYK2 is essential for interferon-beta-mediated phosphorylation of STAT3 and interferon-alpha receptor-1 (IFNAR-1) but not for activation of phosphoinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; EPIDERMAL GROWTH-FACTOR; SIGNALING PATHWAY; PHOSPHATIDYLINOSITOL 3-KINASE; TARGETED DISRUPTION; DEPENDENT ACTIVATION; BINDING; TRANSDUCTION; COMPLEXES; SUBUNIT	TYK2, a Janus kinase, plays both structural and catalytic roles in type I interferon (IFN) signaling. We recently reported (Rani, M. R. S., Gauzzi, C., Pellegrini, S., Fish, E., Wei, T., and Ransohoff, R. M. (1999) J. Biol. Chem. 274, 1891-1897) that catalytically active TYK2 was necessary for IFN-beta to induce the beta-R1 gene. We now report IFN-beta-mediated activation of STATs and other components in UI (TYK2-null) cell lines that were complemented with kinase-negative (U1.KR930) or wildtype TYK2 (U1.wt), We found that IFN-beta induced phosphorylation on tyrosine of STAT3 in U1.wt cells but not in U1.KR930 cells, whereas STAT1 and STATE were activated in both cell lines. Additionally, IFN-beta-mediated phosphorylation of interferon-alpha receptor-1 (IFNAR-1) was defective in IFN-beta treated U1.KR930 cells, but evident in U1.wt cells, In U1A-derived cells, the p85/p110 phosphoinositol 3-kinase isoform was associated with IFNAR-1 but not STAT3, and the association was ligand-independent. Further, IFN-beta treatment stimulated IFNAR-1-associated phosphoinositol kinase activity equally in either U1.wt or U1.KR930 cells. Our results indicate that catalytically active TYK2 is required for IFN-beta-mediated tyrosine phosphorylation of STAT3 and IFNAR-1 in intact cells.	Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, Cleveland, OH 44195 USA; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 3E2, Canada; Berlex Biosci, Richmond, CA 94804 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of Toronto	Ransohoff, RM (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci, NC30, Cleveland, OH 44195 USA.				NCI NIH HHS [1PO1 CA62220] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA062220] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Burfoot MS, 1997, J BIOL CHEM, V272, P24183, DOI 10.1074/jbc.272.39.24183; COFFER P, 1995, ONCOGENE, V10, P985; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; Croze E, 1996, J BIOL CHEM, V271, P33165, DOI 10.1074/jbc.271.52.33165; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Gauzzi MC, 1996, J BIOL CHEM, V271, P20494, DOI 10.1074/jbc.271.34.20494; Ghislain JJ, 1996, J BIOL CHEM, V271, P12408, DOI 10.1074/jbc.271.21.12408; Han YL, 1997, MOL ENDOCRINOL, V11, P1180, DOI 10.1210/me.11.8.1180; Han YL, 1999, J INTERF CYTOK RES, V19, P731, DOI 10.1089/107999099313578; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; Lewerenz M, 1998, J MOL BIOL, V282, P585, DOI 10.1006/jmbi.1998.2026; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; Qureshi SA, 1996, MOL CELL BIOL, V16, P288; Rani MRS, 1999, J BIOL CHEM, V274, P1891, DOI 10.1074/jbc.274.4.1891; Reddy SAG, 1997, J BIOL CHEM, V272, P29167, DOI 10.1074/jbc.272.46.29167; Richter MF, 1998, J BIOL CHEM, V273, P24723, DOI 10.1074/jbc.273.38.24723; Runkel L, 1998, J BIOL CHEM, V273, P8003, DOI 10.1074/jbc.273.14.8003; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Uddin S, 1997, J IMMUNOL, V158, P2390; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; UZE G, 1995, J INTERF CYTOK RES, V15, P3, DOI 10.1089/jir.1995.15.3; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VELAZQUEZ L, 1995, J BIOL CHEM, V270, P3327, DOI 10.1074/jbc.270.7.3327; Yan H, 1996, EMBO J, V15, P1064, DOI 10.1002/j.1460-2075.1996.tb00444.x; Yang CH, 1998, P NATL ACAD SCI USA, V95, P5568, DOI 10.1073/pnas.95.10.5568; Yang CH, 1996, J BIOL CHEM, V271, P8057, DOI 10.1074/jbc.271.14.8057; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	33	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32507	32511		10.1074/jbc.274.45.32507	http://dx.doi.org/10.1074/jbc.274.45.32507			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542297	hybrid			2022-12-27	WOS:000083532100105
J	Chen, CC; Chiu, KT; Sun, YT; Chen, WC				Chen, CC; Chiu, KT; Sun, YT; Chen, WC			Pole of the cyclic AMP-protein kinase a pathway in lipopolysaccharide-induced nitric oxide synthase expression in RAW 264.7 macrophages - Involvement of cyclooxygenase-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-1; NF-KAPPA-B; MESANGIAL CELLS; INDUCTION; ACTIVATION; CAMP; PHARMACOLOGY; MECHANISM; TISSUE	The signaling pathway for lipopolysaccharide (LPS)-induced nitric oxide (NO) release in RAW 264.7 macrophages involves the protein kinase C and p38 activation pathways (Chen, C. C., Wang, J. K., and Lin, S. B. (1998) J. Immunol. 161, 6206-6214; Chen, C. C., and Wang, J. K. (1999) Mel. Pharmacol. 55, 481-488). In this study, the role of the cAMP-dependent protein kinase A (PKA) pathway was investigated. The PEA inhibitors, KT-5720 and H8, reduced LPS-induced NO release and inducible nitric oxide synthase (iNOS) expression. The direct PHA activator, Bt(2)cAMP, caused concentration-dependent NO release and iNOS expression, as confirmed by immunofluorescence studies. The intracellular cAMP concentration did not increase until after 6 h of LPS treatment. Two cAMP-elevating agents, forskolin and cholera toxin, potentiated the LPS-induced NO release and iNOS expression. Stimulation of cells with LPS or Bt(2)cAMP for periods of 10 min to 24 h caused nuclear factor-kappa B (NF-kappa B) activation in the nuclei, as shown by detection of NF-kappa B-specific DNA-protein binding The PKA inhibitor, H8, inhibited the NF-kappa B activation induced by 6- or 12-h treatment with LPS but not that induced after 1, 3, or 24 h. The cyclooxygenase-a (COX-2) inhibitors, NS-398 and indomethacin, attenuated LPS-induced NO release, iNOS expression, and NF-kappa B DNA-protein complex formation. LPS induced COX-2 expression in a time-dependent manner, and prostaglandin E-2 production was induced in parallel. These results suggest that 6 h of treatment with LPS increases intracellular cAMP levels via COX-2 induction and prostaglandin E-2 production, resulting in PKA activation, NF-kappa B activation, iNOS expression, and NO production.	Natl Taiwan Univ, Coll Med, Dept Pharmacol, Taipei 10018, Taiwan	National Taiwan University	Chen, CC (corresponding author), Natl Taiwan Univ, Coll Med, Dept Pharmacol, 1 Jen Ai Rd,1st Sect, Taipei 10018, Taiwan.			CHEN, CHING-CHOW/0000-0002-7810-0939				Chen CC, 1999, MOL PHARMACOL, V55, P481; Chen CC, 1998, J IMMUNOL, V161, P6206; DEWITT D, 1995, CELL, V83, P345, DOI 10.1016/0092-8674(95)90109-4; FOURNIER T, 1995, J IMMUNOL, V155, P2123; FUJIHARA M, 1993, J BIOL CHEM, V268, P14898; HIROKAWA K, 1994, BRIT J PHARMACOL, V112, P396, DOI 10.1111/j.1476-5381.1994.tb13085.x; JEAN YJ, 1996, MOL PHARMACOL, V50, P334; Klein T, 1998, MOL PHARMACOL, V53, P385, DOI 10.1124/mol.53.3.385; Kleinert H, 1996, J BIOL CHEM, V271, P6039, DOI 10.1074/jbc.271.11.6039; KOIDE M, 1993, J BIOL CHEM, V268, P24959; LASKIN DL, 1995, ANNU REV PHARMACOL, V35, P655, DOI 10.1146/annurev.pharmtox.35.1.655; LEONE AM, 1991, J BIOL CHEM, V266, P23790; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; MONCADA S, 1991, PHARMACOL REV, V43, P109; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; Mustafa SB, 1998, J BIOL CHEM, V273, P5073, DOI 10.1074/jbc.273.9.5073; NATHAN C, 1994, J BIOL CHEM, V269, P13725; Nisoli E, 1997, ENDOCRINOLOGY, V138, P676, DOI 10.1210/en.138.2.676; Nusing RM, 1996, BIOCHEM J, V313, P617, DOI 10.1042/bj3130617; Oddis CV, 1996, AM J PHYSIOL-CELL PH, V271, pC429, DOI 10.1152/ajpcell.1996.271.1.C429; OKADA R, 1995, BIOCHIM BIOPHYS ACTA, V1268, P201; ONODERA S, 1991, CHEM PHARM BULL, V39, P991; OTTO JC, 1995, J LIPID MEDIAT CELL, V12, P139, DOI 10.1016/0929-7855(95)00015-I; Pahan K, 1997, J BIOL CHEM, V272, P7786, DOI 10.1074/jbc.272.12.7786; RADDASSI K, 1993, CELL IMMUNOL, V149, P50, DOI 10.1006/cimm.1993.1135; Schmidlin F, 1998, MOL PHARMACOL, V53, P1009; Smith FS, 1997, BIOCHEM J, V326, P187, DOI 10.1042/bj3260187; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VANE J, 1994, NATURE, V367, P215, DOI 10.1038/367215a0; WALTON KM, 1992, MOL NEUROBIOL, V4, P197; XIE QW, 1994, J BIOL CHEM, V269, P4705	33	106	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31559	31564		10.1074/jbc.274.44.31559	http://dx.doi.org/10.1074/jbc.274.44.31559			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531359	hybrid			2022-12-27	WOS:000083379400063
J	Fukuda, M; Mikoshiba, K				Fukuda, M; Mikoshiba, K			A novel alternatively spliced variant of synaptotagmin VI lacking a transmembrane domain - Implications for distinct functions of the two isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-POLYPHOSPHATE BINDING; GROWTH-FACTOR-I; PHOSPHOLIPID-BINDING; C2B DOMAIN; INOSITOL-1,3,4,5-TETRAKISPHOSPHATE BINDING; ENDOPLASMIC-RETICULUM; ANTIBODY INJECTION; RELEASE; CALCIUM; CELLS	Synaptotagmins are a family of membrane proteins that are characterized by a single transmembrane region and tandem C2 domains and that are likely to regulate constitutive and/or regulated vesicle traffic, We have shown that a subclass of synaptotagmins (III, V,VI, and X) forms homo- and heterodimers through an evolutionarily conserved cysteine motif at their N termini (Fukuda, M., Kanno, E., and Mikoshiba, K. (1999) J. Biol. Chem. 274, 31421-31427), In this study, we identified a novel alternatively spliced variant of synaptotagmin (Syt) VI that lacks the N-terminal 85 amino acids including the transmembrane region (thus designated as Syt VI Delta TM). Because it lacks the cysteine motif responsible for self-dimerization, Syt VI Delta TM could not associate with Syt VI even in the presence of Ca2+. Despite lacking the transmembrane region, Syt VI Delta TM can associate with the plasma membrane through the C-terminal 29 amino acids. In adult mouse brain, two closely comigrating bands at M-r similar to 50,000, which closely corresponded to the molecular weight of recombinant Syt VI Delta TM, were detected by anti-Syt VI antibody. These immunoreactive bands were found in both soluble and membrane fractions of mouse brain, indicating that they are membrane-associated proteins (Syt VI Delta TM), but not transmembrane proteins (Syt VI), Expression of Syt VI and Syt VI Delta TM in PC12 or COS-7 cells indicated that the two molecules have a distinct subcellular distribution: Syt VI Delta TM: is present in the cytosol or is associated with the plasma membrane or internal membrane structures, whereas Syt M is localized to the endoplasmic reticulum and/or Golgi-like perinuclear compartment, These results suggest that Syt VI and Syt VI Delta TM may play distinct roles in vesicular trafficking.	RIKEN, Inst Phys & Chem Res, Brain Sci Inst, Dev Neurobiol Lab, Wako, Saitama 3510198, Japan; Univ Tokyo, Inst Med Sci, Dept Mol Neurobiol, Minato Ku, Tokyo 1088639, Japan; Japan Sci & Technol Corp, Calciosignal Net Honkomagome, Calciosignal Net Project, Bunkyo Ku, Tokyo 1130021, Japan	RIKEN; University of Tokyo; Japan Science & Technology Agency (JST)	Fukuda, M (corresponding author), RIKEN, Inst Phys & Chem Res, Brain Sci Inst, Dev Neurobiol Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	mnfukuda@brain.riken.go.jp	Fukuda, MItsunori/I-1511-2015; Mikoshiba, Katsuhiko/N-7943-2015	Fukuda, MItsunori/0000-0002-8620-5853; 				Babity JM, 1997, P NATL ACAD SCI USA, V94, P2638, DOI 10.1073/pnas.94.6.2638; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; Butz S, 1999, J BIOL CHEM, V274, P18290, DOI 10.1074/jbc.274.26.18290; Carreira CM, 1998, J BIOL CHEM, V273, P22224, DOI 10.1074/jbc.273.35.22224; Chapman ER, 1996, J BIOL CHEM, V271, P5844, DOI 10.1074/jbc.271.10.5844; Chapman ER, 1998, J BIOL CHEM, V273, P32966, DOI 10.1074/jbc.273.49.32966; Chapman ER, 1996, BIOCHEM BIOPH RES CO, V225, P326, DOI 10.1006/bbrc.1996.1174; CRAXTON M, 1995, FEBS LETT, V361, P196, DOI 10.1016/0014-5793(95)00176-A; Damer CK, 1996, J NEUROCHEM, V67, P1661; Fukuda M, 1997, BIOESSAYS, V19, P593, DOI 10.1002/bies.950190710; Fukuda M, 1999, J BIOL CHEM, V274, P31421, DOI 10.1074/jbc.274.44.31421; Fukuda M, 1996, J BIOL CHEM, V271, P8430, DOI 10.1074/jbc.271.14.8430; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; Fukuda M, 1997, BIOCHEM J, V323, P421, DOI 10.1042/bj3230421; FUKUDA M, 1995, P NATL ACAD SCI USA, V92, P10708, DOI 10.1073/pnas.92.23.10708; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; HILBUSH BS, 1994, P NATL ACAD SCI USA, V91, P8195, DOI 10.1073/pnas.91.17.8195; HUDSON AW, 1995, P NATL ACAD SCI USA, V92, P5895, DOI 10.1073/pnas.92.13.5895; Ibata K, 1998, J BIOL CHEM, V273, P12267, DOI 10.1074/jbc.273.20.12267; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Lang JC, 1997, EMBO J, V16, P5837, DOI 10.1093/emboj/16.19.5837; LaVallee TM, 1998, J BIOL CHEM, V273, P22217, DOI 10.1074/jbc.273.35.22217; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; Linial M, 1997, J NEUROCHEM, V69, P1781; Lupashin VV, 1996, J CELL BIOL, V132, P277, DOI 10.1083/jcb.132.3.277; MARTIN KC, 1995, P NATL ACAD SCI USA, V92, P11307, DOI 10.1073/pnas.92.24.11307; MIKOSHIBA K, 1995, P NATL ACAD SCI USA, V92, P10703, DOI 10.1073/pnas.92.23.10703; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MIZUTA M, 1994, J BIOL CHEM, V269, P11675; Mochida S, 1997, NEUROSCIENCE, V77, P937; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; OharaImaizumi M, 1997, P NATL ACAD SCI USA, V94, P287, DOI 10.1073/pnas.94.1.287; Osborne SL, 1999, J BIOL CHEM, V274, P59, DOI 10.1074/jbc.274.1.59; Perin MS, 1996, BIOCHEMISTRY-US, V35, P13808, DOI 10.1021/bi960853x; PERIN MS, 1991, J BIOL CHEM, V266, P615; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PIND SN, 1994, J CELL BIOL, V125, P239, DOI 10.1083/jcb.125.2.239; Schiavo G, 1998, BIOCHEM BIOPH RES CO, V248, P1, DOI 10.1006/bbrc.1998.8527; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; Sugita S, 1996, J BIOL CHEM, V271, P1262, DOI 10.1074/jbc.271.3.1262; Tarantini F, 1998, J BIOL CHEM, V273, P22209, DOI 10.1074/jbc.273.35.22209; Thompson CC, 1996, J NEUROSCI, V16, P7832; Veit M, 1996, FEBS LETT, V385, P119, DOI 10.1016/0014-5793(96)00362-6; vonPoser C, 1997, J BIOL CHEM, V272, P14314, DOI 10.1074/jbc.272.22.14314; WENDLAND B, 1991, NEURON, V6, P993, DOI 10.1016/0896-6273(91)90239-V	48	102	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31428	31434		10.1074/jbc.274.44.31428	http://dx.doi.org/10.1074/jbc.274.44.31428			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531344	hybrid			2022-12-27	WOS:000083379400048
J	Landis, C; Back, N; Homsher, E; Tobacman, LS				Landis, C; Back, N; Homsher, E; Tobacman, LS			Effects of tropomyosin internal deletions on thin filament function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; TROPONIN-TROPOMYOSIN; MYOSIN SUBFRAGMENT-1; ALPHA-TROPOMYOSIN; LABELED TROPOMYOSIN; COOPERATIVE BINDING; CARDIAC TROPONIN; ACTIN-FILAMENTS; REGULATED ACTIN; AMINO TERMINUS	Striated muscle tropomyosin spans seven actin monomers and contains seven quasi-repeating regions with loose sequence similarity. Each region contains a hypothesized actin binding motif, To examine the functions of these regions, full-length tropomyosin was compared with tropomyosin internal deletion mutants spanning either five or four actins, Actin-troponin-tropomyosin filaments lacking tropomyosin regions 2-8 exhibited calcium-sensitive regulation in in vitro motility and myosin S1 ATP hydrolysis experiments, similar to filaments with full-length tropomyosin. In contrast, filaments lacking tropomyosin regions 3-4 were inhibitory to these myosin functions, Deletion of regions 2-4, 3-5, or 4-6 had little effect on tropomyosin binding to actin in the presence of troponin or troponin-Ca2+, or in the absence of troponin, However, all of these mutants inhibited myosin cycling, Deletion of the quasi-repeating regions diminished the prominent effect of myosin S1 on tropomyosin-actin binding. Interruption of this cooperative, myosin-tropomyosin interaction was least severe for the mutant lacking regions 2-3 and therefore correlated with inhibition of myosin cycling. Regions 3, 4, and 5 each contributed about 1.5 kcal/mol to this process, whereas regions 2 and 6 contributed much less, We suggest that a myosin-induced conformational change in actin facilitates the azimuthal repositioning of tropomyosin which is an essential part of regulation.	Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA; Univ Calif Los Angeles, Dept Physiol, Los Angeles, CA 90024 USA	University of Iowa; University of Iowa; University of California System; University of California Los Angeles	Tobacman, LS (corresponding author), Univ Iowa, Dept Internal Med, 200 Hawkins Dr,SE610-GH, Iowa City, IA 52242 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038834, R29HL038834] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030988] Funding Source: NIH RePORTER; NHLBI NIH HHS [NHLBI-38834] Funding Source: Medline; NIAMS NIH HHS [AR-30988] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BABU A, 1992, J BIOL CHEM, V267, P15469; BUTTERS CA, 1993, J BIOL CHEM, V268, P15565; Butters CA, 1997, J BIOL CHEM, V272, P13196, DOI 10.1074/jbc.272.20.13196; CabralLilly D, 1997, BIOPHYS J, V73, P1763, DOI 10.1016/S0006-3495(97)78206-7; CANTINO ME, 1993, BIOPHYS J, V64, P211, DOI 10.1016/S0006-3495(93)81358-4; Cassell M, 1996, J BIOL CHEM, V271, P12867, DOI 10.1074/jbc.271.22.12867; CHO YJ, 1990, J BIOL CHEM, V265, P538; CREGG JM, 1993, BIO-TECHNOL, V11, P905, DOI 10.1038/nbt0893-905; CRIDDLE AH, 1985, BIOCHEM J, V232, P343, DOI 10.1042/bj2320343; DAHIYA R, 1994, J BIOL CHEM, V269, P29457; EATON BL, 1976, SCIENCE, V192, P1337, DOI 10.1126/science.131972; Feng L, 1997, J BIOL CHEM, V272, P16829, DOI 10.1074/jbc.272.27.16829; FISHER D, 1995, J BIOL CHEM, V270, P25455, DOI 10.1074/jbc.270.43.25455; GEEVES MA, 1986, PROC R SOC SER B-BIO, V229, P85, DOI 10.1098/rspb.1986.0076; GUTH K, 1987, J BIOL CHEM, V262, P13627; Hammell RL, 1996, J BIOL CHEM, V271, P4236; Hammell RL, 1997, J BIOL CHEM, V272, P22409, DOI 10.1074/jbc.272.36.22409; Haselgrove J. C., 1972, COLD SPRING HARB SYM, V37, P341; HEALD RW, 1988, J BIOL CHEM, V263, P5254; HILL LE, 1992, J BIOL CHEM, V267, P16106; HILL TL, 1980, P NATL ACAD SCI-BIOL, V77, P3186, DOI 10.1073/pnas.77.6.3186; Hinkle A, 1999, J BIOL CHEM, V274, P7157, DOI 10.1074/jbc.274.11.7157; Hinkle A, 1999, J BIOL CHEM, V274, P31750; HitchcockDeGregori SE, 1996, J BIOL CHEM, V271, P3600; HITCHCOCKDEGREGORI SE, 1990, J MOL BIOL, V214, P885, DOI 10.1016/0022-2836(90)90343-K; HOLMES KC, 1995, BIOPHYS J S, V68, P2; Homsher E, 1996, BIOPHYS J, V70, P1881, DOI 10.1016/S0006-3495(96)79753-9; HOMSHER E, 1992, AM J PHYSIOL, V262, P714; Huxley H. E., 1972, COLD SPRING HARB SYM, V37, P361; ISHII Y, 1991, J BIOL CHEM, V266, P6894; ISHII Y, 1990, BIOCHEMISTRY-US, V29, P1160, DOI 10.1021/bi00457a010; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Landis CA, 1997, J BIOL CHEM, V272, P14051, DOI 10.1074/jbc.272.22.14051; LORENZ M, 1995, J MOL BIOL, V246, P108, DOI 10.1006/jmbi.1994.0070; Mabuchi K, 1996, J STRUCT BIOL, V116, P278, DOI 10.1006/jsbi.1996.0043; MAK AS, 1981, J MOL BIOL, V149, P541, DOI 10.1016/0022-2836(81)90486-1; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MCKILLOP DFA, 1993, BIOPHYS J, V65, P693, DOI 10.1016/S0006-3495(93)81110-X; MCLACHLAN AD, 1976, J MOL BIOL, V103, P271, DOI 10.1016/0022-2836(76)90313-2; MEEDEL TH, 1993, J BIOL CHEM, V268, P6755; MEHEGAN JP, 1991, J BIOL CHEM, V266, P966; MONTEIRO PB, 1994, J BIOL CHEM, V269, P10461; MORRIS EP, 1984, BIOCHEMISTRY-US, V23, P2214, DOI 10.1021/bi00305a018; PARRY DAD, 1973, J MOL BIOL, V75, P33, DOI 10.1016/0022-2836(73)90527-5; PHILLIPS GN, 1979, NATURE, V278, P413, DOI 10.1038/278413a0; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; RUIZOPAZO N, 1987, J BIOL CHEM, V262, P4755; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Squire JM, 1998, FASEB J, V12, P761, DOI 10.1096/fasebj.12.10.761; TANOKURA M, 1984, J BIOCHEM, V95, P1417, DOI 10.1093/oxfordjournals.jbchem.a134749; TOBACMAN LS, 1986, BIOCHEMISTRY-US, V25, P798, DOI 10.1021/bi00352a010; TOBACMAN LS, 1987, J BIOL CHEM, V262, P4059; TRYBUS KM, 1980, P NATL ACAD SCI-BIOL, V77, P7209, DOI 10.1073/pnas.77.12.7209; TSUCHIYA T, 1982, BIOPOLYMERS, V21, P979, DOI 10.1002/bip.360210510; Vibert P, 1997, J MOL BIOL, V266, P8, DOI 10.1006/jmbi.1996.0800; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WILLADSEN KA, 1992, J BIOL CHEM, V267, P23746; WILLIAMS DL, 1983, BIOCHEMISTRY-US, V22, P2770, DOI 10.1021/bi00280a027; [No title captured]	59	62	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31279	31285		10.1074/jbc.274.44.31279	http://dx.doi.org/10.1074/jbc.274.44.31279			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531325	hybrid			2022-12-27	WOS:000083379400029
J	McGwire, GB; Becker, RP; Skidgel, RA				McGwire, GB; Becker, RP; Skidgel, RA			Carboxypeptidase M, a glycosylphosphatidylinositol-anchored protein, is localized on both the apical and basolateral domains of polarized Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; MEMBRANE-BOUND CARBOXYPEPTIDASE; GLYCOSYL-PHOSPHATIDYLINOSITOL; RECEPTOR; PEPTIDE; SIGNAL; TRANSCYTOSIS; PURIFICATION; RETENTION; TRANSPORT	Carboxypeptidase M, a glycosylphosphatidyinositol-anchored membrane glycoprotein, is highly expressed in Madin-Darby canine kidney (MDCK) cells, where it was previously shown that the glycosylphosphatidylinositol anchor and N-linked carbohydrate are apical targeting signals. Here, we show that carboxypeptidase id has an unusual, non-polarized distribution, with up to 44% on the basolateral domain of polarized MDCK cells grown on semipermeable inserts, Alkaline phosphatase, as well as five other glycosylphosphatidylinositol-anchored proteins, and transmembrane gamma-glutamyl transpeptidase exhibited the expected apical localization. Basolateral carboxypeptidase was readily released by exogenous phosphatidylinositol-specific phospholipase C, showing it is glycosylphosphatidylinositol-anchored, whereas epical carboxypeptidase M was more resistant to release. In contrast, the spontaneous release of carboxypeptidase M into the medium was much higher on the apical than the basolateral domain. In pulse-chase studies,newly synthesized carboxypeptidase M arrived in equal amounts within 30 min on both domains, indicating direct sorting. After 4-8 h of chase, the steady-state distribution was attained, possibly due to transcytosis from the basolateral to the apical domain. These data suggest the presence of a unique basolateral targeting signal in carboxypeptidase M that competes with its apical targeting signals, resulting in a non-polarized distribution in MDCK cells.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Lab Peptide Res, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Anesthesiol, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Anat & Cell Biol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Skidgel, RA (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, M-C 868,835 S Wolcott, Chicago, IL 60612 USA.		McGwire, Gerd/E-3638-2011		NIDDK NIH HHS [DK41431] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041431, R56DK041431, R29DK041431] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDLI AW, 1991, J BIOL CHEM, V266, P8560; BRETSCHER MS, 1988, EMBO J, V7, P4087, DOI 10.1002/j.1460-2075.1988.tb03302.x; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; CARRETERO OA, 1989, ENDOCRINE MECHANISMS, P219; Carretero Oscar A., 1995, P983; CEREIJIDO M, 1989, ANNU REV PHYSIOL, V51, P785, DOI 10.1146/annurev.physiol.51.1.785; DEDDISH PA, 1990, J BIOL CHEM, V265, P15083; DELAHUNTY MD, 1993, J BIOL CHEM, V268, P12017; FIELD MC, 1994, J BIOL CHEM, V269, P10830; FIGUEROA CD, 1995, J HISTOCHEM CYTOCHEM, V43, P137, DOI 10.1177/43.2.7822771; Fritz BA, 1996, AM J PHYSIOL-GASTR L, V270, pG176, DOI 10.1152/ajpgi.1996.270.1.G176; GERBER LD, 1992, J BIOL CHEM, V267, P12168; Gut A, 1998, EMBO J, V17, P1919, DOI 10.1093/emboj/17.7.1919; Hobert ME, 1997, J BIOL CHEM, V272, P32901, DOI 10.1074/jbc.272.52.32901; Keller P, 1997, J CELL SCI, V110, P3001; LEBIVIC A, 1989, P NATL ACAD SCI USA, V86, P9313; Li XY, 1999, BIOCHEM BIOPH RES CO, V258, P204, DOI 10.1006/bbrc.1999.0619; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1990, J MEMBRANE BIOL, V113, P155, DOI 10.1007/BF01872889; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; LOW MG, 1989, FASEB J, V3, P1600, DOI 10.1096/fasebj.3.5.2522071; LOW MG, 1987, BIOCHEM J, V244, P1; MARATOSFLIER E, 1987, J CELL BIOL, V105, P1595, DOI 10.1083/jcb.105.4.1595; MCGWIRE GB, 1995, J BIOL CHEM, V270, P17154, DOI 10.1074/jbc.270.29.17154; NAFTALIN L, 1969, CLIN CHIM ACTA, V26, P293, DOI 10.1016/0009-8981(69)90381-7; NAGAE A, 1993, AM J RESP CELL MOL, V9, P221, DOI 10.1165/ajrcmb/9.2.221; NAGAE A, 1992, J NEUROCHEM, V59, P2201; ORLOWSKI MARIAN, 1965, ARCH IMMUNOL THERAP EXP, V13, P538; PLANCK SR, 1984, J BIOL CHEM, V259, P3053; RODRIGUEZBOULAN E, 1989, ANNU REV PHYSIOL, V51, P741, DOI 10.1146/annurev.physiol.51.1.741; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SCHAUDIES RP, 1986, ENDOCRINOLOGY, V118, P875, DOI 10.1210/endo-118-2-875; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; Skidgel R.A., 1993, RENIN ANGIOTENSIN SY, V1, DOI DOI 10.1-10.10; Skidgel R. A., 1996, ZINC METALLOPROTEASE, P241; SKIDGEL RA, 1989, J BIOL CHEM, V264, P2236; SKIDGEL RA, 1988, TRENDS PHARMACOL SCI, V9, P299, DOI 10.1016/0165-6147(88)90015-6; SKIDGEL RA, 1984, ANAL BIOCHEM, V140, P520, DOI 10.1016/0003-2697(84)90203-3; SKIDGEL RA, 1984, BIOCHEM PHARMACOL, V33, P3471, DOI 10.1016/0006-2952(84)90122-9; SKIDGEL RA, 1991, METHODS NEUROSCIENCE, V6, P373; TAN FL, 1995, METHOD ENZYMOL, V248, P663; TAN FL, 1989, J BIOL CHEM, V264, P13165	44	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31632	31640		10.1074/jbc.274.44.31632	http://dx.doi.org/10.1074/jbc.274.44.31632			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531371	hybrid			2022-12-27	WOS:000083379400075
J	Cotlin, LF; Siddiqui, MA; Simpson, F; Collawn, JF				Cotlin, LF; Siddiqui, MA; Simpson, F; Collawn, JF			Casein kinase II activity is required for transferrin receptor endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-COATED VESICLES; DEPENDENT PROTEIN-KINASE; MEDIATED ENDOCYTOSIS; ASSEMBLY POLYPEPTIDES; DOWN-REGULATION; ASIALOGLYCOPROTEIN RECEPTOR; STRUCTURAL DETERMINANTS; SURFACE FUNCTIONS; CYTOPLASMIC TAIL; SORTING SIGNALS	The effect of protein kinase inhibitors on transferrin receptor (TR) internalization was examined in HeLa, A431, 3T3-L1 cells, and primary chicken embryo fibro- blasts. We show that TR endocytosis is not affected by tyrosine kinase or protein kinase C inhibitors, but is inhibited by one serine/threonine kinase inhibitor, H-89. Inhibition occurred within 15 min, was completely reversible after H-89 withdrawal, and was specific for endocytosis rather than pinocytosis since a TR mutant lacking an internalization signal was not affected. Interestingly, H-89 also inhibited the internalization of a TR chimera containing the major histocompatibility complex class II invariant chain cytoplasmic tail, indicating that the effect was not specific for the TR. Since H-89 inhibits a number of kinases, we employed a permeabilized cell endocytosis assay to further characterize the kinase. In permeabilized 3T3-L1 cells, addition of pseudosubstrate inhibitor peptides of casein kinase a (CKII) blocked TR internalization by more than 50%, whereas pseudosubstrates of cyclic AMP-dependent kinase A, protein kinase C, and casein kinase I had no effect. Furthermore, addition of purified CKII to the cell-free reactions containing CKII pseudosubstrates reversed the endocytosis block, suggesting that CKII or a CKII-like activity is required for constitutive endocytosis.	Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	University of Alabama System; University of Alabama Birmingham; Scripps Research Institute	Collawn, JF (corresponding author), Univ Alabama, Dept Cell Biol, MCLM 392,UAB Stn, Birmingham, AL 35294 USA.		Simpson, Fiona/ABE-1276-2020; Simpson, Fiona/J-2721-2012	Simpson, Fiona/0000-0002-0271-781X; Simpson, Fiona/0000-0002-0271-781X; Collawn, James/0000-0002-2528-2759	NIDDK NIH HHS [R29-DK47339] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK047339] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGOSTINIS P, 1989, FEBS LETT, V259, P75, DOI 10.1016/0014-5793(89)81498-X; BARZVI D, 1986, J BIOL CHEM, V261, P9614; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BERLIN RD, 1980, J CELL BIOL, V85, P660, DOI 10.1083/jcb.85.3.660; BERLIN RD, 1978, CELL, V15, P327, DOI 10.1016/0092-8674(78)90002-8; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; Crump CM, 1999, FEBS LETT, V444, P195, DOI 10.1016/S0014-5793(99)00066-6; DAVIS RJ, 1987, J BIOL CHEM, V262, P16041; DAVIS RJ, 1986, J BIOL CHEM, V261, P9034; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; DISANTO JP, 1989, IMMUNOGENETICS, V30, P494, DOI 10.1007/BF02421181; EICHHOLTZ T, 1992, J BIOL CHEM, V267, P22490; FALLON RJ, 1994, J BIOL CHEM, V269, P11011; FALLON RJ, 1990, J BIOL CHEM, V265, P3401; FAWCETT DW, 1965, J HISTOCHEM CYTOCHEM, V13, P75, DOI 10.1177/13.2.75; GEORGIEVAHANSON V, 1988, J NEUROCHEM, V50, P307, DOI 10.1111/j.1471-4159.1988.tb13265.x; GLASS DB, 1989, J BIOL CHEM, V264, P8802; Goretzki L, 1997, J CELL SCI, V110, P1395; Hicke L, 1998, J CELL BIOL, V141, P349, DOI 10.1083/jcb.141.2.349; HILL BL, 1988, J BIOL CHEM, V263, P5499; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; Jost M, 1998, CURR BIOL, V8, P1399, DOI 10.1016/S0960-9822(98)00022-0; Kang S, 1998, J BIOL CHEM, V273, P20644, DOI 10.1074/jbc.273.32.20644; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KEEN JH, 1987, J BIOL CHEM, V262, P3864; KLAUSNER RD, 1984, P NATL ACAD SCI-BIOL, V81, P3005, DOI 10.1073/pnas.81.10.3005; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; LAMAZE C, 1993, MOL BIOL CELL, V4, P715, DOI 10.1091/mbc.4.7.715; Le Borgne R, 1998, J BIOL CHEM, V273, P29451, DOI 10.1074/jbc.273.45.29451; LIN HC, 1991, J CELL BIOL, V114, P881, DOI 10.1083/jcb.114.5.881; LITCHFIELD DW, 1992, J BIOL CHEM, V267, P13943; MAHAFFEY DT, 1990, J BIOL CHEM, V265, P16514; MANFREDI JJ, 1987, J BIOL CHEM, V262, P12182; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; MORARU II, 1990, FEBS LETT, V274, P93, DOI 10.1016/0014-5793(90)81337-N; MORRIS SA, 1990, J BIOL CHEM, V265, P3354; ODORIZZI CG, 1994, J CELL BIOL, V126, P317, DOI 10.1083/jcb.126.2.317; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; Panek HR, 1997, EMBO J, V16, P4194, DOI 10.1093/emboj/16.14.4194; PANETTI TS, 1995, J BIOL CHEM, V270, P18593, DOI 10.1074/jbc.270.31.18593; PAULOIN A, 1984, NATURE, V311, P265, DOI 10.1038/311265a0; PAULOIN A, 1993, BIOCHEM J, V296, P409, DOI 10.1042/bj2960409; PYPAERT M, 1987, EUR J CELL BIOL, V45, P23; PYPAERT M, 1991, J CELL BIOL, V114, P1159, DOI 10.1083/jcb.114.6.1159; Raman C, 1998, J BIOL CHEM, V273, P19183, DOI 10.1074/jbc.273.30.19183; Raman C, 1998, J IMMUNOL, V161, P5817; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; RUSSO GL, 1992, J BIOL CHEM, V267, P20317; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; SCHONHORN JE, 1995, J BIOL CHEM, V270, P3698, DOI 10.1074/jbc.270.8.3698; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; SMYTHE E, 1991, EUR J BIOCHEM, V202, P689, DOI 10.1111/j.1432-1033.1991.tb16424.x; VIRSHUP DM, 1988, J CELL BIOL, V106, P39, DOI 10.1083/jcb.106.1.39; WALTER J, 1994, CELL MOL BIOL RES, V40, P473; Wilde A, 1996, J CELL BIOL, V135, P635, DOI 10.1083/jcb.135.3.635; WILEY HS, 1982, J BIOL CHEM, V257, P4222; Wu-Wong JSR, 1999, J BIOL CHEM, V274, P8103, DOI 10.1074/jbc.274.12.8103; ZAREMBA S, 1983, J CELL BIOL, V97, P1339, DOI 10.1083/jcb.97.5.1339; ZERIAL M, 1987, EMBO J, V6, P2661, DOI 10.1002/j.1460-2075.1987.tb02557.x	62	23	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30550	30556		10.1074/jbc.274.43.30550	http://dx.doi.org/10.1074/jbc.274.43.30550			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521437	hybrid			2022-12-27	WOS:000083276700033
J	Qi, JJ; Peters, KW; Liu, CG; Wang, JM; Edinger, RS; Johnson, JP; Watkins, SC; Frizzell, RA				Qi, JJ; Peters, KW; Liu, CG; Wang, JM; Edinger, RS; Johnson, JP; Watkins, SC; Frizzell, RA			Regulation of the amiloride-sensitive epithelial sodium channel by syntaxin 1A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; CFTR CHLORIDE CHANNELS; N-TYPE; CALCIUM CHANNELS; SNARE PROTEINS; PHOSPHORYLATION; TRAFFICKING; EXPRESSION; TRANSPORT; MEMBRANE	The first step in transepithelial sodium absorption lies at the apical membrane where the amiloride-sensitive, epithelial sodium channel, ENaC, facilitates sodium entry into the cell, Here we report that the vesicle traffic regulatory (SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor)) protein, syntaxin 1A (S1A), inhibits ENaC mediated sodium entry. This inhibitory effect is selective for S1A and is not reproduced by syntaxin 3, The inhibition does not require the membrane anchoring domain of syntaxin Ik It was reversed by the S1A-binding protein, Munc-18, but not by a Munc-18 mutant, which lacks syntaxin affinity. Immunostaining of epitope-tagged ENaC subunits showed that syntaxin 1A decreases ENaC current by reducing the number of ENaC channels in the plasma membrane; S1A does not interfere with ENaC protein expression. Immunoprecipitation of syntaxin 1A from the sodium-transporting epithelial cell line, A6, co-precipitates ENaC, These findings indicate that syntaxin 1A and other members of the SNARE machinery are involved in the control of plasma membrane ENaC content, and they suggest that SNARE proteins participate in the regulation of sodium absorption in relation to agonist mediated vesicle insertion-retrieval processes.	Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Frizzell, RA (corresponding author), Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, 3500 Terrace St,S362 BST, Pittsburgh, PA 15261 USA.		Watkins, Simon/ABG-2590-2021	Watkins, Simon/0000-0003-4092-1552	NIDDK NIH HHS [DK47874, DK54814] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054814, R01DK047874] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barbry P, 1997, AM J PHYSIOL-GASTR L, V273, pG571, DOI 10.1152/ajpgi.1997.273.3.G571; BENNETT MK, 1995, CURR OPIN CELL BIOL, V7, P581, DOI 10.1016/0955-0674(95)80016-6; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; Dascher C, 1996, J BIOL CHEM, V271, P15866, DOI 10.1074/jbc.271.27.15866; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Foster LJ, 1998, BIOCHEMISTRY-US, V37, P11089, DOI 10.1021/bi980253t; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Kokko KE, 1997, AM J PHYSIOL-CELL PH, V273, pC548, DOI 10.1152/ajpcell.1997.273.2.C548; Low SH, 1998, J CELL BIOL, V141, P1503, DOI 10.1083/jcb.141.7.1503; MARUNAKA Y, 1991, AM J PHYSIOL, V260, pC1071, DOI 10.1152/ajpcell.1991.260.5.C1071; Nagamatsu S, 1996, J BIOL CHEM, V271, P1160, DOI 10.1074/jbc.271.2.1160; Naren AP, 1998, P NATL ACAD SCI USA, V95, P10972, DOI 10.1073/pnas.95.18.10972; Naren AP, 1997, NATURE, V390, P302, DOI 10.1038/36882; Olson AL, 1997, MOL CELL BIOL, V17, P2425, DOI 10.1128/MCB.17.5.2425; Peters KW, 1999, AM J PHYSIOL-CELL PH, V277, pC174, DOI 10.1152/ajpcell.1999.277.1.C174; Pevsner J, 1996, J NEUROSCI RES, V45, P89, DOI 10.1002/(SICI)1097-4547(19960715)45:2<89::AID-JNR1>3.3.CO;2-K; Rokaw MD, 1996, J BIOL CHEM, V271, P4491; Sheng ZH, 1996, NATURE, V379, P451, DOI 10.1038/379451a0; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Shimkets RA, 1998, P NATL ACAD SCI USA, V95, P3301, DOI 10.1073/pnas.95.6.3301; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Takahashi A, 1996, AM J PHYSIOL-CELL PH, V271, pC1887, DOI 10.1152/ajpcell.1996.271.6.C1887; Wiser O, 1996, EMBO J, V15, P4100, DOI 10.1002/j.1460-2075.1996.tb00785.x; Yokoyama CT, 1997, J NEUROSCI, V17, P6929	26	64	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30345	30348		10.1074/jbc.274.43.30345	http://dx.doi.org/10.1074/jbc.274.43.30345			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521407	hybrid			2022-12-27	WOS:000083276700003
J	Saito, J; Kita, A; Higuchi, Y; Nagata, Y; Ando, A; Miki, K				Saito, J; Kita, A; Higuchi, Y; Nagata, Y; Ando, A; Miki, K			Crystal structure of chitosanase from Bacillus circulans MH-K1 at 1.6-angstrom resolution and its substrate recognition mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-SEQUENCE SIMILARITIES; STREPTOMYCES SP N174; VULGARE L SEEDS; GLYCOSYL HYDROLASES; ANGSTROM RESOLUTION; PROTEIN STRUCTURES; PURIFICATION; CHITINASE; CLASSIFICATION; ENDOCHITINASE	Chitosanase from Bacillus circulans MH-K1 is a 29-kDa extracullular protein composed of 259 amino acids. The crystal structure of chitosanase from B. circulans MH-K1 has been determined by multiwavelength anomalous diffraction method and refined to crystallographic R = 19.2% (R-free = 23.5%) for the diffraction data at 1.6-Angstrom resolution collected by synchrotron radiation. The enzyme has two globular upper and lower domains, which generate the active site deft for the substrate binding. The overall molecular folding is similar to chitosanase from Streptomyces sp. N174, although there is only 20% identity at the amino acid sequence level between both chitosanases. However, there are three regions in which the topology is remarkably different. In addition, the disulfide bridge between Cys(50) and Cys(124) joins the beta 1 strand and the alpha 7 helix, which is not conserved among other chitosanases. The orientation of two backbone helices, which connect the two domains, is also different and is responsible for the differences in size and shape of the active site cleft in these Dove chitosanases. This structural difference in the active site cleft is the reason why the enzymes specifically recognize different substrates and catalyze different types of chitosan degradation.	Kyoto Univ, Grad Sch Sci, Dept Chem, Sakyo Ku, Kyoto 6068502, Japan; Chiba Univ, Grad Sch Sci & Technol, Dept Biotechnol, Matsudo, Chiba 2718510, Japan	Kyoto University; Chiba University	Miki, K (corresponding author), Kyoto Univ, Grad Sch Sci, Dept Chem, Sakyo Ku, Kyoto 6068502, Japan.							ANDO A, 1992, J GEN APPL MICROBIOL, V38, P135, DOI 10.2323/jgam.38.135; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Boucher I, 1995, J BIOL CHEM, V270, P31077, DOI 10.1074/jbc.270.52.31077; BOUCHER I, 1992, APPL MICROBIOL BIOT, V38, P188, DOI 10.1007/BF00174466; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1993, XPLOR VERSION 3 1 MA; FUKAMIZO T, 1995, BIOCHEM J, V311, P377, DOI 10.1042/bj3110377; Fukamizo T, 1997, BIOCHEM CELL BIOL, V75, P687, DOI 10.1139/bcb-75-6-687; HART PJ, 1993, J MOL BIOL, V229, P189, DOI 10.1006/jmbi.1993.1017; HART PJ, 1995, J MOL BIOL, V248, P402, DOI 10.1006/jmbi.1995.0230; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; HOLM L, 1994, FEBS LETT, V340, P129, DOI 10.1016/0014-5793(94)80187-8; HUYNH QK, 1992, J BIOL CHEM, V267, P6635; IZUME M, 1992, BIOSCI BIOTECH BIOCH, V56, P448, DOI 10.1271/bbb.56.448; KLEYWEGT GJ, 1994, ESF CCP4 NEWSLETTER, V31, P9; KLEYWEGT GJ, 1993, ESF CCP4 NEWSLETTER, V28, P56; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lu ZQ, 1996, VIROLOGY, V216, P102, DOI 10.1006/viro.1996.0038; Marcotte EM, 1996, NAT STRUCT BIOL, V3, P155, DOI 10.1038/nsb0296-155; MASSON JY, 1994, GENE, V140, P103, DOI 10.1016/0378-1119(94)90738-2; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mitsutomi M., 1996, CHITIN ENZYMOL, V2, P273; MIYAHARA J, 1986, NUCL INSTRUM METH A, V246, P572, DOI 10.1016/0168-9002(86)90156-7; OKAJIMA S, 1995, J GEN APPL MICROBIOL, V41, P351, DOI 10.2323/jgam.41.351; OKAJIMA S, 1994, J FERMENT BIOENG, V77, P617, DOI 10.1016/0922-338X(94)90142-2; OSSWALD WF, 1994, PLANT CELL PHYSIOL, V35, P811, DOI 10.1093/oxfordjournals.pcp.a078662; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OUAKFAOUI SE, 1992, PHYTOCHEMISTRY, V31, P1513; Parro V, 1997, MICROBIOL-UK, V143, P1321, DOI 10.1099/00221287-143-4-1321; PERRAKIS A, 1994, STRUCTURE, V2, P1169, DOI 10.1016/S0969-2126(94)00119-7; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROUSSEL A, 1992, TURBOFRODO; SAITO JI, 1995, ACTA CRYSTALLOGR D, V51, P856, DOI 10.1107/S090744499500268X; SAKABE N, 1995, REV SCI INSTRUM, V66, P1276, DOI 10.1063/1.1146021; SHARMA P, 1993, PHYSIOL MOL PLANT P, V43, P57, DOI 10.1006/pmpp.1993.1040; Shimosaka M, 1996, J FERMENT BIOENG, V82, P426, DOI 10.1016/S0922-338X(97)86977-2; Song HK, 1996, ACTA CRYSTALLOGR D, V52, P289, DOI 10.1107/S0907444995009061; SONG HW, 1994, J MOL BIOL, V244, P522, DOI 10.1006/jmbi.1994.1750; VERBURG JG, 1991, PLANT PHYSIOL, V95, P450, DOI 10.1104/pp.95.2.450; VONSCHELTINGA ACT, 1994, STRUCTURE, V2, P1181; WANG BC, 1985, METHOD ENZYMOL, V115, P90; YABUKI M, 1988, J GEN APPL MICROBIOL, V34, P255, DOI 10.2323/jgam.34.255; Yamada T, 1997, VIROLOGY, V230, P361, DOI 10.1006/viro.1997.8486; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158; [No title captured]	50	91	99	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30818	30825		10.1074/jbc.274.43.30818	http://dx.doi.org/10.1074/jbc.274.43.30818			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521473	hybrid			2022-12-27	WOS:000083276700069
J	Sorensen, P; Wintersberger, E				Sorensen, P; Wintersberger, E			Sp1 and NF-Y are necessary and sufficient for growth-dependent regulation of the hamster thymidine kinase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE T-ANTIGEN; BINDING TRANSCRIPTION FACTORS; CELL-CYCLE; GENE PROMOTER; RETINOBLASTOMA PROTEIN; HISTONE DEACETYLASE; IN-VIVO; REPRESS TRANSCRIPTION; CLASS-II; EXPRESSION	Thymidine kinase (TK) genes from different species are growth- and cell cycle-regulated in a very similar manner; still, the promoter regions of these genes show little homology to each other. It was previously shown that the murine TK gene is growth-regulated by Sp1 and E2F, Here we have characterized cis-regulatory elements in the hamster promoter that are essential and sufficient to confer efficient and serum-responsive expression. The TK promoter was isolated from baby hamster kidney cells. DNase I protection experiments revealed a protected region from positions -24 to -99 relative to the transcription start site. Within this region, binding sites for the transcription factor Sp1 and a CCAAT box, which interacts with the transcription factor NF-Y, were identified. An E2F-like sequence was found not to bind protein, and its removal did not affect promoter activity. This was supported by the observation that cotransfection of a hamster TK reporter gene construct with E2F-1 does not lead to transactivation of the promoter. A 122-base pair region that contains a single Sp1 site, a CCAAT box, and a TATA element was found to be sufficient for serum-responsive expression of a reporter gene. Mutations that inactivate any one of these three elements caused a strong reduction or a loss of promoter activity.	Univ Vienna, Vienna Bioctr, Inst Mol Biol, A-1030 Vienna, Austria	University of Vienna; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA)	Wintersberger, E (corresponding author), Univ Vienna, Vienna Bioctr, Inst Mol Biol, Dr Bohr Gasse 9, A-1030 Vienna, Austria.	Wi@Mol.Univie.Ac.At						Anderson MM, 1996, J VIROL, V70, P6304, DOI 10.1128/JVI.70.9.6304-6313.1996; ARCOT SS, 1989, J BIOL CHEM, V264, P2343; AUBIN RJ, 1988, SOMAT CELL MOLEC GEN, V14, P155, DOI 10.1007/BF01534401; Baker A, 1997, GENE THER, V4, P773, DOI 10.1038/sj.gt.3300471; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CHANG ZF, 1994, J BIOL CHEM, V269, P17893; Currie RA, 1998, J BIOL CHEM, V273, P1430, DOI 10.1074/jbc.273.3.1430; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; DOU QP, 1994, J BIOL CHEM, V269, P1306; FILATOV D, 1995, J BIOL CHEM, V270, P25239, DOI 10.1074/jbc.270.42.25239; GOOD L, 1995, J CELL PHYSIOL, V163, P636, DOI 10.1002/jcp.1041630326; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Katula KS, 1997, CELL GROWTH DIFFER, V8, P811; Kim EC, 1996, CELL GROWTH DIFFER, V7, P1741; Kim EC, 1997, CELL GROWTH DIFFER, V8, P1329; LEWIS JA, 1986, MOL CELL BIOL, V6, P2262, DOI 10.1128/MCB.6.6.2262; LEWIS JA, 1986, MOL CELL BIOL, V6, P1998, DOI 10.1128/MCB.6.6.1998; LEWIS JA, 1983, MOL CELL BIOL, V3, P1815, DOI 10.1128/MCB.3.10.1815; LI LJ, 1993, P NATL ACAD SCI USA, V90, P3554, DOI 10.1073/pnas.90.8.3554; Li Q, 1998, EMBO J, V17, P6300, DOI 10.1093/emboj/17.21.6300; Linhoff MW, 1997, MOL CELL BIOL, V17, P4589, DOI 10.1128/MCB.17.8.4589; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; MUDRAK I, 1994, MOL CELL BIOL, V14, P1886, DOI 10.1128/MCB.14.3.1886; OGRIS E, 1993, J VIROL, V67, P1765, DOI 10.1128/JVI.67.4.1765-1771.1993; Roder K, 1997, J BIOL CHEM, V272, P21616, DOI 10.1074/jbc.272.34.21616; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SEISER C, 1989, NUCLEIC ACIDS RES, V17, P185, DOI 10.1093/nar/17.1.185; Slansky JE, 1996, BIOESSAYS, V18, P55, DOI 10.1002/bies.950180111; Tommasi S, 1997, J BIOL CHEM, V272, P30483, DOI 10.1074/jbc.272.48.30483; Trouche D, 1996, P NATL ACAD SCI USA, V93, P1439, DOI 10.1073/pnas.93.4.1439; WINTERSBERGER E, 1992, ADV ENZYME REGUL, V32, P241; WRIGHT KL, 1994, EMBO J, V13, P4042, DOI 10.1002/j.1460-2075.1994.tb06721.x; WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	42	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30943	30949		10.1074/jbc.274.43.30943	http://dx.doi.org/10.1074/jbc.274.43.30943			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521489	hybrid			2022-12-27	WOS:000083276700085
J	Urso, B; Cope, DL; Kalloo-Hosein, HE; Hayward, AC; Whitehead, JP; O'Rahilly, S; Siddle, K				Urso, B; Cope, DL; Kalloo-Hosein, HE; Hayward, AC; Whitehead, JP; O'Rahilly, S; Siddle, K			Differences in signaling properties of the cytoplasmic domains of the insulin receptor and insulin-like growth factor receptor in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; PROTEIN-KINASE-B; GLUCOSE-TRANSPORTER GLUT4; TYROSINE KINASE; GLYCOGEN-SYNTHESIS; PHOSPHOINOSITIDE 3-KINASE; TERMINAL DOMAIN; IGF-I; ACTIVATION; PHOSPHORYLATION	Insulin and insulin-like growth factors (IGFs) elicit distinct but overlapping biological effects in vivo. To investigate whether differences in intrinsic signaling capacity of receptors contribute to biological specificity, we constructed chimeric receptors containing the extracellular portion of the neurotrophin receptor TrkC fused to the intracellular portion of the insulin or IGF-I receptors, Chimeras were stably expressed in 3T3-L1 adipocytes at levels comparable to endogenous insulin receptors and were efficiently activated by neurotrophin-3. The wild-type insulin receptor chimera mediated approximately 2-fold greater phosphorylation of insulin receptor substrate 1 (IRS-1), association of IRS-1 with phosphoinositide 3-kinase, stimulation of glucose uptake, and GLUT4 translocation, compared with the IGF-I receptor chimera. In contrast, the IGF-I receptor chimera mediated more effective Shc phosphorylation, association of Shc with Grb2, and activation of mitogen-activated protein kinase compared with the insulin receptor chimera. The two receptors elicited similar activation of protein kinase B, p70S6 kinase, and glycogen synthesis. We conclude that the insulin receptor mediates some aspects of metabolic signaling in adipocytes more effectively than the IGF-I receptor, as a consequence of more efficient phosphorylation of IRS-1 and greater recruitment/activation of phosphoinositide 3-kinase.	Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Cambridge CB2 2QR, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Siddle, K (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Cambridge CB2 2QR, England.	ks14@mole.bio.cam.ac.uk	O'Rahilly, Stephen/ABF-6509-2020; Whitehead, Jonathan/F-5022-2014	O'Rahilly, Stephen/0000-0003-2199-4449; Whitehead, Jonathan/0000-0003-3978-3148				Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Bailyes EM, 1997, BIOCHEM J, V327, P209, DOI 10.1042/bj3270209; Brady MJ, 1998, J BIOL CHEM, V273, P14063, DOI 10.1074/jbc.273.23.14063; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; Chaika OV, 1997, J BIOL CHEM, V272, P11968, DOI 10.1074/jbc.272.18.11968; CHAN CP, 1985, P NATL ACAD SCI USA, V82, P4563, DOI 10.1073/pnas.82.14.4563; Chow JC, 1998, J BIOL CHEM, V273, P4672, DOI 10.1074/jbc.273.8.4672; CODERRE L, 1995, J BIOL CHEM, V270, P27584, DOI 10.1074/jbc.270.46.27584; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dandekar AA, 1998, ENDOCRINOLOGY, V139, P3578, DOI 10.1210/en.139.8.3578; DEMEYTS P, 1995, METABOLISM, V44, P2, DOI 10.1016/0026-0495(95)90214-7; DENTON RM, 1995, EUR J BIOCHEM, V227, P597, DOI 10.1111/j.1432-1033.1995.tb20179.x; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; Esposito DL, 1997, ENDOCRINOLOGY, V138, P2979, DOI 10.1210/en.138.7.2979; FARIA TN, 1994, J BIOL CHEM, V269, P13922; Foletta VC, 1996, IMMUNOL CELL BIOL, V74, P121, DOI 10.1038/icb.1996.17; GRONBORG M, 1993, J BIOL CHEM, V268, P23435; Hajduch E, 1998, DIABETES, V47, P1006, DOI 10.2337/diabetes.47.7.1006; He WM, 1998, J BIOL CHEM, V273, P6860, DOI 10.1074/jbc.273.12.6860; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; HOFMANN C, 1989, J BIOL CHEM, V264, P8606; Holman GD, 1997, DIABETOLOGIA, V40, P991, DOI 10.1007/s001250050780; Imanaka T, 1998, J BIOL CHEM, V273, P25347, DOI 10.1074/jbc.273.39.25347; KallooHosein HE, 1997, J BIOL CHEM, V272, P24325, DOI 10.1074/jbc.272.39.24325; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; KRUGER MS, 1996, EXP CLIN ENDOCR S2, V104, P38; LAMMERS R, 1989, EMBO J, V8, P1369, DOI 10.1002/j.1460-2075.1989.tb03517.x; Laviola L, 1997, J CLIN INVEST, V99, P830, DOI 10.1172/JCI119246; MAEGAWA H, 1988, J BIOL CHEM, V263, P8912; Martin LB, 1998, J BIOL CHEM, V273, P1444, DOI 10.1074/jbc.273.3.1444; MASTICK CC, 1994, ENDOCRINOLOGY, V135, P214, DOI 10.1210/en.135.1.214; Millar CA, 1997, BIOCHEM SOC T, V25, P974, DOI 10.1042/bst0250974; Morris AJ, 1996, P NATL ACAD SCI USA, V93, P8401, DOI 10.1073/pnas.93.16.8401; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1991, J BIOL CHEM, V266, P10616; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; Park BC, 1999, BIOCHEMISTRY-US, V38, P7517, DOI 10.1021/bi9830718; Rother KI, 1998, J BIOL CHEM, V273, P17491, DOI 10.1074/jbc.273.28.17491; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sasaoka T, 1996, ENDOCRINOLOGY, V137, P4427, DOI 10.1210/en.137.10.4427; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Staubs PA, 1998, J BIOL CHEM, V273, P25139, DOI 10.1074/jbc.273.39.25139; STEELEPERKINS G, 1988, J BIOL CHEM, V263, P11486; TAKATA Y, 1991, J BIOL CHEM, V266, P9135; TARTARE S, 1994, J BIOL CHEM, V269, P11449; TAVARE JM, 1993, BIOCHIM BIOPHYS ACTA, V1178, P21, DOI 10.1016/0167-4889(93)90106-Y; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299; WEILAND M, 1991, J CELL PHYSIOL, V149, P428, DOI 10.1002/jcp.1041490311; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; White MF, 1998, CURR TOP MICROBIOL, V228, P179; White MF, 1997, DIABETOLOGIA, V40, pS2, DOI 10.1007/s001250051387; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; XU B, 1995, J BIOL CHEM, V270, P29825; YANG J, 1992, J BIOL CHEM, V267, P10393; ZAPF A, 1994, ENDOCRINOLOGY, V134, P2445, DOI 10.1210/en.134.6.2445	63	54	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30864	30873		10.1074/jbc.274.43.30864	http://dx.doi.org/10.1074/jbc.274.43.30864			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521479	hybrid			2022-12-27	WOS:000083276700075
J	van Santen, Y; Benen, JAE; Schroter, KH; Kalk, KH; Armand, S; Visser, J; Dijkstra, BW				van Santen, Y; Benen, JAE; Schroter, KH; Kalk, KH; Armand, S; Visser, J; Dijkstra, BW			1.68-angstrom crystal structure of endopolygalacturonase II from Aspergillus niger and identification of active site residues by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARALLEL BETA-HELIX; PHAGE-P22 TAILSPIKE PROTEIN; GLYCOSYL HYDROLASES; PECTATE LYASE; 3-DIMENSIONAL STRUCTURE; VIRULENCE FACTOR; POLYGALACTURONASES; RESOLUTION; MODELS; REFINEMENT	Polygalacturonases specifically hydrolyze polygalaturonate, a major constituent of plant cell wall pectin. To understand the catalytic mechanism and substrate and product specificity of these enzymes, we have solved the x-ray structure of endopolygalacturonase LT of Aspergillus niger and we have carried out site-directed mutagenesis studies, The enzyme folds into a right-handed parallel beta-helix with 10 complete turns. The beta-helix is composed of four parallel beta-sheets, and has one very small alpha-helix near the N terminus, which shields the enzyme's hydrophobic core. Loop regions form a cleft on the exterior of the beta-helix, Site-directed mutagenesis of Asp(180), Asp(201), Asp(202) His(223) Arg(256), and Lys(258), which are located in this cleft, results in a severe reduction of activity, demonstrating that these residues are important for substrate binding and/or catalysis, The juxtaposition of the catalytic residues differs from that normally encountered in inverting glycosyl hydrolases, A comparison of the endopolygalacturonase II active site with that of the P22 tailspike rhamnosidase suggests that Asp(180) and Asp(202) activate the attaching nucleophilic water molecule, while Asp(201) protonates the glycosidic oxygen of the scissile bond.	Univ Groningen, Biophys Chem Lab, NL-9747 AG Groningen, Netherlands; Wageningen Univ Agr, Sect Mol Genet & Ind Microorganisms, NL-6703 HA Wageningen, Netherlands	University of Groningen; Wageningen University & Research	Dijkstra, BW (corresponding author), Univ Groningen, Biophys Chem Lab, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.		Dijkstra, Bauke W./H-4308-2019	Dijkstra, Bauke W./0000-0001-9731-6586				Alberts IL, 1998, PROTEIN SCI, V7, P1700, DOI 10.1002/pro.5560070805; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Benen JAE, 1996, PROGR BIOTECHNOL, V14, P221, DOI 10.1016/S0921-0423(96)80257-7; Biely P, 1996, FEBS LETT, V382, P249, DOI 10.1016/0014-5793(96)00171-8; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BUSSINK HJD, 1990, FEBS LETT, V273, P127, DOI 10.1016/0014-5793(90)81066-W; BUSSINK HJD, 1992, EUR J BIOCHEM, V208, P83, DOI 10.1111/j.1432-1033.1992.tb17161.x; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; De Vries J, 1982, CARBOHYD POLYM, V2, P25, DOI DOI 10.1016/0144-8617(82)90043-1; Emsley P, 1996, NATURE, V381, P90, DOI 10.1038/381090a0; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; Jenkins J, 1998, J STRUCT BIOL, V122, P236, DOI 10.1006/jsbi.1998.3985; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JURNAK F, 1994, CURR OPIN STRUC BIOL, V4, P802, DOI 10.1016/0959-440X(94)90259-3; Kester HCM, 1996, EUR J BIOCHEM, V240, P738, DOI 10.1111/j.1432-1033.1996.0738h.x; KESTER HCM, 1990, BIOTECHNOL APPL BIOC, V12, P150; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; Lietzke SE, 1996, PLANT PHYSIOL, V111, P73, DOI 10.1104/pp.111.1.73; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; Mayans O, 1997, STRUCTURE, V5, P677, DOI 10.1016/S0969-2126(97)00222-0; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; ONeill M., 1990, METHODS PLANT BIOCH, V2, P415, DOI [DOI 10.1016/B978-0-12-461012-5.50018-5, 10.1016/b978-0-12-461012-5.50018-5]; OTWINOWSKI Z, 1993, P CCP 4 STUD WEEK DA; Parenicova L, 1998, EUR J BIOCHEM, V251, P72, DOI 10.1046/j.1432-1327.1998.2510072.x; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; Petersen TN, 1997, STRUCTURE, V5, P533, DOI 10.1016/S0969-2126(97)00209-8; PICKERSGILL R, 1994, NAT STRUCT BIOL, V1, P717, DOI 10.1038/nsb1094-717; Pickersgill R, 1998, J BIOL CHEM, V273, P24660, DOI 10.1074/jbc.273.38.24660; Pitson SM, 1998, BIOCHEM BIOPH RES CO, V242, P552, DOI 10.1006/bbrc.1997.8009; SCHOLS HA, 1995, THESIS AGR U WAGENIN; SCHROTER KH, 1994, J MOL BIOL, V243, P351, DOI 10.1006/jmbi.1994.1660; Steinbacher S, 1996, P NATL ACAD SCI USA, V93, P10584, DOI 10.1073/pnas.93.20.10584; STEINBACHER S, 1994, SCIENCE, V265, P383, DOI 10.1126/science.8023158; Steinbacher S, 1997, J MOL BIOL, V267, P865, DOI 10.1006/jmbi.1997.0922; Suykerbuyk MEG, 1997, APPL ENVIRON MICROB, V63, P2507, DOI 10.1128/AEM.63.7.2507-2515.1997; van Asselt EJ, 1998, ACTA CRYSTALLOGR D, V54, P58, DOI 10.1107/S0907444997010330; Vitali J, 1998, PLANT PHYSIOL, V116, P69, DOI 10.1104/pp.116.1.69; WALKINSHAW MD, 1981, J MOL BIOL, V153, P1055, DOI 10.1016/0022-2836(81)90467-8; Yang Y, 1997, RAPID COMMUN MASS SP, V11, P1257; YODER MD, 1995, FASEB J, V9, P335, DOI 10.1096/fasebj.9.5.7896002; YODER MD, 1993, SCIENCE, V260, P1503, DOI 10.1126/science.8502994	46	176	182	3	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30474	30480		10.1074/jbc.274.43.30474	http://dx.doi.org/10.1074/jbc.274.43.30474			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521427	hybrid			2022-12-27	WOS:000083276700023
J	Hattori, K; Hatakeyama, S; Shirane, M; Matsumoto, M; Nakayama, K				Hattori, K; Hatakeyama, S; Shirane, M; Matsumoto, M; Nakayama, K			Molecular dissection of the interactions among I kappa B alpha, FWD1, and Skp1 required for ubiquitin-mediated proteolysis of I kappa B alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-BOX PROTEIN; KINASE COMPLEX; CELL-CYCLE; NEGATIVE REGULATOR; LIGASE COMPLEX; BETA-TRCP; IKK-ALPHA; PHOSPHORYLATION; DEGRADATION; SIGNAL	The SCF complex containing Skp1, Cul1, and the F-box protein FWD1 (the mouse homologue of Drosophila Slimb and Xenopus beta-TrCP) functions as the ubiquitin ligase for I kappa B alpha FWD1 associates with Skp1 through the F-box domain and also recognizes the conserved DS-GXXS motif of I kappa B alpha. The structural requirements for the interactions of FWD1 with I kappa B alpha and with Skp1 have now been investigated further. The D31A mutation (but not the G33A mutation) in the DSGXXS motif of I kappa B alpha abolished the binding of I kappa B alpha to FWD1 and its subsequent ubiquitination without affecting the phosphorylation of I kappa B alpha. The I kappa B alpha mutant D31E still exhibited binding to FWD1 and underwent ubiquitination, These results suggest that, in addition to site-specific phosphorylation at Ser(32) and Ser(36), an acidic amino acid at position 31 is required for FWD1-mediated ubiquitination of I kappa B alpha. Deletion analysis of Skp1 revealed that residues 61-143 of this protein are required for binding to FWD1, On the other hand, the highly conserved residues pro(149), ILe(160), and Leu(164) in the F-box domain of FWD1 were dispensable for binding to Skp1, Together, these data delineate the structural requirements for the interactions among I kappa B alpha, FWD1, and Skp1 that underlie substrate recognition by the SCF ubiquitin ligase complex.	Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Higashi Ku, Fukuoka 8128582, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi 3320012, Japan	Kyushu University; Japan Science & Technology Agency (JST)	Nakayama, K (corresponding author), Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Higashi Ku, Maidashi 3-1-1, Fukuoka 8128582, Japan.		Hatakeyama, Shigetsugu/C-8333-2012	Hatakeyama, Shigetsugu/0000-0002-2150-9979				Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; ELLEDGE SJ, 1998, BIOCHIM BIOPHYS ACTA, V1377, P61; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Fuchs SY, 1999, ONCOGENE, V18, P2039, DOI 10.1038/sj.onc.1202760; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hubbard EJA, 1997, GENE DEV, V11, P3182, DOI 10.1101/gad.11.23.3182; Iwao K, 1999, JPN J CANCER RES, V90, P205, DOI 10.1111/j.1349-7006.1999.tb00734.x; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Kaiser P, 1998, GENE DEV, V12, P2587, DOI 10.1101/gad.12.16.2587; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Koch A, 1999, CANCER RES, V59, P269; Kominami K, 1998, GENES CELLS, V3, P721, DOI 10.1046/j.1365-2443.1998.00225.x; Krek W, 1998, CURR OPIN GENET DEV, V8, P36, DOI 10.1016/S0959-437X(98)80059-2; Kroll M, 1999, J BIOL CHEM, V274, P7941, DOI 10.1074/jbc.274.12.7941; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Li FN, 1997, EMBO J, V16, P5629, DOI 10.1093/emboj/16.18.5629; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; Lyapina SA, 1998, P NATL ACAD SCI USA, V95, P7451, DOI 10.1073/pnas.95.13.7451; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Marikawa Y, 1998, MECH DEVELOP, V77, P75, DOI 10.1016/S0925-4773(98)00134-8; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Michel JJ, 1998, CELL GROWTH DIFFER, V9, P435; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Ng RWM, 1998, FEBS LETT, V438, P183, DOI 10.1016/S0014-5793(98)01299-X; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Suzuki H, 1999, BIOCHEM BIOPH RES CO, V256, P121, DOI 10.1006/bbrc.1999.0296; Suzuki H, 1999, BIOCHEM BIOPH RES CO, V256, P127, DOI 10.1006/bbrc.1999.0289; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Voeller HJ, 1998, CANCER RES, V58, P2520; Weissman AM, 1997, IMMUNOL TODAY, V18, P189, DOI 10.1016/S0167-5699(97)84666-X; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu GY, 1998, P NATL ACAD SCI USA, V95, P15787, DOI 10.1073/pnas.95.26.15787; Yaron A, 1997, EMBO J, V16, P6486, DOI 10.1093/emboj/16.21.6486; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	64	35	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29641	29647		10.1074/jbc.274.42.29641	http://dx.doi.org/10.1074/jbc.274.42.29641			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514433	hybrid			2022-12-27	WOS:000083176400012
J	Ono, M; Yuasa, T; Ra, C; Takai, T				Ono, M; Yuasa, T; Ra, C; Takai, T			Stimulatory function of paired immunoglobulin-like receptor-A in mast cell line by associating with subunits common to Fc receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE 1C; CLASS-I MOLECULES; INHIBITORY RECEPTOR; GAMMA-CHAIN; HIGH-AFFINITY; NK CELLS; MONOCLONAL-ANTIBODY; BETA-SUBUNIT; PROTEIN; ACTIVATION	Paired Ig-like receptors (PIR) are polymorphic type I transmembrane proteins belonging to an Ig superfamily encoded by multiple isotypic genes. They are expressed on immune cells such as mast cells, macrophages, and B lymphocytes. Two subtypes of PIR have been classified according to the difference in the primary structure of the PIR transmembrane and cytoplasmic regions. These subtypes are designated as PIR-A and PIR-B. In this study, the transmembrane and cytoplasmic regions of the PIR-A subtype were shown to mediate activation signal events such as cytoplasmic calcium mobilization, protein tyrosine phosphorylations, and degranulation in rat mast cell line RBL-2H3. The association of the Fc receptor gamma and beta subunits with PIR-A was shown to be responsible for PIP-A function but not required for membrane expression of PIR-A on COS-7 cells. We further revealed the role of two charged amino acid residues in the transmembrane region, namely arginine and glutamic acid, in PIR-A function and its association with the above subunits. In contrast to the inhibitory nature of the PIR-B subtype, present findings reveal that PIR-A potentially acts as a stimulatory receptor in mast cells, suggesting a mechanism for regulation of mast cell functions by the PIR, family.	Tohoku Univ, Dept Experimental Immunol, Inst Dev Aging & Canc, Sendai, Miyagi 9808575, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Tokyo 1010062, Japan; Juntendo Univ, Sch Med, Dept Immunol, Tokyo 1130033, Japan	Tohoku University; Japan Science & Technology Agency (JST); Juntendo University	Takai, T (corresponding author), Tohoku Univ, Dept Experimental Immunol, Inst Dev Aging & Canc, 4-1 Seiryo, Sendai, Miyagi 9808575, Japan.							Arase N, 1997, J EXP MED, V186, P1957, DOI 10.1084/jem.186.12.1957; Arm JP, 1997, J IMMUNOL, V159, P2342; Binstadt BA, 1996, IMMUNITY, V5, P629, DOI 10.1016/S1074-7613(00)80276-9; Blery M, 1998, P NATL ACAD SCI USA, V95, P2446, DOI 10.1073/pnas.95.5.2446; Campbell KS, 1996, J EXP MED, V184, P93, DOI 10.1084/jem.184.1.93; CAMPBELL MA, 1995, EUR J IMMUNOL, V25, P1573, DOI 10.1002/eji.1830250616; Cella M, 1997, J EXP MED, V185, P1743, DOI 10.1084/jem.185.10.1743; Colonna M, 1997, J EXP MED, V186, P1809, DOI 10.1084/jem.186.11.1809; Cosman D, 1997, IMMUNITY, V7, P273, DOI 10.1016/S1074-7613(00)80529-4; Dombrowicz D, 1997, J CLIN INVEST, V99, P915, DOI 10.1172/JCI119256; Dombrowicz D, 1998, IMMUNITY, V8, P517, DOI 10.1016/S1074-7613(00)80556-7; DOMBROWICZ D, 1993, CELL, V75, P969, DOI 10.1016/0092-8674(93)90540-7; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; DREAN EL, 1998, EUR J IMMUNOL, V28, P264; ERNST LK, 1993, P NATL ACAD SCI USA, V90, P6023, DOI 10.1073/pnas.90.13.6023; GORDON JR, 1990, IMMUNOL TODAY, V11, P458, DOI 10.1016/0167-5699(90)90176-A; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hayami K, 1997, J BIOL CHEM, V272, P7320, DOI 10.1074/jbc.272.11.7320; Hazenbos WLW, 1996, IMMUNITY, V5, P181, DOI 10.1016/S1074-7613(00)80494-X; Kubagawa H, 1999, J EXP MED, V189, P309, DOI 10.1084/jem.189.2.309; Kubagawa H, 1997, P NATL ACAD SCI USA, V94, P5261, DOI 10.1073/pnas.94.10.5261; KUROSAKI T, 1991, P NATL ACAD SCI USA, V88, P3837, DOI 10.1073/pnas.88.9.3837; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lanier LL, 1998, NATURE, V391, P703, DOI 10.1038/35642; LANKESTER AC, 1995, J BIOL CHEM, V270, P20305, DOI 10.1074/jbc.270.35.20305; Law CL, 1996, J EXP MED, V183, P547, DOI 10.1084/jem.183.2.547; Lin SQ, 1996, CELL, V85, P985, DOI 10.1016/S0092-8674(00)81300-8; Maeda A, 1998, J EXP MED, V187, P1355, DOI 10.1084/jem.187.8.1355; Maeda A, 1998, J EXP MED, V188, P991, DOI 10.1084/jem.188.5.991; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; MARTIN TR, 1989, J CLIN INVEST, V83, P1375, DOI 10.1172/JCI114025; MORTON HC, 1995, J BIOL CHEM, V270, P29781; Nakajima H, 1999, J IMMUNOL, V162, P5; Nakamura MC, 1997, J EXP MED, V185, P673, DOI 10.1084/jem.185.4.673; Olcese L, 1996, J IMMUNOL, V156, P4531; PFEFFERKORN LC, 1994, J IMMUNOL, V153, P3228; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RAVETCH JV, 1986, SCIENCE, V234, P718, DOI 10.1126/science.2946078; RIVERA J, 1988, MOL IMMUNOL, V25, P647, DOI 10.1016/0161-5890(88)90100-9; ROUSSEAUX J, 1983, J IMMUNOL METHODS, V64, P141, DOI 10.1016/0022-1759(83)90392-7; Saito K, 1995, J ALLERGY CLIN IMMUN, V96, P1152, DOI 10.1016/S0091-6749(95)70200-8; Samaridis J, 1997, EUR J IMMUNOL, V27, P660, DOI 10.1002/eji.1830270313; Singh S, 1996, J BIOL CHEM, V271, P31049, DOI 10.1074/jbc.271.49.31049; SYLVESTRE DL, 1994, SCIENCE, V265, P1095, DOI 10.1126/science.8066448; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; Torkar M, 1998, EUR J IMMUNOL, V28, P3959, DOI 10.1002/(SICI)1521-4141(199812)28:12<3959::AID-IMMU3959>3.0.CO;2-2; TSUJIMURA T, 1995, INT ARCH ALLERGY IMM, V106, P377, DOI 10.1159/000236870; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; Wagtmann N, 1997, CURR BIOL, V7, P615, DOI 10.1016/S0960-9822(06)00263-6; Yamashita Y, 1998, J IMMUNOL, V161, P4042; Yamashita Y, 1998, J BIOCHEM-TOKYO, V123, P358, DOI 10.1093/oxfordjournals.jbchem.a021945	51	42	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30288	30296		10.1074/jbc.274.42.30288	http://dx.doi.org/10.1074/jbc.274.42.30288			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514523	hybrid			2022-12-27	WOS:000083176400102
J	Procopio, WN; Pelavin, PI; Lee, WMF; Yeilding, NM				Procopio, WN; Pelavin, PI; Lee, WMF; Yeilding, NM			Angiopoietin-1 and-2 coiled coil domains mediate distinct homo-oligomerization patterns, but fibrinogen-like domains mediate ligand activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; EXTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; TUMOR ANGIOGENESIS; TIE2 RECEPTOR; EGF RECEPTOR; GROWTH; BINDING; EXPRESSION; DIMERIZATION	Activity of endothelial Tie2 receptor tyrosine kinase is modulated by two naturally occurring, secreted ligands, angiopoietin-1 and -2, which have opposing effects on its phosphorylation. Receptor tyrosine kinase activation requires receptor dimerization/multimerization, which, for many receptors, is mediated by homo-oligomeric ligands binding to and bridging receptor molecules, We show here that angiopoietin-1 and -2 form distinct arrays of disulfide-linked homo-oligomeric complexes. Their mobilities on nonreducing gels suggest that angiopoiedin-2 exists predominantly as a homodimer but also forms higher order multimers. In contrast, angiopoietin-1 forms some homotrimers, but predominantly exists in higher order multimers, These two structurally related, 60% homologous ligands are predominantly composed of an amino-terminal coiled coil domain and a carboxyl-terminal fibrinogen-like domain. We show that their distinct oligomerization patterns are determined by their coiled coil domains and, furthermore, that their coiled coil domains, but not their fibrinogen-like domains, are sufficient to mediate formation of disulfide-linked homo-oligomers, In contrast, the differential effects of these ligands on endothelial Tie2 phosphorylation is mediated by their fibrinogen-like domains. We conclude from these studies that the coiled coil and fibrinogen-like domains of the angiopoietins have distinct functions with the coiled coil domain mediating ligand homo-oligomerization and the fibrinogen-like domain mediating ligand activity.	Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Yeilding, NM (corresponding author), Univ Penn, Dept Med, 421 Curie Blvd,BRB 2-3,Rm 351, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR001956] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007170, R01GM047147] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR01956] Funding Source: Medline; NIGMS NIH HHS [GM47147, T32-GM07170] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAKAWA T, 1991, J BIOL CHEM, V266, P18942; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DUMONT DJ, 1993, ONCOGENE, V8, P1293; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; ECK MJ, 1989, J BIOL CHEM, V264, P17595; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; GREENFIELD C, 1989, EMBO J, V8, P4115, DOI 10.1002/j.1460-2075.1989.tb08596.x; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HURWITZ DR, 1991, J BIOL CHEM, V266, P22035; Koblizek TI, 1997, EUR J BIOCHEM, V244, P774, DOI 10.1111/j.1432-1033.1997.00774.x; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LAX I, 1991, J BIOL CHEM, V266, P13828; Lin PN, 1997, J CLIN INVEST, V100, P2072, DOI 10.1172/JCI119740; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Oritani K, 1996, J CELL BIOL, V134, P771, DOI 10.1083/jcb.134.3.771; Peters KG, 1998, BRIT J CANCER, V77, P51, DOI 10.1038/bjc.1998.8; Sato A, 1998, INT IMMUNOL, V10, P1217, DOI 10.1093/intimm/10.8.1217; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Thanos CD, 1999, SCIENCE, V283, P833, DOI 10.1126/science.283.5403.833; Trinchieri G, 1998, Int Rev Immunol, V16, P365, DOI 10.3109/08830189809043002; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Vikkula M, 1996, CELL, V87, P1181, DOI 10.1016/S0092-8674(00)81814-0; WEBER W, 1984, J BIOL CHEM, V259, P4631; Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; Wong AL, 1997, CIRC RES, V81, P567, DOI 10.1161/01.RES.81.4.567; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489	35	126	141	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30196	30201		10.1074/jbc.274.42.30196	http://dx.doi.org/10.1074/jbc.274.42.30196			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514510	hybrid			2022-12-27	WOS:000083176400089
J	Sahin-Toth, M				Sahin-Toth, M			Hereditary pancreatitis associated mutation Asn(21) -> Ile stabilizes rat trypsinogen in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SERINE PROTEINASE-INHIBITOR; CATIONIC TRYPSINOGEN; BINDING POCKET; ECOTIN; SPECIFICITY; GENE	Arg(117)--> His and Asn(21) --> Ile in human trypsinogen-I have been recently associated with hereditary pancreatitis (HP), The Arg(117) --> His substitution is believed to cause pancreatitis by stabilizing trypsin against autolytic degradation, while the mechanism of action of Asn(21) --> Ile has been unknown. In an effort to understand the effect(s) of this mutation, Thr(21) in the highly homologous rat trypsinogen-II was replaced with Asn or Ile, and the recombinant zymogens and their active trypsin forms were studied. Kinetic parameters of all three trypsins were comparable, and the active enzymes suffered autolysis at similar rates, indicating that neither catalytic properties nor proteolytic stability of trypsin are influenced by mutations at position 21, When incubated at pH 8.0, 37 degrees C, pure zymogens underwent autoactivation with concomitant trypsinolytic degradation in a Ca2+-dependent fashion. Thus, in the presence of 5 mM Ca2+, autoactivation and digestion of the zymogens after Arg(117) and Lys(188) were observed, while in the presence of 1 mM EDTA autoactivation and cleavage at Lys(188) were reduced, and zymogenolysis at the Arg(117) site was enhanced. Overall rates of zymogen degradation in [Asn(21)]- and [Ile(21)]trypsinogens were higher in Ca2+ than in EDTA, while [Thr(21)]trypsinogen demonstrated inverse characteristics. Remarkably, both in the presence and absence of Ca2+, [Ile(21)]trypsinogen exhibited significantly higher stability against autoactivation and proteolysis than zymogens with Asn(21) or Thr(21). The observations suggest that autocatalytic trypsinogen degradation may be an important defense mechanism against excessive trypsin generation in the pancreas, and trypsinogen stabilization by the Asn(21) --> Ile mutation plays a role in the pathogenesis of HP.	Univ Calif Los Angeles, HHMI, MacDonald Res Labs 5 748, Dept Physiol, Los Angeles, CA 90095 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles	Sahin-Toth, M (corresponding author), Univ Calif Los Angeles, HHMI, MacDonald Res Labs 5 748, Dept Physiol, Box 951662, Los Angeles, CA 90095 USA.							COLOMB E, 1979, BIOCHIM BIOPHYS ACTA, V570, P897; Gorry MC, 1997, GASTROENTEROLOGY, V113, P1063, DOI 10.1053/gast.1997.v113.pm9322498; GRAF L, 1987, BIOCHEMISTRY-US, V26, P2616, DOI 10.1021/bi00383a031; GRAF L, 1988, P NATL ACAD SCI USA, V85, P4961, DOI 10.1073/pnas.85.14.4961; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Lengyel Z, 1998, PROTEIN EXPRES PURIF, V12, P291, DOI 10.1006/prep.1997.0837; MAROUX S, 1969, BIOCHIM BIOPHYS ACTA, V181, P59, DOI 10.1016/0005-2795(69)90227-X; Nishimori I, 1999, GUT, V44, P259, DOI 10.1136/gut.44.2.259; Pal G, 1996, FEBS LETT, V385, P165, DOI 10.1016/0014-5793(96)00376-6; PAL G, 1994, FEBS LETT, V342, P57, DOI 10.1016/0014-5793(94)80584-9; PERRAULT J, 1994, GASTROENTEROL CLIN N, V23, P743; RYPNIEWSKI WR, 1994, PROTEIN ENG, V7, P57, DOI 10.1093/protein/7.1.57; SMITH RL, 1969, J BIOL CHEM, V244, P4704; Steer ML, 1998, PANCREAS, V17, P31, DOI 10.1097/00006676-199807000-00003; Teich N, 1998, HUM MUTAT, V12, P39, DOI 10.1002/(SICI)1098-1004(1998)12:1<39::AID-HUMU6>3.0.CO;2-P; Varallyay E, 1998, BIOCHEM BIOPH RES CO, V243, P56, DOI 10.1006/bbrc.1997.8058; Whitcomb David C., 1999, Pancreas, V18, P1, DOI 10.1097/00006676-199901000-00001; Whitcomb DC, 1996, NAT GENET, V14, P141, DOI 10.1038/ng1096-141	18	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29699	29704		10.1074/jbc.274.42.29699	http://dx.doi.org/10.1074/jbc.274.42.29699			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514442	hybrid			2022-12-27	WOS:000083176400021
J	Feaver, WJ; Huang, W; Friedberg, EC				Feaver, WJ; Huang, W; Friedberg, EC			The TFB4 subunit of yeast TFIIH is required for both nucleotide excision repair and RNA polymerase II transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CONSERVED RESIDUES; ACTIVATING KINASE; FACTOR-B; MUTATIONS; GENES; TEMPERATURE; MUTANTS; DNA; CTD	The N-degron strategy has been used to generate a yeast strain harboring a temperature-sensitive allele of TFB4 (tfb4(td)), the gene that encodes the 37-kDa subunit of the transcription/repair factor TFIIH. The tfb4td strain was sensitive to UV radiation and is defective in nucleotide excision repair in vitro. The mutant strain was also found to be an inositol auxotroph due at least in part to an inability to properly induce expression of the INO1 gene. These results indicate that like other subunits of TFIIH, Tfb4 is required for both RNA polymerase II transcription and DNA repair.	Univ Texas, SW Med Ctr, Dept Pathol, Lab Mol Pathol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Friedberg, EC (corresponding author), Univ Texas, SW Med Ctr, Dept Pathol, Lab Mol Pathol, Dallas, TX 75235 USA.		Huang, Wenya/G-9115-2011		NCI NIH HHS [CA12420] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Archambault J, 1996, GENETICS, V142, P737; ARCHAMBAULT J, 1992, MOL GEN GENET, V232, P408, DOI 10.1007/BF00266244; ARNDT KM, 1995, EMBO J, V14, P1490, DOI 10.1002/j.1460-2075.1995.tb07135.x; ARNDT KT, 1989, CELL, V56, P527, DOI 10.1016/0092-8674(89)90576-X; BERROTERAN RW, 1994, MOL CELL BIOL, V14, P226, DOI 10.1128/MCB.14.1.226; DOHMEN RJ, 1994, SCIENCE, V263, P1273, DOI 10.1126/science.8122109; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; Feaver WJ, 1997, J BIOL CHEM, V272, P19319, DOI 10.1074/jbc.272.31.19319; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GUZDER SN, 1994, NATURE, V369, P578, DOI 10.1038/369578a0; Huang WY, 1998, MUTAT RES-DNA REPAIR, V408, P183, DOI 10.1016/S0921-8777(98)00031-7; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; LAWRENCE CW, 1991, METHOD ENZYMOL, V194, P21; LOPES JM, 1991, NUCLEIC ACIDS RES, V19, P1687, DOI 10.1093/nar/19.7.1687; NONET ML, 1989, GENETICS, V123, P715; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SCAFE C, 1990, MOL CELL BIOL, V10, P1270, DOI 10.1128/MCB.10.3.1270; SCAFE C, 1990, MOL CELL BIOL, V10, P1010, DOI 10.1128/MCB.10.3.1010; SIKORSKI RS, 1989, GENETICS, V122, P19; SVEJSTRUP JQ, 1994, J BIOL CHEM, V269, P28044; Svejstrup JQ, 1996, J BIOL CHEM, V271, P643, DOI 10.1074/jbc.271.2.643; WANG ZG, 1994, NATURE, V368, P74, DOI 10.1038/368074a0; WANG ZG, 1995, MOL CELL BIOL, V15, P2288; Wang ZG, 1996, MUTAT RES-DNA REPAIR, V364, P33, DOI 10.1016/0921-8777(96)00019-5; Wang Zhigang, 1995, Methods (Orlando), V7, P177, DOI 10.1006/meth.1995.1023; WOYCHIK NA, 1989, MOL CELL BIOL, V9, P2854, DOI 10.1128/MCB.9.7.2854	29	8	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29564	29567		10.1074/jbc.274.41.29564	http://dx.doi.org/10.1074/jbc.274.41.29564			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506223	hybrid			2022-12-27	WOS:000083017800102
J	Mariottini, P; Shah, ZH; Toivonen, JM; Bagni, C; Spelbrink, JN; Amaldi, F; Jacobs, HT				Mariottini, P; Shah, ZH; Toivonen, JM; Bagni, C; Spelbrink, JN; Amaldi, F; Jacobs, HT			Expression of the gene for mitoribosomal protein S12 is controlled in human cells at the levels of transcription, RNA splicing, and translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; OPEN READING FRAME; MESSENGER-RNA; XENOPUS-LAEVIS; NUCLEAR GENES; EVOLUTIONARY CONSERVATION; 5'-UNTRANSLATED REGION; MITOCHONDRIAL GENOME; RIBOSOMAL-PROTEINS; ESCHERICHIA-COLI	The human gene RPMS12 encodes a protein similar to bacterial ribosomal protein S12 and is proposed to represent the human mitochondrial orthologue, RPMS12 reporter gene expression in cultured human cells supports the idea that the gene product is mitochondrial and is localized to the inner membrane. Human cells contain at least four structurally distinct RPMS12 mRNAs that differ in their 5'-untranslated region (5'-UTR) as a result of alternate splicing and of 5' end heterogeneity. All of them encode the same polypeptide, The full 5'-UTR contains two types of sequence element implicated elsewhere in translational regulation as follows: a short upstream open reading frame and an oligopyrimidine tract similar to that found at the 5' end of mRNAs encoding other growth-regulated proteins, including those of cytosolic ribosomes, The fully spliced (short) mRNA is the predominant form in all cell types studied and is translationally down-regulated in cultured cells in response to serum starvation, even though it lacks both of the putative translational regulatory elements. By contrast, other splice variants containing one or both of these elements are not translationally regulated by growth status but are translated poorly in both growing and non-growing cells. Reporter analysis identified a 26-nucleotide tract of the 5'-UTR of the short mRNA that is essential for translational down-regulation in growth-inhibited cells. Such experiments also confirmed that the 5'-UTR of the longer mRNA variants contains negative regulatory elements for translation. Tissue representation of RPMS12 mRNA is highly variable, following a typical mitochondrial pattern, but the relative levels of the different splice variants are similar in different tissues. These findings indicate a complex, multilevel regulation of RPMS12 gene expression in response to signals mediating growth, tissue specialization, and probably metabolic needs.	Univ Tampere, Inst Med Technol, FIN-33101 Tampere, Finland; Tampere Univ Hosp, FIN-33101 Tampere, Finland; Univ Roma Tor Vergata, Dept Biol, I-00146 Rome, Italy; Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland	Tampere University; Tampere University; Tampere University Hospital; University of Rome Tor Vergata; University of Glasgow	Jacobs, HT (corresponding author), Univ Tampere, Inst Med Technol, POB 607, FIN-33101 Tampere, Finland.	howy.jacobs@uta.fi	Shah, Zahid/G-9410-2014; Spelbrink, Johannes N/L-4661-2015; Toivonen, Janne M./E-5691-2011; Jacobs, Howard T/G-2434-2011	Shah, Zahid/0000-0001-7165-8780; Spelbrink, Johannes N/0000-0002-9756-2602; Toivonen, Janne M./0000-0002-7243-1737; Bagni, Claudia/0000-0002-4419-210X; Jacobs, Howard/0000-0003-1895-6003				AGRAWAL MG, 1987, J BIOL CHEM, V262, P4868; Amaldi F, 1997, Prog Mol Subcell Biol, V18, P1; Amaldi F, 1995, BIOCHEM CELL BIOL, V73, P969, DOI 10.1139/o95-104; AVNI D, 1994, MOL CELL BIOL, V14, P3822, DOI 10.1128/MCB.14.6.3822; BAGNI C, 1992, MOL GEN GENET, V234, P60, DOI 10.1007/BF00272345; BAGNI C, 1993, BIOCHIM BIOPHYS ACTA, V1216, P475, DOI 10.1016/0167-4781(93)90017-8; BYRNE PC, 1995, BIOCHEM BIOPH RES CO, V214, P496, DOI 10.1006/bbrc.1995.2314; CAIZERGUESFERRER M, 1989, GENE DEV, V3, P324, DOI 10.1101/gad.3.3.324; CAO JH, 1995, J VIROL, V69, P1030, DOI 10.1128/JVI.69.2.1030-1036.1995; CARDINALI B, 1993, NUCLEIC ACIDS RES, V21, P2301, DOI 10.1093/nar/21.10.2301; Choi HS, 1996, MOL CELLS, V6, P615; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; Duga S, 1999, EUR J BIOCHEM, V259, P188, DOI 10.1046/j.1432-1327.1999.00029.x; Fewell SW, 1999, MOL CELL BIOL, V19, P826; Fox TD, 1996, EXPERIENTIA, V52, P1130, DOI 10.1007/BF01952112; FREEDMAN LP, 1987, P NATL ACAD SCI USA, V84, P6516, DOI 10.1073/pnas.84.18.6516; Genetic Computer Group, 1994, PROGR MAN WISC PACK; GEYER PK, 1982, MOL CELL BIOL, V2, P685, DOI 10.1128/MCB.2.6.685; Ghilardi N, 1998, BLOOD, V92, P4023, DOI 10.1182/blood.V92.11.4023.423k54_4023_4030; Graack HR, 1998, BIOCHEM J, V329, P433, DOI 10.1042/bj3290433; GROHMANN L, 1992, NUCLEIC ACIDS RES, V20, P5641, DOI 10.1093/nar/20.21.5641; HAMMOND ML, 1988, J BIOL CHEM, V263, P17785; Harigai M, 1996, ONCOGENE, V12, P1369; HAUSWIRTH WW, 1987, MITOCHONDRIA PRACTIC, P176; IMATAKA H, 1994, J BIOL CHEM, V269, P20668; KASPAR RL, 1990, J BIOL CHEM, V265, P3619; KASPAR RL, 1992, J BIOL CHEM, V267, P508; Larsson NG, 1996, NAT GENET, V13, P296, DOI 10.1038/ng0796-296; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; Linz B, 1997, J BIOL CHEM, V272, P9131; Loreni F, 1997, FEBS LETT, V416, P239, DOI 10.1016/S0014-5793(97)01209-X; LORENI F, 1992, EUR J BIOCHEM, V205, P1027, DOI 10.1111/j.1432-1033.1992.tb16870.x; Lovett PS, 1996, MICROBIOL REV, V60, P366, DOI 10.1128/MMBR.60.2.366-385.1996; Maffey L, 1997, MOL GEN GENET, V254, P365, DOI 10.1007/s004380050428; Marty L, 1997, GENOMICS, V41, P453, DOI 10.1006/geno.1997.4691; Marty L, 1996, J BIOL CHEM, V271, P11468, DOI 10.1074/jbc.271.19.11468; MEYUHAS O, 1987, MOL CELL BIOL, V7, P2691, DOI 10.1128/MCB.7.8.2691; Meyuhas Oded, 1996, P65; Meyuhas Oded, 1996, V30, P363; NIJTMANS LGJ, 1995, BBA-MOL CELL RES, V1265, P117, DOI 10.1016/0167-4889(94)00203-Q; OLIVEIRA CC, 1995, J BIOL CHEM, V270, P8936, DOI 10.1074/jbc.270.15.8936; PELLETIER J, 1988, MOL CELL BIOL, V8, P1103, DOI 10.1128/MCB.8.3.1103; PERROTTA G, 1996, MOL GEN GENET, V251, P327; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; RAGAN CI, 1987, MITOCHONDRIA PRACTIC, P80; RAPANOTTI MC, 1995, GENE, V154, P199, DOI 10.1016/0378-1119(94)00873-Q; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Scarpulla RC, 1997, J BIOENERG BIOMEMBR, V29, P109, DOI 10.1023/A:1022681828846; SCHATZ G, 1986, ANN REV CELL BIOL, V4, P289; Shah ZH, 1998, GENOMICS, V48, P384, DOI 10.1006/geno.1997.5166; Shah ZH, 1997, GENE, V204, P55, DOI 10.1016/S0378-1119(97)00521-0; TAPPER DP, 1983, METHOD ENZYMOL, V97, P426; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAY YF, 1988, GENE DEV, V2, P664, DOI 10.1101/gad.2.6.664; YIU GK, 1994, NUCLEIC ACIDS RES, V22, P4599, DOI 10.1093/nar/22.22.4599; ZENGEL JM, 1994, PROG NUCLEIC ACID RE, V47, P331, DOI 10.1016/S0079-6603(08)60256-1; Zhang L, 1998, BIOCHEM J, V332, P773, DOI 10.1042/bj3320773	58	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31853	31862		10.1074/jbc.274.45.31853	http://dx.doi.org/10.1074/jbc.274.45.31853			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542210	Green Published, hybrid			2022-12-27	WOS:000083532100018
J	Zhan, DJ; Santin, AD; Liu, Y; Parham, GP; Li, CL; Meyers, C; Hermonat, PL				Zhan, DJ; Santin, AD; Liu, Y; Parham, GP; Li, CL; Meyers, C; Hermonat, PL			Binding of the human papillomavirus type 16 p97 promoter by the adeno-associated virus Rep78 major regulatory protein correlates with inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; ADENOASSOCIATED VIRUS; BOVINE PAPILLOMAVIRUS; GENE-PRODUCT; DNA-BINDING; IN-VITRO; MUTATIONAL ANALYSIS; HUMAN PARVOVIRUS; HERPES-SIMPLEX; REP68 PROTEIN	Human papillomavirus type 16 (HPV-16) infection is positively associated with cervical cancer, whereas adeno-associated virus (AAV) infection is negatively associated with this same cancer. In earlier studies these two virus types have been shown to directly interact, with AAV inhibiting or enhancing papillomavirus functions depending upon the specific circumstances. One defined interaction between these two viruses is the ability of the AAV Rep78 major regulatory protein to inhibit gene expression of the E6 promoter of BPV-1 (bovine papillomavirus type 1) and HPV types 16 and 18, As Rep78 is a DNA binding transcription factor, we considered whether Rep78 might bind HPV-16 DNA. Here, Rep78 is demonstrated to bind a 44-base pair region (nucleotides 14-56) within the HPV-16 p97 promoter using the electrophoretic mobility shift assay. This region is important for HPV-16 because it includes functional Spl and E2 protein binding motifs as well as part of the origin of replication. Furthermore, two Rep78 amino acid substitution mutants, at positions 77 or 64-65, were identified that did not recognize p97 DNA, Both of these Rep78 mutants were found to be defective for inhibition of p97 promoter activity in HeLa and T-47D nuclear extracts in vitro, in a transient chloramphenicol acetyltransferase assay, as well as defective for full inhibition of HPV-16-directed focus formation. These data, taken together, strongly suggest that the Rep78-p97 promoter interaction is at least partially responsible for Rep78-mediated inhibition of HPV-16, Finally, the finding that Rep78 specifically recognizes p97 DNA is surprising because the p97 promoter region contains no GAGC motifs, the core motif for Rep78 recognition. These data suggest that the p97 promoter may represent a new prototypical DNA target type for Rep78.	Univ Arkansas Med Sci, Dept Obstet & Gynecol, Little Rock, AR 72205 USA; Penn State Univ, Coll Med, Dept Immunol & Microbiol, Hershey, PA 17033 USA	University of Arkansas System; University of Arkansas Medical Sciences; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Hermonat, PL (corresponding author), Univ Arkansas Med Sci, Dept Obstet & Gynecol, Slot 518,4301 W Markham St, Little Rock, AR 72205 USA.				NCI NIH HHS [CA55051] Funding Source: Medline; PHS HHS [IA42764] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA055051] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDROPHY EJ, 1987, NATURE, V325, P70, DOI 10.1038/325070a0; ANTONI BA, 1991, J VIROL, V65, P396, DOI 10.1128/JVI.65.1.396-404.1991; BANTELSCHAAL U, 1984, VIROLOGY, V134, P52, DOI 10.1016/0042-6822(84)90271-X; BATCHU RB, 1995, BIOCHEM BIOPH RES CO, V210, P717, DOI 10.1006/bbrc.1995.1718; BATCHU RB, 1994, CANCER LETT, V86, P23, DOI 10.1016/0304-3835(94)90176-7; BATCHU RB, 1995, BIOCHEM BIOPH RES CO, V208, P714, DOI 10.1006/bbrc.1995.1396; BATCHU RB, 1995, FEBS LETT, V367, P267, DOI 10.1016/0014-5793(95)00584-V; Bishop BM, 1996, FEBS LETT, V397, P97, DOI 10.1016/S0014-5793(96)01149-0; BLACKLOW NR, 1967, P NATL ACAD SCI USA, V58, P1410, DOI 10.1073/pnas.58.4.1410; CHIORINI JA, 1995, J VIROL, V69, P7334, DOI 10.1128/JVI.69.11.7334-7338.1995; CULLEN AP, 1991, J VIROL, V65, P606, DOI 10.1128/JVI.65.2.606-612.1991; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; GEORGFRIES B, 1984, VIROLOGY, V134, P64, DOI 10.1016/0042-6822(84)90272-1; GLOSS B, 1990, J VIROL, V64, P5577, DOI 10.1128/JVI.64.11.5577-5584.1990; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; Han L, 1996, VIRUS GENES, V12, P47, DOI 10.1007/BF00370000; HERMONAT PL, 1991, CANCER RES, V51, P3373; HERMONAT PL, 1992, VIROLOGY, V189, P329, DOI 10.1016/0042-6822(92)90710-7; Hermonat PL, 1997, GYNECOL ONCOL, V66, P487, DOI 10.1006/gyno.1997.4789; HERMONAT PL, 1994, CANCER LETT, V81, P129, DOI 10.1016/0304-3835(94)90193-7; Hermonat PL, 1997, FEBS LETT, V401, P180, DOI 10.1016/S0014-5793(96)01469-X; HERMONAT PL, 1994, CANCER RES, V54, P2278; Hermonat PL, 1998, VIROLOGY, V245, P120, DOI 10.1006/viro.1998.9144; Hermonat PL, 1996, CANCER RES, V56, P5299; HERMONAT PL, 1984, J VIROL, V51, P329, DOI 10.1128/JVI.51.2.329-339.1984; Hermonat PL, 1998, VIROLOGY, V247, P240, DOI 10.1006/viro.1998.9256; HERMONAT PL, 1989, VIROLOGY, V172, P258; HERMONAT PL, 1997, BIOCHEM MOL BIOL INT, V403, P409; HOPPESEYLER F, 1993, J GEN VIROL, V74, P281, DOI 10.1099/0022-1317-74-2-281; HORER M, 1995, J VIROL, V69, P5485; IM DS, 1990, CELL, V61, P447, DOI 10.1016/0092-8674(90)90526-K; KATZ E, 1986, CANCER RES, V46, P3023; KHLEIF SN, 1991, VIROLOGY, V181, P738, DOI 10.1016/0042-6822(91)90909-U; KLEINBAUERNSCHM.P, 1992, J VIROL, V66, P419; Kokorina N A, 1998, J Hum Virol, V1, P441; KYOSTIO SRM, 1995, J VIROL, V69, P6787; LABOW MA, 1986, J VIROL, V60, P251, DOI 10.1128/JVI.60.1.251-258.1986; MAYOR HD, 1976, AM J OBSTET GYNECOL, V126, P100, DOI 10.1016/0002-9378(76)90472-5; MCCARTY DM, 1994, J VIROL, V68, P4988, DOI 10.1128/JVI.68.8.4988-4997.1994; MENDELSON E, 1986, J VIROL, V60, P823, DOI 10.1128/JVI.60.3.823-832.1986; MOSKALUK C, 1988, P NATL ACAD SCI USA, V85, P1826, DOI 10.1073/pnas.85.6.1826; NI TH, 1994, J VIROL, V68, P1128, DOI 10.1128/JVI.68.2.1128-1138.1994; Pereira DJ, 1997, J VIROL, V71, P1747, DOI 10.1128/JVI.71.3.1747-1756.1997; RITTNER K, 1992, J GEN VIROL, V73, P2977, DOI 10.1099/0022-1317-73-11-2977; ROMANCZUK H, 1990, J VIROL, V64, P2849, DOI 10.1128/JVI.64.6.2849-2859.1990; SAMULSKI RJ, 1982, P NATL ACAD SCI-BIOL, V79, P2077, DOI 10.1073/pnas.79.6.2077; SARAFI TR, 1995, VIROLOGY, V211, P385, DOI 10.1006/viro.1995.1421; SCHMITT J, 1989, VIROLOGY, V172, P73, DOI 10.1016/0042-6822(89)90108-6; Sedman J, 1996, EMBO J, V15, P5085, DOI 10.1002/j.1460-2075.1996.tb00889.x; Smith RH, 1997, J VIROL, V71, P4461, DOI 10.1128/JVI.71.6.4461-4471.1997; Su PF, 1996, BRIT J CANCER, V73, P1533, DOI 10.1038/bjc.1996.289; TOBIASCH E, 1994, J MED VIROL, V44, P215, DOI 10.1002/jmv.1890440218; TRATSCHIN JD, 1985, MOL CELL BIOL, V5, P3251, DOI 10.1128/MCB.5.11.3251; TRATSCHIN JD, 1984, J VIROL, V51, P611, DOI 10.1128/JVI.51.3.611-619.1984; Walz C, 1997, J GEN VIROL, V78, P1441, DOI 10.1099/0022-1317-78-6-1441; Weitzman MD, 1996, J VIROL, V70, P2440, DOI 10.1128/JVI.70.4.2440-2448.1996; Wonderling RS, 1997, J VIROL, V71, P2528, DOI 10.1128/JVI.71.3.2528-2534.1997; Wonderling RS, 1996, J VIROL, V70, P4783, DOI 10.1128/JVI.70.7.4783-4786.1996; Yasugi T, 1997, J VIROL, V71, P891, DOI 10.1128/JVI.71.2.891-899.1997	59	28	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31619	31624		10.1074/jbc.274.44.31619	http://dx.doi.org/10.1074/jbc.274.44.31619			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531369	hybrid			2022-12-27	WOS:000083379400073
J	Abe, R; Whitehead, IP; O'Bryan, JP; Der, CJ				Abe, R; Whitehead, IP; O'Bryan, JP; Der, CJ			Involvement of NH2-terminal sequences in the negative regulation of Vav signaling and transforming activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; GTP-BINDING PROTEINS; DBL ONCOGENE PRODUCT; CYCLIN D1 PROMOTER; RHO-FAMILY; PROTOONCOGENE PRODUCT; RAS TRANSFORMATION; GENE-EXPRESSION; C-JUN; ACTIVATION	Deletion of the NH2-terminal 65 amino acids of proto-Vav (to form onco-Vav) activates its transforming activity, suggesting that these sequences serve a negative regulatory role in Vav function. However, the precise role of these NH2-terminal sequences and whether additional NH2-terminal sequences are also involved in negative regulation have not been determined. Therefore, we generated additional NH2-terminal deletion mutants of proto-Vav that lack the NH2-terminal 127, 168, or 186 amino acids, and assessed their abilities to cause focus formation in NIH 3T3 cells and to activate different signaling pathways. Since Vav mutants lacking 168 or 186 NH2-terminal residues showed a several 100-fold greater focus forming activity than that seen with deletion of 65 residues, residues spanning 66 to 187 also contribute significantly to negative regulation of Vav transforming activity. The increase in Vav transforming activity correlated with the activation of the c-Jun, Elk-1, and NF-kappa B transcription factors, as well as increased transcription from the cyclin D1 promoter. Tyrosine 174 is a key site of phosphorylation by Lck in vitro and Lck-mediated phosphorylation has been shown to be essential for proto-Vav GEF function in vitro. However, we found that an NH2-terminal Vav deletion mutant lacking this tyrosine residue (Delta N-186 Vav) retained the ability to be phosphorylated by Lck in vivo and Lck still caused enhancement of Delta N-186 Vav signaling and transforming activity. Thus, Lck can stimulate Vav via a mechanism that does not involve Tyr(174) Or removal of NH2-terminal regulatory activity. Finally, we found that NH2-terminal deletion enhanced the degree of Vav association with the membrane-containing particulate fraction and that an isolated NH2-terminal fragment (residues 1-186) could impair Delta N-186 Vav signaling. Taken together, these observations suggest that the NH2 terminus may serve as a negative regulator of Vav by intramolecular interaction with COOH-terminal sequences to modulate efficient membrane association.	Univ N Carolina, Dept Pharmacol, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Der, CJ (corresponding author), Univ N Carolina, Dept Pharmacol, Lineberger Comprehens Canc Ctr, CB 7295, Chapel Hill, NC 27599 USA.	cjder@med.unc.edu		Der, Channing/0000-0002-7751-2747; O'Bryan, John/0000-0001-5386-1080	NCI NIH HHS [CA55008, CA63071, CA42978] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055008, R01CA042978, R01CA063071] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1992, ONCOGENE, V7, P611; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Bustelo XR, 1996, CRIT REV ONCOGENESIS, V7, P65, DOI 10.1615/CritRevOncog.v7.i1-2.50; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chan AML, 1996, ONCOGENE, V12, P1259; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COX AD, 1995, METHOD ENZYMOL, V255, P195; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; Gimona M, 1998, CURR BIOL, V8, pR674; GRAZIANI G, 1989, ONCOGENE, V4, P823; Groysman M, 1998, ONCOGENE, V17, P1597, DOI 10.1038/sj.onc.1202074; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HAUSER CA, 1995, METHOD ENZYMOL, V255, P412; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hobert O, 1996, MOL CELL BIOL, V16, P3066; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1993, ONCOGENE, V8, P1757; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; RON D, 1989, ONCOGENE, V4, P1067; Schuebel KE, 1996, ONCOGENE, V13, P363; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; Stradal T, 1998, FEBS LETT, V431, P134, DOI 10.1016/S0014-5793(98)00751-0; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; WHITEHEAD IP, 1999, IN PRESS MOL CELL BI; WRIGHT DD, 1994, MOL CELL BIOL, V14, P2429, DOI 10.1128/MCB.14.4.2429; Zohn IE, 1998, MOL CELL BIOL, V18, P1225, DOI 10.1128/MCB.18.3.1225; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	55	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30410	30418		10.1074/jbc.274.43.30410	http://dx.doi.org/10.1074/jbc.274.43.30410			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521418	hybrid			2022-12-27	WOS:000083276700014
J	Bernatchez, PN; Soker, S; Sirois, MG				Bernatchez, PN; Soker, S; Sirois, MG			Vascular endothelial growth factor effect on endothelial cell proliferation, migration, and platelet-activating factor synthesis is Flk-1-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY FACTOR; TYROSINE KINASE; BINDING-SITES; ANTISENSE OLIGONUCLEOTIDES; SIGNAL-TRANSDUCTION; AFFINITY BINDING; IN-VITRO; C-MYC; RECEPTORS; EXPRESSION	Vascular endothelial growth factor (VEGF) is a potent inducer of endothelial cell (EC) proliferation and migration in vitro as well as inflammation in vivo. We showed recently that VEGF effect on vascular permeability was dependent on the synthesis of platelet-activating factor (PAF) by EC, Consequently, we sought to evaluate by antisense knockdown of gene expression the contribution of VEGF receptors (Flt-1 and Flk-1) on these events. VEGF (10(-11) to 10(-8) M) elicited a dose-dependent increase of bovine aortic EC proliferation, migration, and PAF synthesis by up to 2.05-, 1.31- and 35.9-fold above basal levels, respectively. A treatment with two modified antisense oligomers (1-5 x 10(-7) M) directed against Flk-1 mRNA blocked by 100, 91, and 85% the proliferation, migration, and PAF synthesis mediated by VEGF, respectively. A treatment with two antisense oligomers directed against Flt-1 mRNA failed to modulate these activities. The use of placenta growth factor (up to 10(-8) M), an Flt-1-specific agonist, induced only a slight increase (0.6-fold) of PAF synthesis. These data illustrate the crucial role of Flk-1 in EC stimulation by VEGF. The capacity to inhibit the protein synthesis of Flt-1 and Flk-1 by antisense oligonucleotides provides a new approach to block VEGF pathological effects in vivo.	Montreal Heart Inst, Res Ctr, Montreal, PQ H1T 1C8, Canada; Montreal Heart Inst, Dept Pharmacol, Montreal, PQ H1T 1C8, Canada; Childrens Hosp, Dept Urol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Universite de Montreal; Universite de Montreal; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Sirois, MG (corresponding author), Montreal Heart Inst, Res Ctr, 5000 Belangor St, Montreal, PQ H1T 1C8, Canada.							BARLEON B, 1994, J CELL BIOCHEM, V54, P56, DOI 10.1002/jcb.240540107; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; BREIER G, 1992, DEVELOPMENT, V114, P521; BROWN LF, 1995, HUM PATHOL, V26, P86, DOI 10.1016/0046-8177(95)90119-1; BURGESS TL, 1995, P NATL ACAD SCI USA, V92, P4051, DOI 10.1073/pnas.92.9.4051; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; CROOKE RM, 1991, ANTI-CANCER DRUG DES, V6, P609; Cunningham SA, 1997, BIOCHEM BIOPH RES CO, V240, P635, DOI 10.1006/bbrc.1997.7719; Cunningham SA, 1999, AM J PHYSIOL-CELL PH, V276, pC176, DOI 10.1152/ajpcell.1999.276.1.C176; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DVORAK HF, 1995, AM J PATHOL, V146, P1029; EDELMAN ER, 1995, CIRC RES, V76, P176, DOI 10.1161/01.RES.76.2.176; Eriksson A, 1992, GROWTH FACTORS, V6, DOI 10.3109/08977199209008867; FERRARA N, 1993, TRENDS CARDIOVAS MED, V3, P244, DOI 10.1016/1050-1738(93)90046-9; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1991, J NATL CANCER I, V82, P4; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gilbert RE, 1998, LAB INVEST, V78, P1017; GUVAKOVA MA, 1995, J BIOL CHEM, V270, P2620, DOI 10.1074/jbc.270.6.2620; HAUSER S, 1993, GROWTH FACTORS, V9, P259, DOI 10.3109/08977199308991586; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; JAKEMAN LB, 1993, ENDOCRINOLOGY, V133, P848, DOI 10.1210/en.133.2.848; Joukov V, 1998, J BIOL CHEM, V273, P6599, DOI 10.1074/jbc.273.12.6599; KANAKARAJ P, 1991, BIOCHEMISTRY-US, V30, P1761, DOI 10.1021/bi00221a005; Li J, 1996, AM J PHYSIOL-HEART C, V270, pH1803, DOI 10.1152/ajpheart.1996.270.5.H1803; LOKE SL, 1989, P NATL ACAD SCI USA, V86, P3474, DOI 10.1073/pnas.86.10.3474; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; Mochida S, 1996, BIOCHEM BIOPH RES CO, V226, P176, DOI 10.1006/bbrc.1996.1329; PARK JE, 1994, J BIOL CHEM, V269, P25646; Pepper MS, 1998, J CELL PHYSIOL, V177, P439, DOI 10.1002/(SICI)1097-4652(199812)177:3<439::AID-JCP7>3.0.CO;2-2; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; RAVINDRATH N, 1992, ENDOCRINOLOGY, V94, P1192; Sawano A, 1997, BIOCHEM BIOPH RES CO, V238, P487, DOI 10.1006/bbrc.1997.7327; SEETHARAM L, 1995, ONCOGENE, V10, P135; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Sharma H S, 1992, EXS, V61, P255; SHIBUYA M, 1990, ONCOGENE, V5, P519; Sirois MG, 1997, AM J PHYSIOL-HEART C, V272, pH2746, DOI 10.1152/ajpheart.1997.272.6.H2746; STEIN CA, 1995, NAT MED, V1, P1119, DOI 10.1038/nm1195-1119; Takagi H, 1996, DIABETES, V45, P1016, DOI 10.2337/diabetes.45.8.1016; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V34, P1578; TISCHER E, 1991, J BIOL CHEM, V266, P11947; UNEMORI EN, 1992, J CELL PHYSIOL, V153, P557, DOI 10.1002/jcp.1041530317; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; YAKUBOV LA, 1989, P NATL ACAD SCI USA, V86, P6454, DOI 10.1073/pnas.86.17.6454	47	229	244	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					31047	31054		10.1074/jbc.274.43.31047	http://dx.doi.org/10.1074/jbc.274.43.31047			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521504	hybrid			2022-12-27	WOS:000083276700100
J	Hu, CY; Chen, W; Frasch, WD				Hu, CY; Chen, W; Frasch, WD			Metal ligation by Walker Homology B aspartate beta D262 at site 3 of the latent but not activated form of the chloroplast F-1-ATPase from Chlamydomonas reinhardtii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLING FACTOR-I; ESCHERICHIA-COLI F1-ATPASE; NUCLEOTIDE BINDING-SITES; TIGHTLY BOUND ADP; CATALYTIC SITES; DIRECTED MUTAGENESIS; ADENYLATE KINASE; ATP SYNTHASE; COORDINATION; SUBUNITS	Site-directed mutations D262C, D262H, D262N, and D262T were made to the beta subunit Walker Homology B aspartate of chloroplast F-1-ATPase in Chlamydomonas, Photoautotrophic growth and photophosphorylation rates were 3-14% of wild type as were ATPase activities of purified chloroplast F-1 indicating that beta D262 is an essential residue for catalysis, The EPR spectrum of vanadyl bound to Site 3 of chloroplast F-1 as VO2+-ATP gave rise to two EPR species designated B and C in wild type and mutants. V-51-hyperfine parameters of species C, present exclusively in the activated enzyme state, did not change significantly by the mutations examined indicating that it is not an equatorial ligand to VO2+, nor is it hydrogen-bonded to a coordinated water at an equatorial position. Every mutation changed the ratio of EPR species C/B and/or the V-51-hyperfine parameters of species B, the predominant conformation of VO2+-nucleotide bound to Site 3 in the latent (down-regulated) state. The results indicate that the Walker Homology B aspartate coordinates the metal of the predominant metal-nucleotide conformation at Site 3 in the latent state but not in the conformation present exclusively upon activation and elucidates one of the specific changes in metal ligation involved with activation.	Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85287 USA; Arizona State Univ, Grad Program Mol & Cellular Biol, Tempe, AZ 85287 USA; Arizona State Univ, Ctr Study Early Events Photosynthesis, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe	Frasch, WD (corresponding author), Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85287 USA.				NIGMS NIH HHS [GM50202, R01 GM050202] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050202] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ALSHAWI MK, 1992, BIOCHEMISTRY-US, V31, P878, DOI 10.1021/bi00118a033; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; BOYNTON JE, 1988, SCIENCE, V240, P1534, DOI 10.1126/science.2897716; BRUIST MF, 1981, BIOCHEMISTRY-US, V20, P6298, DOI 10.1021/bi00525a003; Chasteen N.D., 1981, BIOL MAGN RESON, V3, P53; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; Chen W, 1999, J BIOL CHEM, V274, P7089, DOI 10.1074/jbc.274.11.7089; DUNCAN TM, 1986, FEBS LETT, V208, P1, DOI 10.1016/0014-5793(86)81519-8; DUNHAM KR, 1981, J BIOL CHEM, V256, P212; FELDMAN RI, 1985, J BIOL CHEM, V260, P3088; FRASCH WD, 1982, BIOCHEMISTRY-US, V21, P3636, DOI 10.1021/bi00258a017; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; FRY DC, 1985, BIOCHEMISTRY-US, V24, P4680, DOI 10.1021/bi00338a030; Hamstra BJ, 1997, INORG CHEM, V36, P4866, DOI 10.1021/ic970284x; Harris D. A., 1987, SPECTROPHOTOMETRY SP; HIGGINS CF, 1986, NATURE, V323, P448, DOI 10.1038/323448a0; Holyk N, 1979, THESIS U NEW HAMPSHI; HOUSEMAN ALP, 1995, BIOCHEMISTRY-US, V34, P3277, DOI 10.1021/bi00010a018; HOUSEMAN ALP, 1994, BIOCHEMISTRY-US, V33, P4910, DOI 10.1021/bi00182a020; HOUSEMAN ALP, 1994, BIOCHEMISTRY-US, V33, P10000, DOI 10.1021/bi00199a025; Hu CY, 1996, BIOCHEMISTRY-US, V35, P12201, DOI 10.1021/bi961105a; MAURIE AM, 1980, THESIS U ILLINOIS UR; MCCARTY RE, 1987, TRENDS BIOCHEM SCI, V12, P234, DOI 10.1016/0968-0004(87)90116-2; MERCHANT S, 1983, EUR J BIOCHEM, V137, P373, DOI 10.1111/j.1432-1033.1983.tb07838.x; Nilges M. J., 1979, THESIS U ILLINOIS UR; ONEAL CC, 1984, J BIOL CHEM, V259, P5761; Sambrook J., 2002, MOL CLONING LAB MANU; SELMANREIMER S, 1981, BIOCHEMISTRY-US, V20, P5476, DOI 10.1021/bi00522a020; SHAPIRO AB, 1991, J BIOL CHEM, V266, P4194; Shirakihara Y, 1997, STRUCTURE, V5, P825, DOI 10.1016/S0969-2126(97)00236-0; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEBBER AN, 1993, J BIOL CHEM, V268, P12990; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; Weber J, 1996, J BIOL CHEM, V271, P18711, DOI 10.1074/jbc.271.31.18711; Weber J, 1998, BIOCHEMISTRY-US, V37, P608, DOI 10.1021/bi972370e; YOHDA M, 1988, BIOCHIM BIOPHYS ACTA, V933, P156, DOI 10.1016/0005-2728(88)90065-5; ZHOU JM, 1988, BIOCHEMISTRY-US, V27, P5129, DOI 10.1021/bi00414a027	39	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30481	30486		10.1074/jbc.274.43.30481	http://dx.doi.org/10.1074/jbc.274.43.30481			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521428	hybrid			2022-12-27	WOS:000083276700024
J	Nogami, K; Shima, M; Hosokawa, K; Suzuki, T; Koide, T; Saenko, EL; Scandella, D; Shibata, M; Kamisue, S; Tanaka, I; Yoshioka, A				Nogami, K; Shima, M; Hosokawa, K; Suzuki, T; Koide, T; Saenko, EL; Scandella, D; Shibata, M; Kamisue, S; Tanaka, I; Yoshioka, A			Role of factor VIIIC2 domain in factor VIII binding to factor Xa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; LIGHT-CHAIN; C2 DOMAIN; VONWILLEBRAND-FACTOR; HEMOPHILIA-A; THROMBIN; ACTIVATION; CLEAVAGE; ANTIBODY; SITE	Factor VIII (FVIII) is activated by proteolytic cleavages with thrombin and factor Xa (FXa) in the intrinsic blood coagulation pathway, The anti-Ca monoclonal antibody ESH8, which recognizes residues 2248-2285 and does not inhibit FVIII binding to von Willebrand factor or phospholipid, inhibited FVIII activation by FXa in a clotting assay. Furthermore, analysis by SDS-polyacrylamide gel electrophoresis showed that ESH8 inhibited FXa cleavage in the presence or absence of phospholipid. The light chain (LCh) fragments (both 80 and 72 kDa) and the recombinant C2 domain dose-dependently bound to immobilized anhydro-FXa, a catalytically inactive derivative of FXa in which dehydroalanine replaces the active-site serine. The affinity (K-d) values for the 80- and 72-kDa LCh fragments and the C2 domain were 55, 51, and 560 nM, respectively. The heavy chain of FVIII did not bind to anhydro-FXa. Similarly, competitive assays using overlapping synthetic peptides corresponding to ESH8 epitopes (residues 2248-2285) demonstrated that a peptide designated EP-2 (residues 2253-2270; TSMYVKEFLISSSQDGHQ) inhibited the binding of the C2 domain or the 72-kDa LCh to anhydro-FXa by more than 95 and 84%, respectively. Our results provide the first evidence for a direct role of the C2 domain in the association between FVIII and FXa.	Nara Med Univ, Dept Pediat, Kashihara, Nara 634, Japan; Fujimori Kogyo Co, Nakahara Ku, Kawasaki, Kanagawa 211, Japan; Himeji Inst Technol, Fac Sci, Dept Life Sci, Kamigori, Hyogo 678, Japan; Amer Red Cross, Holland Lab, Rockville, MD 20855 USA	Nara Medical University; University of Hyogo; American Red Cross	Shima, M (corresponding author), Nara Med Univ, Dept Pediat, 840 Shijo Cho, Kashihara, Nara 634, Japan.	mshima@nmu-gw.cc.naramed-u.ac.jp						ALTIERI DC, 1990, J IMMUNOL, V145, P246; ASHTON RW, 1995, BIOCHEMISTRY-US, V34, P6454, DOI 10.1021/bi00019a027; DONATH MJSH, 1995, J BIOL CHEM, V270, P3648, DOI 10.1074/jbc.270.8.3648; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FOSTER PA, 1990, BLOOD, V75, P1999; FOSTER PA, 1988, J CLIN INVEST, V82, P123, DOI 10.1172/JCI113559; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GILBERT GE, 1990, J BIOL CHEM, V265, P815; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; HOYER LW, 1981, BLOOD, V58, P1; KALAFATIS M, 1994, BIOCHEMISTRY-US, V33, P6538, DOI 10.1021/bi00187a022; KAMISUE S, 1994, BRIT J HAEMATOL, V86, P106, DOI 10.1111/j.1365-2141.1994.tb03259.x; KARLSSON R, 1994, ANAL BIOCHEM, V221, P142, DOI 10.1006/abio.1994.1390; KASPER CK, 1975, THROMB DIATH HAEMOST, V34, P869; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P1233, DOI 10.1128/MCB.9.3.1233; KOEDAM JA, 1990, EUR J BIOCHEM, V189, P229, DOI 10.1111/j.1432-1033.1990.tb15481.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lapan KA, 1997, J BIOL CHEM, V272, P2082; LOLLAR P, 1993, METHOD ENZYMOL, V222, P128; LOLLAR P, 1985, BIOCHEMISTRY-US, V24, P8056, DOI 10.1021/bi00348a033; NEUENSCHWANDER PF, 1992, ARCH BIOCHEM BIOPHYS, V296, P426, DOI 10.1016/0003-9861(92)90593-L; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; Parker ET, 1997, BIOCHEMISTRY-US, V36, P9365, DOI 10.1021/bi970599o; Prescott R, 1997, BLOOD, V89, P3663, DOI 10.1182/blood.V89.10.3663.3663_3663_3671; REGAN LM, 1995, J BIOL CHEM, V270, P8546, DOI 10.1074/jbc.270.15.8546; SAENKO EL, 1995, J BIOL CHEM, V270, P13826, DOI 10.1074/jbc.270.23.13826; Saenko EL, 1997, J BIOL CHEM, V272, P18007, DOI 10.1074/jbc.272.29.18007; SAENKO EL, 1994, J BIOL CHEM, V269, P11601; Saenko EL, 1996, J BIOL CHEM, V271, P27424, DOI 10.1074/jbc.271.44.27424; SCANDELLA D, 1995, BLOOD, V86, P1811, DOI 10.1182/blood.V86.5.1811.bloodjournal8651811; SHIMA M, 1995, BRIT J HAEMATOL, V91, P714, DOI 10.1111/j.1365-2141.1995.tb05374.x; SHIMA M, 1989, BLOOD, V74, P1612; SHIMA M, 1991, INT J HEMATOL, V54, P515; SHIMA M, 1993, THROMB HAEMOSTASIS, V69, P240; SHIMA M, 1992, BRIT J HAEMATOL, V81, P533, DOI 10.1111/j.1365-2141.1992.tb02988.x; SHIMA M, 1986, J NARA MED ASS, V31, P672; Thompson AR, 1997, BLOOD, V90, P1902, DOI 10.1182/blood.V90.5.1902; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; TUDDENHAM EGD, 1994, NUCLEIC ACIDS RES, V22, P3511, DOI 10.1093/nar/22.17.3511; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WEISS HJ, 1977, J CLIN INVEST, V60, P390, DOI 10.1172/JCI108788; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0	43	70	81	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					31000	31007		10.1074/jbc.274.43.31000	http://dx.doi.org/10.1074/jbc.274.43.31000			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521497	hybrid			2022-12-27	WOS:000083276700093
J	Ridder, IS; Rozeboom, HJ; Kalk, KH; Dijkstra, BW				Ridder, IS; Rozeboom, HJ; Kalk, KH; Dijkstra, BW			Crystal structures of intermediates in the dehalogenation of haloalkanoates by L-2-haloacid dehalogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XANTHOBACTER-AUTOTROPHICUS GJ10; SITE-DIRECTED MUTAGENESIS; HALIDE-BINDING-SITE; PSEUDOMONAS SP. YL; X-RAY STRUCTURE; HALOACID DEHALOGENASE; STRUCTURE REFINEMENT; PROTEIN STRUCTURES; REACTION-MECHANISM; ACTIVE-SITE	The L-2-haloacid dehalogenase from the 1,2-dichloroethane-degrading bacterium Xanthobacter autotrophicus GJ10 catalyzes the hydrolytic dehalogenation of small L-2-haloalkanoates to their corresponding D-2-hydroxyalkanoates, with inversion of the configuration at the C-2 atom. The structure of the apoenzyme at pH 8 was refined at 1.5-Angstrom resolution. By lowering the pH, the catalytic activity of the enzyme was considerably reduced, allowing the crystal structure determination of the complexes with L-2-monochloropropionate and monochloroacetate at 1.7 and 2.1 Angstrom resolution, respectively. Both complexes showed unambiguous electron density extending from the nucleophile Asp(8) to the C-2 atom of the dechlorinated substrates corresponding to a covalent enzyme-ester reaction intermediate. The halide ion that is cleaved off is found in line with the Asp8 O delta 1-C-2 bond in a halide-stabilizing cradle made up of Arg(39), Asn(115) and Phe(175). In both complexes, the Asp(8) 0 delta 2 carbonyl oxygen atom interacts with Thr(12), Ser(171) and Asn(173) which possibly constitute the oxyanion hole in the hydrolysis of the ester bond. The carboxyl moiety of the substrate is held in position by interactions with Ser(114), Lys(147) and main chain NR groups. The L-2-monochloropropionate CH3 group is located in a small pocket formed by side chain atoms of Ly(147), Asn(173), Phe(175), and Asp(176). The size and position of the pocket explain the stereospecificity and the limited substrate specificity of the enzyme. These crystallographic results demonstrate that the reaction of the enzyme proceeds via the formation of a covalent enzyme-ester intermediate at the nucleophile Asp(8).	Univ Groningen, Dept Chem, Biophys Chem Lab, NL-9747 AG Groningen, Netherlands; Univ Groningen, Dept Chem, BIOSAN Res Inst, NL-9747 AG Groningen, Netherlands	University of Groningen; University of Groningen	Dijkstra, BW (corresponding author), Univ Groningen, Dept Chem, Biophys Chem Lab, Nijanborgh 4, NL-9747 AG Groningen, Netherlands.	b.w.dijkstra@chem.rug.nl	Dijkstra, Bauke W./H-4308-2019	Dijkstra, Bauke W./0000-0001-9731-6586; Ridder, Ivo Steven/0000-0002-1669-4161; Rozeboom, Henriette/0000-0002-1656-6477				Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; Asano S, 1996, J BIOL CHEM, V271, P2740, DOI 10.1074/jbc.271.5.2740; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Benning MM, 1996, BIOCHEMISTRY-US, V35, P8103, DOI 10.1021/bi960768p; BHAT TN, 1988, J APPL CRYSTALLOGR, V21, P279, DOI 10.1107/S0021889887012755; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; Collet JF, 1997, FEBS LETT, V408, P281, DOI 10.1016/S0014-5793(97)00438-9; DAHMS AS, 1973, J BIOL CHEM, V248, P6592; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fersht A., 1985, ENZYME STRUCTURE MEC; Fetzner S, 1998, APPL MICROBIOL BIOT, V50, P633, DOI 10.1007/s002530051346; Hisano T, 1996, J BIOL CHEM, V271, P20322, DOI 10.1074/jbc.271.34.20322; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; JANSSEN DB, 1985, APPL ENVIRON MICROB, V49, P673, DOI 10.1128/AEM.49.3.673-677.1985; Jeffrey G.A., 2012, HYDROGEN BONDING BIO; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P525, DOI 10.1016/S0076-6879(97)77029-0; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P208, DOI 10.1016/S0076-6879(97)77013-7; KOONIN EV, 1994, J MOL BIOL, V244, P125, DOI 10.1006/jmbi.1994.1711; Krooshof GH, 1998, BIOCHEMISTRY-US, V37, P15013, DOI 10.1021/bi9815187; KURIHARA T, 1995, J BIOCHEM, V117, P1317, DOI 10.1093/oxfordjournals.jbchem.a124861; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li YF, 1998, J BIOCHEM-TOKYO, V124, P20, DOI 10.1093/oxfordjournals.jbchem.a022080; Li YF, 1998, J BIOL CHEM, V273, P15035, DOI 10.1074/jbc.273.24.15035; LIU JQ, 1995, J BIOL CHEM, V270, P18309, DOI 10.1074/jbc.270.31.18309; Liu JQ, 1997, J BIOL CHEM, V272, P3363, DOI 10.1074/jbc.272.6.3363; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MacArthur MW, 1996, J MOL BIOL, V264, P1180, DOI 10.1006/jmbi.1996.0705; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Read RJ, 1997, METHOD ENZYMOL, V277, P110, DOI 10.1016/S0076-6879(97)77009-5; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; Ridder IS, 1999, ACTA CRYSTALLOGR D, V55, P1273, DOI 10.1107/S090744499900534X; Ridder IS, 1999, BIOCHEM J, V339, P223, DOI 10.1042/0264-6021:3390223; Ridder IS, 1997, J BIOL CHEM, V272, P33015, DOI 10.1074/jbc.272.52.33015; RIDDER IS, 1995, PROTEIN SCI, V4, P2619, DOI 10.1002/pro.5560041220; STUCKI G, 1995, ENVIRON SCI TECHNOL, V29, P2339, DOI 10.1021/es00009a028; VANDERPLOEG J, 1991, J BACTERIOL, V173, P7925, DOI 10.1128/jb.173.24.7925-7933.1991; Vellieux FMD, 1997, J APPL CRYSTALLOGR, V30, P396, DOI 10.1107/S0021889896012551; VERSCHUEREN KHG, 1993, BIOCHEMISTRY-US, V32, P9031, DOI 10.1021/bi00086a008; VERSCHUEREN KHG, 1993, NATURE, V363, P693, DOI 10.1038/363693a0	46	67	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30672	30678		10.1074/jbc.274.43.30672	http://dx.doi.org/10.1074/jbc.274.43.30672			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521454	hybrid, Green Published			2022-12-27	WOS:000083276700050
J	Aman, MJ; Migone, TS; Sasaki, A; Ascherman, DP; Zhu, MH; Soldaini, E; Imada, K; Miyajima, A; Yoshimura, A; Leonard, WJ				Aman, MJ; Migone, TS; Sasaki, A; Ascherman, DP; Zhu, MH; Soldaini, E; Imada, K; Miyajima, A; Yoshimura, A; Leonard, WJ			CIS associates with the interleukin-2 receptor beta chain and inhibits interleukin-2-dependent signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED STAT INHIBITOR; IL-2 RECEPTOR; ALPHA-CHAIN; CYTOPLASMIC DOMAINS; MULTIPLE CYTOKINES; JAK-STAT5 PATHWAY; SH2 DOMAIN; GENE; PROTEIN; ACTIVATION	CIS is a cytokine-induced SH2-containing protein that was originally cloned as an interleukin (IL)-3-inducible gene. CIS is known to associate with the IL-3 receptor beta chain and erythropoietin receptor and to inhibit signaling mediated by IL-3 and erythropoietin. We now demonstrate that CLS also interacts with the IL-2 receptor beta chain (IL-2R beta), This interaction requires the A region of IL-2R beta (residues 313-382), which also mediates the association of IL-2R beta with Lck and Jak3. Correspondingly, CIS inhibits functions associated with both of these kinases: Lck-mediated phosphorylation of IL-2R beta and IL-2-mediated activation of Stat5. Thus, we demonstrate that CIS can negatively control at least two independent IL-2 signaling pathways. Although a functional SH2 binding domain of CIS was not required for its interaction with IL-2R beta in vitro, its phosphotyrosine binding capability was essential for the inhibitory action of CIS. On this basis, we have generated a mutant form of CIS protein with an altered SH2 domain that acts as a dominant negative and should prove useful in further understanding CIS action.	NHLBI, Lab Mol Immunol, NIH, Bethesda, MD 20892 USA; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Kurume Univ, Inst Life Sci, Kurume, Fukuoka 8390861, Japan	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Tokyo; Kurume University	Leonard, WJ (corresponding author), NHLBI, Lab Mol Immunol, NIH, Bldg 10,Rm 7N252, Bethesda, MD 20892 USA.		Leonard, Warren/AAA-1397-2022; Yoshimura, Akihiko/K-5515-2013	Imada, Kazunori/0000-0002-0945-0513; Sasaki, Atsuo/0000-0003-2963-4501				Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; AMAN MJ, 1997, CURR BIOL, V12, pR784; Ascherman DP, 1997, J BIOL CHEM, V272, P8704, DOI 10.1074/jbc.272.13.8704; BOUSSIOTIS VA, 1994, SCIENCE, V266, P1039, DOI 10.1126/science.7973657; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Friedman MC, 1996, P NATL ACAD SCI USA, V93, P2077, DOI 10.1073/pnas.93.5.2077; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; JOHN S, 1995, MOL CELL BIOL, V15, P1786; John S, 1996, EMBO J, V15, P5627, DOI 10.1002/j.1460-2075.1996.tb00947.x; KACZMAREK L, 1987, J CELL BIOL, V104, P183, DOI 10.1083/jcb.104.2.183; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Lecine P, 1996, MOL CELL BIOL, V16, P6829; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Lin Jian-Xin, 1997, Cytokine and Growth Factor Reviews, V8, P313; LIN JX, 1993, MOL CELL BIOL, V13, P6201, DOI 10.1128/MCB.13.10.6201; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; Masuhara M, 1997, BIOCHEM BIOPH RES CO, V239, P439, DOI 10.1006/bbrc.1997.7484; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; Minamoto S, 1997, BIOCHEM BIOPH RES CO, V237, P79, DOI 10.1006/bbrc.1997.7080; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nakajima H, 1997, IMMUNITY, V7, P691, DOI 10.1016/S1074-7613(00)80389-1; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; Neel BG, 1997, CURR OPIN IMMUNOL, V9, P405, DOI 10.1016/S0952-7915(97)80088-X; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; OTANI H, 1993, J BIOL CHEM, V268, P22733; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; Ravichandran KS, 1996, P NATL ACAD SCI USA, V93, P5275, DOI 10.1073/pnas.93.11.5275; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SPERISEN P, 1995, J BIOL CHEM, V270, P10743, DOI 10.1074/jbc.270.18.10743; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TOLEDANO MB, 1990, P NATL ACAD SCI USA, V87, P1830, DOI 10.1073/pnas.87.5.1830; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Zhu MH, 1998, J BIOL CHEM, V273, P10719, DOI 10.1074/jbc.273.17.10719	42	83	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30266	30272		10.1074/jbc.274.42.30266	http://dx.doi.org/10.1074/jbc.274.42.30266			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514520	hybrid			2022-12-27	WOS:000083176400099
J	Campbell, PG; Durham, SK; Hayes, JD; Suwanichkul, A; Powell, DR				Campbell, PG; Durham, SK; Hayes, JD; Suwanichkul, A; Powell, DR			Insulin-like growth factor-binding protein-3 binds fibrinogen and fibrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I IGF-I; PLASMINOGEN ACTIVATORS; WOUND FLUID; TISSUE-TYPE; CELLS; LOCALIZATION; PROTEOLYSIS; HEPARIN; ANALOGS; COMPLEX	Following tissue injury, a fibrin network formed at the wound site serves as a scaffold supporting the early migration of stromal cells needed for wound hearing. Growth factors such as insulin-like growth factor-I (IGF-I) concentrate in wounds to stimulate stromal cell function and proliferation. The ability of IGF-binding proteins (IGFBPs) such as IGFBP-3 to reduce the rate of IGF-I clearance from wounds suggests that IGFBP-3 might bind directly to fibrinogen/fibrin. Studies presented here show that IGFBP-3 does indeed bind to fibrinogen and fibrin immobilized on immunocapture plates, with K-d values = 0.67 and 0.70 nM, respectively, and competitive binding studies suggest that the IGFBP-3 heparin binding domain may participate in this binding. IGF-I does not compete for IGFBP-3 binding; instead, IGF-I binds immobilized IGFBP-3 fibrinogen and IGFBP-3 fibrin complexes with affinity similar to that of IGF-I for the type I IGF receptor. In the presence of plasminogen, most IGFBP-3 binds directly to fibrinogen, although 35-40% of the IGFBP-3 binds to fibrinogen-bound plasminogen, IGFBP-3 also binds specifically to native fibrin clots, and addition of exogenous IGFBP-3 increases IGF-I binding. These studies suggest that IGF-I can concentrate at wound sites by binding to fibrin-immobilized IGFBP-3, and that the lower IGF affinity of fibrin-bound IGFBP-3 allows IGF-I release to type I IGF receptors of stromal cells migrating into the fibrin clot.	Carnegie Mellon Univ, Inst Complex Engineered Syst, Pittsburgh, PA 15212 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA	Carnegie Mellon University; Baylor College of Medicine	Powell, DR (corresponding author), Texas Childrens Hosp, Feigin Ctr, MC 3-2482,6621 Fannin, Houston, TX 77030 USA.	dpowell@bcm.tmc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038773] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK-38773] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADELMAN B, 1989, THROMB HAEMOSTASIS, V62, P1078; ANDRESS DL, 1993, BIOCHEM BIOPH RES CO, V195, P25, DOI 10.1006/bbrc.1993.2004; ANGELLOZNICOUD P, 1995, ENDOCRINOLOGY, V136, P5485, DOI 10.1210/en.136.12.5485; ARAI T, 1994, J BIOL CHEM, V269, P20388; BALLARD FJ, 1993, GROWTH REGULAT, V3, P40; Baxter Robert C., 1995, Progress in Growth Factor Research, V6, P215, DOI 10.1016/0955-2235(95)00004-6; BAYNE ML, 1989, J BIOL CHEM, V264, P11004; BLAT C, 1994, J CLIN INVEST, V93, P2286, DOI 10.1172/JCI117229; BOOTH BA, 1995, GROWTH REGULAT, V5, P1; CAMPBELL PG, 1992, ENDOCRINOLOGY, V130, P1401, DOI 10.1210/en.130.3.1401; Campbell PG, 1998, AM J PHYSIOL-ENDOC M, V275, pE321, DOI 10.1152/ajpendo.1998.275.2.E321; Campbell PG, 1997, AM J PHYSIOL-ENDOC M, V273, pE996, DOI 10.1152/ajpendo.1997.273.5.E996; Campbell PG, 1997, AM J PHYSIOL-ENDOC M, V273, pE1005, DOI 10.1152/ajpendo.1997.273.5.E1005; Chan K, 1998, ENDOCRINOLOGY, V139, P559, DOI 10.1210/en.139.2.559; Clark R., 1996, Mezhdunarodnyi Sel'skokhozyaistvennyi Zhurnal, P3; CONOVER CA, 1990, ENDOCRINOLOGY, V127, P2795, DOI 10.1210/endo-127-6-2795; CUBBAGE ML, 1990, J BIOL CHEM, V265, P12642; DOOLITTLE RF, 1987, ANNU REV BIOCHEM, V53, P195; Durham SK, 1997, PEDIATR RES, V42, P335, DOI 10.1203/00006450-199709000-00014; Durham SK, 1999, HORM METAB RES, V31, P216, DOI 10.1055/s-2007-978722; FROST VJ, 1993, J ENDOCRINOL, V138, P545, DOI 10.1677/joe.0.1380545; GREENBERG CS, 1985, BLOOD, V66, P1028; Heding A, 1996, J BIOL CHEM, V271, P13948, DOI 10.1074/jbc.271.24.13948; ICHINOSE A, 1986, J CLIN INVEST, V78, P163, DOI 10.1172/JCI112546; IINO M, 1995, EUR J BIOCHEM, V232, P90, DOI 10.1111/j.1432-1033.1995.tb20785.x; JOBE MI, 1992, CLIN HEMATOLOGY PRIN, P579; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Jones John I., 1995, Progress in Growth Factor Research, V6, P319, DOI 10.1016/0955-2235(95)00015-1; KEIJER J, 1991, BLOOD, V78, P401; KIRSTEIN M, 1992, J CLIN INVEST, V90, P439, DOI 10.1172/JCI115879; LALOU C, 1994, ENDOCRINOLOGY, V135, P2318, DOI 10.1210/en.135.6.2318; LEONG SR, 1992, MOL ENDOCRINOL, V6, P870, DOI 10.1210/me.6.6.870; LIU CY, 1979, J BIOL CHEM, V254, P421; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; Robertson JG, 1996, ENDOCRINOLOGY, V137, P2774, DOI 10.1210/en.137.7.2774; Romer J, 1996, NAT MED, V2, P287, DOI 10.1038/nm0396-287; ROSTAGNO A, 1994, J BIOL CHEM, V269, P31938; ROUY D, 1992, BIOCHEMISTRY-US, V31, P6333, DOI 10.1021/bi00142a024; Sahni A, 1998, J BIOL CHEM, V273, P7554, DOI 10.1074/jbc.273.13.7554; SKOTTNER A, 1990, ACTA PAEDIATR SCAND, P63; TRANTHANG C, 1986, EUR J BIOCHEM, V160, P599, DOI 10.1111/j.1432-1033.1986.tb10080.x; TUSZYNSKI GP, 1985, J BIOL CHEM, V260, P2240; Vogt PM, 1998, PLAST RECONSTR SURG, V102, P117, DOI 10.1097/00006534-199807000-00018; Werner H, 1997, CRIT REV ONCOGENESIS, V8, P71, DOI 10.1615/CritRevOncog.v8.i1.40	45	82	97	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30215	30221		10.1074/jbc.274.42.30215	http://dx.doi.org/10.1074/jbc.274.42.30215			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514513	hybrid			2022-12-27	WOS:000083176400092
J	Sanchez, MA; Ullman, B; Landfear, SM; Carter, NS				Sanchez, MA; Ullman, B; Landfear, SM; Carter, NS			Cloning and functional expression of a gene encoding a P1 type nucleoside transporter from Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASE; UNUSUAL ADENOSINE TRANSPORTER; BLOOD-STREAM FORMS; S-ADENOSYLMETHIONINE; AFRICAN TRYPANOSOMES; MOLECULAR-CLONING; MESSENGER-RNAS; ANALOGS; EI; RHODESIENSE	Nucleoside transporters are Likely to play a central role in the biochemistry of the parasite Trypanosoma brucei, since these protozoa are unable to synthesize purines de novo and must salvage them from their hosts. Furthermore, nucleoside transporters have been implicated in the uptake of antiparasitic and experimental drugs in these and other parasites. We have cloned the gene fora T. brucei nucleoside transporter, TbNT2, and shown that this permease is related in sequence to mammalian equilibrative nucleoside transporters, Expression of the TbNT2 gene in Xenopus oocytes reveals that the permease transports adenosine, inosine, and guanosine and hence has the substrate specificity of the P1 type nucleoside transporters that have been previously characterized by uptake assays in intact parasites. TbNT2 mRNA is expressed in bloodstream form (mammalian host stage) parasites but not in procyclic form (insect stage) parasites, indicating that the gene is developmentally regulated during the parasite life cycle. Genomic Southern blots suggest that there are multiple genes related in sequence to TbNT2, implying the existence of a family of nucleoside transporter genes in these parasites.	Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University	Sanchez, MA (corresponding author), Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	sanchezm@ohsu.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023682, R01AI025920, R37AI023682, R01AI044138] Funding Source: NIH RePORTER; NIAID NIH HHS [AI25920, AI 23682, AI44138] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN TE, 1993, NUCLEIC ACIDS RES, V21, P5431, DOI 10.1093/nar/21.23.5431; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; BACCHI CJ, 1993, BIOCHEM PHARMACOL, V46, P471, DOI 10.1016/0006-2952(93)90524-Z; Bacchi CJ, 1997, ANTIMICROB AGENTS CH, V41, P2108, DOI 10.1128/AAC.41.10.2108; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; Berens Randolph L., 1995, P89, DOI 10.1016/B978-012473345-9/50007-6; BOOTHROYD JC, 1985, ANNU REV MICROBIOL, V39, P475, DOI 10.1146/annurev.mi.39.100185.002355; BRUN R, 1979, ACTA TROP, V36, P289; CAMPBELL DA, 1984, NATURE, V311, P350, DOI 10.1038/311350a0; CARTER NS, 1995, J BIOL CHEM, V270, P28153, DOI 10.1074/jbc.270.47.28153; CARTER NS, 1993, NATURE, V361, P173, DOI 10.1038/361173a0; CHE MX, 1995, J BIOL CHEM, V270, P13596, DOI 10.1074/jbc.270.23.13596; Crawford CR, 1998, J BIOL CHEM, V273, P5288, DOI 10.1074/jbc.273.9.5288; de Koning HP, 1998, J BIOL CHEM, V273, P9486, DOI 10.1074/jbc.273.16.9486; deKoning HP, 1997, MOL BIOCHEM PARASIT, V89, P245, DOI 10.1016/S0166-6851(97)00129-1; Goldberg B, 1997, FASEB J, V11, P256, DOI 10.1096/fasebj.11.4.9068614; Goldberg B, 1998, BIOCHEM PHARMACOL, V56, P95, DOI 10.1016/S0006-2952(98)00118-X; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; Griffiths M, 1997, BIOCHEM J, V328, P739, DOI 10.1042/bj3280739; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; Hofmann K., 1993, BIOL CHEM H-S, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; HUANG QQ, 1994, J BIOL CHEM, V269, P17757; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LANGFORD CK, 1994, J BIOL CHEM, V269, P17939; Mani RS, 1998, J BIOL CHEM, V273, P30818, DOI 10.1074/jbc.273.46.30818; MARR JJ, 1983, MOL BIOCHEM PARASIT, V7, P339, DOI 10.1016/0166-6851(83)90016-6; MILHAUSEN M, 1984, CELL, V38, P721, DOI 10.1016/0092-8674(84)90267-8; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; SALMON D, 1994, CELL, V78, P75, DOI 10.1016/0092-8674(94)90574-6; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Shih S, 1998, J BIOL CHEM, V273, P1534, DOI 10.1074/jbc.273.3.1534; THISSEN JA, 1991, EXP PARASITOL, V72, P243, DOI 10.1016/0014-4894(91)90143-K; Tye CK, 1998, BIOORG MED CHEM LETT, V8, P811, DOI 10.1016/S0960-894X(98)00095-X; Vasudevan G, 1998, P NATL ACAD SCI USA, V95, P9873, DOI 10.1073/pnas.95.17.9873; Vickers MF, 1999, BIOCHEM J, V339, P21, DOI 10.1042/0264-6021:3390021; Yao SYM, 1997, J BIOL CHEM, V272, P28423, DOI 10.1074/jbc.272.45.28423	38	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30244	30249		10.1074/jbc.274.42.30244	http://dx.doi.org/10.1074/jbc.274.42.30244			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514517	hybrid			2022-12-27	WOS:000083176400096
J	Yoon, KS; Hille, R; Hemann, C; Tabita, FR				Yoon, KS; Hille, R; Hemann, C; Tabita, FR			Rubredoxin from the green sulfur bacterium Chlorobium tepidum functions as an electron acceptor for pyruvate ferredoxin oxidoreductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; HYDROGENOBACTER-THERMOPHILUS TK-6; OPEN READING FRAMES; 2 4FE-4S CLUSTERS; PYROCOCCUS-FURIOSUS; PHOTOSYNTHETIC BACTERIUM; AZOTOBACTER-VINELANDII; PSEUDOMONAS-OLEOVORANS; REDUCTION POTENTIALS; GENE-CLUSTER	Rubredoxin (Rd) from the moderately thermophilic green sulfur bacterium Chlorobium tepidum was found to function as an electron acceptor for pyruvate ferredoxin oxidoreductase (PFOR), This enzyme, which catalyzes the conversion of pyruvate to acetyl-CoA and CO2, exhibited an absolute dependence upon the presence of Rd, However, Rd was incapable of participating in the pyruvate, synthase or CO2 fixation reaction of C. tepidum PFOR, for which two different reduced ferredoxins are employed as electron donors, These results suggest a specific functional role for Rd in pyruvate oxidation and provide the initial indication that the two important physiological reactions catalyzed by PFOR/pyruvate synthase are dependent on different electron carriers in the cell, The W-visible spectrum of oxidized Rd, with a monomer molecular weight of 6500, gave a molar absorption coefficient at 492 nm of 6.89 mM(-1) cm(-1) with an A(492)/A(280) ratio of 0.343 and contained one iron atom/molecule. Further spectroscopic studies indicated that the CD spectrum of oxidized C. tepidum Rd exhibited a unique absorption maximum at 385 nm and a shoulder at 420 nm, The EPR spectrum of oxidized Rd also exhibited unusual anisotropic resonances at g = 9.675 and g = 4.322, which is composed of a narrow central feature with broader shoulders to high and low field, The midpoint reduction potential of C. tepidum Rd was determined to be -87 mV, which is the most electronegative value reported for Rd from any source.	Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA; Ohio State Univ, Ctr Plant Biotechnol, Columbus, OH 43210 USA; Ohio State Univ, Dept Med Biochem, Columbus, OH 43210 USA	Ohio State University; Ohio State University; Ohio State University	Tabita, FR (corresponding author), Ohio State Univ, Dept Microbiol, 484 W 12Th Ave, Columbus, OH 43210 USA.			Hemann, Craig/0000-0002-7380-4072	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052322] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52322] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLAKE PR, 1991, BIOCHEMISTRY-US, V30, P10885, DOI 10.1021/bi00109a012; Brereton PS, 1998, BIOCHEMISTRY-US, V37, P7351, DOI 10.1021/bi972864b; BUCHANAN BB, 1969, METHOD ENZYMOL, V28, P170; CAVAGNERO S, 1995, BIOCHEMISTRY-US, V34, P9865, DOI 10.1021/bi00031a007; CHEN JC, 1992, BIOCHIM BIOPHYS ACTA, V1131, P122, DOI 10.1016/0167-4781(92)90111-C; Dobritzsch D, 1998, J BIOL CHEM, V273, P20196, DOI 10.1074/jbc.273.32.20196; Eaton W. A., 1973, IRON SULFUR PROTEINS, V2, P131; EVANS MCW, 1966, P NATL ACAD SCI USA, V55, P928, DOI 10.1073/pnas.55.4.928; EVANS MCW, 1965, P NATL ACAD SCI USA, V53, P1420, DOI 10.1073/pnas.53.6.1420; FU CL, 1994, GENE, V145, P91, DOI 10.1016/0378-1119(94)90328-X; Gao-Sheridan HS, 1998, J BIOL CHEM, V273, P5514, DOI 10.1074/jbc.273.10.5514; GEHRING U, 1972, J BIOL CHEM, V247, P6963; Gomes CM, 1997, J BIOL CHEM, V272, P22502, DOI 10.1074/jbc.272.36.22502; HALL DO, 1969, NATURE, V223, P1342, DOI 10.1038/2231342a0; HORMEL S, 1986, FEBS LETT, V201, P147, DOI 10.1016/0014-5793(86)80588-9; Hughes NJ, 1998, J BACTERIOL, V180, P1119, DOI 10.1128/JB.180.5.1119-1128.1998; Kern D, 1997, SCIENCE, V275, P67, DOI 10.1126/science.275.5296.67; KERSCHER L, 1982, EUR J BIOCHEM, V128, P223; Kyritsis P, 1998, J BIOL CHEM, V273, P15404, DOI 10.1074/jbc.273.25.15404; Lee HJ, 1998, BIOCHEMISTRY-US, V37, P15513, DOI 10.1021/bi981853v; LEE WY, 1995, ARCH BIOCHEM BIOPHYS, V318, P80, DOI 10.1006/abbi.1995.1207; LeGall J, 1998, FEBS LETT, V429, P295, DOI 10.1016/S0014-5793(98)00610-3; LeJohn H B, 1975, Methods Enzymol, V41, P293; LOVENBERG W, 1963, J BIOL CHEM, V238, P3899; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Ma K, 1997, P NATL ACAD SCI USA, V94, P9608, DOI 10.1073/pnas.94.18.9608; MCKENNA EJ, 1970, J BIOL CHEM, V245, P3882; Menon S, 1997, BIOCHEMISTRY-US, V36, P8484, DOI 10.1021/bi970403k; MEYER TE, 1971, BIOCHIM BIOPHYS ACTA, V234, P266, DOI 10.1016/0005-2728(71)90081-8; MILLS WR, 1980, PLANTA, V148, P75, DOI 10.1007/BF00385445; OHOKA H, 1995, FEBS LETT, V365, P30, DOI 10.1016/0014-5793(95)00433-A; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; PEARSON DJ, 1965, METHOD ENZYMOL, V13, P545; PEISACH J, 1971, J BIOL CHEM, V246, P5877; RAGSDALE SW, 1983, J BACTERIOL, V155, P1224, DOI 10.1128/JB.155.3.1224-1237.1983; RAO KK, 1972, BIOCHEM J, V129, P1063, DOI 10.1042/bj1291063; REED LJ, 1990, J BIOL CHEM, V265, P8971; REY L, 1992, J MOL BIOL, V228, P998, DOI 10.1016/0022-2836(92)90886-O; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEKI S, 1988, J BIOCHEM-TOKYO, V103, P583, DOI 10.1093/oxfordjournals.jbchem.a122310; SHIMIZU F, 1989, BIOCHIMIE, V71, P1171, DOI 10.1016/0300-9084(89)90020-5; SIEKER LC, 1994, METHOD ENZYMOL, V243, P203; SMITH ET, 1994, BIOCHEMISTRY-US, V33, P1008, DOI 10.1021/bi00170a020; Swartz PD, 1996, BIOCHEMISTRY-US, V35, P13772, DOI 10.1021/bi960611x; UYEDA K, 1971, J BIOL CHEM, V246, P3111; WAHL RC, 1987, J BIOL CHEM, V262, P10489; WAHLUND TM, 1995, J BACTERIOL, V177, P2583, DOI 10.1128/jb.177.9.2583-2588.1995; WAHLUND TM, 1991, ARCH MICROBIOL, V156, P81, DOI 10.1007/BF00290978; WOOLLEY KJ, 1987, EUR J BIOCHEM, V163, P161, DOI 10.1111/j.1432-1033.1987.tb10750.x; YANG SS, 1980, BIOCHIM BIOPHYS ACTA, V590, P24, DOI 10.1016/0005-2728(80)90143-7; Yoon KS, 1997, BIOSCI BIOTECH BIOCH, V61, P510, DOI 10.1271/bbb.61.510; Yoon KS, 1997, ARCH MICROBIOL, V167, P275, DOI 10.1007/s002030050443; Yoon KS, 1996, J BACTERIOL, V178, P3365, DOI 10.1128/jb.178.11.3365-3368.1996	53	57	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29772	29778		10.1074/jbc.274.42.29772	http://dx.doi.org/10.1074/jbc.274.42.29772			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514453	hybrid			2022-12-27	WOS:000083176400032
J	Chau, ASS; Shibuya, EK				Chau, ASS; Shibuya, EK			Inactivation of p42 mitogen-activated protein kinase is required for exit from M-phase after cyclin destruction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS EGG EXTRACTS; SPINDLE-ASSEMBLY CHECKPOINT; MAP KINASE; CELL-CYCLE; PATHWAY; MITOSIS; CDC25; ARREST; PHOSPHORYLATION; KINETOCHORES	By using cycling Xenopus egg extracts, we have previously found that if mitogen-activated protein kinase (p42 MAPK) is activated on entry into mitosis (M-phase), the extract is arrested with condensed chromosomes and spindle microtubules. Here we show that these arrested extracts have high levels of M-phase promoting factor (MPF, Cyclin B/Cdc2) activity, stabilized levels of Cyclin B, and sustained M-phase-specific phosphorylations, We also examined the role of p42 MAPK in DNA damage checkpoint-arrested extracts that were induced to enter M-phase by the addition of Cdc25C protein. In these extracts, Cdc25C protein triggers the abrupt, premature activation of MPF and entry into M-phase. MPF activity then drops suddenly due to Cyclin B proteolysis, just as p42 MAPK is activated. Unexpectedly, however, M-phase is sustained, as judged by maintenance of M-phase-specific phosphorylations and condensed chromosomes. To determine if this M-phase arrest depended on p42 MAPK activation, we added PD98059 (PD), an inhibitor of p42 MAPK activation, to egg extracts with exogenous Cdc25, Both untreated and PH-treated extracts entered RI-phase simultaneously, with a sharp peak of MPF activity, However, only PH-treated extracts subsequently exited from RI-phase and entered interphase. In PH-treated extracts, p42 MAPK was not activated, and the transition to interphase was accompanied by the formation of decondensed nuclei and the disappearance of M-phase-specific phosphorylation of proteins. These results show that although entry into M-phase requires the activation of MPF, exit from M-phase even after cyclin destruction, is dependent on the inactivation of p42 MAPK.	Univ Alberta, Dept Cell Biol, Mol Mechanisms Growth Control Gr, Edmonton, AB T6G 2H7, Canada	University of Alberta	Shibuya, EK (corresponding author), Univ Alberta, Dept Cell Biol, Mol Mechanisms Growth Control Gr, 6-30 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.							Abrieu A, 1997, EMBO J, V16, P6407, DOI 10.1093/emboj/16.21.6407; Abrieu A, 1996, J CELL SCI, V109, P239; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bitangcol JC, 1998, MOL BIOL CELL, V9, P451, DOI 10.1091/mbc.9.2.451; BOTTORFF D, 1995, MOL CELL BIOL, V15, P5113; Chau ASS, 1998, BIOL CELL, V90, P565, DOI 10.1016/S0248-4900(99)80014-8; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; Kumagai A, 1998, MOL BIOL CELL, V9, P345, DOI 10.1091/mbc.9.2.345; Kumagai A, 1998, J CELL BIOL, V142, P1559, DOI 10.1083/jcb.142.6.1559; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Shapiro PS, 1998, J CELL BIOL, V142, P1533, DOI 10.1083/jcb.142.6.1533; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; SHIBUYA EK, 1992, EMBO J, V11, P3963, DOI 10.1002/j.1460-2075.1992.tb05490.x; Takenaka K, 1997, J CELL BIOL, V136, P1091, DOI 10.1083/jcb.136.5.1091; VANDERVELDEN HMW, 1993, MOL CELL BIOL, V13, P1480, DOI 10.1128/MCB.13.3.1480; VIGERS GPA, 1991, J CELL BIOL, V112, P545, DOI 10.1083/jcb.112.4.545; Walter SA, 1997, MOL BIOL CELL, V8, P2157, DOI 10.1091/mbc.8.11.2157; Wells WAE, 1996, TRENDS CELL BIOL, V6, P228, DOI 10.1016/0962-8924(96)10018-0; Zecevic M, 1998, J CELL BIOL, V142, P1547, DOI 10.1083/jcb.142.6.1547	28	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32085	32090		10.1074/jbc.274.45.32085	http://dx.doi.org/10.1074/jbc.274.45.32085			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542242	hybrid			2022-12-27	WOS:000083532100050
J	Inoue, T; Kamiyama, J; Sakai, T				Inoue, T; Kamiyama, J; Sakai, T			Sp1 and NF-Y synergistically mediate the effect of vitamin D-3 in the p27(Kip1) gene promoter that lacks vitamin D response elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE INHIBITOR P27; TRANSCRIPTION-FACTOR; BINDING PROTEINS; FUNCTIONAL-CHARACTERIZATION; HORMONE-RECEPTOR; LEUKEMIA-CELLS; DNA; DIFFERENTIATION; EXPRESSION; PHOSPHORYLATION	Vitamin D-3 promotes myeloid leukemic cell lines to differentiate terminally into monocytes/macrophages. It has been reported that overexpression of the cdk inhibitor p27(Kip1) results in the differentiation of the myelomonocytic U937 cell line and that this gene is the target of vitamin D-3. To identify the sequences required for the positive regulation of p27(Kip1) transcription by man p27(Kip1) 3.6-kilobase 5'-flanking region of the human was examined by transiently transfecting luciferase reporter constructs into U937 cells. The transcriptional activity of this construct was activated by vitamin D-3. Deletion and mutational analysis revealed that both a GGGCGG sequence (-545/-539) and a CCAAT sequence (-525/-520) were necessary to induce p27(Kip1) gene expression. Importantly, the region containing both of these elements conferred positive responsiveness to vitamin D-3 to a heterologous promoter. Gel shift assays showed that Spl binds to the GGGCGG sequence and that NF-Y binds to the CCAAT sequence. Consistent with the roles of these transcription factors, treatment with vitamin DQ Stimulated the DNA binding activities of these factors to each element and induced the change of one NF-Y subunit. We conclude that vitamin D-3 stimulates transcription of the p27(Kip1) gene by a novel mechanism involving Spl and NF-Y, but not the vitamin D receptor, during the early stages of U937 cell differentiation.	Kyoto Prefectural Univ Med, Dept Prevent Med, Kamigyo Ku, Kyoto 6028566, Japan	Kyoto Prefectural University of Medicine	Sakai, T (corresponding author), Kyoto Prefectural Univ Med, Dept Prevent Med, Kamigyo Ku, Kyoto 6028566, Japan.							ALROY I, 1995, MOL CELL BIOL, V15, P5789; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BHATIA M, 1995, J BIOL CHEM, V270, P15962, DOI 10.1074/jbc.270.27.15962; BOUILLON R, 1995, ENDOCR REV, V16, P200, DOI 10.1210/er.16.2.200; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; Currie RA, 1998, J BIOL CHEM, V273, P1430, DOI 10.1074/jbc.273.3.1430; DEMAY MB, 1990, P NATL ACAD SCI USA, V87, P369, DOI 10.1073/pnas.87.1.369; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Ezura Y, 1997, J BIOL CHEM, V272, P29865, DOI 10.1074/jbc.272.47.29865; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; Hauses M, 1998, J BIOL CHEM, V273, P31844, DOI 10.1074/jbc.273.48.31844; Ishimaru F, 1997, BLOOD, V89, P4136, DOI 10.1182/blood.V89.11.4136; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Jehan F, 1997, P NATL ACAD SCI USA, V94, P10138, DOI 10.1073/pnas.94.19.10138; KAMEI Y, 1993, BIOCHEM BIOPH RES CO, V193, P948, DOI 10.1006/bbrc.1993.1717; Kamiyama J, 1999, FEBS LETT, V455, P281, DOI 10.1016/S0014-5793(99)00899-6; KRIWACKI RW, 1992, P NATL ACAD SCI USA, V89, P9759, DOI 10.1073/pnas.89.20.9759; Li Q, 1998, EMBO J, V17, P6300, DOI 10.1093/emboj/17.21.6300; LI XY, 1992, J BIOL CHEM, V267, P8984; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; Marziali G, 1997, MOL CELL BIOL, V17, P1387, DOI 10.1128/MCB.17.3.1387; Marziali G, 1999, BLOOD, V93, P519, DOI 10.1182/blood.V93.2.519.402a01_519_526; Minami S, 1997, FEBS LETT, V411, P1, DOI 10.1016/S0014-5793(97)00660-1; MINGHETTI PP, 1988, FASEB J, V2, P3043, DOI 10.1096/fasebj.2.15.2847948; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Orita T, 1997, J BIOL CHEM, V272, P23216, DOI 10.1074/jbc.272.37.23216; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PAHL HL, 1991, EXP HEMATOL, V19, P1038; Schrader M, 1997, BIOCHEM BIOPH RES CO, V230, P646, DOI 10.1006/bbrc.1996.6025; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; VANHUIJSDUIJNEN RAMH, 1987, NUCLEIC ACIDS RES, V15, P7265, DOI 10.1093/nar/15.18.7265; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; ZHANG DE, 1994, J BIOL CHEM, V269, P11425; Zhang Y, 1997, BBA-GENE STRUCT EXPR, V1353, P307, DOI 10.1016/S0167-4781(97)00063-8	41	136	138	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32309	32317		10.1074/jbc.274.45.32309	http://dx.doi.org/10.1074/jbc.274.45.32309			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542271	hybrid			2022-12-27	WOS:000083532100079
J	Mercuri, FA; Doege, KJ; Arner, EC; Pratta, MA; Last, K; Fosang, AJ				Mercuri, FA; Doege, KJ; Arner, EC; Pratta, MA; Last, K; Fosang, AJ			Recombinant human aggrecan G1-G2 exhibits native binding properties and substrate specificity for matrix metalloproteinases and aggrecanase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARTILAGE PROTEOGLYCAN DEGRADATION; NEUTROPHIL COLLAGENASE MMP-8; HUMAN ARTICULAR-CARTILAGE; GLOBULAR PROTEIN DOMAINS; HUMAN SYNOVIAL-FLUID; INTERGLOBULAR DOMAIN; KERATAN SULFATE; LINK PROTEIN; MONOCLONAL-ANTIBODIES; N-GLYCOSYLATION	A recombinant human aggrecan G1-G2 fragment comprising amino acids Val(1)-Arg(656) has been expressed in Sf21 cells using a baculovirus expression system. The recombinant G1-G2 (rG1-G2) was purified to homogeneity by hyaluronan-Sepharose affinity chromatography followed by high performance liquid chromatography gel filtration, and gave a single band of M-r 90,000-95,000 by silver stain or immunoblotting with monoclonal antibody 1-C-6. The expressed G1-G2 bound to both hyaluronan and link protein indicating that the immunoglobulin-fold motif and proteoglycan tandem repeat loops of the G1 domain were correctly folded, Further analysis of secondary structure by rotary shadowing electron microscopy confirmed a double globe appearance, but revealed that the rG1-G2 was more compact than its native counterpart. The size of rG1-G2 by SDS-polyacrylamide gel electorphoresis was unchanged following digestion with keratanase and keratanase II and reduced by only 2-5 kDa following digestion with either O-glycosidase or N-glycosidase F. Recombinant G1-G2 was digested with purified matrix metalloproteinases (MMP), isolated aggrecanase, purified atrolysin C, or proteinases present in conditioned medium from cartilage explant cultures, and the products analyzed on SDS gels by silver stain and immunoblotting, Neoepitope antibodies recognizing the N-terminal F(342)FGVG C-terminal DIPEN341 sequences were used to confirm MMP cleavage at the Asn(341) down arrow Phe bond, while neoepitope antibodies recognizing the N-terminal A(374)RGSV or C-terminal ITEGE(373) sequences were used to confirm aggrecanase cleavage at the Glu(373) down arrow Ala bond. Cleavage at the authentic MMP and aggrecanase sites revealed that these proteinases have the same specificity for rG1-G2 as for native aggrecan. Incubation of rG1-G2 with conditioned medium from porcine cartilage cultures revealed that active soluble aggrecanase but no active MMPs, was released following stimulation with interleukin-1 alpha or retinoic acid, Atrolysin C, which cleaves native bovine aggrecan at both the aggrecanase and MMP sites, efficiently cleaved rG1-G2 at the aggrecanase site but failed to cleave at the MMP site. In contrast, native glycosylated G1-G2 with or without keratanase treatment was cleaved by atrolysin C at both the aggrecanase and MMP sites. The results suggest that the presence or absence per se of keratan sulfate on native G1-G2 does not affect the activity of atrolysin C toward the two sites.	Univ Melbourne, Dept Paediat, Royal Childrens Hosp, Orthopaed Mol Biol Res Unit, Parkville, Vic 3052, Australia; Shriners Hosp Crippled Children, Tampa Unit, Tampa, FL 33612 USA; DuPont Pharmaceut Co, Expt Stn E400, Wilmington, DE 19880 USA	Royal Children's Hospital Melbourne; University of Melbourne; DuPont	Fosang, AJ (corresponding author), Univ Melbourne, Dept Paediat, Royal Childrens Hosp, Orthopaed Mol Biol Res Unit, Parkville, Vic 3052, Australia.			Last, Karena/0000-0002-4396-8404; Mercuri, Francesca/0000-0003-1026-2672; Fosang, Amanda/0000-0002-5523-5427				Arner EC, 1997, J BIOL CHEM, V272, P9294; Arner EC, 1999, J BIOL CHEM, V274, P6594, DOI 10.1074/jbc.274.10.6594; ARNER EC, 1997, T ORTHOP RES SOC, V22, P103; BARRY FP, 1995, J BIOL CHEM, V270, P20516, DOI 10.1074/jbc.270.35.20516; BARRY FP, 1992, BIOCHEM J, V286, P761, DOI 10.1042/bj2860761; BJARNASON JB, 1978, BIOCHEMISTRY-US, V17, P3395, DOI 10.1021/bi00609a033; BONNET F, 1985, BIOCHEM J, V228, P77, DOI 10.1042/bj2280077; BUTTNER FH, 1998, T ORTHOP RES SOC, V23, P84; CAMPBELL MA, 1989, BIOCHEM J, V259, P21, DOI 10.1042/bj2590021; CATERSON B, 1986, ARTICULAR CARTILAGE, P59; Chiang N, 1998, ARCH BIOCHEM BIOPHYS, V352, P207, DOI 10.1006/abbi.1998.0620; DAVIDSON DJ, 1993, J CLIN INVEST, V92, P249, DOI 10.1172/JCI116557; DAVIS TR, 1993, IN VITRO CELL DEV-AN, V29A, P842, DOI 10.1007/BF02631361; DAVIS TR, 1995, IN VITRO CELL DEV-AN, V31, P659; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FLANNERY CR, 1992, J BIOL CHEM, V267, P1008; FLANNERY CR, 1993, T ORTHOP RES SOC, V18, P190; FLANNERY CR, 1995, T ORTHOP RES SOC, V20, P102; FOSANG AJ, 1989, BIOCHEM J, V261, P801, DOI 10.1042/bj2610801; FOSANG AJ, 1994, BIOCHEM J, V304, P347, DOI 10.1042/bj3040347; FOSANG AJ, 1991, J BIOL CHEM, V266, P15579; FOSANG AJ, 1995, BIOCHEM J, V310, P337, DOI 10.1042/bj3100337; FOSANG AJ, 1992, J BIOL CHEM, V267, P19470; Fosang AJ, 1996, J CLIN INVEST, V98, P2292, DOI 10.1172/JCI119040; FOSANG AJ, 1993, BIOCHEM J, V295, P273, DOI 10.1042/bj2950273; FOSANG AJ, 1991, BIOCHEM J, V273, P369, DOI 10.1042/bj2730369; Fosang AJ, 1996, FEBS LETT, V380, P17, DOI 10.1016/0014-5793(95)01539-6; Fosang AJ, 1998, FEBS LETT, V430, P186, DOI 10.1016/S0014-5793(98)00667-X; GRABENHORST E, 1993, EUR J BIOCHEM, V215, P189, DOI 10.1111/j.1432-1033.1993.tb18022.x; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; Gu JG, 1997, BIOCHEM BIOPH RES CO, V232, P91, DOI 10.1006/bbrc.1997.6230; HASCALL VC, 1974, J BIOL CHEM, V249, P4242; Hughes CE, 1997, J BIOL CHEM, V272, P20269, DOI 10.1074/jbc.272.32.20269; HUGHES CE, 1992, J BIOL CHEM, V267, P16011; HUGHES CE, 1995, BIOCHEM J, V305, P799, DOI 10.1042/bj3050799; Hughes CE, 1998, J BIOL CHEM, V273, P30576, DOI 10.1074/jbc.273.46.30576; HUTTON S, 1996, T ORTHOP RES SOC, V21, P150; ILIC MZ, 1995, ARCH BIOCHEM BIOPHYS, V322, P22, DOI 10.1006/abbi.1995.1431; ILIC MZ, 1992, ARCH BIOCHEM BIOPHYS, V294, P115, DOI 10.1016/0003-9861(92)90144-L; JARVIS DL, 1995, VIROLOGY, V212, P500, DOI 10.1006/viro.1995.1508; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; KOKLITIS PA, 1991, BIOCHEM J, V276, P217, DOI 10.1042/bj2760217; Krishnan P, 1999, J BIOL CHEM, V274, P10945, DOI 10.1074/jbc.274.16.10945; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARK MW, 1995, BIOCHEM J, V307, P245, DOI 10.1042/bj3070245; Lark MW, 1997, J CLIN INVEST, V100, P93, DOI 10.1172/JCI119526; LARK MW, 1995, J BIOL CHEM, V270, P2550, DOI 10.1074/jbc.270.6.2550; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; Lopez M, 1997, GLYCOBIOLOGY, V7, P635, DOI 10.1093/glycob/7.5.635; LOULAKIS P, 1992, BIOCHEM J, V284, P589, DOI 10.1042/bj2840589; MANNEBERG M, 1994, PROTEIN SCI, V3, P30; MEHMET H, 1986, EUR J BIOCHEM, V157, P385, DOI 10.1111/j.1432-1033.1986.tb09680.x; Mitchell PG, 1996, J CLIN INVEST, V97, P761, DOI 10.1172/JCI118475; MORGELIN M, 1989, J BIOL CHEM, V264, P12080; MORRIS NP, 1986, J BIOL CHEM, V261, P5638; MURPHY G, 1992, J BIOL CHEM, V267, P9612; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; PAULSSON M, 1987, BIOCHEM J, V245, P763, DOI 10.1042/bj2450763; RATCLIFFE A, 1986, BIOCHEM J, V238, P571, DOI 10.1042/bj2380571; Reboul P, 1996, J CLIN INVEST, V97, P2011, DOI 10.1172/JCI118636; Russo S, 1998, FEBS LETT, V436, P11, DOI 10.1016/S0014-5793(98)00951-X; SANDY JD, 1992, J CLIN INVEST, V89, P1512, DOI 10.1172/JCI115742; SANDY JD, 1991, J BIOL CHEM, V266, P8683; SINGER II, 1995, J CLIN INVEST, V95, P2178, DOI 10.1172/JCI117907; STEVENS JW, 1984, J CELL BIOCHEM, V26, P247, DOI 10.1002/jcb.240260405; Sztrolovics R, 1997, BIOCHEM J, V326, P235, DOI 10.1042/bj3260235; Tortorella MD, 1998, J BIOL CHEM, V273, P5846, DOI 10.1074/jbc.273.10.5846; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; TORTORELLA MD, 1995, T ORTHOP RES SOC, V20, P341; VALHMU WB, 1995, BIOCHEM J, V309, P535, DOI 10.1042/bj3090535; WARD RV, 1991, BIOCHEM J, V278, P179, DOI 10.1042/bj2780179; Watanabe H, 1997, J BIOL CHEM, V272, P28057, DOI 10.1074/jbc.272.44.28057; WITTER J, 1987, ARTHRITIS RHEUM-US, V30, P519, DOI 10.1002/art.1780300506; XUE CB, 1997, Patent No. 9718207; YEH JC, 1993, BIOCHEMISTRY-US, V32, P11087, DOI 10.1021/bi00092a019	76	32	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32387	32395		10.1074/jbc.274.45.32387	http://dx.doi.org/10.1074/jbc.274.45.32387			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542281	hybrid			2022-12-27	WOS:000083532100089
J	Tucker, SC; Wisdom, R				Tucker, SC; Wisdom, R			Site-specific heterodimerization by paired class homeodomain proteins mediates selective transcriptional responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SPECIFICITY; MOUSE GENOME; COOPERATIVE INTERACTIONS; CRYSTAL-STRUCTURE; HOX PROTEINS; IN-VIVO; GENE; DROSOPHILA; DOMAIN; HOMEOPROTEIN	Alx4 is a paired class homeodomain protein involved in defining anterior/posterior polarity in the developing limb bud. The paired class of homeodomain proteins cooperatively bind palindromic DNA elements as homodimers or as heterodimers with other paired homeodomain proteins, Previous characterization demonstrates that the strength of the cooperativity as well as the preference for targets is dictated largely by the identity of amino acid 50 of the homeodomain, Here we compare and contrast the DNA binding properties of a glutamine 50 paired homeodomain protein, Alx4, and a lysine 50 paired homeodomain protein, Goosecoid. We demonstrate that Alx4 homodimers, Gsc homodimers, and Alx4/Gsc heterodimers each have distinct DNA binding properties, and each can discriminate between highly related palindromic elements. Using reporter gene assays, we show that Alx4 activates transcription in a site-specific manner, and that Gsc is capable of antagonizing Alx4-mediated activation only from promoter elements that support heterodimer formation. These data demonstrate that paired homeodomain proteins with different DNA binding properties are able to form heterodimeric complexes with unique DNA binding and transcriptional activities. Thus, heterodimerization regulates the DNA binding specificity of these transcription factors and may partially explain how paired homeodomain proteins direct specific developmental functions.	Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA	Vanderbilt University	Wisdom, R (corresponding author), Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA.				NATIONAL CANCER INSTITUTE [T32CA009582, R01CA064118] Funding Source: NIH RePORTER; NCI NIH HHS [2T32 CA09582, R01CA64118] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Biggin MD, 1997, DEVELOPMENT, V124, P4425; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; BRANDON EP, 1995, CURR BIOL, V5, P873, DOI 10.1016/S0960-9822(95)00177-1; BRANDON EP, 1995, CURR BIOL, V5, P625, DOI 10.1016/S0960-9822(95)00127-8; BRANDON EP, 1995, CURR BIOL, V5, P758, DOI 10.1016/S0960-9822(95)00152-7; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; CHANG DT, 1994, DEVELOPMENT, V120, P3339; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DUBOULE D, 1994, GUIDEBOOK HOMEOBOX G, P3; Duncan I, 1996, BIOESSAYS, V18, P91, DOI 10.1002/bies.950180203; GAUNT SJ, 1993, DEVELOPMENT, V117, P769; GEHRING WJ, 1993, GENE, V135, P215, DOI 10.1016/0378-1119(93)90068-E; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; HIRI CC, 1993, NAT GENET, V3, P241; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; Lu Q, 1996, MOL CELL BIOL, V16, P1632; LUESSINK B, 1995, MECH DEVELOP, V52, P51; Mailhos C, 1998, DEVELOPMENT, V125, P937; Miskiewicz P, 1996, DEVELOPMENT, V122, P2709; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; Pflugrad A, 1997, DEVELOPMENT, V124, P1699; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; Qu SM, 1997, DEVELOPMENT, V124, P3999; Qu SM, 1999, DEVELOPMENT, V126, P359; Qu SM, 1997, GENE, V203, P217, DOI 10.1016/S0378-1119(97)00497-6; Qu SM, 1998, DEVELOPMENT, V125, P2711; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; RIVERAPEREZ JA, 1995, DEVELOPMENT, V121, P3005; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; SAUNDERS JW, 1968, EPITHELIAL MESSENCHY; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SMITH DL, 1992, CELL, V68, P133, DOI 10.1016/0092-8674(92)90212-U; Smith ST, 1996, DEVELOPMENT, V122, P3141; ten Berge D, 1998, DEV BIOL, V199, P11, DOI 10.1006/dbio.1998.8921; TICKLE C, 1994, ANNU REV CELL BIOL, V10, P121; TREISMAN J, 1989, CELL, V59, P553; TuckerKellogg L, 1997, STRUCTURE, V5, P1047, DOI 10.1016/S0969-2126(97)00256-6; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VORTKAMP A, 1991, NATURE, V352, P539, DOI 10.1038/352539a0; Watabe T, 1995, GENE DEV, V9, P3038, DOI 10.1101/gad.9.24.3038; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; WILSON DS, 1995, CURR BIOL, V5, P32, DOI 10.1016/S0960-9822(95)00010-8; Yamada G, 1997, BIOCHEM BIOPH RES CO, V233, P161, DOI 10.1006/bbrc.1997.6315; YAMADA G, 1995, DEVELOPMENT, V121, P2917; ZHAO GQ, 1994, MECH DEVELOP, V48, P245, DOI 10.1016/0925-4773(94)90063-9; ZHAO GQ, 1993, P NATL ACAD SCI USA, V90, P8633, DOI 10.1073/pnas.90.18.8633	53	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32325	32332		10.1074/jbc.274.45.32325	http://dx.doi.org/10.1074/jbc.274.45.32325			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542273	hybrid			2022-12-27	WOS:000083532100081
J	Ouzzine, M; Magdalou, J; Burchell, B; Fournel-Gigleux, S				Ouzzine, M; Magdalou, J; Burchell, B; Fournel-Gigleux, S			An internal signal sequence mediates the targeting and retention of the human UDP-glucuronosyltransferase 1A6 to the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MICROSOMES; TRANSMEMBRANE PROTEINS; ESCHERICHIA-COLI; STOP TRANSFER; MEMBRANE; EXPRESSION; GLUCURONIDATION; TRANSLOCATION; BILIRUBIN; DOMAIN	The human UDP-glucuronosyltransferase isoform UGT1A6 is predicted to be a type I transmembrane protein anchored in the endoplasmic reticulum by a single C-terminal transmembrane domain, followed by a short cytoplasmic tail. This topology is thought to be! established through the sequential action of a cleavable N-terminal signal peptide and of a C-terminal stop transfer/anchor sequence, We found that the deletion of the signal peptide did not prevent membrane targeting and insertion of this protein expressed in an in vitro transcription/translation system or in yeast Pichia pastoris, Interestingly, the same results were obtained when the protein was depleted of both the signal peptide and the C-terminal transmembrane domain/cytoplasmic tail sequences, suggesting the presence of an internal topogenic element able to translocate and retain UGT1A6 in the endoplasmic reticulum membrane in vitro and in yeast cells. To identify such a sequence, the insertion of several N-terminal deletion mutants of UGT1A6 into microsomal membranes was investigated in vitro. The data clearly showed that the deletion of the N-terminal end did not affect endoplasmic reticulum targeting and retention until residues 140-240 were deleted, The signal-like activity of the 140-240 region was demonstrated by the ability of this segment to confer endoplasmic reticulum residency to the cytosolic green fluorescent protein expressed in mammalian cells. Finally, we show that this novel topogenic sequence can posttranslationally mediate the translocation of UGT1A6. This study provides the first evidence that the membrane assembly of the human UGT1A6 involves an internal signal retention sequence.	Univ Nancy 1, UMR CNRS 7561, Fac Med, F-54505 Vandoeuvre Les Nancy, France; Univ Dundee, Ninewells Hosp & Med Sch, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland	Universite de Lorraine; University of Dundee	Ouzzine, M (corresponding author), Univ Nancy 1, UMR CNRS 7561, Fac Med, BP 184, F-54505 Vandoeuvre Les Nancy, France.	ouzzine@pharmaco-med.u-nancy.fr	Ouzzine, Mohamed/G-4368-2013	OUZZINE, Mohamed/0000-0003-0058-4950				BLACHLYDYSON E, 1987, J CELL BIOL, V104, P1183, DOI 10.1083/jcb.104.5.1183; BLOBEL G, 1980, P NATL ACAD SCI USA, V79, P3111; BOCK KW, 1993, BIOCHEM PHARMACOL, V45, P1809, DOI 10.1016/0006-2952(93)90437-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAO CCK, 1987, MOL CELL BIOL, V7, P3842, DOI 10.1128/MCB.7.10.3842; CHEN HF, 1995, J BIOL CHEM, V270, P14115, DOI 10.1074/jbc.270.23.14115; Ciotti M, 1998, BIOCHEMISTRY-US, V37, P11018, DOI 10.1021/bi980747q; CONNOLLY T, 1989, J CELL BIOL, V108, P299, DOI 10.1083/jcb.108.2.299; Corsi AK, 1996, J BIOL CHEM, V271, P30299, DOI 10.1074/jbc.271.48.30299; DRAKE RR, 1992, J BIOL CHEM, V267, P11360; Dutton G.F., 1980, GLUCURONIDATION DRUG; FOURNELGIGLEUX S, 1991, MOL PHARMACOL, V39, P177; GARCIA PD, 1988, J CELL BIOL, V106, P1043, DOI 10.1083/jcb.106.4.1043; HARDING D, 1988, P NATL ACAD SCI USA, V85, P8381, DOI 10.1073/pnas.85.22.8381; Herber R, 1995, DRUG METAB DISPOS, V23, P1305; HIGH S, 1991, J CELL BIOL, V113, P25, DOI 10.1083/jcb.113.1.25; Honsho M, 1998, J BIOL CHEM, V273, P20860, DOI 10.1074/jbc.273.33.20860; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LOO TW, 1995, J BIOL CHEM, V270, P19345, DOI 10.1074/jbc.270.33.19345; Lu Y, 1998, J BIOL CHEM, V273, P568, DOI 10.1074/jbc.273.1.568; Mackenzie PI, 1997, PHARMACOGENETICS, V7, P255, DOI 10.1097/00008571-199708000-00001; Meech R, 1996, DNA CELL BIOL, V15, P489, DOI 10.1089/dna.1996.15.489; Meech R, 1998, ARCH BIOCHEM BIOPHYS, V356, P77, DOI 10.1006/abbi.1998.0750; Meech R, 1997, J BIOL CHEM, V272, P26913, DOI 10.1074/jbc.272.43.26913; MIZE NK, 1986, CELL, V47, P711, DOI 10.1016/0092-8674(86)90514-3; Ng DTW, 1996, J CELL BIOL, V134, P269, DOI 10.1083/jcb.134.2.269; OLIVER J, 1995, FEBS LETT, V362, P126, DOI 10.1016/0014-5793(95)00223-V; OUZZINE M, 1994, FEBS LETT, V339, P195, DOI 10.1016/0014-5793(94)80414-1; OUZZINE M, 1994, ARCH BIOCHEM BIOPHYS, V310, P196, DOI 10.1006/abbi.1994.1157; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; PILLOT T, 1993, J BIOL CHEM, V268, P25636; RADOMINSKA A, 1993, J BIOL CHEM, V268, P15127; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; Rapoport TA, 1996, CURR OPIN CELL BIOL, V8, P499, DOI 10.1016/S0955-0674(96)80027-5; RUSSELL DW, 1984, CELL, V37, P577, DOI 10.1016/0092-8674(84)90388-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEPHERD SRP, 1989, BIOCHEM J, V259, P617, DOI 10.1042/bj2590617; SILVE S, 1987, MOL CELL BIOL, V7, P3306, DOI 10.1128/MCB.7.9.3306; TAM LY, 1994, J BIOL CHEM, V269, P32542; Wendt KU, 1997, SCIENCE, V277, P1811, DOI 10.1126/science.277.5333.1811; Yang M, 1997, J BIOL CHEM, V272, P1970, DOI 10.1074/jbc.272.3.1970; YOKOTA H, 1992, J BIOCHEM, V112, P192, DOI 10.1093/oxfordjournals.jbchem.a123876; ZEHAVA CL, 1990, J BIOL CHEM, V265, P4929; Zhang JT, 1996, MOL BIOL CELL, V7, P471, DOI 10.1091/mbc.7.3.471; ZUCKER SD, 1994, J BIOL CHEM, V269, P19262	51	88	89	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31401	31409		10.1074/jbc.274.44.31401	http://dx.doi.org/10.1074/jbc.274.44.31401			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531341	hybrid			2022-12-27	WOS:000083379400045
J	Qadri, I; Siddiqui, A				Qadri, I; Siddiqui, A			Expression of hepatitis B virus polymerase in Ty1-his3AI retroelement of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRAL-DNA SYNTHESIS; REVERSE-TRANSCRIPTASE; RNA INTERMEDIATE; PROTEIN; REPLICATION; ELEMENT; YEAST	Hepatitis B virus (HBV), although a DNA virus, replicates using reverse transcriptase encoded by the HBV polymerase (pol) gene, The biochemical dissection of HBV pol has been hampered by failure to liberate enzymatically active protein from nucleocapsids. Here, we have employed a yeast-based genetic approach to express the HBV reverse transcriptase. In this strategy, the reverse transcriptase of yeast retrotransposon Ty1 element is replaced with the HBV pol gene to produce the hybrid Ty1/HBV element. Additionally, the indicator gene his3AI is combined in an antisense orientation to the transcripts of the hybrid Ty1/HBVRT element. The splicing of his3AI; cDNA synthesis of the Ty1/HBVRT RNA and subsequent integration relies on the reverse transcriptase activity. The production of histidine prototrophs results from the successful reverse transcription of Ty1/HBVRThis3AI transcripts followed by either homologous recombination or integrase-mediated insertion and subsequent expression of HIS3 gene. Using this approach we successfully detected the reverse transcriptase activity of HBV in yeast strains defective in endogenous Ty1 expression. Consistent with the unique priming activity associated with HBV pol, the minus strand DNA synthesis was protein-primed. Deletion of HBV reverse transcriptase (RT) or RNase H domains resulted in a dramatic drop in histidine prototrophs, The addition of HBV encoded HBx protein in virus-like particles during in vitro RT reaction stimulated the RT reaction by severalfold. Furthermore, in the presence of 3TC, a known inhibitor of HBV reverse transcriptase, yeast His(+) growth of His protrophs was not observed. Thus, this approach, which is based on genetic selection in yeast, is safe, economic, and a reliable strategy with a potential for large scale screening of cofactors and inhibitors of HBV polymerase functions.	Univ Colorado, Hlth Sci Ctr, Dept Microbiol B172, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Siddiqui, A (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Microbiol B172, 4200 E 9th Ave, Denver, CO 80262 USA.		Qadri, Ishtiaq/I-6889-2013	Qadri, Ishtiaq/0000-0003-4334-0585				BARTENSCHLAGER R, 1990, J VIROL, V64, P5324, DOI 10.1128/JVI.64.11.5324-5332.1990; BEASLEY RP, 1981, LANCET, V2, P1129; Boeke JD, 1998, CELL, V93, P1087, DOI 10.1016/S0092-8674(00)81450-6; BOEKE JD, 1985, CELL, V40, P491, DOI 10.1016/0092-8674(85)90197-7; CURCIO MJ, 1991, P NATL ACAD SCI USA, V88, P936, DOI 10.1073/pnas.88.3.936; DOMBROSKI BA, 1994, MOL CELL BIOL, V14, P4485, DOI 10.1128/MCB.14.7.4485; FOUREL I, 1994, J VIROL, V68, P1059, DOI 10.1128/JVI.68.2.1059-1065.1994; GERLICH WH, 1980, CELL, V21, P801, DOI 10.1016/0092-8674(80)90443-2; Harrich D, 1997, EMBO J, V16, P1224, DOI 10.1093/emboj/16.6.1224; Hu JM, 1996, P NATL ACAD SCI USA, V93, P1060, DOI 10.1073/pnas.93.3.1060; Lanford RE, 1997, J VIROL, V71, P2996, DOI 10.1128/JVI.71.4.2996-3004.1997; Levin HL, 1997, CELL, V88, P5, DOI 10.1016/S0092-8674(00)81851-6; LOEB DD, 1993, REVERSE TRANSCRIPTAS, P329; MATHIAS SL, 1991, SCIENCE, V254, P1808, DOI 10.1126/science.1722352; NASAL M, 1996, J VIROL, V67, P3254; NASSAL M, 1993, TRENDS MICROBIOL, V1, P222; Nissley DV, 1996, NATURE, V380, P30, DOI 10.1038/380030a0; Nissley DV, 1998, P NATL ACAD SCI USA, V95, P13905, DOI 10.1073/pnas.95.23.13905; Qadri I, 1996, J BIOL CHEM, V271, P15443, DOI 10.1074/jbc.271.26.15443; SEEGER C, 1986, SCIENCE, V232, P477, DOI 10.1126/science.3961490; SEEGER C, 1991, CURR TOP MICROBIOL, V168, P41; SEIFER M, 1993, J VIROL, V67, P4513, DOI 10.1128/JVI.67.8.4513-4520.1993; SUMMERS J, 1982, CELL, V29, P403, DOI 10.1016/0092-8674(82)90157-X; TAVIS JE, 1993, P NATL ACAD SCI USA, V90, P4107, DOI 10.1073/pnas.90.9.4107; WANG GH, 1992, CELL, V71, P663, DOI 10.1016/0092-8674(92)90599-8	25	4	5	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31359	31365		10.1074/jbc.274.44.31359	http://dx.doi.org/10.1074/jbc.274.44.31359			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531336	hybrid			2022-12-27	WOS:000083379400040
J	Ro, HS; Miles, EW				Ro, HS; Miles, EW			Catalytic mechanism of the tryptophan synthase alpha(2)beta(2) complex - Effects of pH, isotopic substitution, and allosteric ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ULTRAVIOLET VISIBLE SPECTROSCOPY; INDUCED CONFORMATIONAL-CHANGES; O-ACETYLSERINE SULFHYDRYLASE; CARBON CARBON LYASES; SALMONELLA-TYPHIMURIUM; ESCHERICHIA-COLI; BETA-SUBUNIT; L-SERINE; PYRIDOXAL-PHOSPHATE; INTERSUBUNIT COMMUNICATION	The mechanism of the tryptophan synthase alpha(2)beta(2) complex from Salmonella typhimurium is explored by determining the effects of pH, of temperature, and of isotopic substitution on the pyridoxal phosphate-dependent reaction of L-serine with indole to form L-tryptophan, The pH dependence of the kinetic parameters indicates that three ionizing groups are involved in substrate binding and catalysis with pK(a)1 = 6.5, pK(a)2 = 7.3, and pK(a)3 = 8.2-9. A significant primary isotope effect (similar to 3.5) on V and V/K is observed at low pH (pH 7), but not at high pH (pH 9), indicating that the base that accepts the alpha-proton (beta Lys-87) is protonated at low pH, slowing the abstraction of the alpha-proton and making this step at least partially rate- limiting. pK(a)2 is assigned to beta Lys-87 on the basis of the kinetic isotope effect results and of the observation that the competitive inhibitors glycine and oxindolyl-L-alanine display single pK(i) values of 7.3. The residue with this pK(a) (beta Lys-87) must be unprotonated for binding glycine or oxindolyl-L-alanine and, by inference, L-serine. Investigations of the temperature dependence of the pK(a) values support the assignment of pK(a)2 to beta Lys-87 and suggest that the ionizing residue with pK(a)1 could be a carboxylate, possibly beta Asp-305, and that the residue associated with a conformational change at pK(a)3 may be beta Lys-167. The occurrence of a closed to open conformational conversion at high pH is supported by investigations of the effects of pH on reaction specificity and on the equilibrium distribution of enzyme-substrate intermediates.	NIDDK, Lab Biochem & Genet, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Miles, EW (corresponding author), NIDDK, Lab Biochem & Genet, NIH, Bldg 8,Rm 225,8 Ctr Dr,MSC 0830, Bethesda, MD 20892 USA.	EdithM@intra.niddk.nih.gov	Ro, Hyeon-Su/V-7023-2019					AHMED SA, 1991, J BIOL CHEM, V266, P21548; AHMED SA, 1994, J BIOL CHEM, V269, P16486; Ahmed SA, 1996, J BIOL CHEM, V271, P29100, DOI 10.1074/jbc.271.46.29100; Cleland W W, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P273; Cleland W W, 1979, Methods Enzymol, V63, P500; Davis L., 1972, ENZYMES, V7, P33; DREWE WF, 1986, BIOCHEMISTRY-US, V25, P2494, DOI 10.1021/bi00357a032; DREWE WF, 1985, BIOCHEMISTRY-US, V24, P3977, DOI 10.1021/bi00336a027; FAEDER EJ, 1971, BIOCHEMISTRY-US, V10, P1041; Fan YX, 1999, BIOCHEMISTRY-US, V38, P7881, DOI 10.1021/bi990307e; FERSHT A, 1985, ENZYME STRUCTURE MEC, P163; GRIMSHAW CE, 1981, BIOCHEMISTRY-US, V20, P5655, DOI 10.1021/bi00523a003; HEILMANN HD, 1978, BIOCHIM BIOPHYS ACTA, V522, P614, DOI 10.1016/0005-2744(78)90092-X; Hur O, 1996, BIOCHEMISTRY-US, V35, P7378, DOI 10.1021/bi960240k; HYDE CC, 1988, J BIOL CHEM, V263, P17857; JENCKS WP, 1959, J AM CHEM SOC, V81, P475, DOI 10.1021/ja01511a053; KAWASAKI H, 1987, J BIOL CHEM, V262, P10678; KIICK DM, 1988, BIOCHEMISTRY-US, V27, P7333, DOI 10.1021/bi00419a023; KIICK DM, 1988, BIOCHEMISTRY-US, V27, P7339, DOI 10.1021/bi00419a024; KNOWLES JR, 1976, CRC CR REV BIOCH MOL, V4, P165, DOI 10.3109/10409237609105457; LANE AN, 1983, EUR J BIOCHEM, V129, P561; LANE AN, 1983, EUR J BIOCHEM, V129, P571; LU ZC, 1993, J BIOL CHEM, V268, P8727; Miles E W, 1995, Subcell Biochem, V24, P207; Miles E W, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P127; Miles E.W., 1986, PYRIDOXAL PHOSPHAT B, V1, P253; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; MILES EW, 1987, METHOD ENZYMOL, V142, P398; MILES EW, 1974, J BIOL CHEM, V249, P2852; MILES EW, 1989, J BIOL CHEM, V264, P6280; Pan P, 1997, TRENDS BIOCHEM SCI, V22, P22, DOI 10.1016/S0968-0004(96)10066-9; PERACCHI A, 1995, BIOCHEMISTRY-US, V34, P9459, DOI 10.1021/bi00029a022; Peracchi A, 1996, BIOCHEMISTRY-US, V35, P1872, DOI 10.1021/bi951889c; PHILLIPS RS, 1984, BIOCHEMISTRY-US, V23, P6228, DOI 10.1021/bi00320a052; PHILLIPS RS, 1985, J BIOL CHEM, V260, P4665; Rhee S, 1998, J BIOL CHEM, V273, P8553, DOI 10.1074/jbc.273.15.8553; Rhee S, 1998, BIOCHEMISTRY-US, V37, P10653, DOI 10.1021/bi980779d; Rhee S, 1997, BIOCHEMISTRY-US, V36, P7664, DOI 10.1021/bi9700429; Rhee S, 1996, BIOCHEMISTRY-US, V35, P4211, DOI 10.1021/bi952506d; Rowlett R, 1998, BIOCHEMISTRY-US, V37, P2961, DOI 10.1021/bi972286z; RUVINOV SB, 1995, J BIOL CHEM, V270, P17333, DOI 10.1074/jbc.270.29.17333; SAVIGE WE, 1980, INT J PEPT PROT RES, V15, P285; Schneider TR, 1998, BIOCHEMISTRY-US, V37, P5394, DOI 10.1021/bi9728957; TAI CH, 1995, BIOCHEMISTRY-US, V34, P12311, DOI 10.1021/bi00038a027; TAI CH, 1993, BIOCHEMISTRY-US, V32, P6433, DOI 10.1021/bi00076a017; Tipton K F, 1979, Methods Enzymol, V63, P183; TURNER PD, 1985, BIOCHIM BIOPHYS ACTA, V832, P280, DOI 10.1016/0167-4838(85)90261-4; Woehl E, 1999, BIOCHEMISTRY-US, V38, P7118, DOI 10.1021/bi982918x; Yang LH, 1997, J BIOL CHEM, V272, P7859, DOI 10.1074/jbc.272.12.7859; Yang LH, 1996, PROTEIN EXPRES PURIF, V8, P126, DOI 10.1006/prep.1996.0082; YANG XJ, 1993, J BIOL CHEM, V268, P22269	51	12	12	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31189	31194		10.1074/jbc.274.44.31189	http://dx.doi.org/10.1074/jbc.274.44.31189			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531312	hybrid			2022-12-27	WOS:000083379400016
J	Edwards, HM; Kam, CM; Powers, JC; Trapani, JA				Edwards, HM; Kam, CM; Powers, JC; Trapani, JA			The human cytotoxic T cell granule serine protease granzyme H has chymotrypsin-like (chymase) activity and is taken up into cytoplasmic vesicles reminiscent of granzyme B-containing endosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TARGET-CELLS; MEDIATED APOPTOSIS; DNA FRAGMENTATION; LYMPHOCYTES; PURIFICATION; SUBSTRATE; PERFORIN; SPECIFICITY; ACTIVATION; RECEPTOR	Serine proteases (granzymes) contained within the cytoplasmic granules of cytotoxic T cells and natural killer cells play a variety of roles including the induction of target cell apoptosis, breakdown of extracellular matrix proteins and induction of cytokine secretion by bystander leukocytes, Different granzymes display proteolytic specificities that mimic the activities of trypsin or chymotrypsin, or may cleave substrates at acidic ("Asp-ase") or at long unbranched amino acids such as Met ("Met-ase"). Here, we report that recombinant granzyme H has chymotrypsin-like (chymase) activity, the first report of a human granzyme with this proteolytic specificity. Recombinant 32-kDa granzyme H expressed in the baculovirus vector pBacPAK8 was secreted from Sf21 cells and recovered by Ni-affinity chromatography, using a poly-His tag encoded at the predicted carboxyl terminus of fall-length granzyme H cDNA. The granzyme H efficiently cleaved Suc-Phe-Leu-Phe-SBzI (v = 185 nM/s at [S] = 0.217 mM) and also hydrolyzed Boc-Ala-Ala-X-SBzI (X = Phe, Tyr, Met, Me, or Nva) with slower rates but had little tryptase or Asp-ase activity. Enzymatic activity was inhibited completely by 0.1 mM 3,4-dichloroisocoumarin and 84% by 1.0 mM phenylmethylsulfonyl fluoride. Fluoresceinated granzyme H was internalized in a temperature-dependent manner by Jurkat cells into endosome-like vesicles, suggesting that it can bind to cell surface receptors similar to those that bind granzyme B. This suggests a hitherto unsuspected intracellular function for granzyme H.	Austin Res Inst, John Connell Lab, Heidelberg, Vic 3084, Australia; Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA	Austin Research Institute; University System of Georgia; Georgia Institute of Technology	Trapani, JA (corresponding author), Austin Res Inst, John Connell Lab, Studley Rd, Heidelberg, Vic 3084, Australia.	j.trapani@ari.unimelb.edu.au		Trapani, Joseph/0000-0003-0983-1532	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054401] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 54401] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beresford PJ, 1997, P NATL ACAD SCI USA, V94, P9285, DOI 10.1073/pnas.94.17.9285; CAPUTO A, 1994, NAT STRUCT BIOL, V1, P364, DOI 10.1038/nsb0694-364; CAUGHEY GH, 1993, GENOMICS, V15, P614, DOI 10.1006/geno.1993.1115; Froelich CJ, 1996, J BIOL CHEM, V271, P29073, DOI 10.1074/jbc.271.46.29073; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HADDAD P, 1991, INT IMMUNOL, V3, P57, DOI 10.1093/intimm/3.1.57; HANSON RD, 1990, P NATL ACAD SCI USA, V87, P960, DOI 10.1073/pnas.87.3.960; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; IRMLER M, 1995, J EXP MED, V181, P1917, DOI 10.1084/jem.181.5.1917; Jackson DS, 1998, J MED CHEM, V41, P2289, DOI 10.1021/jm970543s; Jans DA, 1998, J CELL SCI, V111, P2645; Jans DA, 1999, J BIOL CHEM, V274, P3953, DOI 10.1074/jbc.274.7.3953; KLEIN JL, 1990, TISSUE ANTIGENS, V35, P220, DOI 10.1111/j.1399-0039.1990.tb01787.x; Maclvor DM, 1999, BLOOD, V93, P963, DOI 10.1182/blood.V93.3.963.403k18_963_973; MASSON D, 1987, CELL, V49, P679, DOI 10.1016/0092-8674(87)90544-7; ODAKE S, 1991, BIOCHEMISTRY-US, V30, P2217, DOI 10.1021/bi00222a027; PEITSCH MC, 1994, METHOD ENZYMOL, V244, P80; Pham CTN, 1998, J BIOL CHEM, V273, P1629, DOI 10.1074/jbc.273.3.1629; Pinkoski MJ, 1998, BLOOD, V92, P1044; POE M, 1991, J BIOL CHEM, V266, P98; POWERS JC, 1995, METHOD ENZYMOL, V248, P3; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; Smyth MJ, 1996, J IMMUNOL, V156, P4174; SMYTH MJ, 1993, J IMMUNOL, V151, P6195; SMYTH MJ, 1995, J IMMUNOL, V154, P6299; SMYTH MJ, 1995, IMMUNOL TODAY, V16, P202, DOI 10.1016/0167-5699(95)80122-7; Sower LE, 1996, J IMMUNOL, V156, P2585; SUIDAN HS, 1994, P NATL ACAD SCI USA, V91, P8112, DOI 10.1073/pnas.91.17.8112; Sutton VR, 1997, J IMMUNOL, V158, P5783; TRAPANI JA, 1993, BIOCHEM BIOPH RES CO, V195, P910, DOI 10.1006/bbrc.1993.2131; Trapani JA, 1999, IMMUNOL TODAY, V20, P351, DOI 10.1016/S0167-5699(99)01488-7; Trapani JA, 1996, J BIOL CHEM, V271, P4127; Woodard SL, 1998, J IMMUNOL, V160, P4988	34	88	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30468	30473		10.1074/jbc.274.43.30468	http://dx.doi.org/10.1074/jbc.274.43.30468			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521426	hybrid			2022-12-27	WOS:000083276700022
J	Fleischmann, MM; Ravanel, S; Delosme, R; Olive, J; Zito, F; Wollman, FA; Rochaix, JD				Fleischmann, MM; Ravanel, S; Delosme, R; Olive, J; Zito, F; Wollman, FA; Rochaix, JD			Isolation and characterization of photoautotrophic mutants of Chlamydomonas reinhardtii deficient in state transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYLAKOID MEMBRANE POLYPEPTIDES; PROTEIN-PHOSPHORYLATION; PHOTOSYSTEM-II; NUCLEAR TRANSFORMATION; PHOTOSYNTHETIC SYSTEMS; POLYPHENOL OXIDASE; EXCITATION-ENERGY; LHCII KINASE; WILD-TYPE; IN-VIVO	In photosynthetic cells of higher plants and algae, the distribution of light energy between photosystem I and photosystem II is controlled by light quality through a process called state transition. It involves a reorganization of the light-harvesting complex of photosystem II (LHCII) within the thylakoid membrane whereby light energy captured preferentially by photosystem II is redirected toward photosystem I or vice versa. State transition is correlated with the reversible phosphorylation of several LHCII proteins and requires the presence of functional cytochrome b(6)f complex. Most factors controlling state transition are still not identified. Here we describe the isolation of photoautotrophic mutants of the unicellular alga Chlamydomonas reinhardtii, which are deficient in state transition. Mutant stt7 is unable to undergo state transition and remains blocked in state I as assayed by fluorescence and photoacoustic measurements. Immunocytochemical studies indicate that the distribution of LHCII and of the cytochrome b(6)f complex between appressed and nonappressed thylakoid membranes does not change significantly during state transition in stt7, in contrast to the wild type. This mutant displays the same deficiency in LHCII phosphorylation as observed for mutants deficient in cytochrome b(6)f complex that are known to be unable to undergo state transition. The stt7 mutant grows photoautotrophically, although at a slower rate than wild type, and does not appear to be more sensitive to photoinactivation than the wild-type strain. Mutant stt3-4b is partially deficient in state transition but is still able to phosphorylate LHCII. Potential factors affected in these mutant strains and the function of state transition in C. reinhardtii are discussed.	Univ Geneva, Dept Mol Biol, CH-1211 Geneva 4, Switzerland; Univ Geneva, Dept Plant Biol, CH-1211 Geneva, Switzerland; Inst Biol Phys Chim, F-75005 Paris, France; Univ Denis Diderot, CNRS, Inst Jacques Monod, F-75251 Paris, France	University of Geneva; University of Geneva; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Rochaix, JD (corresponding author), Univ Geneva, Dept Mol Biol, CH-1211 Geneva 4, Switzerland.		Rochaix, Jean-David/ABC-5243-2020	Zito, Francesca/0000-0003-1783-5090; Ravanel, Stephane/0000-0001-9475-4222				ALLEN JF, 1981, NATURE, V291, P25, DOI 10.1038/291025a0; ALLEN JF, 1992, BIOCHIM BIOPHYS ACTA, V1098, P275, DOI 10.1016/S0005-2728(09)91014-3; ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; BASSI R, 1991, PLANTA, V183, P423, DOI 10.1007/BF00197742; BENNETT J, 1980, P NATL ACAD SCI-BIOL, V77, P5253, DOI 10.1073/pnas.77.9.5253; BENNOUN P, 1994, BBA-BIOENERGETICS, V1186, P59, DOI 10.1016/0005-2728(94)90135-X; BENNOUN P, 1986, PLANT MOL BIOL, V6, P151, DOI 10.1007/BF00021484; BULTE L, 1990, BIOCHIM BIOPHYS ACTA, V1020, P72, DOI 10.1016/0005-2728(90)90095-L; CHUA NH, 1975, P NATL ACAD SCI USA, V72, P2175, DOI 10.1073/pnas.72.6.2175; DEBUCHY R, 1989, EMBO J, V8, P2803, DOI 10.1002/j.1460-2075.1989.tb08426.x; DELEPELAIRE P, 1985, BIOCHIM BIOPHYS ACTA, V809, P277, DOI 10.1016/0005-2728(85)90071-4; DELOSME R, 1994, BBA-BIOENERGETICS, V1185, P56, DOI 10.1016/0005-2728(94)90193-7; Delosme R, 1996, BBA-BIOENERGETICS, V1273, P150, DOI 10.1016/0005-2728(95)00143-3; Delphin E, 1995, BBA-BIOENERGETICS, V1232, P91, DOI 10.1016/0005-2728(95)00133-6; FENTON JM, 1990, PHOTOSYNTH RES, V26, P59, DOI 10.1007/BF00048977; GAL A, 1990, J BIOL CHEM, V265, P19742; GAL A, 1992, FEBS LETT, V298, P33, DOI 10.1016/0014-5793(92)80016-A; GILLHAM NW, 1965, GENETICS, V52, P529; GODDE D, 1982, ARCH MICROBIOL, V131, P197, DOI 10.1007/BF00405878; GOLDSCHMIDTCLERMONT M, 1991, CELL, V65, P135, DOI 10.1016/0092-8674(91)90415-U; Gumpel Nicola J., 1994, Trends in Cell Biology, V4, P299, DOI 10.1016/0962-8924(94)90222-4; Gumpel NJ, 1995, PLANT MOL BIOL, V29, P921, DOI 10.1007/BF00014966; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HIND G, 1995, BIOCHEMISTRY-US, V34, P8157, DOI 10.1021/bi00025a022; HORTON P, 1990, BIOCHIM BIOPHYS ACTA, V1017, P160, DOI 10.1016/0005-2728(90)90147-V; KINDLE KL, 1990, P NATL ACAD SCI USA, V87, P1228, DOI 10.1073/pnas.87.3.1228; MICHEL H, 1991, J BIOL CHEM, V266, P17584; OHAD I, 1990, J BIOL CHEM, V265, P1972; OWENS GC, 1982, J CELL BIOL, V93, P712, DOI 10.1083/jcb.93.3.712; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; Race HL, 1996, BIOCHEMISTRY-US, V35, P13006, DOI 10.1021/bi961809k; Rintamaki E, 1997, J BIOL CHEM, V272, P30476, DOI 10.1074/jbc.272.48.30476; Sambrook J., 2002, MOL CLONING LAB MANU; SCHUSTER G, 1986, J CELL BIOL, V103, P71, DOI 10.1083/jcb.103.1.71; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Snyders S, 1999, J BIOL CHEM, V274, P9137, DOI 10.1074/jbc.274.14.9137; SOKOLENKO A, 1995, FEBS LETT, V371, P176, DOI 10.1016/0014-5793(95)00892-D; STURM NR, 1994, MOL CELL BIOL, V14, P6171, DOI 10.1128/MCB.14.9.6171; TURPIN DH, 1990, FEBS LETT, V263, P99, DOI 10.1016/0014-5793(90)80714-T; VALLON O, 1991, P NATL ACAD SCI USA, V88, P8262, DOI 10.1073/pnas.88.18.8262; Vener AV, 1997, P NATL ACAD SCI USA, V94, P1585, DOI 10.1073/pnas.94.4.1585; VENER AV, 1995, J BIOL CHEM, V270, P25225, DOI 10.1074/jbc.270.42.25225; VERNOTTE C, 1979, BIOCHIM BIOPHYS ACTA, V545, P519, DOI 10.1016/0005-2728(79)90160-9; VITRY CD, 1988, BIOCHIM BIOPHYS ACTA, V933, P444; WILLEBRAND KO, 1989, PLANT PHYSIOL, V190, P1084; Wollman F.-A., 1988, PHOTOCATALYTIC PRODU, P210; WOLLMAN FA, 1982, BIOCHIM BIOPHYS ACTA, V680, P352, DOI 10.1016/0005-2728(82)90149-9; WOLLMAN FA, 1988, BIOCHIM BIOPHYS ACTA, V1017, P235; WOLLMAN FA, 1983, J CELL BIOL, V97, P1; Zito F, 1999, EMBO J, V18, P2961, DOI 10.1093/emboj/18.11.2961	50	89	90	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30987	30994		10.1074/jbc.274.43.30987	http://dx.doi.org/10.1074/jbc.274.43.30987			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521495	Green Published, hybrid			2022-12-27	WOS:000083276700091
J	Posner, BA; Gilman, AG; Harris, BA				Posner, BA; Gilman, AG; Harris, BA			Regulators of g protein signaling 6 and 7 - Purification of complexes with G beta 5 and assessment of their effects on G protein-mediated signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; BETA-GAMMA-SUBUNITS; MAMMALIAN ADENYLYL CYCLASES; HETEROTRIMERIC G-PROTEINS; PHOSPHOLIPASE-C ISOZYMES; RGS PROTEINS; ALPHA-SUBUNITS; TRANSITION-STATE; SF9 CELLS; EXPRESSION	Regulators of G protein signaling (RGS) proteins that contain DEP (disheveled, (E) under bar GL-10, (p) under bar leckstrin) and GGL ((G) under bar protein <(gamma)under bar> subunit-(l) under bar ike) domains form a subfamily that includes the mammalian RGS proteins RGS6, RGS7, RGS9, and RGS11. We describe the cloning of RGS6 cDNA, the specificity of interaction of RGS6 and RGS7 with G protein beta subunits, and certain biochemical properties of RGS6/beta 5 and RGS7/beta 5 complexes. After expression in Sf9 cells, complexes of both RGS6 and RGS7 with the G beta 5 subunit (but not G beta s 1-4) are found in the cytosol. When purified, these complexes are similar to RGS11/beta 5 in that they act as GTPase-activating proteins specifically toward G alpha(o). Unlike conventional G(beta gamma) complexes, RGS6/beta 5 and RGS7/beta 5 do not form heterotrimeric complexes with either G alpha(o)-GDP or G alpha(q)-GDP. Neither RGS6/beta 5 nor RGS7/beta 5 altered the activity of adenylyl cyclases types I, II, or V, nor were they able to activate either phospholipase C-beta 1 or -beta 2. However, the RGS/beta 5 complexes inhibited beta(1)gamma(2)-mediated activation of phospholipase C-beta 2. RGS/beta 5 complexes may contribute to the selectivity of signal transduction initiated by receptors coupled to G(i) and G(o) by binding to phospholipase C and stimulating the GTPase activity of G alpha(o).	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Hoechst Marion Roussel Inc, Bridgewater, NJ 08807 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gilman, AG (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R37GM034497] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34497] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; Cabrera JL, 1998, BIOCHEM BIOPH RES CO, V249, P898, DOI 10.1006/bbrc.1998.9218; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Elmore T, 1998, DNA CELL BIOL, V17, P983, DOI 10.1089/dna.1998.17.983; Gold SJ, 1997, J NEUROSCI, V17, P8024; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; Ingi T, 1998, J NEUROSCI, V18, P7178; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Koelle MR, 1997, CURR OPIN CELL BIOL, V9, P143, DOI 10.1016/S0955-0674(97)80055-5; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Lan KL, 1998, J BIOL CHEM, V273, P12794, DOI 10.1074/jbc.273.21.12794; LEE E, 1994, METHOD ENZYMOL, V237, P146; Levay K, 1999, P NATL ACAD SCI USA, V96, P2503, DOI 10.1073/pnas.96.5.2503; Lindorfer MA, 1998, J BIOL CHEM, V273, P34429, DOI 10.1074/jbc.273.51.34429; Makino ER, 1999, P NATL ACAD SCI USA, V96, P1947, DOI 10.1073/pnas.96.5.1947; Panchenko MP, 1998, J BIOL CHEM, V273, P28298, DOI 10.1074/jbc.273.43.28298; PARK DG, 1993, J BIOL CHEM, V268, P4573; Pepperl DJ, 1998, BIOCHEM BIOPH RES CO, V243, P52, DOI 10.1006/bbrc.1997.8056; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P245, DOI 10.1016/S0968-0004(96)30027-3; Saitoh O, 1999, J BIOL CHEM, V274, P9899, DOI 10.1074/jbc.274.14.9899; Shuey DJ, 1998, J NEUROCHEM, V70, P1964; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Thomas EA, 1998, J NEUROSCI RES, V52, P118, DOI 10.1002/(SICI)1097-4547(19980401)52:1<118::AID-JNR11>3.0.CO;2-6; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; Zhang SY, 1996, J BIOL CHEM, V271, P33575, DOI 10.1074/jbc.271.52.33575	39	115	120	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					31087	31093		10.1074/jbc.274.43.31087	http://dx.doi.org/10.1074/jbc.274.43.31087			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521509	hybrid			2022-12-27	WOS:000083276700105
J	Rudolph, MG; Weise, C; Mirold, S; Hillenbrand, B; Bader, B; Wittinghofer, A; Hardt, WD				Rudolph, MG; Weise, C; Mirold, S; Hillenbrand, B; Bader, B; Wittinghofer, A; Hardt, WD			Biochemical analysis of SopE from Salmonella typhimurium, a highly efficient guanosine nucleotide exchange factor for RhoGTPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DBL HOMOLOGY DOMAIN; SEC7 DOMAIN; 3-DIMENSIONAL STRUCTURES; SECONDARY-STRUCTURE; PROTEIN; RAS; RHO; MECHANISM; BINDING; GTPASES	RhoGTPases are key regulators of eukaryotic cell physiology, The bacterial enteropathogen Salmonella typhimurium modulates host cell physiology by translocating specific toxins into the cytoplasm of host cells that induce responses such as apoptotic cell death in macrophages, the production of proinflammatory cytokines, the rearrangement of the host cell actin cytoskeleton (membrane ruffling), and bacterial entry into host cells. One of the translocated toxins is SopE, which has been shown to bind to RhoGTPases of the host cell and to activate RhoGTPase signaling. SopE is sufficient to induce profuse membrane ruffling in Cos cells and to facilitate efficient bacterial internalization. We show here that SopE belongs to a novel class of bacterial toxins that modulate RhoGTPase function by transient interaction, Surface plasmon resonance measurements revealed that the kinetics of formation and dissociation of the SopE.CDC42 complex are in the same order of magnitude as those described for complex formation of GTPases of the Ras superfamily with their cognate guanine nucleotide exchange factors (GEFs), In the presence of excess GDP, dissociation of the SopE.CDC42 complex was accelerated more than 1000-fold. SopE-mediated guanine nucleotide exchange was very efficient (e.g. exchange rates almost 10(5)-fold above the level of the uncatalyzed reaction; substrate affinity), and the kinetic constants were similar to those described for guanine nucleotide exchange mediated by CDC25 or RCC1, Far-UV CD spectroscopy revealed that SopE has a high content of alpha-helical structure, a feature also found in Dbl homology domains, Sec7-like domains, and the Ras-GEF domain of Sos. Despite the lack of any obvious sequence similarity, our data suggest that SopE may closely mimic eukaryotic GEFs.	Univ Munich, Max Von Pettenkofer Inst, D-80336 Munich, Germany; Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany; Free Univ Berlin, Inst Chem Biochem, D-14195 Berlin, Germany	University of Munich; Max Planck Society; Free University of Berlin	Hardt, WD (corresponding author), Univ Munich, Max Von Pettenkofer Inst, Pettenkoferstr 9A, D-80336 Munich, Germany.			Hardt, Wolf-Dietrich/0000-0002-9892-6420; Bader, Benjamin/0000-0002-5299-396X; Rudolph, Markus/0000-0003-0447-1101				Aghazadeh B, 1998, NAT STRUCT BIOL, V5, P1098, DOI 10.1038/4209; Ahmadian MR, 1997, NAT STRUCT BIOL, V4, P686, DOI 10.1038/nsb0997-686; Aktories K, 1997, TRENDS MICROBIOL, V5, P282, DOI 10.1016/S0966-842X(97)01067-6; Betz SF, 1998, P NATL ACAD SCI USA, V95, P7909, DOI 10.1073/pnas.95.14.7909; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; BOUME HR, 1991, NATURE, V349, P117; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chaurand P, 1999, J AM SOC MASS SPECTR, V10, P91, DOI 10.1016/S1044-0305(98)00145-7; Chen LM, 1999, J EXP MED, V189, P1479, DOI 10.1084/jem.189.9.1479; Chen LM, 1996, SCIENCE, V274, P2115, DOI 10.1126/science.274.5295.2115; Cherfils J, 1998, NATURE, V392, P101, DOI 10.1038/32210; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DELEAGE G, 1987, PROTEIN ENG, V1, P289, DOI 10.1093/protein/1.4.289; FRANKEN SM, 1993, BIOCHEMISTRY-US, V32, P8411, DOI 10.1021/bi00084a005; Galan JE, 1999, CURR OPIN MICROBIOL, V2, P46, DOI 10.1016/S1369-5274(99)80008-3; GALAN JE, 1989, P NATL ACAD SCI USA, V86, P6383, DOI 10.1073/pnas.86.16.6383; Groisman EA, 1997, TRENDS MICROBIOL, V5, P343, DOI 10.1016/S0966-842X(97)01099-8; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hardt WD, 1998, P NATL ACAD SCI USA, V95, P2574, DOI 10.1073/pnas.95.5.2574; HART M, 1995, METHOD ENZYMOL, V255, P129; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; JOHN J, 1989, J BIOL CHEM, V264, P13086; JOHN J, 1988, J BIOL CHEM, V263, P11792; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P12543, DOI 10.1021/bi00039a008; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; LENZEN C, 1995, METHOD ENZYMOL, V255, P95; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; LEONARD DA, 1994, BIOCHEMISTRY-US, V33, P12323, DOI 10.1021/bi00206a040; LEVITT M, 1978, BIOCHEMISTRY-US, V17, P4277, DOI 10.1021/bi00613a026; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; MIKI T, 1995, METHOD ENZYMOL, V256, P90; Mossessova E, 1998, CELL, V92, P415, DOI 10.1016/S0092-8674(00)80933-2; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OSHANNESSY DJ, 1992, ANAL BIOCHEM, V205, P132, DOI 10.1016/0003-2697(92)90589-Y; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; Rudolph MG, 1999, PROTEIN SCI, V8, P778; Rudolph MG, 1998, J BIOL CHEM, V273, P18067, DOI 10.1074/jbc.273.29.18067; Schmid FX., 1989, SPECTRAL METHODS CHA, P251; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Sprang SR, 1998, CELL, V95, P155, DOI 10.1016/S0092-8674(00)81746-8; Watson PR, 1998, INFECT IMMUN, V66, P1432, DOI 10.1128/IAI.66.4.1432-1438.1998; Wilkins MR, 1997, ELECTROPHORESIS, V18, P403, DOI 10.1002/elps.1150180314; Wood MW, 1996, MOL MICROBIOL, V22, P327, DOI 10.1046/j.1365-2958.1996.00116.x; YANG JT, 1986, CALCULATION PROTEIN, P208	49	74	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30501	30509		10.1074/jbc.274.43.30501	http://dx.doi.org/10.1074/jbc.274.43.30501			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521431	hybrid			2022-12-27	WOS:000083276700027
J	Suh, WC; Lu, CZ; Gross, CA				Suh, WC; Lu, CZ; Gross, CA			Structural features required for the interaction of the Hsp70 molecular chaperone DnaK with its cochaperone DnaJ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CONFORMATIONAL-CHANGES; SHOCK COGNATE PROTEIN; ESCHERICHIA-COLI DNAJ; ATPASE ACTIVITY; SUBSTRATE-BINDING; MOTIF; SITE; ACTIVATION; STIMULATE; FRAGMENT	Hsp70 family members together with their Hsp40 co-chaperones function as molecular chaperones, using an ATP-controlled cycle of polypeptide binding and release to mediate protein folding. Hsp40 plays a key role in the chaperone reaction by stimulating the ATPase activity and activating the substrate binding of Hsp70. We have explored the interaction between the Escherichia coli Hsp70 family member, DnaK, and its cochaperone partner DnaJ. Our data show that the binding of ATP, subsequent conformational changes in DnaK, and DnaJ-stimulated ATP hydrolysis are all required for the formation of a DnaK-DnaJ complex as monitored by Biacore analysis. In addition, our data imply that the interaction of the J-domain with DnaK depends on the substrate binding stale of DnaK.	Univ Calif San Francisco, Dept Microbiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Stomatol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Gross, CA (corresponding author), Univ Calif San Francisco, Dept Microbiol, 513 Parnassus,Box 0512, San Francisco, CA 94143 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036278, R37GM036278] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36278-13] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Auger I, 1997, J CLIN INVEST, V99, P1818, DOI 10.1172/JCI119348; BUCHBERGER A, 1995, J BIOL CHEM, V270, P16903, DOI 10.1074/jbc.270.28.16903; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; BUKAU B, 1999, MOL CHAPERONES FOLDI; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; FEILFEL B, 1996, EUR J BIOCHEM, V237, P318; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLAHERTY KM, 1994, J BIOL CHEM, V269, P12899; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; Gassler CS, 1998, P NATL ACAD SCI USA, V95, P15229, DOI 10.1073/pnas.95.26.15229; Greene MK, 1998, P NATL ACAD SCI USA, V95, P6108, DOI 10.1073/pnas.95.11.6108; KAMATHLOEB AS, 1995, J BIOL CHEM, V270, P30051; Karzai AW, 1996, J BIOL CHEM, V271, P11236, DOI 10.1074/jbc.271.19.11236; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; MCCARTY JS, 1991, P NATL ACAD SCI USA, V88, P9513, DOI 10.1073/pnas.88.21.9513; Misselwitz B, 1998, MOL CELL, V2, P593, DOI 10.1016/S1097-2765(00)80158-6; OBRIEN MC, 1995, J BIOL CHEM, V270, P2247, DOI 10.1074/jbc.270.5.2247; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; Pierpaoli EV, 1997, J MOL BIOL, V269, P757, DOI 10.1006/jmbi.1997.1072; Rudiger S, 1997, NAT STRUCT BIOL, V4, P342, DOI 10.1038/nsb0597-342; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; Shi L, 1996, BIOCHEMISTRY-US, V35, P3297, DOI 10.1021/bi951984l; Slepenkov SV, 1998, BIOCHEMISTRY-US, V37, P16749, DOI 10.1021/bi981738k; Suh WC, 1998, P NATL ACAD SCI USA, V95, P15223, DOI 10.1073/pnas.95.26.15223; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; WALL D, 1994, J BIOL CHEM, V269, P5446; WALL D, 1995, J BIOL CHEM, V270, P2139, DOI 10.1074/jbc.270.5.2139; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19300, DOI 10.1074/jbc.270.33.19300	30	117	119	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30534	30539		10.1074/jbc.274.43.30534	http://dx.doi.org/10.1074/jbc.274.43.30534			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521435	hybrid			2022-12-27	WOS:000083276700031
J	Barmina, OY; Walling, HW; Fiacco, GJ; Freije, JMP; Lopez-Otin, C; Jeffrey, JJ; Partridge, NC				Barmina, OY; Walling, HW; Fiacco, GJ; Freije, JMP; Lopez-Otin, C; Jeffrey, JJ; Partridge, NC			Collagenase-3 binds to a specific receptor and requires the low density lipoprotein receptor-related protein for internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UROKINASE RECEPTOR; INTERSTITIAL COLLAGENASE; MEDIATED ENDOCYTOSIS; OSTEOBLASTIC CELLS; ALPHA(2)-MACROGLOBULIN RECEPTOR; ALPHA-2-MACROGLOBULIN RECEPTOR; SYNTHESIZE COLLAGENASE; RECYCLING RECEPTORS; MOUSE OSTEOBLASTS; TISSUE INHIBITOR	We have previously identified a specific receptor for collagenase-3 that mediates the binding, internalization, and degradation of this ligand in UMR 106-01 rat osteoblastic osteosarcoma cells. In the present study, we show that collagenase-3 binding is calcium-dependent and occurs in a variety of cell types, including osteoblastic and fibroblastic cells. We also present evidence supporting a two-step mechanism of collagenase-3 binding and internalization involving both a specific collagenase-3 receptor and the low density lipoprotein receptor-related protein. Ligand blot analysis shows that I-125-collagenase-3 binds specifically to two proteins (similar to 170 kDa and similar to 600 kDa) present in UMR 106-01 cells. Western blotting identified the 600-kDa protein as the low density lipoprotein receptor-related protein. Our data suggest that the 170-kDa protein is a specific collagenase-3 receptor. Low density lipoprotein receptor-related protein-null mouse embryo fibroblasts bind but fail to internalize collagenase-3, whereas UMR 106-01 and wildtype mouse embryo fibroblasts bind and internalize collagenase-3. Internalization, but not binding, is inhibited by the 39-kDa receptor-associated protein. We conclude that the internalization of collagenase-3 requires the participation of the low density lipoprotein receptor-related protein and propose a model in which the cell surface interaction of this ligand requires a sequential contribution from two receptors, with the collagenase-3 receptor acting as a high affinity primary binding site and the low density lipoprotein receptor-related protein mediating internalization.	St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA; Univ Oviedo, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain; Albany Med Coll, Dept Biochem, Albany, NY 12208 USA	Saint Louis University; University of Oviedo; Albany Medical College	Partridge, NC (corresponding author), St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, 1402 S Grand Blvd, St Louis, MO 63104 USA.		López-Otín, Carlos/AAB-2106-2020; Freije, José M.P./A-6535-2008	López-Otín, Carlos/0000-0001-6964-1904; Freije, José M.P./0000-0002-4688-8266; Partridge, Nicola/0000-0002-5406-4814	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD005291, R37HD005291] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040661] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 40661] Funding Source: Medline; NICHD NIH HHS [HD 05291] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDREASEN PA, 1994, FEBS LETT, V338, P239, DOI 10.1016/0014-5793(94)80276-9; BROWN MS, 1979, P NATL ACAD SCI USA, V76, P3330, DOI 10.1073/pnas.76.7.3330; BROWN MS, 1983, CELL, V32, P663, DOI 10.1016/0092-8674(83)90052-1; Brown MS, 1997, NATURE, V388, P629, DOI 10.1038/41672; BU GJ, 1994, J BIOL CHEM, V269, P29874; CAWSTON TE, 1981, BIOCHEM J, V195, P159, DOI 10.1042/bj1950159; CONESE M, 1994, J BIOL CHEM, V269, P17886; CONESE M, 1995, J CELL BIOL, V131, P1609, DOI 10.1083/jcb.131.6.1609; EECKHOUT Y, 1977, BIOCHEM J, V166, P21, DOI 10.1042/bj1660021; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HAMILTON JA, 1985, ENDOCRINOLOGY, V116, P2186, DOI 10.1210/endo-116-6-2186; HEATH JK, 1984, BIOCHIM BIOPHYS ACTA, V802, P151, DOI 10.1016/0304-4165(84)90046-1; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; KAHN AJ, 1987, AM J OTOLARYNG, V8, P258, DOI 10.1016/S0196-0709(87)80044-3; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P13070, DOI 10.1074/jbc.270.22.13070; Kounnas MZ, 1996, J BIOL CHEM, V271, P6523, DOI 10.1074/jbc.271.11.6523; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LORENZO JA, 1992, MATRIX, V12, P282, DOI 10.1016/S0934-8832(11)80080-6; LUNDGREN S, 1994, EXP CELL RES, V212, P344, DOI 10.1006/excr.1994.1153; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; MEIKLE MC, 1992, J CELL SCI, V103, P1093; MIKHAILENKO I, 1995, J BIOL CHEM, V270, P9543, DOI 10.1074/jbc.270.16.9543; Moestrup SK, 1996, P NATL ACAD SCI USA, V93, P8612, DOI 10.1073/pnas.93.16.8612; MOKUNO H, 1994, J BIOL CHEM, V269, P13238; MURPHY G, 1987, BIOCHEM J, V248, P265, DOI 10.1042/bj2480265; Nagase H, 1992, Matrix Suppl, V1, P421; Nykjaer A, 1997, EMBO J, V16, P2610, DOI 10.1093/emboj/16.10.2610; NYKJAER A, 1994, J BIOL CHEM, V269, P25668; OMURA TH, 1994, J BIOL CHEM, V269, P24994; PARTRIDGE NC, 1987, ENDOCRINOLOGY, V120, P1956, DOI 10.1210/endo-120-5-1956; QUINN CO, 1990, J BIOL CHEM, V265, P22342; RIFAS L, 1989, J CLIN INVEST, V84, P686, DOI 10.1172/JCI114216; ROSWIT WT, 1983, ARCH BIOCHEM BIOPHYS, V225, P285, DOI 10.1016/0003-9861(83)90032-2; ROSWIT WT, 1992, ARCH BIOCHEM BIOPHYS, V292, P402, DOI 10.1016/0003-9861(92)90009-L; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SHALHOUB V, 1992, J CELL BIOCHEM, V50, P425, DOI 10.1002/jcb.240500411; SIMONSEN ACW, 1994, FEBS LETT, V354, P279, DOI 10.1016/0014-5793(94)01138-9; THOM D, 1977, BIOCHEM J, V168, P187, DOI 10.1042/bj1680187; THOMSON BM, 1987, BIOCHEM BIOPH RES CO, V148, P596, DOI 10.1016/0006-291X(87)90918-1; VARGHESE S, 1994, ENDOCRINOLOGY, V134, P2438, DOI 10.1210/en.134.6.2438; Walling HW, 1998, J CELL PHYSIOL, V177, P563, DOI 10.1002/(SICI)1097-4652(199812)177:4<563::AID-JCP7>3.0.CO;2-B; Warshawsky I, 1996, J BIOL CHEM, V271, P25873, DOI 10.1074/jbc.271.42.25873; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; Wu K, 1996, J BIOL CHEM, V271, P21323, DOI 10.1074/jbc.271.35.21323; Yamazaki H, 1996, J BIOL CHEM, V271, P24761, DOI 10.1074/jbc.271.40.24761; ZHENG G, 1994, J HISTOCHEM CYTOCHEM, V42, P531, DOI 10.1177/42.4.7510321	52	107	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30087	30093		10.1074/jbc.274.42.30087	http://dx.doi.org/10.1074/jbc.274.42.30087			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514495	hybrid			2022-12-27	WOS:000083176400074
J	Bode, JG; Gatsios, P; Ludwig, S; Rapp, UR; Haussinger, D; Heinrich, PC; Graeve, L				Bode, JG; Gatsios, P; Ludwig, S; Rapp, UR; Haussinger, D; Heinrich, PC; Graeve, L			The mitogen-activated protein (MAP) kinase p38 and its upstream activator MAP kinase kinase 6 are involved in the activation of signal transducer and activator of transcription by hyperosmolarity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; INFLAMMATORY CYTOKINES; MAMMALIAN-CELLS; GENE-EXPRESSION; PHOSPHATASE; INTERLEUKIN-6; BINDING; PATHWAY; STRESS; RECEPTOR	Environmental stress (e.g. aniso-osmolarity and UV light), hypoxia/reoxygenation, and reactive oxygen species activate intracellular signaling cascades such as the "stress-responsive" mitogen-activated protein kinases and nuclear factor kappa B. We have recently shown that the Janus tyrosine kinase/signal transducer and activator of transcription (Jak/STAT) pathway is ligand-independently activated by hyperosmotic shock. In the present study, we show that besides STAT1 also the tyrosine phosphatase SNP2 became tyrosine-phosphorylated upon hyperosmolarity. SE 202190 and SE 203580 (specific inhibitors of p38) inhibited both STAT activation and tyrosine phosphorylation of SHP2 induced by hyperosmotic stress. Overexpression of wild-type p38 mitogen-activated protein kinase and its upstream activator mitogen-activated protein kinase kinase 6 (MKK6) resulted in an enhanced STAT1 tyrosine phosphorylation upon osmotic shock. Accordingly, overexpression of dominant negative mutants of p38 and MKK6 largely decreased hyperosmotic STAT1 activation and tyrosine phosphorylation of SHP2. Furthermore, we provide evidence that a genistein-sensitive tyrosine kinase different from Jak1 is involved in stress-activation of STAT1 and tyrosine phosphorylation of SHP2. These results strongly suggest that hyperosmotic shock activates STAT1 and SHP2 via p38 and its upstream activator MKK6.	Rhein Westfal TH Aachen, Inst Biochem, D-52074 Aachen, Germany; Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97078 Wurzburg, Germany; Univ Dusseldorf, Med Klin, D-40255 Dusseldorf, Germany	RWTH Aachen University; University of Wurzburg; Heinrich Heine University Dusseldorf	Heinrich, PC (corresponding author), Klinikum RWTH Aachen, Inst Biochem, Pauwelsstr 30, D-52057 Aachen, Germany.			Ludwig, Stephan/0000-0003-4490-3052				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ARCONE R, 1991, EUR J BIOCHEM, V198, P541, DOI 10.1111/j.1432-1033.1991.tb16048.x; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Flory E, 1996, J VIROL, V70, P2260, DOI 10.1128/JVI.70.4.2260-2268.1996; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Gatsios P, 1998, J BIOL CHEM, V273, P22962, DOI 10.1074/jbc.273.36.22962; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Haussinger D, 1996, BIOCHEM J, V313, P697; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Kim HK, 1998, MOL CELL BIOL, V18, P1525, DOI 10.1128/MCB.18.3.1525; Kovarik P, 1998, EMBO J, V17, P3660, DOI 10.1093/emboj/17.13.3660; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Sambrook J., 2002, MOL CLONING LAB MANU; Schaper F, 1998, BIOCHEM J, V335, P557, DOI 10.1042/bj3350557; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; Schliess F, 1998, ARCH BIOCHEM BIOPHYS, V351, P35, DOI 10.1006/abbi.1997.0517; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; Venema RC, 1998, J BIOL CHEM, V273, P30795, DOI 10.1074/jbc.273.46.30795; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WEIERGRABER O, 1995, EUR J BIOCHEM, V234, P661, DOI 10.1111/j.1432-1033.1995.661_b.x; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	37	95	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30222	30227		10.1074/jbc.274.42.30222	http://dx.doi.org/10.1074/jbc.274.42.30222			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514514	hybrid			2022-12-27	WOS:000083176400093
J	Dalton, SL; Scharf, E; Davey, G; Assoian, RK				Dalton, SL; Scharf, E; Davey, G; Assoian, RK			Transforming growth factor-beta overrides the adhesion requirement for surface expression of alpha(5)beta(1) integrin in normal rat kidney fibroblasts - A necessary effect for induction of anchorage-independent growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE ARREST; TGF-BETA; EXTRACELLULAR-MATRIX; FIBRONECTIN RECEPTOR	We have previously shown that the expression of alpha(5)beta(1) integrin on the cell surface is dependent upon cell adhesion to the extracellular matrix, and we report here that transforming growth factor-beta (TGF-beta) overcomes this requirement in normal rat kidney (NRK) fibroblasts. Thus, suspended NRK cells treated with TGF-beta show levels of surface alpha(5)beta(1) integrin that are equivalent to those seen in adherent cells. Moreover, several experiments showed that this effect is necessary for the induction of anchorage-independent growth by TGF-beta. First, a kinetic analysis showed that surface expression of alpha(5)beta(1) integrin was restored in TGF-beta-treated NRK cells prior to the induction of anchorage-independent growth. Second, NRK cell mutants that have lost their TGF-beta requirement for surface expression of alpha(5)beta(1) integrin were anchorage-independent in the absence of TGF-beta, Third, an antisense oligonucleotide to the beta(1) integrin subunit or, fourth, stable expression of an alpha(5)-antisense cDNA blocked the ability of TGF-beta to stimulate anchorage-independent growth. Thus, TGF-beta overrides the adhesion requirement for surface expression of alpha(5)beta(1) integrin in NRK cells, and this effect is necessary for the induction of anchorage-independent growth.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania	Assoian, RK (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, 3620 Hamilton Walk,167 Johnson Pavill, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048224, R01GM051878] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48224, GM51878] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASSOIAN RK, 1989, ANAL BIOCHEM, V177, P95, DOI 10.1016/0003-2697(89)90020-1; DALTON SL, 1995, MOL BIOL CELL, V6, P1781, DOI 10.1091/mbc.6.12.1781; DALTON SL, 1992, J BIOL CHEM, V267, P3186; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; FAVA RA, 1987, J CELL PHYSIOL, V131, P184, DOI 10.1002/jcp.1041310207; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GUADAGNO TM, 1991, J CELL BIOL, V115, P1419, DOI 10.1083/jcb.115.5.1419; HAN EKH, 1993, J CELL BIOL, V122, P461, DOI 10.1083/jcb.122.2.461; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HEINO J, 1989, J BIOL CHEM, V264, P21806; HEINO J, 1989, J BIOL CHEM, V264, P380; HOTCHIN NA, 1995, J CELL BIOL, V128, P1209, DOI 10.1083/jcb.128.6.1209; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Iavarone A, 1997, NATURE, V387, P417; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; IGNOTZ RA, 1987, CELL, V51, P189, DOI 10.1016/0092-8674(87)90146-2; Kothapalli D, 1997, CELL GROWTH DIFFER, V8, P61; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; ROBERTS CJ, 1988, J BIOL CHEM, V263, P4586; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SCHREINER C, 1991, CANCER RES, V51, P1738; WANG DH, 1995, J BIOL CHEM, V270, P14154, DOI 10.1074/jbc.270.23.14154	26	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30139	30145		10.1074/jbc.274.42.30139	http://dx.doi.org/10.1074/jbc.274.42.30139			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514503	hybrid			2022-12-27	WOS:000083176400082
J	DeLong, CJ; Shen, YJ; Thomas, MJ; Cui, Z				DeLong, CJ; Shen, YJ; Thomas, MJ; Cui, Z			Molecular distinction of phosphatidylcholine synthesis between the CDP-choline pathway and phosphatidylethanolamine methylation pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANDEM MASS-SPECTROMETRY; PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; N-METHYLTRANSFERASE; N-METHYLTRANSFERASE-2; EXPRESSION; CELLS; PROTEINS; GROWTH; LIVER	In addition to the CDP-choline pathway for phosphatidylcholine (PC) synthesis, the liver has a unique phosphatidylethanolamine (PE) methyltransferase activity for PC synthesis via three methylations of the ethanolamine moiety of PE, Previous studies indicate that the two pathways are functionally different and not interchangeable even though PC is the common product of both pathways. This study was designed to test the hypothesis that these two pathways produce different profiles of PC species. The PC species from these two pathways were labeled with specific stable isotope precursors, DS-choline and D4-ethanolamine, and analyzed by electrospray tandem mass spectrometry. Our studies revealed a profound distinction in PC profiles between the CDP-choline pathway and the PE methylation pathway, PC molecules produced from the CDP-choline pathway were mainly comprised of medium chain, saturated (e.g. 16:0/18:0) species. On the other hand, PC molecules from the PE methylation pathway were much more diverse and were comprised of significantly more long chain, polyunsaturated (e.g. 18:0/20:4) species. PC species from the methylation pathway contained a higher percentage of arachidonate and were more diverse than those from the CDP-choline pathway, This profound distinction of PC profiles may contribute to the different functions of these two pathways in the liver.	Wake Forest Univ, Sch Med, Dept Biochem, Winston Salem, NC 27157 USA	Wake Forest University	Cui, Z (corresponding author), Wake Forest Univ, Sch Med, Dept Biochem, Winston Salem, NC 27157 USA.			DeLong, Cynthia/0000-0002-6823-8619	NCI NIH HHS [R01-CA85757, CA-09422] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009422] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERNSTROM K, 1991, ANAL BIOCHEM, V198, P203, DOI 10.1016/0003-2697(91)90530-7; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brugger B, 1997, P NATL ACAD SCI USA, V94, P2339, DOI 10.1073/pnas.94.6.2339; BRYANT DK, 1991, ANAL CHEM, V63, P1110, DOI 10.1021/ac00011a010; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cui Z, 1996, J BIOL CHEM, V271, P2839, DOI 10.1074/jbc.271.5.2839; Cui Z, 1997, BBA-LIPID LIPID MET, V1346, P10, DOI 10.1016/S0005-2760(97)00012-X; Cui Z, 1995, BIOCHEM J, V312, P939, DOI 10.1042/bj3120939; CUI Z, 1993, J BIOL CHEM, V268, P16655; DAVIS RA, 1979, J BIOL CHEM, V254, P2010; ESKO JD, 1982, P NATL ACAD SCI-BIOL, V79, P1698, DOI 10.1073/pnas.79.6.1698; ESKO JD, 1981, J BIOL CHEM, V256, P7388; HOUWELING M, 1995, J BIOL CHEM, V270, P16277, DOI 10.1074/jbc.270.27.16277; JENSEN NJ, 1986, LIPIDS, V21, P580, DOI 10.1007/BF02534056; KERWIN JL, 1994, J LIPID RES, V35, P1102; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; RAETZ CRH, 1982, PHOSPHOLIPIDS, P435; RIDGWAY ND, 1988, J BIOL CHEM, V263, P16856; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; Tessitore L, 1997, BIOCHEM J, V322, P151, DOI 10.1042/bj3220151; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANCE DE, 1988, PROG LIPID RES, V27, P61, DOI 10.1016/0163-7827(88)90005-7; Vance DE, 1998, CURR OPIN LIPIDOL, V9, P125, DOI 10.1097/00041433-199804000-00008; VANCE DE, 1990, BIOCHEM CELL BIOL, V68, P1151, DOI 10.1139/o90-172	24	284	289	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29683	29688		10.1074/jbc.274.42.29683	http://dx.doi.org/10.1074/jbc.274.42.29683			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514439	hybrid			2022-12-27	WOS:000083176400018
J	Ekinci, FJ; Malik, KU; Shea, TB				Ekinci, FJ; Malik, KU; Shea, TB			Activation of the L voltage-sensitive calcium channel by mitogen-activated protein (MAP) kinase following exposure of neuronal cells to beta-amyloid - Map kinase mediates beta-amyloid-induced neurodegeneration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; ALZHEIMERS-DISEASE; TAU-PROTEIN; FREE-RADICALS; HIPPOCAMPAL-NEURONS; NEUROBLASTOMA-CELLS; CORTICAL-NEURONS; TISSUE-INJURY; CA2+ CHANNELS; PHOSPHORYLATION	Neuronal degeneration in Alzheimer's disease (AD) has been variously attributed to increases in cytosolic calcium, reactive oxygen species, and phosphorylated forms of the microtubule-assooiated protein tau, beta-Amyloid (beta A), which accumulates extracellularly in AD brain, induces calcium influx in culture via the L voltage-sensitive calcium channel. Since this channel is normally activated by protein kinase A-mediated phosphorylation, we examined kinase activities recruited following beta A treatment of cortical neurons and SH-SY-5Y neuroblastoma, beta A increased channel phosphorylation; this increase was unaffected by the protein kinase A inhibitor H89 but was reduced by the mitogen-activated protein (MAP) kinase inhibitor PD98059, Pharmacological and antisense oligonucleotide-mediated reduction of MAP kinase activity also reduced beta A-induced accumulation of calcium, reactive oxygen species, phospho-tau immunoreactivity, and apoptosis. These findings indicate that MAP kinase mediates multiple aspects of beta A-induced neurotoxicity and indicates that calcium influx initiates neurodegeneration in AD. beta A increased MAP kinase-mediated phosphorylation of membrane-associated proteins and reduced phosphorylation of cytosolic: proteins without increasing overall MAP kinase activity. Increasing MAP kinase activity with epidermal growth factor did not increase channel phosphorylation, These findings indicate that redirection, rather than increased activation, of MAP kinase activity mediates beta A-induced neurotoxicity.	Univ Massachusetts, Ctr Cellular Neurobiol & Neurodegenerat Res, Dept Sci Biol, Lowell, MA 01854 USA; Univ Tennessee, Ctr Hlth Sci, Coll Med, Dept Pharmacol, Memphis, TN 38163 USA	University of Massachusetts System; University of Massachusetts Lowell; University of Tennessee System; University of Tennessee Health Science Center	Shea, TB (corresponding author), Univ Massachusetts, Ctr Cellular Neurobiol & Neurodegenerat Res, Dept Sci Biol, 1 Univ Ave, Lowell, MA 01854 USA.	Thomas_Shea@uml.edu						ARIAS C, 1995, J NEUROSCI RES, V41, P561, DOI 10.1002/jnr.490410416; BAUDIER J, 1987, J BIOL CHEM, V262, P17577; BEHL C, 1992, BIOCHEM BIOPH RES CO, V186, P944, DOI 10.1016/0006-291X(92)90837-B; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; Boyce JJ, 1997, INT J DEV NEUROSCI, V15, P295, DOI 10.1016/S0736-5748(97)00010-5; BOYNE LJ, 1995, J NEUROSCI RES, V40, P439, DOI 10.1002/jnr.490400403; CHAJRY N, 1994, BIOCHEM BIOPH RES CO, V203, P984, DOI 10.1006/bbrc.1994.2279; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; COTMAN CW, 1992, NEUROBIOL AGING, V13, P587, DOI 10.1016/0197-4580(92)90060-B; CRESSMAN CM, 1995, J NEUROSCI RES, V42, P648, DOI 10.1002/jnr.490420507; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; DYKENS JA, 1994, J NEUROCHEM, V63, P584; EKINCI FJ, 1999, IN PRESS MOL BIOL CE; FREEMAN BA, 1982, LAB INVEST, V47, P412; GIFFIN K, 1991, NEURON, V6, P321, DOI 10.1016/0896-6273(91)90242-R; GOEDERT M, 1993, TRENDS NEUROSCI, V16, P460, DOI 10.1016/0166-2236(93)90078-Z; GRAY CW, 1995, BRAIN RES, V691, P169, DOI 10.1016/0006-8993(95)00669-H; Haas C., 1992, NATURE, V359, P149; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; HARTMANN H, 1993, BIOCHEM BIOPH RES CO, V194, P1216, DOI 10.1006/bbrc.1993.1952; Hong M, 1997, J BIOL CHEM, V272, P25326, DOI 10.1074/jbc.272.40.25326; KHODOROV B, 1993, FEBS LETT, V324, P271, DOI 10.1016/0014-5793(93)80132-E; KOBAYASHI S, 1993, FEBS LETT, V335, P171, DOI 10.1016/0014-5793(93)80723-8; KOH JY, 1990, BRAIN RES, V533, P315, DOI 10.1016/0006-8993(90)91355-K; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; LATIMER DA, 1995, FEBS LETT, V365, P42, DOI 10.1016/0014-5793(95)00434-B; LEDESMA MD, 1992, FEBS LETT, V308, P218, DOI 10.1016/0014-5793(92)81278-T; LIN LW, 1995, DRUG AGING, V6, P136, DOI 10.2165/00002512-199506020-00006; Lin MC, 1996, GWUMC DEPT, P331; LOVESTONE S, 1994, CURR BIOL, V4, P1077, DOI 10.1016/S0960-9822(00)00246-3; LU Q, 1993, J NEUROSCI RES, V35, P439, DOI 10.1002/jnr.490350411; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MATTSON MP, 1993, BRAIN RES, V621, P35, DOI 10.1016/0006-8993(93)90295-X; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MOHIT AA, 1995, NEURON, V14, P67, DOI 10.1016/0896-6273(95)90241-4; MORI H, 1992, J BIOL CHEM, V267, P17082; MunozMontano JR, 1997, FEBS LETT, V411, P183, DOI 10.1016/S0014-5793(97)00688-1; Muthalif MM, 1996, J BIOL CHEM, V271, P30149, DOI 10.1074/jbc.271.47.30149; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PEI JJ, 1994, BRAIN RES, V655, P70, DOI 10.1016/0006-8993(94)91598-9; PERRY G, 1999, IN PRESS NEUROREPORT; PRELLI F, 1988, J NEUROCHEM, V51, P648, DOI 10.1111/j.1471-4159.1988.tb01087.x; Pundreddy S, 1997, NEUROSCI RES COMMUN, V21, P173, DOI 10.1002/(SICI)1520-6769(199711/12)21:3<173::AID-NRC221>3.0.CO;2-P; Pyo H, 1998, NEUROREPORT, V9, P871, DOI 10.1097/00001756-199803300-00020; RAGHUNANDAN R, 1995, BIOCHEM BIOPH RES CO, V215, P1056, DOI 10.1006/bbrc.1995.2571; SCULPTOREANU A, 1993, NATURE, V364, P240, DOI 10.1038/364240a0; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHEA TB, 1990, J NEUROCHEM, V55, P1784, DOI 10.1111/j.1471-4159.1990.tb04969.x; Shea TB, 1997, J NEUROSCI RES, V49, P759, DOI 10.1002/(SICI)1097-4547(19970915)49:6<759::AID-JNR10>3.0.CO;2-N; Shea TB, 1997, J NEUROSCI RES, V50, P114, DOI 10.1002/(SICI)1097-4547(19971001)50:1<114::AID-JNR12>3.0.CO;2-B; Shea TB, 1996, J NEUROCHEM, V66, P1539; SHEA TB, 1993, J NEUROSCI RES, V35, P507, DOI 10.1002/jnr.490350507; SHEA TB, 1995, NEUROREPORT, V6, P1437, DOI 10.1097/00001756-199507100-00019; Shea TB, 1998, NEUROSCI RES COMMUN, V22, P45, DOI 10.1002/(SICI)1520-6769(199801/02)22:1<45::AID-NRC7>3.0.CO;2-S; Simonian NA, 1996, ANNU REV PHARMACOL, V36, P83, DOI 10.1146/annurev.pa.36.040196.000503; SINGH TJ, 1995, FEBS LETT, V358, P4, DOI 10.1016/0014-5793(94)01383-C; SINGH TJ, 1994, FEBS LETT, V267, P358; Takashima A, 1998, NEUROSCI RES, V31, P317, DOI 10.1016/S0168-0102(98)00061-3; Tanaka T, 1998, FEBS LETT, V426, P248, DOI 10.1016/S0014-5793(98)00346-9; Ueda K, 1997, J NEUROCHEM, V68, P265; You YD, 1997, BIOPHYS J, V72, P175, DOI 10.1016/S0006-3495(97)78656-9; Zhou Y, 1996, J NEUROCHEM, V67, P1419	63	148	156	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30322	30327		10.1074/jbc.274.42.30322	http://dx.doi.org/10.1074/jbc.274.42.30322			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514528	hybrid			2022-12-27	WOS:000083176400107
J	Knodler, LA; Noiva, R; Mehta, K; McCaffery, JM; Aley, SB; Svard, SG; Nystul, TG; Reiner, DS; Silberman, JD; Gillin, FD				Knodler, LA; Noiva, R; Mehta, K; McCaffery, JM; Aley, SB; Svard, SG; Nystul, TG; Reiner, DS; Silberman, JD; Gillin, FD			Novel protein-disulfide isomerases from the early-diverging protist Giardia lamblia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-CHAPERONE ACTIVITIES; CYST WALL PROTEIN; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; SURFACE-ANTIGEN; BOND FORMATION; ENERGY-METABOLISM; PEPTIDE BINDING; IN-VITRO; THIOREDOXIN	Protein-disulfide isomerase is essential for formation and reshuffling of disulfide bonds during nascent protein folding in the endoplasmic reticulum, The two thioredoxin-like active sites catalyze a variety of thiol-disulfide exchange reactions. We have characterized three novel protein-disulfide isomerases from the primitive eukaryote Giardia lamblia, Unlike other protein-disulfide isomerases, the giardial enzymes have only one active site. The active-site sequence motif in the giardial proteins (CGHC) is characteristic of eukaryotic protein-disulfide isomerases, and not other members of the thioredoxin superfamily that have one active site, such as thioredoxin and Dsb proteins from Gram-negative bacteria, The three giardial proteins have very different amino acid sequences and molecular masses (26, 50, and 13 kDa). All three enzymes were capable of rearranging disulfide bonds, and giardial protein-disulfide isomerase-2 also displayed oxidant and reductant activities. Surprisingly, the three giardial proteins also hard Ca2+-dependent transglutaminase activity. This is the first report of protein-disulfide isomerases with a single! active site that have diverse roles in protein cross-linking. This study may provide clues to the evolution of key functions of the endoplasmic reticulum in eukaryotic: cells, protein disulfide formation, and isomerization.	Univ Calif San Diego, Sch Med, Dept Pathol, Div Infect Dis, San Diego, CA 92103 USA; Univ Calif San Diego, Sch Med, Ctr Mol Genet, San Diego, CA 92103 USA; Univ S Dakota, Sch Med, Biochem & Mol Biol Grp, Vermillion, SD 57069 USA; Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Houston, TX 77030 USA; Univ Calif San Diego, Div Cellular & Mol Med, La Jolla, CA 92093 USA; Marine Biol Lab, Josephine Bay Paul Ctr Comparat Mol Biol & Evolut, Woods Hole, MA 02543 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of South Dakota; University of Texas System; UTMD Anderson Cancer Center; University of California System; University of California San Diego; Marine Biological Laboratory - Woods Hole	Gillin, FD (corresponding author), Univ Calif San Diego, Sch Med, Dept Pathol, Div Infect Dis, 214 Dickinson St, San Diego, CA 92103 USA.		Reiner, David S./F-6106-2012; Silberman, Jeffrey D/AAK-8220-2020	Reiner, David S./0000-0002-8289-7311; Silberman, Jeffrey D/0000-0002-2965-9197; Knodler, Leigh/0000-0002-3028-2198; Aley, Stephen/0000-0003-1214-4688; Svard, Staffan/0000-0002-7392-1746	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042488, R01AI024285, R21AI024285] Funding Source: NIH RePORTER; NIAID NIH HHS [AI42488, AI24285] Funding Source: Medline; NIGMS NIH HHS [GM53835] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAM RD, 1991, MICROBIOL REV, V55, P706, DOI 10.1128/MMBR.55.4.706-732.1991; Alberts B., 1994, MOL BIOL CELL; ALEY SB, 1993, EXP PARASITOL, V77, P295, DOI 10.1006/expr.1993.1087; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BARDWELL JC, 1991, CELL, V67, P582; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; BROWN DM, 1993, MOL BIOCHEM PARASIT, V61, P155, DOI 10.1016/0166-6851(93)90169-X; Chandrashekar R, 1998, P NATL ACAD SCI USA, V95, P531, DOI 10.1073/pnas.95.2.531; CREIGHTON TE, 1993, J MOL BIOL, V232, P1176, DOI 10.1006/jmbi.1993.1470; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P11725, DOI 10.1021/bi00037a009; DAS S, 1991, J BIOL CHEM, V266, P21318; FAHEY RC, 1984, SCIENCE, V224, P70, DOI 10.1126/science.6322306; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gilbert HF, 1997, J BIOL CHEM, V272, P29399, DOI 10.1074/jbc.272.47.29399; GILLIN FD, 1990, P NATL ACAD SCI USA, V87, P4463, DOI 10.1073/pnas.87.12.4463; Gillin FD, 1996, ANNU REV MICROBIOL, V50, P679, DOI 10.1146/annurev.micro.50.1.679; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hattori K, 1996, J BIOL CHEM, V271, P33032, DOI 10.1074/jbc.271.51.33032; HAWKINS HC, 1991, BIOCHEM J, V275, P349, DOI 10.1042/bj2750349; Hetsko ML, 1998, EXP PARASITOL, V88, P172, DOI 10.1006/expr.1998.4246; HILARIO E, 1995, BIOCHIM BIOPHYS ACTA, V128, P94; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; HUMPHREYS DP, 1995, J BIOL CHEM, V270, P28210; Huppa JB, 1998, CELL, V92, P145, DOI 10.1016/S0092-8674(00)80907-1; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Jeon S, 1998, P NATL ACAD SCI USA, V95, P687, DOI 10.1073/pnas.95.2.687; Kanai S, 1998, J MOL EVOL, V47, P200, DOI 10.1007/PL00006377; Knodler LA, 1998, J BIOL CHEM, V273, P4470, DOI 10.1074/jbc.273.8.4470; LAMBERT N, 1983, BIOCHEM J, V213, P235, DOI 10.1042/bj2130235; LINDMARK DG, 1980, MOL BIOCHEM PARASIT, V1, P1, DOI 10.1016/0166-6851(80)90037-7; LUJAN HD, 1995, J BIOL CHEM, V270, P29307, DOI 10.1074/jbc.270.49.29307; MARTIN JL, 1993, NATURE, V365, P464, DOI 10.1038/365464a0; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; MCCAFFERY JM, 1994, EXP PARASITOL, V79, P236, DOI 10.1006/expr.1994.1087; Mehta K, 1996, MOL BIOCHEM PARASIT, V76, P105, DOI 10.1016/0166-6851(95)02549-9; MOWATT MR, 1995, MOL MICROBIOL, V15, P955, DOI 10.1111/j.1365-2958.1995.tb02364.x; MULLER M, 1988, ANNU REV MICROBIOL, V42, P465, DOI 10.1146/annurev.mi.42.100188.002341; NASH T, 1992, PARASITOL TODAY, V8, P229, DOI 10.1016/0169-4758(92)90119-M; Newton GL, 1996, J BACTERIOL, V178, P1990, DOI 10.1128/jb.178.7.1990-1995.1996; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; NOIVA R, 1993, J BIOL CHEM, V268, P19210; Ostermeier M, 1996, J BIOL CHEM, V271, P10616, DOI 10.1074/jbc.271.18.10616; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; PUIG A, 1994, J BIOL CHEM, V269, P19128; Puig A, 1997, J BIOL CHEM, V272, P32988, DOI 10.1074/jbc.272.52.32988; Que XC, 1996, MOL BIOCHEM PARASIT, V81, P101, DOI 10.1016/0166-6851(96)02698-9; Rietsch A, 1998, ANNU REV GENET, V32, P163, DOI 10.1146/annurev.genet.32.1.163; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Smith MW, 1998, MOL BIOCHEM PARASIT, V95, P267, DOI 10.1016/S0166-6851(98)00113-3; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; Soltys BJ, 1996, J CELL SCI, V109, P1909; Svard SG, 1998, MOL MICROBIOL, V30, P979, DOI 10.1046/j.1365-2958.1998.01125.x; Svard SG, 1999, MOL BIOCHEM PARASIT, V98, P253, DOI 10.1016/S0166-6851(98)00174-1; Tachikawa H, 1997, BIOCHEM BIOPH RES CO, V239, P710, DOI 10.1006/bbrc.1997.7426; TACHIKAWA H, 1995, FEBS LETT, V369, P212, DOI 10.1016/0014-5793(95)00750-4; Vincent MJ, 1998, J BIOL CHEM, V273, P950, DOI 10.1074/jbc.273.2.950; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; Walker KW, 1996, BIOCHEMISTRY-US, V35, P1972, DOI 10.1021/bi952157n; Westphal V, 1999, J MOL BIOL, V286, P1229, DOI 10.1006/jmbi.1999.2560	61	69	71	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29805	29811		10.1074/jbc.274.42.29805	http://dx.doi.org/10.1074/jbc.274.42.29805			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514458	hybrid			2022-12-27	WOS:000083176400037
J	Scotti, PA; Valent, QA; Manting, EH; Urbanus, ML; Driessen, AJM; Oudega, B; Luirink, J				Scotti, PA; Valent, QA; Manting, EH; Urbanus, ML; Driessen, AJM; Oudega, B; Luirink, J			SecA is not required for signal recognition particle-mediated targeting and initial membrane insertion of a nascent inner membrane protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI SRP; ENDOPLASMIC-RETICULUM; PROTONMOTIVE FORCE; RECEPTOR; BINDING; FTSY; RIBONUCLEOPROTEIN; TRANSLOCATION; PERMEASE; VESICLES	In Escherichia coli, signal recognition particle (SRP)-dependent targeting of inner membrane proteins has been described. In vitro cross-linking studies have demonstrated that short nascent chains exposing a highly hydrophobic targeting signal interact with the SRP. This SRP, assisted by its receptor, FtsY, mediates the transfer to a common translocation site in the inner membrane that contains SecA, SecG, and SecY. Here we describe a further in vitro reconstitution of SRP-mediated membrane insertion in which purified ribosome-nascent chain-SRP complexes are targeted to the purified SecYEG complex contained in proteoliposomes in a process that requires the SRP-receptor FtsY and GTP. We found that in this system SecA and ATP are dispensable for both the transfer of the nascent inner membrane protein FtsQ to SecY and its stable membrane insertion. Release of the SRP from nascent FtsQ also occurred in the absence of SecYEG complex indicating a functional interaction of FtsY with lipids. These data suggest that SRP/FtsY and SecB/SecA constitute distinct targeting routes.	Bioctr Amsterdam, Inst Mol Biol Sci, Dept Microbiol, NL-1081 HV Amsterdam, Netherlands; Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Microbiol, NL-9751 NN Haren, Netherlands	University of Amsterdam; University of Groningen	Luirink, J (corresponding author), Bioctr Amsterdam, Inst Mol Biol Sci, Dept Microbiol, De Boelelaan 1087, NL-1081 HV Amsterdam, Netherlands.	luirink@bio.vu.nl	Driessen, Arnold J.M./D-1876-2012; Luirink, Joen/AAB-8658-2021	SCOTTI, Pier-Arnaldo/0000-0003-4427-3695; Driessen, Arnold J.M./0000-0001-9258-9104; Luirink, J./0000-0001-8431-0804				Bassilana M, 1996, EMBO J, V15, P5202, DOI 10.1002/j.1460-2075.1996.tb00905.x; CABELLI RJ, 1991, J BIOL CHEM, V266, P24420; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; deGier JWL, 1996, FEBS LETT, V399, P307, DOI 10.1016/S0014-5793(96)01354-3; deLeeuw E, 1997, FEBS LETT, V416, P225, DOI 10.1016/S0014-5793(97)01238-6; DEVRIJE T, 1987, BIOCHIM BIOPHYS ACTA, V900, P63, DOI 10.1016/0005-2736(87)90278-1; Driessen AJM, 1998, CURR OPIN MICROBIOL, V1, P216, DOI 10.1016/S1369-5274(98)80014-3; Duong F, 1997, EMBO J, V16, P2756, DOI 10.1093/emboj/16.10.2756; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HIGH S, 1991, J CELL BIOL, V113, P25, DOI 10.1083/jcb.113.1.25; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; KUMAMOTO CA, 1993, J BACTERIOL, V175, P2184, DOI 10.1128/JB.175.8.2184-2188.1993; KUSTERS R, 1995, FEBS LETT, V372, P253, DOI 10.1016/0014-5793(95)00997-N; LUIRINK J, 1994, MOL MICROBIOL, V11, P9, DOI 10.1111/j.1365-2958.1994.tb00284.x; LUIRINK J, 1992, NATURE, V359, P741, DOI 10.1038/359741a0; LUIRINK J, 1994, EMBO J, V13, P2289, DOI 10.1002/j.1460-2075.1994.tb06511.x; MACFARLANE J, 1995, EUR J BIOCHEM, V233, P766, DOI 10.1111/j.1432-1033.1995.766_3.x; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; Newitt JA, 1998, J BIOL CHEM, V273, P12451, DOI 10.1074/jbc.273.20.12451; Powers T, 1997, EMBO J, V16, P4880, DOI 10.1093/emboj/16.16.4880; POWERS T, 1995, SCIENCE, V269, P1422, DOI 10.1126/science.7660124; Rapiejko PJ, 1997, CELL, V89, P703, DOI 10.1016/S0092-8674(00)80253-6; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; Traxler B, 1996, J BIOL CHEM, V271, P12394, DOI 10.1074/jbc.271.21.12394; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; Valent QA, 1997, MOL MICROBIOL, V25, P53, DOI 10.1046/j.1365-2958.1997.4431808.x; Valent QA, 1998, EMBO J, V17, P2504, DOI 10.1093/emboj/17.9.2504; van der Does C, 1998, BIOCHEMISTRY-US, V37, P201, DOI 10.1021/bi972105t; WERNER PK, 1992, J BIOL CHEM, V267, P24523; WOLIN SL, 1994, CELL, V77, P787, DOI 10.1016/0092-8674(94)90124-4	31	81	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29883	29888		10.1074/jbc.274.42.29883	http://dx.doi.org/10.1074/jbc.274.42.29883			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514469	Green Published, hybrid			2022-12-27	WOS:000083176400048
J	Swarnakar, S; Temel, RE; Connelly, MA; Azhar, S; Williams, DL				Swarnakar, S; Temel, RE; Connelly, MA; Azhar, S; Williams, DL			Scavenger receptor class B, type I, mediates selective uptake of low density lipoprotein cholesteryl ester	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE ADRENOCORTICAL-CELLS; SR-BI; APOLIPOPROTEIN-E; TARGETED MUTATION; RAT; HDL; EXPRESSION; PROTEIN; CLA-1; LDL	Scavenger receptor, class B, type I (SR-BI) is a cell-surface glycoprotein that mediates selective uptake of high density lipoprotein cholesteryl ester (CE) without the concomitant uptake and degradation of the particle. We have investigated the endocytic and selective uptake of low density lipoprotein (LDL)-CE by SIR-BI using COS-7 cells transiently transfected with mouse SR-BI. Analysis of lipoprotein uptake data showed a concentration-dependent LDL-CE-selective uptake when doubly labeled LDL particles were incubated with SR-BI-expressing COS-7 cells. In contrast to vector-transfected cells, SR-BI-expressing COS-7 cells showed marked increases in LDL cell association and CE uptake by the selective uptake pathway, but only a modest increase in CE uptake by the endocytic pathway. SR-BI-mediated LDL-CE-selective uptake exceeded LDL endocytic uptake by 50-100-fold. SR-BI-mediated LDL-CE-selective uptake was not inhibited by the proteoglycan synthesis inhibitor, p-nitrophenyl-beta-D-xylopyranoside or by the sulfation inhibitor sodium chlorate, indicating that SR-BI-mediated LDL-CE uptake occurs independently of LDL interaction with cell-surface proteoglycan. Analyses with subclones of Y1 adrenocortical cells showed that LDL-CF-selective uptake was proportional to the level of SR-BI expression. Furthermore; antibody directed to the extracellular domain of ESR-BI blocked LDL-CE-selective uptake in adrenocortical cells. Thus, in cells that normally express SR-BI and in transfected COS-7 cells SR-BI mediates the efficient uptake of LDL-CE via the selective uptake mechanism. These results suggest that SR-BI may influence the metabolism of apoB-containing lipoproteins in vivo by mediating LDL-CE uptake into SR-BI-expressing cells.	SUNY Stony Brook, Dept Pharmacal Sci, Med Ctr, Stony Brook, NY 11794 USA; Vet Affairs Palo Alto Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Palo Alto, CA 94304 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Williams, DL (corresponding author), SUNY Stony Brook, Dept Pharmacal Sci, Med Ctr, Stony Brook, NY 11794 USA.				NHLBI NIH HHS [HL 58012, HL 32868] Funding Source: Medline; NIDDK NIH HHS [DK 49705] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032868, R01HL058012] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049705] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Arai T, 1999, J BIOL CHEM, V274, P2366, DOI 10.1074/jbc.274.4.2366; Azhar S, 1998, J LIPID RES, V39, P1616; AZHAR S, 1989, J LIPID RES, V30, P1799; AZHAR S, 1990, BIOCHIM BIOPHYS ACTA, V1047, P148, DOI 10.1016/0005-2760(90)90041-U; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CALVO D, 1993, J BIOL CHEM, V268, P18929; Calvo D, 1997, ARTERIOSCL THROM VAS, V17, P2341, DOI 10.1161/01.ATV.17.11.2341; Cao GP, 1997, J BIOL CHEM, V272, P33068, DOI 10.1074/jbc.272.52.33068; Connelly MA, 1999, J BIOL CHEM, V274, P41, DOI 10.1074/jbc.274.1.41; Cooper AD, 1997, J LIPID RES, V38, P2173; de la Llera-Moya M, 1999, J LIPID RES, V40, P575; Fuki IV, 1997, J CLIN INVEST, V100, P1611, DOI 10.1172/JCI119685; Goldstein J.L., 1989, METABOLIC BASIS INHE, P1215; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; JI ZS, 1994, J BIOL CHEM, V269, P2764; KOLSET SO, 1990, BIOCHEM J, V265, P637, DOI 10.1042/bj2650637; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Murao K, 1997, J BIOL CHEM, V272, P17551, DOI 10.1074/jbc.272.28.17551; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; REAVEN E, 1986, J CLIN INVEST, V77, P1971, DOI 10.1172/JCI112526; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Rigotti A, 1996, J BIOL CHEM, V271, P33545, DOI 10.1074/jbc.271.52.33545; Rothblat GH, 1999, J LIPID RES, V40, P781; Stangl H, 1998, J BIOL CHEM, V273, P31002, DOI 10.1074/jbc.273.47.31002; Swarnakar S, 1998, J BIOL CHEM, V273, P12140, DOI 10.1074/jbc.273.20.12140; Temel RE, 1997, P NATL ACAD SCI USA, V94, P13600, DOI 10.1073/pnas.94.25.13600; Trigatti B, 1999, P NATL ACAD SCI USA, V96, P9322, DOI 10.1073/pnas.96.16.9322; Ueda Y, 1999, J BIOL CHEM, V274, P7165, DOI 10.1074/jbc.274.11.7165; Varban ML, 1998, P NATL ACAD SCI USA, V95, P4619, DOI 10.1073/pnas.95.8.4619; Wang N, 1998, J BIOL CHEM, V273, P32920, DOI 10.1074/jbc.273.49.32920	37	101	103	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29733	29739		10.1074/jbc.274.42.29733	http://dx.doi.org/10.1074/jbc.274.42.29733			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514447	hybrid			2022-12-27	WOS:000083176400026
J	Wieland, K; Ter Laak, AM; Smit, MJ; Kuhne, R; Timmerman, H; Leurs, R				Wieland, K; Ter Laak, AM; Smit, MJ; Kuhne, R; Timmerman, H; Leurs, R			Mutational analysis of the antagonist-binding site of the histamine H-1 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; TRANSMEMBRANE DOMAIN; DIRECTED MUTAGENESIS; PHARMACOLOGICAL CHARACTERIZATION; BETA(2)-ADRENERGIC RECEPTOR; GENOMIC CLONING; AGONIST BINDING; FUNCTIONAL-ROLE; EXPRESSION; GENE	We combined in a previously derived three-dimensional model of the histamine H-1 receptor (Ter Laak, A. M., Timmerman, H., Leurs, a, Nederkoorn, P. H. J., Snail, M. J,, and Donne-Op den Kelder, G. M. (1995) J. Comp. Aid. Mol; Design. 9, 319-330) a pharmacophore for the H-1 antagonist binding site (Ter Laak, A. M., Venhorst, J,, Timmerman, H., and Donne-Op de Kelder, G.M. (1994) J. Med Chem, 38, 3351-3360) with the known interacting amino acid residue Asp(116) (in transmembrane domain III) of the H-1 receptor and verified the predicted receptor- ligand interactions by site-directed mutagenesis. This resulted in the identification of the aromatic amino acids Trp(167), Phe(433), and Phe(436) in transmembrane domains IV and VI of the H-1 receptor as probable interaction points for the trans-aromatic ring of the H-1 antagonists, Subsequently, a specific interaction of carboxylate moieties of two therapeutically important, zwitterionic H-1 antagonists with Lys(200) in transmembrane domain V was predicted. A Lys(200) --> Ala mutation results in a 50- (acrivastine) to 8-fold (d-cetirizine) loss of affinity of these zwitterionic antagonists, In contrast, the affinities of structural analogs of acrivastine and cetirizine lacking the carboxylate group, triprolidine and meclozine, respectively, are unaffected by the Lys(200) --> Ala mutation. These data strongly suggest that Lys(200), unique for the H-1 receptor, acts as a specific anchor point for these "second generation" H-1 antagonists.	Free Univ Amsterdam, Dept Pharmacochem, Leiden Amsterdam Ctr Drug Res, Div Med Chem,Fac Chem, NL-1081 HV Amsterdam, Netherlands; Inst Mol Pharmacol, Biocomp Mol Modelling Grp, D-10315 Berlin, Germany	Leiden University; Leiden University - Excl LUMC; Vrije Universiteit Amsterdam	Leurs, R (corresponding author), Free Univ Amsterdam, Dept Pharmacochem, Leiden Amsterdam Ctr Drug Res, Div Med Chem,Fac Chem, Boelelaan 1083, NL-1081 HV Amsterdam, Netherlands.		Leurs, Rob/ABB-4299-2021; Leurs, Rob/AAC-8508-2022	Leurs, Rob/0000-0003-1354-2848; Smit, Martine/0000-0003-2713-0238; ter Laak, Antonius/0000-0003-1820-002X				BLUML K, 1994, J BIOL CHEM, V269, P18870; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHO W, 1995, J NEUROCHEM, V65, P2105, DOI 10.1046/j.1471-4159.1995.65052105.x; CHOUDHARY MS, 1995, MOL PHARMACOL, V47, P450; COHEN AF, 1985, CLIN PHARMACOL THER, V38, P381, DOI 10.1038/clpt.1985.191; Dale HH, 1910, J PHYSIOL-LONDON, V41, P318; DEBACKER MD, 1993, BIOCHEM BIOPH RES CO, V197, P1601, DOI 10.1006/bbrc.1993.2662; DIXON RAF, 1988, COLD SPRING HARB SYM, V53, P487, DOI 10.1101/SQB.1988.053.01.056; DUBUSKE LM, 1996, J ALLERG CLIN IMMU S, V98, P307; Fourneau E, 1933, ARCH INT PHARMACOD T, V46, P178; FUJIMOTO K, 1993, BIOCHEM BIOPH RES CO, V190, P294, DOI 10.1006/bbrc.1993.1045; FUKUI H, 1994, BIOCHEM BIOPH RES CO, V201, P894, DOI 10.1006/bbrc.1994.1786; GODFREY PP, 1992, SIGNAL TRANSDUCTION, P105; GREEN SA, 1993, J BIOL CHEM, V268, P23116; HIBERT MF, 1993, TRENDS PHARMACOL SCI, V14, P7, DOI 10.1016/0165-6147(93)90106-T; HWA J, 1995, J BIOL CHEM, V270, P23189, DOI 10.1074/jbc.270.39.23189; Inoue I, 1996, GENOMICS, V36, P178, DOI 10.1006/geno.1996.0441; JANSSENS MML, 1994, KIRK OTHMER ENCY CHE, V13, P290; Kristiansen K, 1996, PROTEINS, V26, P81, DOI 10.1002/(SICI)1097-0134(199609)26:1<81::AID-PROT8>3.0.CO;2-J; Kuipers W, 1997, MOL PHARMACOL, V51, P889, DOI 10.1124/mol.51.5.889; LEURS R, 1995, PHARMACOL THERAPEUT, V66, P413, DOI 10.1016/0163-7258(95)00006-3; LEURS R, 1994, BIOCHEM BIOPH RES CO, V201, P295, DOI 10.1006/bbrc.1994.1701; LEURS R, 1995, BIOCHEM BIOPH RES CO, V214, P110, DOI 10.1006/bbrc.1995.2263; MOGUILEVSKY N, 1995, J RECEPT SIGNAL TR R, V15, P91, DOI 10.3109/10799899509045210; MOGUILEVSKY N, 1994, EUR J BIOCHEM, V224, P489, DOI 10.1111/j.1432-1033.1994.00489.x; NAUTA WT, 1968, PHYSICO CHEM ASPECTS, P305; OHTA K, 1994, BIOCHEM BIOPH RES CO, V203, P1096, DOI 10.1006/bbrc.1994.2295; PARDO L, 1992, P NATL ACAD SCI USA, V89, P4009, DOI 10.1073/pnas.89.9.4009; RIHOUX JP, 1993, CLIN REV ALLERG, V11, P65; SMIT MJ, 1995, BIOCHEM BIOPH RES CO, V214, P1138, DOI 10.1006/bbrc.1995.2404; TERLAAK AM, 1995, J COMPUT AID MOL DES, V9, P319, DOI 10.1007/BF00125173; TERLAAK AM, 1995, J MED CHEM, V38, P3351, DOI 10.1021/jm00017a019; TRAIFFORT E, 1994, J NEUROCHEM, V62, P507; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; vanRhee AM, 1996, DRUG DEVELOP RES, V37, P1, DOI 10.1002/(SICI)1098-2299(199601)37:1<1::AID-DDR1>3.0.CO;2-S; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; WESS J, 1993, EMBO J, V12, P331, DOI 10.1002/j.1460-2075.1993.tb05661.x; Wieland K, 1996, P NATL ACAD SCI USA, V93, P9276, DOI 10.1073/pnas.93.17.9276; WOODWARD R, 1994, J NEUROCHEM, V62, P1664; YAMASHITA M, 1991, P NATL ACAD SCI USA, V88, P11515, DOI 10.1073/pnas.88.24.11515; ZHANG MQ, 1997, BURGERS MEDICINAL CH; ZHANG MQ, 1997, CURR MED CHEM, V4, P187; Zhao MM, 1996, MOL PHARMACOL, V50, P1118	43	99	101	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29994	30000		10.1074/jbc.274.42.29994	http://dx.doi.org/10.1074/jbc.274.42.29994			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514483	Green Published, hybrid			2022-12-27	WOS:000083176400062
J	Cook, T; Gebelein, B; Belal, M; Mesa, K; Urrutia, P				Cook, T; Gebelein, B; Belal, M; Mesa, K; Urrutia, P			Three conserved transcriptional repressor domains are a defining feature of the TIEG subfamily of Sp1-like zinc finger proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KRUPPEL-LIKE FACTOR; BOX-BINDING PROTEIN; GROWTH-FACTOR-BETA; ACTIVATION DOMAINS; MOLECULAR-CLONING; HUMAN OSTEOBLASTS; MULTIGENE FAMILY; GENE; CELLS; IDENTIFICATION	Sp1-like transcription factors are characterized by three highly homologous C-terminal zinc finger motifs that bind CC-rich sequences. These proteins behave as either activators or repressors and have begun to be classified into different subfamilies based upon the presence of conserved motifs outside the zinc finger domain. This classification predicts that different Sp1-like subfamilies share certain functional properties. TIEG1 and TIEG2 constitute a new subfamily of transforming growth factor-beta-inducible Sp1-like proteins whose zinc finger motifs also bind GC-rich sequences. However, regions outside of the DNA-binding domain that differ in structure from other Sp1-like family members remain poorly characterized. Here, we have used extensive mutagenesis and GAL4-based transcriptional assays to identify three repression domains within TIEG1 and TIEG2 that we call R1, R2, and R3. R1 is 10 amino acids, R2 is 12 amino acids, and R3 is approximately 80 amino acids long None of these domains share homology with previously described transcriptional regulatory motifs, but they share strong sequence homology and are functionally conserved between TIEG1 and TIEG2. Together, these data demonstrate that TIEG proteins are capable of repressing transcription, define domains critical for this function, and further support the idea that different subfamilies of Sp1-like proteins have evolved to mediate distinct transcriptional functions.	Mayo Clin, Gastroenterol Res Unit, Rochester, MN 55901 USA; Mayo Clin, Dept Mol Neurosci, Rochester, MN 55901 USA; Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55901 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Urrutia, P (corresponding author), Mayo Clin & Mayo Fdn, St Marys Hosp, GI Res Unit, 200 1st St SW, Rochester, MN 55905 USA.		Nakafuku, Masato/J-3068-2013	Cook, Tiffany/0000-0002-3100-5248	NIDDK NIH HHS [DK52913, DK07198, R01 DK052913, R01 DK052913-03] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052913, R56DK052913, T32DK007198] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alevizopoulos A, 1996, J BIOL CHEM, V271, P29672, DOI 10.1074/jbc.271.47.29672; ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; Armstrong JA, 1998, CELL, V95, P93, DOI 10.1016/S0092-8674(00)81785-7; BIEKER JJ, 1995, MOL CELL BIOL, V15, P852; BLOK LJ, 1995, MOL ENDOCRINOL, V9, P1610, DOI 10.1210/me.9.11.1610; Busch K, 1997, MOL ENDOCRINOL, V11, P379, DOI 10.1210/me.11.3.379; Conkright MD, 1999, NUCLEIC ACIDS RES, V27, P1263, DOI 10.1093/nar/27.5.1263; Cook T, 1998, J BIOL CHEM, V273, P25929, DOI 10.1074/jbc.273.40.25929; Cook T, 1999, ANN NY ACAD SCI, V880, P94, DOI 10.1111/j.1749-6632.1999.tb09513.x; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Crossley M, 1996, MOL CELL BIOL, V16, P1695; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; ElRouby S, 1996, ONCOGENE, V13, P2623; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; Geourjon C, 1995, COMPUT APPL BIOSCI, V11, P681; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; Gray S, 1996, CURR OPIN CELL BIOL, V8, P358; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; Imhof A, 1999, MOL CELL BIOL, V19, P194; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KOBAYASHI A, 1995, J BIOCHEM-TOKYO, V117, P91, DOI 10.1093/oxfordjournals.jbchem.a124727; Kojima S, 1997, J BIOCHEM, V121, P389; Koritschoner NP, 1997, J BIOL CHEM, V272, P9573; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Liu CT, 1996, CRIT REV ONCOGENESIS, V7, P101, DOI 10.1615/CritRevOncog.v7.i1-2.70; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; MARTINEZ E, 1991, MOL CELL BIOL, V11, P2937, DOI 10.1128/MCB.11.6.2937; Matsumoto N, 1998, J BIOL CHEM, V273, P28229, DOI 10.1074/jbc.273.43.28229; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Shields JM, 1997, J BIOL CHEM, V272, P18504, DOI 10.1074/jbc.272.29.18504; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; Subramaniam M, 1995, NUCLEIC ACIDS RES, V23, P4907, DOI 10.1093/nar/23.23.4907; Tachibana I, 1997, J CLIN INVEST, V99, P2365, DOI 10.1172/JCI119418; Tanese N, 1996, P NATL ACAD SCI USA, V93, P13611, DOI 10.1073/pnas.93.24.13611; Tau KR, 1998, ENDOCRINOLOGY, V139, P1346, DOI 10.1210/en.139.3.1346; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Yajima S, 1997, J NEUROSCI, V17, P8657; Yet SF, 1998, J BIOL CHEM, V273, P1026, DOI 10.1074/jbc.273.2.1026	46	104	108	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29500	29504		10.1074/jbc.274.41.29500	http://dx.doi.org/10.1074/jbc.274.41.29500			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506214	hybrid			2022-12-27	WOS:000083017800093
J	Galvan, DL; Borrego-Diaz, E; Perez, PJ; Mignery, GA				Galvan, DL; Borrego-Diaz, E; Perez, PJ; Mignery, GA			Subunit oligomerization, and topology of the inositol 1,4,5-trisphosphate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; STRUCTURAL ORGANIZATION; SKELETAL-MUSCLE; COILED COILS; ION-CHANNEL; CALCIUM; PROTEIN; DOMAIN; PHOSPHOLAMBAN; TRISPHOSPHATE	The inositol 1,4,5-trisphosphate receptor (InsP(3)R) is a tetrameric assembly of highly conserved subunits that contain multiple membrane-spanning sequences in the C-terminal region of the protein. In studies aimed at investigating the oligomerization and transmembrane topology of the type-1 InsP(3)R, a series of membrane-spanning region truncation and deletion plasmids were constructed. These plasmids were transiently transfected in COS-1 cells, and the resulting expression products were analyzed for the ability to assemble into tetrameric structures. The topology of the membrane-spanning region truncations and the full-length receptor was determined by immunocytochemical analysis of transfected COS-1 cells using complete or selective permeabilization strategies, Our results are the first to experimentally define the presence of six membrane-spanning regions. These results are consistent with the current model for the organization of the InsP(3)R in the endoplasmic reticulum and show that the truncation mutants are properly targeted and oriented in the endoplasmic reticulum membrane, thus making them amenable reagents to study receptor subunit oligomerization. Fractionation of soluble and membrane protein components revealed that the first two membrane-spanning regions were necessary for membrane targeting of the receptor, Sedimentation and immunoprecipitation experiments show that assembly of the receptor subunits was an additive process as the number of membrane-spanning regions increased. Immunoprecipitations from cells co-expressing the full-length receptor and carboxyl-terminal truncations reveal that constructs expressing the first two or more membrane-spanning domains were capable of co-assembling with the full-length receptor. Inclusion of the fifth membrane-spanning segment significantly enhanced the degree of oligomerization, Furthermore, a deletion construct containing only membrane-spanning regions 5 and 6 oligomerized to a similar extent as that of the wild type protein. Membrane-spanning region deletion constructions that terminate with the receptor's 145 carboxyl-terminal amino acids were found to have enhanced assembly characteristics and implicate the carboxyl terminus as a determinant in oligomerization. Our results reveal a process of receptor assembly involving several distinct yet additive components and define the fifth and sixth membrane spanning regions as the key determinants in receptor oligomerization.	Loyola Univ, Stritch Sch Med, Dept Physiol, Maywood, IL 60153 USA	Loyola University Chicago	Mignery, GA (corresponding author), Loyola Univ, Stritch Sch Med, Dept Physiol, 2160 S 1st Ave, Maywood, IL 60153 USA.		Galvan, Daniel L./L-2768-2019	Galvan, Daniel L./0000-0001-7541-6252	NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH053367] Funding Source: NIH RePORTER; NIMH NIH HHS [R29 MH53367] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARKIN IT, 1995, J MOL BIOL, V248, P824, DOI 10.1006/jmbi.1995.0263; ARKIN IT, 1994, EMBO J, V13, P4757, DOI 10.1002/j.1460-2075.1994.tb06801.x; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Berridge MJ, 1997, NATURE, V386, P759, DOI 10.1038/386759a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BHAKDI S, 1993, MED MICROBIOL IMMUN, V182, P167; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Hagar RE, 1998, NATURE, V396, P81, DOI 10.1038/23954; Joseph SK, 1997, J BIOL CHEM, V272, P1579, DOI 10.1074/jbc.272.3.1579; JOSEPH SK, 1995, BIOCHEM J, V307, P859, DOI 10.1042/bj3070859; Kuroda R, 1996, J BIOCHEM-TOKYO, V120, P828; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MAK DOD, 1999, BIOPHYS J, V76, P375; Marx SO, 1998, SCIENCE, V281, P818, DOI 10.1126/science.281.5378.818; MICHIKAWA T, 1994, J BIOL CHEM, V269, P9184; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIGNERY GA, 1993, METH NEUROSCI, V18, P247; OTTO JC, 1994, J BIOL CHEM, V269, P19868; Perez PJ, 1997, J BIOL CHEM, V272, P23961, DOI 10.1074/jbc.272.38.23961; PERIN MS, 1991, J BIOL CHEM, V266, P3877; Ramos-Franco J, 1998, BIOPHYS J, V75, P2783, DOI 10.1016/S0006-3495(98)77721-5; Ramos-Franco J, 1999, J GEN PHYSIOL, V114, P243, DOI 10.1085/jgp.114.2.243; Ramos-Franco J, 1998, BIOPHYS J, V75, P834, DOI 10.1016/S0006-3495(98)77572-1; SANKARARAMAKRISHNAN R, 1995, BBA-BIOMEMBRANES, V1239, P122, DOI 10.1016/0005-2736(95)00165-Y; Sayers LG, 1997, BIOCHEM J, V323, P273, DOI 10.1042/bj3230273; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; TAKEI K, 1994, NEURON, V12, P327, DOI 10.1016/0896-6273(94)90275-5	31	74	75	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29483	29492		10.1074/jbc.274.41.29483	http://dx.doi.org/10.1074/jbc.274.41.29483			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506212	hybrid			2022-12-27	WOS:000083017800091
J	Prabhakar, R; Boivin, GP; Hoit, B; Wieczorek, DF				Prabhakar, R; Boivin, GP; Hoit, B; Wieczorek, DF			Rescue of high expression beta-tropomyosin transgenic mice by 5-propyl-2-thiouracil - Regulating the alpha-myosin heavy chain promotor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTRACTILE PROTEINS; THYROID-HORMONE; GENE-EXPRESSION; CARDIAC MYOSIN; HEART; HETEROGENEITY; ELEMENTS; MUSCLE; RATS	Tropomyosin is an essential component of the sarcomeric thin filament in striated muscle that participates in the regulation of muscle contraction through Ca2+- mediated activation. The two predominant tropomyosin isoforms expressed in striated muscle are alpha- and beta-tropomyosin, which exhibit an 86% amino acid identity between themselves. Previous studies by our laboratory utilized a transgenic mouse system to overexpress beta-tropomyosin in the heart to address the functional differences between these two tropomyosin isoforms, Interestingly, when a high percentage of beta-tropomyosin replaces alpha-tropomyosin in the hearts of transgenic mice, the mice die due to severe cardiac abnormalities. In this study, we have rescued these high expression beta-tropomyosin mice by turning off the alpha-myosin heavy chain promoter, which is driving the beta-tropomyosin transgene. This down-regulation of the ru-myosin heavy chain promoter was accomplished by the administration of 5-propyl-2-thiouracil, which disrupts thyroid hormone synthesis and inhibits promoter activity through thyroid regulatory elements located in the 5'-flanking region of the promoter. Results show that as beta-tropomyosin expression is down-regulated, alpha-tropomyosin expression is increased, Also, alpha- and beta-myosin heavy chain expression is modified in response to the changes in thyroid hormone expression. Morphological analysis of these rescued mice show a moderate pathological phenotype, characterized by atrial myocytolysis; echocardiographic analyses demonstrate altered ventricular functions, such as peak filling rates and left ventricular fractional shortening. This is the first report demonstrating that transcriptional regulatory elements located within the alpha-myosin heavy chain promoter can be manipulated to rescue potentially lethal phenotypes, such as high expression beta-tropomyosin transgenic mice.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Internal Med, Div Cardiol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Wieczorek, DF (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054912] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54912] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRONSON DD, 1982, J BIOL CHEM, V257, P3937; FLINK IL, 1990, J BIOL CHEM, V265, P11233; HOH JFY, 1978, J MOL CELL CARDIOL, V10, P1053, DOI 10.1016/0022-2828(78)90401-7; HOIT BD, 1995, CIRC RES, V77, P632, DOI 10.1161/01.RES.77.3.632; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; KATZEFF HL, 1994, AM J PHYSIOL, V267, pE63, DOI 10.1152/ajpendo.1994.267.1.E63; Lorenz JN, 1997, AM J PHYSIOL-HEART C, V272, pH1137, DOI 10.1152/ajpheart.1997.272.3.H1137; MATTILA J, 1990, AM J PHYSIOL, V258, pR1464; MORLEY JE, 1981, HORM RES, V14, P18, DOI 10.1159/000179353; Muthuchamy M, 1998, J MOL CELL CARDIOL, V30, P1545, DOI 10.1006/jmcc.1998.0720; Muthuchamy M, 1999, CIRC RES, V85, P47; Muthuchamy M, 1997, TRENDS CARDIOVAS MED, V7, P124, DOI 10.1016/S1050-1738(97)00004-2; Muthuchamy M, 1995, J BIOL CHEM, V270, P30593, DOI 10.1074/jbc.270.51.30593; Ojamaa K, 1996, ENDOCRINOLOGY, V137, P802, DOI 10.1210/en.137.3.802; Palmiter KA, 1996, J BIOL CHEM, V271, P11611, DOI 10.1074/jbc.271.20.11611; POLIKAR R, 1993, CIRCULATION, V87, P1435, DOI 10.1161/01.CIR.87.5.1435; Rethinasamy P, 1998, CIRC RES, V82, P116; Robbins J, 1998, CIRC RES, V82, P134; SCHACHAT F, 1990, DYNAMIC STATE OF MUSCLE FIBERS, P279; SCHACHAT FH, 1985, J BIOL CHEM, V260, P1108; SUBRAMANIAM A, 1993, J BIOL CHEM, V268, P4331; Sussman MA, 1998, J CLIN INVEST, V101, P51, DOI 10.1172/JCI1167	22	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29558	29563		10.1074/jbc.274.41.29558	http://dx.doi.org/10.1074/jbc.274.41.29558			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506222	hybrid			2022-12-27	WOS:000083017800101
J	Delerive, P; De Bosscher, K; Besnard, S; Vanden Berghe, W; Peters, JM; Gonzalez, FJ; Fruchart, JC; Tedgui, A; Haegeman, G; Staels, B				Delerive, P; De Bosscher, K; Besnard, S; Vanden Berghe, W; Peters, JM; Gonzalez, FJ; Fruchart, JC; Tedgui, A; Haegeman, G; Staels, B			Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappa B and AP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORONARY-ARTERY DISEASE; CBP-INDUCED STIMULATION; CREB-BINDING PROTEIN; GLUCOCORTICOID RECEPTOR; C-JUN; NUCLEAR FACTOR; PPAR-GAMMA; LIPOPROTEIN METABOLISM; FUNCTIONAL ANTAGONISM; ANDROGEN RECEPTOR	Interleukin-6 (IL-6) is a pleiotropic cytokine, whose plasma levels are elevated in inflammatory diseases such as atherosclerosis. We have previously reported that peroxisome proliferator-activated receptor alpha (PPAR alpha) Ligands (fibrates) lower elevated plasma concentrations of IL-6 in patients with atherosclerosis and inhibit IL-1-stimulated IL-6 secretion by human aortic smooth muscle cells (SMC). Here, we show that aortic explants isolated from PPAR alpha-null mice display an exacerbated response to inflammatory stimuli, such as li popolysaccharide (LPS), as demonstrated by increased IL-6 secretion. Furthermore, fibrate treatment represses IL-6 mRNA levels in LPS-stimulated aortas of PPAR alpha wild-type, but not of PPAR alpha-null mice, demonstrating a role for PPAR alpha in this fibrate action. in human aortic SMC, fibrates inhibit IL-1-induced IL-6 gene expression. Furthermore, activation of PPAR alpha represses both c-Jun- and p65-induced transcription of the human IL-6 promoter. Transcriptional interference between PPAR alpha and both c-Jun and p65 occurs reciprocally, since c-Jun and p65 also inhibit PPAR alpha-mediated activation of a PPAR response element-driven promoter. This transcriptional interference occurs independent of the promoter context as demonstrated by cotransfection experiments using PPAR alpha, p65, and c-Jun Gal4 chimeras. Overexpression of the transcriptional coactivator cAMP-responsive element-binding protein-binding protein (CBP) does not relieve PPAR alpha-mediated transcriptional repression of p65 and c-Jun, Finally, glutathione S-transferase pull-down experiments demonstrate that PPAR alpha physically interacts with c-dun, p65, and CBP. Altogether these data indicate that fibrates inhibit the vascular inflammatory response via PPAR alpha by interfering with the NF-kappa B and AP-1 transactivation capacity involving direct protein-protein interaction with p65 and c-Jun.	Inst Pasteur, Dept Atherosclerose, U325 INSERM, F-59019 Lille, France; Univ Lille 2, Fac Pharm, F-59000 Lille, France; Univ Ghent, Mol Biol Lab, B-9000 Ghent, Belgium; VIB, B-9000 Ghent, Belgium; INSERM U141, F-75745 Paris 10, France; NCI, Dept Mol Carcinogenesis, NIH, Bethesda, MD 20892 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; Universite de Lille; Ghent University; Flanders Institute for Biotechnology (VIB); Institut National de la Sante et de la Recherche Medicale (Inserm); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Staels, B (corresponding author), Inst Pasteur, Dept Atherosclerose, U325 INSERM, 1 Rue Pr Calmette, F-59019 Lille, France.	bart.staels@pasteur-lille.fr	Peters, Jeffrey/D-8847-2011; Vanden Berghe, Wim/HGE-4696-2022; Berghe, Wim Vanden/S-6425-2018; Staels, Bart/N-9497-2016	Berghe, Wim Vanden/0000-0003-0161-7355; Staels, Bart/0000-0002-3784-1503; De Bosscher, Karolien/0000-0001-5059-9718; Peters, Jeffrey/0000-0003-2782-2998	NATIONAL CANCER INSTITUTE [ZIABC005708, Z01BC005708] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bannister AJ, 1995, ONCOGENE, V11, P2509; BELMIN J, 1995, AM J PHYSIOL-HEART C, V268, pH2288, DOI 10.1152/ajpheart.1995.268.6.H2288; Biswas P, 1998, BLOOD, V91, P258, DOI 10.1182/blood.V91.1.258.258_258_265; BROCKMANN D, 1995, J BIOL CHEM, V270, P10754, DOI 10.1074/jbc.270.18.10754; Bubulya A, 1996, J BIOL CHEM, V271, P24583, DOI 10.1074/jbc.271.40.24583; Caelli T, 1997, INT J PATTERN RECOGN, V11, P1, DOI 10.1142/S0218001497000652; CASTELL JV, 1989, FEBS LETT, V242, P237, DOI 10.1016/0014-5793(89)80476-4; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; Colville-Nash PR, 1998, J IMMUNOL, V161, P978; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; Dowell P, 1997, J BIOL CHEM, V272, P33435, DOI 10.1074/jbc.272.52.33435; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Frick MH, 1997, CIRCULATION, V96, P2137; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Gottlicher M, 1998, J MOL MED-JMM, V76, P480, DOI 10.1007/s001090050242; HINEGARDNER RT, 1971, ANAL BIOCHEM, V39, P197, DOI 10.1016/0003-2697(71)90476-3; Hollenberg AN, 1996, J BIOL CHEM, V271, P28516, DOI 10.1074/jbc.271.45.28516; IKEDA U, 1992, ATHEROSCLEROSIS, V92, P213, DOI 10.1016/0021-9150(92)90280-T; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Madej A, 1998, INT J CLIN PHARM TH, V36, P345; Marx N, 1999, CIRCULATION, V99, P3125, DOI 10.1161/01.CIR.99.24.3125; Marx N, 1998, AM J PATHOL, V153, P17, DOI 10.1016/S0002-9440(10)65540-X; Mehta JL, 1998, J AM COLL CARDIOL, V31, P1217, DOI 10.1016/S0735-1097(98)00093-X; Munoz C, 1996, BLOOD, V88, P3482, DOI 10.1182/blood.V88.9.3482.bloodjournal8893482; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Palvimo JJ, 1996, J BIOL CHEM, V271, P24151, DOI 10.1074/jbc.271.39.24151; RAY A, 1994, J BIOL CHEM, V269, P12940; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rogatsky I, 1998, P NATL ACAD SCI USA, V95, P2050, DOI 10.1073/pnas.95.5.2050; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Ruotolo G, 1998, J AM COLL CARDIOL, V32, P1648, DOI 10.1016/S0735-1097(98)00442-2; Rus HG, 1996, ATHEROSCLEROSIS, V127, P263, DOI 10.1016/S0021-9150(96)05968-0; Saitoh Kiyoshi, 1995, Folia Pharmacologica Japonica, V106, P41, DOI 10.1254/fpj.106.41; SAKAI M, 1995, CANCER RES, V55, P5370; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SHEMSHEDINI L, 1991, EMBO J, V10, P3839, DOI 10.1002/j.1460-2075.1991.tb04953.x; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; Staels B, 1998, CIRCULATION, V98, P2088, DOI 10.1161/01.CIR.98.19.2088; STAELS B, 1992, ARTERIOSCLER THROMB, V12, P286, DOI 10.1161/01.ATV.12.3.286; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; Tilg H, 1997, IMMUNOL TODAY, V18, P428, DOI 10.1016/S0167-5699(97)01103-1; Treuter E, 1998, MOL ENDOCRINOL, V12, P864, DOI 10.1210/me.12.6.864; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Wissink S, 1997, J BIOL CHEM, V272, P22278, DOI 10.1074/jbc.272.35.22278; Xing Z, 1998, J CLIN INVEST, V101, P311, DOI 10.1172/JCI1368; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	61	900	930	1	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32048	32054		10.1074/jbc.274.45.32048	http://dx.doi.org/10.1074/jbc.274.45.32048			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542237	hybrid			2022-12-27	WOS:000083532100045
J	Di Paolo, C; Hefti, HP; Meli, M; Landis, H; Pavlovic, J				Di Paolo, C; Hefti, HP; Meli, M; Landis, H; Pavlovic, J			Intramolecular backfolding of the carboxyl-terminal end of MxA protein is a prerequisite for its oligomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIVIRAL ACTIVITY; INFLUENZA-VIRUS; GTPASE ACTIVITY; DYNAMIN; INTERFERON; INHIBITION; EXPRESSION; TRANSCRIPTION; RESISTANCE; CELLS	Mx proteins are large GTPases, which play a pivotal role in the interferon type I-mediated response against viral infections. The human MxA inhibits the replication of several RNA viruses and is organized in oligomeric structures. Using two different experimental approaches, the mammalian two-hybrid system and an interaction dependent nuclear translocation approach, three domains in the carboxyl-terminal moiety were identified that are involved in the oligomerization of MxA. The first consists of a carboxyl-terminal amphipathic helix (LZ1), which binds to a more proximal part of the same molecule, This intramolecular backfolding is a prerequisite for the formation of an intermolecular complex, This intermolecular interaction is mediated by two domains, a poorly defined region generated by the intramolecular interaction and a domain located between amino acids 363 and 415. Go-expression of wild-type MxA with various mutant fragments thereof revealed that the presence of the carboxyl-terminal region comprising the amphipathic helices LZ1 and LZ2 is necessary and sufficient to exert a dominant negative effect. This finding suggests that the functional interference of the carboxyl-terminal region is due to competition for binding of an as yet unidentified cellular or viral target molecules.	Univ Zurich, Inst Med Virol, CH-8028 Zurich, Switzerland	University of Zurich	Pavlovic, J (corresponding author), Univ Zurich, Inst Med Virol, Gloriastr 30, CH-8028 Zurich, Switzerland.		Pavlovic, Jovan/G-9669-2015	Pavlovic, Jovan/0000-0003-4428-2487				BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; Carr JF, 1997, J BIOL CHEM, V272, P28030, DOI 10.1074/jbc.272.44.28030; CHIANG CM, 1993, PEPTIDE RES, V6, P62; DREIDING P, 1985, VIROLOGY, V140, P192, DOI 10.1016/0042-6822(85)90460-X; FRESE M, 1995, J VIROL, V69, P3904, DOI 10.1128/JVI.69.6.3904-3909.1995; Frese M, 1996, J VIROL, V70, P915, DOI 10.1128/JVI.70.2.915-923.1996; GARBER EA, 1993, VIROLOGY, V194, P715, DOI 10.1006/viro.1993.1312; GAUTIER C, 1989, NUCLEIC ACIDS RES, V17, P8389, DOI 10.1093/nar/17.20.8389; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; ISRAEL A, 1979, ANN INST PASTEUR MIC, VB130, P85; Kanerva M, 1996, VIROLOGY, V224, P55, DOI 10.1006/viro.1996.0506; Landis H, 1998, J VIROL, V72, P1516, DOI 10.1128/JVI.72.2.1516-1522.1998; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MAEDA K, 1992, MOL BIOL CELL, V3, P1181, DOI 10.1091/mbc.3.10.1181; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; Melen K, 1997, J BIOL CHEM, V272, P32353, DOI 10.1074/jbc.272.51.32353; MELEN K, 1992, J BIOL CHEM, V267, P25898; Muhlberg AB, 1997, EMBO J, V16, P6676, DOI 10.1093/emboj/16.22.6676; NAKAYAMA M, 1993, J BIOL CHEM, V268, P15033; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; PAVLOVIC J, 1990, J VIROL, V64, P3370, DOI 10.1128/JVI.64.7.3370-3375.1990; PITOSSI F, 1993, J VIROL, V67, P6726, DOI 10.1128/JVI.67.11.6726-6732.1993; Ponten A, 1997, J VIROL, V71, P2591, DOI 10.1128/JVI.71.4.2591-2599.1997; ROTHMAN JH, 1990, CELL, V61, P1063, DOI 10.1016/0092-8674(90)90070-U; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SCHNEIDERSCHAULIES S, 1994, J VIROL, V68, P6910, DOI 10.1128/JVI.68.11.6910-6917.1994; SCHNORR JJ, 1993, J VIROL, V67, P4760, DOI 10.1128/JVI.67.8.4760-4768.1993; Schumacher B, 1998, J BIOL CHEM, V273, P28365, DOI 10.1074/jbc.273.43.28365; SCHWEMMLE M, 1995, VIROLOGY, V206, P545, DOI 10.1016/S0042-6822(95)80071-9; SCHWEMMLE M, 1995, J BIOL CHEM, V270, P13518, DOI 10.1074/jbc.270.22.13518; Staeheli P, 1990, Adv Virus Res, V38, P147, DOI 10.1016/S0065-3527(08)60862-3; STAEHELI P, 1986, CELL, V44, P147, DOI 10.1016/0092-8674(86)90493-9; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TUMA PL, 1995, J BIOL CHEM, V270, P26707, DOI 10.1074/jbc.270.44.26707; Warnock DE, 1996, J BIOL CHEM, V271, P22310, DOI 10.1074/jbc.271.37.22310; Zhao H, 1996, VIROLOGY, V220, P330, DOI 10.1006/viro.1996.0321; ZURCHER T, 1992, EMBO J, V11, P1657, DOI 10.1002/j.1460-2075.1992.tb05212.x; ZURCHER T, 1992, J VIROL, V66, P5059	41	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32071	32078		10.1074/jbc.274.45.32071	http://dx.doi.org/10.1074/jbc.274.45.32071			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542240	hybrid, Green Accepted			2022-12-27	WOS:000083532100048
J	Hutchison, RS; Steenhuis, JJ; Yocum, CF; Razeghifard, MR; Barry, BA				Hutchison, RS; Steenhuis, JJ; Yocum, CF; Razeghifard, MR; Barry, BA			Deprotonation of the 33-kDa, extrinsic, manganese-stabilizing subunit accompanies photooxidation of manganese in photosystem II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC OXYGEN-EVOLUTION; DIFFERENCE FT-IR; TRANSFORM INFRARED-SPECTROSCOPY; ELECTRON-PARAMAGNETIC-RES; SYNECHOCYSTIS SP PCC-6803; 33 KDA PROTEIN; WATER OXIDATION; O-2-EVOLVING SYSTEM; STRUCTURAL-CHANGES; STATE TRANSITIONS	Photosystem II catalyzes photosynthetic water oxidation. The oxidation of water to molecular oxygen requires four sequential oxidations; the sequentially oxidized forms of the catalytic site are called the S states. An extrinsic subunit, the manganese-stabilizing protein (MSP), promotes the efficient turnover of the S states. MSP can be removed and rebound to the reaction center; removal and reconstitution is associated with a decrease in and then a restoration of enzymatic activity. We have isotopically edited MSP by uniform C-13 labeling of the Escherichia coli-expressed protein and have obtained the Fourier transform infrared spectrum associated with the S-1 to S-2 transition in the presence either of reconstituted C-12 or C-13 MSP, C-13 labeling of MSP is shown to cause 30-60 cm(-1) shifts in a subset of vibrational lines. The derived, isotope-edited vibrational spectrum is consistent with a deprotonation of glutamic/ aspartic acid residues on MSP during the S, to S, transition; the base, which accepts this proton(s), is not located on MSP. This finding suggests that this subunit plays a role as a stabilizer of a charged transition state and, perhaps, as a general acid/base catalyst of oxy gen evolution. These results provide a molecular explanation for known MSP effects on oxygen evolution.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, Gortner Lab 140, St Paul, MN 55108 USA; Univ Michigan, Dept Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Barry, BA (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, Gortner Lab 140, St Paul, MN 55108 USA.							Ahlbrink R, 1998, BIOCHEMISTRY-US, V37, P1131, DOI 10.1021/bi9719152; AKERLUND HE, 1981, FEBS LETT, V124, P229, DOI 10.1016/0014-5793(81)80143-3; BALDWIN MJ, 1994, J AM CHEM SOC, V116, P11349, DOI 10.1021/ja00104a014; BARRY B, 1987, BIOCHEMISTRY-US, V26, P59, DOI 10.1021/bi00375a009; BARRY BA, 1995, METHOD ENZYMOL, V258, P303; BELLAMY LJ, 1980, INFRARED SPECTRA COM, P183; Benson TE, 1997, BIOCHEMISTRY-US, V36, P796, DOI 10.1021/bi962220o; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; Betts SD, 1997, BIOCHEMISTRY-US, V36, P4047, DOI 10.1021/bi962413b; Betts SD, 1996, BIOCHEMISTRY-US, V35, P6302, DOI 10.1021/bi953066t; BRAIMAN MS, 1988, ANNU REV BIOPHYS BIO, V17, P541; BRICKER TM, 1992, BIOCHEMISTRY-US, V31, P4623, DOI 10.1021/bi00134a012; BRITT RD, 1996, OXYGENIC PHOTOSYNTHE, V4, P137; BURNAP RL, 1991, BIOCHEMISTRY-US, V30, P440, DOI 10.1021/bi00216a020; BURNAP RL, 1994, BIOCHEMISTRY-US, V33, P13712, DOI 10.1021/bi00250a023; BURNAP RL, 1992, BIOCHEMISTRY-US, V31, P7404, DOI 10.1021/bi00147a027; Christensen T, 1997, EUR J BIOCHEM, V250, P638, DOI 10.1111/j.1432-1033.1997.00638.x; Chu HA, 1999, BIOCHEMISTRY-US, V38, P4533, DOI 10.1021/bi982807y; DIOUMAEV AK, 1995, J AM CHEM SOC, V117, P10572, DOI 10.1021/ja00147a020; Fierobe HP, 1998, BIOCHEMISTRY-US, V37, P3753, DOI 10.1021/bi972232p; FLETT MS, 1962, SPECTROCHIM ACTA, V18, P1537, DOI 10.1016/S0371-1951(62)80282-3; Haumann M, 1997, FEBS LETT, V410, P243, DOI 10.1016/S0014-5793(97)00596-6; Haumann M, 1997, PHOTOSYNTH RES, V51, P193, DOI 10.1023/A:1005861917596; Herman RC, 1939, J CHEM PHYS, V7, P460, DOI 10.1063/1.1750472; Hutchison RS, 1998, BIOCHEMISTRY-US, V37, P5643, DOI 10.1021/bi9724467; JACKSON M, 1995, CRIT REV BIOCHEM MOL, V30, P95, DOI 10.3109/10409239509085140; Karge M, 1997, BIOCHEMISTRY-US, V36, P8904, DOI 10.1021/bi962342g; Kim S, 1998, BBA-BIOENERGETICS, V1366, P330, DOI 10.1016/S0005-2728(98)00134-0; Kim SY, 1998, BIOPHYS J, V74, P2588, DOI 10.1016/S0006-3495(98)77965-2; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; KUWABARA T, 1985, BIOCHIM BIOPHYS ACTA, V806, P283, DOI 10.1016/0005-2728(85)90107-0; Lancaster CRD, 1996, BIOPHYS J, V70, P2469, DOI 10.1016/S0006-3495(96)79820-X; Lydakis-Simantiris N, 1997, BBA-BIOENERGETICS, V1322, P129, DOI 10.1016/S0005-2728(97)00072-8; MACDONALD GM, 1995, J BIOL CHEM, V270, P8420, DOI 10.1074/jbc.270.15.8420; MACDONALD GM, 1992, BIOCHEMISTRY-US, V31, P9848, DOI 10.1021/bi00155a043; MAYES SR, 1991, BIOCHIM BIOPHYS ACTA, V1060, P1, DOI 10.1016/S0005-2728(05)80112-4; MAYFIELD SP, 1987, EMBO J, V6, P313, DOI 10.1002/j.1460-2075.1987.tb04756.x; McIntosh LP, 1996, BIOCHEMISTRY-US, V35, P9958, DOI 10.1021/bi9613234; Miura T, 1997, J BIOL CHEM, V272, P3788, DOI 10.1074/jbc.272.6.3788; MIYAO M, 1984, FEBS LETT, V168, P118, DOI 10.1016/0014-5793(84)80218-5; MIYAO M, 1983, FEBS LETT, V164, P375, DOI 10.1016/0014-5793(83)80320-2; MIYAO M, 1984, FEBS LETT, V170, P350, DOI 10.1016/0014-5793(84)81342-3; MIYAO M, 1987, BIOCHIM BIOPHYS ACTA, V890, P151, DOI 10.1016/0005-2728(87)90016-8; Nakamoto K., 1986, INFRARED RAMAN SPECT, P191; NAVERRETE JTL, 1994, BIOPOLYMERS, V34, P1065; NOGUCHI T, 1995, BBA-BIOENERGETICS, V1228, P189, DOI 10.1016/0005-2728(94)00171-Z; NOGUCHI T, 1992, BIOCHEMISTRY-US, V31, P5953, DOI 10.1021/bi00141a001; ONO T, 1984, FEBS LETT, V168, P281, DOI 10.1016/0014-5793(84)80263-X; ONO T, 1985, BIOCHIM BIOPHYS ACTA, V806, P331, DOI 10.1016/0005-2728(85)90240-3; ONO T, 1983, FEBS LETT, V164, P252; Pan K, 1998, BIOCHEMISTRY-US, V37, P1357, DOI 10.1021/bi971835y; PHILBRICK JB, 1991, J BIOL CHEM, V266, P13370; RAMIREZ FJ, 1995, SPECTROCHIM ACTA A, V51, P293, DOI 10.1016/0584-8539(94)00188-H; Razeghifard MR, 1997, BIOCHEMISTRY-US, V36, P14474, DOI 10.1021/bi970116g; ROTHSCHILD KJ, 1992, J BIOENERG BIOMEMBR, V24, P147, DOI 10.1007/BF00762674; SAUER K, 1992, MANGANESE REDOX ENZY, P141; SCHOWEN KB, 1982, METHOD ENZYMOL, V87, P551; Seidler A, 1996, EUR J BIOCHEM, V242, P485, DOI 10.1111/j.1432-1033.1996.0485r.x; Seidler A, 1996, BBA-BIOENERGETICS, V1277, P35, DOI 10.1016/S0005-2728(96)00102-8; SEIDLER A, 1995, PHOTOSYNTHESIS LIGHT, V2, P259; Short SA, 1996, J BIOL CHEM, V271, P4978; Steenhuis JJ, 1996, J AM CHEM SOC, V118, P11927, DOI 10.1021/ja961691v; Steenhuis JJ, 1999, J BIOL CHEM, V274, P14609, DOI 10.1074/jbc.274.21.14609; Steenhuis JJ, 1998, J PHYS CHEM B, V102, P4, DOI 10.1021/jp9730609; Steenhuis JJ, 1997, J PHYS CHEM B, V101, P6652, DOI 10.1021/jp971260e; STYRING S, 1988, BIOCHIM BIOPHYS ACTA, V933, P378, DOI 10.1016/0005-2728(88)90046-1; SUSI H, 1986, METHOD ENZYMOL, V130, P290; VASS I, 1992, BIOCHIM BIOPHYS ACTA, V1102, P195, DOI 10.1016/0005-2728(92)90100-G; VASS I, 1987, BIOCHIM BIOPHYS ACTA, V892, P224, DOI 10.1016/0005-2728(87)90178-2; Yamomoto Y., 1981, FEBS LETT, V133, P265; Zhang HM, 1998, BIOCHEMISTRY-US, V37, P5511, DOI 10.1021/bi971787h	71	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31987	31995		10.1074/jbc.274.45.31987	http://dx.doi.org/10.1074/jbc.274.45.31987			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542229	hybrid			2022-12-27	WOS:000083532100037
J	Su, L; Rickert, RC; David, M				Su, L; Rickert, RC; David, M			Rapid STAT phosphorylation via the B cell receptor - Modulatory role of CD19	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; INTERFERON-ALPHA; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; LYMPHOCYTES-B; ACTIVATION; KINASE; EXPRESSION; PROTEINS	Engagement of the B cell receptor (BCR) initiates multiple signaling cascades which mediate different biological responses, depending on the stage of B cell differentiation, antigen binding affinity, and duration of stimulation. Aggregation of co-receptors such as CD19 with the antigen receptor has been suggested to modulate the signals necessary for the development and functioning of the humoral immune system. In this study, we demonstrate that engagement of the antigen receptor on peripheral blood B cells, but not naive splenic B lymphocytes, leads to rapid phosphorylation of signal transducers and activators of transcription 1 (STAT1) on Tyr-701 and Ser-727, Interestingly, phosphorylation on tyrosine diminished with increased stimulation, whereas serine phosphorylation correlated directly with the level of BCR cross linking. In contrast, phosphorylation of STAT3 occurs exclusively on serine and is sensitive to inhibitors of the PI3-kinase and the ERK1/2 pathways. Finally, we show that co ligation of CD19 with the BCR results in increased tyrosine phosphorylation of STAT1 relative to BCR cross-linking alone, establishing CD19 as a positive modulator of BCR-mediated STAT activation.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	David, M (corresponding author), Univ Calif San Diego, Dept Biol, 9500 Gilman Dr,Bonner Hall 3138, La Jolla, CA 92093 USA.			Su, Leon/0000-0001-7654-9997	NATIONAL CANCER INSTITUTE [R01CA080105] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA080105-03, R01 CA080105-01, R01 CA080105-02, R01 CA080105] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; CARTER RH, 1992, SCIENCE, V256, P105, DOI 10.1126/science.1373518; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1993, J BIOL CHEM, V268, P6593; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; ENGEL P, 1995, IMMUNITY, V3, P39, DOI 10.1016/1074-7613(95)90157-4; FEARON DT, 1995, ANNU REV IMMUNOL, V13, P127, DOI 10.1146/annurev.immunol.13.1.127; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GOLD MR, 1992, J IMMUNOL, V148, P2012; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; Gupta S, 1996, EMBO J, V15, P1075, DOI 10.1002/j.1460-2075.1996.tb00445.x; HELM MH, 1995, SCIENCE, V267, P1347; Karras JG, 1996, J IMMUNOL, V157, P2299; LAMER AC, 1993, SCIENCE, V261, P1730; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Mowen K, 1998, J BIOL CHEM, V273, P30073, DOI 10.1074/jbc.273.46.30073; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; RICKERT RC, 1995, NATURE, V376, P352, DOI 10.1038/376352a0; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Tedder TF, 1997, IMMUNITY, V6, P107, DOI 10.1016/S1074-7613(00)80418-5; Tooze RM, 1997, IMMUNITY, V7, P59, DOI 10.1016/S1074-7613(00)80510-5; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	28	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31770	31774		10.1074/jbc.274.45.31770	http://dx.doi.org/10.1074/jbc.274.45.31770			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542198	Green Submitted, hybrid, Green Accepted			2022-12-27	WOS:000083532100006
J	Tseng, CP; Ely, BD; Pong, RC; Wang, Z; Zhou, J; Hsieh, JT				Tseng, CP; Ely, BD; Pong, RC; Wang, Z; Zhou, J; Hsieh, JT			The role of DOC-2/DAB2 protein phosphorylation in the inhibition of AP-1 activity - An underlying mechanism of its tumor-suppressive function in prostate cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C-DELTA; NUCLEAR-LOCALIZATION SIGNAL; DIFFERENTIAL REGULATION; GROWTH-CONTROL; PHORBOL ESTER; DISABLED GENE; CELL-LINE; OVEREXPRESSION; EXPRESSION; EPSILON	DOC-2/DAB2, a novel phosphoprotein with signal-transducing capability, inhibits human prostatic cancer cells (Tseng, C.-P., Ely, B. D., Li, Y., Pong, R.-C., and Hsieh, J.-T. (1998) Endocrinology 139, 3542-3553). However, its mechanism of action is not understood completely, This study delineates the functional significance of DOC-2/DAB2 protein phosphorylation and demonstrates that in vivo activation of protein kinase C (PKC) by 12-O-tetradecanoylphorbol-13-acetate (TPA) induces DOC-2/DAB2 phosphorylation, including a serine residue at position 24, Mutation of Ser(24) to Ala reduced DOC-2/DAB2 phosphorylation by PKC, Using a synthetic Ser(24) peptide (APS(24)KKEKKKGSEKTD) or recombinant DOC-2/DAB2 as substrates, PKC beta II, PKC gamma, and PKC delta (but not casein kinase II) directly phosphorylated Ser24 in vitro. This indicates that DOC-2/DAB2 is a PKC-specific substrate. Since expression of wild-type DOC-2/DAB2, but not the S24A mutant, inhibited TPA-induced AP-I activity in prostatic epithelial cells, phosphorylation of Ser(24) appears to play a critical role in modulating TPA-induced AP-1 activity. Taken together, these data suggest that PKC-regulated phosphorylation of DOC-2/DAB2 protein may help its growth inhibitory function.	Univ Texas, SW Med Ctr, Dept Urol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hsieh, JT (corresponding author), Univ Texas, SW Med Ctr, Dept Urol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.				NCI NIH HHS [CA59939] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA059939] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; FRIEDERICH E, 1992, CELL, V70, P81, DOI 10.1016/0092-8674(92)90535-K; Fukumoto S, 1997, J BIOL CHEM, V272, P13816, DOI 10.1074/jbc.272.21.13816; Fulop V, 1998, ONCOGENE, V17, P419, DOI 10.1038/sj.onc.1201955; GOLDSTEIN DR, 1995, CARCINOGENESIS, V16, P1121, DOI 10.1093/carcin/16.5.1121; GOODE N, 1992, J BIOL CHEM, V267, P16878; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; KIELBASSA K, 1995, J BIOL CHEM, V270, P6156, DOI 10.1074/jbc.270.11.6156; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KRAUSS RS, 1989, ONCOGENE, V4, P991; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; LEHEL C, 1994, J BIOL CHEM, V269, P4761; LEUKEL M, 1995, EUR J CELL BIOL, V68, P133; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Mok SC, 1998, ONCOGENE, V16, P2381, DOI 10.1038/sj.onc.1201769; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; ROBBINS DJ, 1992, MOL BIOL CELL, V3, P299, DOI 10.1091/mbc.3.3.299; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; TAGAWA T, 1995, J CELL BIOL, V130, P255, DOI 10.1083/jcb.130.2.255; TSENG CP, 1994, CARCINOGENESIS, V15, P707, DOI 10.1093/carcin/15.4.707; Tseng CP, 1998, ENDOCRINOLOGY, V139, P3542, DOI 10.1210/en.139.8.3542; Tseng CP, 1996, GENE, V169, P287, DOI 10.1016/0378-1119(95)00816-0; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; XU XX, 1995, J BIOL CHEM, V270, P14184, DOI 10.1074/jbc.270.23.14184; Xu XX, 1998, ONCOGENE, V16, P1561, DOI 10.1038/sj.onc.1201678	30	50	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31981	31986		10.1074/jbc.274.45.31981	http://dx.doi.org/10.1074/jbc.274.45.31981			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542228	hybrid			2022-12-27	WOS:000083532100036
J	Hayakawa, J; Ohmichi, M; Kurachi, H; Ikegami, H; Kimura, A; Matsuoka, T; Jikihara, H; Mercola, D; Murata, Y				Hayakawa, J; Ohmichi, M; Kurachi, H; Ikegami, H; Kimura, A; Matsuoka, T; Jikihara, H; Mercola, D; Murata, Y			Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERNARY COMPLEX-FORMATION; NUCLEAR ANTIGEN GENE; DNA-DAMAGING AGENTS; TYROSINE KINASE; DEPENDENT ACTIVATION; RAS TRANSFORMATION; BINDING PROTEINS; POLYMERASE-BETA; GROWTH-FACTORS; TUMOR-CELLS	We have studied the roles of c-Jun N-terminal protein kinase (JNK) and extracellular signal-regulated protein kinase (ERK) cascade in both the cisplatin-resistant Caov-5 and the cisplatin-sensitive A2780 human ovarian cancer cell Lines. Treatment of both cells with cisplatin but not transplatin isomer activates JNK and ERK, Activation of JNK by cisplatin occurred at 30 min, reached a plateau at 3 h, and declined thereafter, whereas activation of ERK by cisplatin showed a biphasic pattern, indicating the different time frame. Activation of JNK by cisplatin was maximal at 1000 mu M,whereas activation of ERR was maximal at 100 mu M and was less at higher concentrations, indicating the different dose dependence. Cisplatin-induced JNK activation was neither extracellular and intracellular Ca2+. nor protein kinase C-dependent, whereas cisplatin-induced ERK activation was extracellular and intracellular Ca2+- dependent and protein kinase C-dependent. A mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor, PD98059, had no effect on the cisplatin-induced JNK activity, suggesting an absence of cross-talk between the ERR and JNK cascades. We further examined the effect of each cascade on the viability following cisplatin treatment. Either exogenous expression of dominant negative c-Jun or the treatment by PD98059 induced sensitivity to cisplatin in both cells. Our findings suggest that cisplatin-induced DNA damage differentially activates JNK and ERK cascades and that inhibition of either of these cascades sensitizes ovarian cancer cells to cisplatin.	Osaka Univ, Sch Med, Dept Obstet & Gynecol, Suita, Osaka 5650871, Japan; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA	Osaka University; University of California System; University of California San Diego	Ohmichi, M (corresponding author), Osaka Univ, Sch Med, Dept Obstet & Gynecol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		mercola, dan/L-4182-2013	mercola, dan/0000-0002-0281-9840	NCI NIH HHS [CA76173, CA63783] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063783, R01CA076173] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1995, CELL GROWTH DIFFER, V6, P1437; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Bost F, 1999, MOL CELL BIOL, V19, P1938; Cadwallader K, 1997, BIOCHEM J, V321, P795, DOI 10.1042/bj3210795; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DAI TN, 1995, ONCOGENE, V10, P849; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FEUERSTEIN N, 1995, J BIOL CHEM, V270, P9454, DOI 10.1074/jbc.270.16.9454; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Gjerset RA, 1995, MOL CARCINOGEN, V14, P275, DOI 10.1002/mc.2940140408; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HAMILTON TC, 1985, BIOCHEM PHARMACOL, V34, P2583, DOI 10.1016/0006-2952(85)90551-9; HEILAND S, 1993, EUR J BIOCHEM, V217, P813, DOI 10.1111/j.1432-1033.1993.tb18309.x; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HORTON JK, 1995, NUCLEIC ACIDS RES, V23, P3810, DOI 10.1093/nar/23.19.3810; HUANG DY, 1994, MOL CELL BIOL, V14, P4233, DOI 10.1128/MCB.14.6.4233; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KEDAR PS, 1991, P NATL ACAD SCI USA, V88, P3729, DOI 10.1073/pnas.88.9.3729; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; Kudoh S, 1997, CIRC RES, V80, P139, DOI 10.1161/01.RES.80.1.139; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; LOUIE KG, 1986, BIOCHEM PHARMACOL, V35, P467, DOI 10.1016/0006-2952(86)90221-2; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; OHMICHI M, 1994, J BIOL CHEM, V269, P3783; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; POTAPOVA O, 1996, CANCER RES, V56, P2800; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Reimold AM, 1996, NATURE, V379, P262, DOI 10.1038/379262a0; RUBIN E, 1992, CANCER RES, V52, P878; Sanchez-Perez I, 1998, ONCOGENE, V16, P533, DOI 10.1038/sj.onc.1201578; Sawada T, 1997, ENDOCRINOLOGY, V138, P5275, DOI 10.1210/en.138.12.5275; SHERMAN SE, 1985, SCIENCE, V230, P412, DOI 10.1126/science.4048939; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; Townsend KJ, 1998, ONCOGENE, V17, P1223, DOI 10.1038/sj.onc.1202035; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; WILLIAM RH, 1992, P NATL ACAD SCI USA, V89, P8837; WU JX, 1990, ONCOGENE, V5, P989; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YU LJ, 1993, J BIOL CHEM, V268, P7520; Yu R, 1996, CANCER RES, V56, P2954; ZAMBLE DB, 1995, TRENDS BIOCHEM SCI, V20, P435, DOI 10.1016/S0968-0004(00)89095-7; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	70	169	174	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31648	31654		10.1074/jbc.274.44.31648	http://dx.doi.org/10.1074/jbc.274.44.31648			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531373	hybrid			2022-12-27	WOS:000083379400077
J	Murakami, M; Kambe, T; Shimbara, S; Higashino, K; Hanasaki, K; Arita, H; Horiguchi, M; Arita, M; Arai, H; Inoue, K; Kudo, I				Murakami, M; Kambe, T; Shimbara, S; Higashino, K; Hanasaki, K; Arita, H; Horiguchi, M; Arita, M; Arai, H; Inoue, K; Kudo, I			Different functional aspects of the group II subfamily (types IIA and V) and type X secretory phospholipase A(2)s in regulating arachidonic acid release and prostaglandin generation - Implications of cyclooxygenase-2 induction and phospholipid scramblase-mediated cellular membrane perturbation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING-FACTOR-ACETYLHYDROLASE; MURINE P388D(1) MACROPHAGES; MAST-CELLS; MOLECULAR-CLONING; EXPRESSION; PARTICIPATION; FIBROBLASTS; INHIBITION; PLATELETS; RECEPTOR	We have recently reported that members of the heparin-binding group II subfamily of secretory PLL(2)s (sPLA(2)s) (types IIA and V), when transfected into 293 cells, released [H-3]arachidonic acid (AA) preferentially in response to interleukin-l (IL-1) and acted as "signaling" PLA(2)s that were functionally coupled with prostaglandin biosynthesis. Here we show that these group II subfamily sPLA(2)s and the type X sPLA(2) behave in a different manner, the former being more efficiently coupled with the prostaglandin-biosynthetic pathway than the latter, in 293 transfectants. Type X sPLA(2) which bound only minimally to cell surface proteoglycans, augmented the release of both [H-3]AA and [H-3]oleic acid in the presence of serum but not IL-l. Both types IIA and V sPLA(2) the AA released by which was efficiently converted to prostaglandin E-2, markedly augmented IL-1-induced expression of cyclooxygenase (COX)-2 in a heparin-sensitive fashion, whereas type X sPLA(2) lacked the ability to augment COX-2 expression, thereby exhibiting the poor prostaglandin E-2-biosynthetic response unless either of the COX isozymes was forcibly introduced into type X sPLA(2)-expressing cells. Implication of phospholipid scramblase, an enzyme responsible for the perturbation of plasma membrane asymmetry, revealed that the scramblase-transfected cells became more sensitive to types IIA and V, but not X, sPLA(2), releasing both [H-3]AA and [H-3]oleic acid in an IL-1-independent manner. Thus, although phospholipid scramblase-mediated alteration in plasma membrane asymmetry actually led to the increased cellular susceptibility to the group II subfamily of sPLA(2)s, several lines of evidence suggest that it does not entirely mimic their actions on cells after IL-1 signaling. Interestingly, coexpression of type IIA or V, but not X, sPLA(2) and phospholipid scramblase resulted in a marked reduction in cell growth, revealing an unexplored antiproliferative aspect of particular classes of sPLA(2).	Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, Tokyo 142, Japan; Shionogi & Co Ltd, Shionogi Res Labs, Fukushima Ku, Osaka 553, Japan; Univ Tokyo, Fac Pharmaceut Sci, Dept Hlth Chem, Bunkyo Ku, Tokyo 113, Japan	Showa University; Shionogi & Company Limited; University of Tokyo	Kudo, I (corresponding author), Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 142, Japan.			Arita, Makoto/0000-0001-9902-0463				ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; Akiba S, 1997, J BIOCHEM-TOKYO, V122, P859; Atsumi G, 1997, BBA-LIPID LIPID MET, V1349, P43, DOI 10.1016/S0005-2760(97)00082-9; Baker SF, 1998, BIOCHEMISTRY-US, V37, P13203, DOI 10.1021/bi981223t; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balsinde J, 1997, J BIOL CHEM, V272, P20373, DOI 10.1074/jbc.272.33.20373; Balsinde J, 1998, P NATL ACAD SCI USA, V95, P7951, DOI 10.1073/pnas.95.14.7951; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; CHEN J, 1994, J BIOL CHEM, V269, P2365; Chen YJ, 1998, BBA-LIPID LIPID MET, V1394, P57, DOI 10.1016/S0005-2760(98)00098-8; Cupillard L, 1997, J BIOL CHEM, V272, P15745, DOI 10.1074/jbc.272.25.15745; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; DOLE VP, 1960, J BIOL CHEM, V235, P2595; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; Han SK, 1999, J BIOL CHEM, V274, P11881, DOI 10.1074/jbc.274.17.11881; HARA S, 1991, J BIOCHEM, V110, P163, DOI 10.1093/oxfordjournals.jbchem.a123550; Hernandez M, 1998, J BIOL CHEM, V273, P606, DOI 10.1074/jbc.273.1.606; ISHIZAKI J, 1994, J BIOL CHEM, V269, P5897; Ishizaki J, 1999, J BIOL CHEM, V274, P24973, DOI 10.1074/jbc.274.35.24973; Koduri RS, 1998, J BIOL CHEM, V273, P32142, DOI 10.1074/jbc.273.48.32142; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Matsuzawa A, 1997, J BIOL CHEM, V272, P32315, DOI 10.1074/jbc.272.51.32315; Meade EA, 1999, J BIOL CHEM, V274, P8328, DOI 10.1074/jbc.274.12.8328; MURAKAMI M, 1991, FEBS LETT, V294, P247, DOI 10.1016/0014-5793(91)81440-J; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami M, 1996, J BIOL CHEM, V271, P30041, DOI 10.1074/jbc.271.47.30041; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Murakami M, 1999, J BIOL CHEM, V274, P29927, DOI 10.1074/jbc.274.42.29927; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; MURAKAMI M, 1988, J BIOCHEM-TOKYO, V104, P884, DOI 10.1093/oxfordjournals.jbchem.a122577; Murakami M, 1997, FEBS LETT, V413, P249, DOI 10.1016/S0014-5793(97)00916-2; MURAKAMI M, 1989, BIOCHIM BIOPHYS ACTA, V1043, P34; Naraba H, 1998, J IMMUNOL, V160, P2974; PFEILSCHIFTER J, 1993, J CLIN INVEST, V92, P2516, DOI 10.1172/JCI116860; Polgar J, 1997, BIOCHEM J, V327, P259, DOI 10.1042/bj3270259; Reddy ST, 1996, J BIOL CHEM, V271, P186, DOI 10.1074/jbc.271.1.186; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; Sawada H, 1999, EUR J BIOCHEM, V263, P826, DOI 10.1046/j.1432-1327.1999.00565.x; SCHEVITZ RW, 1995, NAT STRUCT BIOL, V2, P458, DOI 10.1038/nsb0695-458; SUGA H, 1993, EUR J BIOCHEM, V218, P807, DOI 10.1111/j.1432-1033.1993.tb18435.x; Tada K, 1998, J IMMUNOL, V161, P5008; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; Zhao J, 1998, J BIOL CHEM, V273, P6603, DOI 10.1074/jbc.273.12.6603; Zhou QS, 1997, J BIOL CHEM, V272, P18240, DOI 10.1074/jbc.272.29.18240	51	151	155	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31435	31444		10.1074/jbc.274.44.31435	http://dx.doi.org/10.1074/jbc.274.44.31435			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531345	hybrid			2022-12-27	WOS:000083379400049
J	Pentikainen, O; Hoffren, AM; Ivaska, J; Kapyla, J; Nyronen, T; Heino, J; Johnson, MS				Pentikainen, O; Hoffren, AM; Ivaska, J; Kapyla, J; Nyronen, T; Heino, J; Johnson, MS			"RKKH" peptides from the snake venom metalloproteinase of Bothrops jararaca bind near the metal ion-dependent adhesion site of the human integrin alpha(2) I-domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; CRYSTAL-STRUCTURE; ECHOVIRUS-1 INTERACTION; COLLAGEN RECEPTOR; DIVALENT-CATION; LIGAND-BINDING; CROTALUS-ATROX; NUCLEIC-ACIDS; ADAMALYSIN-II; FORCE-FIELD	Integrin alpha(1)beta(1) and alpha(2)beta(1) are the major cellular receptors for collagen, and collagens bind to these integrins at the inserted I-domain in their cw subunit. We have previously shown that a cyclic peptide derived from the metalloproteinase domain of the snake venom protein jararhagin blocks the collagen-binding function of the alpha(2) I-domain. Here, we have optimized the structure of the peptide and identified the site where the peptide binds to the alpha(2) I-domain. The peptide sequence Arg-Lys-Lys-His is critical for recognition by the I-domain, and five negatively charged residues surrounding the "metal ion-dependent adhesion site" (MIDAS) of the I-domain, when mutated, show significantly impaired binding of the peptide. Removal of helix alpha C, located along one side of the MIDAS and suggested to be involved in collagen-binding in these I-domains, does not affect peptide binding. This study supports the notion that the metalloproteinase initially binds to the alpha(2) I-domain at a location distant from the active site of the protease, thus blocking collagen binding to the adhesion molecule in the vicinity of the MIDAS, while at the same time leaving the active site free to degrade nearby proteins, the closest being the beta(1) subunit of the alpha(2)beta(1) cell-surface integrin itself.	Abo Akad Univ, Dept Biochem & Pharm, FIN-20520 Turku, Finland; Univ Turku, Turku Ctr Biotechnol, FIN-20520 Turku, Finland; Univ Turku, Dept Med Biochem, MediCity Res Lab, FIN-20520 Turku, Finland; Univ Jyvaskyla, Dept Biol & Environm & Sci, FIN-40351 Jyvaskyla, Finland; Ctr Comp Sci, FIN-02120 Espoo, Finland	Abo Akademi University; University of Turku; University of Turku; University of Jyvaskyla	Johnson, MS (corresponding author), Abo Akad Univ, Dept Biochem & Pharm, Tykistokatu 6 A,POB 66, FIN-20521 Turku, Finland.		Nyrönen, Tommi H./A-3612-2010; Pentikäinen, Olli T/E-1980-2012	Pentikäinen, Olli T/0000-0001-7188-4016; Kapyla, Jarmo/0000-0003-3036-713X; Nyronen, Tommi/0000-0002-5569-5183; Ivaska, Johanna/0000-0002-6295-6556				Baldwin ET, 1998, STRUCTURE, V6, P923, DOI 10.1016/S0969-2126(98)00093-8; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BERGELSON JM, 1994, CELL ADHES COMMUN, V2, P455, DOI 10.3109/15419069409004455; BERGELSON JM, 1995, CURR BIOL, V5, P615, DOI 10.1016/S0960-9822(95)00124-2; BERGELSON JM, 1993, J CLIN INVEST, V92, P232, DOI 10.1172/JCI116555; Bergman DL, 1997, J MOL GRAPH MODEL, V15, P301, DOI 10.1016/S1093-3263(98)00003-5; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Bienkowska J, 1997, J BIOL CHEM, V272, P25162, DOI 10.1074/jbc.272.40.25162; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; *CAMBR CRYST DAT C, 1992, CSD SYST DOC; Camper L, 1998, J BIOL CHEM, V273, P20383, DOI 10.1074/jbc.273.32.20383; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; DELUCA M, 1995, BIOCHEM BIOPH RES CO, V206, P570, DOI 10.1006/bbrc.1995.1081; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Gomis-Ruth FX, 1998, PROTEIN SCI, V7, P283; GOMISRUTH FX, 1994, J MOL BIOL, V239, P513, DOI 10.1006/jmbi.1994.1392; GOMISRUTH FX, 1993, EMBO J, V12, P4151, DOI 10.1002/j.1460-2075.1993.tb06099.x; GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002; GOODSELL DS, 1990, PROTEINS, V8, P195, DOI 10.1002/prot.340080302; HEMLER ME, 1990, CELL DIFFER DEV, V32, P229, DOI 10.1016/0922-3371(90)90035-U; HITE LA, 1992, BIOCHEMISTRY-US, V31, P6203, DOI 10.1021/bi00142a005; HUANG TF, 1989, BIOCHEMISTRY-US, V28, P661, DOI 10.1021/bi00428a037; HUGHES AL, 1992, MOL BIOL EVOL, V9, P216; Huizinga EG, 1997, STRUCTURE, V5, P1147, DOI 10.1016/S0969-2126(97)00266-9; Ivaska J, 1999, J BIOL CHEM, V274, P3513, DOI 10.1074/jbc.274.6.3513; Johnson MS, 1996, METHOD ENZYMOL, V266, P575; JOHNSON MS, 1993, J MOL BIOL, V233, P716, DOI 10.1006/jmbi.1993.1548; JOHNSON MS, 1994, CRIT REV BIOCHEM MOL, V29, P1, DOI 10.3109/10409239409086797; Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1994, J BIOL CHEM, V269, P959; Kamiguti AS, 1997, J BIOL CHEM, V272, P32599, DOI 10.1074/jbc.272.51.32599; King SL, 1997, J BIOL CHEM, V272, P28518, DOI 10.1074/jbc.272.45.28518; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAAKSONEN L, 1992, J MOL GRAPHICS, V10, P33, DOI 10.1016/0263-7855(92)80007-Z; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; Li R, 1998, J CELL BIOL, V143, P1523, DOI 10.1083/jcb.143.6.1523; MERRIT EA, 1997, METHOD ENZYMOL, V177, P505; Morris GM, 1996, J COMPUT AID MOL DES, V10, P293, DOI 10.1007/BF00124499; Muller WEG, 1998, NATURWISSENSCHAFTEN, V85, P11, DOI 10.1007/s001140050444; NEEPER MP, 1990, NUCLEIC ACIDS RES, V18, P4255, DOI 10.1093/nar/18.14.4255; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Oxvig C, 1999, P NATL ACAD SCI USA, V96, P2215, DOI 10.1073/pnas.96.5.2215; PAINE MJI, 1992, J BIOL CHEM, V267, P22869; PISCHEL KD, 1987, J IMMUNOL, V138, P226; Qu AD, 1996, STRUCTURE, V4, P931, DOI 10.1016/S0969-2126(96)00100-1; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SALI A, 1990, TRENDS BIOCHEM SCI, V15, P235, DOI 10.1016/0968-0004(90)90036-B; Salminen TA, 1999, ACTA CRYSTALLOGR D, V55, P1365, DOI 10.1107/S0907444999006009; SANTORO SA, 1991, CELL REGUL, V2, P905, DOI 10.1091/mbc.2.11.905; SHANNON JD, 1989, J BIOL CHEM, V264, P11575; STUCLIFFE MJ, 1987, PROTEIN ENG, V5, P377; SUTCLIFFE MJ, 1987, PROTEIN ENG, V1, P385, DOI 10.1093/protein/1.5.385; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TAKEYA H, 1990, J BIOCHEM-TOKYO, V108, P711, DOI 10.1093/oxfordjournals.jbchem.a123270; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; ZHANG DC, 1994, P NATL ACAD SCI USA, V91, P8447, DOI 10.1073/pnas.91.18.8447	59	28	29	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31493	31505		10.1074/jbc.274.44.31493	http://dx.doi.org/10.1074/jbc.274.44.31493			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531352	hybrid			2022-12-27	WOS:000083379400056
J	Marino, M; Friedlander, JA; McCluskey, RT; Andrews, D				Marino, M; Friedlander, JA; McCluskey, RT; Andrews, D			Identification of a heparin-binding region of rat thyroglobulin involved in megalin binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; LDL RECEPTOR; LOW-DENSITY; SULFATE PROTEOGLYCANS; LIPOPROTEIN-LIPASE; POLYACRYLAMIDE GELS; MASS-SPECTROMETRY; HEYMANN NEPHRITIS; AFFINITY-BINDING; APOLIPOPROTEIN-E	We recently showed that thyroglobulin (Tg) is a heparin-binding protein and that heparin inhibits binding of Tg to its endocytic receptor megalin (gp330), Here we have identified a heparin-binding region in the carboxyl-terminal portion of rat Tg and have studied its involvement in megalin binding. Rat thyroid extracts, obtained by ammonium sulfate precipitation, were separated by column fractionation into four Tg polypeptides, with apparent masses of 660, 330, 210, and 50 kDa. As assessed by enzyme-linked immunoadsorbent assays and ligand blot binding assays, megalin bound to intact Tg (660 and 330 kDa) and, to a even greater extent, to the 210-kDa Tg polypeptide, Furthermore, the 210-kDa Tg polypeptide inhibited megalin binding to intact Tg by similar to 70%, Solid phase assays showed binding of biotin-labeled heparin to intact Tg and to the 210-kDa Tg polypeptide, We characterized the 810-kDa Tg polypeptide by matrix-assisted laser desorption/ionization mass spectrometry analysis and found that it corresponds to the carboxyl-terminal portion of rat Tg, We developed a synthetic peptide corresponding to a 15-amino acid sequence in the carboxyl-terminal portion of rat Tg (Arg(689)-Lys(703)), containing a heparin-binding consensus sequence (SRRLKRP) and demonstrated heparin binding to this peptide. A rabbit antibody raised against the peptide recognized intact Tg in its native conformation and under denaturing conditions. This antibody markedly reduced heparin-binding to intact Tg, indicating that the region of native Tg corresponding to the peptide is involved in heparin binding. Furthermore, the anti-Tg peptide antibody almost completely inhibited binding of megalin to Tg, suggesting that the Tg region containing the peptide sequence is required for megalin binding. Physiologically, Tg binding to megalin on thyroid cells may be facilitated by Tg interaction with heparin-libe molecules (heparan sulfate proteoglycans) via adjacent binding sites.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pathol Res Lab, Charlestown, MA 02129 USA; Univ Pisa, Dept Endocrinol, I-56100 Pisa, Italy	Harvard University; Massachusetts General Hospital; University of Pisa	Marino, M (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pathol Res Lab, 149 13th St, Charlestown, MA 02129 USA.				NIDDK NIH HHS [DK 46301] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046301] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERNIERVALENTIN F, 1990, J BIOL CHEM, V265, P17373; BERNIERVALENTIN F, 1991, ENDOCRINOLOGY, V129, P2194, DOI 10.1210/endo-129-4-2194; Berzofsky Jay A., 1993, P235; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Caturegli P, 1997, CLIN IMMUNOL IMMUNOP, V85, P221, DOI 10.1006/clin.1997.4428; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; Chen H, 1996, BIOCHEM J, V318, P959, DOI 10.1042/bj3180959; CONRAD HE, 1998, HEPARIN BINDING PROT, P367; CONRAD HE, 1998, HEPARIN BINDING PROT, P413; CONSIGLIO E, 1981, J BIOL CHEM, V256, P592; CONSIGLIO E, 1979, J BIOL CHEM, V254, P5065; DILAURO R, 1985, EUR J BIOCHEM, V148, P7; DUNN A, 1996, WERNER INGBARS THYRO, P81; Dunn John T., 1996, P85; Ehring H, 1997, RAPID COMMUN MASS SP, V11, P1867; Emoto N, 1995, THYROID, V5, P455, DOI 10.1089/thy.1995.5.455; EMOTO N, 1994, ENDOCRINOL METAB, V1, P123; ESQUIVEL PS, 1977, J EXP MED, V145, P1250, DOI 10.1084/jem.145.5.1250; Fenselau C, 1997, ANAL CHEM, V69, pA661, DOI 10.1021/ac971831z; Giraud A, 1997, ENDOCRINOLOGY, V138, P2325, DOI 10.1210/en.138.6.2325; GRAVES PN, 1990, MOL ENDOCRINOL, V4, P155, DOI 10.1210/mend-4-1-155; GUTMANN EJ, 1989, AM J PHYSIOL, V257, pC397, DOI 10.1152/ajpcell.1989.257.2.C397; Hill JS, 1998, J BIOL CHEM, V273, P30979, DOI 10.1074/jbc.273.47.30979; JI ZS, 1993, J BIOL CHEM, V268, P10160; Kim PS, 1998, P NATL ACAD SCI USA, V95, P9909, DOI 10.1073/pnas.95.17.9909; KOSTROUCH Z, 1993, ENDOCRINOLOGY, V132, P2645, DOI 10.1210/en.132.6.2645; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LEMANSKY P, 1992, EUR J BIOCHEM, V209, P111, DOI 10.1111/j.1432-1033.1992.tb17267.x; Lundgren S, 1997, J HISTOCHEM CYTOCHEM, V45, P383, DOI 10.1177/002215549704500306; MAHLEY RW, 1994, ANN NY ACAD SCI, V737, P39, DOI 10.1111/j.1749-6632.1994.tb44300.x; Marino M, 1999, J BIOL CHEM, V274, P12898, DOI 10.1074/jbc.274.18.12898; MEDEIROSNETO G, 1993, ENDOCR REV, V14, P165, DOI 10.1210/er.14.2.165; MedeirosNeto G, 1996, J CLIN INVEST, V98, P2838, DOI 10.1172/JCI119112; MIQUELIS R, 1987, J BIOL CHEM, V262, P15291; MOESTRUP SK, 1995, J CLIN INVEST, V96, P1404, DOI 10.1172/JCI118176; MORTZ E, 1994, BIOL MASS SPECTROM, V23, P249, DOI 10.1002/bms.1200230503; MULDER M, 1993, J BIOL CHEM, V268, P9369; Mziaut H, 1996, ENDOCRINOLOGY, V137, P1370, DOI 10.1210/en.137.4.1370; ORLANDO RA, 1994, P NATL ACAD SCI USA, V91, P3161, DOI 10.1073/pnas.91.8.3161; Patterson SD, 1996, ELECTROPHORESIS, V17, P877, DOI 10.1002/elps.1150170509; Perlmutter DH, 1999, LAB INVEST, V79, P623; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; Raychowdhury R, 1996, AM J PATHOL, V148, P1613; ROUSSET B, 1991, MOL CELL ENDOCRINOL, V78, P89; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; Weaver AM, 1997, J LIPID RES, V38, P1841; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; WONG P, 1995, J BIOL CHEM, V270, P25805, DOI 10.1074/jbc.270.43.25805; Zheng G, 1998, ENDOCRINOLOGY, V139, P1462, DOI 10.1210/en.139.3.1462; ZHENG G, 1994, ANN NY ACAD SCI, V737, P154, DOI 10.1111/j.1749-6632.1994.tb44309.x; ZHENG G, 1994, J HISTOCHEM CYTOCHEM, V42, P531, DOI 10.1177/42.4.7510321	52	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30377	30386		10.1074/jbc.274.43.30377	http://dx.doi.org/10.1074/jbc.274.43.30377			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521414	hybrid			2022-12-27	WOS:000083276700010
J	Mineo, C; Gill, GN; Anderson, GW				Mineo, C; Gill, GN; Anderson, GW			Regulated migration of epidermal growth factor receptor from caveolae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-INDUCED INTERNALIZATION; EGF RECEPTOR; TYROSINE KINASE; CONSTITUTIVE ACTIVATION; MEDIATED ENDOCYTOSIS; PROTEIN-KINASE; MAP KINASE; PHOSPHORYLATION; SRC; BINDING	In quiescent fibroblasts, epidermal growth factor (EGF) receptors (EGFR) are initially concentrated in caveolae but rapidly move out of this membrane domain in response to EGF. To better understand the dynamic localization of EGFR to caveolae, we have studied the behavior of wild-type and mutant receptors expressed in cells lacking endogenous EGFR, AU of the receptors we examined, including those missing the first 274 amino acids or most of the cytoplasmic tail, were constitutively concentrated in caveolae. By contrast, migration from caveolae required EGF binding, an active receptor kinase domain, and at least one of the five tyrosine residues present in the regulatory domain of the receptor. Movement appears to be modulated by Src kinase, is blocked by activators of protein kinase C, and occurs independently of internalization by clathrin-coated pits. Two mutant receptors previously shown to induce an oncogenic phenotype lack the ability to move from caveolae in response to EGF, suggesting that a prolonged residence in this domain may contribute to abnormal cell behavior.	Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, Dallas, TX 75235 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of California System; University of California San Diego	Anderson, GW (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, Dallas, TX 75235 USA.				NCI NIH HHS [CA58689] Funding Source: Medline; NHLBI NIH HHS [HL 20948] Funding Source: Medline; NIGMS NIH HHS [GM 43169] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA058689] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043169] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Antonyak MA, 1998, J BIOL CHEM, V273, P2817, DOI 10.1074/jbc.273.5.2817; Baulida J, 1996, J BIOL CHEM, V271, P5251; BILDER GE, 1991, AM J PHYSIOL, V260, P721; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHEN P, 1994, J CELL BIOL, V124, P547, DOI 10.1083/jcb.124.4.547; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Liu PS, 1997, P NATL ACAD SCI USA, V94, P13666, DOI 10.1073/pnas.94.25.13666; LIVNEH E, 1988, MOL CELL BIOL, V8, P2302, DOI 10.1128/MCB.8.6.2302; LUND KA, 1990, J BIOL CHEM, V265, P20517; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MASUI H, 1991, CANCER RES, V51, P6170; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Moscatello DK, 1996, ONCOGENE, V13, P85; NESTEROV A, 1995, P NATL ACAD SCI USA, V92, P8719, DOI 10.1073/pnas.92.19.8719; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; Prigent SA, 1996, J BIOL CHEM, V271, P25639, DOI 10.1074/jbc.271.41.25639; Ringerike T, 1998, J BIOL CHEM, V273, P16639, DOI 10.1074/jbc.273.27.16639; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; Sasaoka T, 1996, J BIOL CHEM, V271, P8338, DOI 10.1074/jbc.271.14.8338; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; vanderHeyden MAG, 1997, EXP CELL RES, V234, P521, DOI 10.1006/excr.1997.3661; Ware MF, 1997, J BIOL CHEM, V272, P30185, DOI 10.1074/jbc.272.48.30185; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263	47	248	257	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30636	30643		10.1074/jbc.274.43.30636	http://dx.doi.org/10.1074/jbc.274.43.30636			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521449	hybrid			2022-12-27	WOS:000083276700045
J	Hua, YJ; Tanaka, Y; Nakamura, K; Sakakibara, M; Nagata, S; Kataoka, H				Hua, YJ; Tanaka, Y; Nakamura, K; Sakakibara, M; Nagata, S; Kataoka, H			Identification of a prothoracicostatic peptide in the larval brain of the silkworm, Bombyx mori	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRYLLUS-BIMACULATUS ENSIFERA; ECDYSONE BIOSYNTHESIS; MOLECULAR-CLONING; OOSTATIC HORMONE; JUVENILE-HORMONE; MANDUCA-SEXTA; GALANIN; NEUROPEPTIDES; GRYLLIDAE; SEQUENCE	Prothoracicotropic hormone (PTTH) stimulates ecdysteroid biosynthesis in the prothoracic gland (PG) of insects. A peptide inhibiting ecdysteroid biosynthesis in the PG was isolated from the extracts of 2,000 larval brains of the silkworm, Bombyx mori, using a protocol that included four reversed-phase high performance liquid chromatography procedures. The primary structure of this prothoracicostatic peptide (Bom-PTSP) was determined to be H-Ala-Trp-Gln-Asp-Leu-Asn-Ser-Ala-Trp-NH2. This neuropeptide has the same sequence as Mas-MIP-I, a myoinhibitory peptide previously isolated from the ventral nerve cord of the tobacco hornworm, Manduca sexta, and is highly homologous with the N-terminal portion of vertebrate peptides of the galanin family. This peptide inhibited PTTH-stimulated ecdysteroidogenesis in the PG at both the spinning and feeding stages, which indicates that Bom-PTSP interferes with PTTH-stimulated ecdysteroidogenesis.	Natl Inst Sericultural & Entomol Sci, Lab Bioact Subst, Tsukuba, Ibaraki 3058634, Japan; Osaka City Univ, Dept Biol, Sumiyoshi Ku, Osaka 558, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Bunkyo Ku, Tokyo 1130032, Japan	National Institute of Agrobiological Sciences - Japan; Osaka Metropolitan University; University of Tokyo	Tanaka, Y (corresponding author), Natl Inst Sericultural & Entomol Sci, Lab Bioact Subst, Ohwashi 1-2, Tsukuba, Ibaraki 3058634, Japan.							BERSANI M, 1991, FEBS LETT, V283, P189, DOI 10.1016/0014-5793(91)80585-Q; BLACKBURN MB, 1995, REGUL PEPTIDES, V57, P213, DOI 10.1016/0167-0115(95)00034-9; Bollenbacher W.E., 1985, P109; BYLEMANS D, 1994, REGUL PEPTIDES, V50, P61, DOI 10.1016/0167-0115(94)90192-9; CARLISLE DB, 1968, NATURE, V220, P706, DOI 10.1038/220706a0; Chung JS, 1996, NEUROPEPTIDES, V30, P95, DOI 10.1016/S0143-4179(96)90061-X; DONLY BC, 1993, P NATL ACAD SCI USA, V90, P8807, DOI 10.1073/pnas.90.19.8807; HUA YJ, 1995, REGUL PEPTIDES, V57, P263, DOI 10.1016/0167-0115(95)00040-I; HUA YJ, 1994, MOL CELL ENDOCRINOL, V104, pR1; Hua YJ, 1997, ARCH INSECT BIOCHEM, V35, P125, DOI 10.1002/(SICI)1520-6327(1997)35:1/2<125::AID-ARCH11>3.3.CO;2-A; ISHIBASHI J, 1994, BIOCHEMISTRY-US, V33, P5912, DOI 10.1021/bi00185a031; KATAOKA H, 1989, SCIENCE, V243, P1481, DOI 10.1126/science.243.4897.1481; KAWAKAMI A, 1990, SCIENCE, V247, P1333, DOI 10.1126/science.2315701; KELLY TJ, 1986, INSECT BIOCHEM, V16, P273, DOI 10.1016/0020-1790(86)90106-X; KELLY TJ, 1984, J EXP ZOOL, V229, P491, DOI 10.1002/jez.1402290318; Kopec S, 1922, BIOL BULL-US, V42, P323, DOI 10.2307/1536759; LOPEZ FJ, 1991, P NATL ACAD SCI USA, V88, P4508, DOI 10.1073/pnas.88.10.4508; Lorenz JI, 1997, EUR J ENTOMOL, V94, P369; LORENZ MW, 1995, J BIOL CHEM, V270, P21103, DOI 10.1074/jbc.270.36.21103; Lorenz MW, 1998, ARCH INSECT BIOCHEM, V38, P32, DOI 10.1002/(SICI)1520-6327(1998)38:1&lt;32::AID-ARCH4&gt;3.0.CO;2-X; Redfern C.P.F., 1989, P182; SCHOOFS L, 1991, REGUL PEPTIDES, V36, P111, DOI 10.1016/0167-0115(91)90199-Q; TAKEDA S, 1986, Bulletin of the Sericultural Experiment Station (Tokyo), V30, P361; TATEMOTO K, 1983, FEBS LETT, V164, P124, DOI 10.1016/0014-5793(83)80033-7; TEMPEL DL, 1990, BRAIN RES, V536, P353, DOI 10.1016/0006-8993(90)90050-L	25	108	122	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31169	31173		10.1074/jbc.274.44.31169	http://dx.doi.org/10.1074/jbc.274.44.31169			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531308	hybrid			2022-12-27	WOS:000083379400012
J	Nagarajan, RP; Liu, J; Chen, Y				Nagarajan, RP; Liu, J; Chen, Y			Smad3 inhibits transforming growth factor-beta and activin signaling by competing with Smad4 for FAST-2 binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAD-RELATED PROTEIN; TGF-BETA; TUMOR-SUPPRESSOR; INDUCED TRANSCRIPTION; MESODERM FORMATION; DNA-BINDING; RECEPTOR; GENE; IDENTIFICATION; ACTIVATION	Transcriptional regulation by transforming growth factor-p and activin is mediated by interaction of Smad2 and Smad3 with specific transcription factors and/or DNA elements. However, Smad3 behaves differently from Smad2 in regulating transcription by a winged-helix transcription factor, FAST-S, on an activin-responsive element (ARE) in the Xenopus Mix.2 promoter. Smad3 alone was able to stimulate the ARE through FAST-S, but inhibited the ARE transactivation mediated by Smad2/Smad4 following receptor activation. We characterized the functional domains that are involved in these two activities of Smad3, Deletion of the MH1 domain as well as mutations of four lysine residues in the MH1 domain abrogated the inhibitory activity of Smad3, but did not compromise the self-stimulatory function. In contrast, deletion of the MH2 domain or a point mutation of glycine 379 within this domain obliterated the self-stimulatory activity of Smad3, but not the inhibitory activity. In an electrophoretic mobility shift assay, we found that Smad3 was able to associate with the FAST-2.ARE complex and that this association was dependent on FAST-2. In addition, Smad3 was not able to directly bind the ARE in a DNase I protection assay, in which FAST-2 binds the ARE around a motif (TGTG-TATT) previously characterized to associate with the human FAST-1 protein. Interestingly, Smad4 was also able to directly associate with the FAST-2.ARE complex through binding with FAST-2. In a gel shift assay, the association of FAST-2 with Smad4 was mutually exclusive from the association with Smad3. Taken together, these data indicate that Smad3 exerts the inhibitory activity by competitive association with FAST-2.	Indiana Univ, Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Chen, Y (corresponding author), Indiana Univ, Sch Med, Dept Med & Mol Genet, 975 W Walnut St,IB130, Indianapolis, IN 46202 USA.	ychen3@iupui.edu	N, Rajendra Prasad/X-1743-2019	N, Rajendra Prasad/0000-0002-3937-8735				Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Bhushan A, 1998, DEV BIOL, V200, P260, DOI 10.1006/dbio.1998.8965; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen Y, 1997, P NATL ACAD SCI USA, V94, P12938, DOI 10.1073/pnas.94.24.12938; Chen Y, 1996, P NATL ACAD SCI USA, V93, P12992, DOI 10.1073/pnas.93.23.12992; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; HUANG HC, 1995, EMBO J, V14, P5965, DOI 10.1002/j.1460-2075.1995.tb00285.x; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liu B, 1999, MOL CELL BIOL, V19, P424; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Maxam A M, 1980, Methods Enzymol, V65, P499; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakayama T, 1998, DEVELOPMENT, V125, P857; Nomura M, 1998, NATURE, V393, P786, DOI 10.1038/31693; SEKELSKY JJ, 1995, GENETICS, V139, P1347; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Tsuneizumi K, 1997, NATURE, V389, P627, DOI 10.1038/39362; VALE W, 1988, RECENT PROG HORM RES, V44, P1; Waldrip WR, 1998, CELL, V92, P797, DOI 10.1016/S0092-8674(00)81407-5; Weinstein M, 1998, P NATL ACAD SCI USA, V95, P9378, DOI 10.1073/pnas.95.16.9378; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Yamamoto N, 1997, BIOCHEM BIOPH RES CO, V238, P574, DOI 10.1006/bbrc.1997.7325; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	52	39	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31229	31235		10.1074/jbc.274.44.31229	http://dx.doi.org/10.1074/jbc.274.44.31229			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531318	hybrid			2022-12-27	WOS:000083379400022
J	Taylor, SC; Batten, TFC; Peers, C				Taylor, SC; Batten, TFC; Peers, C			Hypoxic enhancement of quantal catecholamine secretion - Evidence for the involvement of amyloid beta-peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE ION CHANNELS; RAT PC12 CELLS; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; CALCIUM CHANNELS; CHROMAFFIN CELLS; GENE-EXPRESSION; CAROTID-BODY; INHIBITION; ISCHEMIA	Prolonged exposure to hypoxia (16% O-2) enhanced quantal catecholamine release evoked from O-2-sensing pheochromocytoma (PC12) cells, as monitored using single-cell amperometric recordings. The enhancement of exocytosis was apparent after 12 h of hypoxia and was maximal at 24 h. Elevated levels of secretion were due to the emergence of a Ca2+ influx pathway that persisted during complete blockade of known voltage-gated Ca2+ channels. Secretion triggered by this Ca2+ influx was severely reduced by known inhibitors of Alzheimer's amyloid beta-peptides (A beta Ps), including an N terminus-directed monoclonal antibody. The enhancing effect on secretion of chronic hypoxia was mimicked closely by direct application of A beta P to cells under normoxic conditions, although the effects of A beta P were more rapid at onset, being maximal after only 6 h. The present results suggest that prolonged hypoxia can induce formation of Ca2+-permeable A beta P channels and that such induction can lead directly to excessive neurosecretion. This is a potential contributory factor to A beta P pathophysiology following cerebral ischemia.	Univ Leeds, Inst Cardiovasc Res, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Peers, C (corresponding author), Univ Leeds, Inst Cardiovasc Res, Leeds LS2 9JT, W Yorkshire, England.			Batten, Trevor/0000-0003-3988-5603; Peers, Chris/0000-0002-8354-346X				ARIAS C, 1995, J NEUROSCI RES, V41, P561, DOI 10.1002/jnr.490410416; Arispe N, 1996, P NATL ACAD SCI USA, V93, P1710, DOI 10.1073/pnas.93.4.1710; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; Behl C, 1997, CELL TISSUE RES, V290, P471, DOI 10.1007/s004410050955; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Catterall WA, 1998, CELL CALCIUM, V24, P307, DOI 10.1016/S0143-4160(98)90055-0; Chow Robert H., 1995, P245; Conforti L, 1997, J PHYSIOL-LONDON, V502, P293, DOI 10.1111/j.1469-7793.1997.293bk.x; CZYZYKKRZESKA MF, 1994, J BIOL CHEM, V269, P760; CZYZYKKRZESKA MF, 1992, J NEUROCHEM, V58, P1538, DOI 10.1111/j.1471-4159.1992.tb11376.x; Fraser SP, 1997, TRENDS NEUROSCI, V20, P67, DOI 10.1016/S0166-2236(96)10079-5; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; JELKMANN W, 1992, PHYSIOL REV, V72, P449, DOI 10.1152/physrev.1992.72.2.449; Jendroska K, 1997, Ann N Y Acad Sci, V826, P401, DOI 10.1111/j.1749-6632.1997.tb48492.x; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Kasai H, 1999, TRENDS NEUROSCI, V22, P88, DOI 10.1016/S0166-2236(98)01293-4; Kawahara M, 1997, BIOPHYS J, V73, P67, DOI 10.1016/S0006-3495(97)78048-2; Kobayashi S, 1998, J PHYSIOL-LONDON, V512, P351, DOI 10.1111/j.1469-7793.1998.351be.x; KOGURE K, 1993, STROKE, V24, P2121, DOI 10.1161/01.STR.24.12.2121; Koistinaho J, 1996, NEUROREPORT, V7, P2727, DOI 10.1097/00001756-199611040-00064; Kokmen E, 1996, NEUROLOGY, V46, P154, DOI 10.1212/WNL.46.1.154; Kumar GK, 1998, AM J PHYSIOL-CELL PH, V274, pC1592, DOI 10.1152/ajpcell.1998.274.6.C1592; Liu HY, 1996, J NEUROSCI, V16, P7557; LOPEZBARNEO J, 1994, TRENDS NEUROSCI, V17, P133, DOI 10.1016/0166-2236(94)90084-1; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; Mojet MH, 1997, J PHYSIOL-LONDON, V504, P175, DOI 10.1111/j.1469-7793.1997.175bf.x; Moroney JT, 1996, STROKE, V27, P1283, DOI 10.1161/01.STR.27.8.1283; Peers C, 1997, TRENDS PHARMACOL SCI, V18, P405; PELZER D, 1989, ANN NY ACAD SCI, V560, P138, DOI 10.1111/j.1749-6632.1989.tb24091.x; Rhee SK, 1998, J BIOL CHEM, V273, P13379, DOI 10.1074/jbc.273.22.13379; SCHUBERT D, 1995, P NATL ACAD SCI USA, V92, P1989, DOI 10.1073/pnas.92.6.1989; SMIRNOV SV, 1994, AM J PHYSIOL, V266, pH365, DOI 10.1152/ajpheart.1994.266.1.H365; TATEMICHI TK, 1994, NEUROLOGY, V44, P1885, DOI 10.1212/WNL.44.10.1885; Taylor SC, 1999, J NEUROCHEM, V73, P874, DOI 10.1046/j.1471-4159.1999.0730874.x; Taylor SC, 1998, BIOCHEM BIOPH RES CO, V248, P13, DOI 10.1006/bbrc.1998.8905; Taylor SC, 1999, J PHYSIOL-LONDON, V514, P483, DOI 10.1111/j.1469-7793.1999.483ae.x; TISCHLER AS, 1983, J NEUROCHEM, V40, P364, DOI 10.1111/j.1471-4159.1983.tb11291.x; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754; WU JQ, 1995, EUR J PHARMACOL, V284, pR1, DOI 10.1016/0014-2999(95)00539-W; WYATT CN, 1995, P NATL ACAD SCI USA, V92, P295, DOI 10.1073/pnas.92.1.295; Yokota M, 1996, J CEREBR BLOOD F MET, V16, P1219, DOI 10.1097/00004647-199611000-00016; Zhu WH, 1996, AM J PHYSIOL-CELL PH, V271, pC658, DOI 10.1152/ajpcell.1996.271.2.C658	44	57	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31217	31222		10.1074/jbc.274.44.31217	http://dx.doi.org/10.1074/jbc.274.44.31217			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531316	hybrid			2022-12-27	WOS:000083379400020
J	Hu, WH; Johnson, H; Shu, HB				Hu, WH; Johnson, H; Shu, HB			Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NF-kappa B and JNK activation and apoptosis through distinct pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1-ASSOCIATED PROTEIN TRADD; FADD-DEPENDENT APOPTOSIS; DEATH DOMAIN; CELL-DEATH; KINASE COMPLEX; MEK KINASE-1; TRAIL; TNF; FAMILY; ALPHA	Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF family that interacts with several receptors, including TRAIL-RI, TRAIL-R2, and TRAIL-R4. TRAIL-R1 and TRAIL-R2 can induce apoptosis of cancer cells and activate the transcription factor NF-kappa B. TRAIL-R4 can activate NF-kappa B and protect cells from TRAIL-induced apoptosis. Here we show that TRAIL-R1-, TRAIL-R2-, and TRAIL-R4-induced NF-kappa B activation are mediated by a TRAF2-NIK-I kappa B kinase alpha/beta signaling cascade but is MEKK1 independent. TRAIL receptors also activate the protein kinase JNK. JNK activation by TRAIL-R1 is mediated by a TRAF2-MEKK1-MKK4 but not the TRAF2-NIL-I kappa B kinase alpha/beta Signaling pathway. We also show that activation of NF-kappa B or overexpression of TRAIL-R4 does not protect TRAIL-R1-induced apoptosis. Moreover, inhibition of NF-kappa B by I kappa B alpha sensitizes cells to tumor necrosis factor- but not TRAIL-induced apoptosis. These findings suggest that TRAIL receptors induce apoptosis, NF-kappa B and JNK activation through distinct signaling pathways, and activation of NF-kappa B is not sufficient for protecting cells from TRAIL-induced apoptosis.	Natl Jewish Med & Res Ctr, Div Basic Immunol, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80206 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Shu, HB (corresponding author), Natl Jewish Med & Res Ctr, Div Basic Immunol, 1400 Jackson St,K516C, Denver, CO 80206 USA.							Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MONGKOLSAPAYA J, 1988, J IMMUNOL, V160, P3; NATAGA DS, 1997, CELL, V88, P355; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Park A, 1996, J BIOL CHEM, V271, P9858, DOI 10.1074/jbc.271.16.9858; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Sambrook J., 2002, MOL CLONING LAB MANU; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Screaton GR, 1997, CURR BIOL, V7, P693, DOI 10.1016/S0960-9822(06)00297-1; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; SHU HB, 1995, J CELL SCI, V108, P2955; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; WINSTON BW, 1995, P NATL ACAD SCI USA, V92, P1614, DOI 10.1073/pnas.92.5.1614; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	45	200	209	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30603	30610		10.1074/jbc.274.43.30603	http://dx.doi.org/10.1074/jbc.274.43.30603			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521444	hybrid			2022-12-27	WOS:000083276700040
J	McFerran, BW; Weiss, JL; Burgoyne, RD				McFerran, BW; Weiss, JL; Burgoyne, RD			Neuronal Ca2+ sensor 1 - Characterization of the myristoylated protein, its cellular effects in permeabilized adrenal chromaffin cells, Ca2+-independent membrane association, and interaction with binding proteins, suggesting a role in rapid Ca2+ signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-DEPENDENT EXOCYTOSIS; REGULATED EXOCYTOSIS; NERVOUS-SYSTEM; CA2+-BINDING PROTEIN; MOLECULAR-CLONING; RHODOPSIN KINASE; ESCHERICHIA-COLI; CYCLIC-AMP; PC12 CELLS; RECOVERIN	Overexpression of frequenin and its orthologue neuronal Ca2+ sensor 1 (NCS-1) has been shown to increase evoked exocytosis in neurons and neuroendocrine cells. The site of action of NCS-1 and its biochemical targets that affect exocytosis are unknown. To allow further investigation of NCS-1 function, we have demonstrated that NCS-1 is a substrate for N-myristoyltransferase and generated recombinant myristoylated NCS-1, The bacterially expressed NCS-1 shows Ca2+-induced conformational changes. The possibility that NCS-1 directly interacts with the exocytotic machinery to enhance exocytosis was tested using digitonin-permeabilized chromaffin cells. Exogenous NCS-1 was retained in permeabilized cells but had no effect on Ca2+-dependent release of catecholamine. In addition, exogenous NCS-1 did not regulate cyclic nucleotide levels in this system. These data suggest that the effects of NCS-1 seen in intact cells are likely to be due to an action on the early steps of stimulus-secretion coupling or on Ca2+ homeostasis. Myristoylated NCS-1 bound to membranes in the absence of Ca2+ and endogenous NCS-1 was tightly membrane-associated. Using biotinylated NCS-1, a series of specific binding proteins were detected in cytosol, chromaffin granule membrane, and microsome fractions of adrenal medulla. These included proteins distinct from those detected by biotinylated calmodulin, demonstrating the presence of multiple specific Ca2+-independent and Ca2+-dependent binding proteins as putative targets for NCS-1 action. A model for NCS-1 function, from these data, indicates a constitutive membrane association independent of Ca2+. This differs from the Ca2+ myristoyl switch model for the closely related recoverin and suggests a possible action in rapid Ca2+ signal transduction in response to local Ca2+ signals.	Univ Liverpool, Physiol Lab, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Burgoyne, RD (corresponding author), Univ Liverpool, Physiol Lab, Crown St, Liverpool L69 3BX, Merseyside, England.	burgoyne@liv.ac.uk	Weiss, Jamie/HHS-2536-2022; Burgoyne, Robert D/P-6641-2019; Burgoyne, Robert/C-6706-2008	Burgoyne, Robert D/0000-0002-9219-0387; Burgoyne, Robert/0000-0002-9219-0387; Weiss, Jamie L/0000-0001-6784-5831				ALI SM, 1989, NATURE, V340, P313, DOI 10.1038/340313a0; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; BILLINGSLEY ML, 1985, P NATL ACAD SCI USA, V82, P7585, DOI 10.1073/pnas.82.22.7585; Braunewell KH, 1997, J NEUROCHEM, V68, P2129; Braunewell KH, 1999, CELL TISSUE RES, V295, P1, DOI 10.1007/s004410051207; BURGOYNE RD, 1993, BIOCHEM J, V293, P305, DOI 10.1042/bj2930305; Burgoyne RD, 1997, FEBS LETT, V414, P349, DOI 10.1016/S0014-5793(97)01031-4; BURGOYNE RD, 1992, NEUROMETHODS, V20, P433; CHAMBERLAIN LH, 1995, J CELL BIOL, V130, P1063, DOI 10.1083/jcb.130.5.1063; CHEN CK, 1995, J BIOL CHEM, V270, P18060, DOI 10.1074/jbc.270.30.18060; COX JA, 1994, J BIOL CHEM, V269, P32807; DECASTRO E, 1995, BIOCHEM BIOPH RES CO, V216, P133, DOI 10.1006/bbrc.1995.2601; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; Faurobert E, 1996, J BIOL CHEM, V271, P10256, DOI 10.1074/jbc.271.17.10256; Glenn DE, 1998, J NEUROCHEM, V71, P2023; Hendricks KB, 1999, NAT CELL BIOL, V1, P234, DOI 10.1038/12058; KLENCHIN VA, 1995, J BIOL CHEM, V270, P16147, DOI 10.1074/jbc.270.27.16147; KOBAYASHI M, 1992, BIOCHEM BIOPH RES CO, V189, P511, DOI 10.1016/0006-291X(92)91587-G; KOBAYASHI M, 1993, J BIOL CHEM, V268, P18898; LADANT D, 1995, J BIOL CHEM, V270, P3179; LENZ SE, 1992, MOL BRAIN RES, V15, P133, DOI 10.1016/0169-328X(92)90160-D; Matsuda S, 1999, BIOCHEMISTRY-US, V38, P1310, DOI 10.1021/bi982117u; McFerran BW, 1998, J BIOL CHEM, V273, P22768, DOI 10.1074/jbc.273.35.22768; MORGAN A, 1993, EMBO J, V12, P3747, DOI 10.1002/j.1460-2075.1993.tb06052.x; MORGAN A, 1992, NATURE, V355, P833, DOI 10.1038/355833a0; MORGAN A, 1995, EMBO J, V14, P232, DOI 10.1002/j.1460-2075.1995.tb06996.x; NEF S, 1995, J RECEPT SIGNAL TR R, V15, P365, DOI 10.3109/10799899509045227; OKAZAKI K, 1992, BIOCHEM BIOPH RES CO, V185, P147, DOI 10.1016/S0006-291X(05)80968-4; Olafsson P, 1997, MOL BRAIN RES, V44, P73, DOI 10.1016/S0169-328X(96)00188-X; OLAFSSON P, 1995, P NATL ACAD SCI USA, V92, P8001, DOI 10.1073/pnas.92.17.8001; Olshevskaya EV, 1997, J BIOL CHEM, V272, P14327, DOI 10.1074/jbc.272.22.14327; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; POULAIN C, 1994, PFLUG ARCH EUR J PHY, V427, P71, DOI 10.1007/BF00585944; RAY S, 1992, P NATL ACAD SCI USA, V89, P5705, DOI 10.1073/pnas.89.13.5705; RIVOSECCHI R, 1994, J PHYSIOL-LONDON, V474, P223, DOI 10.1113/jphysiol.1994.sp020015; Schaad NC, 1996, P NATL ACAD SCI USA, V93, P9253, DOI 10.1073/pnas.93.17.9253; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; VONEULER US, 1955, ACTA PHYSIOL SCAND, V33, P45; ZOZULYA S, 1995, METHOD ENZYMOL, V250, P383; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	41	90	92	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30258	30265		10.1074/jbc.274.42.30258	http://dx.doi.org/10.1074/jbc.274.42.30258			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514519	hybrid			2022-12-27	WOS:000083176400098
J	de Moissac, D; Zheng, H; Kirshenbaum, LA				de Moissac, D; Zheng, H; Kirshenbaum, LA			Linkage of the BH4 domain of Bcl-2 and the nuclear factor kappa B signaling pathway for suppression of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; TUMOR-NECROSIS-FACTOR; TRANSCRIPTION FACTOR; VENTRICULAR MYOCYTES; X-L; ALPHA; PROTEIN; INHIBITION; GENE; ACTIVATION	Nuclear factor (NF) kappa B is a ubiquitously expressed transcription factor whose function is regulated by the cytoplasmic inhibitor protein, I kappa B alpha. We have previously shown that I kappa B alpha activity is diminished in ventricular myocytes expressing Bcl-2, (de Moissac, D., Mustapha, S., Greenberg, A. H., and Kirshenbaum, L. A. (1998) J. Biol. Chem. 273, 23946-23951). In view of the growing evidence that the conserved N-terminal BH4 domain of Bcl-2 plays a critical role in suppressing apoptosis, we ascertained whether this region accounts for the underlying effects of Bcl-2 on I kappa B alpha activity. Transfection of human embryonic 293 cells with full length Bcl-2 resulted in a significant 1.9-fold reduction in I kappa B alpha activity (p < 0.006) with a concomitant increase in DNA binding and 3.4-fold increase in NF kappa B-dependent gene transcription (p < 0.022) compared with vector transfected control cells. In contrast, no significant change in I kappa B alpha activity was detected with either a BH4 domain deletion mutant (residues 10-30) or BH4 domain point substitution mutants, I14G, V15G, Y18G, K22G, and L23G (p = 2.77). However, a small 0.60-fold decrease (p < 0.04) in I kappa B alpha activity was noted with the BH4 mutant I19G, suggesting that this residue may not be critical for I kappa B alpha regulation. Furthermore, adenovirus-mediated delivery of an I kappa B alpha mutant to prevent NF kappa B activation impaired the ability of Bcl-2 to suppress apoptosis provoked by TNF alpha plus cycloheximide in ventricular myocytes, The data provide the first evidence for the regulation of I kappa B alpha by Bcl-2 through a mechanism that requires the conserved BH4 domain that links Bcl-2 to the NF kappa B signaling pathway for suppression of apoptosis.	St Boniface Gen Hosp, Res Ctr, Inst Cardiovasc Sci, Winnipeg, MB R2H 2A6, Canada; Univ Manitoba, Fac Med, Dept Physiol, Winnipeg, MB R2H 2A6, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba	Kirshenbaum, LA (corresponding author), St Boniface Gen Hosp, Res Ctr, Inst Cardiovasc Sci, Rm 3016,351 Tache Ave, Winnipeg, MB R2H 2A6, Canada.		Kirshenbaum, Lorrie A./F-5742-2014	Ryplanski, Kairee/0000-0002-3737-7181				BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALLARD DW, 1984, J BIOL CHEM, V259, P3492; Barkett M, 1997, J BIOL CHEM, V272, P29419, DOI 10.1074/jbc.272.47.29419; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; de Moissac D, 1998, J BIOL CHEM, V273, P23946, DOI 10.1074/jbc.273.37.23946; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; Hackam AS, 1998, J CELL BIOL, V141, P1097, DOI 10.1083/jcb.141.5.1097; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Huang DCS, 1998, EMBO J, V17, P1029, DOI 10.1093/emboj/17.4.1029; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; IVANOV VN, 1995, INT IMMUNOL, V7, P1709, DOI 10.1093/intimm/7.11.1709; KIRSHENBAUM LA, 1995, J BIOL CHEM, V270, P7791, DOI 10.1074/jbc.270.14.7791; Kirshenbaum LA, 1997, CIRCULATION, V96, P1580, DOI 10.1161/01.CIR.96.5.1580; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; LAURENTCRAWFORD AG, 1991, VIROLOGY, V185, P829, DOI 10.1016/0042-6822(91)90554-O; Lee LC, 1996, J BIOL CHEM, V271, P23284, DOI 10.1074/jbc.271.38.23284; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Olivetti G, 1997, NEW ENGL J MED, V336, P1131, DOI 10.1056/NEJM199704173361603; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Reed JC, 1997, SEMIN HEMATOL, V34, P9; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; SHIBASAKI F, 1995, J CELL BIOL, V131, P735, DOI 10.1083/jcb.131.3.735; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; URBAN MB, 1991, NEW BIOL, V3, P279; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WARTERS RL, 1992, CANCER RES, V52, P883; WILLIAMS RS, 1993, AM J MED SCI, V306, P129, DOI 10.1097/00000441-199308000-00013; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	41	72	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29505	29509		10.1074/jbc.274.41.29505	http://dx.doi.org/10.1074/jbc.274.41.29505			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506215	hybrid			2022-12-27	WOS:000083017800094
J	Liu, CWY; Wang, RH; Dohadwala, M; Schonthal, AH; Villa-Moruzzi, E; Berndt, N				Liu, CWY; Wang, RH; Dohadwala, M; Schonthal, AH; Villa-Moruzzi, E; Berndt, N			Inhibitory phosphorylation of PP1 alpha catalytic subunit during the G(1)/S transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; TYPE-1 PROTEIN PHOSPHATASE; RETINOBLASTOMA PROTEIN; S-PHASE; AFFINITY-CHROMATOGRAPHY; FUNCTIONAL INACTIVATION; CELL-PROLIFERATION; RESTRICTION POINT; GENE; RB	We have shown earlier that, in cells expressing the retinoblastoma protein (pRB), a protein phosphatase (PP) 1 alpha mutant (T320A) resistant to inhibitory phosphorylation by cyclin-dependent kinases (Cdks) causes G(1) arrest. In this study, we examined the cell cycle-dependent phosphorylation of PP1 alpha in, vivo using three different antibodies. PP1 alpha was phosphorylated at Thr-320 during M-phase and again in late G(1)- through early S-phase. Inhibition of Cdk2 led to a small increase in PP1 activity and also prevented PP1 alpha phosphorylation. In vitro, PP1 alpha was a substrate for Cdk2 but not Cdk4. In pRB-deficient cells, phosphorylation of PP1 alpha occurred in RI-phase but not at G(1)/S G(1)/S phosphorylation was at least partially restored after reintroduction of pRB into these cells. Consistent with this result, PP1 alpha phosphorylated at Thr-320 co-precipitated with pRB during G(1)/S but was found in extracts immunodepleted of pRB in M-phase. In conjunction with earlier studies, these results indicate that PP1 alpha may control PRE function throughout the cell cycle. In addition, our new results suggest that different subpopulations of PP1 alpha regulate the G(1)/S and G(2)/M transitions and that PP1 alpha complexed to pRB requires inhibitory phosphorylation by G(1)-specific Cdks in order to prevent untimely reactivation of PRE and permit transition from G(1)- to S-phase and/or complete S-phase.	Univ So Calif, Childrens Hosp Los Angeles, Sch Med, Div Hematol Oncol, Los Angeles, CA 90027 USA; Univ So Calif, Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA; Univ Pisa, Dipartimento Patol Sperimentale, I-56126 Pisa, Italy	Children's Hospital Los Angeles; University of Southern California; University of Southern California; University of Pisa	Berndt, N (corresponding author), Univ So Calif, Childrens Hosp Los Angeles, Sch Med, Div Hematol Oncol, 4650 Sunset Blvd, Los Angeles, CA 90027 USA.		Schonthal, Axel/ABH-3846-2020		NATIONAL CANCER INSTITUTE [R01CA054167] Funding Source: NIH RePORTER; NCI NIH HHS [CA-54167] Funding Source: Medline; Telethon [1112] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Telethon(Fondazione Telethon)		ABRAHAM RT, 1995, BIOL CELL, V83, P105, DOI 10.1016/0248-4900(96)81298-6; ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; Allen PB, 1998, J BIOL CHEM, V273, P4089, DOI 10.1074/jbc.273.7.4089; AXTON JM, 1990, CELL, V63, P33, DOI 10.1016/0092-8674(90)90286-N; Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Berndt N, 1997, CURR BIOL, V7, P375, DOI 10.1016/S0960-9822(06)00185-0; BERNDT N, 1995, ADV PROTEIN PHOSPHAT, V9, P63; Berndt Norbert, 1999, Frontiers in Bioscience, V4, pD22, DOI 10.2741/Berndt; BOOHER R, 1989, CELL, V57, P1009, DOI 10.1016/0092-8674(89)90339-5; BRAUTIGAN DL, 1990, NATURE, V344, P74, DOI 10.1038/344074a0; BRAUTIGAN DL, 1995, SEMIN CANCER BIOL, V6, P211, DOI 10.1006/scbi.1995.0028; Campos M, 1996, J BIOL CHEM, V271, P28478, DOI 10.1074/jbc.271.45.28478; Cayrol C, 1998, ONCOGENE, V17, P2437, DOI 10.1038/sj.onc.1202189; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; Dohadwala M, 1998, METH MOL B, V93, P191; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; DOONAN JH, 1989, CELL, V57, P987, DOI 10.1016/0092-8674(89)90337-1; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EGLOFF MP, 1995, J MOL BIOL, V254, P942, DOI 10.1006/jmbi.1995.0667; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; FERNANDEZ A, 1992, J CELL BIOL, V116, P1421, DOI 10.1083/jcb.116.6.1421; FUNG YKT, 1993, ONCOGENE, V8, P2659; GLAB N, 1994, FEBS LETT, V353, P207, DOI 10.1016/0014-5793(94)01035-8; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; Kakinoki Y, 1997, J BIOL CHEM, V272, P32308, DOI 10.1074/jbc.272.51.32308; King KL, 1998, ANNU REV PHYSIOL, V60, P601, DOI 10.1146/annurev.physiol.60.1.601; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P2168, DOI 10.1073/pnas.94.6.2168; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; Lundberg AS, 1999, EUR J CANCER, V35, P531; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Morana SJ, 1996, J BIOL CHEM, V271, P18263, DOI 10.1074/jbc.271.30.18263; Mueller Daniel, 1997, Oncogene, V15, P2561; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Oliver Carey J., 1998, Frontiers in Bioscience, V3, pD961; PlanasSilva MD, 1997, CURR OPIN CELL BIOL, V9, P768, DOI 10.1016/S0955-0674(97)80076-2; Puntoni F, 1997, ARCH BIOCHEM BIOPHYS, V340, P177, DOI 10.1006/abbi.1997.9889; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; RUNNEGAR M, 1995, BIOCHEM BIOPH RES CO, V216, P162, DOI 10.1006/bbrc.1995.2605; SCHONTHAL A, 1993, ONCOGENE, V8, P433; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; VILLAMORUZZI E, 1991, FEBS LETT, V293, P67, DOI 10.1016/0014-5793(91)81154-Z; YAMANO H, 1994, EMBO J, V13, P5310, DOI 10.1002/j.1460-2075.1994.tb06865.x; Zhao SM, 1996, ARCH BIOCHEM BIOPHYS, V325, P82, DOI 10.1006/abbi.1996.0010	51	80	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29470	29475		10.1074/jbc.274.41.29470	http://dx.doi.org/10.1074/jbc.274.41.29470			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506210	hybrid			2022-12-27	WOS:000083017800089
J	Petukhova, G; Van Komen, S; Vergano, S; Klein, H; Sung, P				Petukhova, G; Van Komen, S; Vergano, S; Klein, H; Sung, P			Yeast Rad54 promotes Rad51-dependent homologous DNA pairing via ATP hydrolysis-driven change in DNA double helix conformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; REPLICATION PROTEIN-A; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; MEIOTIC RECOMBINATION; COMPLEX-FORMATION; DEPENDENT ATPASE; BINDING-PROTEIN; REPAIR PROTEIN; RECA PROTEIN	Saccharomyces cerevisiae RAD54 gene functions in the formation of heteroduplex DNA, a key intermediate in recombination processes. Rad54 is monomeric in solution, but forms a dimer/oligomer on DNA. Rad54 dimer/oligomer alters the conformation of the DNA double helix in an ATP-dependent manner, as revealed by a change in the DNA linking number in a topoisomerase I-linked reaction. DNA conformational alteration does not occur in the presence of non-hydrolyzable ATP analogues, nor when mutant rad54 proteins defective in ATP hydrolysis replace Rad54. Accordingly the Rad54 ATPase activity is shown to be required for biological function in vivo and for promoting Rad51-mediated homologous DNA pairing in vitro, Taken together, the results are consistent with a model in which a Rad54 dimer/oligomer promotes nascent heteroduplex joint formation via a specific interaction with Rad51 protein and an ability to transiently unwind duplex DNA.	Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA; NYU, Sch Med, Dept Biochem, New York, NY 10016 USA; NYU, Sch Med, Kaplan Canc Ctr, New York, NY 10016 USA	University of Texas System; University of Texas Health San Antonio; New York University; New York University	Klein, H (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA.	kleinh01@mcrcr.med.nyu.edu; sung@uthscsa.edu		Klein, Hannah/0000-0003-4228-8535	NIEHS NIH HHS [ES07061] Funding Source: Medline; NIGMS NIH HHS [GM57814, GM53738] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057814, R01GM053738] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGUILERA A, 1988, GENETICS, V119, P779; Bai Y, 1996, GENE DEV, V10, P2025, DOI 10.1101/gad.10.16.2025; Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Clever B, 1997, EMBO J, V16, P2535, DOI 10.1093/emboj/16.9.2535; Cox MM, 1998, GENES CELLS, V3, P65, DOI 10.1046/j.1365-2443.1998.00175.x; Dresser ME, 1997, GENETICS, V147, P533; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; Furuse M, 1998, EMBO J, V17, P6412, DOI 10.1093/emboj/17.21.6412; GAME JC, 1993, SEMIN CANCER BIOL, V4, P73; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; Gupta RC, 1999, J BIOL CHEM, V274, P1248, DOI 10.1074/jbc.274.3.1248; HARRIS LD, 1989, J MOL BIOL, V206, P19, DOI 10.1016/0022-2836(89)90520-2; He ZG, 1996, J BIOL CHEM, V271, P28243, DOI 10.1074/jbc.271.45.28243; JIANG H, 1993, J BIOL CHEM, V268, P7904; Jiang H, 1996, J BIOL CHEM, V271, P33181, DOI 10.1074/jbc.271.52.33181; Kanaar R, 1996, CURR BIOL, V6, P828, DOI 10.1016/S0960-9822(02)00606-1; Kanaar R, 1998, NATURE, V391, P335, DOI 10.1038/34790; Klein HL, 1997, GENETICS, V147, P1533; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; Moreau S, 1999, MOL CELL BIOL, V19, P556; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; RANDERATH K, 1964, J CHROMATOGR, V16, P111, DOI 10.1016/S0021-9673(01)82445-6; REHRAUER WM, 1993, J BIOL CHEM, V268, P1292; Shan Q, 1996, J BIOL CHEM, V271, P5712, DOI 10.1074/jbc.271.10.5712; Shinohara A, 1998, NATURE, V391, P404, DOI 10.1038/34943; Shinohara M, 1997, GENETICS, V147, P1545; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUNG P, 1987, P NATL ACAD SCI USA, V84, P6045, DOI 10.1073/pnas.84.17.6045; Sung P, 1996, J BIOL CHEM, V271, P27983, DOI 10.1074/jbc.271.45.27983; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; Swagemakers SMA, 1998, J BIOL CHEM, V273, P28292, DOI 10.1074/jbc.273.43.28292; Sweezy MA, 1997, J MOL BIOL, V266, P927, DOI 10.1006/jmbi.1996.0829; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Tan TLR, 1999, CURR BIOL, V9, P325, DOI 10.1016/S0960-9822(99)80142-0; Trujillo KM, 1998, J BIOL CHEM, V273, P21447, DOI 10.1074/jbc.273.34.21447; UMEZU K, 1993, P NATL ACAD SCI USA, V90, P3875, DOI 10.1073/pnas.90.9.3875; Usui T, 1998, CELL, V95, P705, DOI 10.1016/S0092-8674(00)81640-2; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Wong I, 1995, METHOD ENZYMOL, V259, P95; YONESAKI T, 1989, J BIOL CHEM, V264, P7814	55	156	158	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29453	29462		10.1074/jbc.274.41.29453	http://dx.doi.org/10.1074/jbc.274.41.29453			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506208	hybrid			2022-12-27	WOS:000083017800087
J	Xu, XM; Shi, YC; Wu, X; Gambetti, P; Sui, DX; Cui, MZ				Xu, XM; Shi, YC; Wu, X; Gambetti, P; Sui, DX; Cui, MZ			Identification of a novel PSD-95/Dlg/ZO-1 (PDZ)-like protein interacting with the C terminus of presenilin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; FAMILIAL ALZHEIMERS-DISEASE; SIGNALING COMPLEXES; PDZ DOMAINS; GENE; CELLS; RECOGNITION; PEPTIDE; ELEGANS	Presenilin-1 (PS-l) is the most causative Alzheimer gene product, and its function is not well understood. In an attempt to elucidate the function of PS-l, we screened a human brain cDNA library for PS-l-interacting proteins using the yeast two-hybrid system and isolated a novel protein containing a PSD-95/Dlg/ZO-1 (PDZ)-like domain. This novel PS l-associated protein (PSAP) shares a significant similarity with a Caenorhabditis elegans protein of unknown function. Northern blot analysis revealed that PSAP is predominantly expressed in the brain. Deletion of the first four C-terminal amino acid residues of PS-l, which contain the PDZ domain-binding motif (Gln-Phe-Tyr-Ile), reduced the binding activity of PS-l toward PSAP 4-fold. These data suggest that PS-l may associate with a PDZ-Iike domain-containing protein in vivo and thus may participate in receptor or channel clustering and intracellular signaling events in the brain.	Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA; Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA	Case Western Reserve University; Michigan State University; Cleveland Clinic Foundation	Xu, XM (corresponding author), Univ Tennessee, Dept Pathol, 2407 River Dr, Knoxville, TN 37996 USA.			xu, xuemin/0000-0002-7426-272X; Cui, Mei-Zhen/0000-0003-4745-6999	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R35AG008992, P50AG008012] Funding Source: NIH RePORTER; NIA NIH HHS [AG08992, P50 AG08012] Funding Source: Medline; NINDS NIH HHS [NS-37869-01] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; Dewji NN, 1997, P NATL ACAD SCI USA, V94, P14025, DOI 10.1073/pnas.94.25.14025; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Guo Q, 1997, J NEUROSCI, V17, P4212; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kato A, 1998, J BIOL CHEM, V273, P23969, DOI 10.1074/jbc.273.37.23969; Lehmann S, 1997, J BIOL CHEM, V272, P12047, DOI 10.1074/jbc.272.18.12047; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Malin SA, 1998, NEUROBIOL DIS, V4, P398, DOI 10.1006/nbdi.1998.0167; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Ranganathan R, 1997, CURR BIOL, V7, pR770, DOI 10.1016/S0960-9822(06)00401-5; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Smine A, 1998, J BIOL CHEM, V273, P16281, DOI 10.1074/jbc.273.26.16281; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Vito P, 1997, J BIOL CHEM, V272, P28315, DOI 10.1074/jbc.272.45.28315; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Yamamoto A, 1996, BIOCHEM BIOPH RES CO, V226, P536, DOI 10.1006/bbrc.1996.1390	25	43	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32543	32546		10.1074/jbc.274.46.32543	http://dx.doi.org/10.1074/jbc.274.46.32543			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551805	hybrid			2022-12-27	WOS:000083623000005
J	Belman, C; Espinosa, E; Poupot, R; Peyrat, MA; Guiraud, M; Poquet, Y; Bonneville, M; Fournie, JJ				Belman, C; Espinosa, E; Poupot, R; Peyrat, MA; Guiraud, M; Poquet, Y; Bonneville, M; Fournie, JJ			3-formyl-1-butyl pyrophosphate A novel mycobacterial metabolite-activating human gamma delta T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERPENOID BIOSYNTHESIS; NONPEPTIDE ANTIGENS; STIMULATION; 5-PHOSPHATE; LIGANDS; PATHWAY; RECOGNITION; LYMPHOCYTES; PRECURSOR; PYRIDOXOL	Most human blood gamma delta T cells react without major histocompatibility complex restriction to small phosphorylated nonpeptide antigens (phosphoantigens) that are abundantly produced by mycobacteria and several other microbial pathogens. Although isopentenyl pyrophosphate has been identified as a mycobacterial antigen for gamma delta T cells, the structure of several other stimulating compounds with bioactivities around 1000-fold higher than isopentenyl pyrophosphate remains to be elucidated. This paper describes the structural identification of 3-formyl-1-butyl-pyrophosphate as the core of several non-prenyl mycobacterial phosphoantigens bioactive at the nM range. Recognition of this molecule by gamma delta T cells is very selective and relies on its aldehyde and pyrophosphate groups. This novel pyrophosphorylated aldehyde most probably corresponds to a metabolic intermediate of the non-mevalonate pathway of prenyl phosphate biosynthesis in eubacteria and algae. The reactivity to 3-formyl-1-butyl-pyrophosphate supports the view that human gamma delta T cells are physiologically devoted to antimicrobial surveillance.	CHU Purpan, INSERM, U395, F-31024 Toulouse, France; Inst Biol, INSERM, U463, F-44035 Nantes, France; CNRS, Inst Pharmacol & Biol Struct, F-31077 Toulouse, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Fournie, JJ (corresponding author), CHU Purpan, INSERM, U395, BP3028, F-31024 Toulouse, France.	fournie@purpan.inserm.fr	espinosa, eric/E-4872-2013; Fournie, Jean-Jacques/J-7805-2013	espinosa, eric/0000-0002-3512-0921; Fournie, Jean-Jacques/0000-0001-6542-6908				BELMANT C, 1998, NOUVEAUX COMPOSES PH; BLMANT C, 1998, NOUVEAUX COMPOSES PH; BORCH RF, 1971, J AM CHEM SOC, V93, P2897, DOI 10.1021/ja00741a013; Boullier S, 1998, EUR J IMMUNOL, V28, P3399, DOI 10.1002/(SICI)1521-4141(199811)28:11<3399::AID-IMMU3399>3.0.CO;2-W; Bukowski JF, 1998, J IMMUNOL, V161, P286; BURK MR, 1995, EUR J IMMUNOL, V25, P2052, DOI 10.1002/eji.1830250737; CASORATI G, 1989, J EXP MED, V170, P1521, DOI 10.1084/jem.170.5.1521; CIACHINO C, 1994, EUR J IMMUNOL, V24, P1914; CONSTANT P, 1994, SCIENCE, V264, P267, DOI 10.1126/science.8146660; CONSTANT P, 1995, THESIS U P SABATIER, P168; DAVISSON VJ, 1986, J ORG CHEM, V51, P4768, DOI 10.1021/jo00375a005; DELIBERO G, 1991, CURR TOP MICROBIOL, V173, P235; DeLibero G, 1997, IMMUNOL TODAY, V18, P22, DOI 10.1016/S0167-5699(97)80010-2; Fischer S, 1996, IMMUNOL LETT, V52, P69, DOI 10.1016/0165-2478(96)02584-9; Fournie JJ, 1996, RES IMMUNOL, V147, P338, DOI 10.1016/0923-2494(96)89648-9; Halary F, 1997, EUR J IMMUNOL, V27, P2812, DOI 10.1002/eji.1830271111; HOLOSHITZ J, 1993, INT IMMUNOL, V5, P1437, DOI 10.1093/intimm/5.11.1437; LANG F, 1995, J IMMUNOL, V154, P5986; Lois LM, 1998, P NATL ACAD SCI USA, V95, P2105, DOI 10.1073/pnas.95.5.2105; MINGARI MC, 1989, INT J CANCER, P39; MORITA CT, 1995, IMMUNITY, V3, P495, DOI 10.1016/1074-7613(95)90178-7; NAG B, 1992, J IMMUNOL, V148, P2040; PARKER CM, 1990, J EXP MED, V171, P1597, DOI 10.1084/jem.171.5.1597; Poquet Y, 1996, EUR J IMMUNOL, V26, P2344, DOI 10.1002/eji.1830261011; Poquet Y, 1996, ANAL BIOCHEM, V243, P119, DOI 10.1006/abio.1996.0489; PUTRA SR, 1997, ISOPRENOID BIOSYNTHE; Rohmer M, 1996, J AM CHEM SOC, V118, P2564, DOI 10.1021/ja9538344; ROHMER M, 1993, BIOCHEM J, V295, P517, DOI 10.1042/bj2950517; Sprenger GA, 1997, P NATL ACAD SCI USA, V94, P12857, DOI 10.1073/pnas.94.24.12857; Takahashi S, 1998, P NATL ACAD SCI USA, V95, P9879, DOI 10.1073/pnas.95.17.9879; TANAKA Y, 1995, NATURE, V375, P155, DOI 10.1038/375155a0; Tanaka Y, 1996, J MOL MED-JMM, V74, P223, DOI 10.1007/BF00196576; TANAKA Y, 1994, P NATL ACAD SCI USA, V91, P8175, DOI 10.1073/pnas.91.17.8175	33	95	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32079	32084		10.1074/jbc.274.45.32079	http://dx.doi.org/10.1074/jbc.274.45.32079			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542241	hybrid			2022-12-27	WOS:000083532100049
J	Dodelet, VC; Pazzagli, C; Zisch, AH; Hauser, CA; Pasquale, EB				Dodelet, VC; Pazzagli, C; Zisch, AH; Hauser, CA; Pasquale, EB			A novel signaling intermediate, SHEP1, directly couples Eph receptors to R-Ras and Rap1A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; FOCAL ADHESION KINASE; EXCHANGE FACTOR; VAV PROTOONCOGENE; NEURAL DEVELOPMENT; LIGAND ACTIVATION; GDP/GTP EXCHANGE; SEC7 DOMAIN; IN-VITRO; FAMILY	The Eph family of receptor tyrosine kinases has been implicated in many developmental patterning processes, including cell segregation, cell migration, and axon guidance. The cellular components involved in the signaling pathways of the Eph receptors, however, are incompletely characterized. Using a yeast two-hybrid screen, we have identified a novel signaling intermediate, SHEP1 (SH2 domain-containing Eph receptor-binding protein 1), which is expressed in the embryonic and adult brain. SHEP1 contains an Src homology 2 domain that binds to a conserved tyrosine-phosphorylated motif in the juxtamembrane region of the EphB2 receptor and may itself be a target of EphB2 kinase activity, since it becomes heavily tyrosine-phosphorylated in cells expressing activated EphB2, SHEP1 also contains a domain similar to Ras guanine nucleotide exchange factor domains and binds to the GTPases R-Ras and Rap1A, but not Ha-Ras or Ra1A, Thus, SHEP1 directly links activated, tyrosine-phosphorylated Eph receptors to small Ras superfamily GTPases.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Pasquale, EB (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	elenap@ljcrf.edu			NICHD NIH HHS [HD25938, HD26351] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD026351, P01HD025938, R01HD026351] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bairoch A, 1996, NUCLEIC ACIDS RES, V24, P189, DOI 10.1093/nar/24.1.189; Baouz S, 1997, J BIOL CHEM, V272, P6671, DOI 10.1074/jbc.272.10.6671; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Bruckner K, 1998, CURR OPIN NEUROBIOL, V8, P375, DOI 10.1016/S0959-4388(98)80064-0; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Cherfils J, 1998, NATURE, V392, P101, DOI 10.1038/32210; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Collins TL, 1997, IMMUNOL TODAY, V18, P221; Corbalan-Garcia S, 1998, MOL CELL BIOL, V18, P880, DOI 10.1128/MCB.18.2.880; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; Drescher U, 1997, CURR BIOL, V7, pR799, DOI 10.1016/S0960-9822(06)00409-X; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; Ellis C, 1996, ONCOGENE, V12, P1727; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Flanagan JG, 1997, CELL, V90, P403; Garcia-Guzman M, 1999, J BIOL CHEM, V274, P5762, DOI 10.1074/jbc.274.9.5762; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; Huff SY, 1997, ONCOGENE, V14, P133, DOI 10.1038/sj.onc.1200815; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Huynh-Do U, 1999, EMBO J, V18, P2165, DOI 10.1093/emboj/18.8.2165; Ichiba T, 1999, J BIOL CHEM, V274, P14376, DOI 10.1074/jbc.274.20.14376; Lu YM, 1999, J BIOL CHEM, V274, P10047, DOI 10.1074/jbc.274.15.10047; Meima L, 1997, MOL CELL NEUROSCI, V9, P314, DOI 10.1006/mcne.1997.0621; Meima L, 1997, EUR J NEUROSCI, V9, P177, DOI 10.1111/j.1460-9568.1997.tb01365.x; Miranti CK, 1998, CURR BIOL, V8, P1289, DOI 10.1016/S0960-9822(07)00559-3; Mossessova E, 1998, CELL, V92, P415, DOI 10.1016/S0092-8674(00)80933-2; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; Nagase T., 1996, DNA RES, V3; Olson MF, 1996, CURR BIOL, V6, P1628, DOI 10.1016/S0960-9822(02)70786-0; PANDEY A, 1994, J BIOL CHEM, V269, P30154; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; Pasquale EB, 1997, CURR OPIN CELL BIOL, V9, P608, DOI 10.1016/S0955-0674(97)80113-5; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Qian XL, 1998, MOL CELL BIOL, V18, P771, DOI 10.1128/MCB.18.2.771; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; SHAO HN, 1994, J BIOL CHEM, V269, P26606; SOANS C, 1994, ONCOGENE, V9, P3353; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; van Agthoven T, 1998, EMBO J, V17, P2799, DOI 10.1093/emboj/17.10.2799; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; Zisch AH, 1998, ONCOGENE, V16, P2657, DOI 10.1038/sj.onc.1201823; ZMUIDZINAS A, 1995, EMBO J, V14, P1	55	86	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31941	31946		10.1074/jbc.274.45.31941	http://dx.doi.org/10.1074/jbc.274.45.31941			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542222	hybrid			2022-12-27	WOS:000083532100030
J	Han, KH; Green, SR; Tangirala, RK; Tanaka, S; Quehenberger, O				Han, KH; Green, SR; Tangirala, RK; Tanaka, S; Quehenberger, O			Role of the first extracellular loop in the functional activation of CCR2 - The first extracellular loop contains distinct domains necessary for both agonist binding and transmembrane signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; AMINO-TERMINAL DOMAIN; HIGH-AFFINITY BINDING; CHEMOKINE RECEPTOR; MOLECULAR-CLONING; LIGAND-BINDING; INTERLEUKIN-8 RECEPTOR; MULTIPLE DOMAINS; EXPRESSION; IDENTIFICATION	The physiological cellular responses to monocyte che moattractant protein-1 (MCP-1), a potent chemotactic and activating factor for mononuclear leukocytes, are mediated by specific binding to CCR2, The aim of this investigation is to identify receptor microdomains that are involved in high affinity agonist binding and receptor activation, The results from our functional studies in which we utilized neutralizing antisera against CCR2 are consistent with a multidomain binding model, previously proposed by others. The first extracellular loop was of particular interest, because in addition to a ligand-binding domain it contained also information for receptor activation, crucial for transmembrane signaling. Replacement of the first extracellular loop of CCR2 with the corresponding region of CCR1 decreased the MCP-1 binding affinity about 10-fold and prevented transmembrane signaling. A more detailed analysis by site directed mutagenesis revealed that this receptor segment contains two distinct microdomains. The amino acid residues Asn(104) and Glu(105) are. essential for high affinity agonist binding but are not involved in receptor activation. In contrast, the charged amino acid residue His(100) does not contribute to ligand binding but is vital for receptor activation and initiation of transmembrane signaling; We hypothesize that the interaction of agonist with this residue initiates the conformational switch that allows the formation of the functional CCR2-G protein complex.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Quehenberger, O (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	oquehenberger@ucsd.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056989] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI041719] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56989-01] Funding Source: Medline; NIAID NIH HHS [AI41719-01A1] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahuja SK, 1996, J BIOL CHEM, V271, P225, DOI 10.1074/jbc.271.1.225; Arai H, 1996, J BIOL CHEM, V271, P21814, DOI 10.1074/jbc.271.36.21814; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Boring L, 1997, J CLIN INVEST, V100, P2552, DOI 10.1172/JCI119798; CARR MW, 1994, P NATL ACAD SCI USA, V91, P3652, DOI 10.1073/pnas.91.9.3652; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; Frade JMR, 1997, J CLIN INVEST, V100, P497, DOI 10.1172/JCI119558; Gong JH, 1996, J BIOL CHEM, V271, P10521, DOI 10.1074/jbc.271.18.10521; GONG JH, 1995, J EXP MED, V181, P631, DOI 10.1084/jem.181.2.631; Gong JH, 1997, J EXP MED, V186, P131, DOI 10.1084/jem.186.1.131; Han KH, 1999, J LIPID RES, V40, P1053; Han KH, 1998, ARTERIOSCL THROM VAS, V18, P1983, DOI 10.1161/01.ATV.18.12.1983; HEBERT CA, 1993, J BIOL CHEM, V268, P18549; Hebert TE, 1998, BIOCHEM CELL BIOL, V76, P1, DOI 10.1139/bcb-76-1-1; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Kuang YN, 1996, J BIOL CHEM, V271, P3975; KUNA P, 1992, J EXP MED, V175, P489, DOI 10.1084/jem.175.2.489; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Kurihara T, 1997, J EXP MED, V186, P1757, DOI 10.1084/jem.186.10.1757; Kuziel WA, 1997, P NATL ACAD SCI USA, V94, P12053, DOI 10.1073/pnas.94.22.12053; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; Lazareno S, 1997, Methods Mol Biol, V83, P107; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Monteclaro FS, 1996, J BIOL CHEM, V271, P19084, DOI 10.1074/jbc.271.32.19084; Monteclaro FS, 1997, J BIOL CHEM, V272, P23186, DOI 10.1074/jbc.272.37.23186; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MYERS SJ, 1995, J BIOL CHEM, V270, P5786, DOI 10.1074/jbc.270.11.5786; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; Prossnitz ER, 1999, BIOCHEMISTRY-US, V38, P2240, DOI 10.1021/bi982274t; QUEHENBERGER O, 1993, J BIOL CHEM, V268, P18167; Quehenberger O, 1997, BIOCHEM BIOPH RES CO, V238, P377, DOI 10.1006/bbrc.1997.7298; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738; Tangirala RK, 1997, J BIOL CHEM, V272, P8050, DOI 10.1074/jbc.272.12.8050; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; YAMAGAMI S, 1994, BIOCHEM BIOPH RES CO, V202, P1156, DOI 10.1006/bbrc.1994.2049; YE RD, 1994, CHALL MOD MED, V3, P141; YOSHIMURA T, 1990, J IMMUNOL, V145, P292; YOSHIMURA T, 1989, J EXP MED, V169, P1449, DOI 10.1084/jem.169.4.1449; ZHANG YJ, 1994, J BIOL CHEM, V269, P15918	41	45	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32055	32062		10.1074/jbc.274.45.32055	http://dx.doi.org/10.1074/jbc.274.45.32055			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542238	hybrid			2022-12-27	WOS:000083532100046
J	Luo, H; Gilinger, G; Mukherjee, D; Bellofatto, V				Luo, H; Gilinger, G; Mukherjee, D; Bellofatto, V			Transcription initiation at the TATA-less spliced leader RNA gene promoter requires at least two DNA-binding proteins and a tripartite architecture that includes an initiator element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINI-EXON GENE; TRYPANOSOMA-BRUCEI; POLYMERASE-II; SMALL NUCLEAR; LEPTOMONAS-SEYMOURI; SNRNA GENES; SL RNA; EXPRESSION; SEQUENCE; U2	Eukaryotic transcriptional regulatory signals, defined as core and activator promoter elements, have yet to be identified in the earliest diverging group of eukaryotes, the primitive protozoans, which include the Trypanosomatidae family of parasites. The divergence within this family is highlighted by the apparent absence of the "universal" transcription factor TATA-binding protein. To understand gene expression in these protists, we have investigated spliced leader RNA gene transcription. The RNA product of this gene provides an m(7)G cap and a 39-nucleotide leader sequence to all cellular mRNAs via a trans-splicing reaction. Regulation of spliced leader RNA synthesis is controlled by a tripartite promoter located exclusively upstream from the transcription start site. Proteins PBP-1 and PBP-2 bind to two of the three promoter elements in the trypanosomatid Leptomonas seymouri, They represent the first trypanosome transcription factors with typical double-stranded DNA binding site recognition. These proteins ensure efficient transcription. However, accurate initiation is determined an initiator element with a a loose consensus of CYAC/AYR (+1), which differs from that found in metazoan initiator elements as well as from that identified in one of the earliest diverging protozoans, Trichomonas vaginalis, Trypanosomes may utilize initiator element-protein interactions, and not TATA sequence-TATA-binding protein interactions, to direct proper transcription initiation by RNA polymerase II.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Bellofatto, V (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, 185 S Orange Ave, Newark, NJ 07103 USA.				NIAID NIH HHS [AI 29478] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029478] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGAMI R, 1994, NUCLEIC ACIDS RES, V22, P1959, DOI 10.1093/nar/22.11.1959; BANGS JD, 1992, J BIOL CHEM, V267, P9805; BELLOFATTO V, 1988, NUCLEIC ACIDS RES, V16, P3455, DOI 10.1093/nar/16.8.3455; BENAMAR MF, 1991, NUCLEIC ACIDS RES, V19, P5857, DOI 10.1093/nar/19.21.5857; CONNELLY S, 1994, MOL CELL BIOL, V14, P5910, DOI 10.1128/MCB.14.9.5910; Crenshaw-Williams K, 1999, PARASITOL RES, V85, P700, DOI 10.1007/s004360050618; Cross GAM, 1998, MOL BIOCHEM PARASIT, V91, P77, DOI 10.1016/S0166-6851(97)00186-2; FURTERGRAVES EM, 1991, MOL CELL BIOL, V11, P4121, DOI 10.1128/MCB.11.8.4121; GIARDINA C, 1993, SCIENCE, V261, P759, DOI 10.1126/science.8342041; GRAHAM SV, 1995, PARASITOL TODAY, V11, P217, DOI 10.1016/0169-4758(95)80081-6; GUNZL A, 1995, J BIOL CHEM, V270, P17287, DOI 10.1074/jbc.270.29.17287; Gunzl A, 1997, MOL BIOCHEM PARASIT, V85, P67, DOI 10.1016/S0166-6851(96)02816-2; HANNON GJ, 1990, EMBO J, V9, P1915, DOI 10.1002/j.1460-2075.1990.tb08318.x; HARTREE D, 1995, MOL BIOCHEM PARASIT, V71, P27, DOI 10.1016/0166-6851(95)00034-X; Huie JL, 1997, MOL BIOCHEM PARASIT, V90, P183, DOI 10.1016/S0166-6851(97)00146-1; Jensen RC, 1998, NUCLEIC ACIDS RES, V26, P616, DOI 10.1093/nar/26.2.616; Lee MGS, 1996, MOL CELL BIOL, V16, P1220; Lemon KP, 1998, SCIENCE, V282, P1516, DOI 10.1126/science.282.5393.1516; Li JM, 1996, MOL CELL BIOL, V16, P1275; Liston DR, 1999, MOL CELL BIOL, V19, P2380; Lo K, 1996, GENE, V182, P13, DOI 10.1016/S0378-1119(96)00438-6; LOBO SM, 1994, TRANSCRIPTION MECH R, V3, P127; Luo H, 1997, J BIOL CHEM, V272, P33344, DOI 10.1074/jbc.272.52.33344; MAICAS E, 1990, NUCLEIC ACIDS RES, V8, P3387; McAndrew M, 1998, EXP PARASITOL, V90, P65, DOI 10.1006/expr.1998.4317; MOSCH HU, 1992, EMBO J, V11, P4583, DOI 10.1002/j.1460-2075.1992.tb05560.x; NAKAAR V, 1994, MOL CELL BIOL, V14, P6736, DOI 10.1128/MCB.14.10.6736; PAYS E, 1993, EUKARYOTIC MICROBIAL, P99; ROSS L, 1995, J BIOL CHEM, V270, P22086; SAITO RM, 1994, EMBO J, V13, P5460, DOI 10.1002/j.1460-2075.1994.tb06881.x; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; VANHAMME L, 1995, MICROBIOL REV, V59, P223, DOI 10.1128/MMBR.59.2.223-240.1995; Wong MW, 1998, MOL CELL BIOL, V18, P368, DOI 10.1128/MCB.18.1.368; Yoon JB, 1996, MOL CELL BIOL, V16, P1; Yu MC, 1998, MOL BIOCHEM PARASIT, V94, P265, DOI 10.1016/S0166-6851(98)00083-8; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	37	33	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31947	31954		10.1074/jbc.274.45.31947	http://dx.doi.org/10.1074/jbc.274.45.31947			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542223	hybrid			2022-12-27	WOS:000083532100031
J	Meplan, C; Mann, K; Hainaut, P				Meplan, C; Mann, K; Hainaut, P			Cadmium induces conformational modifications of wild-type p53 and suppresses p53 response to DNA damage in cultured cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-SPECIFIC DNA; RAT L6 MYOBLASTS; TUMOR-SUPPRESSOR; OXIDATIVE STRESS; MAMMALIAN-CELLS; IN-VITRO; METALLOTHIONEIN GENE; TRANSITION-METALS; BINDING ACTIVITY; MCF-7 CELLS	The p53 tumor suppressor protein is a transcription factor that binds DNA in a sequence-specific manner through a protein domain stabilized by the coordination of zinc within a tetrahedral cluster of three cysteine residues and one histidine residue. We show that cadmium, a metal that binds thiols with high affinity and substitutes for zinc in the cysteinyl clusters of many proteins, inhibits the binding of recombinant, purified murine p53 to DNA. In human breast cancer MCF7 cells (expressing wild-type p53), exposure to cadmium (5-40 mu M) disrupts native (wild-type) p53 conformation, inhibits DNA binding, and down-regulates transcriptional activation of a reporter gene. Cadmium at 10-30 mu M impairs the p53 induction in response to DNA-damaging agents such as actinomycin D, methylmethane sulfonate, and hydrogen peroxide. Exposure to cadmium at 20 mu M also suppresses the p53-dependent cell cycle arrest in G(1) and G(2)/M phases induced by gamma-irradiation. These observations indicate that cadmium at subtoxic levels impairs p53 function by inducing conformational changes in the wild-type protein. There is evidence that cadmium is carcinogenic to humans, in particular for lung and prostate, and cadmium is known to accumulate in several organs. This inhibition of p53 function could play a role in cadmium carcinogenicity.	Int Agcy Res Canc, Unit Mechanisms Carcinogenesis, F-69372 Lyon 08, France; Univ Alaska Anchorage, Anchorage, AK 99508 USA	World Health Organization; International Agency for Research on Cancer (IARC); University of Alaska System; University of Alaska Anchorage	Hainaut, P (corresponding author), Int Agcy Res Canc, Unit Mechanisms Carcinogenesis, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	hainaut@iarc.fr	Hainaut, Pierre/B-6018-2012	Hainaut, Pierre/0000-0002-1303-1610				Abshire MK, 1996, J TOXICOL ENV HEALTH, V48, P359, DOI 10.1080/009841096161258; Abshire MK, 1996, CARCINOGENESIS, V17, P1349, DOI 10.1093/carcin/17.6.1349; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Bacus SS, 1996, ONCOGENE, V12, P2535; BARTEK J, 1990, ONCOGENE, V5, P893; BARTEK J, 1990, INT J CANCER, V46, P839, DOI 10.1002/ijc.2910460515; Beyersmann D, 1997, TOXICOL APPL PHARM, V144, P247, DOI 10.1006/taap.1997.8125; Bittel D, 1998, J BIOL CHEM, V273, P7127, DOI 10.1074/jbc.273.12.7127; Cai ZZ, 1997, ONCOGENE, V15, P2817, DOI 10.1038/sj.onc.1201445; Calmels S, 1997, CANCER RES, V57, P3365; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; COFFER AI, 1994, BBA-PROTEIN STRUCT M, V1209, P279, DOI 10.1016/0167-4838(94)90197-X; COOGAN TP, 1992, TOXICOL APPL PHARM, V113, P227, DOI 10.1016/0041-008X(92)90118-C; Dally H, 1997, CARCINOGENESIS, V18, P1021, DOI 10.1093/carcin/18.5.1021; DELPHIN C, 1994, EUR J BIOCHEM, V223, P683, DOI 10.1111/j.1432-1033.1994.tb19041.x; DURNAM DM, 1981, J BIOL CHEM, V256, P5712; Ellis K J, 1980, Am J Ind Med, V1, P339, DOI 10.1002/ajim.4700010310; Figueiredo-Pereira ME, 1998, J BIOL CHEM, V273, P12703, DOI 10.1074/jbc.273.21.12703; FREBOURG T, 1992, CANCER RES, V52, P6976; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; Guillot C, 1997, ONCOGENE, V14, P45, DOI 10.1038/sj.onc.1200803; HAINAUT P, 1993, CANCER RES, V53, P1739; Hainaut P, 2000, ADV CANCER RES, V77, P81; HAINAUT P, 1993, CANCER RES, V53, P4469; HAINAUT P, 1995, ONCOGENE, V10, P27; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; KARIN M, 1983, P NATL ACAD SCI-BIOL, V80, P4040, DOI 10.1073/pnas.80.13.4040; Lassus P, 1996, EMBO J, V15, P4566, DOI 10.1002/j.1460-2075.1996.tb00834.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu L, 1999, MOL CELL BIOL, V19, P1202; Maki CG, 1996, CANCER RES, V56, P2649; MARCOVECCHIO JE, 1993, ENVIRON MONIT ASSESS, V25, P119, DOI 10.1007/BF00549133; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; NOCENTINI S, 1987, NUCLEIC ACIDS RES, V15, P4211, DOI 10.1093/nar/15.10.4211; Parks D, 1997, NUCLEIC ACIDS RES, V25, P1289, DOI 10.1093/nar/25.6.1289; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12762, DOI 10.1021/bi9529566; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; PREDKI PF, 1992, J BIOL CHEM, V267, P5842; PRISE KM, 1995, INT J RADIAT BIOL, V67, P393, DOI 10.1080/09553009514550451; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; REID TM, 1994, ENVIRON HEALTH PERSP, V102, P57, DOI 10.2307/3431764; ROELS HA, 1981, ENVIRON RES, V26, P217, DOI 10.1016/0013-9351(81)90199-7; Rossman T G, 1992, IARC Sci Publ, P367; RUSSO T, 1995, J BIOL CHEM, V270, P29386, DOI 10.1074/jbc.270.49.29386; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Shimada H, 1998, J TOXICOL ENV HEAL A, V54, P159; SIMONS SS, 1990, J BIOL CHEM, V265, P1938; SRINIVASAN R, 1993, CANCER RES, V53, P5361; TAKAHASHI K, 1993, INT J CANCER, V55, P453, DOI 10.1002/ijc.2910550322; TAKAHASHI K, 1993, MOL CARCINOGEN, V8, P58, DOI 10.1002/mc.2940080112; THIESEN HJ, 1991, BIOCHEM BIOPH RES CO, V176, P551, DOI 10.1016/S0006-291X(05)80219-0; TSUZUKI K, 1994, ENVIRON HEALTH PERSP, V102, P341, DOI 10.2307/3431817; Verhaegh GW, 1997, MOL CELL BIOL, V17, P5699, DOI 10.1128/MCB.17.10.5699; Verhaegh GW, 1998, MOL CARCINOGEN, V21, P205, DOI 10.1002/(SICI)1098-2744(199803)21:3<205::AID-MC8>3.0.CO;2-K; Waalkes MP, 1999, CARCINOGENESIS, V20, P65, DOI 10.1093/carcin/20.1.65; WAALKES MP, 1992, CRIT REV TOXICOL, V22, P175, DOI 10.3109/10408449209145323; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648; Zheng H, 1996, TOXICOL APPL PHARM, V136, P229, DOI 10.1006/taap.1996.0029	64	153	155	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31663	31670		10.1074/jbc.274.44.31663	http://dx.doi.org/10.1074/jbc.274.44.31663			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531375	hybrid			2022-12-27	WOS:000083379400079
J	Michelson, RJ; Collard, MW; Ziemba, AJ; Persinger, J; Bartholomew, B; Huggenvik, JI				Michelson, RJ; Collard, MW; Ziemba, AJ; Persinger, J; Bartholomew, B; Huggenvik, JI			Nuclear DEAF-1-related (NUDR) protein contains a novel DNA binding domain and represses transcription of the heterogeneous nuclear ribonucleoprotein A2/B1 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; LUNG-CANCER; C-MYC; DROSOPHILA-MELANOGASTER; FUNCTIONAL-ANALYSIS; FUSION PARTNER; TARGET GENES; LIM DOMAINS; RNA; EXPRESSION	Nuclear DEAF-1-related (NUDR) protein is a novel transcriptional regulator with sequence similarity to developmental and oncogenic proteins. NUDR protein deletions were used to localize the DNA binding domain between amino acids 167 and 368, and site-specific DNA photocross-linking indicated at least two sites of protein-DNA contact within this domain. The DNA binding domain contains a proline-rich region and a region with similarity to a Myc-type helix-loop-helix domain but does not include the zinc finger motif at the C terminus, Deoxyribonuclease I protection assays confirmed the presence of multiple NUDR binding motifs (TTC(C/G)G) in the heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNP A2/B1) promoter and also in the 5'-untranslated region (UTR) of hNUDR cDNA. NUDR produced a 65-70% repression of the hnRNP A2/B1 promoter activity, and NUDE binding motifs in the 5'-UTR were found to mediate this repression NUDR-dependent repression was also observed when the 5'-UTR of NUDR was placed onto a heterologous thymidine kinase promoter in an analogous 5'-UTR position but not when placed upstream of transcription initiation. These results suggest that NUDE may regulate the in vivo expression of hnRNP A2/B1 and NUDE genes and imply that inactivation of NUDE could contribute to the overexpression of hnRNP A2/B1 observed in some human cancers.	So Illinois Univ, Sch Med, Dept Physiol, Carbondale, IL 62901 USA; So Illinois Univ, Sch Med, Dept Med Biochem, Carbondale, IL 62901 USA	Southern Illinois University System; Southern Illinois University; Southern Illinois University System; Southern Illinois University	Huggenvik, JI (corresponding author), So Illinois Univ, Sch Med, Dept Physiol, Carbondale, IL 62901 USA.	jhuggenvik@som.siu.edu			NICHD NIH HHS [HD31613, HD32484] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD031613, R29HD032484] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bach I, 1997, GENE DEV, V11, P1370, DOI 10.1101/gad.11.11.1370; BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; Bartholomew B, 1995, METHOD ENZYMOL, V262, P476; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; Breen JJ, 1998, J BIOL CHEM, V273, P4712, DOI 10.1074/jbc.273.8.4712; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; Dent AL, 1996, BLOOD, V88, P1423, DOI 10.1182/blood.V88.4.1423.bloodjournal8841423; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; FEINSTEIN PG, 1995, GENETICS, V140, P573; Gamou T, 1998, BLOOD, V91, P4028, DOI 10.1182/blood.V91.11.4028.411a45_4028_4037; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Gross CT, 1996, EMBO J, V15, P1961, DOI 10.1002/j.1460-2075.1996.tb00547.x; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; Huggenvik JI, 1998, MOL ENDOCRINOL, V12, P1619, DOI 10.1210/me.12.10.1619; John S, 1996, J EXP MED, V183, P743, DOI 10.1084/jem.183.3.743; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; Jurata LW, 1998, J BIOL CHEM, V273, P3152, DOI 10.1074/jbc.273.6.3152; Jurata LW, 1997, MOL CELL BIOL, V17, P5688, DOI 10.1128/MCB.17.10.5688; KASH SF, 1993, MOL CELL BIOL, V13, P2718, DOI 10.1128/MCB.13.5.2718; Kitabayashi I, 1998, MOL CELL BIOL, V18, P846, DOI 10.1128/MCB.18.2.846; KUIPER GGJM, 1993, BIOCHEM J, V296, P161, DOI 10.1042/bj2960161; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; Lannutti BJ, 1996, BIOCHEMISTRY-US, V35, P9821, DOI 10.1021/bi960525x; Lehming N, 1998, P NATL ACAD SCI USA, V95, P7322, DOI 10.1073/pnas.95.13.7322; Liu CT, 1998, CANCER GENE THER, V5, P3; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Lutterbach B, 1998, MOL CELL BIOL, V18, P3604, DOI 10.1128/MCB.18.6.3604; Maira SM, 1996, EMBO J, V15, P5849, DOI 10.1002/j.1460-2075.1996.tb00972.x; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Montuenga LM, 1998, AM J RESP CELL MOL, V19, P554, DOI 10.1165/ajrcmb.19.4.3185; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; Ogbourne S, 1998, BIOCHEM J, V331, P1; Pan QT, 1999, J BIOL CHEM, V274, P8437, DOI 10.1074/jbc.274.13.8437; PLET A, 1995, ONCOGENE, V10, P319; Qiao YL, 1997, CANCER EPIDEM BIOMAR, V6, P893; Robinson L, 1997, P NATL ACAD SCI USA, V94, P7170, DOI 10.1073/pnas.94.14.7170; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; Seeler JS, 1998, P NATL ACAD SCI USA, V95, P7316, DOI 10.1073/pnas.95.13.7316; Sternsdorf T, 1997, IMMUNOBIOLOGY, V198, P307, DOI 10.1016/S0171-2985(97)80051-4; Sugihara TM, 1998, P NATL ACAD SCI USA, V95, P15418, DOI 10.1073/pnas.95.26.15418; TOCKMAN MS, 1988, J CLIN ONCOL, V6, P1685, DOI 10.1200/JCO.1988.6.11.1685; Tockman MS, 1997, CLIN CANCER RES, V3, P2237; TOCKMANMS, 1996, J CELL BIOCHEM, V25, P177; Valge-Archer V, 1998, ONCOGENE, V17, P3199, DOI 10.1038/sj.onc.1202353; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; WOLF DA, 1995, NUCLEIC ACIDS RES, V23, P3373, DOI 10.1093/nar/23.17.3373; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686; Zeng HW, 1998, J BIOL CHEM, V273, P17756, DOI 10.1074/jbc.273.28.17756; Zhou J, 1996, J BIOL CHEM, V271, P10760, DOI 10.1074/jbc.271.18.10760; Zhou J, 1998, CLIN CANCER RES, V4, P1631	59	43	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30510	30519		10.1074/jbc.274.43.30510	http://dx.doi.org/10.1074/jbc.274.43.30510			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521432	hybrid			2022-12-27	WOS:000083276700028
J	Moser, J; Lorenz, S; Hubschwerlen, C; Rompf, A; Jahn, D				Moser, J; Lorenz, S; Hubschwerlen, C; Rompf, A; Jahn, D			Methanopyrus kandleri glutamyl-tRNA reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA REDUCTASE; ESCHERICHIA-COLI; CHLOROPHYLL BIOSYNTHESIS; TRNA(GLU) REDUCTASE; BACILLUS-SUBTILIS; PURIFICATION; INHIBITION; SYNTHETASE; HEME; DEHYDROGENASE	The initial reaction of tetrapyrrole formation in archaea is catalyzed by a NADPH-dependent glutamyl-tRNA reductase (GluTR). The hemA gene encoding GluTR was cloned from the extremely thermophilic archaeon Methanopyrus kandleri and overexpressed in Escherichia coli, Purified recombinant GluTR is a tetrameric enzyme with a native M-r = 190,000 +/- 10,000. Using a newly established enzyme assay, a specific activity of 0.75 nmol h(-1) mg(-1) at 56 degrees C with E. coli glutamyl-tRNA as substrate was measured. A temperature optimum of 90 degrees C and a pH optimum of 8.1 were determined. Neither heme cofactor, nor flavin, nor metal ions were required for GluTR catalysis, Heavy metal compounds, Zn2+, and heme inhibited the enzyme. GluTR inhibition by the newly synthesized inhibitor glutamycin, whose structure is similar to the 3' end of the glutamyl-tRNA substrate, revealed the importance of an intact chemical bond between glutamate and tRNA(Glu) for substrate recognition. The absolute requirement for NADPH in the reaction of GluTR was demonstrated using four NADPH analogues. Chemical modification and site-directed mutagenesis studies indicated that a single cysteinyl residue and a single histidinyl residue were important for catalysis, It was concluded that during GluTR catalysis the highly reactive sulfhydryl group of Cys-48 acts as a nucleophile attacking the alpha-carbonyl group of tRNA-bound glutamate with the formation of an enzyme-localized thioester intermediate and the concomitant release of tRNA(Glu). In the presence of NADPH, direct hydride transfer to enzyme-bound glutamate, possibly facilitated by His-84, leads to glutamate-1-semialdehyde formation. In the absence of NADPH, a newly discovered esterase activity of GluTR hydrolyzes the highly reactive thioester of tRNA(Glu) to release glutamate.	Univ Freiburg, Inst Organ Chem & Biochem, D-79104 Freiburg, Germany; F Hoffmann La Roche & Co Ltd, Preclin Res, CH-4070 Basel, Switzerland	University of Freiburg; Roche Holding	Jahn, D (corresponding author), Univ Freiburg, Inst Organ Chem & Biochem, Albert Str 21, D-79104 Freiburg, Germany.			Jahn, Dieter/0000-0002-4064-9205				Boschi-Muller S, 1999, ARCH BIOCHEM BIOPHYS, V363, P259, DOI 10.1006/abbi.1998.1080; CHAPMAN KT, 1993, J MED CHEM, V36, P4293, DOI 10.1021/jm00078a019; CHEN MW, 1990, J BIOL CHEM, V265, P4054; CHEN MW, 1990, J BIOL CHEM, V265, P4058; FRANKENBERG N, 1999, IN PRESS BIOCHEMISTR; Habenicht A, 1997, BIOL CHEM, V378, P1413; HAILE DJ, 1990, J BIOL CHEM, V265, P12786; HOBEN P, 1985, METHOD ENZYMOL, V113, P55; Hungerer C, 1996, BIOORGAN MED CHEM, V4, P1089, DOI 10.1016/0968-0896(96)00098-3; ILAG LL, 1991, J BACTERIOL, V173, P3408, DOI 10.1128/jb.173.11.3408-3413.1991; JAHN D, 1992, TRENDS BIOCHEM SCI, V17, P215, DOI 10.1016/0968-0004(92)90380-R; JAHN D, 1991, J BIOL CHEM, V266, P2542; JORDAN PM, NEW COMPREHENSIVE BI, V19, P1; KANNANGARA CG, 1994, CIBA F SYMP, V180, P3; MAU YH, 1987, ARCH BIOCHEM BIOPHYS, V255, P75, DOI 10.1016/0003-9861(87)90295-5; Nagradova NK, 1998, BIOCHEMISTRY-MOSCOW+, V63, P504; Perozich J, 1999, PROTEIN SCI, V8, P137, DOI 10.1110/ps.8.1.137; PONTOPPIDAN B, 1994, EUR J BIOCHEM, V225, P529, DOI 10.1111/j.1432-1033.1994.00529.x; PROULX M, 1985, METHOD ENZYMOL, V113, P50; RIEBLE S, 1991, J BIOL CHEM, V266, P9740; SCHRODER I, 1992, BIOCHEM J, V281, P843, DOI 10.1042/bj2810843; Talfournier F, 1998, EUR J BIOCHEM, V252, P447, DOI 10.1046/j.1432-1327.1998.2520447.x; VERKAMP E, 1992, J BIOL CHEM, V267, P8275; Vothknecht UC, 1996, P NATL ACAD SCI USA, V93, P9287, DOI 10.1073/pnas.93.17.9287; Vothknecht UC, 1998, PHYTOCHEMISTRY, V47, P513, DOI 10.1016/S0031-9422(97)00538-4	25	60	65	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30679	30685		10.1074/jbc.274.43.30679	http://dx.doi.org/10.1074/jbc.274.43.30679			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521455	hybrid			2022-12-27	WOS:000083276700051
J	Rawadi, G; Zugaza, JL; Lemercier, B; Marvaud, JC; Popoff, M; Bertoglio, J; Roman-Roman, S				Rawadi, G; Zugaza, JL; Lemercier, B; Marvaud, JC; Popoff, M; Bertoglio, J; Roman-Roman, S			Involvement of small GTPases in Mycoplasma fermentans membrane lipoproteins-mediated activation of macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; ALDRICH-SYNDROME PROTEIN; SIGNALING PATHWAY; RHO-PROTEINS; KINASE; BINDING; CDC42; CASCADES	Mycoplasma fermentans lipoproteins (LAMPf) are capable of activating macrophages and inducing the secretion of proinflammatory cytokines. We have recently reported that mitogen-activated protein kinase (MAPK) pathways and NF-kappa B and activated protein 1 (AP-1) play a crucial role in the activation induced by this bacterial compound. To further elucidate the mechanisms by which LAMPf mediate the activation of macrophages, we assessed the effects of inhibiting small G proteins Rac, Cdc42, and Rho, The Rho-specific inhibitor C3 enzyme completely abolished the secretion of tumor necrosis factor alpha by macrophages stimulated with LAMPf and also inhibited the activation of extracellular signal-regulated kinase (ERK), c-Jun NH2-terminal kinase (JNK), and p38 kinase. In addition, we have shown that LAMPf stimulate Cdc42 and that inhibition of Cdc42 or Rac by dominant negative mutants abrogates LAMPf-mediated activation of JNK and transactivation of NF-kappa B and AP-1 in the murine macrophage cell line RAW 264.7, These results indicate that small G: proteins Rho, Cdc42, and Rac are involved in the cascade of events leading to the macrophage activation by mycoplasma lipoproteins.	Inst Pasteur, Lab Mycoplasmes, F-75724 Paris 15, France; Inst Pasteur, Lab Toxine Microbienne, F-75724 Paris, France; Univ Paris 11, Fac Pharm, INSERM, U461, F-92296 Chatenay Malabry, France; Hoechst Marion Roussel, Ctr Rech Romainville, F-93230 Romainville, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Sanofi-Aventis; Sanofi France	Rawadi, G (corresponding author), Hoechst Marion Roussel, Infect Dis Grp, 102 Route Noisy, F-93230 Romainville, France.		Roman-Roman, Sergio/K-9993-2014; Bustelo, Xose R./A-9526-2010	Roman-Roman, Sergio/0000-0001-6459-2613; Bustelo, Xose R./0000-0001-9398-6072; Rawadi, Georges/0000-0003-4735-2188; ZUGAZA GURRUCHAGA, JOSE LUIS/0000-0003-2287-6671				Aktories K, 1997, TRENDS MICROBIOL, V5, P282, DOI 10.1016/S0966-842X(97)01067-6; Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BRASIER AR, 1994, CURRENT PROTOCOLS MO; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Garcia J, 1998, J BIOL CHEM, V273, P34391, DOI 10.1074/jbc.273.51.34391; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Henderson B, 1996, IMMUNOPHARMACOLOGY, V35, P1, DOI 10.1016/0162-3109(96)00144-0; Henderson B, 1996, MICROBIOL REV, V60, P316, DOI 10.1128/MMBR.60.2.316-341.1996; Hmama Z, 1999, J BIOL CHEM, V274, P1050, DOI 10.1074/jbc.274.2.1050; Johnson DI, 1999, MICROBIOL MOL BIOL R, V63, P54, DOI 10.1128/MMBR.63.1.54-105.1999; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Lopez-Ilasaca M, 1998, BIOCHEM PHARMACOL, V56, P269, DOI 10.1016/S0006-2952(98)00059-8; Marvaud J. C., 1998, Zentralblatt fuer Bakteriologie Supplement, V29, P72; Rawadi G, 1996, INFECT IMMUN, V64, P637, DOI 10.1128/IAI.64.2.637-643.1996; Rawadi G, 1999, J IMMUNOL, V162, P2193; Razin S, 1998, MICROBIOL MOL BIOL R, V62, P1094, DOI 10.1128/MMBR.62.4.1094-1156.1998; RAZIN S, 1985, MYCOPLASMAS, V4; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Renshaw MW, 1996, J BIOL CHEM, V271, P21691, DOI 10.1074/jbc.271.36.21691; Rudolph MG, 1998, J BIOL CHEM, V273, P18067, DOI 10.1074/jbc.273.29.18067; STACEY KJ, 1993, IMMUNOL CELL BIOL, V71, P75, DOI 10.1038/icb.1993.8; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; TaylorRobinson D, 1996, CLIN INFECT DIS, V23, P671, DOI 10.1093/clinids/23.4.671; TaylorRobinson D, 1996, J CLIN PATHOL, V49, P781, DOI 10.1136/jcp.49.10.781; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; Weber KSC, 1998, EUR J IMMUNOL, V28, P2245, DOI 10.1002/(SICI)1521-4141(199807)28:07<2245::AID-IMMU2245>3.0.CO;2-V; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	28	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30794	30798		10.1074/jbc.274.43.30794	http://dx.doi.org/10.1074/jbc.274.43.30794			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521470	hybrid			2022-12-27	WOS:000083276700066
J	Acosta-Serrano, A; Cole, RN; Mehlert, A; Lee, MGS; Ferguson, MAJ; Englund, PT				Acosta-Serrano, A; Cole, RN; Mehlert, A; Lee, MGS; Ferguson, MAJ; Englund, PT			The procyclin repertoire of Trypanosoma brucei - Identification and structural characterization of the Glu-Pro-rich polypeptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACIDIC REPETITIVE PROTEIN; AMANITIN-RESISTANT TRANSCRIPTION; 3'-UNTRANSLATED REGION; AFRICAN TRYPANOSOMES; TRANS-SIALIDASE; SURFACE-ANTIGEN; CULTURE FORMS; EXPRESSION; INSECT; GENES	The surface of the insect stages of the protozoan parasite Trypanosoma brucei is covered by abundant glycosyl phosphatidylinositol (GPI)-anchored glycoproteins known as procyclins. One type of procyclin, the EP isoform, is predicted to have 22-30 Glu-Pro (EP) repeats in its C-terminal domain and is encoded by multiple genes. Because of the similarity of the EP isoform sequences and the heterogeneity of their GPI anchors, it has been impossible to separate and characterize these polypeptides by standard protein fractionation techniques. To facilitate their structural and functional characterization, we used a combination of matrix-assisted laser desorption ionization and electrospray mass spectrometry to analyze the entire procyclin repertoire expressed on the trypanosome cell. This analysis, which required removal of the GPI anchors by aqueous hydrofluoric acid treatment and cleavage at aspartate-proline bonds by mild acid hydrolysis, provided precise information about the glycosylation state and the number of Glu-Pro repeats in these proteins. Using this methodology we detected in a T. brucei clone the glycosylated products of the EP3 gene and two different products of the EP1 gene (EP1-1 and EP1-2). Furthermore, only low amounts of the nonglycosylated products of the GREET and EP2 genes were detected. Because all procyclin genes are transcribed polycistronically, the latter finding indicates that the expression of the GREET and ER2 genes is post-transcriptionaly regulated. This is the first time that the whole procyclin repertoire from procyclic trypanosomes has been characterized at the protein level.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Univ Dundee, Dept Biochem, Dundee DD1 5EH, Scotland; NYU, Sch Med, Dept Pathol, New York, NY 10016 USA	Johns Hopkins University; University of Dundee; New York University	Acosta-Serrano, A (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA.	aacostas@welchlink.welch.jhu.edu	Acosta-Serrano, Alvaro/L-5503-2015; Ferguson, Michael A. J./F-7829-2010	Acosta-Serrano, Alvaro/0000-0002-2576-7959; Ferguson, Michael A. J./0000-0003-1321-8714	NIAID NIH HHS [AI28953, AI21334] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI028953, R01AI028953, R21AI028953, R01AI021334] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BRUN R, 1979, ACTA TROP, V36, P289; Butikofer P, 1997, BIOCHEM J, V326, P415; Butikofer P, 1999, J CELL SCI, V112, P1785; BUTIKOFER P, 1995, ANAL BIOCHEM, V229, P125, DOI 10.1006/abio.1995.1388; CHUNG HMM, 1993, MOL CELL BIOL, V13, P3734, DOI 10.1128/MCB.13.6.3734; CLAYTON CE, 1989, J BIOL CHEM, V264, P15088; CLAYTON CE, 1990, MOL CELL BIOL, V10, P3036, DOI 10.1128/MCB.10.6.3036; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; DECARVALHO LCP, 1993, J EXP MED, V177, P465, DOI 10.1084/jem.177.2.465; DORN PL, 1991, MOL BIOCHEM PARASIT, V44, P133, DOI 10.1016/0166-6851(91)90229-Y; ENGSTLER M, 1993, MOL BIOCHEM PARASIT, V61, P1, DOI 10.1016/0166-6851(93)90153-O; FERGUSON MAJ, 1993, BIOCHEM J, V291, P51, DOI 10.1042/bj2910051; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FIELD MC, 1991, EMBO J, V10, P2731, DOI 10.1002/j.1460-2075.1991.tb07821.x; Furger A, 1997, MOL CELL BIOL, V17, P4372, DOI 10.1128/MCB.17.8.4372; Hotz HR, 1998, MOL BIOCHEM PARASIT, V91, P131, DOI 10.1016/S0166-6851(97)00196-5; Hwa KY, 1999, GLYCOBIOLOGY, V9, P181, DOI 10.1093/glycob/9.2.181; INGLIS AS, 1983, METHOD ENZYMOL, V91, P324; JACKSON DG, 1993, J BIOL CHEM, V268, P1894; Lee MGS, 1996, MOL CELL BIOL, V16, P1220; Mehlert A, 1999, MOL BIOCHEM PARASIT, V98, P291, DOI 10.1016/S0166-6851(98)00168-6; MOWATT MR, 1989, MOL CELL BIOL, V9, P1332, DOI 10.1128/MCB.9.3.1332; MOWATT MR, 1987, MOL CELL BIOL, V7, P2838, DOI 10.1128/MCB.7.8.2838; MOWATT MR, 1988, MOL CELL BIOL, V8, P4055, DOI 10.1128/MCB.8.10.4055; RICHARDSON JP, 1988, MOL BIOCHEM PARASIT, V31, P203, DOI 10.1016/0166-6851(88)90150-8; RODITI I, 1987, NATURE, V325, P272, DOI 10.1038/325272a0; Roditi I, 1998, MOL BIOCHEM PARASIT, V91, P117, DOI 10.1016/S0166-6851(97)00195-3; RODITI I, 1999, IN PRESS MOL BIOCH P; RUDENKO G, 1990, MOL CELL BIOL, V10, P3492, DOI 10.1128/MCB.10.7.3492; RUDENKO G, 1989, EMBO J, V8, P4259, DOI 10.1002/j.1460-2075.1989.tb08611.x; Ruepp S, 1997, J CELL BIOL, V137, P1369, DOI 10.1083/jcb.137.6.1369; Schurch N, 1997, MOL BIOCHEM PARASIT, V89, P109, DOI 10.1016/S0166-6851(97)00107-2; STEBECK CE, 1995, MOL BIOCHEM PARASIT, V71, P1, DOI 10.1016/0166-6851(95)00022-S; Treumann A, 1997, J MOL BIOL, V269, P529, DOI 10.1006/jmbi.1997.1066; VICKERMAN K, 1969, J CELL SCI, V5, P163; Wilson K, 1999, EXP PARASITOL, V91, P222, DOI 10.1006/expr.1998.4366	36	48	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29763	29771		10.1074/jbc.274.42.29763	http://dx.doi.org/10.1074/jbc.274.42.29763			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514452	hybrid			2022-12-27	WOS:000083176400031
J	Ai, LS; Chau, LY				Ai, LS; Chau, LY			Post-transcriptional regulation of H-ferritin mRNA - Identification of a pyrimidine-rich sequence in the 3 '-untranslated region associated with message stability in human monocytic THP-1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; IRON-RESPONSIVE ELEMENT; 3' UNTRANSLATED REGION; BINDING-PROTEIN; GENE-EXPRESSION; POSTTRANSCRIPTIONAL REGULATION; HEAVY-CHAIN; POLYPYRIMIDINE TRACT; MOLECULAR-CLONING; MUSCLE-CELLS	We have previously demonstrated that phorbol myristate acetate (PMA) up-regulates H-ferritin gene expression in myeloid cells by stabilization of its message. In the present report, we showed that insertion of the 3'-untranslated region (3'-UTR) of H-ferritin mRNA at the 3'-end of luciferase coding sequence significantly reduced the stability of luciferase mRNA in human monocytic THP-1 cells. However, the half-life of the chimeric transcript was markedly prolonged after PMA treatment. A cytosolic protein factor from THP-1 cells was found to specifically bind to H-ferritin 3'-UTR. PMA treatment of THP-1 cells resulted in the reduction of the RNA binding activity in a time-dependent manner. Deletion analysis and RNase T1 mapping revealed a pyrimidine-rich sequence within the 3'-UTR which interacts with the protein factor. Competition experiments with homoribopolymers further demonstrated the importance of uridines for the binding activity. Point mutations in uridines of the pyrimidine-rich sequence reduced the protein binding to 3'-UTR, while increasing the stability of the chimeric luciferase transcript. Together, these results demonstrate that the pyrimidine-rich sequence in the 3'-UTR is involved in post-transcriptional regulation of H-ferritin gene expression in myeloid cells.	Acad Sinica, Inst Biomed Sci, Div Cardiovasc Res, Taipei 11529, Taiwan	Academia Sinica - Taiwan	Chau, LY (corresponding author), Acad Sinica, Inst Biomed Sci, Div Cardiovasc Res, Taipei 11529, Taiwan.		Chau, Lee-Young/N-7659-2018	Chau, Lee-Young/0000-0002-6316-2328				AMARA FM, 1994, J BIOL CHEM, V269, P6709; BEAUMONT C, 1987, J BIOL CHEM, V262, P10619; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; CHAZENBALK GD, 1990, J BIOL CHEM, V265, P666; CHEN FY, 1993, EMBO J, V12, P3977, DOI 10.1002/j.1460-2075.1993.tb06075.x; CHOU CC, 1986, MOL CELL BIOL, V6, P566, DOI 10.1128/MCB.6.2.566; COLUCCIDAMATO LG, 1989, BIOCHEM BIOPH RES CO, V165, P506, DOI 10.1016/0006-291X(89)91098-X; DREYFUSS G, 1988, J CELL BIOL, V106, P1419, DOI 10.1083/jcb.106.5.1419; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GHETTI A, 1992, NUCLEIC ACIDS RES, V20, P6910; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; Haynes SR, 1997, MOL CELL BIOL, V17, P2708, DOI 10.1128/MCB.17.5.2708; HENTZE MW, 1987, SCIENCE, V238, P1570, DOI 10.1126/science.3685996; Irwin N, 1997, NUCLEIC ACIDS RES, V25, P1281, DOI 10.1093/nar/25.6.1281; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LEVI S, 1988, J BIOL CHEM, V263, P18086; LIAU G, 1991, J BIOL CHEM, V266, P18819; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; MCCARY GA, 1990, J BIOL CHEM, V265, P7539; MORRIS DR, 1993, BIOCHEMISTRY-US, V32, P2931, DOI 10.1021/bi00063a001; Pang JHS, 1996, BIOCHEM J, V319, P185, DOI 10.1042/bj3190185; Pang JHS, 1996, J CLIN INVEST, V97, P2204, DOI 10.1172/JCI118661; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Sakakibara S, 1996, DEV BIOL, V176, P230, DOI 10.1006/dbio.1996.0130; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Shetty S, 1997, MOL CELL BIOL, V17, P1075, DOI 10.1128/MCB.17.3.1075; STEVENS PW, 1987, MOL CELL BIOL, V7, P1751, DOI 10.1128/MCB.7.5.1751; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; TORTI SV, 1988, J BIOL CHEM, V263, P12638; Tsai KC, 1997, J NEUROSCI, V17, P1950; WEI Y, 1990, BIOCHEM BIOPH RES CO, V169, P289, DOI 10.1016/0006-291X(90)91466-6; ZAIDI SHE, 1994, J BIOL CHEM, V269, P24000; ZAIDI SHE, 1994, J BIOL CHEM, V269, P24007	36	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30209	30214		10.1074/jbc.274.42.30209	http://dx.doi.org/10.1074/jbc.274.42.30209			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514512	hybrid			2022-12-27	WOS:000083176400091
J	Janssen, GMC; Maassen, JA; van den Ouweland, JMW				Janssen, GMC; Maassen, JA; van den Ouweland, JMW			The diabetes-associated 3243 mutation in the mitochondrial tRNA(Leu(UUR)) gene causes severe mitochondrial dysfunction without a strong decrease in protein synthesis rate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER RNA-SYNTHETASE; DNA; AMINOACYLATION; DEFECTS; DISEASE; MTDNA; CELLS; TRANSCRIPTION; TERMINATION; RESPIRATION	Cells harboring patient-derived mitochondria with an A-to-G; transition at nucleotide position 3243 of their mitochondrial DNA display severe loss of respiration when compared with cells containing the wild-type adenine but otherwise identical mitochondrial DNA sequence. The amount and degree of leucylation of tRNA(Leu(UUR)) were both found to be highly reduced in mutant cells. Despite the low level of leucyl-tRNA(Leu(UUR)), the rate of mitochondrial translation was not seriously affected by this mutation. Therefore, decrease of mitochondrial protein synthesis as such does not appear to be a necessary prerequisite for loss of respiration Rather, the mitochondrially encoded proteins seem subject to elevated degradation, leading to a severe reduction in their steady state levels. Our results favor a scheme in which the 3243 mutation causes loss of respiration through accelerated protein degradation, leading to a disequilibrium between the levels of mitochondrial and nuclear encoded respiratory chain subunits and thereby a reduction of functional respiratory chain complexes. The possible mechanisms underlying the pathogenesis of mitochondrial diabetes is discussed.	Leiden Univ, Med Ctr, Dept Mol Cell Biol, NL-2333 AL Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Janssen, GMC (corresponding author), Leiden Univ, Med Ctr, Dept Mol Cell Biol, Wassenaarseweg 72, NL-2333 AL Leiden, Netherlands.							CHAMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156; Chomyn A, 1996, Methods Enzymol, V264, P197, DOI 10.1016/S0076-6879(96)64020-8; CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236; CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221; El Meziane A, 1998, NAT GENET, V18, P350; ENRIQUEZ JA, 1995, NAT GENET, V10, P47, DOI 10.1038/ng0595-47; Enriquez JA, 1996, P NATL ACAD SCI USA, V93, P8300, DOI 10.1073/pnas.93.16.8300; Flierl A, 1997, J BIOL CHEM, V272, P27189, DOI 10.1074/jbc.272.43.27189; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; Grossman LI, 1996, BIOESSAYS, V18, P983, DOI 10.1002/bies.950181208; Jansen JJ, 1997, J AM SOC NEPHROL, V8, P1118; JANSSEN GMC, 1990, RIBOSOMES PROTEIN SY, P51; KADOWAKI T, 1994, NEW ENGL J MED, V330, P962, DOI 10.1056/NEJM199404073301403; KENNELL D, 1977, J MOL BIOL, V114, P1, DOI 10.1016/0022-2836(77)90279-0; Kessler S W, 1981, Methods Enzymol, V73, P442; KING MP, 1993, J BIOL CHEM, V268, P10228; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480; LANKER S, 1992, CELL, V70, P647, DOI 10.1016/0092-8674(92)90433-D; Larsson NG, 1995, ANNU REV GENET, V29, P151, DOI 10.1146/annurev.ge.29.120195.001055; Maassen JA, 1996, DIABETOLOGIA, V39, P375; NEGRUTSKII BS, 1991, P NATL ACAD SCI USA, V88, P4991, DOI 10.1073/pnas.88.11.4991; OGILVIE A, 1979, BIOCHIM BIOPHYS ACTA, V565, P293, DOI 10.1016/0005-2787(79)90206-5; Rossmanith W, 1998, FEBS LETT, V433, P269, DOI 10.1016/S0014-5793(98)00928-4; Sambrook J., 2002, MOL CLONING LAB MANU; SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; van den Ouweland JMW, 1999, DIABETOLOGIA, V42, P485, DOI 10.1007/s001250051183; VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368; VANDENOUWELAND JMW, 1994, THESIS LEIDEN U; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523	32	71	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29744	29748		10.1074/jbc.274.42.29744	http://dx.doi.org/10.1074/jbc.274.42.29744			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514449	hybrid			2022-12-27	WOS:000083176400028
J	Teubl, M; Groschner, K; Kohlwein, SD; Mayer, B; Schmidt, K				Teubl, M; Groschner, K; Kohlwein, SD; Mayer, B; Schmidt, K			Na+/Ca2+ exchange facilitates Ca2+-dependent activation of endothelial nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGE; NA-CA EXCHANGE; CARDIAC MYOCYTES; CELLS; CAVEOLAE; INHIBITION; CURRENTS; PROTEIN; RELEASE; STORE	Recent evidence suggests the expression of a Na+/ Ca2+ exchanger (NCX) in vascular endothelial cells, To elucidate the functional role of endothelial NCX, we studied Ca2+ signaling and Ca2+-dependent activation of endothelial nitric-oxide synthase (eNOS) at normal, physiological Na+ gradients and after loading of endothelial cells with Na+ ions using the ionophore monensin. Monensin-induced Na+ loading markedly reduced Ca2+ entry and, thus, steady-state levels of intracellular free Ca2+ ([Ca2+](i)) in thapsigargin-stimulated endothelial cells due to membrane depolarization. Despite this reduction of overall [Ca2+](i), Ca2+-dependent activation of eNOS was facilitated as indicated by a pronounced leftward shift of the Ca2+ concentration response curve in monensin-treated cells. This facilitation of Ca2+-dependent activation of eNOS was strictly dependent on the presence of Na+ ions during treatment of the cells with monensin, Na+-induced facilitation of eNOS activation was not due to a direct effect of Na+ ions on the Ca2+ sensitivity of the enzyme. Moreover, the effect of Na+ was not related to Na+ entry-induced membrane depolarization or suppression of Ca2+ entry, since neither elevation of extracellular K+ nor the Ca2+ entry blocker 1-(beta-[3-(4-methoxyphenyl)-propoxy]-4-methoxyphenethyl)-1H-imidazole hydrochloride (SK&F 96365) mimicked the effects of Na+ loading. The effects of monensin were completely blocked by 3',4'-dichlorobenzamil, a potent and selective inhibitor of NCX, whereas the structural analog amiloride, which barely affects Na+/Ca2+ exchange, was ineffective. Consistent with a pivotal role of Na+/Ca2+ exchange in Ca2+-dependent activation of eNOS, an NCX protein was detected in caveolin-rich membrane fractions containing both eNOS and caveolin-1. These results demonstrate for the first time a crucial role of cellular Na+ gradients in regulation of eNOS activity and suggest that a tight functional interaction between endothelial NCX and eNOS may take place in caveolae.	Karl Franzens Univ Graz, Inst Pharmakol & Toxikol, A-8010 Graz, Austria; Graz Univ Technol, Inst Biochem & Lebensmittelchem, A-8010 Graz, Austria	University of Graz; Graz University of Technology	Schmidt, K (corresponding author), Karl Franzens Univ Graz, Inst Pharmakol & Toxikol, Univ Pl 2, A-8010 Graz, Austria.	kurt.schmidt@kfunigraz.ac.at	Groschner, Klaus/A-2550-2010; Mayer, Bernd/B-9391-2008	Groschner, Klaus/0000-0002-8659-377X; Mayer, Bernd/0000-0002-2921-3494; Kohlwein, Sepp Dieter/0000-0002-1030-0598				Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Balzer M, 1999, CARDIOVASC RES, V42, P543, DOI 10.1016/S0008-6363(99)00025-5; BRIDGE JHB, 1990, SCIENCE, V248, P376, DOI 10.1126/science.2158147; CANNELL MB, 1991, ANN NY ACAD SCI, V639, P428, DOI 10.1111/j.1749-6632.1991.tb17330.x; CANNELL MB, 1989, J PHYSIOL-LONDON, V419, P555, DOI 10.1113/jphysiol.1989.sp017886; CRESPO LM, 1990, NATURE, V345, P618, DOI 10.1038/345618a0; DOLOR RJ, 1992, AM J PHYSIOL, V262, pC171, DOI 10.1152/ajpcell.1992.262.1.C171; EISNER DA, 1985, AM J PHYSIOL, V248, pC189, DOI 10.1152/ajpcell.1985.248.3.C189; ELLIOTT SJ, 1995, FREE RADICAL BIO MED, V19, P649, DOI 10.1016/0891-5849(95)00080-H; Encabo A, 1996, BRIT J PHARMACOL, V119, P702, DOI 10.1111/j.1476-5381.1996.tb15729.x; Fujimoto T, 1998, J ELECTRON MICROSC, V47, P451, DOI 10.1093/oxfordjournals.jmicro.a023616; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; GERICKE M, 1993, PFLUG ARCH EUR J PHY, V422, P552, DOI 10.1007/BF00374001; Graier WF, 1998, J PHYSIOL-LONDON, V506, P109, DOI 10.1111/j.1469-7793.1998.109bx.x; GROSCHNER K, 1992, BIOCHIM BIOPHYS ACTA, V1137, P162, DOI 10.1016/0167-4889(92)90198-K; Groschner K, 1998, FEBS LETT, V437, P101, DOI 10.1016/S0014-5793(98)01212-5; GROSCHNER K, 1994, CIRC RES, V75, P304, DOI 10.1161/01.RES.75.2.304; HARLOW E, 1988, ANTIBODIES LAB MANUA, P386; IWATA T, 1995, CELL CALCIUM, V17, P263, DOI 10.1016/0143-4160(95)90072-1; Ju H, 1998, J BIOL CHEM, V273, P24025, DOI 10.1074/jbc.273.37.24025; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; JUHASZOVA M, 1994, AM J PHYSIOL, V266, pC234, DOI 10.1152/ajpcell.1994.266.1.C234; KLATT P, 1992, J BIOL CHEM, V267, P11374; LASKEY RE, 1990, J BIOL CHEM, V265, P2613; LEBLANC N, 1990, SCIENCE, V248, P372, DOI 10.1126/science.2158146; LEVI AJ, 1993, CARDIOVASC RES, V27, P1677, DOI 10.1093/cvr/27.9.1677; LI L, 1995, CIRC RES, V76, P396, DOI 10.1161/01.RES.76.3.396; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; List BM, 1997, BIOCHEM J, V323, P159, DOI 10.1042/bj3230159; McDonald KK, 1997, J BIOL CHEM, V272, P31213, DOI 10.1074/jbc.272.50.31213; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; Paltauf-Doburzynska J, 1998, J PHYSIOL-LONDON, V513, P369, DOI 10.1111/j.1469-7793.1998.369bb.x; Pfeiffer S, 1998, MOL PHARMACOL, V53, P795, DOI 10.1124/mol.53.4.795; PHILIPSON KD, 1988, BIOCHIM BIOPHYS ACTA, V945, P298, DOI 10.1016/0005-2736(88)90492-0; Prabhakar P, 1998, J BIOL CHEM, V273, P27383, DOI 10.1074/jbc.273.42.27383; Quednau BD, 1997, AM J PHYSIOL-CELL PH, V272, pC1250, DOI 10.1152/ajpcell.1997.272.4.C1250; REUTER H, 1968, J PHYSIOL-LONDON, V195, P451, DOI 10.1113/jphysiol.1968.sp008467; SAGE SO, 1991, J PHYSIOL-LONDON, V440, P569, DOI 10.1113/jphysiol.1991.sp018725; SCHILLING WP, 1992, BIOCHEM J, V284, P521, DOI 10.1042/bj2840521; Schmidt K, 1999, EUR J BIOCHEM, V259, P25, DOI 10.1046/j.1432-1327.1999.00003.x; SCHMIDT K, 1989, EUR J PHARMACOL, V170, P157, DOI 10.1016/0014-2999(89)90536-0; SCHOEFFTER P, 1986, MOL PHARMACOL, V30, P53; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; SIEGL PKS, 1984, P NATL ACAD SCI-BIOL, V81, P3238, DOI 10.1073/pnas.81.10.3238; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Venema VJ, 1997, BIOCHEM BIOPH RES CO, V236, P155, DOI 10.1006/bbrc.1997.6921; WINQUIST RJ, 1985, J PHARMACOL EXP THER, V235, P644	48	84	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29529	29535		10.1074/jbc.274.41.29529	http://dx.doi.org/10.1074/jbc.274.41.29529			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506218	hybrid			2022-12-27	WOS:000083017800097
J	Hood, BD; Garner, B; Truscott, RJW				Hood, BD; Garner, B; Truscott, RJW			Human lens coloration and aging - Evidence for crystallin modification by the major ultraviolet filter, 3-hydroxy-kynurenine O-beta-D-glucoside	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSOLUBLE PROTEIN-FRACTION; FLUORESCENT COMPOUND; NUCLEAR CATARACT; AGE	The human lens becomes increasingly yellow with age and thereby reduces our perception of blue light. This coloration is associated with lens proteins (crystallins), but its molecular basis was unknown. Here we show that the coloration occurs because of the interaction of crystallins with a UV filter compound, 3-hydroxykynurenine glucoside (3-OHKG), Crystallin modification results from deamination of the 3-OHKG amino acid side chain, yielding an unsaturated ketone that is susceptible to nucleophilic attack by cysteine, histidine, and lysine residues. This novel protein modification contributes to age-related lens coloration and may play a role in human nuclear cataractogenesis.	Univ Wollongong, Dept Chem, Australian Cataract Res Fdn, Wollongong, NSW 2522, Australia	University of Wollongong	Truscott, RJW (corresponding author), Univ Wollongong, Dept Chem, Australian Cataract Res Fdn, POB 1144, Wollongong, NSW 2522, Australia.							BANDO M, 1985, EXP EYE RES, V40, P813, DOI 10.1016/0014-4835(85)90126-5; BESSEMS GJH, 1987, INVEST OPHTH VIS SCI, V28, P1157; BLOEMENDAL H, 1977, SCIENCE, V197, P127, DOI 10.1126/science.877544; BOVA LM, 1999, IN PRESS INVESTIGOPH; DAS SK, 1994, BIOORG MED CHEM LETT, V4, P1219; Dickerson JE, 1997, EXP EYE RES, V65, P451, DOI 10.1006/exer.1997.0343; Dillon J, 1999, PHOTOCHEM PHOTOBIOL, V69, P248, DOI 10.1562/0031-8655(1999)069<0248:TPAOTG>2.3.CO;2; FRIEDMAN M, 1964, J AM CHEM SOC, V86, P3735, DOI 10.1021/ja01072a025; Fu SL, 1998, J BIOL CHEM, V273, P28603, DOI 10.1074/jbc.273.44.28603; Garner B, 1999, J BIOL CHEM, V274, P20847, DOI 10.1074/jbc.274.30.20847; INOUE A, 1993, BIOORG MED CHEM LETT, V3, P345, DOI 10.1016/S0960-894X(01)80907-0; LERMAN S, 1976, OPHTHALMIC RES, V8, P335, DOI 10.1159/000264841; Manthey MK, 1999, J ORG CHEM, V64, P3930, DOI 10.1021/jo982321n; STUTCHBURY GM, 1993, EXP EYE RES, V57, P149, DOI 10.1006/exer.1993.1110; Sweeney MHJ, 1998, EXP EYE RES, V67, P587, DOI 10.1006/exer.1998.0549; TOKUYAMA T, 1967, J AM CHEM SOC, V89, P1017, DOI 10.1021/ja00980a046; TOKUYAMA T, 1958, J CHEM SOC JAPAN, V79, P152; TRUSCOTT RJW, 1977, EXP EYE RES, V24, P159, DOI 10.1016/0014-4835(77)90256-1; TRUSCOTT RJW, 1994, FEBS LETT, V348, P173, DOI 10.1016/0014-5793(94)00601-6; VANHEYNI.R, 1971, NATURE, V230, P393, DOI 10.1038/230393a0; WEALE RA, 1988, J PHYSIOL-LONDON, V395, P577, DOI 10.1113/jphysiol.1988.sp016935; WOOD AM, 1993, EXP EYE RES, V56, P317, DOI 10.1006/exer.1993.1041; YAPPERT MC, 1992, INVEST OPHTH VIS SCI, V33, P3555; YU NT, 1989, EXP EYE RES, V49, P189, DOI 10.1016/0014-4835(89)90089-4	24	102	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32547	32550		10.1074/jbc.274.46.32547	http://dx.doi.org/10.1074/jbc.274.46.32547			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551806	hybrid			2022-12-27	WOS:000083623000006
J	Akiyama, H; Hiraki, Y; Noda, M; Shigeno, C; Ito, H; Nakamura, T				Akiyama, H; Hiraki, Y; Noda, M; Shigeno, C; Ito, H; Nakamura, T			Molecular cloning and biological activity of a novel Ha-ras suppressor gene predominantly expressed in skeletal muscle, heart, brain, and bone marrow by differential display using clonal mouse EC cells, ATDC5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINE ATDC5; IN-VITRO; CHONDROGENESIS; CALCIFICATION; RESISTANT; GROWTH	We cloned a cDNA encoding a novel mouse protein, named A-C1, by differential display between two mouse cell lines: embryonic fibroblast C3HIOT1/2 and chondrogenic ATDC5. The deduced amino acid sequence of A-CI consists of 167 amino acids and shows 46% identity with that of a ras-responsive gene, rat Ha-rev107. Northern blot analysis showed a distinct hybridization band of 3.2 kilobases. Expression of A-C1 mRNA was detected in undifferentiated ATDC5 cells and myoblastic C2C12 cells, while none of C3H10T1/2 cells, NIH3T3 fibroblasts, Balb/c 3T3 fibroblasts, osteoblastic MC3T3-E1 cells, and ST2 bone marrow stromal cells expressed A-C1 mRNA in vitro. Moreover, A-CI mRNA was expressed in skeletal muscle, heart, brain, and bone marrow in adult mice. By in situ hybridization, A-C1 gene expression was localized in hippocampus as well as bone marrow cells. By immunocytochemistry, A-C1 protein was detected in the cytoplasm as web as perinuclear region of the cells. Transfection of A-C1 cDNA into Ha-ras-transformed NIH3T3 cell Line caused increase in the number of flat colonies and inhibition of cell growth. Our data indicate that A-C1 is expressed in some specific tissues in vivo and modulates Ba-ras-mediated signaling pathway.	Kyoto Univ, Grad Sch Med, Dept Orthopaed Surg, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Nucl Med & Diagnost Imaging, Calcium Lab, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Mol Oncol, Kyoto 6068507, Japan; Kyoto Univ, Inst Frontier Med Sci, Dept Mol Interact & Tissue Engn, Kyoto 6068507, Japan	Kyoto University; Kyoto University; Kyoto University; Kyoto University	Akiyama, H (corresponding author), Kyoto Univ, Grad Sch Med, Dept Orthopaed Surg, Kyoto 6068507, Japan.							AARONSON SA, 1968, SCIENCE, V162, P1024, DOI 10.1126/science.162.3857.1024; AHRENS M, 1993, DNA CELL BIOL, V12, P871, DOI 10.1089/dna.1993.12.871; Akiyama H, 1996, J BONE MINER RES, V11, P22; Akiyama H, 1997, BIOCHEM BIOPH RES CO, V235, P142, DOI 10.1006/bbrc.1997.6750; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CHIU CP, 1984, CELL, V37, P879, DOI 10.1016/0092-8674(84)90423-9; FURTH ME, 1987, ONCOGENE, V1, P47; HAJNAL A, 1994, ONCOGENE, V9, P479; IYAMA K, 1991, ANAT RECORD, V229, P462, DOI 10.1002/ar.1092290405; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; OGAWA M, 1988, EMBO J, V7, P1337, DOI 10.1002/j.1460-2075.1988.tb02949.x; Shukunami C, 1998, EXP CELL RES, V241, P1, DOI 10.1006/excr.1998.4045; Shukunami C, 1997, J BONE MINER RES, V12, P1174, DOI 10.1359/jbmr.1997.12.8.1174; Shukunami C, 1996, J CELL BIOL, V133, P457, DOI 10.1083/jcb.133.2.457; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; ZIPORI D, 1985, J CELL PHYSIOL, V122, P81, DOI 10.1002/jcp.1041220113	23	47	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32192	32197		10.1074/jbc.274.45.32192	http://dx.doi.org/10.1074/jbc.274.45.32192			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542256	hybrid			2022-12-27	WOS:000083532100064
J	Disatnik, MH; Rando, TA				Disatnik, MH; Rando, TA			Integrin-mediated muscle cell spreading - The role of protein kinase C in outside-in and inside-out signaling and evidence of integrin cross-talk	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; EXTRACELLULAR-MATRIX; FOCAL ADHESIONS; MUSCULAR-DYSTROPHY; FIBRONECTIN; PHOSPHORYLATION; SURVIVAL; EXPRESSION; TRANSDUCTION; ACTIVATION	Muscle cell survival depends upon the presence of various integrins with affinities for different extracellular matrix proteins. The absence of either alpha(5) or alpha(7) integrins leads to degenerative disorders of skeletal muscle, muscular dystrophies. To understand the cell survival signals that are mediated by integrin engagement with matrix proteins, we studied the early signaling events initiated by the attachment of muscle cells to fibronectin, an interaction that is mediated primarily by alpha(5) integrins, Cells that express alpha(5) integrin rapidly spread on fibronectin, and this process is associated with the phosphorylation of focal adhesion kinase (FAK). Cells deficient in alpha(5) integrin failed to spread or promote FAK phosphorylation when plated on fibronectin, For alpha(5)-expressing cells, both spreading and FAK phosphorylation could be blocked by inhibitors of protein kinase C (PKC), indicating that PKC is necessary for this "outside-in signaling" mediated by alpha(5) integrin. Surprisingly, activators of PKC could promote spreading and FAK phosphorylation in alpha(5)-deficient muscle cells plated on fibronectin, This PKC-induced cell spreading appeared to be due to activation of alpha(4) integrins ("inside-out signaling") since it could be blocked by peptides that specifically inhibit alpha(4) integrin binding to fibronectin, A model of integrin signaling in muscle cells is presented in which there is a positive feedback loop involving PHC in both outside-in and inside-out signaling, and the activation of this cycle is essential for cell spreading and downstream signaling to promote cell survival. In addition, the data indicate a cross-talk that occurs between integrins in which the outside-in signaling via one integrin can promote the activation of another integrin via inside-out signaling.	Stanford Univ, Med Ctr, Dept Neurol & Neurol Sci, Sch Med, Stanford, CA 94305 USA; Vet Affairs Med Ctr, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Rando, TA (corresponding author), Stanford Univ, Med Ctr, Dept Neurol & Neurol Sci, Sch Med, Room A-343, Stanford, CA 94305 USA.	rando@stanford.edu			NINDS NIH HHS [R01 NS-36409] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036409] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BATES RC, 1995, CANCER METAST REV, V14, P191, DOI 10.1007/BF00690291; BROWN PJ, 1988, BIOCHEM BIOPH RES CO, V155, P603, DOI 10.1016/S0006-291X(88)80537-0; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DANILOV YN, 1989, J CELL BIOL, V108, P1925, DOI 10.1083/jcb.108.5.1925; DeNichilo MO, 1996, J BIOL CHEM, V271, P11016, DOI 10.1074/jbc.271.18.11016; Emkey R, 1997, J BIOL CHEM, V272, P31172, DOI 10.1074/jbc.272.49.31172; Faull RJ, 1996, J AM SOC NEPHROL, V7, P1091; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; Haimovich B, 1996, BLOOD, V87, P152, DOI 10.1182/blood.V87.1.152.bloodjournal871152; Haller H, 1998, CIRC RES, V82, P157; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Hayashi YK, 1998, NAT GENET, V19, P94, DOI 10.1038/ng0598-94; Hocking DC, 1998, J CELL BIOL, V141, P241, DOI 10.1083/jcb.141.1.241; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ilic D, 1998, J CELL BIOL, V143, P547; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; Kolanus W, 1997, CURR OPIN CELL BIOL, V9, P725, DOI 10.1016/S0955-0674(97)80127-5; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; Lichtner RB, 1998, EXP CELL RES, V240, P368, DOI 10.1006/excr.1998.4012; MATSUMURA K, 1994, MUSCLE NERVE, V17, P2, DOI 10.1002/mus.880170103; Mayer U, 1997, NAT GENET, V17, P318, DOI 10.1038/ng1197-318; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Montanaro F, 1999, J CELL BIOL, V145, P1325, DOI 10.1083/jcb.145.6.1325; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; ROSALES C, 1995, BBA-REV CANCER, V1242, P77, DOI 10.1016/0304-419X(95)00005-Z; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; Rozengurt E, 1997, ESSAYS BIOCHEM, V32, P73; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; Short SM, 1998, MOL BIOL CELL, V9, P1969, DOI 10.1091/mbc.9.8.1969; Taverna D, 1998, J CELL BIOL, V143, P849, DOI 10.1083/jcb.143.3.849; Vachon PH, 1997, J CLIN INVEST, V100, P1870, DOI 10.1172/JCI119716; Vachon PH, 1996, J CELL BIOL, V134, P1483, DOI 10.1083/jcb.134.6.1483; VUORI K, 1993, J BIOL CHEM, V268, P21459; WOODS A, 1992, J CELL SCI, V101, P277; YAMADA KM, 1984, J CELL BIOL, V99, P29, DOI 10.1083/jcb.99.1.29; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161	41	97	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32486	32492		10.1074/jbc.274.45.32486	http://dx.doi.org/10.1074/jbc.274.45.32486			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542294	hybrid			2022-12-27	WOS:000083532100102
J	Howard, L; Nelson, KK; Maciewicz, RA; Blobel, CP				Howard, L; Nelson, KK; Maciewicz, RA; Blobel, CP			Interaction of the metalloprotease disintegrins MDC9 and MDC15 with two SH3 domain-containing proteins, endophilin I and SH3PX1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; SPERM-EGG FUSION; BINDING PARTNERS; MEMBRANE-FUSION; CELL-ADHESION; SORTING NEXIN; GENE FAMILY; IDENTIFICATION; RECEPTORS; SYNAPTOJANIN	Metalloprotease disintegrins (a disintegrin and metalloprotease (ADAM) and metalloprotease, disintegrin, cysteine-rich proteins (MDC)) are a family of membrane-anchored glycoproteins that function in diverse biological processes, including fertilization, neurogenesis, myogenesis, and ectodomain processing of cytokines and other proteins. The cytoplasmic domains of ADAMs often include putative signaling motifs, such as proline-rich SH3 ligand domains, suggesting that interactions with cytoplasmic proteins may affect metalloprotease disintegrin function. Here we report that two SH3 domain-containing proteins, endophilin I (SH3GL2, SH3p4) and a novel SH3 domain- and phox homology (PX) domain-containing protein, termed SH3PX1, can interact with the cytoplasmic domains of the metalloprotease disintegrins MDC9 and MDC15. These interactions were initially identified in a yeast two-hybrid screen and then confirmed using bacterial fusion proteins and co-immunoprecipitations from eukaryotic cells expressing both binding partners. SHSPX1 and endophilin I both preferentially bind the precursor but not the processed form of MDC9 and MDC15 in COS-7 cells. Since rat endophilin I is thought to play a role in synaptic vesicle endocytosis and SH3PX1 has sequence similarity to sorting nexins in yeast, we propose that endophilin I and SH3PX1 may have a role in regulating the function of MDC9 and MDC15 by influencing their intracellular processing, transport, or final subcellular localization.	Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Cellular Biochem & Biophys Program, New York, NY 10021 USA; AstraZeueca Pharmaceut, Resp & Inflammat Res, Macclesfield SK10 4TG, Cheshire, England	Memorial Sloan Kettering Cancer Center	Blobel, CP (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Cellular Biochem & Biophys Program, Box 368,1275 York Ave, New York, NY 10021 USA.	c-blobel@ski.mskcc.org	Howard, Linda/B-2463-2009	HOWARD, LINDA/0000-0003-4760-7996	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM018585, R55GM051988] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA-08748] Funding Source: Medline; NIGMS NIH HHS [F32GM18585-02, R55GM51988] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; BLOBEL CP, 1990, J CELL BIOL, V111, P69, DOI 10.1083/jcb.111.1.69; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Chen H, 1999, CHEM BIOL, V6, P1, DOI 10.1016/S1074-5521(99)80015-5; Chen MS, 1999, J CELL BIOL, V144, P549, DOI 10.1083/jcb.144.3.549; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; Evans JP, 1997, DEV BIOL, V187, P94, DOI 10.1006/dbio.1997.8612; EVANS JP, 1995, J CELL SCI, V108, P3267; Giachino C, 1997, GENOMICS, V41, P427, DOI 10.1006/geno.1997.4645; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; Haft CR, 1998, MOL CELL BIOL, V18, P7278, DOI 10.1128/MCB.18.12.7278; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; Herren B, 1997, FASEB J, V11, P173, DOI 10.1096/fasebj.11.2.9039960; Howard L, 1996, BIOCHEM J, V317, P45, DOI 10.1042/bj3170045; HUANG TF, 1989, BIOCHEMISTRY-US, V28, P661, DOI 10.1021/bi00428a037; HUANG TF, 1987, J BIOL CHEM, V262, P16157; Inoue D, 1998, J BIOL CHEM, V273, P4180, DOI 10.1074/jbc.273.7.4180; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Kratzschmar J, 1996, J BIOL CHEM, V271, P4593; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Loechel F, 1998, J BIOL CHEM, V273, P16993, DOI 10.1074/jbc.273.27.16993; Lum L, 1998, J BIOL CHEM, V273, P26236, DOI 10.1074/jbc.273.40.26236; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; McLane MA, 1998, P SOC EXP BIOL MED, V219, P109, DOI 10.3181/00379727-219-44322; Merilainen J, 1997, J BIOL CHEM, V272, P23278, DOI 10.1074/jbc.272.37.23278; Micheva KD, 1997, J BIOL CHEM, V272, P27239, DOI 10.1074/jbc.272.43.27239; Micheva KD, 1997, FEBS LETT, V414, P308, DOI 10.1016/S0014-5793(97)01016-8; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; MYLES DG, 1994, P NATL ACAD SCI USA, V91, P4195, DOI 10.1073/pnas.91.10.4195; Nath D, 1999, J CELL SCI, V112, P579; NELSON KK, 1999, IN PRESS BIOCH J; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; PRIMAKOFF P, 1987, J CELL BIOL, V104, P141, DOI 10.1083/jcb.104.1.141; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; QUINN MT, 1993, J BIOL CHEM, V268, P20983; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; Rosendahl MS, 1997, J BIOL CHEM, V272, P24588, DOI 10.1074/jbc.272.39.24588; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1058; Schlondorff J, 1999, J CELL SCI, V112, P3603; Sittler A, 1998, MOL CELL, V2, P427, DOI 10.1016/S1097-2765(00)80142-2; Skehel JJ, 1998, CELL, V95, P871, DOI 10.1016/S0092-8674(00)81710-9; Snell WJ, 1996, CELL, V85, P629, DOI 10.1016/S0092-8674(00)81230-1; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Sotillos S, 1997, DEVELOPMENT, V124, P4769; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Wen CH, 1997, DEVELOPMENT, V124, P4759; Weskamp G, 1996, J CELL BIOL, V132, P717, DOI 10.1083/jcb.132.4.717; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; Yuan RY, 1997, J CELL BIOL, V137, P105, DOI 10.1083/jcb.137.1.105; Zhang XP, 1998, J BIOL CHEM, V273, P7345, DOI 10.1074/jbc.273.13.7345; Zhu GZ, 1999, GENE, V234, P227, DOI 10.1016/S0378-1119(99)00208-5	63	147	169	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31693	31699		10.1074/jbc.274.44.31693	http://dx.doi.org/10.1074/jbc.274.44.31693			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531379	hybrid			2022-12-27	WOS:000083379400083
J	Morris, DP; Phatnani, HP; Greenleaf, AL				Morris, DP; Phatnani, HP; Greenleaf, AL			Phospho-carboxyl-terminal domain binding and the role of a prolyl isomerase in pre-mRNA 3 '-end formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; REPEAT DOMAIN; WW DOMAINS; IN-VIVO; PHOSPHORYLATION; TRANSCRIPTION; GENE; CTD	A phospho-carboxyl-terminal domain (CTD) affinity column created with yeast CTD kinase I and the CTD of RNA polymerase II was used to identify Ess1/Pin1 as a phospho-CTD-binding protein. Ess1/Pin1 is a peptidyl prolyl isomerase involved in both mitotic regulation and pre-mRNA 3'-end formation. Like native Ess1, a GST-Ess1 fusion protein associates specifically with the phosphorylated but not with the unphosphorylated CTD. Further, hyperphosphorylated RNA polymerase II appears to be the dominant Ess1 binding protein in total yeast extracts. We demonstrate that phospho-CTD binding is mediated by the small WW domain of Ess1 rather than the isomerase domain. These findings suggest a mechanism in which the WW domain binds the phosphorylated CTD of elongating RNA polymerase II and the isomerase domain reconfigures the CTD though isomerization of proline residues perhaps by a processive mechanism. This process may be linked to a variety of pre-mRNA maturation events that use the phosphorylated CTD, including the coupled processes of pre-mRNA S'-end formation and transcription termination.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Greenleaf, AL (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.							Albert A, 1999, J CELL SCI, V112, P2493; Ausubel FM, 1994, CURRENT PROTOCOLS MO; CADENA DL, 1987, J BIOL CHEM, V262, P12468; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; Corden JL, 1997, TRENDS BIOCHEM SCI, V22, P413, DOI 10.1016/S0968-0004(97)01125-0; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P388; Crenshaw DG, 1998, EMBO J, V17, P1315, DOI 10.1093/emboj/17.5.1315; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; Du L, 1997, J CELL BIOL, V136, P5, DOI 10.1083/jcb.136.1.5; Gavva NR, 1997, J BIOL CHEM, V272, P24105, DOI 10.1074/jbc.272.39.24105; Greenblatt J, 1997, CURR OPIN CELL BIOL, V9, P310, DOI 10.1016/S0955-0674(97)80002-6; GREENLEAF AL, 1993, TRENDS BIOCHEM SCI, V18, P117, DOI 10.1016/0968-0004(93)90016-G; HANES SD, 1989, YEAST, V5, P55, DOI 10.1002/yea.320050108; Hani J, 1999, J BIOL CHEM, V274, P108, DOI 10.1074/jbc.274.1.108; Hirose Y, 1998, NATURE, V395, P93, DOI 10.1038/25786; Hirose Y, 1999, GENE DEV, V13, P1234, DOI 10.1101/gad.13.10.1234; Ho CK, 1999, MOL CELL, V3, P405, DOI 10.1016/S1097-2765(00)80468-2; Kim E, 1997, J CELL BIOL, V136, P19, DOI 10.1083/jcb.136.1.19; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; LEE JM, 1991, GENE EXPRESSION, V1, P149; LEE JM, 1989, P NATL ACAD SCI USA, V86, P3624, DOI 10.1073/pnas.86.10.3624; Linn H, 1997, BIOL CHEM, V378, P531, DOI 10.1515/bchm.1997.378.6.531; Lu KP, 1996, NATURE, V380, P544; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Maleszka R, 1996, P NATL ACAD SCI USA, V93, P447, DOI 10.1073/pnas.93.1.447; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; Morris DP, 1997, METHODS, V12, P264, DOI 10.1006/meth.1997.0478; Myer VE, 1998, J BIOL CHEM, V273, P27757, DOI 10.1074/jbc.273.43.27757; Nguyen JT, 1998, SCIENCE, V282, P2088, DOI 10.1126/science.282.5396.2088; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; STERNER DE, 1995, MOL CELL BIOL, V15, P5716; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; Wang GL, 1999, MOL CELL BIOL, V19, P342; WEEKS JR, 1993, GENE DEV, V7, P2329, DOI 10.1101/gad.7.12a.2329	36	129	133	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31583	31587		10.1074/jbc.274.44.31583	http://dx.doi.org/10.1074/jbc.274.44.31583			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531363	hybrid			2022-12-27	WOS:000083379400067
J	Tamarit, J; Mulliez, E; Meier, C; Trautwein, A; Fontecave, M				Tamarit, J; Mulliez, E; Meier, C; Trautwein, A; Fontecave, M			The anaerobic ribonucleotide reductase from Escherichia coli - The small protein is an activating enzyme containing a [4Fe-4S](2+) center	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE FORMATE-LYASE; IRON-SULFUR CENTER; MOLECULAR-PROPERTIES; CLUSTER; QUANTITATION; CONVERSION; 2FE-2S; 4FE-4S; SITE; DNA	For deoxyribonucleotide synthesis during anaerobic growth, Escherichia coli cells depend on an oxygen-sensitive class III ribonucleotide reductase, The enzyme system consists of two proteins: protein alpha, on which ribonucleotides bind and are reduced, and protein beta, of which the function is to introduce a catalytically essential glycyl radical on protein alpha, Protein beta can assemble one [4Fe-4S] center per polypeptide enjoying both the [4Fe-4S](2+) and [4Fe-4S](1+) redox state, as shown by iron and sulfide analysis, Mossbauer spectroscopy (delta = 0.43 mm.s(-1), Delta E-Q = 1.0 mm.s(-1), [4Fe-4S](2+)), and EPR spectroscopy (g = 2.03 and 1.93, [4Fe-4S](1+)). This iron center is sensitive to oxygen and can decompose into stable [2Fe-2S](2+) centers during exposure to air. This degraded form is nevertheless active, albeit to a lesser extent because of the conversion of the cluster into [4Fe-4S] forms during the strongly reductive conditions of the assay. Furthermore, protein beta has the potential to activate several molecules of protein alpha, suggesting that protein beta is an activating enzyme rather than a component of an alpha(2)beta(2) complex as previously claimed.	Univ Grenoble 1, Lab Chim & Biochim, Dept Biol Mol & Struct Chim & Biochim, CEA,1087 CNRS,Ctr Redox Biol, F-38054 Grenoble 9, France; Univ Lubeck, Inst Phys, D-23538 Lubeck, Germany	CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); University of Lubeck	Fontecave, M (corresponding author), Univ Grenoble 1, Lab Chim & Biochim, Dept Biol Mol & Struct Chim & Biochim, CEA,1087 CNRS,Ctr Redox Biol, 17 Rue Martyrs, F-38054 Grenoble 9, France.		Tamarit, Jordi/C-6316-2008	Tamarit, Jordi/0000-0003-3227-6928				BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; BIANCHI V, 1993, J BACTERIOL, V175, P1590, DOI 10.1128/JB.175.6.1590-1595.1993; BIANCHI V, 1993, BIOCHEM BIOPH RES CO, V197, P792, DOI 10.1006/bbrc.1993.2548; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Broderick JB, 1997, J AM CHEM SOC, V119, P7396, DOI 10.1021/ja9711425; Duin EC, 1997, BIOCHEMISTRY-US, V36, P11811, DOI 10.1021/bi9706430; ELIASSON R, 1994, J BIOL CHEM, V269, P26052; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; FREY M, 1994, J BIOL CHEM, V269, P12432; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; Khoroshilova N, 1997, P NATL ACAD SCI USA, V94, P6087, DOI 10.1073/pnas.94.12.6087; KING DS, 1995, BIOCHEM BIOPH RES CO, V206, P731, DOI 10.1006/bbrc.1995.1103; Kulzer R, 1998, J BIOL CHEM, V273, P4897, DOI 10.1074/jbc.273.9.4897; Logan DT, 1999, SCIENCE, V283, P1499, DOI 10.1126/science.283.5407.1499; MULLIEZ E, 1995, P NATL ACAD SCI USA, V92, P8759, DOI 10.1073/pnas.92.19.8759; MULLIEZ E, 1993, J BIOL CHEM, V268, P2296; MULLIEZ E, 1999, IN PRESS J BIOL INOR; Ollagnier S, 1996, J BIOL CHEM, V271, P9410, DOI 10.1074/jbc.271.16.9410; Ollagnier S, 1999, J AM CHEM SOC, V121, P6344, DOI 10.1021/ja990073m; Ollagnier S, 1997, J BIOL CHEM, V272, P24216, DOI 10.1074/jbc.272.39.24216; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; Reichard P, 1997, TRENDS BIOCHEM SCI, V22, P81, DOI 10.1016/S0968-0004(97)01003-7; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; SCHULZ C, 1976, J PHYS-PARIS, V37, pC6153; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; Sun XY, 1996, J BIOL CHEM, V271, P6827, DOI 10.1074/jbc.271.12.6827; SUN XY, 1995, J BIOL CHEM, V270, P2443, DOI 10.1074/jbc.270.6.2443; SUN XY, 1993, P NATL ACAD SCI USA, V90, P577, DOI 10.1073/pnas.90.2.577; WONG KK, 1993, BIOCHEMISTRY-US, V32, P14102, DOI 10.1021/bi00214a005	29	63	63	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31291	31296		10.1074/jbc.274.44.31291	http://dx.doi.org/10.1074/jbc.274.44.31291			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531327	Green Published, hybrid			2022-12-27	WOS:000083379400031
J	Tominaga, K; Morisaki, H; Kaneko, Y; Fujimoto, A; Tanaka, T; Ohtsubo, M; Hirai, M; Okayama, H; Ikeda, K; Nakanishi, M				Tominaga, K; Morisaki, H; Kaneko, Y; Fujimoto, A; Tanaka, T; Ohtsubo, M; Hirai, M; Okayama, H; Ikeda, K; Nakanishi, M			Role of human Cds1 (Chk2) kinase in DNA damage checkpoint and its regulation by p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CHECKPOINT; LARGE-T-ANTIGEN; ATAXIA-TELANGIECTASIA CELLS; FISSION YEAST; PROTEIN-KINASE; S-PHASE; GENE; ATM; PATHWAY; MUTATIONS	In response to DNA damage, mammalian cells adopt checkpoint regulation, by phosphorylation and stabilization of p53, to delay cell cycle progression. However, most cancer cells that lack functional p53 retain an unknown checkpoint mechanism(s) by which cells are arrested at the G(2)/M phase. Here we demonstrate that a human homolog of Cds1/Rad53 kinase (hCds1) is rapidly phosphorylated and activated in response to DNA damage not only in normal cells but in cancer cells lacking functional p53. A survey of various cancer cell lines revealed that the expression level of hCds1 mRNA is inversely related to the presence of functional p53. In addition, transfection of normal human fibroblasts with SV40 T antigen or human papilloma viruses E6 or E7 causes a marked induction of hCds1 mRNA, and the introduction of functional p53 into SV40 T antigen- and E6-, but not E7-, transfected cells decreases the hCds1 level, suggesting that p53 negatively regulates the expression of hCds1. In cells without functional ataxia telangiectasia mutated (ATM) protein, phosphorylation and activation of hCds1 were observed in response to DNA damage induced by UV but not by ionizing irradiation. These results suggest that hCds1 is activated through an ATM-dependent as well as -independent pathway and that it may complement the function of p53 in DNA damage checkpoints in mammalian cells.	Nagoya City Univ, Sch Med, Dept Biochem, Mizuho Ku, Nagoya, Aichi 4678601, Japan; Natl Inst Longev Sci, Dept Geriatr Res, Aichi 4748522, Japan; Kurume Univ, Inst Life Sci, Div Mol Genet, Kurume, Fukuoka 8390861, Japan; Univ Tokyo, Grad Sch Sci, Dept Sci Biol, Bunkyo Ku, Tokyo 113, Japan	Nagoya City University; Kurume University; University of Tokyo	Nakanishi, M (corresponding author), Nagoya City Univ, Sch Med, Dept Biochem, Mizuho Ku, 1 Kawasumi,Mizuhocho, Nagoya, Aichi 4678601, Japan.		Tominaga, Kaoru/AAL-4250-2020	Tominaga, Kaoru/0000-0001-8799-528X; ohtsubo, motoaki/0000-0002-2479-3178				Barlow C, 1997, NAT GENET, V17, P453, DOI 10.1038/ng1297-453; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; DUTHU A, 1992, ONCOGENE, V7, P2161; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Fuse T, 1996, BIOCHEM BIOPH RES CO, V225, P759, DOI 10.1006/bbrc.1996.1247; HALBERT CL, 1992, J VIROL, V66, P2125, DOI 10.1128/JVI.66.4.2125-2134.1992; Harrington EA, 1998, P NATL ACAD SCI USA, V95, P11945, DOI 10.1073/pnas.95.20.11945; HIRAI M, 1994, CYTOGENET CELL GENET, V66, P149, DOI 10.1159/000133687; JAT PS, 1986, MOL CELL BIOL, V6, P1204, DOI 10.1128/MCB.6.4.1204; KANEKO Y, 1999, IN PRESS ONCOGENE; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHANNA KK, 1993, ONCOGENE, V8, P3307; Kumagai A, 1998, MOL BIOL CELL, V9, P345, DOI 10.1091/mbc.9.2.345; Kumagai A, 1998, J CELL BIOL, V142, P1559, DOI 10.1083/jcb.142.6.1559; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; Longhese MP, 1998, EMBO J, V17, P5525, DOI 10.1093/emboj/17.19.5525; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; NAKANISHI M, 1995, P NATL ACAD SCI USA, V92, P4532; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Saka Y, 1997, GENE DEV, V11, P3387, DOI 10.1101/gad.11.24.3387; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SASAKI MS, 1994, MUTAT RES, V307, P107, DOI 10.1016/0027-5107(94)90282-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SEGAWA K, 1993, ONCOGENE, V8, P543; Tanikawa M, 1998, J BIOL CHEM, V273, P18522, DOI 10.1074/jbc.273.29.18522; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; YAGINUMA Y, 1991, CANCER RES, V51, P6506; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8; ZALVIDE J, 1995, MOL CELL BIOL, V15, P5800	47	77	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31463	31467		10.1074/jbc.274.44.31463	http://dx.doi.org/10.1074/jbc.274.44.31463			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531348	hybrid			2022-12-27	WOS:000083379400052
J	Mao, ZX; Wiedmann, M				Mao, ZX; Wiedmann, M			Calcineurin enhances MEF2 DNA binding activity in calcium-dependent survival of cerebellar granule neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR MEF2C; GROWTH-FACTOR-I; CYCLOSPORINE-A; MUSCLE DIFFERENTIATION; INDUCED APOPTOSIS; NERVOUS-SYSTEM; FAMILY MEMBER; T-CELL; ACTIVATION; EXPRESSION	Myocyte enhancer factor 2 (MEF2) has been shown recently to be necessary for mediating activity-dependent neuronal survival. In this study, we show that calcium signals regulate MEF2 activity through a serine/threonine phosphatase calcineurin. In cultured primary cerebellar granule neurons, the electrophoretic mobility of MEF2A protein was sensitive to the level of extracellular potassium chloride (KCI) and depolarizing concentrations of KCl led to hypophosphorylation of the protein. The specific inhibitors of calcineurin cyclosporin A (CsA) and FK506 could overcome KCl-dependent MEF2A hypophosphorylation, The effects of CsA and FK506 were KCl specific as they had little effect on MEF2A phosphorylation when granule neurons were cultured in the presence of full media. Hyperphosphorylation of MEF2A led to the loss of its DNA binding activity as determined by DNA mobility shift assay. Consistent with this, CsA/FK506 also inhibited MEF2-dependent reporter gene expression. These findings demonstrate that regulation of MEF2A by calcium signals requires the action of protein phosphatase calcineurin. By maintaining MEF2A in a hypophosphorylated state, calcineurin enhances the DNA binding activity of MEF2A and therefore maximizes its transactivation capability. The identification of MEF2 as a novel target of calcineurin may provide in part a biochemical explanation for the therapeutic and toxic effects of immunosuppressants CsA and FK506.	Rhode Isl Hosp, Dept Med, Liver Res Ctr, Providence, RI 02903 USA; Brown Univ, Sch Med, Providence, RI 02903 USA	Lifespan Health Rhode Island; Rhode Island Hospital; Brown University	Mao, ZX (corresponding author), Rhode Isl Hosp, Dept Med, Liver Res Ctr, Providence, RI 02903 USA.							Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; De Angelis L, 1998, P NATL ACAD SCI USA, V95, P12358, DOI 10.1073/pnas.95.21.12358; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FRANKLIN JL, 1992, TRENDS NEUROSCI, V15, P501, DOI 10.1016/0166-2236(92)90103-F; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; HACK N, 1993, NEUROSCIENCE, V57, P9, DOI 10.1016/0306-4522(93)90108-R; HALPAIN S, 1990, NATURE, V343, P369, DOI 10.1038/343369a0; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; LEIFER D, 1994, NEUROSCIENCE, V63, P1067, DOI 10.1016/0306-4522(94)90573-8; Lin X, 1996, MOL BRAIN RES, V42, P307, DOI 10.1016/S0169-328X(96)00135-0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Liu SF, 1997, EMBO J, V16, P143, DOI 10.1093/emboj/16.1.143; Luo C, 1996, P NATL ACAD SCI USA, V93, P8907, DOI 10.1073/pnas.93.17.8907; LYONS GE, 1995, J NEUROSCI, V15, P5727, DOI 10.1523/jneurosci.15-08-05727.1995; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; Miller TM, 1996, J NEUROSCI, V16, P7487; Miller TM, 1997, J BIOL CHEM, V272, P9847; Molkentin JD, 1996, MOL CELL BIOL, V16, P2627; Molkentin JD, 1996, J BIOL CHEM, V271, P17199, DOI 10.1074/jbc.271.29.17199; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; Rao S, 1998, J BIOL CHEM, V273, P26123, DOI 10.1074/jbc.273.40.26123; Satyaraj E, 1998, J IMMUNOL, V161, P4795; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; Schulz JB, 1996, J NEUROSCI, V16, P4696; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SNYDER SH, 1995, NAT MED, V1, P32, DOI 10.1038/nm0195-32; Swanson BJ, 1998, MOL IMMUNOL, V35, P445, DOI 10.1016/S0161-5890(98)00058-3; WORONICZ JD, 1995, MOL CELL BIOL, V15, P6364; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; Zechner D, 1998, J BIOL CHEM, V273, P8232, DOI 10.1074/jbc.273.14.8232	35	125	127	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					31102	31107		10.1074/jbc.274.43.31102	http://dx.doi.org/10.1074/jbc.274.43.31102			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521511	hybrid			2022-12-27	WOS:000083276700107
J	Beier, F; Taylor, AC; LuValle, P				Beier, F; Taylor, AC; LuValle, P			The Raf-1/MEK/ERK pathway regulates the expression of the p21(Cip1/Waf1) gene in chondrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-RELATED PEPTIDE; MAP KINASE CASCADES; VITAMIN-D-RECEPTOR; CELL-CYCLE ARREST; MICE LACKING; SKELETAL DEVELOPMENT; HERITABLE DISEASES; MOLECULAR INSIGHTS; TRANSGENIC MICE; BONE-FORMATION	The gene encoding the cyclin-dependent kinase inhibitor p21(Cip2/Waf1) is up-regulated in many differentiating cells, including maturing chondrocytes. Since strict control of chondrocyte proliferation is essential for proper bone formation and since p21 is likely involved in this control, we initiated analyses of the mechanisms regulating expression of p21 in chondrocytes. p21 expression and promoter activity was strongly increased during the differentiation of chondrogenic MCT cells. We have identified a 68-base pair fragment conferring transcriptional up-regulation of the p21 gene in chondrocytes. The activity of this fragment required active Raf-1 in MCT cells as well as in primary mouse chondrocytes. Inhibition of downstream factors of Raf-1 (MEK1/2, ERK1/2, and Ets2) also repressed the activity off the 68-base pair fragment in MCT cells. The chemical MEK1/2 inhibitor PD98059 reduced protein levels of p21 in MCTs and primary mouse chondrocytes. These data suggest that signaling through the Raf-1 pathway is necessary for the optimal expression of p21 in chondrocytes and may play an important role in the control of bone formation.	Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	University of Calgary	LuValle, P (corresponding author), Univ Calgary, Dept Biochem & Mol Biol, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	vpalu@acs.ucalgary.ca	Beier, Frank/G-4595-2013; Beier, Frank/T-4734-2019	Beier, Frank/0000-0002-8505-7537; Beier, Frank/0000-0002-8505-7537				Aigner T, 1997, HISTOCHEM CELL BIOL, V107, P435, DOI 10.1007/s004180050130; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; AMIZUKA N, 1994, J CELL BIOL, V126, P1611, DOI 10.1083/jcb.126.6.1611; Amling M, 1997, J CELL BIOL, V136, P205, DOI 10.1083/jcb.136.1.205; Beier F, 1999, J CELL BIOCHEM, V72, P549, DOI 10.1002/(SICI)1097-4644(19990315)72:4<549::AID-JCB10>3.0.CO;2-1; Beier F, 1999, MATRIX BIOL, V18, P109, DOI 10.1016/S0945-053X(99)00009-8; Beier F, 1999, P NATL ACAD SCI USA, V96, P1433, DOI 10.1073/pnas.96.4.1433; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CANCEDDA R, 1995, INT REV CYTOL, V159, P265, DOI 10.1016/S0074-7696(08)62109-9; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Fraichard A, 1997, EMBO J, V16, P4412, DOI 10.1093/emboj/16.14.4412; Funaoka K, 1997, BIOCHEM BIOPH RES CO, V236, P79, DOI 10.1006/bbrc.1997.6909; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HARPER JW, 1993, CELL, V75, P805; Hirsch MS, 1997, DEV DYNAM, V210, P249, DOI 10.1002/(SICI)1097-0177(199711)210:3<249::AID-AJA6>3.0.CO;2-G; HUPPI K, 1994, ONCOGENE, V9, P3017; KANEKO Y, 1994, CALCIFIED TISSUE INT, V54, P426, DOI 10.1007/BF00305531; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; LEFEBVRE V, 1995, J CELL BIOL, V128, P239, DOI 10.1083/jcb.128.1.239; LEFEBVRE V, 1994, MATRIX BIOL, V14, P329, DOI 10.1016/0945-053X(94)90199-6; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Li YC, 1997, P NATL ACAD SCI USA, V94, P9831, DOI 10.1073/pnas.94.18.9831; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Mundlos S, 1997, FASEB J, V11, P227, DOI 10.1096/fasebj.11.4.9068611; Mundlos S, 1997, FASEB J, V11, P125, DOI 10.1096/fasebj.11.2.9039954; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Poluha W, 1997, J BIOL CHEM, V272, P24002, DOI 10.1074/jbc.272.38.24002; Reimann T, 1997, FEBS LETT, V403, P57, DOI 10.1016/S0014-5793(97)00024-0; Reimold AM, 1996, NATURE, V379, P262, DOI 10.1038/379262a0; Serra R, 1997, J CELL BIOL, V139, P541, DOI 10.1083/jcb.139.2.541; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Stewart MC, 1997, CALCIFIED TISSUE INT, V61, P199, DOI 10.1007/s002239900323; Sumarsono SH, 1996, NATURE, V379, P534, DOI 10.1038/379534a0; Sunters A, 1998, DEV GENET, V22, P386, DOI 10.1002/(SICI)1520-6408(1998)22:4<386::AID-DVG8>3.0.CO;2-2; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Xu RH, 1996, P NATL ACAD SCI USA, V93, P834, DOI 10.1073/pnas.93.2.834; Yan Y, 1997, GENE DEV, V11, P973, DOI 10.1101/gad.11.8.973; Yang BS, 1996, MOL CELL BIOL, V16, P538; Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0	55	83	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30273	30279		10.1074/jbc.274.42.30273	http://dx.doi.org/10.1074/jbc.274.42.30273			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514521	hybrid			2022-12-27	WOS:000083176400100
J	Kuhn, DM; Geddes, TJ				Kuhn, DM; Geddes, TJ			Peroxynitrite inactivates tryptophan hydroxylase via sulfhydryl oxidation - Coincident nitration of enzyme tyrosyl residues has minimal impact on catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL NITRIC-OXIDE; SUPEROXIDE-DISMUTASE; CARBON-DIOXIDE; DOPAMINERGIC NEUROTOXICITY; SEROTONIN NEURONS; MDMA ECSTASY; BRAIN; METHAMPHETAMINE; ACID; PROTEINS	Tryptophan hydroxylase, the initial and rate-limiting enzyme in serotonin biosynthesis, is inactivated by peroxynitrite in a concentration-dependent manner. This effect is prevented by molecules that react directly with peroxynitrite such as dithiothreitol, cysteine, glutathione, methionine tryptophan, and uric acid but not by scavengers of superoxide (superoxide dismutase), hydroxyl radical (Me2SO, mannitol), and hydrogen peroxide (catalase), Assuming simple competition kinetics between peroxynitrite scavengers and the enzyme, a second-order rate constant of 3.4 x 10(4) M-1 s(-1) at 25 degrees C and pH 7.4 was estimated. The peroxynitrite-induced loss of enzyme activity was accompanied by a concentration-dependent oxidation of protein sulfhydryl groups, Peroxynitrite-modified tryptophan hydroxylase was resistant to reduction by arsenite, borohydride, and dithiothreitol, suggesting that sulfhydryls were oxidized beyond sulfenic acid. Peroxynitrite also caused the nitration of tyrosyl residues in tryptophan hydroxylase, with a maximal modification of 3.8 tyrosines/monomer, Sodium bicarbonate protected tryptophan hydroxylase from peroxynitrite-induced inactivation and lessened the extent of sulfhydryl oxidation while causing a 2-fold increase in tyrosine nitration, Tetranitromethane, which oxidizes sulfhydryls at pH 6 or 8, but which nitrates tyrosyl residues at pH 8 only, inhibited tryptophan hydroxylase equally at either pH, Acetylation of tyrosyl residues with N-acetylimidazole did not alter tryptophan hydroxylase activity, These data suggest that peroxynitrite inactivates tryptophan hydroxylase via sulfhydryl oxidation, Modification of tyrosyl residues by peroxynitrite plays a relatively minor role in the inhibition of tryptophan hydroxylase catalytic activity.	Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Ctr Mol Med & Genet, Detroit, MI 48201 USA	Wayne State University; Wayne State University	Kuhn, DM (corresponding author), 2125 Scott Hall,540 E Canfield, Detroit, MI 48201 USA.				NIDA NIH HHS [DA10756] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA010756] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Acikgoz O, 1998, BRAIN RES, V813, P200, DOI 10.1016/S0006-8993(98)01020-8; Alvarez B, 1999, J BIOL CHEM, V274, P842, DOI 10.1074/jbc.274.2.842; Ara J, 1998, P NATL ACAD SCI USA, V95, P7659, DOI 10.1073/pnas.95.13.7659; Beal MF, 1997, ANN NEUROL, V42, P644, DOI 10.1002/ana.410420416; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; Berlett BS, 1998, P NATL ACAD SCI USA, V95, P2784, DOI 10.1073/pnas.95.6.2784; Bolanos JP, 1997, J NEUROCHEM, V68, P2227; Bonini MG, 1999, J BIOL CHEM, V274, P10802, DOI 10.1074/jbc.274.16.10802; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASTRO L, 1994, J BIOL CHEM, V269, P29409; COHEN LA, 1968, ANNU REV BIOCHEM, V37, P695, DOI 10.1146/annurev.bi.37.070168.003403; Crow JP, 1996, METHOD ENZYMOL, V269, P185; DARMON MC, 1988, J NEUROCHEM, V51, P312, DOI 10.1111/j.1471-4159.1988.tb04871.x; DSa CM, 1996, J NEUROCHEM, V67, P917; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GARTSIDE SE, 1992, PSYCHOPHARMACOLOGY, V109, P251, DOI 10.1007/BF02245511; Gibb J W, 1997, NIDA Res Monogr, V173, P128; Gow A, 1996, ARCH BIOCHEM BIOPHYS, V333, P42, DOI 10.1006/abbi.1996.0362; GRENETT HE, 1987, P NATL ACAD SCI USA, V84, P5530, DOI 10.1073/pnas.84.16.5530; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; Hirata H, 1998, MOL BRAIN RES, V58, P209, DOI 10.1016/S0169-328X(98)00055-2; Hooper DC, 1998, P NATL ACAD SCI USA, V95, P675, DOI 10.1073/pnas.95.2.675; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; Itzhak Y, 1998, J PHARMACOL EXP THER, V284, P1040; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; Kuhn DM, 1997, J NEUROCHEM, V68, P1495; Kuhn DM, 1997, J NEUROCHEM, V68, P2220; Kuhn DM, 1998, J NEUROSCI, V18, P7111; KUHN DM, 1980, J BIOL CHEM, V255, P4137; Kuhn DM, 1997, J NEUROSCI, V17, P7245; KUHN DM, 1996, J NEUROCHEM, V67, P1071; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MacMillan-Crow LA, 1998, BIOCHEMISTRY-US, V37, P1613, DOI 10.1021/bi971894b; MATSUBARA C, 1983, ANAL BIOCHEM, V130, P128, DOI 10.1016/0003-2697(83)90659-0; McCann UD, 1998, LANCET, V352, P1433, DOI 10.1016/S0140-6736(98)04329-3; MCCANN UD, 1994, NEUROPSYCHOPHARMACOL, V10, P129, DOI 10.1038/npp.1994.15; McCann UD, 1998, J NEUROSCI, V18, P8417; Padmaja S, 1998, ARCH BIOCHEM BIOPHYS, V349, P1, DOI 10.1006/abbi.1997.0407; PAUL SM, 1990, J CLIN PSYCHIAT S, V51, P1; Persichini T, 1998, BIOCHEM BIOPH RES CO, V250, P575, DOI 10.1006/bbrc.1998.9350; Pryor WA, 1997, FREE RADICAL BIO MED, V23, P331, DOI 10.1016/S0891-5849(97)00121-4; PRYOR WA, 1994, P NATL ACAD SCI USA, V91, P11173, DOI 10.1073/pnas.91.23.11173; Przedborski S, 1996, P NATL ACAD SCI USA, V93, P4565, DOI 10.1073/pnas.93.10.4565; RADI R, 1991, J BIOL CHEM, V266, P4244; Radi R, 1996, METHOD ENZYMOL, V269, P354; Radi R, 1999, METHOD ENZYMOL, V301, P353; RADI R, 1994, ARCH BIOCHEM BIOPHYS, V308, P89, DOI 10.1006/abbi.1994.1013; Reist M, 1998, J NEUROCHEM, V71, P2431; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; Riordan J F, 1972, Methods Enzymol, V25, P500, DOI 10.1016/S0076-6879(72)25046-7; Smith MA, 1997, J NEUROSCI, V17, P2653; SOKOLOVS.M, 1966, BIOCHEMISTRY-US, V5, P3582, DOI 10.1021/bi00875a029; Souza JM, 1998, ARCH BIOCHEM BIOPHYS, V360, P187, DOI 10.1006/abbi.1998.0932; STEELE TD, 1994, ADDICTION, V89, P539, DOI 10.1111/j.1360-0443.1994.tb03330.x; Whitaker-Azmitia PM, 1990, ANN NY ACAD SCI, V600, P1; Ye YZ, 1996, METHOD ENZYMOL, V269, P201; Zhang HW, 1997, ARCH BIOCHEM BIOPHYS, V339, P183, DOI 10.1006/abbi.1996.9863; Zheng YW, 1998, BRAIN RES, V795, P257, DOI 10.1016/S0006-8993(98)00313-8	60	60	61	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29726	29732		10.1074/jbc.274.42.29726	http://dx.doi.org/10.1074/jbc.274.42.29726			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514446	hybrid			2022-12-27	WOS:000083176400025
J	Wang, XT; Gorospe, M; Holbrook, NJ				Wang, XT; Gorospe, M; Holbrook, NJ			gadd45 is not required for activation of c-Jun N-terminal kinase or p38 during acute stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; RESPONSES; PATHWAYS; CASCADES	Cells respond to environmental stress with activation of c-Jun N-terminal kinase (JNK) and p38. Recent studies have implicated Gadd45 and two related proteins, MyD118/Gadd45 beta and CR6/Gadd45 gamma, as initiators of JNK/p38 signaling via their interaction with an upstream kinase MTK1. It was proposed that stress-induced expression of the Gadd45-related proteins leads to MTK1 activation and subsequent JNK/p38 activation. Using embryo fibroblasts from gadd45-null mice, we have addressed the requirement for Gadd45 in mediating JNK/p38 activation during acute stress. Comparison of JNH/p38 activities in response to methyl methanesulfonate, hydrogen peroxide, WC irradiation, sorbitol, and anisomycin treatment of gadd45(+/+) and gadd45(-/-) fibroblasts revealed no deficiency in JNK/p38 activation in gadd45(-/-) fibroblasts. In addition, in wild type cells, JNK and p38 activation significantly preceded gadd45 induction with all stresses. Examination of myd118/ gadd45 beta and cr6/gadd45 gamma expression in gadd45(+/+) and gadd45(-/-) fibroblasts revealed similar induction patterns in the two cell types, which, like gadd45 expression, was delayed relative to JNK/p38 activation. We conclude that gadd45 expression is not required for activation of JNK/p38 by environmental stresses, nor are stress-induced increases in myd118/gadd45 beta and cr6/ gadd45 gamma expression necessary for kinase activation in response to such insults.	NIA, Cell Stress & Aging Sect, Biol Chem Lab, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Holbrook, NJ (corresponding author), NIA, Cell Stress & Aging Sect, Biol Chem Lab, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	nikki-holbrook@nih.gov						ABDOLLAHI A, 1991, ONCOGENE, V6, P165; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Davis RJ, 1999, BIOCHEM SOC SYMP, P1; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEARSEY JM, 1995, ONCOGENE, V11, P1675; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Takekawa M, 1997, EMBO J, V16, P4973, DOI 10.1093/emboj/16.16.4973; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; YAN MH, 1994, NATURE, V372, P798; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhang W, 1999, ONCOGENE, V18, P4899, DOI 10.1038/sj.onc.1202885	22	47	50	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29599	29602		10.1074/jbc.274.42.29599	http://dx.doi.org/10.1074/jbc.274.42.29599			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514426	hybrid			2022-12-27	WOS:000083176400005
J	Willars, GB; Heding, A; Vrecl, M; Sellar, R; Blomenrohr, M; Nahorski, SR; Eidne, KA				Willars, GB; Heding, A; Vrecl, M; Sellar, R; Blomenrohr, M; Nahorski, SR; Eidne, KA			Lack of a C-terminal tail in the mammalian gonadotropin-releasing hormone receptor confers resistance to agonist-dependent phosphorylation and rapid desensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; INTERNALIZATION KINETICS; SIGNAL-TRANSDUCTION; NEUROBLASTOMA-CELLS; ALPHA-T3-1 CELLS; BETA-ARRESTIN; KINASE-C; SITES	The mammalian gonadotropin-releasing hormone receptor (GnRH-R) is, at present, the only G-protein-coupled receptor that activates phospholipase C and lacks a C-terminal tail, We have previously demonstrated that this unique structural feature is associated with resistance to rapid desensitization of phosphoinositide signaling in COS-7 and HEK-293 cells (Heding, A., Vrecl, M., Bogerd, J., McGregor, A., Sellar, R., Taylor, P. L., and Eidne, K. A. (1998) J. Biol Chem. 273, 11472-11477). Using receptors tagged with a nonapeptide of the influenza hemagglutinin protein to enable immunoprecipitation, we now demonstrate that the mammalian GnRH-R is not phosphorylated in an agonist-dependent manner. In contrast, the mammalian thyrotropin-releasing hormone receptor and the African catfish GnRH-R, both of which have a C-terminal tail, are phosphorylated in response to agonist challenge. Furthermore, chimeras of the mammalian GnRH-R with the C-terminal tail of either the mammalian thyrotropin-releasing hormone receptor or the catfish GnRH-R are also phosphorylated in an agonist-dependent manner. Only those receptors having C-terminal tails showed desensitization of phosphoinositide responses within 5-10 min of agonist challenge, We also show that the internalization of all these receptors when expressed transiently in COS-7 cells is similar. This dissociates receptor internalization from rapid desensitization and demonstrates that the lack of a C-terminal tail in the mammalian GnRH-R results in an inability of the receptor to undergo agonist-dependent phosphorylation and that this results directly in a resistance to rapid desensitization.	Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England; MRC, Ctr Reprod Biol, Reprod Biol Unit, Edinburgh EH3 9EW, Midlothian, Scotland; Univ Utrecht, Dept Expt Zool, NL-3584 CH Utrecht, Netherlands	University of Leicester; Utrecht University	Willars, GB (corresponding author), Univ Leicester, Dept Cell Physiol & Pharmacol, POB 138,Maurice Shock Bldg,Univ Rd, Leicester LE1 9HN, Leics, England.		Vrecl, Milka/A-6127-2008					ALBLAS J, 1995, J BIOL CHEM, V270, P8944, DOI 10.1074/jbc.270.15.8944; ANDERSON L, 1995, ENDOCRINOLOGY, V136, P5228, DOI 10.1210/en.136.11.5228; ARORA KK, 1995, J BIOL CHEM, V270, P22820, DOI 10.1074/jbc.270.39.22820; ASHWORTH R, 1995, P NATL ACAD SCI USA, V92, P512, DOI 10.1073/pnas.92.2.512; Balmforth AJ, 1997, BRIT J PHARMACOL, V122, P1469, DOI 10.1038/sj.bjp.0701522; Beaumont V, 1998, J BIOL CHEM, V273, P33174, DOI 10.1074/jbc.273.50.33174; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; Cook JVF, 1997, ENDOCRINOLOGY, V138, P2800, DOI 10.1210/en.138.7.2800; DAVIDSON JS, 1994, BIOCHEM J, V300, P299, DOI 10.1042/bj3000299; DOHLMAN HG, 1987, J BIOL CHEM, V262, P14282; FISHER SK, 1994, NEUROCHEM RES, V19, P549, DOI 10.1007/BF00971329; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; Garland AM, 1996, MOL PHARMACOL, V49, P438; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; Heding A, 1998, J BIOL CHEM, V273, P11472, DOI 10.1074/jbc.273.19.11472; ISHII K, 1994, J BIOL CHEM, V269, P1125; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; McArdle CA, 1996, J BIOL CHEM, V271, P23711, DOI 10.1074/jbc.271.39.23711; MCARDLE CA, 1995, ENDOCRINOLOGY, V136, P4864, DOI 10.1210/en.136.11.4864; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; MOENTER SM, 1992, ENDOCRINOLOGY, V130, P503, DOI 10.1210/en.130.1.503; MOENTER SM, 1991, ENDOCRINOLOGY, V129, P1175, DOI 10.1210/endo-129-3-1175; Neill JD, 1997, MOL CELL ENDOCRINOL, V127, P143, DOI 10.1016/S0303-7207(96)04003-8; NEMETH K, 1995, J BIOL CHEM, V270, P27601, DOI 10.1074/jbc.270.46.27601; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Sromek SM, 1998, MOL PHARMACOL, V54, P485, DOI 10.1124/mol.54.3.485; SUGIYA H, 1987, BIOCHEM J, V244, P647, DOI 10.1042/bj2440647; Szekeres PG, 1998, J NEUROCHEM, V70, P1694; TAKANO T, 1994, J BIOL CHEM, V269, P22453; Tensen C, 1997, EUR J BIOCHEM, V243, P134, DOI 10.1111/j.1432-1033.1997.0134a.x; Tobin AB, 1997, J BIOL CHEM, V272, P20844, DOI 10.1074/jbc.272.33.20844; TOBIN AB, 1993, J BIOL CHEM, V268, P9817; Tobin AB, 1997, PHARMACOL THERAPEUT, V75, P135, DOI 10.1016/S0163-7258(97)00053-3; TOBIN AB, 1992, MOL PHARMACOL, V42, P1042; TSUTSUMI M, 1992, MOL ENDOCRINOL, V6, P1163, DOI 10.1210/me.6.7.1163; Vrecl M, 1998, MOL ENDOCRINOL, V12, P1818, DOI 10.1210/me.12.12.1818; Willars GB, 1996, BIOCHEM J, V316, P905, DOI 10.1042/bj3160905; Willars GB, 1998, BIOCHEM J, V333, P301, DOI 10.1042/bj3330301; WOJCIKIEWICZ RJH, 1993, TRENDS PHARMACOL SCI, V14, P279, DOI 10.1016/0165-6147(93)90131-3; Yu R, 1998, MOL ENDOCRINOL, V12, P737, DOI 10.1210/me.12.5.737	42	82	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30146	30153		10.1074/jbc.274.42.30146	http://dx.doi.org/10.1074/jbc.274.42.30146			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514504	hybrid			2022-12-27	WOS:000083176400083
J	Dabney-Smith, C; van den Wijngaard, PWJ; Treece, Y; Vredenberg, WJ; Bruce, BD				Dabney-Smith, C; van den Wijngaard, PWJ; Treece, Y; Vredenberg, WJ; Bruce, BD			The C terminus of a chloroplast precursor modulates its interaction with the translocation apparatus and PIRAC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSIT PEPTIDE; PROTEIN-IMPORT; IN-VITRO; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE/OXYGENASE; ENVELOPE MEMBRANES; ESCHERICHIA-COLI; TRANSPORT; IDENTIFICATION; ACCUMULATION; COMPLEXES	The import of proteins into chloroplasts involves a cleavable, N-terminal targeting sequence known as the transit peptide. Although the transit peptide is both necessary and sufficient to direct precursor import into chloroplasts, the mature domain of some precursors has been shown to modulate targeting and translocation efficiency. To test the influence of the mature domain of the small subunit of Rubisco during import in vitro, the precursor (prSSU), the mature domain (mSSU), the transit peptide (SS-tp), and three C-terminal deletion mutants (Delta 52, Delta 67, and Delta 74) of prSSU were expressed and purified from Escherichia coli, Activity was then evaluated by competitive import of S-35-prSSU. Both IC50 and K-i values consistently suggest that removal of C-terminal prSSU sequences inhibits its interaction with the translocation apparatus. Non-competitive import studies demonstrated that prSSU and Delta 52 were properly processed and accumulated within the chloroplast, whereas Delta 67 and Delta 74 were rapidly degraded via a plastid-localized protease, The ability of prSSU-derived proteins to induce inactivation of the protein-import-related anion channel was also evaluated, Although the C-terminal deletion mutants were less effective at inducing channel closure upon import, they did not effect the mean duration of channel closure. Possible mechanisms by which C-terminal residues of prSSU modulate chloroplast targeting are discussed.	Univ Tennessee, Dept Biochem Cellular & Mol Biol, Knoxville, TN 37996 USA; Univ Tennessee, Ctr Legume Res, Knoxville, TN 37996 USA; Wageningen Univ Agr, Lab Plant Physiol, NL-6703 BD Wageningen, Netherlands	University of Tennessee System; University of Tennessee Knoxville; University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture; Wageningen University & Research	Bruce, BD (corresponding author), Univ Tennessee, Dept Biochem Cellular & Mol Biol, Knoxville, TN 37996 USA.	bbruce@utk.edu	Dabney-Smith, Carole/C-2432-2008	Dabney-Smith, Carole/0000-0003-1347-3870				Akita M, 1997, J CELL BIOL, V136, P983, DOI 10.1083/jcb.136.5.983; Bruce B.D., 1994, PLANT MOL BIOL MANUA, VJ1, P1; BRUCE BD, 1994, ADV MOL CELL BIOL MO, V10, P3289; Chen XJ, 1999, TRENDS CELL BIOL, V9, P222, DOI 10.1016/S0962-8924(99)01554-8; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; Colquhoun David, 1995, P483; Halperin T, 1996, PLANT MOL BIOL, V30, P925, DOI 10.1007/BF00020804; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HIRSCH S, 1994, SCIENCE, V266, P1989, DOI 10.1126/science.7801125; IVEY R, 2000, IN PRESS CELL STRESS; KAVANAGH TA, 1988, MOL GEN GENET, V215, P38, DOI 10.1007/BF00331300; Kindle KL, 1998, PLANT PHYSIOL, V116, P1179, DOI 10.1104/pp.116.3.1179; KLEIN RR, 1992, PLANT PHYSIOL, V98, P546, DOI 10.1104/pp.98.2.546; KO K, 1992, J BIOL CHEM, V267, P13910; Lawrence SD, 1997, J BIOL CHEM, V272, P20357, DOI 10.1074/jbc.272.33.20357; LUBBEN TH, 1989, PLANT MOL BIOL, V12, P13, DOI 10.1007/BF00017443; MARSHALL JS, 1990, P NATL ACAD SCI USA, V87, P374, DOI 10.1073/pnas.87.1.374; Nielsen E, 1997, EMBO J, V16, P935, DOI 10.1093/emboj/16.5.935; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; PERRY SE, 1991, METHOD CELL BIOL, V34, P327; PILON M, 1992, FEBS LETT, V302, P65, DOI 10.1016/0014-5793(92)80286-P; PILON M, 1995, J BIOL CHEM, V270, P3882, DOI 10.1074/jbc.270.8.3882; Pinnaduwage P, 1996, J BIOL CHEM, V271, P32907, DOI 10.1074/jbc.271.51.32907; Rensink WA, 1998, PLANT PHYSIOL, V118, P691, DOI 10.1104/pp.118.2.691; Schnell DJ, 1997, TRENDS CELL BIOL, V7, P303, DOI 10.1016/S0962-8924(97)01111-2; SHANKLIN J, 1995, PLANT CELL, V7, P1713, DOI 10.1105/tpc.7.10.1713; Taylor TC, 1997, BIOCHEMISTRY-US, V36, P4041, DOI 10.1021/bi962818w; VANDENWIGNGAARD P, 1999, IN PRESS BIOPHYS J; vandenWijngaard PWJ, 1997, J BIOL CHEM, V272, P29430, DOI 10.1074/jbc.272.47.29430; VANTHOF R, 1995, J BIOL CHEM, V270, P22368, DOI 10.1074/jbc.270.38.22368; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1991, PLANT MOL BIOL REP, V9, P104; WASMANN CC, 1986, MOL GEN GENET, V205, P446, DOI 10.1007/BF00338081	33	40	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32351	32359		10.1074/jbc.274.45.32351	http://dx.doi.org/10.1074/jbc.274.45.32351			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542276	hybrid			2022-12-27	WOS:000083532100084
J	DiScipio, RG; Linton, SM; Rushmere, NK				DiScipio, RG; Linton, SM; Rushmere, NK			Function of the factor I modules (FIMS) of human complement component C6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE ATTACK COMPLEX; HUMAN PLASMA-PROTEINS; AFFINITY-CHROMATOGRAPHY; COVALENT-BINDING; C5B-7 COMPLEX; HUMAN C5; C7; DEFICIENCY; FRACTIONATION; PURIFICATION	In order to elucidate the function of complement component C6, truncated C6 molecules were expressed recombinantly, These were either deleted of the factor I modules (FIMs) (C6des-748-913) or both complement control protein (CCP) modules and FIMs (C6des-611-913), C6des-748-913 exhibited approximately 60-70% of the hemolytic activity of full-length C6 when assayed for Alternative Pathway activity, but when measured for the Classical Pathway, C6des-748-914 was only 4-6% as effective as C6, The activity difference between C6 and C6des-748-913 for the two complement pathways can be explained by a greater stability of newly formed metastable C5b* when produced by the Alternative Pathway compared with that made by the Classical Pathway. The half-lives of metastable C5b* and the decay of I-125-C5b measured from cells used to activate the Alternative Pathway were found to be about 5-12-fold longer than those same parameters derived from cells that had activated the Classical Pathway. I-125-C5 binds reversibly to C6 in an ionic strength-dependent fashion, but I-125-C5 binds only weakly to C6des-FIMs and not at all to C6des-CCP/FIMs, Therefore, although the FIMs are not required absolutely for C6 activity, these modules promote interaction of C6 with C5 enabling a more efficient bimolecular coupling ultimately leading to the formation of the C5b-6 complex.	La Jolla Inst Expt Med, La Jolla, CA 92037 USA; Univ Wales Coll Cardiff, Coll Med, Dept Biochem Med, Cardiff CF4 4XX, S Glam, Wales	Cardiff University	DiScipio, RG (corresponding author), La Jolla Inst Expt Med, 505 Coast Blvd S, La Jolla, CA 92037 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022415] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 22415] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARROYAVE CM, 1973, J IMMUNOL, V111, P536; CAMPBELL ID, 1991, PHILOS T R SOC B, V332, P165, DOI 10.1098/rstb.1991.0045; CATTERALL CF, 1987, BIOCHEM J, V242, P849, DOI 10.1042/bj2420849; COOPER NR, 1970, J EXP MED, V132, P775, DOI 10.1084/jem.132.4.775; DAVID GS, 1972, BIOCHEM BIOPH RES CO, V48, P464, DOI 10.1016/S0006-291X(72)80074-3; DiScipio R. G, 1998, COMPLEMENT SYSTEM, P50; DISCIPIO RG, 1994, PROTEIN EXPRES PURIF, V5, P178, DOI 10.1006/prep.1994.1028; DISCIPIO RG, 1981, BIOCHEM J, V199, P485, DOI 10.1042/bj1990485; DISCIPIO RG, 1982, MOL IMMUNOL, V19, P1425, DOI 10.1016/0161-5890(82)90189-4; DISCIPIO RG, 1988, J BIOL CHEM, V263, P549; DISCIPIO RG, 1992, J BIOL CHEM, V267, P17087; DISCIPIO RG, 1983, J BIOL CHEM, V258, P629; DISCIPIO RG, 1989, J BIOL CHEM, V264, P16197; DISCIPIO RG, 1992, J IMMUNOL, V149, P2592; DISCIPIO RG, 1994, PROTEIN EXPRES PURIF, V5, P170, DOI 10.1006/prep.1994.1027; EGGERTSEN G, 1981, MOL IMMUNOL, V18, P125, DOI 10.1016/0161-5890(81)90078-X; FARRIES TC, 1988, BIOCHEM J, V252, P47, DOI 10.1042/bj2520047; FEARON DT, 1977, J EXP MED, V146, P22, DOI 10.1084/jem.146.1.22; GERSHONI JM, 1988, METHOD BIOCHEM ANAL, V33, P1; GOLDBERGER G, 1987, J BIOL CHEM, V262, P10065; HAEFLIGER JA, 1989, J BIOL CHEM, V264, P18041; HOBART MJ, 1993, BIOCHEMISTRY-US, V32, P6198, DOI 10.1021/bi00075a012; HOFFMANN LG, 1977, METHODS IMMUNOLOGY I, V4, P137; Kemeny D. M., 1997, IMMUNOCHEMISTRY, V1, P147; KOLB WP, 1973, J EXP MED, V138, P428, DOI 10.1084/jem.138.2.428; LAW SK, 1980, P NATL ACAD SCI-BIOL, V77, P7194, DOI 10.1073/pnas.77.12.7194; LAW SK, 1977, P NATL ACAD SCI USA, V74, P2701, DOI 10.1073/pnas.74.7.2701; Lengweiler S, 1997, BBA-PROTEIN STRUCT M, V1342, P13, DOI 10.1016/S0167-4838(97)00072-1; MARDINEY MR, 1968, AM J PATHOL, V53, P253; MORGAN BP, 1989, CLIN EXP IMMUNOL, V75, P396; MULLEREBERHARD HJ, 1986, ANNU REV IMMUNOL, V4, P503, DOI 10.1146/annurev.iy.04.040186.002443; NELSON RA, 1966, IMMUNOCHEMISTRY, V3, P111, DOI 10.1016/0019-2791(66)90292-8; ORREN A, 1992, IMMUNOLOGY, V75, P10; PATTHY L, 1985, CELL, V41, P657, DOI 10.1016/S0092-8674(85)80046-5; PODACK ER, 1980, J EXP MED, V151, P301, DOI 10.1084/jem.151.2.301; PODACK ER, 1984, J BIOL CHEM, V259, P8641; PODACK ER, 1984, MOL IMMUNOL, V21, P589, DOI 10.1016/0161-5890(84)90044-0; Rushmere NK, 1997, IMMUNOLOGY, V90, P640, DOI 10.1046/j.1365-2567.1997.00200.x; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHIN ML, 1986, J IMMUNOL, V136, P1777; SIM RB, 1981, BIOCHEM J, V193, P115, DOI 10.1042/bj1930115; TRAUT TW, 1986, MOL CELL BIOCHEM, V70, P3; Ullman CG, 1997, BIOCHEM J, V326, P939, DOI 10.1042/bj3260929v; Whaley K., 1997, COMPLEMENT PRACTICAL, V1, P19; WURZNER R, 1995, J CLIN INVEST, V95, P1877, DOI 10.1172/JCI117868; WURZNER R, 1991, CLIN EXP IMMUNOL, V83, P430; WURZNER R, 1995, IMMUNOLOGY, V85, P214	47	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31811	31818		10.1074/jbc.274.45.31811	http://dx.doi.org/10.1074/jbc.274.45.31811			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542204	hybrid			2022-12-27	WOS:000083532100012
J	Levin, MK; Patel, SS				Levin, MK; Patel, SS			The helicase from hepatitis C virus is active as an oligomer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA HELICASE; ESCHERICHIA-COLI; DNA HELICASE; NONSTRUCTURAL PROTEIN-3; CRYSTAL-STRUCTURE; NS3 PROTEIN; DUPLEX DNA; DOMAIN; MUTANT	The helicase from hepatitis C virus (HCV NS3h) residing on the C terminal domain of nonstructural protein 3 was considered to be monomeric by several researchers. Here we demonstrate, based on biochemical kinetic data, that the HCV helicase acts as an oligomer. The increase in the ATPase k(cat) of the NS3h protein with increasing protein concentration provided evidence for oligomerization. A sharp decrease in the unwinding rate was observed when the wild type NS3h was mixed with the ATPase deficient mutants of NS3h protein. This provided strong support for both mixed oligomer formation and subunit interactions for the HCV helicase, Chemical cross-linking of NS3h protein was an inefficient process, but yielded cross-linked protein oligomers of various sizes. The information currently available for HCV helicase is consistent with the hypothesis that oligomers of NS3h are not stable and the helicase subunits exchange during unwinding. Nevertheless, oligomerization of HCV helicase stimulates the ATPase activity, and it is required for the helicase activity.	Ohio State Univ, Dept Biochem, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Patel, SS (corresponding author), UMDNJ, Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Ln, Piscataway, NJ 08854 USA.				NIGMS NIH HHS [GM55310] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahnert P, 1997, J BIOL CHEM, V272, P32267, DOI 10.1074/jbc.272.51.32267; Bird LE, 1998, CURR OPIN STRUC BIOL, V8, P14, DOI 10.1016/S0959-440X(98)80004-3; Cho HS, 1998, J BIOL CHEM, V273, P15045, DOI 10.1074/jbc.273.24.15045; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; Di Bisceglie AM, 1998, LANCET, V351, P351, DOI 10.1016/S0140-6736(97)07361-3; GEORGE JW, 1994, J MOL BIOL, V235, P424, DOI 10.1006/jmbi.1994.1003; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Gwack Y, 1997, EUR J BIOCHEM, V250, P47, DOI 10.1111/j.1432-1033.1997.00047.x; Heilek GM, 1997, J VIROL, V71, P6264, DOI 10.1128/JVI.71.8.6264-6266.1997; HINGORANI MM, 1993, BIOCHEMISTRY-US, V32, P12478, DOI 10.1021/bi00097a028; Kim DW, 1997, J VIROL, V71, P9400, DOI 10.1128/JVI.71.12.9400-9409.1997; KIM DW, 1995, BIOCHEM BIOPH RES CO, V215, P160, DOI 10.1006/bbrc.1995.2447; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; Korolev S, 1998, PROTEIN SCI, V7, P605, DOI 10.1002/pro.5560070309; Lohman TM, 1998, CELL, V93, P9, DOI 10.1016/S0092-8674(00)81139-3; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Luking A, 1998, CRIT REV BIOCHEM MOL, V33, P259, DOI 10.1080/10409239891204233; MATSON SW, 1994, BIOESSAYS, V16, P13, DOI 10.1002/bies.950160103; Mechanic LE, 1999, J BIOL CHEM, V274, P12488, DOI 10.1074/jbc.274.18.12488; MOLLOY JE, 1995, NATURE, V378, P209, DOI 10.1038/378209a0; Moussalli J, 1998, J VIRAL HEPATITIS, V5, P73, DOI 10.1046/j.1365-2893.1998.00086.x; PATEL SS, 1994, BIOCHEMISTRY-US, V33, P7857, DOI 10.1021/bi00191a013; Porter DJT, 1998, J BIOL CHEM, V273, P18906, DOI 10.1074/jbc.273.30.18906; Preugschat F, 1996, J BIOL CHEM, V271, P24449, DOI 10.1074/jbc.271.40.24449; RICHARDSON JP, 1986, J MOL BIOL, V189, P413, DOI 10.1016/0022-2836(86)90313-X; Tai CL, 1996, J VIROL, V70, P8477, DOI 10.1128/JVI.70.12.8477-8484.1996; Tyska MJ, 1999, P NATL ACAD SCI USA, V96, P4402, DOI 10.1073/pnas.96.8.4402; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; Vishnuvardhan D, 1997, FEBS LETT, V402, P209, DOI 10.1016/S0014-5793(96)01532-3; WONG I, 1992, J BIOL CHEM, V267, P7596; Yao NH, 1997, NAT STRUCT BIOL, V4, P463, DOI 10.1038/nsb0697-463	31	97	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31839	31846		10.1074/jbc.274.45.31839	http://dx.doi.org/10.1074/jbc.274.45.31839			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542208	hybrid			2022-12-27	WOS:000083532100016
J	Lu, JF; O'Hara, EB; Trieselmann, BA; Romano, PR; Dever, TE				Lu, JF; O'Hara, EB; Trieselmann, BA; Romano, PR; Dever, TE			The interferon-induced double-stranded RNA-activated protein kinase PKR will phosphorylate serine, threonine, or tyrosine at residue 51 in eukaryotic initiation factor 2 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EIF-2-ALPHA KINASE; TRANSLATIONAL CONTROL; SACCHAROMYCES-CEREVISIAE; DROSOPHILA-MELANOGASTER; DEPENDENT KINASE; INSULIN-RECEPTOR; YEAST; GCN2; GENE; FACTOR-2-ALPHA	The family of eukaryotic initiation factor 2 alpha (eIF2 alpha) protein kinases plays an important role in regulating cellular protein synthesis under stress conditions. The mammalian kinases PKR and HRI and the yeast kinase GCN2 specifically phosphorylate Ser-51 on the a subunit of the translation initiation factor eIF2, By using an in vivo assay in yeast, the substrate specificity of these three eIF2 alpha kinases was examined by substituting Ser-51 in eIF2 alpha with Thr or Tyr. In yeast, phosphorylation of eIF2 inhibits general translation but derepresses translation of the GCN4 mRNA. All three kinases phosphorylated Thr in place of Ser-51 and were able to regulate general and GCN4-specific translation. In addition, both PHR and HRI were found to phosphorylate eIF2 alpha-S51Y and stimulate GCN4 expression. Isoelectric focusing analysis of eIF2 alpha followed by detection using anti-eIF2 alpha and anti-phosphotyrosine-specific antibodies demonstrated that PKR and HRI phosphorylated eIF2 alpha-S51Y on Tyr in vivo. These results provide new insights into the substrate recognition properties of the eIF2 alpha kinases, and they are intriguing considering the potential for alternate substrates for PKR in cellular signaling and growth control pathways.	NICHD, Lab Eukaryot Gene Regulat, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Dever, TE (corresponding author), NICHD, Lab Eukaryot Gene Regulat, NIH, Bldg 6A,Rm B1A-02,6 Ctr Dr,MSC 2716, Bethesda, MD 20892 USA.		Dever, Thomas/GSE-0966-2022	Dever, Thomas/0000-0001-7120-9678	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001010] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001010] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abraham N, 1999, J BIOL CHEM, V274, P5953, DOI 10.1074/jbc.274.9.5953; Abraham N, 1998, EXP CELL RES, V244, P394, DOI 10.1006/excr.1998.4201; BARBER GN, 1991, BIOCHEMISTRY-US, V30, P10356, DOI 10.1021/bi00106a038; Brand SR, 1997, J BIOL CHEM, V272, P8388, DOI 10.1074/jbc.272.13.8388; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Clemens MJ, 1996, TRANSLATIONAL CONTRO, P139; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DER SD, 1995, P NATL ACAD SCI USA, V92, P8841, DOI 10.1073/pnas.92.19.8841; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P4616, DOI 10.1073/pnas.90.10.4616; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DOUVILLE E, 1994, CANCER METAST REV, V13, P1, DOI 10.1007/BF00690414; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Hinnebusch Alan G., 1994, Seminars in Cell Biology, V5, P417, DOI 10.1006/scel.1994.1049; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; ICELY PL, 1991, J BIOL CHEM, V266, P16073; KawagishiKobayashi M, 1997, MOL CELL BIOL, V17, P4146, DOI 10.1128/MCB.17.7.4146; KOROMILAS AE, 1995, J BIOL CHEM, V270, P25426, DOI 10.1074/jbc.270.43.25426; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Langland JO, 1999, BIOCHEMISTRY-US, V38, P6361, DOI 10.1021/bi982410u; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; LINDBERG RA, 1993, ONCOGENE, V8, P351; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; MCMILLAN NAJ, 1995, VIROLOGY, V213, P413, DOI 10.1006/viro.1995.0014; MELLOR H, 1991, BIOCHEM BIOPH RES CO, V178, P430, DOI 10.1016/0006-291X(91)90125-Q; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; Olsen DS, 1998, GENETICS, V149, P1495; RAMIREZ M, 1992, MOL CELL BIOL, V12, P5801, DOI 10.1128/MCB.12.12.5801; ROMANO PR, 1995, MOL CELL BIOL, V15, P365, DOI 10.1128/MCB.15.1.365; Santoyo J, 1997, J BIOL CHEM, V272, P12544, DOI 10.1074/jbc.272.19.12544; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; TAYLOR SS, 1995, FASEB J, V9, P1255, DOI 10.1096/fasebj.9.13.7557015; WEINMASTER G, 1986, J BIOL CHEM, V261, P328; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; [No title captured]	36	46	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32198	32203		10.1074/jbc.274.45.32198	http://dx.doi.org/10.1074/jbc.274.45.32198			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542257	hybrid			2022-12-27	WOS:000083532100065
J	Masson, L; Tabashnik, BE; Liu, YB; Brousseau, R; Schwartz, JL				Masson, L; Tabashnik, BE; Liu, YB; Brousseau, R; Schwartz, JL			Helix 4 of the Bacillus thuringiensis Cry1Aa toxin lines the lumen of the ion channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORDER MEMBRANE-VESICLES; PLANAR LIPID BILAYERS; PORE-FORMING DOMAIN; DELTA-ENDOTOXIN; SELECTIVE CHANNELS; CRYSTAL-STRUCTURE; RESISTANCE; MUTAGENESIS; BINDING; ORGANIZATION	The mode of action of Bacillus thuringiensis insecticidal proteins is not well understood. Based on analogies with other bacterial toxins and ion channels, we hypothesized that charged amino acids in helix 4 of the Cry1Aa toxin are critical for toxicity and ion channel function. Using Plutella xylostella as a model target, we analyzed responses to Cry1Aa and eight proteins with altered helix 4 residues. Toxicity was abolished in five charged residue mutants (E129K, R131Q, R131D, D136N, D136C), however, two charged (R127E and R127N) and one polar (N138C) residue mutant retained wild-type toxicity. Compared with Cry1Aa and toxic mutants, nontoxic mutants did not show greatly reduced binding to brush border membrane vesicles, but their ion channel conductance was greatly reduced in planar lipid bilayers, Substituted cysteine accessibility tests showed that in situ restoration of the negative charge of D136C restored conductance to wild-type levels, The results imply that charged amino acids on the Asp-136 side of helix 4 are essential for toxicity and passage of ions through the channel. These results also support a refined version of the umbrella model of membrane integration in which the side of helix 4 containing Asp-136 faces the aqueous lumen of the ion channel.	Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada; Univ Arizona, Dept Entomol, Tucson, AZ 85721 USA	National Research Council Canada; University of Arizona	Masson, L (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.							AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ARONSON AI, 1995, J BACTERIOL, V177, P4059, DOI 10.1128/jb.177.14.4059-4065.1995; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN XJ, 1995, J BIOL CHEM, V270, P6412, DOI 10.1074/jbc.270.11.6412; CUMMINGS CE, 1994, MOL MEMBR BIOL, V11, P87, DOI 10.3109/09687689409162225; de Maagd RA, 1999, MOL MICROBIOL, V31, P463, DOI 10.1046/j.1365-2958.1999.01188.x; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; GAZIT E, 1995, J BIOL CHEM, V270, P2571, DOI 10.1074/jbc.270.6.2571; Gazit E, 1998, P NATL ACAD SCI USA, V95, P12289, DOI 10.1073/pnas.95.21.12289; GROCHULSKI P, 1995, J MOL BIOL, V254, P447, DOI 10.1006/jmbi.1995.0630; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; Huynh PD, 1997, J GEN PHYSIOL, V110, P229, DOI 10.1085/jgp.110.3.229; James C., 1997, GLOBAL STATUS TRANSG; Jesior J. C., 1994, J APPL CRYSTALLOGR, V27, P1075; Kenyon G L, 1977, Methods Enzymol, V47, P407; KNOWLES BH, 1994, ADV INSECT PHYSIOL, V24, P275, DOI 10.1016/S0065-2806(08)60085-5; LI J, 1996, PROTEIN TOXIN STRUCT, P49; LI JD, 1991, NATURE, V353, P815, DOI 10.1038/353815a0; Liu YB, 1998, J ECON ENTOMOL, V91, P1032, DOI 10.1093/jee/91.5.1032; MASSON L, 1995, J BIOL CHEM, V270, P11887, DOI 10.1074/jbc.270.20.11887; MASSON L, 1989, BIOCHEM J, V269, P507; MAZZA A, 1999, QUANTITATIVE ANAL BI, P163; Montal M, 1996, CURR OPIN STRUC BIOL, V6, P499, DOI 10.1016/S0959-440X(96)80115-1; PARKER MW, 1990, TRENDS BIOCHEM SCI, V15, P126, DOI 10.1016/0968-0004(90)90205-P; PARKER MW, 1993, TRENDS BIOCHEM SCI, V18, P391, DOI 10.1016/0968-0004(93)90096-6; Schwartz JL, 1997, APPL ENVIRON MICROB, V63, P3978, DOI 10.1128/AEM.63.10.3978-3984.1997; Schwartz JL, 1997, FEBS LETT, V410, P397, DOI 10.1016/S0014-5793(97)00626-1; SCHWARTZ JL, 1993, J MEMBRANE BIOL, V132, P53, DOI 10.1007/BF00233051; SCHWARTZ JL, 1999, IN PRESS STRUCTURE F; SLATIN SL, 1990, BIOCHEM BIOPH RES CO, V169, P765, DOI 10.1016/0006-291X(90)90397-6; TABASHNIK BE, 1994, ANNU REV ENTOMOL, V39, P47, DOI 10.1146/annurev.en.39.010194.000403; Tabashnik BE, 1997, P NATL ACAD SCI USA, V94, P12780, DOI 10.1073/pnas.94.24.12780; Tabashnik BE, 1996, APPL ENVIRON MICROB, V62, P2839, DOI 10.1128/AEM.62.8.2839-2844.1996; Tabashnik BE, 1998, PHILOS T R SOC B, V353, P1751, DOI 10.1098/rstb.1998.0327; Uawithya P, 1998, BIOCHEM MOL BIOL INT, V44, P825; WOLFERSBERGER M, 1987, COMP BIOCHEM PHYS A, V86, P301, DOI 10.1016/0300-9629(87)90334-3; WU D, 1992, J BIOL CHEM, V267, P2311	39	95	106	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31996	32000		10.1074/jbc.274.45.31996	http://dx.doi.org/10.1074/jbc.274.45.31996			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542230	hybrid			2022-12-27	WOS:000083532100038
J	Xia, ZC; Zhang, W; Nguyen, BD; La Mar, GN; Kloek, AP; Goldberg, DE				Xia, ZC; Zhang, W; Nguyen, BD; La Mar, GN; Kloek, AP; Goldberg, DE			H-1 NMR investigation of the distal hydrogen bonding network and ligand tilt in the cyanomet complex of oxygen-avid Ascaris suum hemoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; SPERM WHALE MYOGLOBIN; HEME ELECTRONIC-STRUCTURE; SPIN FERRIHEME SYSTEMS; RAY CRYSTAL-STRUCTURE; AXIAL LIGANDS; PARAMAGNETIC PROTEIN; 2-DIMENSIONAL NMR; CYANIDE COMPLEXES; H-1-NMR STRUCTURE	The O-2-avid hemoglobin from the parasitic nematode Ascaris suum exhibits one of the slowest known O-2 off rates. Solution H-1 NMR has been used to investigate the electronic and molecular structural properties of the active site for the cyano-met derivative of the recombinant first domain of this protein. Assignment of the heme, axial His, and majority of the residues in contact with the heme reveals a molecular structure that is the same as reported in the A. suum HbO(2) crystal structure (Yang, J., Kloek, A., Goldberg, D. E., and Mathews, F. S. (1995) Proc. Natl, Acad, Sci. U. S. A. 92, 4224-4228) with the exception that the heme in solution is rotated by 180 degrees about the alpha,gamma-meso axis relative to that in the crystal, The observed dipolar shifts, together with the crystal coordinates of HbO(2), provide the orientation of the magnetic axes in the molecular framework. The major magnetic axis, which correlates with the Fe CN vector, is found oriented similar to 30 degrees away from the heme normal and indicates significant steric tilt because of interaction with Tyr(30)(B10). Th, three side chain labile protons for the distal residues Tyr(30)(B10) and Gln(64)(E7) were identified, and their relaxation, dipolar shifts, and nuclear Overhauser effects to adjacent residues used to place them in the distal pocket. It is shown that these two distal residues exhibit the same orientations ideal for H bonding to the ligand and to each other, as found in the A. suum HbO(2) crystal. It is concluded that the ligated cyanide participates in the same distal H bonding network as ligated O-2. The combination of the strong steric tilt of the bound cyanide and slow ring reorientation of the Tyr(30)(B10) side chain supports a crowded and constrained distal pocket.	Univ Calif Davis, Dept Chem, Davis, CA 95616 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA	University of California System; University of California Davis; Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	La Mar, GN (corresponding author), Univ Calif Davis, Dept Chem, 1 Shields Ave, Davis, CA 95616 USA.	lamar@indigo.ucdavis.edu			NHLBI NIH HHS [HL16087] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016087, R37HL016087] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barrick D, 1997, NAT STRUCT BIOL, V4, P78, DOI 10.1038/nsb0197-78; BERTINI I, 1993, CHEM REV, V93, P2833, DOI 10.1021/cr00024a009; BISIG DA, 1995, J BIOL CHEM, V270, P20754, DOI 10.1074/jbc.270.35.20754; BOLOGNESI M, 1990, J MOL BIOL, V213, P621, DOI 10.1016/S0022-2836(05)80249-9; BRANCACCIO A, 1994, J BIOL CHEM, V269, P13843; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Brennan L, 1997, BBA-PROTEIN STRUCT M, V1342, P1, DOI 10.1016/S0167-4838(97)00071-X; BYRN MP, 1983, J AM CHEM SOC, V105, P4916, DOI 10.1021/ja00353a013; CONTI E, 1993, J MOL BIOL, V233, P498, DOI 10.1006/jmbi.1993.1527; CROSS KJ, 1985, J MAGN RESON, V64, P220, DOI 10.1016/0022-2364(85)90346-4; DALVIT C, 1987, J MOL BIOL, V194, P313, DOI 10.1016/0022-2836(87)90378-0; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; DEBAERE I, 1992, P NATL ACAD SCI USA, V89, P4638, DOI 10.1073/pnas.89.10.4638; DEBAERE I, 1994, P NATL ACAD SCI USA, V91, P1594, DOI 10.1073/pnas.91.4.1594; Decatur SM, 1996, BIOCHEMISTRY-US, V35, P3925, DOI 10.1021/bi952625t; DICKERSON RE, 1983, HEMOGLOBIN STRUCTURE, P65; Dou Y, 1996, BIOCHEMISTRY-US, V35, P7107, DOI 10.1021/bi9600299; EMERSON SD, 1988, J AM CHEM SOC, V110, P4176, DOI 10.1021/ja00221a013; EMERSON SD, 1990, BIOCHEMISTRY-US, V29, P1545, DOI 10.1021/bi00458a028; Huang SC, 1996, J BIOL CHEM, V271, P958, DOI 10.1074/jbc.271.2.958; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JEWSBURY P, 1995, J PHYS CHEM-US, V99, P12677, DOI 10.1021/j100033a047; KAPP OH, 1995, PROTEIN SCI, V4, P2179, DOI 10.1002/pro.5560041024; KLOEK AP, 1994, J BIOL CHEM, V269, P2377; KLOEK AP, 1993, J BIOL CHEM, V268, P17669; Kolczak U, 1997, J AM CHEM SOC, V119, P12643, DOI 10.1021/ja9722133; KRAULIS PJ, 1994, BIOCHEMISTRY-US, V33, P3515, DOI 10.1021/bi00178a008; KURIYAN J, 1986, J MOL BIOL, V192, P133, DOI 10.1016/0022-2836(86)90470-5; LECOMTE JTJ, 1987, J AM CHEM SOC, V109, P7219, DOI 10.1021/ja00257a068; LI TS, 1994, BIOCHEMISTRY-US, V33, P1433, DOI 10.1021/bi00172a021; LI XY, 1988, J AM CHEM SOC, V110, P6024, DOI 10.1021/ja00226a017; MABBUTT BC, 1985, BIOCHIM BIOPHYS ACTA, V832, P175, DOI 10.1016/0167-4838(85)90329-2; Moens L, 1996, MOL BIOL EVOL, V13, P324, DOI 10.1093/oxfordjournals.molbev.a025592; NAGAI K, 1987, NATURE, V329, P858, DOI 10.1038/329858a0; Nguyen BD, 1999, J AM CHEM SOC, V121, P208, DOI 10.1021/ja982555o; Nguyen BD, 1998, J BIOL CHEM, V273, P9517, DOI 10.1074/jbc.273.16.9517; Olson JS, 1997, J BIOL INORG CHEM, V2, P544, DOI 10.1007/s007750050169; OOSTERHUIS WT, 1969, PHYS REV, V178, P439, DOI 10.1103/PhysRev.178.439; Peterson ES, 1997, BIOCHEMISTRY-US, V36, P13110, DOI 10.1021/bi971156n; PHILLIPS SEV, 1981, NATURE, V292, P81, DOI 10.1038/292081a0; Press W., 1986, NUMERICAL RECIPES; QIN J, 1992, J BIOMOL NMR, V2, P597, DOI 10.1007/BF02192849; QIN J, 1992, J MOL BIOL, V224, P891, DOI 10.1016/0022-2836(92)90456-T; QIN J, 1993, J MOL BIOL, V231, P1009, DOI 10.1006/jmbi.1993.1348; Raitsimring AM, 1998, J AM CHEM SOC, V120, P991, DOI 10.1021/ja9722640; RAJARATHNAM K, 1992, J AM CHEM SOC, V114, P9048, DOI 10.1021/ja00049a042; RAJARATHNAM K, 1994, BIOCHEMISTRY-US, V33, P5493, DOI 10.1021/bi00184a018; RANCE M, 1987, J MAGN RESON, V74, P557, DOI 10.1016/0022-2364(87)90277-0; Rashid AK, 1997, J BIOL CHEM, V272, P2992, DOI 10.1074/jbc.272.5.3000; ROYER WE, 1995, J MOL BIOL, V253, P168, DOI 10.1006/jmbi.1995.0543; SANDSTROM J, 1982, DYNAMIC NMR SPECTROS, P12; SHERMAN DR, 1992, P NATL ACAD SCI USA, V89, P11696, DOI 10.1073/pnas.89.24.11696; Shokhirev NV, 1998, J AM CHEM SOC, V120, P981, DOI 10.1021/ja972265s; SHRAGER RL, 1970, J ACM, V17, P446, DOI 10.1145/321592.321597; SHULMAN RG, 1971, J MOL BIOL, V57, P93, DOI 10.1016/0022-2836(71)90121-5; Slebodnick C, 1997, J BIOL INORG CHEM, V2, P521, DOI 10.1007/s007750050165; Spiro TG, 1997, J BIOL INORG CHEM, V2, P516, DOI 10.1007/s007750050164; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; STEIGEMANN W, 1979, J MOL BIOL, V127, P309, DOI 10.1016/0022-2836(79)90332-2; TRAYLOR TG, 1980, J AM CHEM SOC, V102, P2844, DOI 10.1021/ja00528a058; TURNER DL, 1993, EUR J BIOCHEM, V211, P563, DOI 10.1111/j.1432-1033.1993.tb17583.x; TURNER DL, 1995, EUR J BIOCHEM, V227, P829, DOI 10.1111/j.1432-1033.1995.tb20208.x; Vangberg T, 1997, J BIOL INORG CHEM, V2, P526, DOI 10.1007/s007750050166; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; Wu YY, 1996, BBA-PROTEIN STRUCT M, V1298, P261, DOI 10.1016/S0167-4838(96)00137-9; WUTHRICH K, 1986, NMR PROTEINS NUCL AC, P131; Yamamoto Y, 1998, ANNU REP NMR SPECTRO, V36, P1, DOI 10.1016/S0066-4103(08)60005-8; YAMAMOTO Y, 1992, J MOL BIOL, V228, P343, DOI 10.1016/0022-2836(92)90823-3; YANG J, 1995, P NATL ACAD SCI USA, V92, P4224, DOI 10.1073/pnas.92.10.4224; Zhang W, 1997, BIOPHYS J, V73, P1019, DOI 10.1016/S0006-3495(97)78135-9; Zhang W, 1996, EUR J BIOCHEM, V237, P841, DOI 10.1111/j.1432-1033.1996.0841p.x; Zhang W, 1997, J BIOL CHEM, V272, P3000, DOI 10.1074/jbc.272.5.3000; ZHAO XF, 1995, J BIOL CHEM, V270, P20763, DOI 10.1074/jbc.270.35.20763	73	11	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31819	31826		10.1074/jbc.274.45.31819	http://dx.doi.org/10.1074/jbc.274.45.31819			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542205	hybrid			2022-12-27	WOS:000083532100013
J	Maemura, K; Hsieh, CM; Jain, MK; Fukumoto, S; Layne, MD; Liu, YX; Kourembanas, S; Yet, SF; Perrella, MA; Lee, ME				Maemura, K; Hsieh, CM; Jain, MK; Fukumoto, S; Layne, MD; Liu, YX; Kourembanas, S; Yet, SF; Perrella, MA; Lee, ME			Generation of a dominant-negative mutant of endothelial PAS domain protein 1 by deletion of a potent C-terminal transactivation domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIA-INDUCIBLE FACTOR-1; GROWTH-FACTOR GENE; TRANSCRIPTION FACTOR; DIOXIN RECEPTOR; FACTOR 1-ALPHA; CLOCK GENE; CELLS; EXPRESSION; ACTIVATION; DROSOPHILA	Endothelial PAS domain protein 1 (EPAS1) is a basic helix-loop-helix/PAS domain transcription factor that is preferentially expressed in vascular endothelial cells, EPAS1 shares high homology with hypoxia-inducible factor-1 alpha (HIF-1 alpha) and, like HIF-1 alpha, has been shown to bind to the HIF-1-binding site and to activate its downstream genes such as vascular endothelial growth factor (VEGF) and erythropoietin. In this report, we show that EPAS1 increased VEGF gene expression through the DIP-I-binding site. This transactivation was enhanced further by cotransfection of an aryl hydrocarbon receptor nuclear translocator expression plasmid. Deletion analysis of EPAS1 revealed a potent activation domain (amino acids 486-639) essential for EPAS1 to transactivate the VEGF promoter. We confirmed the ability of this domain to activate transcription using a Ga14 fusion protein system. Because a truncated EPAS1 protein lacking the transactivation domain at amino acids 486-639 eliminated induction of the VEGF promoter by wildtype EPAS1, the truncated protein functions as a dominant-negative mutant. Most important, infection of the cells with an adenoviral construct expressing this mutant inhibited the induction of VEGF mRNA under conditions that mimic hypoxia. Our results suggest that EPAS1 is an important regulator of VEGF gene expression. Since VEGF plays a crucial role in angiogenesis, the ability of dominant-negative EPAS1 ito inhibit VEGF promoter activity raises the possibility of a novel approach to inhibiting pathological angiogenesis.	Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Pulm & Crit Care, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Childrens Hosp, Joint Program Neonatol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	Lee, ME (corresponding author), Brigham & Womens Hosp, Dept Med, Program Dev Cardiovasc Biol, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA.		Yet, Shaw-Fang/O-8583-2019; Yet, Shaw-Fang/B-1067-2010	Layne, Matthew/0000-0003-0007-4870; Yet, Shaw-Fang/0000-0001-9097-3962	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL010113, R01HL055454, F32HL009008] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 55454, HL 09008, HL 10113] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CITRI Y, 1987, NATURE, V326, P42, DOI 10.1038/326042a0; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Flamme I, 1997, MECH DEVELOP, V63, P51, DOI 10.1016/S0925-4773(97)00674-6; Flamme I, 1998, AM J PATHOL, V153, P25, DOI 10.1016/S0002-9440(10)65541-1; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; JACKSON FR, 1986, NATURE, V320, P185, DOI 10.1038/320185a0; Jain S, 1998, MECH DEVELOP, V73, P117, DOI 10.1016/S0925-4773(98)00038-0; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Ladoux A, 1997, BIOCHEM BIOPH RES CO, V240, P552, DOI 10.1006/bbrc.1997.7708; LEE ME, 1991, J BIOL CHEM, V266, P16188; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Li H, 1996, J BIOL CHEM, V271, P21262, DOI 10.1074/jbc.271.35.21262; LI H, 1994, J BIOL CHEM, V269, P28098; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; Liu YX, 1998, J BIOL CHEM, V273, P15257, DOI 10.1074/jbc.273.24.15257; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; PATTERSON C, 1995, J BIOL CHEM, V270, P23111, DOI 10.1074/jbc.270.39.23111; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; TISCHER E, 1991, J BIOL CHEM, V266, P11947; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WANG GL, 1998, BLOOD, V82, P8610; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8343, DOI 10.1128/MCB.14.12.8343; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Wilk R, 1996, GENE DEV, V10, P93, DOI 10.1101/gad.10.1.93; Yet SF, 1998, J BIOL CHEM, V273, P1026, DOI 10.1074/jbc.273.2.1026; YOSHIZUMI M, 1995, MOL CELL BIOL, V15, P3266	38	53	64	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31565	31570		10.1074/jbc.274.44.31565	http://dx.doi.org/10.1074/jbc.274.44.31565			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531360	hybrid			2022-12-27	WOS:000083379400064
J	Juszczak, LJ; Friedman, JM				Juszczak, LJ; Friedman, JM			UV resonance Raman spectra of ligand binding intermediates of sol-gel encapsulated hemoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUATERNARY STRUCTURE; CONFORMATIONAL-CHANGES; T-STATE; INOSITOL HEXAPHOSPHATE; SPECTROSCOPY; PROTEINS; DYNAMICS; COMMUNICATION; RESOLUTION; TRANSITION	We report for the first time specific conformational changes for a homogeneous population of ligand-bound adult deoxy human hemoglobin A (HbA) generated by introducing CO into a sample of deoxy-HbA with the effector, inositol hexaphosphate, encapsulated in a porous sol-gel. The preparation of ligand-bound deoxy-HbA results from the speed of ligand diffusion relative to globin conformational dynamics within the sol-gel (1). The ultraviolet resonance Raman (UVRR) difference spectra obtained reveal that E helix motion is initiated upon ligand binding, as signaled by the appearance of an alpha 14 beta 15 Trp W3 band difference at 1559 cm(-1). The subsequent appearance of Tyr (Y8a and Y9a) and W3 (1549 cm(-1)) UVRR difference bands suggest conformational shifts for the penultimate Tyr alpha 140 on the F helix, the "switch" region Tyr alpha 42, and the "hinge" region Trp beta 37. The UVRR results expose a sequence of conformational steps leading up to the ligation-induced T to R quaternary structure transition as opposed to a single, concerted switch. More generally, this report demonstrates that sol-gel encapsulation of proteins can be used to study a sequence of specific conformational events triggered by substrate binding because the traditional limitation of substrate diffusion times is overcome.	Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Friedman, JM (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	jfriedma@aecom.yu.edu			NHLBI NIH HHS [R01 HL58247, P01 HL51084] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058247, P01HL051084] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHER SA, 1993, ANAL CHEM, V65, pA59, DOI 10.1021/ac00052a715; AUSTIN JC, 1993, BIOMOLECULAR SPECT A, V20, P55; Bettati S, 1997, J BIOL CHEM, V272, P32050, DOI 10.1074/jbc.272.51.32050; DAS TK, 1999, IN PRESS BIOSPECTROS; DAVE BC, 1994, ANAL CHEM, V66, pA1120, DOI 10.1021/ac00094a001; ELLERBY LM, 1992, SCIENCE, V255, P1113, DOI 10.1126/science.1312257; FERMI G, 1984, J MOL BIOL, V175, P159, DOI 10.1016/0022-2836(84)90472-8; FRIEDMAN JM, 1994, METHOD ENZYMOL, V232, P205; Henry ER, 1997, BIOCHEMISTRY-US, V36, P6511, DOI 10.1021/bi9619177; Hirsch RE, 1996, J BIOL CHEM, V271, P372, DOI 10.1074/jbc.271.1.372; HOFRICHTER J, 1985, BIOCHEMISTRY-US, V24, P2667, DOI 10.1021/bi00332a012; Hu XH, 1997, BIOCHEMISTRY-US, V36, P15701, DOI 10.1021/bi971136l; Huang SC, 1997, BIOCHEMISTRY-US, V36, P6197, DOI 10.1021/bi970018v; JAYARAMAN V, 1995, SCIENCE, V269, P1843, DOI 10.1126/science.7569921; JAYARAMAN V, 1993, BIOCHEMISTRY-US, V32, P4547, DOI 10.1021/bi00068a009; Juszczak LJ, 1998, J RAMAN SPECTROSC, V29, P963, DOI 10.1002/(SICI)1097-4555(199810/11)29:10/11<963::AID-JRS332>3.0.CO;2-4; Kavanaugh JS, 1998, BIOCHEMISTRY-US, V37, P4358, DOI 10.1021/bi9708702; KITAGAWA T, 1992, PROG BIOPHYS MOL BIO, V58, P1, DOI 10.1016/0079-6107(92)90009-U; Kwiatkowski LD, 1998, BIOCHEMISTRY-US, V37, P4325, DOI 10.1021/bi970866q; MUKERJI I, 1994, BIOCHEMISTRY-US, V33, P13132, DOI 10.1021/bi00248a024; NAGAI M, 1995, J BIOL CHEM, V270, P1636, DOI 10.1074/jbc.270.4.1636; Nagai M, 1999, BIOCHEMISTRY-US, V38, P1243, DOI 10.1021/bi982269p; Nagai M, 1996, J MOL STRUCT, V379, P65, DOI 10.1016/0022-2860(95)09177-7; PERUTZ MF, 1989, Q REV BIOPHYS, V22, P139, DOI 10.1017/S0033583500003826; PERUTZ MF, 1987, ACCOUNTS CHEM RES, V20, P309, DOI 10.1021/ar00141a001; Peterson ES, 1998, BIOCHEMISTRY-US, V37, P4346, DOI 10.1021/bi9708693; RODGERS KR, 1992, J AM CHEM SOC, V114, P3697, DOI 10.1021/ja00036a019; RODGERS KR, 1994, SCIENCE, V265, P1697, DOI 10.1126/science.8085153; ROUSSEAU DL, 1988, BIOL APPLICATIONS RA, V3, P133; SASSAROLI M, 1987, BIOCHEMISTRY-US, V26, P3092, DOI 10.1021/bi00385a022; SCOTT TW, 1984, J AM CHEM SOC, V106, P5677, DOI 10.1021/ja00331a044; Shibayama N, 1999, J MOL BIOL, V285, P1383, DOI 10.1006/jmbi.1998.2407; Shibayama N, 1999, J AM CHEM SOC, V121, P444, DOI 10.1021/ja983652k; SHIBAYAMA N, 1995, J MOL BIOL, V251, P203, DOI 10.1006/jmbi.1995.0427; Sokolov L, 1998, J PHYS CHEM B, V102, P8314, DOI 10.1021/jp982099q; SU C, 1989, J AM CHEM SOC, V111, P3457, DOI 10.1021/ja00191a068; Wang DJ, 1998, BIOCHEMISTRY-US, V37, P9940, DOI 10.1021/bi980295h	37	58	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30357	30360		10.1074/jbc.274.43.30357	http://dx.doi.org/10.1074/jbc.274.43.30357			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521410	hybrid			2022-12-27	WOS:000083276700006
J	McEwen, DG; Green, RP; Naski, MC; Towler, DA; Ornitz, DM				McEwen, DG; Green, RP; Naski, MC; Towler, DA; Ornitz, DM			Fibroblast growth factor receptor 3 gene transcription is suppressed by cyclic adenosine 3 ',5 '-monophosphate - Identification of a chondrocytic regulatory element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-RELATED PEPTIDE; BOVINE CYP17 GENE; CAMP-DEPENDENT TRANSCRIPTION; ORPHAN NUCLEAR RECEPTOR; PARATHYROID-HORMONE; THANATOPHORIC DYSPLASIA; RETINOIC ACID; BONE-GROWTH; METAPHYSEAL CHONDRODYSPLASIA; CONSTITUTIVE ACTIVATION	Signaling through fibroblast growth factor receptors (FGFRs) is critical for the development and patterning of the vertebrate skeleton. Gain-of-function alleles of fgfr2 and fgfr3 have been linked to several dominant skeletal disorders in humans, while null mutations in fgfr3 result in the overgrowth of long bones in a mouse model system. interestingly, the expression pattern of fgfr3 in growth plate chondrocytes overlaps that of the parathyroid hormone (PTH)-related peptide (PTHrP) receptor, a signaling molecule that also regulates endochondral ossification. The coincident expression of these two receptors suggests that their signaling pathways may also interact. To gain insight into the regulatory mechanism(s) that govern the expression of the fgfr3 gene in chondrocytes, we have identified a cell-specific transcriptional regulatory element (CSRh) by measuring the activity of various promoter fragments in FGFR3-expressing (CFK2) and nonexpressing (RCJ) chondrocyte-like cell lines. Furthermore, we demonstrate that activation of PTH/PTHrP receptors, either by stimulation with PTH or through the introduction of activating mutations, represses CSRh-mediated transcriptional activity. Finally, the transcriptional repression of the CSRh element was mimicked by treatment with forskolin, 8-bromo-cAMP, and 3-isobutyl-1-methylxanthine or by overexpression of the catalytic subunit of protein kinase A. Together, these data suggest that protein kinase A activity is a critical factor that regulates fgfr3 gene expression in the proliferative or prehypertrophic compartment of the epiphyseal growth plate, Furthermore, these results provide a possible link between PTHrP signaling and fgfr3 gene expression during the process of endochondral ossification.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Ornitz, DM (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, Campus Box 8103,660 S Euclid Ave, St Louis, MO 63110 USA.			Ornitz, David/0000-0003-1592-7629; Towler, Dwight/0000-0003-2107-7923	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD035692] Funding Source: NIH RePORTER; NICHD NIH HHS [HD35692] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; Alini M, 1996, J BONE MINER RES, V11, P105; Amizuka N, 1996, DEV BIOL, V175, P166, DOI 10.1006/dbio.1996.0104; AMIZUKA N, 1994, J CELL BIOL, V126, P1611, DOI 10.1083/jcb.126.6.1611; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BAKKE M, 1995, ENDOCR RES, V21, P509, DOI 10.3109/07435809509030468; BAKKE M, 1995, MOL ENDOCRINOL, V9, P327, DOI 10.1210/me.9.3.327; BALLOCK RT, 1994, J CELL BIOL, V126, P1311, DOI 10.1083/jcb.126.5.1311; BARON J, 1994, ENDOCRINOLOGY, V135, P2790, DOI 10.1210/en.135.6.2790; BEAVO JA, 1970, MOL PHARMACOL, V6, P597; BELLUS GA, 1995, NAT GENET, V10, P357, DOI 10.1038/ng0795-357; BERNIER SM, 1990, J CELL PHYSIOL, V145, P274, DOI 10.1002/jcp.1041450212; Boudreaux JM, 1996, J BIOL CHEM, V271, P7508, DOI 10.1074/jbc.271.13.7508; Choi EJ, 1993, CURR OPIN CELL BIOL, V5, P269, DOI 10.1016/0955-0674(93)90115-7; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COFFIN JD, 1995, MOL BIOL CELL, V6, P1861, DOI 10.1091/mbc.6.12.1861; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; EdwallArvidsson C, 1996, ANAT EMBRYOL, V193, P453; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1995, MOL CELL BIOL, V15, P2517; GLANVILLE N, 1981, NATURE, V292, P267, DOI 10.1038/292267a0; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GRIGORIADIS AE, 1990, DEV BIOL, V142, P313, DOI 10.1016/0012-1606(90)90352-J; IWAMOTO M, 1991, J BIOL CHEM, V266, P461; IWAMOTO M, 1993, EXP CELL RES, V205, P213, DOI 10.1006/excr.1993.1079; IWAMOTO M, 1994, MICROSC RES TECHNIQ, V28, P483, DOI 10.1002/jemt.1070280604; IWAMOTO M, 1993, EXP CELL RES, V207, P413, DOI 10.1006/excr.1993.1209; Karaplis Andrew C., 1998, Frontiers in Bioscience, V3, pD795; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; Lund J, 1997, STEROIDS, V62, P43, DOI 10.1016/S0039-128X(96)00157-2; McEwen DG, 1998, J BIOL CHEM, V273, P5349, DOI 10.1074/jbc.273.9.5349; McEwen DG, 1997, BIOTECHNIQUES, V22, P1068, DOI 10.2144/97226bm12; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; Naski M C, 1998, Front Biosci, V3, pd781; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; Naski MC, 1998, DEVELOPMENT, V125, P4977; Newberry EP, 1996, MOL ENDOCRINOL, V10, P1029, DOI 10.1210/me.10.8.1029; PETERS K, 1993, DEV BIOL, V155, P423, DOI 10.1006/dbio.1993.1040; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Quarto R, 1997, ENDOCRINOLOGY, V138, P4966, DOI 10.1210/en.138.11.4966; ROUSSEAU F, 1995, NAT GENET, V10, P11, DOI 10.1038/ng0595-11; ROUSSEAU F, 1994, NATURE, V371, P252, DOI 10.1038/371252a0; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; SassoneCorsi P, 1995, ANNU REV CELL DEV BI, V11, P355, DOI 10.1146/annurev.cellbio.11.1.355; Schipani E, 1997, MOL ENDOCRINOL, V11, P851, DOI 10.1210/me.11.7.851; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; Skaer H, 1997, CURR BIOL, V7, pR238, DOI 10.1016/S0960-9822(06)00110-2; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P614, DOI 10.1210/me.8.5.614; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; WATERMAN MR, 1994, J BIOL CHEM, V269, P27783; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; Webster MK, 1997, TRENDS GENET, V13, P178, DOI 10.1016/S0168-9525(97)01131-1; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WILSON TE, 1993, MOL CELL BIOL, V13, P861, DOI 10.1128/MCB.13.2.861; Wingender E, 1996, NUCLEIC ACIDS RES, V24, P238, DOI 10.1093/nar/24.1.238; ZANGER UM, 1992, FASEB J, V6, P719, DOI 10.1096/fasebj.6.2.1311271; ZUSCIK MJ, 1994, ARCH BIOCHEM BIOPHYS, V315, P352, DOI 10.1006/abbi.1994.1511	66	20	20	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30934	30942		10.1074/jbc.274.43.30934	http://dx.doi.org/10.1074/jbc.274.43.30934			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521488	hybrid			2022-12-27	WOS:000083276700084
J	Orsini, MJ; Parent, JL; Mundell, SJ; Benovic, JL				Orsini, MJ; Parent, JL; Mundell, SJ; Benovic, JL			Trafficking of the HIV coreceptor CXCR4 - Role of arrestins and identification of residues in the C-terminal tail that mediate receptor internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; IMMUNODEFICIENCY-VIRUS TYPE-1; DOMINANT-NEGATIVE MUTANT; SMALL-MOLECULE INHIBITOR; T-CELL RECEPTOR; CHEMOKINE RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; BETA-ARRESTIN; DOWN-REGULATION; SIGNAL-TRANSDUCTION	The G protein-coupled chemokine receptor CXCR4 serves as the primary coreceptor for entry of T-cell tropic human immunodeficiency virus. CXCR4 undergoes tonic internalization as well as internalization in response to stimulation with phorbol esters and ligand (SDF-1 alpha). We investigated the trafficking of this receptor, and we attempted to define the residues of CXCR4 that were critical for receptor internalization. In both COS-1 and HEK-293 cells transiently overexpressing CXCR4, SDF-1 alpha and phorbol esters (PMA) promoted rapid internalization of cell surface receptors as assessed by both enzyme-linked immunosorbent assay and immunoflouorescence analysis. Expression of GRK2 and/or arrestins promoted modest additional CXCR4 internalization in response to both PMA and SDF, Both PMA- and SDF-mediated CXCR4 internalization was inhibited by coexpression of dominant negative mutants of dynamin-1 and arrestin-3. Arrestin was also recruited to the plasma membrane and appeared to colocalize with internalized receptors in response to SDF but not PMA. We then evaluated the ability of CXCR4 receptors containing mutations of serines and threonines, as well as a dileucine motif, within the C-terminal tail to be internalized and phosphorylated in response to either PMA or SDF-1 alpha: This analysis showed that multiple residues within the CXCR4 C-terminal tail appear to mediate both PMA- and SDF-1 alpha-mediated receptor internalization. The ability of coexpressed GRK2 and arrestins to promote internalization of the CXCR4 mutants revealed distinct differences between respective mutants and suggested that the integrity of the dileucine motif (IIe-328 and Leu-329) and serines 324, 325, 338, and 339 are critical for receptor internalization.	Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University	Benovic, JL (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, 233 S 10th St, Philadelphia, PA 19107 USA.	benovie@lac.jci.tju.edu			NIDDK NIH HHS [5-T32-DK07705] Funding Source: Medline; NIGMS NIH HHS [GM47419] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007705] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alkhatib G, 1997, VIROLOGY, V234, P340, DOI 10.1006/viro.1997.8673; Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; Arakaki R, 1999, J VIROL, V73, P1719, DOI 10.1128/JVI.73.2.1719-1723.1999; Aramori I, 1997, EMBO J, V16, P4606, DOI 10.1093/emboj/16.15.4606; Bandres JC, 1998, J VIROL, V72, P2500, DOI 10.1128/JVI.72.3.2500-2504.1998; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Cao TT, 1998, J BIOL CHEM, V273, P24592, DOI 10.1074/jbc.273.38.24592; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; CHUANG TT, 1995, J BIOL CHEM, V270, P18660, DOI 10.1074/jbc.270.31.18660; Cole SW, 1999, J IMMUNOL, V162, P1392; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Daunt DA, 1997, MOL PHARMACOL, V51, P711, DOI 10.1124/mol.51.5.711; Davis CB, 1997, J EXP MED, V186, P1793, DOI 10.1084/jem.186.10.1793; DeGraff JL, 1999, J BIOL CHEM, V274, P11253, DOI 10.1074/jbc.274.16.11253; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; Dietrich J, 1998, J BIOL CHEM, V273, P24232, DOI 10.1074/jbc.273.37.24232; Dietrich J, 1997, J CELL BIOL, V138, P271, DOI 10.1083/jcb.138.2.271; Donzella GA, 1998, NAT MED, V4, P72, DOI 10.1038/nm0198-072; Doranz BJ, 1997, J EXP MED, V186, P1395, DOI 10.1084/jem.186.8.1395; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Doranz BJ, 1999, J VIROL, V73, P2752, DOI 10.1128/JVI.73.4.2752-2761.1999; Edinger AL, 1997, P NATL ACAD SCI USA, V94, P14742, DOI 10.1073/pnas.94.26.14742; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Haribabu B, 1997, J BIOL CHEM, V272, P28726, DOI 10.1074/jbc.272.45.28726; Hesselgesser J, 1998, J IMMUNOL, V160, P877; Heveker N, 1998, CURR BIOL, V8, P369, DOI 10.1016/S0960-9822(98)70155-1; Huang L, 1998, J VIROL, V72, P8952, DOI 10.1128/JVI.72.11.8952-8960.1998; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Kinter A, 1998, P NATL ACAD SCI USA, V95, P11880, DOI 10.1073/pnas.95.20.11880; KONG GH, 1994, J BIOL CHEM, V269, P13084; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Lapham CK, 1996, SCIENCE, V274, P602, DOI 10.1126/science.274.5287.602; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Lazari RDM, 1998, J BIOL CHEM, V273, P18316, DOI 10.1074/jbc.273.29.18316; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Littman DR, 1998, CELL, V93, P677, DOI 10.1016/S0092-8674(00)81429-4; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Lu ZH, 1997, P NATL ACAD SCI USA, V94, P6426, DOI 10.1073/pnas.94.12.6426; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; Mack M, 1998, J EXP MED, V187, P1215, DOI 10.1084/jem.187.8.1215; Marechal V, 1999, J VIROL, V73, P3608; Martin KA, 1997, SCIENCE, V278, P1470, DOI 10.1126/science.278.5342.1470; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Nakamura K, 1998, J BIOL CHEM, V273, P24346, DOI 10.1074/jbc.273.38.24346; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; Oppermann M, 1999, J BIOL CHEM, V274, P8875, DOI 10.1074/jbc.274.13.8875; Orsini MJ, 1998, J BIOL CHEM, V273, P34616, DOI 10.1074/jbc.273.51.34616; Parent JL, 1999, J BIOL CHEM, V274, P8941, DOI 10.1074/jbc.274.13.8941; Peacock JW, 1999, J IMMUNOL, V162, P215; Pitcher C, 1999, MOL BIOL CELL, V10, P677, DOI 10.1091/mbc.10.3.677; Popik W, 1998, J VIROL, V72, P6406, DOI 10.1128/JVI.72.8.6406-6413.1998; Proudfoot AEI, 1999, BIOCHEM PHARMACOL, V57, P451; Rucker J, 1998, AIDS RES HUM RETROV, V14, pS241; Rucker J, 1997, J VIROL, V71, P8999, DOI 10.1128/JVI.71.12.8999-9007.1997; Schols D, 1997, ANTIVIR RES, V35, P147, DOI 10.1016/S0166-3542(97)00025-9; Secchiero P, 1999, J IMMUNOL, V162, P2427; Secchiero P, 1998, BLOOD, V92, P4521, DOI 10.1182/blood.V92.12.4521.424k38_4521_4528; Signoret N, 1998, J CELL SCI, V111, P2819; Signoret N, 1997, J CELL BIOL, V139, P651, DOI 10.1083/jcb.139.3.651; Tarasova NI, 1998, J BIOL CHEM, V273, P15883, DOI 10.1074/jbc.273.26.15883; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; TSUGA H, 1994, J BIOL CHEM, V269, P32522; Ugolini S, 1997, J IMMUNOL, V159, P3000; Wang JB, 1998, J LEUKOCYTE BIOL, V64, P642, DOI 10.1002/jlb.64.5.642; Wells TNC, 1998, TRENDS PHARMACOL SCI, V19, P376, DOI 10.1016/S0165-6147(98)01247-4; Winstel R, 1996, P NATL ACAD SCI USA, V93, P2105, DOI 10.1073/pnas.93.5.2105; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Yang AG, 1997, P NATL ACAD SCI USA, V94, P11567, DOI 10.1073/pnas.94.21.11567; Yang XY, 1999, J VIROL, V73, P3460, DOI 10.1128/JVI.73.4.3460-3466.1999; Zhang J, 1999, J BIOL CHEM, V274, P10999, DOI 10.1074/jbc.274.16.10999; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302; Zhang YJ, 1999, J VIROL, V73, P3443, DOI 10.1128/JVI.73.4.3443-3448.1999; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	84	204	210	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					31076	31086		10.1074/jbc.274.43.31076	http://dx.doi.org/10.1074/jbc.274.43.31076			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521508	hybrid			2022-12-27	WOS:000083276700104
J	Yuan, HD; Mao, JH; Li, L; Wu, DQ				Yuan, HD; Mao, JH; Li, L; Wu, DQ			Suppression of glycogen synthase kinase activity is not sufficient for leukemia enhancer factor-1 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNALING PATHWAY; DROSOPHILA; APC; PHOSPHORYLATION; COMPLEX; FAMILY; AXIN; PROTOONCOGENE	Glycogen synthase kinase-3 (GSK) can be regulated by different signaling pathways including those mediated by protein kinase Akt and Wnt proteins. Wnt proteins are believed to activate a transcription factor leukemia enhancer factor-1 (LEF-1) by inhibiting GSK, and Akt was shown to phosphorylate GSK and inhibit its kinase activity. We investigated the effect of an activated Akt on the accumulation of cytosolic beta-catenin and LEF-1-dependent transcription. Although the activated Akt, mAkt, clearly inhibited the kinase activity of GSK, mAkt alone did not induce accumulation of cytosolic beta-catenin or activate LEF-1-dependent transcription. On the contrary, coexpressed Wnt-1 and Frat activated LEF-1 but did not show significant inhibition of GSK-mediated phosphorylation of a peptide substrate. However, mAkt could act synergistically with Wnt-1 or Frat to activate LEF-1. In addition, the interaction of GSK for Axin appeared to decrease in the presence of mAkt, whereas the interaction for Frat remained unchanged. Consistently, a GSK mutant with substitution of a Phe residue for residue Tyr-216, which showed one-fifth of kinase activity of the wild-type GSK, exhibited a reduced association for Axin than the wild-type GSK. These results suggest that inhibition of GSK kinase activity is not sufficient for activation of LEF-1 but may facilitate the activation by reducing the interaction of GSK for Axin, The additional mechanism for LEF-1 activation may require dissociation of GSK from Axin as Frat facilitates the dissociation of GSK from Axin.	Univ Rochester, Dept Pharmacol & Physiol, Rochester, NY 14642 USA; Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai, Peoples R China; Chinese Acad Sci, Shanghai Inst Biochem, Shanghai, Peoples R China	University of Rochester; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Wu, DQ (corresponding author), Univ Rochester, Dept Pharmacol & Physiol, 601 Elmwood Ave, Rochester, NY 14642 USA.	wud@pharmacol.rochester.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053162] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54167, GM53162] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CHAN SDH, 1992, J BIOL CHEM, V267, P25202; Coffer PJ, 1998, BIOCHEM J, V335, P1; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dale TC, 1998, BIOCHEM J, V329, P209; Dickinson ME, 1992, CURR OPIN GENET DEV, V2, P562, DOI 10.1016/S0959-437X(05)80172-8; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; HAWKINS PT, 1997, BIOCHEM SOC T, V25, P710; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Jonkers J, 1997, EMBO J, V16, P441, DOI 10.1093/emboj/16.3.441; Klingensmith J, 1996, MECH DEVELOP, V58, P15, DOI 10.1016/S0925-4773(96)00549-7; KLINGENSMITH J, 1994, DEV BIOL, V166, P396, DOI 10.1006/dbio.1994.1325; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Li L, 1999, J BIOL CHEM, V274, P129, DOI 10.1074/jbc.274.1.129; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PERRIMON N, 1994, CELL, V76, P781, DOI 10.1016/0092-8674(94)90351-4; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; SUSSMAN DJ, 1994, DEV BIOL, V166, P73, DOI 10.1006/dbio.1994.1297; Torres MA, 1999, MOL CELL BIOL, V19, P1427; Tsang M, 1996, DEV DYNAM, V207, P253, DOI 10.1002/(SICI)1097-0177(199611)207:3<253::AID-AJA2>3.0.CO;2-G; WANG QM, 1994, J BIOL CHEM, V269, P14566; Wang YS, 1996, J BIOL CHEM, V271, P4468; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8	37	94	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30419	30423		10.1074/jbc.274.43.30419	http://dx.doi.org/10.1074/jbc.274.43.30419			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521419	hybrid			2022-12-27	WOS:000083276700015
J	Basora, N; Herring-Gillam, FE; Boudreau, F; Perreault, N; Pageot, LP; Simoneau, M; Bouatrouss, Y; Beaulieu, JF				Basora, N; Herring-Gillam, FE; Boudreau, F; Perreault, N; Pageot, LP; Simoneau, M; Bouatrouss, Y; Beaulieu, JF			Expression of functionally distinct variants of the beta(4)A integrin subunit in relation to the differentiation state in human intestinal cell	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUCRASE-ISOMALTASE EXPRESSION; TRANSIENT MOSAIC PATTERNS; CRYPT-VILLUS AXIS; A-CHAIN ISOFORMS; CYTOPLASMIC DOMAIN; EPITHELIAL-CELLS; BETA-4 INTEGRIN; ALPHA(6)BETA(4) INTEGRIN; ALPHA-6-BETA-4 INTEGRIN; SIGNAL-TRANSDUCTION	Integrins are important mediators of cell-laminin interactions. In the small intestinal epithelium, which consists of spatially separated proliferative and differentiated cell populations located, respectively, in the crypt and on the villus, laminins and laminin-binding; integrins are differentially expressed along the cryptvillus axis. One exception to this is the integrin alpha(6)beta(4), which is thought to be ubiquitously expressed by intestinal cells. However, in this study, a re-evaluation of the beta(4) subunit expression with different antibodies revealed that two forms of beta(4) exist in the human intestinal epithelium. Furthermore, we show that differentiated enterocytes express a full-length 205-kDa beta(4)A subunit, whereas undifferentiated crypt cells express a novel beta(4)A subunit that does not contain the COOH-terminal segment of the cytoplasmic domain (beta(4)A(ctd-)). This new form was not found to arise from alternative beta(4) mRNA splicing. Moreover, we found that these two beta(4)A forms can associate into alpha(6)beta(4)A complexes; however, the beta 4A(ctd-) integrin expressed by the undifferentiated crypt cells is not functional for adhesion to laminin-5. Hence, these studies identify a novel alpha(6)beta(4)A(ctd-) integrin expressed in undifferentiated intestinal crypt cells that is functionally distinct.	Univ Sherbrooke, Fac Med, Dept Anat & Biol Cellulaire, CUSE,Ctr Rech Clin,Ctr Rech Biol Dev Epitheliums, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Beaulieu, JF (corresponding author), Univ Sherbrooke, Fac Med, Dept Anat & Biol Cellulaire, CUSE,Ctr Rech Clin,Ctr Rech Biol Dev Epitheliums, Sherbrooke, PQ J1H 5N4, Canada.		Beaulieu, Jean-Francois/D-2054-2010					AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; Basora N, 1997, GASTROENTEROLOGY, V113, P1510, DOI 10.1053/gast.1997.v113.pm9352853; Beaulieu Jean-Francois, 1999, Frontiers in Bioscience, V4, pD310, DOI 10.2741/Beaulieu; BEAULIEU JF, 1989, J BIOL CHEM, V264, P20000; BEAULIEU JF, 1991, BIOCHEM J, V280, P599, DOI 10.1042/bj2800599; BEAULIEU JF, 1994, GASTROENTEROLOGY, V106, P829, DOI 10.1016/0016-5085(94)90740-4; Beaulieu JF, 1997, PROG HISTOCHEM CYTOC, V31, P1; BEAULIEU JF, 1992, J CELL SCI, V102, P427; BEAULIEU JF, 1994, GASTROENTEROLOGY, V107, P957, DOI 10.1016/0016-5085(94)90219-4; Borradori L, 1996, CURR OPIN CELL BIOL, V8, P647, DOI 10.1016/S0955-0674(96)80106-2; BOYLE WJ, 1995, CURR OPIN GASTROEN, V11, P121, DOI 10.1097/00001574-199503000-00006; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARKE AS, 1994, CELL ADHES COMMUN, V2, P1, DOI 10.3109/15419069409014197; CLARKE AS, 1995, J BIOL CHEM, V270, P22673, DOI 10.1074/jbc.270.39.22673; De Arcangelis A, 1996, J CELL BIOL, V133, P417, DOI 10.1083/jcb.133.2.417; DELWEL GO, 1994, MOL BIOL CELL, V5, P203, DOI 10.1091/mbc.5.2.203; DiPersio CM, 1997, J CELL BIOL, V137, P729, DOI 10.1083/jcb.137.3.729; Dowling J, 1996, J CELL BIOL, V134, P559, DOI 10.1083/jcb.134.2.559; ENGVALL E, 1990, CELL REGUL, V1, P731, DOI 10.1091/mbc.1.10.731; FALCIONI R, 1989, MOL CARCINOGEN, V2, P361, DOI 10.1002/mc.2940020611; GIANCOTTI FG, 1992, J CELL BIOL, V118, P951, DOI 10.1083/jcb.118.4.951; Giancotti FG, 1996, J CELL SCI, V109, P1165; HESSLE H, 1984, DIFFERENTIATION, V26, P49, DOI 10.1111/j.1432-0436.1984.tb01372.x; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HIBBS ML, 1991, SCIENCE, V251, P1611, DOI 10.1126/science.1672776; HOGERVORST F, 1990, EMBO J, V9, P765, DOI 10.1002/j.1460-2075.1990.tb08171.x; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KAJIJI S, 1989, EMBO J, V8, P673, DOI 10.1002/j.1460-2075.1989.tb03425.x; KENNEL SJ, 1989, J BIOL CHEM, V264, P15515; LEBLOND CP, 1981, AM J ANAT, V160, P114; LEE EC, 1992, J CELL BIOL, V117, P671, DOI 10.1083/jcb.117.3.671; Leivo I, 1996, J HISTOCHEM CYTOCHEM, V44, P1267, DOI 10.1177/44.11.8918902; LOUVARD D, 1992, ANNU REV CELL BIOL, V8, P157, DOI 10.1146/annurev.cb.08.110192.001105; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; MAINIERO F, 1995, EMBO J, V14, P4470, DOI 10.1002/j.1460-2075.1995.tb00126.x; Menard D., 1994, MEMBRANE PHYSIOPATHO, P319; MERCURIO AM, 1995, TRENDS CELL BIOL, V5, P419, DOI 10.1016/S0962-8924(00)89100-X; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Murgia C, 1998, EMBO J, V17, P3940, DOI 10.1093/emboj/17.14.3940; Niessen CM, 1997, J CELL SCI, V110, P1705; Niessen CM, 1997, MOL BIOL CELL, V8, P555, DOI 10.1091/mbc.8.4.555; NIESSEN CM, 1994, EXP CELL RES, V211, P360, DOI 10.1006/excr.1994.1099; Nievers MG, 1998, J CELL SCI, V111, P1659; OrianRousseau V, 1996, DEV DYNAM, V206, P12, DOI 10.1002/(SICI)1097-0177(199605)206:1<12::AID-AJA2>3.0.CO;2-3; OTOOLE TE, 1995, J BIOL CHEM, V270, P8553, DOI 10.1074/jbc.270.15.8553; Perreault N, 1996, EXP CELL RES, V224, P354, DOI 10.1006/excr.1996.0145; PERREAULT N, 1995, ANAT REC, V242, P242, DOI 10.1002/ar.1092420214; PINTO M, 1983, BIOL CELL, V47, P323; PODOLSKY DK, 1995, TXB GASTROENTEROLOGY, P546; POTTS AJ, 1994, EXP CELL RES, V212, P2, DOI 10.1006/excr.1994.1111; Quaroni A, 1997, GASTROENTEROLOGY, V113, P1198, DOI 10.1053/gast.1997.v113.pm9322515; Rezniczek GA, 1998, J CELL BIOL, V141, P209, DOI 10.1083/jcb.141.1.209; RODIRGUEZBOULAN E, 1989, SCIENCE, V245, P718; Romzek NC, 1998, MOL BIOL CELL, V9, P2715, DOI 10.1091/mbc.9.10.2715; ROUSSELLE P, 1994, J CELL BIOL, V125, P205, DOI 10.1083/jcb.125.1.205; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; Schaapveld RQJ, 1998, J CELL BIOL, V142, P271, DOI 10.1083/jcb.142.1.271; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Sheppard D, 1996, BIOESSAYS, V18, P655, DOI 10.1002/bies.950180809; SIMONASSMANN P, 1994, DEV DYNAM, V201, P71, DOI 10.1002/aja.1002010108; SONNENBERG A, 1992, PATHOL BIOL, V40, P773; SONNENBERG A, 1993, J CELL SCI, V106, P1083; SONNENBERG A, 1988, NATURE, V336, P487, DOI 10.1038/336487a0; SPINARDI L, 1995, J CELL BIOL, V129, P473, DOI 10.1083/jcb.129.2.473; SUZUKI S, 1990, EMBO J, V9, P757, DOI 10.1002/j.1460-2075.1990.tb08170.x; TAMURA RN, 1990, J CELL BIOL, V111, P1593, DOI 10.1083/jcb.111.4.1593; VACHON PH, 1992, GASTROENTEROLOGY, V103, P414, DOI 10.1016/0016-5085(92)90829-N; Vachon PH, 1997, J CLIN INVEST, V100, P1870, DOI 10.1172/JCI119716; Vachon PH, 1996, J CELL PHYSIOL, V166, P198, DOI 10.1002/(SICI)1097-4652(199601)166:1<198::AID-JCP21>3.0.CO;2-A; VACHON PH, 1995, AM J PHYSIOL, V268, P857; vanderNeut R, 1996, NAT GENET, V13, P366, DOI 10.1038/ng0796-366; vanLeusden MR, 1997, BIOCHEM BIOPH RES CO, V235, P826, DOI 10.1006/bbrc.1997.6892; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; WEWER UM, 1994, METHOD ENZYMOL, V245, P85; Xia YP, 1996, J CELL BIOL, V132, P727, DOI 10.1083/jcb.132.4.727	78	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29819	29825		10.1074/jbc.274.42.29819	http://dx.doi.org/10.1074/jbc.274.42.29819			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514460	hybrid			2022-12-27	WOS:000083176400039
J	Fay, PJ; Scandella, D				Fay, PJ; Scandella, D			Human inhibitor antibodies specific for the factor VIII A2 domain disrupt the interaction between the subunit and factor IXa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-C; PORCINE FACTOR-VIII; HEMOPHILIA-A; BINDING-SITE; A1/A3-C1-C2 DIMER; MOLECULAR-BASIS; LIGHT-CHAIN; FACTOR-X; A2-SUBUNIT; IDENTIFICATION	Factor VIIIa, a heterotrimer of the A1, A2, and A3-C1-C2 subunits, increases the catalytic efficiency for factor IXa-catalyzed activation of factor X. A significant fraction of naturally occurring, anti-factor VIII inhibitor antibodies reacts with the A2 domain. Utilizing the capacity for isolated A2 subunit to stimulate factor IXa activity, we show that a panel of these inhibitors block this activity, inhibition of activity parallels the antibody potency as measured in the Bethesda assay. These antibodies also block the A2-dependent increases in fluorescence anisotropy of fluorescein-Phe-Phe-Arg factor IXa. Similar to the IgG fractions, a peptide representing the sequence of the inhibitor epitope (A2 residues 484-509) blocked the A2-dependent stimulation of factor IXa. These results indicate that antibodies possessing this specificity directly inhibit the interaction of A2 subunit with factor IXa, thus abrogating the contribution of this subunit to cofactor activity. Furthermore, these results also suggest that factor VIII residues 484-509 contribute to a factor IXa-interactive site.	Univ Rochester, Med Ctr, Vasc Med Unit, Sch Med,Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Vasc Med Unit, Sch Med,Dept Med, Rochester, NY 14642 USA; Amer Red Cross, Jerome H Holland Lab Biomed Sci, Rockville, MD 20855 USA	University of Rochester; University of Rochester; American Red Cross	Fay, PJ (corresponding author), Univ Rochester, Med Ctr, Vasc Med Unit, Sch Med,Dept Biochem & Biophys, 601 Elmwood Ave,POB 610, Rochester, NY 14642 USA.	Philip_Fay@urmc.rochester.edu			NHLBI NIH HHS [HL 30616, HL 38199, HL 55273] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030616, R01HL055273, R01HL038199] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amano K, 1998, BLOOD, V91, P538, DOI 10.1182/blood.V91.2.538.538_538_548; ARAI M, 1989, J CLIN INVEST, V83, P1978, DOI 10.1172/JCI114107; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CURTIS JE, 1994, J BIOL CHEM, V269, P6246; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; FAY PJ, 1993, J BIOL CHEM, V268, P17861; Fay PJ, 1998, J BIOL CHEM, V273, P19049, DOI 10.1074/jbc.273.30.19049; FAY PJ, 1994, J BIOL CHEM, V269, P20522; FAY PJ, 1991, J BIOL CHEM, V266, P20139; FAY PJ, 1992, J BIOL CHEM, V267, P13246; FAY PJ, 1991, J BIOL CHEM, V266, P8957; Feinstein D I, 1972, Prog Hemost Thromb, V1, P75; HEALEY JF, 1995, J BIOL CHEM, V270, P14505, DOI 10.1074/jbc.270.24.14505; HOYER LW, 1994, SEMIN HEMATOL, V31, P1; KASPER CK, 1975, THROMB DIATH HAEMOST, V34, P869; KemballCook G, 1997, NUCLEIC ACIDS RES, V25, P128, DOI 10.1093/nar/25.1.128; Lapan KA, 1997, J BIOL CHEM, V272, P2082; LAZARCHICK J, 1978, J CLIN INVEST, V62, P1048, DOI 10.1172/JCI109209; Lenting PJ, 1996, J BIOL CHEM, V271, P1935, DOI 10.1074/jbc.271.4.1935; LENTING PJ, 1994, J BIOL CHEM, V269, P7150; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1993, METHOD ENZYMOL, V222, P128; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; LOLLAR P, 1994, J CLIN INVEST, V93, P2497, DOI 10.1172/JCI117259; LOLLAR P, 1992, J BIOL CHEM, V267, P23652; Lollar P, 1995, ADV EXP MED BIOL, V386, P3; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; OBRIEN LM, 1995, J BIOL CHEM, V270, P27087, DOI 10.1074/jbc.270.45.27087; Pemberton S, 1997, BLOOD, V89, P2413, DOI 10.1182/blood.V89.7.2413; Prescott R, 1997, BLOOD, V89, P3663, DOI 10.1182/blood.V89.10.3663.3663_3663_3671; Regan LM, 1996, J BIOL CHEM, V271, P3982; REGAN LM, 1994, J BIOL CHEM, V269, P9445; SCANDELLA D, 1995, BLOOD, V86, P1811, DOI 10.1182/blood.V86.5.1811.bloodjournal8651811; TUDDENHAM EGD, 1994, NUCLEIC ACIDS RES, V22, P3511, DOI 10.1093/nar/22.17.3511; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; Zhong DG, 1998, BLOOD, V92, P136, DOI 10.1182/blood.V92.1.136.413k35_136_142	36	71	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29826	29830		10.1074/jbc.274.42.29826	http://dx.doi.org/10.1074/jbc.274.42.29826			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514461	hybrid			2022-12-27	WOS:000083176400040
J	Knarr, G; Modrow, S; Todd, A; Gething, MJ; Buchner, J				Knarr, G; Modrow, S; Todd, A; Gething, MJ; Buchner, J			BiP-binding sequences in HIV gp160 - Implications for the binding specificity of BiP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; IMMUNOGLOBULIN LIGHT-CHAINS; HSP70 MOLECULAR CHAPERONES; ENVELOPE GLYCOPROTEIN; PEPTIDE-BINDING; INFLUENZA HEMAGGLUTININ; ENDOPLASMIC-RETICULUM; MONOCLONAL-ANTIBODIES; CONFORMATIONAL CHANGE; MEMBRANE-FUSION	BiP, a resident endoplasmic reticulum member of the HSP70 family of molecular chaperones, associates transiently with a wide variety of newly synthesized exocytotic proteins. In addition to immunoglobulin heavy and light chains, the first natural substrates identified for BiP, a number of viral polypeptides including the human immunodeficiency virus type 1 envelope glycoprotein gp160 interact with BiP during their passage through the endoplasmic reticulum. We have used a computer algorithm developed to predict BiP-binding sites within protein primary sequences to identify sites within gp160 that might mediate its association with BiP. Analysis of the ability of 22 synthetic heptapeptides corresponding to predicted binding sites to stimulate the ATPase activity of BiP or to compete with an unfolded polypeptide for binding to BiP indicated that about half of them are indeed recognized by the chaperone. All of the confirmed binding sites are localized within conserved regions of gp160, suggesting a conserved role for BiP in the folding of gp160. Information on the characteristics of confirmed BiP-binding peptides gained in this and previous studies has been utilized to improve the predictive power of the BiP Score algorithm and to investigate the differences in peptide binding specificities of HSP70 family members.	Univ Regensburg, Inst Biophys & Phys Biochem, D-93040 Regensburg, Germany; Univ Regensburg, Inst Med Mikrobiol & Hyg, D-93042 Regensburg, Germany; Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia	University of Regensburg; University of Regensburg; University of Melbourne	Buchner, J (corresponding author), Tech Univ Munich, Inst Org Chem & Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.	johannes.buchner@ch.tum.de	Buchner, Johannes/A-2651-2010	Corlett, Alicia/0000-0003-1146-2465; Buchner, Johannes/0000-0003-1282-7737				ATHERTON E, 1978, J CHEM SOC CHEM COMM, P537, DOI 10.1039/c39780000537; BECKER J, 1994, EUR J BIOCHEM, V219, P11, DOI 10.1111/j.1432-1033.1994.tb19910.x; BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; Brewer J. W., 1997, MOL CHAPERONE PROTEI, P415; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DEDERA D, 1992, J VIROL, V66, P1207, DOI 10.1128/JVI.66.2.1207-1209.1992; DONCH J, 1968, J BACTERIOL, V95, P1555, DOI 10.1128/JB.95.5.1555-1559.1968; EARL PL, 1991, J VIROL, V65, P2047, DOI 10.1128/JVI.65.4.2047-2055.1991; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; Fourie AM, 1997, J BIOL CHEM, V272, P19471, DOI 10.1074/jbc.272.31.19471; Gething MJ, 1995, COLD SPRING HARB SYM, V60, P417, DOI 10.1101/SQB.1995.060.01.046; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GETHING MJ, 1997, MOL CHAPERONES PROTE, P59; GNANN JW, 1987, J VIROL, V61, P2639, DOI 10.1128/JVI.61.8.2639-2641.1987; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HAAS IG, 1994, EXPERIENTIA, V50, P1012, DOI 10.1007/BF01923455; HAAS IG, 1988, P NATL ACAD SCI USA, V85, P2250, DOI 10.1073/pnas.85.7.2250; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; HART TK, 1991, P NATL ACAD SCI USA, V88, P2189, DOI 10.1073/pnas.88.6.2189; Hellman R, 1999, J CELL BIOL, V144, P21, DOI 10.1083/jcb.144.1.21; Hendershot L, 1996, P NATL ACAD SCI USA, V93, P5269, DOI 10.1073/pnas.93.11.5269; HENDERSHOT L, 1987, J CELL BIOL, V104, P761, DOI 10.1083/jcb.104.3.761; Hightower LE, 1994, BIOL HEAT SHOCK PROT, P179; KNARR G, 1995, J BIOL CHEM, V270, P27589, DOI 10.1074/jbc.270.46.27589; KNITTLER MR, 1995, P NATL ACAD SCI USA, V92, P1764, DOI 10.1073/pnas.92.5.1764; KNITTLER MR, 1992, EMBO J, V11, P1573, DOI 10.1002/j.1460-2075.1992.tb05202.x; KOZUTSUMI Y, 1999, J CELL SCI S, V11, P115; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LEONARD CK, 1990, J BIOL CHEM, V265, P10373; MA J, 1990, MOL IMMUNOL, V27, P623, DOI 10.1016/0161-5890(90)90004-J; MACHAMER CE, 1990, J BIOL CHEM, V265, P6879; MIAO B, 1997, MOL CHAPERONES PROTE, P3; MODROW S, 1987, J VIROL, V61, P570, DOI 10.1128/JVI.61.2.570-578.1987; MOORE JP, 1995, J VIROL, V69, P101, DOI 10.1128/JVI.69.1.101-109.1995; NAKAKI T, 1989, MOL CELL BIOL, V9, P2233, DOI 10.1128/MCB.9.5.2233; Otteken A, 1996, J VIROL, V70, P3407, DOI 10.1128/JVI.70.6.3407-3415.1996; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; SKEHEL JJ, 1982, P NATL ACAD SCI-BIOL, V79, P968, DOI 10.1073/pnas.79.4.968; SKERRA A, 1991, BIO-TECHNOL, V9, P273, DOI 10.1038/nbt0391-273; TAKENAKA IM, 1995, J BIOL CHEM, V270, P19839, DOI 10.1074/jbc.270.34.19839; WEI JY, 1995, J BIOL CHEM, V270, P26677, DOI 10.1074/jbc.270.44.26677; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606; [No title captured]	56	45	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29850	29857		10.1074/jbc.274.42.29850	http://dx.doi.org/10.1074/jbc.274.42.29850			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514465	hybrid			2022-12-27	WOS:000083176400044
J	Liu, T; Pemberton, PA; Robertson, AD				Liu, T; Pemberton, PA; Robertson, AD			Three-estate unfolding and self-association of maspin, a tumor-suppressing serpin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MYOEPITHELIAL CELL; PLASMINOGEN-ACTIVATOR; BREAST-CARCINOMA; MOLECULAR-BASIS; CANCER CELLS; PROTEIN; OVALBUMIN; COOPERATIVITY; RECOMBINANT; RESOLUTION	Maspin is a tumor suppressor protein expressed by normal human mammary epithelium but not by many breast tumor cell lines, Recombinant human maspin (rMaspin) inhibits tumor cell motility, invasion, and metastasis and thus has potential value as an anti-cancer therapeutic, Maspin is a member of the serpin family and, although the molecular mechanism by which maspin acts is unknown, recent work suggests that tissue plasminogen activator is a potential target. A puzzling observation in previous cell culture studies was loss of rMaspin activity at higher protein concentrations, One hypothesis to explain these results is self-association of rMaspin at the higher concentrations, which would be consistent with the tendency of serpins to form noncovalent polymers, This hypothesis is addressed by examining the relationship between rMaspin stability and self-association. Urea denaturation of rMaspin at pH 7 and 25 degrees C and at protein concentrations ranging from 0.01 to 0.2 mg/ml has been monitored by circular dichroism and intrinsic tryptophan fluorescence, Denaturation profiles show a protein concentration dependence and indicate the presence of at least one unfolding intermediate. The results suggest that destabilization of native monomeric rMaspin leads to partial unfolding and formation of an intermediate which can self-associate.	Univ Iowa, Coll Med, Dept Biochem, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Ctr Canc, Iowa City, IA 52242 USA; LXR Biotechnol, Richmond, CA 94804 USA	University of Iowa; University of Iowa	Robertson, AD (corresponding author), Univ Iowa, Coll Med, Dept Biochem, Iowa City, IA 52242 USA.		Liu, Ting/GRS-6266-2022		NCRR NIH HHS [S10 RR10409] Funding Source: Medline; NIGMS NIH HHS [GM46869] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR010409] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046869] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEWELL NM, 1993, TRENDS BIOCHEM SCI, V18, P1, DOI 10.1016/0968-0004(93)90077-Z; BRUCH M, 1988, J BIOL CHEM, V263, P16623; Carrell RW, 1998, CURR OPIN STRUC BIOL, V8, P799, DOI 10.1016/S0959-440X(98)80101-2; Dafforn TR, 1999, J BIOL CHEM, V274, P9548, DOI 10.1074/jbc.274.14.9548; Eftink MR, 1995, METHOD ENZYMOL, V259, P487; Fitzpatrick PA, 1996, PROTEIN ENG, V9, P585, DOI 10.1093/protein/9.7.585; FREIRE E, 1991, J MOL BIOL, V222, P687, DOI 10.1016/0022-2836(91)90505-Z; FREIRE E, 1992, BIOCHEMISTRY-US, V31, P250, DOI 10.1021/bi00116a034; HANSEN JC, 1994, BIOCHEMISTRY-US, V33, P13155, DOI 10.1021/bi00249a001; HERVE M, 1990, EUR J BIOCHEM, V191, P653, DOI 10.1111/j.1432-1033.1990.tb19171.x; LAUE TM, 1992, ANAL ULTRACENTRIFUGA, P91; Lee KN, 1998, J BIOL CHEM, V273, P2509, DOI 10.1074/jbc.273.5.2509; Mikus P, 1996, J BIOL CHEM, V271, P10048, DOI 10.1074/jbc.271.17.10048; Onda M, 1997, J BIOL CHEM, V272, P3973, DOI 10.1074/jbc.272.7.3973; Pace C N, 1986, Methods Enzymol, V131, P266; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PEMBERTON PA, 1995, J BIOL CHEM, V270, P15832, DOI 10.1074/jbc.270.26.15832; Pemberton PA, 1997, J HISTOCHEM CYTOCHEM, V45, P1697, DOI 10.1177/002215549704501213; POWELL LM, 1992, J MOL BIOL, V224, P241, DOI 10.1016/0022-2836(92)90587-A; Raschke TM, 1998, CURR OPIN BIOTECH, V9, P80, DOI 10.1016/S0958-1669(98)80088-8; ROYER CA, 1993, PROTEIN SCI, V2, P1844, DOI 10.1002/pro.5560021106; Seftor REB, 1998, CANCER RES, V58, P5681; Shao ZM, 1998, EXP CELL RES, V241, P394, DOI 10.1006/excr.1998.4066; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; SHENG SJ, 1994, J BIOL CHEM, V269, P30988; Sheng SJ, 1998, P NATL ACAD SCI USA, V95, P499, DOI 10.1073/pnas.95.2.499; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; STEIN PE, 1991, J MOL BIOL, V221, P941, DOI 10.1016/0022-2836(91)80185-W; Sternlicht MD, 1997, CLIN CANCER RES, V3, P1949; Umekita Y, 1997, CANCER LETT, V113, P87, DOI 10.1016/S0304-3835(97)04600-4; Wang ZL, 1996, BIOCHEMISTRY-US, V35, P16443, DOI 10.1021/bi961214p; Whisstock J, 1998, TRENDS BIOCHEM SCI, V23, P63, DOI 10.1016/S0968-0004(97)01172-9; YANG JT, 1986, METHOD ENZYMOL, V130, P208; ZAMYATNIN AA, 1984, ANNU REV BIOPHYS BIO, V13, P145, DOI 10.1146/annurev.bb.13.060184.001045; Zhang M, 1997, P NATL ACAD SCI USA, V94, P5673, DOI 10.1073/pnas.94.11.5673; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	36	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29628	29632		10.1074/jbc.274.42.29628	http://dx.doi.org/10.1074/jbc.274.42.29628			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514431	hybrid			2022-12-27	WOS:000083176400010
J	Schroter, S; Derr, P; Conrad, HS; Nimtz, M; Hale, G; Kirchhoff, C				Schroter, S; Derr, P; Conrad, HS; Nimtz, M; Hale, G; Kirchhoff, C			Male-specific modification of human CD52	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED GLYCOPROTEIN; BETA-TRACE PROTEIN; SEMINAL PLASMA; SPERM SURFACE; EPIDIDYMAL MATURATION; MONOCLONAL-ANTIBODIES; CAMPATH-1 ANTIGEN; PEPTIDE BACKBONE; RAT SPERMATOZOA; MESSENGER-RNA	CD52 is an unusually short, bipolar glycopeptide bearing a highly charged N-Linked carbohydrate moiety and a glycosylphosphatidylinositol membrane anchor. It is exclusively expressed on lymphocytes and in the male genital tract where it is shed into the seminal plasma and inserts into the sperm membrane. The sperm surface molecule has potential significance as a target for antibodies that inhibit sperm function and gamete interaction. Western blot analyses suggested cell type-specific modifications of the antigen. It was purified from seminal plasma and a detailed structural analysis performed. The majority of anchor structures in male genital tract CD52 showed 2-inositol palmitoylation, rendering molecules insensitive toward phospholipase C, and a sn-1-alkyl-2-lyso-glycerol structure in place of the diacylated anchor described by Treumann st al. (Treumann, A., Lifely, M. R., Schneider, P,, and Ferguson, M, A. (1995) J. Biol. Chem. 270, 6088-6099). N-Glycans of the male genital tract product were based on bi-, tri-, and tetraan-tennary structures of highly charged (up to -7), terminally sialylated complex-type sugars. A substantial proportion carried varying numbers of lactosamine repeats of which nearly 30% were branched. Different from lymphocytes, 10-15% of all N-glycans of the male genital tract antigen also contained peripheral fucose, These data confirm that male genital tract CD52 is distinct from the lymphocyte form by both N-linked glycans and COOH-terminal attached lipid anchor.	Univ Hamburg, Inst Hormon & Fortpflanzungsforsch, D-22529 Hamburg, Germany; Gesell Biotechnol Forsch mbH, D-38124 Braunschweig, Germany; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of Hamburg; Gesellschaft fur Biotechnologische Forschung mbH; University of Oxford	Kirchhoff, C (corresponding author), Univ Hamburg, Inst Hormon & Fortpflanzungsforsch, Grandweg 64, D-22529 Hamburg, Germany.	kirchhoff@ihf.de		Hale, Geoff/0000-0001-9473-423X				ANUMULA KR, 1992, ANAL BIOCHEM, V203, P101, DOI 10.1016/0003-2697(92)90048-C; BEDFORD JM, 1963, NATURE, V200, P1178, DOI 10.1038/2001178a0; Benoff S, 1997, MOL HUM REPROD, V3, P599, DOI 10.1093/molehr/3.7.599; BOLDT J, 1989, BIOL REPROD, V40, P887, DOI 10.1095/biolreprod40.4.887; Chen R, 1998, P NATL ACAD SCI USA, V95, P9512, DOI 10.1073/pnas.95.16.9512; COOPER GW, 1971, ANAT REC, V169, P300; Diekman AB, 1997, BIOL REPROD, V57, P1136, DOI 10.1095/biolreprod57.5.1136; DIEKMAN AB, 1995, IMMUNOLOGY HUMAN REP, P1; ECCLESTON ED, 1994, MOL REPROD DEV, V37, P110, DOI 10.1002/mrd.1080370115; Ferguson M. A. J., 1992, LIPID MODIFICATION P, P191; GRABENHORST E, 1995, EUR J BIOCHEM, V232, P718, DOI 10.1111/j.1432-1033.1995.718zz.x; HALE G, 1990, TISSUE ANTIGENS, V35, P118, DOI 10.1111/j.1399-0039.1990.tb01767.x; HALE G, 1993, J REPROD IMMUNOL, V23, P189, DOI 10.1016/0165-0378(93)90007-5; Hale G, 1995, IMMUNOTECHNOLOGY, V1, P175, DOI 10.1016/1380-2933(95)00017-8; Hale G, 1998, ENCY IMMUNOLOGY, P402; HAMILTON DW, 1986, BIOL REPROD, V34, P925, DOI 10.1095/biolreprod34.5.925; HOFFMANN A, 1994, J NEUROCHEM, V63, P2185; Ilangumaran S, 1996, TRENDS CELL BIOL, V6, P163, DOI 10.1016/0962-8924(96)20012-1; ILG T, 1992, J BIOL CHEM, V267, P6834; ISOJIMA S, 1989, REPROD FERT DEVELOP, V1, P193, DOI 10.1071/RD9890193; JONES R, 1989, OXFORD REV REPROD B, V11, P285; Kallajoki M, 1998, PROSTATE, V35, P263, DOI 10.1002/(SICI)1097-0045(19980601)35:4<263::AID-PROS5>3.0.CO;2-H; KAMEDA K, 1992, BIOL REPROD, V46, P349, DOI 10.1095/biolreprod46.3.349; KIRCHHOFF C, 1993, MOL REPROD DEV, V34, P8, DOI 10.1002/mrd.1080340103; Kirchhoff C, 1996, MOL HUM REPROD, V2, P9, DOI 10.1093/molehr/2.1.9; Kirchhoff C, 1996, MOL HUM REPROD, V2, P177, DOI 10.1093/molehr/2.3.177; KRULL N, 1993, MOL REPROD DEV, V34, P16, DOI 10.1002/mrd.1080340104; KURPISZ M, 1995, FERTIL STERIL, V63, P158, DOI 10.1016/S0015-0282(16)57312-9; MAHONY MC, 1991, J REPROD IMMUNOL, V19, P269, DOI 10.1016/0165-0378(91)90040-W; MANJUNATH P, 1994, BIOCHEM J, V303, P121, DOI 10.1042/bj3030121; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; Medof ME, 1996, FASEB J, V10, P574, DOI 10.1096/fasebj.10.5.8621057; MOORE A, 1989, BIOCHEM BIOPH RES CO, V160, P460, DOI 10.1016/0006-291X(89)92455-8; MYLES DG, 1993, DEV BIOL, V158, P35, DOI 10.1006/dbio.1993.1166; NIMTZ M, 1993, EUR J BIOCHEM, V213, P39, DOI 10.1111/j.1432-1033.1993.tb17732.x; Pera I, 1997, MOL REPROD DEV, V48, P433, DOI 10.1002/(SICI)1098-2795(199712)48:4<433::AID-MRD3>3.0.CO;2-R; Rooney IA, 1996, J CLIN INVEST, V97, P1675, DOI 10.1172/JCI118594; SCUDDER P, 1984, J BIOL CHEM, V259, P6586; SERRANO AA, 1995, J BIOL CHEM, V270, P27244, DOI 10.1074/jbc.270.45.27244; Soubeyrand S, 1998, BBA-LIPID LIPID MET, V1392, P176, DOI 10.1016/S0005-2760(98)00037-X; TREUMANN A, 1995, J BIOL CHEM, V270, P6088, DOI 10.1074/jbc.270.11.6088; Treumann A, 1997, J MOL BIOL, V269, P529, DOI 10.1006/jmbi.1997.1066; Tsuji Y, 1995, IMMUNOLOGY HUMAN REP, P23; TULSIANI DRP, 1999, J REPROD FERTIL S, V53, P85; VALENTIN H, 1992, TRANSPLANTATION, V54, P97, DOI 10.1097/00007890-199207000-00018; VOLWERK JJ, 1990, BIOCHEMISTRY-US, V29, P8056, DOI 10.1021/bi00487a010; WALTER EI, 1992, J BIOL CHEM, V267, P1245; Wassarman PM, 1999, CELL, V96, P175, DOI 10.1016/S0092-8674(00)80558-9; *WHO, 1992, WHO LAB MAN EX HUM S, P8; XIA MQ, 1991, EUR J IMMUNOL, V21, P1677, DOI 10.1002/eji.1830210714; XIA MQ, 1993, BIOCHEM J, V293, P633, DOI 10.1042/bj2930633; YANAGIMACHI R, 1994, PHYSL REPROD, V0002, P00189; Yeung CH, 1997, MOL REPROD DEV, V48, P267, DOI 10.1002/(SICI)1098-2795(199710)48:2<267::AID-MRD15>3.0.CO;2-V; ZEHEB R, 1984, J BIOL CHEM, V259, P839	54	95	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29862	29873		10.1074/jbc.274.42.29862	http://dx.doi.org/10.1074/jbc.274.42.29862			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514467	hybrid			2022-12-27	WOS:000083176400046
J	Thomas, CJ; Surolia, N; Surolia, A				Thomas, CJ; Surolia, N; Surolia, A			Surface plasmon resonance studies resolve the enigmatic endotoxin neutralizing activity of polymyxin B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; PERMEABILITY-INCREASING PROTEIN; LIPID-A; HOST-DEFENSE; LIPOPOLYSACCHARIDE; BINDING; SPECIFICITY	Polymyxin B (PMB), a cyclic cationic peptide antibiotic, despite its severe side effects continues to occupy a premiere position for treating endotoxicosis. Its mode of neutralization of endotoxin has remained elusive for the last three decades. Several synthetic peptide mimics of PMB, capable of binding endotoxin, have been made. However, the binding ability alone appears to be a deceptive indicator of endotoxin neutralizing activity as molecules with similar binding propensities could either sequester or opsonize the toxin. Hence identification of additional physical parameters which describe adequately the outcome of PMB-endotoxin interaction become imperative. Surface plasmon resonance (SPR) studies reported here show that several mimics of PMB despite exhibiting lipopolysaccharide binding affinities comparable with it but, unlike it, do not sequester the endotoxin. These studies thus provide a striking illustration of the difference in the behavior of PMB, vis a vis its mimics toward the endotoxin lamellae, and define further, in chemical terms, mechanism of the action of PMB and allow us to posit that the design of molecules as effective antidotes for sepsis should incorporate the ability to sequester endotoxin specifically.	Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India; Jawaharlal Nehru Ctr Adv Sci Res, Bangalore 560064, Karnataka, India	Indian Institute of Science (IISC) - Bangalore; Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR)	Surolia, A (corresponding author), Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India.	surolia@mbu.iisc.ernet.in	SUROLIA, AVADESHA/C-5442-2009					CHRIST WJ, 1995, SCIENCE, V268, P80, DOI 10.1126/science.7701344; COOPER MA, 1997, CHEM COMMUN, V1625; CROSS AS, 1994, J ENDOTOXIN RES, V1, P57; David SA, 1996, J ENDOTOXIN RES, V3, P369, DOI 10.1177/096805199600300501; ELSBACH P, 1993, CURR OPIN IMMUNOL, V5, P103, DOI 10.1016/0952-7915(93)90088-A; ELSBACH P, 1993, IMMUNOBIOLOGY, V187, P417, DOI 10.1016/S0171-2985(11)80354-2; FINK PF, 1990, HDB CRITICAL CARE, P619; GALANOS C, 1977, INT REV BIOCH BIOCH, V14, P239; LIEVE L, 1974, ANN NY ACAD SCI, V235, P109; MacKenzie CR, 1997, J BIOL CHEM, V272, P5533, DOI 10.1074/jbc.272.9.5533; MORRISON DC, 1976, IMMUNOCHEMISTRY, V13, P813, DOI 10.1016/0019-2791(76)90181-6; NOVOGRODSKY A, 1994, SCIENCE, V264, P1319, DOI 10.1126/science.8191285; RIFKIND D, 1967, J BACTERIOL, V93, P1463, DOI 10.1128/JB.93.4.1463-1464.1967; RUSTICI A, 1993, SCIENCE, V259, P361, DOI 10.1126/science.8420003; SHIHYI L, 1995, BIOCHIM BIOPHYS ACTA, V1252, P312; Srimal S, 1996, BIOCHEM J, V315, P679, DOI 10.1042/bj3150679; Thomas CJ, 1998, J AM CHEM SOC, V120, P12428, DOI 10.1021/ja981777j; Thomas CJ, 1999, FEBS LETT, V445, P420, DOI 10.1016/S0014-5793(99)00150-7; TOBIAS PS, 1993, IMMUNOBIOLOGY, V187, P227, DOI 10.1016/S0171-2985(11)80341-4; VAARA M, 1983, NATURE, V303, P526, DOI 10.1038/303526a0; YIN ET, 1972, BIOCHIM BIOPHYS ACTA, V261, P284	21	54	55	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29624	29627		10.1074/jbc.274.42.29624	http://dx.doi.org/10.1074/jbc.274.42.29624			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514430	hybrid			2022-12-27	WOS:000083176400009
J	Witteveen, CFB; Giovanelli, J; Kaufman, S				Witteveen, CFB; Giovanelli, J; Kaufman, S			Reactivity of tetrahydrobiopterin bound to nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENYLALANINE-HYDROXYLASE; L-ARGININE; REDUCTIVE ACTIVATION; FLAVIN SEMIQUINONE; HYDROGEN-PEROXIDE; NO SYNTHASE; HEME IRON; BRAIN; GENERATION; SUPEROXIDE	Levels of tetrahydrobiopterin (BH4) bound to nitric-oxide synthase (NOS) were examined during multiple turnovers of the enzyme in the presence of an NADPH-regenerating system. Our findings show that NOS-bound BH4 does not remain in a static state but undergoes redox reactions. Under these experimental conditions, the redox state of BH4 was determined by the balance between calcium/calmodulin (Ca2+/CaM)dependent oxidation of BH4 mediated by the uncoupled formation of superoxide/hydrogen peroxide on the one hand and by reductive regeneration of BH4 on the other hand. BH4 oxidation was appreciably increased in the presence of arginine. Levels of NOS-bound BH4 were also examined under single turnover conditions in the absence of an NADPH-regenerating system and in the presence of added superoxide dismutase and catalase to suppress the accumulation of superoxide and hydrogen peroxide. BH4 oxidation was again dependent on Ca2+/CaM. The insensitivity to superoxide dismutase and catalase suggested that the single turnover oxidation of BH4 did not proceed through superoxide/peroxide, although the involvement of these oxidants could not be definitively excluded. The amount of BH4 oxidized was highest in the presence of arginine, and this oxidation significantly exceeded that in the presence of N-G-hydroxy-L-arginine, The findings that single turnover oxidation of BH4 is stimulated by arginine in the presence of Ca2+/CaM and that BH4 is regenerated are consistent with a role for the pterin as an electron donor in product formation; this role remains to be defined.	NIMH, Neurochem Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Giovanelli, J (corresponding author), NIMH, Neurochem Lab, Bldg 36,Rm 3D30,36 Convent Dr,MSC 4096, Bethesda, MD 20892 USA.							AbuSoud HM, 1997, BIOCHEMISTRY-US, V36, P10811, DOI 10.1021/bi971414g; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32218; [Anonymous], 1980, ENZYMATIC BASIS DETO; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BUBLITZ C, 1977, BIOCHEM MED METAB B, V17, P13, DOI 10.1016/0006-2944(77)90004-7; CAMPOS KL, 1995, J BIOL CHEM, V270, P1721, DOI 10.1074/jbc.270.4.1721; CAMPOS KL, 1992, BIOL NITRIC OXIDE, V2, P47; CITRON BA, 1992, PROTEIN EXPRES PURIF, V3, P93, DOI 10.1016/S1046-5928(05)80024-5; Crow J P, 1995, Curr Top Microbiol Immunol, V196, P57; DAVIS MD, 1988, EUR J BIOCHEM, V173, P345, DOI 10.1111/j.1432-1033.1988.tb14004.x; EBERLEIN G, 1984, J AM CHEM SOC, V106, P7916, DOI 10.1021/ja00337a047; Fee J.A., 1977, SUPEROXIDE SUPEROXID, P19; FELDMAN PL, 1993, CHEM ENG NEWS, V71, P26; FUKUSHIMA T, 1980, ANAL BIOCHEM, V102, P176, DOI 10.1016/0003-2697(80)90336-X; FURFINE ES, 1993, BIOCHEMISTRY-US, V32, P8512, DOI 10.1021/bi00084a017; Gachhui R, 1996, J BIOL CHEM, V271, P20594, DOI 10.1074/jbc.271.34.20594; GIOVANELLI J, 1991, P NATL ACAD SCI USA, V88, P7091, DOI 10.1073/pnas.88.16.7091; Gorren ACF, 1996, BIOCHEMISTRY-US, V35, P16735, DOI 10.1021/bi961931j; Gorren ACF, 1998, BIOCHEMISTRY-MOSCOW+, V63, P734; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Halliwell B, 1995, ACTIVE OXYGEN BIOCH, P313; HASSAN HM, 1980, ENZYMATIC BASIS DETO, V1, P311; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; HEVEL JM, 1992, BIOCHEMISTRY-US, V31, P7160, DOI 10.1021/bi00146a019; HOBBS AJ, 1994, P NATL ACAD SCI USA, V91, P10992, DOI 10.1073/pnas.91.23.10992; HOFMANN H, 1995, BIOCHEMISTRY-US, V34, P13443, DOI 10.1021/bi00041a023; KATOH S, 1970, CHEM BIOL PTERIDINES, P225; KAUFMAN S, 1993, ADV ENZYMOL RAMB, V67, P77; KAUFMAN S, 1959, J BIOL CHEM, V234, P2677; KAUFMAN S, 1961, J BIOL CHEM, V236, P804; KAUFMAN S, 1964, J BIOL CHEM, V239, P332; KAUFMAN S, 1987, ENZYMES B, V18, P217; Kim S, 1998, EXP MOL MED, V30, P221, DOI 10.1038/emm.1998.32; KLATT P, 1994, J BIOL CHEM, V269, P13861; KOMORI Y, 1995, J BIOCHEM-TOKYO, V117, P923, DOI 10.1093/oxfordjournals.jbchem.a124797; KOWLESSUR D, 1995, P NATL ACAD SCI USA, V92, P4743, DOI 10.1073/pnas.92.11.4743; KRISHNA MC, 1994, METHOD ENZYMOL, V234, P752; LEWIS DFV, 1996, CYTOCHROMES P450 STR, P79; MANITZ B, 1992, BIOL NITRIC OXIDE, V2, P116; MAROTA JJA, 1984, BIOCHEMISTRY-US, V23, P1303, DOI 10.1021/bi00301a044; MATSUOKA A, 1994, J BIOL CHEM, V269, P20335; MAYER B, 1995, J BIOL CHEM, V270, P655, DOI 10.1074/jbc.270.2.655; Mayer B, 1997, BIOCHEMISTRY-US, V36, P8422, DOI 10.1021/bi970144z; Miller RT, 1997, BIOCHEMISTRY-US, V36, P15277, DOI 10.1021/bi972022c; MITTAL CK, 1993, BIOCHEM BIOPH RES CO, V193, P126, DOI 10.1006/bbrc.1993.1599; PEARSON AJ, 1974, CHEM IND-LONDON, P233; Perry JM, 1998, P NATL ACAD SCI USA, V95, P11101, DOI 10.1073/pnas.95.19.11101; Pfeiffer S, 1997, BIOCHEM J, V328, P349, DOI 10.1042/bj3280349; POU S, 1992, J BIOL CHEM, V267, P24173; Pou S, 1999, J BIOL CHEM, V274, P9573, DOI 10.1074/jbc.274.14.9573; Presta A, 1998, BIOCHEMISTRY-US, V37, P298, DOI 10.1021/bi971944c; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; RENGASAMY A, 1994, BIOCHEM PHARMACOL, V48, P423, DOI 10.1016/0006-2952(94)90116-3; Riethmuller C, 1999, J BIOL CHEM, V274, P16047, DOI 10.1074/jbc.274.23.16047; Rusche KM, 1998, BIOCHEMISTRY-US, V37, P15503, DOI 10.1021/bi9813936; Schmidt HHHW, 1996, P NATL ACAD SCI USA, V93, P14492, DOI 10.1073/pnas.93.25.14492; STUEHR DJ, 1990, BIOCHEM BIOPH RES CO, V168, P558, DOI 10.1016/0006-291X(90)92357-6; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; WALLICK DE, 1984, BIOCHEMISTRY-US, V23, P1295, DOI 10.1021/bi00301a043; Wang PH, 1996, J BIOL CHEM, V271, P29223, DOI 10.1074/jbc.271.46.29223; Witteveen CFB, 1996, J BIOL CHEM, V271, P4143; Witteveen CFB, 1998, BIOCHEM BIOPH RES CO, V250, P36, DOI 10.1006/bbrc.1998.8807; Xia Y, 1998, J BIOL CHEM, V273, P25804, DOI 10.1074/jbc.273.40.25804; Xia Y, 1997, P NATL ACAD SCI USA, V94, P12705, DOI 10.1073/pnas.94.23.12705; ZHANG J, 1995, ANNU REV PHARMACOL, V35, P213	68	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29755	29762		10.1074/jbc.274.42.29755	http://dx.doi.org/10.1074/jbc.274.42.29755			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514451	hybrid			2022-12-27	WOS:000083176400030
J	Thangaraju, M; Sharma, K; Leber, B; Andrews, DW; Shen, SH; Srikant, CB				Thangaraju, M; Sharma, K; Leber, B; Andrews, DW; Shen, SH; Srikant, CB			Regulation of acidification and apoptosis by SHP-1 and Bcl-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; FAS-MEDIATED APOPTOSIS; BREAST-CANCER CELLS; SOMATOSTATIN ANALOG SMS-201-995; SIGNALING COMPLEX DISC; GROWTH-FACTOR RECEPTOR; HUMAN TUMOR-CELLS; GENE BAX-ALPHA; WILD-TYPE P53; INTRACELLULAR ACIDIFICATION	Recruitment of the SH2 domain containing cytoplasmic protein-tyrosine phosphatase SHP-1 to the membrane by somatostatin (SST) is an early event in its antiproliferative signaling that induces intracellular acidification-dependent apoptosis in breast cancer cells. Fas ligation also induces acidification-dependent apoptosis in a manner requiring the presence of SHP-1 at the membrane. Moreover, we have recently reported that SRP-I is required not only for acidification, but also for apoptotic events that follow acidification (Thangaraju, M., Sharma, K., Liu, D., Shen, S. H., and Srikant, C. B. (1999) Cancer Res. 59, 1649-1654). Here we show that ectopically expressed SHP-1 was predominantly membrane-associated and amplified the cytotoxic signaling initiated upon SST receptor activation and Fas ligation. The catalytically inactive mutant of SHP-1 (SHP-1C455S) abolished the ability of the SST agonists to signal apoptosis by preventing the recruitment of wild type SHP-1 to the membrane. Overexpression of the anti-apoptotic protein Bcl-2 in MCF-7 cells inhibited SST-induced apoptosis upstream of acidification by inhibiting p53-dependent induction of Bax as well as by raising the resting pH(i) and attenuating SST-induced decrease in pH. By contrast, Bcl-2 failed to prevent apoptosis triggered by direct acidification. These data demonstrate that (i) membrane-associated SHP-1 is required for receptor-mediated cytotoxic signaling that causes intracellular acidification and apo ptosis, and (ii) Bcl-2 acts distal to SHP-1 and p53 to prevent SST-induced acidification but cannot inhibit the apoptotic events that ensue intracellular acidification.	Royal Victoria Hosp, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Med, Fraser Labs, Montreal, PQ H3A 1A1, Canada; McMaster Univ, Hlth Sci Ctr, Dept Biochem, Hamilton, ON L8N 325, Canada; McMaster Univ, Hlth Sci Ctr, Dept Med, Hamilton, ON L8N 325, Canada; Natl Res Council Canada, Biotechnol Res Inst, Pharmacol Sector, Montreal, PQ H4P 2R2, Canada	McGill University; Royal Victoria Hospital; McGill University; McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; National Research Council Canada	Srikant, CB (corresponding author), Royal Victoria Hosp, M3-15,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.			Leber, Brian/0000-0001-5502-1480; Andrews, David/0000-0002-9266-7157				Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Bargou RC, 1996, J CLIN INVEST, V97, P2651, DOI 10.1172/JCI118715; BARRY MA, 1993, CANCER RES, V53, P2349; Bedecs K, 1997, BIOCHEM J, V325, P449, DOI 10.1042/bj3250449; BIERY M, 1998, P NATL ACAD SCI USA, V95, P2446; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Cambier JC, 1997, P NATL ACAD SCI USA, V94, P5993, DOI 10.1073/pnas.94.12.5993; CANDI E, 1995, CANCER LETT, V96, P141, DOI 10.1016/0304-3835(95)03924-L; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Cuppen E, 1997, J BIOL CHEM, V272, P30215, DOI 10.1074/jbc.272.48.30215; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DAVID M, 1995, MOL CELL BIOL, V15, P7050; FLORIO T, 1992, J BIOL CHEM, V267, P24169; FLORIO T, 1994, MOL ENDOCRINOL, V8, P1289, DOI 10.1210/me.8.10.1289; Frasch SC, 1998, J BIOL CHEM, V273, P8389, DOI 10.1074/jbc.273.14.8389; Frearson JA, 1997, BIOESSAYS, V19, P417, DOI 10.1002/bies.950190509; Froesch BA, 1999, J BIOL CHEM, V274, P6469, DOI 10.1074/jbc.274.10.6469; Furlong IJ, 1997, J CELL SCI, V110, P653; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; Gibson S, 1999, J BIOL CHEM, V274, P17612, DOI 10.1074/jbc.274.25.17612; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P654, DOI 10.1073/pnas.93.2.654; Jiao HY, 1996, MOL CELL BIOL, V16, P6985; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Kim CN, 1997, CANCER RES, V57, P3115; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kutay Ulrike, 1993, Trends in Cell Biology, V3, P72, DOI 10.1016/0962-8924(93)90066-A; LIEBOW C, 1989, P NATL ACAD SCI USA, V86, P2003, DOI 10.1073/pnas.86.6.2003; Maeda A, 1998, J EXP MED, V187, P1355, DOI 10.1084/jem.187.8.1355; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Meisenholder GW, 1996, J BIOL CHEM, V271, P16260, DOI 10.1074/jbc.271.27.16260; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Neel BG, 1997, CURR OPIN IMMUNOL, V9, P405, DOI 10.1016/S0952-7915(97)80088-X; OWENLYNCH PJ, 1995, J BIOL CHEM, V270, P5956, DOI 10.1074/jbc.270.11.5956; PAN MG, 1992, SCIENCE, V256, P1215, DOI 10.1126/science.256.5060.1215; Patel YC, 1997, TRENDS ENDOCRIN MET, V8, P398, DOI 10.1016/S1043-2760(97)00168-9; Ruiz-Ruiz MD, 1999, CELL DEATH DIFFER, V6, P271, DOI 10.1038/sj.cdd.4400490; Sakakura C, 1997, SURG TODAY, V27, P676, DOI 10.1007/BF02388231; Sakakura C, 1996, INT J CANCER, V67, P101, DOI 10.1002/(SICI)1097-0215(19960703)67:1<101::AID-IJC17>3.0.CO;2-H; Sakakura C, 1997, SURG TODAY, V27, P90, DOI 10.1007/BF01366949; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; Sharma K, 1998, INT J CANCER, V76, P259, DOI 10.1002/(SICI)1097-0215(19980413)76:2<259::AID-IJC14>3.0.CO;2-7; Sharma K, 1998, BIOCHEM BIOPH RES CO, V242, P134, DOI 10.1006/bbrc.1997.7933; Sharma K, 1996, MOL ENDOCRINOL, V10, P1688, DOI 10.1210/me.10.12.1688; SHEARD MA, 1997, INT J CANCER, V737, P57; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SRIKANT CB, 1995, BIOCHEM BIOPH RES CO, V209, P400, DOI 10.1006/bbrc.1995.1517; Srikant CB, 1996, ENDOCRINOLOGY, V137, P3461, DOI 10.1210/en.137.8.3461; Su X, 1996, J IMMUNOL, V156, P4198; SU X, 1995, IMMUNITY, V2, P353, DOI 10.1016/1074-7613(95)90143-4; Takayama H, 1996, J IMMUNOL, V157, P3943; Tenev T, 1997, J BIOL CHEM, V272, P5966, DOI 10.1074/jbc.272.9.5966; Thangaraju M, 1999, CANCER RES, V59, P1649; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Valiante NM, 1996, J EXP MED, V184, P2243, DOI 10.1084/jem.184.6.2243; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wagener C, 1996, INT J CANCER, V67, P138, DOI 10.1002/(SICI)1097-0215(19960703)67:1<138::AID-IJC22>3.0.CO;2-9; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; Wilson DJ, 1996, EUR J IMMUNOL, V26, P989, DOI 10.1002/eji.1830260505; Wu YJ, 1998, CURR BIOL, V8, P1009, DOI 10.1016/S0960-9822(07)00421-6; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YANG J, 1997, SCIENCE, V275, P1126; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; Zanke BW, 1998, CANCER RES, V58, P2801; ZHAO ZH, 1993, P NATL ACAD SCI USA, V90, P4251, DOI 10.1073/pnas.90.9.4251; ZHAO ZH, 1994, P NATL ACAD SCI USA, V91, P5007, DOI 10.1073/pnas.91.11.5007; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x	80	95	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29549	29557		10.1074/jbc.274.41.29549	http://dx.doi.org/10.1074/jbc.274.41.29549			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506221	hybrid			2022-12-27	WOS:000083017800100
J	Moussalli, M; Pipe, SW; Hauri, HP; Nichols, WC; Ginsburg, D; Kaufman, RJ				Moussalli, M; Pipe, SW; Hauri, HP; Nichols, WC; Ginsburg, D; Kaufman, RJ			Mannose-dependent endoplasmic reticulum (ER)-Golgi intermediate compartment-53-mediated ER to Golgi trafficking of coagulation factors V and VIII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPARTMENT PROTEIN ERGIC-53; EARLY SECRETORY PATHWAY; MEMBRANE-PROTEIN; MAMMALIAN-CELLS; B-DOMAIN; TRANSPORT; COPII; EXPRESSION; VESICLES; RETENTION	The endoplasmic reticulum-Golgi intermediate compartment (ERGIC) is the site of segregation of secretory proteins for anterograde transport, via packaging into COPII-coated transport vesicles, ERGIC-53 is a homohexameric transmembrane lectin localized to the ERGIC that exhibits mannose-selective properties in vitro. Null mutations in ERGIC-53 were recently shown to be responsible for the autosomal recessive bleeding disorder, combined deficiency of coagulation factors V and VIII, We have studied the effect of defective ER to Golgi cycling by ERGIC-53 on the secretion of factors V and VIII, The secretion efficiency of factor V and factor VIII was studied in a tetracycline-inducible HeLa cell line overexpressing a wild-type ERGIC-53 or a cytosolic tail mutant of ERGIC-53 (KKAA) that is unable to exit the ER due to mutation of two COOH-terminal phenylalanine residues to alanines, The results show that efficient trafficking of factors V and VIII requires a functional ERGIC-53 cycling pathway and that this trafficking is dependent on post-translational modification of a specific cluster of asparagine (N)-linked oligosaccharides to a fully glucose-trimmed, mannose9 structure.	Univ Michigan, Sch Med, Dept Pediat, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Med, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Childrens Hosp, Med Ctr, Div Human Genet, Cincinnati, OH 45229 USA; Univ Basel, Biozentrum, Dept Pharmacol Neurobiol, CH-4056 Basel, Switzerland	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Cincinnati Children's Hospital Medical Center; University of Basel	Kaufman, RJ (corresponding author), 1150 W Med Ctr Dr,MSRB II,Rm 4570, Ann Arbor, MI 48109 USA.	kaufmanr@umich.edu	Pipe, Steven W./ABC-3843-2020	Pipe, Steven W./0000-0003-2558-2089	NHLBI NIH HHS [HL5217302, HL5734601A1] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057346, R01HL052173] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andersson H, 1999, J BIOL CHEM, V274, P15080, DOI 10.1074/jbc.274.21.15080; ARAR C, 1995, J BIOL CHEM, V270, P3551, DOI 10.1074/jbc.270.8.3551; Berntorp E, 1997, THROMB HAEMOSTASIS, V78, P256; Campbell JL, 1997, P NATL ACAD SCI USA, V94, P837, DOI 10.1073/pnas.94.3.837; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; Fiedler K, 1996, J CELL SCI, V109, P271; Hara-Kuge S, 1999, GLYCOBIOLOGY, V9, P833, DOI 10.1093/glycob/9.8.833; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; ITIN C, 1995, BIOCHEM SOC T, V23, P541, DOI 10.1042/bst0230541; KAPPELER F, 1994, J BIOL CHEM, V269, P6279; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; Kaufman RJ, 1999, HUM GENE THER, V10, P2091, DOI 10.1089/10430349950017095; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; Kuehn MJ, 1998, NATURE, V391, P187, DOI 10.1038/34438; Lahtinen U, 1996, J BIOL CHEM, V271, P4031; Liu Y, 1999, J BIOL CHEM, V274, P5861, DOI 10.1074/jbc.274.9.5861; Marzioch M, 1999, MOL BIOL CELL, V10, P1923, DOI 10.1091/mbc.10.6.1923; Neerman-Arbez M, 1999, BLOOD, V93, P2253; Nichols WC, 1998, CELL, V93, P61, DOI 10.1016/S0092-8674(00)81146-0; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; Pipe SW, 1998, J BIOL CHEM, V273, P8537, DOI 10.1074/jbc.273.14.8537; PITTMAN DD, 1994, BLOOD, V84, P4214, DOI 10.1182/blood.V84.12.4214.bloodjournal84124214; PITTMAN DD, 1993, METHOD ENZYMOL, V222, P236; Powers J, 1998, J CELL BIOL, V142, P1209, DOI 10.1083/jcb.142.5.1209; Scales SJ, 1997, CELL, V90, P1137, DOI 10.1016/S0092-8674(00)80379-7; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; SCHINDLER R, 1993, EUR J CELL BIOL, V61, P1; SCHRODER S, 1995, J CELL BIOL, V131, P895, DOI 10.1083/jcb.131.4.895; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; Springer S, 1999, CELL, V97, P145, DOI 10.1016/S0092-8674(00)80722-9; Tisdale EJ, 1997, J CELL BIOL, V137, P581, DOI 10.1083/jcb.137.3.581; TOOLE JJ, 1986, P NATL ACAD SCI USA, V83, P5939, DOI 10.1073/pnas.83.16.5939; Vollenweider F, 1998, J CELL BIOL, V142, P377, DOI 10.1083/jcb.142.2.377; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8	36	104	111	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32539	32542		10.1074/jbc.274.46.32539	http://dx.doi.org/10.1074/jbc.274.46.32539			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551804	hybrid			2022-12-27	WOS:000083623000004
J	Dunn, CA; O'Handley, SF; Frick, DN; Bessman, MJ				Dunn, CA; O'Handley, SF; Frick, DN; Bessman, MJ			Studies on the ADP-ribose pyrophosphatase subfamily of the Nudix hydrolases and tentative identification of trgB, a gene associated with tellurite resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE TRIPHOSPHATE PYROPHOSPHOHYDROLASE; ESCHERICHIA-COLI MUTT; METHANOCOCCUS-JANNASCHII; CATALYTIC DOMAIN; STREPTOCOCCUS-PNEUMONIAE; MOLECULAR-CLONING; PROTEINS; SEQUENCE; PURIFICATION; ENZYMES	Four Nudix hydrolase genes, ysa1 from Saccharomyces cerevisiae, orf209 from Escherichia coli, yqkg from Bacillus subtilis, and hi0398 from Hemophilus influenzae were amplified, cloned into an expression vector, and transformed into E. coli. The expressed proteins were purified and shown to belong to a subfamily of Nudix hydrolases active on ADP-ribose. Comparison with other members of the subfamily revealed a conserved proline 16 amino acid residues downstream of the Nudix box, common to all of the ADP-ribose pyrophosphatase subfamily. In this same region, a conserved tyrosine designates another subfamily, the diadenosine polyphosphate pyrophosphatases, while an array of eight conserved amino acids is indicative of the NADH pyrophosphatases. On the basis of these classifications, the trgB gene, a tellurite resistance factor from Rhodobacter sphaeroides, was predicted to designate an ADP-ribose pyrophosphatase. In support of this hypothesis, a highly specific ADP-ribose pyrophosphatase gene from the archaebacterium, Methanococcus jannaschii, introduced into E, coli, increased the transformant's tolerance to potassium tellurite.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Johns Hopkins Univ, McCollum Pratt Inst, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University	Bessman, MJ (corresponding author), Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA.	zoot@jhu.edu		Frick, David/0000-0002-2434-7223; Dunn, Christopher/0000-0001-7899-0110; O'Handley, Suzanne/0000-0001-8373-0065	NIGMS NIH HHS [GM 18649] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEYGUNAWARDANA C, 1995, BIOCHEMISTRY-US, V34, P14997, DOI 10.1021/bi00046a006; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMES BN, 1960, J BIOL CHEM, V235, P769; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; BHATNAGAR SK, 1991, J BIOL CHEM, V266, P9050; BHATNAGAR SK, 1988, J BIOL CHEM, V263, P8953; Bucala R, 1992, Adv Pharmacol, V23, P1; BULLIONS LC, 1994, J BIOL CHEM, V269, P12339; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Cartwright JL, 1999, J BIOL CHEM, V274, P8604, DOI 10.1074/jbc.274.13.8604; Cartwright JL, 1999, BIOCHEM BIOPH RES CO, V256, P474, DOI 10.1006/bbrc.1999.0354; Churin J, 1998, FEBS LETT, V431, P481, DOI 10.1016/S0014-5793(98)00819-9; Conyers GB, 1999, J BIOL CHEM, V274, P1203, DOI 10.1074/jbc.274.3.1203; FRICK DN, 1995, J BIOL CHEM, V270, P1529, DOI 10.1074/jbc.270.4.1529; FRICK DN, 1995, J BIOL CHEM, V270, P24086, DOI 10.1074/jbc.270.41.24086; Hankin S, 1997, INT J BIOCHEM CELL B, V29, P317, DOI 10.1016/S1357-2725(96)00153-7; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Ingram SW, 1999, BIOCHEMISTRY-US, V38, P3649, DOI 10.1021/bi982951j; JACOBSON EL, 1994, MOL CELL BIOCHEM, V138, P207, DOI 10.1007/BF00928463; JONES WJ, 1983, ARCH MICROBIOL, V136, P254, DOI 10.1007/BF00425213; Kaneto H, 1996, BIOCHEM J, V320, P855, DOI 10.1042/bj3200855; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P4847, DOI 10.1093/nar/21.20.4847; Kroger H, 1997, GEN PHARMACOL, V28, P257, DOI 10.1016/S0306-3623(96)00181-4; Maksel D, 1998, BIOCHEM J, V329, P313, DOI 10.1042/bj3290313; MARKHAM R, 1952, BIOCHEM J, V52, P552, DOI 10.1042/bj0520552; MATHEW N, 1995, BIOCHEM J, V311, P717, DOI 10.1042/bj3110717; MCDONALD LJ, 1994, MOL CELL BIOCHEM, V138, P221, DOI 10.1007/BF00928465; MEJEAN V, 1994, MOL MICROBIOL, V11, P323, DOI 10.1111/j.1365-2958.1994.tb00312.x; MOSS J, 1994, MOL CELL BIOCHEM, V138, P5; O'Handley SF, 1998, J BIOL CHEM, V273, P3192, DOI 10.1074/jbc.273.6.3192; OGara JP, 1997, APPL ENVIRON MICROB, V63, P4713, DOI 10.1128/AEM.63.12.4713-4720.1997; OHandley SF, 1996, J BIOL CHEM, V271, P24649, DOI 10.1074/jbc.271.40.24649; OLIVERA BM, 1989, ADP RIBOSE TRANSFER, P353; Pennisi E, 1999, SCIENCE, V283, P1105, DOI 10.1126/science.283.5405.1105; Ribeiro JM, 1997, BBA-GEN SUBJECTS, V1336, P403, DOI 10.1016/S0304-4165(97)00051-2; Sheikh S, 1998, J BIOL CHEM, V273, P20924, DOI 10.1074/jbc.273.33.20924; Taylor DE, 1999, TRENDS MICROBIOL, V7, P111, DOI 10.1016/S0966-842X(99)01454-7; VLASSARA H, 1985, P NATL ACAD SCI USA, V82, P5588, DOI 10.1073/pnas.82.17.5588	38	133	143	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32318	32324		10.1074/jbc.274.45.32318	http://dx.doi.org/10.1074/jbc.274.45.32318			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542272	hybrid			2022-12-27	WOS:000083532100080
J	Eggleson, KK; Duffin, KL; Goldberg, DE				Eggleson, KK; Duffin, KL; Goldberg, DE			Identification and characterization of falcilysin, a metallopeptidase involved in hemoglobin catabolism within the malaria parasite Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL PROCESSING PEPTIDASE; INSULIN-DEGRADING ENZYME; BUD-SITE SELECTION; CYSTEINE PROTEINASE; HUMAN-ERYTHROCYTES; DIGESTIVE VACUOLE; ACTIVE-SITE; DEGRADATION; PURIFICATION; RESIDUES	The malaria parasite Plasmodium falciparum degrades hemoglobin in its acidic food vacuole for use as a major nutrient source. A novel metallopeptidase activity, falcilysin, was purified from food vacuoles and characterized. Falcilysin appears to function downstream of the aspartic proteases plasmepsins I and II and the cysteine protease falcipain in the hemoglobin proteolytic pathway. It is unable to cleave hemoglobin or denatured globin but readily destroys peptide fragments of hemoglobin. Falcilysin cleavage sites along the alpha and beta chains of hemoglobin are polar in character, with charged residues located in the P1 and/or P4' positions. In contrast, plasmepsins I and II and falcipain prefer hydrophobic residues around the scissile bond. The gene encoding falcilysin has been cloned. Its coding sequence exhibits features characteristic of clan ME family M16 metallopeptidases, including an "inverted" HXXEH active site motif, Falcilysin shares primary structural features with M16 family members such as insulysin, mitochondrial processing peptidase, nardilysin, and pitrilysin as well as with data base hypothetical proteins that are potential M16 family members. The characterization of falcilysin increases our understanding of hemoglobin catabolism in P. falciparum and the unusual M16 family of metallopeptidases.	Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Microbiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Med, St Louis, MO 63110 USA; Monsanto Co, Monsanto Corp Res, St Louis, MO 63198 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); Monsanto	Goldberg, DE (corresponding author), Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Microbiol, Box 8230,660 S Euclid Ave, St Louis, MO 63110 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI031615] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-31615] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMES N, 1995, SCIENCE, V270, P464, DOI 10.1126/science.270.5235.464; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AULS DS, 1995, METHOD ENZYMOL, V248, P2828; BECKER AB, 1992, P NATL ACAD SCI USA, V89, P3835, DOI 10.1073/pnas.89.9.3835; BECKER AB, 1993, BIOCHEM J, V292, P137, DOI 10.1042/bj2920137; CHENG YSE, 1979, J BIOL CHEM, V254, P4698; CHESNEAU V, 1994, J BIOL CHEM, V269, P2056; CLAUSER KR, 1995, P NATL ACAD SCI USA, V92, P5072, DOI 10.1073/pnas.92.11.5072; CURLEY GP, 1994, J EUKARYOT MICROBIOL, V41, P119, DOI 10.1111/j.1550-7408.1994.tb01483.x; DAME JB, 1994, MOL BIOCHEM PARASIT, V64, P177, DOI 10.1016/0166-6851(94)90024-8; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIVO AA, 1985, J PROTOZOOL, V32, P59, DOI 10.1111/j.1550-7408.1985.tb03013.x; Florent I, 1998, MOL BIOCHEM PARASIT, V97, P149, DOI 10.1016/S0166-6851(98)00143-1; FRANCIS SE, 1994, EMBO J, V13, P306, DOI 10.1002/j.1460-2075.1994.tb06263.x; Francis SE, 1996, MOL BIOCHEM PARASIT, V83, P189, DOI 10.1016/S0166-6851(96)02772-7; FUJITA A, 1994, NATURE, V372, P567, DOI 10.1038/372567a0; GEHM BD, 1991, ENDOCRINOLOGY, V128, P1603, DOI 10.1210/endo-128-3-1603; GINSBURG H, 1986, BIOCHIM BIOPHYS ACTA, V886, P337, DOI 10.1016/0167-4889(86)90168-0; GLUZMAN IY, 1994, J CLIN INVEST, V93, P1602, DOI 10.1172/JCI117140; GOLDBERG DE, 1990, P NATL ACAD SCI USA, V87, P2931, DOI 10.1073/pnas.87.8.2931; GOLDBERG DE, 1991, J EXP MED, V173, P961, DOI 10.1084/jem.173.4.961; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; KIRSCHNER RJ, 1983, J BIOL CHEM, V258, P967; KITADA S, 1995, J BIOCHEM-TOKYO, V117, P1148, DOI 10.1093/oxfordjournals.jbchem.a124836; Kitada S, 1998, J BIOL CHEM, V273, P32547, DOI 10.1074/jbc.273.49.32547; Kolakovich KA, 1997, MOL BIOCHEM PARASIT, V87, P123, DOI 10.1016/S0166-6851(97)00062-5; KROGSTAD DJ, 1985, J CELL BIOL, V101, P2302, DOI 10.1083/jcb.101.6.2302; KUROCHKIN IV, 1994, FEBS LETT, V345, P33, DOI 10.1016/0014-5793(94)00387-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Luker KE, 1996, MOL BIOCHEM PARASIT, V79, P71, DOI 10.1016/0166-6851(96)02651-5; Olliaro P, 1996, JAMA-J AM MED ASSOC, V275, P230, DOI 10.1001/jama.275.3.230; PERLMAN RK, 1993, J BIOL CHEM, V268, P21538; RAWLINGS ND, 1998, HDB PROTEOLYTIC ENZY, P1360; ROSENTHAL PJ, 1991, J CLIN INVEST, V88, P1467, DOI 10.1172/JCI115456; ROSENTHAL PJ, 1992, MOL BIOCHEM PARASIT, V51, P143, DOI 10.1016/0166-6851(92)90209-3; ROSENTHAL PJ, 1988, J CLIN INVEST, V82, P1560, DOI 10.1172/JCI113766; ROSENTHAL PJ, 1993, J CLIN INVEST, V91, P1052, DOI 10.1172/JCI116262; SCHNEIDER H, 1990, J BIOL CHEM, V265, P9881; SHII K, 1986, DIABETES, V35, P675, DOI 10.2337/diabetes.35.6.675; Shimokata K, 1998, J BIOL CHEM, V273, P25158, DOI 10.1074/jbc.273.39.25158; Striebel HM, 1996, ARCH BIOCHEM BIOPHYS, V335, P211, DOI 10.1006/abbi.1996.0500; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; VANDERJAGT DL, 1984, MOL BIOCHEM PARASIT, V10, P45, DOI 10.1016/0166-6851(84)90017-3; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; Yates JR, 1996, J AM SOC MASS SPECTR, V7, P1089, DOI 10.1016/S1044-0305(96)00079-7; YAYON A, 1984, EMBO J, V3, P2695, DOI 10.1002/j.1460-2075.1984.tb02195.x; YAYON A, 1983, J PROTOZOOL, V30, P642, DOI 10.1111/j.1550-7408.1983.tb05336.x	49	199	204	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32411	32417		10.1074/jbc.274.45.32411	http://dx.doi.org/10.1074/jbc.274.45.32411			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542284	hybrid			2022-12-27	WOS:000083532100092
J	El Nemer, W; Colin, Y; Bauvy, C; Codogno, P; Fraser, RH; Cartron, JP; Le van Kim, C				El Nemer, W; Colin, Y; Bauvy, C; Codogno, P; Fraser, RH; Cartron, JP; Le van Kim, C			Isoforms of the lutheran/basal cell adhesion molecule glycoprotein are differentially delivered in polarized epithelial cells - Mapping of the basolateral sorting signal to a cytoplasmic di-leucine motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DARBY CANINE KIDNEY; POLYMERIC IMMUNOGLOBULIN RECEPTOR; BLOOD-GROUP GLYCOPROTEIN; LU-A/LU-B; MDCK CELLS; SURFACE GLYCOPROTEIN; CLATHRIN ADAPTERS; GROUP ANTIGENS; TYROSINE; BINDING	Lu and Lu(v13) are two glycoprotein (gp) isoforms that belong to the immunoglobulin superfamily and carry both the Lutheran (Lu) blood group antigens and the basal cell adhesion molecule epithelial cancer antigen. Lu (85 kDa) and Lu(v13) (78 kDa) gps, which differ only in the length of their cytoplasmic domain, are adhesion molecules that bind laminin. In nonerythroid tissues, the Lu/basal cell adhesion molecule antigens are predominantly expressed in the endothelium of blood vessel walls and in the basement membrane region of normal epithelial cells, whereas they exhibit a nonpolarized expression in some epithelial cancers. Here, we analyzed the polarization of Lu and Lu(v13) gps in epithelial cells by confocal microscopy and domain-selective biotinylation assays. Differentiated human colon carcinoma Caco-2 cells exhibited a polarized expression of endogenous Lu antigens associated with a predominant expression of the Lu isoform at the basolateral domain of the plasma membrane and a very low expression of the Lu(v13) isoform at both the apical and basolateral domains, Analysis of transfected Madin-Darby canine kidney cells revealed a basolateral expression of Lu gp and a nonpolarized expression of Lu(v13) gp, Delivery of Lu(v13) to both apical and basolateral surfaces showed similar kinetics, indicating that this isoform is directly transported to each surface domain. A dileucine motif at position 608-609, specific to the Lu isoform, was characterized as a dominant basolateral sorting signal that prevents Lu gp from taking the apical delivery pathway.	Inst Natl Transfus Sanguine, INSERM U76, F-75015 Paris, France; Hop Paul Brousse, INSERM U504, Villejuif, France; Scottish Natl Blood Transfus Serv, Glasgow G2 5UA, Lanark, Scotland	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Le van Kim, C (corresponding author), Inst Natl Transfus Sanguine, INSERM U76, 6 Alexandre Cabanel, F-75015 Paris, France.		Nemer, Wassim El/N-4247-2017; Codogno, Patrice/G-1384-2013; colin, yves/O-1910-2017; le van kim, caroline/O-7030-2017	Nemer, Wassim El/0000-0001-8184-427X; Codogno, Patrice/0000-0002-5492-3180; colin, yves/0000-0001-5196-4254; le van kim, caroline/0000-0002-3251-1310				AROETI B, 1993, J CELL BIOL, V123, P1149, DOI 10.1083/jcb.123.5.1149; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; BUTOR C, 1992, EXP CELL RES, V203, P115, DOI 10.1016/0014-4827(92)90046-B; CAMPBELL IG, 1994, CANCER RES, V54, P5761; CHESAGARIN P, 1994, INT J ONCOL, V5, P1261; DANIELS G, 1989, VOX SANG, V57, P137, DOI 10.1111/j.1423-0410.1989.tb01151.x; El Nemer W, 1998, J BIOL CHEM, V273, P16686; ElNemer W, 1997, BLOOD, V89, P4608, DOI 10.1182/blood.V89.12.4608; Gut A, 1998, J BIOL CHEM, V273, P29381, DOI 10.1074/jbc.273.45.29381; HANZEL D, 1991, CELL BIOL, V2, P341; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; Honing S, 1997, J BIOL CHEM, V272, P19884, DOI 10.1074/jbc.272.32.19884; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; INGLIS G, 1993, TRANSFUS MED S, V3, P94; LEBIVIC A, 1989, P NATL ACAD SCI USA, V86, P9313; LeGall AH, 1997, J BIOL CHEM, V272, P4559, DOI 10.1074/jbc.272.7.4559; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; Lin SS, 1998, J CELL BIOL, V142, P51, DOI 10.1083/jcb.142.1.51; Maisner A, 1997, J BIOL CHEM, V272, P20793, DOI 10.1074/jbc.272.33.20793; MONLAUZEUR L, 1995, J BIOL CHEM, V270, P12219, DOI 10.1074/jbc.270.20.12219; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; MOSTOV KE, 1986, CELL, V47, P359, DOI 10.1016/0092-8674(86)90592-1; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; Parsons SF, 1997, BLOOD, V89, P4219, DOI 10.1182/blood.V89.11.4219; PARSONS SF, 1987, TRANSFUSION, V27, P61, DOI 10.1046/j.1537-2995.1987.27187121477.x; PARSONS SF, 1995, P NATL ACAD SCI USA, V92, P5496, DOI 10.1073/pnas.92.12.5496; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PINTO M, 1983, BIOL CELL, V47, P323; PRILL V, 1993, EMBO J, V12, P2181, DOI 10.1002/j.1460-2075.1993.tb05866.x; Rahuel C, 1996, BLOOD, V88, P1865; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Reich V, 1996, J CELL SCI, V109, P2133; RETTIG WJ, 1988, P NATL ACAD SCI USA, V85, P3110, DOI 10.1073/pnas.85.9.3110; Roush DL, 1998, J BIOL CHEM, V273, P26862, DOI 10.1074/jbc.273.41.26862; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; Sheikh H, 1996, J BIOL CHEM, V271, P12185, DOI 10.1074/jbc.271.21.12185; Simonsen A, 1998, EUR J CELL BIOL, V76, P25, DOI 10.1016/S0171-9335(98)80014-9; Simpson F, 1996, J CELL BIOL, V133, P749, DOI 10.1083/jcb.133.4.749; Tryggvason K, 1993, CURR OPIN CELL BIOL, V5, P877, DOI 10.1016/0955-0674(93)90038-R; Udani M, 1998, J CLIN INVEST, V101, P2550, DOI 10.1172/JCI1204; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735; Yeaman C, 1999, PHYSIOL REV, V79, P73, DOI 10.1152/physrev.1999.79.1.73; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; YURCHENKO PD, 1993, MOL CELLULAR ASPECTS, P121; Zen Q, 1999, J BIOL CHEM, V274, P728, DOI 10.1074/jbc.274.2.728	46	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31903	31908		10.1074/jbc.274.45.31903	http://dx.doi.org/10.1074/jbc.274.45.31903			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542217	hybrid			2022-12-27	WOS:000083532100025
J	Kuwahara, H; Araki, N; Makino, K; Masuko, N; Honda, S; Kaibuchi, K; Fukunaga, K; Miyamoto, E; Ogawa, M; Saya, H				Kuwahara, H; Araki, N; Makino, K; Masuko, N; Honda, S; Kaibuchi, K; Fukunaga, K; Miyamoto, E; Ogawa, M; Saya, H			A novel NE-dlg/SAP102-associated protein, p51-nedasin, related to the amidohydrolase superfamily, interferes with the association between NE-dlg/SAP102 and N-methyl-D-aspartate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; EFFICIENT GENE ACTIVATION; POSTSYNAPTIC DENSITY; HUMAN HOMOLOG; PDZ DOMAINS; GUANYLATE KINASES; AXONAL GUIDANCE; CRE RECOMBINASE; MEMBRANE; BINDING	The membrane-associated guanylate kinase proteins have been known to interact various membrane receptors with their N-terminal segments designated the PDZ domains and to cluster these receptors at the target site of the cell membrane. NE-dlg/SAP102, a neuronal and endocrine tissue-specific MAGUK family protein, was found to be expressed in both dendrites and cell bodies in neuronal cells. Although NE-dlg/SAP102 localized at dendrites was shown to interact with N-methyl-D-aspartate receptor 2B via the PDZ domains to compose postsynaptic density, the binding proteins existing in the cell body of the neuron are still unknown. Here we report the isolation of a novel NE-dlg/SAP102-associated protein, p51-nedasin. Nedasin has a significant homology with amidohydrolase superfamily proteins and shows identical sequences to a recently identified protein that has guanine aminohydrolase activity. Nedasin has four alternative splice variants (S, Vf, V2, and V3) that exhibited different C-terminal structures. NE-dlg/SAP102 is shown to interact with only the S form of nedasin which is predominantly expressed in brain. The expression of nedasin in neuronal cells increases in parallel with the progress of synaptogenesis and is mainly detected in cell bodies where it co-localizes with NE-dlg/SAP102, Furthermore, nedasin interferes with the association between NE-dlg/SAP102 and NMDA receptor 2B in vitro. These findings suggest that alternative splicing of nedasin may play a role in the formation and/or structural change in synapses during neuronal development by modifying clustering of neurotransmitter receptors at the synaptic sites.	Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 8600811, Japan; Kumamoto Univ, Sch Med, Dept Surg 2, Kumamoto 8600811, Japan; Nara Inst Sci & Technol, Div Signal Transduct, Ikoma 6300101, Japan; Kumamoto Univ, Sch Med, Dept Pharmacol, Kumamoto 8600811, Japan	Kumamoto University; Kumamoto University; Nara Institute of Science & Technology; Kumamoto University	Saya, H (corresponding author), Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, 2-2-1 Honjo, Kumamoto 8600811, Japan.	hsaya@gpo.kumamoto-u.ac.jp	Fukunaga, Kohji/AAI-8811-2021; Saya, Hideyuki/J-4325-2013	Fukunaga, Kohji/0000-0001-8526-2824				ASKANAS V, 1994, AM J PATHOL, V144, P177; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; FUKUNAGA K, 1992, J BIOL CHEM, V267, P22527; Garcia EP, 1998, NEURON, V21, P727, DOI 10.1016/S0896-6273(00)80590-5; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; HEDGECOCK EM, 1985, DEV BIOL, V111, P158, DOI 10.1016/0012-1606(85)90443-9; Holm L, 1997, PROTEINS, V28, P72, DOI 10.1002/(SICI)1097-0134(199705)28:1<72::AID-PROT7>3.0.CO;2-L; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; Hunt CA, 1996, J NEUROSCI, V16, P1380; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; ITO S, 1988, ACTA HISTOCHEM, V83, P99, DOI 10.1016/S0065-1281(88)80078-3; ITO S, 1989, J HISTOCHEM CYTOCHEM, V37, P611, DOI 10.1177/37.5.2649557; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Kanegae Y, 1996, GENE, V181, P207, DOI 10.1016/S0378-1119(96)00516-1; Kim E, 1998, J BIOL CHEM, V273, P1591, DOI 10.1074/jbc.273.3.1591; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KISTNER U, 1993, J BIOL CHEM, V268, P4580; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LAHEY T, 1994, NEURON, V13, P823, DOI 10.1016/0896-6273(94)90249-6; Lau LF, 1996, J BIOL CHEM, V271, P21622, DOI 10.1074/jbc.271.35.21622; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; LI W, 1992, GENETICS, V132, P675; Makino K, 1997, ONCOGENE, V14, P2425, DOI 10.1038/sj.onc.1201087; Marfatia SM, 1996, J CELL BIOL, V135, P753, DOI 10.1083/jcb.135.3.753; Masuko N, 1999, J BIOL CHEM, V274, P5782, DOI 10.1074/jbc.274.9.5782; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; MitraniRosenbaum S, 1996, HUM MOL GENET, V5, P159, DOI 10.1093/hmg/5.1.159; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; NARDIELLO S, 1978, ENZYME, V23, P353, DOI 10.1159/000458600; Niethammer M, 1996, J NEUROSCI, V16, P2157; PERRIMON N, 1988, DEV BIOL, V127, P392, DOI 10.1016/0012-1606(88)90326-0; POLAKIS P, 1995, CURR OPIN GENET DEV, V5, P66, DOI 10.1016/S0959-437X(95)90055-1; Sadowsky MJ, 1998, J BACTERIOL, V180, P152, DOI 10.1128/JB.180.1.152-158.1998; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; TAKESHIMA H, 1994, ONCOGENE, V9, P2135; VANWAEG G, 1986, PURINE PYRIMIDINE ME, P425; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7; Yamamoto T, 1995, J BIOL CHEM, V270, P30557, DOI 10.1074/jbc.270.51.30557; Yuan G, 1999, J BIOL CHEM, V274, P8175, DOI 10.1074/jbc.274.12.8175	44	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32204	32214		10.1074/jbc.274.45.32204	http://dx.doi.org/10.1074/jbc.274.45.32204			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542258	hybrid			2022-12-27	WOS:000083532100066
J	Cote, F; Do, TH; Laflamme, L; Gallo, JM; Gallo-Payet, N				Cote, F; Do, TH; Laflamme, L; Gallo, JM; Gallo-Payet, N			Activation of the AT(2) receptor of angiotensin II induces neurite outgrowth and cell migration in microexplant cultures of the cerebellum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN-2; BETA-TUBULIN ISOTYPE; ADULT-RAT BRAIN; TYPE-2 RECEPTOR; GRANULE CELLS; DIFFERENTIAL EXPRESSION; GENE-EXPRESSION; CONVERTING ENZYME; BLOOD-PRESSURE; PC12W CELLS	Microexplant cultures from three-day-old rats were used to investigate whether angiotensin II (Ang II), through its AT(1) and AT(2) receptors, could be involved in the morphological differentiation of cerebellar cells. Specific activation of the AT(2) receptor during 4-day treatment induced two major morphological changes. The first was characterized by increased elongation of neurites. The second change was cell migration from the edge of the microexplant toward the periphery. Western blot analyses and indirect immuno fluorescence studies revealed an increase in the expression of neuron-specific beta III-tubulin, as well as an increase in expression of the microtubule-associated proteins tau and MAP2. These effects were demonstrated by co-incubation of Ang II with 1 mu M DUP 753 (AT(1) receptor antagonist) or with 10 nM CGP 42112 (AT(2) receptor agonist) but abolished when Ang II was co-incubated with 1 mu M PD 123319 (AT(2) receptor antagonist), indicating that differentiation occurs through AT(2) receptor activation and that the AT(1) receptor inhibits the AT(2) effect. Taken together, these results demonstrate that Ang II is involved in cerebellum development for both neurite outgrowth and cell migration, two important processes in the organization of the various layers of the cerebellum.	Univ Sherbrooke, Fac Med, Serv Endocrinol, Sherbrooke, PQ J1H 5N4, Canada; Univ Sherbrooke, Fac Med, Dept Neurosurg, Sherbrooke, PQ J1H 5N4, Canada; Kings Coll London, Inst Psychiat, Dept Clin Neurosci, London SE5 8AF, England	University of Sherbrooke; University of Sherbrooke; University of London; King's College London	Gallo-Payet, N (corresponding author), Univ Sherbrooke, Fac Med, Serv Endocrinol, Sherbrooke, PQ J1H 5N4, Canada.	ngallo01@courrier.ushorb.ca		Gallo, Jean-Marc/0000-0003-0214-4545				AVILA J, 1994, INT J DEV BIOL, V38, P13; BASILLE M, 1993, NEUROSCIENCE, V57, P329, DOI 10.1016/0306-4522(93)90066-O; BINDER LI, 1984, P NATL ACAD SCI-BIOL, V81, P5613, DOI 10.1073/pnas.81.17.5613; Breault L, 1996, J CLIN ENDOCR METAB, V81, P3914, DOI 10.1210/jc.81.11.3914; BRILLA CG, 1994, J MOL CELL CARDIOL, V26, P809, DOI 10.1006/jmcc.1994.1098; BUISSON B, 1995, J BIOL CHEM, V270, P1670, DOI 10.1074/jbc.270.4.1670; BURGOYNE RD, 1984, NEUROSCIENCE, V11, P157, DOI 10.1016/0306-4522(84)90220-3; BURGOYNE RD, 1988, EMBO J, V7, P2311, DOI 10.1002/j.1460-2075.1988.tb03074.x; CACERES A, 1990, NATURE, V343, P461, DOI 10.1038/343461a0; CAMBRAYDEAKIN MA, 1987, DEV BRAIN RES, V37, P197, DOI 10.1016/0165-3806(87)90241-0; Cavallaro S, 1996, MOL PHARMACOL, V50, P60; CHAI SY, 1987, NEUROSCIENCE, V20, P615; CONNOR JA, 1987, J NEUROSCI, V7, P1384; DIAZNIDO J, 1990, J BIOL CHEM, V265, P13949; Erdmann B, 1996, HYPERTENSION, V28, P818, DOI 10.1161/01.HYP.28.5.818; Ferguson AV, 1998, PROG NEUROBIOL, V54, P169, DOI 10.1016/S0301-0082(97)00065-8; FERREIRA A, 1992, J NEUROSCI RES, V32, P516, DOI 10.1002/jnr.490320407; FUXE K, 1980, NEUROSCI LETT, V18, P245, DOI 10.1016/0304-3940(80)90292-X; Gallinat S, 1997, NEUROSCI LETT, V227, P29, DOI 10.1016/S0304-3940(97)00291-7; Gendron L, 1999, MOL ENDOCRINOL, V13, P1615, DOI 10.1210/me.13.9.1615; Gendron L, 1998, ENDOCR RES, V24, P409, DOI 10.3109/07435809809032623; Goldowitz D, 1998, TRENDS NEUROSCI, V21, P375, DOI 10.1016/S0166-2236(98)01313-7; HEIN L, 1995, NATURE, V377, P744, DOI 10.1038/377744a0; ICHIKI T, 1995, NATURE, V377, P748, DOI 10.1038/377748a0; JIANG YQ, 1992, J CELL SCI, V103, P643; JOHNSON JE, 1995, METHOD CELL BIOL, V46, P243; Johren O, 1996, NEUROREPORT, V7, P1349; Johren O, 1998, BRAIN RES, V793, P176, DOI 10.1016/S0006-8993(98)00170-X; Johren O, 1995, NEUROREPORT, V6, P2549; KANG J, 1992, BRAIN RES, V580, P317, DOI 10.1016/0006-8993(92)90960-H; Khan IA, 1996, BIOCHEMISTRY-US, V35, P3704, DOI 10.1021/bi951247p; Komuro H, 1998, J NEUROSCI, V18, P1478; Komuro H, 1996, NEURON, V17, P275, DOI 10.1016/S0896-6273(00)80159-2; Laferriere NB, 1997, BIOCHEM CELL BIOL, V75, P103, DOI 10.1139/bcb-75-2-103; Laflamme L, 1996, J BIOL CHEM, V271, P22729, DOI 10.1074/jbc.271.37.22729; Lenkei Z, 1996, J COMP NEUROL, V373, P322, DOI 10.1002/(SICI)1096-9861(19960923)373:3<322::AID-CNE2>3.0.CO;2-4; Lenkei Z, 1997, FRONT NEUROENDOCRIN, V18, P383, DOI 10.1006/frne.1997.0155; MATUS A, 1988, ANNU REV NEUROSCI, V11, P29, DOI 10.1146/annurev.neuro.11.1.29; Meffert S, 1996, MOL CELL ENDOCRINOL, V122, P59, DOI 10.1016/0303-7207(96)03873-7; MILLAN MA, 1991, P NATL ACAD SCI USA, V88, P11440, DOI 10.1073/pnas.88.24.11440; MOONEN G, 1982, DEV BRAIN RES, V5, P59, DOI 10.1016/0165-3806(82)90113-4; Munzenmaier DH, 1996, HYPERTENSION, V27, P760, DOI 10.1161/01.HYP.27.3.760; NAKAJIMA M, 1995, P NATL ACAD SCI USA, V92, P10663, DOI 10.1073/pnas.92.23.10663; PRZYBORSKI SA, 1995, DEV BRAIN RES, V89, P187, DOI 10.1016/0165-3806(95)00117-V; RAKIC P, 1981, TRENDS NEUROSCI, V4, P184, DOI 10.1016/0166-2236(81)90060-6; ROCAMORA N, 1993, MOL BRAIN RES, V17, P1, DOI 10.1016/0169-328X(93)90065-W; Schutz S, 1996, AM J PATHOL, V149, P2067; SEGAL RA, 1995, J NEUROSCI, V15, P4970; Shenoy UV, 1999, ENDOCRINOLOGY, V140, P500, DOI 10.1210/en.140.1.500; SMITH CJ, 1995, FEBS LETT, V375, P243, DOI 10.1016/0014-5793(95)01221-Y; SOLOMON F, 1986, METHOD ENZYMOL, V134, P139; STOLL M, 1995, J CLIN INVEST, V95, P651, DOI 10.1172/JCI117710; Stroth U, 1998, MOL BRAIN RES, V53, P187, DOI 10.1016/S0169-328X(97)00298-2; SUMNERS C, 1991, P NATL ACAD SCI USA, V88, P7567, DOI 10.1073/pnas.88.17.7567; TANAKA M, 1995, BIOCHEM BIOPH RES CO, V207, P593, DOI 10.1006/bbrc.1995.1229; TSUTSUMI K, 1993, BRAIN RES, V631, P212, DOI 10.1016/0006-8993(93)91537-3; TSUTSUMI K, 1991, AM J PHYSIOL, V261, pR209, DOI 10.1152/ajpregu.1991.261.1.R209; TSUTSUMI K, 1991, ENDOCRINOLOGY, V129, P1075, DOI 10.1210/endo-129-2-1075; Tsuzuki S, 1996, BIOCHEM BIOPH RES CO, V228, P825, DOI 10.1006/bbrc.1996.1739; Yamada T, 1996, P NATL ACAD SCI USA, V93, P156, DOI 10.1073/pnas.93.1.156; Yoshimura Y, 1996, ENDOCRINOLOGY, V137, P1204, DOI 10.1210/en.137.4.1204; Yu K, 1996, ENDOCRINOLOGY, V137, P2503, DOI 10.1210/en.137.6.2503	62	82	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31686	31692		10.1074/jbc.274.44.31686	http://dx.doi.org/10.1074/jbc.274.44.31686			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531378	hybrid			2022-12-27	WOS:000083379400082
J	Lauvau, G; Gubler, B; Cohen, H; Daniel, S; Caillat-Zucman, S; van Endert, PM				Lauvau, G; Gubler, B; Cohen, H; Daniel, S; Caillat-Zucman, S; van Endert, PM			Tapasin enhances assembly of transporters associated with antigen processing-dependent and -independent peptides with HLA-A2 and HLA-B27 expressed in insect cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; HISTOCOMPATIBILITY COMPLEX ANTIGENS; ENDOPLASMIC-RETICULUM; REVEALS POLYMORPHISM; MOLECULAR CHAPERONES; SURFACE EXPRESSION; TAP TRANSPORTERS; HEAVY-CHAIN; LINE .220; T-CELL	Assembly of HLA class I-peptide complexes is assisted by multiple proteins that associate with HLA molecules in loading complexes. These include the housekeeping chaperones calnexin and calreticulin and two essential proteins, the transporters associated with antigen processing (TAP) for peptide supply, and the protein tapasin which is thought to act as a specialized chaperone. We dissected functional effects of processing cofactors by co-expressing in insect cells various combinations of the human proteins HLA-A2, HLA-B27, beta(2)-microglobulin, TAP, calnexin, calreticulin, and tapasin, Stability at 37 degrees C and surface expression of class I dimers correlated closely in baculovirus-infected Sf9 cells, suggesting that these cells retain empty dimers in the endoplasmic reticulum, Both HLA molecules form substantial quantities of stable complexes with insect cell-produced peptide pools. These pools are TAP-selected cytosolic peptides for HLA-B27 but endoplasmic reticulum-derived, i.e. TAP-independent peptides for HLA-A2. This discrepancy may be due to peptide selection by human TAP which is much better adapted to the HLA-B27 than to the HLA-A2 ligand preferences. HLA class I assembly with peptides from TAP-dependent and -independent pools was enhanced strongly by tapasin, Thus, tapasin acts as a chaperone and/or peptide editor that facilitates assembly of peptides with HLA class I molecules independently of mediating their interaction with TAP and/or retention in the endoplasmic reticulum.	Hop Necker Enfants Malad, INSERM U25, F-75743 Paris 15, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	van Endert, PM (corresponding author), Hop Necker Enfants Malad, INSERM U25, 161 Rue Sevres, F-75743 Paris 15, France.		Gubler, Brigitte/D-9479-2018; van Endert, Peter/R-4606-2017	van Endert, Peter/0000-0003-3782-0750; Caillat-Zucman, Sophie/0000-0002-4535-3550				ALEXANDER J, 1990, IMMUNOGENETICS, V31, P169; ALEXANDER J, 1989, IMMUNOGENETICS, V29, P380, DOI 10.1007/BF00375866; ANDERSON KS, 1993, J IMMUNOL, V151, P3407; ANDROLEWICZ MJ, 1994, P NATL ACAD SCI USA, V91, P12716, DOI 10.1073/pnas.91.26.12716; Arosa FA, 1999, J BIOL CHEM, V274, P16917, DOI 10.1074/jbc.274.24.16917; BAAS EJ, 1992, J EXP MED, V176, P147, DOI 10.1084/jem.176.1.147; Bach JM, 1997, J AUTOIMMUN, V10, P375, DOI 10.1006/jaut.1997.0143; Bangia N, 1999, EUR J IMMUNOL, V29, P1858, DOI 10.1002/(SICI)1521-4141(199906)29:06<1858::AID-IMMU1858>3.0.CO;2-C; Benham AM, 1998, J IMMUNOL, V161, P83; CARRENO BM, 1995, J IMMUNOL, V155, P4726; Copeman J, 1998, EUR J IMMUNOL, V28, P3783, DOI 10.1002/(SICI)1521-4141(199811)28:11<3783::AID-IMMU3783>3.0.CO;2-9; Daniel S, 1997, J IMMUNOL, V159, P2350; Daniel S, 1998, J IMMUNOL, V161, P617; Deng YP, 1998, J IMMUNOL, V161, P1677; GODEAU F, 1992, INT IMMUNOL, V4, P265, DOI 10.1093/intimm/4.2.265; Grandea AG, 1998, IMMUNOGENETICS, V48, P260, DOI 10.1007/s002510050430; Grandea AG, 1997, IMMUNOGENETICS, V46, P477, DOI 10.1007/s002510050308; GRANDEA AG, 1995, SCIENCE, V270, P105, DOI 10.1126/science.270.5233.105; GREENWOOD R, 1994, J IMMUNOL, V153, P5525; Hansen TH, 1997, ADV IMMUNOL, V64, P105, DOI 10.1016/S0065-2776(08)60888-3; Harris MR, 1998, J IMMUNOL, V160, P5404; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; Hughes EA, 1998, CURR BIOL, V8, P709, DOI 10.1016/S0960-9822(98)70278-7; JACKSON MR, 1992, P NATL ACAD SCI USA, V89, P12117, DOI 10.1073/pnas.89.24.12117; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; Lehner PJ, 1998, IMMUNITY, V8, P221, DOI 10.1016/S1074-7613(00)80474-4; LEVY F, 1990, INT IMMUNOL, V2, P995, DOI 10.1093/intimm/2.10.995; Lewis JW, 1998, CURR BIOL, V8, P717, DOI 10.1016/S0960-9822(98)70280-5; Li SL, 1997, P NATL ACAD SCI USA, V94, P8708, DOI 10.1073/pnas.94.16.8708; Li SL, 1999, J BIOL CHEM, V274, P8649, DOI 10.1074/jbc.274.13.8649; Lindquist JA, 1998, EMBO J, V17, P2186, DOI 10.1093/emboj/17.8.2186; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; Marusina K, 1997, BIOCHEMISTRY-US, V36, P856, DOI 10.1021/bi9619738; MOMBURG F, 1994, CURR OPIN IMMUNOL, V6, P32, DOI 10.1016/0952-7915(94)90030-2; Morrice NA, 1998, CURR BIOL, V8, P713, DOI 10.1016/S0960-9822(98)70279-9; NEEFJES JJ, 1988, EUR J IMMUNOL, V18, P801, DOI 10.1002/eji.1830180522; NEEFJES JJ, 1993, J EXP MED, V178, P1971, DOI 10.1084/jem.178.6.1971; Neisig A, 1996, J IMMUNOL, V156, P3196; Niedermann G, 1997, J EXP MED, V186, P209, DOI 10.1084/jem.186.2.209; ORTIZNAVARRETE V, 1991, P NATL ACAD SCI USA, V88, P3594, DOI 10.1073/pnas.88.9.3594; Ortmann B, 1997, SCIENCE, V277, P1306, DOI 10.1126/science.277.5330.1306; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; Peh CA, 1998, IMMUNITY, V8, P531, DOI 10.1016/S1074-7613(00)80558-0; Powis SJ, 1997, EUR J IMMUNOL, V27, P2744, DOI 10.1002/eji.1830271040; Powis SJ, 1996, IMMUNITY, V4, P159, DOI 10.1016/S1074-7613(00)80680-9; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; Schoenhals GJ, 1999, EMBO J, V18, P743, DOI 10.1093/emboj/18.3.743; SCOTT JE, 1995, J IMMUNOL, V155, P143; SETTE A, 1994, MOL IMMUNOL, V31, P813, DOI 10.1016/0161-5890(94)90019-1; Simmons WA, 1997, IMMUNITY, V7, P641, DOI 10.1016/S1074-7613(00)80385-4; SNYDER HL, 1994, J EXP MED, V180, P2389, DOI 10.1084/jem.180.6.2389; Solheim JC, 1997, J IMMUNOL, V158, P2236; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; STAM NJ, 1990, INT IMMUNOL, V2, P113, DOI 10.1093/intimm/2.2.113; Suh WK, 1996, J EXP MED, V184, P337, DOI 10.1084/jem.184.2.337; SUH WK, 1994, SCIENCE, V264, P1322, DOI 10.1126/science.8191286; Suh WK, 1999, J IMMUNOL, V162, P1530; URBAN RG, 1994, P NATL ACAD SCI USA, V91, P1534, DOI 10.1073/pnas.91.4.1534; van Endert PM, 1999, CURR OPIN IMMUNOL, V11, P82, DOI 10.1016/S0952-7915(99)80015-6; VANENDERT PM, 1995, J EXP MED, V182, P1883, DOI 10.1084/jem.182.6.1883; VANENDERT PM, 1994, IMMUNITY, V1, P491, DOI 10.1016/1074-7613(94)90091-4; Vassilakos A, 1998, BIOCHEMISTRY-US, V37, P3480, DOI 10.1021/bi972465g; Vassilakos A, 1996, EMBO J, V15, P1495, DOI 10.1002/j.1460-2075.1996.tb00493.x; WANG J, 1994, J IMMUNOL, V152, P1197; WILLIAMS DB, 1995, CURR OPIN IMMUNOL, V7, P77, DOI 10.1016/0952-7915(95)80032-8; YellenShaw AJ, 1997, J EXP MED, V186, P1655, DOI 10.1084/jem.186.10.1655; Zhang Q, 1998, J IMMUNOL, V160, P831	68	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31349	31358		10.1074/jbc.274.44.31349	http://dx.doi.org/10.1074/jbc.274.44.31349			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531335	hybrid			2022-12-27	WOS:000083379400039
J	Liu, XF; Kim, CS; Kurbanov, FT; Honzatko, RB; Fromm, HJ				Liu, XF; Kim, CS; Kurbanov, FT; Honzatko, RB; Fromm, HJ			Dual mechanisms for glucose 6-phosphate inhibition of human brain hexokinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; C-TERMINAL HALVES; REGULATORY SITE; BINDING PROTEIN; OUTER-MEMBRANE; GLUCOSE-6-PHOSPHATE; PHOSPHATE; ENZYME; PURIFICATION; MUTAGENESIS	Brain hexokinase (HKI) is inhibited potently by its product glucose 6-phosphate (G6P); however, the mechanism of inhibition is unsettled. Two hypotheses have been proposed to account for product inhibition of HKI, In one, G6P binds to the active site (the C-terminal half of HKI) and competes directly with ATP, whereas in the alternative suggestion the inhibitor binds to an allosteric site (the N-terminal half of HKI), which indirectly displaces ATP from the active site. Single mutations within G6P binding pockets, as defined by crystal structures, at either the N- or C-terminal half of HKI have no significant effect on G6P inhibition. On the other hand, the corresponding mutations eliminate product inhibition in a truncated form of HKI, consisting only of the C-terminal half of the enzyme. Only through combined mutations at the active and allosteric sites, using residues for which single mutations had little effect, was product inhibition eliminated in HKI, Evidently, potent inhibition of HKI by G6P can occur from both active and allosteric binding sites. Furthermore, kinetic data reported here, in conjunction with published equilibrium binding data, are consistent with inhibitory sites of comparable affinity linked by a mechanism of negative cooperativity.	Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA	Iowa State University	Fromm, HJ (corresponding author), Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA.	hjfromm@iastate.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS010546, R01NS010546] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 10546] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aleshin AE, 1998, FEBS LETT, V434, P42, DOI 10.1016/S0014-5793(98)00952-1; Aleshin AE, 1998, J MOL BIOL, V282, P345, DOI 10.1006/jmbi.1998.2017; Aleshin AE, 1998, STRUCTURE, V6, P39, DOI 10.1016/S0969-2126(98)00006-9; Ardehali H, 1999, J BIOL CHEM, V274, P15986, DOI 10.1074/jbc.274.23.15986; ARORA KK, 1993, J BIOL CHEM, V268, P18259; BACHELARD HS, 1971, BIOCHEM J, V123, P707, DOI 10.1042/bj1230707; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOU AC, 1974, ARCH BIOCHEM BIOPHYS, V165, P628, DOI 10.1016/0003-9861(74)90290-2; Colowick SP., 1973, ENZYMES, V9, P1, DOI DOI 10.1016/S1874-6047(08)60113-4; CRANE RK, 1954, J BIOL CHEM, V210, P597; CRANE RK, 1962, ENZYMES, V6, P47; ELLISON WR, 1975, J BIOL CHEM, V250, P1864; ELLISON WR, 1974, BIOCHIM BIOPHYS ACTA, V688, P429; Fang TY, 1998, J BIOL CHEM, V273, P19548, DOI 10.1074/jbc.273.31.19548; FERRARI RICHARD A., 1959, ARCH BIOCHEM AND BIOPHYS, V80, P372, DOI 10.1016/0003-9861(59)90264-4; FIEK C, 1982, BIOCHIM BIOPHYS ACTA, V688, P429, DOI 10.1016/0005-2736(82)90354-6; FROMM HJ, 1962, J BIOL CHEM, V237, P1661; GERBER G, 1974, EUR J BIOCHEM, V45, P39, DOI 10.1111/j.1432-1033.1974.tb03527.x; GONZALEZ C, 1964, BIOCHEM BIOPH RES CO, V16, P347, DOI 10.1016/0006-291X(64)90038-5; GROSSBARD L, 1966, J BIOL CHEM, V241, P3546; JARORI GK, 1990, EUR J BIOCHEM, V188, P9, DOI 10.1111/j.1432-1033.1990.tb15364.x; Katzen H M, 1967, Adv Enzyme Regul, V5, P335, DOI 10.1016/0065-2571(67)90025-8; KOSOW DP, 1973, ARCH BIOCHEM BIOPHYS, V157, P114, DOI 10.1016/0003-9861(73)90396-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LINDEN M, 1982, FEBS LETT, V141, P189, DOI 10.1016/0014-5793(82)80044-6; LIU F, 1991, BIOCHEM BIOPH RES CO, V177, P305, DOI 10.1016/0006-291X(91)91983-J; LOWRY OH, 1964, J BIOL CHEM, V239, P31; MAGNANI M, 1992, BIOCHEM J, V285, P193, DOI 10.1042/bj2850193; MEHTA A, 1988, J BIOL CHEM, V263, P15492; Mulichak AM, 1998, NAT STRUCT BIOL, V5, P555, DOI 10.1038/811; NING J, 1969, J BIOL CHEM, V244, P3840; NISHI S, 1988, BIOCHEM BIOPH RES CO, V157, P937, DOI 10.1016/S0006-291X(88)80964-1; PURICH DL, 1971, J BIOL CHEM, V246, P3456; PURICH DL, 1973, ADV ENZYMOL RAMB, V39, P249; RIJKSEN G, 1977, BIOCHIM BIOPHYS ACTA, V485, P75, DOI 10.1016/0005-2744(77)90194-2; ROSE IA, 1967, J BIOL CHEM, V242, P1635; Sebastian S, 1999, ARCH BIOCHEM BIOPHYS, V362, P203, DOI 10.1006/abbi.1998.1043; SIANO DB, 1975, ARCH BIOCHEM BIOPHYS, V170, P587, DOI 10.1016/0003-9861(75)90154-X; SOLHEIM LP, 1981, ARCH BIOCHEM BIOPHYS, V211, P92, DOI 10.1016/0003-9861(81)90433-1; SOLS A, 1976, REFLECTIONS BIOCH, P199; TIEDEMANN H, 1959, Z NATURFORSCH PT B, V14, P477, DOI 10.1515/znb-1959-0728; VOWLES DT, 1979, BIOCHIM BIOPHYS ACTA, V566, P283, DOI 10.1016/0005-2744(79)90032-9; WEILMALHERBE H, 1951, BIOCHEM J, V49, P339, DOI 10.1042/bj0490339; WHITE TK, 1989, ARCH BIOCHEM BIOPHYS, V274, P375, DOI 10.1016/0003-9861(89)90451-7; WHITE TK, 1987, ARCH BIOCHEM BIOPHYS, V259, P402, DOI 10.1016/0003-9861(87)90506-6; WILSON JE, 1995, REV PHYSIOL BIOCH P, V126, P65, DOI 10.1007/BFb0049776; Zeng CB, 1996, BIOCHEMISTRY-US, V35, P13157, DOI 10.1021/bi960750e; ZENG CB, 1995, J BIOL CHEM, V270, P10509, DOI 10.1074/jbc.270.18.10509	48	31	33	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31155	31159		10.1074/jbc.274.44.31155	http://dx.doi.org/10.1074/jbc.274.44.31155			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531306	hybrid			2022-12-27	WOS:000083379400010
J	Sebastian, S; White, JA; Wilson, JE				Sebastian, S; White, JA; Wilson, JE			Characterization of the rat type III hexokinase gene promoter - A functional Octamer 1 motif is critical for basal promoter activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN TRANSCRIPTION FACTORS; POU-DOMAIN; BINDING PROTEIN; NUCLEOTIDE-SEQUENCE; EXPRESSION; ISOZYMES; PURIFICATION; MITOCHONDRIA; LOCALIZATION; ELEMENTS	A 1532-base pair 5'-flanking region of the gene encoding rat type Ill hexokinase has been cloned and sequenced. The total sequence includes positions -1548 to -17 (A of the translational start ATG; as position +1). Using luciferase reporter constructs transfected into PC12 (rat pheochromocytoma) and L2 (rat lung) cells, basal promoter activity has been associated with sequence between -182 and -89. This includes a single transcriptional start site, an adenine at position -134 identified by primer extension. Together with previously cloned cDNA sequence, this accounts for an mRNA of approximately 3.9 kilobases, found by Northern blotting of RNA from rat lung and kidney. Sequence upstream of the transcriptional start site was devoid of canonical TATA and CAAT elements, An octamer 1 (Oct-1) binding site, located between positions -166 and -159 was shown by deletion analysis and site-directed mutation to be critical for promoter activity. Nuclear extracts from PC12 cells contained a protein (or proteins) specifically binding the octamer sequence, and supershift experiments with anti-Oct-1 indicated involvement of this ubiquitously expressed transcription factor in the complex. Sequence including the Oct-1 site and immediately adjacent regions was protected from DNase I digestion in footprinting experiments with nuclear extracts from PC12 cells. Reverse transcription polymerase chain reaction indicated that levels of type IPI hexokinase mRNA in rat tissues increased in the order brain < liver < lung approximate to kidney; immunoblotting indicated that type III hexokinase protein in these tissues increased in a similar manner.	Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	Michigan State University	Wilson, JE (corresponding author), Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA.	WILSONJ@PILOT.MSU.EDU			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS009910] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 09910] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allen CB, 1998, AM J PHYSIOL-LUNG C, V274, pL320, DOI 10.1152/ajplung.1998.274.3.L320; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; DAILEY L, 1994, MOL CELL BIOL, V14, P7758, DOI 10.1128/MCB.14.12.7758; DAS G, 1993, J BIOL CHEM, V268, P25026; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GELB BD, 1992, P NATL ACAD SCI USA, V89, P202, DOI 10.1073/pnas.89.1.202; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; ICHIHARA J, 1995, BBA-GENE STRUCT EXPR, V1260, P365, DOI 10.1016/0167-4781(94)00226-S; IYNEDJIAN PB, 1993, BIOCHEM J, V293, P1; JAFFE J, 1995, BBA-GENE STRUCT EXPR, V1261, P201, DOI 10.1016/0167-4781(94)00246-Y; Katzen H M, 1967, Adv Enzyme Regul, V5, P335, DOI 10.1016/0065-2571(67)90025-8; KATZENELLENBOGE.WM, 1959, CLIN CHIM ACTA, V4, P515; KUROKAWA M, 1982, MOL CELL BIOCHEM, V45, P151; LEWIN B, 1997, GENES, V6, P823; Liu WJ, 1997, ARCH BIOCHEM BIOPHYS, V346, P142, DOI 10.1006/abbi.1997.0295; Malkki M, 1997, DIABETOLOGIA, V40, P1461, DOI 10.1007/s001250050850; MATHUPALA SP, 1995, J BIOL CHEM, V270, P16918, DOI 10.1074/jbc.270.28.16918; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; PARSLOW TG, 1984, P NATL ACAD SCI-BIOL, V81, P2650, DOI 10.1073/pnas.81.9.2650; POLAKIS PG, 1985, ARCH BIOCHEM BIOPHYS, V236, P328, DOI 10.1016/0003-9861(85)90633-2; PRELLER A, 1992, ARCH BIOCHEM BIOPHYS, V294, P482, DOI 10.1016/0003-9861(92)90715-9; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; SCHWAB DA, 1991, ARCH BIOCHEM BIOPHYS, V285, P365, DOI 10.1016/0003-9861(91)90373-Q; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; Sui DX, 1997, ARCH BIOCHEM BIOPHYS, V345, P111, DOI 10.1006/abbi.1997.0241; TAE HJ, 1994, J BIOL CHEM, V269, P10475; Tsai HJ, 1997, ARCH BIOCHEM BIOPHYS, V338, P183, DOI 10.1006/abbi.1996.9850; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; WHALLON JH, 1994, SCANNING, V16, P111; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; WILSON JE, 1995, REV PHYSIOL BIOCH P, V126, P65, DOI 10.1007/BFb0049776; WU T, 1994, NUCLEIC ACIDS RES, V22, P5093, DOI 10.1093/nar/22.23.5093	36	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31700	31706		10.1074/jbc.274.44.31700	http://dx.doi.org/10.1074/jbc.274.44.31700			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531380	hybrid			2022-12-27	WOS:000083379400084
J	Suzuki, T; Ichiyama, A; Saitoh, H; Kawakami, T; Omata, M; Chung, CH; Kimura, M; Shimbara, N; Tanaka, K				Suzuki, T; Ichiyama, A; Saitoh, H; Kawakami, T; Omata, M; Chung, CH; Kimura, M; Shimbara, N; Tanaka, K			A new 30-kDa ubiquitin-related SUMO-1 hydrolase from bovine brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PORE COMPLEX; PROTEINS; CONJUGATION; RANGAP1; MODIFIER; RANBP2	SUMO-1 is a ubiquitin-like protein functioning as an important reversible protein modifier. To date there is no report on a SUMO-1 hydrolase/isopeptidase catalyzing the release of SUMO-1 from its precursor or SUMO-1-ligated proteins in mammalian tissues. Here we found multiple activities that cleave the SUMO-1 moiety from two model substrates, I-125-SUMO-1-alpha NH-HSTVG-SMHISPPEPESEEEEEHYC and/or GST-SUMO-1-S-35-RanGAP1 conjugate, in bovine brain extracts. Of them, a major SUMO-1 C-terminal hydrolase had been partially purified by successive chromatographic operations. The enzyme had the ability to cleave SUMO-1 not only from its precursor but also from a SUMO-1-ligated RanGAP1 but did not exhibit any significant cleavage of the ubiquitin- and NEDD8-precursor, The activity of SUMO-1 hydrolase was almost completely inhibited by N-ethylmaleimide, but not by phenylmethanesulfonyl fluoride, EDTA, and ubiquitin-aldehyde known as a potent inhibitor of deubiquitinylating enzymes. Intriguingly, the apparent molecular mass of the isolated SUMO-1 hydrolase was approximately 30 kDa, which is significantly smaller than the recently identified yeast Smt3/SUMO-1 specific protease Ulp1. These results indicate that there are multiple SUMO-1 hydrolase/isopeptidases in mammalian cells and that the 30-kDa small SUMO-1 hydrolase plays a central role in processing of the SUMO-1-precursor.	Tokyo Metropolitian Inst Med Sci, Bunkyo Ku, Tokyo 1130021, Japan; Hamamatsu Univ Sch Med, Dept Biochem 1, Shizuoka 4313192, Japan; Univ Tokyo, Fac Med, Dept Gastroenterol, Bunkyo Ku, Tokyo 1138655, Japan; Seoul Natl Univ, Coll Nat Sci, Dept Biol Mol, Seoul 151742, South Korea; Seoul Natl Univ, Coll Nat Sci, Res Ctr Cell Differentiat, Seoul 151742, South Korea; Sumitomo Elect Ind Ltd, Biomed Res & Dev Dept, Sakae Ku, Yokohama, Kanagawa 2448588, Japan; Picower Inst Med Res, Manhasset, NY 11030 USA	Hamamatsu University School of Medicine; University of Tokyo; Seoul National University (SNU); Seoul National University (SNU); Sumitomo Electric Industries; Northwell Health	Tanaka, K (corresponding author), Tokyo Metropolitian Inst Med Sci, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1130021, Japan.	tanakak@rinshoken.or.jp		Suzuki, Toshiaki/0000-0002-0650-6251				Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Duprez E, 1999, J CELL SCI, V112, P381; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Johnson PR, 1997, TRENDS CELL BIOL, V7, P408, DOI 10.1016/S0962-8924(97)01132-X; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; KAWAKAMI T, 1999, IN PRESS J BIOCH; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Saitoh H, 1998, CURR BIOL, V8, P121, DOI 10.1016/S0960-9822(98)70044-2; Saitoh H, 1997, TRENDS BIOCHEM SCI, V22, P374, DOI 10.1016/S0968-0004(97)01102-X; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; Takahashi Y, 1999, BIOCHEM BIOPH RES CO, V259, P582, DOI 10.1006/bbrc.1999.0821; Tanaka K, 1998, MOL CELLS, V8, P503; WOO SK, 1995, J BIOL CHEM, V270, P18766, DOI 10.1074/jbc.270.32.18766	21	64	66	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31131	31134		10.1074/jbc.274.44.31131	http://dx.doi.org/10.1074/jbc.274.44.31131			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531301	Green Submitted, hybrid			2022-12-27	WOS:000083379400005
J	Almeida, PC; Nantes, IL; Rizzi, CCA; Judice, WAS; Chagas, JR; Juliano, L; Nader, HB; Tersariol, ILS				Almeida, PC; Nantes, IL; Rizzi, CCA; Judice, WAS; Chagas, JR; Juliano, L; Nader, HB; Tersariol, ILS			Cysteine proteinase activity regulation - A possible role of heparin and heparin-like glycosaminoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CATHEPSIN-B; SULFATE PROTEOGLYCANS; BINDING-SITE; PAPAIN; INHIBITION; RESOLUTION; CONSTANT; MEMBRANE; PEPTIDE; PH	Papain is considered to be the archetype of cysteine proteinases. The interaction of heparin and other glycosaminoglycans with papain may be representative of many mammalian cysteine proteinase-glycosaminoglycan interactions that can regulate the function of this class of proteinases in vivo. The conformational changes in papain structure due to glycosaminoglycan interaction were studied by circular dichroism spectroscopy, and the changes in enzyme behavior were studied by kinetic analysis, monitored with fluorogenic substrate. The presence of heparin significantly increases the a-helix content of papain. Heparin binding to papain was demonstrated by affinity chromatography and shown to be mediated by electrostatic interactions. The incubation of papain with heparin promoted a powerful increase in the affinity of the enzyme for the substrate. In order to probe the glycosaminoglycan structure requirements for the papain interaction, the effects of two other glycosaminoglycans were tested. Like heparin, heparan sulfate, to a lesser degree, was able to decrease the papain substrate affinity, and it simultaneously induced a-helix structure in papain. On the other hand, dermatan sulfate was not able to decrease the substrate affinity and did not induce a-helix structure in papain. Heparin stabilizes the papain structure and thereby its activity at alkaline pH.	Univ Mogi Cruzes, Ctr Interdisciplinar Invest Bioquim, Ctr Ciencias Biomed, BR-08780911 Mogi Das Cruzes, SP, Brazil; Univ Fed Sao Paulo, Escola Paulista Med, Inst Nacl Farmacol, Dept Biofis, BR-04044020 Sao Paulo, Brazil; Univ Fed Sao Paulo, Escola Paulista Med, Inst Nacl Farmacol, Disciplina Biol Mol, BR-04044020 Sao Paulo, Brazil	Universidade de Mogi das Cruzes; Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Sao Paulo (UNIFESP)	Tersariol, ILS (corresponding author), Univ Mogi Cruzes, Ctr Interdisciplinar Invest Bioquim, Ctr Ciencias Biomed, Predoio 2,Sala 22-09,Av Dr Candido X Almeida So, BR-08780911 Mogi Das Cruzes, SP, Brazil.		Dos Santos Tersariol, Ivarne Luis/G-4042-2012; de Almeida, Paulo C/D-8285-2014; Nader, Helena Bonciani/D-9253-2012; Nantes, Iseli Lourenço/B-9517-2012; DE SOUZ A S JUDICE, WAGNER ALVES/O-1050-2013; Juliano, Luiz/D-7204-2012; de Almeida, Paulo/D-4794-2012; DE SOUZA JUDICE, WAGNER ALVES/AAG-3225-2020; Chagas, Jair R/A-1701-2012; Chagas, Jair Ribeiro/AFV-6501-2022	Dos Santos Tersariol, Ivarne Luis/0000-0002-8399-4535; de Almeida, Paulo C/0000-0002-5136-5152; Nantes, Iseli Lourenço/0000-0003-1434-3154; DE SOUZ A S JUDICE, WAGNER ALVES/0000-0002-1608-9105; Juliano, Luiz/0000-0002-5589-2822; Chagas, Jair R/0000-0002-0357-8276; Chagas, Jair Ribeiro/0000-0002-0357-8276; NADER, HELENA/0000-0002-7569-2166				BAKER EN, 1987, BIOL MACROMOLECULES; BARRETT AJ, 1980, BIOCHEM J, V187, P909, DOI 10.1042/bj1870909; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BUCK MR, 1992, BIOCHEM J, V282, P273, DOI 10.1042/bj2820273; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Conrad H. E., 1998, HEPARIN BINDING PROT; Dalet-Fumeron V, 1998, ARCH BIOCHEM BIOPHYS, V358, P283, DOI 10.1006/abbi.1998.0868; DelNery E, 1997, J BIOL CHEM, V272, P25713, DOI 10.1074/jbc.272.41.25713; Dietrich CP, 1998, CELL MOL BIOL, V44, P417; DIETRICH CP, 1983, BIOCHEM BIOPH RES CO, V111, P865, DOI 10.1016/0006-291X(83)91379-7; DUFOUR E, 1988, BIOCHIM BIOPHYS ACTA, V995, P58; ERMOLIEFF J, 1994, J BIOL CHEM, V269, P29502; FERRAN DS, 1992, BIOCHEMISTRY-US, V31, P5010, DOI 10.1021/bi00136a014; FROMMHERZ KJ, 1991, J BIOL CHEM, V266, P15356; Gettins P.G.W., 1996, SERPINS STRUCTURE FU; GINEC N, 1992, FEBS LETT, V24, P305; Hirata IY, 1995, LETT PEPT SCI, V1, P299, DOI DOI 10.1007/BF00119771; IacobuzioDonahue CA, 1997, J BIOL CHEM, V272, P29190, DOI 10.1074/jbc.272.46.29190; Kainulainen V, 1998, J BIOL CHEM, V273, P11563, DOI 10.1074/jbc.273.19.11563; KAMPHUIS IG, 1984, J MOL BIOL, V179, P233, DOI 10.1016/0022-2836(84)90467-4; KATUNUMA N, 1989, INTRACELLULAR PROTEO; Lalmanach G, 1998, J BIOL CHEM, V273, P25112, DOI 10.1074/jbc.273.39.25112; LELLOUCH AC, 1992, BIOCHEMISTRY-US, V31, P2279, DOI 10.1021/bi00123a010; MENARD R, 1990, BIOCHEMISTRY-US, V29, P6706, DOI 10.1021/bi00480a021; Moin K, 1998, BIOL CHEM, V379, P1093, DOI 10.1515/bchm.1998.379.8-9.1093; MORT JS, 1984, ARTHRITIS RHEUM, V27, P509, DOI 10.1002/art.1780270505; NADER HB, 1998, HEPARIN CHEM BIOL PR; Nagler DK, 1997, BIOCHEMISTRY-US, V36, P12608, DOI 10.1021/bi971264+; POLGAR L, 1989, MECH PROTEASE ACTION; SHEAHAN K, 1989, CANCER RES, V49, P3809; Sloane B F, 1988, Adv Exp Med Biol, V233, P259; SLOANE BF, 1986, P NATL ACAD SCI USA, V83, P2483, DOI 10.1073/pnas.83.8.2483; SOLISMENDIOLA S, 1992, BIOCHIM BIOPHYS ACTA, V1118, P288, DOI 10.1016/0167-4838(92)90286-M; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Subramanian SV, 1997, J BIOL CHEM, V272, P14713, DOI 10.1074/jbc.272.23.14713; TIAN WX, 1982, BIOCHEMISTRY-US, V21, P1028, DOI 10.1021/bi00534a031; TURK B, 1994, BIOCHEMISTRY-US, V33, P14800, DOI 10.1021/bi00253a019; TURK B, 1993, BIOCHEMISTRY-US, V32, P375, DOI 10.1021/bi00052a046; Turk B, 1997, BIOL CHEM, V378, P141; Turk D, 1998, BIOL CHEM, V379, P137, DOI 10.1515/bchm.1998.379.2.137; VERNET T, 1995, J BIOL CHEM, V270, P16645, DOI 10.1074/jbc.270.28.16645; YAMAMOTO D, 1991, J BIOL CHEM, V266, P14771; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451	43	51	52	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30433	30438		10.1074/jbc.274.43.30433	http://dx.doi.org/10.1074/jbc.274.43.30433			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521421	hybrid			2022-12-27	WOS:000083276700017
J	Bartkiewicz, M; Houghton, A; Baron, R				Bartkiewicz, M; Houghton, A; Baron, R			Leucine zipper-mediated homodimerization of the adaptor protein c-Cbl - A role in c-Cbl's tyrosine phosphorylation and its association with epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-BINDING DOMAIN; PROTOONCOGENE PRODUCT P120(CBL); CELL ANTIGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; T-CELLS; SIGNALING PATHWAYS; EGF RECEPTOR; HEMATOPOIETIC-CELLS; MOLECULAR-CLONING; 2-HYBRID SYSTEM	The 120-kDa proto-oncogenic protein c-Cbl is a multidomain adaptor protein that is phosphorylated in response to the stimulation of a broad range of cell surface receptors and participates in the assembly of signaling complexes that are formed as a result of the activation of various signal transduction pathways. Several structural features of c-Cbl, including the phosphotyrosine-binding domain, proline-rich domain, and motifs containing phosphotyrosine and phosphoserine residues, mediate the association of c-Cbl with other components of these complexes. In addition to those domains that have been demonstrated to play a role in the binding of c-Cbl to other signaling molecules, c-Cbl also contains a RING finger motif and a putative leucine zipper. In this study, we demonstrate that the previously identified putative leucine zipper mediates the formation of Cbl homodimers. Using the yeast two-hybrid system, we show that deletion of the leucine zipper domain is sufficient to abolish Cbl homodimerization, while Cbl mutants carrying extensive N-terminal truncations retain the ability to dimerize with the full-length Cbl, The requirement of the leucine zipper for the homodimerization of Cbl was confirmed by in vitro binding assays, using deletion variants of the C-terminal half of Cbl with and without the leucine zipper domain, and in cells using Myc and green fluorescent protein (GFP) N-terminal-tagged Cbl variants. In cells, the deletion of the leucine zipper caused a decrease in both the tyrosine phosphorylation of Cbl and its association with the epidermal growth factor receptor following stimulation with epidermal growth factor, thus demonstrating a role for the leucine zipper in c-Cbl's signaling functions. Thus, the leucine zipper domain enables c-Cbl to homodimerize, and homodimerization influences Cbl's signaling function, modulating the activity of Cbl itself and/or affecting Cbl's associations with other signaling proteins in the cell.	Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Orthoped, New Haven, CT 06510 USA	Yale University; Yale University	Baron, R (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, 333 Cedar St, New Haven, CT 06510 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042927] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR42927] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; Anderson SM, 1997, J BIOL CHEM, V272, P739, DOI 10.1074/jbc.272.2.739; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BLAKE TJ, 1991, ONCOGENE, V6, P653; Blank V, 1997, TRENDS BIOCHEM SCI, V22, P437, DOI 10.1016/S0968-0004(97)01105-5; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; Chin H, 1997, BIOCHEM BIOPH RES CO, V239, P412, DOI 10.1006/bbrc.1997.7480; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; Gesbert F, 1998, J BIOL CHEM, V273, P3986, DOI 10.1074/jbc.273.7.3986; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; Hunter S, 1997, MOL ENDOCRINOL, V11, P1213, DOI 10.1210/me.11.9.1213; Inouye C, 1997, SCIENCE, V278, P103, DOI 10.1126/science.278.5335.103; Jain SK, 1997, ONCOGENE, V14, P2217, DOI 10.1038/sj.onc.1201049; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; KLEIN NJ, 1993, INT IMMUNOL, V5, P293, DOI 10.1093/intimm/5.3.293; Langdon WY, 1995, AUST NZ J MED, V25, P859, DOI 10.1111/j.1445-5994.1995.tb02892.x; Law SF, 1996, MOL CELL BIOL, V16, P3327; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; MAEKAWA T, 1993, J CELL SCI, V105, P589; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; Marengere LEM, 1997, J IMMUNOL, V159, P70; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Ojaniemi M, 1997, J BIOL CHEM, V272, P3780, DOI 10.1074/jbc.272.6.3780; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PEARLMAN JA, 1994, FEBS LETT, V354, P183, DOI 10.1016/0014-5793(94)01119-2; Qian Y, 1998, ONCOGENE, V16, P2185, DOI 10.1038/sj.onc.1201753; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; Reuther GW, 1996, VITAM HORM, V52, P149, DOI 10.1016/S0083-6729(08)60410-0; Ribon V, 1997, BIOCHEM J, V324, P839, DOI 10.1042/bj3240839; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; Sakuma H, 1997, J BIOL CHEM, V272, P28622, DOI 10.1074/jbc.272.45.28622; Sattler M, 1996, ONCOGENE, V12, P839; Shao XP, 1997, J BIOL CHEM, V272, P6105, DOI 10.1074/jbc.272.10.6105; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; Thien CBF, 1997, ONCOGENE, V14, P2239, DOI 10.1038/sj.onc.1201193; Thien CBF, 1997, ONCOGENE, V15, P2909, DOI 10.1038/sj.onc.1201468; Tong Q, 1997, J BIOL CHEM, V272, P9043; Uddin S, 1996, BIOCHEM BIOPH RES CO, V225, P833, DOI 10.1006/bbrc.1996.1259; Ueno N, 1997, BIOCHEM BIOPH RES CO, V232, P126, DOI 10.1006/bbrc.1997.6229; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Yablonski D, 1996, P NATL ACAD SCI USA, V93, P13864, DOI 10.1073/pnas.93.24.13864; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	59	64	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30887	30895		10.1074/jbc.274.43.30887	http://dx.doi.org/10.1074/jbc.274.43.30887			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521482	hybrid			2022-12-27	WOS:000083276700078
J	Daff, S; Sagami, I; Shimizu, T				Daff, S; Sagami, I; Shimizu, T			The 42-amino acid insert in the FMN domain of neuronal nitric-oxide synthase exerts control over Ca2+/calmodulin-dependent electron transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; BINDING DOMAIN; REDUCTASE DOMAIN; CALMODULIN; HEME; ACTIVATION; MECHANISM; SUBSTRATE; CAVEOLIN; ISOFORMS	The neuronal and endothelial nitric-oxide synthases (nNOS and eNOS) differ from inducible NOS in their dependence on the intracellular Ca2+ concentration. Both nNOS and eNOS are activated by the reversible binding of calmodulin (CaM) in the presence of Ca2+, whereas inducible NOS binds CaM irreversibly. One major divergence in the close sequence similarity between the NOS isoforms is a 40-50-amino acid insert in the middle of the FMN-binding domains of nNOS and eNOS. It has previously been proposed that this insert forms an autoinhibitory domain designed to destabilize CaM binding and increase its Ca2+ dependence. To examine the importance of the insert we constructed two deletion mutants designed to remove the bulk of it from nNOS. Both mutants (Delta 40 and Delta 42) retained maximal NO synthesis activity at lower concentrations of free Ca2+ than the wild type enzyme. They were also found to retain 30% of their activity in the absence of Ca2+/CaM, indicating that the insert plays an important role in disabling the enzyme when the physiological Ca2+ concentration is low. Reduction of nNOS heme by NADPH under rigorous anaerobic conditions was found to occur in the wild type enzyme only in the presence of Ca2+/CaM. However, reduction of heme in the Delta 40 mutant occurred spontaneously on addition of NADPH in the absence of Ca2+/CaM. This suggests that the insert regulates activity by inhibiting electron transfer from FMN to heme in the absence of Ca2+/CaM and by destabilizing CaM binding at low Ca2+ concentrations, consistent with its role as an autoinhibitory domain.	Tohoku Univ, Inst Chem React Sci, Sendai, Miyagi 9808577, Japan	Tohoku University	Daff, S (corresponding author), Tohoku Univ, Inst Chem React Sci, Sendai, Miyagi 9808577, Japan.			Shimizu, Toru/0000-0002-3950-5554				ABOUSOUD HM, 1995, J BIOL CHEM, V270, P22997; ABOUSOUD HM, 1997, J BIOL CHEM, V272, P17349; ABOUSOUD HM, 1997, BIOCHEMISTRY-US, V36, P10811; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; FAEDER EJ, 1973, ANAL BIOCHEM, V53, P332, DOI 10.1016/0003-2697(73)90442-9; Feelisch M., 1996, METHODS NITRIC OXIDE, P455; Gachhui R, 1996, J BIOL CHEM, V271, P20594, DOI 10.1074/jbc.271.34.20594; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Klatt P, 1996, J BIOL CHEM, V271, P7336, DOI 10.1074/jbc.271.13.7336; Lee SJ, 1998, J BIOL CHEM, V273, P27430, DOI 10.1074/jbc.273.42.27430; Louerat-Oriou B, 1998, EUR J BIOCHEM, V258, P1040, DOI 10.1046/j.1432-1327.1998.2581040.x; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; MATSUOKA A, 1994, J BIOL CHEM, V269, P20335; Michel JB, 1997, J BIOL CHEM, V272, P25907, DOI 10.1074/jbc.272.41.25907; NATHAN C, 1994, J BIOL CHEM, V269, P13725; Newton DC, 1998, ARCH BIOCHEM BIOPHYS, V359, P249, DOI 10.1006/abbi.1998.0917; Nishida CR, 1999, J BIOL CHEM, V274, P14692, DOI 10.1074/jbc.274.21.14692; Nishida CR, 1998, J BIOL CHEM, V273, P5566, DOI 10.1074/jbc.273.10.5566; Picciotto M R, 1996, Adv Pharmacol, V36, P251, DOI 10.1016/S1054-3589(08)60585-2; Presta A, 1998, J AM CHEM SOC, V120, P9460, DOI 10.1021/ja9740374; RICHARDS MK, 1994, BIOCHEMISTRY-US, V33, P14723, DOI 10.1021/bi00253a010; Ruan J, 1996, J BIOL CHEM, V271, P22679, DOI 10.1074/jbc.271.37.22679; Sagami I, 1998, J BIOL CHEM, V273, P2105, DOI 10.1074/jbc.273.4.2105; SAGAMI I, 1998, BIOL NITRIC OXIDE, V6; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; Sato H, 1998, BIOCHEM BIOPH RES CO, V253, P845, DOI 10.1006/bbrc.1998.9851; SESSA WC, 1992, J BIOL CHEM, V267, P15274; SHEN AL, 1989, J BIOL CHEM, V264, P7584; SHIMIZU T, 1994, J BIOL CHEM, V269, P13296; Siddhanta U, 1998, J BIOL CHEM, V273, P18950, DOI 10.1074/jbc.273.30.18950; Stuehr DJ, 1996, METHOD ENZYMOL, V268, P324; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Venema RC, 1996, J BIOL CHEM, V271, P6435, DOI 10.1074/jbc.271.11.6435; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411	40	113	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30589	30595		10.1074/jbc.274.43.30589	http://dx.doi.org/10.1074/jbc.274.43.30589			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521442	hybrid			2022-12-27	WOS:000083276700038
J	Moriguchi, T; Kawachi, K; Kamakura, S; Masuyama, N; Yamanaka, H; Matsumoto, K; Kikuchi, A; Nishida, E				Moriguchi, T; Kawachi, K; Kamakura, S; Masuyama, N; Yamanaka, H; Matsumoto, K; Kikuchi, A; Nishida, E			Distinct domains of mouse dishevelled are responsible for the c-Jun N-terminal kinase/stress-activated protein kinase activation and the axis formation in vertebrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; XENOPUS-EMBRYOS; PLASMA-MEMBRANE; BETA-CATENIN; MAP KINASES; PATHWAYS; POLARITY; STRESS; JNK; IDENTIFICATION	Recent studies have shown that Drosophila Dishevelled (Dsh), an essential component of the wingless signal transduction, is also involved in planar polarity signaling through the c-Jun N-terminal kinase (JNK)/stress-activated protein kinase (SAPK) pathway in Drosophila. Here, we show that expression of a mouse homolog of Dsh (mDvl-1) in NIH3T3 cells activates JNK/SAPK, and its activator MKK7. A C-terminal half of mDvl-1 which contains the DEP domain was sufficient for the activation of JNK/SAPK, whereas an N-terminal half of mDvl-1 as well as the DEP domain is required for stimulation of the TCF/LEF-1-dependent transcriptional activation, a beta-catenin-dependent process. A single amino acid substitution (Met for Lys) within the DEP domain (mDvl-1 (KM)) abolished the JNK/SAPK-activating activity of mDvl-1, but did not affect the activity to activate the LEF-1-dependent transcription. Ectopic expression of mDvl-1 (KM) or an N-terminal half of mDvl-1, but not the C-terminal, was able to induce secondary axis in Xenopus embryos. Because the secondary axis formation is dependent on the Wnt/beta-catenin signaling pathway, these results suggest that distinct domains of mDvl-1 are responsible for the two downstream signaling pathways, the beta-catenin pathway and the JNK/SAPK pathway in vertebrates.	Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan; Nagoya Univ, Grad Sch Sci, Dept Mol Biol, Nagoya, Aichi, Japan; Japan Sci & Technol Corp, CREST, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, Hiroshima 7348551, Japan	Kyoto University; Nagoya University; Japan Science & Technology Agency (JST); Hiroshima University	Nishida, E (corresponding author), Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan.		Moriguchi, Tetsuo/D-7061-2012	Moriguchi, Tetsuo/0000-0002-9598-4991				Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DU SJ, 1995, MOL CELL BIOL, V15, P2625; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Klingensmith J, 1996, MECH DEVELOP, V58, P15, DOI 10.1016/S0925-4773(96)00549-7; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Lawler S, 1997, FEBS LETT, V414, P153, DOI 10.1016/S0014-5793(97)00990-3; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Li L, 1999, J BIOL CHEM, V274, P129, DOI 10.1074/jbc.274.1.129; Lu XH, 1997, J BIOL CHEM, V272, P24751, DOI 10.1074/jbc.272.40.24751; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Orsulic S, 1996, CURR BIOL, V6, P1363, DOI 10.1016/S0960-9822(96)00731-2; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P245, DOI 10.1016/S0968-0004(96)30027-3; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; Semenov MV, 1997, GENOMICS, V42, P302, DOI 10.1006/geno.1997.4713; SOKOL SY, 1995, DEVELOPMENT, V121, P3487; Sokol SY, 1996, CURR BIOL, V6, P1456, DOI 10.1016/S0960-9822(96)00750-6; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SUSSMAN DJ, 1994, DEV BIOL, V166, P73, DOI 10.1006/dbio.1994.1297; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Tsang M, 1996, DEV DYNAM, V207, P253, DOI 10.1002/(SICI)1097-0177(199611)207:3<253::AID-AJA2>3.0.CO;2-G; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087	35	119	121	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30957	30962		10.1074/jbc.274.43.30957	http://dx.doi.org/10.1074/jbc.274.43.30957			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521491	hybrid			2022-12-27	WOS:000083276700087
J	Rhoads, RE				Rhoads, RE			Signal transduction pathways that regulate eukaryotic protein synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							GLYCOGEN-SYNTHASE KINASE-3; P70 S6 KINASE; INITIATION-FACTOR 4E; MESSENGER-RNA TRANSLATION; ELONGATION FACTOR-II; INSULIN-RECEPTOR SUBSTRATE-1; T-CELL ACTIVATION; MAMMALIAN TARGET; PHAS-I; PHOSPHATIDYLINOSITOL 3-KINASE		Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Rhoads, RE (corresponding author), Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, 1501 Kings Highway, Shreveport, LA 71130 USA.				NIGMS NIH HHS [GM20818] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; Aktas H, 1998, P NATL ACAD SCI USA, V95, P8280, DOI 10.1073/pnas.95.14.8280; Azpiazu I, 1996, J BIOL CHEM, V271, P5033; Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; BASERGA R, 1990, CANCER RES, V50, P6769; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Chang YWE, 1997, J BIOL CHEM, V272, P28252, DOI 10.1074/jbc.272.45.28252; Chiaberge S, 1998, J BIOL CHEM, V273, P27070, DOI 10.1074/jbc.273.42.27070; CLARK BFC, 1996, BIOCHIMIE PARIS, V78, P11; Clemens MJ, 1996, TRANSLATIONAL CONTRO, P139; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DARVEAU A, 1985, P NATL ACAD SCI USA, V82, P2315, DOI 10.1073/pnas.82.8.2315; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; Diggle TA, 1998, BIOCHEM J, V336, P525, DOI 10.1042/bj3360525; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; Downward J, 1998, NATURE, V396, P416, DOI 10.1038/24743; DUNCAN R, 1985, J BIOL CHEM, V260, P5493; Fleurent M, 1997, J BIOL CHEM, V272, P4006, DOI 10.1074/jbc.272.7.4006; FLYNN A, 1995, J BIOL CHEM, V270, P21684, DOI 10.1074/jbc.270.37.21684; Fraser CS, 1999, J BIOL CHEM, V274, P196, DOI 10.1074/jbc.274.1.196; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Garcia-Sanz JA, 1998, FASEB J, V12, P299, DOI 10.1096/fasebj.12.3.299; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Hajduch E, 1998, DIABETES, V47, P1006, DOI 10.2337/diabetes.47.7.1006; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; HerreraVelit P, 1997, J BIOL CHEM, V272, P16445, DOI 10.1074/jbc.272.26.16445; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; Hornstein E, 1999, J BIOL CHEM, V274, P1708, DOI 10.1074/jbc.274.3.1708; Iiboshi Y, 1999, J BIOL CHEM, V274, P1092, DOI 10.1074/jbc.274.2.1092; ITO T, 1994, P NATL ACAD SCI USA, V91, P7455, DOI 10.1073/pnas.91.16.7455; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; JOSHI B, 1995, J BIOL CHEM, V270, P14597, DOI 10.1074/jbc.270.24.14597; Kimball SR, 1998, J BIOL CHEM, V273, P30945, DOI 10.1074/jbc.273.47.30945; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Kleijn M, 1998, J BIOL CHEM, V273, P5536, DOI 10.1074/jbc.273.10.5536; Kochetov AV, 1998, FEBS LETT, V440, P351, DOI 10.1016/S0014-5793(98)01482-3; Lawrence JC, 1997, TRENDS BIOCHEM SCI, V22, P345, DOI 10.1016/S0968-0004(97)01101-8; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mendez R, 1997, MOL CELL BIOL, V17, P5184, DOI 10.1128/MCB.17.9.5184; Mendez R, 1996, MOL CELL BIOL, V16, P2857; Merrick WC., 1996, TRANSLATION CONTROL, P31; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; MORLEY SJ, 1991, J BIOL CHEM, V266, P4669; MORLEY SJ, 1989, J BIOL CHEM, V264, P2401; MORLEY SJ, 1990, J BIOL CHEM, V265, P10611; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; MYERS MG, 1994, J BIOL CHEM, V269, P28783; Myers MG, 1998, J BIOL CHEM, V273, P26908, DOI 10.1074/jbc.273.41.26908; NAIRN AC, 1996, TRANSLATIONAL CONTRO, P295; New L, 1999, J BIOL CHEM, V274, P1026, DOI 10.1074/jbc.274.2.1026; NIELSEN FC, 1995, NATURE, V377, P358, DOI 10.1038/377358a0; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Pestova TV, 1998, NATURE, V394, P854, DOI 10.1038/29703; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; Polakiewicz RD, 1998, J BIOL CHEM, V273, P23534, DOI 10.1074/jbc.273.36.23534; Poulin F, 1998, J BIOL CHEM, V273, P14002, DOI 10.1074/jbc.273.22.14002; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Pyronnet S, 1998, ONCOGENE, V16, P2219, DOI 10.1038/sj.onc.1201748; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; RAO GN, 1994, J BIOL CHEM, V269, P7180; Redpath NT, 1996, J BIOL CHEM, V271, P17547, DOI 10.1074/jbc.271.29.17547; REDPATH NT, 1993, EUR J BIOCHEM, V213, P689, DOI 10.1111/j.1432-1033.1993.tb17809.x; Redpath NT, 1996, EMBO J, V15, P2291, DOI 10.1002/j.1460-2075.1996.tb00582.x; Reilly BA, 1998, J BIOL CHEM, V273, P3747, DOI 10.1074/jbc.273.6.3747; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Sable CL, 1998, J BIOL CHEM, V273, P29600, DOI 10.1074/jbc.273.45.29600; SCHEETZ AJ, 1997, P NATL ACAD SCI USA, V94, P14771; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Scott PH, 1998, J BIOL CHEM, V273, P34496, DOI 10.1074/jbc.273.51.34496; Shigemitsu K, 1999, J BIOL CHEM, V274, P1058, DOI 10.1074/jbc.274.2.1058; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Sinaud S, 1999, AM J PHYSIOL-ENDOC M, V276, pE50, DOI 10.1152/ajpendo.1999.276.1.E50; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; TERADA N, 1995, J IMMUNOL, V155, P3418; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Vaughan M, 1998, J BIOL CHEM, V273, P17297, DOI 10.1074/jbc.273.28.17297; VENEMA RC, 1991, J BIOL CHEM, V266, P12574; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; vonManteuffel SR, 1997, MOL CELL BIOL, V17, P5426, DOI 10.1128/MCB.17.9.5426; Wang XM, 1998, J BIOL CHEM, V273, P9373, DOI 10.1074/jbc.273.16.9373; Wang XM, 1998, BIOCHEM J, V334, P261, DOI 10.1042/bj3340261; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Welsh GI, 1996, J BIOL CHEM, V271, P11410, DOI 10.1074/jbc.271.19.11410; WELSH GI, 1997, BIOCH SOC T S, V25, P191; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Wijkander J, 1997, J BIOL CHEM, V272, P21520, DOI 10.1074/jbc.272.34.21520; Xu G, 1998, J BIOL CHEM, V273, P28178, DOI 10.1074/jbc.273.43.28178	103	161	173	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30337	30340		10.1074/jbc.274.43.30337	http://dx.doi.org/10.1074/jbc.274.43.30337			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521405	hybrid			2022-12-27	WOS:000083276700001
J	Tozawa, R; Ishibashi, S; Osuga, J; Yagyu, H; Oka, T; Chen, Z; Ohashi, K; Perrey, S; Shionoiri, F; Yahagi, N; Harada, K; Gotoda, T; Yazaki, Y; Yamada, N				Tozawa, R; Ishibashi, S; Osuga, J; Yagyu, H; Oka, T; Chen, Z; Ohashi, K; Perrey, S; Shionoiri, F; Yahagi, N; Harada, K; Gotoda, T; Yazaki, Y; Yamada, N			Embryonic lethality and defective neural tube closure in mice lacking squalene synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; LEMLI-OPITZ-SYNDROME; MOLECULAR-CLONING; APOLIPOPROTEIN-B; CHOLESTEROL-BIOSYNTHESIS; KNOCKOUT MICE; LDL RECEPTOR; YOLK-SAC; IN-VIVO; GENE	Squalene synthase (SS) catalyzes the reductive head-to-head condensation of two molecules of farnesyl diphosphate to form squalene, the first specific intermediate in the cholesterol biosynthetic pathway. We used gene targeting to knock out the mouse SS gene. The mice heterozygous for the mutation (SS+/-) were apparently normal. SS+/- mice showed 60% reduction in the hepatic mRNA levels of SS compared with SS+/+ mice. Consistently, the SS enzymatic activities were reduced by 50% in the liver and testis, Nevertheless, the hepatic cholesterol synthesis was not different between SS+/- and SS+/+ mice, and plasma lipoprotein profiles were not different irrespective of the presence of the low density lipoprotein receptor, indicating that SS is not a rate-limiting enzyme in the cholesterol biosynthetic pathway. The mice homozygous for the disrupted SS gene (SS-/-) were embryonic lethal around midgestation. E9.5-10.5 SS-/- embryos exhibited severe growth retardation and defective neural tube closure. The lethal phenotype was not rescued by supplementing the dams either with dietary squalene or cholesterol. We speculate that cholesterol is required for the development, particularly of the nervous system, and that the chorioallantoic circulatory system is not mature enough to supply the rapidly growing embryos with maternal cholesterol at this developmental stage.	Univ Tokyo, Dept Metab Dis, Fac Med, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Dept Cardiol, Fac Med, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Dept Pathol, Fac Med, Bunkyo Ku, Tokyo 1138655, Japan	University of Tokyo; University of Tokyo; University of Tokyo	Ishibashi, S (corresponding author), Univ Tokyo, Dept Metab Dis, Fac Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.		Yahagi, Naoya/D-2360-2014	Yahagi, Naoya/0000-0002-1823-1865				ABE I, 1994, NAT PROD REP, V11, P279, DOI 10.1039/np9941100279; Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Amin D, 1997, J PHARMACOL EXP THER, V281, P746; BAXTER A, 1992, J BIOL CHEM, V267, P11705; BELKNAP WM, 1988, J CLIN INVEST, V82, P2077, DOI 10.1172/JCI113829; Bostedor RG, 1997, J BIOL CHEM, V272, P9197; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; CHIN DJ, 1984, NATURE, V308, P613, DOI 10.1038/308613a0; CIOSEK CP, 1993, J BIOL CHEM, V268, P24832; COHEN LH, 1986, BIOCHEM BIOPH RES CO, V138, P335, DOI 10.1016/0006-291X(86)90285-8; Eisele B, 1997, J LIPID RES, V38, P564; Farese RV, 1996, J LIPID RES, V37, P347; FARESE RV, 1995, P NATL ACAD SCI USA, V92, P1774, DOI 10.1073/pnas.92.5.1774; Farese RV, 1998, TRENDS GENET, V14, P115, DOI 10.1016/S0168-9525(97)01377-2; Fitzky BU, 1998, P NATL ACAD SCI USA, V95, P8181, DOI 10.1073/pnas.95.14.8181; FitzPatrick DR, 1998, AM J MED GENET, V75, P145, DOI 10.1002/(SICI)1096-8628(19980113)75:2<145::AID-AJMG5>3.0.CO;2-S; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; FRYKMAN PK, 1995, P NATL ACAD SCI USA, V92, P8453, DOI 10.1073/pnas.92.18.8453; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; HUANG LS, 1995, J CLIN INVEST, V96, P2152, DOI 10.1172/JCI118269; INOUE T, 1995, BBA-GENE STRUCT EXPR, V1260, P49, DOI 10.1016/0167-4781(94)00178-6; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; JOLLIE WP, 1990, TERATOLOGY, V41, P361, DOI 10.1002/tera.1420410403; Jurevics HA, 1997, J LIPID RES, V38, P723; LIU GCK, 1976, J LIPID RES, V17, P38; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; MCKENZIE TL, 1992, J BIOL CHEM, V267, P21368; MINSKER DH, 1983, TERATOLOGY, V28, P449, DOI 10.1002/tera.1420280316; NESS GC, 1994, ARCH BIOCHEM BIOPHYS, V311, P277, DOI 10.1006/abbi.1994.1238; OSUGA J, 1995, BIOCHEM BIOPH RES CO, V214, P653, DOI 10.1006/bbrc.1995.2336; Osuga J, 1998, J CLIN INVEST, V102, P386, DOI 10.1172/JCI1124; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; PRATT HPM, 1982, DEV BIOL, V89, P101, DOI 10.1016/0012-1606(82)90298-6; Raabe M, 1998, P NATL ACAD SCI USA, V95, P8686, DOI 10.1073/pnas.95.15.8686; REPETTO M, 1990, TERATOLOGY, V42, P611, DOI 10.1002/tera.1420420605; Roullet JB, 1997, J BIOL CHEM, V272, P32240, DOI 10.1074/jbc.272.51.32240; Roullet JB, 1996, J CLIN INVEST, V97, P2384, DOI 10.1172/JCI118682; Salen G, 1996, J LIPID RES, V37, P1169; SCALLEN T, 1974, FED PROC, V38, P1733; SCHAFER BL, 1992, J BIOL CHEM, V267, P13229; STORM HM, 1993, LIPIDS, V28, P555, DOI 10.1007/BF02536088; Tabin CJ, 1997, TRENDS CELL BIOL, V7, P442, DOI 10.1016/S0962-8924(97)01159-8; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Willnow TE, 1996, P NATL ACAD SCI USA, V93, P8460, DOI 10.1073/pnas.93.16.8460; Wyne KL, 1998, J LIPID RES, V39, P518; Yamamoto T, 1996, CURR OPIN LIPIDOL, V7, P298, DOI 10.1097/00041433-199610000-00007	52	99	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30843	30848		10.1074/jbc.274.43.30843	http://dx.doi.org/10.1074/jbc.274.43.30843			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521476	hybrid, Green Published			2022-12-27	WOS:000083276700072
J	Wolf, BB; Schuler, M; Echeverri, F; Green, DR				Wolf, BB; Schuler, M; Echeverri, F; Green, DR			Caspase-3 is the primary activator of apoptotic DNA fragmentation via DNA fragmentation factor-45/inhibitor of caspase-activated DNase inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATHEPSIN-D; CLEAVAGE; PROTEASE; INHIBITOR; CPP32; CALPAIN; TARGET	Caspase-3 initiates apoptotic DNA fragmentation by proteolytically inactivating DFF45 (DNA fragmentation factor-45)/ICAD (inhibitor of caspase-activated DNase), which releases active DFF40/CAD (caspase-activated DNase), the inhibitor's associated endonuclease. Here, we examined whether other apoptotic proteinases initiated DNA fragmentation via DFF45/ICAD inactivation. In a cell-free assay, caspases-3, -6, -7, -8, and granzyme B initiated benzoyloxycarbonyl-Asp-Glu-Val-Asp (DEVD) cleaving caspase activity, DFF45/ICAD inactivation, and DNA fragmentation, but calpain and cathepsin D failed to initiate these events. Strikingly, only the DEVD cleaving caspases, caspase-3 and caspase-7, inactivated DFF45/ICAD and promoted DNA fragmentation in an in vitro DFF40/CAD assay, suggesting that granzyme B, caspase-6, and caspase-8 promote DFF45/ICAD inactivation and DNA fragmentation indirectly by activating caspase-3 and/or caspase-7. In vitro, however, caspase-3 inactivated DFF45/ICAD and promoted DNA fragmentation more effectively than caspase-7 and endogenous levels of caspase-7 failed to inactivate DFF45/ICAD in caspase-3 null MCF7 cells and extracts. Together, these data suggest that caspase-3 is the primary inactivator of DFF45/ICAD and therefore the primary activator of apoptotic DNA fragmentation.	La Jolla Inst Allergy & Immunol, Div Cellular Immunol, San Diego, CA 92121 USA; Univ Calif San Diego, Dept Internal Med, San Diego, CA 92103 USA	La Jolla Institute for Immunology; University of California System; University of California San Diego	Wolf, BB (corresponding author), La Jolla Inst Allergy & Immunol, Div Cellular Immunol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.		Green, Douglas R/N-8083-2018	Green, Douglas R/0000-0002-7332-1417	NATIONAL CANCER INSTITUTE [K08CA075268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040646] Funding Source: NIH RePORTER; NCI NIH HHS [CA69831, CA75268-01] Funding Source: Medline; NIAID NIH HHS [AI40646] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; Darmon AJ, 1996, J BIOL CHEM, V271, P21709, DOI 10.1074/jbc.271.36.21709; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Halenbeck R, 1998, CURR BIOL, V8, P537, DOI 10.1016/S0960-9822(98)79298-X; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Liu XS, 1996, J BIOL CHEM, V271, P13371, DOI 10.1074/jbc.271.23.13371; Liu XS, 1999, J BIOL CHEM, V274, P13836, DOI 10.1074/jbc.274.20.13836; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Pike BR, 1998, J NEUROSCI RES, V52, P505, DOI 10.1002/(SICI)1097-4547(19980601)52:5<505::AID-JNR3>3.0.CO;2-G; Roberg K, 1998, AM J PATHOL, V152, P1151; Sakahira H, 1999, J BIOL CHEM, V274, P15740, DOI 10.1074/jbc.274.22.15740; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tang D, 1998, J BIOL CHEM, V273, P28549, DOI 10.1074/jbc.273.44.28549; Wolf BB, 1999, BLOOD, V94, P1683, DOI 10.1182/blood.V94.5.1683.417k37_1683_1692; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Zheng TS, 1998, P NATL ACAD SCI USA, V95, P13618, DOI 10.1073/pnas.95.23.13618	29	410	431	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30651	30656		10.1074/jbc.274.43.30651	http://dx.doi.org/10.1074/jbc.274.43.30651			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521451	hybrid			2022-12-27	WOS:000083276700047
J	Chakraborty, TR; Vancura, A; Balija, VS; Haldar, D				Chakraborty, TR; Vancura, A; Balija, VS; Haldar, D			Phosphatidic acid synthesis in mitochondria - Topography of formation and transmembrane migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; SN-GLYCEROL 3-PHOSPHATE; GLYCEROPHOSPHATE ACYLTRANSFERASE; GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE; TRANSVERSE-PLANE; OUTER-MEMBRANE; PURIFICATION; ENZYMES; CELLS; ACYLATION	The topography of formation and migration of phosphatidic acid (PA) in the transverse plane of rat liver mitochondrial outer membrane (MOM) were investigated. Isolated mitochondria and microsomes, incubated with sn-glycerol 3-phosphate and an immobilized substrate palmitoyl-CoA-agarose, synthesized both lyse-PA and PA. The mitochondrial and microsomal acylation of glycerophosphate with palmitoyl-CoA-agarose was 80-100% of the values obtained in the presence of free palmitoyl-CoA, In another series of experiments, both free polymyxin B and polymyxin B-agarose stimulated mitochondrial glycerophosphate acyltransferase activity approximately a-fold. When PA loaded mitochondria were treated with Liver fatty acid binding protein, a fifth of the phospholipid left the mitochondria. The amount of expel-table PA reduced with the increase in the time of incubation, In another approach, PA-loaded mitochondria were treated with phospholipase A(2). The amount of phospholipase A(2)-sensitive PA reduced when the incubation time was increased. Taken together, the results suggest that lysophosphatidic acid (LPA) and PA are synthesized on the outer surface of the MOM and that PA moves to the inner membrane presumably for cardiolipin formation.	St Johns Univ, Dept Biol Sci, Jamaica, NY 11439 USA	Saint John's University	Haldar, D (corresponding author), St Johns Univ, Dept Biol Sci, Jamaica, NY 11439 USA.			Vancura, Ales/0000-0002-5895-1218	NIGMS NIH HHS [GM-57643] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM057643] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BATES EJ, 1979, BIOCHEM J, V182, P751, DOI 10.1042/bj1820751; BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARROLL MA, 1982, ARCH BIOCHEM BIOPHYS, V214, P17, DOI 10.1016/0003-9861(82)90003-0; DAAE LNW, 1973, BIOCHIM BIOPHYS ACTA, V306, P186, DOI 10.1016/0005-2760(73)90224-5; DAS SK, 1987, LIPIDS, V22, P757, DOI 10.1007/BF02533977; DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V822, P1, DOI 10.1016/0304-4157(85)90002-4; DRICKS LK, 1997, BIOCHIM BIOPHYS ACTA, V1348, P17; FITZPATRICK SM, 1982, J NEUROCHEM, V39, P286, DOI 10.1111/j.1471-4159.1982.tb04738.x; Haldar D, 1983, Trans N Y Acad Sci, V41, P173; HALDAR D, 1979, J BIOL CHEM, V254, P4502; HALDAR D, 1992, METHOD ENZYMOL, V209, P64; HALDAR D, 1990, J BIOL CHEM, V265, P11014; HESLER CB, 1985, J BIOL CHEM, V260, P7452; HESLER CB, 1990, J BIOL CHEM, V265, P6600; HOSTETLER KY, 1982, PHOSPHOLIPIDS, P481; KENNEDY EP, 1953, J BIOL CHEM, V201, P399; KENNEDY EP, 1961, FED PROC, V20, P934; KORNBERG A, 1953, J BIOL CHEM, V204, P345; MONROY G, 1973, J BIOL CHEM, V248, P2845; MONROY G, 1972, J BIOL CHEM, V247, P6884; NACHBAURT J, 1986, BIOCHEM BIOPH RES CO, V33, P315; Nikonov A., 1996, FASEB Journal, V10, pA1110; NIKONOV AV, 1998, RRD LIP RES 2, V2, P207; SAGGERSON ED, 1987, BIOCHEM J, V243, P289, DOI 10.1042/bj2430289; SALEM L, 1962, J CHEM PHYS, V37, P2100, DOI 10.1063/1.1733431; SCHLAME M, 1993, J BIOL CHEM, V268, P74; SCHLAME M, 1990, BIOCHEM J, V272, P589, DOI 10.1042/bj2720589; SMITH ME, 1967, EUR J BIOCHEM, V3, P70, DOI 10.1111/j.1432-1033.1967.tb19499.x; STERN W, 1978, J BIOL CHEM, V253, P8047; Sul HS, 1998, ANNU REV NUTR, V18, P331, DOI 10.1146/annurev.nutr.18.1.331; VANCURA A, 1992, J BIOL CHEM, V267, P14353; VANCURA A, 1994, J BIOL CHEM, V269, P27209; VANDEENEN LLM, 1965, PROGRESS CHEMISTRY 1, V8, P1; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WOJTCZAK L, 1990, BIOCHIM BIOPHYS ACTA, V1044, P284, DOI 10.1016/0005-2760(90)90315-O; YET SF, 1995, BIOCHEMISTRY-US, V34, P7303, DOI 10.1021/bi00022a003	37	25	25	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29786	29790		10.1074/jbc.274.42.29786	http://dx.doi.org/10.1074/jbc.274.42.29786			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514455	hybrid			2022-12-27	WOS:000083176400034
J	Fathy, DB; Leeb, T; Mathis, SA; Leeb-Lundberg, LMF				Fathy, DB; Leeb, T; Mathis, SA; Leeb-Lundberg, LMF			Spontaneous human B2 bradykinin receptor activity determines the action of partial agonists as agonists or inverse agonists - Effect of basal desensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; KININ RECEPTORS; CELLS; ANTAGONIST; ACTIVATION; HOE-140; BINDING; STATE; B1	In this report, we show that desensitization regulates ligand-independent, spontaneous activity of the human B2 bradykinin (BK) receptor, and the level of spontaneous receptor activity determines the action of the BK antagonists and partial receptor agonists NPC17731 and HOE140 as agonists or inverse agonists, Spontaneous receptor activity was monitored by measuring basal cellular phosphoinositide (PI) hydrolysis as a function of the density of the receptor in transiently transfected HEK293 cells, Minimal spontaneous activity of the wildtype B2 receptor was detected in these cells. Mutating a cluster of serines and threonines within the fourth intracellular domain of the receptor, which is critical for agonist-promoted desensitization, significantly increased the spontaneous receptor activity. BK, the natural B2 receptor ligand and, consequently, a full agonist, stimulated PI hydrolysis at high and low levels of spontaneous receptor activity. On the other hand, the partial agonists NPC17731 and HOE140 were stimulatory, or agonists, at the lower level of receptor activity but inhibitory, or inverse agonists, at the higher level of activity. These results show that receptors are desensitized in response to their spontaneous activity. Furthermore, these results, which refute traditional theories, show that the capacity of a drug to modulate a receptor response is not intrinsic to the drug but is also dependent on the cellular environment in which the drug acts.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio	Leeb-Lundberg, LMF (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.		Leeb, Tosso/G-3187-2014	Leeb, Tosso/0000-0003-0553-4880	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041659, R29GM041659] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41659] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIENS EJ, 1954, ARCH INT PHARMACOD T, V99, P32; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Blaukat A, 1996, J BIOL CHEM, V271, P32366, DOI 10.1074/jbc.271.50.32366; Chidiac P, 1996, MOL PHARMACOL, V50, P662; COUGHLIN SR, 1994, CURR OPIN CELL BIOL, V6, P191, DOI 10.1016/0955-0674(94)90135-X; Fathy DB, 1998, J BIOL CHEM, V273, P12210, DOI 10.1074/jbc.273.20.12210; FELETOU M, 1994, BRIT J PHARMACOL, V112, P683, DOI 10.1111/j.1476-5381.1994.tb13130.x; Furchgott RF., 1966, ADV DRUG RES, V3, P21; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HOCK FJ, 1991, BRIT J PHARMACOL, V102, P769, DOI 10.1111/j.1476-5381.1991.tb12248.x; Kenakin T, 1996, PHARMACOL REV, V48, P413; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; KYLE DJ, 1991, J MED CHEM, V34, P2649, DOI 10.1021/jm00112a047; LEEBLUNDBERG LMF, 1994, J BIOL CHEM, V269, P25970; LEEBLUNDBERG LMF, 1990, J BIOL CHEM, V265, P9621; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; Marie J, 1999, MOL PHARMACOL, V55, P92, DOI 10.1124/mol.55.1.92; Mathis SA, 1996, MOL PHARMACOL, V50, P128; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5113; PEI G, 1994, P NATL ACAD SCI USA, V91, P2699, DOI 10.1073/pnas.91.7.2699; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Quitterer U, 1996, BIOCHEMISTRY-US, V35, P13368, DOI 10.1021/bi961163w; Scheer A, 1997, J RECEPT SIGNAL TR R, V17, P57, DOI 10.3109/10799899709036594; Soskic V, 1999, J BIOL CHEM, V274, P8539, DOI 10.1074/jbc.274.13.8539; Stadel JM, 1997, TRENDS PHARMACOL SCI, V18, P430, DOI 10.1016/S0165-6147(97)01117-6; STEPHENSON RP, 1956, BRIT J PHARM CHEMOTH, V11, P379, DOI 10.1111/j.1476-5381.1956.tb00006.x; TROPEA MM, 1992, CAN J PHYSIOL PHARM, V70, P1360, DOI 10.1139/y92-191	28	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29603	29606		10.1074/jbc.274.42.29603	http://dx.doi.org/10.1074/jbc.274.42.29603			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514427	hybrid			2022-12-27	WOS:000083176400006
J	Song, L; De Sarno, P; Jope, RS				Song, L; De Sarno, P; Jope, RS			Muscarinic receptor stimulation increases regulators of G-protein signaling 2 mRNA levels through a protein kinase C-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROBLASTOMA SH-SY5Y CELLS; PHOSPHOINOSITIDE HYDROLYSIS; TYROSINE PHOSPHORYLATION; CHOLINERGIC STIMULATION; OXIDATIVE STRESS; RGS PROTEINS; ACTIVATION; AP-1; EXPRESSION; RGS2/G0S8	RGS2, a member of the Regulators of:G-protein Signaling family, modulates the activity of G-proteins coupled to the phosphoinositide signal transduction system, but little is known about what regulates RGS2, In human neuroblastoma SH-SY5Y cells stimulation of muscarinic receptors by carbachol activates phosphoinositide signaling and also caused a rapid, large, and long lasting increase in RGS2 mRNA levels. Direct activation, of protein kinase C also rapidly increased RGS2 mRNA levels, Inhibition of protein kinase C with Ro318220, GF109203x, or Go6976 or down-regulation of protein kinase C inhibited increases in RGS2 mRNA levels induced by carbachol or by the activation of protein kinase C, Blockade of calcium signaling did not alter carbachol-induced increases in RGS2 mRNA levels. Neither activation of epidermal growth factor receptors nor stimulation of cyclic AMP production with forskolin increased RGS2 mRNA levels, Pretreatment with actinomycin D blocked increases in RGS2 mRNA levels but caused a surprisingly small, although statistically significant, partial blockade of protein kinase C-mediated feedback inhibition of carbachol-induced phosphoinositide hydrolysis. Thus, RGS2 mRNA levels are increased by activation of muscarinic receptors coupled to the phosphoinositide signal transduction system through a protein kinase C-dependent mechanism. This action may contribute to negative feedback control of this signaling cascade, but because the small contribution to negative feedback contrasts with the large and prolonged elevations in RGS2 mRNA levels, we speculate that its primary role may be in modulating other signaling components.	Univ Alabama, Dept Psychiat & Behav Neurobiol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Jope, RS (corresponding author), Univ Alabama, Sparks Ctr 1057, Dept Psychiat, Birmingham, AL 35294 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH038752, R56MH038752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG006569] Funding Source: NIH RePORTER; NIA NIH HHS [AG06569] Funding Source: Medline; NIMH NIH HHS [MH38752] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Alessi DR, 1997, FEBS LETT, V402, P121, DOI 10.1016/S0014-5793(96)01510-4; Beadling C, 1999, J IMMUNOL, V162, P2677; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Burchett SA, 1999, J NEUROCHEM, V72, P1529, DOI 10.1046/j.1471-4159.1999.721529.x; Burchett SA, 1998, J NEUROCHEM, V70, P2216; De Vries L, 1999, TRENDS CELL BIOL, V9, P138, DOI 10.1016/S0962-8924(99)01515-9; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Heximer SP, 1997, DNA CELL BIOL, V16, P589, DOI 10.1089/dna.1997.16.589; Heximer SP, 1997, P NATL ACAD SCI USA, V94, P14389, DOI 10.1073/pnas.94.26.14389; Ingi T, 1998, J NEUROSCI, V18, P7178; Jope RS, 1999, J NEUROSCI RES, V55, P329, DOI 10.1002/(SICI)1097-4547(19990201)55:3<329::AID-JNR8>3.0.CO;2-K; Jope RS, 1997, MOL BRAIN RES, V50, P171, DOI 10.1016/S0169-328X(97)00183-6; Khawaja XZ, 1999, J NEUROCHEM, V72, P174, DOI 10.1046/j.1471-4159.1999.0720174.x; LARSSON C, 1994, EUR J PHARM-MOLEC PH, V268, P19; Li XH, 1998, BIOCHEM J, V331, P599, DOI 10.1042/bj3310599; Li XH, 1996, J NEUROSCI, V16, P5914; Li XH, 1998, MOL BRAIN RES, V53, P196, DOI 10.1016/S0169-328X(97)00290-8; Pacheco MA, 1996, PROG NEUROBIOL, V50, P255, DOI 10.1016/S0301-0082(96)00035-4; Pepperl DJ, 1998, BIOCHEM BIOPH RES CO, V243, P52, DOI 10.1006/bbrc.1997.8056; SIDEROVSKI DP, 1990, DNA CELL BIOL, V9, P579, DOI 10.1089/dna.1990.9.579; Standaert ML, 1999, ENDOCRINOLOGY, V140, P2145, DOI 10.1210/en.140.5.2145; TREJO J, 1991, J BIOL CHEM, V266, P7876; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Yan YB, 1997, J BIOL CHEM, V272, P11924, DOI 10.1074/jbc.272.18.11924; Yeo EJ, 1997, BBA-MOL CELL RES, V1356, P308, DOI 10.1016/S0167-4889(97)00006-2	26	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29689	29693		10.1074/jbc.274.42.29689	http://dx.doi.org/10.1074/jbc.274.42.29689			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514440	hybrid			2022-12-27	WOS:000083176400019
J	Viswanathan, M; Lovett, ST				Viswanathan, M; Lovett, ST			Exonuclease X of Escherichia coli - A novel 3 '-5 ' DNase and DnaQ superfamily member involved in DNA repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WERNER-SYNDROME PROTEIN; DIRECTED MISMATCH REPAIR; SINGLE-STRANDED-DNA; POLYMERASE-I; 3'->5' EXONUCLEASE; KLENOW FRAGMENT; SYNDROME GENE; RECF PATHWAY; TRANSFER-RNA; RECOMBINATION	DNA exonucleases are critical for DNA replication, repair, and recombination. In the bacterium Escherichia coli there are 14 DNA exonucleases including exonucleases I-IX (including the two DNA polymerase I exonucleases), RecJ exonuclease, SbcCD exonuclease, RNase T, and the exonuclease domains of DNA polymerase II and III. Here we report the discovery and characterization of a new E. coli exonuclease, exonuclease X Exonuclease X is a member of a superfamily of proteins that have homology to the 3'-5' exonuclease proofreading subunit (DnaQ) of E. coli DNA polymerase III. We have engineered and purified a (His)(6)-exonuclease X fusion protein and characterized its activity. Exonuclease X is a potent distributive exonuclease, capable of degrading both single-stranded and duplex DNA with 3'-5' polarity. Its high affinity for single-strand DNA and its rapid catalytic rate are similar to the processive exonucleases RecJ and exonuclease I. Deletion of the exoX gene exacerbated the UV sensitivity of a strain lacking RecJ, exonuclease I, and exonuclease VII. When overexpressed, exonuclease X is capable of substituting for exonuclease I in UV repair. As we have proposed for the other single-strand DNA exonucleases, exonuclease X may facilitate recombinational repair by pre-synaptic and/or post-synaptic DNA degradation.	Brandeis Univ, Dept Biol, Waltham, MA 02254 USA; Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02254 USA	Brandeis University; Brandeis University	Lovett, ST (corresponding author), Brandeis Univ, Dept Biol, Waltham, MA 02254 USA.		Lovett, Susan/AAC-1810-2021	Lovett, Susan/0000-0003-2792-1857	NIGMS NIH HHS [R01 GM43889, GM07122] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007122, R01GM043889] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1989, SHORT PROTOCOLS MOL; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; COOPER DL, 1993, J BIOL CHEM, V268, P11823; CORRETTEBENNETT SE, 1995, J BIOL CHEM, V270, P6881, DOI 10.1074/jbc.270.12.6881; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; DEUTSCHER MP, 1985, P NATL ACAD SCI USA, V82, P6427, DOI 10.1073/pnas.82.19.6427; DEUTSCHER MP, 1985, J BIOL CHEM, V260, P7067; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; GRILLEY M, 1993, J BIOL CHEM, V268, P11830; Haggerty TJ, 1997, J BACTERIOL, V179, P6705, DOI 10.1128/jb.179.21.6705-6713.1997; Harris RS, 1998, J BACTERIOL, V180, P989, DOI 10.1128/JB.180.4.989-993.1998; HORII ZI, 1973, J MOL BIOL, V80, P327, DOI 10.1016/0022-2836(73)90176-9; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; KOLODNER R, 1994, MOL MICROBIOL, V11, P23, DOI 10.1111/j.1365-2958.1994.tb00286.x; KOONIN EV, 1997, CURR BIOL, V7, P604; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; KRISTENSEN CS, 1995, J BACTERIOL, V177, P52, DOI 10.1128/jb.177.1.52-58.1995; LEHMAN IR, 1964, J BIOL CHEM, V239, P2628; LI ZW, 1995, P NATL ACAD SCI USA, V92, P6883, DOI 10.1073/pnas.92.15.6883; LOVETT ST, 1989, P NATL ACAD SCI USA, V86, P2627, DOI 10.1073/pnas.86.8.2627; Mian IS, 1997, NUCLEIC ACIDS RES, V25, P3187, DOI 10.1093/nar/25.16.3187; Miesel L, 1996, J BACTERIOL, V178, P3146, DOI 10.1128/jb.178.11.3146-3155.1996; MILLER JH, 1992, SHORT COURSE BACTERI, P268; Morozov V, 1997, TRENDS BIOCHEM SCI, V22, P417, DOI 10.1016/S0968-0004(97)01128-6; Moser MJ, 1997, NUCLEIC ACIDS RES, V25, P5110, DOI 10.1093/nar/25.24.5110; Mushegian AR, 1997, P NATL ACAD SCI USA, V94, P5831, DOI 10.1073/pnas.94.11.5831; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; THOMAS KR, 1978, J BIOL CHEM, V253, P424; Viswanathan M, 1999, GENETICS, V151, P929; Viswanathan M, 1998, GENETICS, V149, P7; Wang J, 1996, BIOCHEMISTRY-US, V35, P8110, DOI 10.1021/bi960178r; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; Zhang XL, 1998, J BACTERIOL, V180, P2779, DOI 10.1128/JB.180.10.2779-2781.1998	42	57	59	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30094	30100		10.1074/jbc.274.42.30094	http://dx.doi.org/10.1074/jbc.274.42.30094			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514496	hybrid			2022-12-27	WOS:000083176400075
J	Akashi, T; Matsumura, T; Ideguchi, T; Iwakiri, K; Kawakatsu, T; Taniguchi, I; Hase, T				Akashi, T; Matsumura, T; Ideguchi, T; Iwakiri, K; Kawakatsu, T; Taniguchi, I; Hase, T			Comparison of the electrostatic binding sites on the surface of ferredoxin for two ferredoxin-dependent enzymes, ferredoxin-NADP(+) reductase and sulfite reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LASER FLASH-PHOTOLYSIS; AMINO-ACID-RESIDUES; NADP+ REDUCTASE; 2FE-2S FERREDOXIN; ANGSTROM RESOLUTION; GLUTAMATE SYNTHASE; ANABAENA PCC-7119; MAIZE FERREDOXIN; DIFFERENTIAL EXPRESSION; NITRITE OXIDOREDUCTASE	Plant-type ferredoxin (Fd), a [2Fe-2S] iron-sulfur protein, functions as an one-electron donor to Fd-NADP(+) reductase (FNR) or sulfite reductase (SiR), interacting electrostatically with them. In order to understand the protein-protein interaction between Fd and these two different enzymes, 10 acidic surface residues in maize Fd (isoform III), Asp-27, Glu-30, Asp-58, Asp-61, Asp-66/ Asp-67, Glu-71/Glu-72, Asp-85, and Glu-93, were substituted with the corresponding amide residues by site-directed mutagenesis. The redox potentials of the mutated Fds were not markedly changed, except for E93Q, the redox potential of which was more positive by 67 mV than that of the wild type. Kinetic experiments showed that the mutations at Asp-66/Asp-67 and Glu-93 significantly affected electron transfer to the two enzymes. Interestingly, D66N/D67N was less efficient in the reaction with FNR than E93Q, whereas this relationship was reversed in the reaction with SiR. The static interaction of the mutant Fds with each the two enzymes was analyzed by gel filtration of a mixture of Fd and each enzyme, and by affinity chromatography on Fd-immobilized resins. The contributions of Asp-66/ Asp-67 and Glu-93 were found to be most important for the binding to FNR and SiR, respectively, in accordance with the kinetic data. These results allowed us to map the acidic regions of Fd required for electron transfer and for binding to FNR and SiR and demonstrate that the interaction sites for the two enzymes are at least partly distinct.	Osaka Univ, Inst Prot Res, Div Enzymol, Osaka 5650871, Japan; Kumamoto Univ, Fac Engn, Dept Appl Chem & Biochem, Kumamoto 8600862, Japan	Osaka University; Kumamoto University	Akashi, T (corresponding author), Osaka Univ, Inst Prot Res, Div Enzymol, Osaka 5650871, Japan.		Hase, Toshiharu/H-9271-2013					Aliverti A, 1997, BBA-PROTEIN STRUCT M, V1342, P45, DOI 10.1016/S0167-4838(97)00079-4; Binda C, 1998, ACTA CRYSTALLOGR D, V54, P1353, DOI 10.1107/S0907444998005137; CAMMACK R, 1977, BIOCHEM J, V168, P205, DOI 10.1042/bj1680205; DEPASCALIS AR, 1994, FEBS LETT, V337, P217, DOI 10.1016/0014-5793(94)80194-0; DEPASCALIS AR, 1993, PROTEIN SCI, V2, P1126, DOI 10.1002/pro.5560020707; Dose MM, 1997, PLANT PHYSIOL, V114, P1047, DOI 10.1104/pp.114.3.1047; FUKUYAMA K, 1995, J BIOCHEM-TOKYO, V117, P1017, DOI 10.1093/oxfordjournals.jbchem.a124800; GOOD L, 1992, NUCLEIC ACIDS RES, V20, P4934, DOI 10.1093/nar/20.18.4934; HASE T, 1991, PLANT PHYSIOL, V97, P1395, DOI 10.1104/pp.97.4.1395; HASE T, 1991, PLANT PHYSIOL, V96, P77, DOI 10.1104/pp.96.1.77; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HIRASAWA M, 1993, BIOCHIM BIOPHYS ACTA, V1140, P304, DOI 10.1016/0005-2728(93)90070-V; HIRASAWA M, 1993, BIOCHIM BIOPHYS ACTA, V1144, P85, DOI 10.1016/0005-2728(93)90034-D; HIRASAWA M, 1991, ARCH BIOCHEM BIOPHYS, V286, P171, DOI 10.1016/0003-9861(91)90024-D; HOLDEN HM, 1994, J BIOENERG BIOMEMBR, V26, P67, DOI 10.1007/BF00763220; Hurley JK, 1997, BIOCHEMISTRY-US, V36, P11100, DOI 10.1021/bi9709001; HURLEY JK, 1993, BIOCHEMISTRY-US, V32, P9346, DOI 10.1021/bi00087a013; IKEMIZU S, 1994, ACTA CRYSTALLOGR D, V50, P167, DOI 10.1107/S0907444993009588; JACOBSON BL, 1993, BIOCHEMISTRY-US, V32, P6788, DOI 10.1021/bi00077a033; Jacquot JP, 1997, FEBS LETT, V400, P293, DOI 10.1016/S0014-5793(96)01407-X; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KIMATA Y, 1989, PLANT PHYSIOL, V89, P1193, DOI 10.1104/pp.89.4.1193; KNAFF DB, 1991, BIOCHIM BIOPHYS ACTA, V1056, P93, DOI 10.1016/S0005-2728(05)80277-4; MATSUBARA H, 1992, ADV INORG CHEM, V38, P223, DOI 10.1016/S0898-8838(08)60065-3; Matsumura T, 1997, PLANT PHYSIOL, V114, P653, DOI 10.1104/pp.114.2.653; Matsumura T, 1999, PLANT PHYSIOL, V119, P481, DOI 10.1104/pp.119.2.481; MEDINA M, 1992, EUR J BIOCHEM, V210, P577, DOI 10.1111/j.1432-1033.1992.tb17457.x; MEDINA M, 1992, EUR J BIOCHEM, V203, P373, DOI 10.1111/j.1432-1033.1992.tb16560.x; Piubelli L, 1996, EUR J BIOCHEM, V236, P465, DOI 10.1111/j.1432-1033.1996.00465.x; PUEYO JJ, 1991, PREP BIOCHEM, V21, P191, DOI 10.1080/10826069108018571; RYPNIEWSKI WR, 1991, BIOCHEMISTRY-US, V30, P4126, DOI 10.1021/bi00231a003; Schmitz S, 1996, BBA-BIOENERGETICS, V1277, P135, DOI 10.1016/S0005-2728(96)00095-3; SIEGEL LM, 1974, J BIOL CHEM, V249, P1587; TAGAWA K, 1968, BIOCHIM BIOPHYS ACTA, V153, P602, DOI 10.1016/0005-2728(68)90188-6; Taniguchi I, 1997, CHEM LETT, P929, DOI 10.1246/cl.1997.929; TSUKIHARA T, 1990, J MOL BIOL, V216, P399, DOI 10.1016/S0022-2836(05)80330-4; WALKER MC, 1991, ARCH BIOCHEM BIOPHYS, V287, P351, DOI 10.1016/0003-9861(91)90489-6; Yonekura-Sakakibara K, 1998, J BIOCHEM, V124, P615, DOI 10.1093/oxfordjournals.jbchem.a022156; ZANETTI G, 1988, BIOCHEMISTRY-US, V27, P3753, DOI 10.1021/bi00410a035	39	71	73	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29399	29405		10.1074/jbc.274.41.29399	http://dx.doi.org/10.1074/jbc.274.41.29399			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506201	hybrid			2022-12-27	WOS:000083017800080
J	Blair, A; Shaul, PW; Yuhanna, IS; Conrad, PA; Smart, EJ				Blair, A; Shaul, PW; Yuhanna, IS; Conrad, PA; Smart, EJ			Oxidized low density lipoprotein displaces endothelial nitric-oxide synthase (eNOS) from plasmalemmal caveolae and impairs eNOS activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; CELL-SURFACE; ARTERY ENDOTHELIUM; MA104 CELLS; CHOLESTEROL; MEMBRANE; RECEPTOR; LOCALIZATION; TRANSPORT; ACYLATION	Hypercholesterolemia-induced vascular disease and atherosclerosis are characterized by a decrease in the bioavailability of endothelium-derived nitric oxide. Endothelial nitric-oxide synthase (eNOS) associates with caveolae and is directly regulated by the caveola protein, caveolin. In the present study, we examined the effects of oxidized low density Lipoprotein (oxLDL) on the subcellular location of eNOS, on eNOS activation, and on caveola cholesterol in endothelial cells. We found that treatment with 10 mu g/ml oxLDL for 60 min caused greater than 90% of eNOS and caveolin to leave caveolae, Treatment with oxLDL also inhibited acetylcholine-indnced activation of eNOS but not prostacyclin production. oxLDL did nob affect total cellular eNOS abundance. Oxidized LDL also did not affect the palmitoylation, myristoylation or phosphorylation of eNOS. Oxidized LDL, but not native LDL, or HDL depleted caveolae of cholesterol by serving as an acceptor for cholesterol. Cyclodextrin also depleted caveolae of cholesterol and caused eNOS and caveolin to translocate from caveolae. Furthermore, removal of oxLDL allowed eNOS and caveolin to return to caveolae. We conclude that oxLDL-induced depletion of caveola cholesterol causes eNOS to leave caveolae and inhibits acetylcholine-induced activation of the enzyme. This process may be an important mechanism in the early pathogenesis of atherosclerosis.	Univ Kentucky, Dept Physiol, Sch Med, Lexington, KY 40536 USA; Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75235 USA; Bucknell Univ, Dept Biol, Lewisburg, PA 17837 USA	University of Kentucky; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Bucknell University	Smart, EJ (corresponding author), Univ Kentucky, Dept Physiol, Sch Med, 800 Rose St,MS 508 C, Lexington, KY 40536 USA.	ejsmart@pop.uky.edu			NHLBI NIH HHS [HL62844, HL58888, HL58475] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062844, R29HL058475, R01HL058888, R01HL058475] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Buege J A, 1978, Methods Enzymol, V52, P302; CAYATTE AJ, 1994, ARTERIOSCLER THROMB, V14, P753, DOI 10.1161/01.ATV.14.5.753; CHANG WJ, 1992, J CELL BIOL, V118, P63, DOI 10.1083/jcb.118.1.63; COHEN RA, 1995, PROG CARDIOVASC DIS, V38, P105, DOI 10.1016/S0033-0620(05)80002-7; DAVDA RK, 1993, HYPERTENSION, V21, P939, DOI 10.1161/01.HYP.21.6.939; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; Feron O, 1998, BIOCHEMISTRY-US, V37, P193, DOI 10.1021/bi972307p; FISHER WR, 1986, METHOD ENZYMOL, V128, P247; FLAVAHAN NA, 1992, CIRCULATION, V85, P1927, DOI 10.1161/01.CIR.85.5.1927; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Graf GA, 1999, J BIOL CHEM, V274, P12043, DOI 10.1074/jbc.274.17.12043; GRAHAM J, 1993, METHODS MOL BIOL, V19; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; GWYNNE JT, 1989, J BIOL CHEM, V264, P8141; HARRISON DG, 1994, BASIC RES CARDIOL, V89, P87; Jun SS, 1998, J CLIN INVEST, V102, P176, DOI 10.1172/JCI2034; KELLEY JL, 1986, METHOD ENZYMOL, V128, P170; KRIEGER M, 1979, J BIOL CHEM, V254, P3845; LantinHermoso RL, 1997, AM J PHYSIOL-LUNG C, V273, pL119, DOI 10.1152/ajplung.1997.273.1.L119; LEFER AM, 1993, ARTERIOSCLER THROMB, V13, P771, DOI 10.1161/01.ATV.13.6.771; LIAO JK, 1995, J BIOL CHEM, V270, P319, DOI 10.1074/jbc.270.1.319; Liu JW, 1997, J CELL BIOL, V137, P1525, DOI 10.1083/jcb.137.7.1525; Liu JW, 1996, BIOCHEMISTRY-US, V35, P13277, DOI 10.1021/bi961720e; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Michel JB, 1997, J BIOL CHEM, V272, P25907, DOI 10.1074/jbc.272.41.25907; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; PLANE F, 1993, ATHEROSCLEROSIS, V103, P73, DOI 10.1016/0021-9150(93)90041-R; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; Sakoda T, 1995, MOL CELL BIOCHEM, V152, P143, DOI 10.1007/BF01076076; SESSA WC, 1995, J BIOL CHEM, V270, P17641, DOI 10.1074/jbc.270.30.17641; SHAUL PW, 1994, J CLIN INVEST, V94, P2231, DOI 10.1172/JCI117585; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Smart EJ, 1996, J CELL BIOL, V134, P1169, DOI 10.1083/jcb.134.5.1169; SMART EJ, 1995, J CELL BIOL, V131, P929, DOI 10.1083/jcb.131.4.929; SMART EJ, 1994, J CELL BIOL, V124, P307, DOI 10.1083/jcb.124.3.307; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525; VANE JR, 1990, NEW ENGL J MED, V323, P27; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563	51	283	296	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32512	32519		10.1074/jbc.274.45.32512	http://dx.doi.org/10.1074/jbc.274.45.32512			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542298	hybrid			2022-12-27	WOS:000083532100106
J	Chan, SL; Tan, KO; Zhang, L; Yee, KSY; Ronca, F; Chan, MY; Yu, VC				Chan, SL; Tan, KO; Zhang, L; Yee, KSY; Ronca, F; Chan, MY; Yu, VC			F1A alpha, a death receptor-binding protein homologous to the Caenorhabditis elegans sex-determining protein, FEM-1, is a caspase substrate that mediates apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; SIGNALING COMPLEX DISC; NECROSIS-FACTOR; DETERMINING GENE; TNF RECEPTOR; NEMATODE SEX; C-ELEGANS; INTERACTING PROTEIN; ADAPTER MOLECULE; 2-HYBRID SYSTEM	Apoptosis is an evolutionarily conserved process that is critical for tissue homeostasis and development including sex determination in essentially all multicellular organisms. Here, we report the cloning of an ankyrin repeat-containing protein, termed F1A alpha, in a yeast two-hybrid screen using the cytoplasmic domain of Fas (CD95/APO-1) as bait. Amino acid sequence analysis indicates that F1A alpha has extensive homology to the sex-determining protein FEM-1 of the Caenorhabditis elegans, which is required for the development of all aspects of the male phenotype. F1A alpha associates with the cytoplasmic domains of Fas and tumor necrosis factor receptor 1, two prototype members of the "death receptor" family. The F1A alpha protein also oligomerizes. Overexpression of F1A alpha induces apoptosis in mammalian cells, and co-expression of Bcl-XL or the dominant negative mutants of either FADD or caspase-9 blocks this effect. Deletion analysis revealed the center region of F1A alpha, including a cluster of five ankyrin repeats to be necessary and sufficient for maximum apoptotic activity, and the N-terminal region appears to regulate negatively this activity. Furthermore, F1A alpha is cleaved by a caspase-3-like protease at Asp(342), and the cleavage-resistant mutant is unable to induce apoptosis upon overexpression. F1Aa is therefore a member of a growing family of death receptor-associated proteins that mediates apoptosis.	Inst Mol & Cell Biol, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Yu, VC (corresponding author), Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.		Yu, Victor/A-7899-2015; Chan, S.L./X-4154-2018	Yu, Victor/0000-0003-3270-4734; Chan, S.L./0000-0002-3270-0525; Tan, Kuan/0000-0002-0947-7337; Zhang, Li/0000-0001-7506-8278				Ahmad M, 1997, CANCER RES, V57, P615; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bai C, 1997, METHOD ENZYMOL, V283, P141; BENNETT V, 1992, J BIOL CHEM, V267, P8703; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Carmi I, 1998, NATURE, V396, P168, DOI 10.1038/24164; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CHU KT, 1995, P NATL ACAD SCI USA, V92, P11894, DOI 10.1073/pnas.92.25.11894; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; deBono M, 1996, GENETICS, V144, P587; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Gaudet J, 1996, MOL BIOL CELL, V7, P1107, DOI 10.1091/mbc.7.7.1107; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; HODGKIN J, 1990, NATURE, V344, P721, DOI 10.1038/344721a0; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kuwabara PE, 1996, GENETICS, V144, P597; KUWABARA PE, 1992, TRENDS GENET, V8, P164, DOI 10.1016/0168-9525(92)90218-S; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liou ML, 1999, J BIOL CHEM, V274, P10145, DOI 10.1074/jbc.274.15.10145; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Mehlen P, 1998, NATURE, V395, P801, DOI 10.1038/27441; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Raymond CS, 1998, NATURE, V391, P691, DOI 10.1038/35618; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Ronca F, 1997, J BIOL CHEM, V272, P4252, DOI 10.1074/jbc.272.7.4252; Ronca F, 1999, J BIOL CHEM, V274, P18128, DOI 10.1074/jbc.274.25.18128; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; SONG HY, 1994, J BIOL CHEM, V269, P22492; SPENCE AM, 1990, CELL, V60, P981, DOI 10.1016/0092-8674(90)90346-G; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; Tan KO, 1999, J BIOL CHEM, V274, P23687, DOI 10.1074/jbc.274.34.23687; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Ventura-Holman T, 1998, GENOMICS, V54, P221, DOI 10.1006/geno.1998.5569; Wallach D, 1997, FEBS LETT, V410, P96, DOI 10.1016/S0014-5793(97)00553-X; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355; Yee KSY, 1998, J BIOL CHEM, V273, P5366, DOI 10.1074/jbc.273.9.5366; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E	62	35	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32461	32468		10.1074/jbc.274.45.32461	http://dx.doi.org/10.1074/jbc.274.45.32461			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542291	hybrid			2022-12-27	WOS:000083532100099
J	Engelman, JA; Zhang, XL; Razani, B; Pestell, RG; Lisanti, MP				Engelman, JA; Zhang, XL; Razani, B; Pestell, RG; Lisanti, MP			p42/44 MAP kinase-dependent and -independent signaling pathways regulate caveolin-1 gene expression - Activation of Ras-MAP kinase and protein kinase A signaling cascades transcriptionally down-regulates caveolin-1 promoter activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONCOGENICALLY TRANSFORMED-CELLS; HUMAN BREAST-CANCER; IN-VIVO; SCAFFOLDING DOMAIN; MEMBRANE DOMAINS; TYROSINE KINASE; PLASMA-MEMBRANE; SEQUENCE; FAMILY; IDENTIFICATION	Caveolin-1 is a principal component of caveolae membranes in vivo. Caveolin-1 mRNA and protein expression are down-regulated in NIH 3T3 cells in response to transformation by activated oncogenes, such as H-Ras(G12V) and v-Abl, The mechanisms governing this down-regulation event remain unknown. Here, we show that caveolin-1 gene expression is directly regulated by activation of the Ras-p42/44 MAP kinase cascade, Down regulation of caveolin-1 protein expression by Ras is independent of (i) the type of activating mutation (G12V versus Q61L) and (ii) the form of activated Ras transfected (H-Ras versus H-Ras versus N-Ras), Treatment of Ras or Raf-transformed MH 3T3 cells with a well characterized MEK inhibitor (PD 98059) restores caveolin-1 protein expression. In contrast, treatment of v-Src and v-Abl transformed NIH 3T3 cells with PD 98059 does not restore caveolin-1 expression. Thus, there must be at least two pathways for down-regulating caveolin-1 expression: one that is p42/44 MAP kinase-dependent and another that is p42/44 MAP kinase-independent. We focused our efforts on the p42/44 MAP kinase-dependent pathway. The activity of a panel of caveolin-1 promoter constructs was evaluated using transient expression in H-Ras(G12V) transformed MR 3T3 cells. We show that caveolin-1 promoter activity is up-regulated similar to 5-fold by inhibition of the p42/44 MAP kinase cascade. Using electrophoretic mobility shift assays we provide evidence that the caveolin-1 promoter (from -156 to -561) is differentially bound by transcription factors in normal and H-Ras(G12V)-transformed cells. We also show that activation of protein kinase A (PKA) signaling is sufficient to down-regulate caveolin-1 protein expression and promoter activity. Thus, we have identified two signaling pathways (Ras-p42/44MAP kinase and PKA) that transcriptionally down-regulate caveolin-1 gene expression.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Lisanti, MP (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Lisanti, Michael/B-6131-2018; Lisanti, Michael P/C-6866-2013	Lisanti, Michael/0000-0003-2034-1382; Razani, Babak/0000-0002-7172-9240	NATIONAL CANCER INSTITUTE [R01CA070897, R01CA080250] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA-80250, R29-CA70897] Funding Source: Medline; NIGMS NIH HHS [T32-GM07288] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Couet J, 1997, TRENDS CARDIOVAS MED, V7, P103, DOI 10.1016/S1050-1738(97)00001-7; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; Engelman JA, 1998, FEBS LETT, V429, P330, DOI 10.1016/S0014-5793(98)00619-X; Engelman JA, 1998, FEBS LETT, V436, P403, DOI 10.1016/S0014-5793(98)01134-X; Engelman JA, 1998, AM J HUM GENET, V63, P1578, DOI 10.1086/302172; Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GUERRERO I, 1985, P NATL ACAD SCI USA, V82, P7810, DOI 10.1073/pnas.82.23.7810; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; PESTELL RG, 1994, J BIOL CHEM, V269, P31090; POLLARD JW, 1979, J CELL PHYSIOL, V98, P571, DOI 10.1002/jcp.1040980315; Razani B, 1999, J BIOL CHEM, V274, P26353, DOI 10.1074/jbc.274.37.26353; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SAGER R, 1994, COLD SPRING HARB SYM, V59, P537, DOI 10.1101/SQB.1994.059.01.060; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SINGH M, 1993, MOL CELL BIOL, V13, P3611, DOI 10.1128/MCB.13.6.3611; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Toya Y, 1998, ENDOCRINOLOGY, V139, P2025, DOI 10.1210/en.139.4.2025; WOOD WM, 1989, J BIOL CHEM, V264, P14840	36	149	154	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32333	32341		10.1074/jbc.274.45.32333	http://dx.doi.org/10.1074/jbc.274.45.32333			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542274	hybrid			2022-12-27	WOS:000083532100082
J	Schmidt, G; Goehring, UM; Schirmer, J; Lerm, M; Aktories, K				Schmidt, G; Goehring, UM; Schirmer, J; Lerm, M; Aktories, K			Identification of the C-terminal part of Bordetella dermonecrotic toxin as a transglutaminase for rho GTPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN STRESS FIBERS; CYTOTOXIC NECROTIZING FACTOR-1; BINDING PROTEIN-RHO; ESCHERICHIA-COLI; GENE-PRODUCT; FACTOR-XIIIA; DEAMIDATION; GLN-63; CELLS; SITE	Bordetella dermonecrotic toxin (DNT) causes the deamidation of glutamine 63 of Rho. Here we identified the region of DNT harboring the enzyme activity and compared the toxin with the cytotoxic necrotizing factor 1, which also deamidates Rho. The DNT fragment (Delta DNT) covering amino acid residues 1136-1451 caused deamidation of RhoA at glutamine 63 as determined by mass spectrometric analysis and by the release of ammonia. In the presence of dansylcadaverine or ethylenediamine, Delta DNT caused transglutamination of Rho. Deamidase and transglutaminase activities were blocked in the mutant proteins Cys(1292) --> Ala, His(1307) --> Ala, and Lys(1310) --> Ala of Delta DNT. Deamidation and transglutamination induced by Delta DNT blocked intrinsic and Rho-GTPase-activating protein-stimulated GTPase activity of RhoA. Delta DNT deamidated and transglutaminated Rac and Cdc42 in the absence and presence of ethylenediamine, respectively. Modification of Rho proteins by Delta DNT was nucleotide-dependent and did not occur with GTP gamma S-loaded GTPases, In contrast to cytotoxic necrotizing factor, which caused the same kinetics of ammonia release in the absence and presence of ethylenediamine, ammonia release by Delta DNT was largely increased in the presence of ethylenediamine, indicating that Delta DNT acts primarily as a transglutaminase.	Univ Freiburg, Inst Pharmakol & Toxikol, D-79104 Freiburg, Germany	University of Freiburg	Aktories, K (corresponding author), Univ Freiburg, Inst Pharmakol & Toxikol, Hermann Herder Str 5, D-79104 Freiburg, Germany.		Aktories, Klaus/CAJ-5682-2022; Lerm, Maria/AAA-1780-2020; Lerm, Maria/AAM-8705-2020	Aktories, Klaus/0000-0002-5397-0436; Lerm, Maria/0000-0002-5092-9892; 				AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; Aktories K, 1997, TRENDS MICROBIOL, V5, P282, DOI 10.1016/S0966-842X(97)01067-6; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HETTASCH JM, 1994, J BIOL CHEM, V269, P28309; Horiguchi Y, 1997, P NATL ACAD SCI USA, V94, P11623, DOI 10.1073/pnas.94.21.11623; HORIGUCHI Y, 1995, J CELL SCI, V108, P3243; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; KANAJI T, 1993, J BIOL CHEM, V268, P11565; Lacerda HM, 1997, J BIOL CHEM, V272, P9587; OSWALD E, 1994, P NATL ACAD SCI USA, V91, P3814, DOI 10.1073/pnas.91.9.3814; Pullinger GD, 1996, INFECT IMMUN, V64, P4163, DOI 10.1128/IAI.64.10.4163-4171.1996; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Schmidt G, 1998, J BIOL CHEM, V273, P13669, DOI 10.1074/jbc.273.22.13669; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; Schmidt G, 1998, NATURWISSENSCHAFTEN, V85, P253, DOI 10.1007/s001140050495; SEKINE A, 1989, J BIOL CHEM, V264, P8602; TAKAGI J, 1995, EUR J BIOCHEM, V232, P773, DOI 10.1111/j.1432-1033.1995.773zz.x; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; WALKER KE, 1994, INFECT IMMUN, V62, P3817, DOI 10.1128/IAI.62.9.3817-3828.1994; WilkBlaszczak MA, 1997, J NEUROSCI, V17, P4094	23	52	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31875	31881		10.1074/jbc.274.45.31875	http://dx.doi.org/10.1074/jbc.274.45.31875			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542213	hybrid			2022-12-27	WOS:000083532100021
J	Tichy, M; Vermaas, W				Tichy, M; Vermaas, W			Accumulation of pre-apocytochrome f in a Synechocystis sp PCC 6803 mutant impaired in cytochrome c maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; HEME ATTACHMENT; CHLAMYDOMONAS-REINHARDTII; SACCHAROMYCES-CEREVISIAE; BIOGENESIS; GENE; MITOCHONDRIA; PROTEINS; PATHWAY; IMPORT	Cytochrome c maturation involves heme transport and covalent attachment of heme to the apoprotein, The 5' end of the ccsB gene, which is involved in the maturation process and resembles the ccs1 gene from Chlamydomonas reinhardtii, was replaced by a chloramphenicol resistance cartridge in the cyanobacterium Synechocystis sp. PCC 6803, The resulting Delta(M1-A24) mutant lacking the first 24 ccsB codons grew only under anaerobic conditions. The mutant retained about 20% of the wild-type amount of processed cytochrome f with heme attached, apparently assembled in a functional cytochrome b(6)f complex, Moreover, the mutant accumulated unprocessed apocytochrome f in its membrane fraction. A pseudorevertant was isolated that regained the ability to grow under aerobic conditions. The locus of the second-site mutation was mapped to ccsB, and the mutation resulted in the formation of a new potential start codon in the intergenic region, between the chloramphenicol resistance marker and ccsB, in frame with the remaining part of ccsB. In this pseudorevertant the amount of holocyt f increased, whereas that of unprocessed apocytochrome f decreased. me suggest that the original deletion mutant Delta(M1-A24) expresses an N-terminally truncated version of the protein. The stable accumulation of unprocessed apocytochrome f in membranes of the Delta(M1-A24) mutant may be explained by its association with truncated and only partially functional CcsB protein resulting in protection from degradation. Our attempt to delete the first 244 codons of ccsB in Synechocystis sp, PCC 6803 was not successful, suggesting that this would lead to a lack of functional cytochrome b(6)f complex, The results suggest that the CcsB protein is an apocytochrome chaperone, which together with CcsA may constitute part of cytochrome c lyase.	Arizona State Univ, Dept Plant Biol, Tempe, AZ 85287 USA; Arizona State Univ, Ctr Study Early Events Photosynthesis, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe	Vermaas, W (corresponding author), Arizona State Univ, Dept Plant Biol, Box 871601, Tempe, AZ 85287 USA.		Tichy, Martin/B-6545-2008	Tichy, Martin/0000-0003-2814-1959				DIAZ A, 1994, FEBS LETT, V347, P173, DOI 10.1016/0014-5793(94)00529-X; DUMONT ME, 1987, EMBO J, V6, P235, DOI 10.1002/j.1460-2075.1987.tb04744.x; Gabbert KK, 1997, J BACTERIOL, V179, P5422, DOI 10.1128/jb.179.17.5422-5428.1997; Goldman BS, 1998, P NATL ACAD SCI USA, V95, P5003, DOI 10.1073/pnas.95.9.5003; Goldman BS, 1998, MOL MICROBIOL, V27, P871, DOI 10.1046/j.1365-2958.1998.00708.x; HOWE G, 1995, MOL GEN GENET, V246, P156, DOI 10.1007/BF00294678; Hubschmann T, 1997, FEBS LETT, V408, P201, DOI 10.1016/S0014-5793(97)00421-3; Inoue K, 1997, J BIOL CHEM, V272, P31747, DOI 10.1074/jbc.272.50.31747; Kranz R, 1998, MOL MICROBIOL, V29, P383, DOI 10.1046/j.1365-2958.1998.00869.x; Manna P, 1997, PLANT MOL BIOL, V35, P407, DOI 10.1023/A:1005875124387; MAYER A, 1995, J BIOL CHEM, V270, P12390, DOI 10.1074/jbc.270.21.12390; NICHOLSON DW, 1989, P NATL ACAD SCI USA, V86, P4340, DOI 10.1073/pnas.86.12.4340; NICHOLSON DW, 1989, J BIOL CHEM, V264, P10156; OHASHI A, 1982, J BIOL CHEM, V257, P3042; Page MD, 1997, MICROBIOL-SGM, V143, P3111, DOI 10.1099/00221287-143-10-3111; Page MD, 1998, TRENDS BIOCHEM SCI, V23, P103, DOI 10.1016/S0968-0004(98)01173-6; Pearce DA, 1998, MICROBIOL-SGM, V144, P467, DOI 10.1099/00221287-144-2-467; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; SAMBONGI Y, 1994, FEBS LETT, V340, P65, DOI 10.1016/0014-5793(94)80174-6; SAMBONGI Y, 1994, FEBS LETT, V344, P207, DOI 10.1016/0014-5793(94)00399-8; Schiott T, 1997, J BACTERIOL, V179, P4523, DOI 10.1128/jb.179.14.4523-4529.1997; Steiner H, 1996, J BIOL CHEM, V271, P32605, DOI 10.1074/jbc.271.51.32605; Sussman JK, 1996, MOL MICROBIOL, V21, P347, DOI 10.1046/j.1365-2958.1996.6371354.x; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; THONYMEYER L, 1995, J BACTERIOL, V177, P4321; ThonyMeyer L, 1997, MICROBIOL MOL BIOL R, V61, P337; ThonyMeyer L, 1997, EUR J BIOCHEM, V246, P794, DOI 10.1111/j.1432-1033.1997.t01-1-00794.x; Tichy M, 1998, BIOCHEMISTRY-US, V37, P1523, DOI 10.1021/bi9723818; Xie ZY, 1998, BBA-BIOENERGETICS, V1365, P309, DOI 10.1016/S0005-2728(98)00085-1; Xie ZY, 1996, J BIOL CHEM, V271, P4632; Xie ZY, 1998, GENETICS, V148, P681; ZOLLNER A, 1992, EUR J BIOCHEM, V207, P1093, DOI 10.1111/j.1432-1033.1992.tb17146.x	32	22	24	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32396	32401		10.1074/jbc.274.45.32396	http://dx.doi.org/10.1074/jbc.274.45.32396			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542282	hybrid			2022-12-27	WOS:000083532100090
J	Truant, R; Kang, YB; Cullen, BR				Truant, R; Kang, YB; Cullen, BR			The human tap nuclear RNA export factor contains a novel transportin-dependent nuclear localizatoin signal that lacks nuclear export signal function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; PROTEIN IMPORT; HNRNP A1; MAMMALIAN-CELLS; BINDING-PROTEIN; POLY(A)(+) RNA; ELEMENT; PATHWAY; DOMAIN; BETA	The human Tap protein mediates the sequence specific nuclear export of RNAs containing the constitutive transport element and is likely also critical for general mRNA export. Here, we demonstrate that a previously defined arginine-rich nuclear localization signal (NLS) present in Tap acts exclusively via the transportin import factor. Previously, transportin has been shown to mediate the nuclear import of several heterogeneous nuclear ribonucleoproteins, including heterogeneous nuclear ribonucleoprotein (hnRNP) Al, by binding to a sequence element termed M9. Although the Tap NLS and the hnRNP Al M9 element are shown to compete for transportin binding, they show no sequence homology, and the Tap NLS does not conform to the recently defined M9 consensus. The Tap NLS also differs from M9 in that only the latter is able to act as a nuclear export signal. The Tap NLS is therefore the first member of a novel class of transportin-specific NLSs that lack nuclear export signal function.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Genet, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University	Cullen, BR (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA.	culle002@mc.duke.edu		Kang, Yibin/0000-0002-1626-6730				ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; Bogerd HP, 1999, J BIOL CHEM, V274, P9771, DOI 10.1074/jbc.274.14.9771; Bonifaci N, 1997, P NATL ACAD SCI USA, V94, P5055, DOI 10.1073/pnas.94.10.5055; BRAY M, 1994, P NATL ACAD SCI USA, V91, P1256, DOI 10.1073/pnas.91.4.1256; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; Englmeier L, 1999, CURR BIOL, V9, P30, DOI 10.1016/S0960-9822(99)80044-X; Fridell RA, 1997, J CELL SCI, V110, P1325; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; GRAUN IC, 1999, EMBO J, V18, P1953; Gruter P, 1998, MOL CELL, V1, P649, DOI 10.1016/S1097-2765(00)80065-9; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; Kang YB, 1999, GENE DEV, V13, P1126, DOI 10.1101/gad.13.9.1126; Katahira J, 1999, EMBO J, V18, P2593, DOI 10.1093/emboj/18.9.2593; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; MICHAEL WM, 1995, CELL, V83, P415; Nakielny S, 1999, EMBO J, V18, P1982, DOI 10.1093/emboj/18.7.1982; Pasquinelli AE, 1997, EMBO J, V16, P7500, DOI 10.1093/emboj/16.24.7500; PinolRoma S, 1997, SEMIN CELL DEV BIOL, V8, P57, DOI 10.1006/scdb.1996.0122; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; Ribbeck K, 1999, CURR BIOL, V9, P47, DOI 10.1016/S0960-9822(99)80046-3; Saavedra C, 1997, CURR BIOL, V7, P619, DOI 10.1016/S0960-9822(06)00288-0; Segref A, 1997, EMBO J, V16, P3256, DOI 10.1093/emboj/16.11.3256; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Siomi MC, 1997, J CELL BIOL, V138, P1181, DOI 10.1083/jcb.138.6.1181; Stutz F, 1998, GENE DEV, V12, P3303, DOI 10.1101/gad.12.21.3303; Truant R, 1998, MOL CELL BIOL, V18, P1449, DOI 10.1128/MCB.18.3.1449; Truant R, 1999, MOL CELL BIOL, V19, P1210; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x	33	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32167	32171		10.1074/jbc.274.45.32167	http://dx.doi.org/10.1074/jbc.274.45.32167			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542253	hybrid			2022-12-27	WOS:000083532100061
J	Wang, HY; Malbon, CC				Wang, HY; Malbon, CC			G(s)alpha repression of adipogenesis via Syk	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEIN; ADIPOSE CELL LINE; ALPHA-SUBUNIT; CRYSTAL-STRUCTURE; ADENYLYL-CYCLASE; TYROSINE-KINASE; DIFFERENTIATION; ACTIVATION; IDENTIFICATION; ADIPOCYTES	G(s)alpha regulates the differentiation of 3T3-L1 mouse embryonic fibroblasts to adipocytes, a process termed adipogenesis, Inducers of adipogenesis lead to a loss of G(s)alpha and derepress differentiation to adipocytes, The broad spectrum tyrosine kinase inhibitor genistein is shown to block induction of adipogenesis, suggesting an early role of tyrosine phosphorylation in adipogenesis, Staining of phosphotyrosine identified prominent staining of a similar to 70-kDa protein, hypothesized to be the tyrosine kinase Syk, Reverse transcription and polymerase chain reaction amplification established the expression of Syk mRNA in these embryonic fibroblasts. Immunoprecipitations with Syk-specific antibodies demonstrated the presence of Syk in fibroblasts and a rapid increase in the amount of phospho-Syk, peaking at 24 h post induction, Clones constitutively expressing G(s)alpha, which can no longer be induced to differentiate, no longer display increased phospho-Syk levels in response to inducers. The linkage between G(s)alpha and Syk was probed by immunoprecipitations revealing association of Syk with G(s)alpha in the absence of induction. Upon induction of adipogenesis, G(s)alpha levels decline and phospho-Syk levels as well as Syk kinase activity increase, Expression of wildtype Syk both potentiates the ability of inducers to act as well as induces adipogenesis itself. Expression of the kinase-deficient Syk had no such effects on adipogenesis. These data provide a new insight into the control of adipogenesis, suggesting that G(s)alpha represses adipogenesis via Syk, Treatment with the inducers promotes a decline in G(s)alpha, increases in levels of phospho-syk, and adipogenesis.	SUNY Stony Brook, Univ Med Ctr, Diabet & Metab Dis Res Program, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; SUNY Stony Brook, Univ Med Ctr, Diabet & Metab Dis Res Program, Dept Mol Pharmacol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stony Brook University Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stony Brook University Hospital	Wang, HY (corresponding author), SUNY Stony Brook, Univ Med Ctr, Diabet & Metab Dis Res Program, Dept Physiol & Biophys, Stony Brook, NY 11794 USA.		malbon, craig/ABF-3604-2020		NIDDK NIH HHS [DK30111] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030111] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bence K, 1997, NATURE, V389, P296, DOI 10.1038/38520; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Cheng AM, 1997, CURR OPIN IMMUNOL, V9, P528, DOI 10.1016/S0952-7915(97)80106-9; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; Harnett M, 1996, IMMUNOL TODAY, V17, P4, DOI 10.1016/0167-5699(96)80558-5; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Liu XX, 1998, J BIOL CHEM, V273, P11685, DOI 10.1074/jbc.273.19.11685; MOXHAM CM, 1993, SCIENCE, V260, P991, DOI 10.1126/science.8493537; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; Rawlings D J, 1995, Semin Immunol, V7, P237, DOI 10.1006/smim.1995.0028; RUSSELL TR, 1976, P NATL ACAD SCI USA, V73, P4516, DOI 10.1073/pnas.73.12.4516; STRITTMATTER SM, 1994, J NEUROSCI, V14, P2327; SU HL, 1993, AM J PHYSIOL, V265, pC1729, DOI 10.1152/ajpcell.1993.265.6.C1729; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; van Oers N S, 1995, Semin Immunol, V7, P227, DOI 10.1006/smim.1995.0027; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; Wang HY, 1997, J BIOL CHEM, V272, P1817, DOI 10.1074/jbc.272.3.1817; WANG HY, 1992, NATURE, V358, P334, DOI 10.1038/358334a0; Wang HY, 1996, J BIOL CHEM, V271, P22022, DOI 10.1074/jbc.271.36.22022; WATKINS DC, 1989, BIOCHEM BIOPH RES CO, V165, P929, DOI 10.1016/0006-291X(89)92692-2; WATKINS DC, 1987, J BIOL CHEM, V262, P10651; WATKINS DC, 1992, SCIENCE, V258, P1373, DOI 10.1126/science.1455234; WATKINS DC, 1989, J BIOL CHEM, V264, P4186	32	35	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32159	32166		10.1074/jbc.274.45.32159	http://dx.doi.org/10.1074/jbc.274.45.32159			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542252	hybrid			2022-12-27	WOS:000083532100060
J	Wright, DJ; Jack, WE; Modrich, P				Wright, DJ; Jack, WE; Modrich, P			The kinetic mechanism of EcoRI endonuclease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SPECIFICITY; RESTRICTION-ENDONUCLEASE; RI ENDONUCLEASE; LINEAR DIFFUSION; MODIFICATION ENZYMES; CRYSTAL-STRUCTURE; CLEAVAGE CENTER; PLASMID DNA; RECOGNITION; SEQUENCES	Steady-state parameters governing cleavage of pBR322 DNA by EcoRI endonuclease are highly sensitive to ionic environment, with K-m and k(cat) increasing 1,000-fold and 15-fold, respectively, when ionic strength is increased from 0.059 to 0.23 M. By contrast, pre-steady-state analysis has shown that recognition, as well as first and second strand cleavage events that occur once the enzyme has arrived at the EcoRI site, are essentially insensitive to ionic strength, and has demonstrated that the rate-limiting step for endonuclease turnover occurs after double-strand cleavage under all conditions tested. Furthermore, processive cleavage of a pBR322 variant bearing two closely spaced EcoRI sites is governed by the same turnover number as hydrolysis of parental pBR322, which contains only a single EcoRI sequence, ruling out slow release of the enzyme from the cleaved site or a slow conformational change subsequent to double-strand cleavage. We attribute the effects of ionic strength on steady-state parameters to nonspecific endonuclease DNA interactions, reflecting facilitated diffusion processes, that occur prior to EcoRI sequence recognition and subsequent to DNA cleavage.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University	Modrich, P (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA.			Modrich, Paul/0000-0001-8708-9885	NIGMS NIH HHS [GM23719] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023719, R37GM023719] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERG OG, 1981, BIOCHEMISTRY-US, V20, P6929, DOI 10.1021/bi00527a028; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; CHENG SC, 1984, J BIOL CHEM, V259, P1571; EHBRECHT HJ, 1985, J BIOL CHEM, V260, P6160; Engler LE, 1997, J MOL BIOL, V269, P82, DOI 10.1006/jmbi.1997.1027; Erskine SG, 1997, BIOCHEMISTRY-US, V36, P7567, DOI 10.1021/bi970155s; FERSHT AR, 1985, EMZYME STRUCTURE MEC; HALFORD SE, 1980, BIOCHEM J, V191, P593, DOI 10.1042/bj1910593; HALFORD SE, 1983, BIOCHEM J, V211, P405, DOI 10.1042/bj2110405; HEDGPETH J, 1972, P NATL ACAD SCI USA, V80, P31; HEITMAN J, 1990, PROTEINS, V7, P185, DOI 10.1002/prot.340070207; JACK WE, 1982, P NATL ACAD SCI-BIOL, V79, P4010, DOI 10.1073/pnas.79.13.4010; JACK WE, 1983, PARTICIPATION OUTSID; JELTSCH A, 1994, BIOCHEMISTRY-US, V33, P10215, DOI 10.1021/bi00200a001; JELTSCH A, 1995, BIOCHEMISTRY-US, V34, P6239, DOI 10.1021/bi00018a028; Jeltsch A, 1996, EMBO J, V15, P5104, DOI 10.1002/j.1460-2075.1996.tb00891.x; Jeltsch A, 1998, BIOCHEMISTRY-US, V37, P2160, DOI 10.1021/bi9719206; JENJACOBSON L, 1983, J BIOL CHEM, V258, P4638; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; KING K, 1989, J BIOL CHEM, V264, P11807; KIRSCH JF, 1964, J AM CHEM SOC, V86, P837, DOI 10.1021/ja01059a019; LANGOWSKI J, 1981, NUCLEIC ACIDS RES, V9, P3483, DOI 10.1093/nar/9.14.3483; LESSER DR, 1990, SCIENCE, V250, P776, DOI 10.1126/science.2237428; LU AL, 1981, J BIOL CHEM, V256, P3200; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; MODRICH P, 1976, J BIOL CHEM, V251, P5866; MODRICH P, 1979, Q REV BIOPHYS, V12, P315, DOI 10.1017/S0033583500005461; Modrich P., 1982, NUCLEASES, P109; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROBERT Y, 1993, CURR OPIN OPHTHALMOL, V4, P35; Rosenberg JM, 1991, CURR OPIN STRUC BIOL, V1, P104, DOI 10.1016/0959-440X(91)90018-O; RUBEN G, 1977, NUCLEIC ACIDS RES, V4, P1803, DOI 10.1093/nar/4.6.1803; RUBIN RA, 1978, NUCLEIC ACIDS RES, V5, P2991, DOI 10.1093/nar/5.8.2991; TERRY BJ, 1985, J BIOL CHEM, V260, P3130; TERRY BJ, 1983, J BIOL CHEM, V258, P9820; THIELKING V, 1992, BIOCHEMISTRY-US, V31, P3727, DOI 10.1021/bi00130a001; VIPOND IB, 1995, BIOCHEMISTRY-US, V34, P1113, DOI 10.1021/bi00004a002; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x; WRIGHT DJ, 1989, J BIOL CHEM, V264, P11816	41	63	64	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31896	31902		10.1074/jbc.274.45.31896	http://dx.doi.org/10.1074/jbc.274.45.31896			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542216	hybrid			2022-12-27	WOS:000083532100024
J	Choi, CY; Lee, YM; Kim, YH; Park, T; Jeon, BH; Schulz, RA; Kim, Y				Choi, CY; Lee, YM; Kim, YH; Park, T; Jeon, BH; Schulz, RA; Kim, Y			The homeodomain transcription factor NK-4 acts as either a transcriptional activator or repressor and interacts with the p300 coactivator and the Groucho corepressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SPECIFICITY; GERM-CELL MIGRATION; GENE-EXPRESSION; HOMEOBOX GENES; COOPERATIVE INTERACTIONS; PROTEIN-INTERACTION; GONADAL MESODERM; DROSOPHILA CBP; HEART; TINMAN	NK-4 (tinman) encodes an NK-2 class homeodomain transcription factor that is required for development of the Drosophila dorsal mesoderm, including heart. Genetic evidence suggests its important role in mesoderm subdivision, yet the properties of NK-4 as a transcriptional regulator and the mechanism of gene transcription by NK-4 are not completely understood. Here, we describe its properties as a transcription factor and its interaction with the p300 coactivator and the Groucho corepressor. We demonstrate that NK-4 can activate or repress target genes in cultured cells, depending on functional domains that are conserved between Drosophila melanogaster and Drosophila virilis NK-4 genes. Using GAL4-NK-4 fusion constructs, we have mapped a transcriptional activation domain (amino acids 1-110) and repression domains (amino acids 111-188 and time homeodomain) and found an inhibitory function for the homeodomain in transactivation by NK-4. Furthermore, we demonstrate that NK-4-dependent transactivation is augmented by the p300 coactivator and show that NK-4 physically interacts with p300 via the activation domain. In addition, cotransfection experiments indicate that the repressor activity of NK-4 is strongly enhanced by the Groucho corepressor. Using immunoprecipitation and in vitro pull-down assays, we show that NK-4 directly interacts with the Groucho corepressor, for which the homeodomain is required. Together, our results indicate that NK-4 can act as either a transcriptional activator or repressor and provide the first evidence of NK-4 interactions with the p300 coactivator and the Groucho corepressor.	NHLBI, Mol Cardiol Lab, NIH, Bethesda, MD 20892 USA; Konkuk Univ, Dept Mol Biol, Chungju, South Korea; Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Konkuk University; University of Texas System; UTMD Anderson Cancer Center	Kim, Y (corresponding author), NHLBI, Mol Cardiol Lab, NIH, Bldg 10 Rm 8N228,10 Ctr Dr MSC1762, Bethesda, MD 20892 USA.	yongsok@helix.nih.gov						Akimaru H, 1997, NATURE, V386, P735, DOI 10.1038/386735a0; Akimaru H, 1997, NAT GENET, V17, P211, DOI 10.1038/ng1097-211; AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; Biggin MD, 1997, DEVELOPMENT, V124, P4425; BODMER R, 1990, DEVELOPMENT, V110, P661; BODMER R, 1993, DEVELOPMENT, V118, P719; Broihier HT, 1998, DEVELOPMENT, V125, P655; BURGLIN T, 1994, GUIDEBOOK HOMEOBOX G, P26; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; DAMANTE G, 1994, NUCLEIC ACIDS RES, V22, P3075, DOI 10.1093/nar/22.15.3075; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; Dubnau J, 1996, NATURE, V379, P694, DOI 10.1038/379694a0; Dubnicoff T, 1997, GENE DEV, V11, P2952, DOI 10.1101/gad.11.22.2952; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; Fisher AL, 1996, MOL CELL BIOL, V16, P2670; FRASCH M, 1995, NATURE, V374, P464, DOI 10.1038/374464a0; FRASCH M, 1988, GENE DEV, V2, P1824, DOI 10.1101/gad.2.12b.1824; Gajewski K, 1998, DEV GENES EVOL, V208, P382, DOI 10.1007/s004270050194; GAJEWSKI K, 1997, EMBO J, V16, P516; GORCZYCA MG, 1994, DEVELOPMENT, V120, P2143; Guichet A, 1997, NATURE, V385, P548, DOI 10.1038/385548a0; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; Haun C, 1998, P NATL ACAD SCI USA, V95, P5072, DOI 10.1073/pnas.95.9.5072; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; Jimenez G, 1997, GENE DEV, V11, P3072, DOI 10.1101/gad.11.22.3072; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; KIM YS, 1989, P NATL ACAD SCI USA, V86, P7716, DOI 10.1073/pnas.86.20.7716; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; Lee YM, 1997, J BIOL CHEM, V272, P17531, DOI 10.1074/jbc.272.28.17531; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; Li XL, 1999, EMBO J, V18, P198, DOI 10.1093/emboj/18.1.198; Li XY, 1996, GENE DEV, V10, P517, DOI 10.1101/gad.10.5.517; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; Moore LA, 1998, DEVELOPMENT, V125, P667; NIRENBERG M, 1995, ANN NY ACAD SCI, V758, P224, DOI 10.1111/j.1749-6632.1995.tb24830.x; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; OKKEMA PG, 1994, DEVELOPMENT, V120, P2175; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; Ranganayakulu G, 1998, DEVELOPMENT, V125, P3037; Riechmann V, 1998, DEVELOPMENT, V125, P713; RiveraPomar R, 1996, NATURE, V379, P746, DOI 10.1038/379746a0; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Schnabel CA, 1996, MOL CELL BIOL, V16, P2678; Schott JJ, 1998, SCIENCE, V281, P108, DOI 10.1126/science.281.5373.108; Schultheiss TM, 1997, GENE DEV, V11, P451, DOI 10.1101/gad.11.4.451; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; STAEHLINGHAMPTON K, 1994, NATURE, V372, P783; Struhl K, 1998, CELL, V94, P1, DOI 10.1016/S0092-8674(00)81213-1; Sussel L, 1998, DEVELOPMENT, V125, P2213; Tolkunova EN, 1998, MOL CELL BIOL, V18, P2804, DOI 10.1128/MCB.18.5.2804; TSAO DHH, 1994, BIOCHEMISTRY-US, V33, P15053, DOI 10.1021/bi00254a014; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; Xu X, 1998, GENE DEV, V12, P2354, DOI 10.1101/gad.12.15.2354; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yin ZZ, 1997, DEVELOPMENT, V124, P4971; Yu Y, 1997, NATURE, V385, P552, DOI 10.1038/385552a0; Zhang HL, 1996, P NATL ACAD SCI USA, V93, P1764, DOI 10.1073/pnas.93.5.1764	71	54	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31543	31552		10.1074/jbc.274.44.31543	http://dx.doi.org/10.1074/jbc.274.44.31543			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531357	hybrid, Green Published			2022-12-27	WOS:000083379400061
J	Ilg, T; Montgomery, J; Stierhof, YD; Handman, E				Ilg, T; Montgomery, J; Stierhof, YD; Handman, E			Molecular cloning and characterization of a novel repeat-containing Leishmania major gene, ppg1, that encodes a membrane-associated form of proteophosphoglycan with a putative glycosylphosphatidylinositol anchor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETED ACID-PHOSPHATASE; SURFACE-ANTIGEN; GLYCOSYLATED PHOSPHATIDYLINOSITOLS; STRUCTURAL CHARACTERIZATION; LINKED OLIGOSACCHARIDES; MONOCLONAL-ANTIBODIES; MEXICANA AMASTIGOTES; TRYPANOSOMA-BRUCEI; LIPOPHOSPHOGLYCAN; PROMASTIGOTES	Leishmania parasites secrete a variety of proteins that are modified by phosphoglycan chains structurally similar to those of the cell surface glycolipid lipophosphoglycan. These proteins are collectively called proteophosphoglycans. We report here the cloning and sequencing of a novel Leishmania major proteophosphoglycan gene, ppg1. It encodes a large polypeptide of approximately 2300 amino acids. The N-terminal domain of approximately 70 kDa exhibits 11 imperfect amino acid repeats that show some homology to promastigote surface glycoproteins of the psa2/gp46 complex. The large central domain apparently consists exclusively of approximately 100 repetitive peptides of the sequence APSASSSSA(P/S)SSSSS(+/-S). Gene fusion experiments demonstrate that these peptide repeats are the targets of phosphoglycosylation in Leishmania and that they form extended filamentous structures reminiscent of mammalian mucins. The C-terminal domain contains a functional glycosylphosphatidylinositol anchor addition signal sequence, which confers cell surface localization to a normally secreted Leishmania acid phosphatase when fused to its C terminus. Antibody binding studies show that the ppg1 gene product is phosphoglycosylated by phosphoglycan repeats and cap oligosaccharides. In contrast to previously characterized proteophosphoglycans, the ppg1 gene product is predominantly membrane-associated and it is expressed on the promastigote cell surface. Therefore this membrane-bound proteophosphoglycan may be important for direct host-parasite interactions.	Max Planck Inst Biol, Abt Membranbiochem, D-72076 Tubingen, Germany; Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia	Max Planck Society; Royal Melbourne Hospital; Walter & Eliza Hall Institute	Ilg, T (corresponding author), Max Planck Inst Biol, Abt Membranbiochem, Corrensstr 38, D-72076 Tubingen, Germany.	thomas.ilg@tuebingen.mpg.de						Al-Qahtani A, 1998, BIOCHEM J, V331, P521, DOI 10.1042/bj3310521; ALEXANDER J, 1992, ADV PARASIT, V31, P175, DOI 10.1016/S0065-308X(08)60022-6; ALMEIDA IC, 1994, BIOCHEM J, V304, P793, DOI 10.1042/bj3040793; BAHR V, 1993, MOL BIOCHEM PARASIT, V58, P107, DOI 10.1016/0166-6851(93)90095-F; BRUN R, 1979, ACTA TROP, V36, P289; BUTTON LL, 1989, MOL BIOCHEM PARASIT, V32, P271, DOI 10.1016/0166-6851(89)90076-5; CARRAWAY K L, 1991, Glycobiology, V1, P131, DOI 10.1093/glycob/1.2.131; CHAN J, 1989, P NATL ACAD SCI USA, V86, P2453, DOI 10.1073/pnas.86.7.2453; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DESCOTEAUX A, 1993, PARASITOL TODAY, V9, P468, DOI 10.1016/0169-4758(93)90105-O; Desjardins M, 1997, J EXP MED, V185, P2061, DOI 10.1084/jem.185.12.2061; HANDMAN E, 1986, J IMMUNOL, V137, P3608; HANDMAN E, 1984, EMBO J, V3, P2301, DOI 10.1002/j.1460-2075.1984.tb02130.x; HOMANS SW, 1992, BIOCHEMISTRY-US, V31, P654, DOI 10.1021/bi00118a004; Ilg T, 1999, BIOCHEM SOC T, V27, P518; Ilg T, 1999, TRENDS GLYCOSCI GLYC, V11, P53, DOI 10.4052/tigg.11.53; ILG T, 1993, EUR J BIOCHEM, V217, P603, DOI 10.1111/j.1432-1033.1993.tb18283.x; ILG T, 1995, EUR J CELL BIOL, V66, P205; Ilg T, 1998, J BIOL CHEM, V273, P13509, DOI 10.1074/jbc.273.22.13509; ILG T, 1994, J BIOL CHEM, V269, P24073; ILG T, 1992, J BIOL CHEM, V267, P6834; Ilg T, 1996, J BIOL CHEM, V271, P21583, DOI 10.1074/jbc.271.35.21583; ILG T, 1994, PARASITOLOGY, V108, pS63, DOI 10.1017/S0031182000075739; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; KELLEHER M, 1992, P NATL ACAD SCI USA, V89, P6, DOI 10.1073/pnas.89.1.6; KILLICKKENDRICK R, 1988, PARASITOL RES, V74, P586, DOI 10.1007/BF00531639; KING DL, 1988, MOL BIOCHEM PARASIT, V28, P285, DOI 10.1016/0166-6851(88)90013-8; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBOWITZ JH, 1990, P NATL ACAD SCI USA, V87, P9736, DOI 10.1073/pnas.87.24.9736; LOHMAN KL, 1990, P NATL ACAD SCI USA, V87, P8393, DOI 10.1073/pnas.87.21.8393; LOVELACE JK, 1986, AM J TROP MED HYG, V35, P1121, DOI 10.4269/ajtmh.1986.35.1121; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MCCONVILLE MJ, 1991, J BIOL CHEM, V266, P15170; MCCONVILLE MJ, 1992, EMBO J, V11, P3593, DOI 10.1002/j.1460-2075.1992.tb05443.x; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; MEDINAACOSTA E, 1993, MOL BIOCHEM PARASIT, V57, P31, DOI 10.1016/0166-6851(93)90241-O; Mengeling BJ, 1997, GLYCOBIOLOGY, V7, P873, DOI 10.1093/glycob/7.7.873-c; MENZ B, 1991, MOL BIOCHEM PARASIT, V47, P101, DOI 10.1016/0166-6851(91)90152-V; MOODY SF, 1993, J BIOL CHEM, V268, P18457; MORAN LS, 1990, GENE, V93, P163, DOI 10.1016/0378-1119(90)90153-I; MURRAY PJ, 1991, J BIOL CHEM, V266, P24477; MURRAY PJ, 1989, J IMMUNOL, V143, P4221; Piedrafita D, 1999, EUR J IMMUNOL, V29, P235, DOI 10.1002/(SICI)1521-4141(199901)29:01&lt;235::AID-IMMU235&gt;3.0.CO;2-S; PIMENTA PFP, 1991, EXP PARASITOL, V72, P191, DOI 10.1016/0014-4894(91)90137-L; Proudfoot L, 1996, P NATL ACAD SCI USA, V93, P10984, DOI 10.1073/pnas.93.20.10984; PUENTES SM, 1990, J IMMUNOL, V145, P4311; SACKS DL, 1994, PARASITOLOGY, V108, pS55, DOI 10.1017/S0031182000075727; SACKS DL, 1989, EXP PARASITOL, V69, P100, DOI 10.1016/0014-4894(89)90176-8; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Stierhof YD, 1998, J MOL BIOL, V282, P137, DOI 10.1006/jmbi.1998.2012; STIERHOF YD, 1994, J CELL BIOL, V125, P321, DOI 10.1083/jcb.125.2.321; Stierhof YD, 1999, EUR J CELL BIOL, V78, P675, DOI 10.1016/S0171-9335(99)80036-3; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; TURCO SJ, 1987, BIOCHEMISTRY-US, V26, P6233, DOI 10.1021/bi00393a042; TURCO SJ, 1992, ANNU REV MICROBIOL, V46, P65, DOI 10.1146/annurev.mi.46.100192.000433; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; Wiese M, 1996, MOL BIOCHEM PARASIT, V82, P153, DOI 10.1016/0166-6851(96)02729-6; WIESE M, 1995, EMBO J, V14, P1067, DOI 10.1002/j.1460-2075.1995.tb07089.x; Wolfram M, 1996, EUR J IMMUNOL, V26, P3153, DOI 10.1002/eji.1830261248	61	53	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31410	31420		10.1074/jbc.274.44.31410	http://dx.doi.org/10.1074/jbc.274.44.31410			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531342	hybrid			2022-12-27	WOS:000083379400046
J	Neels, JG; van den Berg, BMM; Lookene, A; Olivecrona, G; Pannekoek, H; van Zonneveld, AJ				Neels, JG; van den Berg, BMM; Lookene, A; Olivecrona, G; Pannekoek, H; van Zonneveld, AJ			The second and fourth cluster of class A cysteine-rich repeats of the low density lipoprotein receptor-related protein share ligand-binding properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; COMPLEMENT-TYPE REPEATS; ALPHA-2-MACROGLOBULIN RECEPTOR; TISSUE-TYPE; ALPHA(2)-MACROGLOBULIN RECEPTOR; SPECIALIZED CHAPERONE; MOLECULAR CHAPERONE; INTERACTION SITES; 39-KDA PROTEIN; HIGH-AFFINITY	The low density lipoprotein receptor-related protein (LRP) is a multifunctional endocytic cell-surface receptor that binds and internalizes a diverse array of ligands. The receptor contains four putative ligand-binding domains, generally referred to as clusters I, II, III, and IV. In this study, soluble recombinant receptor fragments, representing each of the four individual clusters, were used to map the binding sites of a set of structurally and functionally distinct ligands. Using surface plasmon resonance, we studied the binding of these fragments to methylamine-activated alpha(2)-macroglobulin, pro-urokinase-type plasminogen activator, tissue-type plasminogen activator (t-PA), plasminogen activator inhibitor-1, t-PA plasminogen activator inhibitor-1 complexes, lipoprotein lipase, apolipoprotein E, tissue factor pathway inhibitor, lactoferrin, the light chain of blood coagulation factor MII, and the intracellular chaperone receptor-associated protein (EAF). No binding of the cluster I fragment to any of the tested ligands was observed. The cluster III fragment only bound to the anti-LRP monoclonal antibody alpha(2)MR alpha 3 and weakly to RAP. Except for t-PA, we found that each of the ligands tested binds both to cluster II and to cluster IV. The affinity rate constants of ligand binding to clusters II and IV and to LRP were measured, showing that clusters II and IV display only minor differences in ligand-binding kinetics, Furthermore, we demonstrate that the subdomains C3-C7 of cluster II are essential for binding of ligands and that this segment partially overlaps with a RAP-binding site on cluster II. Finally, we show that one RAP molecule can bind to different clusters simultaneously, supporting a model in which RAP binding to LRP induces a conformational change in the receptor that is incompatible with ligand binding.	Univ Amsterdam, Dept Biochem, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands; Umea Univ, Dept Med Biochem & Biophys, S-90187 Umea, Sweden	University of Amsterdam; Academic Medical Center Amsterdam; Umea University	Neels, JG (corresponding author), Univ Amsterdam, Dept Biochem, Acad Med Ctr, Meibergdreef 15, NL-1105 AZ Amsterdam, Netherlands.	j.g.neels@amc.uva.nl	Neels, Jaap G/F-5534-2010; van Zonneveld, Anton Jan/D-8060-2018	Neels, Jaap G/0000-0002-5900-8395; van Zonneveld, Anton Jan/0000-0002-1676-7738				BENGTSSONOLIVECRONA G, 1991, METHOD ENZYMOL, V197, P345; Bu GJ, 1998, CURR OPIN LIPIDOL, V9, P149, DOI 10.1097/00041433-199804000-00012; Bu GJ, 1998, TRENDS CELL BIOL, V8, P272, DOI 10.1016/S0962-8924(98)01283-5; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; CAMANI C, 1994, J BIOL CHEM, V269, P5770; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; DELAIN E, 1994, ANN NY ACAD SCI, V737, P202, DOI 10.1111/j.1749-6632.1994.tb44313.x; Ellgaard L, 1997, EUR J BIOCHEM, V244, P544, DOI 10.1111/j.1432-1033.1997.00544.x; Gliemann J, 1998, BIOL CHEM, V379, P951; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HIESBERGER T, 1995, J BIOL CHEM, V270, P18219, DOI 10.1074/jbc.270.31.18219; HORN IR, 1995, J BIOL CHEM, V270, P11770, DOI 10.1074/jbc.270.20.11770; Horn IR, 1997, J BIOL CHEM, V272, P13608, DOI 10.1074/jbc.272.21.13608; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; KEIJER J, 1991, BLOOD, V78, P401; Lenting PJ, 1999, J BIOL CHEM, V274, P23734, DOI 10.1074/jbc.274.34.23734; LEYTE A, 1989, BIOCHEM J, V257, P679, DOI 10.1042/bj2570679; Martinho RG, 1996, MOL BIOL CELL, V7, P1771, DOI 10.1091/mbc.7.11.1771; MEIJERS JCM, 1992, BIOCHEMISTRY-US, V31, P4680, DOI 10.1021/bi00134a021; MOESTRUP SK, 1993, J BIOL CHEM, V268, P13691; Neels JG, 1998, FIBRINOLYSIS PROTEOL, V12, P219, DOI 10.1016/S0268-9499(98)80016-7; NIELSEN MS, 1995, J BIOL CHEM, V270, P23713, DOI 10.1074/jbc.270.40.23713; NY T, 1984, P NATL ACAD SCI-BIOL, V81, P5355, DOI 10.1073/pnas.81.17.5355; Obermoeller LM, 1997, J BIOL CHEM, V272, P10761; Obermoeller LM, 1998, J BIOL CHEM, V273, P22374, DOI 10.1074/jbc.273.35.22374; Orlando RA, 1997, P NATL ACAD SCI USA, V94, P2368, DOI 10.1073/pnas.94.6.2368; SANCHO E, 1994, EUR J BIOCHEM, V224, P125, DOI 10.1111/j.1432-1033.1994.tb20003.x; Schuck P, 1996, TRENDS BIOCHEM SCI, V21, P458, DOI 10.1016/S0968-0004(96)20025-8; vanMeijer M, 1996, J BIOL CHEM, V271, P7423, DOI 10.1074/jbc.271.13.7423; Vash B, 1998, BLOOD, V92, P3277, DOI 10.1182/blood.V92.9.3277.421k50_3277_3285; WARSHAWSKY I, 1994, J BIOL CHEM, V269, P3325; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; Willnow TE, 1996, BIOCHEM J, V313, P71, DOI 10.1042/bj3130071; Willnow TE, 1996, EMBO J, V15, P2632, DOI 10.1002/j.1460-2075.1996.tb00623.x; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; WILLNOW TE, 1994, J BIOL CHEM, V269, P15827; WILLNOW TE, 1995, P NATL ACAD SCI USA, V92, P4537, DOI 10.1073/pnas.92.10.4537	40	128	138	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31305	31311		10.1074/jbc.274.44.31305	http://dx.doi.org/10.1074/jbc.274.44.31305			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531329	hybrid			2022-12-27	WOS:000083379400033
J	Alberici, A; Moratto, D; Benussi, L; Gasparini, L; Ghidoni, R; Gatta, LB; Finazzi, D; Frison, GB; Trabucchi, M; Growdon, JH; Nitsch, RM; Binetti, G				Alberici, A; Moratto, D; Benussi, L; Gasparini, L; Ghidoni, R; Gatta, LB; Finazzi, D; Frison, GB; Trabucchi, M; Growdon, JH; Nitsch, RM; Binetti, G			Presenilin 1 protein directly interacts with Bcl-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; AMYLOID PRECURSOR PROTEIN; SPINAL MUSCULAR-ATROPHY; PROGRAMMED CELL-DEATH; IN-VIVO; ENDOPLASMIC-RETICULUM; INCREASED SENSITIVITY; MISSENSE MUTATIONS; CYTOCHROME-C; BETA-CATENIN	Presenilin proteins are involved in familial Alzheimer's disease, a neurodegenerative disorder characterized by massive death of neurons. We describe a direct interaction between presenilin 1 (PS1) and Bcl-2, a key factor in the regulation of apoptosis, by yeast two-hybrid interaction system, by co-immunoprecipitation, and by cross-linking experiments. Our data show that PS1 and Bcl-2 assemble into a macromolecular complex, and that they are released from this complex in response to an apoptotic: stimulus induced by staurosporine. The results support the idea of cross-talk between these two proteins during apoptosis.	Ist Ricovero & Cura Carattere Sci, Ctr S Giovanni Dio, Neurobiol Lab, Alzheimers Dis Unit, I-25123 Brescia, Italy; Univ Brescia, Sch Med, Inst Chem, I-25123 Brescia, Italy; Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00154 Rome, Italy; Univ Zurich, Dept Psychiat Res, CH-8091 Zurich, Switzerland; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02114 USA	University of Brescia; University of Rome Tor Vergata; University of Zurich; Harvard University; Harvard Medical School	Binetti, G (corresponding author), Ist Ricovero & Cura Carattere Sci, Ctr S Giovanni Dio, Neurobiol Lab, Alzheimers Dis Unit, Via Pilastroni 4, I-25123 Brescia, Italy.		finazzi, dario/GYV-1567-2022; Binetti, Giuliano/K-4519-2016; Gasparini, Laura/G-7711-2011; BENUSSI, LUISA/K-4409-2016; Ghidoni, Roberta/K-4507-2016; Frisoni, Giovanni B./K-1360-2016; Frisoni, Giovanni/K-1360-2016	Binetti, Giuliano/0000-0003-2759-5844; Gasparini, Laura/0000-0003-3894-9898; BENUSSI, LUISA/0000-0003-2836-8141; Ghidoni, Roberta/0000-0002-7691-1957; Frisoni, Giovanni B./0000-0002-6419-1753; Finazzi, Dario/0000-0001-5176-2839; Frisoni, Giovanni/0000-0001-7075-7082				BAFFY G, 1993, J BIOL CHEM, V268, P6511; Buxbaum JD, 1998, NAT MED, V4, P1177, DOI 10.1038/2673; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DebBurman SK, 1997, P NATL ACAD SCI USA, V94, P13938, DOI 10.1073/pnas.94.25.13938; Deng GM, 1996, FEBS LETT, V397, P50, DOI 10.1016/S0014-5793(96)01142-8; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Distelhorst CW, 1996, ONCOGENE, V12, P2051; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Gasparini L, 1997, NEUROSCI LETT, V231, P113, DOI 10.1016/S0304-3940(97)00536-3; GASPARINI L, 1998, SOC NEUROSCI, V24, P8; Goedert M, 1998, CURR OPIN NEUROBIOL, V8, P619, DOI 10.1016/S0959-4388(98)80090-1; HACKER G, 1995, CURR BIOL, V5, P622, DOI 10.1016/S0960-9822(95)00126-6; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; Iwahashi H, 1997, NATURE, V390, P413, DOI 10.1038/37144; Keller JN, 1998, J NEUROSCI, V18, P4439; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kruman I, 1998, J NEUROSCI RES, V51, P293, DOI 10.1002/(SICI)1097-4547(19980201)51:3<293::AID-JNR3>3.0.CO;2-B; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Lehmann S, 1997, J BIOL CHEM, V272, P12047, DOI 10.1074/jbc.272.18.12047; Levesque G, 1999, J NEUROCHEM, V72, P999, DOI 10.1046/j.1471-4159.1999.0720999.x; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Murayama M, 1998, FEBS LETT, V433, P73, DOI 10.1016/S0014-5793(98)00886-2; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Roperch JP, 1998, NAT MED, V4, P835, DOI 10.1038/nm0798-835; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Schirmer EC, 1997, P NATL ACAD SCI USA, V94, P13932, DOI 10.1073/pnas.94.25.13932; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Shinozaki K, 1998, INT J MOL MED, V1, P797; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; Takashima A, 1998, P NATL ACAD SCI USA, V95, P9637, DOI 10.1073/pnas.95.16.9637; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Vito P, 1996, J BIOL CHEM, V271, P31025, DOI 10.1074/jbc.271.49.31025; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; Waragai M, 1997, BIOCHEM BIOPH RES CO, V239, P480, DOI 10.1006/bbrc.1997.7488; Welch WJ, 1998, NATURE, V392, P23, DOI 10.1038/32049; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhang WJ, 1998, J NEUROSCI, V18, P914; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208	50	59	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30764	30769		10.1074/jbc.274.43.30764	http://dx.doi.org/10.1074/jbc.274.43.30764			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521466	hybrid			2022-12-27	WOS:000083276700062
J	Alberta, JA; Auger, KR; Batt, D; Iannarelli, P; Hwang, G; Elliott, HL; Duke, R; Roberts, TM; Stiles, CD				Alberta, JA; Auger, KR; Batt, D; Iannarelli, P; Hwang, G; Elliott, HL; Duke, R; Roberts, TM; Stiles, CD			Platelet-derived growth factor stimulation of monocyte chemoattractant protein-1 gene expression is mediated by transient activation of the phosphoinositide 3-kinase signal transduction pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-FOS PROMOTER; MULTIPLE SEQUENCE ELEMENTS; SERUM RESPONSE ELEMENTS; KINASE IN-VITRO; NF-KAPPA-B; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSCRIPTION FACTOR; FACTOR INDUCTION; BINDING SITE; 3T3 CELLS	Platelet-derived growth factor (PDGF) stimulates transcription of an immediate-early gene set in Balb/c 3T3 cells. One cohort of these genes, typified by c-fos, is induced within minutes following activation of PDGF receptors. A second cohort responds to PDGF only after a significant time delay, although induction is still a primary response to receptor activation as shown by "superindnction" in the presence of the protein synthesis inhibitor cycloheximide. PDGF-receptor activated signaling pathways for the "slow" immediate-early genes are poorly resolved. Using gain-of-function mutations together with small molecule inhibitors of kinase activity, we show that activation of PI 3-kinase is both necessary and sufficient for the induction of the prototype slow immediate-early gene, monocyte chemoattractant-1 (MCP-1), Following activation of PDGF receptors, MCP-1 mRNA does not begin to accumulate for at least 90 min. However, only a brief (10 min) interval of PI 3-kinase activity is required to trigger this delayed response. The serine/threonine protein kinase, Akt/PKB, likely functions as a downstream affector of PI 3-kinase for this induction.	Dana Farber Canc Inst, Dept Microbiol & Mol Genet, Div Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Stiles, CD (corresponding author), Dana Farber Canc Inst, Dept Microbiol & Mol Genet, Div Canc Biol, 44 Binney St, Boston, MA 02115 USA.				NICHD NIH HHS [P01 HD24826] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Auger KR, 1996, J BIOL CHEM, V271, P23452, DOI 10.1074/jbc.271.38.23452; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Buchdunger E, 1996, CANCER RES, V56, P100; BUCHDUNGER E, 1995, P NATL ACAD SCI USA, V92, P2558, DOI 10.1073/pnas.92.7.2558; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; ClaessonWelsh L, 1996, INT J BIOCHEM CELL B, V28, P373, DOI 10.1016/1357-2725(95)00156-5; COCHRAN BH, 1984, SCIENCE, V226, P1080, DOI 10.1126/science.6093261; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; Coffer PJ, 1998, BIOCHEM J, V335, P1; Domin J, 1996, J BIOL CHEM, V271, P21614, DOI 10.1074/jbc.271.35.21614; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FRETER RR, 1992, MOL CELL BIOL, V12, P5288, DOI 10.1128/MCB.12.12.5288; Freter RR, 1996, J BIOL CHEM, V271, P17417, DOI 10.1074/jbc.271.29.17417; FRETER RR, 1995, MOL CELL BIOL, V15, P315, DOI 10.1128/MCB.15.1.315; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HALL DJ, 1989, ONCOGENE RES, V4, P177; HALL DJ, 1989, MOL CELL BIOL, V9, P1705, DOI 10.1128/MCB.9.4.1705; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KELLY K, 1988, J BIOL CHEM, V263, P4828; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; Osawa H, 1996, J BIOL CHEM, V271, P16690, DOI 10.1074/jbc.271.28.16690; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; POWIS G, 1994, CANCER RES, V54, P2419; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; Reddy SAG, 1997, J BIOL CHEM, V272, P29167, DOI 10.1074/jbc.272.46.29167; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Sambrook J., 2002, MOL CLONING LAB MANU; Shamah SM, 1997, CANCER RES, V57, P4141; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; Sridhar P, 1999, MOL CELL BIOL, V19, P4219; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; Treisman R, 1990, Semin Cancer Biol, V1, P47; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wagle A, 1998, J BIOL CHEM, V273, P14968, DOI 10.1074/jbc.273.24.14968; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Wang D, 1998, J BIOL CHEM, V273, P25420, DOI 10.1074/jbc.273.39.25420; Wang Y, 1998, CELL GROWTH DIFFER, V9, P513	62	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					31062	31067		10.1074/jbc.274.43.31062	http://dx.doi.org/10.1074/jbc.274.43.31062			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521506	hybrid			2022-12-27	WOS:000083276700102
J	de la Motte, CA; Hascall, VC; Calabro, A; Yen-Lieberman, B; Strong, SA				de la Motte, CA; Hascall, VC; Calabro, A; Yen-Lieberman, B; Strong, SA			Mononuclear leukocytes preferentially bind via CD44 to hyaluronan on human intestinal mucosal smooth muscle cells after virus infection or treatment with Poly(I center dot C)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLAMMATORY BOWEL-DISEASE; ADHESION MOLECULE-1 VCAM-1; INTER-ALPHA-INHIBITOR; DOUBLE-STRANDED-RNA; ENDOTHELIAL-CELLS; CROHNS-DISEASE; ULCERATIVE-COLITIS; MUSCULARIS MUCOSAE; MESENCHYMAL CELLS; MEASLES-VIRUS	Pathological changes in inflammatory bowel disease include an increase in intestinal mucosal mononuclear leukocytes and hyperplasia of the muscularis mucosae smooth muscle cells (M-SMCs), Because virus infections have correlated with disease flare, we tested the response of cultured M-SMCs to respiratory syncytial virus, measles virus, and the viral analogue, poly(I.C). Adhesion of U937 cells and peripheral blood mononuclear cells was used to measure the leukocyte-interactive potential of M-SMCs. Untreated M-SMCs, only minimally adhesive for leukocytes, bound U937 cells after treatment with respiratory syncytial virus or measles virus. Mononuclear leukocytes also bound to poly(I.C)-treated M-SMCs, Although both vascular cell adhesion molecule-1 mRNA and protein increased 3-4-fold in poly(I.C)-treated M-SMC cultures, U937 cell adhesion was not blocked by an anti-vascular cell adhesion molecule-1 monoclonal antibody. However, hyaluronidase digestion of poly(I.C)- or virus-treated M-SMCs dramatically reduced leukocyte adhesion (similar to 75%), Fluorophore-assisted carbohydrate electrophoresis demonstrated a similar to 3-fold increase in surface-bound hyaluronan on poly(I.C)treated M-SMCs compared with untreated controls. In addition, pretreatment of mononuclear cells with a blocking anti-CD44 antibody, greatly decreased adhesion to poly(I.C)-treated M-SMCs. Recognition of this virus-induced hyaluronan/CD44 mechanism of mesenchymal cell/leukocyte interaction introduces a new avenue in the research of gut inflammation.	Cleveland Clin Fdn, Dept Colorectal Surg, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Immunol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Biomed Engn, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Clin Pathol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Strong, SA (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, NB3,9500 Euclid Ave, Cleveland, OH 44195 USA.							ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BLOM A, 1995, J BIOL CHEM, V270, P9698, DOI 10.1074/jbc.270.17.9698; BOYUM A, 1968, SCAND J CLIN LAB INV, V21, P97; Brocke S, 1999, P NATL ACAD SCI USA, V96, P6896, DOI 10.1073/pnas.96.12.6896; Cho JH, 1998, P NATL ACAD SCI USA, V95, P7502, DOI 10.1073/pnas.95.13.7502; COUFFINHAL T, 1993, ARTERIOSCLER THROMB, V13, P407, DOI 10.1161/01.ATV.13.3.407; DeGrendele HC, 1997, SCIENCE, V278, P672, DOI 10.1126/science.278.5338.672; DeGrendele HC, 1996, J EXP MED, V183, P1119, DOI 10.1084/jem.183.3.1119; delaMotte CA, 1997, GASTROENTEROLOGY, V112, pA956; DENNING SM, 1990, J IMMUNOL, V144, P7; DICORLETO PE, 1985, J CLIN INVEST, V75, P1153, DOI 10.1172/JCI111810; DOUKAS J, 1994, AM J PATHOL, V145, P137; Epstein SE, 1996, LANCET, V348, pS13, DOI 10.1016/S0140-6736(96)98005-8; FARMER GW, 1973, GASTROENTEROLOGY, V65, P8; Fiocchi C, 1997, INFLAMM BOWEL DIS, V3, P133, DOI 10.1002/ibd.3780030209; FIOCCHI C, 1993, CAN J GASTROENTEROL, V7, P110, DOI 10.1155/1993/172735; Fuss IJ, 1996, J IMMUNOL, V157, P1261; GRATTAN MT, 1989, JAMA-J AM MED ASSOC, V261, P3561, DOI 10.1001/jama.261.24.3561; HAINES DS, 1991, J CELL BIOCHEM, V46, P9, DOI 10.1002/jcb.240460104; Haller H, 1997, J IMMUNOL, V158, P1061; Heinegard D, 1998, WENN GR INT, V72, P113; HodgeDufour J, 1997, J IMMUNOL, V159, P2492; Hugot JP, 1996, NATURE, V379, P821, DOI 10.1038/379821a0; Jain M, 1996, J CLIN INVEST, V97, P596, DOI 10.1172/JCI118455; Johnston SL, 1997, PEDIATR PULM, P88; KANGRO HO, 1990, GASTROENTEROLOGY, V98, P549, DOI 10.1016/0016-5085(90)90272-3; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; Laurent TC, 1996, ANN MED, V28, P241, DOI 10.3109/07853899609033126; LAZAAR AL, 1994, J EXP MED, V180, P807, DOI 10.1084/jem.180.3.807; LEE EY, 1991, MODERN PATHOL, V4, P87; LESLEY J, 1994, J EXP MED, V180, P383, DOI 10.1084/jem.180.1.383; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LI HM, 1993, AM J PATHOL, V143, P1551; MARUI N, 1993, J CLIN INVEST, V92, P1866, DOI 10.1172/JCI116778; MCGUIRE PG, 1987, J CELL PHYSIOL, V133, P267, DOI 10.1002/jcp.1041330210; MIYAMOTO H, 1995, J GASTROENTEROL, V30, P28, DOI 10.1007/BF01211371; Mohamadzadeh M, 1998, J CLIN INVEST, V101, P97, DOI 10.1172/JCI1604; MONTGOMERY SM, 1999, J MED VIROL, V116, P796; OFFERMANN MK, 1995, EUR J BIOCHEM, V232, P28, DOI 10.1111/j.1432-1033.1995.tb20777.x; PODOLSKY DK, 1991, NEW ENGL J MED, V325, P1008, DOI 10.1056/NEJM199110033251406; POLTE T, 1990, NUCLEIC ACIDS RES, V18, P5901, DOI 10.1093/nar/18.19.5901; PRIETO J, 1994, CELL IMMUNOL, V156, P191, DOI 10.1006/cimm.1994.1164; Roberts AI, 1997, GASTROENTEROLOGY, V113, P144, DOI 10.1016/S0016-5085(97)70089-1; ROMANIC AM, 1994, J CELL BIOL, V125, P1165, DOI 10.1083/jcb.125.5.1165; ROSAI J, 1996, ACKERMANS SURG PATHO, V1, P729; Salmi M, 1998, INFLAMM BOWEL DIS, V4, P149; SHANKAR R, 1992, J BIOL CHEM, V267, P9376; SHIMIZU Y, 1989, J IMMUNOL, V143, P2457; STOSSEL TP, 1971, J CLIN INVEST, V50, P1745, DOI 10.1172/JCI106664; Strong SA, 1998, GASTROENTEROLOGY, V114, P1244, DOI 10.1016/S0016-5085(98)70431-7; Teichtahl H, 1997, CHEST, V112, P591, DOI 10.1378/chest.112.3.591; WAKEFIELD AJ, 1993, J MED VIROL, V39, P345, DOI 10.1002/jmv.1890390415; WAKEFIELD AJ, 1992, J MED VIROL, V38, P183, DOI 10.1002/jmv.1890380306; WEBB DSA, 1990, SCIENCE, V249, P1295, DOI 10.1126/science.1697984; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; WISNIEWSKI HG, 1993, J IMMUNOL, V151, P6593; WISNIEWSKI HG, 1994, BIOCHEMISTRY-US, V33, P7423, DOI 10.1021/bi00189a049; YANG J, 1994, J IMMUNOL, V152, P361	58	167	171	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30747	30755		10.1074/jbc.274.43.30747	http://dx.doi.org/10.1074/jbc.274.43.30747			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521464	hybrid			2022-12-27	WOS:000083276700060
J	Giudici-Orticoni, MT; Guerlesquin, F; Bruschi, M; Nitschke, W				Giudici-Orticoni, MT; Guerlesquin, F; Bruschi, M; Nitschke, W			Interaction-induced redox switch in the electron transfer complex rusticyanin-cytochrome c(4)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC REACTION-CENTER; EXTREME ACID STABILITY; BLUE-COPPER PROTEIN; THIOBACILLUS-FERROOXIDANS; METHYLAMINE DEHYDROGENASE; CRYSTAL-STRUCTURE; BINDING-DYNAMICS; AMICYANIN; OXIDATION; PLASTOCYANIN	The blue copper protein rusticyanin isolated from the acidophilic proteobacterium Thiobacillus ferrooxidans displays a pH-dependent redox midpoint potential with a pK value of 7 on the oxidized form of the protein. The nature of the alterations of optical and EPR spectra observed above the pK value indicated that the redox-linked deprotonation occurs on the epsilon-nitrogen of the histidine ligands to the copper ion. Complex formation between rusticyanin and its probable electron transfer partner, cytochrome c(4), induced a decrease of rusticyanin's redox midpoint potential by more than 100 mV together with spectral changes similar to those observed above the pK value of the free form. Complex formation thus substantially modifies the pK value of the surface-exposed histidine ligand to the copper ion and thereby tunes the redox midpoint potential of the copper site. Comparisons with reports on other blue copper proteins suggest that the surface-exposed histidine ligand is employed as a redox tuning device by many members of this group of soluble electron carriers.	Inst Biol Struct & Mikrobiol, CNRS, UPR 9036, Lab Bioenerget & Ingn Prot, F-13402 Marseille 20, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Nitschke, W (corresponding author), Inst Biol Struct & Microbiol, CNRS, UPR 9036, Lab Bioenerget & Ingn Prot, 31 Chemin Joseph Aiguier, F-13402 Marseille 20, France.		Nitschke, Wolfgang/C-4812-2012	Nitschke, Wolfgang/0000-0003-2084-3032				Appia-Ayme C, 1998, FEMS MICROBIOL LETT, V167, P171, DOI 10.1111/j.1574-6968.1998.tb13224.x; BLAKE RC, 1994, BIOCHEMISTRY-US, V33, P9220, DOI 10.1021/bi00197a025; Botuyan MV, 1996, J MOL BIOL, V263, P752, DOI 10.1006/jmbi.1996.0613; Brugna M, 1999, J BIOL CHEM, V274, P16766, DOI 10.1074/jbc.274.24.16766; CAVAZZA C, 1995, FEMS MICROBIOL LETT, V130, P193; Cavazza C, 1996, EUR J BIOCHEM, V242, P308, DOI 10.1111/j.1432-1033.1996.0308r.x; CHEN LY, 1994, SCIENCE, V264, P86, DOI 10.1126/science.8140419; COX JC, 1978, BIOCHEM J, V174, P497, DOI 10.1042/bj1740497; COX JC, 1978, FEBS LETT, V93, P157, DOI 10.1016/0014-5793(78)80826-6; Drepper F, 1996, BIOCHEMISTRY-US, V35, P1282, DOI 10.1021/bi951471e; Drepper F, 1997, BIOCHEMISTRY-US, V36, P1418, DOI 10.1021/bi961350u; DUTTON PL, 1970, BIOCHEMISTRY-US, V9, P5077, DOI 10.1021/bi00828a006; DUTTON PL, 1971, BIOCHIM BIOPHYS ACTA, V226, P63, DOI 10.1016/0005-2728(71)90178-2; Elbehti A, 1999, J BIOL CHEM, V274, P16760, DOI 10.1074/jbc.274.24.16760; GIUDICIORTICONI MT, 1997, BIOMINE, V97; GRAY KA, 1988, J BIOL CHEM, V263, P13987; GUSS JM, 1986, J MOL BIOL, V192, P361, DOI 10.1016/0022-2836(86)90371-2; HALADJIAN J, 1993, J ELECTROANAL CHEM, V352, P329, DOI 10.1016/0022-0728(93)80276-N; INGLEDEW WJ, 1982, BIOCHIM BIOPHYS ACTA, V683, P89, DOI 10.1016/0304-4173(82)90007-6; INGLEDEW WJ, 1977, FEMS MICROBIOL LETT, V2, P193; KUSANO T, 1992, J BIOL CHEM, V267, P11242; LOMMEN A, 1990, J BIOL CHEM, V265, P2768; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MOSER CC, 1988, BIOCHEMISTRY-US, V27, P2450, DOI 10.1021/bi00407a031; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; NG TCN, 1995, BBA-BIOENERGETICS, V1230, P119, DOI 10.1016/0005-2728(95)00043-I; NUNZI F, 1993, BIOCHIM BIOPHYS ACTA, V1162, P28, DOI 10.1016/0167-4838(93)90123-9; NUNZI F, 1994, BIOCHEM BIOPH RES CO, V203, P1655, DOI 10.1006/bbrc.1994.2376; ONUCHIC JN, 1992, ANNU REV BIOPH BIOM, V21, P340; PETTIGREW GW, 1988, BIOCHEM J, V252, P427, DOI 10.1042/bj2520427; Schoepp B, 1999, ADV INORG CHEM, V47, P335, DOI 10.1016/S0898-8838(08)60082-3; SOLOMON EI, 1992, CHEM REV, V92, P521, DOI 10.1021/cr00012a003; VANDERKOOI J, 1974, ARCH BIOCHEM BIOPHYS, V162, P385, DOI 10.1016/0003-9861(74)90196-9; Walter RL, 1996, J MOL BIOL, V263, P730, DOI 10.1006/jmbi.1996.0612; YAMANAKA T, 1991, DEV GEOCHEM, V6, P267; Zhu ZY, 1998, BIOCHEMISTRY-US, V37, P17128, DOI 10.1021/bi9817919	36	57	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30365	30369		10.1074/jbc.274.43.30365	http://dx.doi.org/10.1074/jbc.274.43.30365			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521412	hybrid			2022-12-27	WOS:000083276700008
J	Roujeinikova, A; Sedelnikova, S; de Boer, GJ; Stuitje, AR; Slabas, AR; Rafferty, JB; Rice, DW				Roujeinikova, A; Sedelnikova, S; de Boer, GJ; Stuitje, AR; Slabas, AR; Rafferty, JB; Rice, DW			Inhibitor binding studies on enoyl reductase reveal conformational changes related to substrate recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARRIER PROTEIN REDUCTASE; ESCHERICHIA-COLI; REFINEMENT; SYSTEM; MODELS; ERRORS; ENVM; MAPS	Enoyl acyl carrier protein reductase (ENR) is involved in fatty acid biosynthesis. In Escherichia coli this enzyme is the target for the experimental family of antibacterial agents, the diazaborines, and for triclosan, a broad spectrum antimicrobial agent. Biochemical studies have suggested that the mechanism of diazaborine inhibition is dependent on NAD(+) and not NADH, and resistance of Brassica napus ENR to diazaborines is thought to be due to the replacement of a glycine in the active site of the E. coli enzyme by an alanine at position 138 in the plant homologue, We present here an x-ray analysis of crystals of B. napus ENR A138G grown in the presence of either NAD(+) or NADH and the structures of the corresponding ternary complexes with thienodiazaborine obtained either by soaking the drug into the crystals or by co-crystallization of the mutant with NAD(+) and diazaborine. Analysis of the ENR A138G complex with diazaborine and NAD(+) shows that the site of diazaborine binding is remarkably close to that reported for E. coli ENR. However, the structure of the ternary ENR A138G-NAD(+)-diazaborine complex obtained using cocrystallization reveals a previously unobserved conformational change affecting 11 residues that flank the active site and move closer to the nicotinamide moiety making extensive van der Waals contacts with diazaborine, Considerations of the mode of substrate binding suggest that this conformational change may reflect a structure of ENR that is important in catalysis.	Univ Sheffield, Krebs Inst Biomolec Res, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England; Vrije Univ Amsterdam, Inst Mol Biol Studies, Dept Genet, NL-1081 HV Amsterdam, Netherlands; Univ Durham, Dept Biol Sci, Durham DH1 3LE, England	University of Sheffield; Vrije Universiteit Amsterdam; Durham University	Rice, DW (corresponding author), Univ Sheffield, Krebs Inst Biomolec Res, Dept Mol Biol & Biotechnol, Firth Court,Western Bank, Sheffield S10 2TN, S Yorkshire, England.		Liu, Shih/Q-1672-2019; Heterocycles, BoronNitrogen/Q-1699-2019	Rafferty, John/0000-0003-1183-7474; Roujeinikova, Anna/0000-0001-8478-4751				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Baldock C, 1998, J MOL BIOL, V284, P1529, DOI 10.1006/jmbi.1998.2271; Baldock C, 1996, SCIENCE, V274, P2107, DOI 10.1126/science.274.5295.2107; BERGLER H, 1994, J BIOL CHEM, V269, P5493; BURGI HB, 1983, ACCOUNTS CHEM RES, V16, P153, DOI 10.1021/ar00089a002; de Boer GJ, 1999, MOL MICROBIOL, V31, P443, DOI 10.1046/j.1365-2958.1999.01182.x; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; HARWOOD JL, 1988, ANNU REV PLANT PHYS, V39, P101, DOI 10.1146/annurev.arplant.39.1.101; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KATER MM, 1994, PLANT MOL BIOL, V25, P771, DOI 10.1007/BF00028873; KATER MM, 1991, PLANT MOL BIOL, V17, P895, DOI 10.1007/BF00037070; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Levy CW, 1999, NATURE, V398, P383, DOI 10.1038/18803; McMurry LM, 1998, NATURE, V394, P531, DOI 10.1038/28970; MOEWS PC, 1975, J MOL BIOL, V91, P201, DOI 10.1016/0022-2836(75)90160-6; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; QUEMARD A, 1995, BIOCHEMISTRY-US, V34, P8235, DOI 10.1021/bi00026a004; RAFFERTY JB, 1995, STRUCTURE, V3, P927, DOI 10.1016/S0969-2126(01)00227-1; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REMINGTON S, 1982, J MOL BIOL, V158, P111, DOI 10.1016/0022-2836(82)90452-1; TRONRUD DE, 1992, ACTA CRYSTALLOGR A, V48, P912, DOI 10.1107/S0108767392005415; TURNOWSKY F, 1989, J BACTERIOL, V171, P6555, DOI 10.1128/jb.171.12.6555-6565.1989; WILKIE J, 1995, J CHEM SOC PERK T 2, P1559, DOI 10.1039/p29950001559	26	48	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30811	30817		10.1074/jbc.274.43.30811	http://dx.doi.org/10.1074/jbc.274.43.30811			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521472	hybrid, Green Published			2022-12-27	WOS:000083276700068
J	D'Angelo, G; Graceffa, P; Wang, CLA; Wrangle, J; Adam, LP				D'Angelo, G; Graceffa, P; Wang, CLA; Wrangle, J; Adam, LP			Mammal-specific, ERK-dependent, caldesmon phosphorylation in smooth muscle - Quantitation using novel anti-phosphopeptide antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NONMUSCLE CALDESMON; MYOSIN PHOSPHATASE; P34CDC2 KINASE; CROSS-LINKING; H-CALDESMON; MAP KINASE; IDENTIFICATION; PURIFICATION; EXPRESSION	Extracellular signal-regulated kinases (ERKs) phosphorylate the high molecular mass isoform of the actin-binding protein caldesmon (h-CaD) at two sites (Ser(759) and Ser(789)) during smooth muscle stimulation. To investigate the role of phosphorylation at these sites, antibodies were generated against phosphopeptides analogous to the sequences around Ser(759) and Ser(789). Affinity-purified antibodies were phosho- and sequence-specific. The major site of phosphorylation in h-CaD in porcine carotid arterial muscle strips was at Ser(789); however, the amount of phosphate did not vary appreciably with either KCl or phorbol ester stimulation. Phosphorylation at Ser(759) of h-CaD was almost undetectable (<0.005 mol of phosphate/mol of protein). Moreover, phosphorylation of the low molecular mass isoform of the protein (l-CaD) at the site analogous to Ser(789) was greater in serum-stimulated cultured smooth muscle cells than in serum-starved cells. Serum-stimulated l-Call phosphorylation was attenuated by the protein kinase inhibitor PD98059. These data 1) identify Ser(789) of h-CaD as the major site of ERK-dependent phosphorylation in carotid arteries; 2) show that the level of phosphorylation at Ser(789) is relatively constant following carotid arterial muscle stimulation, despite an increase in total protein phosphate content; and 3) suggest a functional role for ERK-dependent l-CaD phosphorylation in cell division.	Boston Biomed Res Inst, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Boston Biomedical Research Institute; Harvard University; Harvard Medical School	Adam, LP (corresponding author), Bristol Myers Squibb Co, Cardiovasc Drug Discovery, F14-07,POB 4000, Princeton, NJ 08543 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056035] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030917, P01AR041637] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56035] Funding Source: Medline; NIAMS NIH HHS [AR41637, AR30917] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAM LP, 1992, FEBS LETT, V302, P223, DOI 10.1016/0014-5793(92)80446-N; ADAM LP, 1995, CIRC RES, V76, P183, DOI 10.1161/01.RES.76.2.183; ADAM LP, 1989, J BIOL CHEM, V264, P7698; ADAM LP, 1993, FEBS LETT, V322, P56, DOI 10.1016/0014-5793(93)81110-L; ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; BARANY K, 1992, BIOCHIM BIOPHYS ACTA, V1134, P233, DOI 10.1016/0167-4889(92)90181-A; BARANY M, 1992, ARCH BIOCHEM BIOPHYS, V294, P571, DOI 10.1016/0003-9861(92)90727-E; BRETSCHER A, 1984, J BIOL CHEM, V259, P2873; CHILDS TJ, 1992, J BIOL CHEM, V267, P22853; Franklin MT, 1997, AM J PHYSIOL-CELL PH, V273, pC1819, DOI 10.1152/ajpcell.1997.273.6.C1819; Gerthoffer WT, 1996, J PHYSIOL-LONDON, V495, P597, DOI 10.1113/jphysiol.1996.sp021619; Gerthoffer WT, 1997, AM J PHYSIOL-LUNG C, V272, pL244, DOI 10.1152/ajplung.1997.272.2.L244; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GRACEFFA P, 1991, J BIOL CHEM, V266, P20305; HAYASHI K, 1992, P NATL ACAD SCI USA, V89, P12122, DOI 10.1073/pnas.89.24.12122; HUMPHREY MB, 1992, GENE, V112, P197, DOI 10.1016/0378-1119(92)90376-Z; KHALIL RA, 1993, AM J PHYSIOL, V265, pC406, DOI 10.1152/ajpcell.1993.265.2.C406; MAK AS, 1991, J BIOL CHEM, V266, P19971; MARSTON SB, 1991, BIOCHEM J, V279, P1; NIXON GF, 1995, J PHYSIOL-LONDON, V487, P283, DOI 10.1113/jphysiol.1995.sp020879; SHIMIZU H, 1994, J BIOL CHEM, V269, P30407; SHIRAZI A, 1994, J BIOL CHEM, V269, P31598; SOBUE K, 1991, J BIOL CHEM, V266, P12115; TAMEMOTO H, 1992, J BIOL CHEM, V267, P20293; WATSON MH, 1993, CIRC RES, V73, P109, DOI 10.1161/01.RES.73.1.109; YAMASHIRO S, 1990, NATURE, V344, P675, DOI 10.1038/344675a0; YAMASHIRO S, 1991, NATURE, V349, P169, DOI 10.1038/349169a0	27	63	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30115	30121		10.1074/jbc.274.42.30115	http://dx.doi.org/10.1074/jbc.274.42.30115			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514499	hybrid			2022-12-27	WOS:000083176400078
J	Kholodenko, BN; Demin, OV; Moehren, G; Hoek, JB				Kholodenko, BN; Demin, OV; Moehren, G; Hoek, JB			Quantification of short term signaling by the epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY BINDING; TYROSINE-PHOSPHORYLATED PEPTIDES; ACTIVATED PROTEIN-KINASE; SH2 DOMAIN SPECIFICITY; CELL-CYCLE ARREST; EGF RECEPTOR; LATERAL DIFFUSION; PHOSPHOLIPASE-C; INSULIN-RECEPTOR; RAT HEPATOCYTES	During the past decade, our knowledge of molecular mechanisms involved in growth factor signaling has proliferated almost explosively. However, the kinetics and control of information transfer through signaling networks remain poorly understood. This paper combines experimental kinetic analysis and computational modeling of the short term pattern of cellular responses to epidermal growth factor (EGF) in isolated hepatocytes. The experimental data show transient tyrosine phosphorylation of the EGF receptor (EGFR) and transient or sustained response patterns in multiple signaling proteins targeted by EGFR. Transient responses exhibit pronounced maxima, reached within 15-30 s of EGF stimulation and followed by a decline to relatively low (quasi-steady-state) levels. In contrast to earlier suggestions, we demonstrate that the experimentally observed transients can be accounted for without requiring receptor-mediated activation of specific tyrosine phosphatases, following EGF stimulation. The kinetic model predicts how the cellular response is controlled by the relative levels and activity states of signaling proteins and under what conditions activation patterns are transient or sustained. EGFR. signaling patterns appear to be robust with respect to variations in many elemental rate constants within the range of experimentally measured values. On the other hand, we specify which changes in the kinetic scheme, rate constants, and total amounts of molecular factors involved are incompatible with the experimentally observed kinetics of signal transfer. Quantitation of signaling network responses to growth factors allows us to assess how cells process information controlling their growth and differentiation.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Moscow State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119899, Russia	Jefferson University; Lomonosov Moscow State University	Kholodenko, BN (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, JAH,1020 Locust St, Philadelphia, PA 19107 USA.		Admin, SBI/HGB-2738-2022	Kholodenko, Boris/0000-0002-9483-4975; Hoek, Jan/0000-0001-7127-4218	NIAAA NIH HHS [AA07215, AA07186, AA08714] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA008714, P50AA007186] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; ARGETSINGER LS, 1992, J BIOL CHEM, V267, P22095; Barkai N, 1997, NATURE, V387, P913, DOI 10.1038/43199; Bhalla US, 1999, SCIENCE, V283, P381, DOI 10.1126/science.283.5400.381; BROWN PM, 1994, EUR J BIOCHEM, V225, P223, DOI 10.1111/j.1432-1033.1994.00223.x; CARPENTER G, 1992, FASEB J, V6, P3283, DOI 10.1096/fasebj.6.14.1385243; Carver RS, 1997, ENDOCRINOLOGY, V138, P5195, DOI 10.1210/en.138.12.5195; CHAIDARUN SS, 1994, J ENDOCRINOL, V143, P489, DOI 10.1677/joe.0.1430489; CHERRY RJ, 1979, BIOCHIM BIOPHYS ACTA, V559, P289, DOI 10.1016/0304-4157(79)90009-1; Chook YM, 1996, J BIOL CHEM, V271, P30472, DOI 10.1074/jbc.271.48.30472; Dahmane A, 1996, EUR J CELL BIOL, V69, P335; DECHERT U, 1994, J BIOL CHEM, V269, P5602; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; DENHARTIGH JC, 1992, J CELL BIOL, V119, P349, DOI 10.1083/jcb.119.2.349; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; ELTIS LD, 1991, BIOCHEMISTRY-US, V30, P3663, DOI 10.1021/bi00229a011; Emlet DR, 1997, J BIOL CHEM, V272, P4079, DOI 10.1074/jbc.272.7.4079; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; FOSTER WR, 1993, J NEUROPHYSIOL, V70, P2502, DOI 10.1152/jn.1993.70.6.2502; GLADHAUG IP, 1992, DIGEST DIS SCI, V37, P233, DOI 10.1007/BF01308177; GREENFIELD C, 1989, EMBO J, V8, P4115, DOI 10.1002/j.1460-2075.1989.tb08596.x; GUNTHER N, 1990, J BIOL CHEM, V265, P22082; GUPTA BD, 1990, J PHYSIOL-LONDON, V430, P483, DOI 10.1113/jphysiol.1990.sp018303; HASHIMOTO N, 1992, BIOCHEM J, V284, P569, DOI 10.1042/bj2840569; Haugh JM, 1997, BIOPHYS J, V72, P2014, DOI 10.1016/S0006-3495(97)78846-5; HEARON JOHN Z., 1953, BULL MATH BIOPHYS, V15, P121, DOI 10.1007/BF02476377; HENEGOUWEN PMP, 1992, EXP CELL RES, V199, P90; HOEK JB, 1987, J BIOL CHEM, V262, P682; Huang CYF, 1996, P NATL ACAD SCI USA, V93, P10078, DOI 10.1073/pnas.93.19.10078; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; HUBLER L, 1989, J BIOL CHEM, V264, P1558; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; KHOLODENKO BN, 1995, TRENDS BIOCHEM SCI, V20, P52, DOI 10.1016/S0968-0004(00)88955-0; Kholodenko BN, 1997, FEBS LETT, V414, P430, DOI 10.1016/S0014-5793(97)01018-1; Kholodenko BN, 1998, BBA-GEN SUBJECTS, V1379, P337, DOI 10.1016/S0304-4165(97)00114-1; KOREN R, 1976, BIOCHEMISTRY-US, V15, P1165, DOI 10.1021/bi00650a032; Koshland DE, 1998, SCIENCE, V280, P852, DOI 10.1126/science.280.5365.852; KUSUMI A, 1993, BIOPHYS J, V65, P2021, DOI 10.1016/S0006-3495(93)81253-0; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; LAMB TD, 1992, J PHYSIOL-LONDON, V449, P719, DOI 10.1113/jphysiol.1992.sp019111; LEMMON MA, 1994, BIOCHEMISTRY-US, V33, P5070, DOI 10.1021/bi00183a010; Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281; LIEBMAN PA, 1974, SCIENCE, V185, P457, DOI 10.1126/science.185.4149.457; LITWIN CME, 1992, FEBS LETT, V309, P275, DOI 10.1016/0014-5793(92)80788-I; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MAYO KH, 1989, J BIOL CHEM, V264, P17838; MYERS AC, 1987, J BIOL CHEM, V262, P6494; NAQVI KR, 1974, CHEM PHYS LETT, V28, P280; NORTHRUP SH, 1992, P NATL ACAD SCI USA, V89, P3338, DOI 10.1073/pnas.89.8.3338; OKADA S, 1995, J BIOL CHEM, V270, P20737, DOI 10.1074/jbc.270.35.20737; ORourke MF, 1997, BIOCHEM PHARMACOL, V53, P1445, DOI 10.1016/S0006-2952(97)00085-3; PAN MG, 1995, ONCOGENE, V11, P2005; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; PAYNE G, 1993, P NATL ACAD SCI USA, V90, P4902, DOI 10.1073/pnas.90.11.4902; Pei ZD, 1996, BIOCHEM BIOPH RES CO, V228, P802, DOI 10.1006/bbrc.1996.1735; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; POSNER I, 1992, J BIOL CHEM, V267, P20638; POSNER I, 1994, FEBS LETT, V353, P155, DOI 10.1016/0014-5793(94)00989-9; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; Rameh LE, 1998, J BIOL CHEM, V273, P23750, DOI 10.1074/jbc.273.37.23750; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; Ringerike T, 1998, J BIOL CHEM, V273, P16639, DOI 10.1074/jbc.273.27.16639; ROY LM, 1989, J CELL PHYSIOL, V140, P295, DOI 10.1002/jcp.1041400215; Saso K, 1997, GASTROENTEROLOGY, V112, P2073, DOI 10.1053/gast.1997.v112.pm9178701; SASTRY L, 1995, ONCOGENE, V11, P1107; SCHLESSINGER J, 1994, COLD SPRING HARB SYM, V59, P173, DOI 10.1101/SQB.1994.059.01.021; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Sherrill JM, 1996, BIOCHEMISTRY-US, V35, P5705, DOI 10.1021/bi9602268; Shymko RM, 1997, BIOCHEM J, V326, P463, DOI 10.1042/bj3260463; SMITH MR, 1990, MOL CELL BIOL, V10, P3828, DOI 10.1128/MCB.10.7.3828; SOROKIN A, 1994, J BIOL CHEM, V269, P9752; Thoresen GH, 1998, J CELL PHYSIOL, V175, P10, DOI 10.1002/(SICI)1097-4652(199804)175:1<10::AID-JCP2>3.3.CO;2-6; TORNEY DC, 1983, PROC R SOC LON SER-A, V387, P147, DOI 10.1098/rspa.1983.0055; Tyson JJ, 1996, TRENDS BIOCHEM SCI, V21, P89; VanderHeyden MAG, 1997, FEBS LETT, V410, P265, DOI 10.1016/S0014-5793(97)00599-1; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; WATERS CM, 1990, BIOCHEMISTRY-US, V29, P3563, DOI 10.1021/bi00466a020; WILEY HS, 1989, J BIOL CHEM, V264, P18912; WOFSY C, 1992, BIOPHYS J, V63, P98, DOI 10.1016/S0006-3495(92)81572-2; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; YANG LJ, 1994, J BIOL CHEM, V269, P7156; YAO H, 1995, J BIOL CHEM, V270, P20748, DOI 10.1074/jbc.270.35.20748; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zhang ZY, 1996, J BIOL CHEM, V271, P5386, DOI 10.1074/jbc.271.10.5386; ZHOU M, 1993, BIOCHEMISTRY-US, V32, P8193, DOI 10.1021/bi00083a020	95	448	459	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30169	30181		10.1074/jbc.274.42.30169	http://dx.doi.org/10.1074/jbc.274.42.30169			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514507	hybrid			2022-12-27	WOS:000083176400086
J	Rani, PG; Bachhawat, K; Misquith, S; Surolia, A				Rani, PG; Bachhawat, K; Misquith, S; Surolia, A			Thermodynamic studies of saccharide binding to artocarpin, a B-cell mitogen, reveals the extended nature of its interaction with mannotriose [3,6-di-O-(alpha-D-mannopyranosyl)-D-mannose]	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LECTIN-CARBOHYDRATE INTERACTIONS; LENS-CULINARIS LECTIN; PISUM-SATIVUM LECTIN; CONCANAVALIN-A; TITRATION MICROCALORIMETRY; CORE TRIMANNOSIDE; GLYCOPEPTIDES; SPECIFICITIES; OLIGOMANNOSE; RECOGNITION	The thermodynamics of binding of various saccharides to artocarpin, from Artocarpus integrifolia seeds, a homotetrameric lectin (M-r 65,000) with one binding site per subunit, was determined by isothermal titration calorimetry measurements at 280 and 293 K, The binding enthalpies, Delta H-b, are the same at both temperatures, and the values range from -10.94 to -47.11 kJ mol(-1). The affinities of artocarpin as obtained from isothermal titration calorimetry are in reasonable agreement with the results obtained by enzyme-linked lectin absorbent essay, which is based on the minimum amount of ligand required to inhibit horseradish peroxidase binding to artocarpin in enzyme-linked lectin absorbent essay (Misquith, S,, Rani, P. G., and Surolia, A. (1994) J. Biol. Chem. 269, 30393-30401). The interactions are mainly enthalpically driven and exhibit enthalpy-entropy compensation. The order of binding affinity of artocarpin is as follows: mannotriose >Man alpha 3Man > GlcNAc(2)Man(3)> Me alpha Man >Man >Man alpha 6Man >Man alpha 2Man >Me alpha Glc >Glc, i.e. 7>4>2>1.4>1>0.4>0.3>0.24>0.11. The Delta H for the interaction of Man alpha 3Man, Man alpha 6Man, and Me alpha Man are similar and 20 kJ mol(-1) lower than that of mannotriose, This indicates that, while Man alpha 3Man and Man alpha 6Man interact with the lectin exclusively through their non-reducing end monosaccharide with the subsites specific for the alpha 1,3 and alpha 1,6 arms, the mannotriose interacts with the lectin simultaneously through all three of its mannopyranosyl residues. This study thus underscores the distinction in the recognition of this common oligosaccharide motif in comparison with that displayed by other lectins with related specificity.	Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India; Jawaharlal Nehru Ctr Adv Sci Res, Bangalore 560012, Karnataka, India; St Josephs Coll, Dept Chem, Bangalore 560025, Karnataka, India	Indian Institute of Science (IISC) - Bangalore; Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR); St. Josephs College	Surolia, A (corresponding author), Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India.		SUROLIA, AVADESHA/C-5442-2009					BHATTACHARYYA L, 1989, EUR J BIOCHEM, V178, P721, DOI 10.1111/j.1432-1033.1989.tb14503.x; BUNNMORENO MM, 1981, J IMMUNOL, V127, P427; CHERVENAK MC, 1995, BIOCHEMISTRY-US, V34, P5685, DOI 10.1021/bi00016a045; CHERVENAK MC, 1994, J AM CHEM SOC, V116, P10533, DOI 10.1021/ja00102a021; Dam TK, 1998, J BIOL CHEM, V273, P32826, DOI 10.1074/jbc.273.49.32826; Dam TK, 1998, J BIOL CHEM, V273, P12082, DOI 10.1074/jbc.273.20.12082; de Miranda-Santos I K, 1991, J Immunol Methods, V140, P197; Dong HD, 1996, IMMUNOL INVEST, V25, P65, DOI 10.3109/08820139609059291; GarciaHernandez E, 1997, PROTEINS, V29, P467, DOI 10.1002/(SICI)1097-0134(199712)29:4<467::AID-PROT7>3.0.CO;2-5; Goldstein I.I., 2012, LECTINS PROPERTIES F, P233; Gupta D, 1997, J BIOL CHEM, V272, P6388, DOI 10.1074/jbc.272.10.6388; KAKU H, 1991, CARBOHYD RES, V213, P109, DOI 10.1016/S0008-6215(00)90602-5; Lemieux RU, 1996, ACCOUNTS CHEM RES, V29, P373, DOI 10.1021/ar9600087; MANDAL DK, 1993, BIOCHEMISTRY-US, V32, P5116, DOI 10.1021/bi00070a020; MANDAL DK, 1994, BIOCHEMISTRY-US, V33, P1157, DOI 10.1021/bi00171a015; MANDAL DK, 1994, BIOCHEMISTRY-US, V33, P1149, DOI 10.1021/bi00171a014; MISQUITH S, 1994, J BIOL CHEM, V269, P30393; SCHWARZ FP, 1991, J BIOL CHEM, V266, P24344; SCHWARZ FP, 1993, J BIOL CHEM, V268, P7668; Schwarz FP, 1996, BIOCHEM J, V316, P123, DOI 10.1042/bj3160123; SHARON N, 1989, SCIENCE, V246, P227, DOI 10.1126/science.2552581; SHARON N, 1989, LECTINS; SHARON N, 1990, CHEM BRITAIN ROYAL S; Swaminathan CP, 1998, J AM CHEM SOC, V120, P5153, DOI 10.1021/ja9733696; WILLIAMS BA, 1992, J BIOL CHEM, V267, P22907; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; YANG CP, 1990, OMEGA DATA ORIGIN, P66	27	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29694	29698		10.1074/jbc.274.42.29694	http://dx.doi.org/10.1074/jbc.274.42.29694			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514441	hybrid			2022-12-27	WOS:000083176400020
J	Kaluz, S; Kaluzova, M; Opavsky, R; Pastorekova, S; Gibadulinova, A; Dequiedt, F; Kettmann, R; Pastorek, J				Kaluz, S; Kaluzova, M; Opavsky, R; Pastorekova, S; Gibadulinova, A; Dequiedt, F; Kettmann, R; Pastorek, J			Transcriptional regulation of the MN/CA 9 gene coding for the tumor-associated carbonic anhydrase IX - Identification and characterization of a proximal silencer element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL-CELL CARCINOMA; NEGATIVE REGULATION; NUCLEAR FACTOR-1; DIAGNOSTIC BIOMARKER; DOWN-REGULATION; MN ANTIGEN; EXPRESSION; PROMOTER; PROTEIN; ACTIVATION	The MN/CA 9 (MN) gene encodes a tumor-associated isoenzyme of the carbonic anhydrase family. Functional characterization of the 3.5-kilobase pair MN 5' upstream region by deletion analysis led to the identification of the -173 to +31 fragment as the MN promoter. lie vitro DNase I footprinting revealed the presence of five protected regions (PRs) within the MN promoter. Detailed deletion analysis of the promoter identified PR1 and PR2 (numbered from the transcription start) as the most critical for transcriptional activity. PR4 negatively affected transcription, since its deletion led to increased promoter activity and was confirmed to function as a promoter-, position, and orientation-independent silencer element. Mutational analysis indicated that the direct repeat AGGGCacAGGGC is required for efficient repressor binding. Two components of the repressor complex (35 and 42 kDa) were found to be in direct contact with PR4 by UV cross-linking. Increased cell density, known to induce MN expression, did not affect levels of PR4 binding in HeLa cells. Significantly reduced repressor level seems to be responsible for MN up-regulation in the case of tumorigenic CGL3 as compared with nontumorigenic CGL1 HeLa x normal fibroblast hybrid cells.	Slovak Acad Sci, Inst Virol, Bratislava 84246, Slovakia; Fac Agron, Dept Mol Biol, B-5030 Gembloux, Belgium	Slovak Academy of Sciences	Kaluz, S (corresponding author), Slovak Acad Sci, Inst Virol, Dubravska Cesta 9, Bratislava 84246, Slovakia.		Pastorek, Jaromir/AAR-2647-2020; Pastorekova, Silvia/C-6685-2018	Dequiedt, Franck/0000-0003-1234-7477; Kaluz, Stefan/0000-0002-6273-3766				Adam E, 1996, J VIROL, V70, P1990, DOI 10.1128/JVI.70.3.1990-1999.1996; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOAM DSW, 1990, J BIOL CHEM, V265, P8285; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; CHEN JH, 1993, ONCOGENE, V8, P133; CLARK AR, 1993, BIOCHEM J, V296, P521, DOI 10.1042/bj2960521; ELDEIRY WS, 1992, NAT GENET, V1, P44; Furlong EEM, 1996, J BIOL CHEM, V271, P29688, DOI 10.1074/jbc.271.47.29688; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; Ivanov SV, 1998, P NATL ACAD SCI USA, V95, P12596, DOI 10.1073/pnas.95.21.12596; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; LIAO SY, 1994, AM J PATHOL, V145, P598; Liao SY, 1997, CANCER RES, V57, P2827; Lieskovska J, 1998, INT J ONCOL, V13, P1081; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; Malone CS, 1997, P NATL ACAD SCI USA, V94, P12314, DOI 10.1073/pnas.94.23.12314; MATHEYPREVOT B, 1990, P NATL ACAD SCI USA, V13, P5040; McKiernan JM, 1997, CANCER RES, V57, P2362; Morel Y, 1998, J BIOL CHEM, V273, P26969, DOI 10.1074/jbc.273.41.26969; Mukhopadhyay D, 1998, GENE EXPRESSION, V7, P53; Ogbourne S, 1998, BIOCHEM J, V331, P1; Opavsky R, 1996, GENOMICS, V33, P480, DOI 10.1006/geno.1996.0223; PAN WT, 1990, J BIOL CHEM, V265, P7022; PASTOREK J, 1994, ONCOGENE, V9, P2877; PASTOREKOVA S, 1992, VIROLOGY, V187, P620, DOI 10.1016/0042-6822(92)90464-Z; Pastorekova S, 1997, GASTROENTEROLOGY, V112, P398, DOI 10.1053/gast.1997.v112.pm9024293; PRESTRIDGE DS, 1991, COMPUT APPL BIOSCI, V7, P203; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Rajas F, 1998, BIOCHEM J, V333, P77, DOI 10.1042/bj3330077; RAMJI DP, 1991, NUCLEIC ACIDS RES, V19, P1139, DOI 10.1093/nar/19.5.1139; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; Sambrook J., 2002, MOL CLONING LAB MANU; SATO K, 1992, MOL CELL BIOL, V12, P2525, DOI 10.1128/MCB.12.6.2525; SAWADA S, 1994, CELL, V77, P917, DOI 10.1016/0092-8674(94)90140-6; SCHMIDTGOFF CM, 1993, J BACTERIOL, V175, P1806, DOI 10.1128/JB.175.6.1806-1813.1993; SIRUMCONNOLLY K, 1991, NUCLEIC ACIDS RES, V19, P335, DOI 10.1093/nar/19.2.335; STANBRIDGE EJ, 1981, SOMAT CELL GENET, V7, P699, DOI 10.1007/BF01538758; Tanaka M, 1996, P NATL ACAD SCI USA, V93, P4311, DOI 10.1073/pnas.93.9.4311; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; Tureci O, 1998, P NATL ACAD SCI USA, V95, P7608, DOI 10.1073/pnas.95.13.7608; Turner JR, 1997, HUM PATHOL, V28, P740, DOI 10.1016/S0046-8177(97)90185-4; WANG WD, 1991, MOL CELL BIOL, V11, P4561, DOI 10.1128/MCB.11.9.4561; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; YANG J, 1995, J IMMUNOL, V155, P2498; YE JP, 1994, J BIOL CHEM, V269, P25728; Yeung K, 1997, MOL CELL BIOL, V17, P36, DOI 10.1128/MCB.17.1.36; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686; ZAVADA J, 1993, INT J CANCER, V54, P268, DOI 10.1002/ijc.2910540218; ZIEGLER SF, 1991, ONCOGENE, V6, P283	50	51	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32588	32595		10.1074/jbc.274.46.32588	http://dx.doi.org/10.1074/jbc.274.46.32588			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551812	hybrid			2022-12-27	WOS:000083623000012
J	Delgado, M; Ganea, D				Delgado, M; Ganea, D			Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit interleukin-12 transcription by regulating nuclear factor kappa B and Ets activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATORY FACTOR INTERLEUKIN-12; NITRIC-OXIDE PRODUCTION; NECROSIS-FACTOR-ALPHA; GENE-EXPRESSION; CYCLIC-AMP; PROINFLAMMATORY CYTOKINE; PERITONEAL-MACROPHAGES; MEDIATED TRANSCRIPTION; MURINE MACROPHAGES; IMMUNE-RESPONSES	The vasoactive intestinal peptide (VIP) and the structurally related neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) act as "macrophage-deactivating factors". We showed previously that VIP and PACAP inhibit the production of macrophage-derived tumor necrosis factor-alpha, interleukin (LL)-6, nitric oxide, and IL-12. This study examines the molecular mechanisms involved in the VIP/PACAP inhibition of IL-12 production. VIP and PACAP inhibit IL-12 (p40) gene expression by affecting both NF-kappa B binding and the composition of the Ets-2 binding complex. Both neuropeptides prevent the activation-induced nuclear translocation of the NF-kappa B components p65 and c-Rel by inhibiting the reduction in cytoplasmic I kappa B alpha, Moreover, VIP and PACAP inhibit the synthesis of the interferon responsive factor-1. The decrease in nuclear interferon responsive factor-1 and c-Rel results in alterations of the Ets-S-binding complex. Two transduction pathways, a cAMP-dependent and a cAMP-independent pathway, are involved in the inhibition of IL-12 gene expression and appear to differentially regulate the transcriptional factors involved. Because IL-12 participates in T cell activation and cytolytic T lymphocyte activity and promotes the differentiation of T helper cells into the Th1 subset, the understanding of the mechanisms that affect IL-12 production in normal and pathological conditions could contribute to immune response-based therapies or vaccine designs.	Rutgers State Univ, Dept Biol Sci, Newark, NJ 07102 USA; Univ Complutense Madrid, Dept Biol Celular, E-28040 Madrid, Spain	Rutgers State University Newark; Rutgers State University New Brunswick; Complutense University of Madrid	Ganea, D (corresponding author), Rutgers State Univ, Dept Biol Sci, 101 Warren St, Newark, NJ 07102 USA.	dganea@andromeda.rutgers.edu	Delgado, Mario/P-1524-2016	Delgado, Mario/0000-0003-1893-5982	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI041786, R01AI041786] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 41786-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aoki Y, 1997, ENDOCRINOLOGY, V138, P1930, DOI 10.1210/en.138.5.1930; Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Bellinger DL, 1996, ADV NEUROIMMUNOL, V6, P5, DOI 10.1016/S0960-5428(96)00008-3; CHEN D, 1994, J EXP MED, V179, P931, DOI 10.1084/jem.179.3.931; DANDREA A, 1992, J EXP MED, V176, P1387, DOI 10.1084/jem.176.5.1387; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DelaFuente M, 1996, ADV NEUROIMMUNOL, V6, P75, DOI 10.1016/S0960-5428(96)00002-2; Delgado M, 1998, J BIOL CHEM, V273, P31427, DOI 10.1074/jbc.273.47.31427; Delgado M, 1999, J IMMUNOL, V162, P4685; Delgado M, 1999, J IMMUNOL, V162, P2358; Delgado M, 1999, J IMMUNOL, V162, P1707; Delgado M, 1999, J NEUROIMMUNOL, V96, P167, DOI 10.1016/S0165-5728(99)00023-5; Delgado M, 1996, REGUL PEPTIDES, V62, P161, DOI 10.1016/0167-0115(96)00024-9; Delgado M, 1999, J IMMUNOL, V162, P1200; Dewit D, 1998, IMMUNOL LETT, V60, P57, DOI 10.1016/S0165-2478(97)00129-6; DOHERTY GM, 1992, J IMMUNOL, V149, P1666; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; Ganea D, 1996, ADV NEUROIMMUNOL, V6, P61, DOI 10.1016/S0960-5428(96)00007-1; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GOETZL EJ, 1988, ANN NY ACAD SCI, V840, P540; Gourlet P, 1997, PEPTIDES, V18, P1539, DOI 10.1016/S0196-9781(97)00228-3; Gourlet P, 1997, PEPTIDES, V18, P1555, DOI 10.1016/S0196-9781(97)00230-1; GOURLET P, 1995, EUR J PHARMACOL, V287, P7, DOI 10.1016/0014-2999(95)00467-5; Gri G, 1998, J BIOL CHEM, V273, P6431, DOI 10.1074/jbc.273.11.6431; GUBLER U, 1991, P NATL ACAD SCI USA, V88, P4143, DOI 10.1073/pnas.88.10.4143; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARAGUCHI S, 1995, IMMUNOL TODAY, V16, P595, DOI 10.1016/0167-5699(95)80083-2; Harmar AJ, 1998, PHARMACOL REV, V50, P265; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HEINZEL FP, 1994, INFECT IMMUN, V62, P4244, DOI 10.1128/IAI.62.10.4244-4249.1994; Hernanz A, 1996, J NEUROIMMUNOL, V71, P25, DOI 10.1016/S0165-5728(96)00118-X; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; Karras JG, 1996, J IMMUNOL, V157, P2299; KincyCain T, 1997, J IMMUNOL, V158, P2334; KRAAN TCTMV, 1995, J EXP MED, V181, P775, DOI 10.1084/jem.181.2.775; KUNKEL SL, 1988, J BIOL CHEM, V263, P5380; LASKIN DL, 1995, ANNU REV PHARMACOL, V35, P655, DOI 10.1146/annurev.pharmtox.35.1.655; Ma XJ, 1997, J BIOL CHEM, V272, P10389; Ma XJ, 1996, J EXP MED, V183, P147, DOI 10.1084/jem.183.1.147; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; Manna SK, 1998, J IMMUNOL, V161, P2873; Martinez C, 1996, J IMMUNOL, V156, P4128; Martinez C, 1998, J LEUKOCYTE BIOL, V63, P591, DOI 10.1002/jlb.63.5.591; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; Muchamuel T, 1997, J IMMUNOL, V158, P2898; Muller A, 1998, J NEUROCHEM, V70, P1431; MURPHY TL, 1995, MOL CELL BIOL, V15, P5258; NEUMANN M, 1995, EMBO J, V14, P1991, DOI 10.1002/j.1460-2075.1995.tb07191.x; Ollivier V, 1996, J BIOL CHEM, V271, P20828, DOI 10.1074/jbc.271.34.20828; PaninaBordignon P, 1997, J CLIN INVEST, V100, P1513, DOI 10.1172/JCI119674; Parry GCN, 1997, J IMMUNOL, V159, P5450; Pozo D, 1997, BBA-MOL CELL RES, V1359, P250, DOI 10.1016/S0167-4889(97)00104-3; Romano MF, 1996, J IMMUNOL, V156, P2119; Said SI, 1996, ANN NY ACAD SCI, V805, P379; Said SI, 1996, J CLIN INVEST, V97, P2163, DOI 10.1172/JCI118655; Said SI, 1998, ANN NY ACAD SCI, V865, P226, DOI 10.1111/j.1749-6632.1998.tb11182.x; SCHOENHAUT DS, 1992, J IMMUNOL, V148, P3433; Schomerus C, 1996, CELL TISSUE RES, V286, P305; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SUZUKI YJ, 1994, J IMMUNOL, V153, P5008; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; Trepicchio WL, 1996, J IMMUNOL, V157, P3627; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; Trinchieri G, 1998, Int Rev Immunol, V16, P365, DOI 10.3109/08830189809043002; Trinchieri G, 1998, IMMUNOL RES, V17, P269, DOI 10.1007/BF02786451; TSUNAWAKI S, 1988, NATURE, V334, P260, DOI 10.1038/334260a0; WANG P, 1995, J BIOL CHEM, V270, P9558, DOI 10.1074/jbc.270.16.9558; WOLF S, 1992, FASEB J, V6, pA1335; Xin ZC, 1998, J NEUROIMMUNOL, V89, P206, DOI 10.1016/S0165-5728(98)00140-4	70	103	108	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31930	31940		10.1074/jbc.274.45.31930	http://dx.doi.org/10.1074/jbc.274.45.31930			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542221	hybrid			2022-12-27	WOS:000083532100029
J	Hoober, KL; Glynn, NM; Burnside, J; Coppock, DL; Thorpe, C				Hoober, KL; Glynn, NM; Burnside, J; Coppock, DL; Thorpe, C			Homology between egg white sulfhydryl oxidase and quiescin Q6 defines a new class of flavin-linked sulfhydryl oxidases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; EXPRESSION; GENE	The flavin-dependent sulfhydryl oxidase from chicken egg white catalyzes the oxidation of sulfhydryl groups to disulfides with the reduction of oxygen to hydrogen peroxide. Reduced proteins are the preferred thiol substrates of this secreted enzyme. The egg white oxidase shows an average 64% identity (from randomly distributed peptides comprising more than 30% of the protein sequence) to a human protein, Quiescin Q6, involved in growth regulation. Q6 is strongly expressed when fibroblasts enter reversible quiescence (Coppock, D. L., Cina-Poppe, D., Gilleran, S, (1998) Genomics 54, 460-468). A peptide antibody against Q6 cross-reacts with both the egg white enzyme and a flavin-linked sulfhydryl oxidase isolated from bovine semen. Sequence analyses show that the egg white oxidase joins human Q6, bone-derived growth factor, GEC-3 from guinea pig, and homologs found in a range of multicellular organisms as a member of a new protein family. These proteins are formed from the fusion of thioredoxin and ERV motifs, In contrast, the flavin-linked sulfhydryl oxidase from Aspergillus niger is related to the pyridine nucleotide-dependent disulfide oxidoreductases, and shows no detectable sequence similarity to this newly recognized protein family.	Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA; Univ Delaware, Dept Anim & Food Sci, Newark, DE 19716 USA; Winthrop Univ Hosp, Oncol Res Lab, Mineola, NY 11501 USA; SUNY Stony Brook, Med Ctr, Dept Med, Stony Brook, NY 11790 USA	University of Delaware; University of Delaware; Winthrop University Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Thorpe, C (corresponding author), Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA.	cthorpe@udel.edu	Crozier, Laura B/C-5891-2011; Nolen, Danielle/A-5250-2010		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026643] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26643] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arita Y, 1998, EXP CELL RES, V242, P381, DOI 10.1006/excr.1997.3911; CLARE DA, 1988, ARCH BIOCHEM BIOPHYS, V265, P351, DOI 10.1016/0003-9861(88)90138-5; COPPOCK DL, 1993, CELL GROWTH DIFFER, V4, P483; Coppock DL, 1998, GENOMICS, V54, P460, DOI 10.1006/geno.1998.5605; CORRELL CC, 1993, PROTEIN SCI, V2, P2112, DOI 10.1002/pro.5560021212; DELAMOTTE RS, 1987, BIOCHEMISTRY-US, V26, P7363, DOI 10.1021/bi00397a025; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; Gandhi CR, 1999, HEPATOLOGY, V29, P1435, DOI 10.1002/hep.510290522; Gilbert HF, 1997, J BIOL CHEM, V272, P29399, DOI 10.1074/jbc.272.47.29399; GOLDSMITH LA, 1987, METHOD ENZYMOL, V143, P510; Gunwar S, 1998, J BIOL CHEM, V273, P8767, DOI 10.1074/jbc.273.15.8767; HAGIYA M, 1994, P NATL ACAD SCI USA, V91, P8142, DOI 10.1073/pnas.91.17.8142; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Hoober KL, 1999, BIOCHEMISTRY-US, V38, P3211, DOI 10.1021/bi9820816; Hoober KL, 1999, J BIOL CHEM, V274, P22147, DOI 10.1074/jbc.274.32.22147; Hoober KL, 1996, J BIOL CHEM, V271, P30510, DOI 10.1074/jbc.271.48.30510; Hu LQ, 1997, PROTEIN SCI, V6, P43; JANOLINO VG, 1992, MILCHWISSENSCHAFT, V47, P143; JANOLINO VG, 1975, J BIOL CHEM, V250, P2532; KOSOWER EM, 1995, METHOD ENZYMOL, V251, P133, DOI 10.1016/0076-6879(95)51117-2; KUSAKABE H, 1982, AGR BIOL CHEM TOKYO, V46, P2057, DOI 10.1080/00021369.1982.10865382; LASH LH, 1984, BIOCHIM BIOPHYS ACTA, V779, P191, DOI 10.1016/0304-4157(84)90008-X; McLaughlin SH, 1998, MATRIX BIOL, V16, P369, DOI 10.1016/S0945-053X(98)90010-5; Nevill-Manning CG, 1998, P NATL ACAD SCI USA, V95, P5865, DOI 10.1073/pnas.95.11.5865; OSTROWSKI MC, 1980, BIOCHEMISTRY-US, V19, P2639, DOI 10.1021/bi00553a016; OSTROWSKI MC, 1979, BIOCHEM BIOPH RES CO, V87, P171, DOI 10.1016/0006-291X(79)91662-0; SCHMELZER CH, 1982, BIOCHEM BIOPH RES CO, V107, P196, DOI 10.1016/0006-291X(82)91688-6; Stein G, 1998, YEAST, V14, P171, DOI 10.1002/(SICI)1097-0061(19980130)14:2<171::AID-YEA209>3.0.CO;2-U; Verbakel JM, 1996, US patent, Patent No. [5529926, US5529926]; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121; Zhu Y, 1999, J CELL BIOL, V144, P1069, DOI 10.1083/jcb.144.5.1069	33	87	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31759	31762		10.1074/jbc.274.45.31759	http://dx.doi.org/10.1074/jbc.274.45.31759			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542195	hybrid			2022-12-27	WOS:000083532100003
J	Iwasiow, RM; Nantel, MF; Tiberi, M				Iwasiow, RM; Nantel, MF; Tiberi, M			Delineation of the structural basis for the activation properties of the dopamine D1 receptor subtypes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSTITUTIVELY ACTIVE MUTANTS; LIGAND-BINDING SPECIFICITY; POLAR AMINO-ACIDS; ALPHA(1B)-ADRENERGIC RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; TRANSMEMBRANE DOMAINS; ADRENERGIC-RECEPTOR; AGONIST; MUTATION; IDENTIFICATION	To delineate the structural determinants involved in the constitutive activation of the D1 receptor subtypes, we have constructed chimeras between the D1A and D1B receptors, These chimeras harbored a cognate domain corresponding to transmembrane regions 6 and 7 as well as the third extracellular loop (EL3) and cytoplasmic tail, a domain referred herein to as the terminal receptor locus (TRL), A chimeric D1A receptor harboring the D1B-TRL (chimera 1) displays an increased affinity for dopamine that is indistinguishable from the wild-type D1B receptor. Likewise, a chimeric D1B receptor containing the D1A-TRL cassette (chimera 2) binds dopamine with a reduced affinity that is highly reminiscent of the dopamine affinity for the wild-type D1A receptor. Furthermore, we show that the agonist independent activity of chimera I is identical to the wild-type D1B receptor whereas the chimera 2 displays a low agonist independent activity that is indistinguishable from the wild-type D1A receptor. Dopamine potencies for the wild-type DIA and D1B receptor were recapitulated in cells expressing the chimera 2 or chimera 1, respectively. However, the differences observed in agonist-mediated maximal activation of adenylyl cyclase elicited by the DIA and D1B receptors remain unchanged in cells expressing the chimeric receptors, To gain further mechanistic insights into the structural determinants of the TRL involved in the activation properties of the D1 receptor subtypes, we have engineered two additional chimeric D1 receptors that contain the EL3 region of their respective cognate wild-type counterparts (hD1A-EL3B and hD1B-EL3A), In marked contrast to chimera 1 and 2, dopamine affinity and constitutive activation were partially modulated by the exchange of the EL3, Meanwhile, hD1A-EL3B and hD1B-EL3A mutant receptors display a full switch in the agonist-mediated maximal activation, which is reminiscent of their cognate wild-type counterparts. Overall, our studies suggest a fundamental role for the TRL in shaping the intramolecular interactions implicated in the constitutive activation and coupling properties of the dopamine D1 receptor subtypes.	Ottawa Hosp, Loeb Hlth Res Inst, Ottawa, ON K1Y 4K9, Canada; Univ Ottawa, Dept Med Cellular, Ottawa, ON K1Y 4K9, Canada; Univ Ottawa, Dept Mol Med, Ottawa, ON K1Y 4K9, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa	Tiberi, M (corresponding author), Ottawa Hosp, Loeb Hlth Res Inst, Civ Campus,725 Parkdale Ave, Ottawa, ON K1Y 4K9, Canada.	mtiberi@lri.ca						Alberts GL, 1998, MOL PHARMACOL, V54, P379, DOI 10.1124/mol.54.2.379; Balmforth AJ, 1997, J BIOL CHEM, V272, P4245, DOI 10.1074/jbc.272.7.4245; Cardinaud B, 1997, J BIOL CHEM, V272, P2778, DOI 10.1074/jbc.272.5.2778; CATTERALL WA, 1989, SCIENCE, V243, P236, DOI 10.1126/science.2536189; Charpentier S, 1996, J BIOL CHEM, V271, P28071, DOI 10.1074/jbc.271.45.28071; Cleator JH, 1999, FEBS LETT, V443, P205, DOI 10.1016/S0014-5793(98)01704-9; COLLINS P, 1991, PSYCHOPHARMACOLOGY, V103, P503, DOI 10.1007/BF02244250; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DIDSBURY JR, 1991, P NATL ACAD SCI USA, V88, P11564, DOI 10.1073/pnas.88.24.11564; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Hasegawa H, 1996, J BIOL CHEM, V271, P1857, DOI 10.1074/jbc.271.4.1857; HILDEBRANDT JD, 1991, MOL CELL BIOL, V11, P4830, DOI 10.1128/MCB.11.10.4830; Ishii I, 1997, J BIOL CHEM, V272, P7846, DOI 10.1074/jbc.272.12.7846; JARVIE KR, 1993, ADV NEUROL, V60, P325; Javitch JA, 1997, J BIOL CHEM, V272, P18546, DOI 10.1074/jbc.272.30.18546; JOHNSON RA, 1991, METHOD ENZYMOL, V195, P3; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; Kozell LB, 1997, MOL PHARMACOL, V52, P1137, DOI 10.1124/mol.52.6.1137; KOZELL LB, 1994, J BIOL CHEM, V269, P30299; Leeb T, 1997, J BIOL CHEM, V272, P311; LEFF P, 1995, TRENDS PHARMACOL SCI, V16, P89, DOI 10.1016/S0165-6147(00)88989-0; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; MACKENZIE RG, 1993, FEBS LETT, V32, P59; Martin M. W., 1995, Society for Neuroscience Abstracts, V21, P1118; MILLIGAN G, 1995, TRENDS PHARMACOL SCI, V16, P10, DOI 10.1016/S0165-6147(00)88963-4; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; Motulsky H., 1995, INTUITIVE BIOSTATIST; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Nanevicz T, 1996, J BIOL CHEM, V271, P702, DOI 10.1074/jbc.271.2.702; NIZNIK HB, 1987, MOL CELL ENDOCRINOL, V54, P1, DOI 10.1016/0303-7207(87)90134-1; PARKER EM, 1991, J BIOL CHEM, V266, P9987; PASCHKE R, 1994, J CLIN ENDOCR METAB, V79, P1785, DOI 10.1210/jc.79.6.1785; REN Q, 1993, J BIOL CHEM, V268, P16483; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Scheer A, 1997, P NATL ACAD SCI USA, V94, P808, DOI 10.1073/pnas.94.3.808; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; Seifert R, 1998, J BIOL CHEM, V273, P5109, DOI 10.1074/jbc.273.9.5109; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; Sokal R. R, 1981, BIOMETRY; Sugamori KS, 1998, J NEUROCHEM, V71, P1685; Sugamori KS, 1998, J NEUROCHEM, V71, P2593; SURYANARAYANA S, 1992, J BIOL CHEM, V267, P21991; TIBERI M, 1994, J BIOL CHEM, V269, P27925; TOMIC M, 1993, BIOCHEM BIOPH RES CO, V191, P1020, DOI 10.1006/bbrc.1993.1319; Vassart G, 1997, HORM RES, V48, P47, DOI 10.1159/000191313; WADDINGTON JL, 1994, DOPAMINE RECEPTORS T; Warner DR, 1999, P NATL ACAD SCI USA, V96, P4268, DOI 10.1073/pnas.96.8.4268; Warner DR, 1998, J BIOL CHEM, V273, P23976, DOI 10.1074/jbc.273.37.23976; Zhao MM, 1998, MOL PHARMACOL, V53, P524, DOI 10.1124/mol.53.3.524	52	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31882	31890		10.1074/jbc.274.45.31882	http://dx.doi.org/10.1074/jbc.274.45.31882			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542214	hybrid			2022-12-27	WOS:000083532100022
J	Jones, PS; Parrott, E; White, INH				Jones, PS; Parrott, E; White, INH			Activation of transcription by estrogen receptor alpha and beta is cell type- and promoter-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUINONE REDUCTASE GENE; NF-KAPPA-B; RESPONSE ELEMENT; BREAST-CANCER; BINDING DOMAIN; TGF-ALPHA; IN-VITRO; ER-ALPHA; EXPRESSION; TAMOXIFEN	Tamoxifen acts as a strong estrogen antagonist in human breast but as an estrogen agonist in the uterus. The action of tamoxifen is mediated through estrogen receptors (ER alpha and ER beta), which bind to a variety of responsive elements, to activate transcription. To examine the role of these varied elements in the response to antiestrogens, we studied the activation of a panel of differing promoters, by these compounds, in human breast, bone, and endometrial derived cell lines. No agonistic activity was observed in breast cells, whereas all antiestrogens, particularly tamoxifen, exhibited agonistic effects in uterine cell lines. All antiestrogens studied were agonistic in co-transfections of a collagenase reporter gene and ER beta, but tamoxifen alone was agonist ic with ER alpha in (uterine) HEC-1-A cells. The ER alpha mediated, agonism of tamoxifen was not observed in primary cultures of human uterine stromal cells, whereas the ER beta-mediated agonism of all selective estrogen receptor modulators was present. This suggests that the two receptors operate by distinct pathways and that the response of cells to antiestrogens is dependent on the ER subtypes expressed.	MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England	University of Leicester	Jones, PS (corresponding author), MRC, Toxicol Unit, Hodgkin Bldg,POB 138,Lancaster Rd, Leicester LE1 9HN, Leics, England.							Anolik JH, 1996, J STEROID BIOCHEM, V59, P413, DOI 10.1016/S0960-0760(96)00129-X; Castro-Rivera E, 1998, J STEROID BIOCHEM, V64, P287, DOI 10.1016/S0960-0760(97)00202-1; CHEN XR, 1994, ONCOGENE, V9, P3179; Chu S, 1997, MOL CELL ENDOCRINOL, V132, P195, DOI 10.1016/S0303-7207(97)00133-0; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; deMedeiros SRB, 1997, J BIOL CHEM, V272, P18250, DOI 10.1074/jbc.272.29.18250; Dowsett M, 1999, ENDOCR-RELAT CANCER, V6, P25, DOI 10.1677/erc.0.0060025; Driscoll MD, 1998, J BIOL CHEM, V273, P29321, DOI 10.1074/jbc.273.45.29321; ElAshry D, 1996, J STEROID BIOCHEM, V59, P261, DOI 10.1016/S0960-0760(96)00118-5; Elgort MG, 1996, MOL ENDOCRINOL, V10, P477, DOI 10.1210/me.10.5.477; Eng FCS, 1998, J BIOL CHEM, V273, P28371, DOI 10.1074/jbc.273.43.28371; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Galien R, 1997, NUCLEIC ACIDS RES, V25, P2424, DOI 10.1093/nar/25.12.2424; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; HEDDEN A, 1995, ANN NY ACAD SCI, V761, P109, DOI 10.1111/j.1749-6632.1995.tb31373.x; Hess RA, 1997, J ANDROL, V18, P602; Ishimitsu T, 1998, BIOCHEM BIOPH RES CO, V243, P463, DOI 10.1006/bbrc.1998.8110; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KRISHNAN V, 1994, J BIOL CHEM, V269, P15912; Kuiper GGJM, 1997, FEBS LETT, V410, P87, DOI 10.1016/S0014-5793(97)00413-4; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; LAFYATIS R, 1990, J BIOL CHEM, V265, P19128; Lazennec G, 1997, MOL ENDOCRINOL, V11, P1375, DOI 10.1210/me.11.9.1375; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; Montano MM, 1997, P NATL ACAD SCI USA, V94, P2581, DOI 10.1073/pnas.94.6.2581; Montano MM, 1998, J BIOL CHEM, V273, P25443, DOI 10.1074/jbc.273.39.25443; NARDULLI AM, 1995, MOL ENDOCRINOL, V9, P1064, DOI 10.1210/me.9.8.1064; Norris JD, 1996, MOL ENDOCRINOL, V10, P1605, DOI 10.1210/mend.10.12.8961270; Ogawa S, 1998, BIOCHEM BIOPH RES CO, V243, P122, DOI 10.1006/bbrc.1997.7893; Ogawa S, 1998, FEBS LETT, V423, P129, DOI 10.1016/S0014-5793(98)00079-9; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Petersen DN, 1998, ENDOCRINOLOGY, V139, P1082, DOI 10.1210/en.139.3.1082; Porter W, 1997, MOL ENDOCRINOL, V11, P1569, DOI 10.1210/me.11.11.1569; RAY A, 1994, J BIOL CHEM, V269, P12940; RISHI AK, 1995, CANCER RES, V55, P4999; RUTQVIST LE, 1995, J NATL CANCER I, V87, P645, DOI 10.1093/jnci/87.9.645; Sathya G, 1997, MOL ENDOCRINOL, V11, P1994, DOI 10.1210/me.11.13.1994; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; STEIN B, 1995, MOL CELL BIOL, V15, P4971; Sun GL, 1998, MOL ENDOCRINOL, V12, P882, DOI 10.1210/me.12.6.882; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; UMAYAHARA Y, 1994, J BIOL CHEM, V269, P16433; VIGANO P, 1993, ACTA OBSTET GYN SCAN, V72, P87, DOI 10.3109/00016349309023418; VYHLIDAL C, 1998, TOXICOLOGIST, V42, P160; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; Wood JR, 1998, MOL CELL BIOL, V18, P1927, DOI 10.1128/MCB.18.4.1927; WRENN CK, 1993, J BIOL CHEM, V268, P24089; Yang NN, 1996, ENDOCRINOLOGY, V137, P2075, DOI 10.1210/en.137.5.2075; Yang NN, 1996, SCIENCE, V273, P1222, DOI 10.1126/science.273.5279.1222; Zhao Y, 1998, ONCOGENE, V16, P409, DOI 10.1038/sj.onc.1201768; Zou AH, 1999, MOL ENDOCRINOL, V13, P418, DOI 10.1210/me.13.3.418	53	98	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32008	32014		10.1074/jbc.274.45.32008	http://dx.doi.org/10.1074/jbc.274.45.32008			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542232	hybrid			2022-12-27	WOS:000083532100040
J	Munshi, N; Ganju, RK; Avraham, S; Mesri, EA; Groopman, JE				Munshi, N; Ganju, RK; Avraham, S; Mesri, EA; Groopman, JE			Kaposi's sarcoma-associated herpesvirus-encoded G protein-coupled receptor activation of c-jun amino-terminal kinase/stress-activated protein kinase and lyn kinase is mediated by related adhesion focal tyrosine kinase/proline-rich tyrosine kinase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; MAP KINASE; ENDOTHELIAL-CELLS; MAMMALIAN-CELLS; DNA-SEQUENCES; AIDS; RAFTK; PYK2; PHOSPHORYLATION; CYTOKINES	The Kaposi's sarcoma-associated herpesvirus (KSHV) (also known as human herpesvirus 8) has been implicated in the pathogenesis of Kaposi's sarcoma and B cell primary effusion lymphomas, KSHV encodes a Gr protein-coupled receptor (GPCR) that acts as an oncogene and constitutively activates two protein kinases, c-Jun amino-terminal kinase (JNK)/stress-activated protein kinase (SAPK) and p38 mitogen-activated protein kinase, It also induces the production of vascular endothelial growth factor. These processes are believed to be important in KSHV-GPCR-related oncogenesis. We have characterized the signaling pathways mediated by KSHV-GPCR in a reconstituted 293T cell model in which the related adhesion focal tyrosine kinase (RAFTK) was ectopically expressed. RAFTK has been shown to play an important role in growth factor signaling in endothelium and in B cell antigen receptor signaling in B lymphocytes. KSHV-GPCR induced the tyrosine phosphorylation of RAFTK, Expression of wild-type RAFTK enhanced GPCR-mediated JNK/SAPK activation, whereas dominant negative mutant constructs of RAFTK, such as K457A (which lacks kinase activity) and Y402F (a Src-binding mutant), inhibited KSHV-GPCR-mediated activation of JNK/SAPK. RAFTK also mediated the KSHV-GPCR-induced activation of Lyn, a Src family kinase. However, RAFTK did not mediate the activation of p38 mitogen-activated protein kinase induced by KSHV-GPCR, Human interferon gamma-inducible protein-10, which is known to inhibit KSHV-GPCR activity, was found to reduce RAFTK phosphorylation and JNK/SAPK activation. These results suggest that in cells expressing RAFTK/proline-rich tyrosine kinase 2, such as endothelial and B cells, RAFTK can act to enhance KSHV-GPCR-mediated downstream signaling to transcriptional regulators such as JNK/SAPK.	Harvard Univ, Harvard Inst Med, Div Expt Med & Hematol Oncol, Sch Med,Harvard Inst Med,Robert Mapplethorpe Lab, Boston, MA 02115 USA; Cornell Univ, Coll Med, Div Hematol Oncol, Lab Viral Oncogenesis, New York, NY 10021 USA	Harvard University; Harvard Medical School; Cornell University	Groopman, JE (corresponding author), Harvard Univ, Harvard Inst Med, Div Expt Med & Hematol Oncol, Sch Med,Harvard Inst Med,Robert Mapplethorpe Lab, 4 Blackfan Circle, Boston, MA 02115 USA.							Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Astier A, 1997, J BIOL CHEM, V272, P228; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Boshoff C, 1998, NATURE, V391, P24, DOI 10.1038/34054; Cesarman E, 1999, SEMIN CANCER BIOL, V9, P165, DOI 10.1006/scbi.1998.0118; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Cheong J, 1998, J BIOL CHEM, V273, P22714, DOI 10.1074/jbc.273.35.22714; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Dupin N, 1999, P NATL ACAD SCI USA, V96, P4546, DOI 10.1073/pnas.96.8.4546; ENSOLI B, 1992, IMMUNOL REV, V127, P147, DOI 10.1111/j.1600-065X.1992.tb01412.x; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; Flore O, 1998, NATURE, V394, P588, DOI 10.1038/29093; Gallo RC, 1998, SCIENCE, V282, P1837, DOI 10.1126/science.282.5395.1837; GANEM D, 1995, CURR BIOL, V5, P469, DOI 10.1016/S0960-9822(95)00093-5; Ganju RK, 1998, J VIROL, V72, P6131, DOI 10.1128/JVI.72.7.6131-6137.1998; Ganju RK, 1997, J EXP MED, V185, P1055, DOI 10.1084/jem.185.6.1055; Ganju RK, 1998, BLOOD, V91, P791, DOI 10.1182/blood.V91.3.791.791_791_797; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Geras-Raaka E, 1998, J EXP MED, V188, P405, DOI 10.1084/jem.188.2.405; Geras-Raaka E, 1998, J EXP MED, V187, P801, DOI 10.1084/jem.187.5.801; Geras-Raaka E, 1998, BIOCHEM BIOPH RES CO, V253, P725, DOI 10.1006/bbrc.1998.9557; Gershengorn MC, 1998, J CLIN INVEST, V102, P1469, DOI 10.1172/JCI4461; Karp JE, 1996, HEMATOL ONCOL CLIN N, V10, P1031, DOI 10.1016/S0889-8588(05)70383-X; Lagunoff M, 1999, P NATL ACAD SCI USA, V96, P5704, DOI 10.1073/pnas.96.10.5704; Lee H, 1998, NAT MED, V4, P435, DOI 10.1038/nm0498-435; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; Liu ZY, 1997, BLOOD, V90, P2253, DOI 10.1182/blood.V90.6.2253.2253_2253_2259; Liu ZY, 1997, J CLIN INVEST, V99, P1798, DOI 10.1172/JCI119344; MASOOD R, 1993, AIDS RES HUM RETROV, V9, P741, DOI 10.1089/aid.1993.9.741; Mesri EA, 1999, BLOOD, V93, P4031, DOI 10.1182/blood.V93.12.4031.412a37_4031_4033; Miles Steven A., 1994, Current Opinion in Oncology, V6, P497, DOI 10.1097/00001622-199409000-00009; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Moore PS, 1996, SCIENCE, V274, P1739, DOI 10.1126/science.274.5293.1739; Nicholas J, 1997, J VIROL, V71, P1963, DOI 10.1128/JVI.71.3.1963-1974.1997; Nicholas J, 1997, NAT MED, V3, P287, DOI 10.1038/nm0397-287; Pandey P, 1999, J BIOL CHEM, V274, P10140, DOI 10.1074/jbc.274.15.10140; Qian DP, 1997, J EXP MED, V185, P1253, DOI 10.1084/jem.185.7.1253; Reed JA, 1998, BLOOD, V91, P3825, DOI 10.1182/blood.V91.10.3825.3825_3825_3832; Rosenkilde MM, 1999, J BIOL CHEM, V274, P956, DOI 10.1074/jbc.274.2.956; Sarid R, 1997, NAT MED, V3, P293, DOI 10.1038/nm0397-293; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360	47	50	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31863	31867		10.1074/jbc.274.45.31863	http://dx.doi.org/10.1074/jbc.274.45.31863			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542211	hybrid			2022-12-27	WOS:000083532100019
J	Oakley, RH; Laporte, SA; Holt, JA; Barak, LS; Caron, MG				Oakley, RH; Laporte, SA; Holt, JA; Barak, LS; Caron, MG			Association of beta-arrestin with G protein-coupled receptors during clathrin-mediated endocytosis dictates the profile of receptor resensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; V2 VASOPRESSIN RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; SUBCELLULAR-DISTRIBUTION; WILD-TYPE; AGONIST; INTERNALIZATION; SEQUESTRATION; PHOSPHORYLATION; DESENSITIZATION	Resensitization of G protein-coupled receptors (GPCRs) following agonist-mediated desensitization is a necessary step for maintaining physiological responsiveness. However, the molecular mechanisms governing the nature of GPCR resensitization are poorly understood. Here, we examine the role of beta-arrestin in the resensitization of the beta(2) adrenergic receptor (beta(2)AR), known to recycle and resensitize rapidly, and the vasopressin V2 receptor (V2R), known to recycle and resensitize slowly. Upon agonist activation, both receptors recruit beta-arrestin to the plasma membrane and internalize in a beta-arrestin- and clathrin-dependent manner. However, whereas beta-arrestin dissociates from the beta(2)AR at the plasma membrane, it internalizes with the V2R into endosomes. The differential trafficking of beta-arrestin and the ability of these two receptors to dephosphorylate, recycle, and resensitize is completely reversed when the carboxyl-terminal tails of these two receptors are switched, Moreover, the ability of beta-arrestin to remain associated with desensitized GPCRs during clathrin-mediated endocytosis is mediated by a specific cluster of phosphorylated serine residues in the receptor carboxyl-terminal tail. These results demonstrate that the interaction of beta-arrestin with a specific motif in the GPCR carboxyl-terminal tail dictates the rate of receptor dephosphorylation, recycling, and resensitization, and thus provide direct evidence for a novel mechanism by which beta-arrestins regulate the reestablishment of GPCR responsiveness.	Duke Univ, Med Ctr, Howard Hughes Med Inst Labs, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst Labs, Dept Med, Durham, NC 27710 USA	Duke University; Duke University	Caron, MG (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Box 3287, Durham, NC 27710 USA.		Laporte, Stephane A/F-3282-2012; Laporte, Stephane/ABC-4228-2021	Laporte, Stephane/0000-0002-0633-543X	NHLBI NIH HHS [HL 61365] Funding Source: Medline; NINDS NIH HHS [NS 19576] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019576] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aramori I, 1997, EMBO J, V16, P4606, DOI 10.1093/emboj/16.15.4606; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BARAK LS, 1994, J BIOL CHEM, V269, P2790; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; BIRNHAUMER M, 1992, J BIOL CHEM, V267, P11786; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; FONSECA MI, 1995, J BIOL CHEM, V270, P8902, DOI 10.1074/jbc.270.15.8902; Garland AM, 1996, MOL PHARMACOL, V49, P438; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GUREVICH VV, 1993, J BIOL CHEM, V268, P16879; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; HAUSDORFF WP, 1990, J BIOL CHEM, V265, P1388; Innamorati G, 1998, J BIOL CHEM, V273, P7155, DOI 10.1074/jbc.273.12.7155; Innamorati G, 1997, J BIOL CHEM, V272, P2486; Innamorati G, 1998, P NATL ACAD SCI USA, V95, P2222, DOI 10.1073/pnas.95.5.2222; Ishii I, 1998, J BIOL CHEM, V273, P9878, DOI 10.1074/jbc.273.16.9878; KIESELBACH T, 1994, EUR J BIOCHEM, V226, P87, DOI 10.1111/j.1432-1033.1994.tb20029.x; Krueger KM, 1997, J BIOL CHEM, V272, P5; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Lazari RDM, 1998, J BIOL CHEM, V273, P18316, DOI 10.1074/jbc.273.29.18316; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; McConalogue K, 1998, MOL BIOL CELL, V9, P2305, DOI 10.1091/mbc.9.8.2305; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Nakamura K, 1998, J BIOL CHEM, V273, P24346, DOI 10.1074/jbc.273.38.24346; PALCZEWSKI K, 1989, J BIOL CHEM, V264, P15770; Pfeiffer R, 1998, EXP CELL RES, V244, P327, DOI 10.1006/excr.1998.4159; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; Shih ML, 1999, J BIOL CHEM, V274, P1588, DOI 10.1074/jbc.274.3.1588; SIBLEY DR, 1986, P NATL ACAD SCI USA, V83, P9408, DOI 10.1073/pnas.83.24.9408; Tarasova NI, 1997, J BIOL CHEM, V272, P14817, DOI 10.1074/jbc.272.23.14817; Vogler O, 1998, J BIOL CHEM, V273, P12155, DOI 10.1074/jbc.273.20.12155; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; YU SS, 1993, J BIOL CHEM, V268, P337; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhang J, 1999, J BIOL CHEM, V274, P10999, DOI 10.1074/jbc.274.16.10999; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	42	433	441	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32248	32257		10.1074/jbc.274.45.32248	http://dx.doi.org/10.1074/jbc.274.45.32248			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542263	hybrid			2022-12-27	WOS:000083532100071
J	Cross, JV; Deak, JC; Rich, EA; Qian, YY; Lewis, M; Parrott, LA; Mochida, K; Gustafson, D; Vande Pol, S; Templeton, DJ				Cross, JV; Deak, JC; Rich, EA; Qian, YY; Lewis, M; Parrott, LA; Mochida, K; Gustafson, D; Vande Pol, S; Templeton, DJ			Quinone reductase inhibitors block SAPK/JNK and NF kappa B pathways and potentiate apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; DT-DIAPHORASE; SIGNALING CASCADE; JNK ACTIVATION; CELL-DEATH; JUN KINASE; STRESS; MEKK1	A variety of environmental stresses stimulate the mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase (MEKK) > stress-activated protein kinase (SAPK)-ERK kinase (SEK) > SAPK/c-Jun NH2-terminal kinase (JNK) stress-activated protein kinase cascade and coordinately activate the transcription factor NF kappa B, Mechanisms of stress activation upstream of MEKK1 have not been precisely determined, Redox mechanisms involving sulfhydryls are likely because N-acetyl-cysteine at millimolar concentrations blocks stress signals. Because intracellular sulfhydryl concentrations can be regulated through redox cycling involving reactive quinones (1), we tested the ability of quinone reductase inhibitors to alter stress signaling, Several quinone reductases are inhibited by dicoumarol, a coumarin derivative, Dicoumarol prevented SAPK activation in vivo by chemical cell stressors and also prevented SAPK activation induced by expression of the tumor necrosis factor alpha (TNF alpha) receptor-associated protein TRAF2 but not by expression of truncated active MEKK1, Other coumarin derivatives failed to block. SAPK activation, but other inhibitors of quinone reductases, particularly menadione, similarly blocked SAPK. activation. Cells deficient in a major quinone reductase, NQO1, displayed hypersensitivity to dicoumarol stress inhibition, whereas SAPK in cells reconstituted with the NQO1 gene displayed relative dicoumarol resistance. Consistent with the proposed role of overlapping upstream signaling cascades in activation of NF kappa B, dicoumarol also blocked NF kappa B activation in primary macrophages stimulated with either lipopolysaccharide or TNF alpha In addition, dicoumarol strongly potentiated TNF alpha-induced apoptosis in HeLa cells, probably by blocking the anti-apoptotic effect of NF kappa B, The ability of dicoumarol to simultaneously inhibit SAPK and NF kappa B activation and to potentiate apoptotic cell death suggests that SAPK is not an obligate participant in apoptosis, Dicoumarol, currently in clinical use as an oral anticoagulant, represents a potential therapeutic inhibitor of the SAPK and NF kappa B response.	Case Western Reserve Univ, Inst Pathol, Dept Med, Cleveland, OH 44106 USA; Colorado State Univ, Ctr Environm Toxicol & Technol, Dept Environm Hlth, Ft Collins, CO 80523 USA	Case Western Reserve University; Colorado State University	Templeton, DJ (corresponding author), Case Western Reserve Univ, Inst Pathol, Dept Med, 2085 Adelbert Rd, Cleveland, OH 44106 USA.	djt2@po.cwru.edu	Pol, Scott Vande/AAO-1068-2020; Templeton, Dennis J/F-7695-2011; Cross, Janet V/F-8276-2011	Pol, Scott Vande/0000-0002-0587-4802; 	NATIONAL CANCER INSTITUTE [R01CA066134] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009249, R01HL057940] Funding Source: NIH RePORTER; NCI NIH HHS [CA-66134] Funding Source: Medline; NHLBI NIH HHS [HL-57940, HL-09249-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bogoyevitch MA, 1996, CIRC RES, V79, P162, DOI 10.1161/01.RES.79.2.162; BRUNMARK A, 1989, FREE RADICAL BIO MED, V7, P435, DOI 10.1016/0891-5849(89)90126-3; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Coso OA, 1996, J BIOL CHEM, V271, P3963; Deak JC, 1998, P NATL ACAD SCI USA, V95, P5595, DOI 10.1073/pnas.95.10.5595; Gustafson DL, 1996, MOL PHARMACOL, V50, P728; HOSODA S, 1974, J BIOL CHEM, V249, P6416; JAISWAL AK, 1990, BIOCHEMISTRY-US, V29, P1899, DOI 10.1021/bi00459a034; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LIND C, 1990, METHOD ENZYMOL, V186, P287; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WESTWICK JK, 1995, J CLIN INVEST, V95, P803, DOI 10.1172/JCI117730; YAN MH, 1994, NATURE, V372, P798; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911	25	88	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31150	31154		10.1074/jbc.274.44.31150	http://dx.doi.org/10.1074/jbc.274.44.31150			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531305	hybrid			2022-12-27	WOS:000083379400009
J	Aulak, KS; Mishra, R; Zhou, LY; Hyatt, SL; de Jonge, W; Lamers, W; Snider, M; Hatzoglou, M				Aulak, KS; Mishra, R; Zhou, LY; Hyatt, SL; de Jonge, W; Lamers, W; Snider, M; Hatzoglou, M			Post-transcriptional regulation of the arginine transporter Cat-1 by amino acid availability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; ECOTROPIC RETROVIRUS RECEPTOR; SYNTHETASE GENE-EXPRESSION; 3' UNTRANSLATED REGION; ASPARAGINE SYNTHETASE; C-MYC; PROTEIN-SYNTHESIS; CELL-LINE; ADAPTIVE REGULATION; HEPATOMA-CELLS	The regulation of the high affinity cationic amino acid transporter (Cat-1) by amino acid availability has been studied. In C6 glioma and NRK kidney cells, cat-1 mRNA levels increased 3.8-18-fold following 2 h of amino acid starvation. The transcription rate of the cat-1 gene remained unchanged during amino acid starvation, suggesting a post-transcriptional mechanism of regulation, This mechanism was investigated by expressing a cat-1 mRNA from a tetracycline-regulated promoter. The cat-1 mRNA contained 1.9 kilobase pairs (kb) of coding sequence, 4.5 kb of 3'-untranslated region, and 80 base pairs of 5'-untranslated region. The full-length (7.9 kb) mRNA increased 5-fold in amino acid-depleted cells. However, a 3.4-kb species that results from the usage of an alternative polyadenylation site was not induced, suggesting that the cat-1 mRNA was stabilized by cis-acting RNA sequences within the 3'-UTR, Transcription and protein synthesis were required for the increase in full-length cat-1 mRNA level. Because omission of amino acids from the cell culture medium leads to a substantial decrease in protein synthesis, the translation of the increased cat-1 mRNA was assessed in amino acid-depleted cells. Western blot analysis demonstrated that cat-1 mRNA and protein levels changed in parallel. The increase in protein level was significantly lower than the increase in mRNA level, supporting the conclusion that cat-2 mRNA is inefficiently translated when the supply of amino acids is limited, relative to amino acid-fed cells. Finally, y(+)-mediated transport of arginine in amino acid-fed and -starved cells paralleled Cat-1 protein levels, We conclude that the cat-1 gene is subject to adaptive regulation by amino acid availability, Amino acid depletion initiates molecular events that lead to increased cat-1 mRNA stability. This causes an increase in Cat-1 protein, and y(+) transport once amino acids become available.	Case Western Reserve Univ, Sch Med, Dept Nutr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Univ Amsterdam, Lab Anat & Embryol, Amsterdam, Netherlands	Case Western Reserve University; Case Western Reserve University; University of Amsterdam	Hatzoglou, M (corresponding author), Case Western Reserve Univ, Sch Med, Dept Nutr, 10900 Euclid Ave, Cleveland, OH 44106 USA.	mxh8@po.cwru.edu	Lamers, Wouter H./D-2965-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053307] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK53307-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albrecht G, 1998, J BIOL CHEM, V273, P12696, DOI 10.1074/jbc.273.21.12696; Aulak KS, 1996, J BIOL CHEM, V271, P29799, DOI 10.1074/jbc.271.47.29799; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHEN FY, 1993, EMBO J, V12, P3977, DOI 10.1002/j.1460-2075.1993.tb06075.x; CHEN ZP, 1992, J BIOL CHEM, V267, P6946; CURATOLA AM, 1995, MOL CELL BIOL, V15, P6331; GAURAV L, 1999, SCIENCE, V284, P499; GONG SS, 1991, MOL CELL BIOL, V11, P6059, DOI 10.1128/MCB.11.12.6059; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GUERRINI L, 1993, MOL CELL BIOL, V13, P3202, DOI 10.1128/MCB.13.6.3202; Hosokawa H, 1997, J BIOL CHEM, V272, P8717, DOI 10.1074/jbc.272.13.8717; HUTSON RG, 1994, BIOCHEM J, V304, P745, DOI 10.1042/bj3040745; Hyatt SL, 1997, J BIOL CHEM, V272, P19951, DOI 10.1074/jbc.272.32.19951; Iiboshi Y, 1999, J BIOL CHEM, V274, P1092, DOI 10.1074/jbc.274.2.1092; Ito K, 1997, J BIOL CHEM, V272, P26780, DOI 10.1074/jbc.272.42.26780; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; KALOUSEK MB, 1994, J BIOL CHEM, V269, P6866; KATZ RA, 1983, BIOCHIM BIOPHYS ACTA, V739, P258, DOI 10.1016/0167-4781(83)90099-4; KILBERG MS, 1985, J CELL PHYSIOL, V122, P290, DOI 10.1002/jcp.1041220219; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; LAINE RO, 1994, J BIOL CHEM, V269, P9693; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lenk SE, 1999, J CELL PHYSIOL, V178, P17, DOI 10.1002/(SICI)1097-4652(199901)178:1<17::AID-JCP3>3.0.CO;2-R; Levy O, 1997, P NATL ACAD SCI USA, V94, P5568, DOI 10.1073/pnas.94.11.5568; MACLEOD CL, 1994, J EXP BIOL, V196, P109; Maniatis T., 1982, MOL CLONING; MARTEN NW, 1994, FASEB J, V8, P538, DOI 10.1096/fasebj.8.8.8181673; Merrick WC., 1996, TRANSLATION CONTROL, P31; MORELLO D, 1990, ONCOGENE, V5, P1511; OGAWA H, 1991, J BIOL CHEM, V266, P20412; PAIN VM, 1994, BIOCHIMIE, V76, P718, DOI 10.1016/0300-9084(94)90076-0; Perkins CP, 1997, GENE DEV, V11, P914, DOI 10.1101/gad.11.7.914; PLAKIDOUDYMOCK S, 1993, BIOCHEM J, V295, P749, DOI 10.1042/bj2950749; POHJANPELTO P, 1990, MOL CELL BIOL, V10, P5814, DOI 10.1128/MCB.10.11.5814; PONJANPELTO P, 1990, MOL CELL BIOL, V10, P5814; PRICE N, 1994, BIOCHIMIE, V76, P748, DOI 10.1016/0300-9084(94)90079-5; PUPPI M, 1995, P SOC EXP BIOL MED, V209, P38, DOI 10.3181/00379727-209-43875; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SCORSONE KA, 1987, J BIOL CHEM, V262, P14538; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHENG SJ, 1992, PROTEIN EXPRES PURIF, V3, P337, DOI 10.1016/1046-5928(92)90010-T; WEK SA, 1995, MOL CELL BIOL, V15, P4497; WHITE MF, 1982, J BIOL CHEM, V257, P4450; WU JY, 1994, J VIROL, V68, P1615, DOI 10.1128/JVI.68.3.1615-1623.1994	46	69	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30424	30432		10.1074/jbc.274.43.30424	http://dx.doi.org/10.1074/jbc.274.43.30424			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521420	hybrid			2022-12-27	WOS:000083276700016
J	Feranchak, AP; Roman, RM; Doctor, RB; Salter, KD; Toker, A; Fitz, JG				Feranchak, AP; Roman, RM; Doctor, RB; Salter, KD; Toker, A; Fitz, JG			The lipid products of phosphoinositide 3-kinase contribute to regulation of cholangiocyte ATP and chloride transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUCT EPITHELIAL-CELLS; PROTEIN-KINASE-C; PHOSPHATIDYLINOSITOL 3-KINASE; CYSTIC-FIBROSIS; VOLUME REGULATION; HEPATOMA-CELLS; BILE SECRETION; LIVER-DISEASE; ACTIVATION; CHANNELS	ATP stimulates Cl- secretion and bile formation by activation of purinergic receptors in the apical membrane of cholangiocytes. The purpose of these studies was to determine the cellular origin of biliary ATP and to assess the regulatory pathways involved in its release. In Mz-Cha-1 human cholangiocarcinoma cells, increases in cell volume were followed by increases in phophoinositide (PI) S-kinase activity, ATP release, and membrane Cl- permeability. PI 3-kinase signaling appears to play a regulatory role because ATP release was inhibited by wortmannin or LY294002 and because volume-sensitive current activation was inhibited by intracellular dialysis with antibodies to the 110 kDa-subunit of PI 3-kinase, Similarly, in intact normal rat cholangiocyte monolayers, increases in cell volume stimulated luminal Cl- secretion through a wortmannin-sensitive pathway. To assess the role of PI 3-kinase more directly, cells were dialyzed with the synthetic lipid products of PI 3-kinase, Intracellular delivery of phosphatidylinositol 3,4-bisphosphate, and phosphatidylinositol 3,4,5-trisphosphate activated Cl- currents analogous to those observed following cell swelling. Taken together, these findings indicate that volume-sensitive activation of PI 3-kinase and the generation of lipid messengers modulate cholangiocyte ATP release, Cl- secretion, and, hence, bile formation.	Univ Colorado, Hlth Sci Ctr, Denver, CO 80262 USA; Childrens Hosp, Dept Pediat, Denver, CO USA; Childrens Hosp, Dept Med, Denver, CO USA; Boston Biomed Res Grp, Signal Transduct Grp, Boston, MA 02114 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Children's Hospital Colorado; Children's Hospital Colorado; Boston Biomedical Research Institute	Feranchak, AP (corresponding author), Univ Colorado, Hlth Sci Ctr, 4200 E 9th Ave,Campus Box B-158,Rm 6412, Denver, CO 80262 USA.				NIDDK NIH HHS [DK-46082, DK-43278] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046082, R37DK046082, R01DK043278] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BASAVAPPA S, 1993, GASTROENTEROLOGY, V104, P1796, DOI 10.1016/0016-5085(93)90661-U; Bodily K, 1997, HEPATOLOGY, V25, P403; CHANG D, 1988, COMPUT BIOL MED, V18, P351, DOI 10.1016/0010-4825(88)90022-4; Chari RS, 1996, AM J PHYSIOL-GASTR L, V270, pG246; Coffer PJ, 1998, BIOCHEM J, V335, P1; Derman MP, 1997, J BIOL CHEM, V272, P6465, DOI 10.1074/jbc.272.10.6465; Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; Feranchak AP, 1998, J BIOL CHEM, V273, P14906, DOI 10.1074/jbc.273.24.14906; FITZ JG, 1994, AM J PHYSIOL, V266, pG677, DOI 10.1152/ajpgi.1994.266.4.G677; FITZ JG, 1994, AM J PHYSIOL, V266, pG544, DOI 10.1152/ajpgi.1994.266.4.G544; FITZ JG, 1993, J CLIN INVEST, V91, P319, DOI 10.1172/JCI116188; FITZSIMMONS SC, 1993, J PEDIATR-US, V122, P1, DOI 10.1016/S0022-3476(05)83478-X; Folli F, 1997, GASTROENTEROLOGY, V113, P954, DOI 10.1016/S0016-5085(97)70192-6; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GASKIN KJ, 1988, NEW ENGL J MED, V318, P340, DOI 10.1056/NEJM198802113180602; Grygorczyk R, 1997, AM J PHYSIOL-CELL PH, V272, pC1058; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KNUTH A, 1985, J HEPATOL, V1, P579, DOI 10.1016/S0168-8278(85)80002-7; Krause U, 1996, J BIOL CHEM, V271, P16668, DOI 10.1074/jbc.271.28.16668; LANG F, 1993, RENAL PHYSIOL BIOCH, V16, P48; LIDOFSKY SD, 1993, J BIOL CHEM, V268, P14632; MCGILL J, 1992, HEPATOLOGY, V16, P125; MCGILL JM, 1994, GASTROENTEROLOGY, V107, P236, DOI 10.1016/0016-5085(94)90082-5; MCGILL JM, 1994, AM J PHYSIOL, V266, pG731, DOI 10.1152/ajpgi.1994.266.4.G731; NAGEL RA, 1989, LANCET, V2, P1422; NATHANSON MH, 1991, HEPATOLOGY, V14, P551, DOI 10.1002/hep.1840140324; OBRIEN S, 1992, GUT, V33, P387, DOI 10.1136/gut.33.3.387; OKADA T, 1994, J BIOL CHEM, V269, P3563; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; Roman RM, 1997, J BIOL CHEM, V272, P21970, DOI 10.1074/jbc.272.35.21970; Roman RM, 1999, AM J PHYSIOL-GASTR L, V276, pG1391, DOI 10.1152/ajpgi.1999.276.6.G1391; Roman RM, 1996, AM J PHYSIOL-GASTR L, V271, pG239, DOI 10.1152/ajpgi.1996.271.2.G239; Schlenker T, 1997, AM J PHYSIOL-GASTR L, V273, pG1108, DOI 10.1152/ajpgi.1997.273.5.G1108; SCHLIESS F, 1995, BIOCHEM J, V309, P13, DOI 10.1042/bj3090013; Shimoke K, 1998, FEBS LETT, V437, P221, DOI 10.1016/S0014-5793(98)01235-6; Taylor AL, 1998, AM J PHYSIOL-CELL PH, V275, pC1391, DOI 10.1152/ajpcell.1998.275.5.C1391; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TOKER A, 1994, J BIOL CHEM, V269, P32358; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; VLAHOS CJ, 1995, J IMMUNOL, V154, P2413; Vroman B, 1996, LAB INVEST, V74, P303; Wang Y, 1996, P NATL ACAD SCI USA, V93, P12020, DOI 10.1073/pnas.93.21.12020	45	64	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30979	30986		10.1074/jbc.274.43.30979	http://dx.doi.org/10.1074/jbc.274.43.30979			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521494	hybrid			2022-12-27	WOS:000083276700090
J	Lim, CP; Cao, XM				Lim, CP; Cao, XM			Serine phosphorylation and negative regulation of Stat3 by JNK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; ACTIVATED PROTEIN-KINASES; EPIDERMAL GROWTH-FACTOR; MAP KINASE; C-JUN; TYROSINE PHOSPHORYLATION; MAMMALIAN-CELLS; DNA-BINDING; CELLULAR STRESSES; GENE-EXPRESSION	STATs are activated by various cytokines and growth factors via tyrosine phosphorylation, which leads to sequential dimer formation, nuclear translocation, binding to specific DNA sequences, and regulation of gene expression. Recently, serine phosphorylation of Stat3 on Ser-727 by ERK has been identified in response to epidermal growth factor (EGF). Here, we report that Ser727 phosphorylation of Stat3 can also be induced by JNK and activated either by stress or by its upstream kinase and that various stress treatments induce serine phosphorylation of Stat3 in the absence of tyrosine phosphorylation. Inhibitors of ERK and p38 did not inhibit UV-induced Stat3 serine phosphorylation, suggesting that neither of them is involved. We further demonstrate that JNK1, activated by its upstream kinase MKK7, negatively regulated the tyrosine phosphorylation and DNA binding and transcriptional activities of Stat3 stimulated by EGF. Correspondingly, pretreatment of cells with UV reduced the EGF-stimulated tyrosine phosphorylation and phosphotyrosine-dependent activities of Stat3. The inhibitory effect was not observed for Stat1, Our results suggest that Stat3 is a target of JNK that may regulate Stat3 activity via both Ser-727 phosphorylation-dependent and -independent mechanisms.	Natl Univ Singapore, Inst Mol & Cell Biol, Signal Transduct Lab, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Cao, XM (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, Signal Transduct Lab, 30 Med Dr, Singapore 117609, Singapore.							AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Ceresa BP, 1996, J BIOL CHEM, V271, P12121, DOI 10.1074/jbc.271.21.12121; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EILERS A, 1995, MOL CELL BIOL, V15, P3579; Frank DA, 1997, J CLIN INVEST, V100, P3140, DOI 10.1172/JCI119869; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Gotoh A, 1996, BLOOD, V88, P138; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Jain N, 1999, J BIOL CHEM, V274, P24392, DOI 10.1074/jbc.274.34.24392; Jain N, 1996, J BIOL CHEM, V271, P13530, DOI 10.1074/jbc.271.23.13530; Jain N, 1998, ONCOGENE, V17, P3157, DOI 10.1038/sj.onc.1202238; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; Leaman DW, 1996, MOL CELL BIOL, V16, P369; Lu XH, 1997, J BIOL CHEM, V272, P24751, DOI 10.1074/jbc.272.40.24751; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Ng J, 1997, J BIOL CHEM, V272, P24542, DOI 10.1074/jbc.272.39.24542; Sasse J, 1997, MOL CELL BIOL, V17, P4677, DOI 10.1128/MCB.17.8.4677; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sengupta TK, 1998, P NATL ACAD SCI USA, V95, P11107, DOI 10.1073/pnas.95.19.11107; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; Starr R, 1999, BIOESSAYS, V21, P47, DOI 10.1002/(SICI)1521-1878(199901)21:1<47::AID-BIES6>3.0.CO;2-N; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zhu XJ, 1997, MOL CELL BIOL, V17, P6618, DOI 10.1128/MCB.17.11.6618	52	188	188	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					31055	31061		10.1074/jbc.274.43.31055	http://dx.doi.org/10.1074/jbc.274.43.31055			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521505	hybrid			2022-12-27	WOS:000083276700101
J	Lutsenko, E; Bhagwat, AS				Lutsenko, E; Bhagwat, AS			The role of the Escherichia coli mug protein in the removal of uracil and 3,N-4-ethenocytosine from DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSINE METHYLATION; GLYCOSYLASE; SUBSTRATE; CELLS; GENE	The human thymine-DNA glycosylase has a sequence homolog in Escherichia coli that is described to excise uracils from U.G mismatches (Gallinari, P,, and Jiricny, J. (1996) Nature 383, 735-738) and is named mismatched uracil glycosylase (Mug), It has also been described to remove 3,N-4-ethenocytosine (EC) from epsilon C.G mismatches (Saparbaev, M,, and Laval, J, (1998) Proc, Natl. Acad, Sci. U.S.A. 95, 8508-8513). We used a mug mutant to clarify the role of this protein in DNA repair and mutation avoidance. We find that inactivation of mug has no effect on C to T or 5-methylcytosine to T mutations in E. coli and that this contrasts with the effect of ung defect on C to T mutations and of usr defect on 5-methylcytosine to T mutations. Even under conditions where it is overproduced in cells, Mug has little effect on the frequency of C to T mutations, Because uracil-DNA glycosylase (Ung) and Ver are known to repair U.G and T.G mismatches, respectively, we conclude that Mug does not repair U.G: or T.G mismatches in vivo, A defect in mug also has little effect on forward mutations, suggesting that Muff does not play a role in avoiding mutations due to endogenous damage to DNA in growing E, coli, Cell-free extracts from mug(+) ung cells show very little ability to remove uracil from DNA, but can excise epsilon C, The latter activity is missing in extracts from mug cells, suggesting that Mug may be the only enzyme in E, coli that can remove this mutagenic adduct, Thus, the principal role of Mug in E, coli may be to help repair damage to DNA caused by exogenous chemical agents such as chloroacetaldehyde.	Wayne State Univ, Dept Chem, Detroit, MI 48202 USA	Wayne State University	Bhagwat, AS (corresponding author), Wayne State Univ, Dept Chem, 463 Chem, Detroit, MI 48202 USA.	axb@chem.wayne.edu	Bhagwat, Ashok/ABA-3861-2020; Bhagwat, Ashok/AAU-4186-2021	Bhagwat, Ashok/0000-0003-1188-0579	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053273] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53273] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANDARU B, 1995, J BACTERIOL, V177, P2950, DOI 10.1128/jb.177.10.2950-2952.1995; BARTSCH H, 1994, DRUG METAB REV, V26, P349, DOI 10.3109/03602539409029802; BURGERS PMJ, 1986, J BACTERIOL, V166, P905, DOI 10.1128/jb.166.3.905-913.1986; DUNCAN BK, 1982, J BACTERIOL, V151, P750, DOI 10.1128/JB.151.2.750-755.1982; Gallinari P, 1996, NATURE, V383, P735, DOI 10.1038/383735a0; GUENGERICH FP, 1994, DRUG METAB REV, V26, P47, DOI 10.3109/03602539409029784; HENNECKE F, 1991, NATURE, V353, P776, DOI 10.1038/353776a0; KROKAN H, 1981, NUCLEIC ACIDS RES, V9, P2599, DOI 10.1093/nar/9.11.2599; LEBLANC JP, 1982, J BIOL CHEM, V257, P3477; Lieb M, 1996, MOL MICROBIOL, V20, P467, DOI 10.1046/j.1365-2958.1996.5291066.x; Luria SE, 1943, GENETICS, V28, P491; Lutsenko E, 1999, MUTAT RES-REV MUTAT, V437, P11, DOI 10.1016/S1383-5742(99)00065-4; Neddermann P, 1996, J BIOL CHEM, V271, P12767, DOI 10.1074/jbc.271.22.12767; Saparbaev M, 1998, P NATL ACAD SCI USA, V95, P8508, DOI 10.1073/pnas.95.15.8508; SibghatUllah, 1996, BIOCHEMISTRY-US, V35, P12926, DOI 10.1021/bi961022u; WANG Z, 1989, J BIOL CHEM, V264, P1163; Waters TR, 1998, J BIOL CHEM, V273, P20007, DOI 10.1074/jbc.273.32.20007; WIEBAUER K, 1989, NATURE, V339, P234, DOI 10.1038/339234a0; Wiebauer K, 1993, EXS, V64, P510; WYSZYNSKI M, 1994, P NATL ACAD SCI USA, V91, P1574, DOI 10.1073/pnas.91.4.1574	20	54	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					31034	31038		10.1074/jbc.274.43.31034	http://dx.doi.org/10.1074/jbc.274.43.31034			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521502	hybrid			2022-12-27	WOS:000083276700098
J	Moynihan, TP; Ardley, HC; Nuber, U; Rose, SA; Jones, PF; Markham, AF; Scheffner, M; Robinson, PA				Moynihan, TP; Ardley, HC; Nuber, U; Rose, SA; Jones, PF; Markham, AF; Scheffner, M; Robinson, PA			The ubiquitin-conjugating enzymes UbcH7 and UbcH8 interact with RING finger/IBR motif-containing domains of HHARI and H7-AP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LIGASE; ANGELMAN-SYNDROME; CARRIER PROTEIN; F-BOX; COMPLEX; P53; DEGRADATION; PATHWAY; FAMILY; E6-AP	Ubiquitinylation of proteins appears to be mediated by the specific interplay between ubiquitin-conjugating enzymes (E2s) and ubiquitin-protein ligases (E3s). However, cognate E3s and/or substrate proteins have been identified for only a few E2s, To identify proteins that can interact with the human E2 UbcH7, a yeast two-hybrid screen was performed. Two proteins were identified and termed human homologue of Drosophila ariadne (HHARI) and UbcH7-associated protein (H7-AP1). Both proteins, which are widely expressed, are characterized by the presence of RING finger and in between RING fingers (IBR) domains. No other overt structural similarity was observed between the two proteins. In vitro binding studies revealed that an N-terminal RING finger motif (HHARI) and the IBR domain (HHARI and H7-AP1) are involved in the interaction of these proteins with UbcH7. Furthermore, binding of these two proteins to UbcH7 is specific insofar that both HHARI and H7-AP1 can bind to the closely related E2, UbcH8, but not to the unrelated E2s UbcH5 and UbcH1. Although it is not clear at present whether HHARI and H7-AP1 serve, for instance, as substrates for UbcH7 or represent proteins with E3 activity, our data suggests that a subset of RING finger/IBR proteins are functionally linked to the ubiquitin/proteasome pathway.	Univ Leeds, St Jamess Univ Hosp, Mol Med Unit, Leeds LS9 7TF, W Yorkshire, England; Univ Leeds, St Jamess Univ Hosp, Leeds Dent Inst, Leeds LS9 7TF, W Yorkshire, England; Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany	Saint James's University Hospital; University of Leeds; Saint James's University Hospital; University of Leeds; Helmholtz Association; German Cancer Research Center (DKFZ)	Robinson, PA (corresponding author), Univ Leeds, St Jamess Univ Hosp, Mol Med Unit, Clin Sci Bldg, Leeds LS9 7TF, W Yorkshire, England.	des6par@leeds.ac.uk	Scheffner, Martin/K-2940-2012	Scheffner, Martin/0000-0003-2229-0128				AGUILERA M, 1998, A CONF DROS RES, V39, pA522; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BLUMENFELD N, 1994, J BIOL CHEM, V269, P9574; Burger J, 1997, AM J HUM GENET, V61, P88, DOI 10.1086/513900; CHIEN CT, 1991, P NATL ACAD SCI USA, V74, P5463; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; Hatakeyama S, 1997, J BIOL CHEM, V272, P15085, DOI 10.1074/jbc.272.24.15085; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Hu G, 1999, MOL CELL BIOL, V19, P724; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kubbutat MHG, 1999, CELL GROWTH DIFFER, V10, P87; Kumar S, 1997, J BIOL CHEM, V272, P13548, DOI 10.1074/jbc.272.21.13548; Li SH, 1997, CELL, V90, P469, DOI 10.1016/S0092-8674(00)80507-3; Matsuura T, 1997, NAT GENET, V15, P74, DOI 10.1038/ng0197-74; Mitchell SJ, 1998, AM J HUM GENET, V62, P1070, DOI 10.1086/301821; Morett E, 1999, TRENDS BIOCHEM SCI, V24, P229, DOI 10.1016/S0968-0004(99)01381-X; Moynihan TP, 1998, GENOMICS, V51, P124, DOI 10.1006/geno.1998.5257; Nuber U, 1996, J BIOL CHEM, V271, P2795, DOI 10.1074/jbc.271.5.2795; Perry WL, 1998, NAT GENET, V18, P143, DOI 10.1038/ng0298-143; Potuschak T, 1998, P NATL ACAD SCI USA, V95, P7904, DOI 10.1073/pnas.95.14.7904; ROBINSON PA, 1995, MAMM GENOME, V6, P725, DOI 10.1007/BF00354295; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; Scheffner M., 1998, UBIQUITIN BIOL CELL, P65; SCHNEIDER R, 1990, EMBO J, V9, P1431, DOI 10.1002/j.1460-2075.1990.tb08259.x; Schwarz SE, 1998, J BIOL CHEM, V273, P12148, DOI 10.1074/jbc.273.20.12148; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; SU LK, 1995, CANCER RES, V55, P2972; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Tang AH, 1997, CELL, V90, P459, DOI 10.1016/S0092-8674(00)80506-1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tyers M, 1999, SCIENCE, V284, P601, DOI 10.1126/science.284.5414.601; Varshavsky A., 1998, UBIQUITIN BIOL CELL, P223; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216	43	103	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30963	30968		10.1074/jbc.274.43.30963	http://dx.doi.org/10.1074/jbc.274.43.30963			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521492	hybrid			2022-12-27	WOS:000083276700088
J	Olson, LJ; Zhang, J; Lee, YC; Dahms, NM; Kim, JJP				Olson, LJ; Zhang, J; Lee, YC; Dahms, NM; Kim, JJP			Structural basis for recognition of phosphorylated high mannose oligosaccharides by the cation-dependent mannose 6-phosphate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-SPECIFICITY; ANGSTROM RESOLUTION; ARGININE RESIDUES; LYSOSOMAL-ENZYMES; LIGAND-BINDING; CONCANAVALIN-A; LEGUME LECTIN; PROTEIN; COMPLEX; PURIFICATION	Mannose 6-phosphate receptors (MPRs) play an important role in the targeting of newly synthesized soluble acid hydrolases to the lysosome in higher eukaryotic cells. These acid hydrolases carry mannose 6-phosphate recognition markers on their N-linked oligosaccharides that are recognized by two distinct MPRs: the cation-dependent mannose 6-phosphate receptor and the insulin-like growth factor II/cation-independent mannose 6-phosphate receptor. Although much has been learned about the MPRs, it is unclear how these receptors interact with the highly diverse population of lysosomal enzymes. It is known that the terminal mannose 6-phosphate is essential for receptor binding. However, the results from several studies using synthetic oligosaccharides indicate that the binding site encompasses at least two sugars of the oligosaccharide. We now report the structure of the soluble extracytoplasmic domain of a glycosylation-deficient form of the bovine cation-dependent mannose 6-phosphate receptor complexed to pentamannosyl phosphate, This construct consists of the amino-terminal 154 amino acids (excluding the signal sequence) with glutamine substituted for asparagine at positions 31, 57, 68, and 87. The binding site of the receptor encompasses the phosphate group plus three of the five mannose rings of pentamannosyl phosphate. Receptor specificity for mannose arises from protein contacts with the 2-hydroxyl on the terminal mannose ring adjacent to the phosphate group. Glycosidic linkage preference originates from the minimization of unfavorable interactions between the ligand and receptor.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA	Medical College of Wisconsin; Johns Hopkins University	Kim, JJP (corresponding author), Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA.				NIDDK NIH HHS [DK42667] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042667, R29DK042667, R56DK042667] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		*BIOS MOL SIM, 1995, INS, V2; BOURNE Y, 1990, J BIOL CHEM, V265, P18161; BRETTHAU.RK, 1973, BIOCHEMISTRY-US, V12, P1251, DOI 10.1021/bi00731a002; BRUNGER AT, 1992, X PLOR V 3 1 INSTRUC; DAHMS NM, 1993, J BIOL CHEM, V268, P5457; DAHMS NM, 1987, CELL, V50, P181, DOI 10.1016/0092-8674(87)90214-5; DISTLER JJ, 1991, J BIOL CHEM, V266, P21687; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; HOFLACK B, 1985, J BIOL CHEM, V260, P2008; IMBERTY A, 1990, GLYCOCONJUGATE J, V7, P27, DOI 10.1007/BF01050401; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KOSTER A, 1993, EMBO J, V12, P5219, DOI 10.1002/j.1460-2075.1993.tb06217.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LI M, 1990, ARCH BIOCHEM BIOPHYS, V283, P150, DOI 10.1016/0003-9861(90)90625-9; LIAO DI, 1994, P NATL ACAD SCI USA, V91, P1428, DOI 10.1073/pnas.91.4.1428; LOBEL P, 1988, J BIOL CHEM, V263, P2563; Loris R, 1998, BBA-PROTEIN STRUCT M, V1383, P9, DOI 10.1016/S0167-4838(97)00182-9; LUDWIG T, 1994, EMBO J, V13, P3430, DOI 10.1002/j.1460-2075.1994.tb06648.x; MA ZM, 1992, J BIOL CHEM, V267, P19017; Marron-Terada PG, 1998, BIOCHEMISTRY-US, V37, P17223, DOI 10.1021/bi981883y; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCPHERSON A, 1990, EUR J BIOCHEM, V189, P1, DOI 10.1111/j.1432-1033.1990.tb15454.x; MunierLehmann H, 1996, BIOCHEM SOC T, V24, P133, DOI 10.1042/bst0240133; NAISMITH JH, 1994, ACTA CRYSTALLOGR D, V50, P847, DOI 10.1107/S0907444994005287; Naismith JH, 1996, J BIOL CHEM, V271, P972, DOI 10.1074/jbc.271.2.972; NATOWICZ M, 1983, J CELL BIOL, V96, P915, DOI 10.1083/jcb.96.3.915; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Punnonen EL, 1996, EUR J BIOCHEM, V237, P809, DOI 10.1111/j.1432-1033.1996.0809p.x; RINI JM, 1993, J BIOL CHEM, V268, P10126; Roberts DL, 1998, CELL, V93, P639, DOI 10.1016/S0092-8674(00)81192-7; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; ROUSSEL, 1994, TURBO VERSION 4 2; SHAANAN B, 1991, SCIENCE, V254, P862, DOI 10.1126/science.1948067; STEIN M, 1987, BIOL CHEM H-S, V368, P927, DOI 10.1515/bchm3.1987.368.2.927; TOMODA H, 1991, CARBOHYD RES, V213, P37, DOI 10.1016/S0008-6215(00)90596-2; TONG PY, 1989, J BIOL CHEM, V264, P7970; VARKI A, 1980, J BIOL CHEM, V255, P847; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; WENDLAND M, 1991, J BIOL CHEM, V266, P2917; ZHANG Y, 1993, BIOCHEM J, V295, P841, DOI 10.1042/bj2950841	43	46	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29889	29896		10.1074/jbc.274.42.29889	http://dx.doi.org/10.1074/jbc.274.42.29889			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514470	hybrid			2022-12-27	WOS:000083176400049
J	Ratovitski, EA; Bao, C; Quick, RA; McMillan, A; Kozlovsky, C; Lowenstein, CJ				Ratovitski, EA; Bao, C; Quick, RA; McMillan, A; Kozlovsky, C; Lowenstein, CJ			An inducible nitric-oxide synthase (NOS)-associated protein inhibits NOS dimerization and activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-GAMMA; SKELETAL-MUSCLE; BACTERIAL LIPOPOLYSACCHARIDE; SUBUNIT DIMERIZATION; DIMERIC ENZYME; SMOOTH-MUSCLE; CELL-LINE; TETRAHYDROBIOPTERIN; DOMAIN; INDUCTION	A variety of transcriptional and post-transcriptional mechanisms regulate the expression of the inducible nitric-oxide synthase (iNOS, or NOS2). Although neurons and endothelial cells express proteins that interact with and inhibit neuronal NOS and endothelial NOS, macrophage proteins that inhibit NOS2 have not been identified. We show that murine macrophages express a 110-kDa protein that interacts with NOS2, which we call NOS-associated protein-110 kDa (NAP110). NAP110 directly interacts with the amino terminus of NOS2, and inhibits NOS catalytic activity by preventing formation of NOS2 homodimers. Expression of NAP110 may be a mechanism by which macrophages expressing NOS2 protect themselves from cytotoxic levels of nitric oxide.	Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Lowenstein, CJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, 950 Ross Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.			Lowenstein, Charles/0000-0003-0485-7514	NHLBI NIH HHS [R01 HL5361, P50 HL52315] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL052315] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABUSOUD HM, 1995, BIOCHEMISTRY-US, V34, P11167, DOI 10.1021/bi00035a023; Albakri QA, 1996, J BIOL CHEM, V271, P5414, DOI 10.1074/jbc.271.10.5414; ASSREUY J, 1993, BRIT J PHARMACOL, V108, P833, DOI 10.1111/j.1476-5381.1993.tb12886.x; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; BUSSE R, 1990, FEBS LETT, V265, P133, DOI 10.1016/0014-5793(90)80902-U; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; CHO HJ, 1995, P NATL ACAD SCI USA, V92, P11514, DOI 10.1073/pnas.92.25.11514; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DUKSIN D, 1982, J BIOL CHEM, V257, P3105; Eissa NT, 1998, P NATL ACAD SCI USA, V95, P7625, DOI 10.1073/pnas.95.13.7625; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gao JJ, 1997, J BIOL CHEM, V272, P1226, DOI 10.1074/jbc.272.2.1226; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; Ghosh DK, 1996, BIOCHEMISTRY-US, V35, P1444, DOI 10.1021/bi9521295; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P801, DOI 10.1021/bi00003a013; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; Ghosh S, 1998, J BIOL CHEM, V273, P22267, DOI 10.1074/jbc.273.35.22267; GRISCAVAGE JM, 1993, J IMMUNOL, V151, P6329; GROSS SS, 1993, ADV EXP MED BIOL, V338, P295; GROSS SS, 1992, J BIOL CHEM, V267, P25722; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; Jaffrey SR, 1998, NEURON, V20, P115, DOI 10.1016/S0896-6273(00)80439-0; Ju H, 1998, J BIOL CHEM, V273, P24025, DOI 10.1074/jbc.273.37.24025; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; Karupiah G, 1998, J EXP MED, V188, P1541, DOI 10.1084/jem.188.8.1541; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; KWON NS, 1989, J BIOL CHEM, V264, P20496; Lowenstein CJ, 1996, J CLIN INVEST, V97, P1837, DOI 10.1172/JCI118613; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; Melillo G, 1997, J BIOL CHEM, V272, P12236, DOI 10.1074/jbc.272.18.12236; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN C, 1994, J BIOL CHEM, V269, P13725; Palmer LA, 1998, AM J PHYSIOL-LUNG C, V274, pL212, DOI 10.1152/ajplung.1998.274.2.L212; PERRELLA MA, 1994, J BIOL CHEM, V269, P14595; Presta A, 1998, BIOCHEMISTRY-US, V37, P298, DOI 10.1021/bi971944c; Ratovitski EA, 1999, J BIOL CHEM, V274, P993, DOI 10.1074/jbc.274.2.993; SHIMADA S, 1994, CANCER RES, V54, P3831; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; TZENG E, 1995, P NATL ACAD SCI USA, V92, P11771, DOI 10.1073/pnas.92.25.11771; Venema RC, 1997, J BIOL CHEM, V272, P1276, DOI 10.1074/jbc.272.2.1276; Venema VJ, 1997, J BIOL CHEM, V272, P28187, DOI 10.1074/jbc.272.45.28187; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; VODOVOTZ Y, 1994, J IMMUNOL, V152, P4110; WEISS G, 1994, J EXP MED, V180, P969, DOI 10.1084/jem.180.3.969; WERNERFELMAYER G, 1990, J EXP MED, V172, P1599, DOI 10.1084/jem.172.6.1599; XIE QW, 1994, J BIOL CHEM, V269, P4705; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779	58	68	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30250	30257		10.1074/jbc.274.42.30250	http://dx.doi.org/10.1074/jbc.274.42.30250			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514518	hybrid			2022-12-27	WOS:000083176400097
J	Zhou, YC; Waxman, DJ				Zhou, YC; Waxman, DJ			STAT5b down-regulates peroxisome proliferator-activated receptor alpha transcription by inhibition of ligand-independent activation function region-1 trans-activation domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; 9-CIS RETINOIC ACID; GROWTH-HORMONE; CLOFIBRATE-INDUCTION; RAT HEPATOCYTES; FATTY-ACIDS; SH2 DOMAIN; LIVER; GENE; PROTEIN	Growth hormone-activated STAT5b inhibits by up to 80% the transcriptional activity of peroxisome proliferator-activated receptor (PPAR) alpha, a nuclear receptor activated by diverse environmental chemicals and hypolipidemic drugs classified as peroxisome proliferators. This inhibitory cross-talk between STAT5b and PPAR is now reported for PPAR forms gamma and delta and for thyroid hormone receptor, indicating a more general potential for inhibitory cross-talk between JAK/STAT and nuclear receptor signaling pathways. Further investigations revealed that SOCS-3, a growth hormone-inducible negative regulator of cytokine signaling to STAT5b, abolished the STAT5b inhibitory response. A constitutively active STAT5b mutant failed to inhibit PPAR alpha activity, indicating that STAT5b does not induce synthesis of a more proximal PPARa inhibitor. STAT5b inhibition was not reversed by overexpression of the heterodimerization partner of PPAR (retinoid X receptor) or the nuclear receptor coactivators P300 and SRC-1, suggesting that STAT5b does not inhibit PPAR alpha by competing for these limiting cellular cofactors. STAT5b did not inhibit a chimeric receptor comprised of yeast GAL4 DNA-binding domain linked to the ligand binding/AF-2 trans-activation domain of PPAR alpha indicating that the COOH-terminal AF-2 domain of PPAR is not the target of STAT5b inhibition. Rather, STAT5b inhibited transcription driven by the NH2-terminal ligand-independent AF-1 trans-activation domain of PPAR alpha in a GAL4-linked chimera by similar to 80%. The conservation of this AF-1 trans-activation function in many nuclear receptors suggests that AF-1 may serve as an important target for inhibitory cross-talk between STAT transcription factors and nuclear receptors in a variety of signaling pathways.	Boston Univ, Dept Biol, Div Cell & Mol Biol, Boston, MA 02215 USA	Boston University	Waxman, DJ (corresponding author), Boston Univ, Dept Biol, Div Cell & Mol Biol, 5 Cummington St, Boston, MA 02215 USA.	djw@bio.bu.edu		Waxman, David/0000-0001-7982-9206	NIEHS NIH HHS [ES07381] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES007381] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; Auwerx J, 1999, CELL, V97, P161; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Boucheron C, 1998, J BIOL CHEM, V273, P33936, DOI 10.1074/jbc.273.51.33936; Brun RP, 1997, CURR OPIN LIPIDOL, V8, P212, DOI 10.1097/00041433-199708000-00004; Cella N, 1998, MOL CELL BIOL, V18, P1783, DOI 10.1128/MCB.18.4.1783; Chen JD, 1998, CRIT REV EUKAR GENE, V8, P169, DOI 10.1615/CritRevEukarGeneExpr.v8.i2.40; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVEY HW, 1999, IN PRESS AM J HUMAN; Desvergne B, 1998, J STEROID BIOCHEM, V65, P65, DOI 10.1016/S0960-0760(97)00182-9; Dowell P, 1997, J BIOL CHEM, V272, P33435, DOI 10.1074/jbc.272.52.33435; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Ganguly TC, 1997, J CLIN INVEST, V99, P2906, DOI 10.1172/JCI119485; Gelman L, 1999, J BIOL CHEM, V274, P7681, DOI 10.1074/jbc.274.12.7681; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Gonzalez FJ, 1998, J NATL CANCER I, V90, P1702, DOI 10.1093/jnci/90.22.1702; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; HOWELL BW, 1989, MOL CELL BIOL, V9, P2928, DOI 10.1128/MCB.9.7.2928; Johnson TE, 1997, J STEROID BIOCHEM, V63, P1, DOI 10.1016/S0960-0760(97)00064-2; Juge-Aubry CE, 1999, J BIOL CHEM, V274, P10505, DOI 10.1074/jbc.274.15.10505; JUGEAUBRY CE, 1995, J BIOL CHEM, V270, P18117, DOI 10.1074/jbc.270.30.18117; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; LEE SST, 1995, MOL CELL BIOL, V15, P3012; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; Matuoka K, 1997, BIOCHEM BIOPH RES CO, V239, P488, DOI 10.1006/bbrc.1997.7492; Moutoussamy S, 1998, EUR J BIOCHEM, V255, P1, DOI 10.1046/j.1432-1327.1998.2550001.x; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Park SH, 1999, J BIOL CHEM, V274, P7421, DOI 10.1074/jbc.274.11.7421; Pfitzner E, 1998, MOL ENDOCRINOL, V12, P1582, DOI 10.1210/mend.12.10.0180; RAM PA, 1999, ENDO 1999 SAN DIEGO, V81, P386; Saatcioglu F, 1997, MOL CELL BIOL, V17, P4687, DOI 10.1128/MCB.17.8.4687; SATO T, 1995, BBA-LIPID LIPID MET, V1256, P327, DOI 10.1016/0005-2760(95)00040-J; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; Schoonjans K, 1996, BBA-LIPID LIPID MET, V1302, P93, DOI 10.1016/0005-2760(96)00066-5; Shao DL, 1998, NATURE, V396, P377, DOI 10.1038/24634; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; SUGIYAMA H, 1994, BIOCHEM PHARMACOL, V47, P918, DOI 10.1016/0006-2952(94)90494-4; SUNDSETH SS, 1992, J BIOL CHEM, V267, P3915; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Verdier F, 1998, J BIOL CHEM, V273, P28185, DOI 10.1074/jbc.273.43.28185; Verdier F, 1998, MOL CELL BIOL, V18, P5852, DOI 10.1128/MCB.18.10.5852; YAMADA J, 1994, ARCH BIOCHEM BIOPHYS, V315, P555, DOI 10.1006/abbi.1994.1536; ZHANG BW, 1993, J BIOL CHEM, V268, P12939; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhou YC, 1999, J BIOL CHEM, V274, P2672, DOI 10.1074/jbc.274.5.2672; ZHU YJ, 1993, J BIOL CHEM, V268, P26817; Zhu YJ, 1996, GENE EXPRESSION, V6, P185	57	66	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29874	29882		10.1074/jbc.274.42.29874	http://dx.doi.org/10.1074/jbc.274.42.29874			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514468	hybrid			2022-12-27	WOS:000083176400047
J	Jung, MY; Schmauss, C				Jung, MY; Schmauss, C			Decreased c-fos responses to dopamine D-1 receptor agonist stimulation in mice deficient for D-3 receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; RAT STRIATUM; MESSENGER-RNA; AUTORECEPTOR FUNCTION; MOLECULAR MECHANISMS; GLOBUS-PALLIDUS; GROWTH-FACTOR; MUTANT MICE; AMPHETAMINE; NEURONS	The acute administration of dopamine D-1 receptor agonists induces the expression of the immediate early gene c-fos. In wild type mice, this induction is completely abolished by pretreatment with the D-1-selective antagonist SCH23390, and pretreatment with the D-2-like receptor antagonist eticlopride reduces the levels of c-fos expressed in response to D-1 receptor stimulation. Mice deficient for the dopamine D-3 receptor express levels of D-1 agonist-stimulated c-fos immunoreactivity that are lower than c-fos levels of their wild type littermates. Moreover, the acute blockade of D-2 receptors in D-3 mutant mice further reduces c-fos expression levels. These data indicate that the basal activity of both D-2 and D-3 receptors contributes to D-1 agonist-stimulated c-fos responses. The findings therefore indicate that not only D-2 but also D-3 receptors play a role in dopamine-regulated gene expression.	Columbia Univ, Dept Psychiat, New York, NY 10032 USA; Columbia Univ, Dept Neurosci, New York, NY 10032 USA; CUNY Mt Sinai Sch Med, Grad Program Neurobiol, New York, NY 10029 USA	Columbia University; Columbia University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Schmauss, C (corresponding author), Columbia Univ, Dept Psychiat, 1051 Riverside Dr,Unit 42, New York, NY 10032 USA.							Accili D, 1996, P NATL ACAD SCI USA, V93, P1945, DOI 10.1073/pnas.93.5.1945; BALK JH, 1995, NATURE, V377, P424; BOUTHENET ML, 1991, BRAIN RES, V564, P203, DOI 10.1016/0006-8993(91)91456-B; COLE RL, 1995, NEURON, V14, P813, DOI 10.1016/0896-6273(95)90225-2; CURRAN T, 1985, CANCER SURV, V4, P655; Fields RD, 1997, J NEUROSCI, V17, P7252; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; GERFEN CR, 1992, TRENDS NEUROSCI, V15, P133, DOI 10.1016/0166-2236(92)90355-C; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; Ginty DD, 1997, NEURON, V18, P183, DOI 10.1016/S0896-6273(00)80258-5; GRAYBIEL AM, 1990, P NATL ACAD SCI USA, V87, P6912, DOI 10.1073/pnas.87.17.6912; Jung MY, 1999, NEUROSCIENCE, V91, P911, DOI 10.1016/S0306-4522(98)00705-2; KEEFE KA, 1995, NEUROSCIENCE, V66, P903, DOI 10.1016/0306-4522(95)00024-D; Koeltzow TE, 1998, J NEUROSCI, V18, P2231; KONRADI C, 1994, J NEUROSCI, V14, P5623; LeMoine C, 1997, J NEUROSCI, V17, P8038; Levant B, 1997, PHARMACOL REV, V49, P231; MERCHANT KM, 1994, J PHARMACOL EXP THER, V271, P460; MERCHANT KM, 1993, P NATL ACAD SCI USA, V90, P3447, DOI 10.1073/pnas.90.8.3447; Mercuri NB, 1997, NEUROSCIENCE, V79, P323; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; MORATALLA R, 1992, J NEUROSCI, V12, P2609; Moratalla R, 1996, P NATL ACAD SCI USA, V93, P14928, DOI 10.1073/pnas.93.25.14928; NGUYEN TV, 1992, P NATL ACAD SCI USA, V89, P4270, DOI 10.1073/pnas.89.10.4270; Nimchinsky EA, 1997, J BIOL CHEM, V272, P29229, DOI 10.1074/jbc.272.46.29229; PAUL ML, 1992, J NEUROSCI, V12, P3729, DOI 10.1523/jneurosci.12-10-03729.1992; ROBERTSON GS, 1994, J PHARMACOL EXP THER, V271, P1058; ROBERTSON GS, 1992, NEUROSCIENCE, V46, P315, DOI 10.1016/0306-4522(92)90054-6; Ruskin DN, 1998, J PHARMACOL EXP THER, V286, P272; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; Surmeier DJ, 1996, J NEUROSCI, V16, P6579, DOI 10.1523/jneurosci.16-20-06579.1996; WADDINGTON JL, 1993, D1 D2 DOPAMINE RECEP, P51; Wang JQ, 1996, NEUROSCIENCE, V72, P601, DOI 10.1016/0306-4522(95)00597-8; WHITE FJ, 1993, D1 D2 DOPAMINE RECEP, P79; Xu M, 1997, NEURON, V19, P837, DOI 10.1016/S0896-6273(00)80965-4; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; YOUNG ST, 1991, P NATL ACAD SCI USA, V88, P1291, DOI 10.1073/pnas.88.4.1291	38	33	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29406	29412		10.1074/jbc.274.41.29406	http://dx.doi.org/10.1074/jbc.274.41.29406			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506202	hybrid			2022-12-27	WOS:000083017800081
J	Carter, PH; Shimizu, M; Luck, MD; Gardella, TJ				Carter, PH; Shimizu, M; Luck, MD; Gardella, TJ			The hydrophobic residues phenylalanine 184 and leucine 187 in the type-1 parathyroid hormone (PTH) receptor functionally interact with the amino-terminal portion of PTH-(1-34)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; PROTEIN-LINKED RECEPTOR; (PTH)/PTH-RELATED PEPTIDE; TRANSMEMBRANE RESIDUES; EXTRACELLULAR LOOP; BINDING-AFFINITY; CROSS-LINKING; DOMAIN; SITE; MUTAGENESIS	Recent mutagenesis and cross-linking studies suggest that three regions of the PTH-1 receptor play important roles in ligand interaction: (i) the extreme NH2-terminal region, (ii) the juxtamembrane base of the amino-terminal extracellular domain, and (iii) the third extracellular loop. In this report, Re analyzed the second of these segments in the rat PTH-I receptor (residues 182-190) and its role in functional interaction with short PTH fragment analogs. Twenty-eight singly substituted PTH-I receptors were transiently transfected into COS-7 cells and shown to be fully expressed by surface antibody binding analysis, Alanine scanning analysis identified phe(184), Arg(186), Leu(187), and Ile(190) as important determinants of maximum binding of I-125-Iabeled bovine PTH-(1-34) and I-125-labeled bovine PTH-(3-34) and determinants of responsiveness to the NH2-terminal analog, PTH (1-14) in cAMP stimulation assays. Alanine mutations at these four sites augmented the ability of the COOH-terminal peptide [Glu(22),Trp(23)]PTHrP-(15-36) to inhibit the cAMP response induced by PTH-(1-34). At Phe(184) and Leu(187), hydrophobic substitutions (e.g. Ile, Met, or Leu) preserved PTH-(1-34)-mediated cAMP signaling potency, whereas hydrophilic substitutions (e.g. Asp, Glu, Lys, or Arg) weakened this response by 20-fold or more, as compared with the unsubstituted receptor's response. The results suggest that hydrophobicity at positions occupied by phe(184) and Leu(187) in the PTH-1 receptor plays an important role in determining functional interaction with the 3-14 portion of PTH.	Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Gardella, TJ (corresponding author), Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.				NIDDK NIH HHS [DK11794] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK011794] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abell A, 1996, J BIOL CHEM, V271, P4518; Adams AE, 1998, MOL ENDOCRINOL, V12, P1673, DOI 10.1210/me.12.11.1673; Bergwitz C, 1997, J BIOL CHEM, V272, P28861, DOI 10.1074/jbc.272.46.28861; Bergwitz C, 1996, J BIOL CHEM, V271, P26469, DOI 10.1074/jbc.271.43.26469; Bisello A, 1998, J BIOL CHEM, V273, P22498, DOI 10.1074/jbc.273.35.22498; Bowen WP, 1995, TRENDS PHARMACOL SCI, V16, P413, DOI 10.1016/S0165-6147(00)89091-4; CAO YJ, 1995, BIOCHEM BIOPH RES CO, V212, P673, DOI 10.1006/bbrc.1995.2021; Couvineau A, 1996, J BIOL CHEM, V271, P12795, DOI 10.1074/jbc.271.22.12795; Dautzenberg FM, 1998, P NATL ACAD SCI USA, V95, P4941, DOI 10.1073/pnas.95.9.4941; DeAlmeida VI, 1998, MOL ENDOCRINOL, V12, P750, DOI 10.1210/me.12.5.750; Dong MQ, 1999, J BIOL CHEM, V274, P903, DOI 10.1074/jbc.274.2.903; Gardella TJ, 1996, J BIOL CHEM, V271, P19888, DOI 10.1074/jbc.271.33.19888; GARDELLA TJ, 1994, ENDOCRINOLOGY, V135, P1186, DOI 10.1210/en.135.3.1186; Gardella TJ, 1996, J BIOL CHEM, V271, P12820, DOI 10.1074/jbc.271.22.12820; Holtmann MH, 1996, J PHARMACOL EXP THER, V279, P555; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; KOLAKOWSKI LF, 1994, RECEPTOR CHANNEL, V2, P1; KROEENBERG H, 1997, GENETICS ENDOCRINE M, P389; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE CW, 1995, MOL ENDOCRINOL, V9, P1269, DOI 10.1210/me.9.10.1269; LEE CW, 1994, ENDOCRINOLOGY, V135, P1488, DOI 10.1210/en.135.4.1488; Luck MD, 1999, MOL ENDOCRINOL, V13, P670, DOI 10.1210/me.13.5.670; Mannstadt M, 1998, J BIOL CHEM, V273, P16890, DOI 10.1074/jbc.273.27.16890; Nicole P, 1998, J PHARMACOL EXP THER, V284, P744; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Pellegrini M, 1998, BIOCHEMISTRY-US, V37, P12737, DOI 10.1021/bi981265h; ROST B, 1995, PROTEIN SCI, V4, P521; SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L; STROOP SD, 1995, BIOCHEMISTRY-US, V34, P1050, DOI 10.1021/bi00003a040; Turner PR, 1998, J BIOL CHEM, V273, P3830, DOI 10.1074/jbc.273.7.3830; Zhou AT, 1997, P NATL ACAD SCI USA, V94, P3644, DOI 10.1073/pnas.94.8.3644	32	36	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31955	31960		10.1074/jbc.274.45.31955	http://dx.doi.org/10.1074/jbc.274.45.31955			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542224	hybrid			2022-12-27	WOS:000083532100032
J	Lausen, M; Lynch, N; Schlosser, A; Tornoe, I; Saekmose, SG; Teisner, B; Willis, AC; Crouch, E; Schwaeble, W; Holmskov, U				Lausen, M; Lynch, N; Schlosser, A; Tornoe, I; Saekmose, SG; Teisner, B; Willis, AC; Crouch, E; Schwaeble, W; Holmskov, U			Microfibril-associated protein 4 is present in lung washings and binds to the collagen region of lung surfactant protein D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE GELS; LECTIN ACTIVITY; GAMMA-CHAIN; CD11B CD18; FIBRINOGEN; RECEPTOR; COLLECTINS; TENASCIN; MOLECULE; CARBOHYDRATE	We have purified a glycoprotein from bovine lung washings using affinity chromatography on a maltose-affinity column. On SDS-polyacrylamide gel electrophoresis the protein showed a molecular mass of 36 kDa in the reduced state and 66 kDa in the unreduced state. On gel permeation chromatography the apparent molecular mass was 250 kDa, N-terminal sequencing showed homology to the human matrix protein microfibril-associated protein (hMFAP4), and the glycoprotein was designated bovine MFAP4 (bMFAP4). Lung surfactant protein D (SP-D) was also purified from lung washings, and calcium-dependent binding was demonstrated between bMFAP4 and SP-D. hMFAP4 was cloned, and recombinant hMFAP4 showed the same binding pattern to SP-D as bMFAP4. No binding was seen to recombinant SP-D composed of the neck region and carbohydrate recognition domain of SP-D, indicating that the interaction between MFAP4 and SP-D is mediated via the collagen region of SP-D. MFAP4 also showed calcium-dependent binding to mannan, which was partially inhibited by maltose. Our findings indicate that MFAP4 has two binding specificities, one for collagen and one for carbohydrate, and we suggest that MFAP4 may fix the collectins in the extracellular compartment during inflammation.	Odense Univ, Univ So Denmark, Inst Mol Biol, Dept Immunol & Microbiol, DK-5000 Odense, Denmark; Univ Leicester, Dept Microbiol & Immunol, Leicester LE1 9HN, Leics, England; Univ Oxford, Dept Biochem, MRC, Immunochem Unit, Oxford OX1 3QU, England; Washington Univ, Dept Pathol, St Louis, MO 63110 USA	University of Southern Denmark; University of Leicester; University of Oxford; Washington University (WUSTL)	Holmskov, U (corresponding author), Odense Univ, Univ So Denmark, Inst Mol Biol, Dept Immunol & Microbiol, DK-5000 Odense, Denmark.		Holmskov, Uffe/AAA-3056-2022	Holmskov, Uffe/0000-0002-2391-9445; Schwaeble, Wilhelm/0000-0001-8927-0864; Lynch, Nicholas/0000-0003-3803-3329; Saekmose, Susanne Gjorup/0000-0002-1346-0052				ALTIERI DC, 1993, J BIOL CHEM, V268, P1847; ALTIERI DC, 1990, J BIOL CHEM, V265, P12119; Botas C, 1998, P NATL ACAD SCI USA, V95, P11869, DOI 10.1073/pnas.95.20.11869; BRISTOW J, 1993, J CELL BIOL, V122, P265, DOI 10.1083/jcb.122.1.265; BrownAugsburger P, 1996, J BIOL CHEM, V271, P18912, DOI 10.1074/jbc.271.31.18912; Cai GZ, 1999, AM J PHYSIOL-LUNG C, V276, pL131, DOI 10.1152/ajplung.1999.276.1.L131; Chroneos ZC, 1996, J BIOL CHEM, V271, P16375, DOI 10.1074/jbc.271.27.16375; Clark RA, 1997, J CELL BIOL, V137, P755, DOI 10.1083/jcb.137.3.755; CRAWFORD C, 1990, BIOCHEM J, V265, P575, DOI 10.1042/bj2650575; Crouch EC, 1998, BBA-MOL BASIS DIS, V1408, P278, DOI 10.1016/S0925-4439(98)00073-8; CROUCH EC, 1995, AM J RESP CELL MOL, V12, P410, DOI 10.1165/ajrcmb.12.4.7695920; DANG CV, 1985, J BIOL CHEM, V260, P9713; Eggleton P, 1999, CURR OPIN IMMUNOL, V11, P28, DOI 10.1016/S0952-7915(99)80006-5; Erickson HP, 1993, CURR OPIN CELL BIOL, V5, P869, DOI 10.1016/0955-0674(93)90037-Q; FISHER JH, 1995, AM J RESP CELL MOL, V12, P13, DOI 10.1165/ajrcmb.12.1.7811466; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; GUESDON JL, 1979, J HISTOCHEM CYTOCHEM, V27, P1131, DOI 10.1177/27.8.90074; Hansen S, 1998, IMMUNOBIOLOGY, V199, P165, DOI 10.1016/S0171-2985(98)80025-9; HENSCHEN A, 1979, THROMB HAEMOSTASIS, V41, P662; Holmskov U, 1997, J BIOL CHEM, V272, P13743, DOI 10.1074/jbc.272.21.13743; HOLMSKOV U, 1996, COLLECTINS INNATE IM, P51; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KOBAYASHI R, 1994, BIOCHEM BIOPH RES CO, V198, P1262, DOI 10.1006/bbrc.1994.1178; KOBAYASHI R, 1989, J BIOL CHEM, V264, P17437; Korfhagen TR, 1998, J BIOL CHEM, V273, P28438, DOI 10.1074/jbc.273.43.28438; Kremlev Sergey G., 1997, American Journal of Physiology, V272, pL1070; KREMLEV SG, 1994, AM J PHYSIOL-LUNG C, V267, pL712, DOI 10.1152/ajplung.1994.267.6.L712; Kremlev SG, 1997, AM J PHYSIOL-LUNG C, V272, pL996, DOI 10.1152/ajplung.1997.272.5.L996; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Le Y, 1998, FEBS LETT, V425, P367, DOI 10.1016/S0014-5793(98)00267-1; Lu JH, 1996, BIOCHEM J, V313, P473, DOI 10.1042/bj3130473; Lu JH, 1998, IMMUNOBIOLOGY, V199, P190, DOI 10.1016/S0171-2985(98)80026-0; LUNN CA, 1982, J BIOL CHEM, V257, P1424; MALHOTRA R, 1990, J EXP MED, V172, P955, DOI 10.1084/jem.172.3.955; Matsushita M, 1996, J BIOL CHEM, V271, P2448, DOI 10.1074/jbc.271.5.2448; NAKAJIMA T, 1974, J BIOL CHEM, V249, P7679; Nepomuceno RR, 1997, IMMUNITY, V6, P119, DOI 10.1016/S1074-7613(00)80419-7; NESTERENKO MV, 1994, J BIOCHEM BIOPH METH, V28, P239, DOI 10.1016/0165-022X(94)90020-5; NISHI T, 1991, EUR J BIOCHEM, V202, P643, DOI 10.1111/j.1432-1033.1991.tb16418.x; Ohashi T, 1997, J BIOL CHEM, V272, P14220, DOI 10.1074/jbc.272.22.14220; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; REID KBM, 1996, COLLECTINS INNATE IM, P99; RUBIO S, 1995, J BIOL CHEM, V270, P12162, DOI 10.1074/jbc.270.20.12162; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Turner MW, 1996, IMMUNOL TODAY, V17, P532, DOI 10.1016/0167-5699(96)10062-1; VANIWAARDEN JF, 1992, BIOCHEM J, V286, P5, DOI 10.1042/bj2860005; VNIWAARDEN F, 1990, AM J RESP CELL MOL N, V2, P91; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; Yee VC, 1997, STRUCTURE, V5, P125, DOI 10.1016/S0969-2126(97)00171-8; ZHAO ZY, 1995, HUM MOL GENET, V4, P589, DOI 10.1093/hmg/4.4.589	50	50	53	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32234	32240		10.1074/jbc.274.45.32234	http://dx.doi.org/10.1074/jbc.274.45.32234			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542261	hybrid			2022-12-27	WOS:000083532100069
J	O'Kane, RL; Martinez-Lopez, I; DeJoseph, MR; Vina, JR; Hawkins, RA				O'Kane, RL; Martinez-Lopez, I; DeJoseph, MR; Vina, JR; Hawkins, RA			Na+-dependent glutamate transporters (EAAT1, EAAT2, and EAAT3) of the blood-brain barrier - A mechanism for glutamate removal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-TRANSPORT; GLIAL-CELLS; RAT-BRAIN; SODIUM; LOCALIZATION; EXPRESSION; MEMBRANE; CARRIER; CULTURE; RELEASE	Na+-dependent transporters for glutamate exist on astrocytes (EAAT1 and EAAT2) and neurons (EAAT3), These transporters presumably assist in keeping the glutamate concentration low in the extracellular fluid of brain, Recently, Na+-dependent glutamate transport was described on the abluminal membrane of the blood-brain barrier. To determine whether the above-mentioned transporters participate in glutamate transport of the blood brain barrier, total RNA was extracted from bovine cerebral capillaries. cDNA for EAAT1, EAAT2, and EAAT3 was observed, indicating that mRNA was present. Western blot analysis demonstrated all three transporters were expressed on abluminal membranes, but none was detectable on luminal membranes of the blood brain barrier. Measurement of transport kinetics demonstrated voltage dependence, K+-dependence, and an apparent K-m of 14 mu M (aggregate of the three transporters) at a transmembrane potential of -61 mV. Inhibition of glutamate transport was observed using inhibitors specific for EAAT2 (kainic acid and dihydrokainic acid) and EAAT3 (cysteine). The relative activity of the three transporters was found to be approximately 1:3:6 for EAAT1, EAAT2, and EAAT3, respectively. These transporters may assist in maintaining low glutamate concentrations in the extracellular fluid.	Finch Univ Hlth Sci Chicago Med Sch, Dept Physiol & Biophys, N Chicago, IL 60064 USA; Univ Valencia, Fac Med & Farm, Dept Bioquim & Biol Mol, Valencia 46010, Spain	Chicago Medical School; University of Valencia	Hawkins, RA (corresponding author), Finch Univ Hlth Sci Chicago Med Sch, Dept Physiol & Biophys, 3333 Green Bay Rd, N Chicago, IL 60064 USA.		Viña, Juan R/ABE-5698-2021	Viña, Juan R/0000-0002-4035-3615	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031017] Funding Source: NIH RePORTER; NINDS NIH HHS [NS31017] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARRIZA JL, 1994, J NEUROSCI, V14, P5559; Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; BARBOUR B, 1988, NATURE, V335, P433, DOI 10.1038/335433a0; Benrabh H, 1996, NEUROSCI LETT, V210, P9, DOI 10.1016/0304-3940(96)12635-5; BOUVIER M, 1992, NATURE, V360, P471, DOI 10.1038/360471a0; Bradbury MWB, 1979, CONCEPT BLOOD BRAIN; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREW H, 1987, NATURE, V327, P707, DOI 10.1038/327707a0; BRIGHTMA.MW, 1969, J CELL BIOL, V40, P648, DOI 10.1083/jcb.40.3.648; Castillo J, 1996, STROKE, V27, P1060, DOI 10.1161/01.STR.27.6.1060; CHOI DW, 1987, J NEUROSCI, V7, P357; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELPINO MMS, 1992, J BIOL CHEM, V267, P25951; DELPINO MMS, 1995, J BIOL CHEM, V270, P14913, DOI 10.1074/jbc.270.25.14913; DREWES LR, 1977, AM J PHYSIOL, V233, pE320, DOI 10.1152/ajpendo.1977.233.4.E320; Eliasof S, 1998, VISION RES, V38, P1443, DOI 10.1016/S0042-6989(97)00452-5; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; GEMBA T, 1994, NEUROSCIENCE, V63, P789, DOI 10.1016/0306-4522(94)90523-1; HAWKINS RA, 1995, CELL TISSUE RES, V281, P207, DOI 10.1007/s004410050417; HAWKINS RA, 1983, HDB NEUROCHEMISTRY, V3, P259; HILLE B, 1992, IONIC CHANNELS EXCIT, P11; HUTCHISON HT, 1985, EXP NEUROL, V87, P260, DOI 10.1016/0014-4886(85)90216-X; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANDEL ER, 1991, PRINCIPLES NEURAL SC, P49; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee WJ, 1998, AM J PHYSIOL-CELL PH, V274, pC1101, DOI 10.1152/ajpcell.1998.274.4.C1101; Levy LM, 1998, J NEUROSCI, V18, P9620, DOI 10.1523/jneurosci.18-23-09620.1998; MARTINEZHERNANDEZ A, 1977, SCIENCE, V195, P1356, DOI 10.1126/science.14400; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; OLDENDORF WH, 1976, AM J PHYSIOL, V230, P94, DOI 10.1152/ajplegacy.1976.230.1.94; PARDRIDGE WM, 1979, ADV BIOCH PHYSL, P125; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; REESE TS, 1967, J CELL BIOL, V34, P207, DOI 10.1083/jcb.34.1.207; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; SHAW PJ, 1995, NEURODEGENERATION, V4, P209, DOI 10.1006/neur.1995.0026; STALLCUP WB, 1979, J NEUROCHEM, V32, P57, DOI 10.1111/j.1471-4159.1979.tb04509.x; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; TOSSMAN U, 1986, ACTA PHYSIOL SCAND, V127, P533, DOI 10.1111/j.1748-1716.1986.tb07938.x; VelazFaircloth M, 1996, AM J PHYSIOL-CELL PH, V270, pC67, DOI 10.1152/ajpcell.1996.270.1.C67; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; Wang GJ, 1998, MOL PHARMACOL, V53, P88, DOI 10.1124/mol.53.1.88; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0; Zerangue N, 1996, J PHYSIOL-LONDON, V493, P419, DOI 10.1113/jphysiol.1996.sp021393	44	217	227	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31891	31895		10.1074/jbc.274.45.31891	http://dx.doi.org/10.1074/jbc.274.45.31891			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542215	hybrid			2022-12-27	WOS:000083532100023
J	Raschle, M; Marra, G; Nystrom-Lahti, M; Schar, P; Jiricny, J				Raschle, M; Marra, G; Nystrom-Lahti, M; Schar, P; Jiricny, J			Identification of hMutL beta, a heterodimer of hMLH1 and hPMS1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA MISMATCH REPAIR; NONPOLYPOSIS COLORECTAL-CANCER; TUMOR-CELLS; MICROSATELLITE INSTABILITY; MICE DEFICIENT; COLON-CANCER; MUTL GENE; MUTATIONS; YEAST; PMS1	hMLH1 and hPMS2 function in postreplicative mismatch repair in the form of a heterodimer referred to as hMutL alpha. Tumors or cell Lines lacking this factor display mutator phenotypes and microsatellite instability, and mutations in the hMLH1 and hPMS2 genes predispose to hereditary non-polyposis colon cancer, A third MutL homologue, hPMS1, has also been reported to be mutated in one cancer-prone kindred, but the protein encoded by this locus has so far remained without function. We now show that hPMS1 is expressed in human cells and that it interacts with hMLH1 with high affinity to form the heterodimer hMutL beta. Recombinant hMutL alpha and hMutL beta, expressed in the baculovirus system, were tested for their activity in an in vitro mismatch repair assay. While hMutL alpha could fully complement extracts of mismatch repair-deficient cell lines lacking hMLH1 or hPMS2, hMutL beta failed to do so with any of the different substrates tested in this assay. The involvement of the latter factor in postreplicative mismatch repair thus remains to be demonstrated.	Univ Zurich, Inst Med Radiobiol, CH-8008 Zurich, Switzerland; Paul Scherrer Inst, CH-8008 Zurich, Switzerland	University of Zurich; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute	Jiricny, J (corresponding author), Univ Zurich, Inst Med Radiobiol, August Forel Str 7, CH-8008 Zurich, Switzerland.		Schär, Primo/G-5967-2012	Schär, Primo/0000-0003-1843-6147; Nystrom, Minna/0000-0003-0827-0243				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Akiyama Y, 1997, CANCER RES, V57, P3920; Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Bennett SE, 1997, CANCER RES, V57, P2956; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Drotschmann K, 1998, NUCLEIC ACIDS RES, V26, P948, DOI 10.1093/nar/26.4.948; Drummond JT, 1997, P NATL ACAD SCI USA, V94, P10144, DOI 10.1073/pnas.94.19.10144; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; FISCHEL R, 1993, CELL, V75, P1027; Flores-Rozas H, 1998, P NATL ACAD SCI USA, V95, P12404, DOI 10.1073/pnas.95.21.12404; Glaab WE, 1998, J BIOL CHEM, V273, P26662, DOI 10.1074/jbc.273.41.26662; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; Hampson R, 1997, J BIOL CHEM, V272, P28596, DOI 10.1074/jbc.272.45.28596; HORII A, 1994, BIOCHEM BIOPH RES CO, V204, P1257, DOI 10.1006/bbrc.1994.2598; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JIRICNY J, 1988, P NATL ACAD SCI USA, V85, P8860, DOI 10.1073/pnas.85.23.8860; Johnson RE, 1996, J BIOL CHEM, V271, P7285, DOI 10.1074/jbc.271.13.7285; Kato T, 1998, MUTAT RES-FUND MOL M, V422, P279, DOI 10.1016/S0027-5107(98)00208-5; KOI M, 1994, CANCER RES, V54, P4308; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; Marra G, 1998, P NATL ACAD SCI USA, V95, P8568, DOI 10.1073/pnas.95.15.8568; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271; Narayanan L, 1997, P NATL ACAD SCI USA, V94, P3122, DOI 10.1073/pnas.94.7.3122; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; NystromLahti M, 1996, HUM MOL GENET, V5, P763, DOI 10.1093/hmg/5.6.763; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; Pang QS, 1997, MOL CELL BIOL, V17, P4465, DOI 10.1128/MCB.17.8.4465; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; RISINGER JI, 1995, J BIOL CHEM, V270, P18183, DOI 10.1074/jbc.270.31.18183; Risinger JI, 1998, CANCER RES, V58, P2978; Sambrook J., 2002, MOL CLONING LAB MANU; Schar P, 1997, GENETICS, V146, P1275; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; Yao X, 1999, P NATL ACAD SCI USA, V96, P6850, DOI 10.1073/pnas.96.12.6850	48	146	150	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32368	32375		10.1074/jbc.274.45.32368	http://dx.doi.org/10.1074/jbc.274.45.32368			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542278	hybrid			2022-12-27	WOS:000083532100086
J	Shaked, Y; Rosenmann, H; Talmor, G; Gabizon, R				Shaked, Y; Rosenmann, H; Talmor, G; Gabizon, R			A C-terminal-truncated PrP isoform is present in mature sperm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCRAPIE PRION PROTEINS; CREUTZFELDT-JAKOB-DISEASE; ASPARAGINE-LINKED GLYCOSYLATION; PHOSPHOLIPASE-C; COPPER-BINDING; CELL-SURFACE; MOUSE SPERM; MICE; RESISTANT; CHOLESTEROL	PrPC, the normal isoform of the prion component PrPSc, is a 33-35-kDa glycophosphatidylinositol-anchored glycoprotein expressed in the plasma membrane of many cells and especially in the brain. The specific role of PrPC is unknown, although lately it has been shown to bind copper specifically. We show here that PrPC is present even in mature sperm cells, a polarized cell that retains only the minimal components required for DNA delivery, movement, and energy production, As opposed to PrPC in other cells, PrP in ejaculated sperm cells was truncated in its C terminus in the vicinity of residue 200, Sperm PrP, although membrane-bound, was not released by phosphatidylinositol phospholipase C as web as not localized in cholesterol-rich microdomains (rafts), Although no infertility was reported for PrP-ablated mice in normal situations, our results suggest that sperm cells originating from PrP-ablated mice were significantly more susceptible to high copper concentrations than sperm from wild type mice, allocating a protective role for PrP in specific stress situations related to copper toxicity. Since the functions performed by proteins in sperm cells are limited, these cells may constitute an ideal system to elucidate the function of PrPC.	Hadassah Univ Hosp, Dept Neurol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Gabizon, R (corresponding author), Hadassah Univ Hosp, Dept Neurol, IL-91120 Jerusalem, Israel.							BALDWIN MA, 1994, PHILOS T ROY SOC B, V343, P435, DOI 10.1098/rstb.1994.0041; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BREUCKER H, 1985, CELL TISSUE RES, V240, P303; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Brown DR, 1998, J NEUROCHEM, V70, P1686; Brown DR, 1999, GLIA, V25, P282, DOI 10.1002/(SICI)1098-1136(19990201)25:3<282::AID-GLIA8>3.0.CO;2-N; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; Buschmann A, 1998, BIOCHEM BIOPH RES CO, V253, P693, DOI 10.1006/bbrc.1998.9838; Chan S, 1998, CLIN LAB MED, V18, P673; COLLINGE J, 1994, NATURE, V370, P295, DOI 10.1038/370295a0; Collinge J, 1998, BRIT MED J, V317, P472; Cross NL, 1998, BIOL REPROD, V59, P7, DOI 10.1095/biolreprod59.1.7; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Gabizon R, 1996, NAT MED, V2, P59, DOI 10.1038/nm0196-59; GAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672; GENNIS R, 1995, SCIENCE, V269, P1063, DOI 10.1126/science.7652553; HARAGUCHI T, 1989, ARCH BIOCHEM BIOPHYS, V274, P1, DOI 10.1016/0003-9861(89)90409-8; Harris Z. Leah, 1996, American Journal of Clinical Nutrition, V63, p836S; Holada K, 1998, BRIT J HAEMATOL, V103, P276, DOI 10.1046/j.1365-2141.1998.01032.x; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V207, P621, DOI 10.1006/bbrc.1995.1233; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V214, P993, DOI 10.1006/bbrc.1995.2384; Ironside JW, 1998, J PATHOL, V186, P227, DOI 10.1002/(SICI)1096-9896(1998110)186:3&lt;227::AID-PATH174&gt;3.0.CO;2-3; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P2333, DOI 10.1073/pnas.94.6.2333; KASCZAK RJ, 1997, J VIROL, V61, P3688; Kirchhoff C, 1998, ANDROLOGIA, V30, P225; KRETZSCHMAR HA, 1986, DNA-J MOLEC CELL BIO, V5, P315, DOI 10.1089/dna.1986.5.315; Ladha S, 1998, J MEMBRANE BIOL, V165, P1, DOI 10.1007/s002329900415; MANSON JC, 1994, MOL NEUROBIOL, V8, P121, DOI 10.1007/BF02780662; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; Moore HDM, 1998, ANDROLOGIA, V30, P233; Naslavsky N, 1997, J BIOL CHEM, V272, P6324, DOI 10.1074/jbc.272.10.6324; OVERSTREET JW, 1993, AM J IND MED, V4, P5; PAPA S, 1994, J BIOENERG BIOMEMBR, V26, P609, DOI 10.1007/BF00831535; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Roblero L, 1996, REPROD FERT DEVELOP, V8, P871, DOI 10.1071/RD9960871; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; Shiraishi N, 1998, ARCH BIOCHEM BIOPHYS, V357, P225, DOI 10.1006/abbi.1998.0802; STAHL N, 1990, BIOCHEMISTRY-US, V29, P5405, DOI 10.1021/bi00474a028; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; Stockel J, 1998, BIOCHEMISTRY-US, V37, P7185, DOI 10.1021/bi972827k; TAGUCHI F, 1993, ARCH VIROL, V130, P219, DOI 10.1007/BF01319011; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; TARABOULOS A, 1990, P NATL ACAD SCI USA, V87, P8262, DOI 10.1073/pnas.87.21.8262; Tash JS, 1998, BIOCHEM BIOPH RES CO, V251, P557, DOI 10.1006/bbrc.1998.9516; THALER CD, 1995, BIOCHEMISTRY-US, V34, P7788, DOI 10.1021/bi00024a002; Tobler I, 1996, NATURE, V380, P639, DOI 10.1038/380639a0; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; Viles JH, 1999, P NATL ACAD SCI USA, V96, P2042, DOI 10.1073/pnas.96.5.2042; Yamamoto Toshinobu, 1998, Journal of Toxicological Sciences, V23, P373	53	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32153	32158		10.1074/jbc.274.45.32153	http://dx.doi.org/10.1074/jbc.274.45.32153			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542251	hybrid			2022-12-27	WOS:000083532100059
J	Stacker, SA; Stenvers, K; Caesar, C; Vitali, A; Domagala, T; Nice, E; Roufail, S; Simpson, RJ; Moritz, R; Karpanen, T; Alitalo, K; Achen, MG				Stacker, SA; Stenvers, K; Caesar, C; Vitali, A; Domagala, T; Nice, E; Roufail, S; Simpson, RJ; Moritz, R; Karpanen, T; Alitalo, K; Achen, MG			Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCHAIN DISULFIDE BONDS; VEGF-C; CRYSTAL-STRUCTURE; TYROSINE KINASES; FACTOR FAMILY; IN-VIVO; RECEPTOR; ANGIOGENESIS; BINDING; EXPRESSION	Vascular endothelial growth factor-D (VEGF-D) binds and activates the endothelial cell tyrosine kinase receptors VEGF receptor-2 (VEGFR-2) and VEGF receptor-3 (VEGFR-3), is mitogenic for endothelial cells, and shares structural homology and receptor specificity with VEGF-C, The primary translation product of VEGF-D has long N- and C-terminal polypeptide extensions in addition to a central VEGF homology domain (VHD). The VHD of VEGF-D is sufficient to bind and activate VEGFR-2 and VEGFR-3. Here we report that VEGF-D is proteolytically processed to release the VHD. Studies in 293EBNA cells demonstrated that VEGF-D undergoes Nand C-terminal cleavage events to produce numerous secreted polypeptides including a fully processed form of M-r similar to 21,000 consisting only of the VHD, which is predominantly a non-covalent dimer. Biosensor analysis demonstrated that the VHD has similar to 290- and similar to 40-fold greater affinity for VEGFR-2 and VEGFR-3, respectively, compared with unprocessed VEGF-D. In situ hybridization demonstrated that embryonic lung is a major site of expression of the VEGF-D gene. Processed forms of VEGF-D were detected in embryonic lung indicating that VEGF-D is proteolytically processed in vivo.	Royal Melbourne Hosp, Ludwig Inst Canc Res, Parkville, Vic 3050, Australia; Ludwig Inst Canc Res, Joint Prot Struct Lab, Parkville, Vic 3050, Australia; Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, SF-00014 Helsinki, Finland	Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Walter & Eliza Hall Institute; University of Helsinki	Stacker, SA (corresponding author), Royal Melbourne Hosp, Ludwig Inst Canc Res, POB 2008, Parkville, Vic 3050, Australia.		Alitalo, Kari K/J-5013-2014; Nice, Edouard C/B-1026-2011	Alitalo, Kari K/0000-0002-7331-0902; Karpanen, Terhi/0000-0002-2803-083X; Achen, Marc/0000-0002-3791-803X; Stacker, Steven/0000-0003-4096-9273; Simpson, Richard/0000-0002-9834-0796				Achen MG, 1998, INT J EXP PATHOL, V79, P255, DOI 10.1046/j.1365-2613.1998.700404.x; Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; ANDERSSON M, 1992, J BIOL CHEM, V267, P11260; Cao YH, 1998, P NATL ACAD SCI USA, V95, P14389, DOI 10.1073/pnas.95.24.14389; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Ji H, 1997, ELECTROPHORESIS, V18, P614, DOI 10.1002/elps.1150180345; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Joukov V, 1996, EMBO J, V15, P290; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; KENNEY WC, 1994, J BIOL CHEM, V269, P12351; Korpelainen EI, 1998, CURR OPIN CELL BIOL, V10, P159, DOI 10.1016/S0955-0674(98)80137-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lints TJ, 1996, DEV DYNAM, V205, P457, DOI 10.1002/(SICI)1097-0177(199604)205:4<457::AID-AJA9>3.0.CO;2-H; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; Migdal M, 1998, J BIOL CHEM, V273, P22272, DOI 10.1074/jbc.273.35.22272; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; Nice EC, 1999, BIOESSAYS, V21, P339, DOI 10.1002/(SICI)1521-1878(199904)21:4<339::AID-BIES11>3.0.CO;2-C; OEFNER C, 1992, EMBO J, V11, P3921, DOI 10.1002/j.1460-2075.1992.tb05485.x; Ogawa S, 1998, J BIOL CHEM, V273, P31273, DOI 10.1074/jbc.273.47.31273; Oh SJ, 1997, DEV BIOL, V188, P96, DOI 10.1006/dbio.1997.8639; Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709; Orlandini M, 1996, P NATL ACAD SCI USA, V93, P11675, DOI 10.1073/pnas.93.21.11675; OSTMAN A, 1988, J BIOL CHEM, V263, P16202; OSTMAN A, 1992, J CELL BIOL, V118, P509, DOI 10.1083/jcb.118.3.509; PARK JE, 1994, J BIOL CHEM, V269, P25646; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; POTGENS AJG, 1994, J BIOL CHEM, V269, P32879; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; STACKER SA, 1991, J IMMUNOL, V146, P648; Wise LM, 1999, P NATL ACAD SCI USA, V96, P3071, DOI 10.1073/pnas.96.6.3071; Witzenbichler B, 1998, AM J PATHOL, V153, P381, DOI 10.1016/S0002-9440(10)65582-4; Yamada Y, 1997, GENOMICS, V42, P483, DOI 10.1006/geno.1997.4774	39	260	281	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32127	32136		10.1074/jbc.274.45.32127	http://dx.doi.org/10.1074/jbc.274.45.32127			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542248	hybrid			2022-12-27	WOS:000083532100056
J	Yokoyama, T; Kaya, S; Abe, K; Taniguchi, K; Katoh, T; Yazawa, M; Hayashi, Y; Mardh, S				Yokoyama, T; Kaya, S; Abe, K; Taniguchi, K; Katoh, T; Yazawa, M; Hayashi, Y; Mardh, S			Acid-labile ATP and/or ADP/P-i binding to the tetraprotomeric form of Na/K-ATPase accompanying catalytic phosphorylation-dephosphorylation cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE PHOSPHOENZYME; NA+,K+-ATPASE ACTIVITY; CONFORMATIONAL CHANGE; SUBUNIT INTERACTIONS; LIGHT-CHAINS; ALPHA-CHAIN; NA,K-ATPASE; ENZYME; HALF; SITE	The Na/K-ATPase has been shown to bind 1 and 0.5 mol of P-32/mol of alpha-chain in the presence [gamma-P-32]ATP and [alpha-P-32]ATP, respectively, accompanied by a maximum accumulation of 0.5 mol of ADP-sensitive phosphoenzyme (NaE1P) and potassium sensitive phosphoenzyme (E2P), The former accumulation was followed by the slow constant liberation of P-i, but the latter was accompanied with a rapid similar to 0.25 mol of acid-labile P-i burst. The rubidium (potassium congener)-occluded enzyme (similar to 1.7 mol of rubidium/mol of alpha-chain) completely lost rubidium on the addition of sodium + magnesium, Further addition of similar to 100 mu M [gamma-P-32]ATP and [alpha-P-32]ATP, both induced 0.5 mol of P-32-ATP binding to the enzyme and caused accumulation of similar to 1 mol of rubidium/mol of a-chain, accompanied by a rapid similar to 0.5 mol of P-i burst with no detectable phosphoenzyme under steady state conditions. Electron microscopy of rotary-shadowed soluble and membrane-bound Na/K-ATPases and an antibody-Na/K-ATPase complex, indicated the presence of tetraprotomeric structures (cup), These and other data suggest that Na/K-ATP hydrolysis occurs via four parallel paths, the sequential appearance of (NaE1P:E-ATP)(2), (E2P:E.ATP:E2P:E.ADP/P-i), and (KE2:E.ADP/P-i)(2), each of which has been previously referred to as NaE1P, E2P, and KE2, respectively.	Hokkaido Univ, Grad Sch Sci, Div Chem, Sapporo, Hokkaido 0600810, Japan; Kyorin Univ, Sch Med, Dept Biochem, Mitaka, Tokyo 1811611, Japan; Linkoping Univ, Fac Hlth Sci, Dept Biomed & Surg, S-58185 Linkoping, Sweden	Hokkaido University; Kyorin University; Linkoping University	Taniguchi, K (corresponding author), Hokkaido Univ, Grad Sch Sci, Div Chem, Sapporo, Hokkaido 0600810, Japan.	ktan@ccms1.hucc.hokudai.ac.jp	Abe, Kazuhiro/D-7662-2013	Abe, Kazuhiro/0000-0003-2681-5921				ALBERS RW, 1976, ENZYMES BIOLOGICAL M, V3, P283; Antolovic R, 1999, EUR J BIOCHEM, V261, P181, DOI 10.1046/j.1432-1327.1999.00260.x; ASKARI A, 1980, BIOCHEM BIOPH RES CO, V93, P448, DOI 10.1016/0006-291X(80)91098-0; ASKARI A, 1981, FEBS LETT, V126, P215, DOI 10.1016/0014-5793(81)80245-1; ASKARI A, 1987, J BIOENERG BIOMEMBR, V19, P359, DOI 10.1007/BF00768539; BLOSTEIN R, 1988, METHOD ENZYMOL, V156, P171; ESMANN M, 1985, SODIUM PUMP, P17; FROEHLICH JP, 1976, J BIOL CHEM, V251, P2186; Froehlich JP, 1997, ANN NY ACAD SCI, V834, P280, DOI 10.1111/j.1749-6632.1997.tb52259.x; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; GLYNN IM, 1993, J PHYSIOL-LONDON, V462, P1; HAASE W, 1977, PFLUGERS ARCH, V381, P127; HANSEN O, 1979, NATURE, V280, P410, DOI 10.1038/280410a0; HAYASHI Y, 1989, BIOCHIM BIOPHYS ACTA, V983, P217, DOI 10.1016/0005-2736(89)90237-X; Katoh T, 1998, J BIOL CHEM, V273, P11436, DOI 10.1074/jbc.273.19.11436; KATOH T, 1989, J CELL BIOL, V109, P1549, DOI 10.1083/jcb.109.4.1549; Liu GQ, 1996, FEBS LETT, V390, P323, DOI 10.1016/0014-5793(96)00687-4; MATSUI H, 1983, CURR TOP MEMBR TRANS, V19, P145; PETERS WHM, 1981, NATURE, V290, P338, DOI 10.1038/290338a0; ROSSI RC, 1993, J BIOL CHEM, V268, P12579; SCHONER W, 1994, SODIUM PUMP, P332; SKOU JC, 1992, J BIOENERG BIOMEMBR, V24, P249; SKOU JC, 1957, BIOCHIM BIOPHYS ACTA, V23, P394, DOI 10.1016/0006-3002(57)90343-8; SUZUKI K, 1987, J BIOL CHEM, V262, P11752; TANIGUCHI K, 1984, J BIOL CHEM, V259, P5228; TANIGUCHI K, 1986, J BIOCHEM-TOKYO, V100, P1231, DOI 10.1093/oxfordjournals.jbchem.a121828; TANIGUCHI K, 1982, J BIOL CHEM, V257, P659; TANIGUCHI K, 1988, J BIOL CHEM, V263, P12943; Tsuda T, 1998, J BIOCHEM, V123, P169; Tsuda T, 1998, J BIOL CHEM, V273, P24339, DOI 10.1074/jbc.273.38.24339; Tsuda T, 1998, J BIOL CHEM, V273, P24334, DOI 10.1074/jbc.273.38.24334; TYLER JM, 1980, J ULTRA MOL STRUCT R, V71, P95, DOI 10.1016/S0022-5320(80)90098-2; VILSEN B, 1987, J BIOL CHEM, V262, P10511; WALLER GS, 1985, J BIOL CHEM, V260, P4368; YAMAGUCHI M, 1979, J BIOCHEM-TOKYO, V86, P509, DOI 10.1093/oxfordjournals.jbchem.a132551; YAMAZAKI A, 1994, J BIOCHEM, V116, P1360, DOI 10.1093/oxfordjournals.jbchem.a124688	36	31	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31792	31796		10.1074/jbc.274.45.31792	http://dx.doi.org/10.1074/jbc.274.45.31792			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542201	hybrid			2022-12-27	WOS:000083532100009
J	Gardner, RG; Hampton, RY				Gardner, RG; Hampton, RY			A highly conserved signal controls degradation of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase in eukaryotes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; STEROL-ENHANCED DEGRADATION; RETICULUM MEMBRANE-PROTEIN; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; REGULATED DEGRADATION; SQUALENE EPOXIDASE; MOLECULAR-CLONING; BOUND DOMAIN; IN-VIVO	Sterol synthesis by the mevalonate pathway is modulated, in part, through feedback-regulated degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR). In both mammals and yeast, a non-sterol isoprenoid signal positively regulates the rate of HMGR degradation. To define more precisely the molecule that serves as the source of this signal, we have conducted both pharmacological and genetic manipulations of the mevalonate pathway in yeast. We now demonstrate that farnesyl diphosphate (FPP) is the source of the positive signal for Hmg2p degradation in yeast. This FPP-derived signal does not act by altering the endoplasmic reticulum degradation machinery in general. Rather, the FPP-derived signal specifically modulates Hmg2p stability. In mammalian cells, an FPP-derived molecule also serves as a positive signal for HMGR degradation. Thus, both yeast and mammalian cells employ the same strategy for regulation of HMGR degradation, perhaps by conserved molecular processes.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Hampton, RY (corresponding author), Univ Calif San Diego, Dept Biol, 9500 Gilman Dr, La Jolla, CA 92093 USA.			Gardner, Richard/0000-0003-2162-6275	NIDDK NIH HHS [DK5199601] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051996, R37DK051996] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARONI M, 1986, GENE, V46, P71, DOI 10.1016/0378-1119(86)90168-X; BERGSTROM JD, 1993, P NATL ACAD SCI USA, V90, P80, DOI 10.1073/pnas.90.1.80; BITTER GA, 1984, GENE, V32, P263, DOI 10.1016/0378-1119(84)90002-7; BRADFUTE DL, 1994, J BIOL CHEM, V269, P6645; CHAMBON C, 1990, CURR GENET, V18, P41, DOI 10.1007/BF00321113; CHEREST H, 1985, GENE, V34, P269; CHUN KT, 1990, J BIOL CHEM, V265, P22004; CORRELL CC, 1994, J BIOL CHEM, V269, P17390; Cronin SR, 1999, METHOD ENZYMOL, V302, P58, DOI 10.1016/S0076-6879(99)02010-8; DIETSCHY JM, 1974, J LIPID RES, V15, P508; Faulkner A, 1999, J BIOL CHEM, V274, P14831, DOI 10.1074/jbc.274.21.14831; FEGUEUR M, 1991, CURR GENET, V20, P365, DOI 10.1007/BF00317063; Gardner R, 1998, MOL BIOL CELL, V9, P2611, DOI 10.1091/mbc.9.9.2611; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GULDENER U, 1996, NUCLEIC ACIDS RES, V24, P25196; Hampton RY, 1996, P NATL ACAD SCI USA, V93, P828, DOI 10.1073/pnas.93.2.828; Hampton RY, 1997, P NATL ACAD SCI USA, V94, P12944, DOI 10.1073/pnas.94.24.12944; HAMPTON RY, 1994, J CELL BIOL, V125, P299, DOI 10.1083/jcb.125.2.299; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Hayashi S, 1996, TRENDS BIOCHEM SCI, V21, P27, DOI 10.1016/0968-0004(96)80882-6; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; ISOLA VJ, 1989, J VIROL, V63, P2325, DOI 10.1128/JVI.63.5.2325-2334.1989; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JANDROSITZ A, 1991, GENE, V107, P155, DOI 10.1016/0378-1119(91)90310-8; JENNINGS SM, 1991, P NATL ACAD SCI USA, V88, P6038, DOI 10.1073/pnas.88.14.6038; JINGAMI H, 1987, J CELL BIOL, V104, P1693, DOI 10.1083/jcb.104.6.1693; Johnson PR, 1998, CELL, V94, P217, DOI 10.1016/S0092-8674(00)81421-X; LECUREUX LW, 1994, J CELL SCI, V107, P2635; Lopez D, 1997, ARCH BIOCHEM BIOPHYS, V343, P118, DOI 10.1006/abbi.1997.0162; Meigs TE, 1997, ARCH BIOCHEM BIOPHYS, V345, P1, DOI 10.1006/abbi.1997.0200; Meigs TE, 1996, J BIOL CHEM, V271, P7916, DOI 10.1074/jbc.271.14.7916; MOUNTAIN HA, 1991, YEAST, V7, P781, DOI 10.1002/yea.320070804; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; Rao S, 1999, P NATL ACAD SCI USA, V96, P7797, DOI 10.1073/pnas.96.14.7797; RYDER NS, 1992, BRIT J DERMATOL, V126, P2, DOI 10.1111/j.1365-2133.1992.tb00001.x; RYDER NS, 1989, CLIN EXP DERMATOL, V14, P98, DOI 10.1111/j.1365-2230.1989.tb00900.x; SAKAKIBARA J, 1995, J BIOL CHEM, V270, P17, DOI 10.1074/jbc.270.1.17; SIPERSTEIN MD, 1966, J BIOL CHEM, V241, P602; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310	41	122	128	3	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31671	31678		10.1074/jbc.274.44.31671	http://dx.doi.org/10.1074/jbc.274.44.31671			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531376	hybrid			2022-12-27	WOS:000083379400080
J	Gillespie, PG; Gillespie, SKH; Mercer, JA; Shah, K; Shokat, KM				Gillespie, PG; Gillespie, SKH; Mercer, JA; Shah, K; Shokat, KM			Engineering of the myosin-I beta nucleotide-binding pocket to create selective sensitivity to N-6-modified ADP analogs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION-FACTOR-TU; SITE-DIRECTED MUTAGENESIS; HEAVY-CHAIN GENE; X-RAY STRUCTURES; DICTYOSTELIUM-DISCOIDEUM; MOTOR DOMAIN; HAIR-CELLS; UNCONVENTIONAL MYOSINS; KINETIC CHARACTERIZATION; SUBSTRATE-SPECIFICITY	Distinguishing the cellular functions carried out by enzymes of highly similar structure would be simplified by the availability of isozyme-selective inhibitors. To determine roles played by individual members of the large myosin superfamily, we designed a mutation in myosin's nucleotide-binding pocket that permits binding of adenine nucleotides modified with bulky N-6 substituents. Introduction of this mutation, Y61G in rat myosin-I beta, did not alter the enzyme's affinity for ATP or actin and actually increased its ATPase activity and actin-translocation rate. We also synthesized several N-6-modified ADP analogs that should bind to and inhibit mutant, but not wild-type, myosin molecules, Several of these N-6-modified ADP analogs were more than 40-fold more potent at inhibiting ATP hydrolysis by Y61G than wild-type myosin-I beta; in doing so, these analogs locked Y61G myosin-I beta tightly to actin, N-6-(2-methylbutyl) ADP abolished actin filament motility mediated by Y61G, but not wild-type, myosin-I beta. Furthermore, at small fraction of inhibited Y61G molecules was sufficient to block filament motility mediated by mixtures of wild-type and Y61G myosin-I beta. Introduction of Y61G myosin-I beta molecules into a cell should permit selective inhibition by N-6-modified ADP analogs of cellular processes dependent on myosin-I beta.	Johns Hopkins Univ, Dept Physiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Neurosci, Baltimore, MD 21205 USA; McLaughlin Res Inst, Great Falls, MT 59405 USA; Princeton Univ, Dept Chem, Princeton, NJ 08544 USA; Princeton Univ, Dept Biol Mol, Princeton, NJ 08544 USA	Johns Hopkins University; Johns Hopkins University; McLaughlin Research Institute for Biomedical Sciences, Inc.; Princeton University; Princeton University	Gillespie, PG (corresponding author), Oregon Hlth & Sci Univ, Oregon Hearing Res Ctr, NRC04,3181 Sam Jackson Pk Rd, Portland, OR 97201 USA.	gillespp@ohsu.edu		Barr-Gillespie, Peter/0000-0002-9787-5860; Mercer, John/0000-0003-0307-4438	NATIONAL CANCER INSTITUTE [R01CA070331] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC003279] Funding Source: NIH RePORTER; NCI NIH HHS [CA70331] Funding Source: Medline; NIDCD NIH HHS [DC03279] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ALBANESI JP, 1985, J BIOL CHEM, V260, P8649; ASSAD JA, 1992, J NEUROSCI, V12, P3291; AVRAHAM KB, 1995, NAT GENET, V11, P369, DOI 10.1038/ng1295-369; Bauer CB, 1997, J MOL BIOL, V274, P394, DOI 10.1006/jmbi.1997.1325; BEMENT WM, 1994, P NATL ACAD SCI USA, V91, P6549, DOI 10.1073/pnas.91.14.6549; Bishop AC, 1998, CURR BIOL, V8, P257, DOI 10.1016/S0960-9822(98)70198-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANDE WZ, 1986, METHOD ENZYMOL, V134, P473; COLUCCIO LM, 1994, J CELL SCI, V107, P2279; Cope MJTV, 1996, STRUCTURE, V4, P969, DOI 10.1016/S0969-2126(96)00103-7; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DOHERSTEIN SK, 1993, NATURE, V365, P841; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; GIBSON F, 1995, NATURE, V374, P62, DOI 10.1038/374062a0; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GILLESPIE PG, 1993, NEURON, V11, P581, DOI 10.1016/0896-6273(93)90071-X; GILLESPIE PG, 1993, P NATL ACAD SCI USA, V90, P2710, DOI 10.1073/pnas.90.7.2710; Gillespie PG, 1997, NEURON, V19, P955, DOI 10.1016/S0896-6273(00)80387-6; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; Gulick AM, 1997, BIOCHEMISTRY-US, V36, P11619, DOI 10.1021/bi9712596; Hasson T, 1996, GENOMICS, V36, P431, DOI 10.1006/geno.1996.0488; Hasson T, 1997, J CELL BIOL, V137, P1287, DOI 10.1083/jcb.137.6.1287; HOFFENBERG S, 1995, BIOCHEM BIOPH RES CO, V215, P241, DOI 10.1006/bbrc.1995.2459; Howard J, 1997, NATURE, V389, P561, DOI 10.1038/39247; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HWANG YW, 1987, J BIOL CHEM, V262, P13081; Jontes JD, 1997, P NATL ACAD SCI USA, V94, P14332, DOI 10.1073/pnas.94.26.14332; KANG C, 1994, J BIOL CHEM, V269, P24046; Kapoor TM, 1999, P NATL ACAD SCI USA, V96, P9106, DOI 10.1073/pnas.96.16.9106; KIKUGAWA K, 1973, J MED CHEM, V16, P358, DOI 10.1021/jm00262a011; Kinose F, 1996, J CELL BIOL, V134, P895, DOI 10.1083/jcb.134.4.895; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; Liu Y, 1998, CHEM BIOL, V5, P91, DOI 10.1016/S1074-5521(98)90143-0; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; NISHIZAKA T, 1995, NATURE, V377, P251, DOI 10.1038/377251a0; NOVAK KD, 1995, J CELL BIOL, V131, P1205, DOI 10.1083/jcb.131.5.1205; O'Reilly D.R., 1994, BACULOVIRUS EXPRESSI; Ostap EM, 1996, J CELL BIOL, V132, P1053, DOI 10.1083/jcb.132.6.1053; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PATE E, 1991, BIOPHYS J, V59, P598, DOI 10.1016/S0006-3495(91)82275-5; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; Post PL, 1998, J CELL SCI, V111, P941; POWERS T, 1995, SCIENCE, V269, P1422, DOI 10.1126/science.7660124; Probst FJ, 1998, SCIENCE, V280, P1444, DOI 10.1126/science.280.5368.1444; RUPPERT C, 1995, J CELL SCI, V108, P3775; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; Shah K, 1997, P NATL ACAD SCI USA, V94, P3565, DOI 10.1073/pnas.94.8.3565; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Solc CK, 1994, AUDIT NEUROSCI, V1, P63; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; Sweeney HL, 1996, ANNU REV PHYSIOL, V58, P751, DOI 10.1146/annurev.ph.58.030196.003535; TONOMURA Y, 1967, J BIOCHEM-TOKYO, V61, P460, DOI 10.1093/oxfordjournals.jbchem.a128569; WALLACE RW, 1983, METHOD ENZYMOL, V102, P39; WANG D, 1993, J MUSCLE RES CELL M, V14, P484, DOI 10.1007/BF00297211; Wang FS, 1996, SCIENCE, V273, P660, DOI 10.1126/science.273.5275.660; WARRICK HM, 1986, P NATL ACAD SCI USA, V83, P9433, DOI 10.1073/pnas.83.24.9433; WEIJLAND A, 1994, BIOCHEMISTRY-US, V33, P10711, DOI 10.1021/bi00201a019; WEIJLAND A, 1993, SCIENCE, V259, P1311, DOI 10.1126/science.8446899; WINKELMANN DA, 1995, BIOPHYS J, V68, P2444, DOI 10.1016/S0006-3495(95)80426-1; Zhu T, 1996, BIOCHEMISTRY-US, V35, P513, DOI 10.1021/bi952053c	63	55	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31373	31381		10.1074/jbc.274.44.31373	http://dx.doi.org/10.1074/jbc.274.44.31373			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531338	hybrid			2022-12-27	WOS:000083379400042
J	Scherer-Oppliger, T; Leimbacher, W; Blau, N; Thony, B				Scherer-Oppliger, T; Leimbacher, W; Blau, N; Thony, B			Serine 19 of human 6-pyruvoyltetrahydropterin synthase is phosphorylated by cGMP protein kinase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-CYCLOHYDROLASE-I; 6-PYRUVOYL TETRAHYDROPTERIN SYNTHASE; RENAL MESANGIAL CELLS; GENE-EXPRESSION; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE; TETRAHYDROBIOPTERIN BIOSYNTHESIS; SEPIAPTERIN REDUCTASE; INTERFERON-GAMMA; MAST-CELLS; ENZYME	6-Pyruvoyltetrahydropterin synthase (PTPS) participates in tetrahydrobiopterin cofactor biosynthesis. We previously identified in a PTPS-deficient patient an inactive PTPS allele with an Arg(16) to Cys codon mutation. Arg(16) is located in the protein surface exposed phosphorylation motif Arg(16)-Arg-Ile-Ser, with Ser(19) as the putative phosphorylation site for serine-threonine protein kinases. Purification of recombinant PTPS-S19A from bacterial cells resulted in an active enzyme (k(cat)/K-m = 6.4 x 10(3) M-1 s(-1)), which was similar to wild-type PTPS (k(cat)/K-m = 4.1 x 10(3) M-1 s(-1)). In assays with purified enzymes, wild-type but not PTPS-S19A was a specific substrate for the cGMP-dependent protein kinase (cGK) type I and II. Upon expression in COS-1 cells, PTPS-S19A was stable but not phosphorylated and had a reduced activity of similar to 33% in comparison to wild-type PTPS. Extracts from several human cell lines, including brain, contained a kinase that bound to and phosphorylated immobilized wild-type, but not mutant PTPS. Addition of cGMP stimulated phosphotransferase activity 2-fold. Extracts from transfected COS-1 cells overexpressing cGKII stimulated Ser(19) phosphorylation more than 100-fold, but only 4-fold from cGKI overexpressing cells. Moreover, fibroblast extracts from mice! lacking cGKII exhibited significantly reduced phosphorylation of PTPS. These results suggest that Ser(19) of human PTPS may be a substrate for cGKII phosphorylation also in vivo, a modification that is essential for normal activity.	Univ Zurich, Dept Pediat, Div Clin Chem & Biochem, CH-8032 Zurich, Switzerland	University of Zurich	Thony, B (corresponding author), Univ Zurich, Dept Pediat, Div Clin Chem & Biochem, Steinwiesstr 75, CH-8032 Zurich, Switzerland.	bthony@kispi.unizh.ch		Blau, Nenad/0000-0003-4347-3230				Ausubel FM, 1992, CURRENT PROTOCOLS MO; Blau N, 1997, CHEMISTRY AND BIOLOGY OF PTERIDINES AND FOLATES 1997, P719; Blau N, 1996, J INHERIT METAB DIS, V19, P8, DOI 10.1007/BF01799342; BLAU N, 1993, PTERIDINES, V4, P1; BURGISSER DM, 1995, J MOL BIOL, V253, P358, DOI 10.1006/jmbi.1995.0558; BURGISSER DM, 1994, EUR J BIOCHEM, V219, P497, DOI 10.1111/j.1432-1033.1994.tb19964.x; COLBRAN JL, 1992, J BIOL CHEM, V267, P9589; DSa C, 1996, MOL BRAIN RES, V41, P105, DOI 10.1016/0169-328X(96)00073-3; FUJII M, 1995, FEBS LETT, V375, P263, DOI 10.1016/0014-5793(95)01223-2; HAUER CR, 1992, BIOCHEM BIOPH RES CO, V182, P953, DOI 10.1016/0006-291X(92)91824-A; Hesslinger C, 1998, J BIOL CHEM, V273, P21616, DOI 10.1074/jbc.273.34.21616; HIRAYAMA K, 1995, NEUROCHEM INT, V27, P157, DOI 10.1016/0197-0186(95)00008-V; IMAZUMI K, 1994, BIOCHEM BIOPH RES CO, V205, P1409, DOI 10.1006/bbrc.1994.2822; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KATOH S, 1994, FEBS LETT, V341, P227, DOI 10.1016/0014-5793(94)80462-1; KAUFMAN S, 1993, ANNU REV NUTR, V13, P261, DOI 10.1146/annurev.nu.13.070193.001401; Lapize C, 1998, BIOCHEM BIOPH RES CO, V251, P802, DOI 10.1006/bbrc.1998.9552; Lohmann SM, 1997, TRENDS BIOCHEM SCI, V22, P307, DOI 10.1016/S0968-0004(97)01086-4; OPPLIGER T, 1995, J BIOL CHEM, V270, P29498, DOI 10.1074/jbc.270.49.29498; Orstavik S, 1996, BIOCHEM BIOPH RES CO, V220, P759, DOI 10.1006/bbrc.1996.0477; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Pfeifer A, 1996, SCIENCE, V274, P2082, DOI 10.1126/science.274.5295.2082; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; Ploom T, 1999, J MOL BIOL, V286, P851, DOI 10.1006/jmbi.1998.2511; Pluss C, 1996, BIOCHEM J, V318, P665; Ruth P, 1997, J BIOL CHEM, V272, P10522; Scriver C.R., 1995, METABOLIC MOL BASIS, V7th ed, P1015; Stegenga SL, 1996, J NEUROCHEM, V66, P2541; Thony B, 1997, HUM MUTAT, V10, P11; Thony B, 1997, CHEMISTRY AND BIOLOGY OF PTERIDINES AND FOLATES 1997, P713; THONY B, 1994, AM J HUM GENET, V54, P782; THONY B, 1992, BIOCHEM BIOPH RES CO, V189, P1437, DOI 10.1016/0006-291X(92)90235-D; Turri MO, 1998, BIOL CHEM, V379, P1441; Vaandrager AB, 1998, P NATL ACAD SCI USA, V95, P1466, DOI 10.1073/pnas.95.4.1466; WERNER ER, 1990, J BIOL CHEM, V265, P3189; ZHU M, 1994, J BIOL CHEM, V269, P11825; ZIEGLER I, 1990, J BIOL CHEM, V265, P17026; ZIEGLER I, 1993, J BIOL CHEM, V268, P12544	38	20	23	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31341	31348		10.1074/jbc.274.44.31341	http://dx.doi.org/10.1074/jbc.274.44.31341			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531334	hybrid			2022-12-27	WOS:000083379400038
J	Swaminathan, CP; Nandi, A; Visweswariah, SS; Surolia, A				Swaminathan, CP; Nandi, A; Visweswariah, SS; Surolia, A			Thermodynamic analyses reveal role of water release in epitope recognition by a monoclonal antibody against the human guanylyl cyclase C receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOMYCES SUBTILISIN INHIBITOR; ENTHALPY-ENTROPY COMPENSATION; ANTIGEN-BINDING; MOLECULAR-BASIS; INTERMOLECULAR INTERACTIONS; ANTILYSOZYME ANTIBODIES; 3-DIMENSIONAL STRUCTURE; MUTATIONAL ANALYSIS; CROSS-REACTIVITY; FAB FRAGMENTS	The thermodynamics of a monoclonal antibody (mAb)-peptide interaction have been characterized by isothermal titration microcalorimetry, GCC:B10 mAb, generated against; human guanylyl cyclase C, a membrane-associated receptor and a potential marker for metastatic colon cancer, recognizes the cognate peptide epitope HIPPENIFPLE and its two contiguous mimotopes, HIPPEN and ENIFPLE, specifically and reversibly. The exothermic binding reactions between 6.4 and 42 degrees C are driven by dominant favorable enthalpic contributions between 20 and 42 degrees C, with a large negative heat capacity (Delta C-p) of -421 +/- 27 cal mol(-1) K-1. The unfavorable negative value of entropy (Delta S-b(0)) at 25 degrees C, an unusual feature among protein-protein interactions, becomes a positive one below an inversion temperature of 20.5 degrees C, Enthalpy-entropy compensation due to solvent reorganization accounts for an essentially unchanged free energy of interaction (Delta Delta G(b)(0) congruent to 0). The role of water molecules in the recognition process was tested by coupling an osmotic stress technique with isothermal titration microcalorimetry. The results provide direct and compelling evidence that GCC:B10 mAb recognizes the peptides HIPPENIFPLE, HIPPEN, and ENIFPLE differentially, with a concomitant release of variable and nonadditive numbers of water molecules (15, 7, and 3, respectively) hom the vicinity of the binding site.	Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India; Indian Inst Sci, Dept Mol Reprod Dev & Genet, Bangalore 560012, Karnataka, India; Jawaharlal Nehru Ctr Adv Sci Res, Bangalore 560064, Karnataka, India	Indian Institute of Science (IISC) - Bangalore; Indian Institute of Science (IISC) - Bangalore; Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR)	Surolia, A (corresponding author), Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India.	surolia@mbu.iisc.ernet.in	SUROLIA, AVADESHA/C-5442-2009; Visweswariah, Sandhya/Q-7500-2019	Visweswariah, Sandhya/0000-0003-2786-7344				Baker BM, 1997, J MOL BIOL, V268, P557, DOI 10.1006/jmbi.1997.0977; BAUGH RJ, 1972, J BIOL CHEM, V247, P7498; BHAT TN, 1990, NATURE, V347, P483, DOI 10.1038/347483a0; BHAT TN, 1994, P NATL ACAD SCI USA, V91, P1089, DOI 10.1073/pnas.91.3.1089; Braden BC, 1998, IMMUNOL REV, V163, P45, DOI 10.1111/j.1600-065X.1998.tb01187.x; CHITARRA V, 1993, P NATL ACAD SCI USA, V90, P7711, DOI 10.1073/pnas.90.16.7711; CHOTHIA C, 1975, NATURE, V256, P705, DOI 10.1038/256705a0; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; COLMAN PM, 1988, ADV IMMUNOL, V43, P99; CORRADIN G, 1984, J IMMUNOL, V133, P2915; Craig L, 1998, J MOL BIOL, V281, P183, DOI 10.1006/jmbi.1998.1907; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; Dall'Acqua W, 1998, BIOCHEMISTRY-US, V37, P7981, DOI 10.1021/bi980148j; DallAcqua W, 1996, BIOCHEMISTRY-US, V35, P9667, DOI 10.1021/bi960819i; Davies DR, 1996, P NATL ACAD SCI USA, V93, P7, DOI 10.1073/pnas.93.1.7; DONOVAN JW, 1969, J BIOL CHEM, V244, P1961; DUNITZ JD, 1995, CHEM BIOL, V2, P709, DOI 10.1016/1074-5521(95)90097-7; Faiman GA, 1997, J BIOL CHEM, V272, P31407, DOI 10.1074/jbc.272.50.31407; FIELDS BA, 1995, NATURE, V374, P739, DOI 10.1038/374739a0; Forte LR, 1996, NEWS PHYSIOL SCI, V11, P17; FUKADA H, 1985, BIOCHEMISTRY-US, V24, P5109, DOI 10.1021/bi00340a023; GIANNELLA RA, 1981, ANNU REV MED, V32, P341, DOI 10.1146/annurev.me.32.020181.002013; GOLDANSKII VI, 1995, PROTEIN SOLVENT INTE, P289; GOMEZ J, 1995, J MOL BIOL, V252, P337, DOI 10.1006/jmbi.1995.0501; HIBBITS KA, 1994, BIOCHEMISTRY-US, V33, P3584, DOI 10.1021/bi00178a015; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; JIN L, 1992, J MOL BIOL, V226, P851, DOI 10.1016/0022-2836(92)90636-X; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; Keitel T, 1997, CELL, V91, P811, DOI 10.1016/S0092-8674(00)80469-9; KELLEY RF, 1992, BIOCHEMISTRY-US, V31, P5434, DOI 10.1021/bi00139a003; Keown MB, 1998, BIOCHEMISTRY-US, V37, P8863, DOI 10.1021/bi972354h; Kramer A, 1997, CELL, V91, P799, DOI 10.1016/S0092-8674(00)80468-7; Leffler J. E., 1963, RATES EQUILIBRIA ORG, P315; LEVITT M, 1993, STRUCTURE, V1, P223, DOI 10.1016/0969-2126(93)90011-5; LUMRY R, 1970, BIOPOLYMERS, V9, P1125, DOI 10.1002/bip.1970.360091002; Luque I, 1998, BIOCHEMISTRY-US, V37, P5791, DOI 10.1021/bi9802521; MURPHY KP, 1993, PROTEINS, V15, P113, DOI 10.1002/prot.340150203; Nandi A, 1997, J CELL BIOCHEM, V66, P500, DOI 10.1002/(SICI)1097-4644(19970915)66:4<500::AID-JCB9>3.0.CO;2-P; Nandi A, 1998, PROTEIN SCI, V7, P2175, DOI 10.1002/pro.5560071015; OLIVEIRA AC, 1994, J MOL BIOL, V240, P184, DOI 10.1006/jmbi.1994.1433; Padlan EA, 1996, ADV PROTEIN CHEM, V49, P57, DOI 10.1016/S0065-3233(08)60488-X; Parsegian VA, 1995, METHOD ENZYMOL, V259, P43; Priev A, 1996, BIOCHEMISTRY-US, V35, P2061, DOI 10.1021/bi951842r; ROSS PD, 1981, BIOCHEMISTRY-US, V20, P3096, DOI 10.1021/bi00514a017; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; SCHWARZ FP, 1995, EUR J BIOCHEM, V228, P388; Swaminathan CP, 1998, J AM CHEM SOC, V120, P5153, DOI 10.1021/ja9733696; TAKAHASHI K, 1985, BIOCHEMISTRY-US, V24, P297, DOI 10.1021/bi00323a009; TELLO D, 1993, BIOCHEM SOC T, V21, P943, DOI 10.1042/bst0210943; TIMASHEFF SN, 1993, ANNU REV BIOPH BIOM, V22, P67, DOI 10.1146/annurev.bb.22.060193.000435; TSUMOTO K, 1995, J BIOL CHEM, V270, P18551, DOI 10.1074/jbc.270.31.18551; TSUMOTO K, 1994, J BIOL CHEM, V269, P28777; van Oss CJ, 1997, J MOL RECOGNIT, V10, P203, DOI 10.1002/(SICI)1099-1352(199709/10)10:5<203::AID-JMR366>3.0.CO;2-Z; VANREGENMORTEL MHV, 1994, IMMUNOCHEMISTRY, P277; Weast R. C., 1980, CRC HDB CHEM PHYSICS, pD229; Weber-Bornhauser S, 1998, BIOCHEMISTRY-US, V37, P13011, DOI 10.1021/bi980874m; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Xu D, 1997, J MOL BIOL, V265, P68, DOI 10.1006/jmbi.1996.0712; YANG CP, 1990, OMEGA DATA ORIGIN	61	44	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31272	31278		10.1074/jbc.274.44.31272	http://dx.doi.org/10.1074/jbc.274.44.31272			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531324	hybrid			2022-12-27	WOS:000083379400028
J	Dubin, AE; Huvar, R; D'Andrea, MR; Pyati, J; Zhu, JY; Joy, KC; Wilson, SJ; Galindo, JE; Glass, CA; Luo, L; Jackson, MR; Lovenberg, TW; Erlander, MG				Dubin, AE; Huvar, R; D'Andrea, MR; Pyati, J; Zhu, JY; Joy, KC; Wilson, SJ; Galindo, JE; Glass, CA; Luo, L; Jackson, MR; Lovenberg, TW; Erlander, MG			The pharmacological and functional characteristics of the serotonin 5-HT3A receptor are specifically modified by a 5-MT3B receptor subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTORS; HUMAN 5-HYDROXYTRYPTAMINE(3) RECEPTOR; XENOPUS-OOCYTES; K+ CHANNEL; SPLICE VARIANTS; ION CHANNELS; AGONIST SENSITIVITY; MOLECULAR-CLONING; SENSORY NEURONS; LIGAND-BINDING	While homomers containing 5-HT3A subunits form functional ligand-gated serotonin (5-HT) receptors in heterologous expression systems (Jackson, M. B., and Yakel, J. L. (1995) Annu. Rev. Physiol. 57, 447-468; Lambert, J. J., Peters, J. A., and Hope, A. G. (1995) in Ligand-Voltage-Gated Ion Channels (North, R., ed) pp. 177-211, CRC Press, Inc., Boca Raton, FL), it has been proposed that native receptors may exist as heteromers (Fletcher, S., and Barnes, N. M. (1998) Trends Pharmacol. Sci. 19, 212-215). We report the cloning of a subunit 5-HT3B with similar to 44% amino acid identity to 5-HT3A that specifically modified 5-HT3A receptor kinetics, voltage dependence, and pharmacology. Go-expression of 5-HT3B with 5-HT3A modified the duration of 5-HT3 receptor agonist-induced responses, linearized the current-voltage relationship, increased agonist and antagonist affinity, and reduced cooperativity between subunits. Reverse transcriptase-polymerase chain reaction in situ hybridization revealed co-localization of both 5-HT3B and 5-HT3A in a population of neurons in the amygdala, telencephalon, and entorhinal cortex. Furthermore, 5-HT3A and 5-HT3B mRNAs were expressed in spleen and intestine. Our data suggest that 5-HT3B might contribute to tissue-specific functional changes in 5-HT3-mediated signaling and/or modulation.	RW Johnson Pharmaceut Res Inst, San Diego, CA 92121 USA; RW Johnson Pharmaceut Res Inst, Spring House, PA 19477 USA	Johnson & Johnson; Johnson & Johnson USA; Johnson & Johnson; Johnson & Johnson USA	Dubin, AE (corresponding author), RW Johnson Pharmaceut Res Inst, 3210 Merryfield Row, San Diego, CA 92121 USA.							ABI-DARGHAM A, 1993, J NEUROCHEM, V60, P730, DOI 10.1111/j.1471-4159.1993.tb03208.x; ALDRICH RW, 1983, NATURE, V306, P436, DOI 10.1038/306436a0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARNES JM, 1992, NEUROSCI BIOBEHAV R, V16, P107, DOI 10.1016/S0149-7634(05)80057-0; BARNES JM, 1990, NEUROPHARMACOLOGY, V29, P1037, DOI 10.1016/0028-3908(90)90110-D; Bartrup JT, 1996, J PHYSIOL-LONDON, V490, P679, DOI 10.1113/jphysiol.1996.sp021177; Belelli D, 1995, MOL PHARMACOL, V48, P1054; Boess FG, 1997, NEUROPHARMACOLOGY, V36, P637, DOI 10.1016/S0028-3908(97)00044-0; BOESS FG, 1995, J NEUROCHEM, V64, P1401; BONHAUS DW, 1993, J NEUROCHEM, V61, P1927, DOI 10.1111/j.1471-4159.1993.tb09835.x; BONHAUS DW, 1995, J NEUROCHEM, V65, P104; Brown AM, 1998, J PHYSIOL-LONDON, V507, P653, DOI 10.1111/j.1469-7793.1998.653bs.x; CACHELIN AB, 1991, PFLUG ARCH EUR J PHY, V419, P579, DOI 10.1007/BF00370298; CONLEY EC, 1995, ION CHANNEL FACTS BO, V2, P12; Costall B, 1994, 5 HYDROXYTRYPTAMINE, P203; COUTURIER S, 1990, J BIOL CHEM, V265, P17560; Davies PA, 1999, NATURE, V397, P359, DOI 10.1038/16941; DOWNIE DL, 1995, BRIT J PHARMACOL, V114, P1641, DOI 10.1111/j.1476-5381.1995.tb14952.x; Dubin AE, 1999, J NEUROSCI, V19, P1371; Eglen RM, 1996, CURR PHARM DESIGN, V2, P367; FAN P, 1994, NEUROSCIENCE, V62, P515, DOI 10.1016/0306-4522(94)90384-0; Ferriere F, 1997, BIOCHEM J, V323, P251, DOI 10.1042/bj3230251; Fletcher S, 1998, NEUROPHARMACOLOGY, V37, P397, DOI 10.1016/S0028-3908(98)00052-5; Fletcher S, 1998, TRENDS PHARMACOL SCI, V19, P212, DOI 10.1016/S0165-6147(98)01210-3; Fletcher S, 1997, BRIT J PHARMACOL, V122, P655, DOI 10.1038/sj.bjp.0701439; FRASER SP, 1993, ELECTROPHYSIOLOGY PR, P65; GEBAUER A, 1993, N-S ARCH PHARMACOL, V347, P137; GILL CH, 1995, BRIT J PHARMACOL, V114, P1211, DOI 10.1111/j.1476-5381.1995.tb13335.x; GILON P, 1995, RECEPTOR CHANNEL, V3, P83; GREEN T, 1995, J BIOL CHEM, V270, P6056, DOI 10.1074/jbc.270.11.6056; Greenshaw AJ, 1997, DRUGS, V53, P20, DOI 10.2165/00003495-199753010-00003; GROSS A, 1991, PFLUG ARCH EUR J PHY, V419, P545, DOI 10.1007/BF00370805; GUILLEMARE E, 1992, BIOCHEMISTRY-US, V31, P12463, DOI 10.1021/bi00164a024; Haas KF, 1999, J PHYSIOL-LONDON, V514, P27, DOI 10.1111/j.1469-7793.1999.027af.x; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARGREAVES AC, 1994, MOL PHARMACOL, V46, P1120; HEHL S, 1993, EUR BIOPHYS J BIOPHY, V22, P1, DOI 10.1007/BF00205806; Hermans E, 1999, BRIT J PHARMACOL, V126, P873, DOI 10.1038/sj.bjp.0702359; Hope AG, 1996, BRIT J PHARMACOL, V118, P1237, DOI 10.1111/j.1476-5381.1996.tb15529.x; HOPE AG, 1993, EUR J PHARM-MOLEC PH, V245, P187, DOI 10.1016/0922-4106(93)90128-V; Hoyer D, 1997, NEUROPHARMACOLOGY, V36, P419, DOI 10.1016/S0028-3908(97)00036-1; HUSSY N, 1994, J PHYSIOL-LONDON, V481, P311, DOI 10.1113/jphysiol.1994.sp020441; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; INVERNIZZI R, 1981, Neurochemistry International, V3, P239, DOI 10.1016/0197-0186(81)90006-1; JACKSON MB, 1995, ANNU REV PHYSIOL, V57, P447; JONES KA, 1994, NEUROSCI LETT, V174, P133, DOI 10.1016/0304-3940(94)90004-3; Lankiewicz S, 1998, MOL PHARMACOL, V53, P202, DOI 10.1124/mol.53.2.202; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; LIU Y, 1993, BIOPHYS J, V64, P26, DOI 10.1016/S0006-3495(93)81337-7; LUETJE CW, 1991, J NEUROSCI, V11, P837; Luo L, 1999, NAT MED, V5, P117, DOI 10.1038/4806; Mair ID, 1998, BRIT J PHARMACOL, V124, P1667, DOI 10.1038/sj.bjp.0702037; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; Martin GR, 1998, TRENDS PHARMACOL SCI, V19, P2, DOI 10.1016/S0165-6147(97)01143-7; Meyniel JP, 1997, IMMUNOL LETT, V55, P151, DOI 10.1016/S0165-2478(97)02697-7; MIYAKE A, 1995, MOL PHARMACOL, V48, P407; Morales M, 1997, J NEUROSCI, V17, P3157; MORAN O, 1992, FEBS LETT, V302, P21, DOI 10.1016/0014-5793(92)80275-L; MUELLER EA, 1985, J CLIN ENDOCR METAB, V61, P1179, DOI 10.1210/jcem-61-6-1179; NEIJT HC, 1986, EUR J PHARMACOL, V127, P271, DOI 10.1016/0014-2999(86)90374-2; Niemeyer MI, 1998, BRIT J PHARMACOL, V123, P661, DOI 10.1038/sj.bjp.0701657; NUOVO GJ, 1997, PCR SITU HYBRIDIZATI, P271; PETERS JA, 1989, TRENDS PHARMACOL SCI, V10, P172, DOI 10.1016/0165-6147(89)90230-7; PETERS JA, 1992, TRENDS PHARMACOL SCI, V13, P391, DOI 10.1016/0165-6147(92)90119-Q; RAYMOND LA, 1998, FRONT NEUROBIOL, V3, P177; RAZANIBOROUJERDI S, 1993, BRAIN RES, V623, P195, DOI 10.1016/0006-8993(93)91427-T; ROBERTSON DW, 1992, LIFE SCI, V50, P599, DOI 10.1016/0024-3205(92)90372-V; Ronde P, 1998, J NEUROCHEM, V70, P1094; Salinas M, 1997, J BIOL CHEM, V272, P24371, DOI 10.1074/jbc.272.39.24371; Salinas M, 1997, J BIOL CHEM, V272, P8774, DOI 10.1074/jbc.272.13.8774; Sambrook J., 2002, MOL CLONING LAB MANU; SATO N, 1992, JPN J PHARMACOL, V59, P443, DOI 10.1254/jjp.59.443; SEPULVEDA MI, 1991, BRIT J PHARMACOL, V104, P536, DOI 10.1111/j.1476-5381.1991.tb12464.x; SHAO XM, 1991, J NEUROPHYSIOL, V65, P630, DOI 10.1152/jn.1991.65.3.630; Stocker M, 1999, J NEUROCHEM, V72, P1725, DOI 10.1046/j.1471-4159.1999.721725.x; SUGITA S, 1992, NEURON, V8, P199, DOI 10.1016/0896-6273(92)90121-S; SWOPE SL, 1992, FASEB J, V6, P2514, DOI 10.1096/fasebj.6.8.1375568; TECOTT LH, 1993, P NATL ACAD SCI USA, V90, P1430, DOI 10.1073/pnas.90.4.1430; UETZ P, 1994, FEBS LETT, V339, P302, DOI 10.1016/0014-5793(94)80435-4; van Hooft JA, 1998, P NATL ACAD SCI USA, V95, P11456, DOI 10.1073/pnas.95.19.11456; vanHooft JA, 1997, J NEUROCHEM, V69, P1318; WERNER P, 1994, MOL BRAIN RES, V26, P233, DOI 10.1016/0169-328X(94)90095-7; YAKEL JL, 1993, P NATL ACAD SCI USA, V90, P5030, DOI 10.1073/pnas.90.11.5030; YAKUSHIJI T, 1992, BRIT J PHARMACOL, V107, P853, DOI 10.1111/j.1476-5381.1992.tb14536.x; YANG J, 1992, J PHYSIOL-LONDON, V448, P237, DOI 10.1113/jphysiol.1992.sp019039; YANG J, 1990, J GEN PHYSIOL, V96, P1177, DOI 10.1085/jgp.96.6.1177; Zar J, 1996, BIOSTAT ANAL, P457; Zhong HJ, 1999, BRAIN RES, V816, P544, DOI 10.1016/S0006-8993(98)01232-3	88	222	232	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30799	30810		10.1074/jbc.274.43.30799	http://dx.doi.org/10.1074/jbc.274.43.30799			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521471	hybrid			2022-12-27	WOS:000083276700067
J	Foti, DM; Welihinda, A; Kaufman, RJ; Lee, AS				Foti, DM; Welihinda, A; Kaufman, RJ; Lee, AS			Conservation and divergence of the yeast and mammalian unfolded protein response - Activation of specific mammalian endoplasmic reticulum stress element of the grp78/BiP promoter by yeast Hac1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-ACTING FACTORS; TRANSCRIPTION FACTOR; REGULATORY ELEMENT; ADENOVIRUS E1A; CA2+ DEPLETION; GENE; YY1; INDUCTION; BINDING; CELLS	Yeast Had (yHac1), the transcription factor that binds and activates the unfolded protein response element of endoplasmic reticulum (ER)-chaperone gene promoters, only accumulates in stressed cells after an unconventional splicesosome-free mRNA processing step and escape from translation block In determining whether the novel regulatory mechanisms for yHac1 are conserved in mammalian cells, we discovered a unique unfolded protein response element-like sequence within the endoplasmic reticulum stress element 163, one of the three ER stress elements recently identified in the rat grp78 promoter, The unspliced form of yHac1 is stably expressed in nonstressed mammalian cells and is as active as the spliced form in stimulating the promoter activities of grp genes. Further, the yHac1 mRNA is not processed in response to ER stress in mammalian cells. We identified a CCAGC motif as the yHac1 binding site, which is contained within a YY1 binding site previously shown to be important for mammalian UPR, Dissection of the yHac1 and the YY1 binding sites uncovered specific contact points for an activator protein predicted to be the mammalian homolog of yHac1, the activity of which can be stimulated by YY1. A model of the conserved and unique features of the yeast and mammalian unfolded protein response transcription machinery is proposed.	Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Biochem & Mol Biol, Sch Med, Los Angeles, CA 90089 USA; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA	University of Southern California; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Lee, AS (corresponding author), Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Biochem & Mol Biol, Sch Med, Los Angeles, CA 90089 USA.			Welihinda, Ajith/0000-0002-0049-0850; Lee, Amy/0000-0002-0378-5443	NCI NIH HHS [CA27607] Funding Source: Medline; NHLBI NIH HHS [HV53777] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA027607, R37CA027607] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHANG SC, 1989, MOL CELL BIOL, V9, P2153, DOI 10.1128/MCB.9.5.2153; Chapman RE, 1997, CURR BIOL, V7, P850, DOI 10.1016/S0960-9822(06)00373-3; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; Harlow E, 1988, ANTIBODIES LABORATOR, P471; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; Kawahara T, 1997, MOL BIOL CELL, V8, P1845, DOI 10.1091/mbc.8.10.1845; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; Lee TC, 1998, NUCLEIC ACIDS RES, V26, P3215, DOI 10.1093/nar/26.13.3215; Li WW, 1997, MOL CELL BIOL, V17, P54, DOI 10.1128/MCB.17.1.54; Li WW, 1997, MOL CELL BIOL, V17, P61, DOI 10.1128/MCB.17.1.61; LI WW, 1994, MOL CELL BIOL, V14, P5533, DOI 10.1128/MCB.14.8.5533; LI WWF, 1993, J BIOL CHEM, V268, P12003; LIU ES, 1991, NUCLEIC ACIDS RES, V19, P5425, DOI 10.1093/nar/19.19.5425; Marcus N, 1997, DNA CELL BIOL, V16, P1123, DOI 10.1089/dna.1997.16.1123; McMillan D. Randy, 1994, Current Opinion in Biotechnology, V5, P540, DOI 10.1016/0958-1669(94)90071-X; Mori K, 1996, GENES CELLS, V1, P803, DOI 10.1046/j.1365-2443.1996.d01-274.x; PAHL HL, 1995, EMBO J, V14, P2580, DOI 10.1002/j.1460-2075.1995.tb07256.x; RAMAKRISHNAN M, 1995, DNA CELL BIOL, V14, P373, DOI 10.1089/dna.1995.14.373; Roy B, 1996, J BIOL CHEM, V271, P28995, DOI 10.1074/jbc.271.46.28995; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHI Y, 1997, BIOCHIM BIOPHYS ACTA, V1332, P49; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Welihinda AA, 1997, P NATL ACAD SCI USA, V94, P4289, DOI 10.1073/pnas.94.9.4289; WOODEN SK, 1991, MOL CELL BIOL, V11, P5612, DOI 10.1128/MCB.11.11.5612; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YANT SR, 1995, NUCLEIC ACIDS RES, V23, P4353, DOI 10.1093/nar/23.21.4353; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; ZHOU QJ, 1995, J VIROL, V69, P4323, DOI 10.1128/JVI.69.7.4323-4330.1995; Zhou YH, 1998, J NATL CANCER I, V90, P381, DOI 10.1093/jnci/90.5.381	34	42	48	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30402	30409		10.1074/jbc.274.43.30402	http://dx.doi.org/10.1074/jbc.274.43.30402			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521417	hybrid			2022-12-27	WOS:000083276700013
J	Cladera, J; Martin, I; Ruysschaert, JM; O'Shea, P				Cladera, J; Martin, I; Ruysschaert, JM; O'Shea, P			Characterization of the sequence of interactions of the fusion domain of the simian immunodeficiency virus with membranes - Role of the membrane dipole potential	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID HEAD GROUPS; ENVELOPE GLYCOPROTEIN; PHOSPHATIDYLCHOLINE MEMBRANES; INFRARED-SPECTROSCOPY; INFLUENZA-VIRUS; LIPID VESICLES; PEPTIDE; BILAYERS; RECEPTOR; HIV-1	The simian immunodeficiency virus fusion peptide constitutes a 12-residue N-terminal segment of the gp32 protein that is involved in the fusion between the viral and cellular membranes, facilitating the penetration of the virus in the host cell. Simian immunodeficiency virus fusion peptide is a hydrophobic peptide that in Me2SO forms aggregates that contain beta-sheet pleated structures. When added to aqueous media the peptide forms large colloidal aggregates. In the presence of lipidic membranes, however, the peptide interacts with the membranes and causes small changes of the membrane electrostatic potential as shown by fluorescein phosphatidylethanolamine fluorescence. Thioflavin T fluorescence and Fourier transformed infrared spectroscopy measurements reveal that the interaction of the peptide with the membrane bilayer results in complete disassembly of the aggregates originating from an Me2SO stock solution. Above a lipid/peptide ratio of about 5, the membrane disaggregation and water precipitation processes become dependent on the absolute peptide concentration rather than on the lipid/peptide ratio. A schematic mechanism is proposed, which sheds light on how peptide-peptide interactions can be favored with respect to peptide-lipid interactions at various lipid/peptide ratios. These studies are augmented by the use of the fluorescent dye 1-(3-sulfonatopropyl)-4-[beta[2-(di-n-octylamino)-6-naphthyl]vinyl] pyridinium betaine that shows the interaction of the peptide with the membranes has a clear effect on the magnitude of the so-called dipole potential that arises :From dipolar groups located on the lipid molecules and oriented water molecules at the membrane-water interface. It is shown that the variation of the membrane dipole potential affects the extent of the membrane fusion caused by the peptide and implicates the dipolar properties of membranes in their fusion.	Univ Nottingham, Sch Biomed Sci, Fac Med & Hlth Sci, Queens Med Ctr, Nottingham NG7 2UH, England; Free Univ Brussels, Chim Phys Macromol Interfaces Lab, B-1050 Brussels, Belgium	University of Nottingham; Universite Libre de Bruxelles; Vrije Universiteit Brussel	O'Shea, P (corresponding author), Univ Nottingham, Sch Biomed Sci, Fac Med & Hlth Sci, Queens Med Ctr, Nottingham NG7 2UH, England.	paul.oshea@nottingham.ac.uk	Cladera, Josep/E-6737-2010	Cladera, Josep/0000-0002-1724-3477; O'Shea, paul/0000-0001-9313-8313				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; ALOIA RC, 1993, P NATL ACAD SCI USA, V90, P5181, DOI 10.1073/pnas.90.11.5181; ARRONDO JLR, 1993, PROG BIOPHYS MOL BIO, V59, P23, DOI 10.1016/0079-6107(93)90006-6; BECHINGER B, 1991, BIOCHEMISTRY-US, V30, P3923, DOI 10.1021/bi00230a017; BESCHIASCHVILI G, 1990, BIOCHEMISTRY-US, V29, P52, DOI 10.1021/bi00453a007; Blumenthal R, 1999, MOL MEMBR BIOL, V16, P43, DOI 10.1080/096876899294742; BOSCH ML, 1989, SCIENCE, V244, P694, DOI 10.1126/science.2541505; Brasseur R, 1997, TRENDS BIOCHEM SCI, V22, P167, DOI 10.1016/S0968-0004(97)01047-5; BROCKMAN H, 1994, CHEM PHYS LIPIDS, V73, P57, DOI 10.1016/0009-3084(94)90174-0; BULDT G, 1981, J MEMBRANE BIOL, V58, P81, DOI 10.1007/BF01870972; BULDT G, 1978, NATURE, V271, P182, DOI 10.1038/271182a0; CASTANO EM, 1995, BIOCHEM J, V306, P599, DOI 10.1042/bj3060599; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Cladera J, 1998, BIOPHYS J, V74, P2434, DOI 10.1016/S0006-3495(98)77951-2; Clarke RJ, 1997, BBA-BIOMEMBRANES, V1327, P269, DOI 10.1016/S0005-2736(97)00075-8; Clarke RJ, 1997, BBA-BIOMEMBRANES, V1323, P223, DOI 10.1016/S0005-2736(96)00188-5; Colotto A, 1996, BIOCHEMISTRY-US, V35, P980, DOI 10.1021/bi951991+; Colotto A, 1997, BIOCHEMISTRY-US, V36, P7644, DOI 10.1021/bi970382u; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DEMPSEY C, 1989, BIOCHEMISTRY-US, V28, P6590, DOI 10.1021/bi00442a009; DEMPSEY CE, 1987, BIOCHEMISTRY-US, V26, P5803, DOI 10.1021/bi00392a033; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Durell SR, 1997, MOL MEMBR BIOL, V14, P97, DOI 10.3109/09687689709048170; FRANKLIN JC, 1993, BIOPHYS J, V65, P289, DOI 10.1016/S0006-3495(93)81051-8; GALLAHER WR, 1987, CELL, V50, P327, DOI 10.1016/0092-8674(87)90485-5; Golding C, 1996, BIOCHEMISTRY-US, V35, P10931, DOI 10.1021/bi960905i; GROSS E, 1994, BIOPHYS J, V67, P208, DOI 10.1016/S0006-3495(94)80471-0; KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244; LASKY LA, 1987, CELL, V50, P975, DOI 10.1016/0092-8674(87)90524-1; LEVINE H, 1995, AMYLOID, V2, P1, DOI 10.3109/13506129509031881; LUNEBERG J, 1995, J BIOL CHEM, V270, P27606; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MARTIN I, 1993, BIOCHIM BIOPHYS ACTA, V1145, P124, DOI 10.1016/0005-2736(93)90389-H; Martin I, 1996, J VIROL, V70, P298, DOI 10.1128/JVI.70.1.298-304.1996; MARTIN I, 1994, J VIROL, V68, P1139, DOI 10.1128/JVI.68.2.1139-1148.1994; MARTIN I, 1991, BIOCHEM BIOPH RES CO, V175, P872, DOI 10.1016/0006-291X(91)91646-T; MARTIN J, 1993, NATURE, V366, P279, DOI 10.1038/366279a0; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; NIEVA JL, 1994, BIOCHEMISTRY-US, V33, P3201, DOI 10.1021/bi00177a009; Pereira FB, 1997, BIOPHYS J, V73, P1977, DOI 10.1016/S0006-3495(97)78228-6; RAPAPORT D, 1994, J BIOL CHEM, V269, P15124; SEELIG J, 1987, BIOCHEMISTRY-US, V26, P7535, DOI 10.1021/bi00398a001; SHAI Y, 1995, TRENDS BIOCHEM SCI, V20, P460, DOI 10.1016/S0968-0004(00)89101-X; Siegel DP, 1997, BIOPHYS J, V73, P3089, DOI 10.1016/S0006-3495(97)78336-X; SIMON SA, 1992, BIOPHYS J, V61, P786, DOI 10.1016/S0006-3495(92)81883-0; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; SUREWICZ WK, 1988, BIOCHIM BIOPHYS ACTA, V952, P115, DOI 10.1016/0167-4838(88)90107-0; Trkola A, 1998, J VIROL, V72, P396, DOI 10.1128/JVI.72.1.396-404.1998; WALL J, 1995, MOL MEMBR BIOL, V12, P183, DOI 10.3109/09687689509027506; WALL J, 1995, J CELL SCI, V108, P2673; Wolfe C, 1998, MOL MEMBR BIOL, V15, P221, DOI 10.3109/09687689709044324; Wolfe CA, 1999, MOL MEMBR BIOL, V16, P257, DOI 10.1080/096876899294571	53	58	60	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29951	29959		10.1074/jbc.274.42.29951	http://dx.doi.org/10.1074/jbc.274.42.29951			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514478	hybrid			2022-12-27	WOS:000083176400057
J	Papi, A; Johnston, SL				Papi, A; Johnston, SL			Respiratory epithelial cell expression of vascular cell adhesion molecule-1 and its up-regulation by rhinovirus infection via NF-kappa B and GATA transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; COMMON COLD VIRUS; ASTHMATIC SUBJECTS; GENE-EXPRESSION; IN-VIVO; ULTRASTRUCTURAL-LOCALIZATION; DIFFERENTIAL REGULATION; VCAM-1 EXPRESSION; E-SELECTIN; ICAM-1	Virus infections, the majority of which are rhinovirus infections, are the major cause of asthma exacerbations. Asthma now affects one-fifth of the population, yet treatment of exacerbations is unsatisfactory, and the pathogenesis is unclear. Intraepithelial lymphocyte and eosinophil infiltration and activation are strongly implicated, but the mechanisms regulating these processes are unknown. We hypothesized that lower airway epithelial expression of vascular cell adhesion molecule-1 (VCAM-1) may be important in intraepithelial inflammation and that expression would be induced by pro-inflammatory stimuli and rhinovirus infection. We investigated respiratory epithelial cell VCAM-1 expression and its regulation to identify new targets for treatment of virus-induced asthma exacerbations. We observed constitutive respiratory epithelial cell VCAM-1 expression and that rhinovirus infection, but no other pro-inflammatory stimuli tested increased VCAM-1 cell surface expression in respiratory epithelial cell lines and primary bronchial epithelial cells, We then observed rhinovirus induction of VCAM-1 mRNA expression, promoter activity, and mRNA transcription. Rhinovirus induction of VCAM-1 promoter activity was critically dependent on up-regulation of proteins binding to the -254/-251 and -239/-236 GATA-binding sites and to the -72/-63 and -57/-48 NF-kappa B-binding sites in the VCAM-1 promoter. These studies identify VCAM-1 and the NF-kappa B and GATA transcription factor families as new targets for development of therapeutic interventions for virus-induced asthma exacerbations.	Univ Southampton, Southampton Gen Hosp, Southampton S016 6YD, Hants, England	University of Southampton	Johnston, SL (corresponding author), Univ Southampton, Southampton Gen Hosp, Tremona Rd, Southampton S016 6YD, Hants, England.		Papi, alberto/AAC-1888-2019; Johnston, Sebastian Lennox/I-2423-2012	Johnston, Sebastian Lennox/0000-0003-3009-9200; PAPI, ALBERTO/0000-0002-6924-4500				Ahmad M, 1998, J BIOL CHEM, V273, P4616, DOI 10.1074/jbc.273.8.4616; Atsuta J, 1997, AM J RESP CELL MOL, V17, P571, DOI 10.1165/ajrcmb.17.5.2685; BENTLEY AM, 1993, J ALLERGY CLIN IMMUN, V92, P857, DOI 10.1016/0091-6749(93)90064-M; BLOEMEN PGM, 1993, AM J RESP CELL MOL, V9, P586, DOI 10.1165/ajrcmb/9.6.586; CALHOUN WJ, 1994, J CLIN INVEST, V94, P2200, DOI 10.1172/JCI117581; Campbell MJ, 1997, BRIT MED J, V315, P1012, DOI 10.1136/bmj.315.7114.1012; CHEUNG D, 1995, AM J RESP CRIT CARE, V152, P1490, DOI 10.1164/ajrccm.152.5.7582282; COZENS AL, 1994, AM J RESP CELL MOL, V10, P38, DOI 10.1165/ajrcmb.10.1.7507342; DAMLE NK, 1991, P NATL ACAD SCI USA, V88, P6403, DOI 10.1073/pnas.88.15.6403; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; Doull IJM, 1997, BMJ-BRIT MED J, V315, P858, DOI 10.1136/bmj.315.7112.858; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FRAENKEL DJ, 1995, AM J RESP CRIT CARE, V151, P879; GARNER CM, 1994, CLIN EXP IMMUNOL, V95, P322; Gern JE, 1997, AM J RESP CRIT CARE, V155, P1159, DOI 10.1164/ajrccm.155.3.9117003; Gille J, 1996, BLOOD, V87, P211, DOI 10.1182/blood.V87.1.211.bloodjournal871211; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; Grunberg K, 1997, AM J RESP CRIT CARE, V156, P609; HALPERIN SA, 1985, AM REV RESPIR DIS, V132, P976; HOFER F, 1994, P NATL ACAD SCI USA, V91, P1839, DOI 10.1073/pnas.91.5.1839; Johnston SL, 1998, J IMMUNOL, V160, P6172; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654, DOI 10.1164/ajrccm.154.3.8810601; Johnston SL, 1995, DIAGNOSTIC PROCEDURE, P553; KEDINGER C, 1970, BIOCHEM BIOPH RES CO, V38, P165, DOI 10.1016/0006-291X(70)91099-5; Lechleitner S, 1998, J EXP MED, V187, P2023, DOI 10.1084/jem.187.12.2023; LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843; LHOTTA K, 1991, CLIN SCI, V81, P477, DOI 10.1042/cs0810477; Li XC, 1997, CELL IMMUNOL, V175, P58, DOI 10.1006/cimm.1996.1050; MEAGHER L, 1994, J IMMUNOL METHODS, V175, P237, DOI 10.1016/0022-1759(94)90366-2; Nagata M, 1998, AM J RESP CELL MOL, V19, P158, DOI 10.1165/ajrcmb.19.1.3001; NAGATA M, 1995, J IMMUNOL, V155, P2194; NAKAJIMA S, 1994, AM J PHYSIOL-LUNG C, V267, pL422, DOI 10.1152/ajplung.1994.267.4.L422; NEISH AS, 1995, J BIOL CHEM, V270, P28903, DOI 10.1074/jbc.270.48.28903; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; Ogawa T, 1996, VIRCHOWS ARCH, V429, P283; Ogawa T, 1997, NEPHRON, V75, P54, DOI 10.1159/000189500; OHKAWARA Y, 1995, AM J RESP CELL MOL, V12, P4, DOI 10.1165/ajrcmb.12.1.7529029; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; Papi A, 1999, J BIOL CHEM, V274, P9707, DOI 10.1074/jbc.274.14.9707; PIPKORN U, 1984, PROGR ALLERGY CLIN I, P237; RICE GE, 1990, J EXP MED, V171, P1369, DOI 10.1084/jem.171.4.1369; Richards IM, 1996, AM J RESP CELL MOL, V15, P172, DOI 10.1165/ajrcmb.15.2.8703473; RUCO LP, 1995, J PATHOL, V176, P391, DOI 10.1002/path.1711760410; Sambrook J., 2002, MOL CLONING LAB MANU; Sanders SP, 1998, J VIROL, V72, P934, DOI 10.1128/JVI.72.2.934-942.1998; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1068; SERON D, 1991, NEPHROL DIAL TRANSPL, V6, P917, DOI 10.1093/ndt/6.12.917; SHU HB, 1993, MOL CELL BIOL, V13, P6283, DOI 10.1128/MCB.13.10.6283; SUBAUSTE MC, 1995, J CLIN INVEST, V96, P549, DOI 10.1172/JCI118067; UNCAPHER CR, 1991, VIROLOGY, V180, P814, DOI 10.1016/0042-6822(91)90098-V; VANSEVENTER GA, 1991, J EXP MED, V174, P901, DOI 10.1084/jem.174.4.901; WILSON NM, 1990, ARCH DIS CHILD, V65, P407, DOI 10.1136/adc.65.4.407; WUTHRICH RP, 1993, TRANSPLANTATION, V55, P172, DOI 10.1097/00007890-199301000-00032; WUTHRICH RP, 1992, KIDNEY INT, V42, P903, DOI 10.1038/ki.1992.367; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8; Zhu Z, 1996, J CLIN INVEST, V97, P421, DOI 10.1172/JCI118431	59	74	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30041	30051		10.1074/jbc.274.42.30041	http://dx.doi.org/10.1074/jbc.274.42.30041			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514490	hybrid			2022-12-27	WOS:000083176400069
J	Wellmer, F; Kircher, S; Rugner, A; Frohnmeyer, R; Schafer, E; Harter, A				Wellmer, F; Kircher, S; Rugner, A; Frohnmeyer, R; Schafer, E; Harter, A			Phosphorylation of the parsley bZIP transcription factor CPRF2 is regulated by light	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHALCONE SYNTHASE PROMOTER; SIGNAL-TRANSDUCTION; G-BOX; DIFFERENT PHYTOCHROMES; FACTOR GBF1; PROTEINS; HETERODIMERIZATION; RESPONSIVENESS; PROTOPLASTS; EXPRESSION	The analysis of the complex network of signal transduction chains has demonstrated the importance of transcription factor activities for the control of gene expression. To understand how transcription factor activities in plants are regulated in response to Light, we analyzed the common plant regulatory factor 2 (CPRF2) from parsley (Petroselinum crispum L.) that interacts with promoter elements of light-regulated genes. Here, we demonstrate that CPRF2 is a phosphoprotein in vitro and that its phosphorylation state is rapidly increased in response to light. Phosphorylation in vitro as well as in vivo occurs primarily within the C-terminal half of the factor, and is caused by a cytosolic 40-kDa protein serine kinase. In contrast to other plant basic leucine-zipper motif factors, phosphorylation of CPRF2 does not alter its DNA binding activity. Therefore, me discuss alternative functions of the light-dependent phosphorylation of CPRF2 including the regulation of its nucleocytoplasmic partitioning.	Univ Freiburg, Inst biol Bot 2, D-79104 Freiburg, Germany	University of Freiburg	Harter, A (corresponding author), Univ Freiburg, Inst biol Bot 2, Schanzlestr 1, D-79104 Freiburg, Germany.			Wellmer, Frank/0000-0002-2095-0981				ARMSTRONG GA, 1992, PLANT CELL, V4, P525, DOI 10.1105/tpc.4.5.525; BLOCK A, 1990, P NATL ACAD SCI USA, V87, P5387, DOI 10.1073/pnas.87.14.5387; BOWLER C, 1994, GENE DEV, V8, P2188, DOI 10.1101/gad.8.18.2188; BOWLER C, 1994, PLANT CELL, V6, P1529, DOI 10.1105/tpc.6.11.1529; BUCHHOLZ G, 1995, PLANT PHYSIOL, V108, P227, DOI 10.1104/pp.108.1.227; Ciceri P, 1997, PLANT CELL, V9, P97, DOI 10.1105/tpc.9.1.97; DrogeLaser W, 1997, EMBO J, V16, P726, DOI 10.1093/emboj/16.4.726; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; Feldbrugge M, 1996, MOL GEN GENET, V251, P619, DOI 10.1007/s004380050210; FELDBRUGGE M, 1994, PLANT CELL, V6, P1607, DOI 10.1105/tpc.6.11.1607; FROHNMEYER H, 1994, PLANT J, V5, P437, DOI 10.1111/j.1365-313X.1994.00437.x; Furuya M, 1996, TRENDS PLANT SCI, V1, P301; HAHLBROCK K, 1975, PLANTA, V124, P311, DOI 10.1007/BF00388694; HARTER K, 1994, PLANT CELL, V6, P545, DOI 10.1105/tpc.6.4.545; HARTER K, 1994, P NATL ACAD SCI USA, V91, P5038, DOI 10.1073/pnas.91.11.5038; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; Kendrick RE, 1994, PHOTOMORPHOGENESIS P; Kircher S, 1998, MOL GEN GENET, V257, P595, DOI 10.1007/s004380050687; Kircher S, 1999, J CELL BIOL, V144, P201, DOI 10.1083/jcb.144.2.201; KLIMCZAK LJ, 1995, PLANT CELL, V7, P105, DOI 10.1105/tpc.7.1.105; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MENKENS AE, 1995, TRENDS BIOCHEM SCI, V20, P506, DOI 10.1016/S0968-0004(00)89118-5; MENKENS AE, 1994, P NATL ACAD SCI USA, V91, P2522, DOI 10.1073/pnas.91.7.2522; Meshi T, 1995, PLANT CELL PHYSIOL, V36, P1405; NEUFELD E, 1989, ANAL BIOCHEM, V177, P138, DOI 10.1016/0003-2697(89)90028-6; SCHAFER E, 1978, OPTISCHE STRAHLUNGSQ, P249; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHINDLER U, 1992, EMBO J, V11, P1275, DOI 10.1002/j.1460-2075.1992.tb05171.x; SCHINDLER U, 1992, EMBO J, V11, P1261, DOI 10.1002/j.1460-2075.1992.tb05170.x; SCHULZE-LEFERT P, 1989, PLANT CELL, V1, P707, DOI 10.1105/tpc.1.7.707; SCHULZE-LEFERT P, 1989, EMBO J, V8, P651, DOI 10.1002/j.1460-2075.1989.tb03422.x; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; TERZAGHI WB, 1995, ANNU REV PLANT PHYS, V46, P445, DOI 10.1146/annurev.pp.46.060195.002305; Van Der Geer P., 1993, PROTEIN PHOSPHORYLAT, P31; WEISSHAAR B, 1991, EMBO J, V10, P1777, DOI 10.1002/j.1460-2075.1991.tb07702.x; Whitelam GC, 1997, PLANT CELL ENVIRON, V20, P752, DOI 10.1046/j.1365-3040.1997.d01-100.x	39	36	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29476	29482		10.1074/jbc.274.41.29476	http://dx.doi.org/10.1074/jbc.274.41.29476			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506211	hybrid			2022-12-27	WOS:000083017800090
J	Alirezaei, M; Nairn, AC; Glowinski, J; Premont, J; Marin, P				Alirezaei, M; Nairn, AC; Glowinski, J; Premont, J; Marin, P			Zinc inhibits protein synthesis in neurons - Potential role of phosphorylation of translation initiation factor-2 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCHANGE FACTOR; METHYL-D-ASPARTATE; FACTOR-II; CORTICAL-NEURONS; ALPHA-SUBUNIT; METAL-IONS; GLUTAMATE; RECEPTORS; KINASE; BRAIN	In the central nervous system, Zn2+ is concentrated in the cerebral cortex and hippocampus and has been found to be toxic to neurons. In this study, we show that exposure of cultured cortical neurons from mouse to increasing concentrations of Zn2+ (10-300 mu M) induces a progressive decrease in global protein synthesis. The potency of Zn2+ was increased by about 2 orders of magnitude in the presence of Na+-pyrithione, a Zn2+ ionophore. The basal rate of protein synthesis was restored 3 h after Zn2+ removal. Zn2+ induced a sustained increase in phosphorylation of the Lu subunit of the translation eukaryotic initiation factor-2 (eIF-2 alpha), whereas it triggered a transient increase in phosphorylation of eukaryotic elongation factor-2 (eEF-2). Protein synthesis was still depressed 60 min after the onset of Zn2+ exposure while the state of eEF-2 phosphorylation had already returned to its basal level. Moreover, Zn2+ was less effective than glutamate to increase eEF-2 phosphorylation, whereas it induced a more profound inhibition of protein synthesis. These results suggest that Zn2+-induced inhibition of protein synthesis mainly correlates with the increase in eIF-2 alpha phosphorylation. Supporting further that Zn2+ acts at the initiation step of protein synthesis, it strongly decreased the amount of polyribosomes.	Coll France, INSERM, U114, Chaire Neuropharmacol, F-75231 Paris 05, France; Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Rockefeller University	Premont, J (corresponding author), Coll France, INSERM, U114, Chaire Neuropharmacol, 11 Pl Marcelin Berthelot, F-75231 Paris 05, France.			Nairn, Angus/0000-0002-7075-0195				ALCAZAR A, 1995, J NEUROCHEM, V65, P754; Ascher P, 1998, NAT NEUROSCI, V1, P173, DOI 10.1038/619; ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTINE CW, 1990, J NEUROSCI, V10, P108; Cuajungco MP, 1997, NEUROBIOL DIS, V4, P137, DOI 10.1006/nbdi.1997.0163; Frederickson C. J., 1994, Biological Signals, V3, P127; GABRIELSSON B, 1986, BRAIN RES, V384, P218, DOI 10.1016/0006-8993(86)91157-1; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0; HURST R, 1987, J BIOL CHEM, V262, P15939; KOH JY, 1994, NEUROSCIENCE, V60, P1049, DOI 10.1016/0306-4522(94)90282-8; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUDWIG JC, 1981, AGENTS ACTIONS, V9, P65; Marin P, 1997, J NEUROSCI, V17, P3445; PALFREY HC, 1995, ADV SEC MESS PHOSPH, V30, P191; PRICE NT, 1990, BIOCHIM BIOPHYS ACTA, V1054, P83, DOI 10.1016/0167-4889(90)90208-U; PROSTKO CR, 1995, J BIOL CHEM, V270, P6211, DOI 10.1074/jbc.270.11.6211; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; RASSENDREN FA, 1990, NEURON, V4, P733, DOI 10.1016/0896-6273(90)90199-P; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; RYAZANOV AG, 1993, TRANSLATIONAL REGULA, V2, P433; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; Schinder AF, 1996, J NEUROSCI, V16, P6125; Sensi SL, 1997, J NEUROSCI, V17, P9554; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; SMITH PK, 1985, ANAL BIOCHEM, V150, P6; Spiridon M, 1998, J PHYSIOL-LONDON, V506, P363, DOI 10.1111/j.1469-7793.1998.363bw.x; SRIVASTAVA SP, 1995, J BIOL CHEM, V270, P16619, DOI 10.1074/jbc.270.28.16619; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; WARREN L, 1966, J CELL PHYSIOL, V68, P269, DOI 10.1002/jcp.1040680308; Weiler IJ, 1996, J NEUROCHEM, V66, P197; WEILER IJ, 1993, P NATL ACAD SCI USA, V90, P7168, DOI 10.1073/pnas.90.15.7168; WEISS S, 1986, P NATL ACAD SCI USA, V83, P2238, DOI 10.1073/pnas.83.7.2238; White RJ, 1996, J NEUROSCI, V16, P5688	38	30	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32433	32438		10.1074/jbc.274.45.32433	http://dx.doi.org/10.1074/jbc.274.45.32433			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542287	hybrid			2022-12-27	WOS:000083532100095
J	O'Neill, E; Sze, CC; Shingler, V				O'Neill, E; Sze, CC; Shingler, V			Novel effector control through modulation of a preexisting binding site of the aromatic-responsive sigma(54)-dependent regulator DmpR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLING ATP HYDROLYSIS; SP STRAIN CF600; TRANSCRIPTIONAL ACTIVATOR; TRUNCATED FORM; PROTEIN NTRC; IN-VITRO; PSEUDOMONAS-PUTIDA; FUNCTIONAL DOMAINS; GENETIC-EVIDENCE; RNA-POLYMERASE	The Pseudomonas derived sigma(54)-dependent DmpR activator regulates transcription of the (methyl)phenol catabolic dmp-operon, DmpR is constitutively expressed, but its transcriptional promoting activity is positively controlled in direct response to the presence of multiple aromatic effecters. Previous work has led to a model in which effector binding by the amino-terminal region of the protein relieves repression of an intrinsic ATPase activity essential for its transcriptional promoting property. Here, we address whether the observed differences in the potencies of the multiple effecters (i) reside at the level of different aromatic binding sites, or (ii) are mediated through differential binding affinities; furthermore, we address whether binding of distinct aromatic effecters has different functional consequences for DmpR activity. These questions were addressed by comparing wild type and an effector specificity mutant of DmpR with respect to effector binding characteristics and the ability of aromatics to elicit ATPase activity and transcription, The results demonstrate that six test aromatics all share a common binding site on DmpR and that binding affinities determine the concentration at which DmpR responds to the presence of the effector, but not the magnitude of the responses. Interestingly, this analysis reveals that the novel abilities of the effector specificity mutant are not primarily due to acquisition of new binding abilities, but rather, they reside in being able to productively couple ATPase activity to transcriptional activation. The mechanistic implications of these findings in terms of aromatic control of DmpR activity are discussed.	Umea Univ, Dept Cell & Mol Biol, S-90187 Umea, Sweden	Umea University	Shingler, V (corresponding author), Umea Univ, Dept Cell & Mol Biol, S-90187 Umea, Sweden.		Sze, Chun Chau/A-2200-2011	Sze, Chun Chau/0000-0003-2245-9050; Shingler, Victoria/0000-0002-7349-1678				ABRIL MA, 1989, J BACTERIOL, V171, P6782, DOI 10.1128/jb.171.12.6782-6790.1989; AUSTIN S, 1994, J BIOL CHEM, V269, P18141; AUSTIN S, 1992, EMBO J, V11, P2219, DOI 10.1002/j.1460-2075.1992.tb05281.x; BERGER DK, 1994, P NATL ACAD SCI USA, V91, P103, DOI 10.1073/pnas.91.1.103; Byrne AM, 1996, J BACTERIOL, V178, P6327, DOI 10.1128/jb.178.21.6327-6337.1996; DELGADO A, 1994, J BIOL CHEM, V269, P8059; FERNANDEZ S, 1995, MOL MICROBIOL, V16, P205, DOI 10.1111/j.1365-2958.1995.tb02293.x; Gardan R, 1997, MOL MICROBIOL, V24, P825, DOI 10.1046/j.1365-2958.1997.3881754.x; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; HOPPER S, 1995, J BACTERIOL, V177, P2798, DOI 10.1128/jb.177.10.2798-2803.1995; HUALA E, 1992, J BACTERIOL, V174, P1428, DOI 10.1128/jb.174.4.1428-1431.1992; LEE JH, 1995, P NATL ACAD SCI USA, V92, P9702, DOI 10.1073/pnas.92.21.9702; LEE JH, 1994, J BIOL CHEM, V269, P20401; METTKE I, 1995, J BACTERIOL, V177, P5056, DOI 10.1128/jb.177.17.5056-5061.1995; MORETT E, 1993, J BACTERIOL, V175, P6067, DOI 10.1128/JB.175.19.6067-6074.1993; Ng LC, 1996, J BIOL CHEM, V271, P17281, DOI 10.1074/jbc.271.29.17281; NG LC, 1995, J BACTERIOL, V177, P1485, DOI 10.1128/jb.177.6.1485-1490.1995; North AK, 1996, J MOL BIOL, V260, P317, DOI 10.1006/jmbi.1996.0403; O'Neill E, 1998, MOL MICROBIOL, V28, P131, DOI 10.1046/j.1365-2958.1998.00780.x; Osuna J, 1997, PROTEIN SCI, V6, P543; PAVEL H, 1994, J BACTERIOL, V176, P7550, DOI 10.1128/JB.176.24.7550-7557.1994; PerezMartin J, 1996, CELL, V86, P331, DOI 10.1016/S0092-8674(00)80104-X; PerezMartin J, 1996, J MOL BIOL, V258, P575, DOI 10.1006/jmbi.1996.0270; PORTER SC, 1993, GENE DEV, V7, P2258, DOI 10.1101/gad.7.11.2258; Porter SC, 1995, 2 COMPONENT SIGNAL T, P147; Salto R, 1998, J BACTERIOL, V180, P600, DOI 10.1128/JB.180.3.600-604.1998; Sambrook J., 2002, MOL CLONING LAB MANU; Schirmer F, 1997, J BACTERIOL, V179, P1329, DOI 10.1128/jb.179.4.1329-1336.1997; Shingler V, 1996, MOL MICROBIOL, V19, P409, DOI 10.1046/j.1365-2958.1996.388920.x; SHINGLER V, 1994, J BACTERIOL, V176, P1555, DOI 10.1128/jb.176.6.1555-1560.1994; SHINGLER V, 1993, J BACTERIOL, V175, P1596, DOI 10.1128/JB.175.6.1596-1604.1993; SHINGLER V, 1995, MOL MICROBIOL, V17, P505, DOI 10.1111/j.1365-2958.1995.mmi_17030505.x; SHINGLER V, 1996, PSEUDOMONAS MOL BIOL, P153; Sze CC, 1996, J BACTERIOL, V178, P3727, DOI 10.1128/jb.178.13.3727-3735.1996; Wang YK, 1997, MOL MICROBIOL, V26, P373, DOI 10.1046/j.1365-2958.1997.5851955.x; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N; Widdick D, 1998, FEBS LETT, V437, P70, DOI 10.1016/S0014-5793(98)01206-X	37	30	32	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32425	32432		10.1074/jbc.274.45.32425	http://dx.doi.org/10.1074/jbc.274.45.32425			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542286	hybrid			2022-12-27	WOS:000083532100094
J	Perez-Vilar, J; Hill, RL				Perez-Vilar, J; Hill, RL			The structure and assembly of secreted mucins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							PORCINE SUBMAXILLARY MUCIN; VON-WILLEBRAND-FACTOR; TERMINAL N-ACETYLGALACTOSAMINE; O-GLYCOSYLATION PATTERN; DISULFIDE-BONDED DIMERS; ACETYL-D-GALACTOSAMINE; MOLECULAR-CLONING; ENDOPLASMIC-RETICULUM; XENOPUS-LAEVIS; TANDEM REPEAT		Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Hill, RL (corresponding author), Duke Univ, Med Ctr, Dept Biochem, POB 3711, Durham, NC 27710 USA.	hill@biochem.duke.edu			NIGMS NIH HHS [GM 27566] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aksoy N, 1999, GLYCOBIOLOGY, V9, P739, DOI 10.1093/glycob/9.7.739; ALBONE EF, 1994, J BIOL CHEM, V269, P16845; Asker N, 1998, BIOCHEM J, V335, P381, DOI 10.1042/bj3350381; Asker N, 1998, J BIOL CHEM, V273, P18857, DOI 10.1074/jbc.273.30.18857; Axelsson MAB, 1998, J BIOL CHEM, V273, P18864, DOI 10.1074/jbc.273.30.18864; Bell SL, 1998, EUR J BIOCHEM, V253, P123, DOI 10.1046/j.1432-1327.1998.2530123.x; BOBEK LA, 1993, J BIOL CHEM, V268, P20563; Cohen-Salmon M, 1997, P NATL ACAD SCI USA, V94, P14450, DOI 10.1073/pnas.94.26.14450; Denny PC, 1996, GLYCOBIOLOGY, V6, P43, DOI 10.1093/glycob/6.1.43; DESCHUYTENEER M, 1988, J BIOL CHEM, V263, P2452; Desseyn JL, 1997, J BIOL CHEM, V272, P16873, DOI 10.1074/jbc.272.27.16873; Dohrman A, 1998, BBA-MOL BASIS DIS, V1406, P251, DOI 10.1016/S0925-4439(98)00010-6; ECKHARDT AE, 1991, J BIOL CHEM, V266, P9678; Eckhardt AE, 1997, J BIOL CHEM, V272, P33204, DOI 10.1074/jbc.272.52.33204; ECKHARDT AE, 1987, J BIOL CHEM, V262, P11339; Gao Z, 1998, J BIOL CHEM, V273, P3415, DOI 10.1074/jbc.273.6.3415; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; Gerken TA, 1998, J BIOL CHEM, V273, P26580, DOI 10.1074/jbc.273.41.26580; Gerken TA, 1997, J BIOL CHEM, V272, P9709; GONGQIAO XG, 1996, GLYCOCONJUGATE J, V13, P81; GUM JR, 1992, J BIOL CHEM, V267, P21375; GUM JR, 1994, J BIOL CHEM, V269, P2440; HAUSER F, 1992, J BIOL CHEM, V267, P24620; Herrmann A, 1999, J BIOL CHEM, V274, P15828, DOI 10.1074/jbc.274.22.15828; HILKENS J, 1992, TRENDS BIOCHEM SCI, V17, P359, DOI 10.1016/0968-0004(92)90315-Z; HOFFMANN W, 1988, J BIOL CHEM, V263, P7686; Hovenberg HW, 1996, BIOCHEM J, V318, P319, DOI 10.1042/bj3180319; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; Jiang WP, 1998, BIOCHEM J, V331, P193, DOI 10.1042/bj3310193; Joba W, 1997, J BIOL CHEM, V272, P1805, DOI 10.1074/jbc.272.3.1805; Khatri IA, 1998, BIOCHEM J, V331, P323, DOI 10.1042/bj3310323; Khatri IA, 1997, BBA-BIOMEMBRANES, V1326, P7, DOI 10.1016/S0005-2736(97)00063-1; KOTANI E, 1995, BBA-GENE STRUCT EXPR, V1260, P245, DOI 10.1016/0167-4781(94)00202-E; Legan PK, 1997, J BIOL CHEM, V272, P8791, DOI 10.1074/jbc.272.13.8791; Li DZ, 1998, J BIOL CHEM, V273, P6812, DOI 10.1074/jbc.273.12.6812; MARIANNE T, 1987, BIOCHEM J, V248, P189, DOI 10.1042/bj2480189; MCCOOL DJ, 1994, BIOCHEM J, V302, P111, DOI 10.1042/bj3020111; McNeer RR, 1998, BIOCHEM J, V330, P737, DOI 10.1042/bj3300737; MEITINGER T, 1993, NAT GENET, V5, P376, DOI 10.1038/ng1293-376; Moniaux N, 1999, BIOCHEM J, V338, P325, DOI 10.1042/0264-6021:3380325; OHMORI H, 1994, J BIOL CHEM, V269, P17833; Perez-Vilar J, 1997, J BIOL CHEM, V272, P33410, DOI 10.1074/jbc.272.52.33410; Perez-Vilar J, 1998, J BIOL CHEM, V273, P34527, DOI 10.1074/jbc.273.51.34527; Perez-Vilar J, 1998, J BIOL CHEM, V273, P14442, DOI 10.1074/jbc.273.23.14442; Perez-Vilar J, 1998, J BIOL CHEM, V273, P6982, DOI 10.1074/jbc.273.12.6982; PEREZVILAR J, 1991, J BIOL CHEM, V266, P23967; PerezVilar J, 1996, J BIOL CHEM, V271, P9845, DOI 10.1074/jbc.271.16.9845; PEREZVILAR J, 1999, SIALOBIOLOGY OTHER N; Pigny P, 1996, GENOMICS, V38, P340, DOI 10.1006/geno.1996.0637; ROTH J, 1984, J CELL BIOL, V98, P399, DOI 10.1083/jcb.98.2.399; ROTH J, 1994, P NATL ACAD SCI USA, V91, P8935, DOI 10.1073/pnas.91.19.8935; Sadler JE, 1998, ANNU REV BIOCHEM, V67, P395, DOI 10.1146/annurev.biochem.67.1.395; Sands BE, 1996, ANNU REV PHYSIOL, V58, P253, DOI 10.1146/annurev.ph.58.030196.001345; Shankar V, 1997, AM J RESP CELL MOL, V16, P232, DOI 10.1165/ajrcmb.16.3.9070607; Sheehan JK, 1996, BIOCHEM J, V315, P1055, DOI 10.1042/bj3151055; Sheehan JK, 1999, BIOCHEM J, V338, P507, DOI 10.1042/0264-6021:3380507; Shekels LL, 1998, BIOCHEM J, V330, P1301, DOI 10.1042/bj3301301; SHOGREN RL, 1984, J BIOL CHEM, V259, P4657; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; SUN PD, 1995, ANNU REV BIOPH BIOM, V24, P269, DOI 10.1146/annurev.bb.24.060195.001413; Toribara NW, 1997, J BIOL CHEM, V272, P16398, DOI 10.1074/jbc.272.26.16398; Van den Steen P, 1998, CRIT REV BIOCHEM MOL, V33, P151; van Klinken BJW, 1998, GLYCOBIOLOGY, V8, P67, DOI 10.1093/glycob/8.1.67; VERMA M, 1993, P NATL ACAD SCI USA, V90, P7144, DOI 10.1073/pnas.90.15.7144; Vinall LE, 1998, HUM GENET, V102, P357, DOI 10.1007/s004390050705; Wickstrom C, 1998, BIOCHEM J, V334, P685, DOI 10.1042/bj3340685	67	382	393	2	55	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31751	31754		10.1074/jbc.274.45.31751	http://dx.doi.org/10.1074/jbc.274.45.31751			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542193	hybrid			2022-12-27	WOS:000083532100001
J	Zhu, HJ; Iaria, J; Sizeland, AM				Zhu, HJ; Iaria, J; Sizeland, AM			Smad7 differentially regulates transforming growth factor beta-mediated signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; MAD-RELATED PROTEIN; TGF-BETA; HETEROOLIGOMERIC COMPLEXES; TUMOR-SUPPRESSOR; RECEPTOR; PHOSPHORYLATION; IDENTIFICATION; ACTIVATION; ANTAGONIST	Smad7 has been identified as a negative regulator of transforming growth factor beta (TGF-beta) signaling by interfering with the phosphorylation of other Smad proteins by TGF-beta receptor type I (T beta RI). me established a mink lung epithelial (Mv1Lu) cell line where ectopic expression of Smad7 is tightly controlled by doxycycline using an improved Tet-on system. Once induced by doxycycline, the recombinant Smad7 was localized predominantly in the perinuclear region and in the cytoplasm, However, the type of culture surface alters the subcellular localization of Smad7: on plastic or on fibronectin-coated glass, Smad7 was localized in the cytoplasm; but when the cells were cultured on glass, nuclear localization was observed. TGF-beta stimulation did not alter substantially the cellular distribution of Smad7. Importantly, the expression of recombinant Smad7 differentially inhibited TGF-beta signaling pathways. Consistent with previous studies, Smad7 inhibited TGF-beta-stimulated induction of type 1 plasminogen activator inhibitor as measured by p3TP-Lux reporter. However, expression of Smad7 had Little effect on TGF-beta-induced growth inhibition.	Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia	Ludwig Institute for Cancer Research; Royal Melbourne Hospital	Zhu, HJ (corresponding author), Royal Melbourne Hosp, Ludwig Inst Canc Res, PO, Melbourne, Vic 3050, Australia.			Zhu, Hong-Jian/0000-0002-1478-995X				Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; Attisano Liliana, 1996, Cytokine and Growth Factor Reviews, V7, P327, DOI 10.1016/S1359-6101(96)00042-1; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; CHEN RH, 1995, J BIOL CHEM, V270, P12235, DOI 10.1074/jbc.270.20.12235; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dennler S, 1999, ONCOGENE, V18, P1643, DOI 10.1038/sj.onc.1202729; Derynck R, 1996, CURR BIOL, V6, P1226, DOI 10.1016/S0960-9822(96)00702-6; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HILLEN W, 1994, ANNU REV MICROBIOL, V48, P345, DOI 10.1146/annurev.mi.48.100194.002021; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Itoh S, 1998, J BIOL CHEM, V273, P29195, DOI 10.1074/jbc.273.44.29195; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1997, J BIOL CHEM, V272, P2896, DOI 10.1074/jbc.272.5.2896; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; RAFTERY LA, 1995, GENETICS, V139, P241; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; SEKELSKY JJ, 1995, GENETICS, V139, P1347; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Stroschein SL, 1999, J BIOL CHEM, V274, P9431, DOI 10.1074/jbc.274.14.9431; tenDijke P, 1996, CURR OPIN CELL BIOL, V8, P139; Topper JN, 1996, P NATL ACAD SCI USA, V93, P10417, DOI 10.1073/pnas.93.19.10417; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Wells RG, 1999, J BIOL CHEM, V274, P5716, DOI 10.1074/jbc.274.9.5716; Wong C, 1999, MOL CELL BIOL, V19, P1821; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3; Zhu HJ, 1999, J BIOL CHEM, V274, P11773, DOI 10.1074/jbc.274.17.11773	41	76	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32258	32264		10.1074/jbc.274.45.32258	http://dx.doi.org/10.1074/jbc.274.45.32258			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542264	hybrid			2022-12-27	WOS:000083532100072
J	de la Vega, LA; Stockert, RJ				de la Vega, LA; Stockert, RJ			The cytoplasmic coatomer protein COPI - A potential translational regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASIALOGLYCOPROTEIN RECEPTOR; MESSENGER-RNAS; BINDING-PROTEIN; HEPATIC BINDING; EXPRESSION; MODULATION; SUBUNITS; REGION; LINE; CGMP	Expression of the asialoglycoprotein receptor (ASGR) by the human hepatocellular carcinoma cell lines HepG2 and HuH-7 in response to intracellular cGMP concentrations was previously shown to be regulated at the translational level (1). Stable transfection of COS-7 cells with deletion constructs encoding the asialogyco-protein receptor H2b subunit localized the cGMP-responsive cis-acting element to the mRNA 5'-untranslated region. Resolution by anion exchange chromatography of an S-100 isolated from human liver resulted in the partial purification of an RNA-binding protein specific to this cis-acting element. Northwestern analysis using the 5'-untranslated region as probe indicated that a 140-kDa protein was the potential RNA-binding protein. Sequence of tryptic peptides suggested that the 140-kDa protein was the alpha-COP subunit of coatomer protein COPI, usually associated with trans-Golgi network membrane traffic. Immunoblot analysis confirmed the presence of alpha-COP in the Mono-Q fraction as well as that of a second coatomer subunit, beta-COP. Antibody induced gel retardation supershift confirmed the identification of the RNA-binding proteins as alpha- and beta-COP. Although the RNA recognition motif appears to reside solely in alpha-COP, antibody-induced supershift strongly indicated that the entire coatomer complex was the trans-acting factor. Depletion of S-100 with the antibody to, beta-COP confirmed that the coatomer was the sole protein binding to the ASGR mRNA 5'-untranslated region in liver cytosol and responsible for inhibition of in vitro translation of the asialoglycoprotein receptor.	Albert Einstein Coll Med, Mar Bessin Liver Res Ctr, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Stockert, RJ (corresponding author), Albert Einstein Coll Med, Mar Bessin Liver Res Ctr, Ullmann 123,1300 Morris Pk Ave, Bronx, NY 10461 USA.				NIDDK NIH HHS [DK-32972, DK-17702, DK-41918] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK017702, P01DK041918, R01DK032972] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200; KELLY JH, 1989, IN VITRO CELL DEV B, V25, P217; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; Lowe M, 1995, J BIOL CHEM, V270, P31364, DOI 10.1074/jbc.270.52.31364; MEYUHAS O, 1987, MOL CELL BIOL, V7, P2691, DOI 10.1128/MCB.7.8.2691; NAGY E, 1995, J BIOL CHEM, V270, P2755, DOI 10.1074/jbc.270.6.2755; Pavel J, 1998, P NATL ACAD SCI USA, V95, P2140, DOI 10.1073/pnas.95.5.2140; PORAT N, 1995, INFECT IMMUN, V63, P1498, DOI 10.1128/IAI.63.4.1498-1506.1995; Sheff D, 1996, J BIOL CHEM, V271, P7230, DOI 10.1074/jbc.271.12.7230; SHEFF D, 1996, J BIOL CHEM, V271, P30725; STOCKERT RJ, 1995, PHYSIOL REV, V75, P591, DOI 10.1152/physrev.1995.75.3.591; Stockert RJ, 1997, J BIOL CHEM, V272, P9161; STOCKERT RJ, 1992, J BIOL CHEM, V267, P56; STOCKERT RJ, 1980, CANCER RES, V40, P3632; STOCKERT RJ, 1990, J BIOL CHEM, V265, P1841; TOWIN H, 1979, P NATL ACAD SCI USA, V76, P4350; TREICHEL U, 1994, J GEN VIROL, V75, P3021, DOI 10.1099/0022-1317-75-11-3021; WALDEN WE, 1986, BIOCHEMISTRY-US, V25, P2033, DOI 10.1021/bi00356a030; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WU GY, 1988, J BIOL CHEM, V263, P14621	20	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31135	31138		10.1074/jbc.274.44.31135	http://dx.doi.org/10.1074/jbc.274.44.31135			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531302	hybrid			2022-12-27	WOS:000083379400006
J	Fullwood, Y; dos Santos, M; Hsuan, JJ				Fullwood, Y; dos Santos, M; Hsuan, JJ			Cloning and characterization of a novel human phosphatidylinositol transfer protein, rdgB beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINAL-DEGENERATION-B; CA2+-ACTIVATED SECRETION; DROSOPHILA-MELANOGASTER; GENE ENCODES; MUTANT; CELLS; PHOSPHORYLATION; MEMBRANE; HOMOLOG; ISOFORM	The various PITP, retinal degeneration B (rdgB), and amino-terminal domain interacting receptor (Nir) phosphatidylinositol transfer proteins can be divided into two structural families. The small, soluble PITP isoforms contain only a phosphatidylinositol transfer domain and have been implicated in phosphoinositide signaling and vesicle trafficking. In contrast, the rdgB proteins, which include Nir2 and Nir3, contain an amino-terminal PITP-like domain, an acidic, Ca2+-binding domain, six putative transmembrane domains, and a conserved carboxyl-terminal domain. However, the biological function of rdgB proteins is unclear, Here, we report the isolation of a cDNA encoding a novel rdgB protein, mammalian rdgB beta (MrdgB beta). The 38-kDa MrdgB beta protein contains an amino-terminal PITP-like domain and a short carboxyl-terminal domain. In contrast to other rdgB-like proteins, MrdgB beta contains no transmembrane motifs or the conserved carboxyl-terminal domain. Using Northern and reverse transcription-polymerase chain reaction analysis, we demonstrate that MrdgB beta mRNA is ubiquitously expressed. Immunofluorescence analysis of ectopic MrdgB beta showed cytoplasmic staining, and the ability of recombinant MrdgB beta to transfer phosphatidylinositol in vitro was similar to other PITP-like domains. Although early reports found functional degeneracy in, vitro, the identification of a fifth mammalian PITP-like protein with a unique domain organization and widespread expression supports more recent results that suggest that different PITP-like domains have distinct functions in vivo.	Ludwig Inst Canc Res, London W1P 8BT, England; UCL, Royal Free & Univ Coll Med Sch, Dept Med, London NW3 2PF, England	Ludwig Institute for Cancer Research; University of London; University College London	Hsuan, JJ (corresponding author), Ludwig Inst Canc Res, Courtauld Bldg,91 Riding House St, London W1P 8BT, England.	justin@ludwig.ucl.ac.uk	dos Santos, Maria/B-7426-2012; Hsuan, Justin/C-8825-2009	Hsuan, Justin/0000-0001-6083-7564				Aikawa Y, 1997, BIOCHEM BIOPH RES CO, V236, P559, DOI 10.1006/bbrc.1997.7009; Aikawa Y, 1999, J BIOL CHEM, V274, P20569, DOI 10.1074/jbc.274.29.20569; ALB JG, 1995, P NATL ACAD SCI USA, V92, P8826, DOI 10.1073/pnas.92.19.8826; Allen V, 1997, BIOCHEM J, V327, P545, DOI 10.1042/bj3270545; BLOMQUIST BT, 1988, CELL, V54, P723; Chang JHT, 1997, J NEUROSCI, V17, P5881; Cunningham E, 1996, P NATL ACAD SCI USA, V93, P6589, DOI 10.1073/pnas.93.13.6589; Currie RA, 1997, CURR BIOL, V7, P184, DOI 10.1016/S0960-9822(97)70089-7; DeVries KJ, 1996, EXP CELL RES, V227, P33, DOI 10.1006/excr.1996.0246; DEVRIES KJ, 1995, BIOCHEM J, V310, P643, DOI 10.1042/bj3100643; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Guo J, 1997, DEV GENET, V20, P235; Hamilton BA, 1997, NEURON, V18, P711, DOI 10.1016/S0896-6273(00)80312-8; HARRIS WA, 1977, J GEN PHYSIOL, V69, P261, DOI 10.1085/jgp.69.3.261; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; HOTTA Y, 1970, P NATL ACAD SCI USA, V67, P1156, DOI 10.1073/pnas.67.3.1156; Jones SM, 1998, J BIOL CHEM, V273, P10349, DOI 10.1074/jbc.273.17.10349; KAUFFMANNZEH A, 1995, SCIENCE, V268, P1188, DOI 10.1126/science.7761838; Kearns BG, 1998, TRENDS CELL BIOL, V8, P276, DOI 10.1016/S0962-8924(98)01281-1; LEE YJ, 1994, NEURON, V13, P1143, DOI 10.1016/0896-6273(94)90052-3; Lev S, 1999, MOL CELL BIOL, V19, P2278; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Milligan SC, 1997, J CELL BIOL, V139, P351, DOI 10.1083/jcb.139.2.351; MINKE B, 1990, P NATL ACAD SCI USA, V87, P113, DOI 10.1073/pnas.87.1.113; OHASHI M, 1995, NATURE, V377, P644; OTOUSA JE, 1985, CELL, V40, P839, DOI 10.1016/0092-8674(85)90343-5; Paetkau DW, 1999, GENETICS, V151, P713; SAHLY I, 1992, P NATL ACAD SCI USA, V89, P435, DOI 10.1073/pnas.89.1.435; SMITH DP, 1991, SCIENCE, V254, P1478, DOI 10.1126/science.1962207; STARK WS, 1982, CELL TISSUE RES, V225, P11, DOI 10.1007/BF00216214; SUZUKI E, 1994, J ELECTRON MICROSC, V43, P183; THOMAS GMH, 1993, CELL, V74, P919, DOI 10.1016/0092-8674(93)90471-2; VIHTELIC TS, 1991, GENETICS, V127, P761; VIHTELIC TS, 1993, J CELL BIOL, V122, P1013, DOI 10.1083/jcb.122.5.1013; WIRTZ KWA, 1991, ANNU REV BIOCHEM, V60, P73, DOI 10.1146/annurev.biochem.60.1.73; WOODARD C, 1992, J NEUROGENET, V8, P17, DOI 10.3109/01677069209167269	37	35	38	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31553	31558		10.1074/jbc.274.44.31553	http://dx.doi.org/10.1074/jbc.274.44.31553			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531358	hybrid			2022-12-27	WOS:000083379400062
J	Inouye, S; Hsu, MY; Xu, AG; Inouye, M				Inouye, S; Hsu, MY; Xu, AG; Inouye, M			Highly specific recognition of primer RNA structures for 2 '-OH priming reaction by bacterial reverse transcriptases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; ESCHERICHIA-COLI; MYXOCOCCUS-XANTHUS; BRANCHED RNA; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; LINKED MSDNA; RETRON; BIOSYNTHESIS; RETROELEMENT	A minor population of Escherichia coli contains retroelements called retrons, which encode reverse-transcriptases (RT) to synthesize peculiar satellite DNAs called multicopy single-stranded DNA (msDNA). These RTs recognize specific RNA structures in their individual primer-template RNAs to initiate cDNA synthesis from the 2'-OH group of a specific internal G residue (branching G residue). The resulting products (msDNA) consist of RNA and single-stranded DNA, sharing hardly any sequence homology. Here, we investigated how RT-Ec86 recognizes the specific RNA structure in its primer-template RNA. On the basis of structural comparison with HIV-1 RT, domain exchanges were carried out between two E. coli RTs, RT-Ec86 and RT-Ec73. RT-Ec86 (320 residues) and RT-Ec78 (316 residues) share only 71 identical residues (22%), From the analysis of 10 such constructs, the C-terminal 91-residue sequence of RT-Ec86 was found to be essential for the recognition of the unique stem-loop structure and the branching G residue in the primer-template RNA for retron-Ec86. Using the SELEX (systematic evolution of ligands by exponential enrichment) method with RT-Ec86 and primer RNAs containing random sequences, the identical stem-loop structure (including the 3-U loop) to that found in the retron-Ec86 primer-template RNA was enriched. In addition, the highly conserved 4-base sequence (UAGC), including the branching G residue, was also enriched, These results indicate that the highly diverse C-terminal region recognizes specific stem-loop structures and the branching G residue located upstream of the stem-loop structure. The present results with seemingly primitive RNA-dependent DNA polymerases provide insight into the mechanisms for specific protein RNA recognition.	Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Inouye, M (corresponding author), Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Lane, Piscataway, NJ 08854 USA.		Inouye, Sharon/R-7216-2019		NIGMS NIH HHS [GM 44012] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044012] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DHUNDALE A, 1987, CELL, V51, P1105, DOI 10.1016/0092-8674(87)90596-4; FURUICHI T, 1987, CELL, V48, P47, DOI 10.1016/0092-8674(87)90354-0; HERZER PJ, 1992, MOL MICROBIOL, V6, P345, DOI 10.1111/j.1365-2958.1992.tb01477.x; INOUYE S, 1993, CURR OPIN GENET DEV, V3, P713, DOI 10.1016/S0959-437X(05)80088-7; INOUYE S, 1990, P NATL ACAD SCI USA, V87, P942, DOI 10.1073/pnas.87.3.942; INOUYE S, 1989, CELL, V56, P709, DOI 10.1016/0092-8674(89)90593-X; INOUYE S, 1996, VIRUS GENES, V11, P81; INOUYE S, 1993, REVERSE TRANSCRIPTAS, P391; INOUYE S, 1991, DIRECTED MUTAGENESIS, P71; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LAMPSON BC, 1989, SCIENCE, V243, P1033, DOI 10.1126/science.2466332; Legault P, 1998, CELL, V93, P289, DOI 10.1016/S0092-8674(00)81579-2; LIM D, 1989, CELL, V56, P891, DOI 10.1016/0092-8674(89)90693-4; LIM DB, 1992, MOL MICROBIOL, V6, P3531, DOI 10.1111/j.1365-2958.1992.tb01788.x; Lima TMO, 1997, PLASMID, V38, P25, DOI 10.1006/plas.1997.1298; Mao JR, 1997, J BACTERIOL, V179, P7865, DOI 10.1128/jb.179.24.7865-7868.1997; MAO JR, 1995, J BIOL CHEM, V270, P19684, DOI 10.1074/jbc.270.34.19684; MILLER JG, 1972, SHORT COURSE BACTERI; RICE SA, 1995, J BACTERIOL, V177, P37, DOI 10.1128/jb.177.1.37-45.1995; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMAMOTO T, 1995, J BIOL CHEM, V270, P581, DOI 10.1074/jbc.270.2.581; SHIMAMOTO T, 1993, J BIOL CHEM, V268, P2684; STEITZ TA, 1994, SCIENCE, V266, P2022, DOI 10.1126/science.7528445; SUN J, 1991, J BACTERIOL, V173, P4171, DOI 10.1128/jb.173.13.4171-4181.1991; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; YEE T, 1984, CELL, V38, P203, DOI 10.1016/0092-8674(84)90541-5	29	18	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31236	31244		10.1074/jbc.274.44.31236	http://dx.doi.org/10.1074/jbc.274.44.31236			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531319	hybrid			2022-12-27	WOS:000083379400023
J	Ermakova-Gerdes, S; Vermaas, W				Ermakova-Gerdes, S; Vermaas, W			Inactivation of the open reading frame slr0399 in Synechocystis sp PCC 6803 functionally complements mutations near the Q(A) niche of photosystem II - A possible role of slr0399 as a chaperone for quinone binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE INFLUENCE; ISOFLAVONE REDUCTASE; D1 PROTEIN; PHYTOALEXIN BIOSYNTHESIS; CHLOROPLAST GENOME; MEMBRANE-PROTEINS; CDNA CLONING; SP PCC-6803; D2 PROTEIN; PSBA GENE	The Synechocystis sp. PCC 6803 triple mutant D2R8 with V247M/A249T/M329I mutations in the D2 subunit of the photosystem II is impaired in Q(A) function, has an apparently mobile Q(A), and is unable to grow photoautotrophically. Several photoautotrophic pseudorevertants of this mutant have been isolated, each of which retained the original psbDI mutations of D2R8 Using a newly developed mapping technique, the site of the secondary mutations has been located in the open reading frame slr0399. Two different nucleotide substitutions and a deletion of about 60% of slr0399 were each shown to restore photoautotrophy in different pseudorevertants of the mutant D2R8, suggesting that inactivation of Slr0399 leads to photoautotrophic growth in D2R8. Indeed, a targeted deletion of slr0399 restores photoautotrophy in D2R8 and in other psbDI mutants impaired in QA function. Slr0399 is similar to the hypothetical protein Ycf39, which is encoded in the cyanelle genome of Cyanophora paradoxa; in the chloroplast genomes of diatoms, dinoflagellates, and red algae; and in the nuclear genome of Arabidopsis thaliana. Slr0399 and Ycf39 have a NAD(P)H binding motif near their N terminus and have some similarity to isoflavone reductase-like proteins and to a subunit of the eukaryotic NADH dehydrogenase complex I. Deletion of slr0399 in wild type Synechocystis sp. PCC 6803 has no significant phenotypic effects other than a decrease in thermotolerance under both photoautotrophic and photomixotrophic conditions. We suggest that Slr0399 is a chaperone-like protein that aids in, but is not essential for, quinone insertion and protein folding around Q(A) in photosystem II. Moreover, as the effects of Slr0399 are not limited to photosystem II, this protein may also be involved in assembly of quinones in other photosynthetic and respiratory complexes.	Arizona State Univ, Dept Plant Biol, Tempe, AZ 85287 USA; Arizona State Univ, Ctr Study Early Events Photosynthesis, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe	Ermakova-Gerdes, S (corresponding author), Arizona State Univ, Dept Plant Biol, Box 871601, Tempe, AZ 85287 USA.							BABIYCHUK E, 1995, J BIOL CHEM, V270, P26224, DOI 10.1074/jbc.270.44.26224; Bellamacina CR, 1996, FASEB J, V10, P1257, DOI 10.1096/fasebj.10.11.8836039; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; CARR NG, 1967, ARCH BIOCHEM BIOPHYS, V120, P503, DOI 10.1016/0003-9861(67)90509-7; CHEN ZX, 1991, BIOCHEMISTRY-US, V30, P8846, DOI 10.1021/bi00100a017; CRAMER WA, 1991, ENERGY TRNASDUCTION; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; DinkovaKostova AT, 1996, J BIOL CHEM, V271, P29473, DOI 10.1074/jbc.271.46.29473; DIXON RA, 1995, PHYSIOL PLANTARUM, V93, P385, DOI 10.1111/j.1399-3054.1995.tb02243.x; DIXON RA, 1983, ADV ENZYMOL RAMB, V55, P1; EGGINK G, 1990, J MOL BIOL, V212, P135, DOI 10.1016/0022-2836(90)90310-I; Ellis R. John, 1999, Current Opinion in Structural Biology, V9, P102, DOI 10.1016/S0959-440X(99)80013-X; Ermakova-Gerdes S, 1998, BIOCHEMISTRY-US, V37, P11569, DOI 10.1021/bi9806596; ErmakovaGerdes S, 1996, PLANT MOL BIOL, V30, P243, DOI 10.1007/BF00020111; FEARNLEY IM, 1991, BIOCHEM J, V278, P821, DOI 10.1042/bj2780821; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; GIRARDBASCOU J, 1992, CURR GENET, V22, P47, DOI 10.1007/BF00351741; GRIGORIEVA G, 1982, FEMS MICROBIOL LETT, V13, P367, DOI 10.1111/j.1574-6968.1982.tb08289.x; HAAG E, 1993, BIOCHEMISTRY-US, V32, P4444, DOI 10.1021/bi00067a037; He QF, 1998, P NATL ACAD SCI USA, V95, P5830, DOI 10.1073/pnas.95.10.5830; HIBI N, 1994, PLANT CELL, V6, P723, DOI 10.1105/tpc.6.5.723; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; KALEN A, 1990, LIPIDS, V25, P93, DOI 10.1007/BF02562211; Kaneko T, 1996, DNA Res, V3, P185, DOI 10.1093/dnares/3.3.185; KATOH S, 1988, METHOD ENZYMOL, V167, P269; KLESS H, 1995, J BIOL CHEM, V270, P16536, DOI 10.1074/jbc.270.28.16536; KLESS H, 1994, BIOCHEMISTRY-US, V33, P10501, DOI 10.1021/bi00200a035; KLESS H, 1995, J MOL BIOL, V246, P120, DOI 10.1006/jmbi.1994.0071; KOIVUNIEMI A, 1993, FEBS LETT, V327, P343, DOI 10.1016/0014-5793(93)81017-T; Kowallik KV, 1995, PLANT MOL BIOL REP, V13, P336, DOI 10.1007/BF02669188; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEHEL C, 1993, PLANT PHYSIOL BIOCH, V31, P81; Lers A, 1998, PLANT MOL BIOL, V36, P847, DOI 10.1023/A:1005996515602; MORTON RA, 1965, BIOCH QUINONES, P23; NIXON PJ, 1991, PLANT CELL, V3, P383, DOI 10.1105/tpc.3.4.383; PAIVA NL, 1991, PLANT MOL BIOL, V17, P653, DOI 10.1007/BF00037051; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Petrucco S, 1996, PLANT CELL, V8, P69, DOI 10.1105/tpc.8.1.69; Reith M, 1995, PLANT MOL BIOL REP, V13, P333, DOI 10.1007/BF02669187; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; ROHLEN DA, 1991, FEBS LETT, V278, P75, DOI 10.1016/0014-5793(91)80087-J; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; Schnell DJ, 1998, ANNU REV PLANT PHYS, V49, P97, DOI 10.1146/annurev.arplant.49.1.97; SCHROEDER HU, 1986, FEBS LETT, V199, P23; TAKAHASHI Y, 1985, PHOTOSYNTH RES, V6, P183, DOI 10.1007/BF00032792; THOW G, 1994, BIOCHEMISTRY-US, V33, P5109, DOI 10.1021/bi00183a014; TIEMANN K, 1991, EUR J BIOCHEM, V200, P751, DOI 10.1111/j.1432-1033.1991.tb16241.x; vanEldik GJ, 1997, PLANT MOL BIOL, V33, P923, DOI 10.1023/A:1005749913203; VERMAAS W, 1990, Z NATURFORSCH C, V45, P359; Vermaas WFJ, 1998, METHOD ENZYMOL, V297, P293; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; WU HY, 1995, CURR GENET, V27, P263, DOI 10.1007/BF00326159; Yu JP, 1998, METHOD ENZYMOL, V297, P18	57	35	35	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30540	30549		10.1074/jbc.274.43.30540	http://dx.doi.org/10.1074/jbc.274.43.30540			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521436	Green Submitted, hybrid			2022-12-27	WOS:000083276700032
J	Okajima, T; Fukumoto, S; Ito, H; Kiso, M; Hirabayashi, Y; Urano, T; Furukawa, K; Furukawa, K				Okajima, T; Fukumoto, S; Ito, H; Kiso, M; Hirabayashi, Y; Urano, T; Furukawa, K; Furukawa, K			Molecular cloning of brain-specific GD1 alpha synthase (ST6GalNAc V) containing CAG/glutamine repeats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAL-BETA-1,3GALNAC-SPECIFIC GALNAC ALPHA-2,6-SIALYLTRANSFERASE; INHERITED NEURODEGENERATIVE DISEASES; NEURONAL INTRANUCLEAR INCLUSIONS; EXPRESSION CLONING; GANGLIOSIDE GD1-ALPHA; GLUTAMINE REPEATS; G(D3) SYNTHASE; CELLS; MOUSE; CDNA	A novel member of the mouse CMP-NeuAc: beta-N-acetylgalactosaminide alpha 2,6-sialyltransferase (ST6GalNAc) subfamily, designated ST6GalNAc V, was identified by BLAST analysis of expressed sequence tags. The sequence of the longest cDNA clone of ST6GalNAc V encoded a type II membrane protein with 8 amino acids comprising the cytoplasmic domain, 21 amino acids comprising the transmembrane region, and 306 amino acids comprising the catalytic domain. The predicted amino acid sequence showed homology to the previously cloned ST6GalNAc III and IV, with common amino acid sequences in sialyl motifs L and S among these three enzymes. Eleven CAG repeats were found in the stem region. A fusion protein with protein A and extracts from L cells transfected with ST6GalNAc V in a expression vector showed enzyme activity of alpha 2,6-sialyltransferase almost exclusively for GM1b, but not toward glycoproteins. Sialidase treatment and thin layer chromatography immunostaining revealed that the product was GD1 alpha. Northern blotting revealed that three transcripts of the gene were expressed specifically in brain tissues. It is concluded that this enzyme is involved in the synthesis of GD1 alpha in the nervous tissues, and the CAG repeats may have implications in neurodegenerative diseases.	Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, Nagoya, Aichi 4660065, Japan; Nagasaki Univ, Sch Dent, Dept Pediat Dent, Nagasaki 8528501, Japan; Gifu Univ, Fac Agr, Dept Appl Bioorgan Chem, Gifu 5011193, Japan; Inst Phys & Chem Res, Frontier Res Program, RIKEN, Lab Cellular Glycobiol, Wako, Saitama 3510198, Japan	Nagoya University; Nagasaki University; Gifu University; RIKEN	Furukawa, K (corresponding author), Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, 65 Tsurumai, Nagoya, Aichi 4660065, Japan.	koichi@med.nagoya-u.ac.jp	Okajima, Tetsuya/I-7332-2014	Okajima, Tetsuya/0000-0002-3677-648X; Hirabayashi, Yoshio/0000-0002-5774-7354; Fukumoto, Satoshi/0000-0002-5046-6891; Urano, Takeshi/0000-0003-3383-3554				Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Ecsedy JA, 1998, J LIPID RES, V39, P2218; FURUKAWA K, 1985, BIOCHEMISTRY-US, V24, P7820, DOI 10.1021/bi00347a047; FURUYA S, 1994, J BIOL CHEM, V269, P32418; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; Hamamoto T, 1993, Bioorg Med Chem, V1, P141, DOI 10.1016/S0968-0896(00)82111-2; HARAGUCHI M, 1994, P NATL ACAD SCI USA, V91, P10455, DOI 10.1073/pnas.91.22.10455; HIRABAYASHI Y, 1990, J BIOL CHEM, V265, P8144; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUROSAWA N, 1994, J BIOL CHEM, V269, P19048; Kurosawa N, 1996, J BIOL CHEM, V271, P15109, DOI 10.1074/jbc.271.25.15109; KUROSAWA N, 1994, J BIOL CHEM, V269, P1402; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lee YC, 1999, J BIOL CHEM, V274, P11958, DOI 10.1074/jbc.274.17.11958; LEE YC, 1993, EUR J BIOCHEM, V216, P377, DOI 10.1111/j.1432-1033.1993.tb18155.x; Lloyd KO, 1998, GLYCOCONJUGATE J, V15, P627, DOI 10.1023/A:1006924128550; Mitsuoka C, 1998, J BIOL CHEM, V273, P11225, DOI 10.1074/jbc.273.18.11225; Miyazaki H, 1997, J BIOL CHEM, V272, P24794, DOI 10.1074/jbc.272.40.24794; MOMOEDA M, 1995, BBA-LIPID LIPID MET, V1256, P151, DOI 10.1016/0005-2760(95)00013-3; MURAYAMA K, 1986, CANCER RES, V46, P1395; NAGATA Y, 1992, J BIOL CHEM, V267, P12082; NARA K, 1994, P NATL ACAD SCI USA, V91, P7952, DOI 10.1073/pnas.91.17.7952; Okajima T, 1999, J BIOL CHEM, V274, P11479, DOI 10.1074/jbc.274.17.11479; PAULSON JC, 1982, J BIOL CHEM, V257, P2734; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; Perutz MF, 1996, CURR OPIN STRUC BIOL, V6, P848, DOI 10.1016/S0959-440X(96)80016-9; SASAKI K, 1994, J BIOL CHEM, V269, P15950; Sjoberg ER, 1996, J BIOL CHEM, V271, P7450, DOI 10.1074/jbc.271.13.7450; SPIRO RG, 1974, J BIOL CHEM, V249, P5704; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P455; TAKI T, 1994, ANAL BIOCHEM, V221, P312, DOI 10.1006/abio.1994.1418; TAKI T, 1986, J BIOL CHEM, V261, P3075; Taki T, 1997, CANCER RES, V57, P1882; Tsuji S, 1996, J BIOCHEM-TOKYO, V120, P1; Tsuji S, 1996, GLYCOBIOLOGY, V6, pR5; TSUJI T, 1986, CARBOHYD RES, V151, P391, DOI 10.1016/S0008-6215(00)90358-6; Wiegandt H, 1985, GLYCOLIPIDS, V10, P199, DOI DOI 10.1016/S0167-7306(08)60022-8; YAMASHIRO S, 1993, CANCER RES, V53, P5395	42	63	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30557	30562		10.1074/jbc.274.43.30557	http://dx.doi.org/10.1074/jbc.274.43.30557			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521438	hybrid			2022-12-27	WOS:000083276700034
J	Saito, S; Yamaji, N; Yasunaga, K; Saito, T; Matsumoto, S; Katoh, M; Kobayashi, S; Masuho, Y				Saito, S; Yamaji, N; Yasunaga, K; Saito, T; Matsumoto, S; Katoh, M; Kobayashi, S; Masuho, Y			The fibronectin extra domain A activates matrix metalloproteinase gene expression by an interleukin-1-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; RHEUMATOID-ARTHRITIS; ARTICULAR-CARTILAGE; PLASMA FIBRONECTIN; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; MESSENGER-RNA; CELL-SHAPE; ED-A; INDUCTION	The extra domain-A(EDA), present in fibronectin (FN) molecules arising from alternatively spliced transcripts, appears only during specific biological and pathogenic processes. However, its function is poorly understood. To define the physiologic role of this domain in joint connective tissue, the biological effects on rabbit cartilage explants, chondrocytes, and synovial cells were studied. A recombinant EDA protein (rEDA) increased proteoglycan release (3.6-fold) in cartilage explant cultures and markedly induced production of matrix metalloproteinase (MMP)-1 in chondrocytes. In addition, rEDA induced MMP-1, MMP-3, and MMP-9 in synovial cells. These effects were elicited only by rEDA, while its neighboring type III repeats, III11, or III12, scarcely had any such effects. Interestingly, reorganization of F-actin stress fibers accompanied MMP-1 expression in synovial cells treated with rEDA, suggesting alteration of cellular phenotype, Subsequent Northern blotting revealed expression of pro-inflammatory cytokines, including interleukin (IL)-1 alpha and IL-1 beta, was induced by rEDA prior to MMP-1 expression. Delayed MMP-1 expression suggests that rEDA-induced IL-ls promote MMP-1 expression in an autocrine manner. This hypothesis is supported by the reduction of EDA-induced MIMP-1 production by IL-1 receptor antagonist. The effect of EDA on MMP-1 production was reduced by connection with an adjacent type III repeat on either the NH2 or COOH side of EDA and was abolished by connection on both sides of EDA, suggesting that exposure of either the NH2 or COOH terminus of EDA domain by proteolytic cleavage releases the inducing activity. In agreement with these results, full-length cellular FN did not induce MMP-1 production. Furthermore, a 160-kDa EDA-positive FN fragment, which was purified from human placental tissue and corresponds to the region from NH2 terminus through the EDA, induced MMP-1 production. Taken together, these results suggest that the EDA in FN fragments triggers alterations of cell physiology and plays a role in matrix degradation in joint connective tissue.	Yamanouchi Pharmaceut Co Ltd, Inst Drug Discovery Res, Tsukuba, Ibaraki 3058585, Japan	Astellas Pharmaceuticals	Saito, S (corresponding author), Yamanouchi Pharmaceut Co Ltd, Prod Planning Dept, 3-17-1 Hasune, Tokyo 1748612, Japan.			Yasunaga, Kunio/0000-0002-6259-4743; Saito, Tetsu/0000-0002-9045-6743				ANDREWS HJ, 1992, AGENTS ACTIONS, V37, P147, DOI 10.1007/BF01987904; AOTA S, 1994, J BIOL CHEM, V269, P24756; ARNER EC, 1995, ARTHRITIS RHEUM, V38, P1304, DOI 10.1002/art.1780380919; Bafetti LM, 1998, J BIOL CHEM, V273, P143, DOI 10.1074/jbc.273.1.143; BENNETT VD, 1991, J BIOL CHEM, V266, P5918; BONASSAR LJ, 1995, ARTHRITIS RHEUM, V38, P173, DOI 10.1002/art.1780380205; Boudreau N, 1996, P NATL ACAD SCI USA, V93, P3509, DOI 10.1073/pnas.93.8.3509; Chevalier X, 1996, J RHEUMATOL, V23, P1022; FFRENCHCONSTANT C, 1995, EXP CELL RES, V221, P261, DOI 10.1006/excr.1995.1374; FFRENCHCONSTANT C, 1989, J CELL BIOL, V109, P903, DOI 10.1083/jcb.109.2.903; FUKUDA M, 1982, J BIOL CHEM, V257, P6856; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; GLUKHOVA MA, 1989, J CELL BIOL, V109, P357, DOI 10.1083/jcb.109.1.357; HINO K, 1995, ARTHRITIS RHEUM-US, V38, P678, DOI 10.1002/art.1780380516; HUMPHRIES MJ, 1987, J BIOL CHEM, V262, P6886; Hynes RO, 1990, FIBRONECTINS; INGBER D, 1991, J CELL BIOCHEM, V47, P236, DOI 10.1002/jcb.240470309; JARNAGIN WR, 1994, J CELL BIOL, V127, P2037, DOI 10.1083/jcb.127.6.2037; Jones PL, 1997, J CELL BIOL, V139, P279, DOI 10.1083/jcb.139.1.279; Khan KMF, 1997, J BIOL CHEM, V272, P8270, DOI 10.1074/jbc.272.13.8270; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; KOCH AE, 1994, J IMMUNOL, V152, P4149; KUHN C, 1989, AM REV RESPIR DIS, V140, P1693, DOI 10.1164/ajrccm/140.6.1693; LAINE RA, 1987, METHOD ENZYMOL, V144, P420; MANISCALCO WM, 1995, AM J RESP CELL MOL, V13, P377, DOI 10.1165/ajrcmb.13.4.7546767; Matsumoto S, 1998, AM J PATHOL, V153, P109, DOI 10.1016/S0002-9440(10)65551-4; Matsumoto S, 1996, BBA-GENE STRUCT EXPR, V1307, P137, DOI 10.1016/0167-4781(96)00050-4; Matsumoto SI, 1997, BBA-GENE STRUCT EXPR, V1354, P159, DOI 10.1016/S0167-4781(97)00120-6; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; PETERSEN TE, 1983, P NATL ACAD SCI-BIOL, V80, P137, DOI 10.1073/pnas.80.1.137; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; Saito S, 1997, J BIOCHEM, V122, P49; Serini G, 1998, J CELL BIOL, V142, P873, DOI 10.1083/jcb.142.3.873; SHAPIRO SD, 1993, J BIOL CHEM, V268, P8170; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; WALAKOVITS LA, 1992, ARTHRITIS RHEUM, V35, P35, DOI 10.1002/art.1780350106; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WESTMAYS JA, 1995, P NATL ACAD SCI USA, V92, P6768, DOI 10.1073/pnas.92.15.6768; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; YAMADA KM, 1977, BIOCHEMISTRY-US, V16, P5552, DOI 10.1021/bi00644a025; Zhang YH, 1998, J IMMUNOL, V161, P3071; Zvaifler NJ, 1997, AM J PATHOL, V150, P1125	43	91	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30756	30763		10.1074/jbc.274.43.30756	http://dx.doi.org/10.1074/jbc.274.43.30756			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521465	hybrid			2022-12-27	WOS:000083276700061
J	Sajan, MP; Standaert, ML; Bandyopadhyay, G; Quon, RJ; Burke, TR; Farese, RV				Sajan, MP; Standaert, ML; Bandyopadhyay, G; Quon, RJ; Burke, TR; Farese, RV			Protein kinase C-zeta and phosphoinositide-dependent protein kinase-1 are required for insulin-induced activation of ERK in rat adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; GLUCOSE-TRANSPORT; PHOSPHATIDYLINOSITOL 3-KINASE; 3T3-L1 ADIPOCYTES; SIGNALING PATHWAY; GROWTH-FACTOR; MAP KINASE; WORTMANNIN; STIMULATION; INVOLVEMENT	The mechanisms used by insulin to activate the multifunctional intracellular effecters, extracellular signal-regulated kinases 1 and 2 (ERK1/2), are only partly understood and appear to vary in different cell types. Presently, in rat adipocytes, we found that insulin-induced activation of ERK was blocked (a) by chemical inhibitors of both phosphatidylinositol 3-kinase (PI3K) and protein kinase C (PKC)-zeta, and, moreover, (b) by transient expression of both dominant-negative Delta p85 PI3K subunit and kinase-inactive PKC-zeta. Further, insulin effects on ERK were inhibited by kinase-inactive 3-phosphoinositide-dependent protein kinase-1 (PDK-1), and by mutation of Thr-410 in the activation loop of PKC-zeta, which is the target of PDK-1 and is essential for PI3K/PDK-1-dependent activation of PKC-C In addition to requirements for PI3K, PDK-1, and PKC-zeta, we found that a tyrosine kinase (presumably the insulin receptor), the SH2 domain of GRB2, SOS, RAS, RAF, and MEK1 were required for insulin effects on ERK in the rat adipocyte. Our findings therefore suggested that PDK-1 and PKC-zeta serve as a downstream effecters of PI3K, and act in conjunction with GRB2, SOS, RAS, and RAF, to activate MEK and ERK during insulin action in rat adipocytes.	Univ S Florida, James A Haley Vet Hosp, Coll Med, Res Serv VAR 151, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Internal Med, Tampa, FL 33612 USA; NHLBI, Hypertens Endocrine Branch, NIH, Bethesda, MD 20892 USA; NHLBI, Med Chem Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA	State University System of Florida; University of South Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; State University System of Florida; University of South Florida; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Farese, RV (corresponding author), Univ S Florida, James A Haley Vet Hosp, Coll Med, Res Serv VAR 151, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	rfarese@com1.med.usf.edu	Burke, Terrence R/N-2601-2014; Farese, Robert/B-3605-2015	Quon, Michael/0000-0002-9601-9915; QUON, MICHAEL/0000-0002-5289-3707; Burke, Terrence/0000-0001-9925-8586	NIDDK NIH HHS [R01 DK065969] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL003608] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065969] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Band CJ, 1997, J BIOL CHEM, V272, P138; Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; Bandyopadhyay G, 1999, BIOCHEM J, V337, P461, DOI 10.1042/0264-6021:3370461; Bandyopadhyay G, 1997, ENDOCRINOLOGY, V138, P4721, DOI 10.1210/en.138.11.4721; BANDYOPADHYAY G, 1999, IN PRESS MOL ENDOCRI; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; DENTON RM, 1995, EUR J BIOCHEM, V227, P597, DOI 10.1111/j.1432-1033.1995.tb20179.x; Giglione C, 1998, J BIOL CHEM, V273, P34737, DOI 10.1074/jbc.273.52.34737; Gnudi L, 1997, MOL ENDOCRINOL, V11, P67, DOI 10.1210/me.11.1.67; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lin YL, 1998, BIOCHEM BIOPH RES CO, V246, P172, DOI 10.1006/bbrc.1998.8488; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Mendez R, 1997, MOL CELL BIOL, V17, P5184, DOI 10.1128/MCB.17.9.5184; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SAKAUE H, 1995, J BIOL CHEM, V270, P11304, DOI 10.1074/jbc.270.19.11304; Shimizu Y, 1997, ENDOCRINOLOGY, V138, P248, DOI 10.1210/en.138.1.248; STANDAERT ML, 1995, BIOCHEM BIOPH RES CO, V209, P1082, DOI 10.1006/bbrc.1995.1608; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Suga J, 1997, DIABETES, V46, P735, DOI 10.2337/diabetes.46.5.735; Takeda H, 1999, EMBO J, V18, P386, DOI 10.1093/emboj/18.2.386; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015; YANG YC, 1993, FEBS LETT, V333, P287, DOI 10.1016/0014-5793(93)80672-H; Yao ZJ, 1999, J MED CHEM, V42, P25, DOI 10.1021/jm980388x	32	97	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30495	30500		10.1074/jbc.274.43.30495	http://dx.doi.org/10.1074/jbc.274.43.30495			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521430	hybrid			2022-12-27	WOS:000083276700026
J	Bathori, G; Parolini, I; Tombola, F; Szabo, I; Messina, A; Oliva, M; De Pinto, V; Lisanti, M; Sargiacomo, M; Zoratti, M				Bathori, G; Parolini, I; Tombola, F; Szabo, I; Messina, A; Oliva, M; De Pinto, V; Lisanti, M; Sargiacomo, M; Zoratti, M			Porin is present in the plasma membrane where it is concentrated in caveolae and caveolae-related domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT ANION CHANNEL; HUMAN B-LYMPHOCYTES; OUTER MITOCHONDRIAL-MEMBRANE; SKELETAL-MUSCLE; SARCOPLASMIC-RETICULUM; NEUROSPORA-CRASSA; 31 HL; PROTEIN; EXPRESSION; PURIFICATION	Mitochondrial porin, or voltage-dependent anion channel, is a pore-forming protein first discovered in the outer mitochondrial membrane. Later investigations have provided indications for its presence also in other cellular membranes, including the plasma membrane, and in caveolae. This extra-mitochondrial localization is debated and no clear-cut conclusion has been reached up to now. In this work, we used biochemical and electrophysiological techniques to detect and characterize porin within isolated caveolae and caveolae-like domains (low density Triton-insoluble fractions). A new procedure was used to isolate porin from plasma membrane. The outer surface of cultured CEM cells was biotinylated by an impermeable reagent. Low density Triton-insoluble fractions were prepared from the labeled cells and used as starting material to purify a biotinylated protein with the same electrophoretic mobility and immunoreactivity of mitochondrial porin. In planar bilayers, the porin from these sources formed slightly anion-selective pores with properties indistinguishable from those of mitochondrial porin. This work thus provides a strong indication of the presence of porin in the plasma membrane, and specifically in caveolae and caveolae-like domains.	CNR, Ctr Studi Biomembrane, Dipartimento Sci Biomed Sperimentali, I-35121 Padua, Italy; Ist Super Sanita, Dipartimento Ematol & Oncol, I-00161 Rome, Italy; Univ Catania, Fac Sci MFN, Dipartimento Sci Chim, Lab Biochim & Biol Mol, I-95125 Catania, Italy; Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Consiglio Nazionale delle Ricerche (CNR); Istituto Superiore di Sanita (ISS); University of Catania; Yeshiva University; Albert Einstein College of Medicine	De Pinto, V (corresponding author), Semmelweis Univ, Dept Physiol, Puskin U 9, H-1088 Budapest, Hungary.	vdpbiofa@mbox.unict.it	parolini, Isabella/J-9955-2016; Messina, Angela/ABC-9518-2020; Padova, Ildiko/K-5344-2016; Tombola, Francesco/C-7311-2011; De Pinto, Vito/AAC-2634-2019; Szabo, Ildiko/AAW-5972-2021; Tombola, Francesco/ABA-6002-2020	parolini, Isabella/0000-0001-9863-1051; Szabo, Ildiko/0000-0002-3637-3947; Tombola, Francesco/0000-0002-9315-0352; MESSINA, Angela Anna/0000-0002-5745-9846; Sargiacomo, Massimo/0000-0003-4040-706X; De Pinto, Vito/0000-0001-5513-2906	Telethon [A.059] Funding Source: Medline	Telethon(Fondazione Telethon)		BABEL D, 1991, BIOL CHEM H-S, V372, P1027, DOI 10.1515/bchm3.1991.372.2.1027; Bathori G, 1996, J BIOENERG BIOMEMBR, V28, P191, DOI 10.1007/BF02110650; Bathori G, 1998, BIOCHEM BIOPH RES CO, V243, P258, DOI 10.1006/bbrc.1997.7926; BENZ R, 1994, BBA-REV BIOMEMBRANES, V1197, P167, DOI 10.1016/0304-4157(94)90004-3; BLACHLYDYSON E, 1993, J BIOL CHEM, V268, P1835; Cameron PL, 1997, J NEUROSCI, V17, P9520; COLOMBINI M, 1994, CURR TOP MEMBR, V42, P73, DOI 10.1016/S0070-2161(08)60819-9; DEPINTO V, 1989, EUR J BIOCHEM, V183, P179; DEPINTO V, 1987, BIOCHIM BIOPHYS ACTA, V905, P499, DOI 10.1016/0005-2736(87)90480-9; DERMIETZEL R, 1994, P NATL ACAD SCI USA, V91, P499, DOI 10.1073/pnas.91.2.499; FREITAG H, 1982, EUR J BIOCHEM, V123, P629; Galbiati F, 1998, P NATL ACAD SCI USA, V95, P10257, DOI 10.1073/pnas.95.17.10257; Gunkel N, 1998, GENE DEV, V12, P1652, DOI 10.1101/gad.12.11.1652; HUIZING M, 1994, LANCET, V344, P762, DOI 10.1016/S0140-6736(94)92257-8; JAKOB C, 1995, FEBS LETT, V368, P5, DOI 10.1016/0014-5793(95)00465-L; KAYSER H, 1989, BIOL CHEM H-S, V370, P1265; KLEENE R, 1987, EMBO J, V6, P2627, DOI 10.1002/j.1460-2075.1987.tb02553.x; Larsson NG, 1996, NAT GENET, V13, P296, DOI 10.1038/ng0796-296; LEWIS TM, 1994, NEUROSCI LETT, V181, P83, DOI 10.1016/0304-3940(94)90565-7; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Lithgow T, 1997, TRENDS BIOCHEM SCI, V22, P110, DOI 10.1016/S0968-0004(97)01007-4; NOBILE M, 1988, BIOCHEM BIOPH RES CO, V154, P719, DOI 10.1016/0006-291X(88)90199-4; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Oliva M, 1998, FEBS LETT, V430, P327, DOI 10.1016/S0014-5793(98)00693-0; PAHAPILL PA, 1992, J MEMBRANE BIOL, V125, P171; PALADE GE, 1953, J APPL PHYS, V24, P1424; Parolini I, 1996, BLOOD, V87, P3783, DOI 10.1182/blood.V87.9.3783.bloodjournal8793783; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; POPP B, 1995, BIOCHEMISTRY-US, V34, P3352, DOI 10.1021/bi00010a026; Reymann S, 1998, PFLUG ARCH EUR J PHY, V436, P478, DOI 10.1007/s004240050659; Sampson MJ, 1997, J BIOL CHEM, V272, P18966, DOI 10.1074/jbc.272.30.18966; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; ShoshanBarmatz V, 1996, FEBS LETT, V386, P205, DOI 10.1016/0014-5793(96)00442-5; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Szabo I, 1998, FASEB J, V12, P495, DOI 10.1096/fasebj.12.6.495; THINNES FP, 1989, BIOL CHEM H-S, V370, P1253; Thorp KM, 1996, IMMUNOLOGY, V87, P434, DOI 10.1046/j.1365-2567.1996.486567.x; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525; WIGMAN JE, 1993, J CELL BIOL, V123, P269; WINKELBACH H, 1994, BIOCHEM MED METAB B, V52, P120, DOI 10.1006/bmmb.1994.1042; YU WH, 1995, J BIOL CHEM, V270, P13998, DOI 10.1074/jbc.270.23.13998	43	106	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29607	29612		10.1074/jbc.274.42.29607	http://dx.doi.org/10.1074/jbc.274.42.29607			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514428	hybrid			2022-12-27	WOS:000083176400007
J	Bjorbaek, C; El-Haschimi, K; Frantz, JD; Flier, JS				Bjorbaek, C; El-Haschimi, K; Frantz, JD; Flier, JS			The role of SOCS-3 in leptin signaling and leptin resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OBESE GENE; ERYTHROPOIETIN RECEPTOR; DIABETIC MICE; DB/DB MICE; OB/OB MICE; PROTEIN; ACTIVATION; CELLS; IDENTIFICATION; EXPRESSION	We earlier demonstrated that leptin induces expression of SOCS-3 mRNA in the hypothalamus. Furthermore, transfection data suggest that SOCS-3 is an inhibitor of leptin signaling. However, little is known about the regulation of SOCS-3 expression by leptin and the mechanism by which SOCS-3 inhibits leptin action. We here show that in CHO cells stably expressing the long form of the leptin receptor (CHO-OBRl), leptin induces transient expression of endogenous SOCS-3 mRNA but not of CIS, SOCS-1, or SOCS-2 mRNA. SOCS-3 protein levels were maximal after 2-3 h of leptin treatment and remained elevated at 20 h. Furthermore, in leptin-pretreated CHO-OBRl cells, proximal leptin signaling was blocked for more than 20 h after pretreatment, thus correlating with increased SOCS-3 expression. Leptin pretreatment did not affect cell surface expression of leptin receptors as measured by I-125-Peptin binding assays. In transfected COS cells, forced expression of SOCS-3 results in inhibition of leptin-induced tyrosine phosphorylation of JAK2. Finally, JAK2 co-immunoprecipitates with SOCS-3 in lysates from leptin-treated COS cells. These results suggest that SOCS-3 is a leptin-regulated inhibitor of proximal leptin signaling in vivo. Excessive SOCS-3 activity in leptin-responsive cells is therefore a potential mechanism for leptin resistance, a characteristic feature in human obesity.	Harvard Univ, Sch Med, Dept Med, Div Endocrinol,Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.	Flier, JS (corresponding author), Harvard Univ, Sch Med, Dept Med, Div Endocrinol,Beth Israel Deaconess Med Ctr, 99 Brookline Ave,Res N, Boston, MA 02215 USA.		Bjorbaek, Christian/S-4727-2019; Flier, jeffrey/AAG-6223-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK028082] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK R37 28082] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Auernhammer CJ, 1998, MOL ENDOCRINOL, V12, P954, DOI 10.1210/me.12.7.954; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; Bjorbaek C, 1997, J BIOL CHEM, V272, P32686, DOI 10.1074/jbc.272.51.32686; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Carpenter LR, 1998, P NATL ACAD SCI USA, V95, P6061, DOI 10.1073/pnas.95.11.6061; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Dey BR, 1998, J BIOL CHEM, V273, P24095, DOI 10.1074/jbc.273.37.24095; Elmquist JK, 1998, J COMP NEUROL, V395, P535; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Ghilardi N, 1997, MOL ENDOCRINOL, V11, P393, DOI 10.1210/me.11.4.393; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kieffer TJ, 1997, DIABETES, V46, P1087, DOI 10.2337/diabetes.46.6.1087; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; Masuhara M, 1997, BIOCHEM BIOPH RES CO, V239, P439, DOI 10.1006/bbrc.1997.7484; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; Morton NM, 1998, J BIOL CHEM, V273, P26194, DOI 10.1074/jbc.273.40.26194; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Narazaki M, 1998, P NATL ACAD SCI USA, V95, P13130, DOI 10.1073/pnas.95.22.13130; Ohya K, 1997, J BIOL CHEM, V272, P27178, DOI 10.1074/jbc.272.43.27178; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Song MM, 1998, J BIOL CHEM, V273, P35056, DOI 10.1074/jbc.273.52.35056; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Suzuki R, 1998, ONCOGENE, V17, P2271, DOI 10.1038/sj.onc.1202143; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; Verdier F, 1998, J BIOL CHEM, V273, P28185, DOI 10.1074/jbc.273.43.28185; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Zhang FM, 1997, NATURE, V387, P206, DOI 10.1038/387206a0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	44	489	528	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30059	30065		10.1074/jbc.274.42.30059	http://dx.doi.org/10.1074/jbc.274.42.30059			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514492	hybrid			2022-12-27	WOS:000083176400071
J	Edberg, JC; Yee, AMF; Rakshit, DS; Chang, DJ; Gokhale, JA; Indik, ZK; Schreiber, AD; Kimberly, RP				Edberg, JC; Yee, AMF; Rakshit, DS; Chang, DJ; Gokhale, JA; Indik, ZK; Schreiber, AD; Kimberly, RP			The cytoplasmic domain of human Fc gamma RIa alters the functional properties of the Fc gamma RI center dot gamma-chain receptor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY RECEPTOR; PROTEIN-TYROSINE KINASE; IMMUNOGLOBULIN-G; EPSILON-RI; PHAGOCYTIC FUNCTION; DISTINCT REGIONS; IGE RECEPTOR; C-DELTA; IN-VIVO; SUBUNIT	The gamma/zeta-chain family of proteins mediate cell activation for multiple immunoglobulin receptors, However, the recognition that these receptors may have distinct biologic functions suggests that additional signaling elements may contribute to functional diversity. We hypothesized that the cytoplasmic domain (CY) of the ligand binding alpha-chain alters the biological properties of the receptor complex. Using macrophage Fc gamma RIa as a model system, we created stable transfectants expressing a full-length or a CY deletion mutant of human Fc gamma RIa. Both receptors functionally associate with the endogenous murine gamma-chain. However, we have established that the CY of Fc gamma RIa directly contributes to the functional properties of the receptor complex. Deletion of the Fc gamma RIa CY leads to slower kinetics of receptor-specific phagocytosis and endocytosis as well as lower total phagocytosis despite identical levels of receptor expression. Deletion of the CY also converts the phenotype of calcium independent Fc gamma RIa-specific phagocytosis to a calcium-dependent phenotype, Finally, deletion of the CY abrogates Fc gamma RIa-specific secretion of interleukin-6 but does not, affect production of interleukin-1 beta These results demonstrate a functional role for the CY of Fc gamma RIa and provide a general model for understanding how multiple receptors that utilize the gamma-chain can generate diversity in function.	Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA; Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA; Cornell Univ, Hosp Special Surg, Dept Med, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, New York, NY 10021 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Cornell University; Cornell University; University of Pennsylvania	Edberg, JC (corresponding author), Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, 433A Tinsley Harrison Tower,1900 Univ Blvd, Birmingham, AL 35294 USA.			Kimberly, Robert/0000-0002-5330-3086	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI022193, R01AI022193] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR033062, R01AR042476] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-22193] Funding Source: Medline; NIAMS NIH HHS [R01-AR42476, R01-AR33062] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Crowley MT, 1997, J EXP MED, V186, P1027, DOI 10.1084/jem.186.7.1027; DAERON M, 1994, J IMMUNOL, V152, P783; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; DAVIS W, 1995, EMBO J, V14, P432, DOI 10.1002/j.1460-2075.1995.tb07019.x; DURDEN DL, 1994, BIOCHEM J, V299, P569, DOI 10.1042/bj2990569; EDBERG JC, 1995, J BIOL CHEM, V270, P22301, DOI 10.1074/jbc.270.38.22301; EDBERG JC, 1994, J IMMUNOL, V152, P5826; Edberg JC, 1998, J BIOL CHEM, V273, P8071, DOI 10.1074/jbc.273.14.8071; ERNST LK, 1993, P NATL ACAD SCI USA, V90, P6023, DOI 10.1073/pnas.90.13.6023; GERMANO P, 1994, J BIOL CHEM, V269, P23102; GIBSON AW, 1999, LUPUS MOL CELLULAR P, P557; Greenberg S, 1996, P NATL ACAD SCI USA, V93, P1103, DOI 10.1073/pnas.93.3.1103; GUYRE PM, 1989, J IMMUNOL, V143, P1650; HALEEMSMITH H, 1995, P NATL ACAD SCI USA, V92, P9112, DOI 10.1073/pnas.92.20.9112; HARRISON PT, 1994, J BIOL CHEM, V269, P24396; Hazenbos WLW, 1996, IMMUNITY, V5, P181, DOI 10.1016/S1074-7613(00)80494-X; INDIK Z, 1992, IMMUNOBIOLOGY, V185, P183, DOI 10.1016/S0171-2985(11)80640-6; INDIK ZK, 1994, EXP HEMATOL, V22, P599; INDIK ZK, 1995, BLOOD, V85, P1175, DOI 10.1182/blood.V85.5.1175.bloodjournal8551175; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; Kiefer F, 1998, MOL CELL BIOL, V18, P4209, DOI 10.1128/MCB.18.7.4209; KIMBERLY RP, 1995, ARTHRITIS RHEUM, V38, P306, DOI 10.1002/art.1780380303; KRUTMANN J, 1990, J IMMUNOL, V145, P1337; LETOURNEUR O, 1991, J IMMUNOL, V147, P2652; Lowry MB, 1998, J EXP MED, V187, P161, DOI 10.1084/jem.187.2.161; Matsuda M, 1996, MOL BIOL CELL, V7, P1095, DOI 10.1091/mbc.7.7.1095; McKenzie S E, 1998, Curr Opin Hematol, V5, P16, DOI 10.1097/00062752-199801000-00003; Miller KL, 1996, J EXP MED, V183, P2227, DOI 10.1084/jem.183.5.2227; MITCHELL MA, 1994, BLOOD, V84, P1753; ODIN JA, 1991, SCIENCE, V254, P1785, DOI 10.1126/science.1837175; OHTA Y, 1991, CELL, V67, P275, DOI 10.1016/0092-8674(91)90179-3; PARK JG, 1995, P NATL ACAD SCI USA, V92, P7381, DOI 10.1073/pnas.92.16.7381; PFEFFERKORN LC, 1995, J BIOL CHEM, V270, P8164, DOI 10.1074/jbc.270.14.8164; Pricop L, 1997, J IMMUNOL METHODS, V205, P55, DOI 10.1016/S0022-1759(97)00053-7; PRINS JB, 1993, SCIENCE, V260, P695, DOI 10.1126/science.8480181; QUILLIAM AL, 1993, IMMUNOLOGY, V78, P358; Ravetch JV, 1998, ANNU REV IMMUNOL, V16, P421, DOI 10.1146/annurev.immunol.16.1.421; SCHOLL PR, 1993, P NATL ACAD SCI USA, V90, P8847, DOI 10.1073/pnas.90.19.8847; SCHONEICH JT, 1992, J IMMUNOL, V148, P2181; SIMMS HH, 1991, J IMMUNOL, V147, P265; SOCOLOVSKY M, 1994, EUR J CELL BIOL, V64, P29; Sutterwala FS, 1998, J EXP MED, V188, P217, DOI 10.1084/jem.188.1.217; Sylvestre DL, 1996, IMMUNITY, V5, P387, DOI 10.1016/S1074-7613(00)80264-2; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; vanVugt MJ, 1996, BLOOD, V87, P3593, DOI 10.1182/blood.V87.9.3593.bloodjournal8793593; Vonakis BM, 1997, J BIOL CHEM, V272, P24072, DOI 10.1074/jbc.272.38.24072; Wolf HM, 1996, CLIN EXP IMMUNOL, V105, P537, DOI 10.1046/j.1365-2249.1996.d01-793.x	47	32	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30328	30333		10.1074/jbc.274.42.30328	http://dx.doi.org/10.1074/jbc.274.42.30328			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514529	hybrid			2022-12-27	WOS:000083176400108
J	Fairbanks, MB; Mildner, AM; Leone, JW; Cavey, GS; Mathews, WR; Drong, RF; Slightom, JL; Bienkowski, MJ; Smith, CW; Bannow, CA; Heinrikson, RL				Fairbanks, MB; Mildner, AM; Leone, JW; Cavey, GS; Mathews, WR; Drong, RF; Slightom, JL; Bienkowski, MJ; Smith, CW; Bannow, CA; Heinrikson, RL			Processing of the human heparanase precursor and evidence that the active enzyme is a heterodimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINS; PROTEOGLYCANS; CLEAVAGE; PEPTIDES; CELLS	Human platelet heparanase has been purified to homogeneity and shown to consist of two, non-covalently associated polypeptide chains of molecular masses 50 and 8 kDa. Protein sequencing provided the basis far determination of the full-length cDNA for this novel protein. Based upon this information and results from protein analysis and mass spectrometry, we propose a scheme to define the structural organization of heparanase in relation to its precursor forms, proheparanase and pre-proheparanase. The 8- and 50-kDa chains which make up the active enzyme reside, respectively, at the NH2- and COOH-terminal regions of the inactive: precursor, proheparanase. The heparanase heterodimer is produced by excision and loss of an internal linking segment. This paper is the first to suggest that human heparanase is a two-chain enzyme.	Pharmacia & Upjohn Inc, Prot Sci, Kalamazoo, MI 49001 USA; Pharmacia & Upjohn Inc, Genom Res, Kalamazoo, MI 49001 USA; Pharmacia & Upjohn Inc, Struct Analyt & Med Chem, Kalamazoo, MI 49001 USA; Pharmacia & Upjohn Inc, Res Operat, Kalamazoo, MI 49001 USA	Pfizer; Pfizer; Pfizer; Pfizer	Heinrikson, RL (corresponding author), Pharmacia & Upjohn Inc, Prot Sci, Kalamazoo, MI 49001 USA.							ABRAHAMSSON T, 1992, CIRC RES, V70, P264, DOI 10.1161/01.RES.70.2.264; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Eccles SA, 1999, NAT MED, V5, P735, DOI 10.1038/10455; Finkel E, 1999, SCIENCE, V285, P33, DOI 10.1126/science.285.5424.33; FREEMAN C, 1998, BIOCHEM J, V330, P1371; Gonzalez-Stawinski GV, 1999, BBA-PROTEIN STRUCT M, V1429, P431, DOI 10.1016/S0167-4838(98)00254-4; HOOGEWERF AJ, 1995, J BIOL CHEM, V270, P3268, DOI 10.1074/jbc.270.7.3268; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; Kato M, 1998, NAT MED, V4, P691, DOI 10.1038/nm0698-691; Kussie PH, 1999, BIOCHEM BIOPH RES CO, V261, P183, DOI 10.1006/bbrc.1999.0962; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDBETTER SR, 1987, BIOCHEMISTRY-US, V26, P988, DOI 10.1021/bi00378a003; LOHSE DL, 1992, J BIOL CHEM, V267, P24347; MATZNER Y, 1992, J LEUKOCYTE BIOL, V51, P519, DOI 10.1002/jlb.51.6.519; NAKAJIMA M, 1988, J CELL BIOCHEM, V36, P157, DOI 10.1002/jcb.240360207; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Rechter M, 1999, BIOCHEM BIOPH RES CO, V255, P657, DOI 10.1006/bbrc.1999.0181; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SWITZER RC, 1979, ANAL BIOCHEM, V98, P231, DOI 10.1016/0003-2697(79)90732-2; TANAKA Y, 1993, IMMUNOL TODAY, V14, P111, DOI 10.1016/0167-5699(93)90209-4; THUNBERG L, 1982, J BIOL CHEM, V257, P278; VLODAVSKY I, 1992, INVAS METAST, V12, P112; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518	24	158	172	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29587	29590		10.1074/jbc.274.42.29587	http://dx.doi.org/10.1074/jbc.274.42.29587			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514423	hybrid			2022-12-27	WOS:000083176400002
J	Huang, CS; Li, JX; Ma, WY; Dong, ZG				Huang, CS; Li, JX; Ma, WY; Dong, ZG			JNK activation is required for JB6 cell transformation induced by tumor necrosis factor-alpha but not by 12-O-tetradecanoylphorbol-13-acetate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE KINASE; N-TERMINAL KINASE; SIGNAL-TRANSDUCTION PATHWAYS; NERVE GROWTH-FACTOR; NIH 3T3 CELLS; C-JUN; PROTEIN-KINASE; MAMMALIAN-CELLS; AP-1 TRANSACTIVATION; SELECTIVE ACTIVATION	Signal transduction via mitogen-activated protein kinase pathways plays a key role in a variety of cellular responses, including cell proliferation, differentiation, tumor promotion, and cell death, c-Jun N-terminal kinases (JNKs) are identified as members of the mitogen-activated protein kinase family and are known to phosphorylate and activate several transcription factors, including c-Jun, ATF, and Elk-1. However, the role of JNK activation in tumor promotion is not yet defined. Because previous studies have indicated that exposure of JB6 Cl 41 cells to either 12-O-tetradecanoylphorbol-13-acetate (TPA) or tumor necrosis factor-alpha (TNF-alpha) results in cell transformation, we investigated the role of JNKs in this biological process by using dominant negative JNK, and the cell transformation model JB6 C1 41 cells. Incubation of Cl 41 cells with TNF-alpha led to cell transformation and activation of JNKs, Introduction of the dominant negative mutant of JNK(1) into JB6 Cl 41 cells specifically inhibited TNF-alpha induced activation of JNKs, but not Erks and p38 kinases. Most importantly, expressing dominant negative mutant JNK(1) inhibited TNF-alpha-induced cell transformation but not TPA-induced cell transformation. Our results directly demonstrated for the first time that JNK activation is required for TNF-alpha- but not TPA-induced cell transformation.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	University of Minnesota System	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16Th Ave NE, Austin, MN 55912 USA.			Huang, Chuanshu/0000-0003-4133-5096	NCI NIH HHS [CA74916] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA074916] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adler V, 1996, J BIOL CHEM, V271, P23304, DOI 10.1074/jbc.271.38.23304; BIRD TA, 1994, J BIOL CHEM, V269, P31836; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BRACH MA, 1993, MOL CELL BIOL, V13, P4284, DOI 10.1128/MCB.13.7.4284; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COLBURN NH, 1979, NATURE, V281, P589, DOI 10.1038/281589a0; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; COSCO OA, 1995, CELL, V81, P1137; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DHANWADA KR, 1995, ONCOGENE, V11, P1947; ELBAZ O, 1991, J CLIN INVEST, V87, P838, DOI 10.1172/JCI115087; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; Guo YL, 1998, J BIOL CHEM, V273, P4027, DOI 10.1074/jbc.273.7.4027; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Huang CS, 1999, CANCER RES, V59, P3053; Huang CS, 1999, J BIOL CHEM, V274, P14595, DOI 10.1074/jbc.274.21.14595; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Huang CS, 1997, J BIOL CHEM, V272, P26325, DOI 10.1074/jbc.272.42.26325; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; Rojanasakul Y, 1997, J BIOL CHEM, V272, P3910, DOI 10.1074/jbc.272.7.3910; Sakata N, 1995, J BIOL CHEM, V270, P30823, DOI 10.1074/jbc.270.51.30823; Saklatvala J, 1996, PHILOS T ROY SOC B, V351, P151, DOI 10.1098/rstb.1996.0011; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHUTZE S, 1992, SEMIN ONCOL, V19, P16; SEGER R, 1994, J BIOL CHEM, V269, P25699; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Watts RG, 1998, ONCOGENE, V17, P3493, DOI 10.1038/sj.onc.1202259; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu X, 1996, ONCOGENE, V13, P135; Yu R, 1996, CANCER LETT, V107, P73, DOI 10.1016/0304-3835(96)04345-5; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	57	79	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29672	29676		10.1074/jbc.274.42.29672	http://dx.doi.org/10.1074/jbc.274.42.29672			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514437	hybrid			2022-12-27	WOS:000083176400016
J	Li, R; Debreceni, B; Jia, BQ; Gao, Y; Tigyi, G; Zheng, Y				Li, R; Debreceni, B; Jia, BQ; Gao, Y; Tigyi, G; Zheng, Y			Localization of the PAK1-, WASP-, and IQGAP1-specifying regions of Cdc42	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDRICH-SYNDROME PROTEIN; CELL-CYCLE PROGRESSION; ACTIN-CYTOSKELETON; GTPASE CDC42; P21-ACTIVATED KINASE; SIGNALING PATHWAY; TARGET PROTEINS; FOCAL COMPLEXES; INSERT REGION; RAC GTPASES	The Rho family small GTPase Cdc42 transmits divergent intracellular signals through multiple effector proteins to elicit cellular responses such as cytoskeletal reorganization, Potential effectors of Cdc42 implicated in mediating its cytoskeletal effect in mammalian cells include PAK1, WASP, and IQGAP1, To investigate the determinants of Cdc42-effector specificity, we utilized recombinant Cdc42 mutants and chimeras made between Cdc42 and RhoA to map the regions of Cdc42 contributing to specific effector pal-binding domain (PBD) interaction, Site-directed mutants of the switch I domain and neighboring regions of Cdc42 demonstrated differential binding patterns toward the PBDs of PAK1, WASP, and IQGAP1, suggesting that switch I provides essential determinants for the effector binding, but recognition of each effector by Cdc42 involves a distinct mechanism. Differing from Rad, the switch I domain and the surrounding region (amino acids 29 to 55) of Cdc42 appeared to be sufficient for specific binding to PAK1, whereas determinants outside the switch I domain, residues 157-191 anal 84-120 in particular, were necessary and sufficient to confer specificity to WASP and IQGAP1, respectively. In addition, IQGAP1, but not PAK1 nor WASP, required the unique "insert region," residues 122-134, of Cdc42 to achieve high affinity binding. Microinjection of the constitutively active Cdc42/ RhoA chimeras into serum-starved Swiss 3T3 cells showed that although preserving PAK1- and WASP- binding activity could retain the peripheral. actin microspike (PAM)-inducing activity of Cdc42, interaction with PAK1 or WASP was not required for this activity. Moreover, IQGAP1-binding alone by Cdc42 was insufficient for PAM-induction, Thus, Cdc42 utilizes multiple distinct structural determinants to specify different effector recognition and to elicit PAM-inducing effect.	Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA; Univ Tennessee, Dept Physiol & Biophys, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Zheng, Y (corresponding author), Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA.	yzheng@utmem.edu	Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053943, R01GM060523] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 53943, GM 60523] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; Aspenstrom P, 1997, CURR BIOL, V7, P479, DOI 10.1016/S0960-9822(06)00219-3; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; Bae CD, 1998, J BIOL CHEM, V273, P11596, DOI 10.1074/jbc.273.19.11596; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Bashour AM, 1997, J CELL BIOL, V137, P1555, DOI 10.1083/jcb.137.7.1555; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Castellano F, 1999, CURR BIOL, V9, P351, DOI 10.1016/S0960-9822(99)80161-4; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; Dutartre H, 1996, J CELL SCI, V109, P367; Erickson JW, 1997, J BIOL CHEM, V272, P24443, DOI 10.1074/jbc.272.39.24443; Feltham JL, 1997, BIOCHEMISTRY-US, V36, P8755, DOI 10.1021/bi970694x; Freeman JL, 1996, J BIOL CHEM, V271, P19794, DOI 10.1074/jbc.271.33.19794; Fujisawa K, 1998, J BIOL CHEM, V273, P18943, DOI 10.1074/jbc.273.30.18943; Guo W, 1998, BIOCHEMISTRY-US, V37, P14030, DOI 10.1021/bi981352+; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Huang L, 1998, NAT STRUCT BIOL, V5, P422, DOI 10.1038/nsb0698-422; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; Knaus UG, 1998, J BIOL CHEM, V273, P21512, DOI 10.1074/jbc.273.34.21512; Kolluri R, 1996, P NATL ACAD SCI USA, V93, P5615, DOI 10.1073/pnas.93.11.5615; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Leonard DA, 1997, BIOCHEMISTRY-US, V36, P1173, DOI 10.1021/bi9622837; Li R, 1997, J BIOL CHEM, V272, P32830, DOI 10.1074/jbc.272.52.32830; Li R, 1997, J BIOL CHEM, V272, P4671, DOI 10.1074/jbc.272.8.4671; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rudolph MG, 1998, J BIOL CHEM, V273, P18067, DOI 10.1074/jbc.273.29.18067; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Schwartz MA, 1998, ONCOGENE, V17, P625, DOI 10.1038/sj.onc.1201977; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; WEISSBACH L, 1994, J BIOL CHEM, V269, P20517; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Wu WJ, 1997, J BIOL CHEM, V272, P26153, DOI 10.1074/jbc.272.42.26153; Wu WJ, 1998, J BIOL CHEM, V273, P16655, DOI 10.1074/jbc.273.27.16655; XU XM, 1994, J BIOL CHEM, V269, P23569; Zhang BL, 1997, J BIOL CHEM, V272, P21999, DOI 10.1074/jbc.272.35.21999; Zhang BL, 1998, J BIOL CHEM, V273, P25728, DOI 10.1074/jbc.273.40.25728; Zhang BL, 1998, J BIOL CHEM, V273, P8776, DOI 10.1074/jbc.273.15.8776; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zheng Y, 1996, J BIOL CHEM, V271, P33169, DOI 10.1074/jbc.271.52.33169; Zong H, 1999, J BIOL CHEM, V274, P4551, DOI 10.1074/jbc.274.8.4551	63	53	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29648	29654		10.1074/jbc.274.42.29648	http://dx.doi.org/10.1074/jbc.274.42.29648			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514434	hybrid			2022-12-27	WOS:000083176400013
J	Zenke, FT; King, CC; Bohl, BP; Bokoch, GM				Zenke, FT; King, CC; Bohl, BP; Bokoch, GM			Identification of a central phosphorylation site in p21-activated kinase regulating autoinhibition and kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; RAC GTPASES; ALPHA-PAK; ACTIVATION; AUTOPHOSPHORYLATION; ACTIN; INHIBITION; CLEAVAGE; REVEALS; FAMILY	p21-activated kinases (Pak)/Ste20 kinases are regulated in vitro and in vivo by the small GTP-binding proteins Rac and Cdc42 and lipids, such as sphingosine, which stimulate autophosphorylation and phosphorylation of exogenous substrates, The mechanism of Pak activation by these agents remains unclear. We investigated Pak kinase activation in more detail to gain insight into the interplay between the GTPase/sphingosine binding, an intramolecular inhibitory interaction, and autophosphorylation, We present biochemical evidence that an autoinhibitory domain (ID) contained within amino acid residues 67-150 of Pak1 interacts with the carboxyl-terminal kinase domain and that this interaction is regulated in a GTPase-dependent fashion. Cdc42- and sphingosine-stimulated Pak1 activity can be inhibited in trans by recombinant ID peptide, indicating similarities in their mode of activation. However, Pak1, which was autophosphorylated in response to either GTPase or sphingosine, is highly active and is insensitive to inhibition by the ID peptide, We identified phospho-acceptor site threonine 423 in the kinase activation loop as a critical determinant for the sensitivity to autoinhibition and enzymatic activity. Phosphorylation studies suggested that the stimulatory effect of both GTPase and sphingosine results in exposure of the activation loop, making it accessible for intermolecular phosphorylation.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Bokoch, GM (corresponding author), Scripps Res Inst, Dept Immunol, Immunobiol IMM14,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		King, Cecile/Q-9794-2019	King, Cecile/0000-0003-2193-2563; Zenke, Frank/0000-0002-2226-3755	NIA NIH HHS [AG15430] Funding Source: Medline; NIGMS NIH HHS [GM 39434] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039434] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015430] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; BENNER GE, 1995, J BIOL CHEM, V270, P21121, DOI 10.1074/jbc.270.36.21121; Bokoch GM, 1998, J BIOL CHEM, V273, P8137, DOI 10.1074/jbc.273.14.8137; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Daniels RH, 1999, J BIOL CHEM, V274, P6047, DOI 10.1074/jbc.274.10.6047; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; Knaus UG, 1998, J BIOL CHEM, V273, P21512, DOI 10.1074/jbc.273.34.21512; Lee N, 1997, P NATL ACAD SCI USA, V94, P13642, DOI 10.1073/pnas.94.25.13642; Lian JP, 1998, J IMMUNOL, V161, P4375; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; STEINBERG RA, 1993, MOL CELL BIOL, V13, P2332, DOI 10.1128/MCB.13.4.2332; Taylor SS, 1997, CURR OPIN CHEM BIOL, V1, P219, DOI 10.1016/S1367-5931(97)80013-0; Tu H, 1999, MOL CELL BIOL, V19, P602; Walter BN, 1998, J BIOL CHEM, V273, P28733, DOI 10.1074/jbc.273.44.28733; Yu JS, 1998, BIOCHEM J, V334, P121, DOI 10.1042/bj3340121; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	21	201	206	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32565	32573		10.1074/jbc.274.46.32565	http://dx.doi.org/10.1074/jbc.274.46.32565			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551809	hybrid			2022-12-27	WOS:000083623000009
J	Alvarez-Gonzalez, R; Spring, H; Muller, M; Burkle, A				Alvarez-Gonzalez, R; Spring, H; Muller, M; Burkle, A			Selective loss of poly(ADP-ribose) and the 85-kDa fragment of poly(ADP-ribose) polymerase in nucleoli during alkylation-induced apoptosis of HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; ADP-RIBOSE; CLEAVAGE; DAMAGE; IDENTIFICATION; CASPASE-3; INHIBITOR; SUBSTRATE; KINETICS; DOMAINS	Alkylation treatment of HeLa cells results in the rapid induction of apoptosis as revealed by DNA laddering and cleavage of poly(ADP-ribose) polymerase (PARP) into the 29-and 85-kDa fragments (Kumari S. R., Mendoza-Alvarez, H. & Alvarez-Gonzalez, R, (1998) Cancer Res. 58, 5075-5078). Here, we performed a time-course analysis of (i) poly(ADP-ribose) synthesis and degradation as well as (ii) the subnuclear localization of PARP and its fragments by using confocal laser scanning immunofluorescence microscopy, PARP was activated within 15 min post-treatment, as revealed by nuclear immunostaining with antibody 10H (recognizing poly(ADP-ribose)), This was followed by a late, time-dependent, progressive decline of 10H signals that coincide with the time of PARP cleavage. Strikingly, nucleolar immunostaining with antibodies 10H and C-LI-IO (recognizing the 85-kDa PARP fragment) was lost by 15 min post-treatment, whereas F-I-23 signals (recognizing the 29-kDa fragment) persisted. We hypothesize that the 85-kDa PARP fragment is translocated, along with covalently bound poly(ADP-ribose), from nucleoli to the nucleoplasm, whereas the 29-kDa fragment is retained, because it binds to DNA strand breaks. Our data (i) provide a Link between the known time-dependent bifunctional role of PARP in apoptosis and the subcellular localization of PARP fragments and also (ii) add to the evidence for early proteolytic changes in nucleoli during apoptosis.	Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, Ft Worth, TX 76107 USA; Univ N Texas, Hlth Sci Ctr, Inst Canc Res, Ft Worth, TX 76107 USA; German Canc Res Ctr, Div Tumor Virol, D-6900 Heidelberg, Germany; German Canc Res Ctr, Biomed Struct Anal Unit, D-6900 Heidelberg, Germany	University of North Texas System; University of North Texas Health Science Center; University of North Texas System; University of North Texas Health Science Center; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Alvarez-Gonzalez, R (corresponding author), Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, Ft Worth, TX 76107 USA.		Gonzalez, Rafael Alvarez/I-4560-2019	Alvarez-Gonzalez, Rafael/0000-0003-1038-7512	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM045451] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45451] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMIETZ P, 1987, EUR J BIOCHEM, V169, P365, DOI 10.1111/j.1432-1033.1987.tb13621.x; ALTHAUS FR, 1997, BASE EXCISION REPAIR, P169; ALVAREZGONZALEZ R, 1989, MUTAT RES, V218, P67, DOI 10.1016/0921-8777(89)90012-8; ALVAREZGONZALEZ R, 1986, BIOCHEM BIOPH RES CO, V138, P1055; BENJAMIN RC, 1980, J BIOL CHEM, V255, P502; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; BUKI KG, 1995, J BIOL CHEM, V270, P3370, DOI 10.1074/jbc.270.7.3370; Burkle A, 1998, EXP GERONTOL, V33, P519, DOI 10.1016/S0531-5565(98)00036-9; BURKLE A, 1993, CARCINOGENESIS, V14, P559, DOI 10.1093/carcin/14.4.559; D'Amours D, 1998, RADIAT RES, V150, P3, DOI 10.2307/3579638; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; Depraetere V, 1997, Semin Immunol, V9, P93, DOI 10.1006/smim.1997.0062; DURKACZ BW, 1980, NATURE, V283, P593, DOI 10.1038/283593a0; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; KAMESHITA I, 1984, J BIOL CHEM, V259, P4770; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KAWAMITSU H, 1984, BIOCHEMISTRY-US, V23, P3771, DOI 10.1021/bi00311a032; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kumari SR, 1998, CANCER RES, V58, P5075; KUMARI SR, 2000, IN PRESS CANC INVEST, V18; LAMARRE D, 1988, BIOCHIM BIOPHYS ACTA, V950, P147, DOI 10.1016/0167-4781(88)90007-3; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lin WS, 1997, J BIOL CHEM, V272, P11895, DOI 10.1074/jbc.272.18.11895; Malanga M, 1998, J BIOL CHEM, V273, P11839, DOI 10.1074/jbc.273.19.11839; MARSISCHKY GT, 1995, J BIOL CHEM, V270, P3247, DOI 10.1074/jbc.270.7.3247; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; Mendoza-Alvarez H, 1999, BIOCHEMISTRY-US, V38, P3948, DOI 10.1021/bi982148p; MENDOZAALVAREZ H, 1993, J BIOL CHEM, V268, P22575; OEI SL, 1997, REV PHYSIOL BIOCHEM, V131, P4135; Oliver FJ, 1998, J BIOL CHEM, V273, P33533, DOI 10.1074/jbc.273.50.33533; Rawling JM, 1997, BIOCHEM J, V324, P249, DOI 10.1042/bj3240249; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Samejima K, 1998, J CELL BIOL, V143, P225, DOI 10.1083/jcb.143.1.225; SCHREIBER V, 1992, EMBO J, V11, P3263, DOI 10.1002/j.1460-2075.1992.tb05404.x; SHALL S, 1984, ADV RADIAT BIOL, V11, P1; Smulson ME, 1998, CANCER RES, V58, P3495; Stegh AH, 1998, EMBO J, V17, P5974, DOI 10.1093/emboj/17.20.5974; STELLER H, 1996, SCIENCE, V275, P1445; WIELCKENS K, 1982, J BIOL CHEM, V257, P2872	40	68	73	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32122	32126		10.1074/jbc.274.45.32122	http://dx.doi.org/10.1074/jbc.274.45.32122			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542247	hybrid			2022-12-27	WOS:000083532100055
J	Booth, JW; Belanger, KD; Sannella, MI; Davis, LI				Booth, JW; Belanger, KD; Sannella, MI; Davis, LI			The yeast nucleoporin Nup2p is involved in nuclear export of importin alpha/Srp1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING PROTEIN RANGAP1; PORE COMPLEX PROTEINS; RAN-BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; LOCALIZATION SIGNAL; TRANSPORT FACTORS; RAN/TC4; HOMOLOG; MUTANTS; DOMAIN	The importin alpha.beta heterodimer mediates nuclear import of proteins containing classical nuclear localization signals, After carrying its cargo into the nucleus, the importin dimer dissociates, and Srp1p (the yeast importin cu subunit) is recycled to the cytoplasm in a complex with Cse1p and RanGTP. Nup2p is a yeast FXFG nucleoporin that contains a Ran-binding domain. We find that export of Srp1p from the nucleus is impaired in Delta nup2 mutants. Also, Srp1p fusion proteins accumulate at the nuclear rim in wild-type cells but accumulate in the nuclear interior in Delta nup2 cells. A deletion of NUP2 shows genetic interactions with mutants in SRP1 and PRP20, which encodes the Ran nucleotide exchange factor. Srp1p binds directly to an N-terminal domain of Nup2p. This region of Nup2p is sufficient to allow accumulation of an Srp1p fusion protein at the nuclear rim, but the C-terminal Ran-binding domain of Nup2p is required for efficient Srp1p export. Formation of the Srp1p Cse1p RanGTP export complex releases Srp1p from its binding site in Nup2p. me propose that Nup2p may act as a scaffold that facilitates formation of the Srp1p export complex.	Brandeis Univ, Rosenstiel Ctr, WM Keck Inst Cellular Visualizat, Waltham, MA 02454 USA; Brandeis Univ, Dept Biol, Waltham, MA 02454 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Brandeis University; Brandeis University; Duke University	Davis, LI (corresponding author), Brandeis Univ, Rosenstiel Ctr, WM Keck Inst Cellular Visualizat, MS 029,415 South St, Waltham, MA 02454 USA.			Belanger, Kenneth/0000-0002-7181-0188	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054768] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-54768-04] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; BECKER J, 1995, J BIOL CHEM, V270, P11860, DOI 10.1074/jbc.270.20.11860; BEDDOW AL, 1995, P NATL ACAD SCI USA, V92, P3328, DOI 10.1073/pnas.92.8.3328; BELANGER KD, 1994, J CELL BIOL, V126, P619, DOI 10.1083/jcb.126.3.619; BISCHOFF FR, 1995, P NATL ACAD SCI USA, V92, P1749, DOI 10.1073/pnas.92.5.1749; Bischoff FR, 1997, FEBS LETT, V419, P249, DOI 10.1016/S0014-5793(97)01467-1; BOGERD AM, 1994, J CELL BIOL, V127, P319, DOI 10.1083/jcb.127.2.319; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; DAVIS LI, 1995, ANNU REV BIOCHEM, V64, P865, DOI 10.1146/annurev.bi.64.070195.004245; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DINGWALL C, 1995, P NATL ACAD SCI USA, V92, P7525, DOI 10.1073/pnas.92.16.7525; Doye V, 1997, CURR OPIN CELL BIOL, V9, P401, DOI 10.1016/S0955-0674(97)80014-2; Floer M, 1997, J BIOL CHEM, V272, P19538, DOI 10.1074/jbc.272.31.19538; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Gorlich D, 1996, CELL, V87, P21, DOI 10.1016/S0092-8674(00)81319-7; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; HARLOW E, 1988, ANTIBODIES LAB MANUA, P547; HIGUCHI R, 1989, PCR TECHNOLOGY PRINC, P65; Hood JK, 1998, J BIOL CHEM, V273, P35142, DOI 10.1074/jbc.273.52.35142; Iovine MK, 1995, J CELL BIOL, V131, P1699, DOI 10.1083/jcb.131.6.1699; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Izaurralde E, 1998, RNA, V4, P351; KADOWAKI T, 1994, J CELL BIOL, V126, P649, DOI 10.1083/jcb.126.3.649; KAHANA JA, 1995, P NATL ACAD SCI USA, V92, P9707, DOI 10.1073/pnas.92.21.9707; Kehlenbach RH, 1999, J CELL BIOL, V145, P645, DOI 10.1083/jcb.145.4.645; Kenna MA, 1996, MOL CELL BIOL, V16, P2025; Koepp DM, 1996, J CELL BIOL, V133, P1163, DOI 10.1083/jcb.133.6.1163; Kunzler M, 1998, FEBS LETT, V433, P185, DOI 10.1016/S0014-5793(98)00892-8; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; Kutay U, 1997, EMBO J, V16, P1153, DOI 10.1093/emboj/16.6.1153; LEE WC, 1989, P NATL ACAD SCI USA, V86, P8808, DOI 10.1073/pnas.86.22.8808; LOEB JDJ, 1993, MOL BIOL CELL, V4, P209, DOI 10.1091/mbc.4.2.209; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; OHASHI A, 1982, J BIOL CHEM, V257, P3042; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; Rout MP, 1997, CELL, V89, P715, DOI 10.1016/S0092-8674(00)80254-8; Sambrook J., 2002, MOL CLONING LAB MANU; SCHLENSTEDT G, 1995, EMBO J, V14, P5367, DOI 10.1002/j.1460-2075.1995.tb00221.x; Seedorf M, 1999, MOL CELL BIOL, V19, P1547; Sherman F, 1986, LAB COURSE MANUAL ME; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH DB, 1991, CURRENT PROTOCOLS MO, V2; Solsbacher J, 1998, MOL CELL BIOL, V18, P6805, DOI 10.1128/MCB.18.11.6805; Taura T, 1997, J BIOL CHEM, V272, P31877, DOI 10.1074/jbc.272.50.31877; Taura T, 1998, P NATL ACAD SCI USA, V95, P7427, DOI 10.1073/pnas.95.13.7427; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; WENTE SR, 1992, J CELL BIOL, V119, P705, DOI 10.1083/jcb.119.4.705; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; WILKEN N, 1995, EUR J CELL BIOL, V68, P211; Wozniak RW, 1998, TRENDS CELL BIOL, V8, P184, DOI 10.1016/S0962-8924(98)01248-3; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; XIAO ZX, 1993, MOL CELL BIOL, V13, P4691, DOI 10.1128/MCB.13.8.4691; Yan C, 1998, EMBO J, V17, P7416, DOI 10.1093/emboj/17.24.7416; YANO R, 1994, P NATL ACAD SCI USA, V91, P6880, DOI 10.1073/pnas.91.15.6880; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0	64	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32360	32367		10.1074/jbc.274.45.32360	http://dx.doi.org/10.1074/jbc.274.45.32360			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542277	hybrid			2022-12-27	WOS:000083532100085
J	Carrasco-Marin, E; Petzold, S; Unanue, ER				Carrasco-Marin, E; Petzold, S; Unanue, ER			Two structural states of complexes or peptide and class II major histocompatibility complex revealed by photoaffinity-labeled peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOZYME PEPTIDE; ANTIGEN-BINDING; MOLECULES; PH; I-A(K); DENATURATION; PROTEINS; BARNASE; EPITOPE; HLA-DR1	The complex of the murine class II histocompatibility molecules I-A(k) with high affinity binding peptides were resistant to denaturation when examined by SDS-polyacrylamide gel electrophoresis at various pH levels. In contrast, complexes made with low affinity binding peptides were highly sensitive to denaturation by SDS. This effect was more pronounced at low pH. Placing a photoactivatable probe at the amino terminus of the peptides resulted in their covalent linkage to soluble I-A(k) molecules. We found an inverse relationship between the capacity of peptides to form SDS-stable complexes with I-A(k) and their extent of covalent association with either the alpha or beta chain. The relationship held true for three different peptides in which the main anchor residues were changed so as to affect their binding affinity for I-A(k) molecules. Thus, high affinity peptides generate a complex in which the motion of their amino termini was restricted, whereas complexes of low affinity peptides are more flexible. In agreement with this observation, complexes of I-A(k) with high affinity peptides were highly resistant to proteolysis, in contrast to those formed with weakly binding peptides, which were more likely to be cleaved. Complexes with low affinity peptides generate a structure with enhanced flexibility as compared with complexes with high affinity peptides.	Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Ctr Immunol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Unanue, ER (corresponding author), Washington Univ, Sch Med, Dept Pathol, 660 S Euclid Ave, St Louis, MO 63110 USA.		Marin, Eugenio Carrasco/AAG-1578-2021	Marin, Eugenio Carrasco/0000-0002-3556-9227				Boniface JJ, 1996, J EXP MED, V183, P119, DOI 10.1084/jem.183.1.119; Bouvier M, 1998, NAT STRUCT BIOL, V5, P377, DOI 10.1038/nsb0598-377; CAFLISCH A, 1995, J MOL BIOL, V252, P672, DOI 10.1006/jmbi.1995.0528; CAFLISCH A, 1994, P NATL ACAD SCI USA, V91, P1746, DOI 10.1073/pnas.91.5.1746; CarrascoMarin E, 1996, J IMMUNOL, V156, P450; DONNERMEYER DL, 1989, J IMMUNOL, V142, P1063; Fremont DH, 1998, IMMUNITY, V8, P305, DOI 10.1016/S1074-7613(00)80536-1; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; GOTO Y, 1989, BIOCHEMISTRY-US, V28, P945, DOI 10.1021/bi00429a004; HARDING CV, 1991, P NATL ACAD SCI USA, V88, P2740, DOI 10.1073/pnas.88.7.2740; JARDETZKY TS, 1990, EMBO J, V9, P1797, DOI 10.1002/j.1460-2075.1990.tb08304.x; Kessler BM, 1997, J EXP MED, V185, P629, DOI 10.1084/jem.185.4.629; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; LUESCHER IF, 1990, J IMMUNOL METHODS, V135, P233, DOI 10.1016/0022-1759(90)90277-3; LUESCHER IF, 1990, J BIOL CHEM, V265, P11177; LUESCHER IF, 1988, P NATL ACAD SCI USA, V85, P871, DOI 10.1073/pnas.85.3.871; MOURITSEN S, 1992, J IMMUNOL, V149, P1987; Natarajan SK, 1999, J IMMUNOL, V162, P4030; Natarajan SK, 1999, J IMMUNOL, V162, P3463; Nelson CA, 1996, J IMMUNOL, V157, P755; NELSON CA, 1993, P NATL ACAD SCI USA, V90, P1227, DOI 10.1073/pnas.90.4.1227; NELSON CA, 1994, NATURE, V371, P250, DOI 10.1038/371250a0; Nelson CA, 1996, IMMUNOL REV, V151, P81, DOI 10.1111/j.1600-065X.1996.tb00704.x; Runnels HA, 1996, J EXP MED, V183, P127, DOI 10.1084/jem.183.1.127; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; Verreck FAW, 1996, INT IMMUNOL, V8, P397, DOI 10.1093/intimm/8.3.397	27	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31333	31340		10.1074/jbc.274.44.31333	http://dx.doi.org/10.1074/jbc.274.44.31333			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531333	hybrid			2022-12-27	WOS:000083379400037
J	Hanai, J; Chen, LF; Kanno, T; Ohtani-Fujita, N; Kim, WY; Guo, WH; Imamura, T; Ishidou, Y; Fukuchi, M; Shi, MJ; Stavnezer, J; Kawabata, M; Miyazono, K; Ito, Y				Hanai, J; Chen, LF; Kanno, T; Ohtani-Fujita, N; Kim, WY; Guo, WH; Imamura, T; Ishidou, Y; Fukuchi, M; Shi, MJ; Stavnezer, J; Kawabata, M; Miyazono, K; Ito, Y			Interaction and functional cooperation of PEBP2/CBF with Smads - Synergistic induction of the immunoglobulin germline C alpha promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; TGF-BETA; CLEIDOCRANIAL DYSPLASIA; OSTEOBLAST DIFFERENTIATION; IGA PRODUCTION; TRANSCRIPTION; BINDING; GENE; PROTEINS; CLONING	Smads are signal transducers for members of the transforming growth factor-beta (TGF-beta) superfamily. Upon ligand stimulation, receptor-regulated Smads (R-Smads) are phosphorylated by serine/threonine kinase receptors, form complexes with common-partner Smad, and translocate into the nucleus, where they regulate the transcription of target genes together with other transcription factors. Polyomavirus enhancer binding protein 2/core binding factor (PEEP2/CBF) is a transcription factor complex composed of alpha and beta subunits. The alpha subunits of PEEP2/CBF, which contain the highly conserved Hunt domain, play essential roles in hematopoiesis and osteogenesis. Here we show that three mammalian alpha subunits of PEBP2/CEF form complexes with R-Smads that act in TGF-beta/activin pathways as well as those acting in bone morphogenetic protein (BMP) pathways. Among them, PEBP2 alpha C/CBFA3/AML2 forms a complex with Smads and stimulates transcription of the germline Ig C alpha promoter in a cooperative manner, for which binding of both factors to their specific binding sites is essential. PEEPS may thus be a nuclear target of TGF-beta/BMP signaling.	Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, Tokyo 708455, Japan; Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068507, Japan; Univ Massachusetts, Sch Med, Dept Mol Genet & Microbiol, Grad Program Immunol & Virol, Worcester, MA 01655 USA	Japanese Foundation for Cancer Research; Kyoto University; University of Massachusetts System; University of Massachusetts Worcester	Ito, Y (corresponding author), Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, 1-37-1 Kami Ikebukuro, Tokyo 708455, Japan.	yito@virus.kyoto-u.ac.jp			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023283] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI23283] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; COFFMAN RL, 1989, J EXP MED, V170, P1039, DOI 10.1084/jem.170.3.1039; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; Goto D, 1998, FEBS LETT, V430, P201, DOI 10.1016/S0014-5793(98)00658-9; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; ITO Y, 1997, ONCOGENES TRANSCRIPT, V2, P107; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kanno T, 1998, MOL CELL BIOL, V18, P2444, DOI 10.1128/MCB.18.5.2444; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; LIN YCA, 1992, J IMMUNOL, V149, P2914; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Shi XM, 1999, J BIOL CHEM, V274, P13711, DOI 10.1074/jbc.274.19.13711; SONODA E, 1989, J EXP MED, V170, P1415, DOI 10.1084/jem.170.4.1415; Speck NA, 1995, CRIT REV EUKAR GENE, V5, P337, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.60; Stavnezer J, 1996, CURR OPIN IMMUNOL, V8, P199, DOI 10.1016/S0952-7915(96)80058-6; Verschueren K, 1999, J BIOL CHEM, V274, P20489, DOI 10.1074/jbc.274.29.20489; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Xie XQ, 1999, EUR J IMMUNOL, V29, P488, DOI 10.1002/(SICI)1521-4141(199902)29:02<488::AID-IMMU488>3.0.CO;2-N; XU MZ, 1992, EMBO J, V11, P145, DOI 10.1002/j.1460-2075.1992.tb05037.x; Yagi K, 1999, J BIOL CHEM, V274, P703, DOI 10.1074/jbc.274.2.703; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang YW, 1997, ONCOGENE, V15, P367, DOI 10.1038/sj.onc.1201352; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	43	400	412	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31577	31582		10.1074/jbc.274.44.31577	http://dx.doi.org/10.1074/jbc.274.44.31577			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531362	hybrid			2022-12-27	WOS:000083379400066
J	Kislinger, T; Fu, CF; Huber, B; Qu, W; Taguchi, A; Yan, SD; Hofmann, M; Yan, SF; Pischetsrieder, M; Stern, D; Schmidt, AM				Kislinger, T; Fu, CF; Huber, B; Qu, W; Taguchi, A; Yan, SD; Hofmann, M; Yan, SF; Pischetsrieder, M; Stern, D; Schmidt, AM			N-epsilon-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIALYSIS-RELATED AMYLOIDOSIS; MACROPHAGE SCAVENGER RECEPTOR; HUMAN ENDOTHELIAL-CELLS; OXIDANT STRESS; MAILLARD REACTION; DIABETIC COMPLICATIONS; BINDING-PROTEINS; PERIODONTAL-DISEASE; POTENTIAL MECHANISM; FUNCTIONAL-ANALYSIS	Recent studies suggested that interruption of the interaction of advanced glycation end products (AGEs), with the signal-transducing receptor receptor for AGE (RAGE), by administration of the soluble, extracellular ligand-binding domain of RAGE, reversed vascular hyperpermeability and suppressed accelerated atherosclerosis in diabetic rodents. Since the precise molecular target of soluble RAGE in those settings was not elucidated, we tested the hypothesis that predominant specific AGEs within the tissues in disorders such as diabetes and renal failure, N-epsilon-(carboxymethyl)lysine (CML) adducts, are ligands of RAGE. We demonstrate here that physiologically relevant CML modifications of proteins engage cellular RAGE, thereby activating key cell signaling pathways such as NF-KB and modulating gene expression. Thus, CML-RAGE interaction triggers processes intimately linked to accelerated vascular and inflammatory complications that typify disorders in which inflammation is an established component.	Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; Univ Erlangen Nurnberg, Abt Lebensmittelchem, Inst Pharm & Lebensmittelchem, D-91052 Erlangen, Germany	Columbia University; University of Erlangen Nuremberg	Schmidt, AM (corresponding author), Columbia Univ Coll Phys & Surg, 630 W 168th St,P&S 17-501, New York, NY 10032 USA.		Kislinger, Thomas/A-5934-2008	Kislinger, Thomas/0000-0003-3525-5540	NHLBI NIH HHS [HL60901, HL56881] Funding Source: Medline; NIDDK NIH HHS [DK52495] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056881, P01HL060901] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052495] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMED MU, 1986, J BIOL CHEM, V261, P4889; Anderson MM, 1999, J CLIN INVEST, V104, P103, DOI 10.1172/JCI3042; ARAKI N, 1995, EUR J BIOCHEM, V230, P408, DOI 10.1111/j.1432-1033.1995.0408h.x; Baynes JW, 1999, DIABETES, V48, P1, DOI 10.2337/diabetes.48.1.1; Berg TJ, 1998, DIABETES CARE, V21, P1997, DOI 10.2337/diacare.21.11.1997; Bierhaus A, 1997, CIRCULATION, V96, P2262; BRETT J, 1993, AM J PATHOL, V143, P1699; BROWNLEE M, 1995, ANNU REV MED, V46, P223, DOI 10.1146/annurev.med.46.1.223; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; Degenhardt TP, 1997, KIDNEY INT, V52, P1064, DOI 10.1038/ki.1997.429; Degenhardt TP, 1998, CELL MOL BIOL, V44, P1139; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUNN JA, 1991, BIOCHEMISTRY-US, V30, P1205, DOI 10.1021/bi00219a007; DYER DG, 1993, J CLIN INVEST, V91, P2463, DOI 10.1172/JCI116481; ELKHOURY J, 1994, J BIOL CHEM, V269, P10197; Fu MX, 1996, J BIOL CHEM, V271, P9982, DOI 10.1074/jbc.271.17.9982; GREENE DA, 1987, NEW ENGL J MED, V316, P599; HABEEB AFS, 1966, ANAL BIOCHEM, V14, P328, DOI 10.1016/0003-2697(66)90275-2; Hamada Y, 1996, BIOCHEM BIOPH RES CO, V228, P539, DOI 10.1006/bbrc.1996.1695; Hammes HP, 1999, DIABETOLOGIA, V42, P603, DOI 10.1007/s001250051201; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; Horie K, 1997, J CLIN INVEST, V100, P2995, DOI 10.1172/JCI119853; Ikeda K, 1996, BIOCHEMISTRY-US, V35, P8075, DOI 10.1021/bi9530550; INOUE N, 1985, INT J TISSUE REACT, V7, P27; Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jinnouchi Y, 1998, J BIOCHEM-TOKYO, V123, P1208; Katsuyama K, 1998, ENDOCRINOLOGY, V139, P4506, DOI 10.1210/en.139.11.4506; KLOTZ IM, 1984, J BIOL CHEM, V259, P60; KNECHT KJ, 1991, DIABETES, V40, P190, DOI 10.2337/diabetes.40.2.190; KUME S, 1995, AM J PATHOL, V147, P654; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; Li JF, 1997, J BIOL CHEM, V272, P16498, DOI 10.1074/jbc.272.26.16498; Lindner V, 1998, PATHOBIOLOGY, V66, P311, DOI 10.1159/000028039; LOE H, 1993, DIABETES CARE, V16, P329, DOI 10.2337/diacare.16.1.329; Meng J, 1998, ATHEROSCLEROSIS, V136, P355, DOI 10.1016/S0021-9150(97)00238-4; Miyata T, 1999, FEBS LETT, V445, P202, DOI 10.1016/S0014-5793(99)00122-2; Miyata T, 1995, Curr Opin Nephrol Hypertens, V4, P493, DOI 10.1097/00041552-199511000-00006; Miyata T, 1996, J CLIN INVEST, V98, P1088, DOI 10.1172/JCI118889; MIYATA T, 1993, J CLIN INVEST, V92, P1243, DOI 10.1172/JCI116696; Miyata T, 1996, P NATL ACAD SCI USA, V93, P2353, DOI 10.1073/pnas.93.6.2353; Miyata T, 1999, KIDNEY INT, V55, P389, DOI 10.1046/j.1523-1755.1999.00302.x; NEEPER M, 1992, J BIOL CHEM, V267, P14998; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; Niwa T, 1996, KIDNEY INT, V50, P1303, DOI 10.1038/ki.1996.442; Niwa T, 1997, KIDNEY INT, V51, P187, DOI 10.1038/ki.1997.23; NJOROGE FG, 1987, CARBOHYD RES, V167, P211; ODETTI PR, 1990, DIABETES, V39, P796, DOI 10.2337/diabetes.39.7.796; Owen WF, 1998, KIDNEY INT, V53, P1365, DOI 10.1046/j.1523-1755.1998.00882.x; PALINSKI W, 1995, ARTERIOSCL THROM VAS, V15, P571, DOI 10.1161/01.ATV.15.5.571; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; REDDY S, 1995, BIOCHEMISTRY-US, V34, P10872, DOI 10.1021/bi00034a021; RICHARDSON M, 1994, ARTERIOSCLER THROMB, V14, P760, DOI 10.1161/01.ATV.14.5.760; RITTHALER U, 1995, AM J PATHOL, V146, P688; Schleicher ED, 1997, J CLIN INVEST, V99, P457, DOI 10.1172/JCI119180; SCHMIDT AM, 1995, NAT MED, V1, P1002, DOI 10.1038/nm1095-1002; SCHMIDT AM, 1994, P NATL ACAD SCI USA, V91, P8807, DOI 10.1073/pnas.91.19.8807; SCHMIDT AM, 1995, J CLIN INVEST, V96, P1395, DOI 10.1172/JCI118175; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; Schmidt AM, 1996, J PERIODONTAL RES, V31, P508, DOI 10.1111/j.1600-0765.1996.tb01417.x; SCHMIDT AM, 1993, J CLIN INVEST, V91, P2155, DOI 10.1172/JCI116442; SELL DR, 1989, J BIOL CHEM, V264, P21597; Soulis T, 1997, DIABETOLOGIA, V40, P619, DOI 10.1007/s001250050725; Takeda A, 1996, NEUROSCI LETT, V221, P17, DOI 10.1016/S0304-3940(96)13275-4; UUSITUPA MIJ, 1990, CIRCULATION, V82, P27, DOI 10.1161/01.CIR.82.1.27; VLASSARA H, 1996, DIABETES, V45, P65; Wautier JL, 1996, J CLIN INVEST, V97, P238, DOI 10.1172/JCI118397; WAUTIER JL, 1994, P NATL ACAD SCI USA, V91, P7742, DOI 10.1073/pnas.91.16.7742; WellsKnecht MC, 1997, J CLIN INVEST, V100, P839, DOI 10.1172/JCI119599; WESTWOOD ME, 1995, J PROTEIN CHEM, V14, P359, DOI 10.1007/BF01886793; WOO KL, 1993, J CHROMATOGR, V638, P97, DOI 10.1016/0021-9673(93)85012-V; XIA P, 1994, DIABETES, V43, P1122, DOI 10.2337/diabetes.43.9.1122; YAN SD, 1994, P NATL ACAD SCI USA, V91, P7787, DOI 10.1073/pnas.91.16.7787; YAN SD, 1994, J BIOL CHEM, V269, P9889; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0	76	753	776	1	46	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31740	31749		10.1074/jbc.274.44.31740	http://dx.doi.org/10.1074/jbc.274.44.31740			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531386	hybrid			2022-12-27	WOS:000083379400090
J	Naumann, M; Wessler, S; Bartsch, C; Wieland, B; Covacci, A; Haas, R; Meyer, TF				Naumann, M; Wessler, S; Bartsch, C; Wieland, B; Covacci, A; Haas, R; Meyer, TF			Activation of activator protein 1 and stress response kinases in epithelial cells colonized by Helicobacter pylori encoding the cag pathogenicity island	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SIGNAL-TRANSDUCTION PATHWAYS; JUN NH2-TERMINAL KINASE; PEPTIC-ULCER DISEASE; C-JUN; TRANSCRIPTION FACTORS; INFLAMMATORY CYTOKINES; VIRULENCE FACTORS; JNK; INFECTION	Helicobacter pylori interacts with the apical membrane of the gastric epithelium and induces a number of proinflammatory cytokines/chemokines. The subsequent infiltration of macrophages and granulocytes into the mucosa leads to gastric inflammation accompanied by epithelial degeneration. Gastric diseases, e.g peptic ulcer or gastric adenocarcinoma, are more common among people infected with H, pylori strains producing VacA (vacuolating cytotoxin A) and possessing a cog (cytotoxin-associated antigen A) pathogenicity island. For the induction of the cytokine/chemokine genes in response to H. pylori, we studied the signaling leading to the nuclear activation of the early response transcription factor activator protein 1 (AP-1), We found that H. pylori strains carrying the pathogenicity island induce activation of AP-1 and nuclear factor KB, In contrast to the wild type or an isogenic strain without the vacA gene, isogenic H. pylori strains with mutations in certain cog genes revealed only weak AP-1 and nuclear factor KB activation. In respect to the molecular components that direct AP-1 activity, our results indicate a cascade of the cellular stress response kinases c-Jun N-terminal kinase, MAP kinase kinase 4, and p21-activated kinase, and small Rho-GTPases including Rad and Cdc42, which contributes to the activation of proinflammatory cytokines/chemokines induced by H. pylori encoding the cag pathogenicity island.	Max Planck Inst Infekt Biol, Mol Biol Abt, D-10117 Berlin, Germany; Immunol Res Inst, BIOCINE, IRIS, I-53100 Siena, Italy; Max Von Pettenkofer Inst Hyg & Med Microbiol, Abt Bakteriol, D-80336 Munich, Germany; Max Planck Inst Biol, Abt Infekt Biol, D-72076 Tubingen, Germany	Max Planck Society; Novartis; University of Munich; Max Planck Society	Naumann, M (corresponding author), Max Planck Inst Infekt Biol, Mol Biol Abt, Monbijoustr 2, D-10117 Berlin, Germany.		Meyer, Thomas F. F/J-2485-2013; Naumann, Michael/B-5285-2011; Wessler, Silja/C-6309-2015	Meyer, Thomas F. F/0000-0002-6120-8679; Naumann, Michael/0000-0002-8060-2313; Wessler, Silja/0000-0001-7011-6162				Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; Aktories K, 1997, TRENDS MICROBIOL, V5, P282, DOI 10.1016/S0966-842X(97)01067-6; Atherton JC, 1998, BRIT MED BULL, V54, P105; Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; BLASER MJ, 1987, GASTROENTEROLOGY, V93, P371, DOI 10.1016/0016-5085(87)91028-6; Bodger K, 1998, BRIT MED BULL, V54, P139; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Covacci A, 1998, CURR OPIN MICROBIOL, V1, P96, DOI 10.1016/S1369-5274(98)80148-3; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Glocker E, 1998, INFECT IMMUN, V66, P2346, DOI 10.1128/IAI.66.5.2346-2348.1998; GOODWIN CS, 1986, J CLIN PATHOL, V39, P353, DOI 10.1136/jcp.39.4.353; GRAHAM DY, 1989, GASTROENTEROLOGY, V96, P615, DOI 10.1016/S0016-5085(89)80057-5; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Keates S, 1997, GASTROENTEROLOGY, V113, P1099, DOI 10.1053/gast.1997.v113.pm9322504; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARCHETTI M, 1995, SCIENCE, V267, P1655, DOI 10.1126/science.7886456; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Munzenmaier A, 1997, J IMMUNOL, V159, P6140; Naumann M, 1998, J EXP MED, V188, P1277, DOI 10.1084/jem.188.7.1277; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Ruckdeschel K, 1997, J BIOL CHEM, V272, P15920, DOI 10.1074/jbc.272.25.15920; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHMITT W, 1994, MOL MICROBIOL, V12, P307, DOI 10.1111/j.1365-2958.1994.tb01019.x; Segal ED, 1997, P NATL ACAD SCI USA, V94, P7595, DOI 10.1073/pnas.94.14.7595; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sharma SA, 1998, J IMMUNOL, V160, P2401; TELFORD JL, 1994, J EXP MED, V179, P1653, DOI 10.1084/jem.179.5.1653; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Wilkinson MG, 1998, GENE DEV, V12, P1391, DOI 10.1101/gad.12.10.1391; Wu ZG, 1997, MOL CELL BIOL, V17, P7407, DOI 10.1128/MCB.17.12.7407; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	58	143	149	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31655	31662		10.1074/jbc.274.44.31655	http://dx.doi.org/10.1074/jbc.274.44.31655			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531374	Green Published, hybrid			2022-12-27	WOS:000083379400078
J	Shuttleworth, TJ; Thompson, JL				Shuttleworth, TJ; Thompson, JL			Discriminating between capacitative and arachidonate-activated Ca2+ entry pathways in HEK293 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-INHIBITABLE ADENYLYL-CYCLASE; C6-2B GLIOMA-CELLS; <CA2+>(I) OSCILLATIONS; CALCIUM INFLUX; EXOCRINE CELL; PHOSPHODIESTERASE; STIMULATION; HEPATOCYTES; FREQUENCY	We have recently questioned whether the capacitative or store-operated model for receptor-activated Ca2+ entry can account for the influx of Ca2+ seen at low agonist concentrations, such a those typically producing [Ca2+](i) oscillations. Instead, we have identified an arachidonic: acid-regulated, noncapacitative Ca2+ entry mechanism that appears to be specifically responsible for the receptor-activated entry of Ca2+ under these conditions. However, it is unclear whether these two systems reflect the activity of distinct entry pathways or simply different mechanisms of regulating a common pathway. We therefore used the known selectivity of the Ca2+-stimulated type vm adenylyl cyclase for Ca2+ entry occurring via the capacitative pathway (Fagan, K. A., Mahey, R., and Cooper, D. M. F. (1996) J. Biol. Chem. 271, 12438-12444) to attempt to discriminate between these two entry mechanisms in HEK293 cells. Consistent with the earlier reports, we found that thapsigargin induced an approximate 3-fold increase in adenylyl cyclase activity that was unrelated to global changes in [Ca2+](i) or to the release of Ca2+ from internal stores but was specifically dependent on the induced capacitative entry of Ca2+. In marked contrast, the arachidonate-induced entry of Ca2+ completely failed to affect adenylyl cyclase activity despite producing a substantially greater rate of entry than that induced by thapsigargin, These data demonstrate that the arachidonate-activated entry of Ca2+ occurs via an entirely distinct influx pathway.	Univ Rochester, Med Ctr, Dept Physiol & Pharmacol, Sch Med & Dent, Rochester, NY 14642 USA	University of Rochester	Shuttleworth, TJ (corresponding author), Univ Rochester, Med Ctr, Dept Physiol & Pharmacol, Sch Med & Dent, Box 711,601 Elmwood Ave, Rochester, NY 14642 USA.				NIGMS NIH HHS [GM 40457] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bootman MD, 1996, BIOCHEM J, V314, P347, DOI 10.1042/bj3140347; Burnay MM, 1998, BIOCHEM J, V330, P21, DOI 10.1042/bj3300021; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIONO M, 1995, J BIOL CHEM, V270, P1149, DOI 10.1074/jbc.270.3.1149; CHOI EJ, 1992, J BIOL CHEM, V267, P12440; Cooper Dermot M.F., 1998, Advances in Second Messenger and Phosphoprotein Research, V32, P23; ERNEUX C, 1985, MOL CELL ENDOCRINOL, V43, P123, DOI 10.1016/0303-7207(85)90075-9; Fagan KA, 1998, J BIOL CHEM, V273, P9297, DOI 10.1074/jbc.273.15.9297; Fagan KA, 1996, J BIOL CHEM, V271, P12438, DOI 10.1074/jbc.271.21.12438; GIRARD S, 1993, SCIENCE, V260, P229, DOI 10.1126/science.8385801; KAWANISHI T, 1989, J BIOL CHEM, V264, P12859; MARTIN SC, 1994, FEBS LETT, V352, P32, DOI 10.1016/0014-5793(94)00913-9; MEEKER RB, 1982, MOL PHARMACOL, V22, P310; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; Shuttleworth TJ, 1998, J BIOL CHEM, V273, P32636, DOI 10.1074/jbc.273.49.32636; Shuttleworth TJ, 1999, CELL CALCIUM, V25, P237, DOI 10.1054/ceca.1999.0022; Shuttleworth TJ, 1996, BIOCHEM J, V316, P819, DOI 10.1042/bj3160819; Shuttleworth TJ, 1996, J BIOL CHEM, V271, P21720, DOI 10.1074/jbc.271.36.21720; Shuttleworth TJ, 1996, BIOCHEM J, V313, P815, DOI 10.1042/bj3130815; SHUTTLEWORTH TJ, 1994, CELL CALCIUM, V15, P457, DOI 10.1016/0143-4160(94)90110-4; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; THASTRUP O, 1990, AGENTS ACTIONS, V29, P8, DOI 10.1007/BF01964706; Watson EL, 1998, AM J PHYSIOL-CELL PH, V274, pC557, DOI 10.1152/ajpcell.1998.274.3.C557	25	84	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31174	31178		10.1074/jbc.274.44.31174	http://dx.doi.org/10.1074/jbc.274.44.31174			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531309	hybrid			2022-12-27	WOS:000083379400013
J	Zhou, ZF; Gong, QM; January, CT				Zhou, ZF; Gong, QM; January, CT			Correction of defective protein trafficking of a mutant HERG potassium channel in human long QT syndrome - Pharmacological and temperature effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEPHROGENIC DIABETES-INSIPIDUS; INHERITED CARDIAC-ARRHYTHMIA; CYSTIC-FIBROSIS; INTRACELLULAR-TRANSPORT; CHEMICAL CHAPERONES; KVLQT1 MUTATIONS; MOLECULAR-BASIS; DYSFUNCTION; PHENOTYPE; PATHWAY	The chromosome 7-linked form of congenital long QT syndrome (LQT2) is caused by mutations in the human ether-a-go-go-related gene (HERG) that encodes the rapidly activating delayed rectifier potassium channel. One mechanism for the loss of normal channel function in LQT2 is defective protein trafficking, which results in the failure of the channel protein to reach the plasma membrane. Here we show that the N470D LQT2 mutant protein is trafficking-deficient when expressed at 37 degrees C in HEK293 cells, whereas at 27 degrees C its trafficking to the plasma membrane and channel function are markedly improved. We further show that the antiarrhythmic drug E-4031, which selectively blocks HERO channels, also corrects defective protein trafficking of the N470D mutant and can restore the generation of HERO current. Similar findings were obtained with the drugs astemizole and cisapride, as well as with high concentrations of glycerol. The effect of E-4031 on HERO protein trafficking was concentration-dependent and required low drug concentrations (saturation present at 5 mu M), developed rapidly with drug exposure,and occurred post-translationally. These findings suggest that protein misfolding leading to defective trafficking of some HERO LQT mutations may be corrected by specific pharmacological strategies.	Univ Wisconsin, Dept Med, Cardiol Sect, Madison, WI 53792 USA; Univ Wisconsin, Dept Physiol, Cardiol Sect, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Zhou, ZF (corresponding author), Univ Wisconsin Hosp & Clin, Cardiol Sect, Dept Med, Room H6-354 CSC,600 Highland Ave, Madison, WI 53792 USA.	zhz@medicine.wisc.edu; ctj@medicine.wisc.edu						Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; Brown CR, 1996, CELL STRESS CHAPERON, V1, P117, DOI 10.1379/1466-1268(1996)001<0117:CCCTMP>2.3.CO;2; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; DEEN PMT, 1995, J CLIN INVEST, V95, P2291, DOI 10.1172/JCI117920; Furutani M, 1999, CIRCULATION, V99, P2290, DOI 10.1161/01.CIR.99.17.2290; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Martin MG, 1996, NAT GENET, V12, P216, DOI 10.1038/ng0296-216; Mohammad S, 1997, AM J PHYSIOL-HEART C, V273, pH2534, DOI 10.1152/ajpheart.1997.273.5.H2534; Priori SG, 1998, CIRCULATION, V98, P457; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Sanguinetti MC, 1996, P NATL ACAD SCI USA, V93, P2208, DOI 10.1073/pnas.93.5.2208; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; Smith DF, 1998, PHARMACOL REV, V50, P493; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; Tamarappoo BK, 1998, J CLIN INVEST, V101, P2257, DOI 10.1172/JCI2303; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; Zhang JX, 1997, MOL BIOL CELL, V8, P1943, DOI 10.1091/mbc.8.10.1943; Zhou ZF, 1999, J CARDIOVASC ELECTR, V10, P836, DOI 10.1111/j.1540-8167.1999.tb00264.x; Zhou ZF, 1998, BIOPHYS J, V74, P230, DOI 10.1016/S0006-3495(98)77782-3; Zhou ZF, 1998, J BIOL CHEM, V273, P21061, DOI 10.1074/jbc.273.33.21061; [No title captured]	29	248	274	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31123	31126		10.1074/jbc.274.44.31123	http://dx.doi.org/10.1074/jbc.274.44.31123			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531299	hybrid			2022-12-27	WOS:000083379400003
J	Kim, SY; Grant, P; Lee, JH; Pant, HC; Steinert, PM				Kim, SY; Grant, P; Lee, JH; Pant, HC; Steinert, PM			Differential expression of multiple transglutaminases in human brain - Increased expression and cross-linking by transglutaminases 1 and 2 in Alzheimer's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN EPIDERMAL-KERATINOCYTES; CORNIFIED CELL-ENVELOPE; TISSUE TRANSGLUTAMINASE; PROTRANSGLUTAMINASE-E; CDNA CLONES; RAT-BRAIN; PROTEINS; ENZYME; CALPAIN; FORMS	The transglutaminase (TGase) family of enzymes, of which seven different members are known in the human genome, participate in many biological processes involving cross-linking proteins into large macromolecular assemblies. The TGase 2 enzyme is known to be present in neuronal tissues and may play a role in neuronal degenerative diseases such as Alzheimer's disease (AD) by aberrantly cross-linking proteins. In this paper, we demonstrate by reverse transcriptase-polymase chain reaction and immunological methods with specific antibodies that in fact three members, the TGase 1, TGase 2, and TGase 3 enzymes, and are differentially expressed in various regions of normal human brain tissues. Interestingly, the TGase 1 and 3 enzymes and their proteolytically processed forms are involved in terminal differentiation programs of epithelial cell development and barrier function. In addition, we found that the levels of expression and activity of the TGase 1 and 2 enzymes were both increased in the cortex and cerebellum of AD patients. Furthermore, whereas normal brain tissues contain approximate to 1 residue of cross-link/10,000 residues, AD patient cortex and cerebellum tissues contain 30-50 residues of cross-link/10,000 residues. Together, these findings suggest that multiple TGase enzymes are involved in normal neuronal structure and function, but their elevated expression and cross-linking activity may also contribute to neuronal degenerative disease.	NIAMS, Skin Biol Lab, NIH, Bethesda, MD 20892 USA; NINDS, Neurochem Lab, NIH, Bethesda, MD 20892 USA; Chungnam Natl Univ, Sch Med, Dept Dermatol, Taejon, South Korea	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Chungnam National University	Steinert, PM (corresponding author), NIAMS, Skin Biol Lab, NIH, Bldg 6,Rm 425, Bethesda, MD 20892 USA.	pemast@helix.nih.gov			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041087] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aeschlimann Daniel, 1996, Seminars in Thrombosis and Hemostasis, V22, P437; ANDO M, 1993, MOL CHEM NEUROPATHOL, V19, P121, DOI 10.1007/BF03160173; ANDO M, 1991, NEUROSCI RES, V12, P356, DOI 10.1016/0168-0102(91)90003-H; ANDO Y, 1988, ARCH DERMATOL RES, V280, P380, DOI 10.1007/BF00426618; Appelt DM, 1996, J HISTOCHEM CYTOCHEM, V44, P1421, DOI 10.1177/44.12.8985134; Bae CD, 1995, KOREAN J BIOCHEM, V27, P239; DUDEK SM, 1993, J NEUROCHEM, V61, P1159, DOI 10.1111/j.1471-4159.1993.tb03636.x; FACCHIANO F, 1993, J BIOL CHEM, V268, P4588; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; FOLK JE, 1985, METHOD ENZYMOL, V113, P358; GENTILE V, 1991, J BIOL CHEM, V266, P478; GILAD GM, 1985, J NEUROCHEM, V44, P1385, DOI 10.1111/j.1471-4159.1985.tb08774.x; GILAD GM, 1985, J NEUROCHEM, V45, P1522, DOI 10.1111/j.1471-4159.1985.tb07222.x; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HAND D, 1993, J NEUROCHEM, V61, P1064, DOI 10.1111/j.1471-4159.1993.tb03621.x; HO KC, 1992, J BIOL CHEM, V267, P12660; HOHL D, 1990, DERMATOLOGICA, V180, P201, DOI 10.1159/000248031; HOHL D, 1991, J BIOL CHEM, V266, P6626; Johnson GVW, 1997, BRAIN RES, V751, P323, DOI 10.1016/S0006-8993(96)01431-X; JUNG SW, 1995, J DERMATOL SCI, V10, P98; Kahlem P, 1998, MOL CELL, V1, P595, DOI 10.1016/S1097-2765(00)80059-3; KIM HC, 1990, J BIOL CHEM, V265, P21971; KIM HC, 1991, J BIOL CHEM, V266, P536; KIM IG, 1993, J BIOL CHEM, V268, P12682; KIM SY, 1995, J BIOL CHEM, V270, P18026, DOI 10.1074/jbc.270.30.18026; KIM SY, 1995, J INVEST DERMATOL, V104, P211, DOI 10.1111/1523-1747.ep12612769; KIM SY, 1994, J BIOL CHEM, V269, P27979; KORNER G, 1987, J CELL PHYSIOL, V130, P44, DOI 10.1002/jcp.1041300108; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; LORAND L, 1981, P NATL ACAD SCI-BIOL, V78, P1356, DOI 10.1073/pnas.78.3.1356; MELINO G, 1999, IN PRESS METHODS ENZ; Monsonego A, 1997, J BIOL CHEM, V272, P3724, DOI 10.1074/jbc.272.6.3724; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; PERRY MJM, 1995, NEUROSCIENCE, V65, P1063, DOI 10.1016/0306-4522(94)00556-K; PHILLIPS MA, 1990, P NATL ACAD SCI USA, V87, P9333, DOI 10.1073/pnas.87.23.9333; Piredda L, 1997, CELL DEATH DIFFER, V4, P463, DOI 10.1038/sj.cdd.4400267; PISANO JJ, 1968, SCIENCE, V160, P892, DOI 10.1126/science.160.3830.892; RASMUSSEN LK, 1994, FEBS LETT, V338, P161, DOI 10.1016/0014-5793(94)80356-0; REICHELT KL, 1992, J NEUROCHEM, V59, P500, DOI 10.1111/j.1471-4159.1992.tb09398.x; Reichert Uwe, 1993, P107; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; SAITO KI, 1993, P NATL ACAD SCI USA, V90, P2628, DOI 10.1073/pnas.90.7.2628; SELKOE DJ, 1982, P NATL ACAD SCI-BIOL, V79, P6070, DOI 10.1073/pnas.79.19.6070; SIMON M, 1994, KERATINOCYTE HDB, P275; Steinert PM, 1998, J BIOL CHEM, V273, P11758, DOI 10.1074/jbc.273.19.11758; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; Steinert PM, 1996, BIOCHEM BIOPH RES CO, V221, P101, DOI 10.1006/bbrc.1996.0552; TETZLAFF W, 1988, BRAIN RES, V445, P142, DOI 10.1016/0006-8993(88)91083-9; THOMAZY V, 1989, CELL TISSUE RES, V255, P215; VARANNA G, 1977, DEV NEUROSCI, V19, P172; Yamazaki T, 1997, BIOCHEMISTRY-US, V36, P8377, DOI 10.1021/bi970209y	52	188	191	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30715	30721		10.1074/jbc.274.43.30715	http://dx.doi.org/10.1074/jbc.274.43.30715			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521460	hybrid			2022-12-27	WOS:000083276700056
J	Sakurai, H; Chiba, H; Miyoshi, H; Sugita, T; Toriumi, W				Sakurai, H; Chiba, H; Miyoshi, H; Sugita, T; Toriumi, W			I kappa B kinases phosphorylate NF-kappa B p65 subunit on serine 536 in the transactivation domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; ALPHA; ACTIVATION; SIGNAL; BETA; TRANSCRIPTION; UBIQUITINATION; DEGRADATION; COMPLEX; EPSILON	Recent investigations have elucidated the cytokine-induced NF-kappa B activation pathway. I kappa B kinase (IKK) phosphorylates inhibitors of NF-kappa B (I kappa Bs), The phosphorylation targets them for rapid degradation through a ubiquitin-proteasome pathway, allowing the nuclear translocation of NF-kappa B. We have examined the possibility that IKK can phosphorylate the p65 NF-kappa B subunit as well as I kappa B in the cytokine-induced NF-kappa B activation. In the cytoplasm of HeLa cells, the p65 subunit was rapidly phosphorylated in response to TNF-alpha in a time dependent manner similar to I kappa B phosphorylation. In vitro phosphorylation with GST-fused p65 showed that a p65 phosphorylating activity was present in the cytoplasmic fraction and the target residue was Ser-536 in the carboxyl-terminal transactivation domain. The endogenous IKK complex, overexpressed IKKs, and recombinant IKK beta efficiently phosphorylated the same Ser residue of p65 in vitro. The major phosphorylation site in vivo was also Ser-536. Furthermore, activation of IKKs by NF-kappa B-inducing kinase induced phosphorylation of p65 in vivo. Our finding, together with previous observations, suggests dual roles for IKK complex in the regulation of NF-kappa B.I kappa B complex.	Tanabe Seiyaku Co Ltd, Discovery Res Lab, Yodogawa Ku, Osaka, Japan	Mitsubishi Tanabe Pharma Corporation	Sakurai, H (corresponding author), Tanabe Seiyaku Co Ltd, Discovery Res Lab, Yodogawa Ku, 16-89 Kashima 3 Chome, Osaka, Japan.		Sakurai, Hiroaki/AAE-4294-2019	Sakurai, Hiroaki/0000-0003-0657-9570				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li Z, 1997, MOL CELL BIOL, V17, P6184, DOI 10.1128/MCB.17.10.6184; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rodriguez MS, 1996, ONCOGENE, V12, P2425; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; Sakurai H, 1998, BIOCHEM BIOPH RES CO, V243, P545, DOI 10.1006/bbrc.1998.8124; Sakurai H, 1999, J BIOL CHEM, V274, P10641, DOI 10.1074/jbc.274.15.10641; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; SCHMITZ ML, 1994, J BIOL CHEM, V269, P25613; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; Simeonidis S, 1997, P NATL ACAD SCI USA, V94, P14372, DOI 10.1073/pnas.94.26.14372; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Weil R, 1997, J BIOL CHEM, V272, P9942; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	44	704	716	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30353	30356		10.1074/jbc.274.43.30353	http://dx.doi.org/10.1074/jbc.274.43.30353			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521409	hybrid			2022-12-27	WOS:000083276700005
J	Wojtasek, H; Leal, WS				Wojtasek, H; Leal, WS			Conformational change in the pheromone-binding protein from Bombyx mori induced by pH and by interaction with membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARMYWORM MAMESTRA-BRASSICAE; MOTH ANTHERAEA-POLYPHEMUS; PORE-FORMING DOMAIN; MOLTEN-GLOBULE; MOLECULAR-CLONING; APOLIPOPHORIN-III; MANDUCA-SEXTA; BACTERIAL EXPRESSION; COLICIN-A; ANTENNAE	The pheromone-binding protein (PBP) from Bombyx mori was expressed in Escherichia coli periplasm. It specifically bound radiolabeled bombykol, the natural pheromone for this species. It appeared as a single band both in native and SDS-polyacrylamide gel electrophoresis and was also homogeneous in most chromatographic systems. However, in ion-exchange chromatography, multiple forms sometimes appeared. Attempts to separate them revealed that they could be converted into one another. Analysis of the protein by circular dichroism and fluorescence spectroscopy demonstrated that its tertiary structure was sensitive to pH changes and that a dramatic conformational transition occurred between pH 6.0 and 5.0, This high sensitivity to pH contrasted markedly with its thermal stability and resistance to denaturation by urea. There was also no significant change in CD spectra in the presence of the pheromone, The native protein isolated from male antennae displayed the same changes in its spectroscopic properties as the recombinant material, demonstrating that this phenomenon is not an artifact arising from the. expression system. This conformational transition was reproduced by interaction of the protein with anionic (but not neutral) phospholipid vesicles. Unfolding of the PBP structure triggered by membranes suggests a plausible mechanism for ligand release upon interaction of the PBP-pheromone complex with the surface of olfactory neurons. This pH-linked structural flexibility also explains the heterogeneity reported previously for B, mori PBP and other members of this class of proteins.	Natl Inst Sericultural & Entomol Sci, Lab Chem Prospecting, Tsuchiura, Ibaraki 3058634, Japan		Leal, WS (corresponding author), Natl Inst Sericultural & Entomol Sci, Lab Chem Prospecting, 1-2 Ohwashi, Tsuchiura, Ibaraki 3058634, Japan.		Leal, Walter/ABC-6940-2021	Leal, Walter/0000-0002-6800-1240; Wojtasek, Hubert/0000-0002-2369-3634; Leal Filho, Walter/0000-0002-1241-5225				BALI PK, 1991, BIOCHEMISTRY-US, V30, P9947, DOI 10.1021/bi00105a019; BANUELOS S, 1995, J BIOL CHEM, V270, P29910, DOI 10.1074/jbc.270.50.29910; BREER H, 1990, INSECT BIOCHEM, V20, P735, DOI 10.1016/0020-1790(90)90088-C; BYCHKOVA VE, 1992, BIOCHEMISTRY-US, V31, P7566, DOI 10.1021/bi00148a018; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clyne PJ, 1999, NEURON, V22, P327, DOI 10.1016/S0896-6273(00)81093-4; Davis-Searles PR, 1998, BIOCHEMISTRY-US, V37, P17048, DOI 10.1021/bi981364v; Dyuisekina AE, 1998, MOL BIOL+, V32, P117; Feng L, 1997, INSECT BIOCHEM MOLEC, V27, P405, DOI 10.1016/S0965-1748(97)00012-X; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gursky O, 1996, P NATL ACAD SCI USA, V93, P2991, DOI 10.1073/pnas.93.7.2991; GYORGYI TK, 1988, P NATL ACAD SCI USA, V85, P9851, DOI 10.1073/pnas.85.24.9851; Hildebrand J.G., 1980, RECEPTORS NEUROTRANS, P261; Jeffrey PD, 1998, BIOCHEMISTRY-US, V37, P13978, DOI 10.1021/bi9812064; Kaissling KE, 1996, CHEM SENSES, V21, P257, DOI 10.1093/chemse/21.2.257; Kaissling KE, 1998, CHEM SENSES, V23, P385, DOI 10.1093/chemse/23.4.385; KASANG G, 1989, EXPERIENTIA, V45, P81, DOI 10.1007/BF01990456; KASANG G, 1988, Z NATURFORSCH C, V43, P275; KRIEGER J, 1991, BIOCHIM BIOPHYS ACTA, V1088, P277, DOI 10.1016/0167-4781(91)90064-S; KRIEGER J, 1993, INSECT BIOCHEM MOLEC, V23, P449, DOI 10.1016/0965-1748(93)90052-T; Krieger J, 1996, INSECT BIOCHEM MOLEC, V26, P297, DOI 10.1016/0965-1748(95)00096-8; KRIEGER J, 1992, EUR J BIOCHEM, V203, P161, DOI 10.1111/j.1432-1033.1992.tb19841.x; Maibeche-Coisne M, 1998, EUR J BIOCHEM, V258, P768, DOI 10.1046/j.1432-1327.1998.2580768.x; Maibeche-Coisne M, 1998, INSECT BIOCHEM MOLEC, V28, P815, DOI 10.1016/S0965-1748(98)00080-0; Maida R, 1997, CHEM SENSES, V22, P503, DOI 10.1093/chemse/22.5.503; MCLAUGHLIN S, 1989, ANNU REV BIOPHYS BIO, V18, P113, DOI 10.1146/annurev.biophys.18.1.113; MUGA A, 1993, J BIOL CHEM, V268, P1553; Prestwich GD, 1997, INSECT PHEROMONE RESEARCH, P131; PRESTWICH GD, 1995, CHEM SENSES, V20, P461, DOI 10.1093/chemse/20.4.461; PRESTWICH GD, 1993, PROTEIN SCI, V2, P420; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; PTITSYN OB, 1993, FEBS LETT, V317, P181, DOI 10.1016/0014-5793(93)81272-2; RAMING K, 1990, J COMP PHYSIOL B, V160, P503, DOI 10.1007/BF00258977; RAMING K, 1989, FEBS LETT, V256, P215, DOI 10.1016/0014-5793(89)81751-X; Rogers ME, 1997, J BIOL CHEM, V272, P14792, DOI 10.1074/jbc.272.23.14792; Rosell FI, 1998, J AM CHEM SOC, V120, P11234, DOI 10.1021/ja971756+; RYAN RO, 1993, J BIOL CHEM, V268, P1525; Shin I, 1997, P NATL ACAD SCI USA, V94, P2848, DOI 10.1073/pnas.94.7.2848; Shin I, 1998, BIOCHEMISTRY-US, V37, P4310, DOI 10.1021/bi973005q; Soulages JL, 1998, BIOCHEMISTRY-US, V37, P10203, DOI 10.1021/bi980622l; Tatulian SA, 1996, J MOL BIOL, V260, P312, DOI 10.1006/jmbi.1996.0402; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; Vogt R.G., 1987, P385; VOGT RG, 1981, NATURE, V293, P161, DOI 10.1038/293161a0; VOGT RG, 1989, J NEUROSCI, V9, P3332; VOGT RG, 1991, J NEUROBIOL, V22, P74, DOI 10.1002/neu.480220108; VOGT RG, 1985, P NATL ACAD SCI USA, V82, P8827, DOI 10.1073/pnas.82.24.8827; VOGT RG, 1991, J NEUROSCI, V11, P2972; Vosshall LB, 1999, CELL, V96, P725, DOI 10.1016/S0092-8674(00)80582-6; WIENTZEK M, 1994, J BIOL CHEM, V269, P4605; Wojtasek H, 1998, BIOCHEM BIOPH RES CO, V250, P217, DOI 10.1006/bbrc.1998.9278; ZIEGELBERGER G, 1995, EUR J BIOCHEM, V232, P706, DOI 10.1111/j.1432-1033.1995.tb20864.x	52	193	212	3	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30950	30956		10.1074/jbc.274.43.30950	http://dx.doi.org/10.1074/jbc.274.43.30950			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521490	hybrid			2022-12-27	WOS:000083276700086
J	Thompson, JP; Debinski, W				Thompson, JP; Debinski, W			Mutants of interleukin 13 with altered reactivity toward interleukin 13 receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE-1; SITE-DIRECTED MUTAGENESIS; COMMON GAMMA-CHAIN; HUMAN GLIOMA-CELLS; PSEUDOMONAS EXOTOXIN; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; IL-4 RECEPTOR; COMPONENT; CLONING	Interleukin 13 (IL13) belongs to a family of cytokines whose members exhibit structural homology, despite amino acid sequence dissimilarity. For example, while of limited sequence homology, IL13 and IL4 share a signaling receptor, IL13/4 receptor, on a variety of human normal cells. However, a subclass of II4-independent IL13 receptors is overexpressed on certain transformed cells, including human malignant gliomas. We introduced mutations into human (h) IL13 to determine the site(s) involved in interaction with the shared receptor and/or the glioma-associated receptor. This analysis identified at least three protein regions that are needed for signaling through the shared receptor. These regions were localized to alpha-helices A, C, and D and were mainly separate from the region(s) needed to interact with the glioma-associated receptor. Glutamic acids at positions 13 and 16 in hIL13 alpha-helix A, arginine and serine at positions 66 and 69 in helix C, and arginine at position 109 in helix D were found to be important in inducing biological signaling since their specific mutation resulted in loss and/or gain of function phenomena. We demonstrate that the molecular requirements of hIL13 to interact with its respective receptors are generally distinct and can be controlled by mutagenesis of the cytokine.	Penn State Univ, Coll Med, Neurosurg Sect, Dept Surg, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Debinski, W (corresponding author), Penn State Univ, Coll Med, Neurosurg Sect, Dept Surg, H110,500 Univ Dr, Hershey, PA 17033 USA.	wdebinski@psghs.edu			NATIONAL CANCER INSTITUTE [R01CA074145] Funding Source: NIH RePORTER; NCI NIH HHS [CA 74145] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAMBOROUGH P, 1994, PROTEIN ENG, V7, P1077, DOI 10.1093/protein/7.9.1077; BOCHNER BS, 1995, J IMMUNOL, V154, P799; Caput D, 1996, J BIOL CHEM, V271, P16921, DOI 10.1074/jbc.271.28.16921; Debinski W, 1998, NAT BIOTECHNOL, V16, P449, DOI 10.1038/nbt0598-449; DEBINSKI W, 1993, J BIOL CHEM, V268, P14065; Debinski W, 1995, CLIN CANCER RES, V1, P1253; Debinski W, 1996, J BIOL CHEM, V271, P22428, DOI 10.1074/jbc.271.37.22428; DEBINSKI W, 1995, J BIOL CHEM, V270, P16775, DOI 10.1074/jbc.270.28.16775; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DOHERTY TM, 1993, J IMMUNOL, V151, P7151; EPPINK MHM, 1995, EUR J BIOCHEM, V231, P157, DOI 10.1111/j.1432-1033.1995.0157f.x; Feng NP, 1998, LAB INVEST, V78, P591; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; MALEFYT RD, 1993, J IMMUNOL, V151, P6370; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; Miloux B, 1997, FEBS LETT, V401, P163, DOI 10.1016/S0014-5793(96)01462-7; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; OBIRI NI, 1995, J BIOL CHEM, V270, P8797, DOI 10.1074/jbc.270.15.8797; Obiri NI, 1997, J IMMUNOL, V158, P756; ROZWARSKI DA, 1994, STRUCTURE, V2, P159, DOI 10.1016/S0969-2126(00)00018-6; SALVUCCI ME, 1994, ARCH BIOCHEM BIOPHYS, V314, P178, DOI 10.1006/abbi.1994.1427; Schnarr B, 1997, INT IMMUNOL, V9, P861, DOI 10.1093/intimm/9.6.861; Schnyder B, 1996, BLOOD, V87, P4286, DOI 10.1182/blood.V87.10.4286.bloodjournal87104286; SIRONI M, 1994, BLOOD, V84, P1913; TONY HP, 1994, EUR J BIOCHEM, V225, P659, DOI 10.1111/j.1432-1033.1994.00659.x; VITA N, 1995, J BIOL CHEM, V270, P3512, DOI 10.1074/jbc.270.8.3512; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	32	33	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29944	29950		10.1074/jbc.274.42.29944	http://dx.doi.org/10.1074/jbc.274.42.29944			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514477	hybrid			2022-12-27	WOS:000083176400056
J	Yun, J; Chae, HD; Choy, HE; Chung, J; Yoo, HS; Han, MH; Shin, DY				Yun, J; Chae, HD; Choy, HE; Chung, J; Yoo, HS; Han, MH; Shin, DY			p53 negatively regulates cdc2 transcription via the CCAAT-binding NF-Y transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; CELL-CYCLE; TUMOR SUPPRESSION; MAMMALIAN-CELLS; GENE-EXPRESSION; PROTEIN; PROMOTER; REPRESSION; DNA; INDUCTION	The p53 tumor suppressor protein regulates the transcription of regulatory genes involved in cell cycle arrest and apoptosis. We have reported previously that inducible expression of the p53 gene leads to the cell cycle arrest both at G(1) and G(2)/M in association with induction of p21 and reduction of mitotic cyclins (cyclin A and B) and cdc2 mRNA. In this study, we investigated the mechanism by which p53 regulates transcription of the cdc2 gene. Transient transfection analysis showed that wild type p53 represses whereas various dominant negative mutants of p53 increase cdc2 transcription; The cdc2 promoter activity is not repressed in cells transfected with a transactivation mutant, p53(22/23). An adenovirus oncoprotein, E1B-55K inhibits the p53-mediated repression of the cdc2 promoter, while E1B-19K does not. Since the cdc2 promoter does not contain a TATA sequence, we performed deletion and point mutation analyses and identified the inverted CCAAT sequence located at -76 as a cis-acting element for the p53-mediated regulation. We found that a specific DNA-protein complex is formed at the CCAAT sequence and that this complex contains the NF-Y transcription factor. Consistently, a dominant negative mutant of the NF-YA subunit, NF-YAm29, decreases the cdc2 promoter, and p53 does not further decrease! the promoter activity in the presence of NF-YAm29. These results suggest that p53 negatively regulates cdc2 transcription and that the NF-Y transcription factor is required for the p53-mediated regulation.	Korea Res Inst Biosci & Biotechnol, Biosci Res Div, Taejon 305600, South Korea; Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Advanced Institute of Science & Technology (KAIST)	Shin, DY (corresponding author), Korea Res Inst Biosci & Biotechnol, Biosci Res Div, POB 115, Taejon 305600, South Korea.	dyshin@mail.kribb.re.kr	Chae, Hee-Don/D-2620-2011					AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BORN TL, 1994, MOL CELL BIOL, V14, P5710, DOI 10.1128/MCB.14.9.5710; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Chen HF, 1996, J BIOL CHEM, V271, P13959, DOI 10.1074/jbc.271.24.13959; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Farmer G, 1996, NUCLEIC ACIDS RES, V24, P4281, DOI 10.1093/nar/24.21.4281; Furukawa Y, 1996, J BIOL CHEM, V271, P28469, DOI 10.1074/jbc.271.45.28469; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Harris LC, 1996, CANCER RES, V56, P2029; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; JACKSON SM, 1995, J BIOL CHEM, V270, P21445, DOI 10.1074/jbc.270.37.21445; JaramilloBabb VL, 1996, J BIOL CHEM, V271, P5988, DOI 10.1074/jbc.271.11.5988; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kinzler KW, 1996, NATURE, V379, P19, DOI 10.1038/379019a0; KU DH, 1993, J BIOL CHEM, V268, P2255; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LIN JY, 1995, ONCOGENE, V10, P2387; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; MCGOWAN CH, 1990, MOL CELL BIOL, V10, P3847, DOI 10.1128/MCB.10.7.3847; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PUISIEUX A, 1995, P NATL ACAD SCI USA, V92, P1342, DOI 10.1073/pnas.92.5.1342; RICHTER KH, 1991, CANCER RES, V51, P6010; Roperch JP, 1998, NAT MED, V4, P835, DOI 10.1038/nm0798-835; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; Sandri MI, 1996, NUCLEIC ACIDS RES, V24, P4464, DOI 10.1093/nar/24.22.4464; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; Schwartz D, 1997, ONCOGENE, V15, P2597, DOI 10.1038/sj.onc.1201436; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Tanimoto A, 1998, ONCOGENE, V17, P3103, DOI 10.1038/sj.onc.1202236; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; Wang QJ, 1997, MOL CELL BIOL, V17, P389, DOI 10.1128/MCB.17.1.389; Webster NJG, 1996, CANCER RES, V56, P2781; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0	61	146	148	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29677	29682		10.1074/jbc.274.42.29677	http://dx.doi.org/10.1074/jbc.274.42.29677			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514438	hybrid			2022-12-27	WOS:000083176400017
